{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1a775be-0b2d-566a-80c4-d2db95ca2319", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "VORICONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2b3c0b3-02a6-45c3-a8ea-05d210dc9108", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2b3c0b3-02a6-45c3-a8ea-05d210dc9108", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2b3c0b3-02a6-45c3-a8ea-05d210dc9108"]}], "subject": "CHEBI:10023", "supporting_text": ["4 CONTRAINDICATIONS • Voriconazole tablets are contraindicated in patients with known hypersensitivity to voriconazole or its excipients [see Warnings and Precautions ( 5.5 ) and Adverse Reactions ( 6.1 , 6.2 )]. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents. Refer to the prescribing information for other azole antifungal agents. • Concomitant use of voriconazole tablets with the interacting drugs described and listed below in this section are a guide and not considered a comprehensive list of all possible drugs that may be contraindicated with voriconazole tablets. 1. Concomitant use of voriconazole tablets are contraindicated with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions ( 7 )]: • Eplerenone • Ergot alkaloids (e.g., ergotamine, dihydroergotamine) • Finerenone • Ivabradine • Lurasidone • Naloxegol • Pimozide • Quinidine • Rifabutin [see Clinical Pharmacology ( 12.3 )] • Sirolimus [see Clinical Pharmacology ( 12.3 )] • Tolvaptan • Venetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions ( 7 )]. • Voclosporin 2. Concomitant use of voriconazole tablets are contraindicated with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy [see Drug Interactions ( 7 )]: • Carbamazepine • Efavirenz • Concomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [see Clinical Pharmacology ( 12.3 )]. • Long-acting barbiturates • Rifabutin • Rifampin • Ritonavir • Concomitant use with high-dose ritonavir (400 mg every "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7d1d052-e9f5-57f3-8547-a19fbecff8aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "VORICONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6a1a792-141b-42e8-8bd1-884e4408eb8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6a1a792-141b-42e8-8bd1-884e4408eb8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6a1a792-141b-42e8-8bd1-884e4408eb8a"]}], "subject": "CHEBI:10023", "supporting_text": ["4 CONTRAINDICATIONS • Voriconazole tablets are contraindicated in patients with known hypersensitivity to voriconazole or its excipients [see Warnings and Precautions (5.5) and Adverse Reactions (6.1, 6.2)]. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents. Refer to the prescribing information for other azole antifungal agents. • Concomittant use of voriconazole with the interacting drugs described and listed below in this section are a guide and not considered a comprehensive list of all possible drugs that may be contraindicated with voriconazole. 1. Concomitant use of voriconazole is contraindicated with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reaction [see Drug Interactions (7) ]: • Eplerenone • Ergot alkaloids (e.g., ergotamine, dihydroergotamine) • Finerenone • Ivabradine • Lurasidone • Naloxegol • Pimozide • Quinidine • Rifabutin [see Clinical Pharmacology ( 12.3 )] • Sirolimus [see Clinical Pharmacology ( 12.3 )] • Tolvaptan • Venetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)]. • Voclosporin 2. Concomitant use of voriconazole is contraindicated with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy [see Drug Interactions (7) ]: • Carbamazepine • Efavirenz • Concomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [ see Clinical Pharmacology (12.3) ] . • Long-acting barbiturates • Rifabutin • Rifampin • Ritonavir • Concomitant use with high-dose ritonavir (400 mg every 12 hours) is contraindicated. Concomitant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:688bb162-d650-584a-a199-4e7af0bec984", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020319", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:37ca8eb6-f695-57d7-8549-1d5ed37842c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "object": "MONDO:0044070", "object_location_in_text": [188, 199], "original_object": "candidaemia", "original_subject": "voriconazole", "population_context_qualifier": "adults and children aged two years and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:voriconazole-accord", "https://www.ema.europa.eu/en/documents/product-information/voriconazole-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-accord"]}], "subject": "CHEBI:10023", "supporting_text": ["Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:  treatment of invasive aspergillosis; treatment of candidaemia in non-neutropenic patients; treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.  Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3bb7e5a-964b-50e6-98ec-73affcbd567e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020319", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:37ca8eb6-f695-57d7-8549-1d5ed37842c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "object": "MONDO:0044070", "object_location_in_text": [186, 197], "original_object": "candidaemia", "original_subject": "voriconazole", "population_context_qualifier": "adults and children aged 2 years and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:voriconazole-hikma", "https://www.ema.europa.eu/en/documents/product-information/voriconazole-hikma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-hikma"]}], "subject": "CHEBI:10023", "supporting_text": ["Voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:  treatment of invasive aspergillosis; treatment of candidaemia in non-neutropenic patients; treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.  Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT)recipients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:208a0468-352b-5279-ab6d-e21fbad39634", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1097, 1107], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older in non-neutropenic patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23f25c6b-f075-42dc-ae05-63b5bf410929", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23f25c6b-f075-42dc-ae05-63b5bf410929", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23f25c6b-f075-42dc-ae05-63b5bf410929"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis ( 1.1 ) Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5 ) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis Voriconazole is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiology (12.4) ] . 1.5 Usage Specimens for fungal culture and other "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:229f7055-17da-549c-beec-043f8dadfd83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1114, 1124], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fe672ff-2cef-4f88-ab85-5a4b586da20d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fe672ff-2cef-4f88-ab85-5a4b586da20d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fe672ff-2cef-4f88-ab85-5a4b586da20d"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis ( 1.1 ) Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis Voriconazole tablets are indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiology (12.4) ] . 1.5 Usage Spec"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic status", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d1943c8-4548-553a-9a7f-17c6557cab74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1125, 1135], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older; non-neutropenic patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f2e0784-8e48-f565-e053-2991aa0a0746", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f2e0784-8e48-f565-e053-2991aa0a0746", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f2e0784-8e48-f565-e053-2991aa0a0746"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole for injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis ( 1.1 ) Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus[see Clinical Studies (14.1, 14.5) and Microbiology (12.4)]. 1.2 Candidemia in Non-Neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2, 14.5) and Microbiology (12.4)] 1.3 Esophageal Candidiasis Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) in adults and pediatric patients 2 years of age and older [see Clinical Studies (14.3, 14.5) and Microbiology (12.4)] 1.4 Scedosporiosis and Fusariosis Voriconazole for injection is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52e4f687-d763-5476-bbdf-7831cb74fceb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1074, 1084], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce3ef5cf-3087-4d92-9d94-9eb8287228db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ]. 1.3 Esophageal Candidiasis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ]. 1.4 Scedosporiosis and Fusariosis VFEND is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiology (12.4) ]. 1.5 Usage Specimens for fungal culture and other relevant laboratory studies (including h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55fb375e-aa91-5bae-b49c-9a6184960954", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1140, 1150], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older in non-neutropenic patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b3b67028-f8a0-4a93-9e73-9e8940c22c4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b3b67028-f8a0-4a93-9e73-9e8940c22c4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b3b67028-f8a0-4a93-9e73-9e8940c22c4a"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE . Voriconazole for injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies ( 14.1 , 14.5 ) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies ( 14.2 , 14.5 ) and Microbiology ( 12.4 )] . 1.3 Esophageal Candidiasis Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies ( 14.3 , 14.5 ) and Microbiology ( 12.4 )] . 1.4 Scedosporiosis and Fusariosis Voriconazole for injection is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani, in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59a58f22-057f-538b-b195-bccec583ec65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1106, 1116], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older; non-neutropenic patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c620b2d7-3c2b-4252-8cfc-2f322d624435", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c620b2d7-3c2b-4252-8cfc-2f322d624435", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c620b2d7-3c2b-4252-8cfc-2f322d624435"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis (1.1) Candidemia in non-neutropenics and other deep tissue Candida infections (1.2) Esophageal candidiasis (1.3) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy (1.4) 1.1 Invasive Aspergillosis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) in adults and pediatric patients 2 years of age and older [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis Voriconazole tablets are indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a35a41b5-768a-584d-89e6-08274284d691", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1116, 1126], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "non-neutropenic patients; adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:16a80777-f1f3-45bb-a312-998b07767fe3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=16a80777-f1f3-45bb-a312-998b07767fe3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16a80777-f1f3-45bb-a312-998b07767fe3"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis ( 1.1 ) Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies ( 14.1 , 14.5 ) and Microbiology ( 12.4 )]. 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies ( 14.2 , 14.5 ) and Microbiology ( 12.4 )]. 1.3 Esophageal Candidiasis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies ( 14.3 , 14.5 ) and Microbiology ( 12.4 )]. 1.4 Scedosporiosis and Fusariosis Voriconazole tablets are indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies ( 14.4 ) and Microbiology ( 12.4 )]. 1.5 Us"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae9b91ee-99ff-59e2-8b03-bb4a021e6bb6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1074, 1084], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dac26bcd-7a59-401f-9f66-a0649767cece", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dac26bcd-7a59-401f-9f66-a0649767cece", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dac26bcd-7a59-401f-9f66-a0649767cece"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ]. 1.3 Esophageal Candidiasis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ]. 1.4 Scedosporiosis and Fusariosis VFEND is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiology (12.4) ]. 1.5 Usage Specimens for fungal culture and other relevant laboratory studies (including h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c03192c1-28f1-5808-a88c-7c360471ddd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1074, 1084], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08d08721-1f4c-478a-8abf-d9c402d50553", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08d08721-1f4c-478a-8abf-d9c402d50553", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08d08721-1f4c-478a-8abf-d9c402d50553"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE VFEND is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis VFEND is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis VFEND is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiology (12.4) ] . 1.5 Usage Specimens for fungal culture and other relevant laboratory studies (includin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb5e3f55-82ef-50aa-bcce-15ddff7e8cf7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1122, 1132], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2b3c0b3-02a6-45c3-a8ea-05d210dc9108", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2b3c0b3-02a6-45c3-a8ea-05d210dc9108", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2b3c0b3-02a6-45c3-a8ea-05d210dc9108"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5) and Microbiology (12.4) ]. 1.3 Esophageal Candidiasis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5) and Microbiology (12.4) ]. 1.4 Scedosporiosis and Fusariosis Voriconazole tablets are indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiology (12.4) ]. 1.5 Usage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic patients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2000ca0-ed0f-50fe-af7c-fb207f8dea29", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1123, 1133], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:796cad15-2aef-4823-917d-17b822a6916e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=796cad15-2aef-4823-917d-17b822a6916e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=796cad15-2aef-4823-917d-17b822a6916e"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole tablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies ( 14.1 , 14.5 ) and Microbiology ( 12.4 )]. 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazoletablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies ( 14.2 , 14.5 ) and Microbiology ( 12.4 )]. 1.3 Esophageal Candidiasis Voriconazoletablets are indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies ( 14.3 , 14.5 ) and Microbiology ( 12.4 )]. 1.4 Scedosporiosis and Fusariosis Voriconazole tablets are indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies ( 14.4 ) and Microbiology ( 12.4 )]. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-neutropenic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8a67d63-6f74-5738-aedc-e98b396fa907", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d63c32be-b2e2-5440-99eb-8260c6835a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98188046-4d2b-59ef-a704-755153855d02", "medic_supporting_text_truncated": true, "object": "MONDO:0044070", "object_location_in_text": [1130, 1140], "original_object": "candidemia", "original_subject": "VORICONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older in non-neutropenic patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d962d459-254f-4b78-ae28-7d9ec5d4e4d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d962d459-254f-4b78-ae28-7d9ec5d4e4d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d962d459-254f-4b78-ae28-7d9ec5d4e4d5"]}], "subject": "CHEBI:10023", "supporting_text": ["1 INDICATIONS AND USAGE Voriconazole for Injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis ( 1.1 ) Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) 1.1 Invasive Aspergillosis Voriconazole for Injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus . There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1 , 14.5 ) and Microbiology (12.4) ] . 1.2 Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections Voriconazole for Injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds [see Clinical Studies (14.2 , 14.5 ) and Microbiology (12.4) ] . 1.3 Esophageal Candidiasis Voriconazole for Injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC) [see Clinical Studies (14.3 , 14.5 ) and Microbiology (12.4) ] . 1.4 Scedosporiosis and Fusariosis Voriconazole for Injection is indicated for the treatment of serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii ) and Fusarium spp. including Fusarium solani , in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy [see Clinical Studies (14.4) and Microbiolo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "viral infections of the external canal", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32d2eb23-9c35-5e9c-beeb-629ae9207289", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2d987d10-c3a8-5588-86ba-313d51f87654", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3ac529d-61ef-5687-9e3b-a29919e4c535", "object": "MONDO:0004609", "original_object": "herpes simplex infection", "original_subject": "CIPROFLOXACIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:100241", "supporting_text": ["CIPRO ® HC OTIC is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "viral infections of the external canal", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6127055-09fb-58cc-8a8e-702183e55fab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5a892192-1567-5a76-b0a4-a1d2782bb181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3ac529d-61ef-5687-9e3b-a29919e4c535", "object": "MONDO:0005700", "object_location_in_text": [350, 359], "original_object": "varicella", "original_subject": "CIPROFLOXACIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:100241", "supporting_text": ["CIPRO ® HC OTIC is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26c6e7eb-9e8d-51c5-a2b9-01f47b1688e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0005545", "UMLS:C0276078"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2db26b6-8b26-581d-bb49-ea0abc49cc46", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3ac529d-61ef-5687-9e3b-a29919e4c535", "object": "MONDO:0001051", "object_location_in_text": [50, 70], "original_object": "acute otitis externa", "original_subject": "CIPROFLOXACIN", "population_context_qualifier": "adult and pediatric patients, one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:100241", "supporting_text": ["CIPRO ® HC OTIC is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86bd1068-84c0-54c0-8209-cf0eee119bce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2db26b6-8b26-581d-bb49-ea0abc49cc46", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3ac529d-61ef-5687-9e3b-a29919e4c535", "object": "MONDO:0001051", "object_location_in_text": [118, 138], "original_object": "acute otitis externa", "original_subject": "CIPROFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51dde3f2-adb1-4ed8-83c6-1f63723a2529", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51dde3f2-adb1-4ed8-83c6-1f63723a2529", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51dde3f2-adb1-4ed8-83c6-1f63723a2529"]}], "subject": "CHEBI:100241", "supporting_text": ["1 INDICATIONS AND USAGE Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus . Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:198a7cc7-8d60-530c-990a-0bea7c601479", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b4d4153-bc4f-53d9-b81f-7cb5b933133b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d8a08d7-3fb1-5b4b-8f19-6f1ba213d880", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d0edbd2-02ea-51bc-a381-9a3e0b2ba7c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7fa416a5-79ce-5544-83f8-15011e96bf2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8900a172-3765-5fa5-9a24-aca5ed1b9b23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:922b5ab3-3dd5-5204-b6c6-bd2097852707", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c11ba4de-a3fe-5b77-a4f5-2e8e9d383342", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4dd322b-ac71-54a9-a7a0-c0bca4308ac8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "Pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d67a47f8-71b0-5c19-8103-fa19e45f0c0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbd363fa-d7b4-5fe5-b106-3cc666af8c90", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0001370", "original_object": "pericardial effusions", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1725ca07-6320-52b6-9e63-957f7e88d811", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ebbf8c9-bc9a-5874-8c24-4c63c2d53d81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30dfc0da-3566-5fb9-af54-679e27d57f5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40110245-cfa9-5a5c-97c8-7c5a33d931bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6bb61055-1e49-548b-8bf1-ec69de0ea92a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e4b9145-31a5-5ba0-a67d-c0307ca7eadb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6ee3143-0adf-54e6-94ab-626120d11ba5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c07bd7e4-1670-56ab-946a-bcbab3371f67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbb7a466-68ce-53c9-a7ad-bab178011c38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd07da31-ceaa-5fe0-9695-ebb537be3eff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "original_object": "Pericarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23d3416e-5cfd-5de9-b632-7b4f9f0a710f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bcae8b0-1b55-5009-8018-80e18dc819f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ef0e6ff-1a29-5ade-ab9e-837bee7ba340", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b51b830-0168-5341-8193-5caead7e21db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c11815a-64a9-5d3a-bfa9-1dbaef11705d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f04994f-f82d-535d-8271-3fe63d473ccb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7701e766-efb6-53ee-8464-7f433b9a4625", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "original_object": "bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:801b86bc-7a37-53a1-85e5-f7a4bd7cf57e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb280942-5880-5c2e-a265-f0b8e7b4502a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "object_location_in_text": [1343, 1365], "original_object": "Bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbed3651-0fac-5939-9ed8-7269fbedb0d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2b02c87-6180-5437-b71b-e630b18078ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "MONDO:0006669", "original_object": "bacterial endocarditis", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28c29721-803b-5af0-9ae4-5bd6d12937f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39573496-fa91-53c3-af3e-1256b8d96315", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45d9f916-dffe-5853-9c7b-81ec0731a6fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62eb03a2-769f-5c09-8918-7e912a4caae9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6cfa87cb-b7a5-5462-90a4-5810d3d36128", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:915a0c74-5817-5be5-81b7-8ac59b44cbe4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb80e6b1-c2da-5fd8-a66a-86feeec10b3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e447d4b3-a8ee-58a2-9fba-e071aed7b6d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcdcfa73-48e7-5711-b6a4-9cbf162f8b42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "Cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd0ac6bf-aa3e-5ff9-a6c2-00a1af39a47d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73b471ef-3884-5cab-883f-087145d10ba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C0917996", "original_object": "cerebral aneurysms", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17835768-5469-5160-884e-f297eb06cee7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6083d68-4360-4d47-a1b2-1eb2763024bb"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:390b7a24-39f7-5703-a0d1-0cddf1f64436", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "original_object": "central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c4deb97-9966-4c8e-9ba6-bb260b71e130"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6492dcf5-d73e-5258-987d-de79f77f94cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc2d94e-f856-47da-9d44-24773d97eb87"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7106e6e3-428a-536d-8305-f5208161b70e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=724b0061-f42a-4008-a078-09c800ee9785"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90aaae09-c451-55d6-ab22-f56fbbfa1c2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654ca5d2-d4c1-48f8-90c4-130a21162bb0"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90f92db0-922c-5922-9ad7-5bc2010556d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "original_object": "central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdbbc317-35d3-42ba-94f0-c83891358529"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium tablets, USP are contraindicated in: • Pregnancy Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions (5.7) and Use in Specific Populations (8.1) ]. Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) ]. Warfarin sodium tablets, USP are contraindicated in patients with: • Hemorrhagic tendencies or blood dyscrasias • Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions (5.8) ] • Bleeding tendencies associated with: o Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract o Central nervous system hemorrhage o Cerebral aneurysms, dissecting aorta o Pericarditis and pericardial effusions o Bacterial endocarditis • Threatened abortion, eclampsia, and preeclampsia • Unsupervised patients with conditions associated with potential high level of non-compliance • Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding • Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions (6) ] • Major regional or lumbar block anesthesia • Malignant hypertension • Pregnancy, except in women with mechanical heart valves (4 , 5.7 , 8.1) • Hemorrhagic tendencies or blood dyscrasias (4) • Recent or contemplat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96395c73-cecc-5ea3-8a55-908898f016c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1244c338-9140-425a-bf2a-9da6b4ac0287"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0bc4f6c-6e18-5fa5-8b13-174c418f228a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5fb1a5f-0dda-4f47-8683-ea63ac88a69d"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2de94f6-e533-500f-8588-9166ae8a29d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba65ae56-ca3b-4895-9938-1dde2c3d34bf"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1458140", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb919f80-1da7-5a02-917e-a6590c7e7f83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1458140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:639b3a74-a155-500b-a680-5694b03fccd7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a07fdf4-8f29-5a80-a1a3-853119000d1b", "medic_supporting_text_truncated": true, "object": "UMLS:C3267019", "object_location_in_text": [1227, 1260], "original_object": "Central nervous system hemorrhage", "original_subject": "WARFARIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecd271ad-765e-4ac5-99f4-2e9c6e466336"]}], "subject": "CHEBI:10033", "supporting_text": ["4 CONTRAINDICATIONS Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations ( 8.1 )] . Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [see Warnings and Precautions ( 5.8 )] Bleeding tendencies associated with: − Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract − Central nervous system hemorrhage − Cerebral aneurysms, dissecting aorta − Pericarditis and pericardial effusions − Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves ( 4 , 5.7 , 8.1 ) Hemorrhagic tendencies or blood dyscrasias ( 4 ) Recent or contemplated surgery of the central nervous system (CNS) or eye, o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0042487", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14779593-5be0-58af-9e25-2fcd3f00fd6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0042487", "MONDO:0005068", "MONDO:0005279", "UMLS:C0262935"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:22d38a64-2eee-56e9-bab7-cba1787c4acf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:c77a242a-5092-5a4a-901e-c5bfe5810f7f", "object": "HP:0001907", "object_location_in_text": [108, 123], "original_object": "thromboembolism", "original_subject": "WARFARIN POTASSIUM", "population_context_qualifier": "pediatric", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:WARFARIN POTASSIUM#156-20110223", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:10033", "supporting_text": ["Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0031417", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ba8eed0-3f26-5895-8a41-305963e5643c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031417"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:bec1c4ed-0db7-5288-91e2-ec71dbd6d149", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:3535553e-d186-5a54-9679-3472ea4c21e4", "object": "HP:0001742", "object_location_in_text": [29, 45], "original_object": "nasal congestion", "original_subject": "Xylometazoline 0.5 mg + Ipratropium 0.6 mg Nasal spray", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:10082", "supporting_text": ["For symptomatic treatment of nasal congestion with running nose (rhinorrhea)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001742", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:525a1b39-22a2-58a4-829c-1444b0ae4525", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001742"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:d703b0fe-4e37-5abc-8bbe-ac410b2cd63e", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:3535553e-d186-5a54-9679-3472ea4c21e4", "object": "HP:0031417", "original_object": "rhinorrhea", "original_subject": "Xylometazoline 0.5 mg + Ipratropium 0.6 mg Nasal spray", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:10082", "supporting_text": ["For symptomatic treatment of nasal congestion with running nose (rhinorrhea)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "insomnia characterized by difficulties with sleep onset, insomnia characterized by difficulties with sleep maintenance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ce9ec56-c8be-54be-b50c-268f8d3eeb9c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921216", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:05f85dc6-0b72-5a05-bfb6-45256ab9f99c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f88474f-d2fc-5de0-ab94-6a75bc50c5bf", "object": "MONDO:0013600", "object_location_in_text": [113, 121], "original_object": "insomnia", "original_subject": "ZOLPIDEM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cbda91f7-4411-4016-80d6-0a349931956d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cbda91f7-4411-4016-80d6-0a349931956d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbda91f7-4411-4016-80d6-0a349931956d"]}], "subject": "CHEBI:10125", "supporting_text": ["1 INDICATIONS AND USAGE Zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. Zolpidem tartrate extended-release tablets, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2674108", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e5cafc0-2acf-5274-ba2e-88aa7a6a5309", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2674108"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:adeeed95-73df-5bf1-9560-ee2a797b75a4", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:73a8a4a1-59f4-5999-88c0-4115eaf36764", "object": "HP:0007359", "object_location_in_text": [32, 48], "original_object": "partial seizures", "original_subject": "zonisamide", "population_context_qualifier": "adults, adolescents, and children aged 6 years and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zonisamide-viatris", "https://www.ema.europa.eu/en/documents/product-information/zonisamide-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-viatris"]}], "subject": "CHEBI:10127", "supporting_text": ["Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43f5d788-21cb-5a73-8c15-8aa7985c6ab9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821105", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e13afcc-0b9b-5a8e-aa2a-34d7f88ff7bb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [298, 320], "original_object": "myocardial infarctions", "original_subject": "DILTIAZEM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73b3607a-99d0-44d8-92ef-0074684c9d7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73b3607a-99d0-44d8-92ef-0074684c9d7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73b3607a-99d0-44d8-92ef-0074684c9d7d"]}], "subject": "CHEBI:101278", "supporting_text": ["1 INDICATIONS AND USAGE Diltiazem Hydrochloride Extended-Release Tablets is a nondihydropyridine calcium channel blocker indicated for: • treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) • improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension Diltiazem Hydrochloride Extended-Release Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4535792f-9eae-5267-9baf-c94ff7f9369e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821105", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e13afcc-0b9b-5a8e-aa2a-34d7f88ff7bb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DILTIAZEM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8c8dd18-9d95-4068-9762-bec1eb1bc25c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8c8dd18-9d95-4068-9762-bec1eb1bc25c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8c8dd18-9d95-4068-9762-bec1eb1bc25c"]}], "subject": "CHEBI:101278", "supporting_text": ["1 INDICATIONS AND USAGE Matzim LA (diltiazem hydrochloride) extended-release tablets are a nondihydropyridine calcium channel blocker indicated for: treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension Matzim LA (diltiazem hydrochloride) extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarcti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f60f3c5-06b8-51ab-91bd-31e3c1319dd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821105", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e13afcc-0b9b-5a8e-aa2a-34d7f88ff7bb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [286, 293], "original_object": "strokes", "original_subject": "DILTIAZEM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73b3607a-99d0-44d8-92ef-0074684c9d7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73b3607a-99d0-44d8-92ef-0074684c9d7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73b3607a-99d0-44d8-92ef-0074684c9d7d"]}], "subject": "CHEBI:101278", "supporting_text": ["1 INDICATIONS AND USAGE Diltiazem Hydrochloride Extended-Release Tablets is a nondihydropyridine calcium channel blocker indicated for: • treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) • improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension Diltiazem Hydrochloride Extended-Release Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db4c95af-5d99-5a30-b068-f7b2593db742", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821105", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e13afcc-0b9b-5a8e-aa2a-34d7f88ff7bb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DILTIAZEM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8c8dd18-9d95-4068-9762-bec1eb1bc25c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8c8dd18-9d95-4068-9762-bec1eb1bc25c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8c8dd18-9d95-4068-9762-bec1eb1bc25c"]}], "subject": "CHEBI:101278", "supporting_text": ["1 INDICATIONS AND USAGE Matzim LA (diltiazem hydrochloride) extended-release tablets are a nondihydropyridine calcium channel blocker indicated for: treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension Matzim LA (diltiazem hydrochloride) extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarcti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0025497", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59265339-0fed-592e-85ff-e0a1452e8e56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821105", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025497"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cc7ef117-f91f-56bb-8aeb-cd218f7d7f3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e13afcc-0b9b-5a8e-aa2a-34d7f88ff7bb", "object": "UMLS:C0002962", "original_object": "angina", "original_subject": "DILTIAZEM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dc2b889-8443-4f7f-83be-86c68e179804", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dc2b889-8443-4f7f-83be-86c68e179804", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dc2b889-8443-4f7f-83be-86c68e179804"]}], "subject": "CHEBI:101278", "supporting_text": ["Diltiazem hydrochloride extended-release capsules (once-a-day dosage) are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules (once-a-day dosage) are indicated for the management of chronic stable angina and angina due to coronary artery spasm."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006383", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f17a268a-13e7-5c89-9ce3-08dde2bb97bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821105", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006383"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0a66e702-6577-5214-8cfb-64e3c3faa12d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e13afcc-0b9b-5a8e-aa2a-34d7f88ff7bb", "medic_supporting_text_truncated": true, "object": "UMLS:C0242514", "original_object": "reciprocating tachycardia", "original_subject": "DILTIAZEM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:734beeef-3968-4137-af2c-276e8a9317df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=734beeef-3968-4137-af2c-276e8a9317df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=734beeef-3968-4137-af2c-276e8a9317df"]}], "subject": "CHEBI:101278", "supporting_text": ["Diltiazem Hydrochloride Injection is indicated for the following: Atrial Fibrillation or Atrial Flutter Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76380435-d2fd-5d9b-becb-baedb09e1c02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0df457e2-785a-5b67-b67e-412eda9bf271", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "SULFISOXAZOLE", "population_context_qualifier": "children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60d1aea0-f106-4b20-8ef4-7a80e37f8a50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60d1aea0-f106-4b20-8ef4-7a80e37f8a50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60d1aea0-f106-4b20-8ef4-7a80e37f8a50"]}], "subject": "CHEBI:102484", "supporting_text": [": For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:833b7f4d-816c-5de7-a9ee-f97f7f3c2251", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0df457e2-785a-5b67-b67e-412eda9bf271", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "SULFISOXAZOLE", "population_context_qualifier": "children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb6ea746-3228-4969-8a26-653288662fd7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7"]}], "subject": "CHEBI:102484", "supporting_text": [": For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01a01745-2f5c-5b1d-801e-ac12674241b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e2a428-3df4-59fe-b2ad-3915c67c053a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002239", "object_location_in_text": [280, 307], "original_object": "gastrointestinal hemorrhage", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95269b1f-779c-4ca0-9f86-e74e677f9900", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS GIMOTI is contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2) ] . When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [see Adverse Reactions ( 6 )] . History of TD or dystonic reaction to metoclopramide ( 4 ) When stimulation of gastrointestinal motility might be dangerous ( 4 ) Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) Epilepsy ( 4 ) Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "condition where stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d4a6f19-6999-57f7-9556-a1d084094b0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e2a428-3df4-59fe-b2ad-3915c67c053a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002239", "object_location_in_text": [292, 319], "original_object": "gastrointestinal hemorrhage", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:697ec7b1-945a-4a31-b585-f051dc246165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=697ec7b1-945a-4a31-b585-f051dc246165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=697ec7b1-945a-4a31-b585-f051dc246165"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS Metoclopramide is contraindicated: • In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2 )] . • When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). • In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . • In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . • In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [see Adverse Reactions ( 6 )] . • History of TD or dystonic reaction to metoclopramide ( 4 ) • When stimulation of gastrointestinal motility might be dangerous ( 4 ) • Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) • Epilepsy ( 4 ) • Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5494408c-f559-5a6e-8666-6ead653b77b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e2a428-3df4-59fe-b2ad-3915c67c053a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002239", "object_location_in_text": [297, 324], "original_object": "gastrointestinal hemorrhage", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4828095-94e0-4f71-901c-93837974c658", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4828095-94e0-4f71-901c-93837974c658", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4828095-94e0-4f71-901c-93837974c658"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS Metoclopramide tablets are contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2 )] . When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [see Adverse Reactions ( 6 )] . History of TD or dystonic reaction to metoclopramide ( 4 ) When stimulation of gastrointestinal motility might be dangerous ( 4 ) Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) Epilepsy ( 4 ) Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8419feb0-fdc9-542e-a344-1cf3a985b7d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e2a428-3df4-59fe-b2ad-3915c67c053a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002239", "object_location_in_text": [293, 320], "original_object": "gastrointestinal hemorrhage", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7eeaa7bc-c94f-47d0-94e5-e35ccadca19e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7eeaa7bc-c94f-47d0-94e5-e35ccadca19e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7eeaa7bc-c94f-47d0-94e5-e35ccadca19e"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS Metoclopramide is contraindicated: • In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [ see Warnings and Precautions ( 5.1 , 5.2 ) ]. • When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). • In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [ see Warnings and Precautions ( 5.5 ) ]. • In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [ see Adverse Reactions ( 6 ) ]. • In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [ see Adverse Reactions ( 6 ) ]. • History of TD or dystonic reaction to metoclopramide ( 4 ) • When stimulation of gastrointestinal motility might be dangerous ( 4 ) • Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) • Epilepsy ( 4 ) • Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b53ff0f-216f-597e-8b97-c81c281d90f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e47eec7-38eb-5350-9786-deaf194ec2db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0151664", "original_object": "gastrointestinal perforation", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7eeaa7bc-c94f-47d0-94e5-e35ccadca19e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7eeaa7bc-c94f-47d0-94e5-e35ccadca19e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7eeaa7bc-c94f-47d0-94e5-e35ccadca19e"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS Metoclopramide is contraindicated: • In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [ see Warnings and Precautions ( 5.1 , 5.2 ) ]. • When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). • In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [ see Warnings and Precautions ( 5.5 ) ]. • In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [ see Adverse Reactions ( 6 ) ]. • In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [ see Adverse Reactions ( 6 ) ]. • History of TD or dystonic reaction to metoclopramide ( 4 ) • When stimulation of gastrointestinal motility might be dangerous ( 4 ) • Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) • Epilepsy ( 4 ) • Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffdb3060-e1fa-5845-84c1-24aa0e5c3f80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e47eec7-38eb-5350-9786-deaf194ec2db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0151664", "original_object": "gastrointestinal perforation", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95269b1f-779c-4ca0-9f86-e74e677f9900", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95269b1f-779c-4ca0-9f86-e74e677f9900"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS GIMOTI is contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2) ] . When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [see Adverse Reactions ( 6 )] . History of TD or dystonic reaction to metoclopramide ( 4 ) When stimulation of gastrointestinal motility might be dangerous ( 4 ) Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) Epilepsy ( 4 ) Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a036189-bb7e-5c41-96e6-16496fa9bc0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bc7cba8-1476-5323-b5da-dffa012dd0f7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0549099", "object_location_in_text": [353, 364], "original_object": "perforation", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4828095-94e0-4f71-901c-93837974c658", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4828095-94e0-4f71-901c-93837974c658", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4828095-94e0-4f71-901c-93837974c658"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS Metoclopramide tablets are contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2 )] . When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [see Adverse Reactions ( 6 )] . History of TD or dystonic reaction to metoclopramide ( 4 ) When stimulation of gastrointestinal motility might be dangerous ( 4 ) Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) Epilepsy ( 4 ) Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "condition where stimulation of gastrointestinal motility might be dangerous", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad68b766-6bb3-5a2b-934f-134797cfc476", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bc7cba8-1476-5323-b5da-dffa012dd0f7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0549099", "object_location_in_text": [348, 359], "original_object": "perforation", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:697ec7b1-945a-4a31-b585-f051dc246165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=697ec7b1-945a-4a31-b585-f051dc246165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=697ec7b1-945a-4a31-b585-f051dc246165"]}], "subject": "CHEBI:107736", "supporting_text": ["4 CONTRAINDICATIONS Metoclopramide is contraindicated: • In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2 )] . • When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). • In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . • In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . • In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [see Adverse Reactions ( 6 )] . • History of TD or dystonic reaction to metoclopramide ( 4 ) • When stimulation of gastrointestinal motility might be dangerous ( 4 ) • Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) • Epilepsy ( 4 ) • Hypersensitivity to metoclopramide ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a3e38ce-9057-5c6c-9a00-9abed0e9c5aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cccf04bd-7463-40b8-a41f-cb1093c358d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cccf04bd-7463-40b8-a41f-cb1093c358d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cccf04bd-7463-40b8-a41f-cb1093c358d7"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3894059-80d0-5a8e-b245-2a0731a64f61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ecab710-8b7d-4903-80a8-de66562be55a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ecab710-8b7d-4903-80a8-de66562be55a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ecab710-8b7d-4903-80a8-de66562be55a"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8d13e69-99cc-5810-8c51-5746af71ef74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6efdc63-a9df-4bbd-acf8-75fc9d1b0347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6efdc63-a9df-4bbd-acf8-75fc9d1b0347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6efdc63-a9df-4bbd-acf8-75fc9d1b0347"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b407773d-1c72-56bd-89e9-a18b32fd46c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f50c8fb4-23c4-4762-95bb-e4ca7b289a4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f50c8fb4-23c4-4762-95bb-e4ca7b289a4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f50c8fb4-23c4-4762-95bb-e4ca7b289a4d"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b80d8522-cf9d-5cd4-9fa5-4435258aa2a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc4a13f8-1e9b-4c75-82c0-bcd11f0a9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc4a13f8-1e9b-4c75-82c0-bcd11f0a9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc4a13f8-1e9b-4c75-82c0-bcd11f0a9a66"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c01988a-e39c-50ce-b306-b18b5935f94f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002013", "object_location_in_text": [1251, 1259], "original_object": "vomiting", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a965ee04-6969-5bc2-b0b7-5399c06d2956", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002013", "object_location_in_text": [1248, 1256], "original_object": "vomiting", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution USP is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (diabetic gastric stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e979af03-b0df-56eb-ba0c-bd4fb53e798a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002013", "object_location_in_text": [1251, 1259], "original_object": "vomiting", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:302d277d-fd65-5e11-a290-3da803b8ab31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002018", "object_location_in_text": [1240, 1246], "original_object": "nausea", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution USP is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (diabetic gastric stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46c9b2a8-1702-5f79-832c-b536b87bd216", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002018", "object_location_in_text": [1243, 1249], "original_object": "nausea", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:888ca27c-5711-5cb7-af3b-218aa09190c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002018", "object_location_in_text": [1243, 1249], "original_object": "nausea", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:921d6491-44f7-5db3-8a61-dc3ffae606af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d0a65a1-dbe6-56fb-823d-42ba6d5c915a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002039", "object_location_in_text": [1309, 1317], "original_object": "anorexia", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af0dbbe6-8fef-55b8-842a-a6f519d8f2fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d0a65a1-dbe6-56fb-823d-42ba6d5c915a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002039", "object_location_in_text": [1306, 1314], "original_object": "anorexia", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution USP is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (diabetic gastric stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfa1385d-8d60-5d87-8c89-015fac85d107", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d0a65a1-dbe6-56fb-823d-42ba6d5c915a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "HP:0002039", "object_location_in_text": [1309, 1317], "original_object": "anorexia", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radiological examination of the stomach and/or small intestine", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06e3a1b1-5308-5cbf-892c-9b7522eed895", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b8c3e60-a642-5a31-b1d1-1c3429b20490", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "MONDO:0006769", "original_object": "delayed gastric emptying", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6efdc63-a9df-4bbd-acf8-75fc9d1b0347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6efdc63-a9df-4bbd-acf8-75fc9d1b0347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6efdc63-a9df-4bbd-acf8-75fc9d1b0347"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radiological examination of the stomach and/or small intestine", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:518c2261-4f46-5426-a03d-c52e31bcade4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b8c3e60-a642-5a31-b1d1-1c3429b20490", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "MONDO:0006769", "original_object": "delayed gastric emptying", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cccf04bd-7463-40b8-a41f-cb1093c358d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cccf04bd-7463-40b8-a41f-cb1093c358d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cccf04bd-7463-40b8-a41f-cb1093c358d7"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radiological examination of the stomach and/or small intestine", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0461707-dfe8-5f55-8273-d2662465c352", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b8c3e60-a642-5a31-b1d1-1c3429b20490", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "MONDO:0006769", "original_object": "delayed gastric emptying", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ecab710-8b7d-4903-80a8-de66562be55a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ecab710-8b7d-4903-80a8-de66562be55a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ecab710-8b7d-4903-80a8-de66562be55a"]}], "subject": "CHEBI:107736", "supporting_text": ["Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults. The Prevention of Postoperative Nausea and Vomiting Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults. Small Bowel Intubation Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61e28723-684b-516f-9525-e2c19c41e578", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e822c1a9-4811-5030-8838-b625fcac7570", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0235318", "object_location_in_text": [1536, 1554], "original_object": "abdominal fullness", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cd4b274-6176-4e5b-9765-4f50763bd58f"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution USP is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (diabetic gastric stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2996b229-88b0-5e56-9a3f-cabb07e248e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:decade94-b500-5d2b-b497-cc429120eef8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0267176", "original_object": "diabetic gastroparesis", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0034a97a-fb05-418a-a234-de278907cd2a"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75938908-eff3-55be-90ec-6804083e4057", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:decade94-b500-5d2b-b497-cc429120eef8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0267176", "object_location_in_text": [264, 286], "original_object": "diabetic gastroparesis", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58b3666f-ac0f-811e-e063-6394a90a8e04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58b3666f-ac0f-811e-e063-6394a90a8e04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58b3666f-ac0f-811e-e063-6394a90a8e04"]}], "subject": "CHEBI:107736", "supporting_text": ["1 INDICATIONS AND USAGE Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 ) Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2327fe8-a001-52ae-93bb-5e255c1f0d82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:decade94-b500-5d2b-b497-cc429120eef8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0267176", "object_location_in_text": [264, 286], "original_object": "diabetic gastroparesis", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e70a1b-ac93-ff1d-e063-6394a90aa2da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e70a1b-ac93-ff1d-e063-6394a90aa2da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e70a1b-ac93-ff1d-e063-6394a90aa2da"]}], "subject": "CHEBI:107736", "supporting_text": ["1 INDICATIONS AND USAGE Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 ) Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b49b5095-fcdb-5e52-bc98-f007faf47d78", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:decade94-b500-5d2b-b497-cc429120eef8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0267176", "object_location_in_text": [264, 286], "original_object": "diabetic gastroparesis", "original_subject": "METOCLOPRAMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c143e210-4ce7-44e5-b1e2-bf0e6bfde485", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c143e210-4ce7-44e5-b1e2-bf0e6bfde485", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c143e210-4ce7-44e5-b1e2-bf0e6bfde485"]}], "subject": "CHEBI:107736", "supporting_text": ["1 INDICATIONS AND USAGE Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 ) Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267176", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de048ff4-389e-509c-8606-fd005ea984f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:decade94-b500-5d2b-b497-cc429120eef8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1611a3c7-1000-583d-b827-8e6cd304078c", "object": "UMLS:C0267176", "original_object": "diabetic gastroparesis", "original_subject": "METOCLOPRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3245f-7021-5135-e063-6394a90a7d95"]}], "subject": "CHEBI:107736", "supporting_text": ["The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "tumours without EGFR activating mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f00d3f3-826e-586c-8086-994fd3d85cde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050919", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "MONDO:0005233", "object_location_in_text": [142, 168], "original_object": "non-small cell lung cancer", "original_subject": "erlotinib", "population_context_qualifier": "patients in whom other treatment options are not considered suitable", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tarceva", "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"]}], "subject": "CHEBI:114785", "supporting_text": ["Non-small cell lung cancer (NSCLC) Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours. Pancreatic cancer Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fd683ab-3a9b-5699-bb81-1139aee78cbd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:766baa46-1916-44e8-b599-33017a4194f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=766baa46-1916-44e8-b599-33017a4194f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=766baa46-1916-44e8-b599-33017a4194f1"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen ( 1.1 ) First-line treatment of patients with locally advanced, unrespectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42fb610c-5a25-5ea9-a303-f4d30824897b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50dec2e2-0d1d-5646-a0a0-d19cd0ef93a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53cf8868-cfd8-4c6e-ad9d-3171ff1e4d8c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53cf8868-cfd8-4c6e-ad9d-3171ff1e4d8c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53cf8868-cfd8-4c6e-ad9d-3171ff1e4d8c"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen ( 1.1 ) First-line treatment of patients with locally advanced, unrespectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a5dc4eb-af4a-5e2a-b14d-3e5268ee6952", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a3b2d622-b4d5-4819-862b-f8fd3adcec6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a3b2d622-b4d5-4819-862b-f8fd3adcec6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a3b2d622-b4d5-4819-862b-f8fd3adcec6f"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "EGFR exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c6eae10-8ca6-57ee-b088-ac2f7d4ddafe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ecafc1e-979a-4aff-a276-18fc0b110491", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ecafc1e-979a-4aff-a276-18fc0b110491", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ecafc1e-979a-4aff-a276-18fc0b110491"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"], "temporal_context_qualifier": "after progression following at least one prior chemotherapy regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92e839a2-672b-51e7-b81f-17fee64b186b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccf1e415-4980-462f-8ac2-87979bda149e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccf1e415-4980-462f-8ac2-87979bda149e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccf1e415-4980-462f-8ac2-87979bda149e"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e26303b-f25b-58a0-ae11-498c16ff0de5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d97f401-4853-4a9a-907d-21e8a4d16088", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d97f401-4853-4a9a-907d-21e8a4d16088", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d97f401-4853-4a9a-907d-21e8a4d16088"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablets are a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3a1bba9-cfac-55f5-9afd-0d640a227bdd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c4c7353-b81c-4651-8aac-6d15e88145af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c4c7353-b81c-4651-8aac-6d15e88145af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c4c7353-b81c-4651-8aac-6d15e88145af"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen ( 1.1 ) First-line treatment of patients with locally advanced, unrespectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca887de4-72e9-51aa-b352-dcee00533e0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "population_context_qualifier": "patients receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e36fa076-e23b-437f-bbd2-0433ce333175", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e36fa076-e23b-437f-bbd2-0433ce333175", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e36fa076-e23b-437f-bbd2-0433ce333175"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablets are kinase inhibitors indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8344663-f64f-59d5-8289-63b20e2ae8e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fd0c2b72-59a7-565c-948d-e3abaff13b02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "ERLOTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cff04f5-3693-4d87-a9f8-a2b195e3d26e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cff04f5-3693-4d87-a9f8-a2b195e3d26e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cff04f5-3693-4d87-a9f8-a2b195e3d26e"]}], "subject": "CHEBI:114785", "supporting_text": ["1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 )"], "temporal_context_qualifier": "first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor irritation or injury of the mouth and gums, occasional sore mouth and sore throat", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:387e44b8-1432-56f6-85dd-3472db3ab6ff", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f328dc33-6e25-5fd1-91c8-426c7563abf4", "object": "HP:0012531", "object_location_in_text": [93, 97], "original_object": "pain", "original_subject": "BENZOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a1b4133-0eac-2f8f-e063-6394a90af8f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a1b4133-0eac-2f8f-e063-6394a90af8f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a1b4133-0eac-2f8f-e063-6394a90af8f6"]}], "subject": "CHEBI:116735", "supporting_text": ["Use first aid to help prevent infection in minor oral irritation for the temporary relief of pain due to minor irritation or injury of the mouth and gums occasional sore mouth and sore throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor irritation or injury of the mouth and gums, occasional sore mouth and sore throat", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c3ebc17-27eb-5d73-848c-a4d0afd1bb78", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f328dc33-6e25-5fd1-91c8-426c7563abf4", "object": "HP:0012531", "object_location_in_text": [94, 98], "original_object": "pain", "original_subject": "BENZOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a1c82b4-02b3-d456-e063-6294a90a16bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a1c82b4-02b3-d456-e063-6294a90a16bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a1c82b4-02b3-d456-e063-6294a90a16bb"]}], "subject": "CHEBI:116735", "supporting_text": ["Uses first aid to help prevent infection in minor oral irritation for the temporary relief of pain due to minor irritation or injury of the mouth and gums occasional sore mouth and sore throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "pain not manageable by non-opioid analgesics and weak opioid analgesics", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e8ba711-eee8-5a29-89ea-aaceb7797b66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7f78404b-98d6-5795-aa70-c0417864922f", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:4695ac91-a9af-558c-8feb-af0ceea1ede1", "object": "HP:0012531", "object_location_in_text": [56, 87], "original_object": "moderate to severe chronic pain", "original_subject": "FENTANYL", "population_context_qualifier": "patients who switch from an opioid analgesic", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FENTANYL#126-20131220", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:119915", "supporting_text": ["Drugs with a new additional indication for analgesia in moderate to severe chronic pain which cannot be managed by treatments with non-opioid analgesics and weak opioid analgesics (for use only in patients who switch from an opioid analgesic)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1333034", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:188705be-8504-5b1b-92bf-d89fb3adb43a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080404", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1333034"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:75831ec0-a8d5-59b7-bfa6-0bf6dd6c8e4a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4695ac91-a9af-558c-8feb-af0ceea1ede1", "object": "HP:0032149", "object_location_in_text": [44, 61], "original_object": "breakthrough pain", "original_subject": "fentanyl", "population_context_qualifier": "adults already receiving maintenance opioid therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:instanyl", "https://www.ema.europa.eu/en/documents/product-information/instanyl-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/instanyl"]}], "subject": "CHEBI:119915", "supporting_text": ["Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.  Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer."], "temporal_context_qualifier": "transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1333034", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb58f244-80dd-53ff-ad13-4d7d2ef1cfd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080404", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1333034"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:75831ec0-a8d5-59b7-bfa6-0bf6dd6c8e4a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4695ac91-a9af-558c-8feb-af0ceea1ede1", "object": "HP:0032149", "object_location_in_text": [43, 60], "original_object": "breakthrough pain", "original_subject": "fentanyl", "population_context_qualifier": "adults already receiving maintenance opioid therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pecfent", "https://www.ema.europa.eu/en/documents/product-information/pecfent-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pecfent"]}], "subject": "CHEBI:119915", "supporting_text": ["PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer."], "temporal_context_qualifier": "occurring on a background of otherwise controlled persistent pain"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0596240", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:806aef04-61bc-5a1b-bb80-a5b595a3eb08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["around-the-clock opioid therapy"], "medic_disease_context_ids": ["UMLS:C0596240"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:75831ec0-a8d5-59b7-bfa6-0bf6dd6c8e4a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4695ac91-a9af-558c-8feb-af0ceea1ede1", "object": "HP:0032149", "object_location_in_text": [43, 60], "original_object": "breakthrough pain", "original_subject": "FENTANYL", "population_context_qualifier": "cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73f38bde-2132-2b5a-e053-2a91aa0a6efb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73f38bde-2132-2b5a-e053-2a91aa0a6efb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73f38bde-2132-2b5a-e053-2a91aa0a6efb"]}], "subject": "CHEBI:119915", "supporting_text": ["LAZANDA is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking, for one week or longer, around-the-clock medicine consisting of at least: 60 mg of oral morphine per day, 25 mcg of transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid for a week or longer. Patients must remain on around-the-clock opioids when taking LAZANDA."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21f71fdd-82ab-5cad-984e-95b3528e9b0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e4f748e3-4d1b-5e03-b957-5aee989ef79c", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "VITAMIN A", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:12777", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1514815", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c816400-d4aa-5e76-b713-c8771803867a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210519", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1514815"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fe56182f-a0a3-5375-a069-7b69867c297c", "object": "MONDO:0018906", "original_object": "follicular lymphoma", "original_subject": "duvelisib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:copiktra", "https://www.ema.europa.eu/en/documents/product-information/copiktra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra"]}], "subject": "CHEBI:131169", "supporting_text": ["Copiktra monotherapy is indicated for the treatment of adult patients with:   Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies.  Follicular lymphoma (FL) that is refractory to at least two prior  systemic therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d4d6fb7-1e11-5249-bc08-5c1b7c994f6c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66fd7703-3c3a-5592-abc1-8562af59f624", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [569, 591], "original_object": "myocardial infarctions", "original_subject": "PERINDOPRILAT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90"]}], "subject": "CHEBI:132041", "supporting_text": ["1 INDICATIONS AND USAGE PRESTALIA contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension, to lower blood pressure. PRESTALIA may be used in patients whose blood pressure is not adequately controlled on monotherapy. PRESTALIA may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the ACE inhibitor class to which perindopril principally belongs. There are no controlled trials demonstrating risk reduction with PRESTALIA. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2db76f24-29e9-5ae4-8c73-377eb5f5e100", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66fd7703-3c3a-5592-abc1-8562af59f624", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [557, 564], "original_object": "strokes", "original_subject": "PERINDOPRILAT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90"]}], "subject": "CHEBI:132041", "supporting_text": ["1 INDICATIONS AND USAGE PRESTALIA contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension, to lower blood pressure. PRESTALIA may be used in patients whose blood pressure is not adequately controlled on monotherapy. PRESTALIA may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the ACE inhibitor class to which perindopril principally belongs. There are no controlled trials demonstrating risk reduction with PRESTALIA. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0280100", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53d85751-1890-52f7-9207-841070cffd36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0280100"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2d62dede-3c29-5c9d-9736-0b91732f3ab9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:aa96c6d3-b731-55ef-a76e-dde0401ae90f", "object": "UMLS:C0235280", "object_location_in_text": [45, 56], "original_object": "ototoxicity", "original_subject": "sodium thiosulfate", "population_context_qualifier": "patients 1 month to < 18 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pedmarqsi", "https://www.ema.europa.eu/en/documents/product-information/pedmarqsi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pedmarqsi"]}], "subject": "CHEBI:132112", "supporting_text": ["Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to &lt; 18 years of age with localised, non-metastatic, solid tumours."], "temporal_context_qualifier": "induced by cisplatin chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2984891", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7aed685a-a7a8-54f6-b32c-97033585b596", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190402", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2984891"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:15a1884b-7de2-5258-9ce3-13e01e342bbc", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ac9853d5-d3ca-5755-97ea-eb18eb7dba02", "object": "MONDO:0011282", "object_location_in_text": [122, 148], "original_object": "non small cell lung cancer", "original_subject": "dacomitinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vizimpro", "https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro"]}], "subject": "CHEBI:132268", "supporting_text": ["Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a995e12-7895-5c35-aeeb-aa7f1fc1831c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180927", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac9853d5-d3ca-5755-97ea-eb18eb7dba02", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "DACOMITINIB", "population_context_qualifier": "patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ab27d2f-e385-4e9c-b324-fa69c10b855a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ab27d2f-e385-4e9c-b324-fa69c10b855a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ab27d2f-e385-4e9c-b324-fa69c10b855a"]}], "subject": "CHEBI:132268", "supporting_text": ["1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "decompensated cirrhosis type C", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fda6822-1e26-5e4b-ac12-4e7755206880", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190108", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:8f14421e-67ac-50bb-8b40-92a682ccde1f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b8b2fac4-770d-54fa-bc18-350f3dd35488", "object": "HP:0020071", "object_location_in_text": [84, 91], "original_object": "viremia", "original_subject": "VELPATASVIR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VELPATASVIR#79-20190108", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:133009", "supporting_text": ["A new combination drug with a new active ingredient indicated for: - Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. - Improvement of viremia in patients with decompensated cirrhosis type C. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1608426", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bf2ceb5-f0f1-53ec-b0ec-1e737b3f5591", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_disease_context_ids": ["UMLS:C1608426", "UMLS:C1619727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56371fc3-abc1-549c-b9cf-f4a5d977e47c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8b2fac4-770d-54fa-bc18-350f3dd35488", "object": "MONDO:0005354", "original_object": "chronic hepatitis C virus infection", "original_subject": "VELPATASVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f30631a-ee3b-4cfe-866b-964df3f0a44f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f"]}], "subject": "CHEBI:133009", "supporting_text": ["1 INDICATIONS AND USAGE EPCLUSA is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1608426", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3b52f7f-3e29-5f4c-bdbc-a197095de683", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_disease_context_ids": ["UMLS:C1608426", "UMLS:C1619727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56371fc3-abc1-549c-b9cf-f4a5d977e47c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8b2fac4-770d-54fa-bc18-350f3dd35488", "object": "MONDO:0005354", "original_object": "chronic hepatitis C virus infection", "original_subject": "VELPATASVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0c1a945-4440-4b5c-81aa-693ed3db597c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0c1a945-4440-4b5c-81aa-693ed3db597c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0c1a945-4440-4b5c-81aa-693ed3db597c"]}], "subject": "CHEBI:133009", "supporting_text": ["1 INDICATIONS AND USAGE Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4 ) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. Sofosbuvir and velpatasvir is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3805119", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4fac3393-0ef1-51e2-923e-e67597a6c4d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160429", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3805119"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6f13e1a4-0a54-5648-be23-587af63b98f6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:51305727-435d-57c9-b9c4-affcfc10ecc7", "object": "HP:0000738", "object_location_in_text": [69, 83], "original_object": "hallucinations", "original_subject": "PIMAVANSERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e6bea44-57d6-4bac-9328-46e1ee59f83b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b"]}], "subject": "CHEBI:133017", "supporting_text": ["1 INDICATIONS AND USAGE NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] . NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3805119", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d825b75b-f8e5-5228-afc9-70ec9feea3b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160429", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3805119"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6f13e1a4-0a54-5648-be23-587af63b98f6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:51305727-435d-57c9-b9c4-affcfc10ecc7", "object": "HP:0000738", "object_location_in_text": [79, 93], "original_object": "hallucinations", "original_subject": "PIMAVANSERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:403b6540-c53d-4e92-91b4-36ca6338b2b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=403b6540-c53d-4e92-91b4-36ca6338b2b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=403b6540-c53d-4e92-91b4-36ca6338b2b1"]}], "subject": "CHEBI:133017", "supporting_text": ["1 INDICATIONS AND USAGE Pimavanserin capsule is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis [see Clinical Studies (14) ]. Pimavanserin capsule is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3805119", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d556068c-9254-50f8-ab06-eacb05c9d699", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160429", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3805119"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fabf07ea-a9ba-5d1e-80a6-ef09640a21e9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:51305727-435d-57c9-b9c4-affcfc10ecc7", "object": "HP:0000746", "object_location_in_text": [88, 97], "original_object": "delusions", "original_subject": "PIMAVANSERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e6bea44-57d6-4bac-9328-46e1ee59f83b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b"]}], "subject": "CHEBI:133017", "supporting_text": ["1 INDICATIONS AND USAGE NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] . NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3805119", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8f4f2e1-8279-596b-af15-f174cd942f6d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160429", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3805119"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fabf07ea-a9ba-5d1e-80a6-ef09640a21e9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:51305727-435d-57c9-b9c4-affcfc10ecc7", "object": "HP:0000746", "object_location_in_text": [98, 107], "original_object": "delusions", "original_subject": "PIMAVANSERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:403b6540-c53d-4e92-91b4-36ca6338b2b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=403b6540-c53d-4e92-91b4-36ca6338b2b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=403b6540-c53d-4e92-91b4-36ca6338b2b1"]}], "subject": "CHEBI:133017", "supporting_text": ["1 INDICATIONS AND USAGE Pimavanserin capsule is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis [see Clinical Studies (14) ]. Pimavanserin capsule is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "bowel contents labelling", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c71dfc1-2f97-57fc-bc88-66d64dcbd52a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160328", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:cac39c59-124a-50ba-b816-72d3239ca60d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:d3fd912d-3ade-5edb-9610-44728ac13818", "object": "UMLS:C0935912", "object_location_in_text": [104, 137], "original_object": "computed tomographic colonography", "original_subject": "BARIUM SULFATE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BARIUM SULFATE#110-20160328", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:133326", "supporting_text": ["A drug with a new indication and a new dosage in an additional dosage form indicated for the support of computed tomographic colonography with labelling of bowel contents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002524", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c96fa560-ef27-567d-9701-f24de921dd05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160331", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002524"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2a723c15-9172-5015-a27a-e933a18fbcbf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1d0599df-f3c8-5c60-9ee8-db1f3c379cf2", "object": "MONDO:0021107", "object_location_in_text": [100, 110], "original_object": "narcolepsy", "original_subject": "pitolisant", "population_context_qualifier": "adults, adolescents and children from the age of 6 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:wakix", "https://www.ema.europa.eu/en/documents/product-information/wakix-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/wakix"]}], "subject": "CHEBI:134709", "supporting_text": ["Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f002f93-685c-57ca-a6a0-27f4ab0f3c90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [450, 475], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:998db1e1-3f32-4812-a64b-5a6870ef7f8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=998db1e1-3f32-4812-a64b-5a6870ef7f8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=998db1e1-3f32-4812-a64b-5a6870ef7f8f"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4732d143-e720-5bd9-be00-a16f09ccf31a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [448, 473], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46154d5f-7de1-db5e-e063-6394a90af86e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46154d5f-7de1-db5e-e063-6394a90af86e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46154d5f-7de1-db5e-e063-6394a90af86e"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablet is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduce NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablet is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e3ee141-b183-554a-a8ad-957b21d79125", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [444, 469], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d85015d5-f619-4a58-b6ab-5e39af3f79d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d85015d5-f619-4a58-b6ab-5e39af3f79d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d85015d5-f619-4a58-b6ab-5e39af3f79d8"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:753fa38e-2aa0-5504-960e-77f57360297d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [369, 394], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c39c326-34a2-b7f4-e063-6294a90a6732", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c39c326-34a2-b7f4-e063-6294a90a6732", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c39c326-34a2-b7f4-e063-6294a90a6732"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. Left ventricular ejection fraction (LVEF) is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c2a9037-723b-5732-a515-b3dc5ff57246", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [445, 470], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43bcdbc7-a635-bb4e-e063-6294a90a990f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43bcdbc7-a635-bb4e-e063-6294a90a990f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43bcdbc7-a635-bb4e-e063-6294a90a990f"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, and are indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:885ad95e-8ccb-511d-a547-6b9d2cfa271b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:487102e3-f319-836b-e063-6394a90a4438", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=487102e3-f319-836b-e063-6394a90a4438", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487102e3-f319-836b-e063-6394a90a4438"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and Valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3c78aa8-7781-577e-8909-419d9883e0b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4870fbeb-ce93-7953-e063-6294a90a6142", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4870fbeb-ce93-7953-e063-6294a90a6142", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4870fbeb-ce93-7953-e063-6294a90a6142"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and Valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a813f3ce-56d0-5a4d-9e8e-8d01d4d7aef2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [446, 471], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1fa7066-8ab4-47e3-a701-6c5170700d11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1fa7066-8ab4-47e3-a701-6c5170700d11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1fa7066-8ab4-47e3-a701-6c5170700d11"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS &amp; USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and are expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and are expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac9827c4-24fe-5144-98ec-d53921298c97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [448, 473], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8290ae4c-0d1e-47f6-8029-ddc1c0bd6f6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8290ae4c-0d1e-47f6-8029-ddc1c0bd6f6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8290ae4c-0d1e-47f6-8029-ddc1c0bd6f6d"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablet is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduce NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablet is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6092be5-8274-5f85-891d-c3224d24e312", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [369, 394], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4134afd2-a0a0-a64a-e063-6394a90ae580", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4134afd2-a0a0-a64a-e063-6394a90ae580", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4134afd2-a0a0-a64a-e063-6394a90ae580"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. Left ventricular ejection fraction (LVEF) is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd550226-4de6-5d8b-ae4e-c316826d65b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [446, 471], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59b7a07a-96ee-44b1-8dae-2b42169aa2c5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59b7a07a-96ee-44b1-8dae-2b42169aa2c5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59b7a07a-96ee-44b1-8dae-2b42169aa2c5"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d098b438-675c-5e61-a667-45a477868082", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [446, 471], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3173e592-6f28-4864-9bf0-0ef0452da3de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3173e592-6f28-4864-9bf0-0ef0452da3de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3173e592-6f28-4864-9bf0-0ef0452da3de"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d96cb169-3824-561b-a8d9-d7302092b72a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:064a7c51-de30-4759-8210-e18438e6a187", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=064a7c51-de30-4759-8210-e18438e6a187", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=064a7c51-de30-4759-8210-e18438e6a187"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e778a738-cc14-5ce5-9b88-7f665a2cfab3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [369, 394], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4114a976-2e58-8437-e063-6394a90af298", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4114a976-2e58-8437-e063-6394a90af298", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4114a976-2e58-8437-e063-6394a90af298"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. Left ventricular ejection fraction (LVEF) is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fac5501e-6bd6-5522-8a8c-2c59632801e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48714b95-b4ac-ef3c-e063-6294a90a9a5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48714b95-b4ac-ef3c-e063-6294a90a9a5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48714b95-b4ac-ef3c-e063-6294a90a9a5b"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and Valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:feb9bdb7-7710-50f5-856c-df9838e9817f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150707", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f64b369-d50c-54cf-b16f-09bf349d1c49", "object": "MONDO:0005254", "object_location_in_text": [444, 469], "original_object": "symptomatic heart failure", "original_subject": "SACUBITRIL", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f88efbb-3718-43a1-91d4-da5943ccfca1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f88efbb-3718-43a1-91d4-da5943ccfca1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f88efbb-3718-43a1-91d4-da5943ccfca1"]}], "subject": "CHEBI:134714", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665464", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:340c87e8-d899-581c-b311-826bbb11a3df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150710", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665464"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5f52d329-c1c2-563a-a88d-77435d0db00b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7d4b2a3c-2b65-5372-b757-7fd1e3ddde5e", "object": "HP:0000713", "object_location_in_text": [233, 242], "original_object": "agitation", "original_subject": "BREXPIPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df891816-3fdb-4347-8bf0-c18bc40f1d70", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df891816-3fdb-4347-8bf0-c18bc40f1d70", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df891816-3fdb-4347-8bf0-c18bc40f1d70"]}], "subject": "CHEBI:134716", "supporting_text": ["1 INDICATIONS AND USAGE REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665464", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:781b2322-9d04-5177-bc67-31fbfcd9ddeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150710", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665464"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5f52d329-c1c2-563a-a88d-77435d0db00b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7d4b2a3c-2b65-5372-b757-7fd1e3ddde5e", "object": "HP:0000713", "object_location_in_text": [233, 242], "original_object": "agitation", "original_subject": "BREXPIPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d301358-6291-4ec1-bd87-37b4ad9bd850", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850"]}], "subject": "CHEBI:134716", "supporting_text": ["1 INDICATIONS AND USAGE REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665464", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae77234b-64f3-597c-8eb6-beec23b99ad8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150710", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665464"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5f52d329-c1c2-563a-a88d-77435d0db00b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7d4b2a3c-2b65-5372-b757-7fd1e3ddde5e", "object": "HP:0000713", "object_location_in_text": [233, 242], "original_object": "agitation", "original_subject": "BREXPIPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6991c065-0f6e-433a-8f4f-796e0ece327f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6991c065-0f6e-433a-8f4f-796e0ece327f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6991c065-0f6e-433a-8f4f-796e0ece327f"]}], "subject": "CHEBI:134716", "supporting_text": ["1 INDICATIONS AND USAGE REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0085394", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e76db72-8c51-53bb-b11c-163b6a3f0914", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085394", "UMLS:C0348321"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ed957e52-4167-5f6b-a754-f715601f31d8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bd55cd2e-f208-5b2a-a558-36cc31df68ca", "object": "HP:0100806", "object_location_in_text": [77, 83], "original_object": "sepsis", "original_subject": "CEFTOLOZANE SULFATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CEFTOLOZANE SULFATE#71-20191220", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:134719", "supporting_text": ["A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0085394", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f531d236-8c09-56c9-874a-35d76768a3f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085394", "UMLS:C0348321"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bd55cd2e-f208-5b2a-a558-36cc31df68ca", "object": "MONDO:0005249", "object_location_in_text": [88, 97], "original_object": "pneumonia", "original_subject": "CEFTOLOZANE SULFATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CEFTOLOZANE SULFATE#71-20191220", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:134719", "supporting_text": ["A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "delamanid-sensitive Mycobacterium tuberculosis infection", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07c8bcaf-3ef4-5ef0-a4ce-5960786c7b12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140704", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9d43ec1f-7930-527b-a2d5-5af39f42e441", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:9bfbfefb-4fa6-5ab6-8acb-6dbe3ba43189", "object": "UMLS:C4523850", "object_location_in_text": [67, 109], "original_object": "multidrug-resistant pulmonary tuberculosis", "original_subject": "DELAMANID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DELAMANID#116-20140704", "https://www.pmda.go.jp/files/000209024.pdf"]}], "subject": "CHEBI:134742", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of multidrug-resistant pulmonary tuberculosis caused by delamanid-sensitive Mycobacterium tuberculosis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b])", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:931ec15f-d5a0-56c0-ae32-36a693e73756", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d7dd67bb-5f9a-5160-8ae6-50a6ed8b1d70", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:60ed830a-9bf8-569d-af1c-3ccdddd0cc50", "object": "UMLS:C0042749", "object_location_in_text": [69, 77], "original_object": "viraemia", "original_subject": "SIMEPREVIR SODIUM", "population_context_qualifier": "patients with high level of blood HCV RNA who have untreated chronic hepatitis C serogroup 1 or patients who have not responded to or relapsed with treatment including interferon", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SIMEPREVIR SODIUM#127-20130927", "https://www.pmda.go.jp/files/000227565.pdf"]}], "subject": "CHEBI:134743", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of viraemia in following (1) or (2) patient with chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b]): (1) Patient with high level of blood HCV RNA who have untreated or (2) Patients who have not respond to or relapsed with the treatment including interferon. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b])", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc131002-64de-5947-b7eb-701baaf10ce2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130927", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:60ed830a-9bf8-569d-af1c-3ccdddd0cc50", "object": "MONDO:0005354", "object_location_in_text": [115, 134], "original_object": "chronic hepatitis C", "original_subject": "SIMEPREVIR SODIUM", "population_context_qualifier": "patients with high level of blood HCV RNA who have untreated chronic hepatitis C serogroup 1 or patients who have not responded to or relapsed with treatment including interferon", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SIMEPREVIR SODIUM#127-20130927", "https://www.pmda.go.jp/files/000227565.pdf"]}], "subject": "CHEBI:134743", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of viraemia in following (1) or (2) patient with chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b]): (1) Patient with high level of blood HCV RNA who have untreated or (2) Patients who have not respond to or relapsed with the treatment including interferon. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d0537d6-7aec-5b75-9807-5586648bb571", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66575830-f501-5162-93d1-5f26ed6cd2a4", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTINOXATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:134750", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bdf9f9b-dae9-5da5-adc5-ad10f9dd7efc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66575830-f501-5162-93d1-5f26ed6cd2a4", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTINOXATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:134750", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad2ac4f2-806f-52ad-a509-02f9b252bfd6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66575830-f501-5162-93d1-5f26ed6cd2a4", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTINOXATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b"]}], "subject": "CHEBI:134750", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:128d94bd-26e5-5622-b7ee-59298f065673", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66575830-f501-5162-93d1-5f26ed6cd2a4", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTINOXATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:134750", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d952681-cbe3-5fde-87df-4bd063472862", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66575830-f501-5162-93d1-5f26ed6cd2a4", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTINOXATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b"]}], "subject": "CHEBI:134750", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f8b11f6-57b4-5b1a-b2c9-11b3e0f2dbc1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66575830-f501-5162-93d1-5f26ed6cd2a4", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTINOXATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:134750", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e606f0a-01ae-5f8c-8e7f-77241907cc20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35fa2a5d-339a-5fb2-8a37-7076d0e022a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:362c762e-35bf-5e80-a97b-1db130f5d85c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:214232df-7b53-5523-a118-0c154059ddc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a5a35be-9e24-18dd-e063-6394a90a097f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a5a35be-9e24-18dd-e063-6394a90a097f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a5a35be-9e24-18dd-e063-6394a90a097f"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58e69941-5623-5b6c-a465-7df107a0e6cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses  Helps prevent sunburn.  If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62215fe0-f917-5802-941b-a360e58f595c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:770d8dfb-2764-5cf1-ad42-37d3fa66bda3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d079fee-46c9-584f-894b-edf1c4ebd760", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc068c74-e4a5-540e-80fa-76084009052f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses • helps prevent sunburn • if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8ca529c-5897-5537-bada-3a87341db494", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffa2297f-131e-5836-ba65-a09011a41968", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c869e2d-48ed-5237-9a51-155fac8cf915", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "AVOBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5de9ca1a-3026-258c-e063-6394a90a1c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5de9ca1a-3026-258c-e063-6394a90a1c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5de9ca1a-3026-258c-e063-6394a90a1c1a"]}], "subject": "CHEBI:134751", "supporting_text": ["Uses • Helps prevent sunburn • If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "psychosomatic manifestations", "has_confidence_score": 0.2315, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f707c8a5-38c3-5abe-9b2e-575bbfc98b9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240321", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.2315, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:dc4bfd42-1867-51f0-bd1d-a111a7dde256", "object": "MONDO:0011918", "object_location_in_text": [46, 53], "original_object": "anxiety", "original_subject": "Etifoxine Hydrochloride Bulk drug & Etifoxine Hydrochloride capsules 50 mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135272", "supporting_text": ["Indicated for psychosomatic manifestations of anxiety"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1299393", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abda7363-631b-51c5-bb04-6208ed9a0b0c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060215", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1299393"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a79ca0bd-b165-5d21-a43d-4f05390af036", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0a1fd4ea-3fb0-5d09-b592-b975eebea4a3", "object": "MONDO:0005391", "original_object": "restless-legs syndrome", "original_subject": "rotigotine", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:neupro", "https://www.ema.europa.eu/en/documents/product-information/neupro-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/neupro"]}], "subject": "CHEBI:135351", "supporting_text": ["Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations). Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Note: text states product \"may be less effective\" in this population", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51581086-ae93-58fc-88de-a8e228305d69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0aec8381-12f4-5eaf-b995-31ffac0d3b0b", "object": "UMLS:C0032961", "object_location_in_text": [115, 124], "original_object": "pregnancy", "original_subject": "NORELGESTROMIN", "population_context_qualifier": "women at or above 198 lbs (90 kg)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36445b6a-e0f2-42f7-a8f3-5b80c90b87dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36445b6a-e0f2-42f7-a8f3-5b80c90b87dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36445b6a-e0f2-42f7-a8f3-5b80c90b87dd"]}], "subject": "CHEBI:135398", "supporting_text": ["1 INDICATIONS AND USAGE Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) &lt; 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "progression during or within six months of treatment with rituximab or a rituximab-containing regimen", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2383c23d-e00d-5ca1-a56a-85b01c66b0b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080320", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab", "rituximab-containing regimen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ca4cc74-37c1-5684-8a52-9443d777e093", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ea62a3c-023d-56c2-bf6a-b40f0150b90c", "object": "MONDO:0017594", "object_location_in_text": [719, 755], "original_object": "indolent B-cell non-Hodgkin lymphoma", "original_subject": "BENDAMUSTINE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:353fdf70-2720-41d3-a6fc-7baf0d793282", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=353fdf70-2720-41d3-a6fc-7baf0d793282", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=353fdf70-2720-41d3-a6fc-7baf0d793282"]}], "subject": "CHEBI:135515", "supporting_text": ["1 INDICATIONS AND USAGE GOBARDEN is an alkylating drug indicated for treatment of adult patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) GOBARDEN is indicated for the treatment of adult patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) GOBARDEN is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1335499", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd4df37e-08d1-5ebe-8af0-8472c368076d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080320", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab", "rituximab-containing regimen"], "medic_disease_context_ids": ["UMLS:C1335499"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ca4cc74-37c1-5684-8a52-9443d777e093", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ea62a3c-023d-56c2-bf6a-b40f0150b90c", "object": "MONDO:0017594", "object_location_in_text": [700, 736], "original_object": "indolent B-cell non-Hodgkin lymphoma", "original_subject": "BENDAMUSTINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39d53698-57fa-7c99-fc5b-f52a55684826", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39d53698-57fa-7c99-fc5b-f52a55684826", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d53698-57fa-7c99-fc5b-f52a55684826"]}], "subject": "CHEBI:135515", "supporting_text": ["1 INDICATIONS AND USAGE TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) TREANDA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen."], "temporal_context_qualifier": "during or within six months of treatment with rituximab or a rituximab-containing regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "progression during or within six months of treatment with rituximab or a rituximab-containing regimen", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf2d02c4-8914-5e6b-9833-c984d39e3b06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080320", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab", "rituximab-containing regimen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ca4cc74-37c1-5684-8a52-9443d777e093", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ea62a3c-023d-56c2-bf6a-b40f0150b90c", "object": "MONDO:0017594", "object_location_in_text": [710, 746], "original_object": "indolent B-cell non-Hodgkin lymphoma", "original_subject": "BENDAMUSTINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ace9a43b-f9bd-4896-abfe-0ef4fec67ddf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf"]}], "subject": "CHEBI:135515", "supporting_text": ["1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a0fc7f2-0aad-52b9-93d7-5e104da5d5bf", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77f0a07d-d674-5801-b148-de1e88690f96", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4ca3fce-42c2-5420-adfb-27f89267436f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21dfeac8-ba15-56c1-a516-18a793a4cdfd", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ba475f3-ca57-5f57-887c-69d7e3ff0b13", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4305475c-85ec-5552-bddf-88c2a0195377", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses • helps prevent sunburn • if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54cc5a71-86d7-597f-b15f-c8164675b2aa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ee44cfd-6b88-5dc8-bfb2-60eaa12d45ea", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a5a35be-9e24-18dd-e063-6394a90a097f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a5a35be-9e24-18dd-e063-6394a90a097f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a5a35be-9e24-18dd-e063-6394a90a097f"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ac001be-c8ba-51ab-a645-14c98ac96609", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses  Helps prevent sunburn.  If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86f47583-83d6-5b01-806b-03e8e078f3d7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9774c157-6988-5015-8ce5-962660eb737c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c8086c0-71a2-5714-a60d-45458a62b499", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "OCTOCRYLENE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5de9ca1a-3026-258c-e063-6394a90a1c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5de9ca1a-3026-258c-e063-6394a90a1c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5de9ca1a-3026-258c-e063-6394a90a1c1a"]}], "subject": "CHEBI:135526", "supporting_text": ["Uses • Helps prevent sunburn • If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fd3c75a-dc9d-58a0-ac8e-85466c060627", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2462e9a4-66a7-4340-9a81-617f3417b495", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2462e9a4-66a7-4340-9a81-617f3417b495", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2462e9a4-66a7-4340-9a81-617f3417b495"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:364631e2-4569-574a-ad7d-27aa976336a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:663d992d-23cc-4a8e-acd5-a4bea505ba3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=663d992d-23cc-4a8e-acd5-a4bea505ba3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=663d992d-23cc-4a8e-acd5-a4bea505ba3a"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83c02ef4-01ec-5592-adb1-b54a2ec5096b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dadb9462-953e-4319-b9f8-5b7255d1cf9c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dadb9462-953e-4319-b9f8-5b7255d1cf9c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dadb9462-953e-4319-b9f8-5b7255d1cf9c"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a45559d9-08a6-516d-a492-b8066e205618", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0b8f111-1d76-4b04-9e2f-9fca9e5a0b00"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7ba5708-6ed8-5665-b464-97ef0a459fba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97d8a21e-4618-460f-8cf5-97a9d946039e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97d8a21e-4618-460f-8cf5-97a9d946039e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97d8a21e-4618-460f-8cf5-97a9d946039e"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c033b560-2262-5311-ae97-48d4eb25fcc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [101, 119], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d96b386-febf-a510-a896-033e832c8f30", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d96b386-febf-a510-a896-033e832c8f30", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d96b386-febf-a510-a896-033e832c8f30"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS AND USAGE Solifenacin Succinate Tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddba274c-53bf-5d25-a4cc-b8a5da03b720", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3788df43-42dd-4778-8289-e32b5844358e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3788df43-42dd-4778-8289-e32b5844358e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3788df43-42dd-4778-8289-e32b5844358e"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df967743-f496-537b-8723-400be63bf29a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dfc5d69-8f35-4f57-90b7-46a5f0f0febe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dfc5d69-8f35-4f57-90b7-46a5f0f0febe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dfc5d69-8f35-4f57-90b7-46a5f0f0febe"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5c545c5-72d2-5465-a56d-c8445211bd4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d65dcb9-aa67-4cfb-9d15-43d0de327bd7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d65dcb9-aa67-4cfb-9d15-43d0de327bd7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d65dcb9-aa67-4cfb-9d15-43d0de327bd7"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffdcc194-7387-5fad-886c-5f49c5bc19ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041119", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:783653f2-7b21-5fa5-9ea1-30d9e5ca02e6", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "SOLIFENACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e04812c2-2ff7-4dff-9122-518c18f4935e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e04812c2-2ff7-4dff-9122-518c18f4935e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e04812c2-2ff7-4dff-9122-518c18f4935e"]}], "subject": "CHEBI:135530", "supporting_text": ["1 INDICATIONS &amp; USAGE Solifenacin succinate tablets is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002099", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3739bcc-89d0-534f-ac51-d5eb345a1e35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002099", "MONDO:0005607"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0ab300e9-3dd8-59ef-b7a3-70632e9d8b63", "object": "MONDO:0001358", "object_location_in_text": [30, 42], "original_object": "bronchospasm", "original_subject": "Ambroxol 30mg + Levo salbutamol 1mg+ Guiphenesin 50mg /5ml syrup", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135590", "supporting_text": ["For the symptomatic relief of bronchospasm in bronchial asthma & chronic bronchitis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0421207", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54436895-e242-5b30-908e-2c1e2cea01af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19810101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0421207"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:447349ad-d177-5c11-8f35-0ee6d0b71ac8", "object": "MONDO:0003781", "object_location_in_text": [120, 130], "original_object": "bronchitis", "original_subject": "Reproterol Hydrochloride", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135612", "supporting_text": ["Bronchodilator- Indicated in the treatment of conditions involving reversible airways obstruction viz bronchial asthma, bronchitis etc."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0421207", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d744040b-dcab-5222-9b94-b65e6fcef35b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19810101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0421207"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:622b5bbc-9b53-5f84-81e2-4e499dfc0011", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:447349ad-d177-5c11-8f35-0ee6d0b71ac8", "object": "MONDO:0004979", "object_location_in_text": [102, 118], "original_object": "bronchial asthma", "original_subject": "Reproterol Hydrochloride", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135612", "supporting_text": ["Bronchodilator- Indicated in the treatment of conditions involving reversible airways obstruction viz bronchial asthma, bronchitis etc."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0037763", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22e392f0-1ba9-5fcb-b2de-24597a4ddad2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037763"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:cb509227-5a5c-57d0-b702-11204b1bd8ac", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d6aede8c-5809-5ac5-bb65-4cf1a709a78b", "object": "UMLS:C0231528", "object_location_in_text": [41, 54], "original_object": "muscular pain", "original_subject": "Drotaverine + Aceclofenac (80mg + 100mg) Tablets", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135630", "supporting_text": ["For the treatment of adult patients with muscular pain associated with spasm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-infected corticosteroid responsive dermatoses", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3d189e0-c94f-5103-ad4a-be274c327df5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:c6da2f81-74f0-5a99-a38f-88e03f40d062", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ea77775d-01a2-5d1a-a8bc-75ed8cfdac8c", "object": "MONDO:0004980", "object_location_in_text": [117, 123], "original_object": "eczema", "original_subject": "Halometasone (as monohydrate ) 0.05% Cream", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135724", "supporting_text": ["For the relief of inflammatory and pruritic manifestation of non- infected corticosteroid responsive dermatoses like eczema"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0149518", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:517f7645-9f11-5e35-b1d1-13238c3bebec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149518"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d8a53dd9-3530-5154-98a7-c300d090f2e5", "object": "MONDO:0001126", "object_location_in_text": [21, 34], "original_object": "gastric ulcer", "original_subject": "Sofalcone Capsule (100mg/50mg)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135732", "supporting_text": ["For the treatment of gastric ulcer and management of gastric mucosal lesions (erosion, hemorrhage, redness or edema) associated with acute gastritis or acute exacerbation of chronic gastritis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0149518", "has_confidence_score": 0.48, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bfa9c379-f8e5-5d0d-bfa0-6af74baa85f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149518"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:dc1c322e-ca4f-5a52-8819-5200128cf48b", "medic_pair_confidence": 0.48, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d8a53dd9-3530-5154-98a7-c300d090f2e5", "object": "UMLS:C0854441", "original_object": "gastric mucosal lesions", "original_subject": "Sofalcone Capsule (100mg/50mg)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135732", "supporting_text": ["For the treatment of gastric ulcer and management of gastric mucosal lesions (erosion, hemorrhage, redness or edema) associated with acute gastritis or acute exacerbation of chronic gastritis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0006147", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96ade25d-af99-50e9-8626-5ecdfd878843", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180720", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006147"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4d0bcf7d-c232-5bbb-a94d-396a0047a17e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73a35724-7755-5d5a-8bf7-b2b5e8e4e0b1", "object": "MONDO:0005775", "original_object": "G6PD deficiency", "original_subject": "TAFENOQUINE", "population_context_qualifier": "infants", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:299e49d8-470f-4779-a010-4a1ee0e0c6cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=299e49d8-470f-4779-a010-4a1ee0e0c6cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=299e49d8-470f-4779-a010-4a1ee0e0c6cd"]}], "subject": "CHEBI:135752", "supporting_text": ["4 CONTRAINDICATIONS ARAKODA is contraindicated in: • patients with G6PD deficiency or unknown G6PD status due to the risk of hemolytic anemia [see Warnings and Precautions ( 5.2 )] . • breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if the G6PD status of the infant is unknown [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.2 )] . • patients with a history of psychotic disorders or current psychotic symptoms (i.e., hallucinations, delusions, and/or grossly disorganized behavior) [see Warnings and Precautions ( 5.4 )] • patients with known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA [see Warnings and Precautions ( 5.5 )] . • G6PD deficiency or unknown G6PD status ( 4 ) • Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown ( 4 , 8.2 ) • Patients with a history of psychotic disorders or current psychotic symptoms ( 4 , 5.4 ) • Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "low cardiac function", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c277b99d-2264-57f7-aec9-2cdc5ae73115", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220824", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d5e6f9d2-6e77-554f-a351-e424becfa00e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "HP:0004755", "object_location_in_text": [156, 184], "original_object": "supraventricular tachycardia", "original_subject": "LANDIOLOL HYDROCHLORIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#33-20220824", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["Drugs with a new indication and a new additional pediatric dosage for the treatment of the following tachyarrhythmia in patients with low cardiac function: supraventricular tachycardia, atrial fibrillation, and atrial flutter."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0100806", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7b763f4-7790-5641-b25f-f71a39817351", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200629", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100806"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:6e2673ff-8b10-5f6b-93dc-0a5a212f6d2d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "HP:0011703", "object_location_in_text": [157, 174], "original_object": "sinus tachycardia", "original_subject": "LANDIOLOL HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#56-20200629", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of the following tachyarrhythmia associated with sepsis: atrial fibrillation, atrial flutter, sinus tachycardia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "low cardiac function", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d594e81-7bd6-5a13-bc0d-cb03fa26cf8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220824", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "MONDO:0004981", "object_location_in_text": [186, 205], "original_object": "atrial fibrillation", "original_subject": "LANDIOLOL HYDROCHLORIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#33-20220824", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["Drugs with a new indication and a new additional pediatric dosage for the treatment of the following tachyarrhythmia in patients with low cardiac function: supraventricular tachycardia, atrial fibrillation, and atrial flutter."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0100806", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c118f05-d386-5b48-a288-8586f5d4dc2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200629", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100806"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "MONDO:0004981", "object_location_in_text": [120, 139], "original_object": "atrial fibrillation", "original_subject": "LANDIOLOL HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#56-20200629", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of the following tachyarrhythmia associated with sepsis: atrial fibrillation, atrial flutter, sinus tachycardia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0100806", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43acb8bf-43a0-53d9-9fb0-1e0737d4ad87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200629", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100806"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:25371315-92a9-537e-9f9c-83a38de62d5a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "MONDO:0005310", "object_location_in_text": [141, 155], "original_object": "atrial flutter", "original_subject": "LANDIOLOL HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#56-20200629", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of the following tachyarrhythmia associated with sepsis: atrial fibrillation, atrial flutter, sinus tachycardia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "low cardiac function", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb056bdf-12b8-5b41-9745-6a44ffa2080d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220824", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:25371315-92a9-537e-9f9c-83a38de62d5a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "MONDO:0005310", "object_location_in_text": [211, 225], "original_object": "atrial flutter", "original_subject": "LANDIOLOL HYDROCHLORIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#33-20220824", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["Drugs with a new indication and a new additional pediatric dosage for the treatment of the following tachyarrhythmia in patients with low cardiac function: supraventricular tachycardia, atrial fibrillation, and atrial flutter."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "low cardiac function", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:913bad36-aff9-5e7c-a6c2-20a9ac45491b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131122", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:93a90f4f-d782-57ba-b7aa-59943ea61b5d", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f746a7c-4e9d-5716-a35d-a3043714baf9", "object": "UMLS:C0080203", "object_location_in_text": [78, 93], "original_object": "tachyarrhythmia", "original_subject": "LANDIOLOL HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANDIOLOL HYDROCHLORIDE#124-20131122", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:135809", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3161650", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:947e208c-0049-5a2e-b8ec-673d4853c59e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250402", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C3161650"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b92669c6-1a55-5a06-85d7-4b8291589e19", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b14378f-5f0d-5db5-a53d-d0eb013eb03d", "object": "MONDO:0003634", "object_location_in_text": [56, 67], "original_object": "proteinuria", "original_subject": "ATRASENTAN", "population_context_qualifier": "adults at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a7e7f85-bfd0-44a0-beda-3bcfa8215c64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a7e7f85-bfd0-44a0-beda-3bcfa8215c64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a7e7f85-bfd0-44a0-beda-3bcfa8215c64"]}], "subject": "CHEBI:135810", "supporting_text": ["1 INDICATIONS AND USAGE VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. VANRAFIA is an endothelin receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1 ) This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "local persistence after chemoradiotherapy or radiotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53e143a5-1d18-58e0-b52d-4ca4615209d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3746ba14-2bc4-558c-89a5-b990c265968a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:37bc048e-97f5-589c-b592-6393d3f036b3", "object": "UMLS:C0854761", "object_location_in_text": [61, 88], "original_object": "recurrent esophageal cancer", "original_subject": "TALAPORFIN SODIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TALAPORFIN SODIUM#110-20150526", "https://www.pmda.go.jp/files/000216837.pdf"]}], "subject": "CHEBI:135875", "supporting_text": ["A drug with a new additional indication for the treatment of recurrent esophageal cancer associated with local persistence after chemoradiotherapy or radiotherapy."], "temporal_context_qualifier": "following chemoradiotherapy or radiotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "BCG-refractory disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:325bb3f4-80d2-5370-8f79-a364b4d6bfb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23717ab8-d0ec-5266-9bbb-be13f188f4f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:65fce84d-9855-5879-8c84-025b13dba237", "object": "MONDO:0004703", "original_object": "carcinoma in situ of the urinary bladder", "original_subject": "VALRUBICIN", "population_context_qualifier": "patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e96f30a0-6662-11de-8f80-0002a5d5c51b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e96f30a0-6662-11de-8f80-0002a5d5c51b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e96f30a0-6662-11de-8f80-0002a5d5c51b"]}], "subject": "CHEBI:135876", "supporting_text": ["1 INDICATIONS AND USAGE VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "BCG-refractory condition", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:570e7dad-0336-5672-ba79-749e821bc764", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23717ab8-d0ec-5266-9bbb-be13f188f4f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:65fce84d-9855-5879-8c84-025b13dba237", "object": "MONDO:0004703", "original_object": "carcinoma in situ of the urinary bladder", "original_subject": "VALRUBICIN", "population_context_qualifier": "patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8739ae02-e4c5-0fa2-e053-2a91aa0a1b74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8739ae02-e4c5-0fa2-e053-2a91aa0a1b74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8739ae02-e4c5-0fa2-e053-2a91aa0a1b74"]}], "subject": "CHEBI:135876", "supporting_text": ["1 INDICATIONS AND USAGE Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. • Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0567125", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10a685da-798d-5b22-a254-9910598acceb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000120", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0567125", "UMLS:C0079103"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f61432f1-5063-57f6-9b95-3fa9d8166441", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b779a1ca-9662-5c33-9919-93e324db86ee", "object": "HP:0001622", "original_object": "pre-term birth", "original_subject": "atosiban", "population_context_qualifier": "pregnant adult women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:atosiban-sun", "https://www.ema.europa.eu/en/documents/product-information/atosiban-sun-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/atosiban-sun"]}], "subject": "CHEBI:135899", "supporting_text": ["Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:  regular uterine contractions of at least 30 seconds’ duration at a rate of ? 4 per 30 minutes; a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ? 50%; a gestational age from 24 until 33 completed weeks; a normal foetal heart rate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hepatorenal syndrome with rapid reduction in kidney function", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc1e608e-5e29-5f69-afe4-98c50b8a4886", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2cf7787a-caa5-56ca-8318-55cc25dfe9da", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:98f0890a-a9c4-576e-936f-f47efb9acbd7", "object": "MONDO:0001382", "object_location_in_text": [88, 108], "original_object": "hepatorenal syndrome", "original_subject": "TERLIPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a35b86c-f451-4fac-8499-43019e4da354", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354"]}], "subject": "CHEBI:135905", "supporting_text": ["1 INDICATIONS AND USAGE TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a93d5ec-c022-5d2e-9252-d1517f0a544b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2566f5f2-3256-4f0d-818a-7f34196dbb31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2566f5f2-3256-4f0d-818a-7f34196dbb31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2566f5f2-3256-4f0d-818a-7f34196dbb31"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Fesoterodine fumarate is indicated for the treatment of: Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information is approved for Pfizer Inc.'s TOVIAZ ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4573499d-284a-54e2-a3e8-91c340e90e5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5be745f0-8ae7-4c3c-9962-37d6263326f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5be745f0-8ae7-4c3c-9962-37d6263326f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5be745f0-8ae7-4c3c-9962-37d6263326f1"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Toviaz is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Toviaz is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d88a11d-bf00-5d40-a85e-6c5b4fc92b11", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5e6e146-d39a-471c-e053-2995a90a7538", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5e6e146-d39a-471c-e053-2995a90a7538", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5e6e146-d39a-471c-e053-2995a90a7538"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Fesoterodine fumarate extended-release are indicated for the treatment of: • Overactive bladder(OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Fesoterodine fumarate extended-release tablets are indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:952d92f8-b0a0-51b9-9331-e922e007d362", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c5d2a97-9029-744f-c410-a4bbbe9761a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c5d2a97-9029-744f-c410-a4bbbe9761a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c5d2a97-9029-744f-c410-a4bbbe9761a8"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Fesoterodine fumarate extended-release are indicated for the treatment of: • Overactive bladder(OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Fesoterodine fumarate extended-release tablets are indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cbe5fd4-0b96-59c2-bce2-5d85b3c75135", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "object_location_in_text": [91, 109], "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f79a8796-a5b5-436e-8f94-f13a05eda63f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f79a8796-a5b5-436e-8f94-f13a05eda63f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f79a8796-a5b5-436e-8f94-f13a05eda63f"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Toviaz ® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fed1d6b-eaad-5f5e-9d88-5b77ec94b597", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "object_location_in_text": [91, 109], "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fead426f-b955-4b41-8553-f102d17afa3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fead426f-b955-4b41-8553-f102d17afa3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fead426f-b955-4b41-8553-f102d17afa3a"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Toviaz ® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6b546c2-6edd-5e57-946a-af44995437f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:571147f2-e182-44b5-9d0b-ecfc3265cc2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=571147f2-e182-44b5-9d0b-ecfc3265cc2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=571147f2-e182-44b5-9d0b-ecfc3265cc2d"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Fesoterodine fumarate extended-release tablets are indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. (1.1) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information is approved for Pfizer Inc.’s TOVIAZ ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abd1ced5-c677-5124-926e-a3725c22799b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3cfc4879-a7e3-500f-9b23-319d1659c56e", "object": "MONDO:0006624", "object_location_in_text": [91, 109], "original_object": "overactive bladder", "original_subject": "FESOTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e44e0f9d-6ff7-4a3d-995a-a2768bf9ac26", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e44e0f9d-6ff7-4a3d-995a-a2768bf9ac26", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e44e0f9d-6ff7-4a3d-995a-a2768bf9ac26"]}], "subject": "CHEBI:135920", "supporting_text": ["1 INDICATIONS AND USAGE Toviaz ® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "concurrent use of MAOIs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d45fc5e7-0788-548e-9899-54102d330517", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors (MAOIs)", "linezolid", "intravenous methylene blue"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b07c3cbb-48b9-5a88-b524-a350d5ba6a87", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a13cb74b-b78e-5d6c-8857-0fc41f41c066", "object": "HP:0100735", "original_object": "hypertensive crisis", "original_subject": "LISDEXAMFETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71cdfc97-96af-4378-a44a-6d5d77e7d6b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71cdfc97-96af-4378-a44a-6d5d77e7d6b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71cdfc97-96af-4378-a44a-6d5d77e7d6b7"]}], "subject": "CHEBI:135925", "supporting_text": ["4 CONTRAINDICATIONS ARYNTA is contraindicated in patients with: • Known hypersensitivity to amphetamine products or other ingredients of ARYNTA. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see Adverse Reactions ( 6.2 )]. • Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions ( 5.7 ) and Drug Interactions ( 7.1 )]. • Known hypersensitivity to amphetamine products or other ingredients in ARYNTA ( 4 ) • Use with monoamine oxidase (MAO) inhibitor, or within 14 days of the last MAO inhibitor dose ( 4 , 7.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "increased risk of hypertensive crisis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:244252f2-af2d-5820-8d6f-fa0fd020177a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors (MAOIs)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a13cb74b-b78e-5d6c-8857-0fc41f41c066", "object": "MONDO:0018229", "object_location_in_text": [228, 252], "original_object": "Stevens-Johnson Syndrome", "original_subject": "LISDEXAMFETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecad4442-a644-18e3-6ff2-fdbac45eec47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecad4442-a644-18e3-6ff2-fdbac45eec47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecad4442-a644-18e3-6ff2-fdbac45eec47"]}], "subject": "CHEBI:135925", "supporting_text": ["4 CONTRAINDICATIONS Lisdexamfetamine dimesylate capsules are contraindicated in patients with: Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see Adverse Reactions ( 6.2 )] . Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions ( 5.7 ) and Drug Interactions ( 7.1 )] . Known hypersensitivity to amphetamine products or other ingredients in lisdexamfetamine dimesylate capsules ( 4 ) Use with monoamine oxidase (MAO) inhibitor, or within 14 days of the last MAO inhibitor dose ( 4 , 7.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "increased risk of hypertensive crisis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b17725f-269e-5d9d-b75a-83efc31eb794", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors (MAOIs)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a13cb74b-b78e-5d6c-8857-0fc41f41c066", "object": "MONDO:0018229", "object_location_in_text": [228, 252], "original_object": "Stevens-Johnson Syndrome", "original_subject": "LISDEXAMFETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f2dd6ee-3363-c87c-9693-ed838942556c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f2dd6ee-3363-c87c-9693-ed838942556c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f2dd6ee-3363-c87c-9693-ed838942556c"]}], "subject": "CHEBI:135925", "supporting_text": ["4 CONTRAINDICATIONS Lisdexamfetamine dimesylate capsules are contraindicated in patients with: Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see Adverse Reactions ( 6.2 )] . Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions ( 5.7 ) and Drug Interactions ( 7.1 )] . Known hypersensitivity to amphetamine products or other ingredients in lisdexamfetamine dimesylate capsules ( 4 ) Use with monoamine oxidase (MAO) inhibitor, or within 14 days of the last MAO inhibitor dose ( 4 , 7.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "increased risk of hypertensive crisis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da2b9f42-93d2-581e-8202-6cbe4c27f7f7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors (MAOIs)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a13cb74b-b78e-5d6c-8857-0fc41f41c066", "object": "MONDO:0018229", "object_location_in_text": [228, 252], "original_object": "Stevens-Johnson Syndrome", "original_subject": "LISDEXAMFETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2cedb4c2-1e40-4bc4-b9f4-127150c4afbd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2cedb4c2-1e40-4bc4-b9f4-127150c4afbd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"]}], "subject": "CHEBI:135925", "supporting_text": ["4 CONTRAINDICATIONS Lisdexamfetamine dimesylate capsules are contraindicated in patients with: Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see Adverse Reactions ( 6.2 )] . Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions ( 5.7 ) and Drug Interactions ( 7.1 )] . Known hypersensitivity to amphetamine products or other ingredients in lisdexamfetamine dimesylate capsules ( 4 ) Use with monoamine oxidase (MAO) inhibitor, or within 14 days of the last MAO inhibitor dose ( 4 , 7.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04e863fa-5997-5517-babe-1e3fc8ae81f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f799b9b6-ba79-f335-e053-6294a90aaa68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f799b9b6-ba79-f335-e053-6294a90aaa68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f799b9b6-ba79-f335-e053-6294a90aaa68"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10486f82-48d7-58c5-b0c9-63cad79660d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [180, 189], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d62d754e-2310-4912-b022-603ae925710d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d62d754e-2310-4912-b022-603ae925710d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d62d754e-2310-4912-b022-603ae925710d"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE DEXILANT is a proton pump inhibitor (PPI) indicated for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintaining healing of EE and relief of heartburn. ( 1.2 ) Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to 8 weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to 6 months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks."], "temporal_context_qualifier": "4 weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3561ee58-b441-5131-918c-f8e755cb61fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f44e84f-6219-4445-a67d-df37d18b014d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f44e84f-6219-4445-a67d-df37d18b014d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f44e84f-6219-4445-a67d-df37d18b014d"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:392d9961-9733-51bc-ad86-0eb76aca96e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c7698da-3cda-4301-ae93-02fb64b9c90d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c7698da-3cda-4301-ae93-02fb64b9c90d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c7698da-3cda-4301-ae93-02fb64b9c90d"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3eec3313-4888-54b9-b9e7-0eb7b3efa4aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9abcfb1e-c894-44bb-807a-e4bdd755f28f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9abcfb1e-c894-44bb-807a-e4bdd755f28f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9abcfb1e-c894-44bb-807a-e4bdd755f28f"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5854cfce-c73a-59c1-9f7b-4f10154011b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [224, 233], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ed69e5a-aa78-4118-aa32-59a10f80c901", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ed69e5a-aa78-4118-aa32-59a10f80c901", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ed69e5a-aa78-4118-aa32-59a10f80c901"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a959cd8-1ac0-5f1f-a4f0-dce0f1567c2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dca4887-c75a-4021-8564-b704e9e1fa3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dca4887-c75a-4021-8564-b704e9e1fa3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dca4887-c75a-4021-8564-b704e9e1fa3e"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5cac6f11-5505-5cf0-9b58-60c4c5babc7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [224, 233], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7452a26-db20-42fc-868a-a3e3606ca895", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7452a26-db20-42fc-868a-a3e3606ca895", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7452a26-db20-42fc-868a-a3e3606ca895"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:882c2742-175a-5713-88a6-cd9d15c5336e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [368, 377], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c83616c9-c222-4e3e-91bd-c7839406bb2a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c83616c9-c222-4e3e-91bd-c7839406bb2a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c83616c9-c222-4e3e-91bd-c7839406bb2a"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Healing of Erosive Esophagitis KAPIDEX is indicated for healing of all grades of erosive esophagitis (EE) for up to 8 weeks. 1.2 Maintenance of Healed Erosive Esophagitis KAPIDEX is indicated to maintain healing of EE for up to 6 months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease KAPIDEX is indicated for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks."], "temporal_context_qualifier": "for 4 weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e03befb-fe58-5ca4-94b7-191436d7abf7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [224, 233], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc3de800-bfad-4e2f-b664-d58a67550b2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc3de800-bfad-4e2f-b664-d58a67550b2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc3de800-bfad-4e2f-b664-d58a67550b2f"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a614acb4-e8bf-5732-bba4-43a7f231400f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31d3d485-5f87-4405-b940-490fa4ccf9cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31d3d485-5f87-4405-b940-490fa4ccf9cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31d3d485-5f87-4405-b940-490fa4ccf9cc"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab25d3ab-f001-50eb-92a0-e625bb665c80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [217, 226], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9819f033-3bbe-442e-8e92-45fec77b237d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9819f033-3bbe-442e-8e92-45fec77b237d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9819f033-3bbe-442e-8e92-45fec77b237d"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE DEXILANT is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis DEXILANT ® is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn DEXILANT is indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1b6038b-a659-5ca6-883e-57d098918199", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59e0c5d7-12e9-b5d7-e063-6394a90a7366", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59e0c5d7-12e9-b5d7-e063-6394a90a7366", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59e0c5d7-12e9-b5d7-e063-6394a90a7366"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b848dc87-c43c-5686-8f79-ff3e72c7d7ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [248, 257], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcfe880a-b96d-4a3c-aa21-3998d0bcfe9e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcfe880a-b96d-4a3c-aa21-3998d0bcfe9e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcfe880a-b96d-4a3c-aa21-3998d0bcfe9e"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcc5aefe-a2fd-51a0-80da-9e51733bd443", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cfd5cbe-2b94-5426-87d6-517fc4da0f1b", "object": "HP:0002020", "object_location_in_text": [224, 233], "original_object": "heartburn", "original_subject": "DEXLANSOPRAZOLE", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caad4ada-2cf9-4e12-99df-6ca4388cf0f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caad4ada-2cf9-4e12-99df-6ca4388cf0f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caad4ada-2cf9-4e12-99df-6ca4388cf0f6"]}], "subject": "CHEBI:135931", "supporting_text": ["1 INDICATIONS AND USAGE Dexlansoprazole is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks."], "temporal_context_qualifier": "for four weeks"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:252f1542-fd30-5b0b-a597-8ab8956dc5c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "HP:0000989", "object_location_in_text": [45, 52], "original_object": "itching", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63c1e56c-b573-5027-afb7-1d910d3bc282", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "HP:0000989", "object_location_in_text": [42, 49], "original_object": "itching", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e58e07fb-0ad4-5282-b9f1-5c75897848e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "HP:0000989", "object_location_in_text": [46, 53], "original_object": "itching", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent the recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72349588-9ffc-54d8-8cb0-aa9b2577edf5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "MONDO:0006608", "object_location_in_text": [112, 133], "original_object": "seborrheic dermatitis", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae1113da-135f-5f65-8dad-cceef8436bfe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "MONDO:0006608", "object_location_in_text": [116, 137], "original_object": "seborrheic dermatitis", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent the recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:961dd688-f696-59ea-ac77-82f306090c1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:878aaebf-9e22-57fc-9efe-e5374ff58a20", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0041834", "object_location_in_text": [79, 86], "original_object": "redness", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent the recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3601350-73b9-5936-a3f7-45ec2f7cda18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:878aaebf-9e22-57fc-9efe-e5374ff58a20", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0041834", "object_location_in_text": [75, 82], "original_object": "redness", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba291077-09dd-5c63-aa3d-42e4115b6128", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0221244", "object_location_in_text": [69, 77], "original_object": "dandruff", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05f25574-4dc2-5724-886c-61ff2ea7959b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4537e5e-6bba-5cc6-b0d6-9af57480b179", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0237849", "object_location_in_text": [67, 74], "original_object": "scaling", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent the recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18b3ecb8-10e9-521f-90ce-c1c40d488d5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4537e5e-6bba-5cc6-b0d6-9af57480b179", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0237849", "object_location_in_text": [63, 70], "original_object": "scaling", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef1d9b21-eeae-55be-ac43-426ddcc7c281", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c8e070c1-0dbc-55c5-a717-8e06481ca0cd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0240941", "object_location_in_text": [21, 34], "original_object": "scalp itching", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses Helps eliminate scalp itching, irritation, redness, flaking associated with dandruff and/or seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78d34896-2c78-5351-9e85-bf585591da03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0441723", "object_location_in_text": [55, 65], "original_object": "irritation", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5e3550a-de63-42b5-90d3-5c23cca941c6"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent the recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b8fec82-837e-51b6-96e3-b3b3aaf95bce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C0441723", "object_location_in_text": [51, 61], "original_object": "irritation", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ad7707-9d02-31a6-e053-2a95a90ae7ad"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses helps prevent recurrence of flaking, itching, irritation, scaling and redness associated with dandruff and seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ce50aa3-2c6e-5197-bd03-5e975dab0713", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6d1189e-d531-51c2-9c5a-8e59000408c1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C4324287", "original_object": "scalp redness", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses Helps eliminate scalp itching, irritation, redness, flaking associated with dandruff and/or seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75f8c871-bd1a-5327-97bc-b63d761a89d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e79de5da-60f9-5098-9d7f-153aec2c23d6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "UMLS:C4728166", "original_object": "scalp irritation", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses Helps eliminate scalp itching, irritation, redness, flaking associated with dandruff and/or seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd9475a4-8602-53ff-a503-17b34e3a95fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:816dc0a8-1e16-515d-a977-1772b8711974", "object": "MONDO:0006608", "object_location_in_text": [97, 118], "original_object": "seborrheic dermatitis", "original_subject": "SELENIUM SULFIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b09c3b0d-564e-45e4-b6ff-c1f0c12a9521"]}], "subject": "CHEBI:135934", "supporting_text": ["Uses Helps eliminate scalp itching, irritation, redness, flaking associated with dandruff and/or seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0740447", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce83c1e8-c9bb-5c63-8e3a-231c5e971876", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081120", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0740447"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:256a0194-7fad-5f24-be81-62167fd9083e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:626cb8a6-098c-5939-8cb7-dcd5a0d09dbf", "object": "UMLS:C0740447", "original_object": "diabetic peripheral neuropathy", "original_subject": "TAPENTADOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3d04d70-0155-4147-9ce4-a3b1fad4b373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3d04d70-0155-4147-9ce4-a3b1fad4b373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3d04d70-0155-4147-9ce4-a3b1fad4b373"]}], "subject": "CHEBI:135935", "supporting_text": ["1 INDICATIONS AND USAGE NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. NUCYNTA ER is an opioid agonist indicated for the management of: severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "postmenopausal status", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53102572-3f79-524d-ac3b-dbda55a8ef4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090417", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:53250f41-55b8-5d6b-a97f-f50758039766", "object": "MONDO:0005298", "original_object": "osteoporosis", "original_subject": "bazedoxifene", "population_context_qualifier": "women at increased risk of fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:conbriza", "https://www.ema.europa.eu/en/documents/product-information/conbriza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza"]}], "subject": "CHEBI:135947", "supporting_text": ["Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "WHO Group 1", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a453dff-20cd-5866-8f86-58ef50b61676", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070615", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ed0b935-c4f7-55f6-b02d-1c97780cfa6b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9937b194-4737-5885-929d-a79474cd0c91", "object": "MONDO:0015924", "original_object": "pulmonary arterial hypertension", "original_subject": "AMBRISENTAN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4396bab5-2851-62ef-e063-6294a90af76e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4396bab5-2851-62ef-e063-6294a90af76e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4396bab5-2851-62ef-e063-6294a90af76e"]}], "subject": "CHEBI:135949", "supporting_text": ["1 INDICATIONS AND USAGE Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Ambrisentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "WHO Group 1", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abc24f4b-7025-53a2-9478-5e4036bb533a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070615", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ed0b935-c4f7-55f6-b02d-1c97780cfa6b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9937b194-4737-5885-929d-a79474cd0c91", "object": "MONDO:0015924", "original_object": "pulmonary arterial hypertension", "original_subject": "AMBRISENTAN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:291a782a-77e1-8a8e-e1c8-2626f305c2b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=291a782a-77e1-8a8e-e1c8-2626f305c2b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=291a782a-77e1-8a8e-e1c8-2626f305c2b7"]}], "subject": "CHEBI:135949", "supporting_text": ["1 INDICATIONS AND USAGE Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Ambrisentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0861154", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a0e2fff-31ab-5b82-a240-9a29580894ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190206", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0861154"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:89efb5c9-5434-5ec9-bba2-e17e23171dbb", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:319a74bc-fba4-56b2-bc07-1109eaa79115", "object": "MONDO:0005492", "original_object": "urticaria", "original_subject": "Bilastine tablets 20 mg and Bilastine Bulk", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:135954", "supporting_text": ["For symptomatic treatment of allergic rhino-conjuctivitis (seasonal and perennial) and utricaria in adults"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f7ce5c6-a302-5f38-81ac-86002a3940ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["mycophenolate mofetil"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:707eb0ff-5891-5480-9dfd-196a6a895455", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:51f0a100-874a-5886-bedf-940cccd3a314", "object": "MONDO:0005556", "object_location_in_text": [170, 185], "original_object": "lupus nephritis", "original_subject": "voclosporin", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lupkynis", "https://www.ema.europa.eu/en/documents/product-information/lupkynis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis"]}], "subject": "CHEBI:135957", "supporting_text": ["Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45d999ac-9dd2-5ce1-9934-fd1f889519b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005315", "object_location_in_text": [138, 146], "original_object": "fracture", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d371f0f7-d492-4481-b360-051456d56d65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide Injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e518e3d8-3ac8-51a3-a92a-c8b9779715a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005315", "object_location_in_text": [138, 146], "original_object": "fracture", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab322675-4769-45b0-b146-14fbaa3135d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide Injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2097d4d3-2463-5c3f-a0a7-18e6550febe7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3a7554e-b7b8-5f9b-ab29-3635b2a3cf6c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "UMLS:C0016658", "object_location_in_text": [438, 447], "original_object": "fractures", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d38b470a-2e62-487b-b3e7-134d3d1958b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d38b470a-2e62-487b-b3e7-134d3d1958b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d38b470a-2e62-487b-b3e7-134d3d1958b5"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a synthetic parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:968b9bae-73d1-5d77-8879-c145e684a296", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3a7554e-b7b8-5f9b-ab29-3635b2a3cf6c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "UMLS:C0016658", "object_location_in_text": [438, 447], "original_object": "fractures", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d3f65e2-e8f0-4d33-b79e-989013dd3ca3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d3f65e2-e8f0-4d33-b79e-989013dd3ca3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d3f65e2-e8f0-4d33-b79e-989013dd3ca3"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a synthetic parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05c9b772-e4c3-5b81-b6a6-342dec1544f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [46, 58], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:livogiva", "https://www.ema.europa.eu/en/documents/product-information/livogiva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/livogiva"]}], "subject": "CHEBI:135983", "supporting_text": ["Livogiva is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35f147ed-e001-57a9-b16a-be8ff63c3a2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [54, 66], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:teriparatide-sun", "https://www.ema.europa.eu/en/documents/product-information/teriparatide-sun-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/teriparatide-sun"]}], "subject": "CHEBI:135983", "supporting_text": ["Teriparatide SUN is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:886a8bd6-924d-586c-8495-0282b6f2b218", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [13, 25], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:forsteo", "https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/forsteo"]}], "subject": "CHEBI:135983", "supporting_text": ["Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:997286c4-1ba8-5fbe-99c8-3a45a7c4d50e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [45, 57], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:terrosa", "https://www.ema.europa.eu/en/documents/product-information/terrosa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/terrosa"]}], "subject": "CHEBI:135983", "supporting_text": ["Terrosa is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a30bf21e-c791-5298-a74c-2ce15eb437b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [44, 56], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kauliv", "https://www.ema.europa.eu/en/documents/product-information/kauliv-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv"]}], "subject": "CHEBI:135983", "supporting_text": ["Kauliv is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f019c591-9ce7-5392-9785-9d360b422002", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [45, 57], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:movymia", "https://www.ema.europa.eu/en/documents/product-information/movymia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/movymia"]}], "subject": "CHEBI:135983", "supporting_text": ["Movymia is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3c8a903-5bf1-59ab-8df9-0af18bba4efc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030610", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [47, 59], "original_object": "osteoporosis", "original_subject": "teriparatide", "population_context_qualifier": "women and men at increased risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sondelbay", "https://www.ema.europa.eu/en/documents/product-information/sondelbay-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sondelbay"]}], "subject": "CHEBI:135983", "supporting_text": ["Sondelbay is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:045033f8-5471-52ba-8070-172f8aaf74ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [108, 120], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab322675-4769-45b0-b146-14fbaa3135d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide Injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a84c312-9b6d-5d0a-b4b3-cf515fdac6d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [108, 120], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d3f65e2-e8f0-4d33-b79e-989013dd3ca3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d3f65e2-e8f0-4d33-b79e-989013dd3ca3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d3f65e2-e8f0-4d33-b79e-989013dd3ca3"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a synthetic parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ba3d3aa-8635-582c-b78e-d96a396bc7ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [108, 120], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b007339-dd0d-f019-5e0a-9b1b0f75011c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b007339-dd0d-f019-5e0a-9b1b0f75011c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b007339-dd0d-f019-5e0a-9b1b0f75011c"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6315d9cb-9712-5922-abd3-95cabf8a48dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [93, 105], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d0c89a2-3849-adf6-007d-aeca21cf417c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d0c89a2-3849-adf6-007d-aeca21cf417c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d0c89a2-3849-adf6-007d-aeca21cf417c"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE BONSITY is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, BONSITY reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. BONSITY is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"], "temporal_context_qualifier": "sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9275a9c3-e60f-5dd2-96af-5c9ab3dda3cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [108, 120], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d371f0f7-d492-4481-b360-051456d56d65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide Injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "osteoporosis associated with sustained systemic glucocorticoid therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8eec3b9-4958-59a6-9168-79f2add85940", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [108, 120], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men and women at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d38b470a-2e62-487b-b3e7-134d3d1958b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d38b470a-2e62-487b-b3e7-134d3d1958b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d38b470a-2e62-487b-b3e7-134d3d1958b5"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a synthetic parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "increased risk for fracture", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df62005c-b208-5b6e-ad52-18340fccd4fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "MONDO:0005298", "object_location_in_text": [132, 144], "original_object": "osteoporosis", "original_subject": "TERIPARATIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TERIPARATIDE#150-20110520", "https://www.pmda.go.jp/files/000207926.pdf"]}], "subject": "CHEBI:135983", "supporting_text": ["A drug with a new dosage with a revised treatment period from \"up to 18 months\" to \"up to 24 months\" indicated for the treatment of osteoporosis with an increased risk for fracture."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0410438", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81e02d92-1c34-5f0b-9c7c-b4146f0336f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0410438"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63b14e6f-849c-5559-8f99-86fba1ff047e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "UMLS:C0005938", "object_location_in_text": [461, 470], "original_object": "bone mass", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men with primary or hypogonadal osteoporosis at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab322675-4769-45b0-b146-14fbaa3135d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide Injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0410438", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:831e242c-bde9-504a-92dd-cb1d2ce64a1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0410438"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63b14e6f-849c-5559-8f99-86fba1ff047e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "UMLS:C0005938", "object_location_in_text": [429, 438], "original_object": "bone mass", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men with primary or hypogonadal osteoporosis at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aae667c5-381f-4f92-93df-2ed6158d07b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. FORTEO is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0410438", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85c7fe64-eab0-5442-80df-5a53a210acee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0410438"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63b14e6f-849c-5559-8f99-86fba1ff047e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "UMLS:C0005938", "object_location_in_text": [431, 440], "original_object": "bone mass", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men with primary or hypogonadal osteoporosis at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d0c89a2-3849-adf6-007d-aeca21cf417c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d0c89a2-3849-adf6-007d-aeca21cf417c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d0c89a2-3849-adf6-007d-aeca21cf417c"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE BONSITY is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, BONSITY reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. BONSITY is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0410438", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0f78d76-38c9-5276-b525-07fc9f40b84a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0410438"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63b14e6f-849c-5559-8f99-86fba1ff047e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e655014-b5e2-506c-94cc-36c66aae70ca", "object": "UMLS:C0005938", "object_location_in_text": [461, 470], "original_object": "bone mass", "original_subject": "TERIPARATIDE", "population_context_qualifier": "men with primary or hypogonadal osteoporosis at high risk for fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d371f0f7-d492-4481-b360-051456d56d65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65"]}], "subject": "CHEBI:135983", "supporting_text": ["1 INDICATIONS AND USAGE Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide Injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide Injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pain caused by active cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19310d28-f979-5a87-bf17-81df903c6183", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080424", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0ea39d66-2b23-5a08-b774-92f46622c00c", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "METHYLNALTREXONE", "population_context_qualifier": "adults with advanced illness", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c488fb7c-0a5b-487c-b452-996809d1cb99", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99"]}], "subject": "CHEBI:136007", "supporting_text": ["1 INDICATIONS AND USAGE • RELISTOR is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.1 ) • RELISTOR injection is indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. ( 1.2 ) 1.1 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. 1.2 Opioid-Induced Constipation in Adult Patients with Advanced Illness RELISTOR injection is indicated for the treatment of OIC in adult patients with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care."], "temporal_context_qualifier": "requiring opioid dosage escalation for palliative care"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of arterial or venous thrombotic diseases", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62dab334-7554-5145-b260-2c1b3fe51ed8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ba6d2ce-1c41-599d-bbb7-bd4b8351d697", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:019c92d1-da79-5b10-bd6d-aa1cdfed40cf", "medic_supporting_text_truncated": true, "object": "MONDO:0005015", "original_object": "Diabetes mellitus", "original_subject": "LEVOMEFOLIC ACID", "population_context_qualifier": "females who smoke, if over age 35", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58cd12d3-39b1-4375-b7e0-09ba2378a52b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58cd12d3-39b1-4375-b7e0-09ba2378a52b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58cd12d3-39b1-4375-b7e0-09ba2378a52b"]}], "subject": "CHEBI:136009", "supporting_text": ["4 CONTRAINDICATIONS Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium is contraindicated in females who are known to have or develop the following conditions: • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: • Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] • Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 )] • Have cerebrovascular disease [see Warnings and Precautions ( 5.1 )] • Have coronary artery disease [see Warnings and Precautions ( 5.1 )] • Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 )] • Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 )] • Have uncontrolled hypertension [see Warnings and Precautions ( 5.6 )] • Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.8 )] • Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings and Precautions ( 5.9 )] • Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.10 )] • Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions ( 5.3 )] • Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions ( 5.4 ) and Use in Specific Populations ( 8.7 )] • Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings and Precautions ( 5.5 ) and Drug Interactions ( 7.3 )] . • Renal impairment ( 4 ) • Adrenal insufficiency ( 4 ) • A high risk of arterial or venous thrombotic diseases ( 4 ) • Undiagnosed abnormal uterine bleeding ( 4 ) • Breast cancer ("]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0031139", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82f9eb61-453f-50fb-a1fe-cd3274073935", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170922", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0031139"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f9233e8a-865b-50bb-ae00-8066f81794ad", "object": "HP:0000989", "object_location_in_text": [55, 63], "original_object": "pruritus", "original_subject": "NALFURAFINE HYDROCHLORIDE", "population_context_qualifier": "patients on peritoneal dialysis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NALFURAFINE HYDROCHLORIDE#89-20170922", "https://www.pmda.go.jp/files/000211074.pdf"]}], "subject": "CHEBI:136019", "supporting_text": ["Drugs with a revised indication for the improvement of pruritus in patients on peritoneal dialysis (for use only in patients who have not responded sufficiently to conventional treatments)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0023895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a147dc4b-8f37-5b6e-9a98-59210f4c03b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141226", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0023895"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f9233e8a-865b-50bb-ae00-8066f81794ad", "object": "HP:0000989", "object_location_in_text": [69, 77], "original_object": "pruritus", "original_subject": "NALFURAFINE HYDROCHLORIDE", "population_context_qualifier": "patients with chronic liver diseases; patients for whom conventional therapies are not sufficiently effective", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NALFURAFINE HYDROCHLORIDE#116-20141226", "https://www.pmda.go.jp/files/000211074.pdf"]}], "subject": "CHEBI:136019", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of pruritus in patients with chronic liver diseases (for use only when conventional therapies are not sufficiently effective)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c0ea09b-5bf3-55f0-a61b-37b74891aff5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140926", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:d08e72e7-bd2b-5cdf-ae4a-3f6bc96621a1", "object": "MONDO:0005354", "object_location_in_text": [149, 168], "original_object": "chronic hepatitis C", "original_subject": "VANIPREVIR", "population_context_qualifier": "Patients with high levels of blood HCV RNA who are treatment-naive, or Patients who are non-responders or relapsed to therapy including interferon", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VANIPREVIR#116-20140926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:136047", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of viremia in the following patients with serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C: Patients with high levels of blood HCV RNA who are treatment-naive, or Patients who are non-responders or relapsed to therapy including interferon. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88fa49e5-9eae-5472-8651-d7643b8ba262", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20231101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e563f03-8fb7-5fdc-8317-2e9d0fed80dc", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7c2d313d-85c5-5d98-83a1-0dd7b06e5989", "medic_supporting_text_truncated": true, "object": "UMLS:C0948807", "original_object": "hepatic impairment", "original_subject": "VONOPRAZAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86"]}], "subject": "CHEBI:136048", "supporting_text": ["4 CONTRAINDICATIONS VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK : Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams, clarithromycin or any other macrolide antimicrobial or any component of VOQUEZNA TRIPLE PAK. ( 4.1 ) Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams or any component of VOQUEZNA DUAL PAK. ( 4.1 ) Rilpivirine-containing products. ( 4.1 ) VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component : Pimozide. ( 4.2 ) Lomitapide, lovastatin, and simvastatin. ( 4.2 ) Ergot alkaloids (ergotamine or dihydroergotamine). ( 4.2 ) Colchicine in renal or hepatic impairment. ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin. ( 4.2 ) Lurasidone. ( 4.2 ) 4.1 Contraindications to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Hypersensitivity Reactions VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) [see Warnings and Precautions (5.1) ]. Rilpivirine-containing Products VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. 4.2 Additional Contraindications to VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component Serious Adverse Reactions/Risks Due to Drug Interactions Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of: Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most like"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:393af3fa-16d0-5da2-84cd-a85ed3ca9e2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20231101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7dd6fba1-2634-5f58-85a5-ca9748acce1f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7c2d313d-85c5-5d98-83a1-0dd7b06e5989", "medic_supporting_text_truncated": true, "object": "UMLS:C1565489", "original_object": "renal impairment", "original_subject": "VONOPRAZAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86"]}], "subject": "CHEBI:136048", "supporting_text": ["4 CONTRAINDICATIONS VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK : Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams, clarithromycin or any other macrolide antimicrobial or any component of VOQUEZNA TRIPLE PAK. ( 4.1 ) Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams or any component of VOQUEZNA DUAL PAK. ( 4.1 ) Rilpivirine-containing products. ( 4.1 ) VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component : Pimozide. ( 4.2 ) Lomitapide, lovastatin, and simvastatin. ( 4.2 ) Ergot alkaloids (ergotamine or dihydroergotamine). ( 4.2 ) Colchicine in renal or hepatic impairment. ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin. ( 4.2 ) Lurasidone. ( 4.2 ) 4.1 Contraindications to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Hypersensitivity Reactions VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) [see Warnings and Precautions (5.1) ]. Rilpivirine-containing Products VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. 4.2 Additional Contraindications to VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component Serious Adverse Reactions/Risks Due to Drug Interactions Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of: Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most like"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NSAIDs administration", "has_confidence_score": 0.2069, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2b1cd22-04ae-5b71-9be3-0a4d1225460b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240508", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.2069, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fc884671-9e40-58be-a5a1-cbaf308e286e", "object": "MONDO:0001126", "object_location_in_text": [53, 66], "original_object": "gastric ulcer", "original_subject": "Vonoprazan fumarate Bulk drug& Vonoprazan tablets 10mg/20 mg", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:136048", "supporting_text": [" Treatment of reflux esophagitis(RE)  Treatment of gastric ulcer (GU)  Treatment of duodenal ulcer(DU)  Prevention of recurrence of gastric ulcer or duodenal ulcer during low- dose aspirin administration.  Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration.  Adjunct to Helicobacter pylori eradication associated with: Gastric ulcer, Duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage cancer, or Helicobacter pylori gastritis."], "temporal_context_qualifier": "during NSAIDs administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NSAIDs administration", "has_confidence_score": 0.2069, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f4db91c-6cf8-57c4-b66d-2cd4c7daf63c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240508", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.2069, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fc884671-9e40-58be-a5a1-cbaf308e286e", "object": "MONDO:0005412", "object_location_in_text": [87, 101], "original_object": "duodenal ulcer", "original_subject": "Vonoprazan fumarate Bulk drug& Vonoprazan tablets 10mg/20 mg", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:136048", "supporting_text": [" Treatment of reflux esophagitis(RE)  Treatment of gastric ulcer (GU)  Treatment of duodenal ulcer(DU)  Prevention of recurrence of gastric ulcer or duodenal ulcer during low- dose aspirin administration.  Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration.  Adjunct to Helicobacter pylori eradication associated with: Gastric ulcer, Duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage cancer, or Helicobacter pylori gastritis."], "temporal_context_qualifier": "during NSAIDs administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21929a1d-17cd-5c99-b727-d9f8774606aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20231101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7c2d313d-85c5-5d98-83a1-0dd7b06e5989", "object": "HP:0002020", "object_location_in_text": [110, 119], "original_object": "heartburn", "original_subject": "VONOPRAZAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cc52ac5-77ec-4d66-a770-762a1a960914", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cc52ac5-77ec-4d66-a770-762a1a960914", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cc52ac5-77ec-4d66-a770-762a1a960914"]}], "subject": "CHEBI:136048", "supporting_text": ["1 INDICATIONS AND USAGE VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. VOQUEZNA is a potassium-competitive acid blocker indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. ( 1 ) to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. ( 1 ) for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. ( 1 ) in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults. ( 1 ) in combination with amoxicillin for the treatment of H. pylori infection in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002592", "has_confidence_score": 0.2069, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:988938c0-48f7-5705-850d-e241c1e41cf3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240508", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002592", "HP:0002588", "MONDO:0006226", "MONDO:0008558", "UMLS:C0343378"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:7081799f-b19e-513d-a4e1-b2dfd7d70949", "medic_pair_confidence": 0.2069, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fc884671-9e40-58be-a5a1-cbaf308e286e", "object": "HP:0005202", "original_object": "Helicobacter pylori infection", "original_subject": "Vonoprazan fumarate Bulk drug& Vonoprazan tablets 10mg/20 mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:136048", "supporting_text": [" Treatment of reflux esophagitis(RE)  Treatment of gastric ulcer (GU)  Treatment of duodenal ulcer(DU)  Prevention of recurrence of gastric ulcer or duodenal ulcer during low- dose aspirin administration.  Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration.  Adjunct to Helicobacter pylori eradication associated with: Gastric ulcer, Duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage cancer, or Helicobacter pylori gastritis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0038862", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0916d1fb-3658-5ca7-9815-9b96750620fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150928", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038862"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ef609319-42db-5bbf-8c81-f0f3025c97fe", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a33e000f-f2bd-5fdf-a570-9fa014b69c9a", "object": "MONDO:0011438", "object_location_in_text": [99, 103], "original_object": "acne", "original_subject": "OZENOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OZENOXACIN#108-20150928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:136050", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of superficial skin infections and acne (accompanied by purulent inflammation)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee02fc3f-5288-559b-97ea-2410a7c23554", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190218", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2cf95943-86b8-5af5-b9d1-ac4c0ed8a598", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:26e0e0f8-d2e7-577e-9ce0-bc8f4abd248c", "object": "MONDO:0002049", "object_location_in_text": [42, 65], "original_object": "severe thrombocytopenia", "original_subject": "lusutrombopag", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mulpleo", "https://www.ema.europa.eu/en/documents/product-information/mulpleo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo"]}], "subject": "CHEBI:136051", "supporting_text": ["Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures"], "temporal_context_qualifier": "undergoing invasive procedures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:138657a4-8c81-5aa4-8a6d-356af85d872d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180731", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:26e0e0f8-d2e7-577e-9ce0-bc8f4abd248c", "object": "MONDO:0002049", "object_location_in_text": [67, 83], "original_object": "thrombocytopenia", "original_subject": "LUSUTROMBOPAG", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a390aec3-6e77-45f8-95d3-d4b8c2eeee40", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a390aec3-6e77-45f8-95d3-d4b8c2eeee40", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a390aec3-6e77-45f8-95d3-d4b8c2eeee40"]}], "subject": "CHEBI:136051", "supporting_text": ["1 INDICATIONS AND USAGE MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1 )"], "temporal_context_qualifier": "scheduled to undergo a procedure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40c8d00f-5655-5c0d-802d-c79d4e7b21c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180731", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:26e0e0f8-d2e7-577e-9ce0-bc8f4abd248c", "object": "MONDO:0002049", "object_location_in_text": [67, 83], "original_object": "thrombocytopenia", "original_subject": "LUSUTROMBOPAG", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f6b72db-3abc-4169-9bee-8dc3078357e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f6b72db-3abc-4169-9bee-8dc3078357e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f6b72db-3abc-4169-9bee-8dc3078357e6"]}], "subject": "CHEBI:136051", "supporting_text": ["1 INDICATIONS AND USAGE MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1 )"], "temporal_context_qualifier": "scheduled to undergo a procedure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6fc2604-1437-5c7e-a855-16f06e13079e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180731", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:26e0e0f8-d2e7-577e-9ce0-bc8f4abd248c", "object": "MONDO:0002049", "object_location_in_text": [67, 83], "original_object": "thrombocytopenia", "original_subject": "LUSUTROMBOPAG", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9fd0cfd-717d-4a87-99bc-de7b38807e55", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9fd0cfd-717d-4a87-99bc-de7b38807e55", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9fd0cfd-717d-4a87-99bc-de7b38807e55"]}], "subject": "CHEBI:136051", "supporting_text": ["1 INDICATIONS AND USAGE MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1 )"], "temporal_context_qualifier": "scheduled to undergo a procedure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a370dfa4-c433-51f8-90ca-39791d57140c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150928", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:26e0e0f8-d2e7-577e-9ce0-bc8f4abd248c", "object": "MONDO:0002049", "object_location_in_text": [69, 85], "original_object": "thrombocytopenia", "original_subject": "LUSUTROMBOPAG", "population_context_qualifier": "patients for whom an elective invasive procedure is planned", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LUSUTROMBOPAG#106-20150928", "https://www.pmda.go.jp/files/000215708.pdf"]}], "subject": "CHEBI:136051", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0200043", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87a3d482-b5fa-5fe9-8b93-8e3f0e87e20b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240426", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0200043", "HP:0004313", "UMLS:C3714514", "HP:0031160"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c2615833-32c6-5aac-9e75-5f37426c1d3f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3ae033c9-45f4-5c28-a9f1-f58fea35e502", "object": "MONDO:0023880", "original_object": "WHIM syndrome", "original_subject": "MAVORIXAFOR", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f3a5ee3-ca73-4876-85a0-ed1e108a2237", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f3a5ee3-ca73-4876-85a0-ed1e108a2237", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f3a5ee3-ca73-4876-85a0-ed1e108a2237"]}], "subject": "CHEBI:138865", "supporting_text": ["1 INDICATIONS AND USAGE XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027022", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d5e83e3-c5cc-574e-90d7-8f5f9d2b1d03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027022"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02352720-1489-5a76-b6dd-710acbb540dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d3e4968f-9cc5-5af5-b9bc-07724fb55dcd", "object": "MONDO:0002249", "object_location_in_text": [95, 110], "original_object": "thrombocythemia", "original_subject": "ANAGRELIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:875cc32a-219c-4b6b-802a-98a47cbc9a78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=875cc32a-219c-4b6b-802a-98a47cbc9a78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=875cc32a-219c-4b6b-802a-98a47cbc9a78"]}], "subject": "CHEBI:142290", "supporting_text": ["1 INDICATIONS AND USAGE Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 ) Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027022", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:804014b6-0dee-51eb-9407-e4bdf9c8b941", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027022"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02352720-1489-5a76-b6dd-710acbb540dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d3e4968f-9cc5-5af5-b9bc-07724fb55dcd", "object": "MONDO:0002249", "object_location_in_text": [80, 95], "original_object": "thrombocythemia", "original_subject": "ANAGRELIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb960074-99c1-4a73-941f-f0644a7ec219", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb960074-99c1-4a73-941f-f0644a7ec219", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb960074-99c1-4a73-941f-f0644a7ec219"]}], "subject": "CHEBI:142290", "supporting_text": ["1 INDICATIONS AND USAGE AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. AGRYLIN is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027022", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2b5abc1-ea5a-5106-a7d9-dc2866075421", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027022"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02352720-1489-5a76-b6dd-710acbb540dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d3e4968f-9cc5-5af5-b9bc-07724fb55dcd", "object": "MONDO:0002249", "object_location_in_text": [95, 110], "original_object": "thrombocythemia", "original_subject": "ANAGRELIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56b3959d-4b6b-413f-b753-9d4c20c07466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56b3959d-4b6b-413f-b753-9d4c20c07466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56b3959d-4b6b-413f-b753-9d4c20c07466"]}], "subject": "CHEBI:142290", "supporting_text": ["1 INDICATIONS &amp; USAGE Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027022", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae05227c-b86d-5d06-8673-d7a15e40c5a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027022"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02352720-1489-5a76-b6dd-710acbb540dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d3e4968f-9cc5-5af5-b9bc-07724fb55dcd", "object": "MONDO:0002249", "object_location_in_text": [83, 98], "original_object": "thrombocythemia", "original_subject": "ANAGRELIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5e6cf1e5-94e4-4124-b7bf-e74647532246", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5e6cf1e5-94e4-4124-b7bf-e74647532246", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e6cf1e5-94e4-4124-b7bf-e74647532246"]}], "subject": "CHEBI:142290", "supporting_text": ["Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027022", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1cce3d2-1e67-5422-960f-cfde58cb502b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027022"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02352720-1489-5a76-b6dd-710acbb540dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d3e4968f-9cc5-5af5-b9bc-07724fb55dcd", "object": "MONDO:0002249", "object_location_in_text": [93, 108], "original_object": "thrombocythemia", "original_subject": "ANAGRELIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e031dfb3-56e1-4fea-95f2-c2936e2057a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e031dfb3-56e1-4fea-95f2-c2936e2057a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e031dfb3-56e1-4fea-95f2-c2936e2057a0"]}], "subject": "CHEBI:142290", "supporting_text": ["1 INDICATIONS AND USAGE Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027022", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6080c22-d4f3-5c72-82cc-f22b001aaa00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027022"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02352720-1489-5a76-b6dd-710acbb540dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d3e4968f-9cc5-5af5-b9bc-07724fb55dcd", "object": "MONDO:0002249", "object_location_in_text": [97, 112], "original_object": "thrombocythemia", "original_subject": "ANAGRELIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:614b45a3-7f2e-4348-9e20-ecf8dc440314", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=614b45a3-7f2e-4348-9e20-ecf8dc440314", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=614b45a3-7f2e-4348-9e20-ecf8dc440314"]}], "subject": "CHEBI:142290", "supporting_text": ["1 INDICATIONS AND USAGE Anagrelide capsules USP are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events [see Clinical Studies ( 14 ), Dosage and Administration ( 2 )] . Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a8feb05-b64b-5d5c-afa8-0713aea1094f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20201223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023", "MONDO:0010811"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:58c91f21-d2a6-5e94-9522-2177c56fe668", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "VIBEGRON", "population_context_qualifier": "adult males on pharmacological therapy for benign prostatic hyperplasia (BPH)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25f21d25-14f8-4fda-91f6-7aa8b68aa1c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25f21d25-14f8-4fda-91f6-7aa8b68aa1c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25f21d25-14f8-4fda-91f6-7aa8b68aa1c8"]}], "subject": "CHEBI:142418", "supporting_text": ["1 INDICATIONS AND USAGE GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 ) 1.1 Overactive Bladder in Adults GEMTESA ® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. 1.2 Overactive Bladder in Adult Males with Benign Prostatic Hyperplasia (BPH) GEMTESA is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anaplastic lymphoma kinase (ALK)-positive tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:431daa07-2744-5459-8de3-dd9bbbdb7d4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f844e795-b525-5892-9ce5-55a2823b8675", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "LORLATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:004f93d7-a1cd-4b67-9207-31cdcb5c5976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=004f93d7-a1cd-4b67-9207-31cdcb5c5976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=004f93d7-a1cd-4b67-9207-31cdcb5c5976"]}], "subject": "CHEBI:143117", "supporting_text": ["1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anaplastic lymphoma kinase (ALK)-positive tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe024b73-c5f2-5f0b-9db0-3574714670e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f844e795-b525-5892-9ce5-55a2823b8675", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "LORLATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2b34d62d-e02a-4af3-bc0d-1571dd4ee76d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d"]}], "subject": "CHEBI:143117", "supporting_text": ["1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "melanoma with a BRAF V600 mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ba6c84b-0bc2-549b-974c-81c44c86cbd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180920", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:69f8c6a8-386d-51fd-b56f-5b916cef0816", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ce9d0b7c-6514-5bc8-8dba-725d6d93edb6", "object": "MONDO:0005105", "object_location_in_text": [133, 141], "original_object": "melanoma", "original_subject": "binimetinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mektovi", "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi"]}], "subject": "CHEBI:145371", "supporting_text": ["MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "BRAF V600E or V600K mutation", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fc429f9-dec6-54d6-abaf-7bd06e4619fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180627", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["encorafenib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a6cd3aa-47c4-50fe-bf29-807b42bdb190", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce9d0b7c-6514-5bc8-8dba-725d6d93edb6", "object": "MONDO:0005105", "object_location_in_text": [135, 170], "original_object": "unresectable or metastatic melanoma", "original_subject": "BINIMETINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6c3408ac-d401-4925-8a03-26591afbc240", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240"]}], "subject": "CHEBI:145371", "supporting_text": ["1 INDICATIONS AND USAGE MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. [see Dosage and Administration (2.1) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-small cell lung cancer with a BRAF V600E mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a485246-1f48-5eeb-8429-64f0be6abad7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180920", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ce9d0b7c-6514-5bc8-8dba-725d6d93edb6", "object": "MONDO:0005233", "object_location_in_text": [309, 335], "original_object": "non-small cell lung cancer", "original_subject": "binimetinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mektovi", "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi"]}], "subject": "CHEBI:145371", "supporting_text": ["MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3273990", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57cf46d6-a3f6-5d73-b486-c9e346d353b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180627", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["encorafenib"], "medic_disease_context_ids": ["UMLS:C3273990"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce9d0b7c-6514-5bc8-8dba-725d6d93edb6", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "BINIMETINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6c3408ac-d401-4925-8a03-26591afbc240", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240"]}], "subject": "CHEBI:145371", "supporting_text": ["1 INDICATIONS AND USAGE MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) MEKTOVI is indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. [see Dosage and Administration (2.1) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1511021", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34779176-066d-5827-809f-792931f635cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190108", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1511021"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:219fe20c-9480-5ca2-9ea0-628fd0dc4df1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:ce9d0b7c-6514-5bc8-8dba-725d6d93edb6", "object": "UMLS:C4725093", "object_location_in_text": [67, 88], "original_object": "unresectable melanoma", "original_subject": "BINIMETINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BINIMETINIB#84-20190108", "https://www.pmda.go.jp/files/000240841.pdf"]}], "subject": "CHEBI:145371", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of unresectable melanoma with BRAF gene mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0004808", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a901621-5d1d-5215-84bc-53f254db5190", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191024", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004808"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:291f9833-04c8-5285-8aa9-5f77c892b3e8", "object": "HP:0004808", "object_location_in_text": [104, 127], "original_object": "acute myeloid leukaemia", "original_subject": "gilteritinib", "population_context_qualifier": "adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xospata", "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xospata"]}], "subject": "CHEBI:145372", "supporting_text": ["Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "FLT3 mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9af6906e-1b41-58c3-a538-f0308ace0385", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181128", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:291f9833-04c8-5285-8aa9-5f77c892b3e8", "object": "MONDO:0018874", "original_object": "acute myeloid leukemia", "original_subject": "GILTERITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5ff59aa-9c0d-49a8-9053-1f179b482383", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383"]}], "subject": "CHEBI:145372", "supporting_text": ["1 INDICATIONS AND USAGE XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 ) 1.1 Relapsed or Refractory Acute Myeloid Leukemia XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FLT3 mutation-positive, relapsed or refractory", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba668a3f-5db1-5898-8dae-b17c75e1c509", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:04967439-f0f8-5e8f-9953-03a9841cdb9b", "object": "MONDO:0018874", "object_location_in_text": [113, 135], "original_object": "acute myeloid leukemia", "original_subject": "GILTERITINIB FUMARATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:GILTERITINIB FUMARATE#82-20180921", "https://www.pmda.go.jp/files/000228502.pdf"]}], "subject": "CHEBI:145372", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. [Orphan drug, SAKIGAKE designation]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026538", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:def274aa-9123-5ee6-80d4-77f5abd43364", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190802", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026538"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d081e9d5-9d09-5b1a-9a15-466e46a6a953", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:191b4ae5-c339-5e75-b63e-93482ff45400", "object": "MONDO:0002522", "original_object": "tenosynovial giant cell tumor", "original_subject": "PEXIDARTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b0ec4bf-b2ac-49ee-96af-7740ad3f2e16"]}], "subject": "CHEBI:145373", "supporting_text": ["1 INDICATIONS AND USAGE TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. ( 1 )"], "temporal_context_qualifier": "not amenable to improvement with surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "de novo or secondary acute myeloid leukaemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:171a3c85-cc47-5053-ace1-a91233dacaff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200626", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["low-dose cytarabine"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:aa615433-f655-5c2e-a89b-9a0e50c8ee89", "object": "MONDO:0018874", "original_object": "acute myeloid leukemia", "original_subject": "glasdegib", "population_context_qualifier": "adult patients who are not candidates for standard induction chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:daurismo", "https://www.ema.europa.eu/en/documents/product-information/daurismo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo"]}], "subject": "CHEBI:145428", "supporting_text": ["Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76e24cd6-f438-5d2c-a53b-9eebe3bdb44f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230908", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2995b5ee-1a24-5e32-a2cf-d6acfa69c1a0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8e454fcf-de89-5cbb-a056-3fcbb0620f2a", "object": "UMLS:C0524864", "original_object": "hematopoietic stem cell mobilization", "original_subject": "MOTIXAFORTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e704b2db-f119-40ba-9346-9229e3281c9e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e704b2db-f119-40ba-9346-9229e3281c9e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e704b2db-f119-40ba-9346-9229e3281c9e"]}], "subject": "CHEBI:145536", "supporting_text": ["1 INDICATIONS AND USAGE APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )"], "temporal_context_qualifier": "for collection and subsequent autologous transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89ade1b0-b21c-5ed9-aa9b-495faeb63cb2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230908", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2995b5ee-1a24-5e32-a2cf-d6acfa69c1a0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8e454fcf-de89-5cbb-a056-3fcbb0620f2a", "object": "UMLS:C0524864", "original_object": "hematopoietic stem cell mobilization", "original_subject": "MOTIXAFORTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7cdc584-ebf0-a68e-e053-6294a90a9ea9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7cdc584-ebf0-a68e-e053-6294a90a9ea9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7cdc584-ebf0-a68e-e053-6294a90a9ea9"]}], "subject": "CHEBI:145536", "supporting_text": ["1 INDICATIONS AND USAGE APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )"], "temporal_context_qualifier": "for collection and subsequent autologous transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15644abc-9ade-5c08-bd60-6bddb203efcc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2bf6278-b753-4277-9d77-9cccedaba567", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2bf6278-b753-4277-9d77-9cccedaba567", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2bf6278-b753-4277-9d77-9cccedaba567"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26b7598b-4b5c-572e-9121-19fbbeb38fff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4108873-d2d2-4667-b049-02b89b8f2494", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4108873-d2d2-4667-b049-02b89b8f2494", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4108873-d2d2-4667-b049-02b89b8f2494"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablet is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablet is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29518d59-68d9-5bcb-abf1-920c92a3ea6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:570c3ae7-8011-4944-8935-57d0a66102aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=570c3ae7-8011-4944-8935-57d0a66102aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=570c3ae7-8011-4944-8935-57d0a66102aa"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b2ae7ed-3f54-52d8-9471-5dad7f9f0937", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:801f2143-6816-4f34-b65d-16bb2cf07975", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=801f2143-6816-4f34-b65d-16bb2cf07975", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=801f2143-6816-4f34-b65d-16bb2cf07975"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43cc6092-39a3-585a-a14d-83b54181186b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c088397-f407-4606-95a0-d9fe619888c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c088397-f407-4606-95a0-d9fe619888c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c088397-f407-4606-95a0-d9fe619888c3"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium Chloride Extended-Release Capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium Chloride Extended-Release Capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58856e84-58d3-5053-b2b8-bd62f5e6fa64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1523cb4c-3a52-6c18-e063-6394a90a396f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1523cb4c-3a52-6c18-e063-6394a90a396f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1523cb4c-3a52-6c18-e063-6394a90a396f"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f7d0f85-458b-568d-ba0f-1fddfade1bb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a2fea88-266d-4fc0-a476-66dc6effcff7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a2fea88-266d-4fc0-a476-66dc6effcff7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a2fea88-266d-4fc0-a476-66dc6effcff7"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6624aa04-794b-529d-8508-70188173351d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5c837a4-d1c6-4615-b7ad-27f3162a03aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5c837a4-d1c6-4615-b7ad-27f3162a03aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5c837a4-d1c6-4615-b7ad-27f3162a03aa"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e38178a-f3c0-516c-8066-67369fccf448", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a711666-9e80-4728-b745-e7dc86f57510", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a711666-9e80-4728-b745-e7dc86f57510", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a711666-9e80-4728-b745-e7dc86f57510"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c075fa87-695f-5a9e-b98b-5dfe8d68f3d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:048b4bc7-c77e-40fc-9bfb-bb35c6a3f871", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=048b4bc7-c77e-40fc-9bfb-bb35c6a3f871", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=048b4bc7-c77e-40fc-9bfb-bb35c6a3f871"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS &amp; USAGE Trospium chloride tablets is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7d88c8b-097c-5e9d-a606-88aaf2d8e0e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48d1b484-ee0a-4d66-9b45-4ba34e65ed13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48d1b484-ee0a-4d66-9b45-4ba34e65ed13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48d1b484-ee0a-4d66-9b45-4ba34e65ed13"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e145bc0f-1ab9-58ca-b774-382cbd4bb47d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040528", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a84733ec-e779-57df-a8ed-f02a976a08af", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "TROSPIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:35ae4d64-4625-4fdd-a2d4-e20b87c56876", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=35ae4d64-4625-4fdd-a2d4-e20b87c56876", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=35ae4d64-4625-4fdd-a2d4-e20b87c56876"]}], "subject": "CHEBI:145791", "supporting_text": ["1 INDICATIONS AND USAGE Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "drug-induced coronary spasm", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83231912-2bf3-5158-8633-383e71fb1335", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170825", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:837ccf17-aac1-55d2-bc07-75889b5987eb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:70ff3ce6-7fe5-55d7-abb7-dc594f4c53bc", "object": "MONDO:0005356", "object_location_in_text": [73, 87], "original_object": "coronary spasm", "original_subject": "ACETYLCHOLINE CHLORIDE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACETYLCHOLINE CHLORIDE#92-20170825", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:15355", "supporting_text": ["A drug with a new route of administration indicated for the induction of coronary spasm in a drug- induced coronary spasm provocation test during coronary angiography. [Public knowledge-based application after PAFSC's preliminary assessment]"], "temporal_context_qualifier": "during coronary angiography"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23ce7fca-28e7-5c56-9817-6864c4d48ee5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "MONDO:0005098", "object_location_in_text": [68, 74], "original_object": "stroke", "original_subject": "ASPIRIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f07c8535-f9fb-4697-9b63-1ab22210efc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f07c8535-f9fb-4697-9b63-1ab22210efc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f07c8535-f9fb-4697-9b63-1ab22210efc9"]}], "subject": "CHEBI:15365", "supporting_text": ["1 INDICATIONS AND USAGE AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (1)"], "temporal_context_qualifier": "following transient ischemia of the brain or completed ischemic stroke due to thrombosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:324aaa9b-8dbc-50d5-a2af-f0d4283353c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "MONDO:0005098", "object_location_in_text": [111, 117], "original_object": "stroke", "original_subject": "ASPIRIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:467d6ce3-bc05-4aa1-87cc-3214fd628d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=467d6ce3-bc05-4aa1-87cc-3214fd628d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=467d6ce3-bc05-4aa1-87cc-3214fd628d39"]}], "subject": "CHEBI:15365", "supporting_text": ["1 INDICATIONS AND USAGE Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. • Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3da13997-ff7e-54a6-b19c-60eed0c7c4dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "MONDO:0005098", "object_location_in_text": [111, 117], "original_object": "stroke", "original_subject": "ASPIRIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:465bbdac-a483-689a-811f-32923ea99fa7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=465bbdac-a483-689a-811f-32923ea99fa7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=465bbdac-a483-689a-811f-32923ea99fa7"]}], "subject": "CHEBI:15365", "supporting_text": ["1 INDICATIONS AND USAGE Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7421d13-2cec-5ffa-9c53-c875ea0cc791", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "MONDO:0005098", "object_location_in_text": [68, 74], "original_object": "stroke", "original_subject": "ASPIRIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6473563d-b4df-4434-a74e-f8fa3cb9994f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6473563d-b4df-4434-a74e-f8fa3cb9994f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6473563d-b4df-4434-a74e-f8fa3cb9994f"]}], "subject": "CHEBI:15365", "supporting_text": ["1 INDICATIONS AND USAGE AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (1)"], "temporal_context_qualifier": "following transient ischemia of the brain or completed ischemic stroke due to thrombosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d23543d2-8164-521b-aff5-1642444138df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "MONDO:0005098", "object_location_in_text": [111, 117], "original_object": "stroke", "original_subject": "ASPIRIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92222dd3-7802-2a03-7d30-58cf192cc33e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92222dd3-7802-2a03-7d30-58cf192cc33e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92222dd3-7802-2a03-7d30-58cf192cc33e"]}], "subject": "CHEBI:15365", "supporting_text": ["1 INDICATIONS AND USAGE Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee816858-1854-5150-8d92-92bbce04bfe2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "MONDO:0005098", "object_location_in_text": [68, 74], "original_object": "stroke", "original_subject": "ASPIRIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e729d829-4bd0-4074-85ea-e0f9f5d7cdb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5"]}], "subject": "CHEBI:15365", "supporting_text": ["1 INDICATIONS AND USAGE AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (1)"], "temporal_context_qualifier": "following transient ischemia of the brain or completed ischemic stroke due to thrombosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002315", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:403dfc65-481c-574e-8df9-d430ed6d2fc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002315"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "UMLS:C0235309", "object_location_in_text": [125, 138], "original_object": "upset stomach", "original_subject": "ASPIRIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7"]}], "subject": "CHEBI:15365", "supporting_text": ["Uses for the relief of: heartburn, acid indigestion, and sour stomach when accompanied with headache or body aches and pains upset stomach with headache from overindulgence in food or drink headache, body aches, and pain alone"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002315", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d760aba2-7710-5fd4-a744-30b47d0a38ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002315"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a569b57e-af37-5880-a6ef-d749dbda9aba", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f1f8f61d-fedd-55dc-b998-37cdc9d9393b", "object": "UMLS:C0860277", "object_location_in_text": [57, 69], "original_object": "sour stomach", "original_subject": "ASPIRIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7"]}], "subject": "CHEBI:15365", "supporting_text": ["Uses for the relief of: heartburn, acid indigestion, and sour stomach when accompanied with headache or body aches and pains upset stomach with headache from overindulgence in food or drink headache, body aches, and pain alone"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute promyelocytic leukemia characterized by presence of t(15, 17) translocation or presence of PML/RARα gene expression, 17) translocation or presence of PML/RARα gene expression, anthracycline chemotherapy refractory or relapsed disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d5836a1-a6ed-5b3e-8eda-f8e00ae8c499", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006a9567-eebb-51a6-aba2-f08b5da600ac", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d2ee52cc-4b2e-5d55-8f73-60f5f528ce95", "object": "MONDO:0012883", "original_object": "acute promyelocytic leukemia", "original_subject": "TRETINOIN", "population_context_qualifier": "adults and pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:045258e2-5efb-4147-bf74-4c43af04dccc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=045258e2-5efb-4147-bf74-4c43af04dccc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=045258e2-5efb-4147-bf74-4c43af04dccc"]}], "subject": "CHEBI:15367", "supporting_text": ["1 INDICATIONS AND USAGE Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin capsules are a retinoid indicated for induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL), characterized by presence of t(15;17) translocation or presence of PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute promyelocytic leukemia characterized by presence of t(15, 17) translocation or presence of PML/RARα gene expression, 17) translocation or presence of PML/RARα gene expression, anthracycline chemotherapy refractory or relapsed disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a87c6409-1ba4-554e-8851-3ee10b9008b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006a9567-eebb-51a6-aba2-f08b5da600ac", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d2ee52cc-4b2e-5d55-8f73-60f5f528ce95", "object": "MONDO:0012883", "original_object": "acute promyelocytic leukemia", "original_subject": "TRETINOIN", "population_context_qualifier": "adults and pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c4ae9d9-c2a0-4995-a27a-e3f0f0284db9"]}], "subject": "CHEBI:15367", "supporting_text": ["1 INDICATIONS AND USAGE Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin capsules are a retinoid indicated for induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL), characterized by presence of t(15;17) translocation or presence of PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6d9d1e6-14d0-5d35-a93c-0f5bf71ea4f0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2ed4f6a5-3544-503a-b34b-3659f20047fa", "object": "HP:0012531", "object_location_in_text": [152, 156], "original_object": "pain", "original_subject": "CAMPHOR", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2089c28b-98fd-4797-8940-b0749d8b5df7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2089c28b-98fd-4797-8940-b0749d8b5df7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2089c28b-98fd-4797-8940-b0749d8b5df7"]}], "subject": "CHEBI:15396", "supporting_text": ["Uses • On chest and throat, helps temporarily relieve cough as may occur with common cold and minor bronchial irritation. • For the temporary relief of pain associated with minor skin irritation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "fibrotic conditions of the penis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bad8412-b1ff-5b05-a2c9-ac20a3f9e07a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81c5e5fa-0e43-5ff9-8fd9-0633603b69ce", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5453381-2d41-56db-8035-e7896345f242", "object": "MONDO:0008231", "object_location_in_text": [474, 492], "original_object": "Peyronie's disease", "original_subject": "ALPROSTADIL", "population_context_qualifier": "men", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a295fc1e-d82c-4f44-bc2d-a552bf594c98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98"]}], "subject": "CHEBI:15544", "supporting_text": ["4 CONTRAINDICATIONS CAVERJECT is contraindicated: • in men who have a known hypersensitivity to the drug [see Adverse Reactions (6.1) ] • in men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia [see Warnings and Precautions (5.1) ] • for the treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as anatomical deformation, angulation, cavernosal fibrosis, or Peyronie's disease [see Warnings and Precautions (5.2) ] • in men with penile implants. • Men who have known hypersensitivity to the drug ( 4 ). • Men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia ( 4 ). • Treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as anatomical deformation, angulation, cavernosal fibrosis, or Peyronie's disease ( 4 ). • Men with penile implants ( 4 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3647902", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8efde7d9-44af-5492-a150-bb2775885907", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3647902", "UMLS:C0948238"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:17ab8296-6dc7-538f-8591-b04005ce083f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5453381-2d41-56db-8035-e7896345f242", "object": "MONDO:0005362", "object_location_in_text": [41, 61], "original_object": "erectile dysfunction", "original_subject": "ALPROSTADIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8b8ec8d-1318-43e4-a182-446e9f9579de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de"]}], "subject": "CHEBI:15544", "supporting_text": ["edex ® is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004935", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:245e1950-eff1-5549-bfe3-c43b1288c932", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0004935", "MONDO:0009938", "MONDO:0011514", "MONDO:0008542", "HP:0001680", "MONDO:0000153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d09aeaa6-1ee8-5e4d-ab06-3c8efb04c523", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5453381-2d41-56db-8035-e7896345f242", "object": "MONDO:0011827", "original_object": "patent ductus arteriosus", "original_subject": "ALPROSTADIL", "population_context_qualifier": "neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:930f8c02-46a8-4cff-a484-660468ab23c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=930f8c02-46a8-4cff-a484-660468ab23c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=930f8c02-46a8-4cff-a484-660468ab23c3"]}], "subject": "CHEBI:15544", "supporting_text": ["PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care."], "temporal_context_qualifier": "until corrective or palliative surgery can be performed"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004935", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2757a7d6-0de1-5538-957a-0f8e0f00e4ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0004935", "MONDO:0009938", "MONDO:0011514", "MONDO:0008542", "HP:0001680", "MONDO:0000153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d09aeaa6-1ee8-5e4d-ab06-3c8efb04c523", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5453381-2d41-56db-8035-e7896345f242", "object": "MONDO:0011827", "original_object": "patent ductus arteriosus", "original_subject": "ALPROSTADIL", "population_context_qualifier": "neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:35d229e1-6947-435c-bf54-bfa09cca7e53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=35d229e1-6947-435c-bf54-bfa09cca7e53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=35d229e1-6947-435c-bf54-bfa09cca7e53"]}], "subject": "CHEBI:15544", "supporting_text": ["Alprostadil injection, USP is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. Alprostadil injection, USP should be administered only by trained personnel in facilities that provide pediatric intensive care."], "temporal_context_qualifier": "until corrective or palliative surgery can be performed"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004935", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed410737-979a-5e86-bf50-30b947fe8387", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0004935", "MONDO:0009938", "MONDO:0011514", "MONDO:0008542", "HP:0001680", "MONDO:0000153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d09aeaa6-1ee8-5e4d-ab06-3c8efb04c523", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5453381-2d41-56db-8035-e7896345f242", "object": "MONDO:0011827", "original_object": "patent ductus arteriosus", "original_subject": "ALPROSTADIL", "population_context_qualifier": "neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dea460fa-d05e-4191-8461-f185a711ad89", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dea460fa-d05e-4191-8461-f185a711ad89", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dea460fa-d05e-4191-8461-f185a711ad89"]}], "subject": "CHEBI:15544", "supporting_text": ["PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care."], "temporal_context_qualifier": "until corrective or palliative surgery can be performed"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "unfavourable cervix", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afa4cf67-9c0d-57e5-aaf6-9ead08bd996c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200123", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:0f9df1ae-38ca-50e0-8f55-6ef6a1092ac1", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:2667ed91-c2ec-52d9-aee8-777d5bdc870b", "object": "UMLS:C0600454", "object_location_in_text": [74, 91], "original_object": "cervical ripening", "original_subject": "DINOPROSTONE", "population_context_qualifier": "patients with unfavourable cervix from 37 completed weeks of gestation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DINOPROSTONE#69-20200123", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:15551", "supporting_text": ["A drug with a new route of administration indicated for the initiation of cervical ripening in patients with unfavourable cervix from 37 completed weeks of gestation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58e2afe3-9f0a-5394-a548-08c5c103044f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050812", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0149a7ce-f7d7-5caa-b734-27427ea70749", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:875e2e05-1556-580b-9319-49b3c4cc1af0", "object": "MONDO:0005920", "original_object": "Plasmodium falciparum malaria", "original_subject": "QUININE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce2ffee3-3048-43a0-ac45-ee32ce0c4c33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce2ffee3-3048-43a0-ac45-ee32ce0c4c33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce2ffee3-3048-43a0-ac45-ee32ce0c4c33"]}], "subject": "CHEBI:15854", "supporting_text": ["1 INDICATIONS AND USAGE QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies (14) ]. QUALAQUIN oral capsules are not approved for: Treatment of severe or complicated P. falciparum malaria. Prevention of malaria. Treatment or prevention of nocturnal leg cramps [ see Warnings and Precautions (5.1) ]. QUALAQUIN ® (quinine sulfate) is a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:829f15a2-ab1a-5803-becc-8a3dd3e886b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050812", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0149a7ce-f7d7-5caa-b734-27427ea70749", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:875e2e05-1556-580b-9319-49b3c4cc1af0", "object": "MONDO:0005920", "original_object": "Plasmodium falciparum malaria", "original_subject": "QUININE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2f73c64-b92c-49bf-ad39-e32ac83e4d3d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2f73c64-b92c-49bf-ad39-e32ac83e4d3d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f73c64-b92c-49bf-ad39-e32ac83e4d3d"]}], "subject": "CHEBI:15854", "supporting_text": ["1 INDICATIONS AND USAGE Quinine Sulfate Capsules, USP is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see Clinical Studies ( 14 )]."], "temporal_context_qualifier": "geographical regions where resistance to chloroquine has been documented"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8489b008-ad8b-53aa-bd65-9801220174ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050812", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0149a7ce-f7d7-5caa-b734-27427ea70749", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:875e2e05-1556-580b-9319-49b3c4cc1af0", "object": "MONDO:0005920", "original_object": "Plasmodium falciparum malaria", "original_subject": "QUININE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e782283e-2608-4fd6-a8b2-6c30b9d5d3b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e782283e-2608-4fd6-a8b2-6c30b9d5d3b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e782283e-2608-4fd6-a8b2-6c30b9d5d3b0"]}], "subject": "CHEBI:15854", "supporting_text": ["1 INDICATIONS AND USAGE Quinine sulfate capsules are an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies ( 14 ) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:954ba879-04ae-5a23-bafc-e8d93efe1c1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050812", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0149a7ce-f7d7-5caa-b734-27427ea70749", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:875e2e05-1556-580b-9319-49b3c4cc1af0", "object": "MONDO:0005920", "original_object": "Plasmodium falciparum malaria", "original_subject": "QUININE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1f66fba7-4026-4504-918d-4c88f2835cc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0"]}], "subject": "CHEBI:15854", "supporting_text": ["1 INDICATIONS AND USAGE QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies (14) ]. QUALAQUIN oral capsules are not approved for: Treatment of severe or complicated P. falciparum malaria. Prevention of malaria. Treatment or prevention of nocturnal leg cramps [ see Warnings and Precautions (5.1) ]. QUALAQUIN ® (quinine sulfate) is a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adcdd2e0-eea5-5968-9fab-7aa2a7b497d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050812", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0149a7ce-f7d7-5caa-b734-27427ea70749", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:875e2e05-1556-580b-9319-49b3c4cc1af0", "object": "MONDO:0005920", "original_object": "Plasmodium falciparum malaria", "original_subject": "QUININE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f567d5c7-ea5d-49a7-a035-b47208135f73", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f567d5c7-ea5d-49a7-a035-b47208135f73", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f567d5c7-ea5d-49a7-a035-b47208135f73"]}], "subject": "CHEBI:15854", "supporting_text": ["1 INDICATIONS AND USAGE Quinine sulfate is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see Clinical Studies (14) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.9025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a5c08e2-fe2f-5f2a-993a-8c3726bb76f6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.9025, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19b12ca7-99f4-5bd6-97b6-996b9ba66d53", "object": "MONDO:0005550", "object_location_in_text": [39, 48], "original_object": "infection", "original_subject": "PHENOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45"]}], "subject": "CHEBI:15882", "supporting_text": ["Uses first aid to help protect against infection and for the temporary relief of pain and itching associated with minor burns, minor cuts, scrapes, insect bites, or minor skin irritations."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:861ad89e-1d68-55b2-9596-affeb57145db", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19b12ca7-99f4-5bd6-97b6-996b9ba66d53", "object": "HP:0000989", "object_location_in_text": [90, 97], "original_object": "itching", "original_subject": "PHENOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45"]}], "subject": "CHEBI:15882", "supporting_text": ["Uses first aid to help protect against infection and for the temporary relief of pain and itching associated with minor burns, minor cuts, scrapes, insect bites, or minor skin irritations."], "temporal_context_qualifier": "temporary relief"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ed829ab-7657-535b-af7f-81ec8a84711e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19b12ca7-99f4-5bd6-97b6-996b9ba66d53", "object": "HP:0012531", "object_location_in_text": [81, 85], "original_object": "pain", "original_subject": "PHENOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45"]}], "subject": "CHEBI:15882", "supporting_text": ["Uses first aid to help protect against infection and for the temporary relief of pain and itching associated with minor burns, minor cuts, scrapes, insect bites, or minor skin irritations."], "temporal_context_qualifier": "temporary relief"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a47c5e8-38d2-5c09-9554-5835182cbfd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3a99e131-3d27-5128-8511-fea614b7a81e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:30a54334-95ae-5dd1-bd54-9ae7a981a3f6", "object": "HP:0002401", "object_location_in_text": [79, 99], "original_object": "stroke-like episodes", "original_subject": "TAURINE", "population_context_qualifier": "patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TAURINE#78-20190221", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:15891", "supporting_text": ["A drug with a new additional indication and a new dosage for the inhibition of stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gynecologic infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d0b9923-ff71-5d4c-8d72-22955d3e6468", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "original_object": "endometritis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gynecologic infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7da6f94-c9cc-54ee-8ea7-3dacad5efce6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "original_object": "endometritis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68b90d37-c46d-53bd-971a-23c6a25100bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0003781", "object_location_in_text": [1155, 1165], "original_object": "bronchitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b731035-210e-5362-a52a-67000ea97f9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0003781", "object_location_in_text": [1046, 1056], "original_object": "bronchitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d70c3bf-6d6a-5ef8-b2b4-558e6ce2b8ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "object_location_in_text": [855, 864], "original_object": "pneumonia", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be1eb8b0-d46d-540c-9668-00aa0a3871ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "object_location_in_text": [833, 842], "original_object": "pneumonia", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b2c9c1c-8488-5cce-b8db-f74d2e77b079", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02df5647-0ffb-579b-b695-7f527436d179", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0006032", "object_location_in_text": [782, 790], "original_object": "cystitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8f3a5c9-ee90-5092-8522-a48135ad4613", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02df5647-0ffb-579b-b695-7f527436d179", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0006032", "object_location_in_text": [760, 768], "original_object": "cystitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gynecologic infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a847470-ff24-552c-9965-0e98a708dd52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "original_object": "pelvic cellulitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gynecologic infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f303aa5-a308-5989-970f-06b2612d7681", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "original_object": "pelvic cellulitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2766d750-3b5b-5fc8-92d8-3b8e628ff750", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59be1928-64f0-5f57-baea-0f6a422cce8b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0006939", "object_location_in_text": [741, 755], "original_object": "pyelonephritis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ba3e93b-d56b-5bfd-8709-7da4341e2511", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59be1928-64f0-5f57-baea-0f6a422cce8b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:0006939", "object_location_in_text": [763, 777], "original_object": "pyelonephritis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb7578eb-feea-5e9c-8123-fce3c6d0cc7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [1811, 1822], "original_object": "peritonitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4500795-3b07-4a7d-b432-73cafbb3dbc6"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aztreonam for Injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca Efficacy for this organism in this organ system was studied in fewer than 10 infections. , Citrobacter species , and Serratia marcescens . Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens . Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis , Serratia marcescens , and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species . Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae , Pseudomonas aeruginosa , Citrobacter species including C. f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5323be9-c0a4-566e-8624-0b9f896b7a7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbf280ff-b7f8-5ae5-935b-8a7fec94f974", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [1705, 1716], "original_object": "peritonitis", "original_subject": "AZTREONAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a105eaf-ee77-4016-beeb-d425a5565db2"]}], "subject": "CHEBI:161680", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K. pneumoniae , Enterobacter species including E. cloacae *, Pseudomonas aeruginosa , Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gas", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0dd0154a-320c-502f-a4ac-d2b7585973ae", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:934db977-24c6-57f7-9d06-7e07e6ea8d22", "object": "HP:0003270", "object_location_in_text": [123, 131], "original_object": "bloating", "original_subject": "HYDROXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7"]}], "subject": "CHEBI:16234", "supporting_text": ["Uses for the relief of: • acid indigestion • heartburn • sour stomach • upset stomach due to these symptoms • pressure and bloating commonly referred to as gas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235304", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb94eaed-59a4-5110-9927-5975f2dc0232", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235304", "HP:0002020", "UMLS:C0860277"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:934db977-24c6-57f7-9d06-7e07e6ea8d22", "object": "UMLS:C0235309", "object_location_in_text": [72, 85], "original_object": "upset stomach", "original_subject": "HYDROXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7"]}], "subject": "CHEBI:16234", "supporting_text": ["Uses for the relief of: • acid indigestion • heartburn • sour stomach • upset stomach due to these symptoms • pressure and bloating commonly referred to as gas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1579838", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a99599d-37dd-510f-94c6-1586f5df6afc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171214", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1579838"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6ae7f6b-9dd2-5824-9e15-fc787110e221", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6f3f086-2252-5117-a619-b423cc294f6b", "object": "UMLS:C0036537", "object_location_in_text": [27, 37], "original_object": "secretions", "original_subject": "HYDROGEN PEROXIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50823ff5-ad08-4449-bc4a-9a8ae25ec0d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50823ff5-ad08-4449-bc4a-9a8ae25ec0d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50823ff5-ad08-4449-bc4a-9a8ae25ec0d5"]}], "subject": "CHEBI:16240", "supporting_text": ["Use Aids in the removal of secretions associated with sore mouth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor oral wounds", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fb7fa4a-0f01-5728-bd2a-62ad19072d7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171214", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eed97779-c369-5e75-925a-2a1821eaca50", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6f3f086-2252-5117-a619-b423cc294f6b", "object": "UMLS:C0016542", "object_location_in_text": [375, 391], "original_object": "foreign material", "original_subject": "HYDROGEN PEROXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5dbaadf-76a8-4c48-af2d-f4455e9411f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5dbaadf-76a8-4c48-af2d-f4455e9411f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5dbaadf-76a8-4c48-af2d-f4455e9411f0"]}], "subject": "CHEBI:16240", "supporting_text": ["Uses aids in the removal of phlegm, mucus, or other secretions associated with occasional sore mouth for temporary use in cleansing minor wounds or minor gum inflammation resulting from minor dental procedures, dentures, orthodontic appliances, accidental injury, or other irritations of the mouth and gums for temporary use to cleanse canker sores assists in the removal of foreign material from minor oral wounds"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "occasional sore mouth", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43485b05-d990-53bd-9a9c-a0e8bb313eaa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171214", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf916e25-c5ae-5e3f-a893-e4aa6110df31", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6f3f086-2252-5117-a619-b423cc294f6b", "object": "UMLS:C1579838", "original_object": "sore mouth", "original_subject": "HYDROGEN PEROXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0a07631-6770-48b3-bf7b-19f3f3965cd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0a07631-6770-48b3-bf7b-19f3f3965cd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0a07631-6770-48b3-bf7b-19f3f3965cd9"]}], "subject": "CHEBI:16240", "supporting_text": ["Uses first aid to help prevent the risk of infection in minor cuts, scrapes and burns aids in the removal of phlegm, mucuc, or other secretions associated with occasional sore mouth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1579838", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e91d5c7-ca55-5743-ba4d-d3989f5f702f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171214", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1579838"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf916e25-c5ae-5e3f-a893-e4aa6110df31", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6f3f086-2252-5117-a619-b423cc294f6b", "object": "UMLS:C1579838", "object_location_in_text": [54, 64], "original_object": "sore mouth", "original_subject": "HYDROGEN PEROXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50823ff5-ad08-4449-bc4a-9a8ae25ec0d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50823ff5-ad08-4449-bc4a-9a8ae25ec0d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50823ff5-ad08-4449-bc4a-9a8ae25ec0d5"]}], "subject": "CHEBI:16240", "supporting_text": ["Use Aids in the removal of secretions associated with sore mouth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "accessory bypass tracts", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4b28b48-6c61-5f9b-b3f4-cf15ac0d7bdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891030", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a475fe7-6121-5efc-b250-2995fc50327e", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "ADENOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b701a86-3c4e-4c13-bf9e-aa9e73774c20", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b701a86-3c4e-4c13-bf9e-aa9e73774c20", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b701a86-3c4e-4c13-bf9e-aa9e73774c20"]}], "subject": "CHEBI:16335", "supporting_text": ["INDICATIONS &amp; USAGE Intravenous adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine injection administration. It is important to be sure the adenosine injection solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION). Adenosine Injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosineinjection administration."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04e5b15d-2d71-5790-8c11-d9252bf509f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [60, 97], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2cbc620-59fd-47b6-9e4b-7e3e31533a1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2cbc620-59fd-47b6-9e4b-7e3e31533a1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2cbc620-59fd-47b6-9e4b-7e3e31533a1c"]}], "subject": "CHEBI:16347", "supporting_text": ["CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f24b55c-7808-5b7e-bad4-2c5a0368b005", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [71, 108], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18dc8eae-56c1-46ec-9d21-e17d7b2f91db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18dc8eae-56c1-46ec-9d21-e17d7b2f91db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18dc8eae-56c1-46ec-9d21-e17d7b2f91db"]}], "subject": "CHEBI:16347", "supporting_text": ["INDICATIONS &amp; USAGE Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:399f9282-4095-53f3-bf9a-a8a98347479a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [47, 84], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3563c2f5-9814-4d55-8d90-bd7d6dcff36b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3563c2f5-9814-4d55-8d90-bd7d6dcff36b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3563c2f5-9814-4d55-8d90-bd7d6dcff36b"]}], "subject": "CHEBI:16347", "supporting_text": ["Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see Clinical Pharmacology ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42419a8b-589f-5eba-8a9f-2fedf3899d58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [61, 98], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05ab18c1-fb01-48fa-8f05-0200bb8a5edf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05ab18c1-fb01-48fa-8f05-0200bb8a5edf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05ab18c1-fb01-48fa-8f05-0200bb8a5edf"]}], "subject": "CHEBI:16347", "supporting_text": ["Levocarnitine oral solution is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine oral solution is also indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5272f95b-8b63-525b-825f-782e5e99679b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [65, 102], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ada35959-e317-4161-ae79-3475096c679f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ada35959-e317-4161-ae79-3475096c679f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ada35959-e317-4161-ae79-3475096c679f"]}], "subject": "CHEBI:16347", "supporting_text": ["Levocarnitine Oral Solution USP is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see Clinical Pharmacology ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine Oral Solution USP is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. CONTRAINDICATIONS None known."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77151626-1a4d-58f1-8a96-8b99524fb19a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [60, 97], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2133bc3-9c15-48bd-8b16-b8995a6a14cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2133bc3-9c15-48bd-8b16-b8995a6a14cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2133bc3-9c15-48bd-8b16-b8995a6a14cd"]}], "subject": "CHEBI:16347", "supporting_text": ["CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b329919-557a-5dd0-85da-5710db064c8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [47, 84], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8a590a7-628b-45c5-ac2c-24214a69eaa6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8a590a7-628b-45c5-ac2c-24214a69eaa6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8a590a7-628b-45c5-ac2c-24214a69eaa6"]}], "subject": "CHEBI:16347", "supporting_text": ["Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1ca60b4-c012-5bb1-b43d-a935bc1d41b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [61, 98], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b43fb1-4486-48a0-b571-7754dce350a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b43fb1-4486-48a0-b571-7754dce350a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b43fb1-4486-48a0-b571-7754dce350a3"]}], "subject": "CHEBI:16347", "supporting_text": ["Levocarnitine oral solution is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine oral solution is also indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc6c361c-f744-5267-8721-f2ee81358ad9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [71, 108], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfd0d39f-d3b2-4f0d-b7a2-071a545900f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfd0d39f-d3b2-4f0d-b7a2-071a545900f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfd0d39f-d3b2-4f0d-b7a2-071a545900f4"]}], "subject": "CHEBI:16347", "supporting_text": ["INDICATIONS &amp; USAGE Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1fdb7b7-3642-5417-b0c3-e0a4b9a8b4de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [60, 97], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd904490-83f3-4cd3-bb6f-68e28509b4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd904490-83f3-4cd3-bb6f-68e28509b4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd904490-83f3-4cd3-bb6f-68e28509b4b6"]}], "subject": "CHEBI:16347", "supporting_text": ["CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001985", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1a06453-a24c-5909-bcf4-35ed9af3b15f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001985", "MONDO:0004994"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf4d54a-56e6-5ae6-82cc-f6c49426572d", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:32c8ca09-aaaa-5563-8658-6b39d6fbfd4c", "object": "MONDO:0008919", "object_location_in_text": [56, 93], "original_object": "primary systemic carnitine deficiency", "original_subject": "LEVOCARNITINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f749812-8f02-4eeb-91d9-5dd6fc9fa159", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f749812-8f02-4eeb-91d9-5dd6fc9fa159", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f749812-8f02-4eeb-91d9-5dd6fc9fa159"]}], "subject": "CHEBI:16347", "supporting_text": ["Levocarnitine tablets are indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine tablets are also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002099", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45d0fcdd-461a-521a-9ecf-a1d1d923fd38", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002099", "MONDO:0003781", "MONDO:0004849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1577fc0-9a7f-589e-ae4f-a81b0ee9448a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b32ce91-ee78-5392-a040-55c8b748ecba", "object": "MONDO:0005275", "object_location_in_text": [121, 147], "original_object": "chronic pulmonary diseases", "original_subject": "IODIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90cf3abb-c6d4-4004-8ae2-f528260a72f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90cf3abb-c6d4-4004-8ae2-f528260a72f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90cf3abb-c6d4-4004-8ae2-f528260a72f4"]}], "subject": "CHEBI:16382", "supporting_text": ["INDICATIONS &amp; USAGE Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002099", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67e846fd-e03c-5412-8aa8-e9b439cc3c60", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002099", "MONDO:0003781", "MONDO:0004849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1577fc0-9a7f-589e-ae4f-a81b0ee9448a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b32ce91-ee78-5392-a040-55c8b748ecba", "object": "MONDO:0005275", "object_location_in_text": [106, 132], "original_object": "chronic pulmonary diseases", "original_subject": "IODIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:664e6cd9-6a3c-49ef-a7b2-d09f0338b549", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=664e6cd9-6a3c-49ef-a7b2-d09f0338b549", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=664e6cd9-6a3c-49ef-a7b2-d09f0338b549"]}], "subject": "CHEBI:16382", "supporting_text": ["SSKI ® (potassium iodide oral solution, USP) is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002099", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68ae044d-e68e-5e3b-887e-893aa768130b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002099", "MONDO:0003781", "MONDO:0004849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1577fc0-9a7f-589e-ae4f-a81b0ee9448a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b32ce91-ee78-5392-a040-55c8b748ecba", "object": "MONDO:0005275", "object_location_in_text": [97, 123], "original_object": "chronic pulmonary diseases", "original_subject": "IODIDE", "population_context_qualifier": "patients with tenacious mucus complicating chronic pulmonary disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0bdf305f-ed4a-49d1-8901-edaed8d67850", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0bdf305f-ed4a-49d1-8901-edaed8d67850", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0bdf305f-ed4a-49d1-8901-edaed8d67850"]}], "subject": "CHEBI:16382", "supporting_text": ["Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002099", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d23aa5c-9ac6-5c7d-bf79-71b392100f75", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002099", "MONDO:0003781", "MONDO:0004849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1577fc0-9a7f-589e-ae4f-a81b0ee9448a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b32ce91-ee78-5392-a040-55c8b748ecba", "object": "MONDO:0005275", "object_location_in_text": [106, 132], "original_object": "chronic pulmonary diseases", "original_subject": "IODIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca1d3449-ea29-49a4-8863-365ec95f1553", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca1d3449-ea29-49a4-8863-365ec95f1553", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca1d3449-ea29-49a4-8863-365ec95f1553"]}], "subject": "CHEBI:16382", "supporting_text": ["SSKI ® (potassium iodide oral solution, USP) is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002099", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fadb783f-bb0a-5b2c-830f-4f0009ed422b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002099", "MONDO:0003781", "MONDO:0004849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1577fc0-9a7f-589e-ae4f-a81b0ee9448a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b32ce91-ee78-5392-a040-55c8b748ecba", "object": "MONDO:0005275", "object_location_in_text": [121, 147], "original_object": "chronic pulmonary diseases", "original_subject": "IODIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0bf9487-45d0-4fbc-a8dd-90f505355d14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0bf9487-45d0-4fbc-a8dd-90f505355d14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0bf9487-45d0-4fbc-a8dd-90f505355d14"]}], "subject": "CHEBI:16382", "supporting_text": ["INDICATIONS &amp; USAGE Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0025319", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18104426-427a-58a1-9b3d-0482d3b05ecd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111125", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025319"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c7808cfe-8e33-5097-baf4-6b5264401c3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "HP:0000975", "object_location_in_text": [104, 112], "original_object": "sweating", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ESTRADIOL#149-20111125", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16469", "supporting_text": ["A drug with a new dosage. This drug is indicated for the treatment of vasomotor symptoms (hot flush and sweating) associated with menopausal disorder and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1306878", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f242a0b-276b-598a-b87e-8d37526ca4a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1306878"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c7808cfe-8e33-5097-baf4-6b5264401c3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "HP:0000975", "object_location_in_text": [90, 98], "original_object": "sweating", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ESTRADIOL#173-20081016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16469", "supporting_text": ["A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1306878", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5d9fe21-3ec6-5f3c-98df-469b7210119a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080416", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1306878"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c7808cfe-8e33-5097-baf4-6b5264401c3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "HP:0000975", "object_location_in_text": [109, 117], "original_object": "sweating", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ESTRADIOL#173-20080416", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16469", "supporting_text": ["A drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms associated with climacteric disturbance and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f09b8ce8-e185-5a28-a015-6a8c288f948b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4468bcb9-0b2c-5f45-b010-bfbd72173d88", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "HP:0030016", "original_object": "dyspareunia", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6ce645c0-a550-4ae9-8dbd-3853ee8b7d26", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6ce645c0-a550-4ae9-8dbd-3853ee8b7d26", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ce645c0-a550-4ae9-8dbd-3853ee8b7d26"]}], "subject": "CHEBI:16469", "supporting_text": ["1 INDICATIONS AND USAGE IMVEXXY is an estrogen indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1 ): 1.1 Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, Due to Menopause"], "temporal_context_qualifier": "due to menopause"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0025319", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03c93147-7f3d-5ec2-ae3f-4f63fcf795d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111125", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025319"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:76d559b7-081a-5586-8d91-695a7bf504f8", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "UMLS:C0600142", "object_location_in_text": [90, 99], "original_object": "hot flush", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ESTRADIOL#149-20111125", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16469", "supporting_text": ["A drug with a new dosage. This drug is indicated for the treatment of vasomotor symptoms (hot flush and sweating) associated with menopausal disorder and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1306878", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:349fccd8-6466-528e-9b35-43ab53cc2f31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1306878"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7628a165-45ec-5eff-af9f-c3141ff31e8f", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "UMLS:C0600142", "object_location_in_text": [74, 85], "original_object": "hot flushes", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ESTRADIOL#173-20081016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16469", "supporting_text": ["A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1306878", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:554b8ec2-d75d-5c58-b766-8c2a364833bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080416", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1306878"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7628a165-45ec-5eff-af9f-c3141ff31e8f", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f6ec924-7e02-5205-9b45-eac73aa9542e", "object": "UMLS:C0600142", "object_location_in_text": [93, 104], "original_object": "hot flushes", "original_subject": "ESTRADIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ESTRADIOL#173-20080416", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16469", "supporting_text": ["A drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms associated with climacteric disturbance and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3805211", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d787d8a6-9b7c-5841-9c98-2de41cb16806", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991223", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ventilatory support", "other appropriate agents"], "medic_disease_context_ids": ["UMLS:C3805211"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e69915d-1837-50ee-9962-9ff206407c58", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:30cab5f7-105d-5da2-8096-d0040d8c5264", "object": "MONDO:0005149", "object_location_in_text": [268, 290], "original_object": "pulmonary hypertension", "original_subject": "NITRIC OXIDE", "population_context_qualifier": "term and near-term (>34 weeks gestation) neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff98b29-bcd3-82eb-e063-6394a90abf8c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff98b29-bcd3-82eb-e063-6394a90abf8c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff98b29-bcd3-82eb-e063-6394a90abf8c"]}], "subject": "CHEBI:16480", "supporting_text": ["Noxivent ™ is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (&gt;34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0655c7ef-7977-5982-872a-c8e9a6120233", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:828568a7-1808-4330-b466-01889b2311a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=828568a7-1808-4330-b466-01889b2311a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=828568a7-1808-4330-b466-01889b2311a2"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0da47348-bc81-5d9a-a4a6-61bf76007345", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15aa2f36-ccc6-431a-99a2-45d812ef4bbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15aa2f36-ccc6-431a-99a2-45d812ef4bbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15aa2f36-ccc6-431a-99a2-45d812ef4bbf"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin administration", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18bb00a4-9af2-54b3-830e-4f58de8dbc56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ff09f58-c225-4792-9f1e-9d2b7a413521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ff09f58-c225-4792-9f1e-9d2b7a413521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ff09f58-c225-4792-9f1e-9d2b7a413521"]}], "subject": "CHEBI:16586", "supporting_text": ["CONTRAINDICATIONS Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering Aminocaproic Acid Injection. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic Acid Injection must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:252a8c45-6fa9-50e9-b993-c16f2985a593", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c2612ab-86a4-4c54-a5c0-e837f755965f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c2612ab-86a4-4c54-a5c0-e837f755965f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c2612ab-86a4-4c54-a5c0-e837f755965f"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic Acid Tablets should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering Aminocaproic Acid Tablets. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic Acid Tablets must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28782758-9717-5a31-a52c-5083b73b7300", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cfa601c4-b649-417e-a301-b246f080f1eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cfa601c4-b649-417e-a301-b246f080f1eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfa601c4-b649-417e-a301-b246f080f1eb"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c284188-2328-51bb-8194-fa90c968b80b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d9f615a0-119c-4553-93a7-b30025b5fe14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d9f615a0-119c-4553-93a7-b30025b5fe14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9f615a0-119c-4553-93a7-b30025b5fe14"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic Acid Oral Solution should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering Aminocaproic Acid Oral Solution. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic Acid Oral Solution must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:349dbb1e-4c28-5323-bcb3-6e2bbd81115a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b8f0ddb-00fd-4c22-afae-afe636f95f3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b8f0ddb-00fd-4c22-afae-afe636f95f3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b8f0ddb-00fd-4c22-afae-afe636f95f3a"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: • Platelet count is usually decreased in DIC but normal in primary fibrinolysis. • Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. • The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:771905eb-3e3e-56dc-b60b-4103f2e8fd01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a0d4fa5-8608-4e83-b5c7-d7e088d80281", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a0d4fa5-8608-4e83-b5c7-d7e088d80281", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a0d4fa5-8608-4e83-b5c7-d7e088d80281"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: • Platelet count is usually decreased in DIC but normal in primary fibrinolysis. • Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. • The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e53c4d4-1830-51dc-b7aa-6f4cb6aa7745", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d08ad63-71f5-4286-9622-84295668a293", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d08ad63-71f5-4286-9622-84295668a293", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d08ad63-71f5-4286-9622-84295668a293"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e53b28a-8676-585e-8323-2b70185ea96f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15eadaf4-5801-8044-e063-6394a90a72cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15eadaf4-5801-8044-e063-6394a90a72cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15eadaf4-5801-8044-e063-6394a90a72cf"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fd4c74d-1cd0-55e5-b8f4-944a41da7f57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4a22e559-2dac-42d7-af8d-eb0ebbc2f76d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4a22e559-2dac-42d7-af8d-eb0ebbc2f76d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a22e559-2dac-42d7-af8d-eb0ebbc2f76d"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98da8341-20a4-5e91-9bb3-e3cd332c4d8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2612ee97-1723-40f2-99e6-3a736f63200f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2612ee97-1723-40f2-99e6-3a736f63200f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2612ee97-1723-40f2-99e6-3a736f63200f"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: • Platelet count is usually decreased in DIC but normal in primary fibrinolysis. • Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. • The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f558aa0-fc0c-5c6f-a370-dc90faf6cc2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d6560a3-c67e-428e-b9b8-fab538856b41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d6560a3-c67e-428e-b9b8-fab538856b41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d6560a3-c67e-428e-b9b8-fab538856b41"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "without concomitant heparin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be49bc71-3cfb-5161-b6db-e4b1c0df9ad0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["heparin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2144bf8-1a26-4958-ba10-5358bd69cd23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2144bf8-1a26-4958-ba10-5358bd69cd23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2144bf8-1a26-4958-ba10-5358bd69cd23"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process. When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid. The following tests can be applied to differentiate the two conditions: Platelet count is usually decreased in DIC but normal in primary fibrinolysis. Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Aminocaproic acid must not be used in the presence of DIC without concomitant heparin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1305868", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3096a767-462e-5986-b19f-0c896ddbd105", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1305868"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "UMLS:C0019080", "object_location_in_text": [98, 106], "original_object": "bleeding", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5dc0c33-a0f9-43c4-9f10-3668f4361b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5dc0c33-a0f9-43c4-9f10-3668f4361b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5dc0c33-a0f9-43c4-9f10-3668f4361b87"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic acid tablets, USP is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1305868", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad6fe38a-e648-530c-87f2-34809018023e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1305868"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "UMLS:C0019080", "object_location_in_text": [95, 103], "original_object": "bleeding", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15eadaf4-5801-8044-e063-6394a90a72cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15eadaf4-5801-8044-e063-6394a90a72cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15eadaf4-5801-8044-e063-6394a90a72cf"]}], "subject": "CHEBI:16586", "supporting_text": ["Aminocaproic Acid Injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, fresh whole blood transfusions, fibrinogen infusions, and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures), and portacaval shunt; hematological disorders such as aplastic anemia; acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may frequently be associated with life-threatening complications following severe trauma, anoxia, and shock. Symptomatic of such complications is surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsurgical hematuria", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b192771-e168-53df-a39c-68fa87ec0e57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69a3e54e-dab1-50b1-91c1-10d6aca71a8a", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:438039ab-1ef6-5858-bf0f-050d13876aa5", "object": "UMLS:C0424561", "original_object": "excessive bleeding", "original_subject": "AMINOCAPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:828568a7-1808-4330-b466-01889b2311a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=828568a7-1808-4330-b466-01889b2311a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=828568a7-1808-4330-b466-01889b2311a2"]}], "subject": "CHEBI:16586", "supporting_text": ["INDICATIONS &amp; USAGE Aminocaproic acid oral solution is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNlNGS )."], "temporal_context_qualifier": "accompanying polycystic or neoplastic diseases of the genitourinary system"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "myopia progression", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:804a6ff5-603f-50a4-97a5-38f684dbe98a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250602", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ee97dbb8-ca1f-540a-9455-e4705b0e75bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bf95d7a1-1a88-568a-88e6-52a811a9925c", "object": "MONDO:0001384", "object_location_in_text": [52, 58], "original_object": "myopia", "original_subject": "atropine sulfate", "population_context_qualifier": "paediatric patients; children aged 3-14 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ryjunea", "https://www.ema.europa.eu/en/documents/product-information/ryjunea-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ryjunea"]}], "subject": "CHEBI:16684", "supporting_text": ["Ryjunea is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "healthy eye", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:690b3203-17b8-5f9f-a11f-76ac6b688b6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2d81b6f4-a948-5c63-9fd6-374a9e4a29b3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3f973586-a933-51bc-90f5-f63dc8534e32", "object": "MONDO:0001020", "original_object": "amblyopia", "original_subject": "ATROPINE", "population_context_qualifier": "adults and pediatric patients aged three (3) months and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a116af5c-ba4c-408c-9a02-4bc33772aa8d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a116af5c-ba4c-408c-9a02-4bc33772aa8d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a116af5c-ba4c-408c-9a02-4bc33772aa8d"]}], "subject": "CHEBI:16684", "supporting_text": ["1 INDICATIONS AND USAGE Atropine Sulfate Ophthalmic Solution, 1% is indicated in adults and pediatric patients aged three (3) months and older for: 1.1 Cycloplegia 1.2 Mydriasis 1.3 Penalization of the Healthy Eye in the Treatment of Amblyopia Atropine is an anti-cholinergic indicated in adults and pediatric patients aged three (3) months and older for: • Cycloplegia (1.1) • Mydriasis (1.2) • Penalization of the healthy eye in the treatment of amblyopia (1.3)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the iris and uveal tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27525907-5e67-5df1-8680-3b20d594fcdc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:569c117e-10c3-52d5-ba7d-06802c07e718", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3f973586-a933-51bc-90f5-f63dc8534e32", "object": "UMLS:C1828484", "object_location_in_text": [66, 84], "original_object": "pupillary dilation", "original_subject": "ATROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0a56d60-0914-42b1-af59-c56afe93d18c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0a56d60-0914-42b1-af59-c56afe93d18c"]}], "subject": "CHEBI:16684", "supporting_text": ["For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inability to receive oral or enteral nutrition", "has_confidence_score": 0.2025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df712908-cf78-500e-b11f-6d49a7480fd2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dac96cdf-ee94-5afc-9ef3-ad65df111db3", "medic_pair_confidence": 0.2025, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c7c2bad-3a4d-5be3-b03f-bae7cd3c00cd", "object": "UMLS:C0342919", "original_object": "essential fatty acid deficiency", "original_subject": "SOYBEAN OIL", "population_context_qualifier": "adults and pediatric patients, including term and preterm neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e"]}], "subject": "CHEBI:166975", "supporting_text": ["1 INDICATIONS AND USAGE CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inability to receive oral or enteral nutrition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34898d3a-014b-5570-8b0c-7f797ad07155", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:87c2b028-e0e7-53bd-9ee5-1392df3da9bf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3c7c2bad-3a4d-5be3-b03f-bae7cd3c00cd", "object": "UMLS:C3544299", "original_object": "caloric supplementation", "original_subject": "SOYBEAN OIL", "population_context_qualifier": "adults and pediatric patients, including term and preterm neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e"]}], "subject": "CHEBI:166975", "supporting_text": ["1 INDICATIONS AND USAGE CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2193345-166c-5cb4-9d58-37741df4602f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e7092fb0-8403-536b-8307-6b5041fbc556", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "PYRIDOXINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:16709", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26447cea-2a51-5e49-933d-4ee14031d67f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e7092fb0-8403-536b-8307-6b5041fbc556", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "PYRIDOXINE", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:16709", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal disorders interfering with intake or absorption of vitamins", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5443a4fb-9046-5ba4-ac6a-807607c3f444", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba9eb56f-8a53-5d28-94ad-258959e1639c", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e7092fb0-8403-536b-8307-6b5041fbc556", "object": "MONDO:0024298", "original_object": "vitamin deficiency", "original_subject": "PYRIDOXINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d"]}], "subject": "CHEBI:16709", "supporting_text": ["In disorders requiring parenteral administration of vitamins, i.e. pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "patients on monoamine oxidase (MAO) inhibitor therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c31b4d8c-a879-5166-9758-60618b05fcf0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase (MAO) inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa9d225d-ca19-57d9-8294-28fad9d538b7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38dbadc0-eff2-51f0-935a-8467ad75f72d", "object": "MONDO:0005010", "object_location_in_text": [590, 620], "original_object": "severe coronary artery disease", "original_subject": "CODEINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10"]}], "subject": "CHEBI:16714", "supporting_text": ["Pseudodine™ C Cough Syrup is contraindicated under the following conditions: Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. Hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS, Drug Interactions )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "patients on monoamine oxidase (MAO) inhibitor therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1134601e-ac2e-598a-a466-9887ad10693d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase (MAO) inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d036fe90-e61c-585c-868a-ee042b01d8e7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38dbadc0-eff2-51f0-935a-8467ad75f72d", "object": "MONDO:0005044", "object_location_in_text": [569, 588], "original_object": "severe hypertension", "original_subject": "CODEINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10"]}], "subject": "CHEBI:16714", "supporting_text": ["Pseudodine™ C Cough Syrup is contraindicated under the following conditions: Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. Hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS, Drug Interactions )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:567cb40d-3af3-5111-9aa9-1669aecd211b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38dbadc0-eff2-51f0-935a-8467ad75f72d", "object": "HP:0012735", "object_location_in_text": [27, 32], "original_object": "cough", "original_subject": "CODEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:98f8bf79-825d-c04d-0edd-826d4752736d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=98f8bf79-825d-c04d-0edd-826d4752736d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=98f8bf79-825d-c04d-0edd-826d4752736d"]}], "subject": "CHEBI:16714", "supporting_text": ["Uses Temporarily relieves: cough due to minor throat and bronchial irritation helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes and make coughs more productive"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05e3de0e-8022-547d-9ceb-5747963f8c57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0000001", "object_location_in_text": [186, 222], "original_object": "active secondary progressive disease", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:665d7e74-036c-5f68-5b67-ab84b9b49151", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31d1fc16-c9f3-59c3-80fe-9e1373774a1e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0000001", "object_location_in_text": [220, 256], "original_object": "active secondary progressive disease", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48f56f42-2247-41a9-a1e9-07c3af50e549", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48f56f42-2247-41a9-a1e9-07c3af50e549", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48f56f42-2247-41a9-a1e9-07c3af50e549"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da054204-eff8-5e06-9b46-d43e33a06f16", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0000001", "object_location_in_text": [220, 256], "original_object": "active secondary progressive disease", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8e5184d-5d1d-0a89-e053-2995a90a2d6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8e5184d-5d1d-0a89-e053-2995a90a2d6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8e5184d-5d1d-0a89-e053-2995a90a2d6d"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2921627", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34965727-e6d6-5151-a593-0d8be5e0edbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2921627", "MONDO:0000001"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1436c4ca-b6eb-55a4-975a-a5dcdb58ed4e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0005301", "original_object": "multiple sclerosis", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4003a54-f880-4d06-9b5a-f8043791937b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4003a54-f880-4d06-9b5a-f8043791937b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4003a54-f880-4d06-9b5a-f8043791937b"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43b9d733-289c-5ed4-aa7c-efbc25c3d319", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6709f516-96b9-5616-9e2d-79dc6d2a5db8", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0005301", "original_object": "active secondary progressive multiple sclerosis", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4a200c1-f25a-4aa8-8770-06182fdeda9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4a200c1-f25a-4aa8-8770-06182fdeda9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4a200c1-f25a-4aa8-8770-06182fdeda9d"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2921627", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:972e4965-0e79-5ee1-836d-59c3d7e48557", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2921627", "MONDO:0000001"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1436c4ca-b6eb-55a4-975a-a5dcdb58ed4e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0005301", "original_object": "multiple sclerosis", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb17b3bc-9d54-5237-b073-e7e9f66e550a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6709f516-96b9-5616-9e2d-79dc6d2a5db8", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0005301", "original_object": "active secondary progressive multiple sclerosis", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c7626c6-2b1b-4865-818c-0c79c18c049d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c7626c6-2b1b-4865-818c-0c79c18c049d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c7626c6-2b1b-4865-818c-0c79c18c049d"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d77399a-4d97-55d0-8401-5598d66459bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89a8c733-8977-5103-b6d6-3350cdf84e77", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0005314", "original_object": "relapsing-remitting multiple sclerosis", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4a200c1-f25a-4aa8-8770-06182fdeda9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4a200c1-f25a-4aa8-8770-06182fdeda9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4a200c1-f25a-4aa8-8770-06182fdeda9d"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:71543df1-0df9-57cf-a91c-0e084a4a640e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89a8c733-8977-5103-b6d6-3350cdf84e77", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "MONDO:0005314", "original_object": "relapsing-remitting multiple sclerosis", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c7626c6-2b1b-4865-818c-0c79c18c049d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c7626c6-2b1b-4865-818c-0c79c18c049d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c7626c6-2b1b-4865-818c-0c79c18c049d"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d4d9602-31e5-5c89-bb83-8d81d2acd8a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "UMLS:C2921627", "object_location_in_text": [157, 185], "original_object": "clinically isolated syndrome", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8e5184d-5d1d-0a89-e053-2995a90a2d6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8e5184d-5d1d-0a89-e053-2995a90a2d6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8e5184d-5d1d-0a89-e053-2995a90a2d6d"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b52964ae-b7cd-505c-b4b5-a1f745102a3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "UMLS:C2921627", "object_location_in_text": [157, 185], "original_object": "clinically isolated syndrome", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48f56f42-2247-41a9-a1e9-07c3af50e549", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48f56f42-2247-41a9-a1e9-07c3af50e549", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48f56f42-2247-41a9-a1e9-07c3af50e549"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db68ba07-38ba-5e01-a42f-4f056ea7301e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3dd271da-7357-58e4-99c0-cbabf9109f60", "object": "UMLS:C2921627", "object_location_in_text": [123, 151], "original_object": "clinically isolated syndrome", "original_subject": "MONOMETHYL FUMARATE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:665d7e74-036c-5f68-5b67-ab84b9b49151", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151"]}], "subject": "CHEBI:167450", "supporting_text": ["1 INDICATIONS AND USAGE TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "surgical risk", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44666d97-c51a-5a2f-963e-577a9e8ef353", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830728", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:38faba61-6e4a-596f-8c55-e32d32b1e0ce", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da1e35ad-abd2-5f85-904f-61cd1bf8f998", "object": "MONDO:0005346", "original_object": "gallstone", "original_subject": "CHENODIOL", "population_context_qualifier": "patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bbb86251-9423-40e6-9117-9511ab5fbf63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bbb86251-9423-40e6-9117-9511ab5fbf63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bbb86251-9423-40e6-9117-9511ab5fbf63"]}], "subject": "CHEBI:16755", "supporting_text": ["Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result from a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "surgical risk", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa30cdf4-0e21-5af8-bc78-1850ae4e5d0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830728", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:38faba61-6e4a-596f-8c55-e32d32b1e0ce", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da1e35ad-abd2-5f85-904f-61cd1bf8f998", "object": "MONDO:0005346", "original_object": "gallstone", "original_subject": "CHENODIOL", "population_context_qualifier": "patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d35752ce-bbf7-4690-bf1e-bd024fba85e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d35752ce-bbf7-4690-bf1e-bd024fba85e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d35752ce-bbf7-4690-bf1e-bd024fba85e2"]}], "subject": "CHEBI:16755", "supporting_text": ["Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result from a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de648d70-9aec-599b-9936-b32a2c9cbb10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170410", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7c6db092-c45d-5ad6-b6fe-435d4a99f086", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c919ff79-a3f5-57e2-b3bc-4e9ec37f1f58", "object": "MONDO:0008948", "original_object": "cerebrotendinous xanthomatosis", "original_subject": "chenodeoxycholic acid", "population_context_qualifier": "infants, children and adolescents aged 1 month to 18 years and adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:chenodeoxycholic-acid-leadiant", "https://www.ema.europa.eu/en/documents/product-information/chenodeoxycholic-acid-leadiant-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant"]}], "subject": "CHEBI:16755", "supporting_text": ["Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1960636", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e0efb7b-b225-531e-becc-7119fd47d6f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180208", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1960636", "MONDO:0006920", "MONDO:0005148", "HP:0000822", "UMLS:C0242339", "MONDO:0007147", "MONDO:0004995"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:77623047-4956-530f-b080-9a8b1b169d08", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:62b2111c-bbf0-580b-8708-1f77b3286c8d", "object": "HP:0025502", "object_location_in_text": [271, 281], "original_object": "overweight", "original_subject": "semaglutide", "population_context_qualifier": "adults with BMI ≥27 kg/m2 to <30 kg/m2 in the presence of at least one weight-related comorbidity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:wegovy", "https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy"]}], "subject": "CHEBI:167574", "supporting_text": ["Adults Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of  ≥30 kg/m2 (obesity), or ≥27 kg/m2 to &lt;30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.  For trial results with respect to cardiovascular risk reduction and populations studied, see section 5.1. Adolescents (≥12 years) Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with  obesity* and body weight above 60 kg.  Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. *Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1 in 4.1 of SmPC). Table 1 BMI cut-off points for obesity (≥95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d43e4c0-6503-5707-b607-974acc61940d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230327", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "MONDO:0021187", "MONDO:0005148"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:87e64efc-0059-50f9-8c1f-2c0a8f033dcf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:62b2111c-bbf0-580b-8708-1f77b3286c8d", "object": "MONDO:0011122", "object_location_in_text": [93, 100], "original_object": "obesity", "original_subject": "SEMAGLUTIDE", "population_context_qualifier": "patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and with BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or BMI of 35 kg/m2 or greater", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SEMAGLUTIDE#33-20230327", "https://www.pmda.go.jp/files/000265142.pdf"]}], "subject": "CHEBI:167574", "supporting_text": ["(1) Drugs with a new indication, a new dosage and other characteristics for the treatment of obesity. (2) Drugs with a new indication and a new dosage in an additional dosage form for the treatment of obesity. For use only in patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet the following conditions: • BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or • BMI of 35 kg/m2 or greater"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1514815", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07b258ad-4e29-559b-87c8-f2ef20c8fe44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1514815"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:95889601-0870-5a5b-af75-3ead4105bc1b", "object": "MONDO:0004948", "object_location_in_text": [90, 118], "original_object": "chronic lymphocytic leukemia", "original_subject": "ACALABRUTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACALABRUTINIB#64-20210122", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:167707", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0855095", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f6ba8ad-8208-523c-9827-a0fc19d29b99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20221223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0855095"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:95889601-0870-5a5b-af75-3ead4105bc1b", "object": "MONDO:0004948", "object_location_in_text": [50, 78], "original_object": "chronic lymphocytic leukemia", "original_subject": "ACALABRUTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACALABRUTINIB#40-20221223", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:167707", "supporting_text": ["A drug with a new indication for the treatment of chronic lymphocytic leukemia (including small lymphocytic lymphoma)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0855095", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed5dade2-9b43-5416-9617-ecfb89004092", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0855095"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:85cc4162-590c-58f3-beb9-7122563b7c1e", "object": "MONDO:0004948", "object_location_in_text": [67, 95], "original_object": "chronic lymphocytic leukemia", "original_subject": "ACALABRUTINIB MALEATE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACALABRUTINIB MALEATE HYDRATE#17-20241227", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:167707", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of chronic lymphocytic leukemia (including small lymphocytic lymphoma)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1514815", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41d62cf4-4386-5a1b-b96d-78682d70cc82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1514815"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:1c7c6f36-1658-5144-98f4-434676add777", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:95889601-0870-5a5b-af75-3ead4105bc1b", "object": "UMLS:C0855095", "object_location_in_text": [119, 145], "original_object": "small lymphocytic lymphoma", "original_subject": "ACALABRUTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACALABRUTINIB#64-20210122", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:167707", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "recovery from anesthesia and/or opiate analgesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:129be358-362a-52e2-8e27-e95655e26987", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:163accb7-45e6-4d97-844d-72b606677008", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=163accb7-45e6-4d97-844d-72b606677008", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=163accb7-45e6-4d97-844d-72b606677008"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine transdermal system is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "recovery from anesthesia and/or opiate analgesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1704720b-14fa-5f10-ba4f-baf7141051f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b877a694-a1d0-4280-937a-a06820b12a88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b877a694-a1d0-4280-937a-a06820b12a88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b877a694-a1d0-4280-937a-a06820b12a88"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE TRANSDERM SCŌP is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. TRANSDERM SCŌP is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "recovery from anesthesia and/or opiate analgesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25a1d45b-6aa0-56e4-abfe-a38dec5066bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455ce88-1270-440b-b62e-fe5fef1415ac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455ce88-1270-440b-b62e-fe5fef1415ac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455ce88-1270-440b-b62e-fe5fef1415ac"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine transdermal system is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231287", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bb729e2-c799-58cc-9830-48463bd9ee9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0231287"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "object_location_in_text": [101, 120], "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd031a59-6b8c-49b1-9b4d-e7a7b75e3801", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd031a59-6b8c-49b1-9b4d-e7a7b75e3801", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd031a59-6b8c-49b1-9b4d-e7a7b75e3801"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine Transdermal System is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"], "temporal_context_qualifier": "post-operative"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "recovery from anesthesia and/or opiate analgesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:482046e5-1fe7-532f-92e1-448b1d49d7b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb93bfad-3e37-4a27-92f6-f21703ae7bdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb93bfad-3e37-4a27-92f6-f21703ae7bdf"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine transdermal system is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "recovery from anesthesia and/or opiate analgesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:862f363d-8fca-5901-9880-103ccf726b67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b24c2315-c947-4ad2-89fe-8dc0c45e221b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b24c2315-c947-4ad2-89fe-8dc0c45e221b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b24c2315-c947-4ad2-89fe-8dc0c45e221b"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine transdermal system is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. ( 1 ) • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231287", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b02911ab-29b5-53c3-a875-023b8cc78557", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0231287"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "object_location_in_text": [101, 120], "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba5a1237-4d23-441a-808e-96b97045fbe2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba5a1237-4d23-441a-808e-96b97045fbe2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba5a1237-4d23-441a-808e-96b97045fbe2"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine Transdermal System is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"], "temporal_context_qualifier": "post-operative"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231287", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b85e4dc3-00eb-56bf-bdf3-59c6a69d3f6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0231287"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "object_location_in_text": [101, 120], "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a472ee74-76a7-470f-8564-9018940a82e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a472ee74-76a7-470f-8564-9018940a82e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a472ee74-76a7-470f-8564-9018940a82e8"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine Transdermal System is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"], "temporal_context_qualifier": "post-operative"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231287", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcc145de-5d43-530e-ad82-0a4fdbf71bf4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0231287"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "object_location_in_text": [101, 120], "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5aa64f85-ae52-4a86-a894-a4e536fbe4ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5aa64f85-ae52-4a86-a894-a4e536fbe4ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5aa64f85-ae52-4a86-a894-a4e536fbe4ad"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine Transdermal System is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"], "temporal_context_qualifier": "post-operative"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231287", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fde22e59-e231-579c-8048-f47bce1a38c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0231287"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c243f279-9457-526c-bfdf-bbfa4bf5e5f2", "object": "HP:0002017", "object_location_in_text": [101, 120], "original_object": "nausea and vomiting", "original_subject": "SCOPOLAMINE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d53ee59-e0ef-4332-a6d6-0ac5a6c21b55", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d53ee59-e0ef-4332-a6d6-0ac5a6c21b55", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d53ee59-e0ef-4332-a6d6-0ac5a6c21b55"]}], "subject": "CHEBI:16794", "supporting_text": ["1 INDICATIONS AND USAGE Scopolamine Transdermal System is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )"], "temporal_context_qualifier": "post-operative"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "pediatric neurodevelopmental disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0364ec0f-357e-5b8d-84dd-d5b2d9236294", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200325", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a766b877-2340-5f8f-b4c9-6cb2540d0319", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8e420d75-6bf7-533d-8405-ca0d96fdebd5", "object": "HP:0031354", "object_location_in_text": [69, 94], "original_object": "difficulty falling asleep", "original_subject": "MELATONIN", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MELATONIN#70-20200325", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:16796", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of difficulty falling asleep associated with pediatric neurodevelopmental disorder."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a165219-1668-560d-b331-37d096c2a2b3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5668bfb-2be5-59af-b8e6-f66bfa3da4ab", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "NADH", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:16908", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850666", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28e56a67-62dd-56ec-b187-4697a4d47c22", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0850666"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da5587cb-f7cf-561c-9288-1de8694f2c1f", "object": "MONDO:0005412", "object_location_in_text": [331, 345], "original_object": "duodenal ulcer", "original_subject": "SALICYLIC ACID", "population_context_qualifier": "patients with active duodenal ulcer disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c809fa5-c630-4bf1-a0fc-5ee875008807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c809fa5-c630-4bf1-a0fc-5ee875008807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c809fa5-c630-4bf1-a0fc-5ee875008807"]}], "subject": "CHEBI:16914", "supporting_text": [": The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "overindulgence in food and drink", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:267dd077-0f1a-50fb-943b-4a9c1f3b1760", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da5587cb-f7cf-561c-9288-1de8694f2c1f", "object": "UMLS:C0235309", "object_location_in_text": [43, 56], "original_object": "upset stomach", "original_subject": "SALICYLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d20af4fb-d579-4d1e-86ae-342933f4de75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d20af4fb-d579-4d1e-86ae-342933f4de75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d20af4fb-d579-4d1e-86ae-342933f4de75"]}], "subject": "CHEBI:16914", "supporting_text": ["Uses relieves travelers' diarrhea diarrhea upset stomach due to overindulgence in food and drink, including: heartburn indigestion nausea gas fullness belching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "overindulgence in food and drink", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6754118a-017b-5fcc-a29f-c5652bdaf71b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da5587cb-f7cf-561c-9288-1de8694f2c1f", "object": "UMLS:C0235309", "object_location_in_text": [43, 56], "original_object": "upset stomach", "original_subject": "SALICYLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:67006e82-870d-8d63-e053-2991aa0a02d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=67006e82-870d-8d63-e053-2991aa0a02d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=67006e82-870d-8d63-e053-2991aa0a02d1"]}], "subject": "CHEBI:16914", "supporting_text": ["Uses relieves traveler's diarrhea diarrhea upset stomach due to overindulgence in food and drink, including: heartburn indigestion nausea gas belching fullness"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe419add-a03b-54b5-bcda-2216a51e7aa1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4242ca3c-0de5-5bd7-95df-24a630b60064", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "RIBOFLAVIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:17015", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0355a83-1842-5e83-a514-e3ddf95ad693", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4242ca3c-0de5-5bd7-95df-24a630b60064", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "RIBOFLAVIN", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:17015", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "conjugated estrogens tablets use", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:180de947-13d3-5a32-ad79-04977e92164e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [85, 108], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1cf237ff-c4f8-4faa-a7aa-77599c856889", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889"]}], "subject": "CHEBI:17026", "supporting_text": ["PROMETRIUM ® (progesterone, USP) Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27b7768e-099e-5577-9702-e087dc59214c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:312db3af-9dd2-d5e4-e063-6394a90af999", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=312db3af-9dd2-d5e4-e063-6394a90af999", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=312db3af-9dd2-d5e4-e063-6394a90af999"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:381c4eca-1198-52bc-a0c7-eb37dea053f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42c84fec-e5eb-78f7-e063-6294a90a4c0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42c84fec-e5eb-78f7-e063-6294a90a4c0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42c84fec-e5eb-78f7-e063-6294a90a4c0e"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:480ea751-8784-56cf-bdc8-82c3252d9d24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc62ae6d-b609-432d-863f-a8ecd223d69a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc62ae6d-b609-432d-863f-a8ecd223d69a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc62ae6d-b609-432d-863f-a8ecd223d69a"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:661b5924-5c4e-55fb-a173-4430d38c5778", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:404e0b45-339b-4304-8e33-5f4ffe8f8e25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=404e0b45-339b-4304-8e33-5f4ffe8f8e25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=404e0b45-339b-4304-8e33-5f4ffe8f8e25"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85cffbdc-cb63-505e-a080-2c7f47a5ee01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f392c6d9-1420-4735-aa01-f434da9b31b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f392c6d9-1420-4735-aa01-f434da9b31b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f392c6d9-1420-4735-aa01-f434da9b31b3"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8710d362-b9e4-5290-bbab-2b796da20f9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7615864-be6e-47b4-bf35-145a361d7cc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7615864-be6e-47b4-bf35-145a361d7cc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7615864-be6e-47b4-bf35-145a361d7cc6"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:937a0ded-99ea-52d2-8508-a1f66c47929f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74a7619a-8f74-4889-96f6-5bae478543e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74a7619a-8f74-4889-96f6-5bae478543e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74a7619a-8f74-4889-96f6-5bae478543e8"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:938aec7b-61f4-55b2-be85-d7a57c44d1b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7619751-47b4-47c9-b716-e2a704b350c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7619751-47b4-47c9-b716-e2a704b350c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7619751-47b4-47c9-b716-e2a704b350c8"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdead155-76e5-5d36-8b38-e8c35fa1b2ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5743b2e4-093f-c59a-e063-6394a90aae2b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5743b2e4-093f-c59a-e063-6394a90aae2b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5743b2e4-093f-c59a-e063-6394a90aae2b"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "receiving conjugated estrogens tablets", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2951072-d579-5a30-a454-1fde91b86088", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd97606f-dfa8-5784-a2aa-47e46092ba42", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "MONDO:0041161", "object_location_in_text": [65, 88], "original_object": "endometrial hyperplasia", "original_subject": "PROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:947ebb7c-492b-4b83-aa1c-81e282df6421", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=947ebb7c-492b-4b83-aa1c-81e282df6421", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=947ebb7c-492b-4b83-aa1c-81e282df6421"]}], "subject": "CHEBI:17026", "supporting_text": ["Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3829577", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e2e5929-d165-5477-ae2e-8d320593cec8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C3829577"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0d3e26e7-ae3a-5c3a-a5ec-921ce19866c6", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "HP:0000789", "original_object": "infertility", "original_subject": "PROGESTERONE", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75e97aa1-daa4-45f9-b2e2-1a371302914e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75e97aa1-daa4-45f9-b2e2-1a371302914e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75e97aa1-daa4-45f9-b2e2-1a371302914e"]}], "subject": "CHEBI:17026", "supporting_text": ["Assisted Reproductive Technology Crinone 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (\"ART\") treatment for infertile women with progesterone deficiency. Secondary Amenorrhea Crinone 4% is indicated for the treatment of secondary amenorrhea. Crinone 8% is indicated for use in women who have failed to respond to treatment with Crinone 4%."], "temporal_context_qualifier": "as part of an Assisted Reproductive Technology (\"ART\") treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000789", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05f48a6e-305e-5ee4-835a-8146cb0ffa6d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000789"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40e6a96a-1db1-509b-828c-d8bfc2b7f24e", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "UMLS:C0029976", "object_location_in_text": [149, 168], "original_object": "embryo implantation", "original_subject": "PROGESTERONE", "population_context_qualifier": "infertile women less than 35 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:473ab609-5b9e-3cb8-68d5-4a459a2ea6c1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=473ab609-5b9e-3cb8-68d5-4a459a2ea6c1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=473ab609-5b9e-3cb8-68d5-4a459a2ea6c1"]}], "subject": "CHEBI:17026", "supporting_text": ["1 INDICATIONS AND USAGE Progesterone vaginal insert is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. Progesterone vaginal insert is a progesterone indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d191c12e-b142-5601-ae68-bee2b67f7f26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:635c91c0-6309-5a2a-973c-53f5c7182cc4", "object": "UMLS:C3650625", "object_location_in_text": [41, 66], "original_object": "abnormal uterine bleeding", "original_subject": "PROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcfa4050-d142-b774-369f-8a421eb23c62", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcfa4050-d142-b774-369f-8a421eb23c62", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcfa4050-d142-b774-369f-8a421eb23c62"]}], "subject": "CHEBI:17026", "supporting_text": ["This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a591bb0d-e37d-5d8a-966a-57397fddd7b9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f429e60-86ca-5953-bb50-e43e1da134ae", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "NIACINAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:17154", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb40bd0a-f9fd-5977-8dc4-ab1b272bf971", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f429e60-86ca-5953-bb50-e43e1da134ae", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "NIACINAMIDE", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:17154", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal disorders interfering with intake or absorption of vitamins", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b92d7d2-2e8e-5d66-beaa-3e6d7e89706c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba9eb56f-8a53-5d28-94ad-258959e1639c", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f429e60-86ca-5953-bb50-e43e1da134ae", "object": "MONDO:0024298", "original_object": "vitamin deficiency", "original_subject": "NIACINAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d"]}], "subject": "CHEBI:17154", "supporting_text": ["In disorders requiring parenteral administration of vitamins, i.e. pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aff9a8b6-39a6-5bb6-82fc-27dfde3770a2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:804f7347-a6d9-5ef4-9ca2-4d6945ec48b1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:49a82e22-a6b0-5498-aa94-a466020be51f", "object": "MONDO:0001836", "original_object": "amenorrhea", "original_subject": "HYDROXYPROGESTERONE", "population_context_qualifier": "non-pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:687bcf42-f437-42c7-8909-a91f621f55df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=687bcf42-f437-42c7-8909-a91f621f55df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=687bcf42-f437-42c7-8909-a91f621f55df"]}], "subject": "CHEBI:17252", "supporting_text": ["Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:254f1a61-5c18-5f34-b16e-4ae169dc876c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:49a82e22-a6b0-5498-aa94-a466020be51f", "object": "UMLS:C3650625", "original_object": "abnormal uterine bleeding", "original_subject": "HYDROXYPROGESTERONE", "population_context_qualifier": "non-pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:687bcf42-f437-42c7-8909-a91f621f55df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=687bcf42-f437-42c7-8909-a91f621f55df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=687bcf42-f437-42c7-8909-a91f621f55df"]}], "subject": "CHEBI:17252", "supporting_text": ["Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "viral resistance to the integrase inhibitor class, viral resistance to emtricitabine, viral resistance to tenofovir", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92992978-b939-5334-bab6-d5661f6817a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180621", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f1475649-ce35-5d0b-a657-2c38aa869dc9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:728eabc1-32dd-50f4-8c87-eb9bc9541073", "object": "UMLS:C0276500", "original_object": "human immunodeficiency virus 1 infection", "original_subject": "bictegravir;emtricitabine;tenofovir alafenamide", "population_context_qualifier": "adults and paediatric patients at least 2 years of age and weighing at least 14 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:biktarvy", "https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy"]}], "subject": "CHEBI:172943", "supporting_text": ["Biktarvy is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.(see section 5.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70974b0d-e04e-5e27-9749-c5c5abff6c45", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95f99db4-90c2-5068-a835-640577a4a484", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "PYRIDOXAL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:17310", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:190482be-2a59-5e0e-a61c-21f7077f05b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c62302b-7c83-5ca9-916a-21deaf84f597", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "HP:0000026", "original_object": "male hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "testosterone deficiency or absence", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d94c2a0-6bed-5079-9987-886f457eaedb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f80f025b-17d8-40af-8739-20ce07902045", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. AVEED should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of POME and anaphylaxis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1963961", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca2db637-d927-5cad-888a-b774753fd733", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1963961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed7b5d41-7475-4c10-99b9-b62b3434ae60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established. Safety and efficacy of JATENZO in males less than 18 years old have not been established [ see Use in Specific Populations ( 8.4 ) ]. JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established ( 1 ) Safety and efficacy of JATENZO in males less than 18 years old have not been established ( 1 , 8.4 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deficiency or absence of endogenous testosterone", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0c66cb2-0474-56c0-8a15-eae7bd34d0bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dea6bed1-eaca-11e3-ac10-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dea6bed1-eaca-11e3-ac10-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dea6bed1-eaca-11e3-ac10-0800200c9a66"]}], "subject": "CHEBI:17347", "supporting_text": ["1. INDICATIONS AND USAGE Natesto is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of Natesto in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established. Safety and efficacy of Natesto in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Natesto is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of Natesto in men with \"age-related hypogonadism\" have not been established ( 1 ). Safety and efficacy of Natesto in males less than 18 years old have not been established. ( 1 , 8.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "testosterone deficiency or absence", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d355123d-8d1b-53f6-a339-394fde72c99d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b0b92e9-6d3c-a0e5-e1c7-342999f72580", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b0b92e9-6d3c-a0e5-e1c7-342999f72580", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b0b92e9-6d3c-a0e5-e1c7-342999f72580"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE TLANDO is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), luteinizing hormone (LH)) above the normal range [see Dosage and Administration ( 2.2 )]. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range [see Dosage and Administration ( 2.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deficiency or absence of endogenous testosterone", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5cb877f-1d1f-5c1b-83a0-7ec13b4130ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f7167a7-2a25-47e2-acf5-33f499fce971", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE KYZATREX® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (folliclestimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. KYZATREX® is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:395a37a3-7d10-55ae-9d58-f3af8455349d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0006882", "MONDO:8000015", "UMLS:C0029189", "HP:0000044"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b423c308-507b-5fdf-99e8-c11a7569f9e2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0002146", "original_object": "hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f60c5520-b336-44a2-95d5-f274939fa595", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f60c5520-b336-44a2-95d5-f274939fa595", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f60c5520-b336-44a2-95d5-f274939fa595"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d420184-7325-53cc-bd80-38105ea09782", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0006882", "MONDO:8000015", "UMLS:C0029189", "HP:0000044"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b423c308-507b-5fdf-99e8-c11a7569f9e2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0002146", "original_object": "hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2c73a06-1200-4322-9011-caea5f16db6c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2c73a06-1200-4322-9011-caea5f16db6c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2c73a06-1200-4322-9011-caea5f16db6c"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c452e344-e71c-56fc-a8a1-6e131a049985", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0006882", "MONDO:8000015", "UMLS:C0029189", "HP:0000044"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b423c308-507b-5fdf-99e8-c11a7569f9e2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0002146", "original_object": "hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ca67491-4b30-4a47-af0a-be250215d1f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ca67491-4b30-4a47-af0a-be250215d1f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ca67491-4b30-4a47-af0a-be250215d1f0"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:848ad276-55ce-56ee-ac15-6317816d7d47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73a8d2f1-4f7d-5fa4-9c33-1dd107d3e81d", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0006882", "object_location_in_text": [287, 295], "original_object": "orchitis", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advancing inoperable metastatic mammary cancer", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:936a4648-f0fd-5744-b074-1d0477b4a093", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0e873fb6-d53b-5464-9db3-e95829e8a3e4", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "original_object": "metastatic mammary cancer", "original_subject": "TESTOSTERONE", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82a98132-9d5f-40a5-8c4f-f52f2a5de60e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82a98132-9d5f-40a5-8c4f-f52f2a5de60e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82a98132-9d5f-40a5-8c4f-f52f2a5de60e"]}], "subject": "CHEBI:17347", "supporting_text": ["Males Testosterone enanthate injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) – Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) – Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of testosterone enanthate injection in men with age-related hypogonadism have not been established. Delayed puberty – Testosterone enanthate injection may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). Females Metastatic mammary cancer – Testosterone enanthate injection may be used secondarily in women with advancing inoperable "], "temporal_context_qualifier": "one to five years postmenopausal"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cca2e612-c93e-5123-a4f6-5c05c1b05cde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57b1e1ef-88dd-5b88-8e27-53ef1a89b8ba", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0009047", "object_location_in_text": [252, 266], "original_object": "cryptorchidism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de09aeb4-ba71-509a-a493-d7c09cc5f312", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7f3d7922-e575-5243-b809-0366334d086a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0009421", "object_location_in_text": [226, 244], "original_object": "testicular failure", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gonadotropin or LHRH deficiency, pituitary-hypothalamic injury", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:037f39d7-cfff-5641-adaa-5b394a86cfb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6909596e-4bf7-4e11-8029-b89740a30aec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6909596e-4bf7-4e11-8029-b89740a30aec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6909596e-4bf7-4e11-8029-b89740a30aec"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)- gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of Testosterone Cypionate Injection in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gonadotropin or LHRH deficiency, pituitary-hypothalamic injury", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18b39430-b5f7-5fe6-8c96-f1daf7cbe17d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40a332e3-9c64-4595-91c3-dfef24f3d3bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40a332e3-9c64-4595-91c3-dfef24f3d3bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40a332e3-9c64-4595-91c3-dfef24f3d3bb"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age -related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a9d1fdf-6a6b-51cf-9826-cd2bab07b5b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "medic_supporting_text_truncated": true, "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e89d6458-428c-4256-97a3-f1fa851293c1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e89d6458-428c-4256-97a3-f1fa851293c1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e89d6458-428c-4256-97a3-f1fa851293c1"]}], "subject": "CHEBI:17347", "supporting_text": ["Males Testosterone Enanthate Injection, USP is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) – Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) – Gonadotropin or luteinizing hormone‑releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of Testosterone Enanthate Injection, USP in men with age-related hypogonadism have not been established. Delayed puberty – Testosterone Enanthate Injection, USP may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). Females Metastatic mammary cancer – Testosterone Enanthate Injection, USP may be used secondarily in women with a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "testosterone deficiency or absence", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:342d30df-4934-529e-bcb7-913450e9c30c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f80f025b-17d8-40af-8739-20ce07902045", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. AVEED should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of POME and anaphylaxis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1963961", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35992120-4a3d-55be-ae91-5d44e1b9a690", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1963961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed7b5d41-7475-4c10-99b9-b62b3434ae60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established. Safety and efficacy of JATENZO in males less than 18 years old have not been established [ see Use in Specific Populations ( 8.4 ) ]. JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established ( 1 ) Safety and efficacy of JATENZO in males less than 18 years old have not been established ( 1 , 8.4 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deficiency or absence of endogenous testosterone", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:480b7d5b-eb10-5e4f-a7c9-786061d63cb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dea6bed1-eaca-11e3-ac10-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dea6bed1-eaca-11e3-ac10-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dea6bed1-eaca-11e3-ac10-0800200c9a66"]}], "subject": "CHEBI:17347", "supporting_text": ["1. INDICATIONS AND USAGE Natesto is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of Natesto in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established. Safety and efficacy of Natesto in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Natesto is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of Natesto in men with \"age-related hypogonadism\" have not been established ( 1 ). Safety and efficacy of Natesto in males less than 18 years old have not been established. ( 1 , 8.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "testosterone deficiency or absence", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a91cce4-7729-52d5-acf9-6df1f21dad69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b0b92e9-6d3c-a0e5-e1c7-342999f72580", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b0b92e9-6d3c-a0e5-e1c7-342999f72580", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b0b92e9-6d3c-a0e5-e1c7-342999f72580"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE TLANDO is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), luteinizing hormone (LH)) above the normal range [see Dosage and Administration ( 2.2 )]. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range [see Dosage and Administration ( 2.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deficiency or absence of endogenous testosterone", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8551b04e-bcaf-5fed-bec9-2226e9e8ce77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f7167a7-2a25-47e2-acf5-33f499fce971", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE KYZATREX® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (folliclestimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. KYZATREX® is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd19fd81-13cb-51ee-a9e0-04f1652c5a70", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a3d204c-be26-49e0-8599-0ac12a272e81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d5c9a6b-7e88-5ff2-84c0-e463369d6286", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66a1207f-265d-5d28-94cf-c2a7e578aece", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "MONDO:8000015", "object_location_in_text": [297, 322], "original_object": "vanishing testis syndrome", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad65b1ec-433e-4524-924e-ebad09762126"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31140e26-7fff-50a9-aae1-1e3769700e52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e2f2ed8-7a1c-4d89-aa00-d8a422c8e70b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e2f2ed8-7a1c-4d89-aa00-d8a422c8e70b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e2f2ed8-7a1c-4d89-aa00-d8a422c8e70b"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency, or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47d95446-fd7e-51a6-9f35-de88764fa5aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cfbb53d4-b868-4a28-8436-f9112eb01c39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39"]}], "subject": "CHEBI:17347", "supporting_text": ["DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of DEPO-Testosterone (testosterone cypionate) in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48cc3104-54a7-533a-b696-ed52705950a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd57648c-ce53-459a-9f14-3984fc464428", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd57648c-ce53-459a-9f14-3984fc464428", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd57648c-ce53-459a-9f14-3984fc464428"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4bc45942-d204-50a6-8a13-6fec91ed976b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed65346b-31bc-f872-516d-78d5ab70229e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed65346b-31bc-f872-516d-78d5ab70229e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed65346b-31bc-f872-516d-78d5ab70229e"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate injection in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51ff1dc5-9cd5-5240-a1b1-7beb16cf1a9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2321a581-2e33-4233-a1d4-0711b90e3c57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2321a581-2e33-4233-a1d4-0711b90e3c57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2321a581-2e33-4233-a1d4-0711b90e3c57"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ec266f3-2503-59ce-8901-012e0eb7e233", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edcd5209-70db-4727-991e-3fdd185d9211", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edcd5209-70db-4727-991e-3fdd185d9211", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edcd5209-70db-4727-991e-3fdd185d9211"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65830dd8-b0c2-5c48-85c7-a80cce475293", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fb0c403-3065-498e-b910-c5988269301a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fb0c403-3065-498e-b910-c5988269301a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fb0c403-3065-498e-b910-c5988269301a"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72a7f105-d727-5f05-8811-27352f5da8eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40a332e3-9c64-4595-91c3-dfef24f3d3bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40a332e3-9c64-4595-91c3-dfef24f3d3bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40a332e3-9c64-4595-91c3-dfef24f3d3bb"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age -related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82e83eba-a340-505c-9a60-24bede0ef5a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cab949ca-fde9-c5a9-5561-21e98d86d078", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cab949ca-fde9-c5a9-5561-21e98d86d078", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cab949ca-fde9-c5a9-5561-21e98d86d078"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of Testosterone Cypionate Injection in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b2404f7-a9a1-54f3-b147-fd21e5fd8973", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7df45a8d-7d6b-4776-85e3-529527574a4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7df45a8d-7d6b-4776-85e3-529527574a4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7df45a8d-7d6b-4776-85e3-529527574a4f"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of Testosterone Cypionate Injection in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b05449f1-c912-56aa-8895-97f09472014f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "adult males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed7b5d41-7475-4c10-99b9-b62b3434ae60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60"]}], "subject": "CHEBI:17347", "supporting_text": ["1 INDICATIONS AND USAGE JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established. Safety and efficacy of JATENZO in males less than 18 years old have not been established [ see Use in Specific Populations ( 8.4 ) ]. JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established ( 1 ) Safety and efficacy of JATENZO in males less than 18 years old have not been established ( 1 , 8.4 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c47e3428-0980-5a55-997e-6574d78dca9e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "medic_supporting_text_truncated": true, "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82a98132-9d5f-40a5-8c4f-f52f2a5de60e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82a98132-9d5f-40a5-8c4f-f52f2a5de60e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82a98132-9d5f-40a5-8c4f-f52f2a5de60e"]}], "subject": "CHEBI:17347", "supporting_text": ["Males Testosterone enanthate injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) – Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) – Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of testosterone enanthate injection in men with age-related hypogonadism have not been established. Delayed puberty – Testosterone enanthate injection may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). Females Metastatic mammary cancer – Testosterone enanthate injection may be used secondarily in women with advancing inoperable "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d15e46c2-a6d1-52c2-ae24-8c348d57ef50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f72be32-ede6-44d9-88a0-0653b53a3e47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f72be32-ede6-44d9-88a0-0653b53a3e47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f72be32-ede6-44d9-88a0-0653b53a3e47"]}], "subject": "CHEBI:17347", "supporting_text": ["DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of DEPO-Testosterone (testosterone cypionate) in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3417de6-22f7-55eb-8f0e-490f9bdc1f8b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:327b4357-6948-4cd6-ad6c-e463ab8600ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=327b4357-6948-4cd6-ad6c-e463ab8600ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=327b4357-6948-4cd6-ad6c-e463ab8600ad"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection, USP is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency, or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e392a223-2f99-52a7-9b9e-3babd1b61eed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ced69c7-cd37-efb6-1bf9-e21c01e56f5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ced69c7-cd37-efb6-1bf9-e21c01e56f5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ced69c7-cd37-efb6-1bf9-e21c01e56f5b"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of Testosterone Cypionate Injection in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f486ad3e-fb5e-5809-b780-deb5d2bb2c9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 14, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c1d0cf38-78d8-51ad-9dfd-ffd7d67ff17c", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "TESTOSTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:375dd035-b792-4cb7-9fe6-bb367b87bdba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=375dd035-b792-4cb7-9fe6-bb367b87bdba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=375dd035-b792-4cb7-9fe6-bb367b87bdba"]}], "subject": "CHEBI:17347", "supporting_text": ["Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66c1fcc9-4491-50a1-8503-94cbf11756de", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "HP:0012531", "object_location_in_text": [164, 168], "original_object": "pain", "original_subject": "HYOSCYAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:17486", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bf2e261-8c2e-552a-98f8-78ca930f7b8c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "HP:0012531", "object_location_in_text": [168, 172], "original_object": "pain", "original_subject": "HYOSCYAMINE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:17486", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5572d88-2c48-5404-9f1c-e06507e1d471", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "HP:0012531", "object_location_in_text": [166, 170], "original_object": "pain", "original_subject": "HYOSCYAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:17486", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c089a85c-c6b0-5d89-84ad-97914b18d5ae", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "UMLS:C0021368", "object_location_in_text": [133, 145], "original_object": "inflammation", "original_subject": "HYOSCYAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:17486", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d483b609-a777-5cde-8aaa-0b76361a42fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "UMLS:C0021368", "object_location_in_text": [131, 143], "original_object": "inflammation", "original_subject": "HYOSCYAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:17486", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db607404-3894-5b24-9347-fc470a86c87b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "UMLS:C0021368", "object_location_in_text": [135, 147], "original_object": "inflammation", "original_subject": "HYOSCYAMINE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:17486", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d4c840f-02ab-5c72-8e8c-9aca208ab3fe", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "UMLS:C0549185", "object_location_in_text": [147, 160], "original_object": "hypermotility", "original_subject": "HYOSCYAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:17486", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a320bd1b-8e0a-5ae5-977a-413b71dfba6a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "UMLS:C0549185", "object_location_in_text": [149, 162], "original_object": "hypermotility", "original_subject": "HYOSCYAMINE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:17486", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0d58aac-482f-5e8d-b1a6-dde709e8f0e6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71072e0d-b23b-57a8-a242-0226b2e2f37e", "object": "UMLS:C0549185", "object_location_in_text": [145, 158], "original_object": "hypermotility", "original_subject": "HYOSCYAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:17486", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dae5455c-aa54-5200-ac31-d22724c83a8d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "MONDO:0001358", "object_location_in_text": [243, 255], "original_object": "bronchospasm", "original_subject": "BICARBONATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:17544", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2b156a0-8cf3-5913-a1be-0b6adc551a49", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89efb5c9-5434-5ec9-bba2-e17e23171dbb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "MONDO:0005492", "object_location_in_text": [297, 306], "original_object": "urticaria", "original_subject": "BICARBONATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:17544", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f732288b-ec77-568b-8b0f-815bbc5c739e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "MONDO:0010481", "object_location_in_text": [231, 241], "original_object": "angioedema", "original_subject": "BICARBONATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:17544", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd33bf7f-6390-5595-9cc4-189cd258362c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2aea563-aded-590c-b540-d1cb2e140e70", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "MONDO:0800337", "object_location_in_text": [257, 291], "original_object": "acute tubulointerstitial nephritis", "original_subject": "BICARBONATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:17544", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cac54eb-8f90-5183-b304-816fd73f9640", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0021564", "UMLS:C0684339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "HP:0000989", "object_location_in_text": [70, 77], "original_object": "itching", "original_subject": "BICARBONATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:223d1de8-7940-bbdc-e063-6294a90a51d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=223d1de8-7940-bbdc-e063-6294a90a51d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=223d1de8-7940-bbdc-e063-6294a90a51d8"]}], "subject": "CHEBI:17544", "supporting_text": ["Uses Temproarily protects and helps relieve minor skin irritation and itching due to insect bite poison ivy, oak sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235575", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e96a4af-8f63-557e-b639-93f5e5a231b3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0235575"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e11b1829-2ae6-55e7-b6a1-0f982aeecb26", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "UMLS:C0595916", "original_object": "nephrotoxicity", "original_subject": "BICARBONATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96093b76-5d98-4d2b-b851-20207a8864db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96093b76-5d98-4d2b-b851-20207a8864db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96093b76-5d98-4d2b-b851-20207a8864db"]}], "subject": "CHEBI:17544", "supporting_text": ["Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0161558", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca43b7e0-119c-5c57-a804-10453dc57775", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0161558", "UMLS:C0161544", "UMLS:C0392621"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3134bf8-c0b1-51bc-bee2-bfbd7feed683", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f053af1-df03-56cc-b9a5-c0ed2a6c05c5", "object": "UMLS:C0013221", "original_object": "drug intoxication", "original_subject": "BICARBONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96093b76-5d98-4d2b-b851-20207a8864db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96093b76-5d98-4d2b-b851-20207a8864db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96093b76-5d98-4d2b-b851-20207a8864db"]}], "subject": "CHEBI:17544", "supporting_text": ["Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0040300", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74483176-5dcf-5218-99f7-66148398ed54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070907", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C0040300"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:574a2ef2-9461-542d-bac5-4f22d348aa0f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:79719884-7e6d-55a0-8cd3-294f2d8714ad", "object": "MONDO:0100342", "object_location_in_text": [96, 112], "original_object": "malignant glioma", "original_subject": "5-aminolevulinic acid hydrochloride", "population_context_qualifier": "adult patients", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gliolan", "https://www.ema.europa.eu/en/documents/product-information/gliolan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan"]}], "subject": "CHEBI:17549", "supporting_text": ["Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (World Health Organization grade III and IV)."], "temporal_context_qualifier": "during surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a656ae1-6248-57d3-a591-a8336d357fb7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [534, 560], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:173fb4ee-a227-52eb-98ab-deddc21d278d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [529, 555], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:415a921a-bd06-5ff7-9667-dc1d3030cf02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [529, 555], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:655b5d95-6f57-5968-8b8c-6cfa8bac4f25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [529, 555], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8db6903b-797e-519d-b9bd-04adc4299d7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [534, 560], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44bcc16c-341d-49e8-a1c6-95d084667aca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44bcc16c-341d-49e8-a1c6-95d084667aca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44bcc16c-341d-49e8-a1c6-95d084667aca"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection, USP in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection, USP in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection, USP in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection, USP is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection, USP is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6078c44-2e94-58ce-a19c-0208db0f2ef1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [534, 560], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5949d02-29eb-4626-ad35-b7614bb0fa95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5949d02-29eb-4626-ad35-b7614bb0fa95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5949d02-29eb-4626-ad35-b7614bb0fa95"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbf04889-34ea-50fd-a194-a86d8003e26f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [534, 560], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5af49a48-f1c0-467d-b5da-ac9f1ae8e34c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5af49a48-f1c0-467d-b5da-ac9f1ae8e34c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5af49a48-f1c0-467d-b5da-ac9f1ae8e34c"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8ea01ba-fbbf-57e5-9aa4-63a6253767ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [540, 566], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9f8fe5ba-943f-4f0a-9618-6083101faa28", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9f8fe5ba-943f-4f0a-9618-6083101faa28", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f8fe5ba-943f-4f0a-9618-6083101faa28"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed6f5941-e3e4-5d45-9be8-cf138e1a6180", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0005233", "object_location_in_text": [529, 555], "original_object": "non-small cell lung cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:400bb9db-4bbf-50af-83dc-67cf3bb1d206", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:328a8f5f-170c-5fae-a7f9-fd34be806834", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0006047", "object_location_in_text": [1569, 1599], "original_object": "adenocarcinoma of the pancreas", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b46b812-5b5d-52e9-849c-123706dcb398", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:328a8f5f-170c-5fae-a7f9-fd34be806834", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0006047", "object_location_in_text": [1569, 1599], "original_object": "adenocarcinoma of the pancreas", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c9d42bb-9cd6-5151-b555-2acfd2c7ffa3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:328a8f5f-170c-5fae-a7f9-fd34be806834", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0006047", "object_location_in_text": [1569, 1599], "original_object": "adenocarcinoma of the pancreas", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d7309a1-d4fa-5fbb-bc05-72b7257e4ebf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:328a8f5f-170c-5fae-a7f9-fd34be806834", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0006047", "object_location_in_text": [1569, 1599], "original_object": "adenocarcinoma of the pancreas", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "platinum-based therapy", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b43ef86-f7ec-5fec-8402-eb33542f310b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:151af2de-1718-5c6b-97d3-0c791bffb052", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:27ceb37f-d53a-5093-8c24-76c030a855ac", "object": "MONDO:0008170", "original_object": "ovarian cancer", "original_subject": "Gemcitabine Injection 38mg/ml", "population_context_qualifier": "patients with advanced ovarian cancer that has recurred at least 6 months after completion of platinum based therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:175901", "supporting_text": ["Ovarian cancer-Gemcitabine injection in combination with cisplatin is indicated for the treatment of patients with advanced ovarian cancer that has replaced at least 6 months after completion of platinum based therapy. Breast Cancer-Gemcitabine injection in combination with paclitaxel is indicated for the first line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. Non-small cell lung cancer- Gemcitabine injection is indicated in combination with cisplatin for the first line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (stage IV) non-small cell lung cancer. Pancreatic cancer- Gemcitabine injection is indicated as first-line treatment for patient with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine injection is indicated for patients previously treated with 5- EU."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26f97864-67a6-5f40-ad10-0795fe1b18be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [147, 170], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:381203bc-d0c6-5e22-9120-ab4f8edff6b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [149, 172], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "population_context_qualifier": "patients that has relapsed at least 6 months after completion of platinum-based therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06dd9d40-74fc-4409-93b1-a46be7126331", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06dd9d40-74fc-4409-93b1-a46be7126331"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:480b96c4-26da-5bfd-9a51-79319631d2c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f3951c-d13f-4662-ad4b-ecfc07f59104", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f3951c-d13f-4662-ad4b-ecfc07f59104", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f3951c-d13f-4662-ad4b-ecfc07f59104"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ff54d65-2e08-5b40-a644-94d207634e8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa445f68-1e55-a587-76dc-def068bc9c74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa445f68-1e55-a587-76dc-def068bc9c74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa445f68-1e55-a587-76dc-def068bc9c74"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy (1.1) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated (1.2) in combination with cisplatin for the treatment of non-small cell lung cancer (1.3) as a single agent for the treatment of pancreatic cancer (1.4) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer. 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with 5-FU."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59cd239f-17be-529a-9ac4-c63bfb3d3336", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [147, 170], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5abf8e91-2004-5993-94ea-a0d96548953d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [139, 162], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a625c92b-c569-4b98-8d2e-2b3f5e12b34f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a625c92b-c569-4b98-8d2e-2b3f5e12b34f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a625c92b-c569-4b98-8d2e-2b3f5e12b34f"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67459c69-24a3-525f-91c8-2e8fe39ab1d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c550dd16-a5e8-44be-87f2-210c15bbb513", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c81cbec-a6b1-5cdf-ace8-6e0c0ef16c4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [149, 172], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "population_context_qualifier": "patients that has relapsed at least 6 months after completion of platinum-based therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e18ed1cb-7dd0-4001-bfda-17d1f4587fb8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e18ed1cb-7dd0-4001-bfda-17d1f4587fb8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76ef9c9e-0a29-5ed3-a094-54e18294c22e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88849d4a-24ea-539a-9c58-d21a11bb5451", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5949d02-29eb-4626-ad35-b7614bb0fa95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5949d02-29eb-4626-ad35-b7614bb0fa95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5949d02-29eb-4626-ad35-b7614bb0fa95"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:894696d1-6de8-5fb7-83d5-1a23d56c7b96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [147, 170], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a061f034-992d-50ae-9639-789a5f5c65a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [139, 162], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d16907e7-a8c8-4039-ace4-cf4e24ba68c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adbbe305-fe22-5724-bdf5-b91888a9de96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5af49a48-f1c0-467d-b5da-ac9f1ae8e34c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5af49a48-f1c0-467d-b5da-ac9f1ae8e34c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5af49a48-f1c0-467d-b5da-ac9f1ae8e34c"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7d4319a-c380-5cd7-a8e9-26299ba29465", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [149, 172], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "population_context_qualifier": "patients that has relapsed at least 6 months after completion of platinum-based therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc02a23b-3ff9-4441-aa91-8e9e629a7315", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc02a23b-3ff9-4441-aa91-8e9e629a7315", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc02a23b-3ff9-4441-aa91-8e9e629a7315"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb689569-efa3-5e34-aa14-d8853f0804d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [151, 174], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44bcc16c-341d-49e8-a1c6-95d084667aca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44bcc16c-341d-49e8-a1c6-95d084667aca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44bcc16c-341d-49e8-a1c6-95d084667aca"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection, USP in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection, USP in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection, USP in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection, USP is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection, USP is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edfc5a30-e4c6-54f9-9f6d-967476b2aaeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [147, 170], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based therapy relapse", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8bf2713-4b5c-5f80-90ce-6ddd875160c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["carboplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "MONDO:0008170", "object_location_in_text": [133, 156], "original_object": "advanced ovarian cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e11eeff7-bcaf-4bf1-8da8-88138e01af84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e11eeff7-bcaf-4bf1-8da8-88138e01af84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e11eeff7-bcaf-4bf1-8da8-88138e01af84"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE AVGEMSI is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer AVGEMSI in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer AVGEMSI in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer AVGEMSI in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer AVGEMSI is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. AVGEMSI is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "at least 6 months after completion of platinum-based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "ovarian cancer which has progressed after cancer chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:758ffc6a-6817-5410-ac64-13627b30693b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:151af2de-1718-5c6b-97d3-0c791bffb052", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:760ba5d3-406e-5d46-85a0-ad4657fb5501", "object": "MONDO:0008170", "object_location_in_text": [77, 91], "original_object": "ovarian cancer", "original_subject": "GEMCITABINE HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:GEMCITABINE HYDROCHLORIDE#162-20110223", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:175901", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Public knowledge-based application after PAFSC's preliminary assessment]"], "temporal_context_qualifier": "after cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bfaaf11-5c87-5838-ba53-c298f4fe4a4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [323, 347], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eafcebc8-ddef-bb6b-fd0a-9d8b9962cdc4"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f97ae93-1d83-5347-9dd7-c3344e201946", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [323, 347], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5949d02-29eb-4626-ad35-b7614bb0fa95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5949d02-29eb-4626-ad35-b7614bb0fa95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5949d02-29eb-4626-ad35-b7614bb0fa95"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior anthracycline-containing adjuvant chemotherapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5414e208-63ea-5b60-b68e-524d21a0ab9b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [313, 337], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a625c92b-c569-4b98-8d2e-2b3f5e12b34f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a625c92b-c569-4b98-8d2e-2b3f5e12b34f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a625c92b-c569-4b98-8d2e-2b3f5e12b34f"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "after failure of prior anthracycline-containing adjuvant chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior anthracycline-containing adjuvant chemotherapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5955978c-dc9d-5596-87a0-755bb6602a52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [323, 347], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c550dd16-a5e8-44be-87f2-210c15bbb513", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anthracycline-containing adjuvant chemotherapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:707a2e37-d625-505e-8f9e-76bda2a19939", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [320, 344], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "population_context_qualifier": "patients with prior anthracycline-containing adjuvant chemotherapy failure (unless anthracyclines were clinically contraindicated)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa445f68-1e55-a587-76dc-def068bc9c74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa445f68-1e55-a587-76dc-def068bc9c74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa445f68-1e55-a587-76dc-def068bc9c74"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy (1.1) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated (1.2) in combination with cisplatin for the treatment of non-small cell lung cancer (1.3) as a single agent for the treatment of pancreatic cancer (1.4) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer. 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with 5-FU."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior anthracycline-containing adjuvant chemotherapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:805a1ee8-09b0-5cbb-a92c-7e4808d1606d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [323, 347], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f3951c-d13f-4662-ad4b-ecfc07f59104", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f3951c-d13f-4662-ad4b-ecfc07f59104", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f3951c-d13f-4662-ad4b-ecfc07f59104"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior anthracycline-containing adjuvant chemotherapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93360fb6-395e-5119-a616-9225392f0972", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [313, 337], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d16907e7-a8c8-4039-ace4-cf4e24ba68c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d16907e7-a8c8-4039-ace4-cf4e24ba68c0"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) • in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) • as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with fluorouracil."], "temporal_context_qualifier": "after failure of prior anthracycline-containing adjuvant chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:999a6ace-2b1c-5ac2-8fc7-3b41f6776991", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [319, 343], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d80176fe-3e8b-48be-87c2-9c603013b3fa"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c08ceee-5e06-5601-9298-73204ecd4321", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [319, 343], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22af3507-4b4f-4cad-9d61-89ffc4aabbc7"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a484a364-bb0c-54ec-ba8d-e5cd73a0e406", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [323, 347], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5af49a48-f1c0-467d-b5da-ac9f1ae8e34c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5af49a48-f1c0-467d-b5da-ac9f1ae8e34c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5af49a48-f1c0-467d-b5da-ac9f1ae8e34c"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine for injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine for injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab1d8bf2-c278-5c6a-9661-c799390f019d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [319, 343], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73ae04d8-38f9-4d3d-b0c2-71d22af1fc86"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anthracycline-containing adjuvant chemotherapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e55b2b5f-dd7d-54f4-a8b3-c97620ef193a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [305, 329], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "population_context_qualifier": "patients without clinical contraindication to anthracyclines", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e11eeff7-bcaf-4bf1-8da8-88138e01af84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e11eeff7-bcaf-4bf1-8da8-88138e01af84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e11eeff7-bcaf-4bf1-8da8-88138e01af84"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE AVGEMSI is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer AVGEMSI in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer AVGEMSI in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer AVGEMSI in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer AVGEMSI is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. AVGEMSI is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea3ac86e-889d-50b0-9c73-d633410460f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960515", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e7703c1-5b50-5c63-8cb4-073c161633fa", "object": "UMLS:C0278488", "object_location_in_text": [319, 343], "original_object": "metastatic breast cancer", "original_subject": "GEMCITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0b1b715-9ff8-43ca-9e49-465f1f380084"]}], "subject": "CHEBI:175901", "supporting_text": ["1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer Gemcitabine Injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine Injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine Injection is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal disorders interfering with intake or absorption of vitamins", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb838fc3-5932-533e-b88b-bbecf3cba53c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160415", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba9eb56f-8a53-5d28-94ad-258959e1639c", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f32108e0-fa10-5ada-86bf-21e302dd5668", "object": "MONDO:0024298", "original_object": "vitamin deficiency", "original_subject": "FLAVIN MONONUCLEOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d"]}], "subject": "CHEBI:17621", "supporting_text": ["In disorders requiring parenteral administration of vitamins, i.e. pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "viral infections of the external canal", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff554dc1-3ddc-5d4c-baef-4265943f489f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2d987d10-c3a8-5588-86ba-313d51f87654", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0004609", "original_object": "herpes simplex infection", "original_subject": "HYDROCORTISONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:17650", "supporting_text": ["CIPRO ® HC OTIC is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "viral infections of the external canal", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e335a270-78b7-54ef-bc25-18ed61c26106", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5a892192-1567-5a76-b0a4-a1d2782bb181", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0005700", "object_location_in_text": [350, 359], "original_object": "varicella", "original_subject": "HYDROCORTISONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:17650", "supporting_text": ["CIPRO ® HC OTIC is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bbf55a7-a64f-5635-a10f-9de427439af1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57c6aadb-fa88-044f-e063-6394a90a3db8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57c6aadb-fa88-044f-e063-6394a90a3db8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57c6aadb-fa88-044f-e063-6394a90a3db8"]}], "subject": "CHEBI:17650", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24c3bfa7-3b56-5ad4-838d-34e79345814d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bcd103f3-3dc8-4394-b8fd-8f8ddb721f77", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bcd103f3-3dc8-4394-b8fd-8f8ddb721f77", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bcd103f3-3dc8-4394-b8fd-8f8ddb721f77"]}], "subject": "CHEBI:17650", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52751eaa-fb58-58bc-b039-1a1604622db2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0005545", "UMLS:C0276078"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2db26b6-8b26-581d-bb49-ea0abc49cc46", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0001051", "object_location_in_text": [50, 70], "original_object": "acute otitis externa", "original_subject": "HYDROCORTISONE", "population_context_qualifier": "adult and pediatric patients, one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:17650", "supporting_text": ["CIPRO ® HC OTIC is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016167", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4fe2f1b7-82b8-5777-91ca-4057b9cd514a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016167", "UMLS:C0033775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cbbac17-5f77-587b-8828-e5c679598c28", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0004872", "object_location_in_text": [120, 131], "original_object": "hemorrhoids", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3881327f-c3fc-7df2-e063-6294a90a468d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3881327f-c3fc-7df2-e063-6294a90a468d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3881327f-c3fc-7df2-e063-6294a90a468d"]}], "subject": "CHEBI:17650", "supporting_text": ["INDICATIONS: Indicated for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a6d7e6c-5961-5f38-811e-55bd4797f4b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c6da2f81-74f0-5a99-a38f-88e03f40d062", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0004980", "object_location_in_text": [114, 120], "original_object": "eczema", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1299392", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e4c226f-3e97-5e3e-98af-284f19544476", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1299392"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0004980", "object_location_in_text": [234, 251], "original_object": "atopic dermatitis", "original_subject": "HYDROCORTISONE", "population_context_qualifier": "pediatric patients 3 months of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ddf699f4-1ae0-48c3-8d2a-56aa1a2c5bc1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ddf699f4-1ae0-48c3-8d2a-56aa1a2c5bc1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddf699f4-1ae0-48c3-8d2a-56aa1a2c5bc1"]}], "subject": "CHEBI:17650", "supporting_text": ["1 INDICATIONS AND USAGE Hydrocortisone Butyrate Cream (lipid), 0.1% is indicated for: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults. The topical treatment of mild to moderate atopic dermatitis in pediatric patients 3 months of age and older. Hydrocortisone Butyrate Cream (lipid), 0.1% is a corticosteroid indicated for: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults. ( 1 ) The topical treatment of mild to moderate atopic dermatitis in pediatric patients 3 months of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bac56aa6-df30-5ffc-9235-401c1be2102e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c6da2f81-74f0-5a99-a38f-88e03f40d062", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0004980", "object_location_in_text": [114, 120], "original_object": "eczema", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd6c6cc9-b683-56e9-99d8-52ea90c2e54d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c6da2f81-74f0-5a99-a38f-88e03f40d062", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0004980", "object_location_in_text": [117, 123], "original_object": "eczema", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5665b0af-87ad-569a-abe8-6429ff95bbe0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e4da0f7-8759-5a9f-a717-c9916426f669", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0005083", "object_location_in_text": [213, 222], "original_object": "psoriasis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:598cc0a7-e4a4-5a73-b173-0571541344cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e4da0f7-8759-5a9f-a717-c9916426f669", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0005083", "object_location_in_text": [213, 222], "original_object": "psoriasis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fdb36013-42f7-5e89-85be-0a852f05e326", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e4da0f7-8759-5a9f-a717-c9916426f669", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0005083", "object_location_in_text": [148, 157], "original_object": "psoriasis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transverse colon involvement, ascending colon involvement", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f9e831c-69a6-5671-a915-34b08fe1a29c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0005101", "object_location_in_text": [93, 111], "original_object": "ulcerative colitis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40654d12-56e4-4489-be49-19c60ad918ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40654d12-56e4-4489-be49-19c60ad918ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40654d12-56e4-4489-be49-19c60ad918ad"]}], "subject": "CHEBI:17650", "supporting_text": ["Hydrocortisone Rectal Suspension, USP is indicated as adjunctive therapy in the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. It has proved useful also in some cases involving the transverse and ascending colons."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transverse colon involvement, ascending colon involvement", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0ba6844-eafe-57ea-abc7-2b52f83ebe22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0005101", "object_location_in_text": [93, 111], "original_object": "ulcerative colitis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb69485-bfa5-4751-b0ca-a0a0efb6b2b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb69485-bfa5-4751-b0ca-a0a0efb6b2b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb69485-bfa5-4751-b0ca-a0a0efb6b2b8"]}], "subject": "CHEBI:17650", "supporting_text": ["Hydrocortisone Rectal Suspension, USP is indicated as adjunctive therapy in the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. It has proved useful also in some cases involving the transverse and ascending colons."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010164", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91948be1-d13a-5405-a3ee-4cff257923dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010164", "UMLS:C0037392", "UMLS:C0011740", "UMLS:C0336902"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c58bdc0-a444-5dee-a358-e5d7866d437c", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0006547", "object_location_in_text": [78, 84], "original_object": "rashes", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5025f53a-02e0-0f6a-e063-6394a90adbbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5025f53a-02e0-0f6a-e063-6394a90adbbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5025f53a-02e0-0f6a-e063-6394a90adbbf"]}], "subject": "CHEBI:17650", "supporting_text": ["For the temporary relief of itching associated with minor skin irritation and rashes due to eczema poison ivy, oak, and sumac cosmetics soaps and detergents jewelry insect bites Other uses of this product should be only under advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bceeeb6-3082-5c94-882d-9041a3f577ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0006608", "object_location_in_text": [126, 147], "original_object": "seborrheic dermatitis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6568213-2d51-578a-bc1e-bb601f105518", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0006608", "object_location_in_text": [224, 245], "original_object": "seborrheic dermatitis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee90c5f9-760a-5e3f-a68b-35c323686c4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "MONDO:0006608", "object_location_in_text": [224, 245], "original_object": "seborrheic dermatitis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3275580", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d2d9004-45ff-5548-b751-c5e4f691ca82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3275580"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65eefd58-b166-4d71-ade6-45c8fdf86922", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922"]}], "subject": "CHEBI:17650", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflam"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular inflammatory conditions unresponsive to topical corticosteroids", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7520e12-5511-5862-b38e-2872c2e98810", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "medic_supporting_text_truncated": true, "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65eefd58-b166-4d71-ade6-45c8fdf86922", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65eefd58-b166-4d71-ade6-45c8fdf86922"]}], "subject": "CHEBI:17650", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflam"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1662f588-bd25-5ad8-9599-a5c500b0bdcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fd095211-24b7-5e56-84cf-72f3214b6d7d", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0021564", "object_location_in_text": [122, 134], "original_object": "insect bites", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5580cf24-2b23-5f54-bb18-21eaf6ac9014", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fd095211-24b7-5e56-84cf-72f3214b6d7d", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0021564", "object_location_in_text": [122, 134], "original_object": "insect bites", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:755d0c0a-09a4-5e4e-8dd3-191555a34fca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fd095211-24b7-5e56-84cf-72f3214b6d7d", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0021564", "object_location_in_text": [159, 171], "original_object": "insect bites", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b6b3e23-5908-59da-b3d4-dc6543a84351", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bf0ded75-4548-5103-a42b-3711268610dc", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0330962", "object_location_in_text": [196, 208], "original_object": "poison sumac", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c79678b1-069f-5d9f-a38c-5f4a92a639a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bf0ded75-4548-5103-a42b-3711268610dc", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0330962", "object_location_in_text": [160, 172], "original_object": "poison sumac", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5c1abc7-ac93-592d-8836-411981c3d7cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bf0ded75-4548-5103-a42b-3711268610dc", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0330962", "object_location_in_text": [160, 172], "original_object": "poison sumac", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ef42622-226c-5f23-91c1-92af0bcfe763", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbf8511d-4b9a-5c21-8070-d7eb900f707d", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0446292", "object_location_in_text": [148, 158], "original_object": "poison oak", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b93a1bf6-b87d-5278-82ca-3371b074c769", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbf8511d-4b9a-5c21-8070-d7eb900f707d", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0446292", "object_location_in_text": [185, 195], "original_object": "poison oak", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9795f90-48cc-5c52-87e3-94a617f705aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbf8511d-4b9a-5c21-8070-d7eb900f707d", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0446292", "object_location_in_text": [148, 158], "original_object": "poison oak", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "itching associated with minor skin irritations, inflammation, and rashes", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28e265fa-5bda-5d27-b2dc-799047443790", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:025f8d72-4f2b-55b5-b55c-a3037255dd46", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0684339", "object_location_in_text": [173, 183], "original_object": "poison ivy", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4df38c1a-943b-7ba3-e063-6394a90af88e"]}], "subject": "CHEBI:17650", "supporting_text": ["USES *for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: * eczema * seborrheic dermatitis psoriasis* insect bites* poison ivy* poison oak*poison sumac * cosmetics*jewelry* detergents* soaps * Other uses of this product should be only under the advice and supervision of a doctor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69439a0e-5d03-5152-8417-4767f1e462fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:025f8d72-4f2b-55b5-b55c-a3037255dd46", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0684339", "object_location_in_text": [136, 146], "original_object": "poison ivy", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b95d30b0-6ebd-4989-a6ac-1a42e5d4aba5"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afaa1d68-d3a4-58bb-8df7-3f68480df03f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368", "MONDO:0006547"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:025f8d72-4f2b-55b5-b55c-a3037255dd46", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb59abbe-09f3-5820-a16a-6e862fe03cdf", "object": "UMLS:C0684339", "object_location_in_text": [136, 146], "original_object": "poison ivy", "original_subject": "HYDROCORTISONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f25f2e14-4fc9-4c92-880d-e5f9279d4ecd"]}], "subject": "CHEBI:17650", "supporting_text": ["Uses for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes due to: eczema, insect bites, poison ivy, poison oak, poison sumac, soaps, jewelry, detergents, cosmetics, psoriasis, seborrheic dermatitis, for external genital, feminine and anal itching, other uses of this product should be only under the advice and supervision of a doctor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deleterious or suspected deleterious germline BRCA -mutated", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:166f4c9b-e267-5410-b6ca-b4794f641dee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170327", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["platinum-based chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5de0d314-475c-5f61-8191-eac348e21c0e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f237ac-1b77-5b52-abbd-af5785c9a00f", "medic_supporting_text_truncated": true, "object": "MONDO:0002158", "original_object": "fallopian tube cancer", "original_subject": "NIRAPARIB", "population_context_qualifier": "adult patients in a complete or partial response to platinum-based chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7f675e2-159c-490c-b6f4-3f16d9492b7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d"]}], "subject": "CHEBI:176844", "supporting_text": ["1 INDICATIONS AND USAGE ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.1 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.2 , 2.1 ) 1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA ‑ authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] . 1.2 Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA mut) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deleterious or suspected deleterious germline BRCA -mutated", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1408ca6a-02ac-5d99-9d7c-4d80ae1bf7dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170327", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["platinum-based chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6baec09c-c6b1-517f-88ee-6894ac2e3db6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f237ac-1b77-5b52-abbd-af5785c9a00f", "medic_supporting_text_truncated": true, "object": "MONDO:0005140", "original_object": "epithelial ovarian cancer", "original_subject": "NIRAPARIB", "population_context_qualifier": "adult patients in a complete or partial response to platinum-based chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7f675e2-159c-490c-b6f4-3f16d9492b7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d"]}], "subject": "CHEBI:176844", "supporting_text": ["1 INDICATIONS AND USAGE ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.1 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.2 , 2.1 ) 1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA ‑ authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] . 1.2 Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA mut) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deleterious or suspected deleterious germline BRCA -mutated", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d37f3b0b-a538-5148-999e-b839bd4ac059", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170327", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["platinum-based chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0251c-38aa-58bd-8959-7d40767c064b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f237ac-1b77-5b52-abbd-af5785c9a00f", "medic_supporting_text_truncated": true, "object": "MONDO:0015686", "original_object": "primary peritoneal cancer", "original_subject": "NIRAPARIB", "population_context_qualifier": "adult patients in a complete or partial response to platinum-based chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7f675e2-159c-490c-b6f4-3f16d9492b7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d"]}], "subject": "CHEBI:176844", "supporting_text": ["1 INDICATIONS AND USAGE ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: o a deleterious or suspected deleterious BRCA mutation, and/or o genomic instability. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.1 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA. ( 1.2 , 2.1 ) 1.1 First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA ‑ authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] . 1.2 Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA mut) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "cystathionine beta-synthase (CBS) deficiency, 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency, cobalamin cofactor metabolism defect", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6a81c2f-61ce-521b-8957-8c327b42ee83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070214", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["vitamin B6 (pyridoxine)", "vitamin B12 (cobalamin)", "folate"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f5cced9d-2fb1-5566-941e-2a9511229fc7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e1a82bff-3aae-58ae-9e00-0287a2008548", "object": "MONDO:0004737", "object_location_in_text": [24, 38], "original_object": "homocystinuria", "original_subject": "betaine anhydrous", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cystadane", "https://www.ema.europa.eu/en/documents/product-information/cystadane-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cystadane"]}], "subject": "CHEBI:17750", "supporting_text": ["Adjunctive treatment of homocystinuria, involving deficiencies or defects in:  cystathionine beta-synthase (CBS); 5,10-methylene-tetrahydrofolate reductase (MTHFR); cobalamin cofactor metabolism (cbl).  Cystadane should be used as supplement to other therapies such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a specific diet."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, Cobalamin cofactor metabolism (cbl) defect", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f8b6a43-0752-576e-9b35-0a1c604aa856", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5cced9d-2fb1-5566-941e-2a9511229fc7", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5982b70f-eee8-59aa-beb8-b93113f0f1d1", "object": "MONDO:0004737", "object_location_in_text": [96, 110], "original_object": "homocystinuria", "original_subject": "BETAINE", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99b667fa-b00c-465b-bbed-36f317078115", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99b667fa-b00c-465b-bbed-36f317078115", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99b667fa-b00c-465b-bbed-36f317078115"]}], "subject": "CHEBI:17750", "supporting_text": ["1 INDICATIONS &amp; USAGE Betaine Anhydrous for Oral Solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect Betaine Anhydrous for Oral Solution is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are: Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, Cobalamin cofactor metabolism (cbl) defect", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35f4f36e-666f-5516-85db-545cb0dcf254", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5cced9d-2fb1-5566-941e-2a9511229fc7", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5982b70f-eee8-59aa-beb8-b93113f0f1d1", "object": "MONDO:0004737", "object_location_in_text": [94, 108], "original_object": "homocystinuria", "original_subject": "BETAINE", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef44452a-5707-0d39-cbba-2fa285fb994c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef44452a-5707-0d39-cbba-2fa285fb994c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef44452a-5707-0d39-cbba-2fa285fb994c"]}], "subject": "CHEBI:17750", "supporting_text": ["1 INDICATIONS AND USAGE Betaine Anhydrous for Oral Solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are: • Cystathionine beta-synthase (CBS) deficiency • 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency • Cobalamin cofactor metabolism (cbl) defect Betaine Anhydrous for Oral Solution is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are ( 1 ): • Cystathionine beta-synthase (CBS) deficiency • 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency • Cobalamin cofactor metabolism (cbl) defect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, Cobalamin cofactor metabolism (cbl) defect", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92c79e13-073d-5b4a-9ac1-10b7b7d02d99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5cced9d-2fb1-5566-941e-2a9511229fc7", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5982b70f-eee8-59aa-beb8-b93113f0f1d1", "object": "MONDO:0004737", "object_location_in_text": [70, 84], "original_object": "homocystinuria", "original_subject": "BETAINE", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31a684d0-cd98-4e46-b43a-ccbd17c41559", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31a684d0-cd98-4e46-b43a-ccbd17c41559", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31a684d0-cd98-4e46-b43a-ccbd17c41559"]}], "subject": "CHEBI:17750", "supporting_text": ["1 INDICATIONS AND USAGE CYSTADANE ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are: Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect CYSTADANE is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are ( 1 ): Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, Cobalamin cofactor metabolism (cbl) defect", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f72767d5-e0dd-57aa-af55-3908e5272b32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5cced9d-2fb1-5566-941e-2a9511229fc7", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5982b70f-eee8-59aa-beb8-b93113f0f1d1", "object": "MONDO:0004737", "object_location_in_text": [95, 109], "original_object": "homocystinuria", "original_subject": "BETAINE", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ee8a95c3-df9f-6e55-e053-2a95a90ab17b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ee8a95c3-df9f-6e55-e053-2a95a90ab17b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee8a95c3-df9f-6e55-e053-2a95a90ab17b"]}], "subject": "CHEBI:17750", "supporting_text": ["1. INDICATIONS AND USAGE Betaine Anhydrous for Oral Solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are: • Cystathionine beta-synthase (CBS) deficiency • 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency • Cobalamin cofactor metabolism (cbl) defect Betaine Anhydrous for Oral Solution is a methylating agent indicated in pediatric and adult patients for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations. Included within the category of homocystinuria are: • Cystathionine beta-synthase (CBS) deficiency • 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency • Cobalamin cofactor metabolism (cbl) defect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20efd566-531e-5e86-8f00-bc323e649a5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5982b70f-eee8-59aa-beb8-b93113f0f1d1", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "BETAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:17750", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9219008-21db-5ac4-adeb-72f4a20d4d89", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33b265d0-c624-5928-8086-f5bb0b267076", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0235266", "original_object": "eye irritation", "original_subject": "GLYCERIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c61b011-c20d-54aa-9992-8640a903af34", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0014724", "object_location_in_text": [180, 187], "original_object": "burning", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c831c58-8cb3-56df-9350-e225b323ffe7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0014724", "object_location_in_text": [180, 187], "original_object": "burning", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edbf08d3-045a-568c-9932-8e7acc98b843", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0014724", "object_location_in_text": [99, 106], "original_object": "burning", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e018c8a-c21b-542d-815d-d0f280f55087", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e3bec2a-ef29-5a26-8a4c-5e70eed8bbf1", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0441723", "object_location_in_text": [99, 121], "original_object": "burning and irritation", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9cb261ed-b708-1189-e053-2a95a90a547d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9cb261ed-b708-1189-e053-2a95a90a547d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9cb261ed-b708-1189-e053-2a95a90a547d"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses For the relief of redness of the eye due to minor eye irritations For the temporary relief of burning and irritation due to dryness of the eye For use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:330b9436-609e-51c5-b2be-0b7a202205ce", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0441723", "object_location_in_text": [59, 69], "original_object": "irritation", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:894d3790-2eaf-5392-a8c6-815db0240ab9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e3bec2a-ef29-5a26-8a4c-5e70eed8bbf1", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0441723", "original_object": "burning and irritation", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:326a1462-78d1-42d6-8257-7e4f00d1f215", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=326a1462-78d1-42d6-8257-7e4f00d1f215", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=326a1462-78d1-42d6-8257-7e4f00d1f215"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses for use as a protectant against further irritation or to relieve dryness of the eye for the temporary relief of burning &amp; irritation due to dryness of the eye relieves redness of the eye due to minor eye irritations"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c261fbb1-d3ed-5e93-b28d-36c1901e8de1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0441723", "object_location_in_text": [52, 62], "original_object": "irritation", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f933ab67-0bca-58f9-9c4f-c70b73daa7ff", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9622a4f2-e274-53bd-819b-cd383bf0f25c", "object": "UMLS:C0441723", "object_location_in_text": [52, 62], "original_object": "irritation", "original_subject": "GLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52"]}], "subject": "CHEBI:17754", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e8ad569-c8b2-5c15-a1c5-6f3672c221af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220601", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:36e22d02-36e7-5b87-870d-d8bb37cfcf87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47de3ee2-1e2c-53b0-89b6-f5e03d6b691a", "object": "HP:0001250", "object_location_in_text": [65, 73], "original_object": "seizures", "original_subject": "GANAXOLONE", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d91612c4-b03a-4be4-a1ee-6a13e3b83d4e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d91612c4-b03a-4be4-a1ee-6a13e3b83d4e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d91612c4-b03a-4be4-a1ee-6a13e3b83d4e"]}], "subject": "CHEBI:177658", "supporting_text": ["1 INDICATIONS AND USAGE ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acquired HSDD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50705f32-9018-5ac2-b41c-24140b1fd62b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190621", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5866fa6a-7ffa-574a-b634-1a521736e95c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9be7cb2c-d7df-5047-9924-9c389b80cab4", "object": "MONDO:0001821", "original_object": "hypoactive sexual desire disorder", "original_subject": "BREMELANOTIDE", "population_context_qualifier": "premenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf"]}], "subject": "CHEBI:177849", "supporting_text": ["1 INDICATIONS AND USAGE VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52aeb151-554c-5f86-af27-bef2f759de97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20260310", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:f74f3946-eb2b-569b-8c04-ab30724afcf6", "object": "MONDO:0005233", "object_location_in_text": [82, 108], "original_object": "non-small cell lung cancer", "original_subject": "Sotorasib 240mg Film Coated Tablets.", "population_context_qualifier": "adult patients who have received at least one prior systemic therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:178199", "supporting_text": ["Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one prior systemic therapy"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3274012", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e51a0d9b-185f-5676-991a-71f2e06a763b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220106", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3274012"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1714358f-f7ba-5d82-a059-2d4f4f999d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8b777139-75dc-53a5-8b5c-63e6e733a267", "object": "MONDO:0005233", "object_location_in_text": [70, 105], "original_object": "advanced non-small cell lung cancer", "original_subject": "sotorasib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lumykras", "https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras"]}], "subject": "CHEBI:178199", "supporting_text": ["Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy."], "temporal_context_qualifier": "who have progressed after at least one prior line of systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "KRAS G12C-mutated", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a140ed04-662f-5168-9b4c-36956d71ba6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210528", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f90a7c2f-dab0-535c-b702-45a12363a216", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8b777139-75dc-53a5-8b5c-63e6e733a267", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "locally advanced or metastatic non-small cell lung cancer", "original_subject": "SOTORASIB", "population_context_qualifier": "adult patients who have received at least one prior systemic therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c80a362c-7ac3-4894-a076-0691e68ef8c1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1"]}], "subject": "CHEBI:178199", "supporting_text": ["1 INDICATIONS AND USAGE LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) 1.1 KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) LUMAKRAS as a single agent is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) LUMAKRAS, in combination with panitumumab, is indicated for the treatment of adult patients with KRAS G12C -mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy [see Dosage and Administr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "KRAS G12C-mutated", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f278d1b3-76ec-56a2-83ac-4adfda2d7ae0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210528", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["panitumumab"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7883379b-4d29-511d-963a-a4eb81b67307", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8b777139-75dc-53a5-8b5c-63e6e733a267", "medic_supporting_text_truncated": true, "object": "UMLS:C4721579", "original_object": "metastatic colorectal cancer", "original_subject": "SOTORASIB", "population_context_qualifier": "adult patients who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c80a362c-7ac3-4894-a076-0691e68ef8c1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1"]}], "subject": "CHEBI:178199", "supporting_text": ["1 INDICATIONS AND USAGE LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) 1.1 KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) LUMAKRAS as a single agent is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) LUMAKRAS, in combination with panitumumab, is indicated for the treatment of adult patients with KRAS G12C -mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy [see Dosage and Administr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002901", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:618d0c88-bdb8-55ac-93dc-b08c4cd161e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0002901"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d8c2648-1dbe-56fd-8184-51ce84ec922b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "MONDO:0005890", "object_location_in_text": [824, 848], "original_object": "osteitis fibrosa cystica", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients undergoing chronic renal dialysis", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bdb9c0d4-bdb3-4174-a4d9-55c423f38476", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bdb9c0d4-bdb3-4174-a4d9-55c423f38476", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdb9c0d4-bdb3-4174-a4d9-55c423f38476"]}], "subject": "CHEBI:17823", "supporting_text": ["INDICATIONS &amp; USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03d37dd7-1c0e-5d4d-983a-057c0f9c1202", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32205cfc-7939-4105-a4b9-2ed327c5e0cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32205cfc-7939-4105-a4b9-2ed327c5e0cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32205cfc-7939-4105-a4b9-2ed327c5e0cc"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08ca404f-9ad4-52ab-a695-a432a7cab30f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [512, 524], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:626f23d5-31e6-41ca-a696-191a4f2bc7ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=626f23d5-31e6-41ca-a696-191a4f2bc7ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=626f23d5-31e6-41ca-a696-191a4f2bc7ef"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e3a0ce0-d0a9-5eea-8424-8314877423b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypopara-thyroidism", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26ac6b4d-9576-4710-856b-aca114ea84cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26ac6b4d-9576-4710-856b-aca114ea84cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26ac6b4d-9576-4710-856b-aca114ea84cf"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypopara-thyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:106829a0-828f-53e7-971c-e9b480ca81d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypopara-thyroidism", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2b48f57a-c023-485d-b846-cab3aaaad486", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2b48f57a-c023-485d-b846-cab3aaaad486", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b48f57a-c023-485d-b846-cab3aaaad486"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypopara-thyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1679a098-fd16-5735-970f-1f724f011c72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bebefb2a-7365-48e2-9681-83ed4b41e26e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bebefb2a-7365-48e2-9681-83ed4b41e26e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bebefb2a-7365-48e2-9681-83ed4b41e26e"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29fc3b7c-7ab7-54bf-9ce1-309565b81bbd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [512, 524], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8465337c-86ca-ea9d-e053-2991aa0ab167", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8465337c-86ca-ea9d-e053-2991aa0ab167", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8465337c-86ca-ea9d-e053-2991aa0ab167"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:465fc5b3-4bca-5ac8-867a-a4e2e15981e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [491, 503], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e1fcb1c7-11a9-4a23-a64a-2c8ce9698321", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e1fcb1c7-11a9-4a23-a64a-2c8ce9698321", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1fcb1c7-11a9-4a23-a64a-2c8ce9698321"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54e2f792-f7d4-5295-9f4c-63c64fd6eb4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36820cd0-7b30-4454-9005-09d71e1d5796", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36820cd0-7b30-4454-9005-09d71e1d5796", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36820cd0-7b30-4454-9005-09d71e1d5796"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67576e8c-e14c-5646-b1a4-2cdf69327cdd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:261398eb-80b8-4c3d-9d2b-3a8004347a75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=261398eb-80b8-4c3d-9d2b-3a8004347a75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=261398eb-80b8-4c3d-9d2b-3a8004347a75"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:720c36cb-7ee5-59a6-bf6b-ab54f019b1b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [512, 524], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf621b22-b783-416f-aee3-e0dbfdb782ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf621b22-b783-416f-aee3-e0dbfdb782ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf621b22-b783-416f-aee3-e0dbfdb782ca"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99e9e8b8-b774-56cd-8eaf-97276e7b76e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [516, 528], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bdb9c0d4-bdb3-4174-a4d9-55c423f38476", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bdb9c0d4-bdb3-4174-a4d9-55c423f38476", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdb9c0d4-bdb3-4174-a4d9-55c423f38476"]}], "subject": "CHEBI:17823", "supporting_text": ["INDICATIONS &amp; USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad46da38-7bd8-5585-b2e9-a5f9288de263", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [508, 520], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:29b8cc1f-0491-0a95-e063-6294a90a223d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=29b8cc1f-0491-0a95-e063-6294a90a223d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29b8cc1f-0491-0a95-e063-6294a90a223d"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2106335-6e0e-55b2-ac8a-bda2dad61314", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [512, 524], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45f78bbe-4bbc-404d-a061-ead3db50908e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45f78bbe-4bbc-404d-a061-ead3db50908e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45f78bbe-4bbc-404d-a061-ead3db50908e"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1ef9a1f-884e-5847-a801-be283a9ec9ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [493, 505], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec93b667-aad2-4e3a-adc6-952f070a0c0a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec93b667-aad2-4e3a-adc6-952f070a0c0a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec93b667-aad2-4e3a-adc6-952f070a0c0a"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2418f5e-703e-5a65-bd66-474b1a0389b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [520, 532], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bd717a4-5fdf-4697-a6b2-9df55c6517bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bd717a4-5fdf-4697-a6b2-9df55c6517bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bd717a4-5fdf-4697-a6b2-9df55c6517bb"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol Oral Solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Oral Solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, Calcitriol Oral Solution administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Oral Solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4d907f3-6bc9-596a-b7ab-73002dc1ee62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [491, 503], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdcaffc6-e14e-4607-b77b-fc78a8382f60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d77eb1d7-606c-58de-afa5-5fb3ffcdb745", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [492, 504], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:554a54a0-3e46-4a9d-8e54-3d853302dbbb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=554a54a0-3e46-4a9d-8e54-3d853302dbbb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=554a54a0-3e46-4a9d-8e54-3d853302dbbb"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342342", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3e7e57c-cf9b-5cf0-9b0d-3d700ffbea20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342342", "MONDO:0019992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "HP:0002901", "object_location_in_text": [493, 505], "original_object": "hypocalcemia", "original_subject": "CALCITRIOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34f53d71-78b0-5237-e063-6294a90a2bbd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34f53d71-78b0-5237-e063-6294a90a2bbd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34f53d71-78b0-5237-e063-6294a90a2bbd"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002901", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bd0ab28-b619-5227-a076-805919dd086a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002901"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66f386df-39bc-5abe-b2bc-f65906a9cfa8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "MONDO:0800486", "object_location_in_text": [134, 156], "original_object": "metabolic bone disease", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients undergoing chronic renal dialysis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bdb9c0d4-bdb3-4174-a4d9-55c423f38476", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bdb9c0d4-bdb3-4174-a4d9-55c423f38476", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdb9c0d4-bdb3-4174-a4d9-55c423f38476"]}], "subject": "CHEBI:17823", "supporting_text": ["INDICATIONS &amp; USAGE Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4551529", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:682af481-e334-5d6d-82da-a373ca0b6817", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4551529"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66f386df-39bc-5abe-b2bc-f65906a9cfa8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "MONDO:0800486", "object_location_in_text": [124, 146], "original_object": "metabolic bone disease", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients undergoing chronic renal dialysis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bd717a4-5fdf-4697-a6b2-9df55c6517bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bd717a4-5fdf-4697-a6b2-9df55c6517bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bd717a4-5fdf-4697-a6b2-9df55c6517bb"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol Oral Solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Oral Solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, Calcitriol Oral Solution administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Oral Solution is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002901", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79ace8ac-3caf-59a9-89ce-7032a683a86a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002901"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66f386df-39bc-5abe-b2bc-f65906a9cfa8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "MONDO:0800486", "object_location_in_text": [110, 132], "original_object": "metabolic bone disease", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients undergoing chronic renal dialysis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e1fcb1c7-11a9-4a23-a64a-2c8ce9698321", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e1fcb1c7-11a9-4a23-a64a-2c8ce9698321", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1fcb1c7-11a9-4a23-a64a-2c8ce9698321"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002901", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f50af24e-70da-553a-a8bf-ea3132192905", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002901"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66f386df-39bc-5abe-b2bc-f65906a9cfa8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bd8929ff-6eed-5c83-930e-6823dd261e8b", "object": "MONDO:0800486", "object_location_in_text": [110, 132], "original_object": "metabolic bone disease", "original_subject": "CALCITRIOL", "population_context_qualifier": "patients undergoing chronic renal dialysis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdcaffc6-e14e-4607-b77b-fc78a8382f60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdcaffc6-e14e-4607-b77b-fc78a8382f60"]}], "subject": "CHEBI:17823", "supporting_text": ["Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "suspected coronary artery disease", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d18945c-8618-511a-998d-3e70d08aaf59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1020, 1043], "original_object": "coronary artery disease", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "Adults and pediatric patients 12 years of age and over", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) CT imaging of the head and body. (270 mg Iodine/mL and 320 mg Iodine/mL) excretory urography. (270 mg Iodine/mL) peripheral venography. (320 mg Iodine/mL) coronary computed tomography"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active Crohn's disease", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be4a39be-a2ea-582d-bb89-e8dbeec42dad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a82e12e2-e9e6-5717-a5f3-b8af061469fe", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "MONDO:0005011", "original_object": "Crohn's disease", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active ulcerative colitis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c35deaf-4927-573d-96ef-b656adef1a23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "MONDO:0005101", "object_location_in_text": [898, 916], "original_object": "ulcerative colitis", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active rheumatoid arthritis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:636a9d60-3407-52a4-99c7-c02530027288", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate", "non-biologic disease-modifying anti-rheumatic drugs (DMARDs)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "MONDO:0008383", "object_location_in_text": [286, 306], "original_object": "rheumatoid arthritis", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active polyarticular juvenile idiopathic arthritis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a95d55f5-f083-5941-83e3-02ce1b43046a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "MONDO:0018456", "object_location_in_text": [378, 421], "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:701c8ce3-461a-593a-b899-a76655a0bdb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "ISOPROPYL ALCOHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:579bd1fe-51a1-403f-a422-0fb701aab57d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=579bd1fe-51a1-403f-a422-0fb701aab57d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=579bd1fe-51a1-403f-a422-0fb701aab57d"]}], "subject": "CHEBI:17824", "supporting_text": ["Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bed38e4-e2a9-5712-8f4f-c20e5a288b7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9560931-c961-5226-86dc-27ddc31ab723", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "UMLS:C0406317", "original_object": "chronic plaque psoriasis", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "adult patients who are candidates for systemic therapy or phototherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:760d432c-f088-59ba-90f1-3c5ab6a54323", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9560931-c961-5226-86dc-27ddc31ab723", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28e93de7-50e5-5543-8741-3fa00668cdd6", "object": "UMLS:C0406317", "original_object": "chronic plaque psoriasis", "original_subject": "ISOPROPYL ALCOHOL", "population_context_qualifier": "adult patients who are candidates for systemic therapy or phototherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:608d4f0d-b19f-46d3-749a-7159aa5f933d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d"]}], "subject": "CHEBI:17824", "supporting_text": ["1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced hemorrhagic cystitis", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31a112e6-4840-5cf5-92df-4dbeb4fc88aa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "object_location_in_text": [125, 145], "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7af968c-05cf-4438-94ba-96a2baf9c367", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7af968c-05cf-4438-94ba-96a2baf9c367", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7af968c-05cf-4438-94ba-96a2baf9c367"]}], "subject": "CHEBI:17905", "supporting_text": ["1 INDICATIONS AND USAGE Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis."], "temporal_context_qualifier": "ifosfamide administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced hemorrhagic cystitis", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a890ceb-f413-5944-871c-ea781a603869", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "object_location_in_text": [115, 135], "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe1683ef-0569-411e-8188-0499884632ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe1683ef-0569-411e-8188-0499884632ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe1683ef-0569-411e-8188-0499884632ad"]}], "subject": "CHEBI:17905", "supporting_text": ["1 INDICATIONS AND USAGE Mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced hemorrhagic cystitis", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52531f03-1330-5cbe-8c89-e19c2b3dc91e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "object_location_in_text": [115, 135], "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a880160b-fa82-453a-a971-29ab897876a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a880160b-fa82-453a-a971-29ab897876a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a880160b-fa82-453a-a971-29ab897876a7"]}], "subject": "CHEBI:17905", "supporting_text": ["1 INDICATIONS AND USAGE Mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced injury", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:937ce0e1-fc14-5866-b721-4631984a1942", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "population_context_qualifier": "patients receiving ifosfamide", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8012b97b-4e39-451f-8e04-542d196e8bc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8012b97b-4e39-451f-8e04-542d196e8bc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8012b97b-4e39-451f-8e04-542d196e8bc6"]}], "subject": "CHEBI:17905", "supporting_text": ["1 INDICATIONS AND USAGE Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis L imitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna isa cytoprotective agent indicated asa prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. ( 1 )"], "temporal_context_qualifier": "following ifosfamide administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced hemorrhagic cystitis", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbf8f998-37c4-51d1-bd50-60b9ec821698", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "object_location_in_text": [125, 145], "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef161ede-0451-43c8-b0e5-cb108b138e38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef161ede-0451-43c8-b0e5-cb108b138e38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef161ede-0451-43c8-b0e5-cb108b138e38"]}], "subject": "CHEBI:17905", "supporting_text": ["1 INDICATIONS AND USAGE Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis."], "temporal_context_qualifier": "ifosfamide administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced hemorrhagic cystitis", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edf718fc-d5a6-586c-ae4a-7085cf7ef5d5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "object_location_in_text": [126, 146], "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49e9c804-9e88-4774-8faf-35bd61b3a8e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49e9c804-9e88-4774-8faf-35bd61b3a8e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49e9c804-9e88-4774-8faf-35bd61b3a8e9"]}], "subject": "CHEBI:17905", "supporting_text": ["1. INDICATIONS AND USAGE Mesna injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis."], "temporal_context_qualifier": "ifosfamide administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ifosfamide-induced hemorrhagic cystitis", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f642ad84-7c7f-5571-b4ac-7bb66c4e2388", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2c24c34-5254-5ae0-92fb-434d4b7ed794", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1d29643f-4ab2-54a6-b3e0-ebf69b391eed", "object": "MONDO:0000496", "object_location_in_text": [115, 135], "original_object": "hemorrhagic cystitis", "original_subject": "2-MERCAPTOETHANESULFONIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90d64539-33ad-47e8-9de7-17d6c5baaba4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90d64539-33ad-47e8-9de7-17d6c5baaba4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90d64539-33ad-47e8-9de7-17d6c5baaba4"]}], "subject": "CHEBI:17905", "supporting_text": ["1 INDICATIONS AND USAGE Mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "viral infections of the external canal", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ccf5331-3611-571c-9679-52c580f9f113", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090409", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2d987d10-c3a8-5588-86ba-313d51f87654", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9032f064-1736-5c64-a24b-8a9b8a2f7512", "object": "MONDO:0004609", "original_object": "herpes simplex infection", "original_subject": "BENZYL ALCOHOL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:17987", "supporting_text": ["CIPRO ® HC OTIC is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "viral infections of the external canal", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffe0aebe-7a61-5c11-8fe2-ca6043290c43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090409", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5a892192-1567-5a76-b0a4-a1d2782bb181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9032f064-1736-5c64-a24b-8a9b8a2f7512", "object": "MONDO:0005700", "object_location_in_text": [350, 359], "original_object": "varicella", "original_subject": "BENZYL ALCOHOL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:17987", "supporting_text": ["CIPRO ® HC OTIC is contraindicated in persons with a history of hypersensitivity to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in viral infections of the external canal including varicella and herpes simplex infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc4b71eb-4e27-5ae4-83e0-2f5dc3c54890", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090409", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0005545", "UMLS:C0276078"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2db26b6-8b26-581d-bb49-ea0abc49cc46", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9032f064-1736-5c64-a24b-8a9b8a2f7512", "object": "MONDO:0001051", "object_location_in_text": [50, 70], "original_object": "acute otitis externa", "original_subject": "BENZYL ALCOHOL", "population_context_qualifier": "adult and pediatric patients, one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14b45f78-0bc0-4e25-831e-d2a0006b2b87"]}], "subject": "CHEBI:17987", "supporting_text": ["CIPRO ® HC OTIC is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0200114", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8949779d-e6a5-5928-8371-d76ba4764c3d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0200114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2fe957a7-4f06-541e-963d-8c8f0cfd01e0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c189c452-09f5-5cd6-a55e-764006330761", "object": "MONDO:0003019", "object_location_in_text": [93, 104], "original_object": "hypokalemia", "original_subject": "CHLORIDE", "population_context_qualifier": "patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:727be945-df2a-4fbf-ade4-f242e2647976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=727be945-df2a-4fbf-ade4-f242e2647976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=727be945-df2a-4fbf-ade4-f242e2647976"]}], "subject": "CHEBI:17996", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium Chloride is a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0200114", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3779829-6d97-5250-8d6f-6819addbf0f6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0200114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2fe957a7-4f06-541e-963d-8c8f0cfd01e0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c189c452-09f5-5cd6-a55e-764006330761", "object": "MONDO:0003019", "object_location_in_text": [93, 104], "original_object": "hypokalemia", "original_subject": "CHLORIDE", "population_context_qualifier": "patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ea55ded1-e076-43de-ad3c-c75e7d0a4ebc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ea55ded1-e076-43de-ad3c-c75e7d0a4ebc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea55ded1-e076-43de-ad3c-c75e7d0a4ebc"]}], "subject": "CHEBI:17996", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium Chloride is a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "excessive perspiration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08aaf28a-f6ec-5203-87aa-f63a4d2a0d30", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e47c5b5a-9742-5a2c-8067-b302f3d687d4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c189c452-09f5-5cd6-a55e-764006330761", "object": "UMLS:C0085592", "original_object": "heat cramps", "original_subject": "CHLORIDE", "population_context_qualifier": "patients experiencing excessive perspiration", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff376144-28a1-8811-e053-6394a90aa995", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff376144-28a1-8811-e053-6394a90aa995", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff376144-28a1-8811-e053-6394a90aa995"]}], "subject": "CHEBI:17996", "supporting_text": ["USES FOR THE PREPARATION OF NORMAL ISOTONIC SOLUTION OF SODIUM CHLORIDE. AS AN ELECTROLYTE REPLENISHER FOR THE PREVENTION OF HEAT CRAMPS DUE TO EXCESSIVE PERSPIRATION. ANY ALTERNATIVE USE AS DIRECTED BY A PHYSICIAN."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042880", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26a742a6-9228-580e-a3cd-c7455d234d89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042880"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a97fe23-ffdf-5924-8462-1969caea3bdd", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c67d5785-3b19-5acd-a631-724c6285f729", "object": "MONDO:0001531", "original_object": "coagulation disorder", "original_subject": "PHYTONADIONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5686f34b-446a-00ae-e063-6394a90a6029", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5686f34b-446a-00ae-e063-6394a90a6029", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5686f34b-446a-00ae-e063-6394a90a6029"]}], "subject": "CHEBI:18067", "supporting_text": ["Phytonadione injectable emulsion, USP is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by Vitamin K deficiency or interference with Vitamin K activity. Phytonadione injectable emulsion is indicated in­­ anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; ­­ prophylaxis and therapy of hemorrhagic disease of the newborn; ­­ hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with phytonadione injectable emulsion metabolism, e.g., salicylates."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "swine dysentery caused by Branchyspira hydodysenteriae", "has_confidence_score": 0.132781, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14f43e70-d437-518b-8893-f686e0a450c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:464c28cb-973e-55e7-8dc8-c2311c455c87", "medic_pair_confidence": 0.132781, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:c6fe9e0e-a5d0-5ca1-a663-29d5808a8fe0", "object": "UMLS:C0275879", "object_location_in_text": [32, 47], "original_object": "swine dysentery", "original_subject": "Tiamulin hydrogen fumarate solution for injection 162 mg/ml (additional Dosage form)", "population_context_qualifier": "individual animals with a known history of exposure to diseased animals", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:181016", "supporting_text": ["For treatment and prevention of swine dysentery caused by Branchyspira hydodysenteriae. The product is not appropriate for use for the prevention of disease at the level of herd treatment but should only be used for prevention of swine dysentery in individual animals with a known history of exposure to diseased animals."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392172", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2430fd8e-d190-58a7-b08b-4cbefcbe0055", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C5392172"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89c1bbfc-8d8f-5c69-b935-96e95b1d82b1", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "MONDO:0005504", "original_object": "diphtheria", "original_subject": "PENICILLIN G", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a4e5124-618b-ce44-e063-6394a90a43e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a4e5124-618b-ce44-e063-6394a90a43e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a4e5124-618b-ce44-e063-6394a90a43e3"]}], "subject": "CHEBI:18208", "supporting_text": ["Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. indications&amp;usage section"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b07d2c1-29f3-5b8d-8028-bbba7f6fc3cb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "PENICILLIN G", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a4e5124-618b-ce44-e063-6394a90a43e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a4e5124-618b-ce44-e063-6394a90a43e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a4e5124-618b-ce44-e063-6394a90a43e3"]}], "subject": "CHEBI:18208", "supporting_text": ["Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. indications&amp;usage section"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible streptococci", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f129efd-ec9a-5917-b779-110af640895a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd099f10-e8c8-5785-9177-9f0b44238e82", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "HP:0002788", "original_object": "upper-respiratory tract infections", "original_subject": "PENICILLIN G", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d"]}], "subject": "CHEBI:18208", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R 900/300 and other antibacterial drugs, Bicillin C-R 900/300 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bicillin C-R 900/300 is indicated in the treatment of infections as described below that are susceptible to serum levels characteristic of this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R 900/300 is indicated in the treatment of the following in pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very susceptible to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible Streptococcus pneumoniae . NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21c8dcab-235b-5c38-ad5e-f19969b1d37f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [756, 768], "original_object": "endocarditis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e917a98-e761-55c0-a8ea-ca4ca7f7cd0a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [756, 768], "original_object": "endocarditis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:431b022f-da8f-5f99-964f-7c6b588d1697", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [756, 768], "original_object": "endocarditis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ddcdb0c-e6f9-5509-89a4-efc763beeda1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [722, 729], "original_object": "empyema", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:934ac0d0-5553-5e1a-b978-053d0b553a57", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [722, 729], "original_object": "empyema", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9975350f-f168-586a-ba26-6bd03a956620", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [722, 729], "original_object": "empyema", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18a40d82-05fd-5386-9cb5-9e21794d3368", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "object_location_in_text": [731, 740], "original_object": "pneumonia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44e1af74-b8cb-5e46-b12b-1c6a20a0c7dc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "object_location_in_text": [731, 740], "original_object": "pneumonia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible Streptococcus pneumoniae", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93aea7fd-f68e-5380-a684-555b51998fe1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "MONDO:0005249", "original_object": "pneumonia", "original_subject": "PENICILLIN G", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d"]}], "subject": "CHEBI:18208", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R 900/300 and other antibacterial drugs, Bicillin C-R 900/300 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bicillin C-R 900/300 is indicated in the treatment of infections as described below that are susceptible to serum levels characteristic of this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R 900/300 is indicated in the treatment of the following in pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very susceptible to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible Streptococcus pneumoniae . NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4339087-d971-58b3-a340-812808361f17", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "object_location_in_text": [731, 740], "original_object": "pneumonia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible Streptococcus pneumoniae", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5963fec8-c5b1-5d47-8cb3-3a411a022396", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24e87000-4a01-519b-b67a-4d622141c0b6", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "MONDO:0005441", "object_location_in_text": [1352, 1364], "original_object": "otitis media", "original_subject": "PENICILLIN G", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d"]}], "subject": "CHEBI:18208", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R 900/300 and other antibacterial drugs, Bicillin C-R 900/300 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bicillin C-R 900/300 is indicated in the treatment of infections as described below that are susceptible to serum levels characteristic of this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R 900/300 is indicated in the treatment of the following in pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very susceptible to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible Streptococcus pneumoniae . NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible pneumococci", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d4c3c25-7f18-537a-b1ba-20ac609c0f4c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24e87000-4a01-519b-b67a-4d622141c0b6", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "MONDO:0005441", "object_location_in_text": [1364, 1376], "original_object": "otitis media", "original_subject": "PENICILLIN G", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:337fde53-92a3-4a56-97c2-4bbb31bc9d0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=337fde53-92a3-4a56-97c2-4bbb31bc9d0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=337fde53-92a3-4a56-97c2-4bbb31bc9d0e"]}], "subject": "CHEBI:18208", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c54383c-3a80-5f9a-9f83-c621772193f9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:94a309f1-e5d3-5ab3-9e85-66405b4213e8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005498", "original_object": "botulism", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"], "temporal_context_qualifier": "adjunctive therapy to antitoxin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:748c6739-1e96-577f-b40d-c6b66991e607", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:94a309f1-e5d3-5ab3-9e85-66405b4213e8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005498", "original_object": "botulism", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"], "temporal_context_qualifier": "adjunctive therapy to antitoxin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e379dfee-9082-5efd-9be3-cd24c9a32196", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:94a309f1-e5d3-5ab3-9e85-66405b4213e8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005498", "original_object": "botulism", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"], "temporal_context_qualifier": "adjunctive therapy to antitoxin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57e46ff4-a558-59fb-8a11-23bddcdbf2dd", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e8c52fc1-9709-5104-9c68-2de8ac1e1ae9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005526", "object_location_in_text": [1181, 1188], "original_object": "tetanus", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"], "temporal_context_qualifier": "adjunctive therapy to human tetanus immune globulin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f07dc19-0f05-50f7-b3d5-a6e328a1bfda", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e8c52fc1-9709-5104-9c68-2de8ac1e1ae9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005526", "object_location_in_text": [1181, 1188], "original_object": "tetanus", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"], "temporal_context_qualifier": "adjunctive therapy to human tetanus immune globulin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81bb939c-1674-5b1e-905f-e3ae111ac27e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e8c52fc1-9709-5104-9c68-2de8ac1e1ae9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005526", "object_location_in_text": [1181, 1188], "original_object": "tetanus", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"], "temporal_context_qualifier": "adjunctive therapy to human tetanus immune globulin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Actinomyces israelii infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0550051c-84b7-5b7e-8fe8-f69c162c793c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1db717a8-9595-5f43-8f64-a30d529ceb43", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005631", "original_object": "actinomycosis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Actinomyces israelii infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f33114c-a301-55fb-8b57-7f9a00622101", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1db717a8-9595-5f43-8f64-a30d529ceb43", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005631", "original_object": "actinomycosis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Actinomyces israelii infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0233e9c-efe9-51b0-8384-11630a609e04", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1db717a8-9595-5f43-8f64-a30d529ceb43", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005631", "original_object": "actinomycosis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:240fea18-2508-5fa6-9d00-ff24e70e8019", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02c0fb32-43e9-5df1-a38f-fab1ca3de1d3", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005767", "object_location_in_text": [1163, 1175], "original_object": "gas gangrene", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d1a37d2-5064-5fa7-88b8-6fa98b48e382", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02c0fb32-43e9-5df1-a38f-fab1ca3de1d3", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005767", "object_location_in_text": [1163, 1175], "original_object": "gas gangrene", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Clostridium species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c77dcf4d-8771-5bf0-af15-d449da3c84c1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:02c0fb32-43e9-5df1-a38f-fab1ca3de1d3", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005767", "object_location_in_text": [1163, 1175], "original_object": "gas gangrene", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14f676a8-38fc-56e3-8393-b656be82f88a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "object_location_in_text": [742, 754], "original_object": "pericarditis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c0160ae-35c3-5daa-bf86-5f3675a6742c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "object_location_in_text": [742, 754], "original_object": "pericarditis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbe7df51-eee0-53a1-b392-8ff148f3b62c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25b4cd22-7206-5744-8b2d-64eac2814a92", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0005904", "object_location_in_text": [742, 754], "original_object": "pericarditis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible streptococci", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4cafeefc-fa82-5e5f-ac13-c167b1d972fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5193f5d-7fa8-5022-b2db-3d891e479a4d", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "MONDO:0013898", "object_location_in_text": [1011, 1042], "original_object": "skin and soft-tissue infections", "original_subject": "PENICILLIN G", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba7b9199-4710-4189-a85d-77ed75befe4d"]}], "subject": "CHEBI:18208", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R 900/300 and other antibacterial drugs, Bicillin C-R 900/300 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bicillin C-R 900/300 is indicated in the treatment of infections as described below that are susceptible to serum levels characteristic of this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R 900/300 is indicated in the treatment of the following in pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very susceptible to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible Streptococcus pneumoniae . NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible streptococci", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:810fd201-7cb0-55c5-b693-e830a0e6fc70", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5193f5d-7fa8-5022-b2db-3d891e479a4d", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "object": "MONDO:0013898", "object_location_in_text": [1025, 1056], "original_object": "skin and soft-tissue infections", "original_subject": "PENICILLIN G", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:337fde53-92a3-4a56-97c2-4bbb31bc9d0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=337fde53-92a3-4a56-97c2-4bbb31bc9d0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=337fde53-92a3-4a56-97c2-4bbb31bc9d0e"]}], "subject": "CHEBI:18208", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32b22b41-a429-5b1b-b214-24ca7b5fec77", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [770, 780], "original_object": "meningitis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d88e27cc-3d45-55dc-996b-9cdf161986d9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [770, 780], "original_object": "meningitis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec8b8463-b73d-5246-9e71-d7f4c28c7344", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [770, 780], "original_object": "meningitis", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:168f886f-fb16-5d3e-9145-12068edd05a3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f7ea103-56cc-492f-b862-af45f9aed980"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036690", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49a6ac8d-3a8e-502e-94bb-8f88447efe02", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036690"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1442486a-05d6-4dce-8b95-857a30f478c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1442486a-05d6-4dce-8b95-857a30f478c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1442486a-05d6-4dce-8b95-857a30f478c2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Me"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a69d665a-a814-5e07-90f1-b55b859a48ad", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efef4846-9497-41af-8dd6-518f86eca7f2"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3f6b1c5-78a3-505d-9999-4909d2b34bd5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90dbeb6c-3c1f-5d26-ad59-81b958b84b0e", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "PENICILLIN G", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8aaefb6-3f7d-4bc5-b40a-1c58c3054320"]}], "subject": "CHEBI:18208", "supporting_text": ["Therapy Penicillin G Potassium for Injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (Penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococca"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reduced cardiac output", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:037fe74f-3864-5293-b679-dbd141655f34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88dc22c7-af8f-583b-be96-4b4b6c5353d0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8cb4b3ae-9368-5066-90a0-429595923d20", "object": "HP:0031273", "object_location_in_text": [118, 123], "original_object": "shock", "original_subject": "DOPAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:38431050-007e-41b2-e063-6394a90a1d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=38431050-007e-41b2-e063-6394a90a1d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38431050-007e-41b2-e063-6394a90a1d64"]}], "subject": "CHEBI:18243", "supporting_text": ["1 INDICATIONS AND USAGE Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. Dopamine HCl Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reduced cardiac output", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:061ddfe0-5d52-5001-89c0-27177cb5a04f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88dc22c7-af8f-583b-be96-4b4b6c5353d0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8cb4b3ae-9368-5066-90a0-429595923d20", "object": "HP:0031273", "object_location_in_text": [118, 123], "original_object": "shock", "original_subject": "DOPAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1f306ad2-3606-4525-5a8a-ce78f426c1a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1f306ad2-3606-4525-5a8a-ce78f426c1a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f306ad2-3606-4525-5a8a-ce78f426c1a2"]}], "subject": "CHEBI:18243", "supporting_text": ["1 INDICATIONS AND USAGE Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. Dopamine HCl Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reduced cardiac output", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5082ee9f-7e2b-53be-ad58-deda31d34696", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88dc22c7-af8f-583b-be96-4b4b6c5353d0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8cb4b3ae-9368-5066-90a0-429595923d20", "object": "HP:0031273", "object_location_in_text": [118, 123], "original_object": "shock", "original_subject": "DOPAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45b0729e-529b-02f6-e063-6294a90a31d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45b0729e-529b-02f6-e063-6294a90a31d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45b0729e-529b-02f6-e063-6294a90a31d3"]}], "subject": "CHEBI:18243", "supporting_text": ["1 INDICATIONS AND USAGE Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. Dopamine HCl Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reduced cardiac output", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0a6db08-33e0-521e-a6a8-91448466763a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88dc22c7-af8f-583b-be96-4b4b6c5353d0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8cb4b3ae-9368-5066-90a0-429595923d20", "object": "HP:0031273", "object_location_in_text": [118, 123], "original_object": "shock", "original_subject": "DOPAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e499952-46c7-4172-8c70-186312e240a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e499952-46c7-4172-8c70-186312e240a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e499952-46c7-4172-8c70-186312e240a3"]}], "subject": "CHEBI:18243", "supporting_text": ["1 INDICATIONS AND USAGE Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. Dopamine HCl Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16601a37-407b-5070-bea8-36b89ec14ce3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [208, 222], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51452b31-ff68-4e0c-b982-c15502ebf1d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE CYTOMEL is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:283397b3-2e56-5537-9367-e4431bedd57f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [227, 241], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "population_context_qualifier": "congenital or acquired", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0b0f2db9-642d-d84f-b102-b43de34bbe75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0b0f2db9-642d-d84f-b102-b43de34bbe75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b0f2db9-642d-d84f-b102-b43de34bbe75"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fa4ba32-a924-5484-9c18-34aaa89e3508", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b18e24fd-def0-4ff4-aa08-5f91c03c6f9e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b18e24fd-def0-4ff4-aa08-5f91c03c6f9e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b18e24fd-def0-4ff4-aa08-5f91c03c6f9e"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43df93c0-2f72-5694-8ec9-623e7fe6eb5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c97dc9ec-af73-4836-aa0d-c27e66e792a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c97dc9ec-af73-4836-aa0d-c27e66e792a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c97dc9ec-af73-4836-aa0d-c27e66e792a9"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47a06e52-4029-5b67-a0bc-36ede892d405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:21002702-422b-1402-73b8-670314d8e579", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=21002702-422b-1402-73b8-670314d8e579", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21002702-422b-1402-73b8-670314d8e579"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ec874f4-fda2-514a-90bb-7348d7b491c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c54cf95f-6465-4203-b98b-a54ba5a26843", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c54cf95f-6465-4203-b98b-a54ba5a26843", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c54cf95f-6465-4203-b98b-a54ba5a26843"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5667db45-e080-505f-993c-fa00fb9ffed8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5222f13d-7222-4845-b863-49e7558f5b1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5222f13d-7222-4845-b863-49e7558f5b1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5222f13d-7222-4845-b863-49e7558f5b1a"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a3f090d-cb47-5b9c-a17e-d5746cec137b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d6b6f92-89e8-497a-ab23-d0afa2137d1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d6b6f92-89e8-497a-ab23-d0afa2137d1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d6b6f92-89e8-497a-ab23-d0afa2137d1f"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism (1.1) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer (1.2) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy (1.3)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a8714d2-2882-5568-bdbe-328755636f7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [220, 234], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:115a84c2-0126-4dd7-816e-1873875f1e49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=115a84c2-0126-4dd7-816e-1873875f1e49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=115a84c2-0126-4dd7-816e-1873875f1e49"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72804e00-9fbc-55b2-8e3f-af940c3d9c08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [218, 232], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:548d684a-86f5-4e57-9844-d8cf0a84e068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=548d684a-86f5-4e57-9844-d8cf0a84e068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=548d684a-86f5-4e57-9844-d8cf0a84e068"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73d6f89b-9e5d-556e-8191-d4e6a9725765", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [211, 225], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d3633e3-44b7-4f62-9fe4-e5c7c4129345", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d3633e3-44b7-4f62-9fe4-e5c7c4129345", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d3633e3-44b7-4f62-9fe4-e5c7c4129345"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8090e3e1-f771-578f-b231-02631007a7b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [218, 232], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db65bcd8-e9c9-4095-9975-03be1f443823", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db65bcd8-e9c9-4095-9975-03be1f443823", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db65bcd8-e9c9-4095-9975-03be1f443823"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94fe5e4c-5674-56df-8433-7bc02dd4c220", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [218, 232], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26cf6872-f4d4-41dd-8957-a000f13efbb3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26cf6872-f4d4-41dd-8957-a000f13efbb3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26cf6872-f4d4-41dd-8957-a000f13efbb3"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0320c8e-582b-5de8-8077-b1f30ba1ce93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [205, 219], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0dcec611-2b7a-4cf3-80c3-7389be2f0a94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0dcec611-2b7a-4cf3-80c3-7389be2f0a94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dcec611-2b7a-4cf3-80c3-7389be2f0a94"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE LIOMNY is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"], "temporal_context_qualifier": "congenital or acquired"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac37f788-8fa7-5a11-ae2d-4dd5df59c40b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [218, 232], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1133ebe8-38c2-2505-e063-6294a90aaa2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1133ebe8-38c2-2505-e063-6294a90aaa2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1133ebe8-38c2-2505-e063-6294a90aaa2f"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4fd9b51-0b47-5d3b-acb6-c20307c8f58d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [218, 232], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76fa4eb6-fefa-4e97-9543-f81e465743e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76fa4eb6-fefa-4e97-9543-f81e465743e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76fa4eb6-fefa-4e97-9543-f81e465743e6"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca70390c-be26-507b-b7ea-2afb8138b81b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [227, 241], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "population_context_qualifier": "congenital or acquired", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ababc2ad-0458-663e-e053-2a95a90a5a86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ababc2ad-0458-663e-e053-2a95a90a5a86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ababc2ad-0458-663e-e053-2a95a90a5a86"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6f0b0f7-3738-538d-b55f-f9599bcfe98a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a76c9be-3ea3-542f-bd45-66af18babdb2", "object": "MONDO:0005420", "object_location_in_text": [220, 234], "original_object": "hypothyroidism", "original_subject": "LIOTHYRONINE", "population_context_qualifier": "congenital or acquired", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57744c7c-af44-4bc4-a5a8-79f05710f469", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57744c7c-af44-4bc4-a5a8-79f05710f469", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57744c7c-af44-4bc4-a5a8-79f05710f469"]}], "subject": "CHEBI:18258", "supporting_text": ["1 INDICATIONS AND USAGE Liothyronine sodium is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5af0e96a-4f59-5ec9-847a-66be65d42fd6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0ca6c166-ed31-58be-a855-3e2c5956a330", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "PHOSPHATIDYL SERINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:18303", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14868b7b-f3cd-5a04-b0f7-be2883997f66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000821", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6a86715-4459-5638-883d-f17a22f2377e", "object": "MONDO:0005420", "object_location_in_text": [258, 272], "original_object": "hypothyroidism", "original_subject": "LEVOTHYROXINE", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a7ade79-0165-4e31-b84e-667416c00c7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a7ade79-0165-4e31-b84e-667416c00c7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a7ade79-0165-4e31-b84e-667416c00c7e"]}], "subject": "CHEBI:18332", "supporting_text": ["1 INDICATION AND USAGE TIROSINT is L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:295e59e8-0e2c-5d0d-9d05-0652b4680ce8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000821", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6a86715-4459-5638-883d-f17a22f2377e", "object": "MONDO:0005420", "object_location_in_text": [258, 272], "original_object": "hypothyroidism", "original_subject": "LEVOTHYROXINE", "population_context_qualifier": "adult and pediatric patients, including neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ddcaec1-a58f-340b-9bc1-bbe048b8c885", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ddcaec1-a58f-340b-9bc1-bbe048b8c885", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ddcaec1-a58f-340b-9bc1-bbe048b8c885"]}], "subject": "CHEBI:18332", "supporting_text": ["1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:309f564b-d876-57e5-8574-8d87e52c1e43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000821", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6a86715-4459-5638-883d-f17a22f2377e", "object": "MONDO:0005420", "original_object": "hypothyroidism", "original_subject": "LEVOTHYROXINE", "population_context_qualifier": "adult and pediatric patients, including neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d378add-f13d-40f2-99dc-0f2340ab44b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d378add-f13d-40f2-99dc-0f2340ab44b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d378add-f13d-40f2-99dc-0f2340ab44b7"]}], "subject": "CHEBI:18332", "supporting_text": ["1 INDICATION AND USAGE TIROSINT-SOL is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000832", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1b93d17-c262-5f4b-90e6-bfa54f02702d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000821", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000832", "MONDO:0016410", "MONDO:0010140"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d0327a4-70b9-547e-b79d-53ab35ea0b26", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6a86715-4459-5638-883d-f17a22f2377e", "object": "MONDO:0005420", "object_location_in_text": [205, 219], "original_object": "hypothyroidism", "original_subject": "LEVOTHYROXINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cba64919-3b74-a03a-e053-2995a90a3d89", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cba64919-3b74-a03a-e053-2995a90a3d89", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cba64919-3b74-a03a-e053-2995a90a3d89"]}], "subject": "CHEBI:18332", "supporting_text": ["1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5c70c16-daaa-599a-9f18-9117e857e6e9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b320cb2f-35d7-59dd-8da2-58f718603f9a", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "THIAMINE ION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:18385", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bff3a75a-39cb-5dd2-ba43-58c9758e3e8f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b320cb2f-35d7-59dd-8da2-58f718603f9a", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "THIAMINE ION", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:18385", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77d0bd08-c6dc-5dc2-b0d6-fbcc5a0e3df3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e358e50d-4694-51e1-b106-ba2d94ffc761", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "COBAMAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:18408", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor irritation or injury of the mouth and gums, occasional sore mouth and sore throat", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bcc2eb6-7434-535f-ad88-d386790ef425", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a5aa23bd-c68e-589b-a037-3b2253619a15", "object": "HP:0012531", "object_location_in_text": [94, 98], "original_object": "pain", "original_subject": "BENZALKONIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a1c82b4-02b3-d456-e063-6294a90a16bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a1c82b4-02b3-d456-e063-6294a90a16bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a1c82b4-02b3-d456-e063-6294a90a16bb"]}], "subject": "CHEBI:188978", "supporting_text": ["Uses first aid to help prevent infection in minor oral irritation for the temporary relief of pain due to minor irritation or injury of the mouth and gums occasional sore mouth and sore throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor irritation or injury of the mouth and gums, occasional sore mouth and sore throat", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbc07617-5c45-5a17-b6b5-b23c766188d1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a5aa23bd-c68e-589b-a037-3b2253619a15", "object": "HP:0012531", "object_location_in_text": [93, 97], "original_object": "pain", "original_subject": "BENZALKONIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a1b4133-0eac-2f8f-e063-6394a90af8f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a1b4133-0eac-2f8f-e063-6394a90af8f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a1b4133-0eac-2f8f-e063-6394a90af8f6"]}], "subject": "CHEBI:188978", "supporting_text": ["Use first aid to help prevent infection in minor oral irritation for the temporary relief of pain due to minor irritation or injury of the mouth and gums occasional sore mouth and sore throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0dd6983-6bcb-5d66-a13d-67a9dd0f7ba4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220915", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "UMLS:C0242339", "MONDO:0007147", "MONDO:0004995", "MONDO:0006920", "MONDO:0005148"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f629277d-14d5-5598-b08b-e1834dfd193b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:80e49138-05bf-55d0-9a6c-751e174acf7f", "object": "HP:0001824", "object_location_in_text": [619, 630], "original_object": "weight loss", "original_subject": "tirzepatide", "population_context_qualifier": "adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mounjaro", "https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro"]}], "subject": "CHEBI:194186", "supporting_text": ["Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise  as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes.  For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of  ≥ 30 kg/m2 (obesity) or  ≥ 27 kg/m2 to &lt; 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d35cb616-d1a6-519c-9d60-0c3d53ae519c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220915", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "UMLS:C0242339", "MONDO:0007147", "MONDO:0004995", "MONDO:0006920", "MONDO:0005148"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:77623047-4956-530f-b080-9a8b1b169d08", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:80e49138-05bf-55d0-9a6c-751e174acf7f", "object": "HP:0025502", "object_location_in_text": [761, 771], "original_object": "overweight", "original_subject": "tirzepatide", "population_context_qualifier": "adults with an initial Body Mass Index (BMI) of ≥ 27 kg/m2 to < 30 kg/m2", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mounjaro", "https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro"]}], "subject": "CHEBI:194186", "supporting_text": ["Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise  as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes.  For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of  ≥ 30 kg/m2 (obesity) or  ≥ 27 kg/m2 to &lt; 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e862424-b052-5f6d-b7d1-57aa62e1453d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220915", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "UMLS:C0242339", "MONDO:0007147", "MONDO:0004995", "MONDO:0006920", "MONDO:0005148"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:87e64efc-0059-50f9-8c1f-2c0a8f033dcf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:80e49138-05bf-55d0-9a6c-751e174acf7f", "object": "MONDO:0011122", "object_location_in_text": [719, 726], "original_object": "obesity", "original_subject": "tirzepatide", "population_context_qualifier": "adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m2", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mounjaro", "https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro"]}], "subject": "CHEBI:194186", "supporting_text": ["Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise  as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes.  For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. Weight management Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of  ≥ 30 kg/m2 (obesity) or  ≥ 27 kg/m2 to &lt; 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a10c2108-fbcd-5e6e-830b-9c897df34718", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "MONDO:0021187", "MONDO:0005148"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:87e64efc-0059-50f9-8c1f-2c0a8f033dcf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:80e49138-05bf-55d0-9a6c-751e174acf7f", "object": "MONDO:0011122", "object_location_in_text": [90, 97], "original_object": "obesity", "original_subject": "TIRZEPATIDE", "population_context_qualifier": "patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet BMI criteria of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or BMI of 35 kg/m2 or greater", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TIRZEPATIDE#10-20241227", "https://www.pmda.go.jp/files/000278664.pdf"]}], "subject": "CHEBI:194186", "supporting_text": ["Drugs with a new indication, a new dosage, and other characteristics for the treatment of obesity. For use only in patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet the following conditions: • BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or • BMI of 35 kg/m2 or greater"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "steroid responsive conditions", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59e2c0c0-1c8b-50e2-b161-3e0b2e03b61c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:c6da2f81-74f0-5a99-a38f-88e03f40d062", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:f91f509f-f6cc-55be-b967-8dddeaf04cd9", "object": "MONDO:0004980", "object_location_in_text": [68, 74], "original_object": "eczema", "original_subject": "Halobetasol 0.05% + Clotrimazole 1.0% cream", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:197151", "supporting_text": ["For the treatment of steroid responsive fungal infections including eczema and psoriasis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "steroid responsive conditions", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:596dd0eb-dca5-5bb1-baac-0d5fa7782b36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:8e4da0f7-8759-5a9f-a717-c9916426f669", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:f91f509f-f6cc-55be-b967-8dddeaf04cd9", "object": "MONDO:0005083", "object_location_in_text": [79, 88], "original_object": "psoriasis", "original_subject": "Halobetasol 0.05% + Clotrimazole 1.0% cream", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:197151", "supporting_text": ["For the treatment of steroid responsive fungal infections including eczema and psoriasis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a97d0e0-6519-5dcf-b905-4e863a9ae279", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518bd432-f0d0-4fc4-944c-b9d1a01e2064", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518bd432-f0d0-4fc4-944c-b9d1a01e2064", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518bd432-f0d0-4fc4-944c-b9d1a01e2064"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19c6a6cf-95a1-5416-8feb-dc711239bf22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e88e49b9-c292-48c5-b19e-630ffa6447e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e88e49b9-c292-48c5-b19e-630ffa6447e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e88e49b9-c292-48c5-b19e-630ffa6447e7"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a3a1f4d-77e8-5938-93dc-a578234492fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71b2bb18-4a48-42c2-b03a-dccf581a0d97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71b2bb18-4a48-42c2-b03a-dccf581a0d97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71b2bb18-4a48-42c2-b03a-dccf581a0d97"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: • tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d803d42-cab5-50b7-a329-bf6f191b4c36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c28a462-c6d6-70ba-e063-6394a90ae8f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c28a462-c6d6-70ba-e063-6394a90ae8f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c28a462-c6d6-70ba-e063-6394a90ae8f3"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3144e767-4b83-5dfc-a3ce-e6efb4c7adb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3e6c0b0-399f-41e4-9df9-109ee2917995", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3e6c0b0-399f-41e4-9df9-109ee2917995", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3e6c0b0-399f-41e4-9df9-109ee2917995"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4bee411b-d7b8-5074-beed-85a0ff846c39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d67f5ac-ea5f-12d7-e063-6294a90a96cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d67f5ac-ea5f-12d7-e063-6294a90a96cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d67f5ac-ea5f-12d7-e063-6294a90a96cb"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: • tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:851127db-a4ac-5bd1-bef6-a6a044857765", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5783edbf-2ce6-4b7e-8df3-2e421c63d0e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5783edbf-2ce6-4b7e-8df3-2e421c63d0e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5783edbf-2ce6-4b7e-8df3-2e421c63d0e8"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93f2e055-e938-59e6-b9ee-36f7c69d9220", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9f361f24-a0a1-4e43-a158-8c830c9adca7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9f361f24-a0a1-4e43-a158-8c830c9adca7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f361f24-a0a1-4e43-a158-8c830c9adca7"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98cd9474-09cf-502c-96da-4a0b11b160f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f283ffd8-860a-4e97-8e22-94b907f75c8d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f283ffd8-860a-4e97-8e22-94b907f75c8d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f283ffd8-860a-4e97-8e22-94b907f75c8d"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2b83e9d-e148-5cd3-ad4c-a5b2c212fa80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f68bd51a-9166-47a1-81f7-e379a93ab823", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f68bd51a-9166-47a1-81f7-e379a93ab823", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f68bd51a-9166-47a1-81f7-e379a93ab823"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7f4f49b-523a-5c79-b052-1bf23d479d04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac3280b7-00aa-46cd-84e2-0a11992028ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac3280b7-00aa-46cd-84e2-0a11992028ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac3280b7-00aa-46cd-84e2-0a11992028ab"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9076420-34a0-5ed1-8d22-2a6296917d4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45cfa88b-8146-4349-99cc-beec70455709", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45cfa88b-8146-4349-99cc-beec70455709", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45cfa88b-8146-4349-99cc-beec70455709"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb81d3c4-8e4f-54c2-b156-0159649d6fbe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:289e5003-7d08-c141-e063-6394a90abca3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=289e5003-7d08-c141-e063-6394a90abca3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=289e5003-7d08-c141-e063-6394a90abca3"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf4e8849-b0fd-5bf8-9d53-edca5a7ef7e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42b46e02-4d1f-411e-be9e-227f62ba5a86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42b46e02-4d1f-411e-be9e-227f62ba5a86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42b46e02-4d1f-411e-be9e-227f62ba5a86"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2dd2da2-b777-5928-91c8-85beb23e5a08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5079b009-7f34-4d34-8f01-821365f04ca2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5079b009-7f34-4d34-8f01-821365f04ca2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5079b009-7f34-4d34-8f01-821365f04ca2"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e06cdc2d-1a86-5d4c-b1f2-c991aff209f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a578c749-4264-4d5c-9357-ed482a04fb8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a578c749-4264-4d5c-9357-ed482a04fb8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a578c749-4264-4d5c-9357-ed482a04fb8b"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003401", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5d198c0-b9be-5246-981c-718f179a1c37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003401", "HP:0012531", "UMLS:C0014724", "HP:0000989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:20677423-b69a-5819-b9fb-cea98127fd1d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f330e54-abfb-5616-b046-da7b0e22f26b", "object": "MONDO:0043653", "original_object": "herpes simplex labialis", "original_subject": "DOCOSANOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe56bf08-1efd-4996-a276-06b6039085f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe56bf08-1efd-4996-a276-06b6039085f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe56bf08-1efd-4996-a276-06b6039085f3"]}], "subject": "CHEBI:197511", "supporting_text": ["Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: • tingling, pain, burning, and/or itching"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "corticosteroid responsive dermatosis", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bba7668d-5135-59b4-996f-86919b0aa87a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970307", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:66cd544e-b420-5c1d-9980-6bf0745d390a", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ca75baec-9ac0-5c2e-b10e-03f31cf2954c", "object": "MONDO:0002406", "original_object": "inflammatory dermatosis", "original_subject": "Desonide 0.05% Cream", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:204734", "supporting_text": ["For relief of the inflammatory and pruritic manifestation of corticosteroid responsive dermatosis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses of the scalp", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ae7017c-6f16-5c2b-93c3-a02ff2b4f0fc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75fa0ad3-156e-5e0d-94af-d01be71b0358", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "CLOBETASOL", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:446209ba-61ad-46b5-99f7-039ae7fca757", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=446209ba-61ad-46b5-99f7-039ae7fca757", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=446209ba-61ad-46b5-99f7-039ae7fca757"]}], "subject": "CHEBI:205919", "supporting_text": ["INDICATIONS &amp; USAGE Clobetasol propionate topical solution is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 mL/week because of the potential for the drug to suppress the HPA axis. This product is not recommended for use in pediatric patients under 12 years of age."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses of the scalp", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ffcf2a5-b257-5cb0-ae69-8a2b743553a1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75fa0ad3-156e-5e0d-94af-d01be71b0358", "object": "UMLS:C0021368", "original_object": "inflammation", "original_subject": "CLOBETASOL", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:446209ba-61ad-46b5-99f7-039ae7fca757", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=446209ba-61ad-46b5-99f7-039ae7fca757", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=446209ba-61ad-46b5-99f7-039ae7fca757"]}], "subject": "CHEBI:205919", "supporting_text": ["INDICATIONS &amp; USAGE Clobetasol propionate topical solution is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 mL/week because of the potential for the drug to suppress the HPA axis. This product is not recommended for use in pediatric patients under 12 years of age."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22b8237e-46eb-5142-ba14-ee6635b3bd37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [68, 82], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "adults and pediatric patients who weigh 5 kg or greater", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:472f158a-5ab9-4308-8e49-1116e6ea3d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=472f158a-5ab9-4308-8e49-1116e6ea3d39"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE ACETADOTE is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI). ACETADOTE is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 )."], "temporal_context_qualifier": "after ingestion of a potentially hepatotoxic quantity of acetaminophen with acute ingestion or from repeated supratherapeutic ingestion (RSI)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36cc121d-89c7-5856-9faf-ce6da7b9cb81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [83, 97], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with acute ingestion or from repeated supratherapeutic ingestion (RSI)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2324d60b-4f49-4759-a46e-a06bfce7e8aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2324d60b-4f49-4759-a46e-a06bfce7e8aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2324d60b-4f49-4759-a46e-a06bfce7e8aa"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:831f396c-b851-5365-b8b1-b15a3823088b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [83, 97], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "adults and pediatric patients who weigh 5 kg or greater", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3b0310d2-4e70-4b94-8d69-cb5999a32b54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3b0310d2-4e70-4b94-8d69-cb5999a32b54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b0310d2-4e70-4b94-8d69-cb5999a32b54"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with an acute ingestion or from repeated supratherapeutic ingestion (RSI) (1)."], "temporal_context_qualifier": "after ingestion of a potentially hepatotoxic quantity of acetaminophen with acute ingestion or from repeated supratherapeutic ingestion (RSI)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aca1cc4a-b996-59c3-91d4-85391422c13e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [83, 97], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with acute ingestion or from repeated supratherapeutic ingestion (RSI)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e2e187e-2445-43b1-b66c-b828e2adf022", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e2e187e-2445-43b1-b66c-b828e2adf022", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e2e187e-2445-43b1-b66c-b828e2adf022"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0c9e2c6-669b-5f6b-88bb-72d833cb13f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [83, 97], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with acute ingestion or from repeated supratherapeutic ingestion (RSI)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8d3ed96-d7ee-43f4-986c-a7d04808711a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8d3ed96-d7ee-43f4-986c-a7d04808711a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8d3ed96-d7ee-43f4-986c-a7d04808711a"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) (1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4dff09a-098f-5a20-a3c8-ec4e652b5dd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "medic_supporting_text_truncated": true, "object": "UMLS:C0160390", "object_location_in_text": [122, 136], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8cca4e4c-85a2-d575-e053-2995a90a6599", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8cca4e4c-85a2-d575-e053-2995a90a6599", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8cca4e4c-85a2-d575-e053-2995a90a6599"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Overdose incidences are divided into two types; Acute Ingestion or Repeated Supratherapeutic Ingestion (RSI). [see Dosage and Administration ( 2 ) and Acetaminophen Assays – Interpretation and Methodology -(Acute or Repeated Supratherapeutic Ingestion) ( 1.1 , 1.2 )] . On admission for suspected acetaminophen overdose, a serum blood sample should be drawn at least 4 hours after ingestion to determine the acetaminophen level and will serve as a basis for determining the need for treatment with acetylcysteine. If the patient presents after 4 hours post-ingestion, the serum acetaminophen sample should be determined immediately. Acetylcysteine Injection should be administered within 8 hours from acetaminophen ingestion for maximal protection against hepatic injury for patients whose serum acetaminophen levels fall above the \"possible\" toxicity line on the Rumack-Matthew nomogram (line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours); [see Acetaminophen Assays – Interpretation and Methodology (1.1, 1.2 )] . If the time of ingestion is unknown, or the serum acetaminophen level is not available, cannot be interpreted, or is not available within the 8 hour time interval from acetaminophen ingestion, Acetylcysteine Injection should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion of an overdose of acetaminophen, regardless of the quantity reported to have been ingested. The aspartate aminotransferase (AST, SGOT), alanine aminotranferase (ALT, SGPT), bilirubin, prothrombin time, creatinine, blood urea nitrogen (BUN), blood glucose, and electrolytes also should be determined in order to monitor hepatic and renal function and electrolyte and fluid balance. NOTE: The critical ingestion-treatment interval for maxi"], "temporal_context_qualifier": "within 8 hours from acetaminophen ingestion"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2ae8ce1-5c72-5829-8472-332ed5644236", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [83, 97], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with acute ingestion or from repeated supratherapeutic ingestion (RSI)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:277963a0-8ab2-4305-a688-28e47e87c584", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=277963a0-8ab2-4305-a688-28e47e87c584", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277963a0-8ab2-4305-a688-28e47e87c584"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd4bf52f-f173-5b37-81d4-b3c70b028402", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "medic_supporting_text_truncated": true, "object": "UMLS:C0160390", "object_location_in_text": [122, 136], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d990ef51-ced2-4359-b99b-092334d2dc9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d990ef51-ced2-4359-b99b-092334d2dc9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d990ef51-ced2-4359-b99b-092334d2dc9b"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Overdose incidences are divided into two types; Acute Ingestion or Repeated Supratherapeutic Ingestion (RSI). [see Dosage and Administration ( 2 ) and Acetaminophen Assays – Interpretation and Methodology -(Acute or Repeated Supratherapeutic Ingestion) ( 1.1 , 1.2 )] . On admission for suspected acetaminophen overdose, a serum blood sample should be drawn at least 4 hours after ingestion to determine the acetaminophen level and will serve as a basis for determining the need for treatment with acetylcysteine. If the patient presents after 4 hours post-ingestion, the serum acetaminophen sample should be determined immediately. Acetylcysteine Injection should be administered within 8 hours from acetaminophen ingestion for maximal protection against hepatic injury for patients whose serum acetaminophen levels fall above the \"possible\" toxicity line on the Rumack-Matthew nomogram (line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours); [see Acetaminophen Assays – Interpretation and Methodology (1.1, 1.2 )] . If the time of ingestion is unknown, or the serum acetaminophen level is not available, cannot be interpreted, or is not available within the 8 hour time interval from acetaminophen ingestion, Acetylcysteine Injection should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion of an overdose of acetaminophen, regardless of the quantity reported to have been ingested. The aspartate aminotransferase (AST, SGOT), alanine aminotranferase (ALT, SGPT), bilirubin, prothrombin time, creatinine, blood urea nitrogen (BUN), blood glucose, and electrolytes also should be determined in order to monitor hepatic and renal function and electrolyte and fluid balance. NOTE: The critical ingestion-treatment interval for maxi"], "temporal_context_qualifier": "within 8 hours from acetaminophen ingestion"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0572025", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcd78ae4-14a2-5907-bd65-d3385fa02288", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0572025"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3c2636d3-d5b5-5a10-97c4-bf4393a34a3d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0160390", "object_location_in_text": [83, 97], "original_object": "hepatic injury", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "adults and pediatric patients who weigh 5 kg or greater", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ae53725-1abb-4122-9c85-f26c2c31566c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ae53725-1abb-4122-9c85-f26c2c31566c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ae53725-1abb-4122-9c85-f26c2c31566c"]}], "subject": "CHEBI:22198", "supporting_text": ["1 INDICATIONS AND USAGE Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion (RSI) ( 1 )."], "temporal_context_qualifier": "after ingestion of a potentially hepatotoxic quantity of acetaminophen with acute ingestion or from repeated supratherapeutic ingestion (RSI)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mucous obstruction", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10ca4c3c-b15e-514c-b94d-66e8d537400f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8628ba2-94b6-54da-8582-4a7a5ceae051", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "HP:0100750", "original_object": "atelectasis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fc95feb-0e11-50e2-a02c-ac85b6b58d1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0003781", "object_location_in_text": [224, 234], "original_object": "bronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65541c1e-6688-5200-a340-b3855aeb15f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0003781", "object_location_in_text": [224, 234], "original_object": "bronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7901be8e-a4a8-57b7-a76a-53ddf1b4227c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0003781", "object_location_in_text": [217, 227], "original_object": "bronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abaa921e-718a-5d46-b1c5-b2150d2dbb57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0003781", "object_location_in_text": [208, 218], "original_object": "bronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c394ca0c-dc36-5591-9df1-1ef26f1c6c70", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0003781", "object_location_in_text": [208, 218], "original_object": "bronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e503b55b-b394-536b-a0f1-954b1e11e76d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0003781", "object_location_in_text": [222, 232], "original_object": "bronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:011f1f87-3450-5d16-9eaa-465f5b2d051d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d571f5d-63fd-599a-99fa-6bf1ea7ee78b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0004822", "object_location_in_text": [264, 278], "original_object": "bronchiectasis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:179e0ac2-dbd7-53a1-a7fc-805693fe6697", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d571f5d-63fd-599a-99fa-6bf1ea7ee78b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0004822", "object_location_in_text": [280, 294], "original_object": "bronchiectasis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58605f0b-79d0-558b-81d0-467e836fb7d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d571f5d-63fd-599a-99fa-6bf1ea7ee78b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0004822", "object_location_in_text": [278, 292], "original_object": "bronchiectasis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ccefc21-3623-5027-91e7-fa187a360b3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d571f5d-63fd-599a-99fa-6bf1ea7ee78b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0004822", "object_location_in_text": [264, 278], "original_object": "bronchiectasis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:809311b2-20fd-58c0-b412-1790b73f27f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d571f5d-63fd-599a-99fa-6bf1ea7ee78b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0004822", "object_location_in_text": [273, 287], "original_object": "bronchiectasis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d57ec390-81ca-5235-b87a-e7478a03a728", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d571f5d-63fd-599a-99fa-6bf1ea7ee78b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0004822", "object_location_in_text": [280, 294], "original_object": "bronchiectasis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0842b5a0-f82d-52cc-90c0-e1278f37888f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0005249", "object_location_in_text": [364, 373], "original_object": "pneumonia", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41a5707b-3190-58cc-afd6-8aa0420e4426", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0005249", "object_location_in_text": [364, 373], "original_object": "pneumonia", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:721c155a-e8f4-5829-836a-223e3ff99c64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0005249", "object_location_in_text": [362, 371], "original_object": "pneumonia", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ceb6851-5bca-565b-a851-50ad0f98fd2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0005249", "object_location_in_text": [357, 366], "original_object": "pneumonia", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83150d1f-fe02-58c8-8a33-11fa41bf04cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0005249", "object_location_in_text": [348, 357], "original_object": "pneumonia", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9cf443a-fb46-5e96-96fa-d3beeb3cf1e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0005249", "object_location_in_text": [348, 357], "original_object": "pneumonia", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fbdef5f-895a-5a6a-aff8-f1a5a05f0d59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0018076", "object_location_in_text": [259, 271], "original_object": "tuberculosis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a366f3c-f188-573f-b09d-2e86e45dcfc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0018076", "object_location_in_text": [266, 278], "original_object": "tuberculosis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:812ace33-8723-5d64-b010-1887f0e1dca3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0018076", "object_location_in_text": [250, 262], "original_object": "tuberculosis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab81a6ff-c74d-5cfb-bf10-ef549b9ea7ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0018076", "object_location_in_text": [264, 276], "original_object": "tuberculosis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1b6a53a-d8be-5a46-ad90-74930775fc59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0018076", "object_location_in_text": [266, 278], "original_object": "tuberculosis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d64d273a-9fbb-5552-96e8-3c91d7655300", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0018076", "object_location_in_text": [250, 262], "original_object": "tuberculosis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e1ec907-088c-510c-8de9-df1bb07a7011", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72cbb0be-7c80-53c5-8bb1-0ba154ec8d4d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0021925", "object_location_in_text": [371, 388], "original_object": "tracheobronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fcac981-15f7-5dba-8e61-a5dab7cd4d8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72cbb0be-7c80-53c5-8bb1-0ba154ec8d4d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0021925", "object_location_in_text": [380, 397], "original_object": "tracheobronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cb65413-b7b7-54b0-a886-46730685abcf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72cbb0be-7c80-53c5-8bb1-0ba154ec8d4d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0021925", "object_location_in_text": [371, 388], "original_object": "tracheobronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f2ec7ed-d389-5123-b303-5cc8de5d54b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72cbb0be-7c80-53c5-8bb1-0ba154ec8d4d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0021925", "object_location_in_text": [387, 404], "original_object": "tracheobronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5c87486-24dc-59c6-bb50-8846856f1936", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72cbb0be-7c80-53c5-8bb1-0ba154ec8d4d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0021925", "object_location_in_text": [387, 404], "original_object": "tracheobronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc44a4b9-e367-5947-81dd-a8402e86a899", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72cbb0be-7c80-53c5-8bb1-0ba154ec8d4d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "MONDO:0021925", "object_location_in_text": [385, 402], "original_object": "tracheobronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:040373ab-bbac-5b2b-9f68-76ae640b41b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2fb8664-8a40-5367-b564-b0cf3910d241", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0264348", "object_location_in_text": [236, 264], "original_object": "chronic asthmatic bronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2eb7398e-f3c2-571f-a0d7-e1422a9c389c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2fb8664-8a40-5367-b564-b0cf3910d241", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0264348", "object_location_in_text": [220, 248], "original_object": "chronic asthmatic bronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a05e131-f058-5d7e-9f03-4525e0697365", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2fb8664-8a40-5367-b564-b0cf3910d241", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0264348", "object_location_in_text": [220, 248], "original_object": "chronic asthmatic bronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f3556cc-62ac-519c-b5e3-4620c8e1d036", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2fb8664-8a40-5367-b564-b0cf3910d241", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0264348", "object_location_in_text": [229, 257], "original_object": "chronic asthmatic bronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f37363a-10f1-5b2d-914a-3f4f97c1c867", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2fb8664-8a40-5367-b564-b0cf3910d241", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0264348", "object_location_in_text": [236, 264], "original_object": "chronic asthmatic bronchitis", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e359712-5606-5227-90d3-c3779d002c36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2fb8664-8a40-5367-b564-b0cf3910d241", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C0264348", "object_location_in_text": [234, 262], "original_object": "chronic asthmatic bronchitis", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e344002-3750-5681-bd0c-d7e3a176a8b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50ca61e6-05de-52dc-b45a-be05513b32bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C1265792", "object_location_in_text": [190, 207], "original_object": "chronic emphysema", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b48fab-cef6-465c-a1e0-d085b3988bc4"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1096000", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80c58c1d-58ef-5bfd-a343-2c58048a71f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1096000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50ca61e6-05de-52dc-b45a-be05513b32bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C1265792", "object_location_in_text": [188, 205], "original_object": "chronic emphysema", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d50c8ab6-26f8-4669-89d1-c4d26698159a"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a895609-65d2-511c-99ed-c2e94130f119", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50ca61e6-05de-52dc-b45a-be05513b32bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C1265792", "object_location_in_text": [190, 207], "original_object": "chronic emphysema", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d81039e-20ef-5144-e053-2a95a90a89fd"]}], "subject": "CHEBI:22198", "supporting_text": [": Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf9eb956-6ec4-5075-94ac-72697c35df5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50ca61e6-05de-52dc-b45a-be05513b32bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C1265792", "object_location_in_text": [174, 191], "original_object": "chronic emphysema", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c90fca12-12fb-4cf6-bd6f-83bc0d95df81"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4c8dfd1-9cfc-54c7-8a6f-d67c810c9c5a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50ca61e6-05de-52dc-b45a-be05513b32bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C1265792", "object_location_in_text": [183, 200], "original_object": "chronic emphysema", "original_subject": "ACETYLCYSTEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8165ad85-98e7-438f-9567-5cfda88d0ebf"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "abnormal, viscid, or inspissated mucous secretions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5da17cc-33c8-5168-b156-b94adb0ed5f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50ca61e6-05de-52dc-b45a-be05513b32bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9005f7-e872-5771-9834-62978d9320d4", "object": "UMLS:C1265792", "object_location_in_text": [174, 191], "original_object": "chronic emphysema", "original_subject": "ACETYLCYSTEINE", "population_context_qualifier": "patients with abnormal, viscid, or inspissated mucous secretions", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5558a5f5-e821-473b-7d8a-5d33d09f0586"]}], "subject": "CHEBI:22198", "supporting_text": ["Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0694546", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdefd55b-34c9-5deb-b7af-bf8873d5bfb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170703", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694546"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:8121650a-5e2b-57a8-9558-dce045c5a7a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:4ee0f2ec-c0a9-5d4d-8ad4-1173245c2219", "object": "MONDO:0021187", "object_location_in_text": [67, 82], "original_object": "hyperlipidaemia", "original_subject": "PEMAFIBRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PEMAFIBRATE#88-20170703", "https://www.pmda.go.jp/files/000266893.pdf"]}], "subject": "CHEBI:228365", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of hyperlipidaemia (including familial hyperlipidaemia)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Dravet's syndrome", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef2d6f3d-6df6-567b-94d5-55eca4653544", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120928", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["clobazam", "sodium valproate"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:4a8845be-186f-5c49-bb69-e385085f485e", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:dc860cff-71cd-5a17-981c-3cb94384a728", "object": "UMLS:C0234535", "original_object": "refractory clonic seizures", "original_subject": "STIRIPENTOL", "population_context_qualifier": "patients with Dravet's syndrome whose seizures are not adequately controlled with clobazam and sodium valproate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:STIRIPENTOL#134-20120928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:228488", "supporting_text": ["Drugs with a new active ingredient indicated for use in conjunction with clobazam and sodium valproate as adjunctive therapy of refractory generalized tonic-clonic and clonic seizures in patients with Dravet’s syndrome whose seizures are not adequately controlled with clobazam and sodium valproate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20676b86-a2be-5e6a-9967-aac2aa2309f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:51022653-4a66-5e43-8264-e828fdcf2b39", "object": "MONDO:0004948", "object_location_in_text": [498, 526], "original_object": "chronic lymphocytic leukemia", "original_subject": "PIRTOBRUTINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd551845-0878-49a4-860f-839b83f6b801", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801"]}], "subject": "CHEBI:229212", "supporting_text": ["1 INDICATIONS AND USAGE JAYPIRCA ® is a kinase inhibitor indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ) This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. ( 1.2 ) Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. ( 1.3 ) 1.1 Mantle Cell Lymphoma JAYPIRCA ® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. 1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance or intolerance to other BTK inhibitors", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2380fa5a-2f18-5f51-aee7-69a3d8598278", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240624", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:61e52b95-0e57-51eb-b24e-33129a9a417e", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:51022653-4a66-5e43-8264-e828fdcf2b39", "object": "MONDO:0018876", "object_location_in_text": [66, 109], "original_object": "relapsed or refractory mantle cell lymphoma", "original_subject": "PIRTOBRUTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PIRTOBRUTINIB#15-20240624", "https://www.pmda.go.jp/files/000275223.pdf"]}], "subject": "CHEBI:229212", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of relapsed or refractory mantle cell lymphoma with resistance or intolerance to other BTK inhibitors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9943705-b1c9-5b34-b22e-c5622ca537ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c7c6f36-1658-5144-98f4-434676add777", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:51022653-4a66-5e43-8264-e828fdcf2b39", "object": "UMLS:C0855095", "object_location_in_text": [530, 556], "original_object": "small lymphocytic lymphoma", "original_subject": "PIRTOBRUTINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd551845-0878-49a4-860f-839b83f6b801", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801"]}], "subject": "CHEBI:229212", "supporting_text": ["1 INDICATIONS AND USAGE JAYPIRCA ® is a kinase inhibitor indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ) This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. ( 1.2 ) Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. ( 1.3 ) 1.1 Mantle Cell Lymphoma JAYPIRCA ® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. 1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ER-positive, HER2-negative, ESR1-mutated breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dca32f23-f210-582b-a9c2-84eb083d53c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6656d3f3-6874-5df4-8dfa-45e18270d3fe", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "ELACESTRANT", "population_context_qualifier": "postmenopausal women or adult men", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa66ae5c-2bd2-4444-8178-b55651e054ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef"]}], "subject": "CHEBI:229213", "supporting_text": ["1 INDICATIONS AND USAGE ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] , with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy ( 1 )"], "temporal_context_qualifier": "with disease progression following at least one line of endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100245", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb37247e-41c1-58c1-a8a4-74453cf128ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20231127", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100245"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:85829a29-9346-553a-915f-b00311871dfc", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ade0c958-c6ae-52c8-abcb-5ef40f36144d", "object": "HP:0100245", "object_location_in_text": [81, 95], "original_object": "desmoid tumors", "original_subject": "NIROGACESTAT", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f172e6ff-3190-41b0-b95a-58a7ef9e9e1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f172e6ff-3190-41b0-b95a-58a7ef9e9e1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f172e6ff-3190-41b0-b95a-58a7ef9e9e1e"]}], "subject": "CHEBI:229217", "supporting_text": ["1 INDICATIONS AND USAGE OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721579", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45afe843-d2bc-5034-b1b1-dcf8c03e7a6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20231108", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4721579"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7883379b-4d29-511d-963a-a4eb81b67307", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5169849b-564a-5241-85b8-10225e08bc4d", "object": "UMLS:C4721579", "original_object": "metastatic colorectal cancer", "original_subject": "FRUQUINTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:186d786e-dc8a-45f2-b5e1-01ac0201879f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=186d786e-dc8a-45f2-b5e1-01ac0201879f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=186d786e-dc8a-45f2-b5e1-01ac0201879f"]}], "subject": "CHEBI:229221", "supporting_text": ["1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. ( 1 )"], "temporal_context_qualifier": "previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cd4a332-f2d0-52ba-8236-2d9fa56482d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240617", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fulvestrant"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cb6a30e1-4fb6-558a-9cf1-a1da2ec6043c", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "capivasertib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:truqap", "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/truqap"]}], "subject": "CHEBI:229222", "supporting_text": ["Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, Truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practice standards should be considered."], "temporal_context_qualifier": "following recurrence or progression on or after an endocrine-based regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Acinetobacter baumannii-calcoaceticus complex", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33b105a6-9997-5fa2-865d-64e48e829ca4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:84db3b32-9f97-57ae-9d7f-277971648f21", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f207600e-263b-569d-a12d-3d9d91f096e7", "object": "UMLS:C2189270", "object_location_in_text": [293, 334], "original_object": "ventilator-associated bacterial pneumonia", "original_subject": "DURLOBACTAM", "population_context_qualifier": "patients 18 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72"]}], "subject": "CHEBI:229539", "supporting_text": ["1 INDICATIONS AND USAGE XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Acinetobacter baumannii-calcoaceticus complex", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b3b9fc9-a89f-5e10-b336-9cd17e6f2474", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:44fe585a-fe5c-5f41-9696-afd7501909bb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f207600e-263b-569d-a12d-3d9d91f096e7", "object": "UMLS:C4727977", "object_location_in_text": [251, 288], "original_object": "hospital-acquired bacterial pneumonia", "original_subject": "DURLOBACTAM", "population_context_qualifier": "patients 18 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72"]}], "subject": "CHEBI:229539", "supporting_text": ["1 INDICATIONS AND USAGE XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001878", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e8bf84b-3aa0-5d53-9eef-62d6142b35d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001878"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c3bf2c21-c492-5c7a-81a4-8ba4ad50b7a6", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2af52146-1a10-52ba-bc35-6bb60322dac2", "object": "MONDO:0100244", "object_location_in_text": [114, 150], "original_object": "paroxysmal nocturnal haemoglobinuria", "original_subject": "iptacopan", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:fabhalta", "https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/fabhalta"]}], "subject": "CHEBI:229652", "supporting_text": ["Paroxysmal nocturnal haemoglobinuria Fabhalta is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Complement 3 glomerulopathy Fabhalta is indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0149518", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7bcb3241-bf4d-5956-8265-1304fcc4d3a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149518", "MONDO:0005001"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:dc1c322e-ca4f-5a52-8819-5200128cf48b", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:c578203a-1aac-57ed-8c16-48414abf13df", "object": "UMLS:C0854441", "original_object": "gastric mucosal lesions", "original_subject": "ROXATIDINE ACETATE HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ROXATIDINE ACETATE HYDROCHLORIDE#155-20110121", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:230550", "supporting_text": ["Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis."], "temporal_context_qualifier": "during acute gastritis or acute exacerbation phase of chronic gastritis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncontrolled blood phenylalanine concentrations", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3b2b437-d54c-5d20-9019-5db5bbd5642c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ab94df1-bd0b-5fbe-bdb0-8e6448d892ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92e4f2d6-015e-5b5a-8f8c-4331b4f42888", "object": "MONDO:0009861", "original_object": "phenylketonuria", "original_subject": "PEGVALIASE", "population_context_qualifier": "adult and pediatric patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6dba844a-db02-44f8-8593-ce497ed9406c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6dba844a-db02-44f8-8593-ce497ed9406c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6dba844a-db02-44f8-8593-ce497ed9406c"]}], "subject": "CHEBI:230846", "supporting_text": ["1 INDICATIONS AND USAGE PALYNZIQ is indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88fa5740-09a6-54b1-99ed-2d9afdab120b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170313", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aromatase inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4fd01f2d-cae2-56e7-8204-720ed972f476", "object": "MONDO:0007254", "original_object": "early breast cancer", "original_subject": "RIBOCICLIB", "population_context_qualifier": "adults at high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaeaef94-f3f5-4367-8ea2-b181d7be2da8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8"]}], "subject": "CHEBI:230905", "supporting_text": ["1 INDICATIONS AND USAGE KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) 1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88fa5740-09a6-54b1-99ed-2d9afdab120b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170313", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fulvestrant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4fd01f2d-cae2-56e7-8204-720ed972f476", "object": "MONDO:0007254", "original_object": "advanced or metastatic breast cancer", "original_subject": "RIBOCICLIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaeaef94-f3f5-4367-8ea2-b181d7be2da8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8"]}], "subject": "CHEBI:230905", "supporting_text": ["1 INDICATIONS AND USAGE KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) 1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy."], "temporal_context_qualifier": "following disease progression on endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6569ae5c-82ee-5aa6-868d-2defaaefc40e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200103", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Fulvestrant"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:e65d8d3a-0ebd-5034-a9fa-c0a2cf882937", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "Alpelisib film coated tablets 50mg, 150mg, 200mg", "population_context_qualifier": "postmenopausal women, and men", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:231324", "supporting_text": ["Alpelisib is a kinase inhibitor indicated in combination with Fulvestrant for the treatment of postmenopausal women, and men, with Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen."], "temporal_context_qualifier": "following progression on or after an endocrine-based regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39806663-7535-58b3-ab00-bca2a186f630", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190524", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fulvestrant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:843d3619-55f8-5f53-ade5-f2845db2e012", "object": "MONDO:0007254", "object_location_in_text": [215, 251], "original_object": "advanced or metastatic breast cancer", "original_subject": "ALPELISIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b20b4e18-7a4b-4500-a08f-06c6dab0ee5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b20b4e18-7a4b-4500-a08f-06c6dab0ee5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b20b4e18-7a4b-4500-a08f-06c6dab0ee5b"]}], "subject": "CHEBI:231324", "supporting_text": ["1 INDICATIONS AND USAGE PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen."], "temporal_context_qualifier": "following progression on or after an endocrine-based regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe manifestations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c35251c2-5d54-53f2-92c2-a63ea81723a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190524", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6664622-d71a-500f-9a1b-e312cdd66e53", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:843d3619-55f8-5f53-ade5-f2845db2e012", "object": "MONDO:0035162", "original_object": "PIK3CA-Related Overgrowth Spectrum", "original_subject": "ALPELISIB", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:638069a4-aee0-46c9-9e21-54ad449c163c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=638069a4-aee0-46c9-9e21-54ad449c163c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=638069a4-aee0-46c9-9e21-54ad449c163c"]}], "subject": "CHEBI:231324", "supporting_text": ["1 INDICATIONS AND USAGE VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VIJOICE is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-negative locally advanced or metastatic breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:483c60d3-21d5-5b54-858d-624daf7cbbf6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42017936-a55b-55b6-914e-df9d67fd4c3c", "object": "MONDO:0007254", "object_location_in_text": [291, 304], "original_object": "breast cancer", "original_subject": "TALAZOPARIB", "population_context_qualifier": "adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBCAm)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13839d4f-6acf-4ffb-a128-79df59319273", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13839d4f-6acf-4ffb-a128-79df59319273", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13839d4f-6acf-4ffb-a128-79df59319273"]}], "subject": "CHEBI:231344", "supporting_text": ["1 INDICATIONS AND USAGE TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ( 1.1 ) HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) • In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). ( 1.2 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene ( BRCA )-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA [see Dosage and Administration (2.1) ] . 1.2 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see Dosage and Administration (2.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-negative locally advanced or metastatic breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:689a4b91-2894-5cb7-8780-38c1c36bd32e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42017936-a55b-55b6-914e-df9d67fd4c3c", "object": "MONDO:0007254", "object_location_in_text": [291, 304], "original_object": "breast cancer", "original_subject": "TALAZOPARIB", "population_context_qualifier": "adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b653221e-971f-4452-92d4-797924f1ff59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b653221e-971f-4452-92d4-797924f1ff59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b653221e-971f-4452-92d4-797924f1ff59"]}], "subject": "CHEBI:231344", "supporting_text": ["1 INDICATIONS AND USAGE TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ( 1.1 ) HRR Gene-Mutated mCRPC • In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). ( 1.2 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene ( BRCA )-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA [see Dosage and Administration (2.1) ] . 1.2 HRR Gene-mutated mCRPC TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see Dosage and Administration (2.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-negative locally advanced or metastatic breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b5c6611-6f14-54cb-9371-39850973e723", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42017936-a55b-55b6-914e-df9d67fd4c3c", "object": "MONDO:0007254", "object_location_in_text": [291, 304], "original_object": "breast cancer", "original_subject": "TALAZOPARIB", "population_context_qualifier": "adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBCAm)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6fd147f-a77e-4a0b-9280-e82ecc41b4be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6fd147f-a77e-4a0b-9280-e82ecc41b4be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6fd147f-a77e-4a0b-9280-e82ecc41b4be"]}], "subject": "CHEBI:231344", "supporting_text": ["1 INDICATIONS AND USAGE TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ( 1.1 ) HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) • In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). ( 1.2 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene ( BRCA )-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA [see Dosage and Administration (2.1) ] . 1.2 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see Dosage and Administration (2.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-negative locally advanced or metastatic breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0bb581d-b9f7-57b7-8fc4-fa75814ec515", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42017936-a55b-55b6-914e-df9d67fd4c3c", "object": "MONDO:0007254", "object_location_in_text": [291, 304], "original_object": "breast cancer", "original_subject": "TALAZOPARIB", "population_context_qualifier": "adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBCAm)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2423edd-6d24-495c-aec1-c2f457f08d9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2423edd-6d24-495c-aec1-c2f457f08d9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2423edd-6d24-495c-aec1-c2f457f08d9a"]}], "subject": "CHEBI:231344", "supporting_text": ["1 INDICATIONS AND USAGE TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ( 1.1 ) HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) • In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). ( 1.2 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene ( BRCA )-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA [see Dosage and Administration (2.1) ] . 1.2 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see Dosage and Administration (2.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "residual haemolytic anaemia", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c148f44b-c6a2-5760-957e-e37a7c41aa0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240419", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ravulizumab", "eculizumab"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c3bf2c21-c492-5c7a-81a4-8ba4ad50b7a6", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e50a7ffa-7a7d-550c-a653-74dfe0c0fcb1", "object": "MONDO:0100244", "original_object": "paroxysmal nocturnal haemoglobinuria", "original_subject": "danicopan", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:voydeya", "https://www.ema.europa.eu/en/documents/product-information/voydeya-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/voydeya"]}], "subject": "CHEBI:231416", "supporting_text": ["Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4727711", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5c229a9-84f2-5fd6-ae0b-facab8c7bde5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4727711"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3ded201f-7ca1-5515-8d38-ae0700f185e3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0001056", "object_location_in_text": [112, 126], "original_object": "gastric cancer", "original_subject": "TRASTUZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TRASTUZUMAB#162-20110310", "https://www.pmda.go.jp/files/000263433.pdf"]}], "subject": "CHEBI:231601", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. [Priority review]"], "temporal_context_qualifier": "unresectable advanced or recurrent"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be4debb2-ed35-50bc-848d-1f9b0e0f4db4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "capecitabine or 5-fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adults; patients who have not received prior treatment for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce2a2492-85e3-4b0a-872a-047f44e4203d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce2a2492-85e3-4b0a-872a-047f44e4203d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce2a2492-85e3-4b0a-872a-047f44e4203d"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ontruzant is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer Ontruzant is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.3 Metastatic Gastric Cancer Ontruzant is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d76f3399-495a-5801-9fa3-780876353eb7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "capecitabine", "5-fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "patients who have not received prior treatment for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b7938e6-14c7-4a65-9605-967542ecfb8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b7938e6-14c7-4a65-9605-967542ecfb8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b7938e6-14c7-4a65-9605-967542ecfb8f"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated for: • The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer • as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel • as part of a treatment regimen with docetaxel and carboplatin • as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated: • In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b3422bb-e59c-5a59-a6c7-2a3b008d37df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4f46f08-eddb-5bd4-8ef8-3db22259806f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0006804", "original_object": "inflammatory breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "neoadjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HER2 positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0413fd2a-46c6-540d-9a4e-f5299e9bab9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000828", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [1116, 1135], "original_object": "early breast cancer", "original_subject": "trastuzumab", "population_context_qualifier": "adult patients with locally advanced (including inflammatory) disease or tumours > 2 cm in diameter", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:trazimera", "https://www.ema.europa.eu/en/documents/product-information/trazimera-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera"]}], "subject": "CHEBI:231601", "supporting_text": ["Breast cancer Metastatic breast cancer Trazimera is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer: (MBC):  as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.  Early breast cancer Trazimera is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).  following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant Trazimera therapy, for locally advanced (including inflammatory) disease or tumours &gt; 2 cm in diameter.  Trazimera should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. Metastatic gastric cancer Trazimera in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenoc"], "temporal_context_qualifier": "neoadjuvant chemotherapy followed by adjuvant Trazimera therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fdcd28d-f601-5513-a8c6-19974eb12f05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0007254", "object_location_in_text": [420, 439], "original_object": "early breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adult patients at high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27d6b34f-e4a5-5752-b5b2-e6592e3c4d49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0007254", "object_location_in_text": [130, 143], "original_object": "breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adults; patients who have received one or more chemotherapy regimens for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce2a2492-85e3-4b0a-872a-047f44e4203d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce2a2492-85e3-4b0a-872a-047f44e4203d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce2a2492-85e3-4b0a-872a-047f44e4203d"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ontruzant is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer Ontruzant is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.3 Metastatic Gastric Cancer Ontruzant is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bc5365e-7978-5a41-a15e-dc179de24f57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0007254", "object_location_in_text": [119, 132], "original_object": "breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "patients who have received one or more chemotherapy regimens for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b7938e6-14c7-4a65-9605-967542ecfb8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b7938e6-14c7-4a65-9605-967542ecfb8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b7938e6-14c7-4a65-9605-967542ecfb8f"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated for: • The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.1 ). 1.1 Adjuvant Breast Cancer Ogivri is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer • as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel • as part of a treatment regimen with docetaxel and carboplatin • as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer Ogivri is indicated: • In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ]. 1.3 Metastatic Gastric Cancer Ogivri is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.1) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4ffa6b6-fb2e-5c0b-b823-54bb63c1fdb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adults; patients who have received one or more chemotherapy regimens for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9c5e894-27d2-4245-a653-df986fed3c56", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9c5e894-27d2-4245-a653-df986fed3c56", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9c5e894-27d2-4245-a653-df986fed3c56"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE TRAZIMERA is a HER2/neu receptor antagonist indicated in adults for: • The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product. ( 1 , 2.2 ) 1.1 Adjuvant Breast Cancer TRAZIMERA is indicated in adults for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer • as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel • as part of a treatment regimen with docetaxel and carboplatin • as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer TRAZIMERA is indicated in adults: • In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer • As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]. 1.3 Metastatic Gastric Cancer TRAZIMERA is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4721209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b59d8736-04a3-56d6-a10d-908597acfc92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000828", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aromatase inhibitor"], "medic_disease_context_ids": ["UMLS:C4721209"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "medic_supporting_text_truncated": true, "object": "UMLS:C0278488", "object_location_in_text": [117, 141], "original_object": "metastatic breast cancer", "original_subject": "trastuzumab", "population_context_qualifier": "postmenopausal patients not previously treated with trastuzumab", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:trazimera", "https://www.ema.europa.eu/en/documents/product-information/trazimera-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera"]}], "subject": "CHEBI:231601", "supporting_text": ["Breast cancer Metastatic breast cancer Trazimera is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer: (MBC):  as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.  Early breast cancer Trazimera is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).  following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant Trazimera therapy, for locally advanced (including inflammatory) disease or tumours &gt; 2 cm in diameter.  Trazimera should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. Metastatic gastric cancer Trazimera in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:622c81d8-e2fb-529d-9afe-ac6c1d2e4b79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "UMLS:C0278488", "object_location_in_text": [633, 657], "original_object": "metastatic breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adult patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e340d965-b296-535d-9e7a-696252b85ff8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980925", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bbe7853a-cb5a-5790-bf85-289c36093cff", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "TRASTUZUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:231601", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "neoadjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4727069", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1eaa28f-346c-5f3b-872b-3a2b5cfc7670", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4727069"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:34419ab2-2f73-5f87-82d4-9de83301cf2f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c54afd6-a6d5-50c8-9606-72fc324a87b5", "medic_supporting_text_truncated": true, "object": "MONDO:0005086", "object_location_in_text": [1942, 1962], "original_object": "renal cell carcinoma", "original_subject": "NIVOLUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f570b9c4-6846-4de2-abfa-4d0a4ae4e394", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394"]}], "subject": "CHEBI:231614", "supporting_text": ["1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combina"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278987", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cecffd23-b86b-5449-a004-8aceacf71fa7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278987"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c54afd6-a6d5-50c8-9606-72fc324a87b5", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [549, 575], "original_object": "non-small cell lung cancer", "original_subject": "NIVOLUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f570b9c4-6846-4de2-abfa-4d0a4ae4e394", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394"]}], "subject": "CHEBI:231614", "supporting_text": ["1 INDICATIONS AND USAGE OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combina"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4544822", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0db9a85-7cf8-5889-8094-7e4f0e033b75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250825", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4544822"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b9b6c184-e4c2-5ba1-b012-3dbdcfee1913", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6c54afd6-a6d5-50c8-9606-72fc324a87b5", "object": "MONDO:0005575", "original_object": "unresectable colorectal cancer", "original_subject": "NIVOLUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NIVOLUMAB#5-20250825", "https://www.pmda.go.jp/files/000246571.pdf"]}], "subject": "CHEBI:231614", "supporting_text": ["Drugs with a new indication and new dosage for the treatment of unresectable, advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "cancer chemotherapy progression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb9221fa-4f43-58a0-bb36-c2a369f0dcce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:16d60a81-ff41-59e0-af0d-f82db0893908", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6c54afd6-a6d5-50c8-9606-72fc324a87b5", "object": "MONDO:0007576", "original_object": "oesophageal cancer", "original_subject": "NIVOLUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NIVOLUMAB#74-20200221", "https://www.pmda.go.jp/files/000246571.pdf"]}], "subject": "CHEBI:231614", "supporting_text": ["1) Drugs with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. 2) Drugs with a new indication for the treatment of unresectable advanced or recurrent oesophageal cancer that has progressed after cancer chemotherapy. 2) [Priority review]"], "temporal_context_qualifier": "following cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4544822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a3e01cc-d69f-5c77-9b6c-a725a2f39154", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250825", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4544822"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:e9aa8b04-259b-5ec3-a92f-495d2ffa3c21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6c54afd6-a6d5-50c8-9606-72fc324a87b5", "object": "UMLS:C0854750", "original_object": "recurrent colorectal cancer", "original_subject": "NIVOLUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NIVOLUMAB#5-20250825", "https://www.pmda.go.jp/files/000246571.pdf"]}], "subject": "CHEBI:231614", "supporting_text": ["Drugs with a new indication and new dosage for the treatment of unresectable, advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "cancer chemotherapy progression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27a03305-56f3-5ef7-b786-6a15761a1aad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ba606606-98ec-52db-ad43-bd02fc667552", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6c54afd6-a6d5-50c8-9606-72fc324a87b5", "object": "UMLS:C4544822", "original_object": "microsatellite instability-high colorectal cancer", "original_subject": "NIVOLUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NIVOLUMAB#74-20200221", "https://www.pmda.go.jp/files/000246571.pdf"]}], "subject": "CHEBI:231614", "supporting_text": ["1) Drugs with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. 2) Drugs with a new indication for the treatment of unresectable advanced or recurrent oesophageal cancer that has progressed after cancer chemotherapy. 2) [Priority review]"], "temporal_context_qualifier": "following cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "intermediate or poor risk advanced renal cell carcinoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:593d69ae-2023-5ff3-bc9c-7a4465bc4805", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110325", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["nivolumab"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:34419ab2-2f73-5f87-82d4-9de83301cf2f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48593e59-5527-5451-9ac7-1e89db37e413", "medic_supporting_text_truncated": true, "object": "MONDO:0005086", "object_location_in_text": [595, 615], "original_object": "renal cell carcinoma", "original_subject": "IPILIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2265ef30-253e-11df-8a39-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66"]}], "subject": "CHEBI:231679", "supporting_text": ["1 INDICATIONS AND USAGE YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) as determined by an FDA-authorized test in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13a46ebe-a0b0-5530-a999-5c3f060ccc52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110325", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69f8c6a8-386d-51fd-b56f-5b916cef0816", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48593e59-5527-5451-9ac7-1e89db37e413", "medic_supporting_text_truncated": true, "object": "MONDO:0005105", "object_location_in_text": [168, 176], "original_object": "melanoma", "original_subject": "IPILIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2265ef30-253e-11df-8a39-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66"]}], "subject": "CHEBI:231679", "supporting_text": ["1 INDICATIONS AND USAGE YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) as determined by an FDA-authorized test in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment "], "temporal_context_qualifier": "following complete resection, including total lymphadenectomy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a25c96a5-7ba8-546c-b6aa-8f18996297b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110325", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["nivolumab"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4db18fd6-759e-58ad-bde9-03459dacc042", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48593e59-5527-5451-9ac7-1e89db37e413", "medic_supporting_text_truncated": true, "object": "MONDO:0005575", "object_location_in_text": [868, 885], "original_object": "colorectal cancer", "original_subject": "IPILIMUMAB", "population_context_qualifier": "adults and pediatric patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2265ef30-253e-11df-8a39-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66"]}], "subject": "CHEBI:231679", "supporting_text": ["1 INDICATIONS AND USAGE YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) as determined by an FDA-authorized test in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4544822", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e52637f-3064-505c-a8e4-5da7de85e4c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250825", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4544822"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b9b6c184-e4c2-5ba1-b012-3dbdcfee1913", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:48593e59-5527-5451-9ac7-1e89db37e413", "object": "MONDO:0005575", "original_object": "unresectable colorectal cancer", "original_subject": "IPILIMUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IPILIMUMAB#5-20250825", "https://www.pmda.go.jp/files/000244665.pdf"]}], "subject": "CHEBI:231679", "supporting_text": ["Drugs with a new indication and new dosage for the treatment of unresectable, advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4544822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebd86921-6118-5915-8283-9acfcc01d2ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250825", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4544822"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:e9aa8b04-259b-5ec3-a92f-495d2ffa3c21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:48593e59-5527-5451-9ac7-1e89db37e413", "object": "UMLS:C0854750", "original_object": "recurrent colorectal cancer", "original_subject": "IPILIMUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IPILIMUMAB#5-20250825", "https://www.pmda.go.jp/files/000244665.pdf"]}], "subject": "CHEBI:231679", "supporting_text": ["Drugs with a new indication and new dosage for the treatment of unresectable, advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "mesenchymal epithelial transition factor gene exon 14 (METex14) skipping", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae77355b-b719-54ce-93a3-f656190e21de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1714358f-f7ba-5d82-a059-2d4f4f999d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e229c112-0323-546b-8550-952fdda83388", "object": "MONDO:0005233", "original_object": "advanced non-small cell lung cancer", "original_subject": "capmatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tabrecta", "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta"]}], "subject": "CHEBI:231693", "supporting_text": ["Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy."], "temporal_context_qualifier": "following prior treatment with immunotherapy and/or platinum based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "mesenchymal epithelial transition (MET) exon 14 skipping", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5f2aa48-0be3-5b31-b4df-890800c9feeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210512", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8bce6e75-17f8-5ff5-a8a9-b1ea5473248f", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "Capmatinib 150mg and 200mg film coated tablets", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:231693", "supporting_text": ["Capmatinib is a kinase inhibitor indicated for the treatment of adult patient with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal epithelial transition (MET) exon 14 skipping."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mesenchymal-epithelial transition (MET) exon 14 skipping", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:450a2835-cbe6-592d-acd5-98ea318cc82e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200506", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e229c112-0323-546b-8550-952fdda83388", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "CAPMATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:455892c3-d144-4ba8-9ab4-79cabff9876d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d"]}], "subject": "CHEBI:231693", "supporting_text": ["1 INDICATIONS AND USAGE TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56098fc3-9ddf-58c8-ae26-e34af9bf3cb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210716", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:294e5738-49d8-5e64-8a0a-2f5345d6aaf4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4d4360dd-19d8-5473-9b29-089952e4622b", "object": "MONDO:0005173", "object_location_in_text": [85, 102], "original_object": "actinic keratosis", "original_subject": "tirbanibulin", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:klisyri", "https://www.ema.europa.eu/en/documents/product-information/klisyri-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri"]}], "subject": "CHEBI:231702", "supporting_text": ["Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4763761", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:419fa93d-6a60-58f1-bdaf-7dd838e2e9c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251001", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763761", "UMLS:C4288754"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a1f36477-a908-52bd-997c-7a0a8b9e38c9", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:27c96bfe-67b4-5431-b57b-c2489cab7166", "object": "UMLS:C4288754", "object_location_in_text": [71, 102], "original_object": "metastatic urothelial carcinoma", "original_subject": "Erdafitinib Tablets 3 mg, 4 mg and 5 mg.", "population_context_qualifier": "adult patients with susceptible FGFR3 genetic alterations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:232556", "supporting_text": ["Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy."], "temporal_context_qualifier": "disease progressed on or after at least one line of prior systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763761", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fb526d7-85a6-589c-8fba-445c1db646c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190412", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763761"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1f36477-a908-52bd-997c-7a0a8b9e38c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4cb667a6-d655-5654-8bfa-ba13c5f8f478", "object": "UMLS:C4288754", "original_object": "metastatic urothelial carcinoma", "original_subject": "ERDAFITINIB", "population_context_qualifier": "adult patients with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee"]}], "subject": "CHEBI:232556", "supporting_text": ["1 INDICATIONS AND USAGE BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. ( 1 , 2.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FGFR3 gene mutation or fusion gene", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8d432cf-2ef1-5b27-9722-352e2c49c60a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:4d2b7d0a-a677-576b-bb06-3e5fec2eb11d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:4cb667a6-d655-5654-8bfa-ba13c5f8f478", "object": "UMLS:C4725799", "object_location_in_text": [66, 99], "original_object": "unresectable urothelial carcinoma", "original_subject": "ERDAFITINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ERDAFITINIB#17-20241227", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:232556", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of unresectable urothelial carcinoma with FGFR3 gene mutation or fusion gene that has progressed after cancer chemotherapy."], "temporal_context_qualifier": "after cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4288754", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:247894cb-f116-5ab6-8fce-01ff8e7aa0a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190412", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4288754"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5c811097-3928-5299-8fe7-0bda1105ad19", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4cb667a6-d655-5654-8bfa-ba13c5f8f478", "object": "UMLS:C4763761", "original_object": "locally advanced urothelial carcinoma", "original_subject": "ERDAFITINIB", "population_context_qualifier": "adult patients with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee"]}], "subject": "CHEBI:232556", "supporting_text": ["1 INDICATIONS AND USAGE BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. ( 1 , 2.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anaplastic lymphoma kinase (ALK)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10a02eba-73a6-5d85-9ce4-eb6f8e184d02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5e050c9b-617b-5ebd-9104-ae29fa0fb09e", "object": "UMLS:C0278987", "object_location_in_text": [129, 166], "original_object": "metastatic non-small cell lung cancer", "original_subject": "BRIGATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0fe9ff20-d402-41f3-bc1e-7002ea7007db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db"]}], "subject": "CHEBI:232810", "supporting_text": ["1 INDICATIONS AND USAGE ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f586c26-c2e4-54ce-ac9c-2ea74c8bbf71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170928", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen", "aromatase inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c1ba5c3-a9a1-5ba2-9f74-abfd83a6c714", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [291, 310], "original_object": "early breast cancer", "original_subject": "ABEMACICLIB", "population_context_qualifier": "adults at high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be4bc0de-0fdc-4d46-8d25-be43c79e6a06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06"]}], "subject": "CHEBI:233362", "supporting_text": ["1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) in combination with imlunestrant for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. ( 1.2 , 2.1 ) as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progressi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f586c26-c2e4-54ce-ac9c-2ea74c8bbf71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c1ba5c3-a9a1-5ba2-9f74-abfd83a6c714", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [485, 521], "original_object": "advanced or metastatic breast cancer", "original_subject": "ABEMACICLIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be4bc0de-0fdc-4d46-8d25-be43c79e6a06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06"]}], "subject": "CHEBI:233362", "supporting_text": ["1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) in combination with imlunestrant for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. ( 1.2 , 2.1 ) as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progressi"], "temporal_context_qualifier": "disease progression following endocrine therapy and prior chemotherapy in the metastatic setting"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4b0d0ed-9c9d-58fc-bae0-9e1b00c9bab8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:dcdea64a-65e7-539b-8d1f-bf7b161bb094", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8c1ba5c3-a9a1-5ba2-9f74-abfd83a6c714", "object": "MONDO:0007254", "original_object": "inoperable breast cancer", "original_subject": "ABEMACICLIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ABEMACICLIB#82-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:233362", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)- negative inoperable or recurrent breast cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f176851c-284d-5f71-9cb9-1c9bf6b31a54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:bb0c3178-1cd3-5255-b6af-cb1cfdba3be2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8c1ba5c3-a9a1-5ba2-9f74-abfd83a6c714", "object": "UMLS:C0278493", "object_location_in_text": [173, 196], "original_object": "recurrent breast cancer", "original_subject": "ABEMACICLIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ABEMACICLIB#82-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:233362", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)- negative inoperable or recurrent breast cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba653fff-55f3-53de-bbdb-578eb9706323", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d4e0e673-42e5-572a-a9f4-c9524948b6a0", "object": "MONDO:0000001", "object_location_in_text": [184, 220], "original_object": "active secondary progressive disease", "original_subject": "PONESIMOD", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5be69660-738c-4db7-b0d4-517aa873dc41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41"]}], "subject": "CHEBI:233412", "supporting_text": ["1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7a41fbf-2c61-5b72-9103-7ff1e0114121", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d4e0e673-42e5-572a-a9f4-c9524948b6a0", "object": "MONDO:0000001", "object_location_in_text": [184, 220], "original_object": "active secondary progressive disease", "original_subject": "PONESIMOD", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c025ba8-ba51-272e-e063-6294a90ad120", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c025ba8-ba51-272e-e063-6294a90ad120", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c025ba8-ba51-272e-e063-6294a90ad120"]}], "subject": "CHEBI:233412", "supporting_text": ["1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:124dc7b9-01c2-5fff-a89a-c321f140b5d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d4e0e673-42e5-572a-a9f4-c9524948b6a0", "object": "UMLS:C2921627", "object_location_in_text": [121, 149], "original_object": "clinically isolated syndrome", "original_subject": "PONESIMOD", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5be69660-738c-4db7-b0d4-517aa873dc41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5be69660-738c-4db7-b0d4-517aa873dc41"]}], "subject": "CHEBI:233412", "supporting_text": ["1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:424a87d9-bd5e-5d0b-9f92-1c535c145c18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d4e0e673-42e5-572a-a9f4-c9524948b6a0", "object": "UMLS:C2921627", "object_location_in_text": [121, 149], "original_object": "clinically isolated syndrome", "original_subject": "PONESIMOD", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c025ba8-ba51-272e-e063-6294a90ad120", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c025ba8-ba51-272e-e063-6294a90ad120", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c025ba8-ba51-272e-e063-6294a90ad120"]}], "subject": "CHEBI:233412", "supporting_text": ["1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268108", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5bbef9f6-a949-59a8-bac9-1d79497f17b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1941ad84-b5a4-5251-8343-3f708f47dfdb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d71d1e2b-3446-5c46-a492-39fbcb16b460", "object": "MONDO:0005393", "original_object": "gout", "original_subject": "COLCHICINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3"]}], "subject": "CHEBI:23359", "supporting_text": ["INDICATIONS &amp; USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268108", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63a98bca-0413-5b01-b858-e83ce3a6cbc1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1941ad84-b5a4-5251-8343-3f708f47dfdb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d71d1e2b-3446-5c46-a492-39fbcb16b460", "object": "MONDO:0005393", "original_object": "gout", "original_subject": "COLCHICINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:573e61e5-f5e1-4119-9d8e-d9a961a1baa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=573e61e5-f5e1-4119-9d8e-d9a961a1baa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=573e61e5-f5e1-4119-9d8e-d9a961a1baa9"]}], "subject": "CHEBI:23359", "supporting_text": ["INDICATIONS &amp; USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "frequent, recurrent acute attacks of gout", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:165315ee-0d7c-5fea-aec1-7c7801173c13", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37d938ad-d287-5f70-9b7e-502d4f4dfbef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d71d1e2b-3446-5c46-a492-39fbcb16b460", "object": "UMLS:C0268108", "object_location_in_text": [21, 44], "original_object": "chronic gouty arthritis", "original_subject": "COLCHICINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b85d3e27-70ff-4533-b463-410e4fb23813", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b85d3e27-70ff-4533-b463-410e4fb23813", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b85d3e27-70ff-4533-b463-410e4fb23813"]}], "subject": "CHEBI:23359", "supporting_text": ["For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "frequent, recurrent acute attacks of gout", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61af66f4-68a2-502c-9472-27fdedff8c2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37d938ad-d287-5f70-9b7e-502d4f4dfbef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d71d1e2b-3446-5c46-a492-39fbcb16b460", "object": "UMLS:C0268108", "object_location_in_text": [21, 44], "original_object": "chronic gouty arthritis", "original_subject": "COLCHICINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0567fe6-132b-463b-bc46-9f5a2a2478fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0567fe6-132b-463b-bc46-9f5a2a2478fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0567fe6-132b-463b-bc46-9f5a2a2478fb"]}], "subject": "CHEBI:23359", "supporting_text": ["For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "virologically suppressed", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b96d2cfa-0516-5763-a506-88ea8ed581e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20221222", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:945ed148-f597-5c19-a224-34440781f98c", "object": "UMLS:C2363741", "object_location_in_text": [178, 193], "original_object": "HIV-1 infection", "original_subject": "LENACAPAVIR", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5652804-29c4-40d7-aeb2-0142ed2a7b5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5652804-29c4-40d7-aeb2-0142ed2a7b5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5652804-29c4-40d7-aeb2-0142ed2a7b5b"]}], "subject": "CHEBI:234519", "supporting_text": ["1 INDICATIONS AND USAGE SUNLENCA, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated: in combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. ( 1.1 ) for oral loading as a component of the initiation regimen for BIXLENVO (bictegravir [BIC]/lenacapavir [LEN]), a complete regimen for the treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO. ( 1.2 ) 1.1 Treatment of HIV-1 in Heavily Treatment-Experienced Adults SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. 1.2 Oral Loading for Initiation of BIXLENVO SUNLENCA tablets are indicated for oral loading as a component of the initiation regimen for BIXLENVO (bictegravir [BIC]/lenacapavir [LEN]), a complete regimen for treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO [see Dosage and Administration (2.3) ] ."], "temporal_context_qualifier": "to replace the current antiretroviral regimen in those on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a46e6b7f-23db-502b-bffd-1095863b3087", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3a833b6d-cb77-55b7-a61f-5d8ec5308638", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "FLAVIN ADENINE DINUCLEOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:24040", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin procedure", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf07b812-9b63-582c-8897-f690e178f723", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecaad3ea-9589-5c90-8343-edf645912968", "object": "HP:0000989", "object_location_in_text": [46, 53], "original_object": "itching", "original_subject": "DIBUCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03"]}], "subject": "CHEBI:247956", "supporting_text": ["Use For temporary relief of local discomfort, itching, pain, soreness, or burning associated with minor skin procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin procedure", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a26e32fa-29f2-59b2-b5d0-5bf9fb9767c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecaad3ea-9589-5c90-8343-edf645912968", "object": "HP:0012531", "object_location_in_text": [55, 59], "original_object": "pain", "original_subject": "DIBUCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03"]}], "subject": "CHEBI:247956", "supporting_text": ["Use For temporary relief of local discomfort, itching, pain, soreness, or burning associated with minor skin procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin procedure", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0f61c66-bebb-5774-a4da-634e1e7b0917", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecaad3ea-9589-5c90-8343-edf645912968", "object": "UMLS:C0014724", "object_location_in_text": [74, 81], "original_object": "burning", "original_subject": "DIBUCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03"]}], "subject": "CHEBI:247956", "supporting_text": ["Use For temporary relief of local discomfort, itching, pain, soreness, or burning associated with minor skin procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin procedure", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10e89786-8895-521a-8988-7421f5f654de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d5995f4-1e33-5d4c-8e9c-2b102173bdb8", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecaad3ea-9589-5c90-8343-edf645912968", "object": "UMLS:C0234233", "object_location_in_text": [61, 69], "original_object": "soreness", "original_subject": "DIBUCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c290118-7880-2a98-e063-6294a90a4c03"]}], "subject": "CHEBI:247956", "supporting_text": ["Use For temporary relief of local discomfort, itching, pain, soreness, or burning associated with minor skin procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1262211", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40858c05-8f79-5413-baf1-22650b7a3f0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000209", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1262211"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e45493c5-16b4-58bd-b61c-1bf5b317e3f6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf205249-78b0-59b0-9398-f491c8e572c9", "object": "HP:0002027", "original_object": "abdominal pain", "original_subject": "ALOSETRON", "population_context_qualifier": "women with severe diarrhea-predominant irritable bowel syndrome", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d62b2c5a-1693-4e67-96d5-197e1fdc8694", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d62b2c5a-1693-4e67-96d5-197e1fdc8694", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d62b2c5a-1693-4e67-96d5-197e1fdc8694"]}], "subject": "CHEBI:253342", "supporting_text": ["1 INDICATIONS &amp; USAGE Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men. Alosetron Tablets are a selective serotonin 5-HT3 antagonist indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. ( 1 ) Severe IBS includes diarrhea and 1 or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1262211", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ab8ded6-08cb-594f-91ec-6d96e3bcdc89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000209", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1262211"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3fb7f57-b3b7-54e1-b968-962b86f54d6c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf205249-78b0-59b0-9398-f491c8e572c9", "object": "HP:0002607", "object_location_in_text": [510, 528], "original_object": "fecal incontinence", "original_subject": "ALOSETRON", "population_context_qualifier": "women with severe diarrhea-predominant irritable bowel syndrome", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d62b2c5a-1693-4e67-96d5-197e1fdc8694", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d62b2c5a-1693-4e67-96d5-197e1fdc8694", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d62b2c5a-1693-4e67-96d5-197e1fdc8694"]}], "subject": "CHEBI:253342", "supporting_text": ["1 INDICATIONS &amp; USAGE Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men. Alosetron Tablets are a selective serotonin 5-HT3 antagonist indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. ( 1 ) Severe IBS includes diarrhea and 1 or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1262211", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f20ed653-0eab-5be2-8f32-ce3ca81a08a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000209", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1262211"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e094f36a-5f5b-5525-badb-75867585da02", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf205249-78b0-59b0-9398-f491c8e572c9", "object": "HP:0012701", "original_object": "bowel urgency", "original_subject": "ALOSETRON", "population_context_qualifier": "women with severe diarrhea-predominant irritable bowel syndrome", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d62b2c5a-1693-4e67-96d5-197e1fdc8694", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d62b2c5a-1693-4e67-96d5-197e1fdc8694", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d62b2c5a-1693-4e67-96d5-197e1fdc8694"]}], "subject": "CHEBI:253342", "supporting_text": ["1 INDICATIONS &amp; USAGE Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men. Alosetron Tablets are a selective serotonin 5-HT3 antagonist indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. ( 1 ) Severe IBS includes diarrhea and 1 or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "varicose veins of the lower extremities", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:999ead2f-abf9-5b21-96a2-a3ae043cd1cb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c5e8a47c-f14a-52a5-b7b8-15628be218f8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d288b95d-6ccd-5ba5-8050-5644181e89f6", "object": "HP:0002619", "object_location_in_text": [126, 140], "original_object": "varicose veins", "original_subject": "TETRADECYL", "population_context_qualifier": "patients with competent valves; great surgical risks", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c76f4b3b-9f93-349f-e053-2995a90a2d57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c76f4b3b-9f93-349f-e053-2995a90a2d57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c76f4b3b-9f93-349f-e053-2995a90a2d57"]}], "subject": "CHEBI:25457", "supporting_text": ["INDICATIONS &amp; USAGE Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4edd2849-5365-5de9-82ff-4c2405c4bdf8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [116, 128], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "patients 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9324e2eb-26fd-4f14-9f10-e5aa467306f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9324e2eb-26fd-4f14-9f10-e5aa467306f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9324e2eb-26fd-4f14-9f10-e5aa467306f4"]}], "subject": "CHEBI:2549", "supporting_text": ["1 INDICATIONS AND USAGE PROAIR RESPICLICK is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm PROAIR RESPICLICK is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm PROAIR RESPICLICK is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:740a50b0-d5de-504e-ab88-3597436f15f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [137, 149], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "patients 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52e209ac-7156-4496-ba5a-42ee59d45deb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52e209ac-7156-4496-ba5a-42ee59d45deb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52e209ac-7156-4496-ba5a-42ee59d45deb"]}], "subject": "CHEBI:2549", "supporting_text": ["1 INDICATIONS AND USAGE Albuterol sulfate inhalation aerosol is a beta 2 -adrenergic agonist indicated for: • Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) • Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm Albuterol sulfate inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol sulfate inhalation aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd5f4085-dd55-5ea0-94cc-ff474787d74b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [115, 127], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "patients 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:667ce3ec-5217-4b10-b712-f3e54fbbf087", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=667ce3ec-5217-4b10-b712-f3e54fbbf087", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=667ce3ec-5217-4b10-b712-f3e54fbbf087"]}], "subject": "CHEBI:2549", "supporting_text": ["1 INDICATIONS AND USAGE ProAir Digihaler is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm ProAir ® Digihaler ® is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm ProAir Digihaler is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0095b3f-b326-5bb3-960b-2be83de73a5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [134, 146], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "patients 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e449282-ee58-4e36-b983-85c4e6f0864d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e449282-ee58-4e36-b983-85c4e6f0864d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e449282-ee58-4e36-b983-85c4e6f0864d"]}], "subject": "CHEBI:2549", "supporting_text": ["1 INDICATIONS AND USAGE Albuterol Sulfate Inhalation Aeroso is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dca8239e-f5f9-59ef-b805-08b03093f386", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [133, 145], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "adults and children 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9188951-3711-412c-89c6-e8db784dcb65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9188951-3711-412c-89c6-e8db784dcb65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9188951-3711-412c-89c6-e8db784dcb65"]}], "subject": "CHEBI:2549", "supporting_text": ["Albuterol sulfate inhalation aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5718fb10-f10d-5b19-aced-83ace4e212c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [55, 67], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "adults and children 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd47559a-84f6-42a5-a00e-48754505418e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd47559a-84f6-42a5-a00e-48754505418e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd47559a-84f6-42a5-a00e-48754505418e"]}], "subject": "CHEBI:2549", "supporting_text": ["Albuterol Sulfate Syrup is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:975d20f2-4996-569c-9171-53183e8a2107", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [69, 81], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54172384-9726-4a11-901e-3fb8f1baccae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54172384-9726-4a11-901e-3fb8f1baccae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54172384-9726-4a11-901e-3fb8f1baccae"]}], "subject": "CHEBI:2549", "supporting_text": ["Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e1dc86de-2e6d-5ea4-aea8-9a9ff544c6e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:200f6a78-07b5-5bd8-af19-0996d13e8536", "object": "MONDO:0001358", "object_location_in_text": [50, 62], "original_object": "bronchospasm", "original_subject": "ALBUTEROL", "population_context_qualifier": "adults and children 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a22af54a-c010-ab8b-e053-2a95a90a8862", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a22af54a-c010-ab8b-e053-2a95a90a8862", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a22af54a-c010-ab8b-e053-2a95a90a8862"]}], "subject": "CHEBI:2549", "supporting_text": ["Albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:057f5297-805f-52dd-8717-3184050a76f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [236, 248], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63d9d4aa-5f92-45b0-98d0-d6ec38b727cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride tablets will avoid the development of influenza A virus pneumonitis or other complications in high-risk patients. There is no clinical evidence indicating that amantadine hydrochloride tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride tablets: Amantadine hydrochloride tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24953252-c576-5626-951a-5da2ee14cb74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4d8f36f-d668-4728-8dca-b1c22bd9aedb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4d8f36f-d668-4728-8dca-b1c22bd9aedb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4d8f36f-d668-4728-8dca-b1c22bd9aedb"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Oth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e1f6600-3c15-5556-8161-40c6a250e26a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aa6bc18-1cee-4b6d-b7c3-0bac6a924ece", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aa6bc18-1cee-4b6d-b7c3-0bac6a924ece", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aa6bc18-1cee-4b6d-b7c3-0bac6a924ece"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride tablets will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride tablets: • Amantadine hydrochloride tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3037958e-f588-55a7-aedb-63330589bf9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [236, 248], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5989098d-2855-4b5f-9a06-64a83656c078", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5989098d-2855-4b5f-9a06-64a83656c078", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5989098d-2855-4b5f-9a06-64a83656c078"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride oral solution USP is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride: • Amantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, cha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e35da20-6c6d-5aaa-b3bb-dae862b11a10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:547904f3-84a3-1ccb-e063-6294a90a6fb6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=547904f3-84a3-1ccb-e063-6294a90a6fb6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=547904f3-84a3-1ccb-e063-6294a90a6fb6"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules, USP are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules, USP are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules, USP will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules, USP are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules, USP. Amantadine hydrochloride capsules, USP are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b3fae97-eb0c-5500-bd67-2782c77e07ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "Parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25af52ee-9b29-4c07-a383-62d4537b63e0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25af52ee-9b29-4c07-a383-62d4537b63e0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25af52ee-9b29-4c07-a383-62d4537b63e0"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine Hydrochloride are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride are also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions. Influenza a Prophylaxis Amantadine Hydrochloride are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. Because Amantadine Hydrochloride do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, Amantadine Hydrochloride prophylaxis should be considered for the 2- to 4- week time period required to develop an antibody response. Influenza A Treatment Amantadine Hydrochloride are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with Amantadine Hydrochloride will avoid the development of influenza A virus pneumonitis or other complications in high-risk patients. There is no clinical evidence indicating that Amantadine Hydrochloride are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with Amantadine Hydrochloride: Amantadine Hydrochloride are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral vir"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6466db1c-b78e-5892-9c6d-261f846a2460", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2f7da34-ad78-4db3-9af1-bdd341e09f16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2f7da34-ad78-4db3-9af1-bdd341e09f16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f7da34-ad78-4db3-9af1-bdd341e09f16"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. • Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d0f525a-38cc-5732-bb96-967fc929bdb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5119801d-a5cb-4adf-96b2-08cc3a0ba594", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5119801d-a5cb-4adf-96b2-08cc3a0ba594", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5119801d-a5cb-4adf-96b2-08cc3a0ba594"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Oth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c914201-dae8-536b-b25b-a40cbad2caed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6326d7f5-4c7c-4541-8db1-c582f1525f60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6326d7f5-4c7c-4541-8db1-c582f1525f60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6326d7f5-4c7c-4541-8db1-c582f1525f60"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Oth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8dc813eb-6780-56b1-bb45-069acd1d0019", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [237, 249], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48c949e3-86e0-c639-e063-6294a90acdba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48c949e3-86e0-c639-e063-6294a90acdba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48c949e3-86e0-c639-e063-6294a90acdba"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine Hydrochloride Oral Solution, USP is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis: Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment: Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride: • Amantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9136438-5e23-5ec0-8b73-8a611f661fcb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c5e0c61-372b-4d1b-8882-e13f6af8fed0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c5e0c61-372b-4d1b-8882-e13f6af8fed0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c5e0c61-372b-4d1b-8882-e13f6af8fed0"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4- week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride tablets will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride tablets: Amantadine hydrochloride tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations cou"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b52b3bd3-4e97-5d0a-8c57-9a6ade6802ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [248, 260], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da693bb0-0cc8-485d-89a7-c8cf28d440f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules, USP are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules, USP are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules, USP will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules, USP are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules, USP. • Amantadine hydrochloride capsules, USP are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance muta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7b098d1-1d99-5678-9f6f-027b53d8e5a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [246, 258], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c448cb3-7996-4a83-a9ad-23a00a431fbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c448cb3-7996-4a83-a9ad-23a00a431fbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c448cb3-7996-4a83-a9ad-23a00a431fbe"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride oral solution is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride oral solution is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride oral solution is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride oral solution does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride oral solution prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride oral solution is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride oral solution will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride oral solution is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride oral solution: Amantadine hydrochloride oral solution is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e24f45b9-bb3c-54c3-9d62-15562719f9b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [236, 248], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a99bb98-82a4-4b9e-9216-554dade72a3c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a99bb98-82a4-4b9e-9216-554dade72a3c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a99bb98-82a4-4b9e-9216-554dade72a3c"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine Hydrochloride Tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine Hydrochloride Tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because Amantadine Hydrochloride Tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, Amantadine Hydrochloride Tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine Hydrochloride Tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with Amantadine Hydrochloride Tablets will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that Amantadine Hydrochloride Tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with Amantadine Hydrochloride Tablets: • Amantadine Hydrochloride Tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e588b57e-3e9b-5cbb-a1aa-59f94649af08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [246, 258], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52aa093c-82cc-4d81-b072-86a2b8adc9c5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52aa093c-82cc-4d81-b072-86a2b8adc9c5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52aa093c-82cc-4d81-b072-86a2b8adc9c5"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride oral solution is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride oral solution is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride oral solution is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride oral solution does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride oral solution prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride oral solution is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride oral solution will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride oral solution is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride oral solution: Amantadine hydrochloride oral solution is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e86f26b2-6f6f-5feb-a1d8-f89e4e6c5143", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "object_location_in_text": [237, 249], "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25dd8a3c-6b11-2ea1-e063-6294a90a50cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25dd8a3c-6b11-2ea1-e063-6294a90a50cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25dd8a3c-6b11-2ea1-e063-6294a90a50cf"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine Hydrochloride Oral Solution, USP is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis: Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment: Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride: • Amantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0877854", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee70d235-7727-55ac-8653-53fada3c1fcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877854"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "HP:0001300", "original_object": "parkinsonism", "original_subject": "AMANTADINE", "population_context_qualifier": "elderly patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ff05131-f634-4688-86e9-9bc33a8d11c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ff05131-f634-4688-86e9-9bc33a8d11c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ff05131-f634-4688-86e9-9bc33a8d11c4"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride tablets will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride tablets: Amantadine hydrochloride tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations coul"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "carbon monoxide intoxication", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25c7ca0b-825b-5696-a63d-a8bdcd0b4179", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32996ae9-2434-5be8-a9d5-ee0c0e398556", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "MONDO:0006966", "original_object": "symptomatic parkinsonism", "original_subject": "AMANTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c5e0c61-372b-4d1b-8882-e13f6af8fed0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c5e0c61-372b-4d1b-8882-e13f6af8fed0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c5e0c61-372b-4d1b-8882-e13f6af8fed0"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine hydrochloride tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine hydrochloride tablets prophylaxis should be considered for the 2- to 4- week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride tablets will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride tablets: Amantadine hydrochloride tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations cou"], "temporal_context_qualifier": "which may follow injury to the nervous system by carbon monoxide intoxication"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "injury to the nervous system by carbon monoxide intoxication", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4bd45c72-12a2-5493-9cc9-5db882c70fe9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32996ae9-2434-5be8-a9d5-ee0c0e398556", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "MONDO:0006966", "original_object": "symptomatic parkinsonism", "original_subject": "AMANTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a99bb98-82a4-4b9e-9216-554dade72a3c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a99bb98-82a4-4b9e-9216-554dade72a3c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a99bb98-82a4-4b9e-9216-554dade72a3c"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine Hydrochloride Tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine Hydrochloride Tablets are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because Amantadine Hydrochloride Tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, Amantadine Hydrochloride Tablets prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine Hydrochloride Tablets are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with Amantadine Hydrochloride Tablets will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that Amantadine Hydrochloride Tablets are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with Amantadine Hydrochloride Tablets: • Amantadine Hydrochloride Tablets are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "injury to the nervous system by carbon monoxide intoxication", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df595c84-1d3a-5c6a-ae9e-beb7e09d5833", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32996ae9-2434-5be8-a9d5-ee0c0e398556", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "MONDO:0006966", "original_object": "symptomatic parkinsonism", "original_subject": "AMANTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da693bb0-0cc8-485d-89a7-c8cf28d440f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da693bb0-0cc8-485d-89a7-c8cf28d440f3"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules, USP are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules, USP are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules, USP will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules, USP are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules, USP. • Amantadine hydrochloride capsules, USP are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance muta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "carbon monoxide intoxication", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f704dfb5-faed-59e8-b614-52435716636d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32996ae9-2434-5be8-a9d5-ee0c0e398556", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6ef8b33-e987-5796-94c5-f6bf4e59444a", "medic_supporting_text_truncated": true, "object": "MONDO:0006966", "original_object": "symptomatic parkinsonism", "original_subject": "AMANTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2f7da34-ad78-4db3-9af1-bdd341e09f16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2f7da34-ad78-4db3-9af1-bdd341e09f16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f7da34-ad78-4db3-9af1-bdd341e09f16"]}], "subject": "CHEBI:2618", "supporting_text": ["Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. • Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:849f28fd-b641-5ee1-8df3-3282c1cf5c4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0000822", "MONDO:0005009"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2fe957a7-4f06-541e-963d-8c8f0cfd01e0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae197019-9cc1-58ba-949f-87e1957f181e", "object": "MONDO:0003019", "object_location_in_text": [151, 162], "original_object": "hypokalemia", "original_subject": "AMILORIDE", "population_context_qualifier": "digitalized patients; patients with significant cardiac arrhythmias", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71f5c703-94d4-49b0-9c2d-374b9cbcab85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85"]}], "subject": "CHEBI:2639", "supporting_text": ["Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0680e54c-90c5-5bb6-8e01-b74fa90e2703", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d09173a1-5e3c-4c86-8c7c-15238925ef50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d09173a1-5e3c-4c86-8c7c-15238925ef50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d09173a1-5e3c-4c86-8c7c-15238925ef50"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is l"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1090df04-c0e8-54bd-ab6a-9e1dbaa47873", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58a67272-c4c7-4e2c-85a5-9d39034d12c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58a67272-c4c7-4e2c-85a5-9d39034d12c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58a67272-c4c7-4e2c-85a5-9d39034d12c3"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23c792b8-9cd2-5e20-951e-9e3e3dcc9b8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e748fff-6bd9-5a18-8ab7-536d2919b016", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4cc6d7e-923b-e81c-e053-2995a90a0731", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4cc6d7e-923b-e81c-e053-2995a90a0731", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4cc6d7e-923b-e81c-e053-2995a90a0731"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blockers and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5cdc1330-0021-5b0e-8847-c958638044ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e0fbf93-cc64-4fa5-b586-c2020614c884", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e0fbf93-cc64-4fa5-b586-c2020614c884", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e0fbf93-cc64-4fa5-b586-c2020614c884"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blockers and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69667d14-9315-5b13-bb3d-18abe1aeaf31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edf9b22c-e37e-4b4e-8a64-20bb036c7d2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets, USP are calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) o Amlodipine besylate tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, th"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:71011e7e-0d42-5f2b-a6f1-e7f2133476df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5866d1ee-631d-d09e-e063-6294a90abe01", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5866d1ee-631d-d09e-e063-6294a90abe01", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5866d1ee-631d-d09e-e063-6294a90abe01"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: * Hypertension ( 1.1 ) ○ Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. * Coronary Artery Disease ( 1.2 ) ○ Chronic Stable Angina ○ Vasospastic Angina (Prinzmetal's or Variant Angina) ○ Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c1e861c-049d-50c0-b8db-bbd9d4c56750", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:886a7f97-60a4-4206-a6c7-5206069ed487", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=886a7f97-60a4-4206-a6c7-5206069ed487", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=886a7f97-60a4-4206-a6c7-5206069ed487"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Sdamlo is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Sdamlo is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease in adults ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt;40% 1.1 Hypertension Sdamlo is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b10c1cb-3be4-51b2-99bb-d0a1215a446b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58d2fbed-3904-3e31-e063-6294a90af21d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58d2fbed-3904-3e31-e063-6294a90af21d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58d2fbed-3904-3e31-e063-6294a90af21d"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blockers and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bb6a51f-3109-59cb-a7fc-2b8367357ca2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4926f00c-ee19-3e10-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4926f00c-ee19-3e10-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4926f00c-ee19-3e10-e054-00144ff88e88"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablet, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablet, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adc6a2ab-6473-5c05-9aed-69fcd0f1f9b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ad016ec-e158-4325-9f45-4460cf78dd98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ad016ec-e158-4325-9f45-4460cf78dd98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ad016ec-e158-4325-9f45-4460cf78dd98"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aef36408-049b-5df3-bdcf-275dc9edd46d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [569, 591], "original_object": "myocardial infarctions", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE PRESTALIA contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension, to lower blood pressure. PRESTALIA may be used in patients whose blood pressure is not adequately controlled on monotherapy. PRESTALIA may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the ACE inhibitor class to which perindopril principally belongs. There are no controlled trials demonstrating risk reduction with PRESTALIA. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb040fa9-e097-58c7-839b-bbcb240471f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44f7e13f-b90f-477b-86cf-21667d90f9a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44f7e13f-b90f-477b-86cf-21667d90f9a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44f7e13f-b90f-477b-86cf-21667d90f9a9"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c73bea32-3299-595b-b0b1-7345420df253", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79f41cd2-6d58-4b03-8b0c-ca91398bc1a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79f41cd2-6d58-4b03-8b0c-ca91398bc1a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79f41cd2-6d58-4b03-8b0c-ca91398bc1a9"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension (1.1) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease (1.2) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc904f87-a32c-5a82-9dc6-6de59f16b0eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c0f83f4-06ad-4bb1-a8e3-dcac43b840cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c0f83f4-06ad-4bb1-a8e3-dcac43b840cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c0f83f4-06ad-4bb1-a8e3-dcac43b840cf"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension (1.1) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease (1.2) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d264099f-53ff-5d43-abb1-9d0b41bce9ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1080fcea-a5da-499d-a855-690c13559071", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1080fcea-a5da-499d-a855-690c13559071", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1080fcea-a5da-499d-a855-690c13559071"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% ​1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eaa93822-0e78-5166-b656-184f4fd4cb4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58336a97-807a-2859-e063-6294a90ad338", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58336a97-807a-2859-e063-6294a90ad338", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58336a97-807a-2859-e063-6294a90ad338"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is l"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1ff2d85-0da9-51be-97b0-6b9e1e4a3059", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6efc0ef6-0424-44fc-a9ea-eb30c3b83239", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6efc0ef6-0424-44fc-a9ea-eb30c3b83239", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6efc0ef6-0424-44fc-a9ea-eb30c3b83239"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: * Hypertension ( 1.1 ) ○ Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. * Coronary Artery Disease ( 1.2 ) ○ Chronic Stable Angina ○ Vasospastic Angina (Prinzmetal's or Variant Angina) ○ Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f33e1c4a-4ab7-561e-aa52-24b6befb3864", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:204f27e9-5041-4677-b313-866ca69abad9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=204f27e9-5041-4677-b313-866ca69abad9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=204f27e9-5041-4677-b313-866ca69abad9"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:078651f8-70af-50a1-bb42-91ac9d731b07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e0fbf93-cc64-4fa5-b586-c2020614c884", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e0fbf93-cc64-4fa5-b586-c2020614c884", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e0fbf93-cc64-4fa5-b586-c2020614c884"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blockers and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b7c5e7c-56e6-513c-9157-6c945096cb88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c0f83f4-06ad-4bb1-a8e3-dcac43b840cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c0f83f4-06ad-4bb1-a8e3-dcac43b840cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c0f83f4-06ad-4bb1-a8e3-dcac43b840cf"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension (1.1) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease (1.2) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c2e78b3-0b42-5137-90ff-01cade97be83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58336a97-807a-2859-e063-6294a90ad338", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58336a97-807a-2859-e063-6294a90ad338", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58336a97-807a-2859-e063-6294a90ad338"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is l"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10227f99-b137-5849-84e6-8a7de0d99591", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58a67272-c4c7-4e2c-85a5-9d39034d12c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58a67272-c4c7-4e2c-85a5-9d39034d12c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58a67272-c4c7-4e2c-85a5-9d39034d12c3"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10f7dd37-03b3-5db3-bf80-6c80b355e906", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5866d1ee-631d-d09e-e063-6294a90abe01", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5866d1ee-631d-d09e-e063-6294a90abe01", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5866d1ee-631d-d09e-e063-6294a90abe01"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: * Hypertension ( 1.1 ) ○ Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. * Coronary Artery Disease ( 1.2 ) ○ Chronic Stable Angina ○ Vasospastic Angina (Prinzmetal's or Variant Angina) ○ Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28a93615-54b1-5ea1-9bef-8b4d1a000056", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4926f00c-ee19-3e10-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4926f00c-ee19-3e10-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4926f00c-ee19-3e10-e054-00144ff88e88"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablet, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablet, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3cf3ce82-d8a8-50a1-8258-03c349ad0e7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:204f27e9-5041-4677-b313-866ca69abad9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=204f27e9-5041-4677-b313-866ca69abad9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=204f27e9-5041-4677-b313-866ca69abad9"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4cbbf875-2736-5f32-9583-a1d04324aba5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edf9b22c-e37e-4b4e-8a64-20bb036c7d2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edf9b22c-e37e-4b4e-8a64-20bb036c7d2d"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets, USP are calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) o Amlodipine besylate tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, th"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:587256e4-da65-5d3a-b76f-ba2a2cd0c08f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1080fcea-a5da-499d-a855-690c13559071", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1080fcea-a5da-499d-a855-690c13559071", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1080fcea-a5da-499d-a855-690c13559071"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% ​1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c5cf7bc-3dfd-5edf-98f9-0d4890ca87b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58d2fbed-3904-3e31-e063-6294a90af21d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58d2fbed-3904-3e31-e063-6294a90af21d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58d2fbed-3904-3e31-e063-6294a90af21d"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blockers and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81ae77a2-d68c-573e-bff1-a16c47c649a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ad016ec-e158-4325-9f45-4460cf78dd98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ad016ec-e158-4325-9f45-4460cf78dd98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ad016ec-e158-4325-9f45-4460cf78dd98"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:829002fe-62f3-54d1-a4a7-0f9236c9596b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d09173a1-5e3c-4c86-8c7c-15238925ef50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d09173a1-5e3c-4c86-8c7c-15238925ef50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d09173a1-5e3c-4c86-8c7c-15238925ef50"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is l"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90304f12-ee90-5f14-81a8-aa6135796b27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [557, 564], "original_object": "strokes", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE PRESTALIA contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension, to lower blood pressure. PRESTALIA may be used in patients whose blood pressure is not adequately controlled on monotherapy. PRESTALIA may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the ACE inhibitor class to which perindopril principally belongs. There are no controlled trials demonstrating risk reduction with PRESTALIA. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96cd6710-ecaa-5f91-8948-128b97005c84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:886a7f97-60a4-4206-a6c7-5206069ed487", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=886a7f97-60a4-4206-a6c7-5206069ed487", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=886a7f97-60a4-4206-a6c7-5206069ed487"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Sdamlo is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Sdamlo is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease in adults ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt;40% 1.1 Hypertension Sdamlo is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac38478f-c09e-554a-8469-f996f6544796", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4cc6d7e-923b-e81c-e053-2995a90a0731", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4cc6d7e-923b-e81c-e053-2995a90a0731", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4cc6d7e-923b-e81c-e053-2995a90a0731"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Amlodipine besylate tablets are calcium channel blockers and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3dc903a-a87f-51f3-918f-b24d9003a1cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6efc0ef6-0424-44fc-a9ea-eb30c3b83239", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6efc0ef6-0424-44fc-a9ea-eb30c3b83239", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6efc0ef6-0424-44fc-a9ea-eb30c3b83239"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: * Hypertension ( 1.1 ) ○ Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. * Coronary Artery Disease ( 1.2 ) ○ Chronic Stable Angina ○ Vasospastic Angina (Prinzmetal's or Variant Angina) ○ Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d222709d-b28e-5dfe-91c6-5af70bb70d8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79f41cd2-6d58-4b03-8b0c-ca91398bc1a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79f41cd2-6d58-4b03-8b0c-ca91398bc1a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79f41cd2-6d58-4b03-8b0c-ca91398bc1a9"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension (1.1) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease (1.2) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbabbf3d-b94b-59b4-8ec6-9f47daa94edc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3cd4048-32d3-5a1c-974d-173c98d4c68a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "AMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44f7e13f-b90f-477b-86cf-21667d90f9a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44f7e13f-b90f-477b-86cf-21667d90f9a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44f7e13f-b90f-477b-86cf-21667d90f9a9"]}], "subject": "CHEBI:2668", "supporting_text": ["1 INDICATIONS &amp; USAGE Amlodipine besylate tablets is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction &lt; 40% 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely resp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "confirmed or suspected vasospastic angina", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37facb83-6bf1-5467-b906-05b90fd3a287", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920731", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7bea912-a802-599b-b0a6-a72db0fd5420", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7304754b-4bb8-5ed3-bbe5-37df6fa5065c", "medic_supporting_text_truncated": true, "object": "MONDO:0006021", "original_object": "vasospastic angina", "original_subject": "AMLODIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c29aadb-b8fc-83c8-e063-6394a90a7a16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c29aadb-b8fc-83c8-e063-6394a90a7a16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c29aadb-b8fc-83c8-e063-6394a90a7a16"]}], "subject": "CHEBI:2668", "supporting_text": ["1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic diseases", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99fe5cb8-93bc-5691-9f8c-652737e46fd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2653599a-a680-5938-92c3-aa47d423f9ef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f1c4ca7f-9c7d-520a-94aa-80fedd990919", "object": "HP:0012450", "object_location_in_text": [54, 74], "original_object": "chronic constipation", "original_subject": "SODIUM CHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SODIUM CHLORIDE#77-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:26710", "supporting_text": ["A new combination drug indicated for the treatment of chronic constipation (excluding constipation due to organic diseases)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "neurotic or reactive depressive disorders, endogenous and psychotic depression, depression accompanied by anxiety and agitation", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6ba6e8b-22dc-5d9c-9df3-5a080d50549b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19810101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:26622e45-7c0a-5a6e-a127-34eeea6d8ccd", "object": "MONDO:0002050", "object_location_in_text": [57, 67], "original_object": "depression", "original_subject": "Amoxapine 25mg/50mg/100mg/150mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:2675", "supporting_text": ["Anti depressant- Indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depression, depression accompanied by anxiety and agitation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8af56f1d-335b-5d5a-973f-d1ad47c4c082", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e563f03-8fb7-5fdc-8317-2e9d0fed80dc", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "UMLS:C0948807", "original_object": "hepatic impairment", "original_subject": "AMOXICILLIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86"]}], "subject": "CHEBI:2676", "supporting_text": ["4 CONTRAINDICATIONS VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK : Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams, clarithromycin or any other macrolide antimicrobial or any component of VOQUEZNA TRIPLE PAK. ( 4.1 ) Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams or any component of VOQUEZNA DUAL PAK. ( 4.1 ) Rilpivirine-containing products. ( 4.1 ) VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component : Pimozide. ( 4.2 ) Lomitapide, lovastatin, and simvastatin. ( 4.2 ) Ergot alkaloids (ergotamine or dihydroergotamine). ( 4.2 ) Colchicine in renal or hepatic impairment. ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin. ( 4.2 ) Lurasidone. ( 4.2 ) 4.1 Contraindications to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Hypersensitivity Reactions VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) [see Warnings and Precautions (5.1) ]. Rilpivirine-containing Products VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. 4.2 Additional Contraindications to VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component Serious Adverse Reactions/Risks Due to Drug Interactions Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of: Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most like"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea17aa66-c23e-586f-aa35-881e3c8a3fff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7dd6fba1-2634-5f58-85a5-ca9748acce1f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "UMLS:C1565489", "original_object": "renal impairment", "original_subject": "AMOXICILLIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86"]}], "subject": "CHEBI:2676", "supporting_text": ["4 CONTRAINDICATIONS VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK : Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams, clarithromycin or any other macrolide antimicrobial or any component of VOQUEZNA TRIPLE PAK. ( 4.1 ) Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams or any component of VOQUEZNA DUAL PAK. ( 4.1 ) Rilpivirine-containing products. ( 4.1 ) VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component : Pimozide. ( 4.2 ) Lomitapide, lovastatin, and simvastatin. ( 4.2 ) Ergot alkaloids (ergotamine or dihydroergotamine). ( 4.2 ) Colchicine in renal or hepatic impairment. ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin. ( 4.2 ) Lurasidone. ( 4.2 ) 4.1 Contraindications to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Hypersensitivity Reactions VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) [see Warnings and Precautions (5.1) ]. Rilpivirine-containing Products VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. 4.2 Additional Contraindications to VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component Serious Adverse Reactions/Risks Due to Drug Interactions Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of: Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most like"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b9153a1-c785-5306-aa59-aecaba256e75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2732a8c7-9e4b-43c9-9712-df4b237ab69c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2732a8c7-9e4b-43c9-9712-df4b237ab69c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2732a8c7-9e4b-43c9-9712-df4b237ab69c"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β­-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin for oral suspension, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole: Amoxicillin for oral suspension, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duoden"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6bc442a4-6574-5e6c-a014-0aa6a70ace4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "MONDO:0005412", "object_location_in_text": [249, 263], "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40adc1d3-7ce7-4698-aa7f-b5dbaaecec00", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40adc1d3-7ce7-4698-aa7f-b5dbaaecec00", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40adc1d3-7ce7-4698-aa7f-b5dbaaecec00"]}], "subject": "CHEBI:2676", "supporting_text": ["H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence The components in lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets and other antibacterial drugs, lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Escherichia coli, beta-lactamase–producing Klebsiella species, beta-lactamase–producing Enterobacter species", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba546f17-4a7b-54a5-b182-5ac376052600", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Escherichia coli, beta-lactamase–producing Klebsiella species, beta-lactamase–producing Enterobacter species", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4e31bf2-7794-5602-a364-eb6003cb1238", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f8f6d90-48e9-52fc-a7b8-5455d0a72146", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69b5e712-a230-5a57-90f9-f5f5c1426cde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:027ef6b8-7a77-557f-ad92-f5c8b14522ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; patients allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ecf56fe-3e72-713a-e063-6294a90ac3d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ecf56fe-3e72-713a-e063-6294a90ac3d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ecf56fe-3e72-713a-e063-6294a90ac3d5"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bf73db3-dc39-5721-b7f8-63ba3bb80ceb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; patients allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b07b5ac4-253e-4c83-91c3-3fdc46e91a0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b07b5ac4-253e-4c83-91c3-3fdc46e91a0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b07b5ac4-253e-4c83-91c3-3fdc46e91a0f"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e3cd1f1-ae30-5147-bd81-fa2083de849a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; patients allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d6d8372-dd7f-42a0-a447-fd699beb0aab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d6d8372-dd7f-42a0-a447-fd699beb0aab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d6d8372-dd7f-42a0-a447-fd699beb0aab"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b981cde-8355-5e44-aed6-f95715eb1031", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:586a5911-e30b-40ed-a056-9e67920ca951", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=586a5911-e30b-40ed-a056-9e67920ca951", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=586a5911-e30b-40ed-a056-9e67920ca951"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin tablets are a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms. • Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract. ( 1.1 to 1.4 ) • In combination for treatment of H. pylori infection and duodenal ulcer disease. ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin tablets and other antibacterial drugs, amoxicillin tablets should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Infections of the Ear, Nose, and Throat Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . 1.2 Infections of the Genitourinary Tract Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis , or Enterococcus faecalis. 1.3 Infections of the Skin and Skin Structure Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli. 1.4 Infections of the Lower Respiratory Tract Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae. 1.5 Helicobacter pylori Infection Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole: Amoxicillin tablets, in combination with clarithromycin plus lansoprazole as triple therapy, are indicated for the treatment of patients with H. pylori in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c071c13-03e0-5f72-bda0-004ec1bdce7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:112be0b9-19ff-5d84-8593-22e5b09509d6", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "Duodenal ulcer disease", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; clarithromycin allergic or intolerant patients; patients with suspected or known clarithromycin resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37eb415-77b2-41b0-8d20-64e821e4b05d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37eb415-77b2-41b0-8d20-64e821e4b05d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37eb415-77b2-41b0-8d20-64e821e4b05d"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin tablets, in combination with clarithromycin plus lansoprazole as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole : Amoxicillin tablets, in combination with lansoprazole delayed-release capsules as dual therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:404fbc96-45d8-550a-ae45-f6585b666f97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; patients allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63b395ca-f0ea-4429-b8aa-18f495596e4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63b395ca-f0ea-4429-b8aa-18f495596e4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63b395ca-f0ea-4429-b8aa-18f495596e4d"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b0367a4-ab8c-5b7a-8b41-980cfaaeacf5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; patients allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b3ab9ea-caee-4186-9068-43ca527c098d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b3ab9ea-caee-4186-9068-43ca527c098d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b3ab9ea-caee-4186-9068-43ca527c098d"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd03dbb2-338b-580b-bcaa-fbbca76cfd47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only; patients allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d978882-d938-40cf-96be-59052d9599fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d978882-d938-40cf-96be-59052d9599fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d978882-d938-40cf-96be-59052d9599fe"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli , Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin tablets, amoxicillin for oral suspension, amoxicillin tablets (chewable), and amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb982cc3-323f-558f-ab7d-1aaf71b3dc69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lansoprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [1475, 1489], "original_object": "duodenal ulcer", "original_subject": "AMOXICILLIN", "population_context_qualifier": "Adult Patients only", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:61a9829b-4792-4caa-b75a-b84812f28d4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=61a9829b-4792-4caa-b75a-b84812f28d4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=61a9829b-4792-4caa-b75a-b84812f28d4a"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus species . (α- and β-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract: Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp ., or H. influenzae . Adult Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease: Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole: ​​​​​​​ Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole: Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in who"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "S. pneumoniae infection, H. influenzae infection, M. catarrhalis infection", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a3bd58e-ab87-5a63-b684-5ce37d80604b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49b41f71-3324-5b2b-ad04-ad6d835e7323", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "MONDO:0005441", "original_object": "recurrent or persistent acute otitis media", "original_subject": "AMOXICILLIN", "population_context_qualifier": "pediatric patients aged 3 months to 12 years weighing less than or equal to 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59979859-8c9b-4173-a5e3-2e6312fd9d79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59979859-8c9b-4173-a5e3-2e6312fd9d79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59979859-8c9b-4173-a5e3-2e6312fd9d79"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE AUGMENTIN ES-600 is indicated for the treatment of pediatric patients aged 3 months to 12 years weighing less than or equal to 40 kg with: Recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs less than or equal to 2 mcg/mL), H. influenzae (including beta-lactamase-producing strains), or M. catarrhalis (including beta-lactamase-producing strains) characterized by the following risk factors: - Antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) day care attendance [see Microbiology (12.4)] ."], "temporal_context_qualifier": "characterized by antibacterial exposure for acute otitis media within the preceding 3 months, and either age 2 years, or younger or day care attendance"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e32781b-5ca7-5f27-9656-38e416a46d3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15d9c229-0d23-52ff-bfb2-0fd72199aa8c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "MONDO:0005961", "original_object": "sinusitis", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7cf557a-a630-5659-beba-a72d2f9ccb28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15d9c229-0d23-52ff-bfb2-0fd72199aa8c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "MONDO:0005961", "original_object": "sinusitis", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9771fc3f-dde5-5650-af5e-ac1e2b97e836", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100618", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:36fcdc3f-d32b-5afd-9a06-de2e6589f1de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fc70885c-c273-59ee-9f58-bd11f22e4c85", "object": "MONDO:0006226", "object_location_in_text": [99, 120], "original_object": "gastric MALT lymphoma", "original_subject": "AMOXICILLIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AMOXICILLIN HYDRATE#157-20100618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:2676", "supporting_text": ["Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c59719a1-c7f3-5a99-a755-bbd6f00c057d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100618", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:167ca84e-afeb-5167-804f-04ad88cc5aa7", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fc70885c-c273-59ee-9f58-bd11f22e4c85", "object": "MONDO:0008558", "object_location_in_text": [198, 233], "original_object": "idiopathic thrombocytopenic purpura", "original_subject": "AMOXICILLIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AMOXICILLIN HYDRATE#157-20100618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:2676", "supporting_text": ["Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase-producing pathogens, S. pneumoniae with reduced susceptibility to penicillin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c9f7ef3-9ae5-549a-af1f-f03fd3bac19f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:67eb57d0-058f-509e-b435-b2978472c1c6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "UMLS:C0275556", "object_location_in_text": [275, 300], "original_object": "acute bacterial sinusitis", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium Extended Release Tablets is indicated for the treatment of infections in adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets with: community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected beta-lactamase-producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs equal to 2 mcg/mL)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "S. pneumoniae with reduced susceptibility to penicillin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:257e2eac-33fb-5a0a-9cd0-306fd129ebc9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "UMLS:C0694549", "object_location_in_text": [243, 271], "original_object": "community-acquired pneumonia", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium Extended Release Tablets is indicated for the treatment of infections in adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets with: community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected beta-lactamase-producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs equal to 2 mcg/mL)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a092277-2b48-52b6-822a-d0ab9e79c326", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:979e7e20-d8ad-51f9-a71a-ca4abee265ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c261b9a-187d-5533-98aa-521a304c931f", "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "AMOXICILLIN", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:2676", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "MAOI use", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9bf535b-ffdf-5bfa-b983-21437e931cbd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors (MAOIs)", "linezolid", "intravenous methylene blue"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b07c3cbb-48b9-5a88-b524-a350d5ba6a87", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "HP:0100735", "original_object": "hypertensive crisis", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:243e88e7-6621-47e9-8d5c-3f79bcb088bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=243e88e7-6621-47e9-8d5c-3f79bcb088bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=243e88e7-6621-47e9-8d5c-3f79bcb088bb"]}], "subject": "CHEBI:2679", "supporting_text": ["4 CONTRAINDICATIONS Amphetamine extended-release orally disintegrating tablets are contraindicated: In patients known to be hypersensitive to amphetamine, or other components of amphetamine extended-release orally disintegrating tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions ( 5.7 ), Drug Interactions ( 7.1 )] . Known hypersensitivity to amphetamine products or other ingredients in amphetamine extended-release orally disintegrating tablets. ( 4 ) Use of monoamine oxidase inhibitor (MAOI) or within 14 days of the last MAOI dose. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0100735", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3305a90e-e4a6-5568-88e8-46b9f78006c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MAOI", "linezolid", "intravenous methylene blue"], "medic_disease_context_ids": ["HP:0100735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0010481", "object_location_in_text": [225, 235], "original_object": "angioedema", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cffbbb15-d776-41ae-a8a6-687f2c07bfa4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cffbbb15-d776-41ae-a8a6-687f2c07bfa4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cffbbb15-d776-41ae-a8a6-687f2c07bfa4"]}], "subject": "CHEBI:2679", "supporting_text": ["In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see ADVERSE REACTIONS ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS and DRUG INTERACTIONS ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0100735", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d41eaa5-b26c-5f92-847e-b63fdb68e7ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MAOI", "linezolid", "intravenous methylene blue"], "medic_disease_context_ids": ["HP:0100735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0010481", "object_location_in_text": [225, 235], "original_object": "angioedema", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef3590cc-49ae-44f7-85a9-7c11f58d467e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef3590cc-49ae-44f7-85a9-7c11f58d467e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef3590cc-49ae-44f7-85a9-7c11f58d467e"]}], "subject": "CHEBI:2679", "supporting_text": ["In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see ADVERSE REACTIONS ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS and DRUG INTERACTIONS ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0100735", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca86924d-46f9-5331-9711-9f163d734ccc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MAOI", "linezolid", "intravenous methylene blue"], "medic_disease_context_ids": ["HP:0100735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0010481", "object_location_in_text": [225, 235], "original_object": "angioedema", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4564e404-8d71-4585-ab78-55857f477143", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4564e404-8d71-4585-ab78-55857f477143", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4564e404-8d71-4585-ab78-55857f477143"]}], "subject": "CHEBI:2679", "supporting_text": ["In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see ADVERSE REACTIONS ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS and DRUG INTERACTIONS ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0100735", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:549ca173-69d3-5d90-9894-b746288e38c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MAOI", "linezolid", "intravenous methylene blue"], "medic_disease_context_ids": ["HP:0100735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:97099ef1-6968-562f-927a-4f57797e76ae", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0100053", "object_location_in_text": [240, 262], "original_object": "anaphylactic reactions", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4564e404-8d71-4585-ab78-55857f477143", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4564e404-8d71-4585-ab78-55857f477143", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4564e404-8d71-4585-ab78-55857f477143"]}], "subject": "CHEBI:2679", "supporting_text": ["In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see ADVERSE REACTIONS ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS and DRUG INTERACTIONS ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0100735", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89347772-7407-5f33-b900-653a0ce4ebdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MAOI", "linezolid", "intravenous methylene blue"], "medic_disease_context_ids": ["HP:0100735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:97099ef1-6968-562f-927a-4f57797e76ae", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0100053", "object_location_in_text": [240, 262], "original_object": "anaphylactic reactions", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef3590cc-49ae-44f7-85a9-7c11f58d467e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef3590cc-49ae-44f7-85a9-7c11f58d467e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef3590cc-49ae-44f7-85a9-7c11f58d467e"]}], "subject": "CHEBI:2679", "supporting_text": ["In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see ADVERSE REACTIONS ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS and DRUG INTERACTIONS ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0100735", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dd3dfca-21a7-5ec7-912a-1e7f51664df1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MAOI", "linezolid", "intravenous methylene blue"], "medic_disease_context_ids": ["HP:0100735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:97099ef1-6968-562f-927a-4f57797e76ae", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0100053", "object_location_in_text": [240, 262], "original_object": "anaphylactic reactions", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cffbbb15-d776-41ae-a8a6-687f2c07bfa4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cffbbb15-d776-41ae-a8a6-687f2c07bfa4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cffbbb15-d776-41ae-a8a6-687f2c07bfa4"]}], "subject": "CHEBI:2679", "supporting_text": ["In patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see ADVERSE REACTIONS ]. Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS and DRUG INTERACTIONS ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "During or within 14 days following the administration of monoamine oxidase inhibitors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:436b95cc-b019-59f6-ac1b-e7208f7ede01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d438eb03-444f-5f85-9466-dd17d533c262", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "UMLS:C0020546", "original_object": "hypertensive crises", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89c5b52f-3c2a-41d5-8624-9ee51c512c72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89c5b52f-3c2a-41d5-8624-9ee51c512c72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89c5b52f-3c2a-41d5-8624-9ee51c512c72"]}], "subject": "CHEBI:2679", "supporting_text": ["• Known hypersensitivity to amphetamine products. • During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "During or within 14 days following the administration of monoamine oxidase inhibitors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec22e91a-dbad-5cc5-a237-97b9e19e0170", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d438eb03-444f-5f85-9466-dd17d533c262", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "UMLS:C0020546", "original_object": "hypertensive crises", "original_subject": "AMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:432db708-91b7-4802-88c3-ceef597b91da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=432db708-91b7-4802-88c3-ceef597b91da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=432db708-91b7-4802-88c3-ceef597b91da"]}], "subject": "CHEBI:2679", "supporting_text": ["• Known hypersensitivity to amphetamine products. • During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system dysfunction", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f7b0be5-75bf-54af-a412-8e4780a17a23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f5a2ccc-3836-57ba-ad79-e543c837f4cb", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "AMPHETAMINE", "population_context_qualifier": "children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53d40847-e0d3-48ec-81a7-ec5478553565", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53d40847-e0d3-48ec-81a7-ec5478553565", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53d40847-e0d3-48ec-81a7-ec5478553565"]}], "subject": "CHEBI:2679", "supporting_text": ["Amphetamine sulfate tablets, USP 5 mg and 10 mg are indicated for: 1. Narcolepsy 2. Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. 3. Exogenous Obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in use of the drug, such as those described below."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fd528c4-0ece-5d4d-b6d3-d7e90aa4eb2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "medic_supporting_text_truncated": true, "object": "MONDO:0002026", "original_object": "candidiasis", "original_subject": "AMPHOTERICIN B", "population_context_qualifier": "patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f24975c-5191-4fc2-a8da-e57358f8e154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f24975c-5191-4fc2-a8da-e57358f8e154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f24975c-5191-4fc2-a8da-e57358f8e154"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. DESCRIPTION OF CLINICAL STUDIES Eleven clinical studies supporting the efficacy and safety of amphotericin B were conducted. This clinical program included both controlled and uncontrolled studies . These studies, which involved 2,171 patients, included patients with confirmed systemic mycoses, empirical therapy, and visceral leishmaniasis. Nineteen hundred and forty-six (1,946) episodes were evaluable for efficacy, of which 1,280 (302 pediatric and 978 adults) were treated with amphotericin B. Three controlled empirical therapy trials compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B. One of these studies was conducted in a pediatric population, one in adults, and a third in patients aged 2 years or more. In addition, a controlled empirical therapy trial comparing the safety of amphotericin B liposome for injection to Abelcet ® (amphotericin B lipid complex) was conducted in patients aged 2 years or more. One controlled trial compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B in HIV patients with cryptococcal me"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0051761", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:387774b1-eee5-560b-aa6b-67c29f76af1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0051761"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:27788351-0c46-5038-a96d-89cc740e8d4a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0002026", "original_object": "Candida infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a96a734f-d1c4-4d42-93c2-7c336da7f7b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a96a734f-d1c4-4d42-93c2-7c336da7f7b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a96a734f-d1c4-4d42-93c2-7c336da7f7b9"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: • Empirical therapy for presumed fungal infection in febrile, neutropenic patients. • Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractoriness", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a42c73da-68b8-5b57-908f-c18f7908bde1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0002026", "original_object": "candidiasis", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02aadef1-390b-4270-b56d-33452eb89dde", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES) . See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af8f9be2-df7f-5135-a42c-fb89aae83a61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0002026", "original_object": "candidiasis", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:593cffa0-c305-48b6-8ec7-331e0ff91d2b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=593cffa0-c305-48b6-8ec7-331e0ff91d2b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=593cffa0-c305-48b6-8ec7-331e0ff91d2b"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES) . See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef63aa71-a63c-522b-af18-bd0abc4bca3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:27788351-0c46-5038-a96d-89cc740e8d4a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0002026", "original_object": "Candida infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7be6506-4d20-401e-a0ff-02ad7c33158a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a"]}], "subject": "CHEBI:2682", "supporting_text": ["Am B isome is indicated for the following: • Empirical therapy for presumed fungal infection in febrile, neutropenic patients. • Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with Am B isome, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractoriness", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a4de19e-05e3-5d57-bbfa-56ab3c6aef75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2f57153-05ee-58dd-8030-8c31ceca7d82", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0005657", "original_object": "aspergillosis", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02aadef1-390b-4270-b56d-33452eb89dde", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES) . See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6300e004-9f05-5ec6-9b8b-cd7df188470a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:098d426b-0db5-5110-834c-0182ac84022f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0005657", "original_object": "Aspergillus infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7be6506-4d20-401e-a0ff-02ad7c33158a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a"]}], "subject": "CHEBI:2682", "supporting_text": ["Am B isome is indicated for the following: • Empirical therapy for presumed fungal infection in febrile, neutropenic patients. • Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with Am B isome, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a71215e-1ba4-5a72-9a98-84d101f86b76", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2f57153-05ee-58dd-8030-8c31ceca7d82", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "medic_supporting_text_truncated": true, "object": "MONDO:0005657", "original_object": "aspergillosis", "original_subject": "AMPHOTERICIN B", "population_context_qualifier": "patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f24975c-5191-4fc2-a8da-e57358f8e154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f24975c-5191-4fc2-a8da-e57358f8e154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f24975c-5191-4fc2-a8da-e57358f8e154"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. DESCRIPTION OF CLINICAL STUDIES Eleven clinical studies supporting the efficacy and safety of amphotericin B were conducted. This clinical program included both controlled and uncontrolled studies . These studies, which involved 2,171 patients, included patients with confirmed systemic mycoses, empirical therapy, and visceral leishmaniasis. Nineteen hundred and forty-six (1,946) episodes were evaluable for efficacy, of which 1,280 (302 pediatric and 978 adults) were treated with amphotericin B. Three controlled empirical therapy trials compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B. One of these studies was conducted in a pediatric population, one in adults, and a third in patients aged 2 years or more. In addition, a controlled empirical therapy trial comparing the safety of amphotericin B liposome for injection to Abelcet ® (amphotericin B lipid complex) was conducted in patients aged 2 years or more. One controlled trial compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B in HIV patients with cryptococcal me"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ca50ba9-e885-56d2-8fcf-2b235bcbe3bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2f57153-05ee-58dd-8030-8c31ceca7d82", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0005657", "original_object": "aspergillosis", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:593cffa0-c305-48b6-8ec7-331e0ff91d2b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=593cffa0-c305-48b6-8ec7-331e0ff91d2b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=593cffa0-c305-48b6-8ec7-331e0ff91d2b"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES) . See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0051761", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7eb18e6-d67f-50c2-a0ce-3213e15d1cb3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0051761"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:098d426b-0db5-5110-834c-0182ac84022f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0005657", "original_object": "Aspergillus infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a96a734f-d1c4-4d42-93c2-7c336da7f7b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a96a734f-d1c4-4d42-93c2-7c336da7f7b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a96a734f-d1c4-4d42-93c2-7c336da7f7b9"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: • Empirical therapy for presumed fungal infection in febrile, neutropenic patients. • Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aee78518-b4da-543e-be4b-a670f87076e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:04edfe2c-631b-5103-89e9-8bfeeff7bbd8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "medic_supporting_text_truncated": true, "object": "MONDO:0005724", "original_object": "cryptococcosis", "original_subject": "AMPHOTERICIN B", "population_context_qualifier": "patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f24975c-5191-4fc2-a8da-e57358f8e154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f24975c-5191-4fc2-a8da-e57358f8e154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f24975c-5191-4fc2-a8da-e57358f8e154"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. DESCRIPTION OF CLINICAL STUDIES Eleven clinical studies supporting the efficacy and safety of amphotericin B were conducted. This clinical program included both controlled and uncontrolled studies . These studies, which involved 2,171 patients, included patients with confirmed systemic mycoses, empirical therapy, and visceral leishmaniasis. Nineteen hundred and forty-six (1,946) episodes were evaluable for efficacy, of which 1,280 (302 pediatric and 978 adults) were treated with amphotericin B. Three controlled empirical therapy trials compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B. One of these studies was conducted in a pediatric population, one in adults, and a third in patients aged 2 years or more. In addition, a controlled empirical therapy trial comparing the safety of amphotericin B liposome for injection to Abelcet ® (amphotericin B lipid complex) was conducted in patients aged 2 years or more. One controlled trial compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B in HIV patients with cryptococcal me"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5f34378-7586-5d15-8aec-3128620853fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:04edfe2c-631b-5103-89e9-8bfeeff7bbd8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "MONDO:0005724", "original_object": "cryptococcosis", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:593cffa0-c305-48b6-8ec7-331e0ff91d2b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=593cffa0-c305-48b6-8ec7-331e0ff91d2b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=593cffa0-c305-48b6-8ec7-331e0ff91d2b"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES) . See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractoriness", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ec4fb51-b239-504f-8c32-29c2f3eb2fcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a416c66c-5bbd-5eb9-b7f7-9abe57e5ff43", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "UMLS:C0740272", "original_object": "cryptococcal infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02aadef1-390b-4270-b56d-33452eb89dde", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02aadef1-390b-4270-b56d-33452eb89dde"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES) . Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES) . See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0051761", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1076d551-2605-5065-b2a4-1d930bacb43a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0051761"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cddcfe06-5015-5e01-9c68-dfc536a580bc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "UMLS:C5235087", "original_object": "Cryptococcus infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a96a734f-d1c4-4d42-93c2-7c336da7f7b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a96a734f-d1c4-4d42-93c2-7c336da7f7b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a96a734f-d1c4-4d42-93c2-7c336da7f7b9"]}], "subject": "CHEBI:2682", "supporting_text": ["Amphotericin B liposome for injection is indicated for the following: • Empirical therapy for presumed fungal infection in febrile, neutropenic patients. • Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "amphotericin B deoxycholate refractory infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7edb7325-7d6b-5fce-ab4f-ba72933ef5ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cddcfe06-5015-5e01-9c68-dfc536a580bc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ed7971-4a89-543d-8177-cb8c92fabe29", "object": "UMLS:C5235087", "original_object": "Cryptococcus infection", "original_subject": "AMPHOTERICIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7be6506-4d20-401e-a0ff-02ad7c33158a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a"]}], "subject": "CHEBI:2682", "supporting_text": ["Am B isome is indicated for the following: • Empirical therapy for presumed fungal infection in febrile, neutropenic patients. • Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with Am B isome, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "localized, non-metastatic solid tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a4fc8f0-c169-5df7-973b-f5297982557f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2d62dede-3c29-5c9d-9736-0b91732f3ab9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3da3efd5-3a6b-505a-9bec-d54227c9ae4d", "object": "UMLS:C0235280", "object_location_in_text": [67, 78], "original_object": "ototoxicity", "original_subject": "THIOSULFATE", "population_context_qualifier": "pediatric patients 1 month of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f98c7076-2a7b-4fd7-ab90-eed5e9137bae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f98c7076-2a7b-4fd7-ab90-eed5e9137bae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f98c7076-2a7b-4fd7-ab90-eed5e9137bae"]}], "subject": "CHEBI:26977", "supporting_text": ["1 INDICATIONS AND USAGE PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to anastrozole tablets or excipients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc32f51f-14c2-5b18-a091-4121ebb7d9e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89efb5c9-5434-5ec9-bba2-e17e23171dbb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0005492", "object_location_in_text": [1030, 1039], "original_object": "urticaria", "original_subject": "ANASTROZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774"]}], "subject": "CHEBI:2704", "supporting_text": ["4 CONTRAINDICATIONS Women of premenopausal endocrine status, including pregnant women (4.1, 8.1) Patients with demonstrated hypersensitivity to anastrozole tablets or any excipient (4.2) 4.1 Pregnancy and Premenopausal Women Anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole tablets are contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women using anastrozole tablets. If anastrozole tablets are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy. [see Use in Specific Populations (8.1) ] 4.2 Hypersensitivity Anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria. [see Adverse Reactions (6.2) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to anastrozole tablets or excipients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5575add-cca3-5ae7-b6dc-dc49276b88eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0010481", "object_location_in_text": [1014, 1024], "original_object": "angioedema", "original_subject": "ANASTROZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774"]}], "subject": "CHEBI:2704", "supporting_text": ["4 CONTRAINDICATIONS Women of premenopausal endocrine status, including pregnant women (4.1, 8.1) Patients with demonstrated hypersensitivity to anastrozole tablets or any excipient (4.2) 4.1 Pregnancy and Premenopausal Women Anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole tablets are contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women using anastrozole tablets. If anastrozole tablets are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy. [see Use in Specific Populations (8.1) ] 4.2 Hypersensitivity Anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria. [see Adverse Reactions (6.2) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to anastrozole tablets or excipients", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:207de725-bec6-56fa-8aed-895ce995a882", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a701aee-4250-566d-838e-eea7a5818cf5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0100053", "object_location_in_text": [1001, 1012], "original_object": "anaphylaxis", "original_subject": "ANASTROZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774"]}], "subject": "CHEBI:2704", "supporting_text": ["4 CONTRAINDICATIONS Women of premenopausal endocrine status, including pregnant women (4.1, 8.1) Patients with demonstrated hypersensitivity to anastrozole tablets or any excipient (4.2) 4.1 Pregnancy and Premenopausal Women Anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. Anastrozole tablets are contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women using anastrozole tablets. If anastrozole tablets are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy. [see Use in Specific Populations (8.1) ] 4.2 Hypersensitivity Anastrozole tablets are contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients. Observed reactions include anaphylaxis, angioedema, and urticaria. [see Adverse Reactions (6.2) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23700c57-1462-5346-862d-cec6fc9a394a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c7ca16a-662f-58d8-a1b2-c86d347287a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f40b925f-9f43-321d-e053-2a95a90aca8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f40b925f-9f43-321d-e053-2a95a90aca8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f40b925f-9f43-321d-e053-2a95a90aca8b"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c7ca16a-662f-58d8-a1b2-c86d347287a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [292, 336], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f40b925f-9f43-321d-e053-2a95a90aca8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f40b925f-9f43-321d-e053-2a95a90aca8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f40b925f-9f43-321d-e053-2a95a90aca8b"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54e2e102-d1fc-505a-8230-113182c2cd8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca9d4aff-ffdf-4a46-ad20-e47e5886a19e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54e2e102-d1fc-505a-8230-113182c2cd8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [292, 336], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca9d4aff-ffdf-4a46-ad20-e47e5886a19e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c58af75-2da9-5693-8611-246950776621", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e0ac746-f17d-5436-8bd9-7538d81cc9d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [153, 172], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da6ae05c-81e9-492a-a4c9-be3f1f367b59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da6ae05c-81e9-492a-a4c9-be3f1f367b59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da6ae05c-81e9-492a-a4c9-be3f1f367b59"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e0ac746-f17d-5436-8bd9-7538d81cc9d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [287, 331], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da6ae05c-81e9-492a-a4c9-be3f1f367b59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da6ae05c-81e9-492a-a4c9-be3f1f367b59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da6ae05c-81e9-492a-a4c9-be3f1f367b59"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:635ab1ee-1fd4-563c-98ad-6633de0f9243", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:640874e6-d383-5f0f-b3bd-94c58104b216", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [126, 145], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58390d1f-7390-a21f-e063-6294a90a0479", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58390d1f-7390-a21f-e063-6294a90a0479", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58390d1f-7390-a21f-e063-6294a90a0479"]}], "subject": "CHEBI:2704", "supporting_text": ["1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:826f452c-1c16-5f13-bb59-6e6e6809713b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:362034e9-2830-19a5-e063-6394a90a8dfb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=362034e9-2830-19a5-e063-6394a90a8dfb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=362034e9-2830-19a5-e063-6394a90a8dfb"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:826f452c-1c16-5f13-bb59-6e6e6809713b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [292, 336], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:362034e9-2830-19a5-e063-6394a90a8dfb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=362034e9-2830-19a5-e063-6394a90a8dfb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=362034e9-2830-19a5-e063-6394a90a8dfb"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a67eff29-74d7-516b-9e9b-19ce7040f2f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d4f90d4-e535-4681-a863-3d774a2064e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a67eff29-74d7-516b-9e9b-19ce7040f2f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [292, 336], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d4f90d4-e535-4681-a863-3d774a2064e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a91cff46-03af-5a7c-9069-56fa193d5f98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af0c71ef-74ea-5da1-977a-9fab8996031a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b09fc1e1-b4cd-585b-8db4-f083323834ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0c2672b-e07b-4f6c-e053-2a95a90a2e5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0c2672b-e07b-4f6c-e053-2a95a90a2e5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0c2672b-e07b-4f6c-e053-2a95a90a2e5d"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6d6ce7f-9d55-5aa7-9f8f-a0985ecac702", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54da5c12-cfaf-7a14-e063-6394a90a3635", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54da5c12-cfaf-7a14-e063-6394a90a3635", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54da5c12-cfaf-7a14-e063-6394a90a3635"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6d6ce7f-9d55-5aa7-9f8f-a0985ecac702", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [283, 327], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54da5c12-cfaf-7a14-e063-6394a90a3635", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54da5c12-cfaf-7a14-e063-6394a90a3635", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54da5c12-cfaf-7a14-e063-6394a90a3635"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c48b0160-08aa-54ae-81f2-d24f355c729c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb285a77-d661-54fe-92e7-794de0bbef91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [150, 169], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX ( 1.3 ) 1.1 Adjuvant Treatment ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da584a38-8d77-5034-929e-1c9723bd5ce5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d1d5818-1594-4f54-90a9-ae9a9afcdc67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da584a38-8d77-5034-929e-1c9723bd5ce5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [292, 336], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d1d5818-1594-4f54-90a9-ae9a9afcdc67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed6f8195-90c2-5bfa-8fcc-c28b997d044a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3869be8-6593-5003-971d-bd148ffba53e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9f5b8af-38a4-5bff-ac4d-516c8e8ea843", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer (1.1) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer (1.2) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets (1.3) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd4b6b12-990b-56c5-8dac-2d13d68f2b0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94a46579-0d79-89c7-e053-2995a90a6467", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94a46579-0d79-89c7-e053-2995a90a6467", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94a46579-0d79-89c7-e053-2995a90a6467"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd4b6b12-990b-56c5-8dac-2d13d68f2b0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "MONDO:0007254", "object_location_in_text": [292, 336], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94a46579-0d79-89c7-e053-2995a90a6467", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94a46579-0d79-89c7-e053-2995a90a6467", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94a46579-0d79-89c7-e053-2995a90a6467"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c2f07ba-5d7f-55d5-8dda-0c8c706d0aac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41db1aef-b122-5d1f-8233-a57ff1dafdb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor-unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49e7e0da-907d-5d64-9827-9351318eba55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX ( 1.3 ) 1.1 Adjuvant Treatment ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e16992e-2d74-5e82-b340-a4dcdae80d54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68bfcc91-ec5a-52dc-ac8e-edcd32e80629", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0c2672b-e07b-4f6c-e053-2a95a90a2e5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0c2672b-e07b-4f6c-e053-2a95a90a2e5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0c2672b-e07b-4f6c-e053-2a95a90a2e5d"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c3c7acc-09fe-5768-97d4-04965e04b896", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58390d1f-7390-a21f-e063-6294a90a0479", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58390d1f-7390-a21f-e063-6294a90a0479", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58390d1f-7390-a21f-e063-6294a90a0479"]}], "subject": "CHEBI:2704", "supporting_text": ["1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93c33ffc-3b07-5aa3-a5bd-0c59fc1d1ec6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeb98efe-bee6-5aa6-9140-7d5b36678bff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c432b9cf-b67e-56f6-bbc9-377f209009de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db8e05ec-a175-5cbc-8e2a-8a6fee0cfac0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb92ca3d-51f7-56d6-88a9-78b4ee74f1f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer (1.1) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer (1.2) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets (1.3) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec68b205-7df0-5924-81d8-a008c791a9bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:233c564c-648a-5ef9-bea5-d1f5e1e05692", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [358, 380], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94a46579-0d79-89c7-e053-2995a90a6467", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94a46579-0d79-89c7-e053-2995a90a6467", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94a46579-0d79-89c7-e053-2995a90a6467"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "disease progression following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3dc996a3-9e9e-50a9-97c8-be9cd0a66a90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [358, 380], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f40b925f-9f43-321d-e053-2a95a90aca8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f40b925f-9f43-321d-e053-2a95a90aca8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f40b925f-9f43-321d-e053-2a95a90aca8b"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "disease progression following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression following tamoxifen therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e623d9f-7d32-5f55-8467-63db616d20c5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [355, 377], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da6ae05c-81e9-492a-a4c9-be3f1f367b59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da6ae05c-81e9-492a-a4c9-be3f1f367b59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da6ae05c-81e9-492a-a4c9-be3f1f367b59"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ec18060-d673-55d8-bdfd-68171f94a91e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [358, 380], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca9d4aff-ffdf-4a46-ad20-e47e5886a19e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "disease progression following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73833736-a04f-55d6-8692-227214d645f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [349, 371], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80c17879-0331-5c4b-a7fd-4fe4a640e9f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [349, 371], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90335d45-100d-5a11-ae88-cf3ea9e56c94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [349, 371], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression following tamoxifen therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a19c0546-e7fd-5e69-bf3a-2c5485a015ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [352, 374], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX ( 1.3 ) 1.1 Adjuvant Treatment ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a25e39a1-9c34-57e5-8f21-2ecb8b0de228", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [349, 371], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3be886b-c311-542d-bd82-9b3f9afb5c8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [358, 380], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d1d5818-1594-4f54-90a9-ae9a9afcdc67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "disease progression following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7968e19-68a9-5cdc-b146-cdf1d9a6fc90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [349, 371], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54da5c12-cfaf-7a14-e063-6394a90a3635", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54da5c12-cfaf-7a14-e063-6394a90a3635", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54da5c12-cfaf-7a14-e063-6394a90a3635"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d236f740-fa08-5462-985e-91fb33e7f466", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [358, 380], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:362034e9-2830-19a5-e063-6394a90a8dfb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=362034e9-2830-19a5-e063-6394a90a8dfb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=362034e9-2830-19a5-e063-6394a90a8dfb"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "disease progression following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbf5df4d-f348-59b2-bd44-ded20db2b785", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495917", "object_location_in_text": [358, 380], "original_object": "advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d4f90d4-e535-4681-a863-3d774a2064e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "disease progression following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13a6d71a-a218-5935-a050-53029bbb1556", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor-unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bfc7f4e-c790-5753-9a75-b6879f2876cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX ( 1.3 ) 1.1 Adjuvant Treatment ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39db0ada-c1b3-5ac4-be73-bbcd231f53e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69be1c52-93db-e2c3-e053-2a91aa0af774"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer (1.1) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer (1.2) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets (1.3) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b8ddc8c-8788-5c62-a243-a3377facda0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5b53383-0366-4ae2-9aa4-88b56c0bbd07"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:576db74b-7a50-5cf1-bd4e-e0b22b63e4c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0c2672b-e07b-4f6c-e053-2a95a90a2e5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0c2672b-e07b-4f6c-e053-2a95a90a2e5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0c2672b-e07b-4f6c-e053-2a95a90a2e5d"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5efebf79-7f22-5091-95bc-d55a3f74dbdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58390d1f-7390-a21f-e063-6294a90a0479", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58390d1f-7390-a21f-e063-6294a90a0479", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58390d1f-7390-a21f-e063-6294a90a0479"]}], "subject": "CHEBI:2704", "supporting_text": ["1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:723275c7-8425-5b5d-8bcd-a9a4079996cc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b964f555-25d2-47ad-8942-f195f062445c"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cc47bbd-4ebd-5c93-90c7-7ce7ffc78e0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a314cf4e-fcb1-55ff-b3d5-5d43d772e622", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b642bc52-be40-5687-b8b1-abae2c100ce7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba115ac6-161b-5f4f-852c-ae8a244b3564", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9fa3677-dbff-5c25-82bb-f2697a9b2ca9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:673a12a7-04df-5eed-bb63-c9395d7275ce", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANASTROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aabd8f88-2b52-4d43-8dc6-61605988c4dc"]}], "subject": "CHEBI:2704", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal disorders interfering with intake or absorption of vitamins", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:011168b8-cbe0-5fd2-8abe-c93d431310e3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba9eb56f-8a53-5d28-94ad-258959e1639c", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:82f685a4-0dde-543c-a825-92a8cdb3db0e", "object": "MONDO:0024298", "original_object": "vitamin deficiency", "original_subject": "DEXPANTHENOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d"]}], "subject": "CHEBI:27373", "supporting_text": ["In disorders requiring parenteral administration of vitamins, i.e. pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1963961", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4b0f706-73eb-5018-a5d6-e6b2390e182c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1963961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "medic_supporting_text_truncated": true, "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "METHYLTESTOSTERONE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:77bb4ef4-c10e-4acc-8225-651d003f4561", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561"]}], "subject": "CHEBI:27436", "supporting_text": ["1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenita or acquired) — Testicular failure due to cryptohidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Pri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1963961", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4baff45-e433-5434-bb24-33aada6461db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1963961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56156a43-efe7-563b-9da1-8a2337ba8f3b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "medic_supporting_text_truncated": true, "object": "HP:0000815", "original_object": "primary hypogonadism", "original_subject": "METHYLTESTOSTERONE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9bed4886-fcd0-4056-be8d-5bb4d15081ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9bed4886-fcd0-4056-be8d-5bb4d15081ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bed4886-fcd0-4056-be8d-5bb4d15081ce"]}], "subject": "CHEBI:27436", "supporting_text": ["1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07736ff0-d569-50d1-a417-dac3be790f2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "object": "MONDO:0002050", "object_location_in_text": [304, 314], "original_object": "depression", "original_subject": "METHYLTESTOSTERONE", "population_context_qualifier": "patients not improved by estrogens alone", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39355c9a-509a-4918-8a9c-ae155950df3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39355c9a-509a-4918-8a9c-ae155950df3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39355c9a-509a-4918-8a9c-ae155950df3e"]}], "subject": "CHEBI:27436", "supporting_text": ["Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8697a1f-523d-5040-afe9-f43ed665f838", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "object": "MONDO:0002050", "object_location_in_text": [304, 314], "original_object": "depression", "original_subject": "METHYLTESTOSTERONE", "population_context_qualifier": "patients not improved by estrogens alone", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:759907a1-2da7-47df-bf7f-e642f60b998f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=759907a1-2da7-47df-bf7f-e642f60b998f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=759907a1-2da7-47df-bf7f-e642f60b998f"]}], "subject": "CHEBI:27436", "supporting_text": ["Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1721799-1225-53e8-abdc-027a900ee168", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "object": "MONDO:0002050", "object_location_in_text": [280, 290], "original_object": "depression", "original_subject": "METHYLTESTOSTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae"]}], "subject": "CHEBI:27436", "supporting_text": ["Indications &amp; Usage COVARYXT® and COVARYX® H.S. are indicated in the treatment of Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) COVARYXT® and COVARYX® H.S. HAVE NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (See BOXED WARNINGS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1963961", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24501e0c-d20e-50e1-8fb8-b43521dd99ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1963961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "medic_supporting_text_truncated": true, "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "METHYLTESTOSTERONE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9bed4886-fcd0-4056-be8d-5bb4d15081ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9bed4886-fcd0-4056-be8d-5bb4d15081ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bed4886-fcd0-4056-be8d-5bb4d15081ce"]}], "subject": "CHEBI:27436", "supporting_text": ["1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1963961", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf89c343-1c98-5673-88b2-637d6920b72e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1963961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2152b52c-055a-5e93-a447-66619e55cbae", "medic_supporting_text_truncated": true, "object": "MONDO:0018555", "original_object": "hypogonadotropic hypogonadism", "original_subject": "METHYLTESTOSTERONE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:77bb4ef4-c10e-4acc-8225-651d003f4561", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561"]}], "subject": "CHEBI:27436", "supporting_text": ["1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenita or acquired) — Testicular failure due to cryptohidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Pri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05d76f5f-622f-5c7d-8afc-770275326cb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6243a3ae-e683-595d-a7f1-47c121d44e23", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0001266", "object_location_in_text": [1214, 1229], "original_object": "mild erysipelas", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8c11af69-146f-47ed-b12a-7b201fec7e50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8c11af69-146f-47ed-b12a-7b201fec7e50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c11af69-146f-47ed-b12a-7b201fec7e50"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d2812c9-5c1e-5d86-8636-296630462924", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6243a3ae-e683-595d-a7f1-47c121d44e23", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0001266", "object_location_in_text": [1214, 1229], "original_object": "mild erysipelas", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5972712-f735-46ed-a94a-b84668bb6a82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5972712-f735-46ed-a94a-b84668bb6a82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5972712-f735-46ed-a94a-b84668bb6a82"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b40c9a4-bb0e-5efa-803d-bae180e8823c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6243a3ae-e683-595d-a7f1-47c121d44e23", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0001266", "object_location_in_text": [1214, 1229], "original_object": "mild erysipelas", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ac283c-fe6a-49f0-ae85-90ab98e38272", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ac283c-fe6a-49f0-ae85-90ab98e38272", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ac283c-fe6a-49f0-ae85-90ab98e38272"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fe67b18-a841-5fb2-af49-6413083b87c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6243a3ae-e683-595d-a7f1-47c121d44e23", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0001266", "object_location_in_text": [1214, 1229], "original_object": "mild erysipelas", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:546c367a-c786-8326-e063-6294a90ae76c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=546c367a-c786-8326-e063-6294a90ae76c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=546c367a-c786-8326-e063-6294a90ae76c"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:659d3efe-bc83-5ed4-a535-d4d3b356e9b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6243a3ae-e683-595d-a7f1-47c121d44e23", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0001266", "object_location_in_text": [1214, 1229], "original_object": "mild erysipelas", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e6fd2f-e595-f788-e063-6394a90a0ea2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e6fd2f-e595-f788-e063-6394a90a0ea2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e6fd2f-e595-f788-e063-6394a90a0ea2"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mild to moderately severe infections of the respiratory tract", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79179966-9226-52ec-ae8c-f321101b0efe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:28c974a7-47e8-5650-9a9e-d4d07b844bb3", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005114", "original_object": "pneumococcal infections", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f9fa2c8-4d25-48a8-9257-43c33d08e83a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f9fa2c8-4d25-48a8-9257-43c33d08e83a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f9fa2c8-4d25-48a8-9257-43c33d08e83a"]}], "subject": "CHEBI:27446", "supporting_text": ["Indications &amp; Usage Section To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections– penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be acc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0011947", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb48c7a4-f09b-50c7-9350-0716e8252886", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011947"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:28c974a7-47e8-5650-9a9e-d4d07b844bb3", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005114", "original_object": "pneumococcal infections", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8f797fb-979c-4eab-a3a6-ad4edcb9ff07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8f797fb-979c-4eab-a3a6-ad4edcb9ff07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8f797fb-979c-4eab-a3a6-ad4edcb9ff07"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections– penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:296ca404-8d93-5d2e-8ff7-2e0c0b43b4c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcf988d3-b26b-513f-b46a-272c7ded4a63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005952", "object_location_in_text": [1195, 1208], "original_object": "scarlet fever", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:546c367a-c786-8326-e063-6294a90ae76c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=546c367a-c786-8326-e063-6294a90ae76c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=546c367a-c786-8326-e063-6294a90ae76c"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:578ed010-f377-5c21-92de-dd6fc95971cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcf988d3-b26b-513f-b46a-272c7ded4a63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005952", "object_location_in_text": [1195, 1208], "original_object": "scarlet fever", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e6fd2f-e595-f788-e063-6394a90a0ea2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e6fd2f-e595-f788-e063-6394a90a0ea2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e6fd2f-e595-f788-e063-6394a90a0ea2"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:710d70d8-aec2-562c-a44e-9e7c3ce4e7f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcf988d3-b26b-513f-b46a-272c7ded4a63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005952", "object_location_in_text": [1195, 1208], "original_object": "scarlet fever", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5972712-f735-46ed-a94a-b84668bb6a82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5972712-f735-46ed-a94a-b84668bb6a82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5972712-f735-46ed-a94a-b84668bb6a82"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba495c97-3ccc-5dcf-b682-00345cfaa08a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcf988d3-b26b-513f-b46a-272c7ded4a63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005952", "object_location_in_text": [1195, 1208], "original_object": "scarlet fever", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8c11af69-146f-47ed-b12a-7b201fec7e50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8c11af69-146f-47ed-b12a-7b201fec7e50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c11af69-146f-47ed-b12a-7b201fec7e50"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcal Infections (without bacteremia)", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb0f8156-b4a7-56aa-a17c-8bdbabe3e77e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcf988d3-b26b-513f-b46a-272c7ded4a63", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0005952", "object_location_in_text": [1195, 1208], "original_object": "scarlet fever", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ac283c-fe6a-49f0-ae85-90ab98e38272", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ac283c-fe6a-49f0-ae85-90ab98e38272", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ac283c-fe6a-49f0-ae85-90ab98e38272"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mild to moderately severe infections of the oropharynx", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6cf7010-7c20-5be4-bd22-8f71f20f1549", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:80202931-b16f-5837-8575-5464e5dca6c2", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0006865", "original_object": "fusospirochetosis", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f9fa2c8-4d25-48a8-9257-43c33d08e83a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f9fa2c8-4d25-48a8-9257-43c33d08e83a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f9fa2c8-4d25-48a8-9257-43c33d08e83a"]}], "subject": "CHEBI:27446", "supporting_text": ["Indications &amp; Usage Section To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections– penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be acc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149778", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5790bc24-103d-5944-a3d7-0869655abd3e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149778"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:47b8a241-2be4-5dd6-8f86-9c008946f8fd", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0024313", "original_object": "staphylococcal infections", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8f797fb-979c-4eab-a3a6-ad4edcb9ff07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8f797fb-979c-4eab-a3a6-ad4edcb9ff07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8f797fb-979c-4eab-a3a6-ad4edcb9ff07"]}], "subject": "CHEBI:27446", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections– penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involvin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mild infections of the skin and soft tissues", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:beab6a92-a70e-50d6-9d47-77878f6f415c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:47b8a241-2be4-5dd6-8f86-9c008946f8fd", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa2a9e09-e2ff-57e8-acd4-403f8c6e9b6a", "medic_supporting_text_truncated": true, "object": "MONDO:0024313", "original_object": "staphylococcal infections", "original_subject": "PENICILLIN V", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f9fa2c8-4d25-48a8-9257-43c33d08e83a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f9fa2c8-4d25-48a8-9257-43c33d08e83a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f9fa2c8-4d25-48a8-9257-43c33d08e83a"]}], "subject": "CHEBI:27446", "supporting_text": ["Indications &amp; Usage Section To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infections– penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be acc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2569770f-eecd-5a86-bfd5-f51843c21885", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54db8b21-87b9-5e0c-e063-6394a90ae8ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54db8b21-87b9-5e0c-e063-6394a90ae8ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54db8b21-87b9-5e0c-e063-6394a90ae8ea"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."], "temporal_context_qualifier": "tropical or nontropical sprue"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f48f24c-2057-5f81-842a-21aa89bbc226", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b868b314-591d-458b-be82-2bcd0b73cce1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b868b314-591d-458b-be82-2bcd0b73cce1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b868b314-591d-458b-be82-2bcd0b73cce1"]}], "subject": "CHEBI:27470", "supporting_text": ["1 INDICATIONS AND USAGE QUIOFIC is indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. QUIOFIC is a folate analog indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53fc2148-da20-5fa5-bf22-13642d1fb0e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7778ac96-7817-455a-a177-22ecb276c67f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7778ac96-7817-455a-a177-22ecb276c67f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7778ac96-7817-455a-a177-22ecb276c67f"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."], "temporal_context_qualifier": "tropical or nontropical sprue"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eda3fbd-1765-5b00-8dd4-416c84c7494e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412", "MONDO:0001078", "MONDO:0005130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1ff09408-b565-532e-ab34-86513ff2f70a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "object_location_in_text": [49, 70], "original_object": "megaloblastic anemias", "original_subject": "FOLIC ACID", "population_context_qualifier": "infants, children, pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1cca8e7-3177-421e-a49c-478ed766f643", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1cca8e7-3177-421e-a49c-478ed766f643", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1cca8e7-3177-421e-a49c-478ed766f643"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid, USP is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid, USP (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fea3cef-5150-5942-8032-e7f75d806c81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96618bf8-6c03-4df3-9896-b7ef27ca392a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96618bf8-6c03-4df3-9896-b7ef27ca392a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96618bf8-6c03-4df3-9896-b7ef27ca392a"]}], "subject": "CHEBI:27470", "supporting_text": ["1 INDICATIONS AND USAGE FOLIC ACID oral solution is indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. FOLIC ACID oral solution is a folate analog indicated for the treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a07c6059-99ae-511c-86d4-43e045a29cb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:27470", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1173fa4-ee52-5662-9cba-8231d1d2d48a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412", "MONDO:0001078", "MONDO:0005130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1ff09408-b565-532e-ab34-86513ff2f70a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "object_location_in_text": [49, 70], "original_object": "megaloblastic anemias", "original_subject": "FOLIC ACID", "population_context_qualifier": "infants, children, pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:544e394d-3555-8ab1-e063-6394a90ade00", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=544e394d-3555-8ab1-e063-6394a90ade00", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=544e394d-3555-8ab1-e063-6394a90ade00"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid, USP is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid, USP (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cba5f9d0-ae14-5f30-8e05-1c7fcccd6809", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "population_context_qualifier": "patients with nontropical sprue", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5b2b84d-9f5e-4b81-ba10-9f2854e5dce9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5b2b84d-9f5e-4b81-ba10-9f2854e5dce9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5b2b84d-9f5e-4b81-ba10-9f2854e5dce9"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic Acid Injection, USP alone is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid as may be seen in tropical or nontropical sprue, in anemias of nutritional origin, pregnancy, infancy or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf70067b-4a16-5caa-855b-97d35f897ae4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "population_context_qualifier": "patients with tropical or nontropical sprue", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:368b69a8-a021-47e3-a6d7-e3497d7363b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=368b69a8-a021-47e3-a6d7-e3497d7363b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=368b69a8-a021-47e3-a6d7-e3497d7363b1"]}], "subject": "CHEBI:27470", "supporting_text": ["INDICATIONS &amp; USAGE Folic acid, USP is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:debdc217-9063-5c7f-bbce-05b6b9419f45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03b0aee4-804a-de63-e063-6394a90a6635", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03b0aee4-804a-de63-e063-6394a90a6635", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03b0aee4-804a-de63-e063-6394a90a6635"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."], "temporal_context_qualifier": "tropical or nontropical sprue"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df52364e-115b-506f-82bf-a6a6b853b5a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412", "MONDO:0001078", "MONDO:0005130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1ff09408-b565-532e-ab34-86513ff2f70a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "object_location_in_text": [49, 70], "original_object": "megaloblastic anemias", "original_subject": "FOLIC ACID", "population_context_qualifier": "infants, children, pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0baa10dd-6d1d-4946-8236-566451132da3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0baa10dd-6d1d-4946-8236-566451132da3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0baa10dd-6d1d-4946-8236-566451132da3"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid, USP is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid, USP (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e1b11822-0c4d-5011-8d0f-5c23d886b537", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:624469a1-ded9-453a-973e-c5a2f0602bb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=624469a1-ded9-453a-973e-c5a2f0602bb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=624469a1-ded9-453a-973e-c5a2f0602bb0"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."], "temporal_context_qualifier": "tropical or nontropical sprue"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5f0d6cf-1255-519d-8816-a1122f48200d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bda4687e-929a-434d-ab59-909cf2ed73a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bda4687e-929a-434d-ab59-909cf2ed73a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bda4687e-929a-434d-ab59-909cf2ed73a2"]}], "subject": "CHEBI:27470", "supporting_text": ["Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood."], "temporal_context_qualifier": "tropical or nontropical sprue"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fc46ae9-2615-59ea-817c-e323c88ed054", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "FOLIC ACID", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:27470", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:047a5b4e-8141-5b44-8c74-a995b29dec4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a575610-e205-54ca-8f12-53b063873b41", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "FOLIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:27470", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03c3f599-703e-5ded-b26f-8d3bb28b3a42", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5a2ff2-c38e-5f33-8b00-7402af2f2c3c", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:90f6b196-bf25-5227-8869-489f3c816c59", "object": "HP:0031088", "original_object": "vaginal dryness", "original_subject": "B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0625060-29c7-4cda-b6f9-cfa15e59775e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0625060-29c7-4cda-b6f9-cfa15e59775e"]}], "subject": "CHEBI:27560", "supporting_text": ["ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d591b37-df9d-5b74-830f-8c0725038b45", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7fc0ee8d-99cb-5f03-b835-8414dc447f98", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "SELENIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:27568", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05b72e27-9a9b-53e6-8466-96d8870a95ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7227cc5-0a80-47df-baf8-09f1b22b187e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7227cc5-0a80-47df-baf8-09f1b22b187e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7227cc5-0a80-47df-baf8-09f1b22b187e"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d30ee72-3894-55af-9801-2c50a8c584ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dd56001-4941-4ff0-9f30-02a1bcc4fe7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dd56001-4941-4ff0-9f30-02a1bcc4fe7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dd56001-4941-4ff0-9f30-02a1bcc4fe7e"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41075c29-9c09-5da0-9265-8338db068e93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4813b9dd-5f58-44bb-ad64-cdb331828080", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4813b9dd-5f58-44bb-ad64-cdb331828080", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4813b9dd-5f58-44bb-ad64-cdb331828080"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41925668-e868-5bea-83b1-edd1ba082bcc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84a582a9-c7e5-4159-a5eb-a47a96b4afc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84a582a9-c7e5-4159-a5eb-a47a96b4afc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84a582a9-c7e5-4159-a5eb-a47a96b4afc0"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:448024ba-a1d4-5d71-8c13-22ee83371d62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37135ba5-63fd-427f-9b4a-8b7d1009bbca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37135ba5-63fd-427f-9b4a-8b7d1009bbca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37135ba5-63fd-427f-9b4a-8b7d1009bbca"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46e84f45-e11a-5547-a6af-623b3e6a80b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71f1fbbb-428e-4bf7-bc20-2946c1079bd3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71f1fbbb-428e-4bf7-bc20-2946c1079bd3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71f1fbbb-428e-4bf7-bc20-2946c1079bd3"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59b0ef8e-6b8c-503a-a52e-92caef1721d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6fba129-ac6e-4d04-bd09-8470be4e7ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6fba129-ac6e-4d04-bd09-8470be4e7ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6fba129-ac6e-4d04-bd09-8470be4e7ecc"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c74978b-8480-56a5-8cb7-1651c2e0034b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60f656ff-97b1-4a89-99af-8100483c2bac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60f656ff-97b1-4a89-99af-8100483c2bac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60f656ff-97b1-4a89-99af-8100483c2bac"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:602a7775-f1e8-5c97-8a1a-f91332adba08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b339843f-0324-4996-88a0-0619fd6f867b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b339843f-0324-4996-88a0-0619fd6f867b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b339843f-0324-4996-88a0-0619fd6f867b"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75388e3b-f3de-5500-a616-330d79c2adea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0700a910-79aa-4431-aecf-637fe14fcae8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0700a910-79aa-4431-aecf-637fe14fcae8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0700a910-79aa-4431-aecf-637fe14fcae8"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76f7ecb9-d20c-53ab-baa1-b15e2185d40d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:07fd0bde-8f7c-47d2-9e81-2c1eee259fa6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=07fd0bde-8f7c-47d2-9e81-2c1eee259fa6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fd0bde-8f7c-47d2-9e81-2c1eee259fa6"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:799da33a-5c14-592c-97ac-441512721640", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9152bc5-5817-4a6a-9d2a-0dd77074f501", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9152bc5-5817-4a6a-9d2a-0dd77074f501", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9152bc5-5817-4a6a-9d2a-0dd77074f501"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f13491c-1ce0-5d2e-b3d7-fa03c32ef8f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [53, 58], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bde94a48-05d0-45a0-a589-ec05b7d16532", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bde94a48-05d0-45a0-a589-ec05b7d16532", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bde94a48-05d0-45a0-a589-ec05b7d16532"]}], "subject": "CHEBI:27690", "supporting_text": ["INDICATIONS &amp; USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2fbd899-606c-53d6-80f6-14d1d998dce4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:268db224-d5db-457c-86bc-972c9fe07917", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=268db224-d5db-457c-86bc-972c9fe07917", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=268db224-d5db-457c-86bc-972c9fe07917"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7581667-2d61-5af2-85b3-b060b8e3884d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9af15152-d46f-4bc3-a16e-b70a472bc52a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9af15152-d46f-4bc3-a16e-b70a472bc52a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9af15152-d46f-4bc3-a16e-b70a472bc52a"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8e9ef3b-4fb8-5c7d-b664-c328041f481f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9bd730d-c06e-47ef-b003-4dde6336f8ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9bd730d-c06e-47ef-b003-4dde6336f8ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9bd730d-c06e-47ef-b003-4dde6336f8ae"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8cedb39-3ed2-5b9e-a4ec-78ffc19ae5f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:240ab24b-3124-4805-80c2-36dd1945e3b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=240ab24b-3124-4805-80c2-36dd1945e3b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=240ab24b-3124-4805-80c2-36dd1945e3b3"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets, USP are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced edema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0768725-6c11-559a-8d79-1d08baa6c5ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6f3a2f-0819-50ba-a3e6-c4d81d3d5178", "object": "HP:0000969", "object_location_in_text": [29, 34], "original_object": "edema", "original_subject": "ACETAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0913db35-3f08-4d82-8394-486bd9a487c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0913db35-3f08-4d82-8394-486bd9a487c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0913db35-3f08-4d82-8394-486bd9a487c4"]}], "subject": "CHEBI:27690", "supporting_text": ["For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:038d76dd-4b26-524d-87c8-33c815ed8988", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:167d5eb4-8540-5313-b219-7bed259b8f93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:389bf260-165c-508c-97cc-e6e89e3df596", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cfb770d-ddc0-5287-9eca-15d70c806378", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0002315", "object_location_in_text": [133, 141], "original_object": "headache", "original_subject": "CAFFEINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:912723d0-edab-507b-8cc1-d0084749f6f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0002315", "object_location_in_text": [92, 100], "original_object": "headache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2122506-ab57-5187-818e-37c159e56892", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0002315", "object_location_in_text": [92, 100], "original_object": "headache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28588767-d918-5f23-a311-bdba515a3017", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e7a691b-250f-57b4-bf3f-a38e4efaecda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0003270", "object_location_in_text": [83, 91], "original_object": "bloating", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d39690b-7ff6-540a-976b-148f6a62bee1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:819c9ab1-b024-5395-b5bd-f89e7d2db890", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c54ca81-d9a5-549f-93ad-9ac077930f6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0003270", "object_location_in_text": [102, 110], "original_object": "bloating", "original_subject": "CAFFEINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afb8aaf8-4e28-5a00-bdde-db2195864083", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0003270", "object_location_in_text": [83, 91], "original_object": "bloating", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f8bb970-2735-5d9a-a4a2-0d64555a3db5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0012378", "object_location_in_text": [170, 177], "original_object": "fatigue", "original_subject": "CAFFEINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ed06c9e-fb10-5421-b42e-46a8dba13acd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7dc372de-871e-54b2-bc14-fd776ece3860", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bbf1a5c-80be-59a8-abd8-868ea88305a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0012378", "object_location_in_text": [130, 137], "original_object": "fatigue", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e4704d8-f48b-51f5-94cf-8e8c61c2d826", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0012378", "object_location_in_text": [130, 137], "original_object": "fatigue", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3f2240e-3cda-584d-8b76-3ea9eff1abf7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1dfafad3-641d-501e-8fc5-5753639bbd81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cb16cbc-7d0b-5edd-bffa-f21cacc67e31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fc2b728-b519-5409-a9ff-492ec47f2524", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa87e912-8e59-552a-a713-200f672b9a24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "CAFFEINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05c85423-e63e-5f32-b072-4933947a2cf1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b0cb798-2dfc-5fdb-98d9-e393aa2063cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0004604", "object_location_in_text": [121, 129], "original_object": "backache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53fb0f2b-8969-50ea-abea-b6be7980b384", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0004604", "object_location_in_text": [121, 129], "original_object": "backache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:672c4b81-aa36-55ad-b894-1e5dd5deb149", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb2d2e4e-70ea-56bb-8cc7-c8bb9e88d427", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0004604", "object_location_in_text": [144, 152], "original_object": "backache", "original_subject": "CAFFEINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd3d66f3-32d6-51cc-9ed3-8f6a4551f6c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:676f2440-61d9-51c6-920c-0e367feab31c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0026821", "object_location_in_text": [114, 120], "original_object": "cramps", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abe007ec-ea93-5bc0-9f8c-0f837995e8c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0026821", "object_location_in_text": [114, 120], "original_object": "cramps", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f351913-7ccd-507a-a559-a97de392ca85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0231528", "object_location_in_text": [155, 167], "original_object": "muscle aches", "original_subject": "CAFFEINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48af51b7-1bea-54f1-8971-92f7a6dd0601", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0231528", "object_location_in_text": [101, 113], "original_object": "muscle aches", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:652d498f-928f-5cad-b149-441debf176d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8889f448-2594-5a15-b062-5497291fd9ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0231528", "object_location_in_text": [101, 113], "original_object": "muscle aches", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da8f68c6-e0a4-5e76-848d-6a3b00c5bf35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9149cd5-e12a-52af-afe1-064b6d779e77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:27732", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "overdosage with CNS depressant drugs", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58c2228d-9d02-5f71-8020-826665631086", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980114", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_section"], "medic_co_administered_with": ["narcotic analgesics", "alcohol"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd91f9a1-b389-510f-854b-1c085654bdd4", "object": "UMLS:C0235063", "object_location_in_text": [101, 123], "original_object": "respiratory depression", "original_subject": "CAFFEINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2c6b352-f837-4903-8e4c-fb0a2b20bb60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2c6b352-f837-4903-8e4c-fb0a2b20bb60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2c6b352-f837-4903-8e4c-fb0a2b20bb60"]}], "subject": "CHEBI:27732", "supporting_text": ["Caffeine and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe caffeine and other analeptics should not be used in these conditions and recommend other supportive therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:532e5eb0-5e9c-5cea-b3b0-508ece09c97d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "object": "MONDO:0005412", "object_location_in_text": [662, 676], "original_object": "duodenal ulcer", "original_subject": "TETRACYCLINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fe5d2db-c59d-4e15-acd7-f9df8eca45aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa"]}], "subject": "CHEBI:27902", "supporting_text": ["1 INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PYLERA is a combination antibacterial indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . (1.1) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence."], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62d58c87-ef8a-5112-960c-f72254e6377b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "object": "MONDO:0005412", "object_location_in_text": [302, 316], "original_object": "duodenal ulcer", "original_subject": "TETRACYCLINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5cdacbf5-67be-42eb-bd54-8acc32ea1abc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5cdacbf5-67be-42eb-bd54-8acc32ea1abc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5cdacbf5-67be-42eb-bd54-8acc32ea1abc"]}], "subject": "CHEBI:27902", "supporting_text": ["1 INDICATIONS AND USAGE PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63f0686c-b15e-568a-9291-7a43dd5d3f93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "object": "MONDO:0005412", "object_location_in_text": [302, 316], "original_object": "duodenal ulcer", "original_subject": "TETRACYCLINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c50626a2-5969-490b-a88a-a4ee45e79615", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c50626a2-5969-490b-a88a-a4ee45e79615", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c50626a2-5969-490b-a88a-a4ee45e79615"]}], "subject": "CHEBI:27902", "supporting_text": ["1 INDICATIONS AND USAGE PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3241943", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1eaedd63-bc3f-520f-9539-515d448aaf56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3241943"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f63986d-2f51-54c5-93e9-e446fdc12fde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3241943", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7906db1-5357-5042-98d4-2049a90a4289", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3241943"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1fe9cae-0d3d-5034-9148-f8066a4511b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fee5f525-b4ff-5729-a7cd-f82fc12a3129", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b9e381f-2a9e-5b84-beda-bc03d15edfc1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c6d9c18-3f77-5f00-be22-a96a72659539", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Streptococcus pyogenes, infection caused by Streptococcus pneumoniae, infection caused by Hemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8237789a-fa46-59ad-9ebf-c81caa75ce6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af72c2c6-b097-50f7-a73b-7954781ee20f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Streptococcus pyogenes, infection caused by Streptococcus pneumoniae, infection caused by Hemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8280fdb-fc3e-53be-8130-526250bd2f61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31e95fe2-282c-562a-b7b2-f2077a765967", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1492, 1500], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02e88b4a-57ae-4ef6-ba48-97c657202b94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02e88b4a-57ae-4ef6-ba48-97c657202b94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02e88b4a-57ae-4ef6-ba48-97c657202b94"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36ca6a86-055d-5c30-b750-d3a162221f47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1504, 1512], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48cf8d1e-0d2b-5fe4-a6db-f3bc0557b951", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1492, 1500], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:588aad63-33bc-5b9c-8c89-e9478cd991fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1492, 1500], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22208459-3e6f-46a7-9f7f-f2c254a38132", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22208459-3e6f-46a7-9f7f-f2c254a38132", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22208459-3e6f-46a7-9f7f-f2c254a38132"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydia trachomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61e51307-0a5f-54b8-9f76-69f0977cfe98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1490, 1498], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fc6cced-b83b-523e-9a9b-7656256d280a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1495, 1503], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7762170c-dcee-567f-9216-9bc1f01de8f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1494, 1502], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a406164f-9259-54c5-aa82-4dd4a72bc0a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1539, 1547], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c522c860-84ce-4c61-ab72-077de73195df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c522c860-84ce-4c61-ab72-077de73195df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c522c860-84ce-4c61-ab72-077de73195df"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline hydrochloride tablets should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp .) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd985f1d-452e-537a-813e-8229387b5c67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1504, 1512], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydia trachomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2c7dfd8-0640-59c1-8868-08af867a58c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1490, 1498], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2f0baa9-5284-5206-aa1e-b260d78c89a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "object_location_in_text": [1494, 1502], "original_object": "trachoma", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Hemophilus ducreyi", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:175c09db-5370-52c1-8b2c-d812b46a87d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Hemophilus ducreyi", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b91e7452-096f-5c02-851a-98999865a6ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2c8ca01-7a29-5208-89d2-7ecc42995907", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["omeprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:112be0b9-19ff-5d84-8593-22e5b09509d6", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [379, 401], "original_object": "duodenal ulcer disease", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c29bfde9-5eb4-422a-bd30-4bce45e73dc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c29bfde9-5eb4-422a-bd30-4bce45e73dc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c29bfde9-5eb4-422a-bd30-4bce45e73dc0"]}], "subject": "CHEBI:27902", "supporting_text": ["1 INDICATIONS AND USAGE Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b40d31eb-af92-5274-8565-5105d4cbe076", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["omeprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [380, 394], "original_object": "duodenal ulcer", "original_subject": "TETRACYCLINE", "population_context_qualifier": "patients with active duodenal ulcer or history of duodenal ulcer disease within the past 5 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4d66e80-f0bc-4e64-a0f0-630ef673da1b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4d66e80-f0bc-4e64-a0f0-630ef673da1b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4d66e80-f0bc-4e64-a0f0-630ef673da1b"]}], "subject": "CHEBI:27902", "supporting_text": ["1 INDICATIONS AND USAGE Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules are a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidem"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850666", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f815f88a-c7c9-5d29-800c-d68d9aa36ea9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0850666"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "object": "MONDO:0005412", "object_location_in_text": [331, 345], "original_object": "duodenal ulcer", "original_subject": "TETRACYCLINE", "population_context_qualifier": "patients with active duodenal ulcer disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c809fa5-c630-4bf1-a0fc-5ee875008807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c809fa5-c630-4bf1-a0fc-5ee875008807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c809fa5-c630-4bf1-a0fc-5ee875008807"]}], "subject": "CHEBI:27902", "supporting_text": [": The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07165e16-fa50-5635-87ff-29657b7d5372", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f520010-dfc6-5ccd-be0c-50615a4030b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8aa385da-d706-5031-af54-bb2d624827b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c7b0317-70ab-533d-9bf2-6916a0247955", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7726b2b-8e3d-594e-96c4-10d51d4e37fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Brucella species", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10c586f8-330c-5863-ba98-c07048bf84ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10f38582-1f60-5157-9ff6-cd42c7de0655", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Brucella species", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1200d445-361e-5add-a354-c27f35995074", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08440f22-7aa1-59af-b751-1742ab501095", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Klebsiella granulomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:431177fe-602f-5f4a-80c0-8109fe19be67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Klebsiella granulomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5133ff6e-369e-570b-b582-24b69abc78ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3a9badd-2289-5143-9dd9-00a62d380105", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4e1afb7-9e78-5ed6-b491-652ead82d12d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:164dfae4-d6cc-54c6-ac0e-28f930b8de3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1573, 1597], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydia trachomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35def220-e071-5fc4-a9a5-f283f560cf02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1569, 1593], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b7085f0-eeb5-5a1c-bd6b-3045d766108f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1571, 1595], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8042e36d-97bd-5db0-a288-5d5f1c46ab6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1583, 1607], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:902cab29-4746-596b-8a16-e4fe3a03431c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1571, 1595], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22208459-3e6f-46a7-9f7f-f2c254a38132", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22208459-3e6f-46a7-9f7f-f2c254a38132", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22208459-3e6f-46a7-9f7f-f2c254a38132"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92e42bb9-0467-5418-8658-cd801c5e3e6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1574, 1598], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9374f82f-d5cb-5776-937c-e89e6cef207e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1583, 1607], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a88055c8-1229-510c-9d65-6f2a938b5d9b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1571, 1595], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02e88b4a-57ae-4ef6-ba48-97c657202b94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02e88b4a-57ae-4ef6-ba48-97c657202b94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02e88b4a-57ae-4ef6-ba48-97c657202b94"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdac40cc-9f2f-5f3f-9f43-504f731f77ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1618, 1642], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c522c860-84ce-4c61-ab72-077de73195df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c522c860-84ce-4c61-ab72-077de73195df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c522c860-84ce-4c61-ab72-077de73195df"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline hydrochloride tablets should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp .) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bef6b0a5-9e47-5a19-8b88-eca8fa2c3188", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1573, 1597], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydia trachomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb0fd033-6958-5436-8444-378dc1e148b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "object_location_in_text": [1569, 1593], "original_object": "inclusion conjunctivitis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:012c5d2f-52c8-582f-8f4f-ee603918b9d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1613, 1637], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27c0dde7-778e-5850-aceb-fe2eb71119db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1623, 1647], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:520e5861-fb30-5366-a2af-d459fe87a5bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1658, 1682], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c522c860-84ce-4c61-ab72-077de73195df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c522c860-84ce-4c61-ab72-077de73195df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c522c860-84ce-4c61-ab72-077de73195df"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline hydrochloride tablets should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp .) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c0291a0-a31f-50e3-9460-3111febf91b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1614, 1638], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62512f64-dab8-5f80-9258-1b41a334bc79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1613, 1637], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d4d56c4-3125-5779-90f3-a84d46bca2d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1611, 1635], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:776e0c12-c513-5578-a198-a9b1d9fa652f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1611, 1635], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22208459-3e6f-46a7-9f7f-f2c254a38132", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22208459-3e6f-46a7-9f7f-f2c254a38132", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22208459-3e6f-46a7-9f7f-f2c254a38132"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydia trachomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a884b4f8-1e69-5278-bf63-54efbe493f9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1609, 1633], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydia trachomatis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1b7c39a-71ce-5b1b-9228-04f75ae3e9f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1609, 1633], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d29f6872-afea-50ec-8a99-e060df60f5f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1611, 1635], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02e88b4a-57ae-4ef6-ba48-97c657202b94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02e88b4a-57ae-4ef6-ba48-97c657202b94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02e88b4a-57ae-4ef6-ba48-97c657202b94"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed2c5a9c-854a-5992-8c6f-f30ea169f080", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "object_location_in_text": [1623, 1647], "original_object": "lymphogranuloma venereum", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydophila psittaci", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58f146dc-2a86-581f-b4bd-52a470865de6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59f8dcbc-b83d-5009-8421-701dbe4c74d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Chlamydophila psittaci", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e600559-a6c6-557e-be77-6d73e68ae48e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbb2c6d3-c16f-520f-9ec1-8e1e93223a7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9a1479b-7bf4-5f70-bb28-ddd51b5bbde1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Vibrio cholerae", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fe46d8f-98be-5614-b8de-48192a199a52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dfd592bc-68ae-5d50-9f17-71c38fe4f483", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0015766", "original_object": "cholera", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Vibrio cholerae", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:996bf8cd-6189-539b-b703-cf7027a03d40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dfd592bc-68ae-5d50-9f17-71c38fe4f483", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0015766", "original_object": "cholera", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Francisella tularensis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12286ad6-8333-5dc9-94e6-8792ba32bb19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Francisella tularensis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bcd9d81-8f41-5088-8b6f-e4899afe80cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Yersinia pestis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a23694cf-ef23-5ad9-9fdd-8a6382f2dbeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Yersinia pestis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f25ad54b-6542-5f22-a73b-44096e05bbb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by rickettsia", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d250484-6a62-5e25-85a4-636e1041faa7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c8a6294c-9f40-5f36-a7eb-924275c9d2f6", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019186", "object_location_in_text": [1388, 1395], "original_object": "Q fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035583", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30f77581-ff84-502e-a90b-62b8ad704f45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0035583"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c8a6294c-9f40-5f36-a7eb-924275c9d2f6", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019186", "object_location_in_text": [1397, 1404], "original_object": "Q fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by rickettsia", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59e5caec-29fc-5c52-83b7-a81de7eca4bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c8a6294c-9f40-5f36-a7eb-924275c9d2f6", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019186", "object_location_in_text": [1388, 1395], "original_object": "Q fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035583", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8442ae23-818c-5ffc-8729-bdd8543ede42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0035583"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c8a6294c-9f40-5f36-a7eb-924275c9d2f6", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019186", "object_location_in_text": [1397, 1404], "original_object": "Q fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by rickettsia", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12adb9f5-1f0c-5cb8-a160-b5c9f92393e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0c31023-890a-55fb-9308-e64f927f647b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019359", "object_location_in_text": [1333, 1361], "original_object": "Rocky Mountain spotted fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035583", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27625f8b-fe98-5a2f-819a-4516e4bdd36e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0035583"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0c31023-890a-55fb-9308-e64f927f647b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019359", "object_location_in_text": [1342, 1370], "original_object": "Rocky Mountain spotted fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by rickettsia", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ca7ff9f-71e0-5633-867d-dff93f89290c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0c31023-890a-55fb-9308-e64f927f647b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019359", "object_location_in_text": [1333, 1361], "original_object": "Rocky Mountain spotted fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035583", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7467ea8b-c8d0-55f1-9ea0-0b50dbaee4e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0035583"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0c31023-890a-55fb-9308-e64f927f647b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019359", "object_location_in_text": [1342, 1370], "original_object": "Rocky Mountain spotted fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035583", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:037f0adc-40fc-5255-a70a-c0646ba6155f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0035583"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484cf33-310d-52a0-b017-d281c7bb2944", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019360", "object_location_in_text": [1406, 1420], "original_object": "rickettsialpox", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by rickettsia", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7669003e-a6aa-5e6b-b124-f27f47999a07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484cf33-310d-52a0-b017-d281c7bb2944", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019360", "object_location_in_text": [1397, 1411], "original_object": "rickettsialpox", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035583", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5600abe-1459-5c19-872f-c524f664bfb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0035583"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484cf33-310d-52a0-b017-d281c7bb2944", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019360", "object_location_in_text": [1406, 1420], "original_object": "rickettsialpox", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by rickettsia", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dcb84ed8-8e19-550c-bc5e-a21509f56971", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484cf33-310d-52a0-b017-d281c7bb2944", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019360", "object_location_in_text": [1397, 1411], "original_object": "rickettsialpox", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Borrelia sp.", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3044055-ce97-50fb-acb2-8f0f05535612", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c9208db-5f4f-4382-854f-6786b1e458db"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infection caused by Borrelia sp.", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7b5f6d7-7d8e-52d0-b82d-7e92f0321d27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e4b5b3-e093-46e7-b28e-a2c4821c5b63"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi. Tularemia caused by Francisella tularensis. Plaque caused by Yersinia pestis. Cholera caused by Vibrio cholerae. Brucellosis caused by Brucella species (tetracycline may be used "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ad928e3-f71a-54b6-a513-f29fd7ae0fd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014321", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95bc20af-038e-5b2c-b9ab-fc9948c26af0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dde6732-a7a7-5fb3-95b5-08fd36adc396", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014323", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e58335fd-e907-58c7-9e9b-3d8d8967a030", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014323"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccd30048-a226-455f-971b-5dbf14b22e9d"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014323", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fde3c180-3b48-5dc9-9445-d02294e8f7b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014323"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d48071a0-c397-42f8-b8ad-158282e745e3"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: • Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. • Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) • Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) • Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. • Psittacosis caused by Chlamydophila psittaci . • Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. • Granuloma inquinale caused by Klebsiella granulomatis . • Relapsing fever caused by Borrelia sp . • Bartonellosis caused by Bartonella bacilliformis . • Chancroid caused by Hemophilus ducreyi . • Tularemia caused by Francisella tularensis . • Plaque caused by Yersinia pestis . • Cholera caused by Vibrio cholerae . • Brucellosis caused by Brucella "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d29da57-88fe-5bfe-8779-a43928191f44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1f8bbcc0-ce1c-584f-9a5a-f6ca27d209a2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "skin and soft tissue infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32a409a0-fea6-411a-8218-c1c7df46d664"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ). Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp . Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:899a200b-6d37-5766-85a3-6b28c17d541d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1f8bbcc0-ce1c-584f-9a5a-f6ca27d209a2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "skin and soft tissue infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b504e612-5aef-47fa-8f7b-dfb754011b9f"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94dc7a18-f1ef-54f0-a636-f1d93b12e21b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1f8bbcc0-ce1c-584f-9a5a-f6ca27d209a2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0cd3efba-4c1c-50a9-b3a9-37de377c56ff", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "skin and soft tissue infections", "original_subject": "TETRACYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae29aa18-6efb-47c9-bbd7-cbe8af1b7f38"]}], "subject": "CHEBI:27902", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:485d7356-b003-5dd1-bef3-4cbd11b0883a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ed957e52-4167-5f6b-a754-f715601f31d8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5416f474-8b64-5fc5-9da1-d0985396223f", "object": "HP:0100806", "object_location_in_text": [65, 71], "original_object": "sepsis", "original_subject": "VANCOMYCIN HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VANCOMYCIN HYDROCHLORIDE#116-20140523", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28001", "supporting_text": ["A drug with new additional indications for the treatment of: (1) sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or (2) febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ee9b46c-a78e-59d7-a1e9-7d13cacb06df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:5697556d-666c-5105-89a4-80ff6e86f625", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5416f474-8b64-5fc5-9da1-d0985396223f", "object": "MONDO:0000565", "object_location_in_text": [73, 95], "original_object": "infective endocarditis", "original_subject": "VANCOMYCIN HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VANCOMYCIN HYDROCHLORIDE#116-20140523", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28001", "supporting_text": ["A drug with new additional indications for the treatment of: (1) sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or (2) febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "C. difficile infection", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:580205d9-3669-5413-8175-872e1f5b63ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:28fe3c01-cf87-41c0-87fd-f93a40524335", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=28fe3c01-cf87-41c0-87fd-f93a40524335", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28fe3c01-cf87-41c0-87fd-f93a40524335"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin Hydrochloride for Oral Solution is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile . Parenteral administration of vancomycin is not effective for the above indications; therefore, Vancomycin Hydrochloride for Oral Solution must be given orally for these infections. Orally administered Vancomycin Hydrochloride for Oral Solution is not effective for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Oral Solution and other antibacterial drugs, Vancomycin Hydrochloride for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "C. difficile infection", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb0b623f-d118-5ecd-a589-49962fc02910", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c47d5c4-8cdb-4701-8d7a-8a6e79025b53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c47d5c4-8cdb-4701-8d7a-8a6e79025b53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c47d5c4-8cdb-4701-8d7a-8a6e79025b53"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin Hydrochloride for Oral Solution is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile . Parenteral administration of vancomycin is not effective for the above indications; therefore, Vancomycin Hydrochloride for Oral Solution must be given orally for these infections. Orally administered Vancomycin Hydrochloride for Oral Solution is not effective for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Oral Solution and other antibacterial drugs, Vancomycin Hydrochloride for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "enterococci", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2af782cc-922c-5bfd-85c1-0a4bc229298f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [792, 804], "original_object": "endocarditis", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride for injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride for injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride for injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin has been reported to be effective only in combination with an aminoglycoside. Vancomycin hydrochloride for injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin hydrochloride for injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "enterococci", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8650b5cc-2a3c-5659-a7b7-b0ec5ae89b55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [792, 804], "original_object": "endocarditis", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b01aaa02-8f1d-4b57-96a5-337503428af1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b01aaa02-8f1d-4b57-96a5-337503428af1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b01aaa02-8f1d-4b57-96a5-337503428af1"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride for injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride for injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride for injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin has been reported to be effective only in combination with an aminoglycoside. Vancomycin hydrochloride for injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin hydrochloride for injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1a7778b-2bb4-509d-bb98-3d0da279df0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:0d4c9b27-da45-5002-812e-f896628eddc2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5416f474-8b64-5fc5-9da1-d0985396223f", "object": "MONDO:0005246", "object_location_in_text": [153, 166], "original_object": "osteomyelitis", "original_subject": "VANCOMYCIN HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VANCOMYCIN HYDROCHLORIDE#116-20140523", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28001", "supporting_text": ["A drug with new additional indications for the treatment of: (1) sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or (2) febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c933d86e-e423-520c-bf55-dea67886254f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:247045da-2eee-5588-96e8-0b2dec379881", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5416f474-8b64-5fc5-9da1-d0985396223f", "object": "MONDO:0005578", "object_location_in_text": [168, 177], "original_object": "arthritis", "original_subject": "VANCOMYCIN HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VANCOMYCIN HYDROCHLORIDE#116-20140523", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28001", "supporting_text": ["A drug with new additional indications for the treatment of: (1) sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or (2) febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6c45957-9efb-5faf-94cd-a46ad0c44d33", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5416f474-8b64-5fc5-9da1-d0985396223f", "object": "MONDO:1010128", "object_location_in_text": [179, 190], "original_object": "peritonitis", "original_subject": "VANCOMYCIN HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VANCOMYCIN HYDROCHLORIDE#116-20140523", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28001", "supporting_text": ["A drug with new additional indications for the treatment of: (1) sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or (2) febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0075176", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0455208e-9f5c-57b9-9cc0-c33b55028c58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0075176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e092e2-125a-513c-823d-f84f12aa5fdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "medic_supporting_text_truncated": true, "object": "UMLS:C0152965", "original_object": "staphylococcal septicemia", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride for injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride for injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride for injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin has been reported to be effective only in combination with an aminoglycoside. Vancomycin hydrochloride for injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin hydrochloride for injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0075176", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44e832ec-0ac8-56b5-98e2-654f3fc43922", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0075176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e092e2-125a-513c-823d-f84f12aa5fdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "medic_supporting_text_truncated": true, "object": "UMLS:C0152965", "original_object": "staphylococcal septicemia", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06dcfd36-942f-4752-86ad-4c5a6fc3e48f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06dcfd36-942f-4752-86ad-4c5a6fc3e48f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06dcfd36-942f-4752-86ad-4c5a6fc3e48f"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin Hydrochloride for Injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin Hydrochloride for Injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin Hydrochloride for Injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin Hydrochloride for Injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), Vancomycin Hydrochloride for Injection, USP has been reported to be effective only in combination with an aminoglycoside. Vancomycin Hydrochloride for Injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin Hydrochloride for Injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin hydroc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0075176", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6f2c426-3c0b-58c7-9157-a87e94b2bbda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0075176"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59e092e2-125a-513c-823d-f84f12aa5fdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3b2aa1-7a86-5f39-9d0f-306c6152906f", "medic_supporting_text_truncated": true, "object": "UMLS:C0152965", "original_object": "staphylococcal septicemia", "original_subject": "VANCOMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b01aaa02-8f1d-4b57-96a5-337503428af1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b01aaa02-8f1d-4b57-96a5-337503428af1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b01aaa02-8f1d-4b57-96a5-337503428af1"]}], "subject": "CHEBI:28001", "supporting_text": ["Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride for injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride for injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride for injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin has been reported to be effective only in combination with an aminoglycoside. Vancomycin hydrochloride for injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin hydrochloride for injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "interstitial cystitis (Hunner type)", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5325c062-acef-5a7e-96c1-e87711483dec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210122", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:00af12b5-7bd0-5f3f-8ce1-7681448f3243", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:443b3588-5d89-5fa1-b0ad-5f11f37e4445", "object": "UMLS:C0404484", "object_location_in_text": [79, 98], "original_object": "chronic pelvic pain", "original_subject": "DIMETHYL SULFOXIDE", "population_context_qualifier": "patients with interstitial cystitis (Hunner type)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DIMETHYL SULFOXIDE#57-20210122", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28262", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of symptoms (chronic pelvic pain, pressure and discomfort perceived to be related to the urinary bladder; lower urinary tract symptoms such as persistent urge to void and urinary frequency) in patients with interstitial cystitis (Hunner type)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "interstitial cystitis (Hunner type)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87c91b11-ddda-57ec-ba0b-2ee01fb7e0a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210122", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2e9eedd0-9375-5050-a199-a439e579b493", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:443b3588-5d89-5fa1-b0ad-5f11f37e4445", "object": "UMLS:C0574785", "original_object": "lower urinary tract symptoms", "original_subject": "DIMETHYL SULFOXIDE", "population_context_qualifier": "patients with interstitial cystitis (Hunner type)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DIMETHYL SULFOXIDE#57-20210122", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28262", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of symptoms (chronic pelvic pain, pressure and discomfort perceived to be related to the urinary bladder; lower urinary tract symptoms such as persistent urge to void and urinary frequency) in patients with interstitial cystitis (Hunner type)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0264714", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b44943fc-4031-5759-9577-5fb7ccbbe74a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160915", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0264714", "MONDO:0001208", "UMLS:C5139167"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:277448d8-f6d7-591b-b763-c1248c4d5c18", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:485508bd-4f36-564d-b6c4-1f342438cc3e", "object": "MONDO:0005399", "object_location_in_text": [52, 74], "original_object": "venous thromboembolism", "original_subject": "enoxaparin sodium", "population_context_qualifier": "adults bedridden due to acute illnesses", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:inhixa", "https://www.ema.europa.eu/en/documents/product-information/inhixa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa"]}], "subject": "CHEBI:28304", "supporting_text": ["Inhixa is indicated for adults for:  Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery. Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL). Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism. Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA). Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL). Blood clot prevention in the extracorporeal circulation during haemodialysis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e632e30-41fc-59b4-aa47-e3c57a1f4c9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [438, 476], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef309d83-7262-4874-8580-f4ca254f963a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef309d83-7262-4874-8580-f4ca254f963a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef309d83-7262-4874-8580-f4ca254f963a"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures Heparin Sodium Injection is an anticoagulant indicated for ( 1 ) Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36efff69-fbd2-57c0-b4c4-3bcfeb967c93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8c4edd2-ee9e-4558-6b8c-b83adc242a0a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8c4edd2-ee9e-4558-6b8c-b83adc242a0a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8c4edd2-ee9e-4558-6b8c-b83adc242a0a"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism; • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin Sodium Injection is an anticoagulant indicated for ( 1 ): • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:490ddf16-5c1b-5a3f-962a-80952007ca83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:62cfd1bb-894f-4429-b362-1e40981dccc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=62cfd1bb-894f-4429-b362-1e40981dccc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=62cfd1bb-894f-4429-b362-1e40981dccc6"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism. • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM INJECTION is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5670b0ac-1843-5271-ab18-5960a66768f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9cd7abe6-3923-4007-8491-273ef6e05ad7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9cd7abe6-3923-4007-8491-273ef6e05ad7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9cd7abe6-3923-4007-8491-273ef6e05ad7"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism; • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin Sodium Injection is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76e9171c-38da-5ed1-b9ba-5d9075647c5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f67eea4e-80ff-48da-8b04-8addc5cd31d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f67eea4e-80ff-48da-8b04-8addc5cd31d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f67eea4e-80ff-48da-8b04-8addc5cd31d1"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism. • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM INJECTION is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e5e7856-548f-5a36-b8e9-355904121d2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [446, 484], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:301b19bc-21c2-4a35-9d29-569b08d855c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=301b19bc-21c2-4a35-9d29-569b08d855c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=301b19bc-21c2-4a35-9d29-569b08d855c4"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures Heparin Sodium Injection is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:affc2df3-c7f1-59a0-9358-5151337dc975", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [438, 476], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ebe4b4d-cb28-47e8-9598-6105d250b3d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ebe4b4d-cb28-47e8-9598-6105d250b3d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ebe4b4d-cb28-47e8-9598-6105d250b3d2"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures Heparin Sodium Injection is an anticoagulant indicated for ( 1 ) Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2d1fff1-02b6-5e3f-ad6d-596302c7db8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism. • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM INJECTION is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd82ba7f-930a-5b99-8a26-4f35faf981c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [446, 484], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0cc5f44-9a67-4274-a48a-d6118e96d391", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0cc5f44-9a67-4274-a48a-d6118e96d391", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0cc5f44-9a67-4274-a48a-d6118e96d391"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures Heparin Sodium Injection is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfcee346-fafc-5b46-ae53-b36172338c45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [438, 476], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45dc6b8b-ed5d-40a2-8d9c-084c863ae93a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45dc6b8b-ed5d-40a2-8d9c-084c863ae93a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45dc6b8b-ed5d-40a2-8d9c-084c863ae93a"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures Heparin Sodium Injection is an anticoagulant indicated for (1) Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease Atrial fibrillation with embolization Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e145ebc3-7304-5053-b065-3c50c9ff5073", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ea0a519-dc7c-42e3-939e-2a7c80eedd25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ea0a519-dc7c-42e3-939e-2a7c80eedd25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ea0a519-dc7c-42e3-939e-2a7c80eedd25"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism; • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin Sodium Injection is an anticoagulant indicated for ( 1 ): • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute and chronic consumptive coagulopathies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2fc2573-940e-5b41-ba0f-735eb4b36018", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67547a6c-9045-503c-b8c4-bbc8f6804e4f", "object": "MONDO:0001243", "object_location_in_text": [449, 487], "original_object": "disseminated intravascular coagulation", "original_subject": "HEPARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:239b4816-6a55-451b-bf40-e611be07d12f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=239b4816-6a55-451b-bf40-e611be07d12f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=239b4816-6a55-451b-bf40-e611be07d12f"]}], "subject": "CHEBI:28304", "supporting_text": ["1 INDICATIONS AND USAGE Heparin Sodium Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; • Atrial fibrillation with embolization; • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism. • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM INJECTION is an anticoagulant indicated for ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease • Atrial fibrillation with embolization • Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cardiac rhythm dependent upon a junctional or idioventricular pacemaker", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51fee842-b5f6-5bff-82fa-066dbe6fe432", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985dae6-b6d5-5766-a1b3-df9fbe34ee59", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "object": "MONDO:0000468", "object_location_in_text": [379, 410], "original_object": "complete atrioventricular block", "original_subject": "QUINIDINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC"]}], "subject": "CHEBI:28593", "supporting_text": ["Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine. In the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block. Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cardiac rhythm dependent upon a junctional or idioventricular pacemaker", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e884650-9a3a-5bb7-ba1a-97a2d60c5154", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985dae6-b6d5-5766-a1b3-df9fbe34ee59", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "object": "MONDO:0000468", "object_location_in_text": [379, 410], "original_object": "complete atrioventricular block", "original_subject": "QUINIDINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0d6341b-d880-4f0b-8844-bc788c03004a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0d6341b-d880-4f0b-8844-bc788c03004a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0d6341b-d880-4f0b-8844-bc788c03004a"]}], "subject": "CHEBI:28593", "supporting_text": ["Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine. In the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block. Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cardiac rhythm dependent upon a junctional or idioventricular pacemaker", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c99a98ac-f4ce-5114-a2c0-0d12308ef0a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985dae6-b6d5-5766-a1b3-df9fbe34ee59", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "object": "MONDO:0000468", "object_location_in_text": [379, 410], "original_object": "complete atrioventricular block", "original_subject": "QUINIDINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02a34403-3cb9-4de7-8c40-9da281a8e5e1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02a34403-3cb9-4de7-8c40-9da281a8e5e1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02a34403-3cb9-4de7-8c40-9da281a8e5e1"]}], "subject": "CHEBI:28593", "supporting_text": ["Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine. In the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block. Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64f7d60a-caba-5897-9a2f-d4ab48b08fcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "medic_supporting_text_truncated": true, "object": "HP:0004308", "object_location_in_text": [1448, 1471], "original_object": "ventricular arrhythmias", "original_subject": "QUINIDINE", "population_context_qualifier": "patients with recurrent documented ventricular arrhythmias that in the judgment of the physician are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5023f053-fcc4-4c2c-aa59-9ec198ad185e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5023f053-fcc4-4c2c-aa59-9ec198ad185e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5023f053-fcc4-4c2c-aa59-9ec198ad185e"]}], "subject": "CHEBI:28593", "supporting_text": ["Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see DOSAGE AND ADMINISTRATION ), then quinidine gluconate should be discontinued. Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. The increased risk of death should specifically be considered. Quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure. Suppression of ventricular arrhythmias Quinidine gluconate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical st"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b54bebc1-c934-5fe1-8f65-c765bef7d5c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "medic_supporting_text_truncated": true, "object": "HP:0004308", "original_object": "ventricular arrhythmias", "original_subject": "QUINIDINE", "population_context_qualifier": "patients in the judgment of the physician are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=A08A0F0B-6CF5-4FA4-A861-0B054D6FDDFC"]}], "subject": "CHEBI:28593", "supporting_text": ["Conversion of Atrial Fibrillation/ Flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see DOSAGE AND ADMINISTRATION ), then quinidine gluconate should be discontinued. Reduction of Frequency of Relapse into Atrial Fibrillation/Flutter Chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. The increased risk of death should specifically be considered. Quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure. Suppression of Ventricular Arrhythmias Quinidine gluconate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0476669-3cea-5771-acd1-00b6f93f0e10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "medic_supporting_text_truncated": true, "object": "HP:0004308", "object_location_in_text": [1448, 1471], "original_object": "ventricular arrhythmias", "original_subject": "QUINIDINE", "population_context_qualifier": "patients with recurrent documented ventricular arrhythmias that in the judgment of the physician are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3af30c3b-944e-4293-baa5-38965b1d1137", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3af30c3b-944e-4293-baa5-38965b1d1137", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3af30c3b-944e-4293-baa5-38965b1d1137"]}], "subject": "CHEBI:28593", "supporting_text": ["Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see DOSAGE AND ADMINISTRATION ), then quinidine gluconate should be discontinued. Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. The increased risk of death should specifically be considered. Quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure. Suppression of ventricular arrhythmias Quinidine gluconate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical st"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed0f1335-93f6-5ee1-8a48-f922882f83c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "medic_supporting_text_truncated": true, "object": "HP:0004308", "object_location_in_text": [1448, 1471], "original_object": "ventricular arrhythmias", "original_subject": "QUINIDINE", "population_context_qualifier": "patients with recurrent documented ventricular arrhythmias that in the judgment of the physician are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad2ad985-cca2-25b5-e053-2995a90a402f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad2ad985-cca2-25b5-e053-2995a90a402f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad2ad985-cca2-25b5-e053-2995a90a402f"]}], "subject": "CHEBI:28593", "supporting_text": ["Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see DOSAGE AND ADMINISTRATION ), then quinidine gluconate should be discontinued. Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. The increased risk of death should specifically be considered. Quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure. Suppression of ventricular arrhythmias Quinidine gluconate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical st"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032150", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:019bc2ce-f901-5b47-96fc-f8ce0429864f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25488a10-45ff-5e94-8a8e-42e576f8abc4", "medic_supporting_text_truncated": true, "object": "MONDO:0005136", "original_object": "malaria", "original_subject": "QUINIDINE", "population_context_qualifier": "patients with life-threatening malaria", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02a34403-3cb9-4de7-8c40-9da281a8e5e1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02a34403-3cb9-4de7-8c40-9da281a8e5e1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02a34403-3cb9-4de7-8c40-9da281a8e5e1"]}], "subject": "CHEBI:28593", "supporting_text": ["Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see ), then quinidine sulfate should be discontinued. DOSAGE AND ADMINISTRATION Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. The increased risk of death should specifically be considered. Quinidine sulfate should be used only after alternative measures ( use of other drugs to control the ventricular rate) have been found to be inadequate. e.g., In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia during therapy, and a single recurrence should not be interpreted as therapeutic failure. will recur Suppression of ventricular arrhythmias Quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical stimulation and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38b4b1af-f2fa-57cb-aa8b-46feda6ac67d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47be2dbf-6577-56de-8f1a-c3539145ef72", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "MOLYBDENUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:28685", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvar and vaginal atrophy", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad28df7e-013a-581e-92c7-a0afced110cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20161116", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4468bcb9-0b2c-5f45-b010-bfbd72173d88", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae6010ee-b9fe-55bf-bde6-3b2c8ba0df09", "object": "HP:0030016", "original_object": "dyspareunia", "original_subject": "PRASTERONE", "population_context_qualifier": "due to menopause", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ada639d4-bac0-2ad0-e053-2a95a90afce7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ada639d4-bac0-2ad0-e053-2a95a90afce7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ada639d4-bac0-2ad0-e053-2a95a90afce7"]}], "subject": "CHEBI:28689", "supporting_text": ["1 INDICATIONS AND USAGE INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e7292c7-834a-5459-9710-464db327ec29", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d928625e-c1ef-4f25-8d25-764c8c6aab67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d928625e-c1ef-4f25-8d25-764c8c6aab67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d928625e-c1ef-4f25-8d25-764c8c6aab67"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin hydrochloride for injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer Doxorubicin hydrochloride for injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin hydrochloride for injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b104be7-0fd8-5a18-bff3-77a18ab1a1bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33ddfdb1-b4bc-464d-a186-49c4b156279f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33ddfdb1-b4bc-464d-a186-49c4b156279f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33ddfdb1-b4bc-464d-a186-49c4b156279f"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6cccb1bb-080c-525e-9ce3-543cb6225492", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74b14803-afc8-4a2e-ba92-43f1a72025eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74b14803-afc8-4a2e-ba92-43f1a72025eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74b14803-afc8-4a2e-ba92-43f1a72025eb"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: •as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). •for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor,metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:812da73b-b309-520b-b600-f6fe3340821b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f62aa88d-1e25-4049-87ec-99d42edd1d31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f62aa88d-1e25-4049-87ec-99d42edd1d31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f62aa88d-1e25-4049-87ec-99d42edd1d31"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1) . for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2) . 1.1 Adjuvant Breast Cancer DOXOrubicin HCl for Injection, USP is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see Clinical Studies (14.1 )]. 1.2 Other Cancers Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97ea9750-bf5e-5257-8280-540c9160a2cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae80bd3a-b99a-4e01-a444-b9d05687f00e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae80bd3a-b99a-4e01-a444-b9d05687f00e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae80bd3a-b99a-4e01-a444-b9d05687f00e"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms' tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af8f1685-495f-558a-8e4c-ad2581e63cf0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1fd148fb-0fbc-4b6f-b790-23546fb46a71", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:baed2e4f-8697-58b6-9067-621833674799", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d31d7f58-66d0-4826-b6b5-5914c031965f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d31d7f58-66d0-4826-b6b5-5914c031965f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d31d7f58-66d0-4826-b6b5-5914c031965f"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ) • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of • acute lymphoblastic leukemia • acute myeloblastic leukemia • Hodgkin lymphoma • non-Hodgkin lymphoma (NHL) • metastatic breast cancer • metastatic Wilms' tumor • metastatic neuroblastoma • metastatic soft tissue sarcoma • metastatic bone sarcoma • metastatic ovarian carcinoma • metastatic transitional cell bladder carcinoma • metastatic thyroid carcinoma • metastatic gastric carcinoma • metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2a5aff0-dff3-5333-8dc1-96cb25e18f97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36924f82-6c05-4989-9f41-a398c0ad48e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36924f82-6c05-4989-9f41-a398c0ad48e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36924f82-6c05-4989-9f41-a398c0ad48e6"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer DOXOrubicin HCl Injection, USP is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see Clinical Studies (14.1 )]. 1.2 Other Cancers Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741343", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d84bf211-15e2-51fb-bc7c-43a3a39d6b85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "DOXORUBICIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:971de64b-ff09-4370-afd9-6eb1093ad27d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=971de64b-ff09-4370-afd9-6eb1093ad27d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=971de64b-ff09-4370-afd9-6eb1093ad27d"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). 1.1 Adjuvant Breast Cancer DOXOrubicin HCl Injection, USP is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see Clinical Studies (14.1 )]. 1.2 Other Cancers Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms’ tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma"], "temporal_context_qualifier": "following resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "platinum-based cancer medicine resistance", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72586439-fa1d-554c-9799-edfb9c28d903", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0008170", "object_location_in_text": [266, 289], "original_object": "advanced ovarian cancer", "original_subject": "doxorubicin", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zolsketil-pegylated-liposomal", "https://www.ema.europa.eu/en/documents/product-information/zolsketil-pegylated-liposomal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zolsketil-pegylated-liposomal"]}], "subject": "CHEBI:28748", "supporting_text": ["Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults: • breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease; • advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working; • multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine); • Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "platinum-based chemotherapy resistance", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb81df1e-244f-51b0-a48b-3db7c851b23e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a5103bd9-473f-5ff8-b0fb-a898cb7f4d48", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0008170", "object_location_in_text": [165, 188], "original_object": "advanced ovarian cancer", "original_subject": "doxorubicin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:caelyx-pegylated-liposomal", "https://www.ema.europa.eu/en/documents/product-information/caelyx-pegylated-liposomal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/caelyx-pegylated-liposomal"]}], "subject": "CHEBI:28748", "supporting_text": ["Caelyx&nbsp;pegylated liposomal is indicated:  as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk; for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen; in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant; for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (&lt;200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.  Caelyx pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standarddoxorubicin (or other anthracycline)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based chemotherapy failure", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b012521e-ebaa-5881-a59f-0f1d9b619f22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:151af2de-1718-5c6b-97d3-0c791bffb052", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0008170", "object_location_in_text": [585, 599], "original_object": "ovarian cancer", "original_subject": "DOXORUBICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55889588-c5f1-d9bc-e063-6294a90a5791", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55889588-c5f1-d9bc-e063-6294a90a5791", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55889588-c5f1-d9bc-e063-6294a90a5791"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer : After failure of platinum-based chemotherapy ( 1.1 ) AIDS-related Kaposi’s Sarcoma : After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) Multiple Myeloma : In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi’s Sarcoma Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. 1.3 Multiple Myeloma Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy."], "temporal_context_qualifier": "after progression or recurrence following platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based chemotherapy failure", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7d4fdb5-17a7-5acd-a3c5-e4206b598bad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:151af2de-1718-5c6b-97d3-0c791bffb052", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0008170", "object_location_in_text": [585, 599], "original_object": "ovarian cancer", "original_subject": "DOXORUBICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9cb8a8d-944f-4fe1-bfba-c55904a79fda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9cb8a8d-944f-4fe1-bfba-c55904a79fda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9cb8a8d-944f-4fe1-bfba-c55904a79fda"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer : After failure of platinum-based chemotherapy ( 1.1 ) AIDS-related Kaposi’s Sarcoma : After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) Multiple Myeloma : In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi’s Sarcoma Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. 1.3 Multiple Myeloma Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy."], "temporal_context_qualifier": "after progression or recurrence following platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-based chemotherapy failure", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eef51fb1-7805-51af-8c64-eab757c8b5b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:151af2de-1718-5c6b-97d3-0c791bffb052", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "MONDO:0008170", "object_location_in_text": [585, 599], "original_object": "ovarian cancer", "original_subject": "DOXORUBICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0885dddf-727e-4692-92dd-a26c69cc278d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0885dddf-727e-4692-92dd-a26c69cc278d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0885dddf-727e-4692-92dd-a26c69cc278d"]}], "subject": "CHEBI:28748", "supporting_text": ["1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer : After failure of platinum-based chemotherapy ( 1.1 ) AIDS-related Kaposi’s Sarcoma : After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) Multiple Myeloma : In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi’s Sarcoma Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. 1.3 Multiple Myeloma Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy."], "temporal_context_qualifier": "after progression or recurrence following platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1441e9b-352d-5cd0-92cc-0274e3d1eb3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960620", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:934e2d1c-9bca-57c0-8795-ffcfe3df26b9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fbacd63b-11f5-5b64-87a6-05978e73be68", "object": "UMLS:C0276535", "original_object": "AIDS-related Kaposi's sarcoma", "original_subject": "doxorubicin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:caelyx-pegylated-liposomal", "https://www.ema.europa.eu/en/documents/product-information/caelyx-pegylated-liposomal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/caelyx-pegylated-liposomal"]}], "subject": "CHEBI:28748", "supporting_text": ["Caelyx&nbsp;pegylated liposomal is indicated:  as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk; for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen; in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant; for treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (&lt;200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.  Caelyx pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standarddoxorubicin (or other anthracycline)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3922ae4f-a2d7-5ba0-b4d0-54a42193eccc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c4ed615-8633-5a97-bfe2-2f215429618c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "HP:0001342", "original_object": "Cerebral hemorrhage", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89da40c1-bab1-422e-b326-8ebcbdbc81f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89da40c1-bab1-422e-b326-8ebcbdbc81f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89da40c1-bab1-422e-b326-8ebcbdbc81f3"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58aec768-71be-5b24-95f2-026900413a72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c4ed615-8633-5a97-bfe2-2f215429618c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "HP:0001342", "original_object": "Cerebral hemorrhage", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:594b939f-d399-835e-e063-6294a90a4422", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=594b939f-d399-835e-e063-6294a90a4422", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=594b939f-d399-835e-e063-6294a90a4422"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e70ee0d-37fc-5474-88e3-b08e585f28cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c4ed615-8633-5a97-bfe2-2f215429618c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "HP:0001342", "original_object": "Cerebral hemorrhage", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b150cd2-fac8-86ce-e063-6294a90a67b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b150cd2-fac8-86ce-e063-6294a90a67b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b150cd2-fac8-86ce-e063-6294a90a67b9"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:931b13c8-e3c4-529f-a243-3f8c277dce1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c4ed615-8633-5a97-bfe2-2f215429618c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "HP:0001342", "original_object": "Cerebral hemorrhage", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dbd638f-35b6-366c-e063-6294a90a5c5e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dbd638f-35b6-366c-e063-6294a90a5c5e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dbd638f-35b6-366c-e063-6294a90a5c5e"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74f992c8-7067-5f33-a889-9531d93ead7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbde325f-0663-5123-8349-27f7b3060bf8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "UMLS:C0876926", "original_object": "Traumatic brain injury", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:594b939f-d399-835e-e063-6294a90a4422", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=594b939f-d399-835e-e063-6294a90a4422", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=594b939f-d399-835e-e063-6294a90a4422"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a10843f4-2269-50f8-ba0d-1d28719f7d69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbde325f-0663-5123-8349-27f7b3060bf8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "UMLS:C0876926", "original_object": "Traumatic brain injury", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dbd638f-35b6-366c-e063-6294a90a5c5e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dbd638f-35b6-366c-e063-6294a90a5c5e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dbd638f-35b6-366c-e063-6294a90a5c5e"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab56ed21-8c25-5fee-941b-7d07f3a886bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbde325f-0663-5123-8349-27f7b3060bf8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "UMLS:C0876926", "original_object": "Traumatic brain injury", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89da40c1-bab1-422e-b326-8ebcbdbc81f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89da40c1-bab1-422e-b326-8ebcbdbc81f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89da40c1-bab1-422e-b326-8ebcbdbc81f3"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002516", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c829d079-5cfa-59db-9760-272b72b81cbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002516"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbde325f-0663-5123-8349-27f7b3060bf8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "UMLS:C0876926", "original_object": "Traumatic brain injury", "original_subject": "NITROGLYCERIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b150cd2-fac8-86ce-e063-6294a90a67b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b150cd2-fac8-86ce-e063-6294a90a67b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b150cd2-fac8-86ce-e063-6294a90a67b9"]}], "subject": "CHEBI:28787", "supporting_text": ["4 CONTRAINDICATIONS Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) Severe anemia (4.2) Increased intracranial pressure (4.3) Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) Circulatory failure and shock (4.5) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0349071", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afbffc69-9ece-5f15-af41-826186d67574", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0349071"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "HP:0012531", "original_object": "pain", "original_subject": "NITROGLYCERIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:603aa9ed-54c4-4a35-ade4-690fa44850e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4"]}], "subject": "CHEBI:28787", "supporting_text": ["1 INDICATIONS AND USAGE RECTIV ® (nitroglycerin) Ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. RECTIV is a nitrate vasodilator indicated for the treatment of moderate to severe pain associated with chronic anal fissure ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0349071", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:313d603c-7a86-560f-b4d2-342c9c2bac3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0349071"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1ac0ba7-49d1-557c-9f28-ef78cc6f2b9f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6d9cbff5-dc9c-573f-8af5-b3b893ffefa0", "object": "UMLS:C0349071", "object_location_in_text": [137, 157], "original_object": "chronic anal fissure", "original_subject": "NITROGLYCERIN", "population_context_qualifier": "patients with moderate to severe pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:603aa9ed-54c4-4a35-ade4-690fa44850e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4"]}], "subject": "CHEBI:28787", "supporting_text": ["1 INDICATIONS AND USAGE RECTIV ® (nitroglycerin) Ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. RECTIV is a nitrate vasodilator indicated for the treatment of moderate to severe pain associated with chronic anal fissure ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf5c9e69-8082-566f-a28f-05289cb8adc9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "HP:0000969", "object_location_in_text": [511, 516], "original_object": "edema", "original_subject": "TOBRAMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae"]}], "subject": "CHEBI:28864", "supporting_text": [": Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31369cdd-6364-5c28-98c5-4bc429bfb0fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "UMLS:C0021368", "object_location_in_text": [521, 533], "original_object": "inflammation", "original_subject": "TOBRAMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae"]}], "subject": "CHEBI:28864", "supporting_text": [": Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2a4d1dc-68f4-5d01-8dda-4c088b82ee42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "HP:0002586", "original_object": "Peritonitis", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole- negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram- negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate ma"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d9dbbcd-4588-5dbc-ba20-4f65d7bd8ec1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "HP:0002783", "object_location_in_text": [265, 299], "original_object": "Lower respiratory tract infections", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole- negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram- negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate ma"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:348c7e1c-199a-5c3b-90d7-900431a12d62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2f8bf02-57f8-4d34-937a-32411fc6bfba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2f8bf02-57f8-4d34-937a-32411fc6bfba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2f8bf02-57f8-4d34-937a-32411fc6bfba"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. Tobramycin is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa. (1) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:391352b7-af43-51af-837a-e77b544c6c41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d8b7b6c-3072-48e9-87c8-51160b9df9bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d8b7b6c-3072-48e9-87c8-51160b9df9bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d8b7b6c-3072-48e9-87c8-51160b9df9bc"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74e65862-ca87-5359-b340-dc891c81932f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [64, 79], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a3c3871-1d3a-44d6-8be3-526b30123ef7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a3c3871-1d3a-44d6-8be3-526b30123ef7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3c3871-1d3a-44d6-8be3-526b30123ef7"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE TOBI is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt; 25% or &gt; 75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. TOBI is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt; 25% or &gt; 75% predicted, or patients colonized with Burkholderia cepacia. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e04a95a-364e-514d-bdc1-7d57c390dd0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5f65e5b-c851-45da-a0e8-215d9a4e6ad3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5f65e5b-c851-45da-a0e8-215d9a4e6ad3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5f65e5b-c851-45da-a0e8-215d9a4e6ad3"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89e64185-a7e3-5e0c-8970-b656f8958f04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [179, 194], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dad13445-f591-4829-96f9-1598ba03dff8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dad13445-f591-4829-96f9-1598ba03dff8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dad13445-f591-4829-96f9-1598ba03dff8"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE TOBRAMYCIN INHALATION SOLUTION PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV 1 &lt; 25% or &gt; 75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. TOBRAMYCIN INHALATION SOLUTION PAK contains tobramycin, an aminoglycoside antibacterial drug indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a28fe1aa-dce8-5c45-b00f-d4c0cdbb353c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8205898-0162-4e6c-bcf1-87cb074ab9ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8205898-0162-4e6c-bcf1-87cb074ab9ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8205898-0162-4e6c-bcf1-87cb074ab9ae"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be602a13-699e-5fd1-8282-2d209af8241e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d044738-a715-fdee-7849-521e8981e6ec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d044738-a715-fdee-7849-521e8981e6ec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d044738-a715-fdee-7849-521e8981e6ec"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 ) ]. Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c47f2fb1-746c-5eac-9fdc-39cb772f264c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7803ac83-1250-451b-8ad8-2c0a343c3031", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7803ac83-1250-451b-8ad8-2c0a343c3031", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7803ac83-1250-451b-8ad8-2c0a343c3031"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e55b8d73-7e5d-599b-816a-e3be6b1bebe0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "MONDO:0009061", "object_location_in_text": [90, 105], "original_object": "cystic fibrosis", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5563e8af-c6c9-42a2-974d-7d364a47f00a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5563e8af-c6c9-42a2-974d-7d364a47f00a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5563e8af-c6c9-42a2-974d-7d364a47f00a"]}], "subject": "CHEBI:28864", "supporting_text": ["1 INDICATIONS AND USAGE Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. Tobramycin inhalation solution is an aminoglycoside antibacterial indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) &lt;25% or &gt;75% predicted, or patients colonized with Burkholderia cepacia ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8c127ec-14f2-5be2-930c-6214afd31087", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0006929", "MONDO:0020920", "UMLS:C0022729", "UMLS:C0948205", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:772a8710-d3ab-5df7-aaed-c2e96659afe2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "MONDO:0021201", "original_object": "skin infection", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole-negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate may "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:047210ae-e796-5638-b861-d0c00346b6f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0006929", "MONDO:0020920", "UMLS:C0022729", "UMLS:C0948205", "UMLS:C0085394", "MONDO:0005545", "UMLS:C5208103", "UMLS:C0948204"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole-negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate may "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d390773-c05a-5cb6-a4ca-62dee9255fa1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [578, 589], "original_object": "peritonitis", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole-negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate may "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab0c1f4d-c6cd-571f-921f-9715b885f178", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "MONDO:0020920", "UMLS:C0022729"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "neonate, child, and adult", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole-negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate may "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fef726d4-b4d3-5a8e-986a-4c78d9f63a01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [167, 177], "original_object": "Septicemia", "original_subject": "TOBRAMYCIN", "population_context_qualifier": "neonate, child, and adult", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole- negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram- negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate ma"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0854135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e595400f-fbec-56f4-8d2d-82d1a2718da5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854135", "UMLS:C0022729", "UMLS:C0948205", "UMLS:C0085394", "MONDO:0020920", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f6dd0305-3506-58ce-bfb4-ce55a4630086", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "UMLS:C0149725", "original_object": "lower respiratory tract infection", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4751a4f-c9c1-60c5-e053-2995a90aeba9"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole-negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate may "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8fa4dba-b9b2-5a14-962a-fd10130979df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:328efcac-9be5-5c3b-9777-e1372227177c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "medic_supporting_text_truncated": true, "object": "UMLS:C0231242", "object_location_in_text": [784, 834], "original_object": "Complicated and recurrent urinary tract infections", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b50d1b5-ea8a-5844-358a-493f1965c07f"]}], "subject": "CHEBI:28864", "supporting_text": ["Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa , E. coli , and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa , Klebsiella sp, Enterobacter sp, Serratia sp, E. coli , and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli , Klebsiella sp, and Enterobacter sp. Skin, bone, and skin structure infections caused by P. aeruginosa , Proteus sp , E. coli , Klebsiella sp, Enterobacter sp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa , Proteus sp, (indole-positive and indole- negative), E. coli , Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus , Providencia sp, and Citrobacter sp. Aminoglycosides, including tobramycin sulphate, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram- negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin sulphate ma"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemical, radiation or thermal burns, or penetration of foreign bodies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a77620f-186b-529f-a1ec-ef971cb1ff21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4647225-c122-5c93-85c6-0ee0fd6baed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2bcb2fb3-3c88-5783-84d9-d844cc536c99", "object": "UMLS:C0339289", "object_location_in_text": [591, 605], "original_object": "corneal injury", "original_subject": "TOBRAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae"]}], "subject": "CHEBI:28864", "supporting_text": [": Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncomplicated urinary tract infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49568ccd-d93a-5c68-9434-23109887b3b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1f1e64d-d992-5cd6-9390-1dcdca6aa37b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0001650", "object_location_in_text": [103, 117], "original_object": "acute cystitis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99becde1-fca5-4d82-8c3e-36ded62fc0d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99becde1-fca5-4d82-8c3e-36ded62fc0d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99becde1-fca5-4d82-8c3e-36ded62fc0d1"]}], "subject": "CHEBI:28915", "supporting_text": ["Fosfomycin Tromethamine is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin Tromethamine is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with Fosfomycin Tromethamine, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncomplicated urinary tract infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:556d6eeb-434b-5e70-8249-796f22fc8e7a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1f1e64d-d992-5cd6-9390-1dcdca6aa37b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0001650", "object_location_in_text": [154, 168], "original_object": "acute cystitis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48e352bc-52ea-4778-905a-60ef38a5c18a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48e352bc-52ea-4778-905a-60ef38a5c18a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48e352bc-52ea-4778-905a-60ef38a5c18a"]}], "subject": "CHEBI:28915", "supporting_text": ["INDICATIONS &amp; USAGE Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncomplicated urinary tract infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bded84a8-19c1-55a2-92d2-6006179177ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1f1e64d-d992-5cd6-9390-1dcdca6aa37b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0001650", "object_location_in_text": [103, 117], "original_object": "acute cystitis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3ba67e7-aaca-e682-277a-94e20b0abad7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3ba67e7-aaca-e682-277a-94e20b0abad7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3ba67e7-aaca-e682-277a-94e20b0abad7"]}], "subject": "CHEBI:28915", "supporting_text": ["Fosfomycin Tromethamine is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin Tromethamine is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with Fosfomycin Tromethamine, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncomplicated urinary tract infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c777f336-614a-5ff2-87a3-c00538f69ccf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1f1e64d-d992-5cd6-9390-1dcdca6aa37b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0001650", "object_location_in_text": [154, 168], "original_object": "acute cystitis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fa61bd4-fc55-0987-e063-6394a90abce2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fa61bd4-fc55-0987-e063-6394a90abce2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fa61bd4-fc55-0987-e063-6394a90abce2"]}], "subject": "CHEBI:28915", "supporting_text": ["INDICATIONS &amp; USAGE Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncomplicated urinary tract infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d15b7e6f-85fc-5c8f-9339-b8722d2476ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1f1e64d-d992-5cd6-9390-1dcdca6aa37b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0001650", "object_location_in_text": [154, 168], "original_object": "acute cystitis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36bca22f-49ea-42ce-926b-035c42eb6038", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36bca22f-49ea-42ce-926b-035c42eb6038", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36bca22f-49ea-42ce-926b-035c42eb6038"]}], "subject": "CHEBI:28915", "supporting_text": ["INDICATIONS &amp; USAGE Fosfomycin Tromethamine Granules for Oral Solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin Tromethamine Granules for Oral Solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES section)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "uncomplicated urinary tract infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef30c65b-e3ec-5573-b361-4c0f10cd7ae9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c1f1e64d-d992-5cd6-9390-1dcdca6aa37b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0001650", "object_location_in_text": [154, 168], "original_object": "acute cystitis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b9167a9-80e9-44e1-a609-c3eb78960acf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b9167a9-80e9-44e1-a609-c3eb78960acf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b9167a9-80e9-44e1-a609-c3eb78960acf"]}], "subject": "CHEBI:28915", "supporting_text": ["INDICATIONS &amp; USAGE Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552431", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72b9938b-ad9b-5bb3-bf05-f354818878ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552431"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d3c14ff-4863-506d-a90a-e281f0355803", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:493aa5a1-61c0-51b5-82c3-caf1fe216f64", "object": "MONDO:0003529", "object_location_in_text": [185, 205], "original_object": "acute pyelonephritis", "original_subject": "FOSFOMYCIN", "population_context_qualifier": "patients 18 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:855574f2-39f8-43bc-a3d2-79dbb578cb94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=855574f2-39f8-43bc-a3d2-79dbb578cb94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=855574f2-39f8-43bc-a3d2-79dbb578cb94"]}], "subject": "CHEBI:28915", "supporting_text": ["1 INDICATIONS AND USAGE CONTEPO is an epoxide antibacterial indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including acute pyelonephritis caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis CONTEPO is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible isolates of Escherichia coli and Klebsiella pneumoniae . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of CONTEPO and other antibacterial drugs, CONTEPO should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01ea5ec7-b2d9-54b3-ae97-730704b35d5a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "HP:0012531", "object_location_in_text": [47, 51], "original_object": "pain", "original_subject": "EPINEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e"]}], "subject": "CHEBI:28918", "supporting_text": ["Uses: Temporarily relieves local discomfort or pain or burning associated with anorectal disorders."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12989623-72a4-53c6-85ca-2e9231e334b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "HP:0012531", "original_object": "pain", "original_subject": "EPINEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58793581-8826-9a74-e063-6294a90a2465"]}], "subject": "CHEBI:28918", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8ca16e5-bd4c-5d80-ac40-2cae47c080bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "HP:0012531", "original_object": "pain", "original_subject": "EPINEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2"]}], "subject": "CHEBI:28918", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036983", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4912714-918b-5d18-b9be-6049b71eb112", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036983"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "MONDO:0005468", "object_location_in_text": [164, 175], "original_object": "hypotension", "original_subject": "EPINEPHRINE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55befbe4-c819-4367-bbe7-de5841786aac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55befbe4-c819-4367-bbe7-de5841786aac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55befbe4-c819-4367-bbe7-de5841786aac"]}], "subject": "CHEBI:28918", "supporting_text": ["1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) For emergency treatment of allergic reactions (Type 1), including anaphylaxis. ( 1.2 ) For induction and maintenance of mydriasis during intraocular surgery. ( 1.3 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/mL is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. 1.2 Anaphylaxis Emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. The signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. 1.3 Induction and Maintenance of Mydriasis during Intraocular Surgery Induction and maintenance of mydriasis during intraocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036983", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de1cf210-49cc-512d-bad4-c74d1799fc79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036983"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "MONDO:0005468", "object_location_in_text": [164, 175], "original_object": "hypotension", "original_subject": "EPINEPHRINE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79ca73ca-d3c0-40af-9dec-e2f4ce669cda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79ca73ca-d3c0-40af-9dec-e2f4ce669cda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79ca73ca-d3c0-40af-9dec-e2f4ce669cda"]}], "subject": "CHEBI:28918", "supporting_text": ["1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock ( 1.1 ) For emergency treatment of allergic reactions (Type 1), including anaphylaxis ( 1.2 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection, 1 mg/mL is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. 1.2 Anaphylaxis Emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. The signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1527304", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:810ecce4-4739-5b71-881f-6f7101a460f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240822", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1527304", "UMLS:C0016452", "MONDO:0100054", "HP:0410139"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1a701aee-4250-566d-838e-eea7a5818cf5", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "MONDO:0100053", "object_location_in_text": [43, 54], "original_object": "anaphylaxis", "original_subject": "epinephrine", "population_context_qualifier": "adults and children with a body weight ≥30 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eurneffy", "https://www.ema.europa.eu/en/documents/product-information/eurneffy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eurneffy"]}], "subject": "CHEBI:28918", "supporting_text": ["Emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children with a body weight ≥30&nbsp;kg.&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39aa62a7-3d35-5d24-84de-9f38f2b21d9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "UMLS:C0014724", "object_location_in_text": [55, 62], "original_object": "burning", "original_subject": "EPINEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e"]}], "subject": "CHEBI:28918", "supporting_text": ["Uses: Temporarily relieves local discomfort or pain or burning associated with anorectal disorders."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aee6a973-505b-5c2b-bbb2-01ca26f2283b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:436d4e04-ca59-508a-8100-86bee47fd0ad", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "UMLS:C0234215", "original_object": "discomfort", "original_subject": "EPINEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2"]}], "subject": "CHEBI:28918", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4a9262b-2bd5-5a23-8c96-1883c574dfa1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:436d4e04-ca59-508a-8100-86bee47fd0ad", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c912ec4a-e6f5-5273-8233-f821342ee700", "object": "UMLS:C0234215", "original_object": "discomfort", "original_subject": "EPINEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58793581-8826-9a74-e063-6294a90a2465"]}], "subject": "CHEBI:28918", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RANKL inhibitor administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fed567a2-9a73-5955-ab51-db9f4de8e6d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["denosumab [genetical recombination]"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:19efeb77-4966-58c9-bf7b-ee15167818e3", "object": "HP:0002901", "object_location_in_text": [105, 117], "original_object": "hypocalcemia", "original_subject": "CHOLECALCIFEROL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CHOLECALCIFEROL#139-20130228", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:28940", "supporting_text": ["A combination prescription drug with a similar formulation indicated for the treatment and prevention of hypocalcemia in association with administration of RANKL inhibitors (e.g. denosumab [genetical recombination]) [Expedited review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:934332e8-7333-56ea-91ad-cdd771db3a3d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19efeb77-4966-58c9-bf7b-ee15167818e3", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "CHOLECALCIFEROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:28940", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:646e2f93-2ff5-56b8-9648-85249dbaed9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da5d9570-d090-59b5-b379-c1c397e0ed7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "Urinary tract infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be77e7c3-067b-56c8-82d3-de0e91864ceb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "HP:5210217", "original_object": "Bacterial meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0cbe262e-a15e-5d59-b2fb-ce46003a8f62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [617, 629], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly sus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d0c9154-236b-5ab1-b79b-a8c6e1fea5ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [622, 634], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851881", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2742a170-3ed4-5cf4-9790-55b03be7e4ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851881", "MONDO:0021680"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "original_object": "endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7bf2897-8272-4c7d-84e9-6fbba0ea63fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7bf2897-8272-4c7d-84e9-6fbba0ea63fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7bf2897-8272-4c7d-84e9-6fbba0ea63fa"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, S taphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria m onocytogenes , N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or stron"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e639a07-d650-52b9-993f-2a02a34fc0a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [622, 634], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:498877b7-be73-53ee-bfbb-fa2ee0212cea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [623, 635], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a123ea9-59ed-5353-a091-71765ba2a55b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [622, 634], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c16fb3e-af62-56ff-9671-2b8747192366", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [620, 632], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851881", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aad75daa-511a-5b30-965b-1bd4055d250a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851881"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "original_object": "endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:519f3ba6-606f-bfc4-e063-6294a90af884", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=519f3ba6-606f-bfc4-e063-6294a90af884", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=519f3ba6-606f-bfc4-e063-6294a90af884"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly su"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c56af5ab-3643-5083-a016-9904785dabaf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [621, 633], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c930dc20-9e26-5065-8683-c1db58c8f7a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "original_object": "endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851881", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee8cc185-4372-5aaa-943f-729e683b5cba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851881", "MONDO:0021680"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "original_object": "endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:519f2131-79e7-569f-e063-6394a90a2f93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=519f2131-79e7-569f-e063-6394a90a2f93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=519f2131-79e7-569f-e063-6394a90a2f93"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli , Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp ., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665800", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f075d948-8511-524f-bbaf-e4f9b8b46ad5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_disease_context_ids": ["UMLS:C3665800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [616, 628], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd9f6bfe-8ec6-58da-bd8b-fd96b9cd47dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "object_location_in_text": [620, 632], "original_object": "Endocarditis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036125", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b5744a4-1356-556a-a330-b615476d26dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036125"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:87217c0a-bcba-58b4-887b-23a666bb7164", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0005619", "object_location_in_text": [1201, 1214], "original_object": "typhoid fever", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:38ec7b7a-9caf-45f2-88a1-0f78f089a1e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=38ec7b7a-9caf-45f2-88a1-0f78f089a1e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38ec7b7a-9caf-45f2-88a1-0f78f089a1e4"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by S. pneumoniae, Staphylococcus aureus (penicillinase and non-penicillinase producing), H. influenzae and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin-G-susceptible staphylococci and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. Indicated surgical procedures should be performed. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03398024-733d-5d06-a705-608be832e3f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0018150", "UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [350, 370], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25c9e412-2c9b-5896-bfe8-2f16603f8d1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b29d3bd-05a4-5892-b112-036831c76911", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [347, 367], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7336f52e-2cab-5eb5-ba66-effebad414c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [354, 374], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:919e4818-d2fc-5512-a7e0-f7f205edb3be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [354, 374], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:948a331a-a061-5292-8431-444d099e7ca8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0018150", "UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [353, 373], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aab0cae1-efd7-5c7a-8e02-9810ae3c0f47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [354, 374], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:caa4509e-8570-57cb-a3ca-588ef940c187", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [354, 374], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e559f548-acb2-5fb1-94a4-cd3863047dba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "object_location_in_text": [348, 368], "original_object": "Bacterial Meningitis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly sus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:167c619a-5bca-5cc1-9f38-9425fb4ac6cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1075, 1099], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fde1101-e535-5670-a67d-de8dc745de08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1068, 1092], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly sus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4340e095-ffb2-591e-8204-9aff9f6dbf62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1071, 1095], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83284c59-a444-5c3f-9aef-1565bc23a2fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1071, 1095], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b5617bd-0a9d-5871-9cbd-4dafc545c7b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1071, 1095], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ed675e8-ff0b-5360-b75d-8c4894417220", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1068, 1092], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8271f6e-ffb3-596b-aea0-5610c0718858", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1071, 1095], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8110f25-9c41-59a3-b9e3-fdab697bf02b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "object_location_in_text": [1070, 1094], "original_object": "Urinary Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b440cab-46d6-5279-aded-26fb6e34959e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "Respiratory tract infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37c4ed2a-13ce-5cea-8557-02cccca48737", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "MONDO:0005545", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59a97686-993e-50a4-8224-873cfd100a65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "MONDO:0005545", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [156, 184], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8efd59e5-8662-5821-a28a-500288e583dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [161, 189], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e21513f-6e0d-5361-a966-94aaf3c04844", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "MONDO:0005545", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [156, 184], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be948027-343f-5cb0-b151-c1ca8818c92f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "MONDO:0005545", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [156, 184], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly sus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb5da27b-0a83-599d-809c-a7297cc3844a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [161, 189], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f55d9302-0322-5155-b884-8b7abc6f5b85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [161, 189], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd36fbd5-5c9b-5635-bb3e-349f23e13742", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [161, 189], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff1005f7-7cda-5bc0-afc2-6f1a4f183520", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C1541907"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [161, 189], "original_object": "Respiratory Tract Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:428e7ac9-047c-5a35-a29f-7bbcbed1e0af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [768, 788], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60f26a92-ac4f-5e3b-b1ec-40b9c332d07c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [768, 788], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:635ef487-60e1-54b7-b673-61dfacdeb4fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [767, 787], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64139300-6810-5963-9b15-e8904682848d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "original_object": "gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8aa0897c-5543-5ce9-83c7-20a8268414f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [771, 791], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ab70c4a-cce2-50b2-8097-0580845d8d6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [764, 784], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b548057-6dd2-5555-8613-a33d630425aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [768, 788], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:912db418-6016-5893-ac63-8b781f929720", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [768, 788], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f208d75a-ae99-5da6-ac09-ff04df8ce4e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0713fcb2-5c6c-5ed0-9d64-a424d4b4b0fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036685", "object_location_in_text": [767, 787], "original_object": "Gram-negative sepsis", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b85770d-73e7-5f54-bddf-a236e6992233", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [605, 615], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e148e33-18bf-50fb-8673-7c3679418571", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [607, 617], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:381d0e07-1491-51e7-a868-12314c8c0733", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [602, 612], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly sus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f351d51-47d9-5789-8e42-55e68ef62c25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [608, 618], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a94077d-77ef-5a15-9327-b32d04c0ab81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [607, 617], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5a97eec-dbe3-582c-bf62-d62655576ff0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [601, 611], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organism infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9ab614a-5f65-5e73-9e1f-c37173045f9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:519f3ba6-606f-bfc4-e063-6294a90af884", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=519f3ba6-606f-bfc4-e063-6294a90af884", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=519f3ba6-606f-bfc4-e063-6294a90af884"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly su"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms, Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1821509-102c-50a6-b497-0f525cf64aa0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [606, 616], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba7da8e7-c5df-5426-9ef2-26567ed54da7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms, Streptococcus spp., penicillin G-susceptible staphylococci, enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc3d0bcb-f8c8-5916-bb40-c06cd085197d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [605, 615], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organism infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e27fe76c-3a4b-56eb-b07a-d4b9ca0acbe9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:519f2131-79e7-569f-e063-6394a90a2f93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=519f2131-79e7-569f-e063-6394a90a2f93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=519f2131-79e7-569f-e063-6394a90a2f93"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli , Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp ., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organism infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e67e26c0-46ec-5ccb-b5a0-9ff59c86e0dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7bf2897-8272-4c7d-84e9-6fbba0ea63fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7bf2897-8272-4c7d-84e9-6fbba0ea63fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7bf2897-8272-4c7d-84e9-6fbba0ea63fa"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, S taphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria m onocytogenes , N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or stron"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e98d8b00-3943-5566-b5a7-ca5b10feaa25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "object_location_in_text": [607, 617], "original_object": "Septicemia", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036125", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04eb22b7-f80f-51cc-b319-96cc58cf9d7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036125"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1156, 1183], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d94837-ca25-4728-932b-139d3bf4c716"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including S treptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp. , and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Salmonella typhi (typhoid fever), Salmonella spp., Shigella spp. (dysentery)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2eb8a5a7-3a83-5df0-81a4-10f3f3d85894", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1159, 1186], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e95c91-3767-493c-8716-38e61e7c6674"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036125", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:311713f8-034a-5643-9e5f-df5b7d456d04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036125"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "original_object": "gastrointestinal infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06ca924c-5f3a-4924-90f4-5ba623daaa0e"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly suspect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036125", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e127900-5730-548a-bd7f-91c69161eb96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036125", "MONDO:0005619", "MONDO:0001517"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78988f6a-a73b-4d3b-9a76-d61a748c3c16"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli , Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infection s caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Salmonella typhi (typhoid fever), Salmonella spp., Shigella spp. (dysentery)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9567dc8d-0d7c-520e-885c-529b51f0b3b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1158, 1185], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d2aebe8-4f04-49dd-b1e5-80b962868dc3"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0036125", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2279016-2584-54ee-a5dd-2cf48a4370d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036125"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1155, 1182], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a04e8c-8f78-46b3-8f45-56ef225a4f74"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae . Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection and other antibacterial drugs, ampicillin for injection should be used only to treat or prevent infections that are proven or strongly sus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Salmonella typhi (typhoid fever), Salmonella spp., Shigella spp. (dysentery)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb9903dd-06f3-5d4b-a1f9-9222b91a44a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1163, 1190], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b3796dd-6f81-4999-ae2b-a13a72795729"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci . Bacterial Meningitis caused by E. coli, Group B Streptococci , and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci , and enterococci . Gram-negative sepsis caused by E. coli , Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are prov"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Salmonella typhi (typhoid fever), Salmonella spp., Shigella spp. (dysentery)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea303049-260e-54b4-90e3-ecee0a777982", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1159, 1186], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=402e7cc7-5ae8-c113-e063-6394a90aa54a"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Salmonella typhi (typhoid fever), Salmonella spp., Shigella spp. (dysentery)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed336878-ce1f-51ba-b651-b31ec5e7e6cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "original_object": "Gastrointestinal infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a194f310-a669-4d8f-8c04-ee9ca01939b1"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli , Group B streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis) . The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci . Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Salmonella typhi (typhoid fever), Salmonella spp., Shigella spp. (dysentery)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6c0efd8-059c-5e6f-a65a-b749925d290b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2508945-9cc0-5ad0-b829-9fb6cea1a62f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f31edfcf-d09f-5e91-b580-1d49039d7744", "medic_supporting_text_truncated": true, "object": "UMLS:C4082764", "object_location_in_text": [1159, 1186], "original_object": "Gastrointestinal Infections", "original_subject": "AMPICILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd0f9fa-5b86-42f7-9a9f-767123638d39"]}], "subject": "CHEBI:28971", "supporting_text": ["Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae , Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae , and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus spp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella spp. responds to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis. Urinary Tract Infections caused by sensitive strains of E. coli and Proteus mirabilis . Gastrointestinal Infections caused by Salmonella typhi (typhoid fever), other Salmonella spp., and Shigella spp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin for injection, USP and other antibacterial drugs, ampicillin for injection, USP should be used only to treat or prevent infections that are proven o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a71eaeb-8921-51a9-9bcb-43a7bc80f84c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5bd4a152-d629-5cd5-b6df-950d98787b00", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "ATENOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8104a825-a0f1-4383-acbd-83670caee197", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8104a825-a0f1-4383-acbd-83670caee197", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8104a825-a0f1-4383-acbd-83670caee197"]}], "subject": "CHEBI:2904", "supporting_text": ["Hypertension Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a345fb8-f4f8-5c1a-8cc4-8da1922432d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5bd4a152-d629-5cd5-b6df-950d98787b00", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "ATENOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bdbf6779-8e9b-4ce1-a361-ede4914dd2f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bdbf6779-8e9b-4ce1-a361-ede4914dd2f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdbf6779-8e9b-4ce1-a361-ede4914dd2f3"]}], "subject": "CHEBI:2904", "supporting_text": ["Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients wi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b216636-f3cb-589e-94d0-b964dfb42a96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5bd4a152-d629-5cd5-b6df-950d98787b00", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "ATENOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8104a825-a0f1-4383-acbd-83670caee197", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8104a825-a0f1-4383-acbd-83670caee197", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8104a825-a0f1-4383-acbd-83670caee197"]}], "subject": "CHEBI:2904", "supporting_text": ["Hypertension Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fca033ff-b69a-5623-8f6d-8a6397414f2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5bd4a152-d629-5cd5-b6df-950d98787b00", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "ATENOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bdbf6779-8e9b-4ce1-a361-ede4914dd2f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bdbf6779-8e9b-4ce1-a361-ede4914dd2f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdbf6779-8e9b-4ce1-a361-ede4914dd2f3"]}], "subject": "CHEBI:2904", "supporting_text": ["Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients wi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85cffe40-b69e-520d-848c-dc5dcb3da368", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171002", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dee69c01-3196-5710-aa06-5113f659a6ea", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "ASCORBIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:29073", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53a4a11c-ef11-59c2-a52f-5ded72ae2c9b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171002", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dee69c01-3196-5710-aa06-5113f659a6ea", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "ASCORBIC ACID", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:29073", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ce87adb-071c-5065-8617-89c99dcf2b51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171002", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dee69c01-3196-5710-aa06-5113f659a6ea", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "ASCORBIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:29073", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.731025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f8ab62a-af34-5625-aa8e-acc78c882b3c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0021564", "UMLS:C0684339", "UMLS:C0949898"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.731025, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4b2aed1c-4e0d-5caa-a6d3-128186a30439", "object": "HP:0000989", "object_location_in_text": [69, 76], "original_object": "itching", "original_subject": "SODIUM CATION", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:226c1420-d771-204f-e063-6294a90af9f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=226c1420-d771-204f-e063-6294a90af9f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=226c1420-d771-204f-e063-6294a90af9f6"]}], "subject": "CHEBI:29101", "supporting_text": ["Uses Temprarily protects and helps relieve minor skin irritation and itching due to, insect bites, poison ivy, oak, or sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0200114", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c85cb535-6df7-5576-85d0-9c2e17b126e4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0200114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2fe957a7-4f06-541e-963d-8c8f0cfd01e0", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4420fb5f-24f0-50a3-a81e-e6d29f52d3ef", "object": "MONDO:0003019", "object_location_in_text": [120, 131], "original_object": "hypokalemia", "original_subject": "POTASSIUM CATION", "population_context_qualifier": "patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccaaa3a2-a273-41c7-9e54-429539ea0140", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccaaa3a2-a273-41c7-9e54-429539ea0140", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccaaa3a2-a273-41c7-9e54-429539ea0140"]}], "subject": "CHEBI:29103", "supporting_text": ["1 INDICATIONS AND USAGE Potassium chloride extended-release capsules are indicated for the treatment and prophylaxis of hypokalemia in adults and children with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride extended-release capsules contain potassium chloride, a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001742", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3627c7e8-f2a8-52d0-9ac8-880cc0bed583", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070730", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001742"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2836a887-1c4e-5d29-a4a7-aab0e9ace351", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:794aa14d-dcdc-5469-b009-378c12df2610", "object": "MONDO:0005324", "object_location_in_text": [25, 51], "original_object": "seasonal allergic rhinitis", "original_subject": "desloratadine;pseudoephedrine", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aerinaze", "https://www.ema.europa.eu/en/documents/product-information/aerinaze-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aerinaze"]}], "subject": "CHEBI:291342", "supporting_text": ["Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0002915", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bf7b963-afe7-503b-8b47-9543bd60118f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831123", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0002915"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f26f540-868c-5ecf-8e5f-f02544a4816b", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a0080c75-5a96-5da5-af34-ee4bbaf9a27e", "object": "UMLS:C0021932", "object_location_in_text": [100, 123], "original_object": "endotracheal intubation", "original_subject": "ATRACURIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71d4bc78-57df-474b-8b19-811a959f1fce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71d4bc78-57df-474b-8b19-811a959f1fce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71d4bc78-57df-474b-8b19-811a959f1fce"]}], "subject": "CHEBI:2914", "supporting_text": ["Atracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:571886f0-df93-5185-8405-69a672566f25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19710101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8b5442d0-d9f3-5060-9599-2c4931cc1eeb", "object": "MONDO:0005324", "object_location_in_text": [83, 92], "original_object": "hay fever", "original_subject": "Azatadine Maleate 1mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:2947", "supporting_text": ["Anti-allergic- indicated for the symptomatic relief of allergic conditions such as hay fever, vasomotor rhinitis, urticaria, pruritus of allergic origin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b18461c-fa98-552a-ab18-13bb178aaef2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19710101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:89efb5c9-5434-5ec9-bba2-e17e23171dbb", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8b5442d0-d9f3-5060-9599-2c4931cc1eeb", "object": "MONDO:0005492", "object_location_in_text": [114, 123], "original_object": "urticaria", "original_subject": "Azatadine Maleate 1mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:2947", "supporting_text": ["Anti-allergic- indicated for the symptomatic relief of allergic conditions such as hay fever, vasomotor rhinitis, urticaria, pruritus of allergic origin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6088b217-d766-5f08-be94-1ba6be95ddd4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19710101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:f18c7fe5-31da-5029-8e98-cfacb2a4ac08", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8b5442d0-d9f3-5060-9599-2c4931cc1eeb", "object": "MONDO:0006004", "object_location_in_text": [94, 112], "original_object": "vasomotor rhinitis", "original_subject": "Azatadine Maleate 1mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:2947", "supporting_text": ["Anti-allergic- indicated for the symptomatic relief of allergic conditions such as hay fever, vasomotor rhinitis, urticaria, pruritus of allergic origin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "previous treatment with alkylating agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:047224a3-a353-5be4-81e1-84616999a6cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b94e55d7-5a5c-5e85-82d1-dc20b2af04ad", "object": "MONDO:0008383", "object_location_in_text": [134, 154], "original_object": "rheumatoid arthritis", "original_subject": "AZATHIOPRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f251f372-c881-483e-8035-c6a8a6bfb4e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f251f372-c881-483e-8035-c6a8a6bfb4e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f251f372-c881-483e-8035-c6a8a6bfb4e8"]}], "subject": "CHEBI:2948", "supporting_text": ["Azathioprine should not be given to patients who have shown hypersensitivity to the drug. Azathioprin should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with azathioprine."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prior treatment with alkylating agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:725d8f44-f64b-54f0-ae91-8e0f69e74b88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b94e55d7-5a5c-5e85-82d1-dc20b2af04ad", "object": "MONDO:0008383", "original_object": "rheumatoid arthritis", "original_subject": "AZATHIOPRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0"]}], "subject": "CHEBI:2948", "supporting_text": ["Azathioprine Sodium for Injection should not be given to patients who have shown hypersensitivity to the drug. Azathioprine should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan or others) may have a prohibitive risk of malignancy if treated with azathioprine."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "previous treatment with alkylating agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0804115-f888-52a9-8c3e-564e7fc823fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b94e55d7-5a5c-5e85-82d1-dc20b2af04ad", "object": "MONDO:0008383", "original_object": "rheumatoid arthritis", "original_subject": "AZATHIOPRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d62b6e4-a9d4-4818-e063-6394a90aa208", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d62b6e4-a9d4-4818-e063-6394a90aa208", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d62b6e4-a9d4-4818-e063-6394a90aa208"]}], "subject": "CHEBI:2948", "supporting_text": [": IMURAN should not be given to patients who have shown hypersensitivity to the drug. IMURAN should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with IMURAN."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "previous treatment with alkylating agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e941285c-5852-537c-af52-053b03aa4119", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b94e55d7-5a5c-5e85-82d1-dc20b2af04ad", "object": "MONDO:0008383", "object_location_in_text": [134, 154], "original_object": "rheumatoid arthritis", "original_subject": "AZATHIOPRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5116b22b-1460-5535-e063-6394a90acbe5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5116b22b-1460-5535-e063-6394a90acbe5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5116b22b-1460-5535-e063-6394a90acbe5"]}], "subject": "CHEBI:2948", "supporting_text": ["Azathioprine should not be given to patients who have shown hypersensitivity to the drug. Azathioprin should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with azathioprine."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "previous treatment with alkylating agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f18569ff-5145-555a-8c97-65277acd14c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b94e55d7-5a5c-5e85-82d1-dc20b2af04ad", "object": "MONDO:0008383", "object_location_in_text": [134, 154], "original_object": "rheumatoid arthritis", "original_subject": "AZATHIOPRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc6dc4bd-2121-4613-9d90-4a504010c98a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc6dc4bd-2121-4613-9d90-4a504010c98a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc6dc4bd-2121-4613-9d90-4a504010c98a"]}], "subject": "CHEBI:2948", "supporting_text": ["Azathioprine should not be given to patients who have shown hypersensitivity to the drug. Azathioprin should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with azathioprine."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "previous treatment with alkylating agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2116120-254a-50d6-86b5-9bea15ad50cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b94e55d7-5a5c-5e85-82d1-dc20b2af04ad", "object": "MONDO:0008383", "original_object": "rheumatoid arthritis", "original_subject": "AZATHIOPRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:606101a0-6244-7eff-e053-2a91aa0acadd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=606101a0-6244-7eff-e053-2a91aa0acadd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=606101a0-6244-7eff-e053-2a91aa0acadd"]}], "subject": "CHEBI:2948", "supporting_text": [": IMURAN should not be given to patients who have shown hypersensitivity to the drug. IMURAN should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with IMURAN."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory ocular condition", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:495b52d5-ab85-5b00-a445-ff698053eb8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:d7c2fc73-5cff-5e60-92b3-695a5e28d7c2", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:6de89354-1df8-5dc0-ba14-db91c214872a", "object": "UMLS:C0015404", "object_location_in_text": [73, 100], "original_object": "bacterial ocular infections", "original_subject": "Azithromycin + Dexamethasone (10mg + 1mg) Eye Drops", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:2955", "supporting_text": ["For post operative steroid responsive inflammatory ocular condition when bacterial ocular infections or a risk of bacterial ocular infections exists."], "temporal_context_qualifier": "post operative"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "conjunctivitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4efb3826-e0c7-5561-a74a-92d76c5f5774", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190618", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9bc098e8-5b2c-57b1-b5bf-3816aca629f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:43ccc2f1-640c-54f2-858b-6c4be171f455", "object": "MONDO:0003799", "object_location_in_text": [73, 87], "original_object": "conjunctivitis", "original_subject": "AZITHROMYCIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AZITHROMYCIN HYDRATE#71-20190618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:2955", "supporting_text": ["A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blepharitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e9af091-af91-52cf-8fe3-179551b522a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190618", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:470e5df9-0dc4-5d04-bb32-a865aaad4ece", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:43ccc2f1-640c-54f2-858b-6c4be171f455", "object": "MONDO:0004785", "object_location_in_text": [89, 100], "original_object": "blepharitis", "original_subject": "AZITHROMYCIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AZITHROMYCIN HYDRATE#71-20190618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:2955", "supporting_text": ["A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22f6a040-eb63-57a3-b37d-7e3db6264209", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190618", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a301bc82-ea0d-52a1-aaf8-ba426d57ed8c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:43ccc2f1-640c-54f2-858b-6c4be171f455", "object": "MONDO:0004926", "object_location_in_text": [116, 130], "original_object": "dacryocystitis", "original_subject": "AZITHROMYCIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AZITHROMYCIN HYDRATE#71-20190618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:2955", "supporting_text": ["A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hordeolum caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb90e855-e4c9-5d6e-8b77-425923d5fd35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190618", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca7235d4-1b8f-51bd-a5c7-9dbd7fa5ad08", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:43ccc2f1-640c-54f2-858b-6c4be171f455", "object": "MONDO:0005800", "object_location_in_text": [102, 111], "original_object": "hordeolum", "original_subject": "AZITHROMYCIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AZITHROMYCIN HYDRATE#71-20190618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:2955", "supporting_text": ["A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1e91561-692d-55a6-805d-9f3a0a031704", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040401", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:99bbd32a-6f44-54cf-84be-6c986ea7d5b8", "object": "UMLS:C0694549", "object_location_in_text": [49, 77], "original_object": "community-acquired pneumonia", "original_subject": "TELITHROMYCIN", "population_context_qualifier": "patients 18 years old and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba1cca98-f350-4655-88e3-6ef990779fb9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba1cca98-f350-4655-88e3-6ef990779fb9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba1cca98-f350-4655-88e3-6ef990779fb9"]}], "subject": "CHEBI:29688", "supporting_text": ["KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037929", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:018cb3f2-7f8a-5470-b020-314076bc4e32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037929", "MONDO:0002545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:22289652-7765-56e9-b03f-07540f70916d", "object": "HP:0001257", "object_location_in_text": [73, 83], "original_object": "spasticity", "original_subject": "BACLOFEN", "population_context_qualifier": "patients with spinal cord injuries and other spinal cord diseases", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebbfec9e-621c-4d04-8a1c-81d2eb9e9c74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebbfec9e-621c-4d04-8a1c-81d2eb9e9c74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebbfec9e-621c-4d04-8a1c-81d2eb9e9c74"]}], "subject": "CHEBI:2972", "supporting_text": ["Baclofen tablets are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037929", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2707b899-54aa-58a1-b879-0222627f2428", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037929", "MONDO:0002545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:22289652-7765-56e9-b03f-07540f70916d", "object": "HP:0001257", "object_location_in_text": [67, 77], "original_object": "spasticity", "original_subject": "BACLOFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9076d6ce-bbc2-4a9f-9cb9-2de1b675b9aa"]}], "subject": "CHEBI:2972", "supporting_text": ["1 INDICATIONS AND USAGE FLEQSUVY is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. FLEQSUVY may also be of some value in patients with spinal cord injuries and other spinal cord diseases."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037929", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4df727d3-2c31-54b4-9d07-61366041c89f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037929", "MONDO:0002545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:22289652-7765-56e9-b03f-07540f70916d", "object": "HP:0001257", "object_location_in_text": [78, 88], "original_object": "spasticity", "original_subject": "BACLOFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00c6c924-ddfd-4a75-afd7-f6561ff9abbc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00c6c924-ddfd-4a75-afd7-f6561ff9abbc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00c6c924-ddfd-4a75-afd7-f6561ff9abbc"]}], "subject": "CHEBI:2972", "supporting_text": ["Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets, USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets, USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037929", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ddeb7fc-ddd0-5667-b769-bb38201af628", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037929", "MONDO:0002545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:22289652-7765-56e9-b03f-07540f70916d", "object": "HP:0001257", "object_location_in_text": [78, 88], "original_object": "spasticity", "original_subject": "BACLOFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e2cd27d-91c7-4f15-96cc-3971769dbeaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e2cd27d-91c7-4f15-96cc-3971769dbeaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e2cd27d-91c7-4f15-96cc-3971769dbeaa"]}], "subject": "CHEBI:2972", "supporting_text": ["Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets, USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets, USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037929", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0662c19-6efb-58ca-ba22-7d1c1f4dba06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037929", "MONDO:0002545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:22289652-7765-56e9-b03f-07540f70916d", "object": "HP:0001257", "object_location_in_text": [78, 88], "original_object": "spasticity", "original_subject": "BACLOFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac9b720f-b755-49f1-9850-efb26feadaeb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac9b720f-b755-49f1-9850-efb26feadaeb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac9b720f-b755-49f1-9850-efb26feadaeb"]}], "subject": "CHEBI:2972", "supporting_text": ["Baclofen tablets, USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets, USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets, USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3839044", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6069f93-2664-5985-bc88-f2262c15fc1b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3839044"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ed91d44a-c917-55d4-9cab-3d2f0563f5e9", "object": "MONDO:0005366", "object_location_in_text": [21, 56], "original_object": "chronic Hepatitis B virus infection", "original_subject": "Fumarate bulk & 25 mg", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:29806", "supporting_text": ["For the treatment of chronic Hepatitis B virus infection in adults with compensated liver disease"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d62e40ab-e830-5dd9-845a-6c8aa065a8b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910625", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b8e0dbe-9733-595f-a988-087f3e2a7e2e", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "BENAZEPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f265e6dd-f47e-4511-9468-282184bcd1b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f265e6dd-f47e-4511-9468-282184bcd1b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f265e6dd-f47e-4511-9468-282184bcd1b1"]}], "subject": "CHEBI:3011", "supporting_text": ["1 INDICATIONS AND USAGE Benazepril HCl tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at hi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e34a09e0-0cc7-559a-afb3-16be376b1b83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910625", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b8e0dbe-9733-595f-a988-087f3e2a7e2e", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "BENAZEPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff732cfa-9ded-4226-b464-19c90a6865ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff732cfa-9ded-4226-b464-19c90a6865ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff732cfa-9ded-4226-b464-19c90a6865ae"]}], "subject": "CHEBI:3011", "supporting_text": ["1. INDICATIONS AND USAGE Benazepril Hydrochloride Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients wh"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3dd39b5d-7a5c-5a0b-aeed-65e4e59cf731", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910625", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b8e0dbe-9733-595f-a988-087f3e2a7e2e", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "BENAZEPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff732cfa-9ded-4226-b464-19c90a6865ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff732cfa-9ded-4226-b464-19c90a6865ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff732cfa-9ded-4226-b464-19c90a6865ae"]}], "subject": "CHEBI:3011", "supporting_text": ["1. INDICATIONS AND USAGE Benazepril Hydrochloride Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients wh"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeda63f0-98bf-57a5-b6c1-922046cc45dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910625", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b8e0dbe-9733-595f-a988-087f3e2a7e2e", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "BENAZEPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f265e6dd-f47e-4511-9468-282184bcd1b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f265e6dd-f47e-4511-9468-282184bcd1b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f265e6dd-f47e-4511-9468-282184bcd1b1"]}], "subject": "CHEBI:3011", "supporting_text": ["1 INDICATIONS AND USAGE Benazepril HCl tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at hi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cad69c6f-1d3c-5810-a162-2a18a85b4f05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1fe7d86a-f732-589e-b896-0b30b594cc57", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "BENDROFLUMETHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f"]}], "subject": "CHEBI:3013", "supporting_text": ["INDICATIONS Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is sim"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0989cda4-4ce7-58fe-b4eb-3d50e633ab89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1fe7d86a-f732-589e-b896-0b30b594cc57", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "BENDROFLUMETHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f"]}], "subject": "CHEBI:3013", "supporting_text": ["INDICATIONS Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is sim"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001987", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f167627-c2a0-5c0a-86ab-0574bd458bf9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001987", "UMLS:C3888557"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0001298", "original_object": "encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle.( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a74d9065-552d-5c54-8749-e6d25ddee0ce", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0001298", "original_object": "encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. AMMONUL is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0008281", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a93fb943-f246-559e-ab58-a2d2be6fe03b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0008281"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0001298", "original_object": "encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0008281", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad71a2c9-1572-5fb8-80ff-1439bc4cb000", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0008281"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0001298", "object_location_in_text": [192, 206], "original_object": "encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0008281", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f23a0630-e3c7-52ae-956b-2f17c23615d9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0008281"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0001298", "object_location_in_text": [192, 206], "original_object": "encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3888557", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a4a4945-73bb-5cfd-b1b2-bd3975de03ed", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3888557"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecd3a591-c68d-55bc-b71d-f877881eca90", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0001987", "original_object": "hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle.( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1482bcd1-96ef-5b25-97da-b4a092fb3c12", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [156, 176], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2805da96-3a4a-5925-82e4-d6148217c528", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [156, 176], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:392e1775-ce72-57f5-a4a4-0c71d2872eb1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [172, 192], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f05c9d9-cc34-5b9e-b0b9-a33c1dae3eb0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [156, 176], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54d13c22-9b10-5207-b620-3e039c6bf981", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [172, 192], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7688b4ae-754d-5ea4-a8d5-1087fb21be7d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [163, 183], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77c2512c-7762-5e0f-b475-211498287086", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [163, 183], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b71a534-077b-53ec-b303-4cae94c68107", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [120, 140], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. AMMONUL is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1ae87ee-75a7-584e-8756-9049785f38eb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [163, 183], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edb41b2c-4333-5d04-949a-a1ba68bd7904", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "HP:0008281", "object_location_in_text": [172, 192], "original_object": "acute hyperammonemia", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e23eaf4-2040-59f0-a6d6-2e7a62839380", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43bdbaf8-5fed-55a1-8584-376836028ede", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6acdef8b-1c61-5d65-8230-51a88ddb1f09", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e4bb92e-365b-516f-9d94-1ceecca47f25", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a783340a-81ce-568a-93bc-24c5622317b7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba0e1578-6ec2-57eb-8461-75802b4e14a2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6fbc4fa1-4e68-567b-b778-655100441a31", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLACETIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508"]}], "subject": "CHEBI:30745", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98ecf29b-a270-5834-aafc-f6da148bdd18", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0001298", "original_object": "encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. AMMONUL is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001987", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aad15022-5880-5824-b08b-1ffb4f341ea0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001987", "UMLS:C3888557"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0001298", "original_object": "encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle.( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0008281", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c105509d-236d-578f-b662-be1cd589d181", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0008281"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0001298", "original_object": "encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0008281", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3f81351-fd26-5d77-ad1f-8aac943d2705", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0008281"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0001298", "object_location_in_text": [192, 206], "original_object": "encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0008281", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4410cd7-4d2e-532b-a17a-56dde4d7cead", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0008281"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bfc4abd-9a8c-5645-b4d6-30633f887104", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0001298", "object_location_in_text": [192, 206], "original_object": "encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3888557", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31eb20d7-5d21-5d11-a83e-d3b09df93970", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3888557"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecd3a591-c68d-55bc-b71d-f877881eca90", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0001987", "original_object": "hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d20768fe-4516-483a-a082-ff1df9ad1d99"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle.( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:407d2617-3f9a-5c03-bba7-2699b9f452e7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [156, 176], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc7bfe3-6faa-45a3-befb-9ad7963c0571"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:577fe9e7-3228-5c41-a8c1-53924380c7f3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [172, 192], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b939727-fe4d-53bd-8b8e-0ecd3bffc9f4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [163, 183], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:651924d7-2fc5-5bf0-93ff-7cb0a968f108", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [163, 183], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ade864c-a117-51af-b0a5-99adcdc09d07", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [172, 192], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad84e542-fd8f-5afd-8cb7-201c3f59a71f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [172, 192], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0726a0f-a2fe-5b10-83d9-a57080e0416d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [156, 176], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f17c50f-3761-4470-bf3b-63837a287b8a"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2a57a64-470b-5d0c-b11f-b426424df43f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [163, 183], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f09a3a5c-dd41-5c21-91bd-b85ed3f97450", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [156, 176], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=204e84a7-5440-4537-9e40-06eb56c415e9"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. (1) Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f27a51f2-d158-5b58-a8fb-29eb27ec211d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0008281", "object_location_in_text": [120, 140], "original_object": "acute hyperammonemia", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d564f2b1-9fc7-4201-8066-d745ac3a671f"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. AMMONUL is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:435969e5-9982-5f06-a0d6-13551b66078f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0012531", "object_location_in_text": [166, 170], "original_object": "pain", "original_subject": "BENZOIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:30746", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba86a044-05cb-5816-b996-baab572ed3dd", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "HP:0012531", "object_location_in_text": [164, 168], "original_object": "pain", "original_subject": "BENZOIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:30746", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:959dbe4d-e55c-52d1-a0c3-19cebfc92b42", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C0021368", "object_location_in_text": [131, 143], "original_object": "inflammation", "original_subject": "BENZOIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:30746", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2770cca-f610-5f54-916d-735ff8c58032", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C0021368", "object_location_in_text": [133, 145], "original_object": "inflammation", "original_subject": "BENZOIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:30746", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.57, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3037d126-e267-5ede-b41d-ba1c89192bee", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.57, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C0549185", "object_location_in_text": [145, 158], "original_object": "hypermotility", "original_subject": "BENZOIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:30746", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.57, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36a911ad-8dbb-559f-a5c1-a354406481c5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.57, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C0549185", "object_location_in_text": [147, 160], "original_object": "hypermotility", "original_subject": "BENZOIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:30746", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68da75d7-9a29-5618-8b95-58b5cc2255f3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8fafc39b-69db-40f3-8a09-ee859e8cef19"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99dc4b73-e000-593e-881b-1db9efcf4f9a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab40b62b-9f8d-4394-92d5-09d9f1941eaa"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b55464f4-2e27-5410-8b5c-3ded2a2afdae", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=329655ae-c3c0-46b2-a925-e49777f2076b"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9ff61b0-5b50-5d54-aaeb-606564ad8b35", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee1e9a2-bbe5-2419-e053-2a95a90ac3ef"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce9c57dd-8ddb-5201-9ed3-6eb2a46036ab", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3529be10-0004-4628-9ca1-67a8acd86b51"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "urea cycle enzyme deficiencies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb56e048-e50b-56ee-9236-a3b4c1874904", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55f739ce-3e2f-5885-a0f2-a8a29cf4c2a6", "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "BENZOIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9067c301-74f9-457a-9b0f-b7e9b06a3508"]}], "subject": "CHEBI:30746", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see Warnings and Precautions (5) ]. Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002020", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3178304-8793-5e7b-be3b-dd1edbf70d5a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002020", "UMLS:C0860277", "UMLS:C0235304"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fc4607ed-b66e-5edd-aa9a-ad0640d2967e", "object": "UMLS:C0235309", "object_location_in_text": [72, 85], "original_object": "upset stomach", "original_subject": "CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff6ac79d-564d-4abf-83c7-b01751249c7f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff6ac79d-564d-4abf-83c7-b01751249c7f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff6ac79d-564d-4abf-83c7-b01751249c7f"]}], "subject": "CHEBI:30769", "supporting_text": ["Uses for the relief of: • heartburn • sour stomach • acid indigestion • upset stomach associated with these symptoms"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "suspected coronary artery disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3a67ece-73df-55c1-80d3-979957ab4df2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1020, 1043], "original_object": "coronary artery disease", "original_subject": "BETAMETHASONE", "population_context_qualifier": "Adults and pediatric patients 12 years of age and over", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50"]}], "subject": "CHEBI:3077", "supporting_text": ["1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) CT imaging of the head and body. (270 mg Iodine/mL and 320 mg Iodine/mL) excretory urography. (270 mg Iodine/mL) peripheral venography. (320 mg Iodine/mL) coronary computed tomography"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1379a6e0-4af6-5fa4-9cea-8e80d4ec7f85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2154b33-0f61-49af-e053-2995a90a1810", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2154b33-0f61-49af-e053-2995a90a1810", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2154b33-0f61-49af-e053-2995a90a1810"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14ae6bb6-4ce6-57f6-834c-96a51b07c71a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c85be0f-2731-44f1-a18e-d3852d54846f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c85be0f-2731-44f1-a18e-d3852d54846f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c85be0f-2731-44f1-a18e-d3852d54846f"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:311b1bd6-1066-5fa6-b33c-dbf7d6f320af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02db1402-701c-483c-bfd6-8b7a543ae8ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02db1402-701c-483c-bfd6-8b7a543ae8ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02db1402-701c-483c-bfd6-8b7a543ae8ef"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b7d9e63-c9a8-5666-8931-90d03a594e42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d265d143-343f-41ec-9cb4-18d83edb772b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d265d143-343f-41ec-9cb4-18d83edb772b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d265d143-343f-41ec-9cb4-18d83edb772b"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5514ba78-17e1-5616-9e9a-246423af724a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e19dd44-06a9-03bc-e063-6294a90a3a31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e19dd44-06a9-03bc-e063-6294a90a3a31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e19dd44-06a9-03bc-e063-6294a90a3a31"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62cc37da-8459-55d1-94c4-42523a5d508a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9854715-1825-72ba-e053-2995a90a804c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9854715-1825-72ba-e053-2995a90a804c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9854715-1825-72ba-e053-2995a90a804c"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:794f7aab-7756-5054-8544-53a6190137f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7281d272-5342-4738-b35c-42570459e9d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7281d272-5342-4738-b35c-42570459e9d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7281d272-5342-4738-b35c-42570459e9d4"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:831f87e4-1cfe-5152-a7a7-0e06171a01ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0173ed23-9f7c-466e-9eba-f6859d05f987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0173ed23-9f7c-466e-9eba-f6859d05f987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0173ed23-9f7c-466e-9eba-f6859d05f987"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86d7aeb7-2f7c-5482-bf0e-484a805d4c43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64badc1a-8922-c6e3-e053-2991aa0a8b1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64badc1a-8922-c6e3-e053-2991aa0a8b1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64badc1a-8922-c6e3-e053-2991aa0a8b1c"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96a71b4f-3ec8-5341-98fb-18f4cd6a2051", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8711d17-de6a-45e3-8027-b650308207ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8711d17-de6a-45e3-8027-b650308207ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8711d17-de6a-45e3-8027-b650308207ed"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be8b5fdb-b76f-5967-abbd-e8775a8f8880", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:784476d2-5e5c-fdba-a677-8973a777b5ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=784476d2-5e5c-fdba-a677-8973a777b5ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=784476d2-5e5c-fdba-a677-8973a777b5ef"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf74c4b7-30a6-5d50-8670-368f60e22841", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfa4b6f5-3b66-430a-af41-60e3f12982bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfa4b6f5-3b66-430a-af41-60e3f12982bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfa4b6f5-3b66-430a-af41-60e3f12982bc"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5498341-d0e2-5b45-a7c4-0dd878ecc5f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 13, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "BETAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5718b3bd-77b3-8034-e063-6294a90af5e0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5718b3bd-77b3-8034-e063-6294a90af5e0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5718b3bd-77b3-8034-e063-6294a90af5e0"]}], "subject": "CHEBI:3077", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014531", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad48d4b6-50b1-52c6-801b-1add8bff4457", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014531", "UMLS:C4505442", "UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "MONDO:0001461", "object_location_in_text": [191, 205], "original_object": "tinea corporis", "original_subject": "BETAMETHASONE", "population_context_qualifier": "patients 17 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030a1460-3522-43af-a75d-29c99570698f"]}], "subject": "CHEBI:3077", "supporting_text": ["Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014531", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48c18384-00f1-5fe2-a0a1-03aa98b5bb06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014531", "UMLS:C4505442", "UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "MONDO:0005984", "object_location_in_text": [160, 171], "original_object": "tinea pedis", "original_subject": "BETAMETHASONE", "population_context_qualifier": "patients 17 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030a1460-3522-43af-a75d-29c99570698f"]}], "subject": "CHEBI:3077", "supporting_text": ["Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014531", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c238684e-ce2d-5f35-a03e-6d93e7b2e74b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014531", "UMLS:C4505442", "UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b7e3246d-c916-5926-9d22-88ffe651b8e2", "object": "UMLS:C1384589", "object_location_in_text": [173, 185], "original_object": "tinea cruris", "original_subject": "BETAMETHASONE", "population_context_qualifier": "patients 17 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030a1460-3522-43af-a75d-29c99570698f"]}], "subject": "CHEBI:3077", "supporting_text": ["Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "parenteral support dependence", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ee3d9a0-0984-5725-bd25-25b42fa1e419", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010607", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3cd36ca3-f417-5990-9701-7846454677b8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:561b5ef1-da95-50df-8e85-7c95cda374d2", "object": "MONDO:0015183", "original_object": "Short Bowel Syndrome", "original_subject": "ALCOHOL", "population_context_qualifier": "adults and pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66b69c1e-b25c-44d3-b5ff-1c1de9a516fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa"]}], "subject": "CHEBI:30879", "supporting_text": ["1 INDICATIONS AND USAGE GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cec1dab8-b488-5091-8c59-98aeb50fbb92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010607", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0018555"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:561b5ef1-da95-50df-8e85-7c95cda374d2", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "ALCOHOL", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edcd5209-70db-4727-991e-3fdd185d9211", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edcd5209-70db-4727-991e-3fdd185d9211", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edcd5209-70db-4727-991e-3fdd185d9211"]}], "subject": "CHEBI:30879", "supporting_text": ["Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of testosterone cypionate in men with \"age-related hypogonadism\" (also referred to as \"late-onset hypogonadism\") have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ac7a44f-ddbc-5595-90b5-caccbb48da8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:88593042-fb98-5f62-ad0d-fccc3c5e2ab1", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "AMCINONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7dc754e-eeff-4c30-a52a-629c72ad2415", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7dc754e-eeff-4c30-a52a-629c72ad2415", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7dc754e-eeff-4c30-a52a-629c72ad2415"]}], "subject": "CHEBI:31199", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bffaad4f-bcb6-5e9c-ab03-d794887bf70f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:88593042-fb98-5f62-ad0d-fccc3c5e2ab1", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "AMCINONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac5c3e79-52f7-434e-92ae-24bd32b45edc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac5c3e79-52f7-434e-92ae-24bd32b45edc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac5c3e79-52f7-434e-92ae-24bd32b45edc"]}], "subject": "CHEBI:31199", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic and mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eb6cadc-ea71-5ae8-b47b-827cd0fd01d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0001866", "original_object": "bipolar I disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:abb8ad7e-7998-4485-a09f-a2892190f4ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=abb8ad7e-7998-4485-a09f-a2892190f4ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abb8ad7e-7998-4485-a09f-a2892190f4ad"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole Tablets are indicated for the treatment of: • Schizophrenia • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder • Irritability Associated with Autistic Disorder • Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole is indicated for: • Schizophrenia ( 14.1 ) • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) • Irritability Associated with Autistic Disorder ( 14.4 ) • Treatment of Tourette’s Disorder ( 14.5 )"], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Acute manic and mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ad9b71d-2d64-58d2-bb2b-cf244c3899c5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0001866", "original_object": "bipolar I disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14910dae-da81-3d73-d0a4-e98d13917c69", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14910dae-da81-3d73-d0a4-e98d13917c69", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14910dae-da81-3d73-d0a4-e98d13917c69"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia [see Clinical Studies (14.1) ] Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see Clinical Studies (14.2)] Adjunctive Treatment of Major Depressive Disorder [see Clinical Studies (14.3) ] Irritability Associated with Autistic Disorder [see Clinical Studies (14.4) ] Treatment of Tourette’s Disorder [see Clinical Studies ( 14.5 )] Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia (14.1) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I (14.2) Adjunctive Treatment of Major Depressive Disorder (14.3) Irritability Associated with Autistic Disorder (14.4) Treatment of Tourette's disorder (14.5)"], "temporal_context_qualifier": "acute treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic and mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b55350f-90ca-55a3-b331-9f5d764f2353", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0001866", "original_object": "bipolar I disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:476b92f3-cf7b-4c09-ac67-6ed35e6811d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=476b92f3-cf7b-4c09-ac67-6ed35e6811d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476b92f3-cf7b-4c09-ac67-6ed35e6811d5"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole orally disintegrating tablets are indicated for the treatment of: Schizophrenia [see Clinical Studies (14.1) ] Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [ see Clinical Studies (14.2) ] Irritability Associated with Autistic Disorder [see Clinical Studies (14.4) ] Treatment of Tourette’s Disorder [see Clinical Studies (14.5) ] Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I ( 14.2 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette's disorder ( 14.5 )"], "temporal_context_qualifier": "acute treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic and mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b481745d-a71e-5381-b73d-86b6a1899b96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0001866", "original_object": "bipolar I disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b72c0cff-9f4d-42e2-b884-d06dea3e6378", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b72c0cff-9f4d-42e2-b884-d06dea3e6378", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b72c0cff-9f4d-42e2-b884-d06dea3e6378"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole tablets are indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette’s Disorder ( 14.5 )"], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic and mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca256901-4bc5-5e56-8bef-51351d59e5e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0001866", "original_object": "bipolar I disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:686d0088-ac61-41df-8909-ae12f7957644", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=686d0088-ac61-41df-8909-ae12f7957644", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=686d0088-ac61-41df-8909-ae12f7957644"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole Tablets are indicated for the treatment of: • Schizophrenia • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder • Irritability Associated with Autistic Disorder • Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole is indicated for: • Schizophrenia ( 14.1 ) • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) • Irritability Associated with Autistic Disorder ( 14.4 ) • Treatment of Tourette’s Disorder ( 14.5 )"], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic and mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2b851ce-ce88-545e-abe8-8f1c6e2d07cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0001866", "original_object": "bipolar I disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7bf7d35e-46a1-4e8f-aeb5-8a93223a4abc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7bf7d35e-46a1-4e8f-aeb5-8a93223a4abc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7bf7d35e-46a1-4e8f-aeb5-8a93223a4abc"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole tablets are indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette’s Disorder ( 14.5 )"], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000737", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21f70038-02da-5205-aa96-7935e8fcdb82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000737"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f1c87e48-9465-58ed-8085-2bc1d3949773", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0005258", "original_object": "autism spectrum disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:686d0088-ac61-41df-8909-ae12f7957644", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=686d0088-ac61-41df-8909-ae12f7957644", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=686d0088-ac61-41df-8909-ae12f7957644"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole Tablets are indicated for the treatment of: • Schizophrenia • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder • Irritability Associated with Autistic Disorder • Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole is indicated for: • Schizophrenia ( 14.1 ) • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) • Irritability Associated with Autistic Disorder ( 14.4 ) • Treatment of Tourette’s Disorder ( 14.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000737", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43cc1f97-e46f-552f-82e6-36530e90eccd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000737"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f1c87e48-9465-58ed-8085-2bc1d3949773", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0005258", "original_object": "autism spectrum disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:476b92f3-cf7b-4c09-ac67-6ed35e6811d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=476b92f3-cf7b-4c09-ac67-6ed35e6811d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476b92f3-cf7b-4c09-ac67-6ed35e6811d5"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole orally disintegrating tablets are indicated for the treatment of: Schizophrenia [see Clinical Studies (14.1) ] Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [ see Clinical Studies (14.2) ] Irritability Associated with Autistic Disorder [see Clinical Studies (14.4) ] Treatment of Tourette’s Disorder [see Clinical Studies (14.5) ] Aripiprazole is an atypical antipsychotic. The oral formulation is indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I ( 14.2 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette's disorder ( 14.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000737", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90aa6b9e-a576-5b67-af54-4c09e93d096c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000737"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f1c87e48-9465-58ed-8085-2bc1d3949773", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b774ea56-1194-5c9e-bb70-32a08ee05341", "object": "MONDO:0005258", "original_object": "autism spectrum disorder", "original_subject": "ARIPIPRAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:abb8ad7e-7998-4485-a09f-a2892190f4ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=abb8ad7e-7998-4485-a09f-a2892190f4ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abb8ad7e-7998-4485-a09f-a2892190f4ad"]}], "subject": "CHEBI:31236", "supporting_text": ["1 INDICATIONS AND USAGE Aripiprazole Tablets are indicated for the treatment of: • Schizophrenia • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder • Irritability Associated with Autistic Disorder • Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. Aripiprazole is indicated for: • Schizophrenia ( 14.1 ) • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) • Irritability Associated with Autistic Disorder ( 14.4 ) • Treatment of Tourette’s Disorder ( 14.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16b4f27f-9591-510c-b866-8dbef14e9d68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ded201f-7ca1-5515-8d38-ae0700f185e3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0001056", "original_object": "gastric cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3b1a2b5-f1ce-45ea-afd8-68aac53665fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3b1a2b5-f1ce-45ea-afd8-68aac53665fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3b1a2b5-f1ce-45ea-afd8-68aac53665fa"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:298969a0-e2f8-5460-a0a0-affec344a9b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ded201f-7ca1-5515-8d38-ae0700f185e3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0001056", "original_object": "gastric cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e28a5ef7-4731-f8ac-e053-2995a90a21bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e28a5ef7-4731-f8ac-e053-2995a90a21bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e28a5ef7-4731-f8ac-e053-2995a90a21bf"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:719f1e16-425e-5bed-9753-ad3335f2ade6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ded201f-7ca1-5515-8d38-ae0700f185e3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0001056", "original_object": "gastric cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5753679a-506c-4ac4-b8b2-b27c664d1d40", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5753679a-506c-4ac4-b8b2-b27c664d1d40", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5753679a-506c-4ac4-b8b2-b27c664d1d40"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4721579", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77cc2f45-0f70-57f1-bd50-61580c11c929", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4721579"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4db18fd6-759e-58ad-bde9-03459dacc042", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "object": "MONDO:0005575", "object_location_in_text": [197, 214], "original_object": "colorectal cancer", "original_subject": "capecitabine", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:capecitabine-medac", "https://www.ema.europa.eu/en/documents/product-information/capecitabine-medac-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac"]}], "subject": "CHEBI:31348", "supporting_text": ["Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer. Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "failure of taxanes and an anthracycline containing chemotherapy regimen", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8c5da0b-0909-5303-be6c-303af4bc7db7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "object": "MONDO:0007254", "object_location_in_text": [399, 443], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "capecitabine", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ecansya", "https://www.ema.europa.eu/en/documents/product-information/ecansya-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya"]}], "subject": "CHEBI:31348", "supporting_text": ["Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Ecansya is indicated for the treatment of metastatic colorectal cancer. Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on prior anthracycline-containing chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:141af4f9-d078-5a45-b8ba-02cb095c04b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [561, 597], "original_object": "advanced or metastatic breast cancer", "original_subject": "CAPECITABINE", "population_context_qualifier": "patients with advanced or metastatic breast cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c5af84-900a-4372-b056-bfea70c129cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c5af84-900a-4372-b056-bfea70c129cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c5af84-900a-4372-b056-bfea70c129cf"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE . Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients wit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anthracycline-containing chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24e120d3-a1a5-5797-b0f4-ac7ba06062a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [559, 595], "original_object": "advanced or metastatic breast cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8345d55e-ad02-4726-a04b-1a46e3337a4b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8345d55e-ad02-4726-a04b-1a46e3337a4b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8345d55e-ad02-4726-a04b-1a46e3337a4b"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior anthracycline-containing chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f1411a3-e33e-5669-9ebd-19a9ecfe9a25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "CAPECITABINE", "population_context_qualifier": "patients with advanced or metastatic breast cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e702d84d-7162-4751-bf37-d724cc7e45a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e702d84d-7162-4751-bf37-d724cc7e45a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e702d84d-7162-4751-bf37-d724cc7e45a5"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer XELODA is indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer XELODA is indicated for the: treatment of patients with advanced or metastati"], "temporal_context_qualifier": "after disease progression on prior anthracycline-containing chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on prior anthracycline-containing chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65358049-4ea9-59da-bf1f-258a8b623a2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [568, 604], "original_object": "advanced or metastatic breast cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:29885ada-b743-419c-8f15-edd4247c76ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=29885ada-b743-419c-8f15-edd4247c76ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29885ada-b743-419c-8f15-edd4247c76ca"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine tablets are a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: • treatment "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on prior anthracycline-containing chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5c430c3-8cb3-5c01-8f61-5f8d411f60d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [574, 610], "original_object": "advanced or metastatic breast cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:007e3432-c8aa-2a76-52ba-c346924c08a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=007e3432-c8aa-2a76-52ba-c346924c08a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=007e3432-c8aa-2a76-52ba-c346924c08a7"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine tablet is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. ( 1.2 ) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: • tre"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior anthracycline-containing chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9355922-3ddb-53ad-8057-792502629ff7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [567, 603], "original_object": "advanced or metastatic breast cancer", "original_subject": "CAPECITABINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c873e5b-51c2-4685-86c5-53f98563b093", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c873e5b-51c2-4685-86c5-53f98563b093", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c873e5b-51c2-4685-86c5-53f98563b093"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine tablets is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patien"], "temporal_context_qualifier": "after disease progression on prior anthracycline-containing chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "stage-III (Dukes' stage-C) colon cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8b38c3a-9c33-5ddc-9ce0-d564b61d5f55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "object": "MONDO:0021063", "object_location_in_text": [119, 131], "original_object": "colon cancer", "original_subject": "capecitabine", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:capecitabine-medac", "https://www.ema.europa.eu/en/documents/product-information/capecitabine-medac-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac"]}], "subject": "CHEBI:31348", "supporting_text": ["Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer. Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated."], "temporal_context_qualifier": "following surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37027c61-2256-5837-a510-7fc33021ef1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "UMLS:C0278488", "object_location_in_text": [1756, 1780], "original_object": "metastatic breast cancer", "original_subject": "CAPECITABINE", "population_context_qualifier": "patients resistant to both paclitaxel and an anthracycline-containing regimen; patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2871c37d-5e55-437b-a434-fc86d845492a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2871c37d-5e55-437b-a434-fc86d845492a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2871c37d-5e55-437b-a434-fc86d845492a"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer • Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer Capecitabine tablets USP is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5- fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes' C colon cancer. Capecitabine tablets USP are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine tablets monotherapy. Use of capecitabine tablets USP instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer Capecitabine tablets USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:150b6e31-8ba1-5e4d-a465-978ea430afc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5a34c72f-8802-598f-bf07-b5ef65fe4daf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "UMLS:C5400195", "object_location_in_text": [1004, 1036], "original_object": "gastroesophageal junction cancer", "original_subject": "CAPECITABINE", "population_context_qualifier": "adults who have not received prior treatment for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5753679a-506c-4ac4-b8b2-b27c664d1d40", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5753679a-506c-4ac4-b8b2-b27c664d1d40", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5753679a-506c-4ac4-b8b2-b27c664d1d40"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92e902e4-2f3c-55d4-8cf6-33c185371e7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5a34c72f-8802-598f-bf07-b5ef65fe4daf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "UMLS:C5400195", "object_location_in_text": [1004, 1036], "original_object": "gastroesophageal junction cancer", "original_subject": "CAPECITABINE", "population_context_qualifier": "adults who have not received prior treatment for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3b1a2b5-f1ce-45ea-afd8-68aac53665fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3b1a2b5-f1ce-45ea-afd8-68aac53665fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3b1a2b5-f1ce-45ea-afd8-68aac53665fa"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0827a91-4e86-5ef9-b409-1ec8a396f6cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980430", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5a34c72f-8802-598f-bf07-b5ef65fe4daf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c888cf1d-25f3-5015-b528-048505da0ca9", "medic_supporting_text_truncated": true, "object": "UMLS:C5400195", "object_location_in_text": [1004, 1036], "original_object": "gastroesophageal junction cancer", "original_subject": "CAPECITABINE", "population_context_qualifier": "adults who have not received prior treatment for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e28a5ef7-4731-f8ac-e053-2995a90a21bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e28a5ef7-4731-f8ac-e053-2995a90a21bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e28a5ef7-4731-f8ac-e053-2995a90a21bf"]}], "subject": "CHEBI:31348", "supporting_text": ["1 INDICATIONS AND USAGE Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) 1.1 Colorectal Cancer Capecitabine tablets are indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. 1.2 Breast Cancer Capecitabine tablets are indicated for the: treatment of patients with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05fb27e8-d754-51b9-9329-1f6e140b59b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e176b6ef-2ff6-498b-a9d8-7a634d147f37", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e176b6ef-2ff6-498b-a9d8-7a634d147f37", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e176b6ef-2ff6-498b-a9d8-7a634d147f37"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e92272d-91a8-5d12-834f-9f210a2f1a91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9eb057eb-29ce-40d2-9ac8-ed107f25f5ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9eb057eb-29ce-40d2-9ac8-ed107f25f5ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9eb057eb-29ce-40d2-9ac8-ed107f25f5ab"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278689", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24430315-adf5-5496-a853-66df336ba627", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278689"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients with recurrent disease after prior chemotherapy; patients previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4baa639-287b-4d97-923f-ce5c6add531c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4baa639-287b-4d97-923f-ce5c6add531c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4baa639-287b-4d97-923f-ce5c6add531c"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a661d54-dc0c-5a14-a196-1e671b652d6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5484d2f0-0cc2-4bba-8f26-c7f6539a9606", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5484d2f0-0cc2-4bba-8f26-c7f6539a9606", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5484d2f0-0cc2-4bba-8f26-c7f6539a9606"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d872b18-8677-5dd1-a54a-1a55088a8ffd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48aa7ef3-9f44-2a08-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48aa7ef3-9f44-2a08-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48aa7ef3-9f44-2a08-e054-00144ff88e88"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52457ccd-629c-5dff-8d36-510dad1955dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c275825-0275-4c73-b650-e4c1519f13b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c275825-0275-4c73-b650-e4c1519f13b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c275825-0275-4c73-b650-e4c1519f13b8"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52e37fe8-254f-5323-a76b-54f8b10c8c31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:47677091-fd20-49af-933c-c9dd2be21de9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=47677091-fd20-49af-933c-c9dd2be21de9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=47677091-fd20-49af-933c-c9dd2be21de9"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt;2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin Injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f95e622-3bac-5fa1-bffe-603ec9e30570", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330f5a2-2cad-402f-bcbb-26245a753276", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330f5a2-2cad-402f-bcbb-26245a753276", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330f5a2-2cad-402f-bcbb-26245a753276"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abd7810b-71bf-5c29-899c-da6bb940534f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5fe9a20-47a5-45b9-ab06-c6158d9b6aca"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3aaebd6-2e76-522b-bc15-04413cbd2d00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f64a0cbe-7fe3-407e-8933-21c30e1a1ebc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f64a0cbe-7fe3-407e-8933-21c30e1a1ebc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f64a0cbe-7fe3-407e-8933-21c30e1a1ebc"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d450d96a-4265-5800-aa84-260cb29604dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5abfcb87-bb02-4384-9c9d-7d0e3e809311", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5abfcb87-bb02-4384-9c9d-7d0e3e809311", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5abfcb87-bb02-4384-9c9d-7d0e3e809311"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8473d99-20ae-5fa6-ac7f-bcc84bd70f3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c89cedc-e48b-445c-ad05-54dbe60e4fb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c89cedc-e48b-445c-ad05-54dbe60e4fb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c89cedc-e48b-445c-ad05-54dbe60e4fb0"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt; 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."], "temporal_context_qualifier": "recurrent after prior chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "prior cisplatin treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec911f30-12dc-5b94-987a-dcf2879858ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890303", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06938bd5-39f3-5f56-853b-41124d6f6d8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:21ac14ef-2848-548a-a63e-02af9b5977e1", "object": "MONDO:0005140", "object_location_in_text": [133, 150], "original_object": "ovarian carcinoma", "original_subject": "CARBOPLATIN", "population_context_qualifier": "patients who have been previously treated with cisplatin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3ae9880-44bb-4f4e-93d8-8a5e21708a30", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3ae9880-44bb-4f4e-93d8-8a5e21708a30", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3ae9880-44bb-4f4e-93d8-8a5e21708a30"]}], "subject": "CHEBI:31355", "supporting_text": ["INDICATIONS Initial Treatment of Advanced Ovarian Carcinoma Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of Carboplatin Injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt;2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin Injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acute, sub-acute and chronic infections", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d657143e-c9ba-5c45-8a54-7c3aa4d6915f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120701", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:1d81dbe1-c7de-52c0-b358-ede5c33f0cdd", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ee997c1a-cfcc-5657-912f-c425c5cbe3b7", "object": "MONDO:0002465", "object_location_in_text": [450, 462], "original_object": "broncholitis", "original_subject": "Clenbuterol Hydrochloride Solution for injection 30mcg/ml", "population_context_qualifier": "horses", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31410", "supporting_text": ["For the treatment of equine respiratory diseases in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is contributing factor and improved muco-ciliary clearance is desirable. The product should be used alone or as an adjuvant therapy. The product is of particular value in cases of: - Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospam e.g. Bronchitis, broncholitis and Bronchopneumonia - Acute, sub-acute and chronic respiratory allergies. - Chronic obstructive pulmonary disease (COPD)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acute, sub-acute and chronic infections", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80956380-3651-5e65-ac43-1ab6613ae9a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120701", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ee997c1a-cfcc-5657-912f-c425c5cbe3b7", "object": "MONDO:0003781", "original_object": "bronchitis", "original_subject": "Clenbuterol Hydrochloride Solution for injection 30mcg/ml", "population_context_qualifier": "horses", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31410", "supporting_text": ["For the treatment of equine respiratory diseases in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is contributing factor and improved muco-ciliary clearance is desirable. The product should be used alone or as an adjuvant therapy. The product is of particular value in cases of: - Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospam e.g. Bronchitis, broncholitis and Bronchopneumonia - Acute, sub-acute and chronic respiratory allergies. - Chronic obstructive pulmonary disease (COPD)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acute, sub-acute and chronic infections", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2dd8ef79-2712-5f56-a69e-3b6f7d987bf8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120701", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:4890a9d5-1fac-531e-afeb-3eccd574465c", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ee997c1a-cfcc-5657-912f-c425c5cbe3b7", "object": "MONDO:0005682", "original_object": "bronchopneumonia", "original_subject": "Clenbuterol Hydrochloride Solution for injection 30mcg/ml", "population_context_qualifier": "horses", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31410", "supporting_text": ["For the treatment of equine respiratory diseases in horses where airway obstruction due to bronchospasm and/or accumulation of mucus is contributing factor and improved muco-ciliary clearance is desirable. The product should be used alone or as an adjuvant therapy. The product is of particular value in cases of: - Acute, sub-acute and chronic infections where the presence of mucus and/or micro-organisms may stimulate bronchospam e.g. Bronchitis, broncholitis and Bronchopneumonia - Acute, sub-acute and chronic respiratory allergies. - Chronic obstructive pulmonary disease (COPD)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1705869", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f009ea08-cf4c-5034-878c-a1fd4111fa0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080623", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1705869"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8c3721f-cf12-5e6b-9928-eaf1d62999f1", "object": "HP:0012531", "object_location_in_text": [143, 147], "original_object": "pain", "original_subject": "DIFLUPREDNATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f9a1987-6a04-4764-94e5-7053997c058b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f9a1987-6a04-4764-94e5-7053997c058b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f9a1987-6a04-4764-94e5-7053997c058b"]}], "subject": "CHEBI:31485", "supporting_text": ["1 INDICATIONS AND USAGE Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) The treatment of endogenous anterior uveitis. ( 1.2 ) 1.1 Ocular Surgery Difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. 1.2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1705869", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdace67a-9e0d-5a11-b976-7a9576a9f29e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080623", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1705869"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8c3721f-cf12-5e6b-9928-eaf1d62999f1", "object": "UMLS:C0021368", "object_location_in_text": [126, 138], "original_object": "inflammation", "original_subject": "DIFLUPREDNATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f9a1987-6a04-4764-94e5-7053997c058b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f9a1987-6a04-4764-94e5-7053997c058b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f9a1987-6a04-4764-94e5-7053997c058b"]}], "subject": "CHEBI:31485", "supporting_text": ["1 INDICATIONS AND USAGE Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) The treatment of endogenous anterior uveitis. ( 1.2 ) 1.1 Ocular Surgery Difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. 1.2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0be93c24-8b59-5a03-9d11-4ed5ca114960", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070726", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5392833"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:9c1f4417-2f13-52c7-ac8d-2075c7a4fe39", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:9e8bf682-400d-5b47-bbdc-ec995aba904b", "object": "UMLS:C0235031", "object_location_in_text": [19, 38], "original_object": "neurologic symptoms", "original_subject": "Idaravone Injection (1.5mg/ml).", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31530", "supporting_text": ["For improvement of neurologic symptoms, disorders of activitis of daily living and functional disorder associated with acute ischemic stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.513, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa53a39b-ce80-5da6-9dba-4c8b12b1c4c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070726", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5392833"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:35676973-44e8-5756-8a4d-bd0595009a0f", "medic_pair_confidence": 0.513, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:9e8bf682-400d-5b47-bbdc-ec995aba904b", "object": "UMLS:C0277785", "object_location_in_text": [83, 102], "original_object": "functional disorder", "original_subject": "Idaravone Injection (1.5mg/ml).", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31530", "supporting_text": ["For improvement of neurologic symptoms, disorders of activitis of daily living and functional disorder associated with acute ischemic stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance to non-nucleoside reverse transcriptase inhibitor class, high viral load", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49944fef-18a9-595d-b1e1-e148fb9517f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160621", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3e96d3a8-b1d7-5f28-bb2b-638f59d433d2", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:191191c6-1898-5bfa-ad9f-78b19bf50043", "object": "UMLS:C0276500", "original_object": "human immunodeficiency virus-1 infection", "original_subject": "emtricitabine;rilpivirine;tenofovir alafenamide", "population_context_qualifier": "adults and adolescents aged 12 years and older with body weight at least 35 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emtricitabine-rilpivirine-tenofovir-alafenamide-viatris", "https://www.ema.europa.eu/en/documents/product-information/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris"]}], "subject": "CHEBI:31536", "supporting_text": ["Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100 000 HIV 1 RNA copies/mL&nbsp;(see sections 4.2, 4.4 and 5.1).&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance to non nucleoside reverse transcriptase inhibitor class, viral load", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b1ca056-8f03-559f-b889-6e2d3973a6e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160621", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f1475649-ce35-5d0b-a657-2c38aa869dc9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:191191c6-1898-5bfa-ad9f-78b19bf50043", "object": "UMLS:C0276500", "original_object": "human immunodeficiency virus 1 infection", "original_subject": "emtricitabine;rilpivirine;tenofovir alafenamide", "population_context_qualifier": "adults and adolescents aged 12 years and older with body weight at least 35 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:odefsey", "https://www.ema.europa.eu/en/documents/product-information/odefsey-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey"]}], "subject": "CHEBI:31536", "supporting_text": ["Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ? 100,000 HIV 1 RNA copies/mL."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NRTI resistance, toxicities", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67ea4e06-cb80-54b8-9467-ad3751509e97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:17f3610b-31ae-5c05-855f-1c61bd1127ad", "object": "UMLS:C2363741", "object_location_in_text": [13, 28], "original_object": "HIV-1 infection", "original_subject": "emtricitabine;tenofovir disoproxil", "population_context_qualifier": "adolescents, aged 12 to < 18 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:truvada", "https://www.ema.europa.eu/en/documents/product-information/truvada-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/truvada"]}], "subject": "CHEBI:31536", "supporting_text": ["Treatment of HIV-1 infection:  Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years.  Pre-exposure prophylaxis (PrEP):  Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NRTI resistance, toxicities", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96063f50-5bc8-5f82-abce-4837f8b6dbb7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:17f3610b-31ae-5c05-855f-1c61bd1127ad", "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "emtricitabine;tenofovir disoproxil", "population_context_qualifier": "adolescents aged 12 to < 18 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emtricitabine-tenofovir-disoproxil-krka-dd", "https://www.ema.europa.eu/en/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka-dd"]}], "subject": "CHEBI:31536", "supporting_text": ["Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e804f8d-c2db-51a3-b797-3a539f2b135a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399ef3f8-5be3-5f76-98c7-402a9c0c79fd", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "object": "UMLS:C1565489", "original_object": "moderate renal impairment", "original_subject": "EPLERENONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8323922-191d-4bfc-8871-fbe15a8a7b58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8323922-191d-4bfc-8871-fbe15a8a7b58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8323922-191d-4bfc-8871-fbe15a8a7b58"]}], "subject": "CHEBI:31547", "supporting_text": ["4 CONTRAINDICATIONS For All Patients Eplerenone tablets are contraindicated in all patients with: serum potassium &gt;5.5 mEq/L at initiation, creatinine clearance ≤30 mL/min, or concomitant administration of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). [See DRUG INTERACTIONS , 7.1 CYP3A4 Inhibitors , CLINICAL PHARMACOLOGY , 12.3 Pharmacokinetics .] For Patients Treated for Hypertension Eplerenone tablets is contraindicated for the treatment of hypertension in patients with: type 2 diabetes with microalbuminuria, serum creatinine &gt;2.0 mg/dL in males or &gt;1.8 mg/dL in females, creatinine clearance &lt;50 mL/min, or concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone or triamterene). [See WARNINGS AND PRECAUTIONS , 5.1 Hyperkalemia , ADVERSE REACTIONS , 6.2 Clinical Laboratory Test Findings , 7 DRUG INTERACTIONS , and CLINICAL PHARMACOLOGY , 12.3 Pharmacokinetics .] For all patients: Serum potassium &gt;5.5 mEq/L at initiation (4) Creatinine clearance ≤30 mL/min (4) Concomitant use with strong CYP3A4 inhibitors (4, 7.1) For the treatment of hypertension: Type 2 diabetes with microalbuminuria (4) Serum creatinine &gt;2.0 mg/dL in males, &gt;1.8 mg/dL in females (4) Creatinine clearance &lt;50 mL/min (4) Concomitant use of potassium supplements or potassium-sparing diuretics (4)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ff98b12-e927-5b1a-9665-fae213c26e68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399ef3f8-5be3-5f76-98c7-402a9c0c79fd", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "object": "UMLS:C1565489", "original_object": "moderate renal impairment", "original_subject": "EPLERENONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4743a48b-d4b5-4054-85e1-9d64cc40de25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4743a48b-d4b5-4054-85e1-9d64cc40de25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4743a48b-d4b5-4054-85e1-9d64cc40de25"]}], "subject": "CHEBI:31547", "supporting_text": ["4 CONTRAINDICATIONS For All Patients Eplerenone tablets are contraindicated in all patients with: serum potassium &gt;5.5 mEq/L at initiation, creatinine clearance ≤30 mL/min, or concomitant administration of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). [See DRUG INTERACTIONS , 7.1 CYP3A4 Inhibitors , CLINICAL PHARMACOLOGY , 12.3 Pharmacokinetics .] For Patients Treated for Hypertension Eplerenone tablets is contraindicated for the treatment of hypertension in patients with: type 2 diabetes with microalbuminuria, serum creatinine &gt;2.0 mg/dL in males or &gt;1.8 mg/dL in females, creatinine clearance &lt;50 mL/min, or concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone or triamterene). [See WARNINGS AND PRECAUTIONS , 5.1 Hyperkalemia , ADVERSE REACTIONS , 6.2 Clinical Laboratory Test Findings , 7 DRUG INTERACTIONS , and CLINICAL PHARMACOLOGY , 12.3 Pharmacokinetics .] For all patients: Serum potassium &gt;5.5 mEq/L at initiation (4) Creatinine clearance ≤30 mL/min (4) Concomitant use with strong CYP3A4 inhibitors (4, 7.1) For the treatment of hypertension: Type 2 diabetes with microalbuminuria (4) Serum creatinine &gt;2.0 mg/dL in males, &gt;1.8 mg/dL in females (4) Creatinine clearance &lt;50 mL/min (4) Concomitant use of potassium supplements or potassium-sparing diuretics (4)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c450990-5047-5005-abca-ca5e3468644c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49b9759a-c1b9-4ebe-874b-81fb82a42755", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49b9759a-c1b9-4ebe-874b-81fb82a42755", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49b9759a-c1b9-4ebe-874b-81fb82a42755"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f3414b1-dcad-5cec-8e18-02db2d9d779a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a52bedc-8e2c-4116-a296-a87770676b4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE INSPRA is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c239fb7-7754-527d-8bb4-d353fee07a38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:316d3a98-4cd1-4499-a34c-cac87e016944", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=316d3a98-4cd1-4499-a34c-cac87e016944", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=316d3a98-4cd1-4499-a34c-cac87e016944"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been a re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c3c5a69-4486-59b4-86db-cfa059e3d602", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b66a393-8af1-42bc-9673-89fe471147ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b66a393-8af1-42bc-9673-89fe471147ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b66a393-8af1-42bc-9673-89fe471147ee"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS &amp; USAGE Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40 %) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone tablets is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47f9e2ec-235b-5062-a4ef-0da72a6823a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4286699b-2320-4d3d-831c-32085f36fb67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4286699b-2320-4d3d-831c-32085f36fb67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4286699b-2320-4d3d-831c-32085f36fb67"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤ 40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome bene"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d39fa93-c0f8-5d90-b022-750056b89ca6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0886e4e-5710-4053-9270-4d7de34068e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0886e4e-5710-4053-9270-4d7de34068e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0886e4e-5710-4053-9270-4d7de34068e7"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94e4f599-db4d-57b3-8850-7bd26258c9d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2002cf90-2d4a-43b1-bcd6-c447cbc7010f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2002cf90-2d4a-43b1-bcd6-c447cbc7010f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2002cf90-2d4a-43b1-bcd6-c447cbc7010f"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been a re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d62f0dce-5e75-59d1-bcf2-106f05e4dbfe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25a1c77c-7008-4b07-af14-5522a282783a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25a1c77c-7008-4b07-af14-5522a282783a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25a1c77c-7008-4b07-af14-5522a282783a"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone tablets are an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5dcf032-ec4d-53d7-a718-7fd3d44685ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d953457e-0aff-6c38-e053-2995a90a7d32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d953457e-0aff-6c38-e053-2995a90a7d32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d953457e-0aff-6c38-e053-2995a90a7d32"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been a re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb179a38-18f8-565f-afda-e99499766d41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone Tablets are an aldosterone antagonist indicated for: Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone Tablets are indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone Tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1dd30328-f5a6-583c-986f-bf16373d9dfa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49b9759a-c1b9-4ebe-874b-81fb82a42755", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49b9759a-c1b9-4ebe-874b-81fb82a42755", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49b9759a-c1b9-4ebe-874b-81fb82a42755"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28f7ff79-fdb6-5f4f-84f4-ab7f6dad16ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2a51c12-bdc2-4b3b-8e9e-bf363c2817ed"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone Tablets are an aldosterone antagonist indicated for: Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone Tablets are indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone Tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4de1344a-c114-52fa-8c6c-d6a2d7e78fea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b66a393-8af1-42bc-9673-89fe471147ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b66a393-8af1-42bc-9673-89fe471147ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b66a393-8af1-42bc-9673-89fe471147ee"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS &amp; USAGE Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40 %) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone tablets is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8bc3c31-5816-5086-a038-6e23216e5885", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:316d3a98-4cd1-4499-a34c-cac87e016944", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=316d3a98-4cd1-4499-a34c-cac87e016944", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=316d3a98-4cd1-4499-a34c-cac87e016944"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been a re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0f2efb6-9310-5845-b049-a7f8d577bcdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25a1c77c-7008-4b07-af14-5522a282783a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25a1c77c-7008-4b07-af14-5522a282783a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25a1c77c-7008-4b07-af14-5522a282783a"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone tablets are an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1485641-f5a5-5f62-8386-fe966d146aa5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2002cf90-2d4a-43b1-bcd6-c447cbc7010f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2002cf90-2d4a-43b1-bcd6-c447cbc7010f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2002cf90-2d4a-43b1-bcd6-c447cbc7010f"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been a re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e251b16c-2bd2-55d8-affb-372fd3aa111c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0886e4e-5710-4053-9270-4d7de34068e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0886e4e-5710-4053-9270-4d7de34068e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0886e4e-5710-4053-9270-4d7de34068e7"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8b5b2e1-0b38-51dd-a78e-eec4db9d6546", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d953457e-0aff-6c38-e053-2995a90a7d32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d953457e-0aff-6c38-e053-2995a90a7d32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d953457e-0aff-6c38-e053-2995a90a7d32"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI) . 1.2 Hypertension Eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV ) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been a re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eeac5bf8-8226-53cf-b465-7a6d982c6c0c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a52bedc-8e2c-4116-a296-a87770676b4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE INSPRA is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome benefit has been "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0b359fd-d390-5ddf-a350-c5d5f97c00ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "EPLERENONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4286699b-2320-4d3d-831c-32085f36fb67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4286699b-2320-4d3d-831c-32085f36fb67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4286699b-2320-4d3d-831c-32085f36fb67"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction Eplerenone is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤ 40%) (HFrEF) after an acute myocardial infarction (MI). 1.2 Hypertension Eplerenone is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce CV morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent CV outcome bene"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0025169", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6cad7b01-38ba-5fe2-9638-78dc891c4a40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025169"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6849c126-828f-5ce8-95f2-ae98435fe4ec", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "object": "MONDO:0005009", "object_location_in_text": [697, 721], "original_object": "congestive heart failure", "original_subject": "EPLERENONE", "population_context_qualifier": "stable patients with ejection fraction ≤40%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7bc9486-8e61-4ba1-827f-2cd8c304b454", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE INSPRA is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. ( 1.2 ) Hypertension, alone or combined with other agents. ( 1.3 ) 1.1 Patient Selection Considerations Serum potassium levels should be measured before initiating INSPRA therapy, and INSPRA should not be prescribed if serum potassium is &gt;5.5 mEq/L. [See CONTRAINDICATIONS (4) ] . 1.2 Congestive Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable patients with left ventricular (LV) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (CHF) after an acute myocardial infarction (MI). 1.3 Hypertension INSPRA is indicated for the treatment of hypertension. INSPRA may be used alone or in combination with other antihypertensive agents."], "temporal_context_qualifier": "after an acute myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0025169", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f0bb6df-efed-5ec5-93e4-239558d895f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025169", "MONDO:0004781"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "EPLERENONE", "population_context_qualifier": "stable patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4743a48b-d4b5-4054-85e1-9d64cc40de25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4743a48b-d4b5-4054-85e1-9d64cc40de25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4743a48b-d4b5-4054-85e1-9d64cc40de25"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. (1.2) Hypertension, alone or combined with other agents. (1.3) 1.1 Patient Selection Considerations Serum potassium levels should be measured before initiating eplerenone therapy and eplerenone should not be prescribed if serum potassium is &gt;5.5 mEq/L. [See 4 CONTRAINDICATIONS ]. 1.2 Congestive Heart Failure Post-Myocardial Infarction Eplerenone is indicated to improve survival of stable patients with left ventricular (LV) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (CHF) after an acute myocardial infarction (MI). 1.3 Hypertension Eplerenone is indicated for the treatment of hypertension. Eplerenone may be used alone or in combination with other antihypertensive agents."], "temporal_context_qualifier": "after an acute myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0025169", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:844d2ad5-f293-5ed0-8b7b-42f87cb2e6a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020927", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025169", "MONDO:0004781"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:083aaac2-01c3-52e6-85fb-a79f888ce06d", "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "EPLERENONE", "population_context_qualifier": "stable patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8323922-191d-4bfc-8871-fbe15a8a7b58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8323922-191d-4bfc-8871-fbe15a8a7b58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8323922-191d-4bfc-8871-fbe15a8a7b58"]}], "subject": "CHEBI:31547", "supporting_text": ["1 INDICATIONS AND USAGE Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. (1.2) Hypertension, alone or combined with other agents. (1.3) 1.1 Patient Selection Considerations Serum potassium levels should be measured before initiating eplerenone therapy and eplerenone should not be prescribed if serum potassium is &gt;5.5 mEq/L. [See 4 CONTRAINDICATIONS ]. 1.2 Congestive Heart Failure Post-Myocardial Infarction Eplerenone is indicated to improve survival of stable patients with left ventricular (LV) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (CHF) after an acute myocardial infarction (MI). 1.3 Hypertension Eplerenone is indicated for the treatment of hypertension. Eplerenone may be used alone or in combination with other antihypertensive agents."], "temporal_context_qualifier": "after an acute myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002149", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6487e894-4d4a-52a1-8cb7-ad81a7340a74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002149"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:269a2b4a-830f-5d2e-b743-62018e1202a0", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:5a7c34dc-d4ab-5d45-89c0-cd86df81d98d", "object": "HP:0001997", "object_location_in_text": [148, 163], "original_object": "gouty arthritis", "original_subject": "Febuxostat Tablets 80mg / 120mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31596", "supporting_text": ["For treatment of chronic hyperuricemia in conditions where urate depression has already occured (including a history, or presence of tophus and /or gouty arthritis)."], "temporal_context_qualifier": "in conditions where urate depression has already occured"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0221248", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bdf1240-28ea-53ba-b066-26b9eafdda0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080421", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221248", "HP:0001997"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1199907e-65cf-56a8-b4c9-8df478c50574", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:442daa49-5624-5dea-8e83-ff9a15dcb1c6", "object": "HP:0002149", "object_location_in_text": [30, 52], "original_object": "chronic hyperuricaemia", "original_subject": "febuxostat", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:adenuric", "https://www.ema.europa.eu/en/documents/product-information/adenuric-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric"]}], "subject": "CHEBI:31596", "supporting_text": ["80 mg strength:  Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Adenuric is indicated in adults.  120 mg strength:  Adenuric is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Adenuric is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS). Adenuric is indicated in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0221248", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58afe2fe-7dd5-513e-bb7b-6f6bc51d5cdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080421", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221248", "HP:0001997"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1199907e-65cf-56a8-b4c9-8df478c50574", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:442daa49-5624-5dea-8e83-ff9a15dcb1c6", "object": "HP:0002149", "object_location_in_text": [53, 75], "original_object": "chronic hyperuricaemia", "original_subject": "febuxostat", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:febuxostat-viatris", "https://www.ema.europa.eu/en/documents/product-information/febuxostat-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-viatris"]}], "subject": "CHEBI:31596", "supporting_text": ["Febuxostat Viatris is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Viatris is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).&nbsp;&nbsp; Febuxostat Viatris is indicated in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0221248", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75d23f91-7acd-506c-80e3-58c9cf3e3661", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080421", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221248", "HP:0001997"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1199907e-65cf-56a8-b4c9-8df478c50574", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:442daa49-5624-5dea-8e83-ff9a15dcb1c6", "object": "HP:0002149", "object_location_in_text": [50, 72], "original_object": "chronic hyperuricaemia", "original_subject": "febuxostat", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:febuxostat-krka", "https://www.ema.europa.eu/en/documents/product-information/febuxostat-krka-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-krka"]}], "subject": "CHEBI:31596", "supporting_text": ["Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Krka is indicated in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001997", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af84f40f-3c15-5905-bdd1-2a6fa25397f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001997", "UMLS:C0221248"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6839be57-dcc9-56a0-b7d7-90009db97719", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:5a7c34dc-d4ab-5d45-89c0-cd86df81d98d", "object": "MONDO:0002144", "object_location_in_text": [17, 38], "original_object": "chronic hyperuricemia", "original_subject": "Febuxostat Tablets 80mg / 120mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31596", "supporting_text": ["For treatment of chronic hyperuricemia in conditions where urate depression has already occured (including a history, or presence of tophus and /or gouty arthritis)."], "temporal_context_qualifier": "following urate depression"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002149", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f26caf4a-896d-5785-b274-51fad6d11d63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080421", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002149"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1941ad84-b5a4-5251-8343-3f708f47dfdb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:442daa49-5624-5dea-8e83-ff9a15dcb1c6", "object": "MONDO:0005393", "original_object": "gout", "original_subject": "febuxostat", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:febuxostat-krka", "https://www.ema.europa.eu/en/documents/product-information/febuxostat-krka-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-krka"]}], "subject": "CHEBI:31596", "supporting_text": ["Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Krka is indicated in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002149", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:595fa03e-7471-5af4-8d60-f0dfd016e01b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002149"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:c96d37c1-65ee-5aa3-a2cc-e1f20abe1041", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:5a7c34dc-d4ab-5d45-89c0-cd86df81d98d", "object": "UMLS:C0221248", "object_location_in_text": [133, 139], "original_object": "tophus", "original_subject": "Febuxostat Tablets 80mg / 120mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:31596", "supporting_text": ["For treatment of chronic hyperuricemia in conditions where urate depression has already occured (including a history, or presence of tophus and /or gouty arthritis)."], "temporal_context_qualifier": "in conditions where urate depression has already occured"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "intradetrusor injection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b5ac8a9-8b58-5f31-bf7f-d37b2f2d363f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4d1c0c7-3240-564b-bab9-d11e5c06a1f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "HP:0000016", "object_location_in_text": [356, 373], "original_object": "urinary retention", "original_subject": "BOTULINUM TOXIN TYPE A", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38"]}], "subject": "CHEBI:3160", "supporting_text": ["4 CONTRAINDICATIONS BOTOX is contraindicated: In patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions ( 5.4 )] . In the presence of infection at the proposed injection site(s). For intradetrusor injection in patients with a urinary tract infection; or in patients with urinary retention or post-void residual (PVR) urine volume &gt;200 mL who are not routinely performing clean intermittent self-catheterization (CIC) [see Warnings and Precautions ( 5.12 , 5.13 )] . Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation ( 4 , 5.4 , 6 ) Infection at the proposed injection site ( 4 ) Intradetrusor Injections: Urinary tract infection or urinary retention ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "intradetrusor injection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb9de84b-52be-5709-844e-e035dcca1f93", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4d1c0c7-3240-564b-bab9-d11e5c06a1f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "HP:0000016", "object_location_in_text": [356, 373], "original_object": "urinary retention", "original_subject": "BOTULINUM TOXIN TYPE A", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300"]}], "subject": "CHEBI:3160", "supporting_text": ["4 CONTRAINDICATIONS BOTOX is contraindicated: In patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions ( 5.4 )] . In the presence of infection at the proposed injection site(s). For intradetrusor injection in patients with a urinary tract infection; or in patients with urinary retention or post-void residual (PVR) urine volume &gt;200 mL who are not routinely performing clean intermittent self-catheterization (CIC) [see Warnings and Precautions ( 5.12 , 5.13 )] . Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation ( 4 , 5.4 , 6 ) Infection at the proposed injection site ( 4 ) Intradetrusor Injections: Urinary tract infection or urinary retention ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "intradetrusor injection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59a383e7-7d88-5618-9395-3ba15c0b8b39", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "BOTULINUM TOXIN TYPE A", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38"]}], "subject": "CHEBI:3160", "supporting_text": ["4 CONTRAINDICATIONS BOTOX is contraindicated: In patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions ( 5.4 )] . In the presence of infection at the proposed injection site(s). For intradetrusor injection in patients with a urinary tract infection; or in patients with urinary retention or post-void residual (PVR) urine volume &gt;200 mL who are not routinely performing clean intermittent self-catheterization (CIC) [see Warnings and Precautions ( 5.12 , 5.13 )] . Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation ( 4 , 5.4 , 6 ) Infection at the proposed injection site ( 4 ) Intradetrusor Injections: Urinary tract infection or urinary retention ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "intradetrusor injection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a17e041-23c6-5cf7-94f4-9d4b836d301e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "BOTULINUM TOXIN TYPE A", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300"]}], "subject": "CHEBI:3160", "supporting_text": ["4 CONTRAINDICATIONS BOTOX is contraindicated: In patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions ( 5.4 )] . In the presence of infection at the proposed injection site(s). For intradetrusor injection in patients with a urinary tract infection; or in patients with urinary retention or post-void residual (PVR) urine volume &gt;200 mL who are not routinely performing clean intermittent self-catheterization (CIC) [see Warnings and Precautions ( 5.12 , 5.13 )] . Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation ( 4 , 5.4 , 6 ) Infection at the proposed injection site ( 4 ) Intradetrusor Injections: Urinary tract infection or urinary retention ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1960870", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2381f832-c9b4-5466-b395-d0feac1f5215", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C1960870"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f99bd60c-a77b-533e-bd80-abda1c428032", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "HP:0002315", "object_location_in_text": [798, 807], "original_object": "headaches", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300"]}], "subject": "CHEBI:3160", "supporting_text": ["1 INDICATIONS AND USAGE BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1960870", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:482d8e43-6854-5c15-b7d9-c92815de29ee", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C1960870"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f99bd60c-a77b-533e-bd80-abda1c428032", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "HP:0002315", "object_location_in_text": [798, 807], "original_object": "headaches", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38"]}], "subject": "CHEBI:3160", "supporting_text": ["1 INDICATIONS AND USAGE BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268849", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22678322-7bce-5ce3-b969-17e455b39a7e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268849", "MONDO:0043797", "MONDO:0005301"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:109f310a-0da4-5ce1-ae0d-09b30de83e84", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "HP:0000020", "object_location_in_text": [178, 198], "original_object": "urinary incontinence", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "adults who have an inadequate response to or are intolerant of an anticholinergic medication", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300"]}], "subject": "CHEBI:3160", "supporting_text": ["1 INDICATIONS AND USAGE BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268849", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c31b84a-4bee-55d0-9fb4-08fdcdbfe679", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268849", "MONDO:0043797", "MONDO:0005301"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:109f310a-0da4-5ce1-ae0d-09b30de83e84", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "HP:0000020", "object_location_in_text": [178, 198], "original_object": "urinary incontinence", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "adults who have an inadequate response to or are intolerant of an anticholinergic medication", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38"]}], "subject": "CHEBI:3160", "supporting_text": ["1 INDICATIONS AND USAGE BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18fb78ca-b08f-5874-a299-e0ff413f3b79", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "adults who have an inadequate response to or are intolerant of an anticholinergic medication", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6f42753-d31e-4b23-8da0-4b990fee4b38"]}], "subject": "CHEBI:3160", "supporting_text": ["1 INDICATIONS AND USAGE BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b418053d-6a60-59cb-a07a-56037ffb48ce", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "adults who have an inadequate response to or are intolerant of an anticholinergic medication", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300"]}], "subject": "CHEBI:3160", "supporting_text": ["1 INDICATIONS AND USAGE BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "lower limb spasticities, juvenile cerebral palsy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e727b27a-7369-5020-b50f-8d1ccb9f7178", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9a76320d-415b-583d-be56-deb1381e9d83", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0e0b0c3f-dc39-537a-997b-2035af2f757d", "object": "UMLS:C0014670", "object_location_in_text": [77, 94], "original_object": "equinus deformity", "original_subject": "BOTULINUM TOXIN TYPE A", "population_context_qualifier": "patients 2 years or older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BOTULINUM TOXIN TYPE A#172-20090223", "https://www.pmda.go.jp/files/000216948.pdf"]}], "subject": "CHEBI:3160", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of equinus deformity associated with lower limb spasticities in juvenile cerebral palsy in patients 2 years or older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e5c84bd-6e4d-5748-9dbc-c0ef9c686149", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e118267-d791-5277-8a36-7b38f2338e23", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "FLUOCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:372a6a06-c9de-48d5-ad02-c4004038f85e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=372a6a06-c9de-48d5-ad02-c4004038f85e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=372a6a06-c9de-48d5-ad02-c4004038f85e"]}], "subject": "CHEBI:31623", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff9ac8e5-6d70-5bcf-80d6-9e1a7ba8ba97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e118267-d791-5277-8a36-7b38f2338e23", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "FLUOCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:de5b78ab-ff79-3e0f-cad4-ecab11ebbdcd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=de5b78ab-ff79-3e0f-cad4-ecab11ebbdcd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de5b78ab-ff79-3e0f-cad4-ecab11ebbdcd"]}], "subject": "CHEBI:31623", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3495949", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:426e8558-962f-5c38-b40f-6fc8fb8c017e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040309", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3495949", "UMLS:C0278488"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5e0e7e26-ede9-594a-a3db-9a12b160d600", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0006512", "original_object": "estrogen receptor positive breast cancer", "original_subject": "fulvestrant", "population_context_qualifier": "postmenopausal women with disease progression on antiestrogen therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:fulvestrant-mylan", "https://www.ema.europa.eu/en/documents/product-information/fulvestrant-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/fulvestrant-mylan"]}], "subject": "CHEBI:31638", "supporting_text": ["Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:  not previously treated with endocrine therapy, or with disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:00a91d32-f4be-54ed-9798-a6f16e258a3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f36f19ad-f044-4dba-80b6-d074ddffcd86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f36f19ad-f044-4dba-80b6-d074ddffcd86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f36f19ad-f044-4dba-80b6-d074ddffcd86"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1712af2e-c17e-58d0-a138-e42c838c3b37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [448, 484], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ed06e0e-c17b-4c71-8d03-888bcde4a638", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ed06e0e-c17b-4c71-8d03-888bcde4a638", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ed06e0e-c17b-4c71-8d03-888bcde4a638"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3204a01e-a6bc-52c8-9db0-4ab1e884186a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:306c283b-9abe-4985-856b-1957f1f3af8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=306c283b-9abe-4985-856b-1957f1f3af8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=306c283b-9abe-4985-856b-1957f1f3af8b"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:361fc0b6-ca2c-5ca2-95e0-07b45c97d56a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:840cd7c0-9f33-f74e-f136-de7fe899bfb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=840cd7c0-9f33-f74e-f136-de7fe899bfb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=840cd7c0-9f33-f74e-f136-de7fe899bfb4"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive , human epidermal growth factor receptor 2 (HER2)-ne gative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive , HER2-ne gative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive , HER2-ne gative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37045e25-9eab-5933-9518-ae0a3bdcbaa3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [448, 484], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f05b699-c440-42c1-9557-46759a10ab17", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f05b699-c440-42c1-9557-46759a10ab17", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f05b699-c440-42c1-9557-46759a10ab17"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bb9145f-2408-5132-9441-25c6ad16232c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [502, 538], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a03f714-b109-4256-80a6-78c82127d624", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a03f714-b109-4256-80a6-78c82127d624", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a03f714-b109-4256-80a6-78c82127d624"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d55f0e0-d05f-5d45-9dd7-26eb19c026fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:994edf79-20a5-4e3a-bb35-c4fe3e65acba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=994edf79-20a5-4e3a-bb35-c4fe3e65acba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=994edf79-20a5-4e3a-bb35-c4fe3e65acba"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d3373fd-8393-5522-a7ce-57c6924e4319", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80b6dfe6-449d-4e2f-af90-bfbf9b04163b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80b6dfe6-449d-4e2f-af90-bfbf9b04163b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80b6dfe6-449d-4e2f-af90-bfbf9b04163b"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausalwomen not previouslytreatedwith endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausalwomen with disease progressionfollowingendocrinetherapy.( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer inpostmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer incombination with palbociclib or abemaciclib in women with disease progression after endocrinetherapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bb809f6-1314-5950-8990-727d85965e03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc7b4eac-3b63-53d2-e053-2995a90ad5e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc7b4eac-3b63-53d2-e053-2995a90ad5e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc7b4eac-3b63-53d2-e053-2995a90ad5e7"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97f20151-faa6-5721-a4d2-4ba66c9de3db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b02915fe-6c44-48c1-aaeb-997ddc59a595", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b02915fe-6c44-48c1-aaeb-997ddc59a595", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b02915fe-6c44-48c1-aaeb-997ddc59a595"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0ca00af-cac3-55ee-9ded-14f7c8b1e6e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b471eb51-488e-5312-e053-2a95a90a8116", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b471eb51-488e-5312-e053-2a95a90a8116", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b471eb51-488e-5312-e053-2a95a90a8116"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8c9291b-d098-54e1-8d63-710ba6646af0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [470, 506], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e20d8ca3-8837-4003-8b01-1ebec342062a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e20d8ca3-8837-4003-8b01-1ebec342062a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e20d8ca3-8837-4003-8b01-1ebec342062a"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afdf929e-0e4b-51ba-ba13-ee8c43a28e86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57352662-d2fa-4dce-828f-4c51e46e0b4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57352662-d2fa-4dce-828f-4c51e46e0b4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57352662-d2fa-4dce-828f-4c51e46e0b4d"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HR-positive, HER2-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b984d821-4950-51a1-af65-6abf1d8fbbe6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [504, 540], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99cf8b69-4c23-4886-80e9-b23e348b5bd7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy • Fulvestrant injection is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb8f2636-ca5a-5c00-891e-4bca0a941993", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [496, 532], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a51aa693-b433-4b2d-a71b-9ba029b10ce3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a51aa693-b433-4b2d-a71b-9ba029b10ce3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a51aa693-b433-4b2d-a71b-9ba029b10ce3"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbe74a5c-bda3-5580-857b-6458399a3883", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [448, 484], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46086fe7-190d-4963-97bc-1fe22d36e6d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46086fe7-190d-4963-97bc-1fe22d36e6d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46086fe7-190d-4963-97bc-1fe22d36e6d2"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f09ced45-a643-50d0-abb2-ec39b603d161", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [448, 484], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff1a60cb-90f9-50c8-af6e-aa7769e8ce1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "MONDO:0007254", "object_location_in_text": [502, 538], "original_object": "advanced or metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women with disease progression after endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:141f439e-078c-4a59-acff-ebf7685f55b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=141f439e-078c-4a59-acff-ebf7685f55b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=141f439e-078c-4a59-acff-ebf7685f55b8"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa0abd4d-6329-56c6-b20e-31f0a351f663", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C0278488", "object_location_in_text": [375, 399], "original_object": "metastatic breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or Combination Therapy Fulvestrant is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1)"], "temporal_context_qualifier": "with disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:168b0c17-d48a-5307-a373-b975d77faf01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f36f19ad-f044-4dba-80b6-d074ddffcd86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f36f19ad-f044-4dba-80b6-d074ddffcd86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f36f19ad-f044-4dba-80b6-d074ddffcd86"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29000405-f62b-58d1-a47f-1c1423c8ba17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80b6dfe6-449d-4e2f-af90-bfbf9b04163b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80b6dfe6-449d-4e2f-af90-bfbf9b04163b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80b6dfe6-449d-4e2f-af90-bfbf9b04163b"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausalwomen not previouslytreatedwith endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausalwomen with disease progressionfollowingendocrinetherapy.( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer inpostmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer incombination with palbociclib or abemaciclib in women with disease progression after endocrinetherapy. ( 1 )"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f0188ae-c3ba-5ac0-8dc9-53cde11ce388", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [169, 191], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e20d8ca3-8837-4003-8b01-1ebec342062a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e20d8ca3-8837-4003-8b01-1ebec342062a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e20d8ca3-8837-4003-8b01-1ebec342062a"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3668ec44-285d-56cd-8aed-35b499bc4aba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:994edf79-20a5-4e3a-bb35-c4fe3e65acba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=994edf79-20a5-4e3a-bb35-c4fe3e65acba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=994edf79-20a5-4e3a-bb35-c4fe3e65acba"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:372f9e7c-5334-521d-a44a-0cb07a2ce16d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [184, 206], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99cf8b69-4c23-4886-80e9-b23e348b5bd7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy • Fulvestrant injection is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:479eaaa8-420d-5fcc-8db3-b619108b7c30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57352662-d2fa-4dce-828f-4c51e46e0b4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57352662-d2fa-4dce-828f-4c51e46e0b4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57352662-d2fa-4dce-828f-4c51e46e0b4d"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47ea99db-0938-5edf-ac5c-4f4581977092", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:840cd7c0-9f33-f74e-f136-de7fe899bfb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=840cd7c0-9f33-f74e-f136-de7fe899bfb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=840cd7c0-9f33-f74e-f136-de7fe899bfb4"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive , human epidermal growth factor receptor 2 (HER2)-ne gative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive , HER2-ne gative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive , HER2-ne gative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49a0e2d7-739d-5b2d-bf30-2a350b6d822e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [202, 224], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fa81b3f-3139-5ada-bb9b-dbc6e94b7fb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [202, 224], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f05b699-c440-42c1-9557-46759a10ab17", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f05b699-c440-42c1-9557-46759a10ab17", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f05b699-c440-42c1-9557-46759a10ab17"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86c64fbd-5da2-51a9-ad21-2bff28145a6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b471eb51-488e-5312-e053-2a95a90a8116", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b471eb51-488e-5312-e053-2a95a90a8116", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b471eb51-488e-5312-e053-2a95a90a8116"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a132081c-fe2d-5748-b6f2-0cb9d4dbc974", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [184, 206], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:141f439e-078c-4a59-acff-ebf7685f55b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=141f439e-078c-4a59-acff-ebf7685f55b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=141f439e-078c-4a59-acff-ebf7685f55b8"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4623936-6e0f-5a83-bef5-806c9cecf221", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:306c283b-9abe-4985-856b-1957f1f3af8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=306c283b-9abe-4985-856b-1957f1f3af8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=306c283b-9abe-4985-856b-1957f1f3af8b"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. (1) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. (1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. (1)"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b343a2aa-ddb2-525b-b5f0-71aa3e97977a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "abemaciclib"], "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [172, 194], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or Combination Therapy Fulvestrant is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1)"], "temporal_context_qualifier": "with disease progression after endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8f48ce7-6390-5a8b-8321-266374b8988f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b02915fe-6c44-48c1-aaeb-997ddc59a595", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b02915fe-6c44-48c1-aaeb-997ddc59a595", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b02915fe-6c44-48c1-aaeb-997ddc59a595"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3bd6c62-e979-508f-847b-add1ca3b702f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc7b4eac-3b63-53d2-e053-2995a90ad5e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc7b4eac-3b63-53d2-e053-2995a90ad5e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc7b4eac-3b63-53d2-e053-2995a90ad5e7"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e023a8d7-5c53-572e-859d-83804f78b216", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [202, 224], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ed06e0e-c17b-4c71-8d03-888bcde4a638", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ed06e0e-c17b-4c71-8d03-888bcde4a638", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ed06e0e-c17b-4c71-8d03-888bcde4a638"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0427629", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee4bf57d-fcbb-5b57-94f5-7a1368359787", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0427629"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [202, 224], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46086fe7-190d-4963-97bc-1fe22d36e6d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46086fe7-190d-4963-97bc-1fe22d36e6d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46086fe7-190d-4963-97bc-1fe22d36e6d2"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy."], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9677e2b-5cd0-5148-b842-d913b641172a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [182, 204], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a51aa693-b433-4b2d-a71b-9ba029b10ce3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a51aa693-b433-4b2d-a71b-9ba029b10ce3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a51aa693-b433-4b2d-a71b-9ba029b10ce3"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fbfdff7f-1d41-57ad-9724-bb90e95a5b69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:525f3555-0dbd-56cf-8350-c9ec4a38f372", "object": "UMLS:C3495917", "object_location_in_text": [184, 206], "original_object": "advanced breast cancer", "original_subject": "FULVESTRANT", "population_context_qualifier": "postmenopausal women with disease progression following endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a03f714-b109-4256-80a6-78c82127d624", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a03f714-b109-4256-80a6-78c82127d624", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a03f714-b109-4256-80a6-78c82127d624"]}], "subject": "CHEBI:31638", "supporting_text": ["1 INDICATIONS AND USAGE Monotherapy Fulvestrant injection is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. Fulvestrant is an estrogen receptor antagonist indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) • HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) • HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )"], "temporal_context_qualifier": "following endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "suspected coronary artery disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41065f3c-7f8f-5e34-a24e-c11f3980a2c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960322", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b047fa4-41c0-556a-9dc0-2236c5611438", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1020, 1043], "original_object": "coronary artery disease", "original_subject": "IODIXANOL", "population_context_qualifier": "Adults and pediatric patients 12 years of age and over", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50"]}], "subject": "CHEBI:31705", "supporting_text": ["1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) CT imaging of the head and body. (270 mg Iodine/mL and 320 mg Iodine/mL) excretory urography. (270 mg Iodine/mL) peripheral venography. (320 mg Iodine/mL) coronary computed tomography"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "suspected coronary artery disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eee1370-eca1-5126-9cfa-dec3b690b9ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960322", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b047fa4-41c0-556a-9dc0-2236c5611438", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1020, 1043], "original_object": "coronary artery disease", "original_subject": "IODIXANOL", "population_context_qualifier": "Adults and pediatric patients 12 years of age and over", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0fe89ea2-04f7-46c5-9c35-220d8c144a95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0fe89ea2-04f7-46c5-9c35-220d8c144a95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fe89ea2-04f7-46c5-9c35-220d8c144a95"]}], "subject": "CHEBI:31705", "supporting_text": ["1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) CT imaging of the head and body. (270 mg Iodine/mL and 320 mg Iodine/mL) excretory urography. (270 mg Iodine/mL) peripheral venography. (320 mg Iodine/mL) coronary computed tomography"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0701807", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18e5553e-557c-5ff8-9328-b69342a63937", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0701807"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:914b256f-0d33-5a2e-9d2b-91f52ed348cd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "HP:0025560", "object_location_in_text": [632, 654], "original_object": "anterior chamber cells", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:244f64ad-00c1-5368-a589-517eae8780e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "MONDO:0005642", "object_location_in_text": [175, 198], "original_object": "allergic conjunctivitis", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16b70a21-0608-5280-84dc-51c52c08b281", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "MONDO:0006604", "object_location_in_text": [200, 212], "original_object": "acne rosacea", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a103b1f-9b9c-5d94-a19a-ca3410746842", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "MONDO:0006814", "object_location_in_text": [271, 277], "original_object": "iritis", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18c5e688-b072-5dd8-820f-d3ea1e6cf53e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "UMLS:C0010543", "object_location_in_text": [279, 287], "original_object": "cyclitis", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e69f532b-30eb-5f38-ba01-cdab252507e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "UMLS:C0153027", "object_location_in_text": [246, 269], "original_object": "herpes zoster keratitis", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de9b483a-c481-5664-8b0c-3e6016189d2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980309", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57abf4c8-8486-5d6e-833c-9fe4d1cb47ab", "object": "UMLS:C0259799", "object_location_in_text": [214, 244], "original_object": "superficial punctate keratitis", "original_subject": "LOTEPREDNOL ETABONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7ae762f-5e0b-4f64-9323-8f44db2c0b4c"]}], "subject": "CHEBI:31784", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RANKL inhibitor administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ce65bb8-f10a-5cbd-b679-65af12267714", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["denosumab [genetical recombination]"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:37ff8f99-0cfc-5514-93a2-82053a1a3b1c", "object": "HP:0002901", "object_location_in_text": [105, 117], "original_object": "hypocalcemia", "original_subject": "MAGNESIUM CARBONATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MAGNESIUM CARBONATE#139-20130228", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:31793", "supporting_text": ["A combination prescription drug with a similar formulation indicated for the treatment and prevention of hypocalcemia in association with administration of RANKL inhibitors (e.g. denosumab [genetical recombination]) [Expedited review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77d6c450-f1cd-5ee4-a0c4-700987e30288", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6bdc2284-f321-535f-b37e-1e23e91c164a", "object": "MONDO:0004979", "object_location_in_text": [402, 408], "original_object": "asthma", "original_subject": "BROMPHENIRAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01ea6357-24dc-4056-9fd2-9e643650b91f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01ea6357-24dc-4056-9fd2-9e643650b91f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01ea6357-24dc-4056-9fd2-9e643650b91f"]}], "subject": "CHEBI:3183", "supporting_text": ["Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (MAOI) (see PRECAUTIONS - Drug Interactions ). Antihistamines should not be used to treat lower respiratory tract conditions including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f57fd4ca-fd22-5036-9c40-4b2f3d17ad46", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "MONDO:0005002"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6bdc2284-f321-535f-b37e-1e23e91c164a", "object": "HP:0012735", "object_location_in_text": [138, 143], "original_object": "cough", "original_subject": "BROMPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef"]}], "subject": "CHEBI:3183", "supporting_text": ["Uses Nighttime temporarily relieves these symptoms occuring with a cold, hay fever, or other upper respiratory allergies nasal congestion cough runny nose sneezing itchy, watery eyes itching of the nose or throat Daytime temporaily relieves cough due to minor throat and bronchial irritation occuring with a cold, and nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy, watery eyes sneezing itching of the nose or throat temporarily restores freer breathing through the nose"], "temporal_context_qualifier": "occuring with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0376362a-94c8-5a97-93f3-5bb864d32617", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dc8dfb1-dec8-43b3-b2ea-05eac054b2c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dc8dfb1-dec8-43b3-b2ea-05eac054b2c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dc8dfb1-dec8-43b3-b2ea-05eac054b2c6"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:086eda31-7e79-5e73-a6ca-8cda4c8d3dfc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f299b2d2-86ed-4fb8-822e-65455a0bb75a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f299b2d2-86ed-4fb8-822e-65455a0bb75a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f299b2d2-86ed-4fb8-822e-65455a0bb75a"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:265fc6ae-3214-53e6-bc3c-000c2d510041", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:873fa936-157a-4f85-bc70-5df31d71d122", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=873fa936-157a-4f85-bc70-5df31d71d122", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=873fa936-157a-4f85-bc70-5df31d71d122"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8b6225b-8587-53f1-ad1f-8a610eb4835d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad618953-c185-50eb-ab5a-0098a100543c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bb4febd-0ed4-48c9-ba2a-e22183a2143f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bb4febd-0ed4-48c9-ba2a-e22183a2143f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bb4febd-0ed4-48c9-ba2a-e22183a2143f"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba5cd8e9-4a2c-518b-ab15-448423e29c38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ee2e0da9-5ae7-405b-8dd1-635be72bc439", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ee2e0da9-5ae7-405b-8dd1-635be72bc439", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee2e0da9-5ae7-405b-8dd1-635be72bc439"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c212c945-a257-590d-a473-63215b70bc93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6f89dc3-a594-4b5b-8728-272e20c1ecb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6f89dc3-a594-4b5b-8728-272e20c1ecb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6f89dc3-a594-4b5b-8728-272e20c1ecb5"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf614a2f-7b26-5477-8fed-559e54ffa86a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fad0f147-6595-4412-87a7-2afca0192a96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fad0f147-6595-4412-87a7-2afca0192a96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fad0f147-6595-4412-87a7-2afca0192a96"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e57b7994-6965-522d-8f40-6912b5f18fc1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [157, 169], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11377169-7986-45b1-8298-6f0533efa3c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11377169-7986-45b1-8298-6f0533efa3c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11377169-7986-45b1-8298-6f0533efa3c3"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin Injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3146254", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec60bc22-7b36-5ffd-a93d-bd3f6d44fe42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020809", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["infusional fluorouracil", "leucovorin"], "medic_disease_context_ids": ["UMLS:C3146254"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903bcd43-1c5d-5e0e-89b5-d3de4196f9a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:903d5aaa-f453-5b58-bf66-db69723d42ec", "object": "MONDO:0021063", "object_location_in_text": [161, 173], "original_object": "colon cancer", "original_subject": "OXALIPLATIN", "population_context_qualifier": "patients who have undergone complete resection of the primary tumor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ac38523-480b-4c0f-97a1-7dfa1432923c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ac38523-480b-4c0f-97a1-7dfa1432923c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ac38523-480b-4c0f-97a1-7dfa1432923c"]}], "subject": "CHEBI:31941", "supporting_text": ["1 INDICATIONS AND USAGE Oxaliplatin injection USP, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin injection USP is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) treatment of advanced colorectal cancer. (1)"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3161650", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea05e449-6821-5331-bcfd-db7dadd34231", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19940214", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C3161650"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb6795ae-66a3-58b2-b3be-b472eb589793", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1e7a163f-afc4-5691-b086-2c3e40a99d98", "object": "UMLS:C3161650", "original_object": "primary immunoglobulin A nephropathy", "original_subject": "BUDESONIDE", "population_context_qualifier": "adults who are at risk for disease progression", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:938cada4-d6bf-4252-836f-dd40f9eadb4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=938cada4-d6bf-4252-836f-dd40f9eadb4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=938cada4-d6bf-4252-836f-dd40f9eadb4d"]}], "subject": "CHEBI:3207", "supporting_text": ["1 INDICATIONS AND USAGE TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. TARPEYO is a corticosteroid indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "repeated exacerbations", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35b0f0a1-abf0-5be7-8ae5-dc93515358b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d445c893-a868-556e-8713-2cf6b75cfbc9", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8986c26e-8d93-50b4-b0ee-ca69eb26d9c7", "object": "MONDO:0005002", "object_location_in_text": [482, 486], "original_object": "COPD", "original_subject": "budesonide;formoterol", "population_context_qualifier": "adults, aged 18 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:duoresp-spiromax", "https://www.ema.europa.eu/en/documents/product-information/duoresp-spiromax-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/duoresp-spiromax"]}], "subject": "CHEBI:3207", "supporting_text": ["Asthma DuoResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate:  in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?? adrenoceptor agonists.  or  in patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists.  COPDDuoResp Spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV?) &lt;70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3161650", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30fe62aa-be16-50e3-a8a6-0942bcb4c42d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180108", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3161650"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:cb6795ae-66a3-58b2-b3be-b472eb589793", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1e7a163f-afc4-5691-b086-2c3e40a99d98", "object": "UMLS:C3161650", "original_object": "primary immunoglobulin A nephropathy", "original_subject": "budesonide", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kinpeygo", "https://www.ema.europa.eu/en/documents/product-information/kinpeygo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo"]}], "subject": "CHEBI:3207", "supporting_text": ["Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "upper gastric intestinal region disorder", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:690165a8-49e9-518d-8e4f-6520684b4575", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:12fd3ad5-d5f0-580f-ba6f-a3db6f43b536", "object": "MONDO:0005412", "object_location_in_text": [65, 79], "original_object": "duodenal ulcer", "original_subject": "Roxatidine Acetate Hcl 75mg SR Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:32107", "supporting_text": ["Anti ulcer- Disorders in the upper gastric intestinal region i.e duodenal ulcer, benign gastric ulcers."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e3f0007-0be5-5c91-949c-2f47ec795b21", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f01d3d3-dc59-5661-879e-6daa723a5ff9", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [300, 306], "original_object": "asthma", "original_subject": "SACCHARIN", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:32111", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ae1adba-91c7-5627-9660-b18f52cb02ab", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f01d3d3-dc59-5661-879e-6daa723a5ff9", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [328, 345], "original_object": "atopic dermatitis", "original_subject": "SACCHARIN", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:32111", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b63ecb3f-0f83-54a1-b192-515a5ae25c00", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f01d3d3-dc59-5661-879e-6daa723a5ff9", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [308, 326], "original_object": "contact dermatitis", "original_subject": "SACCHARIN", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:32111", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular inflammatory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82b47a91-d6c7-5e50-a8df-205f30f1b3ec", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f01d3d3-dc59-5661-879e-6daa723a5ff9", "medic_supporting_text_truncated": true, "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "SACCHARIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:32111", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8783ad53-83b5-5803-9ee5-0b15ec18044d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f01d3d3-dc59-5661-879e-6daa723a5ff9", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [347, 361], "original_object": "serum sickness", "original_subject": "SACCHARIN", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:32111", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic diseases", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfe28b7d-13f3-51b9-bd51-e5103ac129da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2653599a-a680-5938-92c3-aa47d423f9ef", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3aae4ad1-ebf0-5bb5-874a-194186a5224a", "object": "HP:0012450", "object_location_in_text": [54, 74], "original_object": "chronic constipation", "original_subject": "SODIUM BICARBONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SODIUM BICARBONATE#77-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:32139", "supporting_text": ["A new combination drug indicated for the treatment of chronic constipation (excluding constipation due to organic diseases)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "abrupt discontinuation of alcohol", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bd0844b-8a01-5c93-bbfe-80cba0e1e56c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b82ee3a-4616-5406-9162-330c25d7092a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "medic_supporting_text_truncated": true, "object": "MONDO:0005433", "original_object": "alcohol withdrawal", "original_subject": "BUPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81d251aa-a8e8-493e-94ed-12f6fb8902e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81d251aa-a8e8-493e-94ed-12f6fb8902e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81d251aa-a8e8-493e-94ed-12f6fb8902e6"]}], "subject": "CHEBI:3219", "supporting_text": ["4 CONTRAINDICATIONS Bupropion hydrochloride tablets are contraindicated in patients with a seizure disorder. Bupropion hydrochloride tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride tablets [see Warnings and Precautions (5.3)]. Bupropion hydrochloride tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3), Drug Interactions (7.3)]. The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride tablets or within 14 days of discontinuing treatment with bupropion hydrochloride tablets are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.4), Drug Interactions (7.6)]. Bupropion hydrochloride tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)]. •Seizure disorder. (4, 5.3) •Current or prior diagnosis of bulimia or anorexia nervosa. (4, 5.3) •Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. (4, 5.3) •Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride tablets or within 14 days of stopping treatment with bupropion hydroch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "abrupt discontinuation of alcohol", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0632f97-93a8-5b42-b72c-3c53b1bc27c5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b82ee3a-4616-5406-9162-330c25d7092a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "medic_supporting_text_truncated": true, "object": "MONDO:0005433", "original_object": "alcohol withdrawal", "original_subject": "BUPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b47c5515-a438-40bc-b8ad-26a6cf9676b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b47c5515-a438-40bc-b8ad-26a6cf9676b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b47c5515-a438-40bc-b8ad-26a6cf9676b7"]}], "subject": "CHEBI:3219", "supporting_text": ["4 CONTRAINDICATIONS Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a seizure disorder. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate release formulation of bupropion [see Warnings and Precautions ( 5.3 )]. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions ( 5.3 ), Drug Interactions ( 7.3 )] . The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (SR) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (SR) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (SR) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (SR) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (SR) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration ( 2.4 , 2.5 ), Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.6 )]. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (SR). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions ( 5.8 )]. Seizure disorder. ( 4 , 5.3 ) Current or prior diagnosis of bulimia or anorexia nervosa. ( 4 , 5.3 ) Abrupt discontinuation of alcohol, ben"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "abrupt discontinuation of barbiturates", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1fcfe1dd-0b83-5bb2-977e-a96bab2edf7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06bb8f6d-b090-5380-aaa0-2c280aee99b9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "medic_supporting_text_truncated": true, "object": "UMLS:C1827973", "original_object": "barbiturate withdrawal", "original_subject": "BUPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b47c5515-a438-40bc-b8ad-26a6cf9676b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b47c5515-a438-40bc-b8ad-26a6cf9676b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b47c5515-a438-40bc-b8ad-26a6cf9676b7"]}], "subject": "CHEBI:3219", "supporting_text": ["4 CONTRAINDICATIONS Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a seizure disorder. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate release formulation of bupropion [see Warnings and Precautions ( 5.3 )]. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions ( 5.3 ), Drug Interactions ( 7.3 )] . The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (SR) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (SR) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (SR) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (SR) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (SR) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration ( 2.4 , 2.5 ), Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.6 )]. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (SR). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions ( 5.8 )]. Seizure disorder. ( 4 , 5.3 ) Current or prior diagnosis of bulimia or anorexia nervosa. ( 4 , 5.3 ) Abrupt discontinuation of alcohol, ben"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "abrupt discontinuation of barbiturates", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abf9e11e-8575-59e6-9aed-d7a204a5ae67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:06bb8f6d-b090-5380-aaa0-2c280aee99b9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "medic_supporting_text_truncated": true, "object": "UMLS:C1827973", "original_object": "barbiturate withdrawal", "original_subject": "BUPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81d251aa-a8e8-493e-94ed-12f6fb8902e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81d251aa-a8e8-493e-94ed-12f6fb8902e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81d251aa-a8e8-493e-94ed-12f6fb8902e6"]}], "subject": "CHEBI:3219", "supporting_text": ["4 CONTRAINDICATIONS Bupropion hydrochloride tablets are contraindicated in patients with a seizure disorder. Bupropion hydrochloride tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride tablets [see Warnings and Precautions (5.3)]. Bupropion hydrochloride tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3), Drug Interactions (7.3)]. The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride tablets or within 14 days of discontinuing treatment with bupropion hydrochloride tablets are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.4), Drug Interactions (7.6)]. Bupropion hydrochloride tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)]. •Seizure disorder. (4, 5.3) •Current or prior diagnosis of bulimia or anorexia nervosa. (4, 5.3) •Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. (4, 5.3) •Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride tablets or within 14 days of stopping treatment with bupropion hydroch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "abrupt discontinuation of benzodiazepines", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69139ee6-8552-5ed1-bedd-dbffda2e020a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:837f0e2e-1fc4-5de6-b402-baaf687dabfc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "medic_supporting_text_truncated": true, "object": "UMLS:C2062728", "original_object": "benzodiazepine withdrawal", "original_subject": "BUPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81d251aa-a8e8-493e-94ed-12f6fb8902e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81d251aa-a8e8-493e-94ed-12f6fb8902e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81d251aa-a8e8-493e-94ed-12f6fb8902e6"]}], "subject": "CHEBI:3219", "supporting_text": ["4 CONTRAINDICATIONS Bupropion hydrochloride tablets are contraindicated in patients with a seizure disorder. Bupropion hydrochloride tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride tablets [see Warnings and Precautions (5.3)]. Bupropion hydrochloride tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3), Drug Interactions (7.3)]. The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride tablets or within 14 days of discontinuing treatment with bupropion hydrochloride tablets are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.4), Drug Interactions (7.6)]. Bupropion hydrochloride tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)]. •Seizure disorder. (4, 5.3) •Current or prior diagnosis of bulimia or anorexia nervosa. (4, 5.3) •Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. (4, 5.3) •Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride tablets or within 14 days of stopping treatment with bupropion hydroch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "abrupt discontinuation of benzodiazepines", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dafe0fbe-bb16-569c-8432-f5cd76869733", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:837f0e2e-1fc4-5de6-b402-baaf687dabfc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "medic_supporting_text_truncated": true, "object": "UMLS:C2062728", "original_object": "benzodiazepine withdrawal", "original_subject": "BUPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b47c5515-a438-40bc-b8ad-26a6cf9676b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b47c5515-a438-40bc-b8ad-26a6cf9676b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b47c5515-a438-40bc-b8ad-26a6cf9676b7"]}], "subject": "CHEBI:3219", "supporting_text": ["4 CONTRAINDICATIONS Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a seizure disorder. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate release formulation of bupropion [see Warnings and Precautions ( 5.3 )]. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions ( 5.3 ), Drug Interactions ( 7.3 )] . The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (SR) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (SR) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (SR) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (SR) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (SR) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration ( 2.4 , 2.5 ), Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.6 )]. Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (SR). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions ( 5.8 )]. Seizure disorder. ( 4 , 5.3 ) Current or prior diagnosis of bulimia or anorexia nervosa. ( 4 , 5.3 ) Abrupt discontinuation of alcohol, ben"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665464", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64c87eb3-c2c6-5d24-85d0-4e14fa08089d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665464"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5f52d329-c1c2-563a-a88d-77435d0db00b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62b88d5b-6353-5e4a-971b-db9c104fd413", "object": "HP:0000713", "object_location_in_text": [322, 331], "original_object": "agitation", "original_subject": "BUPROPION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcefda7c-9a68-278e-e053-2995a90aec79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79"]}], "subject": "CHEBI:3219", "supporting_text": ["1 INDICATIONS AND USAGE AUVELITY is a combination of dextromethorphan, an uncompetitive N -methyl D -aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults ( 1.1 ) the treatment of agitation associated with dementia due to Alzheimer’s disease ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0100543", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c229a81b-9246-5ab3-8110-2f644c73f9d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100543"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:5f52d329-c1c2-563a-a88d-77435d0db00b", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:51170fd6-c7bf-5817-beac-a083f5d79d7c", "object": "HP:0000713", "object_location_in_text": [21, 30], "original_object": "agitation", "original_subject": "Tiapride Hydrochloride Tablets 25mg/50mg/100mg", "population_context_qualifier": "adult patients with cognitive impairment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:32220", "supporting_text": ["For the treatment of agitation and aggressiveness in adult patients with cognitive impairment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0100543", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:174bb31f-898b-5cb1-ba72-a8d578dd8545", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100543"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:d957cc3a-81e8-5e97-bf4c-9792044fcfac", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:51170fd6-c7bf-5817-beac-a083f5d79d7c", "object": "HP:0000718", "object_location_in_text": [35, 49], "original_object": "aggressiveness", "original_subject": "Tiapride Hydrochloride Tablets 25mg/50mg/100mg", "population_context_qualifier": "adult patients with cognitive impairment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:32220", "supporting_text": ["For the treatment of agitation and aggressiveness in adult patients with cognitive impairment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7bae843a-dd1e-5a03-b43d-0c9ed22caf1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:059bdb4e-8f6a-5ab1-bb4b-cd7e828cc574", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0001942", "object_location_in_text": [389, 417], "original_object": "Generalized Anxiety Disorder", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bcce49d3-c8eb-9f9b-e053-2995a90a67d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bcce49d3-c8eb-9f9b-e053-2995a90a67d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bcce49d3-c8eb-9f9b-e053-2995a90a67d9"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge\", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b15e9ef5-15f1-5e6b-a7f9-dc061b44bede", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:059bdb4e-8f6a-5ab1-bb4b-cd7e828cc574", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0001942", "object_location_in_text": [389, 417], "original_object": "Generalized Anxiety Disorder", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb0091ad-97f6-431b-b2b9-e03171eed274", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb0091ad-97f6-431b-b2b9-e03171eed274", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb0091ad-97f6-431b-b2b9-e03171eed274"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge\", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0491d6c6-db15-56be-bdb3-22ae0a8258cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9fc7091-b3ce-45fd-8d89-aeebdd81c327", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9fc7091-b3ce-45fd-8d89-aeebdd81c327", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9fc7091-b3ce-45fd-8d89-aeebdd81c327"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive diso"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:319ef425-a048-5497-a5a5-ee8857e122d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2acc7da1-d5b8-4404-a3c6-d51ed82cc4fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2acc7da1-d5b8-4404-a3c6-d51ed82cc4fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2acc7da1-d5b8-4404-a3c6-d51ed82cc4fd"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34e08781-ac99-5ac7-96aa-059e009e368f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd05160d-24c6-4371-8b2c-c0f78c8b468e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd05160d-24c6-4371-8b2c-c0f78c8b468e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd05160d-24c6-4371-8b2c-c0f78c8b468e"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive diso"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52dcb587-9898-557c-a9e2-793ba2ec9a36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fdacb3d3-f574-431a-8324-2278edc16bce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fdacb3d3-f574-431a-8324-2278edc16bce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdacb3d3-f574-431a-8324-2278edc16bce"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6869c5ac-2b1f-57e6-bf37-4d9906326771", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [73, 80], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef8fc378-7fee-4d20-81ec-31211e34dc6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef8fc378-7fee-4d20-81ec-31211e34dc6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef8fc378-7fee-4d20-81ec-31211e34dc6e"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets, USP are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets, USP has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, USP relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68f18939-efb0-5c22-867b-84511b941df8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [57, 64], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f101c5f3-d533-474d-a8bf-90d054933d16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f101c5f3-d533-474d-a8bf-90d054933d16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f101c5f3-d533-474d-a8bf-90d054933d16"]}], "subject": "CHEBI:3223", "supporting_text": ["Bucapsol TM capsules are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge\", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69b82431-77c7-5e55-bdd2-d44cbc1b9471", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef90af23-d97e-4094-971b-1d8114218b10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef90af23-d97e-4094-971b-1d8114218b10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef90af23-d97e-4094-971b-1d8114218b10"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72ceb651-6d2c-55ab-9b94-f2297fdaf052", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dc1ee33-e5aa-4462-8fb9-9bbdf5463488", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dc1ee33-e5aa-4462-8fb9-9bbdf5463488", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dc1ee33-e5aa-4462-8fb9-9bbdf5463488"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a dep"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8508f499-6cdb-51f8-a07d-156831678ed9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55810b17-4796-49d0-90e4-8e075d62eda4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55810b17-4796-49d0-90e4-8e075d62eda4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55810b17-4796-49d0-90e4-8e075d62eda4"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0299861-7c20-5053-9421-22eb4347aaf1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [73, 80], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:801803eb-be17-4064-8813-7ccf52316cde", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=801803eb-be17-4064-8813-7ccf52316cde", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=801803eb-be17-4064-8813-7ccf52316cde"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets, USP are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets, USP has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, USP relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disor"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4f51761-5066-561b-bd18-3f4749871774", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [73, 80], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed2b56fe-e02f-46bc-808a-352f9bbb5b57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed2b56fe-e02f-46bc-808a-352f9bbb5b57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed2b56fe-e02f-46bc-808a-352f9bbb5b57"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets, USP are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets, USP has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, USP relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdaa2dac-c52a-5bd7-b11b-138382e30fe6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5718bc19-07b2-b61d-e063-6394a90a6e80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5718bc19-07b2-b61d-e063-6394a90a6e80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5718bc19-07b2-b61d-e063-6394a90a6e80"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df85c7f1-fdc6-5f1b-8bb4-94b46862fd2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [73, 80], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b217f341-7d51-475d-887f-f16786164c7b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b217f341-7d51-475d-887f-f16786164c7b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b217f341-7d51-475d-887f-f16786164c7b"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets, USP are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets, USP has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, USP relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3a12368-719a-5275-b09d-76bda6cb1593", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c9eafb9-9ce1-4b28-900c-8fcb4b23424e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c9eafb9-9ce1-4b28-900c-8fcb4b23424e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c9eafb9-9ce1-4b28-900c-8fcb4b23424e"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e74dda74-4a9d-5b58-9371-192ac8ca40d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d883a13-4877-c6c7-e063-6294a90a5137", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d883a13-4877-c6c7-e063-6294a90a5137", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d883a13-4877-c6c7-e063-6294a90a5137"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive diso"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e98d7c99-2e84-57ed-a127-ab3050d9a295", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa4d5cac-f687-4440-99d2-8bb27cf2f4ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa4d5cac-f687-4440-99d2-8bb27cf2f4ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa4d5cac-f687-4440-99d2-8bb27cf2f4ed"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1. Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as a "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f168026a-628e-52f6-b29e-63566c61b0ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [73, 80], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3155e607-bc7f-4e90-9edf-8e862dd5737d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3155e607-bc7f-4e90-9edf-8e862dd5737d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3155e607-bc7f-4e90-9edf-8e862dd5737d"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets, USP are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets, USP has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, USP relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8b7151b-b6db-5d73-9b87-fb3e17f3e41a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860929", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf64e7a7-9c69-5d01-8516-1557242e73df", "medic_supporting_text_truncated": true, "object": "MONDO:0011918", "object_location_in_text": [68, 75], "original_object": "anxiety", "original_subject": "BUSPIRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b222cb0-0061-4a3e-9d0f-e9f120e7f5d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b222cb0-0061-4a3e-9d0f-e9f120e7f5d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b222cb0-0061-4a3e-9d0f-e9f120e7f5d9"]}], "subject": "CHEBI:3223", "supporting_text": ["Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse, and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling \"on edge,\" irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de5afa6c-80d7-5854-82da-4836c9ae9f5b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:27b3bd63-a8c8-5505-a317-a2e8e5782b6f", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "TITANIUM DIOXIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b"]}], "subject": "CHEBI:32234", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e25943ad-7768-51f7-8159-d8d8cb89d683", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:27b3bd63-a8c8-5505-a317-a2e8e5782b6f", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "TITANIUM DIOXIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb6ac681-ff74-4420-a4f6-843d5f2b6d6b"]}], "subject": "CHEBI:32234", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:748e867d-5fd4-5db5-85b0-48eac1d846ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070615", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "HP:0000020", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:a98aa097-329b-5d93-9a70-984f1e76803e", "object": "MONDO:0006624", "object_location_in_text": [21, 39], "original_object": "overactive bladder", "original_subject": "Tolterodine Tartrate Extended release tablets 2mg/4mg (Additional Dosage Form)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:32245", "supporting_text": ["For the treatment of overactive bladder with symptoms of urge urinary incontinence, urinary incontinence, urgency and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001394", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29bd0160-0d37-56b3-83fe-6e030611442e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130913", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001394"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a2beffe2-74a8-5069-89dd-86536d3d5d9d", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:20774876-5093-5334-a165-710785e872ae", "object": "HP:0000969", "object_location_in_text": [78, 93], "original_object": "fluid retention", "original_subject": "TOLVAPTAN", "population_context_qualifier": "patients who have not responded sufficiently to other diuretics such as loop diuretics", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TOLVAPTAN#124-20130913", "https://www.pmda.go.jp/files/000208511.pdf"]}], "subject": "CHEBI:32246", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of fluid retention in patients with hepatic cirrhosis who have not responded sufficiently to other diuretics such as loop diuretics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e43d0eae-8d87-5e95-9926-5a68e667978e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fcb5215e-12be-5e69-9d27-552313767db1", "object": "MONDO:0006624", "object_location_in_text": [21, 39], "original_object": "overactive bladder", "original_subject": "Trospium Chloride film coated tablet 20mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:32270", "supporting_text": ["For the treatment of overactive bladder with the symptoms of urge urinary incontinence, urgency, and urinary frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "predominantly classic subfoveal choroidal neovascularisation", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13272d1c-7f60-5b6e-9415-0ec95f8a1b8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000727", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:be3c4314-3087-56d3-a62e-8c124bc2a944", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fb3c5766-5d19-574d-a4af-e2844a44f096", "object": "UMLS:C0271084", "original_object": "exudative age-related macular degeneration", "original_subject": "verteporfin", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:visudyne", "https://www.ema.europa.eu/en/documents/product-information/visudyne-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/visudyne"]}], "subject": "CHEBI:32293", "supporting_text": ["Visudyne is indicated for the treatment of:  adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or; adults with subfoveal choroidal neovascularisation secondary to pathological myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0393759", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:662e24e4-2802-5ab3-b2c2-0ba296199672", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960816", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0393759", "UMLS:C0751249"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:05f85dc6-0b72-5a05-bfb6-45256ab9f99c", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:bd265ffe-4b4b-5372-8f35-23ad704efe6f", "object": "MONDO:0013600", "object_location_in_text": [24, 32], "original_object": "insomnia", "original_subject": "Zopiclone BP 7.5mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:32315", "supporting_text": ["Short term treatment of insomnia, transient, situational or chronic insomnia and insomnia secondary to psychiatric disorders where it is desilitating or severe."], "temporal_context_qualifier": "short term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:209c3233-d183-5bb7-9d0f-91d77602979d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961018", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1de4112-2f70-5dba-8aec-24f7edeaa6ff", "object": "HP:0000989", "object_location_in_text": [35, 42], "original_object": "itching", "original_subject": "BUTENAFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d8a17ae-4e25-f591-e063-6394a90a35dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d8a17ae-4e25-f591-e063-6394a90a35dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d8a17ae-4e25-f591-e063-6394a90a35dd"]}], "subject": "CHEBI:3238", "supporting_text": ["Uses cures most jock itch relieves itching, burning, crackling, and scaling which accompany this condition"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:204d34ea-1b76-5c07-bec4-a1b6157efe56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961018", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1de4112-2f70-5dba-8aec-24f7edeaa6ff", "object": "UMLS:C0014724", "object_location_in_text": [44, 51], "original_object": "burning", "original_subject": "BUTENAFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d8a17ae-4e25-f591-e063-6394a90a35dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d8a17ae-4e25-f591-e063-6394a90a35dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d8a17ae-4e25-f591-e063-6394a90a35dd"]}], "subject": "CHEBI:3238", "supporting_text": ["Uses cures most jock itch relieves itching, burning, crackling, and scaling which accompany this condition"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a7ffb6f-819c-596c-8ff0-fdf4b178217e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961018", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4537e5e-6bba-5cc6-b0d6-9af57480b179", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1de4112-2f70-5dba-8aec-24f7edeaa6ff", "object": "UMLS:C0237849", "object_location_in_text": [68, 75], "original_object": "scaling", "original_subject": "BUTENAFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d8a17ae-4e25-f591-e063-6394a90a35dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d8a17ae-4e25-f591-e063-6394a90a35dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d8a17ae-4e25-f591-e063-6394a90a35dd"]}], "subject": "CHEBI:3238", "supporting_text": ["Uses cures most jock itch relieves itching, burning, crackling, and scaling which accompany this condition"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000989", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c5655ac-160a-5bb7-aa86-8cc5e398c5e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961018", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000989", "UMLS:C0014724", "UMLS:C0237849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1de4112-2f70-5dba-8aec-24f7edeaa6ff", "object": "UMLS:C1384589", "object_location_in_text": [16, 25], "original_object": "jock itch", "original_subject": "BUTENAFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:83830b24-bc94-4764-a6ca-3193abd9de66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=83830b24-bc94-4764-a6ca-3193abd9de66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=83830b24-bc94-4764-a6ca-3193abd9de66"]}], "subject": "CHEBI:3238", "supporting_text": ["Uses cures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000989", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96bf1562-06b9-5060-b01b-bf986c55385c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961018", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000989", "UMLS:C0014724", "UMLS:C0237849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1de4112-2f70-5dba-8aec-24f7edeaa6ff", "object": "UMLS:C1384589", "object_location_in_text": [16, 25], "original_object": "jock itch", "original_subject": "BUTENAFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9dfa08fb-0913-4326-b1eb-1425df6a2c82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9dfa08fb-0913-4326-b1eb-1425df6a2c82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9dfa08fb-0913-4326-b1eb-1425df6a2c82"]}], "subject": "CHEBI:3238", "supporting_text": ["Uses cures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000989", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb0ad6f2-40d3-5c58-bf76-bb15e0528e98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961018", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000989", "UMLS:C0014724", "UMLS:C0237849"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1de4112-2f70-5dba-8aec-24f7edeaa6ff", "object": "UMLS:C1384589", "object_location_in_text": [16, 25], "original_object": "jock itch", "original_subject": "BUTENAFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b13e8ad-b7dd-49e7-9469-3cac077c763e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b13e8ad-b7dd-49e7-9469-3cac077c763e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b13e8ad-b7dd-49e7-9469-3cac077c763e"]}], "subject": "CHEBI:3238", "supporting_text": ["Uses cures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections caused by Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc0a06cc-b186-5671-95fd-4310841b716c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851125", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3a7ea3c-8fdf-5597-a294-4ea79d554908", "object": "MONDO:0006014", "object_location_in_text": [98, 122], "original_object": "vulvovaginal candidiasis", "original_subject": "BUTOCONAZOLE", "population_context_qualifier": "non-pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:125d8ede-db38-4eb9-a6be-19208687f36a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=125d8ede-db38-4eb9-a6be-19208687f36a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=125d8ede-db38-4eb9-a6be-19208687f36a"]}], "subject": "CHEBI:3240", "supporting_text": ["GYNAZOLE • 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida ). The diagnosis should be confirmed by KOH smears and/or cultures (see CLINICAL STUDIES ). Note: GYNAZOLE • 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is safe and effective in non-pregnant women; however, the safety and effectiveness of this product in pregnant women has not been established (see PRECAUTIONS - Pregnancy )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic diseases", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e4da982-b005-589f-a8f1-63a37137bfd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2653599a-a680-5938-92c3-aa47d423f9ef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:41ae53b1-ca17-53df-995a-233057dff9e8", "object": "HP:0012450", "object_location_in_text": [54, 74], "original_object": "chronic constipation", "original_subject": "POTASSIUM CHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:POTASSIUM CHLORIDE#77-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:32588", "supporting_text": ["A new combination drug indicated for the treatment of chronic constipation (excluding constipation due to organic diseases)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0872104", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4149969c-16f6-5a66-8d4f-e216f1c961e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220916", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0872104"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:cb1964d5-d459-545a-b217-bb894d8603f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:01ce151c-1471-5a2d-989c-f8b12bc0982a", "object": "MONDO:0011972", "object_location_in_text": [68, 101], "original_object": "ovarian hyperstimulation syndrome", "original_subject": "CABERGOLINE", "population_context_qualifier": "[patients undergoing assisted reproductive technology]", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CABERGOLINE#35-20220916", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:3286", "supporting_text": ["A drug with a new indication and a new dosage for the prevention of ovarian hyperstimulation syndrome associated with assisted reproductive technology. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RANKL inhibitor administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a529afc-1aa7-51eb-a6e7-5861ecc41045", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["denosumab [genetical recombination]"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:53deb0df-e716-571f-9a60-b2fa28300628", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:56896717-59b5-577f-8f92-8cfa1dcc0c26", "object": "HP:0002901", "object_location_in_text": [105, 117], "original_object": "hypocalcemia", "original_subject": "PRECIPITATED CALCIUM CARBONATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PRECIPITATED CALCIUM CARBONATE#139-20130228", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:3311", "supporting_text": ["A combination prescription drug with a similar formulation indicated for the treatment and prevention of hypocalcemia in association with administration of RANKL inhibitors (e.g. denosumab [genetical recombination]) [Expedited review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95d71a4d-1b92-5a95-b917-7dccf51ea564", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f312ae3e-6c7f-53ce-bf0c-b932982dd619", "object": "MONDO:0005412", "object_location_in_text": [662, 676], "original_object": "duodenal ulcer", "original_subject": "BISMUTH", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fe5d2db-c59d-4e15-acd7-f9df8eca45aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa"]}], "subject": "CHEBI:33301", "supporting_text": ["1 INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PYLERA is a combination antibacterial indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . (1.1) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence."], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f524549-3b48-508c-a04d-0f0023e2a3c8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [326, 348], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:904b357e-97bf-475e-90a5-f0449f2a428e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=904b357e-97bf-475e-90a5-f0449f2a428e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=904b357e-97bf-475e-90a5-f0449f2a428e"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ). • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization ( 1.2 ). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21495e9d-f14f-5f6e-b2d4-d08f5e2d4916", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [325, 347], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a67f4f53-76c7-4239-9dd6-fef8e8019e9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a67f4f53-76c7-4239-9dd6-fef8e8019e9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a67f4f53-76c7-4239-9dd6-fef8e8019e9a"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization (1.2) . 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21de9a34-6f3a-5d7a-8876-b41355274e67", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [325, 347], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a515af5-bd53-43f1-b40a-aa0f332bc2ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a515af5-bd53-43f1-b40a-aa0f332bc2ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a515af5-bd53-43f1-b40a-aa0f332bc2ab"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29c70e9a-7e38-53a0-9bc5-33bf38f22186", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [325, 347], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d23fe59a-2ad6-4885-a0d8-2239048f05a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d23fe59a-2ad6-4885-a0d8-2239048f05a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d23fe59a-2ad6-4885-a0d8-2239048f05a3"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2) 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a2e2635-5b7d-5978-bfe7-58146bac49ae", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9da86c48-5911-4512-8c71-eca4a6418cf6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9da86c48-5911-4512-8c71-eca4a6418cf6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9da86c48-5911-4512-8c71-eca4a6418cf6"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 year to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ). Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization ( 1.2 ). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46930320-0605-5fe1-846a-5a85d94dd325", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [325, 347], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5b43fa0-6678-4219-99f1-10d273d49baf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5b43fa0-6678-4219-99f1-10d273d49baf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5b43fa0-6678-4219-99f1-10d273d49baf"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f1c6eb5-af05-59ac-9fad-a9946aeecb69", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [317, 339], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4621249c-1f44-4d95-8513-a1a2b1859e41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4621249c-1f44-4d95-8513-a1a2b1859e41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4621249c-1f44-4d95-8513-a1a2b1859e41"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil is indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84cc8de9-9d14-542e-a076-83f6d4c7a073", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de"]}], "subject": "CHEBI:3347", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a87ec0c-df94-5dda-a836-c73298e0e5e1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d"]}], "subject": "CHEBI:3347", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3e5596e-db86-5f3d-812e-5db24e36f662", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [325, 347], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f2b2fa3-249b-4756-a3f1-3223a004d9cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f2b2fa3-249b-4756-a3f1-3223a004d9cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f2b2fa3-249b-4756-a3f1-3223a004d9cb"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2) 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aed79d16-442d-59e9-8893-acd730f85e2a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee"]}], "subject": "CHEBI:3347", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7aee213-6e83-590c-9ef4-9dbac65e8161", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [325, 347], "original_object": "myocardial infarctions", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9afc130e-a784-49fe-9772-27c492724f08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9afc130e-a784-49fe-9772-27c492724f08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9afc130e-a784-49fe-9772-27c492724f08"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:010a5e3b-5e92-5ab9-b9fd-76389a6899fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [305, 312], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4621249c-1f44-4d95-8513-a1a2b1859e41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4621249c-1f44-4d95-8513-a1a2b1859e41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4621249c-1f44-4d95-8513-a1a2b1859e41"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil is indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16c73fe3-c4a2-54e2-9f06-b1ffef80b853", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee"]}], "subject": "CHEBI:3347", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18ce8457-73be-502f-9f8c-bccf5bb19ced", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9da86c48-5911-4512-8c71-eca4a6418cf6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9da86c48-5911-4512-8c71-eca4a6418cf6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9da86c48-5911-4512-8c71-eca4a6418cf6"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 year to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ). Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization ( 1.2 ). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b5bd251-5b78-55d2-b8a3-645ad52def7c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de"]}], "subject": "CHEBI:3347", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ddf3e7b-c0ab-58fc-a624-2c4fc0a78426", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [313, 320], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a515af5-bd53-43f1-b40a-aa0f332bc2ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a515af5-bd53-43f1-b40a-aa0f332bc2ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a515af5-bd53-43f1-b40a-aa0f332bc2ab"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41499b98-ce96-5abc-87d1-2e60085c98d1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [314, 321], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:904b357e-97bf-475e-90a5-f0449f2a428e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=904b357e-97bf-475e-90a5-f0449f2a428e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=904b357e-97bf-475e-90a5-f0449f2a428e"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ). • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization ( 1.2 ). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:988df23c-d16d-5aa0-81fe-524533c3f8b1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [313, 320], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5b43fa0-6678-4219-99f1-10d273d49baf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5b43fa0-6678-4219-99f1-10d273d49baf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5b43fa0-6678-4219-99f1-10d273d49baf"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b96bc13d-414a-5a2e-9cdf-2178b54200fc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [313, 320], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9afc130e-a784-49fe-9772-27c492724f08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9afc130e-a784-49fe-9772-27c492724f08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9afc130e-a784-49fe-9772-27c492724f08"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:caf9e2ea-4204-50aa-8ce9-f26352ad946d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d"]}], "subject": "CHEBI:3347", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0568677-2b25-53d7-b189-88c401448c9e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [313, 320], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f2b2fa3-249b-4756-a3f1-3223a004d9cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f2b2fa3-249b-4756-a3f1-3223a004d9cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f2b2fa3-249b-4756-a3f1-3223a004d9cb"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2) 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7a4df5a-ed63-5128-ad0d-1dee4ba393b1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [313, 320], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a67f4f53-76c7-4239-9dd6-fef8e8019e9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a67f4f53-76c7-4239-9dd6-fef8e8019e9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a67f4f53-76c7-4239-9dd6-fef8e8019e9a"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization (1.2) . 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9cd6ece-3550-5f2d-bdb9-e4d9a58de763", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [313, 320], "original_object": "strokes", "original_subject": "CANDESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d23fe59a-2ad6-4885-a0d8-2239048f05a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d23fe59a-2ad6-4885-a0d8-2239048f05a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d23fe59a-2ad6-4885-a0d8-2239048f05a3"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2) 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA class II-IV", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:402b1ba4-03b3-5668-8c0c-a1c1af2a17f3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afad0657-20ba-505a-a059-ea9ae96f4b84", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [359, 372], "original_object": "heart failure", "original_subject": "CANDESARTAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15601654-76da-04cf-e063-6394a90a2cb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15601654-76da-04cf-e063-6394a90a2cb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15601654-76da-04cf-e063-6394a90a2cb5"]}], "subject": "CHEBI:3347", "supporting_text": ["1 INDICATIONS AND USAGE Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 to &lt; 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil is indicated for the treatment of hypertension in adults and in children 1 to &lt;17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231528", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43c13762-aa62-5ba7-a0e6-191ca47f70d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091116", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C0231528", "UMLS:C0080194", "UMLS:C0038045", "MONDO:0005578", "HP:0003552", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3a6b9b-93fc-5f12-87f6-ce23c26d9d03", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dfd614f0-ef7c-5806-bd58-47d2662d080a", "object": "HP:0002829", "original_object": "joint pain", "original_subject": "CAPSAICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05a09ee5-e7a4-4758-8b16-f60b945a7d82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05a09ee5-e7a4-4758-8b16-f60b945a7d82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05a09ee5-e7a4-4758-8b16-f60b945a7d82"]}], "subject": "CHEBI:3374", "supporting_text": ["Uses Temporarily relieves mild to moderate aches and pains of muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, bruises."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:888084b5-f7a6-5849-aec8-9e704cc9323a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091116", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dfd614f0-ef7c-5806-bd58-47d2662d080a", "object": "MONDO:0016586", "object_location_in_text": [545, 566], "original_object": "systemic mastocytosis", "original_subject": "CAPSAICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c"]}], "subject": "CHEBI:3374", "supporting_text": ["Ranitdine Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16e4df1b-251e-5e5f-b793-99200b1aa762", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091116", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dfd614f0-ef7c-5806-bd58-47d2662d080a", "object": "MONDO:0019610", "object_location_in_text": [514, 540], "original_object": "Zollinger-Ellison syndrome", "original_subject": "CAPSAICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c"]}], "subject": "CHEBI:3374", "supporting_text": ["Ranitdine Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0231528", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eb45cc8-b21f-55df-a7a0-ec9731a72282", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091116", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0231528", "UMLS:C0080194", "UMLS:C0038045", "MONDO:0005578", "HP:0003552", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dfd614f0-ef7c-5806-bd58-47d2662d080a", "object": "UMLS:C0231528", "original_object": "muscle aches", "original_subject": "CAPSAICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05a09ee5-e7a4-4758-8b16-f60b945a7d82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05a09ee5-e7a4-4758-8b16-f60b945a7d82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05a09ee5-e7a4-4758-8b16-f60b945a7d82"]}], "subject": "CHEBI:3374", "supporting_text": ["Uses Temporarily relieves mild to moderate aches and pains of muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, bruises."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "type I insulin-dependent diabetes mellitus", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae908145-e933-5f60-a6ce-78d7af23b335", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37aad416-1ba6-52bc-a674-3de39d01bd82", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0001106", "original_object": "renal insufficiency", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3362b7a8-026a-b277-e063-6394a90a9dc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3362b7a8-026a-b277-e063-6394a90a9dc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3362b7a8-026a-b277-e063-6394a90a9dc6"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria ˃500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril, it should be noted that i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "type I insulin-dependent diabetes mellitus", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5142574-62d3-5d66-b941-6a133533eff1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37aad416-1ba6-52bc-a674-3de39d01bd82", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0001106", "original_object": "renal insufficiency", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria ˃500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril, it should be noted that i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2102d5ed-4d58-572f-84bc-332a1e3b6e42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6849c126-828f-5ce8-95f2-ae98435fe4ec", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005009", "object_location_in_text": [856, 880], "original_object": "congestive heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2120f554-a09b-464c-9b86-786dd9f112b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2120f554-a09b-464c-9b86-786dd9f112b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2120f554-a09b-464c-9b86-786dd9f112b1"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril is indicated for the treatment of diabetic nephropathy (proteinuria &gt;500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril, it should be noted that in controlled trials ACE inhibi"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a408a06-88bf-5ece-8eca-9be18f2a898f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6849c126-828f-5ce8-95f2-ae98435fe4ec", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005009", "object_location_in_text": [881, 905], "original_object": "congestive heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccbffd30-4b21-4522-bdb8-abba8d592017", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccbffd30-4b21-4522-bdb8-abba8d592017", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccbffd30-4b21-4522-bdb8-abba8d592017"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0f5e92a-918e-504d-a64f-efb7713136f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6849c126-828f-5ce8-95f2-ae98435fe4ec", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005009", "object_location_in_text": [881, 905], "original_object": "congestive heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a91ac7f-b75d-d111-e063-6394a90a2a93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a91ac7f-b75d-d111-e063-6394a90a2a93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a91ac7f-b75d-d111-e063-6394a90a2a93"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f378a10d-65f6-517a-8a45-a48f2cdbfd2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6849c126-828f-5ce8-95f2-ae98435fe4ec", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005009", "object_location_in_text": [881, 905], "original_object": "congestive heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00871911-8c79-433c-87d5-181f4c973d5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00871911-8c79-433c-87d5-181f4c973d5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00871911-8c79-433c-87d5-181f4c973d5b"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02ab894a-b026-5f56-bf28-59cbad013ae3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [899, 912], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d3779b0-83d9-4b6f-a043-f7768cd7fce6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d3779b0-83d9-4b6f-a043-f7768cd7fce6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d3779b0-83d9-4b6f-a043-f7768cd7fce6"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril ta"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03d2af43-1c4a-5352-9599-7952848cb56b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [879, 892], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b44ab6e-6cd9-4e12-b9be-d2e4d954acb5"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria ˃500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril, it should be noted that i"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3dc2807c-5a44-5683-8e40-772b2980b982", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [897, 910], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d117c8bd-50a8-7355-e053-2a95a90ac70f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d117c8bd-50a8-7355-e053-2a95a90ac70f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d117c8bd-50a8-7355-e053-2a95a90ac70f"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Hypertension Captopril Tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril Tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril Tablets, are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopril "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b9ed1fb-d818-5da6-8806-144e0c8b3b87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [892, 905], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a91ac7f-b75d-d111-e063-6394a90a2a93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a91ac7f-b75d-d111-e063-6394a90a2a93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a91ac7f-b75d-d111-e063-6394a90a2a93"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6158b787-a9e1-544e-902c-6d6a73925f65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [897, 910], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:607687f4-63cf-411c-a20b-21d238a6b7a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=607687f4-63cf-411c-a20b-21d238a6b7a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=607687f4-63cf-411c-a20b-21d238a6b7a7"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Hypertension Captopril Tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril Tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril Tablets, are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopril "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:661bf9c9-6176-5fcb-96a0-93e17641cbe2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [919, 932], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3aa39c24-1f08-4b52-b30a-a158a742db0a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3aa39c24-1f08-4b52-b30a-a158a742db0a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3aa39c24-1f08-4b52-b30a-a158a742db0a"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, USP, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets, USP may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets, USP are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril Tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril Tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril Tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7708b105-f7ae-5d7c-b853-53824c4df689", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [874, 887], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f87bcd5-6fc8-4084-9644-519fa5ee8a6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f87bcd5-6fc8-4084-9644-519fa5ee8a6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f87bcd5-6fc8-4084-9644-519fa5ee8a6b"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted t"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c344309-7f46-5049-8cf0-bb2914eafed2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [892, 905], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccbffd30-4b21-4522-bdb8-abba8d592017", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccbffd30-4b21-4522-bdb8-abba8d592017", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccbffd30-4b21-4522-bdb8-abba8d592017"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88d85a19-911d-54d2-848e-cad863f3b903", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [897, 910], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65ed6e70-f1ee-437e-965c-d1b1fdadd832", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65ed6e70-f1ee-437e-965c-d1b1fdadd832", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65ed6e70-f1ee-437e-965c-d1b1fdadd832"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Hypertension Captopril Tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril Tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril Tablets, are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopril "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aab261e7-7522-5bb9-84b8-c82b22cc4cff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [879, 892], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3362b7a8-026a-b277-e063-6394a90a9dc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3362b7a8-026a-b277-e063-6394a90a9dc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3362b7a8-026a-b277-e063-6394a90a9dc6"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria ˃500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril, it should be noted that i"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:acb12876-a630-59d7-ab37-b82b5a8963a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [892, 905], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00871911-8c79-433c-87d5-181f4c973d5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00871911-8c79-433c-87d5-181f4c973d5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00871911-8c79-433c-87d5-181f4c973d5b"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c43cb54c-8e8d-50ac-802d-2d49fbfb2a12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [899, 912], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b54feb0-13cd-46a8-9924-f12880381196", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b54feb0-13cd-46a8-9924-f12880381196", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b54feb0-13cd-46a8-9924-f12880381196"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension: Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril Tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril Tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril Tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopri"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e66012b9-3778-5eb2-994f-26653b4ab70d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [893, 906], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1395ba5b-2fc9-41ff-9c43-e0740d781dee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1395ba5b-2fc9-41ff-9c43-e0740d781dee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1395ba5b-2fc9-41ff-9c43-e0740d781dee"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it sh"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0df52c88-e337-509d-9463-22305930af28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00871911-8c79-433c-87d5-181f4c973d5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00871911-8c79-433c-87d5-181f4c973d5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00871911-8c79-433c-87d5-181f4c973d5b"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a8d3435-03e2-57ef-8186-1826f41363ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a91ac7f-b75d-d111-e063-6394a90a2a93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a91ac7f-b75d-d111-e063-6394a90a2a93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a91ac7f-b75d-d111-e063-6394a90a2a93"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e90ff738-4054-5ed9-8f0b-5fcdd833f8bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with ejection fraction ≤40%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ccbffd30-4b21-4522-bdb8-abba8d592017", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ccbffd30-4b21-4522-bdb8-abba8d592017", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccbffd30-4b21-4522-bdb8-abba8d592017"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction  40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it s"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfb7d818-4552-529b-97ee-27a352fb5dd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [892, 905], "original_object": "heart failure", "original_subject": "CAPTOPRIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ba4e010-9852-c864-e063-6294a90ae41a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ba4e010-9852-c864-e063-6294a90ae41a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ba4e010-9852-c864-e063-6294a90ae41a"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction &lt; 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decrease the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, i"], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31ab4bbb-a25d-5bf1-b61d-e0c59af8b0f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:607687f4-63cf-411c-a20b-21d238a6b7a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=607687f4-63cf-411c-a20b-21d238a6b7a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=607687f4-63cf-411c-a20b-21d238a6b7a7"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Hypertension Captopril Tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril Tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril Tablets, are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopril "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adf93c36-89d8-5064-9439-2de02a650a45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65ed6e70-f1ee-437e-965c-d1b1fdadd832", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65ed6e70-f1ee-437e-965c-d1b1fdadd832", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65ed6e70-f1ee-437e-965c-d1b1fdadd832"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Hypertension Captopril Tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril Tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril Tablets, are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopril "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dec6d22f-b624-54c0-a9b3-38515213c829", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92824f78-3527-5a88-9f97-f8521e184b90", "medic_supporting_text_truncated": true, "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CAPTOPRIL", "population_context_qualifier": "clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d117c8bd-50a8-7355-e053-2a95a90ac70f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d117c8bd-50a8-7355-e053-2a95a90ac70f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d117c8bd-50a8-7355-e053-2a95a90ac70f"]}], "subject": "CHEBI:3380", "supporting_text": ["Hypertension Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Hypertension Captopril Tablets, are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction Captopril Tablets, are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤ 40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy Captopril Tablets, are indicated for the treatment of diabetic nephropathy (proteinuria &gt; 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril Tablets, USP decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of Captopril "], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "true trigeminal neuralgia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bee7ad7-19f9-501f-99cd-c672d54c0196", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:05b2f23c-0863-559f-a332-3c466f4c2e6c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:647a63cd-8285-5060-ac1e-51bc6e9f0bb3", "object": "MONDO:0008599", "object_location_in_text": [780, 800], "original_object": "trigeminal neuralgia", "original_subject": "CARBAMAZEPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52cf3ba9-0a7c-4809-830e-af93d1532726", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52cf3ba9-0a7c-4809-830e-af93d1532726", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52cf3ba9-0a7c-4809-830e-af93d1532726"]}], "subject": "CHEBI:3387", "supporting_text": ["Epilepsy Carbamazepine tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS , General ). Trigeminal Neuralgia Carbamazepine tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "true trigeminal neuralgia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb589d09-5f99-5ab2-9967-91ea34b820c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:05b2f23c-0863-559f-a332-3c466f4c2e6c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:647a63cd-8285-5060-ac1e-51bc6e9f0bb3", "object": "MONDO:0008599", "object_location_in_text": [780, 800], "original_object": "trigeminal neuralgia", "original_subject": "CARBAMAZEPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9fca7d59-dd9e-4fd8-bf34-e2f7e5a36801", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9fca7d59-dd9e-4fd8-bf34-e2f7e5a36801", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9fca7d59-dd9e-4fd8-bf34-e2f7e5a36801"]}], "subject": "CHEBI:3387", "supporting_text": ["Epilepsy Carbamazepine tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS , General ). Trigeminal Neuralgia Carbamazepine tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "end-of-dose motor fluctuations", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a401327-d290-517a-899e-7c24887b02eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20031017", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ff3349d9-f157-5de6-b3cc-374b03ccfd66", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8e9d09dd-16bd-5dd7-8dc2-843c505693bd", "object": "MONDO:0005180", "object_location_in_text": [62, 81], "original_object": "Parkinson's disease", "original_subject": "levodopa;carbidopa;entacapone", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:stalevo", "https://www.ema.europa.eu/en/documents/product-information/stalevo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo"]}], "subject": "CHEBI:3395", "supporting_text": ["Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment."], "temporal_context_qualifier": "not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "end-of-dose motor fluctuations", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aabda2a4-eb4b-56ba-b833-3b611e5b31db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20031017", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ff3349d9-f157-5de6-b3cc-374b03ccfd66", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8e9d09dd-16bd-5dd7-8dc2-843c505693bd", "object": "MONDO:0005180", "object_location_in_text": [90, 109], "original_object": "Parkinson's disease", "original_subject": "levodopa;carbidopa;entacapone", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:levodopa-carbidopa-entacapone-orion", "https://www.ema.europa.eu/en/documents/product-information/levodopa-carbidopa-entacapone-orion-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/levodopa-carbidopa-entacapone-orion"]}], "subject": "CHEBI:3395", "supporting_text": ["Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment."], "temporal_context_qualifier": "not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "end-of-dose motor fluctuations", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2698920-4144-55b4-9c6b-4d5863d4661f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20031017", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ff3349d9-f157-5de6-b3cc-374b03ccfd66", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8e9d09dd-16bd-5dd7-8dc2-843c505693bd", "object": "MONDO:0005180", "original_object": "Parkinson's disease", "original_subject": "levodopa;carbidopa;entacapone", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:corbilta", "https://www.ema.europa.eu/en/documents/product-information/corbilta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/corbilta"]}], "subject": "CHEBI:3395", "supporting_text": ["Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment."], "temporal_context_qualifier": "not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a8a25e7-d76c-5723-b805-8330fd8c261d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a3a977f-76be-5274-bbc2-50ed846638a7", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CARBINOXAMINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14266e97-674b-b6a9-37a2-a955f0a01c4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14266e97-674b-b6a9-37a2-a955f0a01c4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14266e97-674b-b6a9-37a2-a955f0a01c4f"]}], "subject": "CHEBI:3398", "supporting_text": ["Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angio-edema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergens and foods", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e2b0c49-2f21-5633-b823-3293897f5e8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a3a977f-76be-5274-bbc2-50ed846638a7", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CARBINOXAMINE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c40b3f4e-2d71-41a1-a1fc-f64f38724879", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c40b3f4e-2d71-41a1-a1fc-f64f38724879", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c40b3f4e-2d71-41a1-a1fc-f64f38724879"]}], "subject": "CHEBI:3398", "supporting_text": ["1 INDICATIONS AND USAGE Karbinal ER is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled Amelioration of the severity of allergic reactions to blood or plasma Karbinal ER is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis ( 1 ) Vasomotor rhinitis ( 1 ) Allergic conjunctivitis due to inhalant allergens and foods ( 1 ) Mild, uncomplicated allergic skin manifestations of urticaria and angioedema ( 1 ) Dermatographism ( 1 ) As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled ( 1 ) Amelioration of the severity of allergic reactions to blood or plasma ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:973132f0-dbf9-56f0-8b94-6142073055a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2a3a977f-76be-5274-bbc2-50ed846638a7", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CARBINOXAMINE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:199f46e5-6288-5627-e063-6294a90ae086", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=199f46e5-6288-5627-e063-6294a90ae086", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=199f46e5-6288-5627-e063-6294a90ae086"]}], "subject": "CHEBI:3398", "supporting_text": ["1 INDICATIONS AND USAGE Carbinoxamine Maleate extended-release oral suspension is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled Amelioration of the severity of allergic reactions to blood or plasma Carbinoxamine Maleate extended-release oral suspension is an H1 receptor antagonist indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis ( 1 ) Vasomotor rhinitis ( 1 ) Allergic conjunctivitis due to inhalant allergens and foods ( 1 ) Mild, uncomplicated allergic skin manifestations of urticaria and angioedema ( 1 ) Dermatographism (1) As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled ( 1 ) Amelioration of the severity of allergic reactions to blood or plasma ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032961", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fac85ea-157c-576c-a6b8-8ad388ce5763", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54f63946-b8c9-5cbd-afe9-7afaf3544459", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "HP:0001788", "original_object": "premature rupture of membranes", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost Tromethamine Injection is indicated for aborting pregnancy between the 13 th and 20 th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost Tromethamine Injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of Carboprost Tromethamine Injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, Carboprost Tromethamine Injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "in intrauterine methods with loss of drug and insufficient or absent uterine activity"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "second trimester abortion", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f110886-a652-5f30-9014-69397e24aaeb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54f63946-b8c9-5cbd-afe9-7afaf3544459", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "HP:0001788", "original_object": "premature rupture of membranes", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa42587d-7213-4a46-9050-9bbfbb081de5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa42587d-7213-4a46-9050-9bbfbb081de5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa42587d-7213-4a46-9050-9bbfbb081de5"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "in intrauterine methods with loss of drug and insufficient or absent uterine activity"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "second trimester abortion", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e228567d-911d-52a5-ac6b-b750dc4e088c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54f63946-b8c9-5cbd-afe9-7afaf3544459", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "HP:0001788", "original_object": "premature rupture of membranes", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a1284cf-002f-4887-a3c0-d73d04b2b869", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a1284cf-002f-4887-a3c0-d73d04b2b869", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a1284cf-002f-4887-a3c0-d73d04b2b869"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "in intrauterine methods with loss of drug and insufficient or absent uterine activity"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0867ecfb-52cd-599b-95aa-60ea184700aa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa42587d-7213-4a46-9050-9bbfbb081de5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa42587d-7213-4a46-9050-9bbfbb081de5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa42587d-7213-4a46-9050-9bbfbb081de5"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "which has not responded to conventional methods of management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f1dd94b-50cb-5bba-912f-0130c561a03f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ffc3a941-4d73-4273-a879-1565133a4d5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ffc3a941-4d73-4273-a879-1565133a4d5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ffc3a941-4d73-4273-a879-1565133a4d5d"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fb7bdaf-6d24-5f9a-9c9c-167649aa19f2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dcda284-cfea-4b95-b432-a3d5af536e63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dcda284-cfea-4b95-b432-a3d5af536e63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dcda284-cfea-4b95-b432-a3d5af536e63"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection USP is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection USP has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection USP used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "postpartum"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b159e82-028b-532c-b882-1ba093a71bef", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost Tromethamine Injection is indicated for aborting pregnancy between the 13 th and 20 th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost Tromethamine Injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of Carboprost Tromethamine Injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, Carboprost Tromethamine Injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "postpartum"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f59bae3-1499-5f7f-a48f-e65f1f8694e6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:461f80d0-b66c-f093-e063-6294a90a8893", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=461f80d0-b66c-f093-e063-6294a90a8893", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=461f80d0-b66c-f093-e063-6294a90a8893"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b30420e-211a-5cfe-bb57-0b0533dc1d3b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d74a448c-ba91-4490-8550-9e675c39b427", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d74a448c-ba91-4490-8550-9e675c39b427", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d74a448c-ba91-4490-8550-9e675c39b427"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76b5179d-e954-57cb-9f72-7621d07d237f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "population_context_qualifier": "patients in whom conventional methods of management have failed", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a8a6acbf-81db-4fe3-aec8-ee7aa7af4d32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a8a6acbf-81db-4fe3-aec8-ee7aa7af4d32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8a6acbf-81db-4fe3-aec8-ee7aa7af4d32"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ad578bd-1a82-55df-9950-fedd69515e42", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [722, 743], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d282998-ff0c-480a-bd80-155606ef0a65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d282998-ff0c-480a-bd80-155606ef0a65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d282998-ff0c-480a-bd80-155606ef0a65"]}], "subject": "CHEBI:3403", "supporting_text": ["HEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. HEMABATE is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of HEMABATE has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, HEMABATE used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "postpartum"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80d64ae2-1d61-5ddf-9960-3f19d54b5b2d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a1284cf-002f-4887-a3c0-d73d04b2b869", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a1284cf-002f-4887-a3c0-d73d04b2b869", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a1284cf-002f-4887-a3c0-d73d04b2b869"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "which has not responded to conventional methods of management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85677b67-491a-5fef-b5c7-cb369dc1ceb0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [760, 781], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6ae32fdb-e0a9-4742-a90a-5c32ad9269ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6ae32fdb-e0a9-4742-a90a-5c32ad9269ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ae32fdb-e0a9-4742-a90a-5c32ad9269ff"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "due to uterine atony which has not responded to conventional methods of management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cd0c25f-57c3-551f-93e1-cfd3273f0ddc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eac3fd1c-ca4b-4aa3-9dc2-e7dbeb4c122a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eac3fd1c-ca4b-4aa3-9dc2-e7dbeb4c122a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eac3fd1c-ca4b-4aa3-9dc2-e7dbeb4c122a"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection is indicated for aborting pregnancy between the 13 th and 20 th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "postpartum"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d1a05e1-e035-549e-addf-bd19ccdbe75c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [760, 781], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd306a6-bf50-a354-46e5-d9fa8da619af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd306a6-bf50-a354-46e5-d9fa8da619af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd306a6-bf50-a354-46e5-d9fa8da619af"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "due to uterine atony which has not responded to conventional methods of management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b94100e8-a850-5f23-98cd-3d3e84b8b518", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d79f4342-2d37-4a47-958e-ab800d4f3918", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d79f4342-2d37-4a47-958e-ab800d4f3918", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d79f4342-2d37-4a47-958e-ab800d4f3918"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd7aa8b4-6c89-5b66-8e0f-4fd96acaeac9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [784, 805], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42736d6a-0ab3-4c3c-897d-406aad5a49c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42736d6a-0ab3-4c3c-897d-406aad5a49c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42736d6a-0ab3-4c3c-897d-406aad5a49c2"]}], "subject": "CHEBI:3403", "supporting_text": ["INDICATIONS &amp; USAGE Carboprost tromethamine injection, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "refractory to conventional management methods"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb9c2170-172d-5279-96a3-468958c3a297", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1cde9c7-b005-484f-8497-343c5ecd4f0a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1cde9c7-b005-484f-8497-343c5ecd4f0a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1cde9c7-b005-484f-8497-343c5ecd4f0a"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d225eab8-adfe-5dbe-92e0-c08eb764d64e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4c3b724-8c36-4d18-86b1-5ecee40cfbf4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4c3b724-8c36-4d18-86b1-5ecee40cfbf4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4c3b724-8c36-4d18-86b1-5ecee40cfbf4"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da60e115-0c62-5d99-a4b0-a222d77328cb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "population_context_qualifier": "patients refractory to conventional management", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84efd1c0-6323-4469-9535-237f96fcb383", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84efd1c0-6323-4469-9535-237f96fcb383", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84efd1c0-6323-4469-9535-237f96fcb383"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de539c85-5279-5c46-bcfc-a64a9561a66f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [760, 781], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1fc164ae-9964-17b3-4b92-d25b0ddb805e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1fc164ae-9964-17b3-4b92-d25b0ddb805e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fc164ae-9964-17b3-4b92-d25b0ddb805e"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "due to uterine atony which has not responded to conventional methods of management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee40bfad-06ba-5fd6-85f6-ee482f071504", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [743, 764], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32cb34f5-e199-4cf8-a848-aaec7d42bd10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32cb34f5-e199-4cf8-a848-aaec7d42bd10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32cb34f5-e199-4cf8-a848-aaec7d42bd10"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life-threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "postpartum"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0b8a368-1634-51d0-a492-3ccd8deb8cbb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oxytocin", "ergot preparations"], "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8ddc0be-9eda-577e-97c8-8c5aef714e83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0032797", "object_location_in_text": [760, 781], "original_object": "postpartum hemorrhage", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce9f0ea6-69f9-6b68-2811-3b51e34acea6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce9f0ea6-69f9-6b68-2811-3b51e34acea6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce9f0ea6-69f9-6b68-2811-3b51e34acea6"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection, USP is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."], "temporal_context_qualifier": "due to uterine atony which has not responded to conventional methods of management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032961", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f10be8f8-da8d-582b-9ab0-bb1018f82cb3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37785535-4f11-5bcd-9f19-277606516eda", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C0233308", "original_object": "spontaneous rupture of membranes", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost Tromethamine Injection is indicated for aborting pregnancy between the 13 th and 20 th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost Tromethamine Injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of Carboprost Tromethamine Injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, Carboprost Tromethamine Injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "second trimester abortion", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be9689e4-ce6a-5591-aaab-063c5b546947", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:84bacd47-4148-54de-b67b-314c6dd26187", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C1720767", "original_object": "retained fetus", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eac3fd1c-ca4b-4aa3-9dc2-e7dbeb4c122a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eac3fd1c-ca4b-4aa3-9dc2-e7dbeb4c122a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eac3fd1c-ca4b-4aa3-9dc2-e7dbeb4c122a"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost tromethamine injection is indicated for aborting pregnancy between the 13 th and 20 th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of carboprost tromethamine injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, carboprost tromethamine injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032961", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfa76f5d-1999-584b-8e9f-0ae985d67826", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032961"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:84bacd47-4148-54de-b67b-314c6dd26187", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86db1929-9227-5346-9eca-56daf3408673", "object": "UMLS:C1720767", "original_object": "retained fetus", "original_subject": "CARBOPROST", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5054c6a-c54e-4ddf-8280-a154b90cac07"]}], "subject": "CHEBI:3403", "supporting_text": ["Carboprost Tromethamine Injection is indicated for aborting pregnancy between the 13 th and 20 th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Carboprost Tromethamine Injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of Carboprost Tromethamine Injection has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, Carboprost Tromethamine Injection used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4288305", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d996151-36c2-535e-8b56-5df36badf7ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["surgery"], "medic_disease_context_ids": ["UMLS:C4288305"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52fd8a1d-33c4-54f0-9233-ce32edb91e8f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cb0e43a7-3128-5292-865b-a84def680923", "object": "MONDO:0018177", "object_location_in_text": [175, 187], "original_object": "glioblastoma", "original_subject": "CARMUSTINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:38962a55-a514-4c48-bea5-f99a8da4beec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=38962a55-a514-4c48-bea5-f99a8da4beec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38962a55-a514-4c48-bea5-f99a8da4beec"]}], "subject": "CHEBI:3423", "supporting_text": ["1 INDICATIONS AND USAGE GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation ( 1 ) and recurrent glioblastoma as an adjunct to surgery ( 1 )"], "temporal_context_qualifier": "recurrent"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:181404c9-c092-55a1-b04e-82133a9d75e2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:495eac20-b1fe-529f-969b-06ac3090d9a1", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OXYBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:34283", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a2f6b61-dd89-51b2-b679-89f254c450cc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:495eac20-b1fe-529f-969b-06ac3090d9a1", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OXYBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:34283", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2010e9fd-c914-5f75-a87f-ae024f58800a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:495eac20-b1fe-529f-969b-06ac3090d9a1", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OXYBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb4225-bfb5-47e2-80fe-733761ba4069"]}], "subject": "CHEBI:34283", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:814f3a37-94ed-592c-8fbc-be5e18f2e475", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:495eac20-b1fe-529f-969b-06ac3090d9a1", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OXYBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6de17911-4bce-46c9-906b-07d899a36ceb"]}], "subject": "CHEBI:34283", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef74e7df-a840-5e79-b29d-f93452fc1a3d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:495eac20-b1fe-529f-969b-06ac3090d9a1", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "OXYBENZONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f"]}], "subject": "CHEBI:34283", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:297f5aeb-d90a-5a8b-9acc-cff4127e5517", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:196536eb-8b94-45da-a2f3-f554d6bf88e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=196536eb-8b94-45da-a2f3-f554d6bf88e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=196536eb-8b94-45da-a2f3-f554d6bf88e9"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ac69c6f-99f0-5dd4-91d4-b6205c632500", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab8aa773-0ed1-4d59-a1bb-f46cf882644f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab8aa773-0ed1-4d59-a1bb-f46cf882644f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab8aa773-0ed1-4d59-a1bb-f46cf882644f"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0349782", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:571aa999-2397-53b7-8fe8-980961f055a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0349782"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa6b4014-e9d7-4074-95fc-4b48d91da83b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa6b4014-e9d7-4074-95fc-4b48d91da83b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa6b4014-e9d7-4074-95fc-4b48d91da83b"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol phosphate extended-release capsules are an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure. ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients. ( 1.2 ) hypertension. ( 1.3 ) 1.1 Heart Failure Carvedilol phosphate extended-release capsules are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol phosphate extended-release capsules are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ]. 1.3 Hypertension Carvedilol phosphate extended-release capsules are indicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4 )] . They can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ] ."], "temporal_context_qualifier": "following myocardial infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic or cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:673d82bb-8b3a-57d6-95fb-1aed1cc16f72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "object_location_in_text": [137, 158], "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7d6bfff-fbb6-4a1f-aa13-babbb9a1e878", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7d6bfff-fbb6-4a1f-aa13-babbb9a1e878", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7d6bfff-fbb6-4a1f-aa13-babbb9a1e878"]}], "subject": "CHEBI:3441", "supporting_text": ["1. INDICATIONS AND USAGE . Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )]​ 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79fd49b3-715e-52c2-8f23-7e00cbecd79a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:574c419f-3b9e-2171-e063-6394a90a0e90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=574c419f-3b9e-2171-e063-6394a90a0e90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=574c419f-3b9e-2171-e063-6394a90a0e90"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol is indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8150468f-6232-5cde-8fba-afc1312e0977", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol is indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85510eb6-a0a6-5b93-af27-1e0505d0d270", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5572c43-61fe-459f-a40a-5cd7f26d1ec4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5572c43-61fe-459f-a40a-5cd7f26d1ec4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5572c43-61fe-459f-a40a-5cd7f26d1ec4"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:994183c0-ac40-53e1-9a6a-7b798ea8e51c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e98593a-8424-48c8-acc0-671f4b566aee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e98593a-8424-48c8-acc0-671f4b566aee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e98593a-8424-48c8-acc0-671f4b566aee"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic or cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ed3db20-dd7b-5c79-b851-ca2a4734b237", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "object_location_in_text": [137, 158], "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58280d18-5960-1730-e063-6394a90a4f64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58280d18-5960-1730-e063-6394a90a4f64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58280d18-5960-1730-e063-6394a90a4f64"]}], "subject": "CHEBI:3441", "supporting_text": ["1. INDICATIONS AND USAGE . Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )]​ 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adb14079-5433-533d-b3e5-e41e99010d82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:683bd1c4-fb9d-46cc-9bd4-6a6e455cadfb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=683bd1c4-fb9d-46cc-9bd4-6a6e455cadfb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=683bd1c4-fb9d-46cc-9bd4-6a6e455cadfb"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6cb099b-65e2-5c68-9518-30c6f0442241", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32098c09-7580-4975-a3e1-31b619c04c69", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32098c09-7580-4975-a3e1-31b619c04c69", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32098c09-7580-4975-a3e1-31b619c04c69"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b940068c-d056-5eed-a595-ac68f668dda9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95300809-be15-461e-904e-b56aba676975", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95300809-be15-461e-904e-b56aba676975", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95300809-be15-461e-904e-b56aba676975"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol is indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2dfbc7c-c5aa-560a-b3ae-3b372f4910c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39cf31cc-8f3d-4919-a93a-f997ad6850dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39cf31cc-8f3d-4919-a93a-f997ad6850dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39cf31cc-8f3d-4919-a93a-f997ad6850dc"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce2660bb-b690-527c-adfd-004dc97e3ee1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed11cd4e-d7c9-8446-e053-2995a90afd6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed11cd4e-d7c9-8446-e053-2995a90afd6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed11cd4e-d7c9-8446-e053-2995a90afd6e"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1455fbaa-5787-50d3-b036-ace01b49c366", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58337744-a130-35ef-e063-6294a90a080b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58337744-a130-35ef-e063-6294a90a080b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58337744-a130-35ef-e063-6294a90a080b"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e46c67d-774f-5dad-b807-11fb532eb967", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "object_location_in_text": [534, 549], "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol is indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4352f3bc-fa83-50a6-a1ae-814aaccfe31b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "object_location_in_text": [534, 549], "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:574c419f-3b9e-2171-e063-6394a90a0e90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=574c419f-3b9e-2171-e063-6394a90a0e90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=574c419f-3b9e-2171-e063-6394a90a0e90"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol is indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a0d02cc-bd77-501c-820f-da6c5aefc61e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "object_location_in_text": [558, 573], "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec6d8d73-9d18-4a9e-ae0c-0ea12059e78e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec6d8d73-9d18-4a9e-ae0c-0ea12059e78e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec6d8d73-9d18-4a9e-ae0c-0ea12059e78e"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha-/beta-adrenergic blocking agent indicated for the treatment of: • mild to severe chronic heart failure ( 1.1 ) • left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) • hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d866c36-0a7f-586e-a3b3-befa90d9c3be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5b907f8-84a0-5fb2-e7ec-4c82246195f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ) and Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2 ) ]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6340eb37-b423-5591-a5c2-fd23ea28f1a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:07c619c6-4a0c-445e-94fa-664a54f68a39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39"]}], "subject": "CHEBI:3441", "supporting_text": ["1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ]. 1.3 Hypertension COREG is indicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97152abe-0481-505d-b800-1c90fa05bdf6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c297a25-6194-45c1-e063-6294a90ae8ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c297a25-6194-45c1-e063-6294a90ae8ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c297a25-6194-45c1-e063-6294a90ae8ed"]}], "subject": "CHEBI:3441", "supporting_text": ["1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dccbf9e9-eb94-5eef-a559-344b2b9ae323", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "object_location_in_text": [534, 549], "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95300809-be15-461e-904e-b56aba676975", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95300809-be15-461e-904e-b56aba676975", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95300809-be15-461e-904e-b56aba676975"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol is indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffa9429c-c75f-5a8c-a05f-bbfe8be0ec0c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:616d8d85-6069-558b-b2eb-2d8862e5677b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0019993", "original_object": "hospitalization", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a82149f-aade-2a9b-e053-2995a90a9daf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a82149f-aade-2a9b-e053-2995a90a9daf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a82149f-aade-2a9b-e053-2995a90a9daf"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ) and Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2 ) ]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14f56007-fecd-5125-b472-eea4270588e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a82149f-aade-2a9b-e053-2995a90a9daf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a82149f-aade-2a9b-e053-2995a90a9daf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a82149f-aade-2a9b-e053-2995a90a9daf"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ) and Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2 ) ]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c4fcfbe-a619-50e8-bc9e-da828d3fce9b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c297a25-6194-45c1-e063-6294a90ae8ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c297a25-6194-45c1-e063-6294a90ae8ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c297a25-6194-45c1-e063-6294a90ae8ed"]}], "subject": "CHEBI:3441", "supporting_text": ["1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbf9f164-b5fd-556f-a9d3-ee9553c6d954", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:07c619c6-4a0c-445e-94fa-664a54f68a39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39"]}], "subject": "CHEBI:3441", "supporting_text": ["1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ]. 1.3 Hypertension COREG is indicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2287517-9a1e-5703-9259-5452e66a4b0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0026566", "original_object": "mortality", "original_subject": "CARVEDILOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5b907f8-84a0-5fb2-e7ec-4c82246195f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ) and Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2 ) ]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16f1bf62-76c9-539a-b53e-1a4840b90a64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "population_context_qualifier": "patients on diuretics, ACE inhibitors, and digitalis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5b907f8-84a0-5fb2-e7ec-4c82246195f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5b907f8-84a0-5fb2-e7ec-4c82246195f5"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ) and Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2 ) ]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0349782", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d08dabb9-aa8a-5eba-86ac-80817575ba62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0349782"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:07c619c6-4a0c-445e-94fa-664a54f68a39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07c619c6-4a0c-445e-94fa-664a54f68a39"]}], "subject": "CHEBI:3441", "supporting_text": ["1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ]. 1.3 Hypertension COREG is indicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ischemic origin, cardiomyopathic origin", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8a597e7-c877-5f0f-83ba-7fd618b4d22d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "MONDO:0005009", "original_object": "chronic heart failure", "original_subject": "CARVEDILOL", "population_context_qualifier": "patients on diuretics, ACE inhibitors, and digitalis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a82149f-aade-2a9b-e053-2995a90a9daf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a82149f-aade-2a9b-e053-2995a90a9daf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a82149f-aade-2a9b-e053-2995a90a9daf"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [ see Drug Interactions ( 7.4 ) and Clinical Studies ( 14.1 ) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [ see Clinical Studies ( 14.2 ) ]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [ see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [ see Drug Interactions ( 7.2 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001635", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e67cf5e0-2b0b-5cc7-839b-a2a47023a12a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950914", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001635"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c5f207e-fcdb-5f3c-9650-683ba3ed1e68", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:20f83181-b333-56f3-b70d-e877c428dc78", "object": "UMLS:C0220921", "original_object": "survival", "original_subject": "CARVEDILOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58337744-a130-35ef-e063-6294a90a080b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58337744-a130-35ef-e063-6294a90a080b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58337744-a130-35ef-e063-6294a90a080b"]}], "subject": "CHEBI:3441", "supporting_text": ["1 INDICATIONS AND USAGE Carvedilol tablets are an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0267167", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e15492b-e922-5b71-aea5-1e3dd5cfd93f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267167"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:93ce626a-5d1a-564f-81b3-a2fc25bf99aa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:263ecfae-904b-51e4-b1b0-48ab777909ed", "object": "HP:0033843", "object_location_in_text": [67, 88], "original_object": "postprandial fullness", "original_subject": "ACOTIAMIDE HYDROCHLORIDE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACOTIAMIDE HYDROCHLORIDE HYDRATE#132-20130325", "https://www.pmda.go.jp/files/000153467.pdf"]}], "subject": "CHEBI:34523", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of postprandial fullness, upper abdominal bloating, and early satiation in functional dyspepsia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0267167", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10a20c91-c174-5f2c-8fca-f7e3520e43f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267167"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2704d4cb-9a75-519b-828c-d6bf9f631cbd", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:263ecfae-904b-51e4-b1b0-48ab777909ed", "object": "UMLS:C0036239", "object_location_in_text": [120, 135], "original_object": "early satiation", "original_subject": "ACOTIAMIDE HYDROCHLORIDE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ACOTIAMIDE HYDROCHLORIDE HYDRATE#132-20130325", "https://www.pmda.go.jp/files/000153467.pdf"]}], "subject": "CHEBI:34523", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of postprandial fullness, upper abdominal bloating, and early satiation in functional dyspepsia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "colistin-resistant bacterial infection", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8da5f1f6-f8b7-5e91-8919-2751cf9d2468", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3109ac36-2166-574e-85e8-806d8b00870c", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:ff37005c-77d5-5c7e-aeb1-547b0fd74cc6", "object": "MONDO:0006635", "original_object": "infections caused by Acinetobacter", "original_subject": "COLISTIN SODIUM METHANESULFONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:COLISTIN SODIUM METHANESULFONATE#117-20150326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:34650", "supporting_text": ["A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "colistin-resistant bacterial infection", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6da3dda3-5707-58c9-8fa5-ab4a8344dfeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:cc56cf8f-5f41-5ba8-ac0b-2633aa76ee27", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:ff37005c-77d5-5c7e-aeb1-547b0fd74cc6", "object": "MONDO:0040732", "original_object": "infections caused by Pseudomonas aeruginosa", "original_subject": "COLISTIN SODIUM METHANESULFONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:COLISTIN SODIUM METHANESULFONATE#117-20150326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:34650", "supporting_text": ["A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "colistin-resistant bacterial infection", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db1168c0-a856-532d-8ba6-d1dadafcb398", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:5ce4347b-114e-5bb0-8f6a-7271a2107406", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:ff37005c-77d5-5c7e-aeb1-547b0fd74cc6", "object": "UMLS:C0022729", "original_object": "infections caused by Klebsiella", "original_subject": "COLISTIN SODIUM METHANESULFONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:COLISTIN SODIUM METHANESULFONATE#117-20150326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:34650", "supporting_text": ["A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "colistin-resistant bacterial infection", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:915d5cf2-f4da-5e8a-b46a-84313fa58b8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9299b87d-e1e3-5cfe-8b8a-7026b9e74327", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:ff37005c-77d5-5c7e-aeb1-547b0fd74cc6", "object": "UMLS:C0948205", "original_object": "infections caused by Enterobacter", "original_subject": "COLISTIN SODIUM METHANESULFONATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:COLISTIN SODIUM METHANESULFONATE#117-20150326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:34650", "supporting_text": ["A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:323b97b3-e3bf-5519-8db5-3f28d6c6b9da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701", "UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41bc5f5a-5e1d-4cb6-a795-9f1756a8f074", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41bc5f5a-5e1d-4cb6-a795-9f1756a8f074", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41bc5f5a-5e1d-4cb6-a795-9f1756a8f074"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3500c62a-81d7-523d-9cc3-ddb71484f7b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701", "UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27009a05-4d2b-4618-be76-39f348240eda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27009a05-4d2b-4618-be76-39f348240eda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27009a05-4d2b-4618-be76-39f348240eda"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil for oral suspension USP is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fe99538-c85f-5db0-a46a-4208ccc35828", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701", "UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de1e8c93-f001-538a-8d5b-debe64b136fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701", "UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fb524c1-f985-2a8f-e063-6394a90aab7f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9d13781-4556-5609-81d8-48cff7810de4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033701", "UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97193a92-12ff-cfab-e053-2a95a90a9f14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97193a92-12ff-cfab-e053-2a95a90a9f14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97193a92-12ff-cfab-e053-2a95a90a9f14"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:314330c2-4015-534d-b7f6-afa68875e8b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "object_location_in_text": [335, 346], "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41bc5f5a-5e1d-4cb6-a795-9f1756a8f074", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41bc5f5a-5e1d-4cb6-a795-9f1756a8f074", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41bc5f5a-5e1d-4cb6-a795-9f1756a8f074"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38f65aa4-64ce-5090-8fba-64b334ec4790", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "object_location_in_text": [335, 346], "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fb524c1-f985-2a8f-e063-6394a90aab7f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cc0d809-a400-5c14-b484-a7b83b821476", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "object_location_in_text": [335, 346], "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7e74b63-9d5c-7baa-e053-2a95a90a98b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7e74b63-9d5c-7baa-e053-2a95a90a98b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7e74b63-9d5c-7baa-e053-2a95a90a98b2"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b74a972b-24b6-52fc-80e7-4c3595dfbce7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "object_location_in_text": [335, 346], "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97193a92-12ff-cfab-e053-2a95a90a9f14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97193a92-12ff-cfab-e053-2a95a90a9f14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97193a92-12ff-cfab-e053-2a95a90a9f14"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bba71908-8357-5d28-abec-5db93c3afcab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "object_location_in_text": [335, 346], "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d69c380d-f524-5ae6-b061-4a1c185fac64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "object_location_in_text": [335, 346], "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02566385-46f3-255a-e063-6294a90a1d1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02566385-46f3-255a-e063-6294a90a1d1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02566385-46f3-255a-e063-6294a90a1d1c"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8ac8895-3ac2-5871-9c7a-38036537bd07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0001039", "original_object": "tonsillitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27009a05-4d2b-4618-be76-39f348240eda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27009a05-4d2b-4618-be76-39f348240eda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27009a05-4d2b-4618-be76-39f348240eda"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil for oral suspension USP is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22043dea-b674-5aec-8c05-5bc338f00434", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41bc5f5a-5e1d-4cb6-a795-9f1756a8f074", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41bc5f5a-5e1d-4cb6-a795-9f1756a8f074", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41bc5f5a-5e1d-4cb6-a795-9f1756a8f074"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30fc0155-0bf2-56c8-8a34-4b8e09bc2b6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fb524c1-f985-2a8f-e063-6394a90aab7f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fb524c1-f985-2a8f-e063-6394a90aab7f"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44465aef-3de5-5061-bb12-c92e67a5575a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27009a05-4d2b-4618-be76-39f348240eda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27009a05-4d2b-4618-be76-39f348240eda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27009a05-4d2b-4618-be76-39f348240eda"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil for oral suspension USP is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial drugs, cefadroxil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73b89dda-7777-59ec-83bf-13f1acb20818", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97193a92-12ff-cfab-e053-2a95a90a9f14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97193a92-12ff-cfab-e053-2a95a90a9f14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97193a92-12ff-cfab-e053-2a95a90a9f14"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89823a80-af7f-50ed-b045-d8244d3af4fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02566385-46f3-255a-e063-6294a90a1d1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02566385-46f3-255a-e063-6294a90a1d1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02566385-46f3-255a-e063-6294a90a1d1c"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9f9183d-ad61-567d-8898-5360ad7c5f01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7e74b63-9d5c-7baa-e053-2a95a90a98b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7e74b63-9d5c-7baa-e053-2a95a90a98b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7e74b63-9d5c-7baa-e053-2a95a90a98b2"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Streptococcus pyogenes (Group A beta-hemolytic streptococci)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f98c8b04-095f-58c7-a322-1445b75c7b55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecda37a5-8c24-567c-94f8-c71fcb6febfa", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFADROXIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab9cf28c-7c16-4bfa-879d-c360b4d1d5a6"]}], "subject": "CHEBI:3479", "supporting_text": ["Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50b7da98-109e-57ad-921d-98cd78c162f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aeaff508-b547-53be-997d-3398359ca68a", "object": "MONDO:0001461", "object_location_in_text": [140, 154], "original_object": "tinea corporis", "original_subject": "LULICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7016010-ce43-4c09-8d21-aeb697ffed31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31"]}], "subject": "CHEBI:34825", "supporting_text": ["1 INDICATIONS AND USAGE LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . LUZU (luliconazole) Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cad35ba3-3dc4-54e7-81a8-706a6359991f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aeaff508-b547-53be-997d-3398359ca68a", "object": "MONDO:0001461", "object_location_in_text": [133, 147], "original_object": "tinea corporis", "original_subject": "LULICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ccda3ba-9c98-468d-83c6-7f0cc7c88c33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ccda3ba-9c98-468d-83c6-7f0cc7c88c33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ccda3ba-9c98-468d-83c6-7f0cc7c88c33"]}], "subject": "CHEBI:34825", "supporting_text": ["1 INDICATIONS AND USAGE Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . Luliconazole Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:368693e0-e181-5e6a-b6ee-270f1945df77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aeaff508-b547-53be-997d-3398359ca68a", "object": "UMLS:C1384589", "object_location_in_text": [122, 134], "original_object": "tinea cruris", "original_subject": "LULICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7016010-ce43-4c09-8d21-aeb697ffed31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7016010-ce43-4c09-8d21-aeb697ffed31"]}], "subject": "CHEBI:34825", "supporting_text": ["1 INDICATIONS AND USAGE LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . LUZU (luliconazole) Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:512e07ff-d2ca-550a-a329-8f21d41aa758", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aeaff508-b547-53be-997d-3398359ca68a", "object": "UMLS:C1384589", "object_location_in_text": [115, 127], "original_object": "tinea cruris", "original_subject": "LULICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ccda3ba-9c98-468d-83c6-7f0cc7c88c33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ccda3ba-9c98-468d-83c6-7f0cc7c88c33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ccda3ba-9c98-468d-83c6-7f0cc7c88c33"]}], "subject": "CHEBI:34825", "supporting_text": ["1 INDICATIONS AND USAGE Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . Luliconazole Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:469af279-1104-5b43-953b-091317a3e316", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038411"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "original_object": "tonsillitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Pediatric Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6a35dc3-86a2-55b2-8fd4-f903f044bb7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038411"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "original_object": "tonsillitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Pediatric Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54bc137d-0aa3-5359-8047-37d2ea088757", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Adults and Adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:996cde16-fe3d-50d3-9d4b-ae6d5a197849", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Adults and Adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33b53c8e-cef9-53f8-aa0a-561d712849fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038411"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Pediatric Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73ed3ce3-9e5a-5d37-a8b2-e0d5554c91e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038411"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Pediatric Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3066102d-563d-521a-bbfb-223c56c475e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0317568", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "UMLS:C0694549", "original_object": "community-acquired pneumonia", "original_subject": "CEFDINIR", "population_context_qualifier": "Adults and Adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43ed5320-a756-5012-a459-b7fa61867765", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0317568", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "UMLS:C0694549", "original_object": "community-acquired pneumonia", "original_subject": "CEFDINIR", "population_context_qualifier": "Adults and Adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28270ef3-9977-5ff7-abcd-34b4616583d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0317568", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f427cde-156a-5da5-8253-2fe337625cee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "original_object": "acute exacerbation of chronic bronchitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Adults and Adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca6779d1-c237-5e2b-8ef5-d87f21489a0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0317568", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f427cde-156a-5da5-8253-2fe337625cee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "original_object": "acute exacerbation of chronic bronchitis", "original_subject": "CEFDINIR", "population_context_qualifier": "Adults and Adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b91ec55-eb70-517c-8d6e-70540bff2cea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "CEFDINIR", "population_context_qualifier": "Pediatric Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0eeac6df-bad7-413e-8b41-0660f3a99373"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d827beaf-e912-5aac-aa31-fee725d73901", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0038410", "UMLS:C0006132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:caf8913c-beff-5d14-8c09-ffc3aa1ad0e8", "medic_supporting_text_truncated": true, "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "CEFDINIR", "population_context_qualifier": "Pediatric Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d1212c9-604f-4999-8f7d-e7cf300705ef"]}], "subject": "CHEBI:3485", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis Caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE : For information on use in pediatric patients, see Pediatric Use and DOSAGE AND ADMINISTRATION . Pharyngitis/Tonsillitis Caused by Streptococcus pyogenes (see CLINICAL STUDIES ). NOTE : Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e402b34-cedb-5dc1-9e9d-e4cd0b478f70", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "HP:0012531", "object_location_in_text": [168, 172], "original_object": "pain", "original_subject": "PHENYL SALICYLATE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:34918", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9cca3b0-bdae-53b5-8868-55a100292e17", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "HP:0012531", "object_location_in_text": [166, 170], "original_object": "pain", "original_subject": "PHENYL SALICYLATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:34918", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e07f3785-8708-5a62-8538-1c6e5f9cdceb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "HP:0012531", "object_location_in_text": [164, 168], "original_object": "pain", "original_subject": "PHENYL SALICYLATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:34918", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:285ed636-b65f-599d-89b4-04f2f3b85853", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "UMLS:C0021368", "object_location_in_text": [133, 145], "original_object": "inflammation", "original_subject": "PHENYL SALICYLATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:34918", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68b261fd-02c4-5857-b0ea-0e829d9e5ab8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "UMLS:C0021368", "object_location_in_text": [131, 143], "original_object": "inflammation", "original_subject": "PHENYL SALICYLATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:34918", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad0ff025-fe25-5023-98c3-13375b1c8d7e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "UMLS:C0021368", "object_location_in_text": [135, 147], "original_object": "inflammation", "original_subject": "PHENYL SALICYLATE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:34918", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38a1b807-5353-5b64-a71a-19b67091f234", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "UMLS:C0549185", "object_location_in_text": [147, 160], "original_object": "hypermotility", "original_subject": "PHENYL SALICYLATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:34918", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bab18888-ef36-5f7b-a9e8-ae52ed616049", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "UMLS:C0549185", "object_location_in_text": [149, 162], "original_object": "hypermotility", "original_subject": "PHENYL SALICYLATE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:34918", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd7ddc5b-465a-50dc-a4ae-001f7b4625cd", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4009fd5-bcea-5397-831f-c12fd67d025e", "object": "UMLS:C0549185", "object_location_in_text": [145, 158], "original_object": "hypermotility", "original_subject": "PHENYL SALICYLATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:34918", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c68af85-ed45-5fe7-9e73-c42dc227cf27", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce5646cb-a450-4c2c-8499-6ecf71b12b0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:155a5318-71bd-5f76-9823-c03ad78e8947", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b405104-650b-c8e3-e063-6294a90a9e8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b405104-650b-c8e3-e063-6294a90a9e8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b405104-650b-c8e3-e063-6294a90a9e8a"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bfdf600-9767-586c-88fc-3c40bf8be77c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dae9cbf2-65b5-49fa-898b-924c39b86c57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dae9cbf2-65b5-49fa-898b-924c39b86c57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dae9cbf2-65b5-49fa-898b-924c39b86c57"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:469c4ef6-f6d8-5fd4-aa29-4cbc0e4e2389", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b42f335-1ad5-39c1-e063-6294a90a0f48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b42f335-1ad5-39c1-e063-6294a90a0f48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b42f335-1ad5-39c1-e063-6294a90a0f48"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c202cc2-ce3e-5cce-892f-df872efc62e0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d6d7f50-9838-47e3-8214-53e2dbeeadea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d6d7f50-9838-47e3-8214-53e2dbeeadea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d6d7f50-9838-47e3-8214-53e2dbeeadea"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyn"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6878851f-ff59-50e9-a108-96cb266760a6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [659, 670], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8519a9d8-7106-4545-bc58-859ee9a6708e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8519a9d8-7106-4545-bc58-859ee9a6708e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8519a9d8-7106-4545-bc58-859ee9a6708e"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7babd939-4525-5768-9ab6-cb14aee4c54b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b42e396-942d-2637-e063-6294a90aca98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b42e396-942d-2637-e063-6294a90aca98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b42e396-942d-2637-e063-6294a90aca98"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c4d4246-bf9d-5084-ad5c-4b3a9fc8a130", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [682, 693], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d5ca5b6-282b-4683-908c-854782255739", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d5ca5b6-282b-4683-908c-854782255739", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d5ca5b6-282b-4683-908c-854782255739"]}], "subject": "CHEBI:3504", "supporting_text": ["INDICATIONS &amp; USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeac9222-5161-5d43-9de0-5b283b357642", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb313728-09f1-aff8-e053-6394a90a30a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6b6bae2-decc-53c5-9809-4a88dcc99fd9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [658, 669], "original_object": "tonsillitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe827f61-9336-72e7-e053-6394a90af75f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe827f61-9336-72e7-e053-6394a90af75f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe827f61-9336-72e7-e053-6394a90af75f"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:071bd8af-3eb4-5405-82f4-609e93198fe3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb313728-09f1-aff8-e053-6394a90a30a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15c90df1-d705-5f98-8795-00033ba45ba3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe827f61-9336-72e7-e053-6394a90af75f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe827f61-9336-72e7-e053-6394a90af75f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe827f61-9336-72e7-e053-6394a90af75f"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e4da12a-bd64-5efd-9244-8e55f51113fc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b42e396-942d-2637-e063-6294a90aca98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b42e396-942d-2637-e063-6294a90aca98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b42e396-942d-2637-e063-6294a90aca98"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53347eca-81b9-5041-887d-986cce24c351", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8519a9d8-7106-4545-bc58-859ee9a6708e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8519a9d8-7106-4545-bc58-859ee9a6708e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8519a9d8-7106-4545-bc58-859ee9a6708e"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5718729b-ea1f-5fae-be29-507b2020b844", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b42f335-1ad5-39c1-e063-6294a90a0f48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b42f335-1ad5-39c1-e063-6294a90a0f48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b42f335-1ad5-39c1-e063-6294a90a0f48"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b11fcf5-dc81-584b-878b-3f2de47891cd", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d6d7f50-9838-47e3-8214-53e2dbeeadea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d6d7f50-9838-47e3-8214-53e2dbeeadea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d6d7f50-9838-47e3-8214-53e2dbeeadea"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyn"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be888fad-babf-5176-84fd-065b5fc72939", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce5646cb-a450-4c2c-8499-6ecf71b12b0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e00e102c-142d-59c4-b224-5fcefccfef54", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b405104-650b-c8e3-e063-6294a90a9e8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b405104-650b-c8e3-e063-6294a90a9e8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b405104-650b-c8e3-e063-6294a90a9e8a"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0196e1e-18ff-598f-b970-e2c50b8e0b72", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dae9cbf2-65b5-49fa-898b-924c39b86c57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dae9cbf2-65b5-49fa-898b-924c39b86c57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dae9cbf2-65b5-49fa-898b-924c39b86c57"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e56d71d9-e47b-5c02-9d5f-d6f12324724c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114", "UMLS:C1096746"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d5ca5b6-282b-4683-908c-854782255739", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d5ca5b6-282b-4683-908c-854782255739", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d5ca5b6-282b-4683-908c-854782255739"]}], "subject": "CHEBI:3504", "supporting_text": ["INDICATIONS &amp; USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1457e626-4a15-5550-af14-1619dc61d85d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe827f61-9336-72e7-e053-6394a90af75f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe827f61-9336-72e7-e053-6394a90af75f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe827f61-9336-72e7-e053-6394a90af75f"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31066561-97e4-583b-ac4f-d2286f51d49a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b405104-650b-c8e3-e063-6294a90a9e8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b405104-650b-c8e3-e063-6294a90a9e8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b405104-650b-c8e3-e063-6294a90a9e8a"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a0dfc93-132f-5d57-98db-882bbc65a05d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d5ca5b6-282b-4683-908c-854782255739", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d5ca5b6-282b-4683-908c-854782255739", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d5ca5b6-282b-4683-908c-854782255739"]}], "subject": "CHEBI:3504", "supporting_text": ["INDICATIONS &amp; USAGE Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:735df248-7e4a-5867-af83-511fbb859f78", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce5646cb-a450-4c2c-8499-6ecf71b12b0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce5646cb-a450-4c2c-8499-6ecf71b12b0e"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a40e85a4-8f3c-5b61-8bd6-9f0fd12e733e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b42e396-942d-2637-e063-6294a90aca98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b42e396-942d-2637-e063-6294a90aca98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b42e396-942d-2637-e063-6294a90aca98"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c73e2b49-803d-57c4-b6f1-74242e981c6b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b42f335-1ad5-39c1-e063-6294a90a0f48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b42f335-1ad5-39c1-e063-6294a90a0f48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b42f335-1ad5-39c1-e063-6294a90a0f48"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d30319ac-3d1d-5448-a0e9-6d4506c92b61", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dae9cbf2-65b5-49fa-898b-924c39b86c57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dae9cbf2-65b5-49fa-898b-924c39b86c57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dae9cbf2-65b5-49fa-898b-924c39b86c57"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d688c7d1-6cf1-5931-94bb-e2acc09f8503", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d6d7f50-9838-47e3-8214-53e2dbeeadea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d6d7f50-9838-47e3-8214-53e2dbeeadea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d6d7f50-9838-47e3-8214-53e2dbeeadea"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyn"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed64f80e-70f8-5e04-925c-45f651f2eae7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb313728-09f1-aff8-e053-6394a90a30a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb313728-09f1-aff8-e053-6394a90a30a8"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilusinfluenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:febef701-bee3-5944-b8a5-8bf731cd918e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:45fc1ace-dbf4-5553-bce5-017e699ccc92", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPODOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8519a9d8-7106-4545-bc58-859ee9a6708e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8519a9d8-7106-4545-bc58-859ee9a6708e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8519a9d8-7106-4545-bc58-859ee9a6708e"]}], "subject": "CHEBI:3504", "supporting_text": ["Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:203b060b-0556-5fd0-b199-975ffc5254bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [753, 764], "original_object": "tonsillitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c924c12-fa53-42a1-bab9-f4daf435c466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c924c12-fa53-42a1-bab9-f4daf435c466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c924c12-fa53-42a1-bab9-f4daf435c466"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97366c18-935e-500e-a5f4-5f933d381ca3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [753, 764], "original_object": "tonsillitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af24a86f-8072-49a6-94ec-2f17fe81812b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af24a86f-8072-49a6-94ec-2f17fe81812b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af24a86f-8072-49a6-94ec-2f17fe81812b"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99001e8e-562d-5412-810a-b06767f838b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [753, 764], "original_object": "tonsillitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9111a81-07c4-4458-b994-a4ad504986d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9111a81-07c4-4458-b994-a4ad504986d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9111a81-07c4-4458-b994-a4ad504986d8"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6c1a470-b0e3-5fdb-b759-3319410cee21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "original_object": "tonsillitis", "original_subject": "CEFPROZIL", "population_context_qualifier": "patients with mild to moderate infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:225011b9-0f3a-4afc-ac80-bd1f3739bb3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=225011b9-0f3a-4afc-ac80-bd1f3739bb3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=225011b9-0f3a-4afc-ac80-bd1f3739bb3b"]}], "subject": "CHEBI:3506", "supporting_text": ["Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). LOWER RESPIRATORY TRACT Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections cau"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c173e0aa-4dbc-598c-a45f-0b33d73d29ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [753, 764], "original_object": "tonsillitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6133611e-19c1-4df2-8c23-8573aaf63020", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6133611e-19c1-4df2-8c23-8573aaf63020", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6133611e-19c1-4df2-8c23-8573aaf63020"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8be18cb-cb96-5d6f-8294-4e547315f3e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "object_location_in_text": [753, 764], "original_object": "tonsillitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5d28d57-1f3c-4c80-ad78-0f67635f5428", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5d28d57-1f3c-4c80-ad78-0f67635f5428", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5d28d57-1f3c-4c80-ad78-0f67635f5428"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03897278-0e3a-5543-8530-e63bee4ddf21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c924c12-fa53-42a1-bab9-f4daf435c466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c924c12-fa53-42a1-bab9-f4daf435c466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c924c12-fa53-42a1-bab9-f4daf435c466"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c9d138e-33ea-5bde-b3c0-7a5fd8f2563a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5d28d57-1f3c-4c80-ad78-0f67635f5428", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5d28d57-1f3c-4c80-ad78-0f67635f5428", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5d28d57-1f3c-4c80-ad78-0f67635f5428"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c9d0ce3-9424-5cb6-a3ce-5ba1b4e0703a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPROZIL", "population_context_qualifier": "patients with mild to moderate infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:225011b9-0f3a-4afc-ac80-bd1f3739bb3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=225011b9-0f3a-4afc-ac80-bd1f3739bb3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=225011b9-0f3a-4afc-ac80-bd1f3739bb3b"]}], "subject": "CHEBI:3506", "supporting_text": ["Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). LOWER RESPIRATORY TRACT Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections cau"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c3987f8-f7f6-5bce-87de-3d64c9f5205c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9111a81-07c4-4458-b994-a4ad504986d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9111a81-07c4-4458-b994-a4ad504986d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9111a81-07c4-4458-b994-a4ad504986d8"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8ea6738-1a5b-5fd3-b690-2acd761059b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6133611e-19c1-4df2-8c23-8573aaf63020", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6133611e-19c1-4df2-8c23-8573aaf63020", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6133611e-19c1-4df2-8c23-8573aaf63020"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eca7d77e-1405-527f-9e58-f419389dd1d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4e131d7-fcf5-55e7-bba9-e80437874606", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CEFPROZIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af24a86f-8072-49a6-94ec-2f17fe81812b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af24a86f-8072-49a6-94ec-2f17fe81812b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af24a86f-8072-49a6-94ec-2f17fe81812b"]}], "subject": "CHEBI:3506", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4524048", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8adade2d-7601-5c72-a0b2-9dee8cd5e6a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160623", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4524048", "UMLS:C4552431", "UMLS:C0949083"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5f91158d-2ca0-59db-8ad8-9832a5cce733", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:579ab184-66c7-5499-bc00-8d2e3406f459", "object": "MONDO:0005229", "original_object": "bacteraemia", "original_subject": "ceftazidime;avibactam", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zavicefta", "https://www.ema.europa.eu/en/documents/product-information/zavicefta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta"]}], "subject": "CHEBI:3508", "supporting_text": ["Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:  Complicated intra-abdominal infection (cIAI) Complicated urinary tract infection (cUTI), including pyelonephritis Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)  Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f729f934-95bc-5a8e-8947-4093a0f86fcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038411"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61995812-0666-5fb2-b854-077f9a60fea2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:60a9f41c-83aa-5432-a4b7-c9199da22aa2", "object": "MONDO:0002258", "original_object": "pharyngitis and tonsillitis", "original_subject": "CEFTIBUTEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dd58c88-142f-41ad-bc31-0a4fff074970", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970"]}], "subject": "CHEBI:3510", "supporting_text": ["CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the CEDAX product for the prophylaxis of subsequent rheumatic fever are not available."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:037d7c95-4e75-51ce-860d-9df64927e352", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0006132", "UMLS:C0038411"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:60a9f41c-83aa-5432-a4b7-c9199da22aa2", "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "CEFTIBUTEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dd58c88-142f-41ad-bc31-0a4fff074970", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970"]}], "subject": "CHEBI:3510", "supporting_text": ["CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the CEDAX product for the prophylaxis of subsequent rheumatic fever are not available."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06c214f2-a50e-5d8a-a7cb-6c2993ed5fde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0006132", "UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9131d5fc-c239-548c-9cc6-6d6a73500938", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:60a9f41c-83aa-5432-a4b7-c9199da22aa2", "object": "UMLS:C1735365", "original_object": "acute bacterial exacerbations of chronic bronchitis", "original_subject": "CEFTIBUTEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dd58c88-142f-41ad-bc31-0a4fff074970", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dd58c88-142f-41ad-bc31-0a4fff074970"]}], "subject": "CHEBI:3510", "supporting_text": ["CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the CEDAX product for the prophylaxis of subsequent rheumatic fever are not available."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07acfcc8-6bbd-5418-8ff5-0a2a1e567b52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dde35903-76cb-5b1f-b257-c6f72387cbdd", "object": "MONDO:0005324", "object_location_in_text": [48, 57], "original_object": "hay fever", "original_subject": "CETIRIZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0d89544-9f04-561c-e053-2995a90a35bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0d89544-9f04-561c-e053-2995a90a35bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0d89544-9f04-561c-e053-2995a90a35bd"]}], "subject": "CHEBI:3561", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61178f51-78c3-59f3-97a0-bc14d804d87c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dde35903-76cb-5b1f-b257-c6f72387cbdd", "object": "MONDO:0005324", "object_location_in_text": [48, 57], "original_object": "hay fever", "original_subject": "CETIRIZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26f2c3c1-a2f2-474a-950a-8cfe07f289fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26f2c3c1-a2f2-474a-950a-8cfe07f289fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26f2c3c1-a2f2-474a-950a-8cfe07f289fa"]}], "subject": "CHEBI:3561", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat nasal congestion reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0699757", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15487e50-7309-5751-bba1-3e462f416f6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0699757"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b82ee3a-4616-5406-9162-330c25d7092a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d40880a6-d0b1-5211-9b2d-31b21a8dbbf6", "object": "MONDO:0005433", "original_object": "alcohol withdrawal", "original_subject": "CHLORDIAZEPOXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd5f82b0-5a56-4728-941a-c8c2a0d51cc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd5f82b0-5a56-4728-941a-c8c2a0d51cc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd5f82b0-5a56-4728-941a-c8c2a0d51cc4"]}], "subject": "CHEBI:3611", "supporting_text": ["Chlordiazepoxide Hydrochloride Capsules are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide hydrochloride capsules in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0699757", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32966191-0751-5776-9e19-753863166fdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0699757"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b82ee3a-4616-5406-9162-330c25d7092a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d40880a6-d0b1-5211-9b2d-31b21a8dbbf6", "object": "MONDO:0005433", "original_object": "alcohol withdrawal", "original_subject": "CHLORDIAZEPOXIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e198c16-a929-4028-8f96-25dd23f74b10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e198c16-a929-4028-8f96-25dd23f74b10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e198c16-a929-4028-8f96-25dd23f74b10"]}], "subject": "CHEBI:3611", "supporting_text": ["Chlordiazepoxide hydrochloride capsules are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide hydrochloride capsules in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e5bcea2-edcc-5e55-b60d-d50c8d275750", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "MONDO:0002050", "object_location_in_text": [280, 290], "original_object": "depression", "original_subject": "ANHYDROUS LACTOSE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae"]}], "subject": "CHEBI:36219", "supporting_text": ["Indications &amp; Usage COVARYXT® and COVARYX® H.S. are indicated in the treatment of Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) COVARYXT® and COVARYX® H.S. HAVE NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (See BOXED WARNINGS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:412460c0-5acf-5c20-9d0c-dd881830e01c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f335a5e-a86a-5f7b-ad43-74008b4ccfa9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1fb05e0-ded2-5ecc-b8ff-a4fea4b89387", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9443085-fc92-552c-86e2-b55477d56c5a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:417a913b-0d51-505b-a9a4-2a2dd0b13d4d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b91ed4af-50d1-5a40-a66b-85bc0e28d096", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2e127f4-0975-5010-a975-3329f6b3f7ad", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0381997-2ebb-589b-b22b-e84700ce630c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79a50566-3eb7-5436-9f05-e0452c4ade65", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3da447-8e7c-2aaa-e053-2a91aa0a2821"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fd631ab-4132-51ee-9f4b-2471c3d08e9d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39df1668-8344-4c42-9bd7-7907bd571f6e"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad0cd345-bd8b-50af-ac8a-640dd2da4b8e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f86d2158-b078-3f74-e053-6394a90aa4b6"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor-positive or hormone receptor unknown", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee78d10a-c084-59c2-b1bf-e473ed50287d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:492b1ba8-029d-5319-959c-723e1e47e798", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "ANHYDROUS LACTOSE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513e8413-af48-4acc-e063-6294a90a24b4"]}], "subject": "CHEBI:36219", "supporting_text": ["1 INDICATIONS AND USAGE Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole."], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "geographic areas where resistance to chloroquine is not present", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11c784e6-cb7b-5fa6-9d96-691d1c2ae9f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f44c776e-211c-5490-afca-fa12b761f8c6", "object": "MONDO:0005136", "object_location_in_text": [80, 87], "original_object": "malaria", "original_subject": "CHLOROQUINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ee944d28-f596-4163-a502-e779c0d622bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ee944d28-f596-4163-a502-e779c0d622bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee944d28-f596-4163-a502-e779c0d622bc"]}], "subject": "CHEBI:3638", "supporting_text": ["Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "geographic areas where resistance to chloroquine is not present", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:499c32a2-c72e-5b71-8027-9b0ac14b5b64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f44c776e-211c-5490-afca-fa12b761f8c6", "object": "MONDO:0005136", "object_location_in_text": [80, 87], "original_object": "malaria", "original_subject": "CHLOROQUINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff199f31-bfda-45f8-adbd-4662f7054f1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff199f31-bfda-45f8-adbd-4662f7054f1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff199f31-bfda-45f8-adbd-4662f7054f1c"]}], "subject": "CHEBI:3638", "supporting_text": ["Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P. malariae, P. ovale, and P. vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d3bb280-6799-554d-bbb8-1577137287ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9709ffde-7034-42be-97be-f5f39eeacf72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9709ffde-7034-42be-97be-f5f39eeacf72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9709ffde-7034-42be-97be-f5f39eeacf72"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24368be0-2440-579a-bb78-32265a1e8875", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85ab0b93-c716-4889-87db-9e76e75df7c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85ab0b93-c716-4889-87db-9e76e75df7c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85ab0b93-c716-4889-87db-9e76e75df7c7"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31f980f0-4dac-5b50-b650-2c93ba291bb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2bd42d3a-bf89-4d74-a252-9b914106a570", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2bd42d3a-bf89-4d74-a252-9b914106a570", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2bd42d3a-bf89-4d74-a252-9b914106a570"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:407c8be9-8788-54d3-983a-10219be9256d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e8cebc0-7fcf-dca8-e053-2a95a90a3369", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e8cebc0-7fcf-dca8-e053-2a95a90a3369", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e8cebc0-7fcf-dca8-e053-2a95a90a3369"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:510fe591-2671-5bd8-ab62-461495008349", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8137906-946c-455d-87c0-0e130cd9266f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8137906-946c-455d-87c0-0e130cd9266f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8137906-946c-455d-87c0-0e130cd9266f"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:619b48c6-fe56-5976-9a3d-e1749b181e17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd8f9e23-d08a-4d96-8fe9-35ab2bc861c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd8f9e23-d08a-4d96-8fe9-35ab2bc861c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd8f9e23-d08a-4d96-8fe9-35ab2bc861c8"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6772a7ac-cdc9-551a-8dc0-8b4757410167", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2122d619-3f5b-48f6-8f0b-7693199abbdb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2122d619-3f5b-48f6-8f0b-7693199abbdb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2122d619-3f5b-48f6-8f0b-7693199abbdb"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d00f596-e84b-5599-9288-3a663e3cb373", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:472e9a45-4060-3b2a-e063-6294a90a716a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=472e9a45-4060-3b2a-e063-6294a90a716a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=472e9a45-4060-3b2a-e063-6294a90a716a"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b6475a6-dfc9-5923-b947-ebefb13fa807", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:432cd4ca-c728-48ff-beec-2485f5e02512", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0119ac1-02ab-5125-951e-eb14afbaeefa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d3b09b67-e8da-450d-8a52-b3c40605de26", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d3b09b67-e8da-450d-8a52-b3c40605de26", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d3b09b67-e8da-450d-8a52-b3c40605de26"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6b1ec8d-785f-54e6-95cf-6d4754ae2bc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2a38be8-43e6-4a56-9556-fe3dad412b82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2a38be8-43e6-4a56-9556-fe3dad412b82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2a38be8-43e6-4a56-9556-fe3dad412b82"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc439f83-980c-5af0-978d-f6b1dc6c75ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa086a21-de85-4b03-af58-49b70acf8cf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa086a21-de85-4b03-af58-49b70acf8cf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa086a21-de85-4b03-af58-49b70acf8cf0"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4d7b0d4-d659-5fd4-9377-d50ca7c336b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2a8b8a3-187f-4000-bde3-b40bb0e5600f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2a8b8a3-187f-4000-bde3-b40bb0e5600f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2a8b8a3-187f-4000-bde3-b40bb0e5600f"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7a59135-32c2-521a-a074-24cf10d1d2f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0dc38655-01b1-413e-9139-2466014cb4d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0dc38655-01b1-413e-9139-2466014cb4d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dc38655-01b1-413e-9139-2466014cb4d0"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:deef6650-5645-5084-9e89-822ef9c7cb47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d43718e5-66d7-44f9-9fc8-80d38d3e41ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d43718e5-66d7-44f9-9fc8-80d38d3e41ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d43718e5-66d7-44f9-9fc8-80d38d3e41ce"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0fdcf6d-e010-5132-bc35-7c0af79534ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2ca3aa1-9e3b-4eca-af26-165562cee7bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2ca3aa1-9e3b-4eca-af26-165562cee7bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2ca3aa1-9e3b-4eca-af26-165562cee7bc"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8962bc0-06af-5b30-b809-c260d37b2726", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ae79c1e-f523-4358-9f8b-7382a03d59bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ae79c1e-f523-4358-9f8b-7382a03d59bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ae79c1e-f523-4358-9f8b-7382a03d59bc"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9515221-663f-5433-98d9-a82f3367479d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41b86f9d-d7e2-4296-8d88-e8257c7cbed2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41b86f9d-d7e2-4296-8d88-e8257c7cbed2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41b86f9d-d7e2-4296-8d88-e8257c7cbed2"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "combativeness and/or explosive hyperexcitable behavior", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec12e81d-6089-5249-8675-142fd858d66d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:977db961-fef0-5bf8-aed1-85ad734cc1b2", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 19, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:02b47877-2f9b-548d-8aa8-f9667c493523", "object": "HP:0000708", "object_location_in_text": [399, 425], "original_object": "severe behavioral problems", "original_subject": "CHLORPROMAZINE", "population_context_qualifier": "children 1 to 12 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1d8fd92-bba6-4521-8cea-3e1089ffd951", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1d8fd92-bba6-4521-8cea-3e1089ffd951", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1d8fd92-bba6-4521-8cea-3e1089ffd951"]}], "subject": "CHEBI:3647", "supporting_text": ["For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fe2abdf-9ab7-58bb-af44-66b9903dd238", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b059bb48-1ada-5009-8952-1558066b62d0", "object": "MONDO:0002898", "original_object": "skin cancer", "original_subject": "ZINC OXIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3491a921-44c3-ced9-e063-6294a90ac12c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3491a921-44c3-ced9-e063-6294a90ac12c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3491a921-44c3-ced9-e063-6294a90ac12c"]}], "subject": "CHEBI:36560", "supporting_text": ["Uses Helps prevent sunburn if used as directed with other sun protection measures(see ​directions) ​, decreases the risk of skkin cancer and early signs of aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b276476-a4b9-5071-8424-aa23fd0675d1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b059bb48-1ada-5009-8952-1558066b62d0", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "ZINC OXIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d46359e7-b585-c43a-e053-2995a90a0863", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d46359e7-b585-c43a-e053-2995a90a0863", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d46359e7-b585-c43a-e053-2995a90a0863"]}], "subject": "CHEBI:36560", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0035fe20-ecb3-5b82-938c-3e71742335d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [50, 57], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:552926da-0dfb-4248-e063-6294a90ab4a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=552926da-0dfb-4248-e063-6294a90ab4a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=552926da-0dfb-4248-e063-6294a90ab4a8"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a523ea9-13c2-5789-992f-2882f2ae6e54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [50, 57], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:521c3e73-7f51-8282-e063-6294a90a8c72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=521c3e73-7f51-8282-e063-6294a90a8c72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=521c3e73-7f51-8282-e063-6294a90a8c72"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59152676-1fb4-50fc-b1fc-0d51a5476e1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [50, 57], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:521c263e-d29c-2564-e063-6394a90a2e1d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=521c263e-d29c-2564-e063-6394a90a2e1d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=521c263e-d29c-2564-e063-6394a90a2e1d"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a9c5278-e455-5f03-b13b-769dde4bfe97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [45, 52], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c2a84bc-8fec-5d33-e063-6294a90a6c8e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c2a84bc-8fec-5d33-e063-6294a90a6c8e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c2a84bc-8fec-5d33-e063-6294a90a6c8e"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e3bf291-ba9c-559c-adef-ebb2041698d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [70, 77], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f9934e4-ec37-9f68-e063-6394a90ab9a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f9934e4-ec37-9f68-e063-6394a90ab9a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f9934e4-ec37-9f68-e063-6394a90ab9a4"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses Uses For relief, and to help prevent reoccurance, of flaking and itching associated with dandruff and seborrheic dermatitis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6aae5f69-554e-5d76-ba3f-8c683487a7b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [45, 52], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c91a2a0-d941-5534-9fda-14df8c575bfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [50, 57], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:552912b2-be58-0333-e063-6394a90a85c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=552912b2-be58-0333-e063-6394a90a85c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=552912b2-be58-0333-e063-6394a90a85c0"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:946d1aa2-90ae-545a-af80-a0af21c91ca7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [45, 52], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecfde5bc-6100-d00c-e053-2995a90ac5dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecfde5bc-6100-d00c-e053-2995a90ac5dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecfde5bc-6100-d00c-e053-2995a90ac5dc"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa2de12f-4476-5dd3-b79a-29a35c7b77af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [51, 58], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6a704df-edd8-4960-a088-246519e2aecf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6a704df-edd8-4960-a088-246519e2aecf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6a704df-edd8-4960-a088-246519e2aecf"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevents recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b397decd-ed84-5e81-9e12-2794b33b27ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [45, 52], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a834d00-cc79-1a8e-e063-6294a90ab245", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a834d00-cc79-1a8e-e063-6294a90ab245", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a834d00-cc79-1a8e-e063-6294a90ab245"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5378175-d012-5ac1-aa2a-b85aa830059a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [44, 51], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb274920-ea6a-386b-e053-6394a90a22e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb274920-ea6a-386b-e053-6394a90a22e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb274920-ea6a-386b-e053-6394a90a22e4"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d59e2dad-befd-5bad-a20a-22000c20a2de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [45, 52], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d38902f-a6ae-620f-e063-6394a90ae932", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d38902f-a6ae-620f-e063-6394a90ae932", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d38902f-a6ae-620f-e063-6394a90ae932"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "flaking and itching", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:292d0627-a162-5046-bea1-efb0ec7b0d02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [64, 72], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5459e831-41e7-f1c7-e063-6394a90ae098", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5459e831-41e7-f1c7-e063-6394a90ae098", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5459e831-41e7-f1c7-e063-6394a90ae098"]}], "subject": "CHEBI:36578", "supporting_text": ["helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34f07ced-17cf-51ac-a5bc-8ac59fed3993", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [69, 77], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a3ac96a-04ec-6865-e063-6394a90a9fb8"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d104219-2a2a-5084-b924-ce1776f99e0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [75, 83], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6a704df-edd8-4960-a088-246519e2aecf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6a704df-edd8-4960-a088-246519e2aecf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6a704df-edd8-4960-a088-246519e2aecf"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevents recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42037514-3434-55b2-ac36-85c37ff5f438", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [74, 82], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "population_context_qualifier": "(none specified)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:521c263e-d29c-2564-e063-6394a90a2e1d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=521c263e-d29c-2564-e063-6394a90a2e1d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=521c263e-d29c-2564-e063-6394a90a2e1d"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "flaking and itching", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:456b28d4-8051-5a6f-a64f-320c3be938bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [64, 72], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:545780f9-a202-95e9-e063-6394a90a982f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=545780f9-a202-95e9-e063-6394a90a982f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=545780f9-a202-95e9-e063-6394a90a982f"]}], "subject": "CHEBI:36578", "supporting_text": ["helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6651166c-077f-57fa-8bc8-da602a44dae4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [68, 76], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb274920-ea6a-386b-e053-6394a90a22e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb274920-ea6a-386b-e053-6394a90a22e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb274920-ea6a-386b-e053-6394a90a22e4"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e711819-eb6d-5e91-9f96-0e8862ca6556", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [68, 76], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a62b282f-e928-42bb-b595-d5f2066aac63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a62b282f-e928-42bb-b595-d5f2066aac63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a62b282f-e928-42bb-b595-d5f2066aac63"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of flaking and itching associated with dandruff"], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a0c0ca7-8f22-5810-9b06-6dda33653d78", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [69, 77], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ecfde5bc-6100-d00c-e053-2995a90ac5dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ecfde5bc-6100-d00c-e053-2995a90ac5dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ecfde5bc-6100-d00c-e053-2995a90ac5dc"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5a8dbe2-d058-5fe2-a20f-b8b51370df8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [69, 77], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a834d00-cc79-1a8e-e063-6294a90ab245", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a834d00-cc79-1a8e-e063-6294a90ab245", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a834d00-cc79-1a8e-e063-6294a90ab245"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7b24bef-4499-5ab0-8391-95219f6e8c84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [74, 82], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "population_context_qualifier": "(none specified)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:552926da-0dfb-4248-e063-6294a90ab4a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=552926da-0dfb-4248-e063-6294a90ab4a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=552926da-0dfb-4248-e063-6294a90ab4a8"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd0c1397-ac9d-5b33-95a1-9ee0108b83af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [74, 82], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "population_context_qualifier": "(none specified)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:552912b2-be58-0333-e063-6394a90a85c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=552912b2-be58-0333-e063-6394a90a85c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=552912b2-be58-0333-e063-6394a90a85c0"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d86c1a92-9a1e-5597-a5a0-1e14a3bcb20c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [69, 77], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d38902f-a6ae-620f-e063-6394a90ae932", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d38902f-a6ae-620f-e063-6394a90ae932", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d38902f-a6ae-620f-e063-6394a90ae932"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddce7e7b-d40f-5a75-803f-0dcfe7374b0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [69, 77], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c2a84bc-8fec-5d33-e063-6294a90a6c8e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c2a84bc-8fec-5d33-e063-6294a90a6c8e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c2a84bc-8fec-5d33-e063-6294a90a6c8e"]}], "subject": "CHEBI:36578", "supporting_text": ["Uses helps prevent recurrence of flaking and itching associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f669f6f9-1ebd-5246-8379-ae18857c6668", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0221244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [74, 82], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "population_context_qualifier": "(none specified)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:521c3e73-7f51-8282-e063-6294a90a8c72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=521c3e73-7f51-8282-e063-6294a90a8c72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=521c3e73-7f51-8282-e063-6294a90a8c72"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps prevent recurrence of scalp flaking and itching associated with dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa6fd78e-fedb-5912-8e9c-9e01c5ae64cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "HP:0000989", "object_location_in_text": [30, 37], "original_object": "itching", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps eliminates flaking, itching and scaling associated with dandruff and seborrheic dermatitis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:039f14c3-5c62-5b97-b31c-9710f9c77d8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:19f3d370-85c9-50db-8ce2-1aba9b976104", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "MONDO:0006608", "object_location_in_text": [79, 100], "original_object": "seborrheic dermatitis", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps eliminates flaking, itching and scaling associated with dandruff and seborrheic dermatitis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000989", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0250bfbb-04a6-58ad-9908-e7e5393f20b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0000989", "UMLS:C0441723"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [94, 102], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7885a86b-f1a4-f2cc-e053-2991aa0ab677", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7885a86b-f1a4-f2cc-e053-2991aa0ab677", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7885a86b-f1a4-f2cc-e053-2991aa0ab677"]}], "subject": "CHEBI:36578", "supporting_text": ["Use • Helps prevent and control recurrence of itching, flaking and irritation associated with dandruff."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50bd7f4e-79e4-50a3-b315-1a467de06696", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [66, 74], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps eliminates flaking, itching and scaling associated with dandruff and seborrheic dermatitis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240941", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a4804c7-8da8-55da-bbc5-d6616e1b84da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8012e4e9-3fc7-505b-b056-b88d08abd97e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0221244", "object_location_in_text": [45, 53], "original_object": "dandruff", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96b26da0-d0d7-77ed-e053-2995a90a7a78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96b26da0-d0d7-77ed-e053-2995a90a7a78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96b26da0-d0d7-77ed-e053-2995a90a7a78"]}], "subject": "CHEBI:36578", "supporting_text": ["Use Controls scalp itching an flaking due to dandruff"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eab5805-b8dc-5d70-92c8-a86f02ea721c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860310", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0221244", "MONDO:0006608"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4537e5e-6bba-5cc6-b0d6-9af57480b179", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14ba3fa3-ac86-5928-9987-507beec94e47", "object": "UMLS:C0237849", "object_location_in_text": [42, 49], "original_object": "scaling", "original_subject": "PYRITHIONE ZINC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ca1715c-5296-f56f-e063-6394a90a9b5b"]}], "subject": "CHEBI:36578", "supporting_text": ["Use helps eliminates flaking, itching and scaling associated with dandruff and seborrheic dermatitis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0457949", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fe94033-60f1-53bc-9f4a-1ff8d43e7f4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160318", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0457949"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:57bc4c4d-6673-58bb-af91-a6a371a1f5fe", "object": "HP:0012531", "object_location_in_text": [60, 64], "original_object": "pain", "original_subject": "DULOXETINE HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DULOXETINE HYDROCHLORIDE#107-20160318", "https://www.pmda.go.jp/files/000229930.pdf"]}], "subject": "CHEBI:36796", "supporting_text": ["Drugs with a new additional indication for the treatment of pain associated with chronic low back pain."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53c2e779-c0c9-5e20-8d4d-9cea9ff5eb7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "MONDO:0016586", "object_location_in_text": [1259, 1280], "original_object": "systemic mastocytosis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis,multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72e23681-a388-532b-bad4-5ec60ac748a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbcd023b-54b2-59ac-9489-156ec4fa5837", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "MONDO:0017169", "object_location_in_text": [1281, 1308], "original_object": "multiple endocrine adenomas", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis,multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b943217-a1e4-5e78-bbf9-d48da1177674", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "MONDO:0019610", "object_location_in_text": [1231, 1257], "original_object": "Zollinger-Ellison Syndrome", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis,multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05cf308b-0ebc-53b8-b22e-0e4a6a139c47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1d73350-4e7e-428a-90a5-6000fd373a4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1d73350-4e7e-428a-90a5-6000fd373a4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1d73350-4e7e-428a-90a5-6000fd373a4f"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09950d6a-a0b4-5e77-9ec0-602cca8f9d0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06c0a509-026f-44e0-9975-a94a8de51d43", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06c0a509-026f-44e0-9975-a94a8de51d43"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine tablets beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD ). 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Erosive gastroesophageal reflux disease (GERD)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a0be360-ed17-56cf-8cce-0b3f90801a3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e35846d8-1647-46fa-b304-70f6fc7447e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e35846d8-1647-46fa-b304-70f6fc7447e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e35846d8-1647-46fa-b304-70f6fc7447e2"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets USP are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established [see DOSAGE AND ADMINISTRATION , Erosive Gastroesophageal Reflux ( GERD )]. 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c8a0945-694c-52c4-bbf8-1f0038e0f8ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:28fd7158-a617-436a-8f5c-71ffbaafe527", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=28fd7158-a617-436a-8f5c-71ffbaafe527", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28fd7158-a617-436a-8f5c-71ffbaafe527"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine tablets beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD ). 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1161a3f1-0738-54f5-9577-01a8ec4fe36d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c2e1f52-4021-4f70-9b2b-63af17094187", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c2e1f52-4021-4f70-9b2b-63af17094187", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c2e1f52-4021-4f70-9b2b-63af17094187"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: • Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. • Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. • Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established [see DOSAGE AND ADMINISTRATION , Erosive Gastroesophageal Reflux ( GERD )]. • The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d3d0db5-a180-5004-aeaf-81b5560f1381", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db482bd8-e68d-3a38-e053-2995a90a38a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db482bd8-e68d-3a38-e053-2995a90a38a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db482bd8-e68d-3a38-e053-2995a90a38a5"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine tablets beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD ). 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e0a79ac-d5b8-5b73-bedd-644541153125", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2ec923a-2b88-43c0-ac2a-7ae20c053039", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2ec923a-2b88-43c0-ac2a-7ae20c053039", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2ec923a-2b88-43c0-ac2a-7ae20c053039"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e372f2d-d969-5456-b61f-a3b4afbac736", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8b50bd9-bc1b-4da5-96c5-8eb917c8937f"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis,multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Erosive gastroesophageal reflux disease (GERD)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92168f5f-4924-560b-8995-8e2516b8bcb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e482d51-798a-4ab3-aa27-66630aaf62e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e482d51-798a-4ab3-aa27-66630aaf62e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e482d51-798a-4ab3-aa27-66630aaf62e2"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets USP are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established [see DOSAGE AND ADMINISTRATION , Erosive Gastroesophageal Reflux ( GERD )]. 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:991f2be3-7a2a-55fd-ad33-6a651769afaa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:28fa98b3-6c78-4b7b-9a37-84c879dbf58a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=28fa98b3-6c78-4b7b-9a37-84c879dbf58a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28fa98b3-6c78-4b7b-9a37-84c879dbf58a"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine tablets beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD ). 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a51f74cd-a3d7-59b3-be7a-3cfe51826c4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebd53065-c080-4045-a398-64d3f3b1460f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebd53065-c080-4045-a398-64d3f3b1460f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebd53065-c080-4045-a398-64d3f3b1460f"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine tablets beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD ). 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abf4c86e-50a3-50e4-ba0b-be19f1b883a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b27f10b3-3913-401c-90a4-f92dc5de763e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b27f10b3-3913-401c-90a4-f92dc5de763e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b27f10b3-3913-401c-90a4-f92dc5de763e"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux disease", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8711a61-defa-5aa6-ad4b-d61f0fb30730", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e40bb1f6-338a-42e7-9217-8c32d14ccfd3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e40bb1f6-338a-42e7-9217-8c32d14ccfd3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e40bb1f6-338a-42e7-9217-8c32d14ccfd3"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine Hydrochloride Oral Solution is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see Dosage and Administration-Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to 5 years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see Dosage and Administration-GERD ). (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "erosive gastroesophageal reflux", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4eaa26b-bb1b-555d-8890-6a60c29b7c5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aaf8b28a-3998-5134-9906-f9467c7e331c", "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "CIMETIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01997826-7ca1-473e-bfc9-075b14b58a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01997826-7ca1-473e-bfc9-075b14b58a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01997826-7ca1-473e-bfc9-075b14b58a35"]}], "subject": "CHEBI:3699", "supporting_text": ["Cimetidine tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine tablets at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of cimetidine tablets and antacids is not recommended, since antacids have been reported to interfere with the absorption of cimetidine. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine tablets 400 mg at bedtime for periods of up to 5 years. 3. Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. 4. Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine tablets beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD ). 5. The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HMG-CoA reductase inhibitor use, lovastatin use, simvastatin use", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcf6284a-7730-59e0-94ca-705e311abc90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["HMG-CoA reductase inhibitors (statins)", "lovastatin", "simvastatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aab231a7-5d85-55df-a952-b0c503d5f463", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "object": "MONDO:0005290", "object_location_in_text": [1360, 1374], "original_object": "rhabdomyolysis", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e899f4a-a2e9-445c-a0ed-6ad811e997e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see Drug Interactions ). There have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes . Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins), lovastatin or simvastatin, due to the risk of rhabdomyolysis. Treatment with these agents should be discontinued during clarithromycin treatment ( see WARNINGS ). For information about contraindications of other drugs indicated in combination with BIAXIN, refer to the CONTRAINDICATIONS section of their package inserts."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c3d565b-568b-5cef-898e-e1ba39d20b3a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de833a19-2341-5a7c-8b7a-20c2863f54c2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0006874", "object_location_in_text": [127, 147], "original_object": "cholestatic jaundice", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d2e5f4f-b115-597d-93c9-ed92715b0708", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de833a19-2341-5a7c-8b7a-20c2863f54c2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0006874", "object_location_in_text": [127, 147], "original_object": "cholestatic jaundice", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47c63398-9c67-573f-ad46-6ca74894543a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de833a19-2341-5a7c-8b7a-20c2863f54c2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0006874", "object_location_in_text": [127, 147], "original_object": "cholestatic jaundice", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5be5f12-6392-4d7d-ab23-ebc205ac1a85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5be5f12-6392-4d7d-ab23-ebc205ac1a85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5be5f12-6392-4d7d-ab23-ebc205ac1a85"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions ( 5.1 )] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin with cisapride and pimozide is contraindicated [see Drug Interactions ( 7 )] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )] . Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c476954e-5055-52bf-b067-8c8fa75f2bf5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de833a19-2341-5a7c-8b7a-20c2863f54c2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0006874", "object_location_in_text": [127, 147], "original_object": "cholestatic jaundice", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0be243c6-de02-45dd-8210-cab1bbc8dfa7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0be243c6-de02-45dd-8210-cab1bbc8dfa7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0be243c6-de02-45dd-8210-cab1bbc8dfa7"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions ( 5.1 )] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions ( 7 )] . There have been postmarketing reports of drug interactions when clarithromycin is co‑administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )]. Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Wa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e29ba7fc-b1ba-54aa-8ebc-e07cf1a21cd3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de833a19-2341-5a7c-8b7a-20c2863f54c2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0006874", "object_location_in_text": [127, 147], "original_object": "cholestatic jaundice", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:471f638a-9dd1-09d3-e063-6294a90a2d4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=471f638a-9dd1-09d3-e063-6294a90a2d4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=471f638a-9dd1-09d3-e063-6294a90a2d4f"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f31cd5dc-1945-52ca-9185-46eaa87e429b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de833a19-2341-5a7c-8b7a-20c2863f54c2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0006874", "object_location_in_text": [127, 147], "original_object": "cholestatic jaundice", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f98aacb4-2f01-3e94-e053-6294a90a9aa0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f98aacb4-2f01-3e94-e053-6294a90a9aa0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f98aacb4-2f01-3e94-e053-6294a90a9aa0"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions ( 5.1 )] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions ( 7 )] . There have been postmarketing reports of drug interactions when clarithromycin is co‑administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )]. Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Wa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:095c0a3f-cdb9-5d39-b415-2d360a070dee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [148, 167], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0dfc0de4-3272-538c-aabe-c5bd8637cbb7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [148, 167], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f98aacb4-2f01-3e94-e053-6294a90a9aa0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f98aacb4-2f01-3e94-e053-6294a90a9aa0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f98aacb4-2f01-3e94-e053-6294a90a9aa0"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions ( 5.1 )] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions ( 7 )] . There have been postmarketing reports of drug interactions when clarithromycin is co‑administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )]. Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Wa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92cdacd1-49f4-510c-ae9c-ff9ddd7225e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [148, 167], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5be5f12-6392-4d7d-ab23-ebc205ac1a85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5be5f12-6392-4d7d-ab23-ebc205ac1a85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5be5f12-6392-4d7d-ab23-ebc205ac1a85"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions ( 5.1 )] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin with cisapride and pimozide is contraindicated [see Drug Interactions ( 7 )] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )] . Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa61432b-814f-5d7d-a37f-c57d60b3fee7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [154, 173], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fad1e5a3-59f9-4868-9937-d3b061ab8f00", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fad1e5a3-59f9-4868-9937-d3b061ab8f00", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fad1e5a3-59f9-4868-9937-d3b061ab8f00"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS • Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) • Cisapride and pimozide ( 4.2 ) • History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) • Colchicine in renal or hepatic impairment ( 4.4 ) • Lomitapide, lovastatin, and simvastatin ( 4.5 ) • Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) • Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [ see Warnings and Precautions ( 5.1 ) ]. 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin with cisapride and pimozide is contraindicated [ see Drug Interactions ( 7 ) ]. There have been postmarketing reports of drug interactions when clarithromycin is co‑ administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin with lomitapide is contraindicated due to potential for markedly increased transaminases [ see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 ) ]. Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [ see Warnings and Precautions ( 5.4 ) and Dru"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce3283d6-d1d4-51d1-92fa-3a512068354a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [141, 160], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:de33ba3a-9df1-4076-8d5f-b603d2698096", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=de33ba3a-9df1-4076-8d5f-b603d2698096", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de33ba3a-9df1-4076-8d5f-b603d2698096"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug (4.1) Cisapride, pimozide (4.2) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3) Colchicine in renal or hepatic impairment (4.4) Lomitapide, lovastatin, and simvastatin (4.5) Ergot alkaloids (ergotamine or dihydroergotamine) (4.6) Lurasidone (4.7) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1)] . 4.2 Cisapride and Pimozide Concomitant administration of Clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7)] . There have been postmarketing reports of drug interactions when clarithromycin is co­ administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7)] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8e7c6ab-b1cf-5ea9-911d-3adfca4cd871", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [148, 167], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:471f638a-9dd1-09d3-e063-6294a90a2d4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=471f638a-9dd1-09d3-e063-6294a90a2d4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=471f638a-9dd1-09d3-e063-6294a90a2d4f"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7dbdc19-7dc9-5d14-9074-3c47567806e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [148, 167], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with prior use of clarithromycin", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe4db578-e5f3-515d-8a7c-939a75383d9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:065b5b8c-5343-539e-b5cb-73de5d4f5142", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0086565", "object_location_in_text": [148, 167], "original_object": "hepatic dysfunction", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0be243c6-de02-45dd-8210-cab1bbc8dfa7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0be243c6-de02-45dd-8210-cab1bbc8dfa7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0be243c6-de02-45dd-8210-cab1bbc8dfa7"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) Cisapride and pimozide ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) Colchicine in renal or hepatic impairment ( 4.4 ) Lomitapide, lovastatin, and simvastatin ( 4.5 ) Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) Lurasidone ( 4.7 ) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions ( 5.1 )] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions ( 7 )] . There have been postmarketing reports of drug interactions when clarithromycin is co‑administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )]. Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Wa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:380105c5-4e93-50ea-81a6-6b87317a7e8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e563f03-8fb7-5fdc-8317-2e9d0fed80dc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0948807", "original_object": "hepatic impairment", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa69ea92-0b41-43fb-918f-ed80e0dedf04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa69ea92-0b41-43fb-918f-ed80e0dedf04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa69ea92-0b41-43fb-918f-ed80e0dedf04"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug (4.1) Cisapride and pimozide (4.2) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3) Colchicine in renal or hepatic impairment (4.4) Lomitapide, lovastatin, and simvastatin (4.5) Ergot alkaloids (ergotamine or dihydroergotamine) (4.6) Lurasidone (4.7) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precaut"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0549184", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd7a4c57-9075-582e-8fe6-b42c0d602632", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_disease_context_ids": ["UMLS:C0549184"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e563f03-8fb7-5fdc-8317-2e9d0fed80dc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "object": "UMLS:C0948807", "original_object": "hepatic impairment", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see Drug Interactions ). There have been postmarketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes . Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see WARNINGS ). For information about contraindications of other drugs indicated in combination with clarithromycin, refer to the CONTRAINDICATIONS section of their package inserts."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e42e9d4c-6280-5a8e-9854-4391844ada2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2e563f03-8fb7-5fdc-8317-2e9d0fed80dc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0948807", "original_object": "hepatic impairment", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK : Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams, clarithromycin or any other macrolide antimicrobial or any component of VOQUEZNA TRIPLE PAK. ( 4.1 ) Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams or any component of VOQUEZNA DUAL PAK. ( 4.1 ) Rilpivirine-containing products. ( 4.1 ) VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component : Pimozide. ( 4.2 ) Lomitapide, lovastatin, and simvastatin. ( 4.2 ) Ergot alkaloids (ergotamine or dihydroergotamine). ( 4.2 ) Colchicine in renal or hepatic impairment. ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin. ( 4.2 ) Lurasidone. ( 4.2 ) 4.1 Contraindications to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Hypersensitivity Reactions VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) [see Warnings and Precautions (5.1) ]. Rilpivirine-containing Products VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. 4.2 Additional Contraindications to VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component Serious Adverse Reactions/Risks Due to Drug Interactions Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of: Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most like"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0568724b-97d1-5702-8ba3-638cbcc26fc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7dd6fba1-2634-5f58-85a5-ca9748acce1f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C1565489", "original_object": "renal impairment", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa69ea92-0b41-43fb-918f-ed80e0dedf04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa69ea92-0b41-43fb-918f-ed80e0dedf04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa69ea92-0b41-43fb-918f-ed80e0dedf04"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug (4.1) Cisapride and pimozide (4.2) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3) Colchicine in renal or hepatic impairment (4.4) Lomitapide, lovastatin, and simvastatin (4.5) Ergot alkaloids (ergotamine or dihydroergotamine) (4.6) Lurasidone (4.7) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1) ] . 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7) ] . There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets. Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7) ] . Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precaut"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "colchicine use", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:391d911c-00c4-5a60-95d6-0015043e4fef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7dd6fba1-2634-5f58-85a5-ca9748acce1f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C1565489", "original_object": "renal impairment", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86"]}], "subject": "CHEBI:3732", "supporting_text": ["4 CONTRAINDICATIONS VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK : Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams, clarithromycin or any other macrolide antimicrobial or any component of VOQUEZNA TRIPLE PAK. ( 4.1 ) Known hypersensitivity to vonoprazan, amoxicillin or any other beta-lactams or any component of VOQUEZNA DUAL PAK. ( 4.1 ) Rilpivirine-containing products. ( 4.1 ) VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component : Pimozide. ( 4.2 ) Lomitapide, lovastatin, and simvastatin. ( 4.2 ) Ergot alkaloids (ergotamine or dihydroergotamine). ( 4.2 ) Colchicine in renal or hepatic impairment. ( 4.2 ) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin. ( 4.2 ) Lurasidone. ( 4.2 ) 4.1 Contraindications to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK Hypersensitivity Reactions VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated in patients with a known hypersensitivity to any component of VOQUEZNA TRIPLE PAK: vonoprazan, amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins), or clarithromycin (or other macrolide antibacterial drugs, e.g., erythromycin) or VOQUEZNA DUAL PAK: vonoprazan or amoxicillin (or other β-lactam antibacterials, e.g., penicillins and cephalosporins) [see Warnings and Precautions (5.1) ]. Rilpivirine-containing Products VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are contraindicated with rilpivirine-containing products [see Drug Interactions (7) ]. 4.2 Additional Contraindications to VOQUEZNA TRIPLE PAK Due to the Clarithromycin Component Serious Adverse Reactions/Risks Due to Drug Interactions Because of the clarithromycin component, VOQUEZNA TRIPLE PAK is contraindicated with concomitant use of: Pimozide: There have been postmarketing reports of drug interactions when clarithromycin is co-administered with pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most like"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0549184", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:877d81be-0d54-54ad-bb1d-693637efafbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["colchicine"], "medic_disease_context_ids": ["UMLS:C0549184"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7dd6fba1-2634-5f58-85a5-ca9748acce1f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "object": "UMLS:C1565489", "original_object": "renal impairment", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see Drug Interactions ). There have been postmarketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes . Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see WARNINGS ). For information about contraindications of other drugs indicated in combination with clarithromycin, refer to the CONTRAINDICATIONS section of their package inserts."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fafd0e6-f3e0-5032-847b-35e398bbf221", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "object": "MONDO:0005412", "object_location_in_text": [249, 263], "original_object": "duodenal ulcer", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40adc1d3-7ce7-4698-aa7f-b5dbaaecec00", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40adc1d3-7ce7-4698-aa7f-b5dbaaecec00", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40adc1d3-7ce7-4698-aa7f-b5dbaaecec00"]}], "subject": "CHEBI:3732", "supporting_text": ["H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence The components in lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets and other antibacterial drugs, lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab9d7952-96f4-5e5d-b7f0-467f3b2059e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0001039", "original_object": "tonsillitis", "original_subject": "CLARITHROMYCIN", "population_context_qualifier": "Children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP and clarithromycin for oral suspension, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d289b6a6-104b-5cd9-ba17-eed68411db38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "UMLS:C1096746", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eecaa867-cc8f-5e61-b07f-ebc0b662f398", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0002186", "original_object": "acute maxillary sinusitis", "original_subject": "CLARITHROMYCIN", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP and clarithromycin for oral suspension, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bce361f-3645-5961-b6ac-d688b0104521", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "CLARITHROMYCIN", "population_context_qualifier": "Children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP and clarithromycin for oral suspension, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05116d45-1c06-5108-85f6-7229440a0ebe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["amoxicillin", "lansoprazole", "omeprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "Duodenal ulcer", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9eb306e0-ccfb-418c-82ca-204f20a788f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9eb306e0-ccfb-418c-82ca-204f20a788f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9eb306e0-ccfb-418c-82ca-204f20a788f7"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae . Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae . Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae , Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare. Clarithromycin tablets, USP in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets, USP in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27eff87e-8b5f-578c-b949-28f3bd569c5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["omeprazole", "ranitidine bismuth citrate"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "Duodenal ulcer", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e899f4a-a2e9-445c-a0ed-6ad811e997e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e899f4a-a2e9-445c-a0ed-6ad811e997e6"]}], "subject": "CHEBI:3732", "supporting_text": ["BIAXIN Filmtab (clarithromycin tablets, USP) and BIAXIN Granules (clarithromycin for oral suspension, USP) are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults (BIAXIN Filmtab Tablets and Granules for Oral Suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae . Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae . Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae , Streptococcus pneumoniae , or Chlamydia pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare BIAXIN (clarithromycin) Filmtab tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . BIAXIN Filmtab tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850666", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66571d8e-c3b8-57a1-9c2b-4db5bbefc82e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["amoxicillin", "PREVACID (lansoprazole)", "PRILOSEC (omeprazole) Delayed-Release Capsules"], "medic_disease_context_ids": ["UMLS:C0850666"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1920f943-bbf1-cfd9-7475-96a35680a9e0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1920f943-bbf1-cfd9-7475-96a35680a9e0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1920f943-bbf1-cfd9-7475-96a35680a9e0"]}], "subject": "CHEBI:3732", "supporting_text": ["1.1 Acute Bacterial Exacerbation of Chronic Bronchitis Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Indications and Usage (1.9)]. 1.2 Acute Maxillary Sinusitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Indications and Usage (1.9)]. 1.3 Community-Acquired Pneumonia Clarithromycin tablets are indicated [see Indications and Usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: • Haemophilus influenzae (in adults) • Mycoplasma pneumoniae, Streptococcus pneumoniae, Chlamydophila pneumoniae (clarithromycin tablets [in adults and pediatric patients]) 1.4 Pharyngitis / Tonsillitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. 1.5 Uncomplicated Skin and Skin Structure Infections Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Acute Otitis Media Clarithromycin tablets are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Clinical Studies (14.2)]. 1.7 Treatement of Prophylaxis of Disseminated Mycobacterial Infections Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Mycobacterium avium or Mycobacterium intracellulare in patients with advanced HIV infection [see Clini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bc7edae-2a5c-5e2c-8aca-656c37ff095d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["omeprazole", "ranitidine bismuth citrate"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [1711, 1725], "original_object": "duodenal ulcer", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP and clarithromycin for oral suspension, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08dc3168-88d6-550f-bc7c-9cf0f49a218c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100618", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:36fcdc3f-d32b-5afd-9a06-de2e6589f1de", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "object": "MONDO:0006226", "object_location_in_text": [99, 120], "original_object": "gastric MALT lymphoma", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CLARITHROMYCIN#157-20100618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:3732", "supporting_text": ["Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68f2ba85-b1d8-5707-b05b-216c1f75262b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100618", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:167ca84e-afeb-5167-804f-04ad88cc5aa7", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "object": "MONDO:0008558", "object_location_in_text": [198, 233], "original_object": "idiopathic thrombocytopenic purpura", "original_subject": "CLARITHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CLARITHROMYCIN#157-20100618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:3732", "supporting_text": ["Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:413da81d-1d15-506f-aed7-a9f3fabb53eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C0694549", "original_object": "community-acquired pneumonia", "original_subject": "CLARITHROMYCIN", "population_context_qualifier": "Children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP and clarithromycin for oral suspension, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b531a6b-a792-55ac-bb94-5dfd8edd1047", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "UMLS:C1096597", "UMLS:C1096746", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5d9e2-1103-5061-846c-63b680d3ad49", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0bd69ff0-2918-5454-b970-92756295b91d", "medic_supporting_text_truncated": true, "object": "UMLS:C1735365", "original_object": "acute bacterial exacerbation of chronic bronchitis", "original_subject": "CLARITHROMYCIN", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94c182ed-f2d6-4f7f-bdd9-69b136c54623"]}], "subject": "CHEBI:3732", "supporting_text": ["Clarithromycin tablets, USP and clarithromycin for oral suspension, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). Acute maxillary sinusitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae , Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules or TRITEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037383", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b28c1c7-ab98-5737-ae20-fd52f12730bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037383", "HP:0031417", "HP:0000989", "UMLS:C0423153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec052dff-f081-5cd9-ac49-74554830869a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da5dcdd2-7eba-529b-b7d3-29547fb047ef", "object": "MONDO:0011786", "object_location_in_text": [98, 115], "original_object": "allergic rhinitis", "original_subject": "CLEMASTINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf8a3449-8bb3-4d5c-8d0d-557590e49ee5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf8a3449-8bb3-4d5c-8d0d-557590e49ee5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf8a3449-8bb3-4d5c-8d0d-557590e49ee5"]}], "subject": "CHEBI:3738", "supporting_text": ["Clemastine Fumarate Tablets USP, 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets USP, 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0037383", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3a5ed79-fae4-5a48-83d3-0522351268da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037383", "HP:0031417", "HP:0000989", "UMLS:C0423153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec052dff-f081-5cd9-ac49-74554830869a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da5dcdd2-7eba-529b-b7d3-29547fb047ef", "object": "MONDO:0011786", "object_location_in_text": [98, 115], "original_object": "allergic rhinitis", "original_subject": "CLEMASTINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a35ed77-e35c-4c54-ad7f-1b92e450fa20", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a35ed77-e35c-4c54-ad7f-1b92e450fa20", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a35ed77-e35c-4c54-ad7f-1b92e450fa20"]}], "subject": "CHEBI:3738", "supporting_text": ["Clemastine Fumarate Tablets USP, 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets USP, 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5aca42a3-534f-574b-bfec-ac1f7a15c3f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [752, 764], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45"]}], "subject": "CHEBI:3745", "supporting_text": ["CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patte"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:688400e6-4ea4-5701-8c17-ffaea865e3e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [721, 733], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8e2c5c0-da2c-5450-a958-9eb4f212efb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [770, 782], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; seri­ous skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, loc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a93bd7d3-77de-5909-a9bc-d87db184102f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [760, 772], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9d8e39b-28ca-55d3-a0c4-33d44e275857", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [721, 733], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and suscepti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8ccd819-4aa6-5285-96a4-2c60fbd71417", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [1161, 1173], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f31c04fa-c2f2-5af4-b009-bd020661a63d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [721, 733], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f69076dd-cfd0-5786-984e-6ecff29aa1f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bcaa5b65-c602-5b50-8f1c-1ddfd813b5e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000744", "object_location_in_text": [779, 791], "original_object": "lung abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules, USP are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, USP and other antibacterial drugs, clindamycin hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:064c6bf5-1eae-554c-b929-95f51c6901d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1015, 1027], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1cad5f2e-e2cc-53c5-848f-b67ea48e4ff1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1054, 1066], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1262234", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43b64db0-5e35-5b3f-97f9-cfbbf798eda8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1262234"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1433, 1445], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a8707ee-ed13-516c-8060-3dfabf5df629", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1073, 1085], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules, USP are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, USP and other antibacterial drugs, clindamycin hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6dd66abb-9da2-5f0c-b8dc-c146c48c00c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1066, 1078], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; seri­ous skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, loc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5f089f7-82f3-5a89-85dd-9069967b9367", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1015, 1027], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and suscepti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de8c1786-181a-541e-88af-2c6f2e16404d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1046, 1058], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45"]}], "subject": "CHEBI:3745", "supporting_text": ["CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patte"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efd32ce7-9a8b-530e-bb41-ab066dfe5f37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:331919a6-dbd2-52b8-8f82-560813bc5c9a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0000918", "object_location_in_text": [1015, 1027], "original_object": "endometritis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33949666-c023-5ee6-ac12-d312521280be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [734, 741], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; seri­ous skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, loc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ca1f534-906f-5ad1-a5be-a379dc752964", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [743, 750], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules, USP are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, USP and other antibacterial drugs, clindamycin hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42596831-99e7-5221-a1c0-0360fca2322d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [717, 724], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45"]}], "subject": "CHEBI:3745", "supporting_text": ["CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patte"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4854e73a-bd58-5ac9-977c-3f8c34157241", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [685, 692], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and suscepti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d33cf87-4bef-5cc3-be70-7ff95836470a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [685, 692], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f6feb58-e707-5a56-9464-b0f7dcbaffb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [725, 732], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be42a697-1205-5b64-846a-4b737ec45a85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [1148, 1155], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious respiratory tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa3b2e42-e23b-598d-9a9c-c3c160743d85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b7a3adb4-d94c-53c1-825e-6115d01d18e1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005242", "object_location_in_text": [685, 692], "original_object": "empyema", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002783", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5deadb49-3a93-53d5-9d26-4c4d7d3f0415", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002783"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "object_location_in_text": [1137, 1146], "original_object": "pneumonia", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d5cd254-7d82-5748-b4d5-ff0d767a2928", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1123, 1140], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules, USP are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, USP and other antibacterial drugs, clindamycin hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2497a1b1-044c-5105-9c7b-942655073700", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1104, 1121], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:272d2158-cad9-5177-a725-d3b322cb75b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1096, 1113], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45"]}], "subject": "CHEBI:3745", "supporting_text": ["CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patte"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46bb1ea2-1f84-5a77-a894-6e899b586684", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1065, 1082], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f57194f-e434-5cb5-b25b-716831daa38e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1065, 1082], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and suscepti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1262234", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:892aa51a-3e9a-52c8-b75e-3444b81de90e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1262234"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1483, 1500], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbd5703e-172c-5cad-ac38-fb509a933268", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1065, 1082], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections of the female pelvis and genital tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf79bd6c-c5fe-529b-98d5-1bca72a0a790", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:08613202-ad89-5e5c-bc27-b7052e3faed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:0006887", "object_location_in_text": [1116, 1133], "original_object": "pelvic cellulitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; seri­ous skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, loc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1afcbd08-cd57-5e49-b1f8-f75a51a14ace", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [823, 834], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7974a930-1ce7-5c8d-95c8-24079207b747", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [881, 892], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules, USP are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, USP and other antibacterial drugs, clindamycin hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9862365d-6631-519c-9dea-a24cc46aa6bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [862, 873], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aea1eeaf-6f90-5aec-9407-9711ed71c5a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [872, 883], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; seri­ous skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, loc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b19bc3aa-bde8-5402-b84e-b6ffb2324213", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [1612, 1623], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce4dc736-7fa1-53c3-8e17-7fe47caedc32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [823, 834], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db1350be-4827-5be5-a391-e0efdd2f2c7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [854, 865], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45"]}], "subject": "CHEBI:3745", "supporting_text": ["CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patte"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3fe5edd-b0a8-573a-90b3-86b4f560d62f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [823, 834], "original_object": "peritonitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and suscepti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fe9dbc3-b079-5115-a834-8e4019ea5a3a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [839, 862], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d3e6ec5-93e9-4ce0-8276-b19aa97eb772"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules USP and other antibacterial drugs, clindamycin hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and suscepti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ffc9dec-dbd7-5cb2-9dc3-6e3567f6ca1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [839, 862], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c4fce0-0472-45a3-b4c6-192d97ca1818"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:647db047-5860-51c8-87ef-d97b1f4eef1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [888, 911], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; seri­ous skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, loc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72d2b3bb-ff22-5fe6-9c1d-6b77d0327fc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [839, 862], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b9f898f-6a91-44f8-9508-f9ddfaad27bc"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility p"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f521414-e362-5e71-9368-5731a16b8969", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [897, 920], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dbd8448-c1e5-46df-8060-50ef82380445"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules, USP are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, USP and other antibacterial drugs, clindamycin hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7538e07-996f-5465-920d-6ebb3fa13cd2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [870, 893], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ef87b6c-9d32-44ac-8c55-8bf01424cc45"]}], "subject": "CHEBI:3745", "supporting_text": ["CLEOCIN PEDIATRIC (clindamycin palmitate HCl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PEDIATRIC and other antibacterial drugs, CLEOCIN PEDIATRIC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patte"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2a2abca-c984-5586-b4de-5c75a08e9d77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [1628, 1651], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112209", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7d8f961-915e-58c7-95da-5507230e4971", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3071dc23-d15b-5cbe-b76f-258c9eb1b44a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0243001", "object_location_in_text": [878, 901], "original_object": "intra-abdominal abscess", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851989", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d076a36f-173f-56a9-8471-f49ccea90f84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851989"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56879e3e-9db3-5ca5-aa27-02172d1a0484", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d6bdcfe5-d22e-5d03-900a-c8b9405f85a6", "medic_supporting_text_truncated": true, "object": "UMLS:C0600123", "object_location_in_text": [1849, 1881], "original_object": "acute hematogenous osteomyelitis", "original_subject": "CLINDAMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799"]}], "subject": "CHEBI:3745", "supporting_text": ["Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis ), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infectio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dapsone-resistant lepromatous leprosy, lepromatous leprosy complicated by erythema nodosum leprosum", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb381fe2-5d74-51c8-b9f0-7249770625b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861215", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5ed7b317-659a-562c-a5bb-0f7dc3aba7d2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ed597ea0-1a13-5bbd-bd23-7fb8d38ae2e9", "object": "MONDO:0005127", "object_location_in_text": [88, 107], "original_object": "lepromatous leprosy", "original_subject": "CLOFAZIMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e07448f-f888-4747-80ab-570c1b621250", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e07448f-f888-4747-80ab-570c1b621250", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e07448f-f888-4747-80ab-570c1b621250"]}], "subject": "CHEBI:3749", "supporting_text": ["1 INDICATIONS AND USAGE LAMPRENE is an antimycobacterial indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. ( 1.1 ) To prevent the development of drug-resistance, LAMPRENE should be used only as a part of combination therapy for initial treatment of lepromatous leprosy. ( 1.2 ) 1.1 Lepromatous Leprosy LAMPRENE is indicated in combination with other anti-leprosy drugs for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy, and lepromatous leprosy complicated by erythema nodosum leprosum. 1.2 Usage To prevent the development of drug-resistance, LAMPRENE should be used only as a part of combination therapy for initial treatment of lepromatous (multibacillary) leprosy [see Dosage and Administration (2.1)] . For further guidance on the treatment of leprosy, contact the National Hansen’s Disease Clinical Center, Baton Rouge, Louisiana (LA) at (1-800-642-2477) or http://www.hrsa.gov/hansensdisease/clinicalcenter.html ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "undetermined etiology", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ebe307f-bf39-5969-af98-e0a87370aff1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52a41f05-1f3b-5633-9972-af7fb56ad7bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e273d9bd-7fd9-5219-946b-40a50b8d573e", "medic_supporting_text_truncated": true, "object": "MONDO:1060209", "object_location_in_text": [509, 529], "original_object": "secondary amenorrhea", "original_subject": "CLOMIPHENE", "population_context_qualifier": "patients most likely to achieve success with clomiphene therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72719958-7454-4c54-9bb4-f3054d0c5d82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72719958-7454-4c54-9bb4-f3054d0c5d82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72719958-7454-4c54-9bb4-f3054d0c5d82"]}], "subject": "CHEBI:3752", "supporting_text": ["Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "undetermined etiology", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b051147-f390-5c45-ab17-e34a1134080b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52a41f05-1f3b-5633-9972-af7fb56ad7bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e273d9bd-7fd9-5219-946b-40a50b8d573e", "medic_supporting_text_truncated": true, "object": "MONDO:1060209", "object_location_in_text": [509, 529], "original_object": "secondary amenorrhea", "original_subject": "CLOMIPHENE", "population_context_qualifier": "patients most likely to achieve success with clomiphene therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ca373c1-4dba-4126-8616-5c533d606fe5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ca373c1-4dba-4126-8616-5c533d606fe5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ca373c1-4dba-4126-8616-5c533d606fe5"]}], "subject": "CHEBI:3752", "supporting_text": ["Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004034", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5edcfa64-92f2-5b8f-abf2-a3cb8541aa0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0004034", "UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca2bd1de-9d64-5c0b-984d-d190563cf5c1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0000262", "object_location_in_text": [88, 98], "original_object": "otomycosis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "patients 18 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef0658c3-9c6b-4705-89d8-cf0644c80fcb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef0658c3-9c6b-4705-89d8-cf0644c80fcb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef0658c3-9c6b-4705-89d8-cf0644c80fcb"]}], "subject": "CHEBI:3764", "supporting_text": ["1 INDICATIONS AND USAGE CLOTIC is indicated for the treatment of fungal otitis externa (otomycosis) due to Aspergillus species and Candida species in patients 18 years of age and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27dade8d-cbb3-5a56-be24-dd0139a091b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [353, 367], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58797118-4576-57ed-9fc0-1b3088e79357", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [359, 373], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "nonprescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4bd825f4-f5e2-aab7-e063-6394a90ad6a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4bd825f4-f5e2-aab7-e063-6394a90ad6a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bd825f4-f5e2-aab7-e063-6394a90ad6a4"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution Spray product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:925a7d22-1977-5cdf-aa4a-f75959571d0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [317, 331], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur. Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014531", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:971c14cf-f849-5bd4-8063-5fe73d48b7e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014531", "UMLS:C4505442", "UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [191, 205], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "patients 17 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030a1460-3522-43af-a75d-29c99570698f"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98946b2d-e2f9-5201-86ab-02449a3ffffc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [353, 367], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "nonprescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e2041a0-8bef-4be4-b2b1-556446c4a778", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e2041a0-8bef-4be4-b2b1-556446c4a778", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e2041a0-8bef-4be4-b2b1-556446c4a778"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription CLOTRIMAZOLE TOPICAL SOLUTION product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ceaaa4d6-c862-5194-8810-0391ae8ca56a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [353, 367], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "nonprescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c64e2290-593f-48a2-a15d-41689f836fda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c64e2290-593f-48a2-a15d-41689f836fda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c64e2290-593f-48a2-a15d-41689f836fda"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription CLOTRIMAZOLE TOPICAL SOLUTION product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e773e563-f43a-5726-beb4-8415897ecb66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0001461", "object_location_in_text": [353, 367], "original_object": "tinea corporis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "nonprescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b67ebafe-0b9d-4fb0-a897-7c9a5691696e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b67ebafe-0b9d-4fb0-a897-7c9a5691696e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b67ebafe-0b9d-4fb0-a897-7c9a5691696e"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription CLOTRIMAZOLE TOPICAL SOLUTION product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006837", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19d116d2-96d3-549e-b480-343de539c650", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006837"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0002026", "object_location_in_text": [93, 104], "original_object": "candidiasis", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276680", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3225321d-301b-5b60-a9f9-b254d3a8c786", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276680"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0002026", "object_location_in_text": [93, 104], "original_object": "candidiasis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "prescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c64e2290-593f-48a2-a15d-41689f836fda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c64e2290-593f-48a2-a15d-41689f836fda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c64e2290-593f-48a2-a15d-41689f836fda"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription CLOTRIMAZOLE TOPICAL SOLUTION product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276680", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:500135ed-6f05-5bc0-be68-88513e821e1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276680"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0002026", "object_location_in_text": [93, 104], "original_object": "candidiasis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "prescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b67ebafe-0b9d-4fb0-a897-7c9a5691696e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b67ebafe-0b9d-4fb0-a897-7c9a5691696e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b67ebafe-0b9d-4fb0-a897-7c9a5691696e"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription CLOTRIMAZOLE TOPICAL SOLUTION product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276680", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f17a5ba-1db1-5ec8-93a2-82b9ed975107", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276680"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0002026", "object_location_in_text": [99, 110], "original_object": "candidiasis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "prescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4bd825f4-f5e2-aab7-e063-6394a90ad6a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4bd825f4-f5e2-aab7-e063-6394a90ad6a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bd825f4-f5e2-aab7-e063-6394a90ad6a4"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution Spray product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006837", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2947875-9ff8-5748-ba26-7a3775ec883e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006837"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0002026", "object_location_in_text": [65, 76], "original_object": "candidiasis", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur. Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276680", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1650119-c4fd-581e-9b23-6278b1e3a379", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276680"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0002026", "object_location_in_text": [93, 104], "original_object": "candidiasis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "prescription users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e2041a0-8bef-4be4-b2b1-556446c4a778", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e2041a0-8bef-4be4-b2b1-556446c4a778", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e2041a0-8bef-4be4-b2b1-556446c4a778"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription CLOTRIMAZOLE TOPICAL SOLUTION product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032030", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42161b9b-341a-5b2c-a6f8-90648ecd4b23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032030"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:807f572f-abe5-5ab0-9756-61a614b1e489", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0005915", "object_location_in_text": [133, 149], "original_object": "tinea versicolor", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032030", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e25a448e-c49f-5d60-bdbc-32333e92650c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032030"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:807f572f-abe5-5ab0-9756-61a614b1e489", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0005915", "object_location_in_text": [105, 121], "original_object": "tinea versicolor", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur. Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014531", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6be53084-df02-5826-bb6d-e48649961934", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014531", "UMLS:C4505442", "UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0005984", "object_location_in_text": [160, 171], "original_object": "tinea pedis", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "patients 17 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030a1460-3522-43af-a75d-29c99570698f"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2b62eb7-660c-59db-ace7-187669f8998d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0005984", "object_location_in_text": [286, 297], "original_object": "tinea pedis", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur. Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5340fe1-9556-56f2-b015-c9c54b124e06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "MONDO:0005984", "object_location_in_text": [322, 333], "original_object": "tinea pedis", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34322e81-9913-5381-b1c5-5fb998372df2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "UMLS:C1384589", "object_location_in_text": [299, 311], "original_object": "tinea cruris", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53cafc9f-7761-83a9-e063-6294a90a3437"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole cream USP is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur. Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014531", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e798e76-f998-5cd9-a228-c1451a536d07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014531", "UMLS:C4505442", "UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "UMLS:C1384589", "object_location_in_text": [173, 185], "original_object": "tinea cruris", "original_subject": "CLOTRIMAZOLE", "population_context_qualifier": "patients 17 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030a1460-3522-43af-a75d-29c99570698f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030a1460-3522-43af-a75d-29c99570698f"]}], "subject": "CHEBI:3764", "supporting_text": ["Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9b3ce13-62a5-5752-a205-c167e2fa2892", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bda5acdf-15a1-58c7-acb2-d6d8c5af23ae", "object": "UMLS:C1384589", "object_location_in_text": [335, 347], "original_object": "tinea cruris", "original_subject": "CLOTRIMAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15368c2a-572f-41fb-a3a1-7b1eb842faa8"]}], "subject": "CHEBI:3764", "supporting_text": ["Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease, recent myocardial infarction (MI), recent stroke", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:069bdd1b-0430-5f04-84b4-083bd274fa76", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c03a895c-2d74-4d7f-891f-b752ce409b68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c03a895c-2d74-4d7f-891f-b752ce409b68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c03a895c-2d74-4d7f-891f-b752ce409b68"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome • For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) • For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ded011e-6c48-5b78-88b8-a59ed39ab2e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e51d4bcc-01df-409d-9179-45e6536ac25b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e51d4bcc-01df-409d-9179-45e6536ac25b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e51d4bcc-01df-409d-9179-45e6536ac25b"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome o For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) o For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a5a3b44-a5a4-5bd1-a90d-f95cefac6cf1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "population_context_qualifier": "patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8406b8e3-e203-402f-8858-2748119e2351", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8406b8e3-e203-402f-8858-2748119e2351", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8406b8e3-e203-402f-8858-2748119e2351"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1dbd39b5-e75a-5f14-b199-e80038548539", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "object_location_in_text": [203, 224], "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edae8df1-caf9-ff72-1304-5ae8b355f8e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent myocardial infarction ; recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:200e2782-d561-5a8d-937d-a51c11216ce1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "object_location_in_text": [203, 224], "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db1161c9-6efd-4361-a766-6a37c241ccee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db1161c9-6efd-4361-a766-6a37c241ccee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db1161c9-6efd-4361-a766-6a37c241ccee"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS(unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin. • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8afd7fb6-40c3-54f2-b5e4-72ef21b75db2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94a5cdc4-e063-1d46-e053-2995a90a7e15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94a5cdc4-e063-1d46-e053-2995a90a7e15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94a5cdc4-e063-1d46-e053-2995a90a7e15"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f672de1-eaed-5e30-8060-54c366c72497", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "population_context_qualifier": "patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2969deac-274b-4042-9c90-9522e62a979d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2969deac-274b-4042-9c90-9522e62a979d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2969deac-274b-4042-9c90-9522e62a979d"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4d70375-5e32-5b28-bc18-df2bcd04f64f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "object_location_in_text": [198, 219], "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55731d95-0c99-ff61-e063-6394a90a1ab5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55731d95-0c99-ff61-e063-6394a90a1ab5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55731d95-0c99-ff61-e063-6394a90a1ab5"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS &amp; USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent MI, recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c83fe552-cad3-5fed-bab6-94cd571cfa03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "object_location_in_text": [203, 224], "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:669f0bc6-f173-484d-8efe-c006683b25d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=669f0bc6-f173-484d-8efe-c006683b25d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=669f0bc6-f173-484d-8efe-c006683b25d1"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS(unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin. • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de78b24f-b21d-5db0-aa44-f0c3fd5a5c90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "object_location_in_text": [200, 221], "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65ea4dc6-acb2-4609-9a4c-4866ef0ccb11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65ea4dc6-acb2-4609-9a4c-4866ef0ccb11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65ea4dc6-acb2-4609-9a4c-4866ef0ccb11"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent MI"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe13f2d7-759c-5c08-b33e-b9ffe366d747", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005068", "object_location_in_text": [194, 215], "original_object": "myocardial infarction", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab32a331-2cea-453b-bba1-5451d38edd73", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab32a331-2cea-453b-bba1-5451d38edd73", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab32a331-2cea-453b-bba1-5451d38edd73"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent myocardial infarction ; recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0777aaec-a2da-5804-aa31-deebae1e3b7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab32a331-2cea-453b-bba1-5451d38edd73", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab32a331-2cea-453b-bba1-5451d38edd73", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab32a331-2cea-453b-bba1-5451d38edd73"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent myocardial infarction ; recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2198578f-ed6e-54bf-b9ab-5bc04bbf03c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94a5cdc4-e063-1d46-e053-2995a90a7e15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94a5cdc4-e063-1d46-e053-2995a90a7e15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94a5cdc4-e063-1d46-e053-2995a90a7e15"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease, recent myocardial infarction (MI), recent stroke", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f5a557c-6fe9-50ca-9584-8b482cfcc51a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [326, 332], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c03a895c-2d74-4d7f-891f-b752ce409b68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c03a895c-2d74-4d7f-891f-b752ce409b68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c03a895c-2d74-4d7f-891f-b752ce409b68"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome • For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) • For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d516b07-65bf-5186-a5b9-131a9dc13425", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [309, 315], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e51d4bcc-01df-409d-9179-45e6536ac25b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e51d4bcc-01df-409d-9179-45e6536ac25b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e51d4bcc-01df-409d-9179-45e6536ac25b"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome o For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) o For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9262d781-beaf-5c41-ae9a-b66861f115cc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [324, 330], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:669f0bc6-f173-484d-8efe-c006683b25d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=669f0bc6-f173-484d-8efe-c006683b25d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=669f0bc6-f173-484d-8efe-c006683b25d1"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS(unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin. • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a350c095-6ed8-542b-aa62-91244563a61c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [311, 317], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55731d95-0c99-ff61-e063-6394a90a1ab5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55731d95-0c99-ff61-e063-6394a90a1ab5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55731d95-0c99-ff61-e063-6394a90a1ab5"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS &amp; USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent MI, recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcba166b-4cb4-5919-b425-20c463a88ef5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [324, 330], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db1161c9-6efd-4361-a766-6a37c241ccee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db1161c9-6efd-4361-a766-6a37c241ccee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db1161c9-6efd-4361-a766-6a37c241ccee"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS(unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin. • Clopidogrel tablets is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2539a71-8fb6-50a5-8262-ab5dc9f96b34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [324, 330], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edae8df1-caf9-ff72-1304-5ae8b355f8e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent myocardial infarction ; recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca37a0d7-0e0e-55b4-91cb-2f97d2051362", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "population_context_qualifier": "patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8406b8e3-e203-402f-8858-2748119e2351", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8406b8e3-e203-402f-8858-2748119e2351", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8406b8e3-e203-402f-8858-2748119e2351"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "established peripheral arterial disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de81ed2f-820d-5c34-8f71-0eaf1874be2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [322, 328], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65ea4dc6-acb2-4609-9a4c-4866ef0ccb11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65ea4dc6-acb2-4609-9a4c-4866ef0ccb11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65ea4dc6-acb2-4609-9a4c-4866ef0ccb11"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel tablets is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel tablets are indicated to reduce the rate of MI and stroke."], "temporal_context_qualifier": "recent stroke"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1998297", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f12b3a5b-2c18-5fad-b4d1-6a721100a01c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1998297"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "CLOPIDOGREL", "population_context_qualifier": "patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2969deac-274b-4042-9c90-9522e62a979d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2969deac-274b-4042-9c90-9522e62a979d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2969deac-274b-4042-9c90-9522e62a979d"]}], "subject": "CHEBI:37941", "supporting_text": ["1 INDICATIONS AND USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/ non–ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "ST segment elevation acute myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cc573d5-6737-56ce-9c1d-e98252fb7c42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980714", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ASA"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f1745571-4fb4-572c-902f-4ee752930c10", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:569e85be-0c2c-5e5a-a645-9902d536f063", "object": "MONDO:0004781", "object_location_in_text": [596, 623], "original_object": "acute myocardial infarction", "original_subject": "clopidogrel", "population_context_qualifier": "Adult patients; medically treated patients eligible for thrombolytic therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:clopidogrel-ratiopharm", "https://www.ema.europa.eu/en/documents/product-information/clopidogrel-ratiopharm-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-ratiopharm"]}], "subject": "CHEBI:37941", "supporting_text": ["Secondary prevention of atherothrombotic events Clopidogrel is indicated in:  Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Adult patients suffering from acute coronary syndrome:  Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.    Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5cea2e7d-d6fb-549d-bae6-3f4d70e0e469", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a27ee976-db66-5d5a-b2df-65b534d7e395", "medic_supporting_text_truncated": true, "object": "HP:0003124", "original_object": "hypercholesterolemia", "original_subject": "COLESTIPOL", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03ca5800-4211-4383-a332-be88bd9b5304", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03ca5800-4211-4383-a332-be88bd9b5304", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03ca5800-4211-4383-a332-be88bd9b5304"]}], "subject": "CHEBI:3814", "supporting_text": ["INDICATIONS &amp; USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal No No ≥190 (≥4.9) &lt;160 (&lt;4.1) No Yes ≥160 (≥4.1) &lt;130 (&lt;3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C &lt;35 mg/dL (0."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "elevated LDL-C", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fdc3f66-5f69-525f-87c0-80ebf4feacdc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a27ee976-db66-5d5a-b2df-65b534d7e395", "medic_supporting_text_truncated": true, "object": "HP:0003124", "original_object": "hypercholesterolemia", "original_subject": "COLESTIPOL", "population_context_qualifier": "patients who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:153e9154-1804-4d73-94b7-a31a1d37c420", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=153e9154-1804-4d73-94b7-a31a1d37c420", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=153e9154-1804-4d73-94b7-a31a1d37c420"]}], "subject": "CHEBI:3814", "supporting_text": ["Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atheroschlerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; female: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C &lt;35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥ 60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥ 190 (≥ 4.9) &lt; 160 (&lt; 4.1) No "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003124", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cd94b79-f4c0-5780-b4be-94a87511db4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003124"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a27ee976-db66-5d5a-b2df-65b534d7e395", "medic_supporting_text_truncated": true, "object": "HP:0003124", "original_object": "hypercholesterolemia", "original_subject": "COLESTIPOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e270911-f27b-44d4-b0a2-33506418cc1d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e270911-f27b-44d4-b0a2-33506418cc1d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e270911-f27b-44d4-b0a2-33506418cc1d"]}], "subject": "CHEBI:3814", "supporting_text": ["Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. COLESTID Tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, COLESTID Tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C &lt;35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) &lt;160 (&lt;4.1) No Yes ≥160 (≥4.1) &lt;130 (&lt;3.4) Yes Y"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e529ae02-bab7-5bc2-8e92-19a03802ba05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "FLUVASTATIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0a7247c-5d83-4bc1-840f-c58314d14195", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0a7247c-5d83-4bc1-840f-c58314d14195", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0a7247c-5d83-4bc1-840f-c58314d14195"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: • Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( 1.1 ) • Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( 1.1 ) • Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( 1.2 ) • Slow the progression of atherosclerosis in patients with CHD ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.2025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18afd005-4661-52e7-826a-4403d86a778c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f74edd78-78a3-5963-96b2-aec5b5142ff3", "medic_pair_confidence": 0.2025, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C0877341", "original_object": "coronary revascularization", "original_subject": "FLUVASTATIN", "population_context_qualifier": "patients with clinically evident CHD", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2dddb57-aea3-45f2-ad06-2b209a8d934b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2dddb57-aea3-45f2-ad06-2b209a8d934b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2dddb57-aea3-45f2-ad06-2b209a8d934b"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) • 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) • 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) • 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) • 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fd40ae3-eaa0-5990-8c8c-845dddb1cb1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f74edd78-78a3-5963-96b2-aec5b5142ff3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C0877341", "original_object": "coronary revascularization", "original_subject": "FLUVASTATIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd12fae6-f277-4679-a7a8-b98719fe6fa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd12fae6-f277-4679-a7a8-b98719fe6fa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd12fae6-f277-4679-a7a8-b98719fe6fa9"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. LESCOL/LESCOL XL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.24, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97ce9f2b-7f8f-5fdb-a10c-f9cf869168bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "FLUVASTATIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0a7247c-5d83-4bc1-840f-c58314d14195", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0a7247c-5d83-4bc1-840f-c58314d14195", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0a7247c-5d83-4bc1-840f-c58314d14195"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: • Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( 1.1 ) • Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( 1.1 ) • Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( 1.2 ) • Slow the progression of atherosclerosis in patients with CHD ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.2025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9ee544b-7fc2-5fb5-a691-a2bcb688c71a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f74edd78-78a3-5963-96b2-aec5b5142ff3", "medic_pair_confidence": 0.2025, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C0877341", "original_object": "coronary revascularization", "original_subject": "FLUVASTATIN", "population_context_qualifier": "patients with clinically evident CHD", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0674ec5-22b9-4ab9-a118-54c83cda3ec2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0674ec5-22b9-4ab9-a118-54c83cda3ec2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0674ec5-22b9-4ab9-a118-54c83cda3ec2"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) • 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) • 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) • 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) • 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d45c86d0-1dba-567d-949f-3e11e5160f57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:93a1bdb9-e200-5ad5-bb79-21a4686c3236", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C1735363", "original_object": "coronary artery disease progression", "original_subject": "FLUVASTATIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd12fae6-f277-4679-a7a8-b98719fe6fa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd12fae6-f277-4679-a7a8-b98719fe6fa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd12fae6-f277-4679-a7a8-b98719fe6fa9"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. LESCOL/LESCOL XL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) 1.2"], "temporal_context_qualifier": "in patients with CHD"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003124", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:812c8245-e53e-5a2e-afc4-9d7e14a01a0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003124"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [485, 505], "original_object": "hypercholesterolemia", "original_subject": "FLUVASTATIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e38126a5-9d6a-422f-812c-a01610108162", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e38126a5-9d6a-422f-812c-a01610108162", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e38126a5-9d6a-422f-812c-a01610108162"]}], "subject": "CHEBI:38561", "supporting_text": ["Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains &gt; 190 mg/dL or LDL-C remains &gt; 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG &lt;400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels &gt;400 mg/dL (&gt;4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertrigl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003124", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b291379-4769-536e-a2d8-f299aa3c06df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003124"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [485, 505], "original_object": "hypercholesterolemia", "original_subject": "FLUVASTATIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d466214-78a8-44cd-923c-c286a0f74f66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d466214-78a8-44cd-923c-c286a0f74f66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d466214-78a8-44cd-923c-c286a0f74f66"]}], "subject": "CHEBI:38561", "supporting_text": ["Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains &gt; 190 mg/dL or LDL-C remains &gt; 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG &lt;400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels &gt;400 mg/dL (&gt;4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertrigl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "CHD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23cc650b-7a3d-578f-b5a8-0e74551a7f9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:87034601-b796-5965-a507-9280c48f019f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "MONDO:0005311", "original_object": "atherosclerosis", "original_subject": "FLUVASTATIN", "population_context_qualifier": "patients with CHD", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0674ec5-22b9-4ab9-a118-54c83cda3ec2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0674ec5-22b9-4ab9-a118-54c83cda3ec2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0674ec5-22b9-4ab9-a118-54c83cda3ec2"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) • 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) • 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) • 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) • 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "CHD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce46ce4b-c2e1-5b30-89af-82b68606adde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:87034601-b796-5965-a507-9280c48f019f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "MONDO:0005311", "original_object": "atherosclerosis", "original_subject": "FLUVASTATIN", "population_context_qualifier": "patients with CHD", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2dddb57-aea3-45f2-ad06-2b209a8d934b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2dddb57-aea3-45f2-ad06-2b209a8d934b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2dddb57-aea3-45f2-ad06-2b209a8d934b"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) • 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) • 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) • 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) • 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:428c9699-7981-5945-8719-67312153d7f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.225, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "FLUVASTATIN", "population_context_qualifier": "patients with clinically evident CHD", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0674ec5-22b9-4ab9-a118-54c83cda3ec2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0674ec5-22b9-4ab9-a118-54c83cda3ec2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0674ec5-22b9-4ab9-a118-54c83cda3ec2"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) • 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) • 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) • 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) • 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident CHD", "has_confidence_score": 0.225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d312ada3-e74a-5a1e-a3f9-0f7f35bfabde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.225, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "FLUVASTATIN", "population_context_qualifier": "patients with clinically evident CHD", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2dddb57-aea3-45f2-ad06-2b209a8d934b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2dddb57-aea3-45f2-ad06-2b209a8d934b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2dddb57-aea3-45f2-ad06-2b209a8d934b"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) • 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) • 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) • 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) • 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:190bf544-4303-5cbe-a545-b2aac143a52d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C0342879", "object_location_in_text": [623, 651], "original_object": "primary hypercholesterolemia", "original_subject": "FLUVASTATIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0a7247c-5d83-4bc1-840f-c58314d14195", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0a7247c-5d83-4bc1-840f-c58314d14195", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0a7247c-5d83-4bc1-840f-c58314d14195"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. Fluvastatin capsules are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: • Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( 1.1 ) • Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( 1.1 ) • Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( 1.2 ) • Slow the progression of atherosclerosis in patients with CHD ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:217aa987-664c-5e9f-9608-35517e2f2c7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042f8cc-b223-5ffb-a041-216b41371b06", "object": "UMLS:C0342879", "object_location_in_text": [616, 644], "original_object": "primary hypercholesterolemia", "original_subject": "FLUVASTATIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd12fae6-f277-4679-a7a8-b98719fe6fa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd12fae6-f277-4679-a7a8-b98719fe6fa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd12fae6-f277-4679-a7a8-b98719fe6fa9"]}], "subject": "CHEBI:38561", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. LESCOL/LESCOL XL is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia ( ) 1.1 Reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( ) 1.1 Reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD ( ) 1.2 Slow the progression of atherosclerosis in patients with CHD ( ) 1.2"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "imatinib mesilate treatment failure due to resistance or intolerance", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b8a9520-9345-509d-ada8-b895a1badacd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060719", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3da58aab-cd57-5c90-80d0-e7bf79a66ef9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "HP:0100723", "original_object": "gastrointestinal stromal tumour", "original_subject": "sunitinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sutent", "https://www.ema.europa.eu/en/documents/product-information/sutent-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sutent"]}], "subject": "CHEBI:38940", "supporting_text": ["Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with Sutent as first-line treatment is limited (see section 5.1)."], "temporal_context_qualifier": "after failure of imatinib mesilate treatment due to resistance or intolerance"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "imatinib treatment failure", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4b4554e-ed3a-5199-bbf2-dc211d490dc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060719", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3da58aab-cd57-5c90-80d0-e7bf79a66ef9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "HP:0100723", "original_object": "gastrointestinal stromal tumour", "original_subject": "sunitinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sunitinib-accord", "https://www.ema.europa.eu/en/documents/product-information/sunitinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord"]}], "subject": "CHEBI:38940", "supporting_text": ["Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults."], "temporal_context_qualifier": "after failure of imatinib treatment due to resistance or intolerance"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "imatinib mesylate intolerance or resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7386548c-f898-5526-9599-8dbffd1188ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "SUNITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9479e5f-914f-46ca-95c1-327c66457e47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9479e5f-914f-46ca-95c1-327c66457e47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9479e5f-914f-46ca-95c1-327c66457e47"]}], "subject": "CHEBI:38940", "supporting_text": ["1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."], "temporal_context_qualifier": "after disease progression on or intolerance to imatinib mesylate"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on or intolerance to imatinib mesylate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:929c80fa-2887-55bc-83c2-36caff13dedd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "SUNITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dbfcc02-dacc-4f0c-9f41-095783b68e27", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dbfcc02-dacc-4f0c-9f41-095783b68e27", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dbfcc02-dacc-4f0c-9f41-095783b68e27"]}], "subject": "CHEBI:38940", "supporting_text": ["1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."], "temporal_context_qualifier": "after disease progression on or intolerance to imatinib mesylate"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "imatinib mesylate intolerance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93d097e8-b444-5050-8406-7e4c84c5c865", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "SUNITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04d34bce-1296-d2b9-e063-6394a90a7018", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04d34bce-1296-d2b9-e063-6394a90a7018", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04d34bce-1296-d2b9-e063-6394a90a7018"]}], "subject": "CHEBI:38940", "supporting_text": ["1 INDICATIONS AND USAGE Sunitinib malate is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."], "temporal_context_qualifier": "after disease progression on or intolerance to imatinib mesylate"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "imatinib mesylate intolerance or resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:acc08edb-f50f-53b5-9766-0ce0c1f31bd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "SUNITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0772eb61-ca42-39de-e063-6294a90a6632", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0772eb61-ca42-39de-e063-6294a90a6632", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0772eb61-ca42-39de-e063-6294a90a6632"]}], "subject": "CHEBI:38940", "supporting_text": ["1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."], "temporal_context_qualifier": "after disease progression on or intolerance to imatinib mesylate"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "imatinib mesylate intolerance, disease progression on imatinib mesylate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc347c1d-2d47-5e18-bbbe-6d69af6f7146", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "SUNITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c"]}], "subject": "CHEBI:38940", "supporting_text": ["1 INDICATIONS AND USAGE SUTENT is a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 ) 1.1 Gastrointestinal Stromal Tumor SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma SUTENT is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "imatinib mesylate intolerance, disease progression on imatinib mesylate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee3bd9f8-51d5-50b8-9cad-c65e9555165b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "SUNITINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06e0ad28-6637-4f54-879c-2c194aece5fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06e0ad28-6637-4f54-879c-2c194aece5fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06e0ad28-6637-4f54-879c-2c194aece5fd"]}], "subject": "CHEBI:38940", "supporting_text": ["1 INDICATIONS AND USAGE Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1) treatment of adult patients with advanced renal cell carcinoma (RCC). (1.2) adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. (1.3) treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. (1.4) 1.1 Gastrointestinal Stromal Tumor Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). 1.3 Adjuvant Treatment of Renal Cell Carcinoma Sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. 1.4 Advanced Pancreatic Neuroendocrine Tumors Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease."], "temporal_context_qualifier": "after disease progression on or intolerance to imatinib mesylate"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c945b4b-047c-5dfe-a1db-47eee8b74f00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060719", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9e721691-4684-570a-a973-d7f290693371", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "UMLS:C0242363", "object_location_in_text": [518, 551], "original_object": "pancreatic neuroendocrine tumours", "original_subject": "sunitinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sutent", "https://www.ema.europa.eu/en/documents/product-information/sutent-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sutent"]}], "subject": "CHEBI:38940", "supporting_text": ["Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with Sutent as first-line treatment is limited (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:daed81bc-4340-5361-8468-a706fa28bce9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060719", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9e721691-4684-570a-a973-d7f290693371", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9a2822da-65e3-5825-9267-1514f8474735", "object": "UMLS:C0242363", "original_object": "pancreatic neuroendocrine tumours", "original_subject": "sunitinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sunitinib-accord", "https://www.ema.europa.eu/en/documents/product-information/sunitinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord"]}], "subject": "CHEBI:38940", "supporting_text": ["Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0457345", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39dd7e60-196f-5e05-a820-47e81852685a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130327", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0457345", "MONDO:0006115"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d0692545-20a9-5e9c-b557-2f313555125d", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ab9aabfb-2d6a-5b44-a6bf-df61fd49dc83", "object": "MONDO:0011996", "original_object": "Philadelphia chromosome-positive chronic myelogenous leukaemia", "original_subject": "bosutinib", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:bosulif", "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"]}], "subject": "CHEBI:39112", "supporting_text": ["Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years and older with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• Adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.• Adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options."], "temporal_context_qualifier": "previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)]"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "accelerated phase Ph+ CML, blast phase Ph+ CML", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94c380cd-52ef-5c6c-8598-bd0ff9a36e8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120904", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43933201-b655-54a7-89ce-79bd5342013a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ab9aabfb-2d6a-5b44-a6bf-df61fd49dc83", "object": "MONDO:0011996", "object_location_in_text": [179, 207], "original_object": "chronic myelogenous leukemia", "original_subject": "BOSUTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:adc84ad5-a04d-4fee-9ba8-91f7abd928e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3"]}], "subject": "CHEBI:39112", "supporting_text": ["1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )"], "temporal_context_qualifier": "resistance or intolerance to prior therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "accelerated phase Ph+ CML, blast phase Ph+ CML", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d382167e-d483-5f62-9dea-52608253df5e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120904", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43933201-b655-54a7-89ce-79bd5342013a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ab9aabfb-2d6a-5b44-a6bf-df61fd49dc83", "object": "MONDO:0011996", "object_location_in_text": [179, 207], "original_object": "chronic myelogenous leukemia", "original_subject": "BOSUTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5929f91-6496-4c0e-97e8-0bd524e15763", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5929f91-6496-4c0e-97e8-0bd524e15763", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5929f91-6496-4c0e-97e8-0bd524e15763"]}], "subject": "CHEBI:39112", "supporting_text": ["1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )"], "temporal_context_qualifier": "resistance or intolerance to prior therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0457343", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0567096f-1e4a-5b53-8535-0879d6e029eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200629", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0457343"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7f3145d4-6f7a-5642-a73e-432ca4f26e1d", "object": "MONDO:0011996", "object_location_in_text": [97, 121], "original_object": "chronic myeloid leukemia", "original_subject": "BOSUTINIB HYDRATE", "population_context_qualifier": "newly-diagnosed", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BOSUTINIB HYDRATE#61-20200629", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:39112", "supporting_text": ["A drug with a new indication and a new dosage for the treatment of newly-diagnosed chronic phase chronic myeloid leukemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002020", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:315e9c3b-0d41-5186-8e97-dab9eadd27bf", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002020", "UMLS:C0235304", "UMLS:C0860277"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01ab3642-60ce-550a-b1c3-f254cfdfbe34", "object": "UMLS:C0235309", "object_location_in_text": [72, 85], "original_object": "upset stomach", "original_subject": "CALCIUM CATION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f9ea017-a48d-a225-e063-6294a90a9ec3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f9ea017-a48d-a225-e063-6294a90a9ec3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f9ea017-a48d-a225-e063-6294a90a9ec3"]}], "subject": "CHEBI:39123", "supporting_text": ["Uses for the relief of: • heartburn • acid indigestion • sour stomach • upset stomach associated with these symptoms"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002020", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:376eac9c-cad7-5cfc-9d7b-da028cbb1dff", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002020", "UMLS:C0235304", "UMLS:C0860277"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01ab3642-60ce-550a-b1c3-f254cfdfbe34", "object": "UMLS:C0235309", "object_location_in_text": [72, 85], "original_object": "upset stomach", "original_subject": "CALCIUM CATION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f9eb848-c337-ae59-e063-6294a90aef9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f9eb848-c337-ae59-e063-6294a90aef9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f9eb848-c337-ae59-e063-6294a90aef9d"]}], "subject": "CHEBI:39123", "supporting_text": ["Uses for the relief of: • heartburn • acid indigestion • sour stomach • upset stomach associated with these symptoms"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7d7a3da-a384-5b13-b603-e49c05471e5a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:159944af-d3ed-5eae-9120-f4b7cc6560e0", "object": "MONDO:0006624", "object_location_in_text": [21, 39], "original_object": "overactive bladder", "original_subject": "Darifenacin (as hydrobromide) 7.5mg/15mg ER tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:391960", "supporting_text": ["For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03bffe04-1945-53a7-ba7a-8793b4de2b69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [120, 138], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2aa9544-0136-463d-a73b-1a299534446a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2aa9544-0136-463d-a73b-1a299534446a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2aa9544-0136-463d-a73b-1a299534446a"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e9fa186-3da7-512a-9575-a4743b580868", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [92, 110], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da7c2732-232c-4e71-92d9-577ef8617f56", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da7c2732-232c-4e71-92d9-577ef8617f56", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da7c2732-232c-4e71-92d9-577ef8617f56"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin is muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablets are muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d1882fc-61aa-57fe-bb67-03b16627d315", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [118, 136], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e9f2cec-8c9f-7668-dfb4-6ab57c9d3e8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e9f2cec-8c9f-7668-dfb4-6ab57c9d3e8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e9f2cec-8c9f-7668-dfb4-6ab57c9d3e8a"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin extended-release tablets are muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75b47d92-aba5-5594-8edb-005c693e5502", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [96, 114], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e8470d1-c3e6-4644-b70a-aa47ddf79676", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e8470d1-c3e6-4644-b70a-aa47ddf79676", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e8470d1-c3e6-4644-b70a-aa47ddf79676"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. ( 1 ) Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e0355fe-6aa7-5ca5-9e75-dfbaffd5ce8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [120, 138], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d09e16f4-42a9-402f-a37b-2eca55ceafbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d09e16f4-42a9-402f-a37b-2eca55ceafbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d09e16f4-42a9-402f-a37b-2eca55ceafbf"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6cbee23-d62a-5ea0-ac8b-b8e707d92bce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [92, 110], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9f6952c8-e547-4f3e-a978-a88d6ea9dc10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9f6952c8-e547-4f3e-a978-a88d6ea9dc10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f6952c8-e547-4f3e-a978-a88d6ea9dc10"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin is muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablets are muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e212ac79-b1b9-5dd1-a733-ba71c4fc1ff1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [72, 90], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ae60119-e22c-4806-a5d8-db7c9e8984a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ae60119-e22c-4806-a5d8-db7c9e8984a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ae60119-e22c-4806-a5d8-db7c9e8984a2"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS &amp; USAGE Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e793f673-a187-5f59-8c70-ce02415b2d88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [84, 102], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a293cece-e97a-4e67-be72-b187568e3b11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a293cece-e97a-4e67-be72-b187568e3b11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a293cece-e97a-4e67-be72-b187568e3b11"]}], "subject": "CHEBI:391960", "supporting_text": ["ENABLEX ® (darifenacin) extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fffeddf2-5d55-5ca2-bbb3-b667748f4105", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:995ec49b-78f5-5c40-a297-5c2b1645b944", "object": "MONDO:0006624", "object_location_in_text": [96, 114], "original_object": "overactive bladder", "original_subject": "DARIFENACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:28ed5b58-46dd-4140-a877-4b422f780a94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=28ed5b58-46dd-4140-a877-4b422f780a94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28ed5b58-46dd-4140-a877-4b422f780a94"]}], "subject": "CHEBI:391960", "supporting_text": ["1 INDICATIONS AND USAGE Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Darifenacin extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4020898", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24f346d3-2ec2-562e-a15d-69178f453a29", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4020898"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:0664dc34-b2fc-5be8-ac55-bb7540f0d019", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2a0c5d7d-4023-5358-82d3-1ab6eeb76ab5", "object": "UMLS:C0042023", "object_location_in_text": [50, 77], "original_object": "increased urinary frequency", "original_subject": "darifenacin hydrobromide", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emselex", "https://www.ema.europa.eu/en/documents/product-information/emselex-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emselex"]}], "subject": "CHEBI:391960", "supporting_text": ["Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4020898", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eeeb9dbb-bd4a-5584-983b-4013f6344a42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4020898"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2a0c5d7d-4023-5358-82d3-1ab6eeb76ab5", "object": "UMLS:C0150045", "object_location_in_text": [25, 42], "original_object": "urge incontinence", "original_subject": "darifenacin hydrobromide", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emselex", "https://www.ema.europa.eu/en/documents/product-information/emselex-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emselex"]}], "subject": "CHEBI:391960", "supporting_text": ["Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4020898", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51c0e792-9d80-59f0-ad06-0ec3562e04f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4020898"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2a0c5d7d-4023-5358-82d3-1ab6eeb76ab5", "object": "UMLS:C0439609", "object_location_in_text": [82, 89], "original_object": "urgency", "original_subject": "darifenacin hydrobromide", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emselex", "https://www.ema.europa.eu/en/documents/product-information/emselex-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emselex"]}], "subject": "CHEBI:391960", "supporting_text": ["Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "atherosclerotic arterial disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0701f0ed-3ec8-5250-ab02-c528942c4f26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:6a350576-c569-5f71-bed9-9aaec02a163e", "object": "UMLS:C0242339", "object_location_in_text": [21, 33], "original_object": "dyslipidemia", "original_subject": "Atorvastatin 10mg + Aspirin 75/150mg Capsules", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:39548", "supporting_text": ["For the treatment of dyslipidemia associated with atherosclerotic arterial disease with risk of myocardial infarction, stroke or peripheral vascular disease"], "temporal_context_qualifier": "with risk of myocardial infarction, stroke or peripheral vascular disease"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65757584-d99e-532f-9712-2d9be9120329", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961217", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e58c492-a05a-5317-bd70-96e46c9b0db8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75b9e2b5-fa37-5c0b-b9f6-53edddfb4bda", "medic_supporting_text_truncated": true, "object": "UMLS:C0342882", "original_object": "heterozygous familial hypercholesterolemia", "original_subject": "ATORVASTATIN", "population_context_qualifier": "Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:61c29f52-7dcd-44ac-a8aa-4f54f0901f04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=61c29f52-7dcd-44ac-a8aa-4f54f0901f04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=61c29f52-7dcd-44ac-a8aa-4f54f0901f04"]}], "subject": "CHEBI:39548", "supporting_text": ["1 INDICATIONS AND USAGE Atorvastatin calcium tablets are indicated: To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor (statin) indicated (1): To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c6c092b-0d2e-5bc0-bd5f-60496cb3a797", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d846c2df-fe42-527a-a007-f60f6d7b6af4", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "HP:0002076", "original_object": "migraine headaches", "original_subject": "VALPROIC ACID", "population_context_qualifier": "pregnant women; women of childbearing potential not using effective contraception", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:719f43cf-333d-4cf0-99a6-097243b101ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=719f43cf-333d-4cf0-99a6-097243b101ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=719f43cf-333d-4cf0-99a6-097243b101ef"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Divalproex sodium extended-release tablets are contraindicated in patients: with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1) ]. known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1) ]. with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions (5.12, 5.13, 5.14)]. with known urea cycle disorders [see Warnings and Precautions (5.6) ]. being treated for prophylaxis of migraine headaches: who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1) ]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12a9ec39-9c5b-5d74-acc2-f2e84481ec49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women of childbearing potential", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d4df6ad-3d53-4664-9200-749487bf3689", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d4df6ad-3d53-4664-9200-749487bf3689", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d4df6ad-3d53-4664-9200-749487bf3689"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproic acid capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1) ] . Valproic acid capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1) ] . Valproic acid capsules are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12) ] . Valproic acid capsules are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6) ] . For use in prophylaxis of migraine headaches: Valproic acid capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2 , 5.3 , 5.4) and Use in Specific Populations (8.1) ] . Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prophylaxis of migraine headaches", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2eb4a692-796f-5bc3-9b5a-4d3e05600d67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e86a610-45ef-4be7-a3ab-f656f5b32706", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e86a610-45ef-4be7-a3ab-f656f5b32706", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e86a610-45ef-4be7-a3ab-f656f5b32706"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS • Divalproex sodium delayed-release capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1) ]. • Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1) ]. • Divalproex sodium delayed-release capsules are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12) ]. • Divalproex sodium delayed-release capsules are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6) ]. • For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2 , 5.3 , 5.4) and Use in Specific Populations (8.1) ]. • Hepatic disease or significant hepatic dysfunction (4 , 5.1) • Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) (4 , 5.1) • Suspected POLG-related disorder in children under two years of age (4 , 5.1) • Known hypersensitivity to the drug (4 , 5.12) • Urea cycle disorders (4 , 5.6) • Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception (4 , 8.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "migraine headaches prophylaxis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44a8af48-cf24-57a7-91f7-f42c9d8b66f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d19f389-7180-4e01-845f-519b7ea60ba0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d19f389-7180-4e01-845f-519b7ea60ba0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d19f389-7180-4e01-845f-519b7ea60ba0"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproic acid oral solution should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 ) ]. Valproic acid oral solution is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 ) ]. Valproic acid oral solution is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.12 ) ]. Valproic acid oral solution is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 ) ]. For use in prophylaxis of migraine headaches: Valproic acid oral solution is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations( 8.1 )]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prophylaxis of migraine headaches", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:474a3f31-34d0-5c89-bc7c-e4bfd4c4c1da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3dfb6da1-f66a-4618-9f74-d2d6c16c0b58"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS • Valproate sodium injection should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )] . • Valproate sodium injection is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )] . • Valproate sodium injection is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.11 )] . • Valproate sodium injection is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 )] . • For use in prophylaxis of migraine headaches: Valproate sodium injection is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )] . • Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) • Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) • Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) • Known hypersensitivity to the drug ( 4 , 5.11 ) • Urea cycle disorders ( 4 , 5.6 ) • Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5162f2ee-1f7f-541c-b27a-4bb950d246aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1edd220d-d151-4177-9a29-9fee36489fb7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1edd220d-d151-4177-9a29-9fee36489fb7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1edd220d-d151-4177-9a29-9fee36489fb7"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )] . Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )] . Valproic acid is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.12 )] . Valproic acid is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 )] . For use in prophylaxis of migraine headaches: Valproic acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )] . Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prophylaxis of migraine headaches", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c7e6fc1-fe05-50a0-abf3-3e3dce31b90e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women of childbearing potential", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bcf57b31-4811-4104-82b3-46fb91a53ee0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bcf57b31-4811-4104-82b3-46fb91a53ee0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bcf57b31-4811-4104-82b3-46fb91a53ee0"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproate Sodium Injection should not be administered to patients with hepatic disease or significant hepatic dysfunction [see WARNINGS AND PRECAUTIONS ( 5.1 ) ]. Valproate Sodium Injection is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see WARNINGS AND PRECAUTIONS ( 5.1 ) ]. Valproate Sodium Injection is contraindicated in patients with known hypersensitivity to the drug [see WARNINGS AND PRECAUTIONS ( 5.11 ) ]. Valproate Sodium Injection is contraindicated in patients with known urea cycle disorders [see WARNINGS AND PRECAUTIONS ( 5.6 ) ]. For use in prophylaxis of migraine headaches: Valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see WARNINGS AND PRECAUTIONS ( 5.2 , 5.3 , 5.4 ) and USE IN SPECIFIC POPULATIONS ( 8.1 )]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.11 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f4d2060-1c7f-5b3a-b3cc-78fd45a36ffb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a2155d0-e79d-3e11-e063-6294a90a4aae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a2155d0-e79d-3e11-e063-6294a90a4aae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a2155d0-e79d-3e11-e063-6294a90a4aae"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )] . Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )] . Valproic acid is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.12 )] . Valproic acid is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 )] . For use in prophylaxis of migraine headaches: Valproic acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )] . Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prophylaxis of migraine headaches", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b62e04b-3c6b-5f41-873a-e75a8b65eea6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproate Sodium Injection should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )] . Valproate Sodium Injection is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )] . Valproate Sodium Injection is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.11 )] . Valproate Sodium Injection is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 )] . For use in prophylaxis of migraine headaches: Valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.11 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74b90f9a-624d-572f-825e-b89843874478", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:589ae3a6-8b2e-d931-d36b-1937287ab5c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=589ae3a6-8b2e-d931-d36b-1937287ab5c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=589ae3a6-8b2e-d931-d36b-1937287ab5c0"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Divalproex sodium delayed-release capsules are contraindicated in patients: with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )]. known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )]. with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions ( 5.12 , 5.13 , 5.14 )]. with known urea cycle disorders [see Warnings and Precautions ( 5.6 )]. being treated for prophylaxis of migraine headaches: who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4, 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74ea7336-88fc-538e-84c6-1e0fd80cf1a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "pregnant women; women of childbearing potential not using effective contraception", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:773a289b-65ed-4045-80c5-f00e28c1c079", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=773a289b-65ed-4045-80c5-f00e28c1c079", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=773a289b-65ed-4045-80c5-f00e28c1c079"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Divalproex sodium delayed-release capsules is contraindicated in patients: with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )]. known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )]. with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions ( 5.12 , 5.13 , 5.14 )]. with known urea cycle disorders [see Warnings and Precautions ( 5.6 )]. being treated for prophylaxis of migraine headaches: who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prophylaxis of migraine headaches", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b31a4578-bacf-54e1-bb05-22d43c443562", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women of childbearing potential", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a687b2f-246d-4736-a20c-92421c263268", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproate Sodium Injection should not be administered to patients with hepatic disease or significant hepatic dysfunction [see WARNINGS AND PRECAUTIONS ( 5.1 ) ]. Valproate Sodium Injection is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see WARNINGS AND PRECAUTIONS ( 5.1 ) ]. Valproate Sodium Injection is contraindicated in patients with known hypersensitivity to the drug [see WARNINGS AND PRECAUTIONS ( 5.11 ) ]. Valproate Sodium Injection is contraindicated in patients with known urea cycle disorders [see WARNINGS AND PRECAUTIONS ( 5.6 ) ]. For use in prophylaxis of migraine headaches: Valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see WARNINGS AND PRECAUTIONS ( 5.2 , 5.3 , 5.4 ) and USE IN SPECIFIC POPULATIONS ( 8.1 )]. Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.11 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002076", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc125f1a-7ae6-5758-8779-c4ddd5834e45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "population_context_qualifier": "women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a33f7657-ad0f-43e9-ba48-024746e6d08e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a33f7657-ad0f-43e9-ba48-024746e6d08e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a33f7657-ad0f-43e9-ba48-024746e6d08e"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )] . Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )] . Valproic acid is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.12 )] . Valproic acid is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 )] . For use in prophylaxis of migraine headaches: Valproic acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )] . Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) Known hypersensitivity to the drug ( 4 , 5.12 ) Urea cycle disorders ( 4 , 5.6 ) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "migraine headaches prophylaxis", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d213c299-977c-5f02-a103-908179d6af86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b619f73-44e5-4a99-b425-a96cb2228c87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b619f73-44e5-4a99-b425-a96cb2228c87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b619f73-44e5-4a99-b425-a96cb2228c87"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1) ] . Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1) ] . Valproic acid is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12) ] . Valproic acid is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6) ] . For use in prophylaxis of migraine headaches: Valproic acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2 , 5.3 , 5.4) and Use in Specific Populations (8.1) ] . Hepatic disease or significant hepatic dysfunction (4 , 5.1) Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) (4 , 5.1) Suspected POLG-related disorder in children under two years of age (4 , 5.1) Known hypersensitivity to the drug (4 , 5.12) Urea cycle disorders (4 , 5.6) Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception (4 , 8.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prophylaxis of migraine headaches", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff31cf54-b76f-5f6d-99c9-e47e7feadf1e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "VALPROIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c572ece7-03d3-4c2a-aeb5-61f2023b28ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c572ece7-03d3-4c2a-aeb5-61f2023b28ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c572ece7-03d3-4c2a-aeb5-61f2023b28ea"]}], "subject": "CHEBI:39867", "supporting_text": ["4 CONTRAINDICATIONS • Valproate sodium injection should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1 )] . • Valproate sodium injection is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1 )] . • Valproate sodium injection is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.11 )] . • Valproate sodium injection is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6 )] . • For use in prophylaxis of migraine headaches: Valproate sodium injection is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) and Use in Specific Populations ( 8.1 )] . • Hepatic disease or significant hepatic dysfunction ( 4 , 5.1 ) • Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG) ( 4 , 5.1 ) • Suspected POLG-related disorder in children under two years of age ( 4 , 5.1 ) • Known hypersensitivity to the drug ( 4 , 5.11 ) • Urea cycle disorders ( 4 , 5.6 ) • Prophylaxis of migraine headaches: Pregnant women, women of childbearing potential not using effective contraception ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100754", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6a44ee6-9e8d-53af-bb45-33f0d0116c5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100754"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "MONDO:0004985", "object_location_in_text": [147, 163], "original_object": "bipolar disorder", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2de86096-4ec7-47df-94db-9c7f6e5df424", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2de86096-4ec7-47df-94db-9c7f6e5df424", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2de86096-4ec7-47df-94db-9c7f6e5df424"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Divalproex sodium extended-release tablets are indicated for: • Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) • Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Divalproex sodium extended-release tablets are valproate and are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities). The efficacy of divalproex sodium extended-release tablets is based in part on studies of divalproex sodium delayed-release tablets in this indication, and was confirmed in a 3-week trial with patients meeting DSM-IV TR criteria for bipolar I disorder, manic or mixed type, who were hospitalized for acute mania [see Clinical Studies ( 14.1 )]. The effectiveness of valproate for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium extended-release tablets for extended periods should continually reevaluate the long-term risk-benefits of the drug for the individual patient. 1.2 Epilepsy Divalproex sodium extended-release tablets are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pedi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100754", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e923d3fa-321f-5ea7-96d0-5ad211ef42a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100754"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "MONDO:0004985", "object_location_in_text": [129, 145], "original_object": "bipolar disorder", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1004e77e-b572-4d39-8ddd-5325612dad7b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1004e77e-b572-4d39-8ddd-5325612dad7b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1004e77e-b572-4d39-8ddd-5325612dad7b"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Divalproex sodium is an anti-epileptic drug indicated for: • Treatment of manic episodes associated with bipolar disorder ( 1.1 ) • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) • Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Divalproex sodium is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clinical Studies ( 14.1 )] . The safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. 1.2 Epilepsy Divalproex sodium delayed-release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium delayed-release tablets are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium o"], "temporal_context_qualifier": "acute mania"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01388a6d-4c45-5133-b2d8-9a75f0bcaf7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [234, 256], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9cef1ec-ba52-4849-8889-87898d6f4199", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9cef1ec-ba52-4849-8889-87898d6f4199", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9cef1ec-ba52-4849-8889-87898d6f4199"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid Capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid Capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 ) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d51a36d-990f-5419-b9cb-76a18f292dec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [224, 246], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53c5aa-d7a5-49ba-8227-c2d67ced23e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53c5aa-d7a5-49ba-8227-c2d67ced23e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53c5aa-d7a5-49ba-8227-c2d67ced23e2"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions (5.1) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions (5.2 , 5.3 , 5.4) , Use in Specific Populations (8.1) , and Patient Counseling Information (17) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Contraindications (4"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13e63ee4-e857-5e09-9bdc-77b89bbda04a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [234, 256], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8785a152-3010-4370-aaf5-11315a1a56e1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8785a152-3010-4370-aaf5-11315a1a56e1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8785a152-3010-4370-aaf5-11315a1a56e1"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid Capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid Capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 ) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:180bc70a-67b9-57e3-9f71-1378d046b55b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [234, 256], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ceb52870-76d0-4108-a1d4-ba7096fbacdd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ceb52870-76d0-4108-a1d4-ba7096fbacdd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ceb52870-76d0-4108-a1d4-ba7096fbacdd"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid Capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid Capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 ) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b30e829-2b06-5987-9a6d-351d94474a0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3dfb6da1-f66a-4618-9f74-d2d6c16c0b58"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproate sodium injection is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions: • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproate sodium injection is indicated as an intravenous alternative in patients for whom oral administration of valproate products is temporarily not feasible in the following conditions: Valproate sodium injection is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproate sodium injection is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d88e6a9-65c4-5aac-b876-0308e6b8a3f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c572ece7-03d3-4c2a-aeb5-61f2023b28ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c572ece7-03d3-4c2a-aeb5-61f2023b28ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c572ece7-03d3-4c2a-aeb5-61f2023b28ea"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproate sodium injection is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions: • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproate sodium injection is indicated as an intravenous alternative in patients for whom oral administration of valproate products is temporarily not feasible in the following conditions: Valproate sodium injection is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproate sodium injection is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e6a2f74-92b2-55c6-a136-5705809463e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [353, 375], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d5fc1c1-d3c0-497e-971b-6c4dba9a3fad"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproate Sodium Injection is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproate Sodium Injection is indicated as an intravenous alternative in patients for whom oral administration of valproate products is temporarily not feasible in the following conditions: Valproate Sodium Injection is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproate Sodium Injection is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a18605d-5f57-5d41-a81b-843bed73e486", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [247, 269], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34a0d45a-4388-7d8b-e063-6394a90a6c3f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34a0d45a-4388-7d8b-e063-6394a90a6c3f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34a0d45a-4388-7d8b-e063-6394a90a6c3f"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid is an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precaution ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopment disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 )] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d3a4de5-9488-5455-9281-90d7136bf3ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [353, 375], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bcf57b31-4811-4104-82b3-46fb91a53ee0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bcf57b31-4811-4104-82b3-46fb91a53ee0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bcf57b31-4811-4104-82b3-46fb91a53ee0"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproate Sodium Injection is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproate Sodium Injection is indicated as an intravenous alternative in patients for whom oral administration of valproate products is temporarily not feasible in the following conditions: Valproate Sodium Injection is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproate Sodium Injection is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See WARNINGS AND PRECAUTIONS ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d845ded-61ed-54a6-b304-6af44a77368c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [224, 246], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d5cb52e-37dd-4dfa-a6f4-09f9548846c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d5cb52e-37dd-4dfa-a6f4-09f9548846c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d5cb52e-37dd-4dfa-a6f4-09f9548846c6"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions (5.1) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions (5.2 , 5.3 , 5.4) , Use in Specific Populations (8.1) , and Patient Counseling Information (17) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Contraindications (4"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e1d9413-ebdf-56e4-8703-76531d8c940b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2314af65-b928-42a9-91eb-6372909ab4f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2314af65-b928-42a9-91eb-6372909ab4f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2314af65-b928-42a9-91eb-6372909ab4f5"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid oral solution is indicated for: • Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 )] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:640933d2-a2dd-5e13-80b5-7513b2889069", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [353, 375], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a687b2f-246d-4736-a20c-92421c263268", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a687b2f-246d-4736-a20c-92421c263268"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproate Sodium Injection is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproate Sodium Injection is indicated as an intravenous alternative in patients for whom oral administration of valproate products is temporarily not feasible in the following conditions: Valproate Sodium Injection is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproate Sodium Injection is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See WARNINGS AND PRECAUTIONS ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65814c4a-d02c-5959-afb4-037c9254679b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [234, 256], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec41025a-ed7d-48c8-9005-08e3a9417f30", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec41025a-ed7d-48c8-9005-08e3a9417f30", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec41025a-ed7d-48c8-9005-08e3a9417f30"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid Capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid Capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 ) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e31955a-a759-5c29-aae5-566cb53a19d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [233, 255], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4619aff4-0f80-444f-858d-42e4137aa809", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4619aff4-0f80-444f-858d-42e4137aa809", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4619aff4-0f80-444f-858d-42e4137aa809"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Depakote Sprinkle Capsules are an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Depakote Sprinkle Capsules are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Depakote Sprinkle Capsules are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ) , Use in Specific Populations ( 8.1 ) , and Patient Counseling Information ( 17 ) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7afc2754-1b04-56a5-ae22-1faac14217ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1004e77e-b572-4d39-8ddd-5325612dad7b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1004e77e-b572-4d39-8ddd-5325612dad7b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1004e77e-b572-4d39-8ddd-5325612dad7b"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Divalproex sodium is an anti-epileptic drug indicated for: • Treatment of manic episodes associated with bipolar disorder ( 1.1 ) • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) • Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Divalproex sodium is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clinical Studies ( 14.1 )] . The safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. 1.2 Epilepsy Divalproex sodium delayed-release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium delayed-release tablets are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Simple absence is defined as very brief clouding of the sensorium o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b63f5e8-20ba-5e26-8bdf-e6234ac90a39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [238, 260], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1edd220d-d151-4177-9a29-9fee36489fb7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1edd220d-d151-4177-9a29-9fee36489fb7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1edd220d-d151-4177-9a29-9fee36489fb7"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid oral solution is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 )] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using ef"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ce44c29-0eb1-58a8-9545-0ced56c4221a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [224, 246], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65c1589e-c591-4b79-b75e-884c0d609ae8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65c1589e-c591-4b79-b75e-884c0d609ae8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65c1589e-c591-4b79-b75e-884c0d609ae8"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions (5.1) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions (5.2 , 5.3 , 5.4) , Use in Specific Populations (8.1) , and Patient Counseling Information (17) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Contraindications (4"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e634dca-03b5-5020-a2bb-a62746705cb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [234, 256], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:453444b6-1f50-49de-ab3c-1e429c83bffa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=453444b6-1f50-49de-ab3c-1e429c83bffa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=453444b6-1f50-49de-ab3c-1e429c83bffa"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid Capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid Capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 ) ] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9d8be23-f565-5947-aa64-43fa7de083f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [247, 269], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cef3e335-5891-412f-89c4-79fcd2f145b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cef3e335-5891-412f-89c4-79fcd2f145b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cef3e335-5891-412f-89c4-79fcd2f145b7"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic Acid is an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precaution ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopment disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 )] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdd59ecb-a369-5cee-9878-8fa4aba0fcc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 17, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a33f7657-ad0f-43e9-ba48-024746e6d08e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a33f7657-ad0f-43e9-ba48-024746e6d08e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a33f7657-ad0f-43e9-ba48-024746e6d08e"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient CounselingInformation ( 17 )] . For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Contraindication"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002121", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3f33401-69a1-53bc-8a75-12bbf12e695e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f1c66db-cc17-5553-b92d-33e22040b0e9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6aa66259-63b2-50b4-b409-eeb1dd08a995", "medic_supporting_text_truncated": true, "object": "UMLS:C4015120", "object_location_in_text": [238, 260], "original_object": "multiple seizure types", "original_subject": "VALPROIC ACID", "population_context_qualifier": "patients with multiple seizure types which include absence seizures", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8051ad62-3b6e-461e-8090-60f5c0a904f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8051ad62-3b6e-461e-8090-60f5c0a904f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8051ad62-3b6e-461e-8090-60f5c0a904f4"]}], "subject": "CHEBI:39867", "supporting_text": ["1 INDICATIONS AND USAGE Valproic acid oral solution is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. See Warnings and Precautions ( 5.1 ) for statement regarding fatal hepatic dysfunction. 1.2 Important Limitations Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable [ see Warnings and Precautions ( 5.2 , 5.3 , 5.4 ), Use in Specific Populations ( 8.1 ), and Patient Counseling Information ( 17 ) ]. For prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0196bb90-f9db-59b7-a3df-1d9639e329b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "population_context_qualifier": "patients requiring adjunct to rest and physical therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:214e511d-d40d-55ab-b6b1-fa1b195361f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:280b8235-caf6-5054-a2f7-f783b43f4872", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to two or three weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d822907-58cc-5ede-9222-230df6dd7851", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3012f9d8-2525-58a7-8280-08cce50efa56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39fb0471-c8a9-5bab-b84f-d7646b92a67d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d3f4296-c276-5be1-9e32-4f6916c387fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "population_context_qualifier": "patients requiring adjunct to rest and physical therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d8c3e01-bbf7-5dea-bdfb-48843a0fa40e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "population_context_qualifier": "patients requiring adjunct to rest and physical therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6404bac7-9f61-5705-8db1-f777471b580f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "population_context_qualifier": "patients requiring adjunct to rest and physical therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76d26386-ce2a-54a4-9dcc-d1f3e7c893d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to two or three weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f964257-ad4c-5e7e-92ef-1e9c1ba9e4cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [151, 163], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d"]}], "subject": "CHEBI:3996", "supporting_text": ["1 INDICATIONS AND USAGE Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion."], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80a3b2b8-6d6f-50ec-bac1-a2e89d081544", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to two or three weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83bf0dc1-4c1a-57c7-b7dc-cb178e9c7929", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c3d2aca-6a76-5cac-be89-6fa35962a0f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "population_context_qualifier": "patients requiring adjunct to rest and physical therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f973cf6-feb3-5026-99f3-82b60c90dbff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d22f4941-dd09-501e-bc0a-a5dd46bfd503", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc714594-6f61-5131-9e01-d1ca4a408dbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to two or three weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e18fa2c6-f1a5-5d58-afb7-d4b6490076d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [114, 126], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to 2 or 3 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6585d50-fc1e-5e09-bf86-729ca10c5563", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [109, 121], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to two or three weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef5fd15a-f0bf-5b16-99b5-4f7b8411b140", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0003394", "object_location_in_text": [90, 102], "original_object": "muscle spasm", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine HCl is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."], "temporal_context_qualifier": "short periods (up to two or three weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:033f1028-6257-5c4c-85c6-598159c0f1da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11f60ad9-83d6-52ef-afb1-f1fc321e2ef2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:143ac6e9-3d75-5856-905f-575a7074b537", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14f8efe4-2f08-5016-a517-64ee5d1311a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [126, 130], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine HCl is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:161d19a2-650b-5e23-831e-27f6b6698d20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [187, 191], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d"]}], "subject": "CHEBI:3996", "supporting_text": ["1 INDICATIONS AND USAGE Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion."], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:226e69b5-b1b8-537a-bf54-9759326752ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d1e24b9-ef84-5bb7-b0d7-3a55c100398b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ec90fec-4471-55ff-8a91-fd674fe9b935", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3609c777-7651-5812-997c-82fd9e137653", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3919a20b-e40f-57bb-8726-4a3ac7339c48", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56d98193-b9a4-5549-b25a-e1cc7c2eec6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:702d4d82-dba3-5fd9-990d-df39caab169b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a738bbe-09c7-5929-b349-e853ac069c8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3f56361-5bc8-56db-a769-8765c5fa35b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c43b28e9-18a3-5034-9efb-db95864f4c4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca7c376a-651c-5215-8ad8-bd902d85b959", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4a3b263-1b85-5af5-b47e-1c552e2d1c2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5dd71d3-535b-55c6-a0f2-8461a0bf0955", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec217140-8ba1-51cb-bcd0-8b548393f152", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [145, 149], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f48c622b-47a5-5d04-8ec9-6db71f4f2c1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "HP:0012531", "object_location_in_text": [150, 154], "original_object": "pain", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0621d1f7-c53a-5f18-90bb-66a2581b0506", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1fefb0ec-f37d-5baf-86eb-6992b01d5c14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21792a3c-be39-5b8a-bec9-45dd20bba8a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [328, 338], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d"]}], "subject": "CHEBI:3996", "supporting_text": ["1 INDICATIONS AND USAGE Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion."], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26e2e868-d71b-5986-9411-58bbad455afe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3620cdf6-303a-5fd1-b890-1cadf0fb5771", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4334b14c-30cb-5af8-a415-d9afa6a45196", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:496a10b4-fde6-5b9d-b64d-ebd2d1a90463", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:610171e7-cc36-556e-bd4d-345e1f677730", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:751afe7b-6c26-5f3a-af66-39e8adcb8844", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ca3556d-047f-5fec-b1be-839d8e36b5fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e92445e-b921-5a84-a52c-97af054218cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a33dadfe-83eb-542c-ba4b-253a856076a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a76ac2f6-2144-5f9c-98b4-4ed6b84954fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b043568d-dada-5c54-9ea8-06c4bd2f7ad5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0c08314-d6d9-5635-8905-9bbe28b00040", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:baed4c63-1aa8-5a65-bcf8-3d39e5aaa41a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9911afb-8dc6-577f-bc3c-837256a921b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [267, 277], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine HCl is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9ca577a-7efe-55f2-be63-1ffeda0efd24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [286, 296], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da91f70d-4d9a-53f2-93ca-c5c429d174f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dedb2e5e-2080-5b5e-b96a-83aa39043612", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dddeeb03-3773-5d98-8d08-02ad93989ad4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0234233", "object_location_in_text": [291, 301], "original_object": "tenderness", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1735dfca-a596-51fa-9873-42eb85b07b1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2286776-a7de-42dc-b745-d250e741eeb6"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e64e26e-1ec4-5e8d-b948-3f340123a9da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [344, 364], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=550d3e5a-c95f-4094-a500-1a02ea35a18d"]}], "subject": "CHEBI:3996", "supporting_text": ["1 INDICATIONS AND USAGE Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion."], "temporal_context_qualifier": "acute"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:215d47e8-f212-5477-9de2-d0a4e5ebc091", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37056cab-953e-43ba-9b4c-163a739a52f7"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:257b3093-7f3f-5eea-9893-178dc28c621b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7829a96a-3668-4d88-90e9-0ecbedb2bd7e"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2592ef0d-588c-503e-b5f2-4e14c7e541d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59b428fa-5013-4b2b-872f-16ba4a9d4f5d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26ea456a-7d67-5bf5-adc3-aed9e550ac80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c66b5ed-f773-0779-e053-2995a90ad1f1"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:330cbf63-ed6a-5d76-925d-b8dd9b8a9a57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee4feec-4590-fa7f-e063-6394a90a5550"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:384aebc4-5e43-5bd9-9a8d-b1db130f474b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34e57aff-dc4b-4631-9d57-31020244835d"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b3cffec-553b-5032-83ce-d07b937535c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d0d6eec-28e8-6fca-e063-6294a90a59cd"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69648ea3-5fd4-5c5b-9cba-0c61fad553ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8566e45-6159-4877-aaa6-1cf968ccb450"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8086f63f-9fbf-52df-a63c-7a64694eaedc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c732db1-8321-82a4-e053-2991aa0aa8a0"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:875cf139-f33e-50e4-98f8-ffa47da11f0c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12454c61-8782-43d5-8426-9e79232b68ae"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b284774-aa76-5760-a89b-d24f6ef98577", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [279, 299], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d9e34cc-eee9-4147-abf8-c810a80e39d2"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine HCl is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9481637b-b1c1-5ef2-9063-0a0d99b30ea6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf5d4de9-79c3-4935-be69-89e98d7b54cc"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac200757-0f6d-597e-964b-cb92c0cb52d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71185d15-3fd7-42b7-83a6-8357e3aaef43"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6635d92-bfa6-523e-9c8f-ba3d8f3ee216", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9161cb5e-63e5-41d7-9bde-66c7b7b7a2f3"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc6b1b3e-65a4-5615-8800-ce7be26be9f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3baeda95-d098-437a-b360-87a9c3f3fd9b"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcb3fd50-3864-538c-9544-b41ce0e5a48d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4ae481f-9e47-470a-b4d1-5a33c0df8761"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0ac0c40-62c0-51d2-b3a8-5c378a6e0949", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [298, 318], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3aaa4808-7f2d-410c-9b6c-193549ec0845"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute, painful musculoskeletal conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f78cf054-0914-5a1b-b555-05c41ebab61d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dcd6103a-8487-5a37-9fd7-331a200b18bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:709d2718-036d-5832-9abc-0decc8924c41", "object": "UMLS:C0518456", "object_location_in_text": [303, 323], "original_object": "limitation of motion", "original_subject": "CYCLOBENZAPRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d536e88-62be-45bd-bd09-0efc53fe12b9"]}], "subject": "CHEBI:3996", "supporting_text": ["Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acute painful musculoskeletal conditions", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d5c7f17-0001-555a-a3ac-73d3a2672377", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:b26f7dbb-0e34-5f34-921f-3bc00b235e3f", "object": "HP:0003394", "object_location_in_text": [54, 66], "original_object": "muscle spasm", "original_subject": "CyclobenzaprineHcl. Tablets 5mg/10mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:3997", "supporting_text": ["As adjunct to rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions"], "temporal_context_qualifier": "adjunct to rest and physical therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acute, painful, musculoskeletal conditions", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d5c7f17-0001-555a-a3ac-73d3a2672377", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:43f61a4c-4ee5-53e4-a39a-04059c54f1a7", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:a5998b7c-24ec-5206-9477-caa19cf64b92", "object": "HP:0003394", "object_location_in_text": [57, 69], "original_object": "muscle spasm", "original_subject": "Cyclobenzaprine HCl ER Capsule 15/30mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:3997", "supporting_text": ["As an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful, musculoskeletal conditions."], "temporal_context_qualifier": "as an adjunct to rest and physical therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disseminated disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14c1cab9-de0c-537c-a5c4-e31dc99ada91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6722b1c3-cb86-5920-b9d7-3d05e7644a1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "MONDO:0005072", "object_location_in_text": [292, 305], "original_object": "neuroblastoma", "original_subject": "CYCLOPHOSPHAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cef038cc-efab-46d9-99c2-95bb11d6c9bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cef038cc-efab-46d9-99c2-95bb11d6c9bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cef038cc-efab-46d9-99c2-95bb11d6c9bc"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide is an alkylating drug indicated for treatment of: • Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disseminated disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28740fa1-f7b3-5dec-9421-d1c15ec038b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6722b1c3-cb86-5920-b9d7-3d05e7644a1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "MONDO:0005072", "object_location_in_text": [290, 303], "original_object": "neuroblastoma", "original_subject": "CYCLOPHOSPHAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d6447e3-22c9-48d9-87c0-d0b576d7ea9e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d6447e3-22c9-48d9-87c0-d0b576d7ea9e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d6447e3-22c9-48d9-87c0-d0b576d7ea9e"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma (1.1) Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disseminated disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e01ddd6-1d27-5cc9-a5de-e904edd7bbb7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6722b1c3-cb86-5920-b9d7-3d05e7644a1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "MONDO:0005072", "object_location_in_text": [292, 305], "original_object": "neuroblastoma", "original_subject": "CYCLOPHOSPHAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6bae5c14-9e87-4fb6-ae9c-4d875c1ecffe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6bae5c14-9e87-4fb6-ae9c-4d875c1ecffe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6bae5c14-9e87-4fb6-ae9c-4d875c1ecffe"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide is an alkylating drug indicated for treatment of: • Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disseminated disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aef68cd8-8cb7-5ef9-8fc0-19f04b475bc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6722b1c3-cb86-5920-b9d7-3d05e7644a1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "MONDO:0005072", "object_location_in_text": [290, 303], "original_object": "neuroblastoma", "original_subject": "CYCLOPHOSPHAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8057d1a-e8af-42ab-9da2-b545730b2655", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8057d1a-e8af-42ab-9da2-b545730b2655", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8057d1a-e8af-42ab-9da2-b545730b2655"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma (1.1) Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disseminated disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aff35e99-3ce5-5855-a411-94b2a2e5ad32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6722b1c3-cb86-5920-b9d7-3d05e7644a1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "MONDO:0005072", "object_location_in_text": [340, 353], "original_object": "neuroblastoma", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:988d2f71-1dc7-45b5-b2df-187e68224973", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=988d2f71-1dc7-45b5-b2df-187e68224973", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=988d2f71-1dc7-45b5-b2df-187e68224973"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disseminated disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6d64e3a-bc2f-518f-9816-b6b103501a3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6722b1c3-cb86-5920-b9d7-3d05e7644a1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "MONDO:0005072", "object_location_in_text": [684, 697], "original_object": "neuroblastoma", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1eb470-0bba-457d-94e3-b9508f0d398a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1eb470-0bba-457d-94e3-b9508f0d398a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1eb470-0bba-457d-94e3-b9508f0d398a"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult and pediatric patients with: Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "adrenocorticosteroid therapy failure or intolerance", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:159c2c55-6646-5241-a182-3bf74f768614", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "object_location_in_text": [494, 527], "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:591d9955-3d9c-4cdc-a308-2f1288376b9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=591d9955-3d9c-4cdc-a308-2f1288376b9f"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "biopsy proven minimal change nephrotic syndrome", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15c55660-7e1a-53e3-82e5-23d94106abff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "object_location_in_text": [491, 524], "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1de02105-9c5b-4d11-bddf-bf8450d88b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1de02105-9c5b-4d11-bddf-bf8450d88b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1de02105-9c5b-4d11-bddf-bf8450d88b78"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Disease s: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3cf622b3-26c4-547b-b69a-8162f7af3814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:988d2f71-1dc7-45b5-b2df-187e68224973", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=988d2f71-1dc7-45b5-b2df-187e68224973", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=988d2f71-1dc7-45b5-b2df-187e68224973"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "adrenocorticosteroid therapy failure or intolerance", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:844fc292-177d-54e2-8059-ef30794e8138", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "object_location_in_text": [496, 529], "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97ab446f-5017-4180-ae65-0a355289b0ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97ab446f-5017-4180-ae65-0a355289b0ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97ab446f-5017-4180-ae65-0a355289b0ed"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "adrenocorticosteroid therapy failure or intolerance", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92623105-d938-519b-bc04-e9f5165f764e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:769ded74-6186-40a8-8e44-ceff67287451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=769ded74-6186-40a8-8e44-ceff67287451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=769ded74-6186-40a8-8e44-ceff67287451"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide Tablets is an alkylating drug indicated for treatment of: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "adrenocorticosteroid therapy inadequate response or intolerance", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb0b502c-5a10-5b31-8f09-feb78a82655f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8627c83f-c057-495d-9f78-8b67bda97b3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8627c83f-c057-495d-9f78-8b67bda97b3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8627c83f-c057-495d-9f78-8b67bda97b3e"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "adrenocorticosteroid therapy failure or intolerance", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd627c22-e8f4-5d58-8528-33c00f7820e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2246fea4-0222-527c-b590-da8992a721a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1279419e-3420-5ca2-92dd-2c155b48acf3", "object": "UMLS:C1704321", "object_location_in_text": [490, 523], "original_object": "minimal change nephrotic syndrome", "original_subject": "CYCLOPHOSPHAMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d3396d8-4c03-4a28-890a-d87c6c53a74e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d3396d8-4c03-4a28-890a-d87c6c53a74e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d3396d8-4c03-4a28-890a-d87c6c53a74e"]}], "subject": "CHEBI:4027", "supporting_text": ["1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27772d04-4499-5a85-9909-0f2925a51dbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6181382c-f4e3-5949-93b0-fef3ce1062a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "HP:0000112", "object_location_in_text": [211, 222], "original_object": "nephropathy", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36526c80-5a70-47c4-a0a6-785ccc346703", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36526c80-5a70-47c4-a0a6-785ccc346703", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36526c80-5a70-47c4-a0a6-785ccc346703"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a2d102d-ee2f-5966-8d09-5647c8f448a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6181382c-f4e3-5949-93b0-fef3ce1062a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "HP:0000112", "object_location_in_text": [211, 222], "original_object": "nephropathy", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d330416-4289-762e-e063-6294a90a532e"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b852c9a-21e3-5785-b581-008d11429e25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6181382c-f4e3-5949-93b0-fef3ce1062a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "HP:0000112", "object_location_in_text": [211, 222], "original_object": "nephropathy", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abea5ae9-47ff-5522-9754-098e29d9f304", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6181382c-f4e3-5949-93b0-fef3ce1062a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "HP:0000112", "object_location_in_text": [211, 222], "original_object": "nephropathy", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea62c933-2ff4-5f50-bf8d-95a7496dcf37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6181382c-f4e3-5949-93b0-fef3ce1062a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "HP:0000112", "object_location_in_text": [211, 222], "original_object": "nephropathy", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07c5f17f-5f1e-571f-ad39-c04277f996b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dbced9a-ef6f-455e-8d5d-b635409521db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dbced9a-ef6f-455e-8d5d-b635409521db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dbced9a-ef6f-455e-8d5d-b635409521db"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e6f1074-45b7-5025-ad4c-e3be9a842635", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da78d290-c71f-44bc-8db4-58fe4195e2f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da78d290-c71f-44bc-8db4-58fe4195e2f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da78d290-c71f-44bc-8db4-58fe4195e2f8"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2551d2c5-39d3-5eba-a87d-8b449378c63d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:211e47c6-85b9-43e8-9e07-6cc4b8f708a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=211e47c6-85b9-43e8-9e07-6cc4b8f708a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211e47c6-85b9-43e8-9e07-6cc4b8f708a0"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d79d30d-ccb8-5bb3-9ddf-65e3a1026ff1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d330416-4289-762e-e063-6294a90a532e"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4dfc3ddb-d623-51a4-901e-a5c9c2edc28d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36526c80-5a70-47c4-a0a6-785ccc346703", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36526c80-5a70-47c4-a0a6-785ccc346703", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36526c80-5a70-47c4-a0a6-785ccc346703"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7117ff71-2a39-5621-91ce-1fc886dc753d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76ca6bea-5f63-4e76-b161-1dbcbad18421", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76ca6bea-5f63-4e76-b161-1dbcbad18421", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76ca6bea-5f63-4e76-b161-1dbcbad18421"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ad52152-b6db-5dc9-8f60-0deeb81627db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9419f45f-53de-579e-ba87-9a50eff7d4f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f130c9c0-45d8-42bc-a040-04bb077671f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f130c9c0-45d8-42bc-a040-04bb077671f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f130c9c0-45d8-42bc-a040-04bb077671f8"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0f07f93-c942-551b-94ad-4359bd6d38a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f50e91e-66a7-4fd4-888a-9f1986aa661c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f50e91e-66a7-4fd4-888a-9f1986aa661c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f50e91e-66a7-4fd4-888a-9f1986aa661c"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba17bce2-abd8-5720-aafc-ef7601c7eb07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2bc06f3-a717-5135-8cf5-6f004f0b9138", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d33d9029-15a9-4b60-bd01-42cfecf1eadc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d33d9029-15a9-4b60-bd01-42cfecf1eadc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d33d9029-15a9-4b60-bd01-42cfecf1eadc"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de9aa153-442c-57ca-a01a-9a5c4473b2a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e35694d4-f566-5c76-a26a-aa7f2e5857f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:583df4b8-a1d4-01ed-e063-6394a90af007", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=583df4b8-a1d4-01ed-e063-6394a90af007", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=583df4b8-a1d4-01ed-e063-6394a90af007"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: • The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) • The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels • The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f533ee78-00ce-543d-9b89-575fc8da11f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd8f8b8b-f25e-46e9-969a-65363b66e09b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd8f8b8b-f25e-46e9-969a-65363b66e09b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd8f8b8b-f25e-46e9-969a-65363b66e09b"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f71b03a8-c3ed-58a8-9f5c-5af4165aee14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1c11f74-1de2-484c-b40b-d0013e8fd01a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1c11f74-1de2-484c-b40b-d0013e8fd01a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1c11f74-1de2-484c-b40b-d0013e8fd01a"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fad5876c-5220-5dfc-96ac-32ef301c899d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:773fbc15-4c5e-5fd2-a3fb-9d0a56bd8f14", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0149896", "original_object": "primary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2ab2389-ccaf-487b-9985-50e3539e7617", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2ab2389-ccaf-487b-9985-50e3539e7617", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2ab2389-ccaf-487b-9985-50e3539e7617"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e709181-3bb5-5c9b-8585-6b932540b0c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f130c9c0-45d8-42bc-a040-04bb077671f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f130c9c0-45d8-42bc-a040-04bb077671f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f130c9c0-45d8-42bc-a040-04bb077671f8"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25e7abd3-9a8e-5b04-8a6a-4dcf2cda9773", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd8f8b8b-f25e-46e9-969a-65363b66e09b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd8f8b8b-f25e-46e9-969a-65363b66e09b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd8f8b8b-f25e-46e9-969a-65363b66e09b"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:472f3d04-24cf-5a1e-9788-7e6f752389df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b2ab2389-ccaf-487b-9985-50e3539e7617", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b2ab2389-ccaf-487b-9985-50e3539e7617", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2ab2389-ccaf-487b-9985-50e3539e7617"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60c9d25e-affc-5646-bf6a-b4f51c25b5ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ffcbc32-5996-41cd-acdc-cc4af8cdaf4f"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65c46d34-8994-593b-ac70-b502704397ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [128, 142], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:583df4b8-a1d4-01ed-e063-6394a90af007", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=583df4b8-a1d4-01ed-e063-6394a90af007", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=583df4b8-a1d4-01ed-e063-6394a90af007"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: • The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) • The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels • The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7aa66032-d485-5f20-a348-0cbc2767ad50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36526c80-5a70-47c4-a0a6-785ccc346703", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36526c80-5a70-47c4-a0a6-785ccc346703", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36526c80-5a70-47c4-a0a6-785ccc346703"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:810448c0-1079-5971-81f9-1e2bd08b5f77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76ca6bea-5f63-4e76-b161-1dbcbad18421", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76ca6bea-5f63-4e76-b161-1dbcbad18421", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76ca6bea-5f63-4e76-b161-1dbcbad18421"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93384d98-7933-5b15-b9a8-6105af933d93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:211e47c6-85b9-43e8-9e07-6cc4b8f708a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=211e47c6-85b9-43e8-9e07-6cc4b8f708a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211e47c6-85b9-43e8-9e07-6cc4b8f708a0"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:948ce5d2-ca3a-5c0e-82b5-3db4ff01f3ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4dbced9a-ef6f-455e-8d5d-b635409521db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4dbced9a-ef6f-455e-8d5d-b635409521db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dbced9a-ef6f-455e-8d5d-b635409521db"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abcab7a3-c60e-56ab-87b9-07f2936ebf5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d330416-4289-762e-e063-6294a90a532e"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b218c771-868b-5c38-8fd7-9ffab558fc10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d03e30f0-2f5a-5049-b5c3-a5179818b6b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eefcd1f9-3016-5bec-97ed-acad87f5dab0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d33d9029-15a9-4b60-bd01-42cfecf1eadc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d33d9029-15a9-4b60-bd01-42cfecf1eadc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d33d9029-15a9-4b60-bd01-42cfecf1eadc"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efb99d09-8397-5d15-ae09-fb7d106ce864", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f50e91e-66a7-4fd4-888a-9f1986aa661c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f50e91e-66a7-4fd4-888a-9f1986aa661c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f50e91e-66a7-4fd4-888a-9f1986aa661c"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f492150a-87dc-5ccf-a245-518a4bc89208", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1c11f74-1de2-484c-b40b-d0013e8fd01a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1c11f74-1de2-484c-b40b-d0013e8fd01a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1c11f74-1de2-484c-b40b-d0013e8fd01a"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxylate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxalate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0409908", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9dfbe77-c116-5f6e-9904-e337e39b53cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1cc62471-1f22-5fde-bf4a-8ca0a563ecc2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0409908", "object_location_in_text": [126, 140], "original_object": "secondary gout", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults with signs and symptoms", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da78d290-c71f-44bc-8db4-58fe4195e2f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da78d290-c71f-44bc-8db4-58fe4195e2f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da78d290-c71f-44bc-8db4-58fe4195e2f8"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57be1c4b-344d-5751-8438-4d48aa560195", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:85df2a5f-f23e-5e0b-b3b5-79f19018b49a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0541875", "object_location_in_text": [164, 181], "original_object": "joint destruction", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb1cb8ea-cf1c-4ad3-afeb-c11986f0e9bc"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81ecbe89-343a-5bf2-9a7d-a9b058d9dbdd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:85df2a5f-f23e-5e0b-b3b5-79f19018b49a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0541875", "object_location_in_text": [164, 181], "original_object": "joint destruction", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71fd88d2-cfd8-4abd-bb15-7ef2699ccf9d"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0149896", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3c8543c-d658-5733-8d9e-8bd21d3a7d06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149896", "UMLS:C0409908"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:85df2a5f-f23e-5e0b-b3b5-79f19018b49a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddeed59-79ad-5861-8d7d-ceaf2a6ed98f", "object": "UMLS:C0541875", "object_location_in_text": [164, 181], "original_object": "joint destruction", "original_subject": "ALLOPURINOL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d330416-4289-762e-e063-6294a90a532e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d330416-4289-762e-e063-6294a90a532e"]}], "subject": "CHEBI:40279", "supporting_text": ["1 INDICATIONS AND USAGE Allopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d219390-051b-5367-9ed9-987fc44e835b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:233862a1-5fdc-5063-895e-4eca072ffcf1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a902a95f-072a-4487-99a9-109a93f8b23c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a902a95f-072a-4487-99a9-109a93f8b23c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a902a95f-072a-4487-99a9-109a93f8b23c"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies in Adults .) Coronary Heart Disease Lovastatin Tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin Tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. Adolescent Patients With Heterozygous Familial Hypercholesterolemia Lovastatin Tablets are indicated as an adjunct to diet to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30b9d989-3c77-5022-b3cf-c7870e2f2e8b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, with average to moderately elevated total-C and LDL-C and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22c9f2d8-7bcd-4415-bbc8-505720033966", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22c9f2d8-7bcd-4415-bbc8-505720033966", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22c9f2d8-7bcd-4415-bbc8-505720033966"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:426988c8-b1a3-5a28-94cb-80a699d18e12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e285cd0-fe93-555d-8b5e-c7f83c653054", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:892781ce-f92f-5e1b-8dce-a6f88b096e2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bbef592-1ac5-5d49-9743-dbb18a428c6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91332c54-1a27-4e6b-e053-2a95a90a42cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91332c54-1a27-4e6b-e053-2a95a90a42cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91332c54-1a27-4e6b-e053-2a95a90a42cd"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies in Adults .) Coronary Heart Disease Lovastatin Tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin Tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. Adolescent Patients With Heterozygous Familial Hypercholesterolemia Lovastatin Tablets are indicated as an adjunct to diet to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a21def03-1c21-5a39-a610-f82a71ec1333", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains &gt;189 mg/dL or LDL-C remains &gt;160 mg/dL and: there is a positive family history"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf7ad92b-be05-5529-9c2c-b075d82f60d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6c3ea29-72e3-5eaa-b7a1-b8268cce74a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cef0b772-c733-5d76-b564-8211a3606f4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, with average to moderately elevated total-C and LDL-C and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:397949f9-ce60-424f-9902-90e65a34f4de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=397949f9-ce60-424f-9902-90e65a34f4de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=397949f9-ce60-424f-9902-90e65a34f4de"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6ff34f1-ba8c-57bb-9a64-acd2f0f06ce1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff5fa528-8a9b-56af-9c49-ebf949e8db26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27ecdc37-47cf-567c-a2f9-7f0636626c77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, with average to moderately elevated total-C and LDL-C and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:397949f9-ce60-424f-9902-90e65a34f4de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=397949f9-ce60-424f-9902-90e65a34f4de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=397949f9-ce60-424f-9902-90e65a34f4de"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c0aef92-0dac-5a8a-b43e-fda40e024724", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:509d1963-47d0-5073-acab-25abd7f935c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91332c54-1a27-4e6b-e053-2a95a90a42cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91332c54-1a27-4e6b-e053-2a95a90a42cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91332c54-1a27-4e6b-e053-2a95a90a42cd"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies in Adults .) Coronary Heart Disease Lovastatin Tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin Tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. Adolescent Patients With Heterozygous Familial Hypercholesterolemia Lovastatin Tablets are indicated as an adjunct to diet to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56f840ed-f6a0-531c-82f6-8054cfdd0564", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74f74f3e-564d-5589-9306-ea1cf8ddd16c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78fc18db-274b-562e-b288-77bac479c11a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, with average to moderately elevated total-C and LDL-C and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22c9f2d8-7bcd-4415-bbc8-505720033966", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22c9f2d8-7bcd-4415-bbc8-505720033966", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22c9f2d8-7bcd-4415-bbc8-505720033966"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a01372a-7b8f-5781-99a0-f6d3619947d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b431970b-f6cb-5f1f-a400-bcbe9a2d6be9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8fc9da6-d26f-521e-89ed-ab42bc104e39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbe7bde2-94da-5103-a788-99928d8b85d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e70ba3d1-0a1a-548f-a9a5-55ba216c57cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a902a95f-072a-4487-99a9-109a93f8b23c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a902a95f-072a-4487-99a9-109a93f8b23c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a902a95f-072a-4487-99a9-109a93f8b23c"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies in Adults .) Coronary Heart Disease Lovastatin Tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin Tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. Adolescent Patients With Heterozygous Familial Hypercholesterolemia Lovastatin Tablets are indicated as an adjunct to diet to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e918a491-3410-5ade-8993-d22161254e71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e997996e-feb4-57fb-b4ca-c7d90c74da81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "MONDO:0006805", "original_object": "unstable angina", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains &gt;189 mg/dL or LDL-C remains &gt;160 mg/dL and: there is a positive family history"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "type-IIa hyperlipoproteimemia, type-IIb hyperlipoproteimemia", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a801f3dd-8ba9-5ff4-9470-8f825e573b90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951005", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d7a34141-5c9f-5d5a-b4f0-cd8e8e35508b", "object": "UMLS:C0342879", "object_location_in_text": [49, 77], "original_object": "primary hypercholesterolemia", "original_subject": "Lovastatin 10mg/20mg/40mg Tablet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:40303", "supporting_text": ["Reduction of total LDL cholestrol in patients of primary hypercholesterolemia (type-IIa & IIb hyperlipoproleinemia)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:103d241b-eec8-531f-b4e0-910dceb39f89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1999cbd0-7bbf-54c2-8855-8614810b9e91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b3fea00-7bc5-50fb-8dbb-07740937ee96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, with average to moderately elevated total-C and LDL-C and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:397949f9-ce60-424f-9902-90e65a34f4de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=397949f9-ce60-424f-9902-90e65a34f4de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=397949f9-ce60-424f-9902-90e65a34f4de"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3801feed-d1b4-5911-a0d9-8f44447a22f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53ec6d75-1d80-5758-89b1-bcc57443f03f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, with average to moderately elevated total-C and LDL-C and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22c9f2d8-7bcd-4415-bbc8-505720033966", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22c9f2d8-7bcd-4415-bbc8-505720033966", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22c9f2d8-7bcd-4415-bbc8-505720033966"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55ce1db2-a7bf-5a98-9415-f80e24a4ff48", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c398ae0-bd97-534a-8cde-51e36f20b2d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91332c54-1a27-4e6b-e053-2a95a90a42cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91332c54-1a27-4e6b-e053-2a95a90a42cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91332c54-1a27-4e6b-e053-2a95a90a42cd"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies in Adults .) Coronary Heart Disease Lovastatin Tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin Tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. Adolescent Patients With Heterozygous Familial Hypercholesterolemia Lovastatin Tablets are indicated as an adjunct to diet to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fc6b192-04e9-5149-b25c-ee5c9e113268", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4ffd08b-b038-51cf-82f2-05f8e39c8974", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdbf6f83-60ba-5f79-bd30-c87b9474a2a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ced5b9d3-9ba8-5ccd-a9e2-3090744a6ef1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a902a95f-072a-4487-99a9-109a93f8b23c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a902a95f-072a-4487-99a9-109a93f8b23c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a902a95f-072a-4487-99a9-109a93f8b23c"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with Lovastatin Tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin Tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, Lovastatin Tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies in Adults .) Coronary Heart Disease Lovastatin Tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin Tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. Adolescent Patients With Heterozygous Familial Hypercholesterolemia Lovastatin Tablets are indicated as an adjunct to diet to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "average to moderately elevated total-C and LDL-C and below average HDL-C", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4b7da33-b502-59c5-bec5-2d849a7e64a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e59c44fc-7337-5c11-81cf-1cdcadad487f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fc21de-209b-53c9-a00b-31c3e88db186", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0877341", "original_object": "coronary revascularization procedures", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains &gt;189 mg/dL or LDL-C remains &gt;160 mg/dL and: there is a positive family history"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c934674a-bfe7-5f4a-8e50-f8c84fc85cea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "HP:0003124", "original_object": "hypercholesterolemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fd9d5c7-8025-4049-8b5b-ae3d22db507f"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains &gt;189 mg/dL or LDL-C remains &gt;160 mg/dL and: there is a positive family history"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03ab9774-ee65-57df-a5a6-257adab392db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f99e0b4c-e757-4ccd-e053-6294a90ab722"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b8a0346-75f7-5295-ba67-25fd9fbaca4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f265a6-2aa5-4205-9159-40133ae93ac0"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1841ec69-8320-5c30-bbda-32b0888e9d44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [109, 121], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db47ddae-c574-427f-e053-2a95a90aae48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db47ddae-c574-427f-e053-2a95a90aae48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db47ddae-c574-427f-e053-2a95a90aae48"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevaions Type Lipoproteins elevated major minor I chylonicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-densit lipoprotein Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2347d7bd-57b6-504b-8af6-ae90057c6c35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff040b3c-6790-40d7-bd64-a4073b4a2045"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:285d33e7-2ba0-579a-86b3-0b9309602593", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df7ddf4f-d569-431e-81f1-9129d7043150"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49875965-0e56-5232-bb08-fcc483eda2f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [109, 121], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ea4df37b-21e9-4dc3-83af-1be1b50bfdc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ea4df37b-21e9-4dc3-83af-1be1b50bfdc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea4df37b-21e9-4dc3-83af-1be1b50bfdc9"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: • Myocardial infarction • Unstable angina • Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevaions Type Lipoproteins elevated major minor I chylonicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-densit lipoprotein Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6afcf05b-5df1-5abf-bafc-546b3f71eaa2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [109, 121], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56680dfa-abe6-4587-b222-364315fd78f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56680dfa-abe6-4587-b222-364315fd78f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56680dfa-abe6-4587-b222-364315fd78f4"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: • Myocardial infarction • Unstable angina • Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevaions Type Lipoproteins elevated major minor I chylonicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-densit lipoprotein Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d3f6b8a-925e-5abe-b0f7-ef0ee7dbd691", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f308fe1c-23a9-6409-e053-2995a90abfd9"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f0dbaee-50be-5731-8403-9da556b6f1c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca59cbd4-a4c1-aebe-e053-2a95a90ae968"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a03201b4-968e-53c7-a24e-e67655d2eb83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=030c0f79-6bb5-4876-bf8e-b7a25b25dd38"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3da2748-71da-512d-9d65-7cc1fc9b4734", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [109, 121], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9438d8a0-ca5b-4676-aab9-d0241ccff6c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9438d8a0-ca5b-4676-aab9-d0241ccff6c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9438d8a0-ca5b-4676-aab9-d0241ccff6c9"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY , Clinical Studies .) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias Lipid Elevaions Type Lipoproteins elevated major minor I chylonicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-densit lipoprotein Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f07a381f-6cfb-5d17-a2ce-b9b73849f4ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870831", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95a85acf-4468-5e5b-9cd0-a19a1afb5db9", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:44d5c082-aefb-5a7a-ac4c-8427a0488015", "medic_supporting_text_truncated": true, "object": "UMLS:C0242339", "object_location_in_text": [121, 133], "original_object": "dyslipidemia", "original_subject": "LOVASTATIN", "population_context_qualifier": "individuals at risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e75b5808-ec66-4da7-90bc-e53611aa1b34"]}], "subject": "CHEBI:40303", "supporting_text": ["Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c3d245c-f7f0-5c35-9603-109b483d0fdc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80e13d3f-f4db-4bb4-95d5-5ac1afa70e7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80e13d3f-f4db-4bb4-95d5-5ac1afa70e7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80e13d3f-f4db-4bb4-95d5-5ac1afa70e7e"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38924651-3830-566c-a7a8-fc02fd39eef7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80411af3-03ee-4330-830b-f69f2a373ef9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80411af3-03ee-4330-830b-f69f2a373ef9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80411af3-03ee-4330-830b-f69f2a373ef9"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4056d48a-4245-5a15-9b1d-38a29ae7d76b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:426acecc-aef4-099c-e063-6294a90a54eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=426acecc-aef4-099c-e063-6294a90a54eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=426acecc-aef4-099c-e063-6294a90a54eb"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.4896, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a22281a8-cc0a-5006-bd94-1d4a4f883f18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03e69414-8a25-4ed8-b7ac-16445b879b1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03e69414-8a25-4ed8-b7ac-16445b879b1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03e69414-8a25-4ed8-b7ac-16445b879b1f"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitisAllergic conjunctivitis due to inhalant allergens and foodsMild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasmaCold urticariaDermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e995479-1756-5988-b5f1-61b9da04cc51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:29694306-715c-54ba-9c56-66d307dc84d7", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005271", "original_object": "allergic reaction", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd2f3f0e-1bb8-432b-bcbb-01b4f550d022", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd2f3f0e-1bb8-432b-bcbb-01b4f550d022", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd2f3f0e-1bb8-432b-bcbb-01b4f550d022"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticarial and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergen exposure, food allergen exposure", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2713ee5e-1d64-5958-aced-3f8c394b713b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:500276c9-d478-256d-e063-6294a90a6f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=500276c9-d478-256d-e063-6294a90a6f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=500276c9-d478-256d-e063-6294a90a6f13"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergen exposure, food allergen exposure", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3dd0b731-6f8a-59ee-8790-f7cb417705d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50b3abc0-d86a-e8f5-e063-6394a90ad25e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50b3abc0-d86a-e8f5-e063-6394a90ad25e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50b3abc0-d86a-e8f5-e063-6394a90ad25e"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44afa93b-a350-52dc-b4f8-6d57147df7bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c0b47c0-ecd2-450f-9dcb-c262db92866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c0b47c0-ecd2-450f-9dcb-c262db92866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c0b47c0-ecd2-450f-9dcb-c262db92866e"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f2ef5ba-59bb-5b40-8830-a95b554c4a00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc75bd79-63b7-6388-e053-6394a90ac377", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc75bd79-63b7-6388-e053-6394a90ac377", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc75bd79-63b7-6388-e053-6394a90ac377"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59e37971-8343-5c1e-9436-e0dbccc7dbfa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b28c2ca0-140d-44d8-a59e-75fbfe8eabdd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b28c2ca0-140d-44d8-a59e-75fbfe8eabdd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b28c2ca0-140d-44d8-a59e-75fbfe8eabdd"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergen sensitivity", "has_confidence_score": 0.560764, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63403926-c619-5096-a5e2-8bd2386d8bdc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.560764, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03e69414-8a25-4ed8-b7ac-16445b879b1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03e69414-8a25-4ed8-b7ac-16445b879b1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03e69414-8a25-4ed8-b7ac-16445b879b1f"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitisAllergic conjunctivitis due to inhalant allergens and foodsMild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasmaCold urticariaDermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c6218d9-adcd-5f64-ae58-bf3710f314b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22eaef18-b5cc-421a-910e-d569f00b4599", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22eaef18-b5cc-421a-910e-d569f00b4599", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22eaef18-b5cc-421a-910e-d569f00b4599"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2ee3033-d8a9-567a-bd47-bd86493184b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d668d93-8c9e-479e-ad8d-59656c8dec1b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d668d93-8c9e-479e-ad8d-59656c8dec1b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d668d93-8c9e-479e-ad8d-59656c8dec1b"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3969b47-84d5-5a85-99b4-733167532974", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6d91eae-db29-4e62-89da-1ad764de7ae1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6d91eae-db29-4e62-89da-1ad764de7ae1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6d91eae-db29-4e62-89da-1ad764de7ae1"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b71125ef-ac7b-59fe-8901-6d89f79931d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99fb821a-fe33-4468-9026-9729a8deff08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99fb821a-fe33-4468-9026-9729a8deff08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99fb821a-fe33-4468-9026-9729a8deff08"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c919fdb9-37a9-5ff8-8562-1acdd897cb25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2851bd5c-fcc8-4a7a-9be3-950ea799dee1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2851bd5c-fcc8-4a7a-9be3-950ea799dee1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2851bd5c-fcc8-4a7a-9be3-950ea799dee1"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergen exposure, food allergen exposure", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0ea1e85-a659-5734-b529-b6a4bc9dc34b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:582b86c6-f9b2-278d-e063-6394a90a923d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=582b86c6-f9b2-278d-e063-6394a90a923d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=582b86c6-f9b2-278d-e063-6394a90a923d"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergen exposure, food allergen exposure", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd96ceab-1429-50cc-817f-c1e416764373", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1acfd050-6c07-a269-e063-6394a90a77e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1acfd050-6c07-a269-e063-6394a90a77e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1acfd050-6c07-a269-e063-6394a90a77e8"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:deeb2e77-035e-54d0-acec-9c065416eaf6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dfe4478-76d9-9b8f-e063-6394a90aefe8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dfe4478-76d9-9b8f-e063-6394a90aefe8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dfe4478-76d9-9b8f-e063-6394a90aefe8"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea07d68c-2089-5bf2-8b3c-01cf2f2cded2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95c03949-0e9a-e3b5-e053-2995a90a56b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95c03949-0e9a-e3b5-e053-2995a90a56b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95c03949-0e9a-e3b5-e053-2995a90a56b6"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f640ff4f-782b-52d3-9756-cd87fe6f5f95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3aed50-cc9e-4897-9735-361225e9e5f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3aed50-cc9e-4897-9735-361225e9e5f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3aed50-cc9e-4897-9735-361225e9e5f2"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:037b3d01-c805-5877-9226-6a598ea802e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:500276c9-d478-256d-e063-6294a90a6f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=500276c9-d478-256d-e063-6294a90a6f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=500276c9-d478-256d-e063-6294a90a6f13"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a0e0d43-a146-5e24-9596-8817c36214e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99fb821a-fe33-4468-9026-9729a8deff08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99fb821a-fe33-4468-9026-9729a8deff08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99fb821a-fe33-4468-9026-9729a8deff08"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27d30c8c-ea4c-52f7-82dc-1c0ffd75c5e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50b3abc0-d86a-e8f5-e063-6394a90ad25e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50b3abc0-d86a-e8f5-e063-6394a90ad25e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50b3abc0-d86a-e8f5-e063-6394a90ad25e"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37d18068-1350-577e-a206-2575c521eb81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d668d93-8c9e-479e-ad8d-59656c8dec1b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d668d93-8c9e-479e-ad8d-59656c8dec1b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d668d93-8c9e-479e-ad8d-59656c8dec1b"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45c167c8-c221-55b6-b0a5-e078c3e0a054", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22eaef18-b5cc-421a-910e-d569f00b4599", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22eaef18-b5cc-421a-910e-d569f00b4599", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22eaef18-b5cc-421a-910e-d569f00b4599"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4fc35f28-1c0c-522c-aa38-b1ba094bee44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dfe4478-76d9-9b8f-e063-6394a90aefe8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dfe4478-76d9-9b8f-e063-6394a90aefe8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dfe4478-76d9-9b8f-e063-6394a90aefe8"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67bbd0ac-a5c0-5962-8684-0ce5769774d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:582b86c6-f9b2-278d-e063-6394a90a923d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=582b86c6-f9b2-278d-e063-6394a90a923d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=582b86c6-f9b2-278d-e063-6394a90a923d"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:824d7d4c-94ca-5ce4-bf77-f5e506e14efe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3aed50-cc9e-4897-9735-361225e9e5f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3aed50-cc9e-4897-9735-361225e9e5f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3aed50-cc9e-4897-9735-361225e9e5f2"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98863b36-0e8e-5834-8137-27c804a3643d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005841", "UMLS:C0278347"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1acfd050-6c07-a269-e063-6394a90a77e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1acfd050-6c07-a269-e063-6394a90a77e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1acfd050-6c07-a269-e063-6394a90a77e8"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5acbf92-86a8-53df-aabf-c974c5b38182", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b28c2ca0-140d-44d8-a59e-75fbfe8eabdd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b28c2ca0-140d-44d8-a59e-75fbfe8eabdd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b28c2ca0-140d-44d8-a59e-75fbfe8eabdd"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2cba3f2-db5e-5af3-bae5-8e8a0529c63f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6d91eae-db29-4e62-89da-1ad764de7ae1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6d91eae-db29-4e62-89da-1ad764de7ae1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6d91eae-db29-4e62-89da-1ad764de7ae1"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b40ab9e7-9f19-5ea5-a327-a1b0bbb1a8f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c0b47c0-ecd2-450f-9dcb-c262db92866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c0b47c0-ecd2-450f-9dcb-c262db92866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c0b47c0-ecd2-450f-9dcb-c262db92866e"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd8468e4-3e5f-5379-8824-29b885c75aa6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95c03949-0e9a-e3b5-e053-2995a90a56b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95c03949-0e9a-e3b5-e053-2995a90a56b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95c03949-0e9a-e3b5-e053-2995a90a56b6"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7c89648-f449-5760-983f-9fe3dcc23afe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc75bd79-63b7-6388-e053-6394a90ac377", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc75bd79-63b7-6388-e053-6394a90ac377", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc75bd79-63b7-6388-e053-6394a90ac377"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0005768", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1d30ed3-bfa8-5976-8ed1-66568f58c708", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005768", "UMLS:C0032105"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b1d06162-7876-520c-911d-2570d6749165", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "CYPROHEPTADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2851bd5c-fcc8-4a7a-9be3-950ea799dee1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2851bd5c-fcc8-4a7a-9be3-950ea799dee1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2851bd5c-fcc8-4a7a-9be3-950ea799dee1"]}], "subject": "CHEBI:4046", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0000817", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17d3307e-94f5-51fb-85da-807a9569f60f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0000817"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:38304441-2b7b-5ca8-a86a-dc5c34bda741", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa2e14d2-ad96-5cde-a6d1-de9385ffbd40", "medic_supporting_text_truncated": true, "object": "UMLS:C0030790", "original_object": "acute pelvic infections", "original_subject": "ERTAPENEM", "population_context_qualifier": "adult patients and pediatric patients (3 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf3cfa6b-211c-452b-b18b-e462b21e6909", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf3cfa6b-211c-452b-b18b-e462b21e6909", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf3cfa6b-211c-452b-b18b-e462b21e6909"]}], "subject": "CHEBI:404903", "supporting_text": ["1 INDICATIONS AND USAGE Ertapenem for Injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for Injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for Injection and other antibacterial drugs, Ertapenem for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.7) 1.1 Complicated Intra-Abdominal Infections Ertapenem for Injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis Ertapenem for Injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae , Streptococcus pyoge"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diabetic foot infections without osteomyelitis", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17713d6f-e3e5-5850-b6ef-c220916b3328", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011121", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa2e14d2-ad96-5cde-a6d1-de9385ffbd40", "medic_supporting_text_truncated": true, "object": "UMLS:C4552480", "object_location_in_text": [1669, 1715], "original_object": "complicated skin and skin structure infections", "original_subject": "ERTAPENEM", "population_context_qualifier": "adult patients and pediatric patients (3 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33f3b99b-fa82-42e0-26bf-f49891ae3d22", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22"]}], "subject": "CHEBI:404903", "supporting_text": ["1 INDICATIONS AND USAGE INVANZ is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. ( 1.1 ) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) Community-acquired pneumonia. ( 1.3 ) Complicated urinary tract infections including pyelonephritis. ( 1.4 ) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) INVANZ is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) 1.1 Complicated Intra-Abdominal Infections INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae , Streptococcus pyogenes , Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Bacteroides fragilis , Peptostreptococcus"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diabetic foot infections without osteomyelitis", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3439f2e0-faf6-59d2-80b1-0ff1bd93a708", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011121", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa2e14d2-ad96-5cde-a6d1-de9385ffbd40", "medic_supporting_text_truncated": true, "object": "UMLS:C4552480", "object_location_in_text": [1779, 1825], "original_object": "complicated skin and skin structure infections", "original_subject": "ERTAPENEM", "population_context_qualifier": "adult patients and pediatric patients (3 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf3cfa6b-211c-452b-b18b-e462b21e6909", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf3cfa6b-211c-452b-b18b-e462b21e6909", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf3cfa6b-211c-452b-b18b-e462b21e6909"]}], "subject": "CHEBI:404903", "supporting_text": ["1 INDICATIONS AND USAGE Ertapenem for Injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for Injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for Injection and other antibacterial drugs, Ertapenem for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.7) 1.1 Complicated Intra-Abdominal Infections Ertapenem for Injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis Ertapenem for Injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae , Streptococcus pyoge"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diabetic foot infections without osteomyelitis", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c58e05e-b2c8-5e8a-aca1-5301f7714aee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011121", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa2e14d2-ad96-5cde-a6d1-de9385ffbd40", "medic_supporting_text_truncated": true, "object": "UMLS:C4552480", "object_location_in_text": [1771, 1817], "original_object": "complicated skin and skin structure infections", "original_subject": "ERTAPENEM", "population_context_qualifier": "adult patients and pediatric patients (3 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b050245-aa03-4e28-e063-6394a90aeabc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b050245-aa03-4e28-e063-6394a90aeabc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b050245-aa03-4e28-e063-6394a90aeabc"]}], "subject": "CHEBI:404903", "supporting_text": ["1 INDICATIONS AND USAGE Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. ( 1.1 ) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) Community-acquired pneumonia. ( 1.3 ) Complicated urinary tract infections including pyelonephritis. ( 1.4 ) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) 1.1 Complicated Intra-Abdominal Infections Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae , Streptococcus pyogenes , Es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diabetic foot infections without osteomyelitis", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddf514ff-fe14-581f-9765-649e087dd626", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011121", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa2e14d2-ad96-5cde-a6d1-de9385ffbd40", "medic_supporting_text_truncated": true, "object": "UMLS:C4552480", "object_location_in_text": [1771, 1817], "original_object": "complicated skin and skin structure infections", "original_subject": "ERTAPENEM", "population_context_qualifier": "adult patients and pediatric patients (3 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:468105b9-48b3-4477-82c7-e7fb92460e28", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=468105b9-48b3-4477-82c7-e7fb92460e28", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=468105b9-48b3-4477-82c7-e7fb92460e28"]}], "subject": "CHEBI:404903", "supporting_text": ["1 INDICATIONS AND USAGE Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. ( 1.1 ) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) Community-acquired pneumonia. ( 1.3 ) Complicated urinary tract infections including pyelonephritis. ( 1.4 ) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) 1.1 Complicated Intra-Abdominal Infections Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae , Streptococcus pyogenes , Es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "reduction of breast cancer incidence in high-risk patients, risk reduction of invasive breast cancer after treatment of DCIS", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeb4849b-67ff-5db4-8695-a81d2cab97b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:86587b97-88c4-598d-9bd6-e905a4cd7807", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae9a18f2-40a3-5022-bdef-b9638d48d89b", "object": "HP:0002625", "original_object": "deep vein thrombosis", "original_subject": "TAMOXIFEN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e6ff055-590c-41e6-9530-1fdf04cdbd02", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02"]}], "subject": "CHEBI:41774", "supporting_text": ["4 CONTRAINDICATIONS SOLTAMOX is contraindicated in patients with known hypersensitivity (e.g., angioedema, serious skin reactions) to tamoxifen or any other SOLTAMOX ingredient [see Adverse Reactions (6.2) ] . SOLTAMOX is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ]. Known hypersensitivity to tamoxifen or any other SOLTAMOX ingredient ( 4 ) In patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus, if the indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "reduction of breast cancer incidence in high-risk patients, risk reduction of invasive breast cancer after treatment of DCIS", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e60e6a2-115a-57cc-b92c-5895de791de1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c077bb86-125c-593c-a201-779e0766e19e", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae9a18f2-40a3-5022-bdef-b9638d48d89b", "object": "MONDO:0005279", "object_location_in_text": [336, 353], "original_object": "pulmonary embolus", "original_subject": "TAMOXIFEN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e6ff055-590c-41e6-9530-1fdf04cdbd02", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02"]}], "subject": "CHEBI:41774", "supporting_text": ["4 CONTRAINDICATIONS SOLTAMOX is contraindicated in patients with known hypersensitivity (e.g., angioedema, serious skin reactions) to tamoxifen or any other SOLTAMOX ingredient [see Adverse Reactions (6.2) ] . SOLTAMOX is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ]. Known hypersensitivity to tamoxifen or any other SOLTAMOX ingredient ( 4 ) In patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus, if the indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "high risk for breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d0de228-2f4d-5add-a657-f7c596944040", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae9a18f2-40a3-5022-bdef-b9638d48d89b", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [96, 109], "original_object": "breast cancer", "original_subject": "TAMOXIFEN", "population_context_qualifier": "women at high risk for breast cancer", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:151ce76c-2d44-4c82-850d-ab213bea4d6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b"]}], "subject": "CHEBI:41774", "supporting_text": ["Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. Adjuvant Treatment of Breast Cancer Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. Tamoxifen reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen therapy for breast cancer. Ductal Carcinoma in Situ (DCIS) In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support 5 years of adjuvant tamoxifen therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fc8eb89-0546-585e-8371-9b899773499a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae9a18f2-40a3-5022-bdef-b9638d48d89b", "medic_supporting_text_truncated": true, "object": "UMLS:C0278488", "object_location_in_text": [91, 115], "original_object": "metastatic breast cancer", "original_subject": "TAMOXIFEN", "population_context_qualifier": "premenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb53eeb7-83fc-469e-b9e3-df5f27bfec7b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb53eeb7-83fc-469e-b9e3-df5f27bfec7b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb53eeb7-83fc-469e-b9e3-df5f27bfec7b"]}], "subject": "CHEBI:41774", "supporting_text": ["Metastatic Breast Cancer: Tamoxifen citrate tablets, USP are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. Adjuvant Treatment of Breast Cancer: Tamoxifen citrate tablets, USP are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets, USP are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. Tamoxifen reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen therapy for breast cancer. Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support 5 years of adjuvant tamoxifen therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women: Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0279754", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bdc2ca6-006b-5c97-be6f-5c764dba107b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0279754"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae9a18f2-40a3-5022-bdef-b9638d48d89b", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "TAMOXIFEN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e6ff055-590c-41e6-9530-1fdf04cdbd02", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e6ff055-590c-41e6-9530-1fdf04cdbd02"]}], "subject": "CHEBI:41774", "supporting_text": ["1 INDICATIONS AND USAGE SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 ) For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer ( 1.2 ) To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS) ( 1.3 ) To reduce the incidence of breast cancer in adult women at high risk ( 1.4 ) 1.1 Metastatic Breast Cancer SOLTAMOX is indicated for the treatment of adult patients with estrogen receptor-positive metastatic breast cancer. 1.2 Adjuvant Treatment of Breast Cancer SOLTAMOX is indicated: for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer to reduce the occurrence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer. 1.3 Ductal Carcinoma in Situ In adult women with DCIS, following breast surgery and radiation, SOLTAMOX is indicated to reduce the risk of invasive breast cancer [see Boxed Warning and Clinical Studies (14.3) ] . 1.4 Reduction in Breast Cancer Incidence in Women at High Risk SOLTAMOX is indicated to reduce the incidence of breast cancer in adult women at high risk for breast cancer. [see Boxed Warning and Clinical Studies (14.4) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d725a5ab-947d-5c66-b88e-3ff73ba9cba4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae9a18f2-40a3-5022-bdef-b9638d48d89b", "medic_supporting_text_truncated": true, "object": "UMLS:C0278488", "object_location_in_text": [85, 109], "original_object": "metastatic breast cancer", "original_subject": "TAMOXIFEN", "population_context_qualifier": "premenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6c6a643-57d6-7ea5-7da0-e8a66802468a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6c6a643-57d6-7ea5-7da0-e8a66802468a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6c6a643-57d6-7ea5-7da0-e8a66802468a"]}], "subject": "CHEBI:41774", "supporting_text": ["Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. Adjuvant Treatment of Breast Cancer Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. Tamoxifen reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen therapy for breast cancer. Ductal Carcinoma in Situ (DCIS) In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support 5 years of adjuvant tamoxifen therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02436299-fd40-5505-894e-14b74351e3b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "HP:0000969", "object_location_in_text": [511, 516], "original_object": "edema", "original_subject": "DEXAMETHASONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae"]}], "subject": "CHEBI:41879", "supporting_text": [": Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23eda123-c60d-5b6d-a9c3-af2ea72ad03b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "HP:0000969", "object_location_in_text": [435, 440], "original_object": "edema", "original_subject": "DEXAMETHASONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83"]}], "subject": "CHEBI:41879", "supporting_text": ["For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae , Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . This product does not provide adequate coverage against: Serratia marcescens and S treptococci , including Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5af3e747-7ef7-5d2f-b33d-cb2f85287d6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "UMLS:C0021368", "object_location_in_text": [521, 533], "original_object": "inflammation", "original_subject": "DEXAMETHASONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae"]}], "subject": "CHEBI:41879", "supporting_text": [": Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6f9cded-07da-5371-ae4c-e20eb5b515b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "UMLS:C0021368", "object_location_in_text": [445, 457], "original_object": "inflammation", "original_subject": "DEXAMETHASONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83"]}], "subject": "CHEBI:41879", "supporting_text": ["For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae , Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . This product does not provide adequate coverage against: Serratia marcescens and S treptococci , including Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0020165", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86ea13bc-f453-5f45-b049-ed69c0a09ee6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100726", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0020165", "MONDO:0002303"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1ce954c0-1dbd-5133-9ad5-5fece1ce7448", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "HP:0040049", "object_location_in_text": [62, 76], "original_object": "macular oedema", "original_subject": "dexamethasone", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ozurdex", "https://www.ema.europa.eu/en/documents/product-information/ozurdex-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex"]}], "subject": "CHEBI:41879", "supporting_text": ["Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO). Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis. Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy."], "temporal_context_qualifier": "following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0020165", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:daf145ad-fbde-50fc-a932-8540a06d19b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0020165", "MONDO:0002303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:26c4951a-3944-5d92-ac45-19c9d0513de4", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "MONDO:0003005", "object_location_in_text": [84, 97], "original_object": "macular edema", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b204f44-6e8a-4d17-803c-268f0b04679f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b204f44-6e8a-4d17-803c-268f0b04679f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b204f44-6e8a-4d17-803c-268f0b04679f"]}], "subject": "CHEBI:41879", "supporting_text": ["1 INDICATIONS AND USAGE OZURDEX is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) 1.1 Retinal Vein Occlusion OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). 1.2 Posterior Segment Uveitis OZURDEX is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. 1.3 Diabetic Macular Edema OZURDEX is indicated for the treatment of diabetic macular edema."], "temporal_context_qualifier": "following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3331732a-dd1b-533e-bddb-081815664b49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [133, 139], "original_object": "asthma", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:702094bd-2d84-5b4b-b37c-da1374cd3091", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [133, 139], "original_object": "asthma", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Beryllio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d60457bf-021c-5ccd-851e-c938502d263d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:622b5bbc-9b53-5f84-81e2-4e499dfc0011", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "original_object": "bronchial asthma", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, and Nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis, and Regional enteritis. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), and Congenital (erythroid) hypoplastic anemia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, and Trichinosis with neurologic or myocardial involvement. Neoplastic Diseases For palliative management of: Leukemia and lymphomas in adults, and Acute leukemia of childhood. Ophthalmic Diseases Severe acute and chronic allergic and infla"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0053e58b-6fda-5289-9f0a-5b6d0ff59918", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [141, 158], "original_object": "atopic dermatitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:543fa91b-c6af-5660-a5ca-66b66339bcb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [141, 158], "original_object": "atopic dermatitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Beryllio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a25275fa-9572-53ac-9b6c-7212d704e3f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "original_object": "atopic dermatitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, and Nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis, and Regional enteritis. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), and Congenital (erythroid) hypoplastic anemia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, and Trichinosis with neurologic or myocardial involvement. Neoplastic Diseases For palliative management of: Leukemia and lymphomas in adults, and Acute leukemia of childhood. Ophthalmic Diseases Severe acute and chronic allergic and infla"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:323c39ee-204c-50ce-8410-c2c73feb3256", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "original_object": "contact dermatitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, and Nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis, and Regional enteritis. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), and Congenital (erythroid) hypoplastic anemia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, and Trichinosis with neurologic or myocardial involvement. Neoplastic Diseases For palliative management of: Leukemia and lymphomas in adults, and Acute leukemia of childhood. Ophthalmic Diseases Severe acute and chronic allergic and infla"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f0d504e-7de8-59f5-823f-a91a2c90f8fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [160, 178], "original_object": "contact dermatitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ae5f767-55f0-5012-b213-bbf6e3af178f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [160, 178], "original_object": "contact dermatitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Beryllio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd4abbb4-22d0-5230-b1fe-30810f5f923b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1333, 1355], "original_object": "tuberculous meningitis", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Beryllio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93df75de-ad94-5142-9ffd-16387a0768d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [257, 271], "original_object": "serum sickness", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a41e6e26-9ebb-4b06-866e-a24af21c644c"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Beryllio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc8e0bfd-be36-5675-ae41-35998c08572e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [258, 272], "original_object": "serum sickness", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a37486b9-4323-41fc-ac7e-869d95dc9568"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee3fb020-dbc4-5b34-b904-4d1519c32a98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "original_object": "serum sickness", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075717e3-be2a-4bb3-bead-492761bfb287"]}], "subject": "CHEBI:41879", "supporting_text": ["Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, and Nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis, and Regional enteritis. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), and Congenital (erythroid) hypoplastic anemia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, and Trichinosis with neurologic or myocardial involvement. Neoplastic Diseases For palliative management of: Leukemia and lymphomas in adults, and Acute leukemia of childhood. Ophthalmic Diseases Severe acute and chronic allergic and infla"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemical, radiation or thermal burns, or penetration of foreign bodies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab037148-3e7e-5f96-99e0-16039bccfe7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4647225-c122-5c93-85c6-0ee0fd6baed9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:005f05fa-b1a6-5258-be02-faa519528c80", "object": "UMLS:C0339289", "object_location_in_text": [591, 605], "original_object": "corneal injury", "original_subject": "DEXAMETHASONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05fd0c36-39b4-4a43-8490-eb8dfc0920ae"]}], "subject": "CHEBI:41879", "supporting_text": [": Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4725671", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22c0bef5-281c-5767-8fac-ed45588b7792", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901128", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C4725671"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:db539975-ba6f-5caa-8839-cdd1d9465456", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fb6b6626-4583-5a08-8a40-f62f343ad3f0", "object": "UMLS:C4725671", "original_object": "high-risk neuroblastoma", "original_subject": "EFLORNITHINE", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6716d8cc-66e6-4cee-935c-ccb85ed984f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6716d8cc-66e6-4cee-935c-ccb85ed984f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6716d8cc-66e6-4cee-935c-ccb85ed984f5"]}], "subject": "CHEBI:41948", "supporting_text": ["1 INDICATIONS AND USAGE IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. IWILFIN is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. ( 1 )"], "temporal_context_qualifier": "who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "myelodysplasia-related changes", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b77c62d0-a86f-5f2a-8fb7-46b11cbdee7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180823", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cc457604-6c69-5573-a8ab-21fa1621630d", "object": "HP:0004808", "object_location_in_text": [96, 119], "original_object": "acute myeloid leukaemia", "original_subject": "daunorubicin;cytarabine", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vyxeos-liposomal", "https://www.ema.europa.eu/en/documents/product-information/vyxeos-liposomal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal"]}], "subject": "CHEBI:41977", "supporting_text": ["Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blast crisis of chronic myeloid leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:732472ba-a5b2-5544-beaf-ac6ba5678aea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:339f0029-196c-5efd-948d-249d6e885188", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3e1330a0-eb16-5043-8d02-cb94daf3faca", "object": "MONDO:0010643", "object_location_in_text": [56, 70], "original_object": "acute leukemia", "original_subject": "DAUNORUBICIN HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DAUNORUBICIN HYDROCHLORIDE#64-20210224", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:41977", "supporting_text": ["A drug with a new dosage indicated for the treatment of acute leukemia (including blast crisis of chronic myeloid leukemia). [Public knowledge-based application]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "French-American-British (FAB) classifications M1 through M7", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15bf46ee-dd73-5baf-b853-efe896bc7723", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900927", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["other approved antileukemic drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6a8f90e8-0d1c-5b02-afda-a477bdc65678", "object": "MONDO:0018874", "original_object": "acute myeloid leukemia", "original_subject": "IDARUBICIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9b337d5-50f7-4ea9-9df4-72c86e4c0b91", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9b337d5-50f7-4ea9-9df4-72c86e4c0b91", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9b337d5-50f7-4ea9-9df4-72c86e4c0b91"]}], "subject": "CHEBI:42068", "supporting_text": ["Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "French-American-British (FAB) classifications M1 through M7", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b8ec662-6dd5-5d48-8bcb-a72b237701d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900927", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["other approved antileukemic drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6a8f90e8-0d1c-5b02-afda-a477bdc65678", "object": "MONDO:0018874", "original_object": "acute myeloid leukemia", "original_subject": "IDARUBICIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c20b574-285b-49eb-a98e-6752e4bb481d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c20b574-285b-49eb-a98e-6752e4bb481d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c20b574-285b-49eb-a98e-6752e4bb481d"]}], "subject": "CHEBI:42068", "supporting_text": ["Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000958", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18ae33a2-f6f6-5306-9d3d-82fd876a2318", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000958", "MONDO:0024304"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c11f6ff-5e52-5c9f-890d-cc4d64b15931", "object": "HP:0000989", "object_location_in_text": [135, 142], "original_object": "itching", "original_subject": "LACTIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34d21510-062e-40ab-b074-ae3a0dc65e68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34d21510-062e-40ab-b074-ae3a0dc65e68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34d21510-062e-40ab-b074-ae3a0dc65e68"]}], "subject": "CHEBI:42111", "supporting_text": ["Ammonium Lactate Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N. gonorrhoeae, C. trachomatis", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3a3a6d1-6f3f-52c0-a59c-2593368f8933", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:78c1a3df-66e1-526d-a5f2-2cf5d80258bc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "object": "MONDO:0004854", "object_location_in_text": [161, 182], "original_object": "ophthalmia neonatorum", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "infants", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd708a-9238-fea1-e063-6394a90a37b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd708a-9238-fea1-e063-6394a90a37b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd708a-9238-fea1-e063-6394a90a37b1"]}], "subject": "CHEBI:42355", "supporting_text": [": For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "penicillinase-producing N. gonorrhoeae", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63946f7a-ae30-5ed6-9d8b-948886b834cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25bb2db9-2ed1-5b6d-9c30-15e14b8fe7c0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "object": "MONDO:0016047", "object_location_in_text": [161, 171], "original_object": "ophthalmia", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "infants born to mothers with clinically apparent gonorrhea", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd708a-9238-fea1-e063-6394a90a37b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd708a-9238-fea1-e063-6394a90a37b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd708a-9238-fea1-e063-6394a90a37b1"]}], "subject": "CHEBI:42355", "supporting_text": [": For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79d715bb-3d0a-5080-85f7-1c4495156fbe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038411", "UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c78f547-338b-561b-8380-bb188dfcda3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04775721-ab87-4b66-808c-d67a21032385"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma In the treatment of infections due to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23a6cfad-2a46-561e-8255-5461fbfb8efc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "patients with mild to moderate degree infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31f6fa6d-ab91-5761-84c8-7eafb2eeabd5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3645203c-fd56-54cd-8971-21bc594288f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038411", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60d7d694-d4f4-5270-a260-e93a927bd092", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0038411", "UMLS:C0038410", "UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6efc9b95-c544-52fa-b18f-bd910c722126", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Syphilis caused by Treponema pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aaf028a2-8a64-50c5-96e5-2df794131d66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets, USP and other antibacterial drugs, erythromycin ethylsuccinate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets, USP are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by S treptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.9025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3f3ebba-7ace-5554-87e4-eb8a5343ab92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.9025, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "object_location_in_text": [747, 781], "original_object": "Upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "mild to moderate degree", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0554628", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0b830c3-f1a6-5865-aabf-c73014748fb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["sulfonamides"], "medic_disease_context_ids": ["UMLS:C0554628", "MONDO:0005114", "UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14dc67f6-7ae7-5270-8391-114ddbdf2f76", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d27eecc-d296-54ea-b588-04a99811d802", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e8d9e34-9433-53e7-a7f5-02f3d84123ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010154", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54357eaa-60b6-5575-b6f0-bcb1fba04110", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010154"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:835ad815-6585-5fb3-b880-017279d0c0d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "Erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87e0a0ee-3cdb-5b5f-9de1-b19625d2302f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04775721-ab87-4b66-808c-d67a21032385"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma In the treatment of infections due to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97519936-e151-5023-82b4-9535ce3395ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets, USP and other antibacterial drugs, erythromycin ethylsuccinate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets, USP are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by S treptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba93079b-4163-58ab-9abf-dd551893d538", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0948946", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc922762-8010-5234-90dd-0f3558ae4b6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0948946"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d760b431-8df8-5481-abeb-f6856e7951dc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0002885", "original_object": "erythrasma", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Syphilis caused by Treponema pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010150", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55474db3-d346-5478-969e-9b75851e999e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["antitoxin"], "medic_disease_context_ids": ["UMLS:C0010150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89c1bbfc-8d8f-5c69-b935-96e95b1d82b1", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0005504", "original_object": "diphtheria", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0023861", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebb84e2d-18d5-56b5-a3f7-cfe62620db04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0023861"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0d90fba9-4cdc-5a9b-84c8-66eea9d370da", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0005828", "original_object": "listeriosis", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c83e197-82c6-5b10-b67b-a1072f0b85d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Syphilis caused by Treponema pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10e1353d-202d-5749-85eb-0d12d0c27ce2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "oral erythromycins only", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets, USP and other antibacterial drugs, erythromycin ethylsuccinate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets, USP are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by S treptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014323", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d2c9711-0b90-5f65-a3e8-e701efe41b03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014323"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:735ba183-9abc-5d0c-9220-98492838fc40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "oral erythromycins only", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:756cecf8-6289-574f-9b2f-db5e64c04104", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "oral formulation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04775721-ab87-4b66-808c-d67a21032385"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma In the treatment of infections due to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0a7e186-f709-537a-92ae-ed3716c91f49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6601173-7956-559b-9eb4-e7cde3e35ca5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "oral formulation users", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9a48699-defc-51c7-b91d-c063f4eb3127", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "Intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f390a909-da90-5e5a-9379-8c0e77cbadb3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "original_object": "intestinal amebiasis", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "oral erythromycins only", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39780af9-c650-5bd0-bfc6-c66f792a97b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60d1aea0-f106-4b20-8ef4-7a80e37f8a50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60d1aea0-f106-4b20-8ef4-7a80e37f8a50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60d1aea0-f106-4b20-8ef4-7a80e37f8a50"]}], "subject": "CHEBI:42355", "supporting_text": [": For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81225, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:774601ee-d4df-533a-a095-1e43851b3d17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.81225, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb6ea746-3228-4969-8a26-653288662fd7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb6ea746-3228-4969-8a26-653288662fd7"]}], "subject": "CHEBI:42355", "supporting_text": [": For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b9a1719-6f8f-58a8-9b4c-878067f3e049", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d9eb7cb-0b11-4f6e-8a9c-1bcff37fe0b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d9eb7cb-0b11-4f6e-8a9c-1bcff37fe0b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d9eb7cb-0b11-4f6e-8a9c-1bcff37fe0b5"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to preven"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e26bd9a-9629-5ea9-a90a-efcd26b23b5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6f9565b-6d9d-40e3-87f8-9f38ede9173a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6f9565b-6d9d-40e3-87f8-9f38ede9173a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6f9565b-6d9d-40e3-87f8-9f38ede9173a"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H . influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin lactobionate for injection, USP followed by erythromycin stearate or erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N . gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhea, patients who are suspected of also having syphilis should have a microscopic examination for T . pallidum (by i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ce3e818-abb8-522a-9946-68e584b38d90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b455bbdb-a3f1-470f-aa5f-ed83ac2e228d"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:485e9a04-e6c8-5f3e-9b83-1750f6414387", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5097cf40-983b-52db-83e2-e42e3c01bc36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91479d92-3bf3-4eb3-81bd-8ce4956d4347"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:521d5e7e-2deb-59d4-96ec-47b28761bce6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb641ed4-8093-4e15-9cb9-8921b1093d50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb641ed4-8093-4e15-9cb9-8921b1093d50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb641ed4-8093-4e15-9cb9-8921b1093d50"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release tablets and other antibacterial drugs, erythromycin delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin delayed-release tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carrier"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fcfa09f-0bb2-50ce-bc7e-7c3825792e6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78139f33-0965-4bbb-a53f-6d7fd4fa9a81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78139f33-0965-4bbb-a53f-6d7fd4fa9a81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78139f33-0965-4bbb-a53f-6d7fd4fa9a81"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to preven"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66ec1baa-b8f4-5d9e-bbeb-6d0abf50a1b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d80f96e-3bbe-4fa5-89a8-694c61dd5e8f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ec591da-55cc-5f1f-89c7-f854231a373f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2dcb48a-212c-1b0c-ec35-ee2ade85847f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2dcb48a-212c-1b0c-ec35-ee2ade85847f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2dcb48a-212c-1b0c-ec35-ee2ade85847f"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria e, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Syphilis caused by Treponema pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoea e: Erythromycin lacto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78539e36-4e1a-59d5-a281-7296f75bb961", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7f7faaf-dc05-4d51-86c6-bf5d61562e48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7f7faaf-dc05-4d51-86c6-bf5d61562e48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7f7faaf-dc05-4d51-86c6-bf5d61562e48"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to preven"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8468d99a-1ea2-5c71-9cc3-2e873a40a669", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db70798e-5e07-41d6-afe9-82c272bc5cc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db70798e-5e07-41d6-afe9-82c272bc5cc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db70798e-5e07-41d6-afe9-82c272bc5cc0"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to preven"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026941", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:972de048-1090-5d17-9dca-b9d53d27cace", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0026941"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca65a48f-5fe6-4b31-8359-51dbc31f6d4e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca65a48f-5fe6-4b31-8359-51dbc31f6d4e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca65a48f-5fe6-4b31-8359-51dbc31f6d4e"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H . influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin lactobionate for injection, USP followed by erythromycin stearate or erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N . gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhea, patients who are suspected of also having syphilis should have a microscopic examination for T .pallidum (by im"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bb76195-14b6-5043-80fa-d3d151781d00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49b3ca93-43cc-439c-8f5d-e3ea2e87ad2f"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of E.E.S. and other antibacterial drugs, E.E.S. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3c70c95-9252-5c6b-88c6-4048facbaef8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04775721-ab87-4b66-808c-d67a21032385"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma In the treatment of infections due to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abd0c7f2-ff30-5769-81e6-3fd0a23a9142", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddd9ad9a-fc60-409a-a2b3-be51482ef751"]}], "subject": "CHEBI:42355", "supporting_text": ["Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Syphilis caused by Treponema pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb133b36-b5ba-5619-89cb-aec13f6e2d3a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23a0564e-dca9-41bc-b2c7-0461169f65f9"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets, USP and other antibacterial drugs, erythromycin ethylsuccinate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets, USP are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by S treptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2de3375-b8df-5265-9d66-e75b5f652771", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4a3fffd-ce02-450f-bbcc-d425374e3e32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4a3fffd-ce02-450f-bbcc-d425374e3e32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4a3fffd-ce02-450f-bbcc-d425374e3e32"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erythromycin Ethylsuccinate and other antibacterial drugs, Erythromycin Ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin Ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenza e are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d865844a-8425-53ed-af8d-d1a679b60ba1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [1631, 1659], "original_object": "Respiratory tract infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3de1e0b9-473b-44c0-a644-5fa14ad69a83"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate for oral suspension USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027573", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e50c095d-bfc5-514c-ac56-99490081b650", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027573"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:07790c0e-8013-5606-adb6-2200fba09373", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0149959", "original_object": "acute pelvic inflammatory disease", "original_subject": "ERYTHROMYCIN", "population_context_qualifier": "female patients with a history of sensitivity to penicillin", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c05e1f7-a3d4-8e69-e063-6394a90aecc3"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, USP and other antibacterial drugs, erythromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablet, USP are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.57, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a06f2eb-53ef-5100-bb79-e51fb960007d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9e19032-20b9-53fa-908e-10e17bc749d8", "medic_pair_confidence": 0.57, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:034364a2-a4d3-56d8-abd5-8b49173f0841", "medic_supporting_text_truncated": true, "object": "UMLS:C0518948", "original_object": "Chlamydia trachomatis infections", "original_subject": "ERYTHROMYCIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04775721-ab87-4b66-808c-d67a21032385", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04775721-ab87-4b66-808c-d67a21032385"]}], "subject": "CHEBI:42355", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma In the treatment of infections due to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0877267", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be4d2fab-4353-5fb8-8ffd-38dccbfdcbc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110817", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0877267", "MONDO:0005906"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:52f3abaf-46f4-5e2b-bf96-4f1ca9dd95f4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bf588eff-ec25-515a-a505-d9356d767325", "object": "MONDO:0001039", "object_location_in_text": [83, 94], "original_object": "tonsillitis", "original_subject": "SITAFLOXACIN HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SITAFLOXACIN HYDRATE#148-20110817", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:4304", "supporting_text": ["Drugs with a new dosage indicated for the treatment of pharyngitis and laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis, and jaw inflammation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "angioedema of all types (cutaneous, abdominal, laryngeal)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8419fecc-2859-5b61-90ab-0fae1bb577c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba71935d-291b-500e-a659-46d70a35b26a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7fe4264d-e62b-53bc-8d3b-6bf1bb909207", "object": "MONDO:0019623", "original_object": "hereditary angioedema", "original_subject": "DANAZOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:35a21f89-cf5f-4e8b-8400-3ef7023bc49c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=35a21f89-cf5f-4e8b-8400-3ef7023bc49c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=35a21f89-cf5f-4e8b-8400-3ef7023bc49c"]}], "subject": "CHEBI:4315", "supporting_text": ["Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1fb4b49b-cd90-5596-864d-bc953d853066", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d018cbb-21b2-5f63-e063-6394a90aadc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d018cbb-21b2-5f63-e063-6394a90aadc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d018cbb-21b2-5f63-e063-6394a90aadc3"]}], "subject": "CHEBI:4325", "supporting_text": ["INDICATIONS &amp; USAGE Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30d8a0f5-dbaf-5856-a0e9-a52c0368d504", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58e7b363-99fb-4225-8df1-db2114d74928", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58e7b363-99fb-4225-8df1-db2114d74928", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58e7b363-99fb-4225-8df1-db2114d74928"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42ce542e-406c-51c0-9551-2f8aa8e81309", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2b87248b-66df-70ac-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2b87248b-66df-70ac-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b87248b-66df-70ac-e054-00144ff8d46c"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c731852-1277-570a-8062-bced9f547288", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:459c00e0-2124-8965-e063-6294a90a4278", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=459c00e0-2124-8965-e063-6294a90a4278", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=459c00e0-2124-8965-e063-6294a90a4278"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f94a0b3-86ea-5cd1-a8b4-85e10248496f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93028aff-54f0-4f94-b925-a91400118294", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93028aff-54f0-4f94-b925-a91400118294", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93028aff-54f0-4f94-b925-a91400118294"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e013f1d-5fdb-517f-aa22-364ac90dde5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d97e6985-b508-43c0-8c1f-6dfe9cc8a528", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d97e6985-b508-43c0-8c1f-6dfe9cc8a528", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d97e6985-b508-43c0-8c1f-6dfe9cc8a528"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f223f4b-3c82-5a21-a9ec-b2bead62d552", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6c2159ce-5ef2-418c-bb14-e58f55438f80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6c2159ce-5ef2-418c-bb14-e58f55438f80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c2159ce-5ef2-418c-bb14-e58f55438f80"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f8f7676-1f98-5d51-9204-ee049f3a44f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fa58b58-f588-4a0e-9e49-0f687bc294c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fa58b58-f588-4a0e-9e49-0f687bc294c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fa58b58-f588-4a0e-9e49-0f687bc294c9"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:917dadb8-6f89-5e7b-b8b3-880ba3032b42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d317576-5edd-4c27-a00d-68b5944c04a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d317576-5edd-4c27-a00d-68b5944c04a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d317576-5edd-4c27-a00d-68b5944c04a8"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5904f79-00ca-5191-9f2a-d768c66a9223", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:839d7440-ba0e-4c56-b648-d374b155cf03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=839d7440-ba0e-4c56-b648-d374b155cf03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=839d7440-ba0e-4c56-b648-d374b155cf03"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa763403-f142-5a3b-aad1-e52caca19c89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13777ba5-17f0-4364-a754-af12514abbb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13777ba5-17f0-4364-a754-af12514abbb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13777ba5-17f0-4364-a754-af12514abbb0"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0763efd-d2b8-5f01-91af-a846234bef4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d3fc4934-d48b-4a29-9022-0c82bbdad399", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d3fc4934-d48b-4a29-9022-0c82bbdad399", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d3fc4934-d48b-4a29-9022-0c82bbdad399"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d81815d3-a9c8-50f2-9795-b5221b3b1e24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e369b26d-219a-4e23-b8d4-f94048d36acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e369b26d-219a-4e23-b8d4-f94048d36acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e369b26d-219a-4e23-b8d4-f94048d36acd"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd11bdf4-5ad5-5393-882b-cc5e322ba8dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d026bb6-05da-e9cf-e063-6394a90a2485", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d026bb6-05da-e9cf-e063-6394a90a2485", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d026bb6-05da-e9cf-e063-6394a90a2485"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfb1e298-1298-56fb-98ea-d6a9c24b910e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50204029-4c29-5b8d-e063-6394a90af383", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50204029-4c29-5b8d-e063-6394a90af383", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50204029-4c29-5b8d-e063-6394a90af383"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfd9454b-76d0-56fc-8091-c631e6ea9366", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13002250-b4c5-5890-e063-6394a90a2036", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13002250-b4c5-5890-e063-6394a90a2036", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13002250-b4c5-5890-e063-6394a90a2036"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee1fefe5-2774-59c2-822e-a417cc480dfc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:20e8ca55-513e-8935-e063-6394a90a11cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=20e8ca55-513e-8935-e063-6394a90a11cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=20e8ca55-513e-8935-e063-6394a90a11cd"]}], "subject": "CHEBI:4325", "supporting_text": ["INDICATIONS &amp; USAGE Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3a286cc-6bfa-5e55-9795-9d97dcb6934f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb312185-b9f1-4fa4-9481-bcf5d9bb3edf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb312185-b9f1-4fa4-9481-bcf5d9bb3edf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb312185-b9f1-4fa4-9481-bcf5d9bb3edf"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Dapsone resistance", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd7748af-f2b6-59e2-97f3-82c77adc1f41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cb5f2b39-0895-54c1-a810-1dbcd31ba836", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a498d4e-2ec7-5a2f-b93d-6302afc57132", "object": "MONDO:0005124", "original_object": "leprosy", "original_subject": "DAPSONE", "population_context_qualifier": "all forms except for cases of proven Dapsone resistance", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9cfe5fe7-abc7-4f48-a597-1b1a5c70a354", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9cfe5fe7-abc7-4f48-a597-1b1a5c70a354", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9cfe5fe7-abc7-4f48-a597-1b1a5c70a354"]}], "subject": "CHEBI:4325", "supporting_text": ["Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f099085-93d6-5800-9fdc-6b403b9b99a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "HP:0002315", "original_object": "headache", "original_subject": "IBUPROFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114"]}], "subject": "CHEBI:43415", "supporting_text": ["Uses temporarily: • reduces fever • relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:535e8126-812f-5d0a-9a09-238c45ca649d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:582872c5-180c-5e54-862e-aed1a7020add", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "MONDO:0002258", "original_object": "pharyngitis", "original_subject": "IBUPROFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114"]}], "subject": "CHEBI:43415", "supporting_text": ["Uses temporarily: • reduces fever • relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3376791f-7846-5a20-a274-d9a0afdd8169", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "MONDO:0005709", "object_location_in_text": [78, 89], "original_object": "common cold", "original_subject": "IBUPROFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114"]}], "subject": "CHEBI:43415", "supporting_text": ["Uses temporarily: • reduces fever • relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81f729e6-99c8-5c8d-aab6-7448c17f10d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b0bc1e0-1cbf-58cd-b2ed-4dab3857fea8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "MONDO:0005812", "original_object": "influenza", "original_subject": "IBUPROFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114"]}], "subject": "CHEBI:43415", "supporting_text": ["Uses temporarily: • reduces fever • relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic PDA", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3e82feb-808d-5453-8a1b-0f387b6e45cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d09aeaa6-1ee8-5e4d-ab06-3c8efb04c523", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "MONDO:0011827", "original_object": "patent ductus arteriosus", "original_subject": "IBUPROFEN", "population_context_qualifier": "premature infants weighing between 500 and 1500 g, no more than 32 weeks gestational age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f5ede6f-b0b7-4fc8-969e-652f60ead047", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f5ede6f-b0b7-4fc8-969e-652f60ead047", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f5ede6f-b0b7-4fc8-969e-652f60ead047"]}], "subject": "CHEBI:43415", "supporting_text": ["1 INDICATIONS AND USAGE NeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. NeoProfen is a nonsteroidal anti-inflammatory drug indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27916d08-6952-52a2-8ee4-856bb2d400e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ce5a485-7af9-58c5-8c1d-3902190e339d", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "UMLS:C0040460", "original_object": "toothache", "original_subject": "IBUPROFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cfdcd94-95cb-4447-a14b-cdb49a1e3114"]}], "subject": "CHEBI:43415", "supporting_text": ["Uses temporarily: • reduces fever • relieves minor aches and pains due to the common cold, flu, sore throat, headaches and toothaches"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transfusion-dependent anemias", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7f611c7-babc-5b44-b5dc-bf4bce1d95c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c444e2c0-e4c8-5309-9dfa-19f29f5b6885", "object": "UMLS:C1739382", "object_location_in_text": [131, 152], "original_object": "chronic iron overload", "original_subject": "DEFEROXAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72348776-4971-bc49-8b66-67a2422567d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72348776-4971-bc49-8b66-67a2422567d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72348776-4971-bc49-8b66-67a2422567d4"]}], "subject": "CHEBI:4356", "supporting_text": ["INDICATIONS &amp; USAGE Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48addab1-049c-5e75-bc2d-6fbe4e9d2d7a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005044", "object_location_in_text": [127, 139], "original_object": "hypertension", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34ebeea1-6812-4697-84c4-b2ae4f39e55f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34ebeea1-6812-4697-84c4-b2ae4f39e55f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34ebeea1-6812-4697-84c4-b2ae4f39e55f"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablets USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is gre"], "temporal_context_qualifier": "fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3216fbe-d52b-58e1-baa5-dd3f71f69bce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005044", "object_location_in_text": [127, 139], "original_object": "hypertension", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa5d68e7-c2b9-41eb-ade4-2cd57edc1533", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa5d68e7-c2b9-41eb-ade4-2cd57edc1533", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa5d68e7-c2b9-41eb-ade4-2cd57edc1533"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablets USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is gre"], "temporal_context_qualifier": "fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04319296-9694-5450-beb2-039ba49b1917", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [568, 590], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42f49299-7ae5-4d30-86eb-66b739c0e95d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42f49299-7ae5-4d30-86eb-66b739c0e95d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42f49299-7ae5-4d30-86eb-66b739c0e95d"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0843c7a7-365f-5843-ad44-bdc3f339b146", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e6364a4-6d66-4151-8197-d45e2a762895", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e6364a4-6d66-4151-8197-d45e2a762895", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e6364a4-6d66-4151-8197-d45e2a762895"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1790bac7-6483-5178-a5a7-f85d5bab2651", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:764d51bf-731f-4a37-8e30-e79328cf5a12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=764d51bf-731f-4a37-8e30-e79328cf5a12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=764d51bf-731f-4a37-8e30-e79328cf5a12"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: • Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) • Adjunct therapy for heart failure ( 1.2 ) • Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31cc3b03-8ef2-5a92-832f-7e8724d26b63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:463308ef-16cb-41d8-8d29-6aae2c5a7b0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=463308ef-16cb-41d8-8d29-6aae2c5a7b0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=463308ef-16cb-41d8-8d29-6aae2c5a7b0f"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85a7ad9b-6cb5-5d45-b52b-e27f03d1e2e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34953f77-bae1-41fe-af11-3ea0b3ceaa11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34953f77-bae1-41fe-af11-3ea0b3ceaa11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34953f77-bae1-41fe-af11-3ea0b3ceaa11"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ea317fb-7ee6-55b3-b320-72bf9cec1439", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9470b102-3c81-469a-a4c5-6816d9d39b07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9470b102-3c81-469a-a4c5-6816d9d39b07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9470b102-3c81-469a-a4c5-6816d9d39b07"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a00fe92d-e4bb-5854-9d4d-04e1ec440810", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a33d860a-1e17-45b7-aede-51ab3223bebd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a33d860a-1e17-45b7-aede-51ab3223bebd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a33d860a-1e17-45b7-aede-51ab3223bebd"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b00fe59a-e719-54f0-a9e8-7db736b52c9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [562, 583], "original_object": "myocardial infarction", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c57e8bc8-ff50-431e-9c1a-384503584d02", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c57e8bc8-ff50-431e-9c1a-384503584d02", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57e8bc8-ff50-431e-9c1a-384503584d02"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0ae8bbd-1957-50cd-bcaf-ab5ce7502e09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [568, 590], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:560513ef-4d2c-8ca0-e063-6394a90a674a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=560513ef-4d2c-8ca0-e063-6394a90a674a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=560513ef-4d2c-8ca0-e063-6394a90a674a"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c337623c-c018-5a8e-b346-ff6e15f4d366", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [568, 590], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12d6fe7e-b5a2-4d49-9a06-a6150234d061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12d6fe7e-b5a2-4d49-9a06-a6150234d061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12d6fe7e-b5a2-4d49-9a06-a6150234d061"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0f74004-448f-563d-9019-a5cda54ecc4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34bb4602-ccff-4939-91b9-26a63bfd40f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34bb4602-ccff-4939-91b9-26a63bfd40f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34bb4602-ccff-4939-91b9-26a63bfd40f7"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3c27861-4ff4-5b75-916b-866fb3101317", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88b5a2c0-6ad2-48e7-9ffe-715d9159f389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88b5a2c0-6ad2-48e7-9ffe-715d9159f389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88b5a2c0-6ad2-48e7-9ffe-715d9159f389"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eaf526bf-bb8f-5955-ab56-4c4f523577fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [568, 590], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5eff766f-82e2-4cd6-e053-2a91aa0a4782", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5eff766f-82e2-4cd6-e053-2a91aa0a4782", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5eff766f-82e2-4cd6-e053-2a91aa0a4782"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9ccaf4c-07fc-5ab7-94cf-1e03db617f89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [568, 590], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:705582ed-da8c-418f-8bb2-fc0b74ed0a88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=705582ed-da8c-418f-8bb2-fc0b74ed0a88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=705582ed-da8c-418f-8bb2-fc0b74ed0a88"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9e73185-68a9-581e-9754-cb331fb46e27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [581, 603], "original_object": "myocardial infarctions", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2e09150-22f2-4028-b214-917d686200ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2e09150-22f2-4028-b214-917d686200ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2e09150-22f2-4028-b214-917d686200ad"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2630cb83-9640-5b88-ad5a-d89f31a95796", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [556, 563], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:560513ef-4d2c-8ca0-e063-6394a90a674a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=560513ef-4d2c-8ca0-e063-6394a90a674a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=560513ef-4d2c-8ca0-e063-6394a90a674a"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2abb4e64-bc09-5e3e-b241-32747159da08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [556, 563], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12d6fe7e-b5a2-4d49-9a06-a6150234d061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12d6fe7e-b5a2-4d49-9a06-a6150234d061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12d6fe7e-b5a2-4d49-9a06-a6150234d061"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e114e7e-5505-5dec-8a31-2dbd8f87232e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [550, 556], "original_object": "stroke", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c57e8bc8-ff50-431e-9c1a-384503584d02", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c57e8bc8-ff50-431e-9c1a-384503584d02", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57e8bc8-ff50-431e-9c1a-384503584d02"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3070ada5-5041-513f-8231-2f5c95f6f6d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88b5a2c0-6ad2-48e7-9ffe-715d9159f389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88b5a2c0-6ad2-48e7-9ffe-715d9159f389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88b5a2c0-6ad2-48e7-9ffe-715d9159f389"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59092b9a-4f7c-58ec-9adc-086803b00188", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a33d860a-1e17-45b7-aede-51ab3223bebd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a33d860a-1e17-45b7-aede-51ab3223bebd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a33d860a-1e17-45b7-aede-51ab3223bebd"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66fff4f7-f967-5c25-804f-e779fcbbb92e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2e09150-22f2-4028-b214-917d686200ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2e09150-22f2-4028-b214-917d686200ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2e09150-22f2-4028-b214-917d686200ad"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ba7b64e-51dc-515f-a4f7-50fde192af48", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:764d51bf-731f-4a37-8e30-e79328cf5a12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=764d51bf-731f-4a37-8e30-e79328cf5a12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=764d51bf-731f-4a37-8e30-e79328cf5a12"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: • Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) • Adjunct therapy for heart failure ( 1.2 ) • Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c19062d-6ac3-55ad-8004-0842c537d0c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:463308ef-16cb-41d8-8d29-6aae2c5a7b0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=463308ef-16cb-41d8-8d29-6aae2c5a7b0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=463308ef-16cb-41d8-8d29-6aae2c5a7b0f"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a383ae75-bdca-5fc6-9552-9a6bf66fec9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [556, 563], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42f49299-7ae5-4d30-86eb-66b739c0e95d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42f49299-7ae5-4d30-86eb-66b739c0e95d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42f49299-7ae5-4d30-86eb-66b739c0e95d"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3a53715-0027-5fa2-a14e-b241653a6602", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34953f77-bae1-41fe-af11-3ea0b3ceaa11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34953f77-bae1-41fe-af11-3ea0b3ceaa11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34953f77-bae1-41fe-af11-3ea0b3ceaa11"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbf2c2ae-23d0-58f5-a909-23df51225ee3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [556, 563], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:705582ed-da8c-418f-8bb2-fc0b74ed0a88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=705582ed-da8c-418f-8bb2-fc0b74ed0a88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=705582ed-da8c-418f-8bb2-fc0b74ed0a88"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e01d4da8-fbe6-59a9-b25c-337c0e889a54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34bb4602-ccff-4939-91b9-26a63bfd40f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34bb4602-ccff-4939-91b9-26a63bfd40f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34bb4602-ccff-4939-91b9-26a63bfd40f7"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f600c2aa-2e32-50a6-8b90-142468bc2a95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [556, 563], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5eff766f-82e2-4cd6-e053-2a91aa0a4782", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5eff766f-82e2-4cd6-e053-2a91aa0a4782", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5eff766f-82e2-4cd6-e053-2a91aa0a4782"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb35c8c4-4447-5b3b-8c7e-7e9f29e51400", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [569, 576], "original_object": "strokes", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9470b102-3c81-469a-a4c5-6816d9d39b07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9470b102-3c81-469a-a4c5-6816d9d39b07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9470b102-3c81-469a-a4c5-6816d9d39b07"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is grea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb4d3021-e10b-5e75-91a9-ba772278b77b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5773a221-bca6-5bc7-bb8c-8c5e716a0d11", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "LISINOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e6364a4-6d66-4151-8197-d45e2a762895", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e6364a4-6d66-4151-8197-d45e2a762895", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e6364a4-6d66-4151-8197-d45e2a762895"]}], "subject": "CHEBI:43755", "supporting_text": ["1 INDICATIONS AND USAGE Lisinopril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older (1.1) Adjunct therapy for heart failure (1.2) Treatment of Acute Myocardial Infarction (1.3) 1.1 Hypertension Lisinopril tablets are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7441defe-cf7c-5b55-9405-a2ce045e0943", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:645af8f4-0843-4afb-9ddc-f587f38adb68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=645af8f4-0843-4afb-9ddc-f587f38adb68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=645af8f4-0843-4afb-9ddc-f587f38adb68"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetra"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a34ba7e4-f0e5-55c7-8b81-0cfa9f3710a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88e03cb0-25f5-41a5-b77f-58ab8f3be181", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88e03cb0-25f5-41a5-b77f-58ab8f3be181", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88e03cb0-25f5-41a5-b77f-58ab8f3be181"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetra"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abf5db56-8798-5b53-89fc-ee551b1bbd50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10f80874-0289-4a23-8f42-b3e8fe43e1cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10f80874-0289-4a23-8f42-b3e8fe43e1cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10f80874-0289-4a23-8f42-b3e8fe43e1cb"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetra"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b702af30-6ccb-51d7-a7ae-8e4331fed3ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb2535cd-9d5b-5757-86bf-e96bb5b9acd4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "HP:0000010", "object_location_in_text": [1535, 1559], "original_object": "urinary tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6adaf70-5ff9-4395-bff1-0f332090cb80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6adaf70-5ff9-4395-bff1-0f332090cb80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6adaf70-5ff9-4395-bff1-0f332090cb80"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline hydrochloride tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline hydrochloride tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe73831a-45e8-516b-afa5-0fb336e97d66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "HP:0000010", "object_location_in_text": [1535, 1559], "original_object": "urinary tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:539add06-e0a0-401a-b4f6-20776084aa9c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=539add06-e0a0-401a-b4f6-20776084aa9c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=539add06-e0a0-401a-b4f6-20776084aa9c"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline hydrochloride tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline hydrochloride tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b0a5131-7376-517f-9712-9b22c411660a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05d3bbe7-c829-5350-b45a-f2b6437de216", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b66ec71-975d-55ba-ad9a-c3578e12532c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb68ae69-f80c-5d1b-8932-195cf25f6640", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6ff7bf8-37fb-5026-b187-269da9f3d1ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3518e4de-b2e4-53ae-9238-c07bdce860d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b957adb7-f7bd-5cc6-b498-39a6171fe5a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac8729f1-13b5-5ffd-8803-e1a64de1d3d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50c78d5a-208f-5955-a811-8e36b8bbcb5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca31a15c-c00f-5ea7-a881-77b8141c6d20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89e99af5-4af6-507a-a456-a229345d2beb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25bdeb57-6133-5b55-8d67-ac143e3a5a6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6adaf70-5ff9-4395-bff1-0f332090cb80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6adaf70-5ff9-4395-bff1-0f332090cb80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6adaf70-5ff9-4395-bff1-0f332090cb80"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline hydrochloride tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline hydrochloride tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a7887bf-8b02-50d9-b1b9-b45fcaebbe7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10f80874-0289-4a23-8f42-b3e8fe43e1cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10f80874-0289-4a23-8f42-b3e8fe43e1cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10f80874-0289-4a23-8f42-b3e8fe43e1cb"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetra"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77f600f5-98ca-5247-9f26-225878fbff26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88e03cb0-25f5-41a5-b77f-58ab8f3be181", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88e03cb0-25f5-41a5-b77f-58ab8f3be181", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88e03cb0-25f5-41a5-b77f-58ab8f3be181"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetra"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8867aa9e-d87d-5773-b752-342f4f72099d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:645af8f4-0843-4afb-9ddc-f587f38adb68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=645af8f4-0843-4afb-9ddc-f587f38adb68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=645af8f4-0843-4afb-9ddc-f587f38adb68"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetra"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6db7a19-e88e-5520-bf44-2f41e1954264", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:539add06-e0a0-401a-b4f6-20776084aa9c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=539add06-e0a0-401a-b4f6-20776084aa9c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=539add06-e0a0-401a-b4f6-20776084aa9c"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline hydrochloride tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline hydrochloride tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline hydrochloride tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d36ac7b2-1a0d-50b9-b78d-a13826b75a6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:753549a7-71ce-5444-9f56-2904170d4366", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0027573", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76ec7a3c-deea-5c9a-ab98-d8bbc13935f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0027573"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da2320dc-e105-51d0-8542-9fdf0904e7a8", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "original_object": "infections", "original_subject": "DEMECLOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ff23e3b-e111-47fd-9776-1d89d6da049b"]}], "subject": "CHEBI:4392", "supporting_text": ["Demeclocycline HCl tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum due to Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections cause by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Demeclocycline HCl tablets are indicated for treatment of infections by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Demeclocycline HCl tablets are indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4552431", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af2d9ece-8232-56f4-ba74-a29f348ccabb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181120", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552431", "UMLS:C4524048", "UMLS:C0949083"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5f91158d-2ca0-59db-8ad8-9832a5cce733", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36f6fab0-2464-563b-8634-d02417711b55", "object": "MONDO:0005229", "object_location_in_text": [305, 316], "original_object": "bacteraemia", "original_subject": "meropenem;vaborbactam", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vaborem", "https://www.ema.europa.eu/en/documents/product-information/vaborem-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem"]}], "subject": "CHEBI:43968", "supporting_text": ["Vaborem is indicated for the treatment of the following infections in adults:  Complicated urinary tract infection (cUTI), including pyelonephritis Complicated intra-abdominal infection (cIAI) Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).  Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05a0f652-a28b-55b4-952f-71ccf98b064b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960621", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0027575", "UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:31f79402-74c5-521b-a57b-20a7089b7549", "object": "MONDO:0006670", "object_location_in_text": [159, 179], "original_object": "bacterial meningitis", "original_subject": "MEROPENEM", "population_context_qualifier": "pediatric patients 3 months of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5154b6f-bca8-4f1e-907b-48ea34caf483", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5154b6f-bca8-4f1e-907b-48ea34caf483", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5154b6f-bca8-4f1e-907b-48ea34caf483"]}], "subject": "CHEBI:43968", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae , in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for Injection is a penem antibacterial indicated for the treatment of bacterial meningitis in pediatric patients 3 months of age and older only. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bde80f76-68bb-5477-8fa9-ce771e01cc13", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960621", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0027575", "UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:31f79402-74c5-521b-a57b-20a7089b7549", "object": "MONDO:0006670", "object_location_in_text": [104, 124], "original_object": "bacterial meningitis", "original_subject": "MEROPENEM", "population_context_qualifier": "pediatric patients 3 months of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:240325ba-47a8-4ad1-bcab-6772069ee790", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=240325ba-47a8-4ad1-bcab-6772069ee790", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=240325ba-47a8-4ad1-bcab-6772069ee790"]}], "subject": "CHEBI:43968", "supporting_text": ["1 INDICATIONS AND USAGE Meropenem for Injection is a penem antibacterial indicated for the treatment of bacterial meningitis in pediatric patients 3 months of age and older only. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae , Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae, in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7079e82-9872-54bf-a664-6bcae92a9197", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960621", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0027575", "UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:31f79402-74c5-521b-a57b-20a7089b7549", "object": "MONDO:0006670", "object_location_in_text": [159, 179], "original_object": "bacterial meningitis", "original_subject": "MEROPENEM", "population_context_qualifier": "pediatric patients 3 months of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6902fee1-6022-4145-a79a-4680ad1fb1e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6902fee1-6022-4145-a79a-4680ad1fb1e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6902fee1-6022-4145-a79a-4680ad1fb1e8"]}], "subject": "CHEBI:43968", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae , in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for Injection is a penem antibacterial indicated for the treatment of bacterial meningitis in pediatric patients 3 months of age and older only. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "gram negative bacteria infection", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d34bb851-a615-512a-82a1-acd349810cc8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:f6dd0305-3506-58ce-bfb4-ce55a4630086", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:b3cb48aa-0157-57e4-a0a4-a2f949d823d6", "object": "UMLS:C0149725", "object_location_in_text": [21, 54], "original_object": "lower respiratory tract infection", "original_subject": "Meropenem IP 1000mg + Sulbactam sodium USP 500mg injection", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:43968", "supporting_text": ["For the treatment of lower respiratory tract infection caused by gram negative bacteria in adults only"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1709246", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:269b5cda-9352-5d34-a7c3-102e377a12e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1709246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "METHOTREXATE", "population_context_qualifier": "pregnant women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4741a44f-0d0b-4380-84f6-231a8d1560fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4741a44f-0d0b-4380-84f6-231a8d1560fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4741a44f-0d0b-4380-84f6-231a8d1560fb"]}], "subject": "CHEBI:44185", "supporting_text": ["4 CONTRAINDICATIONS is contraindicated in: Methotrexate Tablets is contraindicated in: Pregnant women receiving Methotrexate Tablets for treatment of non-neoplastic diseases [see Warnings and Precautions ( 5.1 ), and Use in Specific Populations ( 8.1 , 8.3 )]. Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate. [see Warnings and Precautions ( 5.2 )]. In pregnancy for non-neoplastic diseases ( 4 ) History of severe hypersensitivity to Methotrexate ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1709246", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:535ff695-f92d-5b68-8018-313badfc2c9e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1709246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "METHOTREXATE", "population_context_qualifier": "pregnant", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd035a9f-cd40-4314-b9d8-2294b8a924e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd035a9f-cd40-4314-b9d8-2294b8a924e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd035a9f-cd40-4314-b9d8-2294b8a924e2"]}], "subject": "CHEBI:44185", "supporting_text": ["4 CONTRAINDICATIONS Methotrexate Injection is contraindicated in: Patients with history of severe hypersensitivity to methotrexate [see Warnings and Precautions ( 5.2 )] . Pregnancy in patients with non-neoplastic diseases [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )] . History of severe hypersensitivity to methotrexate. ( 4 ) Pregnancy: in patients with non-neoplastic diseases. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1709246", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:589d3f95-e8ed-5200-b85d-99957193a12b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1709246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "METHOTREXATE", "population_context_qualifier": "pregnant women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0b54b5c4-2466-4f85-b9a0-ad93ec4a06a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0b54b5c4-2466-4f85-b9a0-ad93ec4a06a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b54b5c4-2466-4f85-b9a0-ad93ec4a06a1"]}], "subject": "CHEBI:44185", "supporting_text": ["4 CONTRAINDICATIONS Methotrexate tablets are contraindicated in: • Pregnant women receiving methotrexate tablets for treatment of non-neoplastic diseases [see Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate [see Warnings and Precautions (5.2) ] . • In pregnancy for non-neoplastic diseases ( 4 ) • History of severe hypersensitivity to methotrexate ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1709246", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b7540e8-a909-571c-82a3-367def9bb7b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1709246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "METHOTREXATE", "population_context_qualifier": "pregnant women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:874c7f43-a3be-4236-89cc-24c44e3c5813", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=874c7f43-a3be-4236-89cc-24c44e3c5813", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=874c7f43-a3be-4236-89cc-24c44e3c5813"]}], "subject": "CHEBI:44185", "supporting_text": ["4 CONTRAINDICATIONS is contraindicated in: Methotrexate Tablets is contraindicated in: Pregnant women receiving Methotrexate Tablets for treatment of non-neoplastic diseases [see Warnings and Precautions ( 5.1 ), and Use in Specific Populations ( 8.1 , 8.3 )]. Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate. [see Warnings and Precautions ( 5.2 )]. In pregnancy for non-neoplastic diseases ( 4 ) History of severe hypersensitivity to Methotrexate ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1709246", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1ed0ad6-5ce2-51a6-8d09-bcb14df65302", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1709246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "METHOTREXATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:757d6cef-6696-7a1c-8074-01258aaa8bdd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=757d6cef-6696-7a1c-8074-01258aaa8bdd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=757d6cef-6696-7a1c-8074-01258aaa8bdd"]}], "subject": "CHEBI:44185", "supporting_text": ["Methotrexate tablets are contraindicated in: •Pre gnant women receiving methotrexate tablets for treatment of non-neoplastic diseases [see Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)]. • Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate [see Warnings and Precautions (5.2)]. • In pregnancy for non-neoplastic diseases (4) • History of severe hypersensitivity to methotrexate (4)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C1709246", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd5f7a21-fca4-53df-8841-e3112f447f09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1709246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "METHOTREXATE", "population_context_qualifier": "pregnant women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70c09984-2b36-424f-8b27-3fd0cd4e833d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70c09984-2b36-424f-8b27-3fd0cd4e833d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70c09984-2b36-424f-8b27-3fd0cd4e833d"]}], "subject": "CHEBI:44185", "supporting_text": ["4 CONTRAINDICATIONS Methotrexate tablets are contraindicated in: • Pregnant women receiving methotrexate tablets for treatment of non-neoplastic diseases [see Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Patients with a history of a severe hypersensitivity reactions, including anaphylaxis, to methotrexate [see Warnings and Precautions (5.2) ] . • In pregnancy for non-neoplastic diseases ( 4 ) • History of severe hypersensitivity to methotrexate ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "insufficient response to phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy, and retinoids", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3447516-6ba6-5a7f-b82c-aca12eb963b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160818", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8e4da0f7-8759-5a9f-a717-c9916426f669", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "MONDO:0005083", "original_object": "psoriasis", "original_subject": "methotrexate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:jylamvo", "https://www.ema.europa.eu/en/documents/product-information/jylamvo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/jylamvo"]}], "subject": "CHEBI:44185", "supporting_text": ["In rheumatological and dermatological diseases  Active rheumatoid arthritis in adult patients. Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate. Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.  In oncology  Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs)", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77e1a1c1-263d-5b0b-ab35-6a5332eec2fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160818", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d6846b61-be5e-5ced-b5ca-0efff29bb214", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "MONDO:0011429", "original_object": "juvenile idiopathic arthritis", "original_subject": "methotrexate", "population_context_qualifier": "adolescents and children aged 3 years and over", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:jylamvo", "https://www.ema.europa.eu/en/documents/product-information/jylamvo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/jylamvo"]}], "subject": "CHEBI:44185", "supporting_text": ["In rheumatological and dermatological diseases  Active rheumatoid arthritis in adult patients. Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate. Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.  In oncology  Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e496746-9c8c-538d-a409-b6e2069b7d9c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160818", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d6846b61-be5e-5ced-b5ca-0efff29bb214", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "MONDO:0011429", "original_object": "juvenile idiopathic arthritis", "original_subject": "methotrexate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nordimet", "https://www.ema.europa.eu/en/documents/product-information/nordimet-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet"]}], "subject": "CHEBI:44185", "supporting_text": ["Nordimet is indicated for the treatment of:  active rheumatoid arthritis in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate, moderate to severe plaque&nbsp;psoriasis in adults who are candidates&nbsp;for systemic therapy, and severe psoriatic arthritis in adult patients,&nbsp; induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "articular symptoms", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a13009b-7b12-5313-9c09-97e0fa2bb939", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d6846b61-be5e-5ced-b5ca-0efff29bb214", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:38d0158c-95ea-5a94-86c3-27c123e8c657", "object": "MONDO:0011429", "object_location_in_text": [66, 95], "original_object": "juvenile idiopathic arthritis", "original_subject": "METHOTREXATE", "population_context_qualifier": "juvenile", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHOTREXATE#173-20080924", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:44185", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of juvenile idiopathic arthritis accompanied by articular symptoms. [Expedited review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "symptomatic sickle-cell syndrome", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5040e33f-f76d-5b07-840f-897382f00104", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070629", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:e8acbe8f-928f-5d81-bf59-a81dd45516cf", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:37f48c74-0d4f-5e30-8915-77ab66cf5ace", "object": "MONDO:0005632", "object_location_in_text": [92, 112], "original_object": "acute chest syndrome", "original_subject": "hydroxycarbamide", "population_context_qualifier": "paediatric and adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:siklos", "https://www.ema.europa.eu/en/documents/product-information/siklos-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/siklos"]}], "subject": "CHEBI:44423", "supporting_text": ["Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Orthopaedic condition, ENT condition, Dental condition", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0900cd04-232e-588d-bd3f-0c26bddafac1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090516", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:6645f295-ea5f-506a-af2b-3f34d0f7296a", "object": "UMLS:C0184567", "original_object": "acute pain", "original_subject": "Nimesulide ER 200mg ( Additional Indication)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:44445", "supporting_text": ["Acute pain in Orthopaedic, ENT, Dental and Post Operative condition"], "temporal_context_qualifier": "Post Operative condition :: Post Operative condition"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e65294a-406e-527c-acc3-6af59e7dcf31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1be9b473-a46f-5bab-9f1f-767daedf24e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "MONDO:0002269", "original_object": "Gastroenteritis", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)] . Polydipsia [see Warnings and Precautions (5.1)] . Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning] . Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d8ad6c3-a562-5cd5-9c7f-dc2e2f121249", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1be9b473-a46f-5bab-9f1f-767daedf24e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "MONDO:0002269", "object_location_in_text": [1126, 1141], "original_object": "gastroenteritis", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )] . Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.4 , 8.5 )] . Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )] . Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning ] . Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning ] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning ] . Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a13a0fe2-fce6-593c-9359-c00bc2d263a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1be9b473-a46f-5bab-9f1f-767daedf24e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "MONDO:0002269", "original_object": "Gastroenteritis", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin Acetate Injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin Acetate Injection [see Warnings and Precautions (5.4) , Adverse Reactions (6) , Description (11) ]. Desmopressin Acetate Injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5 , 8.6) and Clinical Pharmacology (12.3) ]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ], Use in Specific Populations (8.4 , 8.5) ]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1) ] . Polydipsia [see Warnings and Precautions (5.1) ] . Concomitant use with loop diuretics [see Boxed Warning ]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning ] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning ] . Desmopressin Acetate Injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7f23fee-e828-564f-a80c-926d82cb3cd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1be9b473-a46f-5bab-9f1f-767daedf24e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "MONDO:0002269", "original_object": "Gastroenteritis", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )], Use in Specific Populations ( 8.4 , 8.5 )]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )]. Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning]. During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning]. Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e34e12b2-5d60-5548-9669-140ae727044f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1be9b473-a46f-5bab-9f1f-767daedf24e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "MONDO:0002269", "original_object": "Gastroenteritis", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )], Use in Specific Populations ( 8.4 , 8.5 )]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )]. Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning]. During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning]. Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e839d5ff-b898-525c-9008-678d20821a47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1be9b473-a46f-5bab-9f1f-767daedf24e2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "MONDO:0002269", "original_object": "Gastroenteritis", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdec2cc2-4fd9-474e-884f-d0599e40948f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdec2cc2-4fd9-474e-884f-d0599e40948f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdec2cc2-4fd9-474e-884f-d0599e40948f"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)] . Polydipsia [see Warnings and Precautions (5.1)] . Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning] . Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10234880-8bee-59c9-a567-a762add4d775", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d1c28d8f-6a61-56a5-8465-cc3b8f21e892", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0243026", "original_object": "Systemic infection", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdec2cc2-4fd9-474e-884f-d0599e40948f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdec2cc2-4fd9-474e-884f-d0599e40948f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdec2cc2-4fd9-474e-884f-d0599e40948f"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)] . Polydipsia [see Warnings and Precautions (5.1)] . Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning] . Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17f2688b-747f-5f83-93aa-4108ea1a3867", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d1c28d8f-6a61-56a5-8465-cc3b8f21e892", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0243026", "original_object": "Systemic infection", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)] . Polydipsia [see Warnings and Precautions (5.1)] . Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning] . Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:979ede36-6d45-5146-9453-80c1ad22f61f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d1c28d8f-6a61-56a5-8465-cc3b8f21e892", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0243026", "object_location_in_text": [1174, 1192], "original_object": "systemic infection", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )] . Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.4 , 8.5 )] . Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )] . Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning ] . Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning ] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning ] . Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb277eea-0939-58a6-b905-101a19323353", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d1c28d8f-6a61-56a5-8465-cc3b8f21e892", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0243026", "original_object": "Systemic infection", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin Acetate Injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin Acetate Injection [see Warnings and Precautions (5.4) , Adverse Reactions (6) , Description (11) ]. Desmopressin Acetate Injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5 , 8.6) and Clinical Pharmacology (12.3) ]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ], Use in Specific Populations (8.4 , 8.5) ]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1) ] . Polydipsia [see Warnings and Precautions (5.1) ] . Concomitant use with loop diuretics [see Boxed Warning ]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning ] . During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning ] . Desmopressin Acetate Injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc2449e4-4c61-5121-8bd1-1e53fda3a78e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d1c28d8f-6a61-56a5-8465-cc3b8f21e892", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0243026", "original_object": "Systemic infection", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )], Use in Specific Populations ( 8.4 , 8.5 )]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )]. Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning]. During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning]. Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "illnesses that can cause fluid or electrolyte imbalance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6308758-55da-5bfe-b5de-a52d9cb08b0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d1c28d8f-6a61-56a5-8465-cc3b8f21e892", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0243026", "original_object": "Systemic infection", "original_subject": "DESMOPRESSIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2"]}], "subject": "CHEBI:4450", "supporting_text": ["4 CONTRAINDICATIONS Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of Desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )]. Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )], Use in Specific Populations ( 8.4 , 8.5 )]. Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )]. Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning]. Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning]. During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning]. Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition: Heart failure Uncontrolled hypertension Known hypersensitivity to desmopressin acetate or to any of the components ( 4 ) Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min ( 4 ) Hyponatremia or a history of hyponatremia ( 4 ) Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion ( 4 ) Polydipsia ( 4 ) Concomitant use with loop diuretics or systemic or inhaled glucocorticoids ( 4 ) During illnesses that can cause fluid or electrolyte imbalance ( 4 ) Heart failure or uncontrolled hypertension ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15768995-c3a7-594f-81fb-ad6c4f1d4d7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84dbb392-4535-4cbc-af60-75abb494f26e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84dbb392-4535-4cbc-af60-75abb494f26e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84dbb392-4535-4cbc-af60-75abb494f26e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1881232a-ba04-5c33-b9d1-7461c0143a49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate disease with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:220b10a1-d85f-57c9-a397-8f8231915a2c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:29df0492-f7ef-47bb-aa67-4ef9e5c2846f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=29df0492-f7ef-47bb-aa67-4ef9e5c2846f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29df0492-f7ef-47bb-aa67-4ef9e5c2846f"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:279834ae-451a-58a5-8c98-b74a8525f24b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f730b23-fb6e-584a-bc87-59c38d67561b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10b29aa2-274e-4c29-bccd-424bd3761758", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10b29aa2-274e-4c29-bccd-424bd3761758", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10b29aa2-274e-4c29-bccd-424bd3761758"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6401af25-94bb-56ef-be03-111e79ed83fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate disease with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:700cf4f9-17c4-5b1c-a37b-f5503ef87dc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "object_location_in_text": [508, 516], "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72e7d21c-2183-5469-aefd-6e9d835c8765", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate disease with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2e21331-4d54-4fa7-8f0d-31fe23a981aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2e21331-4d54-4fa7-8f0d-31fe23a981aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2e21331-4d54-4fa7-8f0d-31fe23a981aa"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d54ec5cc-326c-52c2-bffc-b03ebb9114dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0019080", "original_object": "bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0848232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5149c95-ecdf-5392-8e4b-458ea05c370a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190618", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0848232"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:cc8df867-ca58-5c70-a26c-d6818964a29b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:aa466ec9-95db-5a76-889e-ea27ef57571d", "object": "HP:0000017", "object_location_in_text": [116, 124], "original_object": "nocturia", "original_subject": "DESMOPRESSIN ACETATE HYDRATE", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DESMOPRESSIN ACETATE HYDRATE#69-20190618", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:4450", "supporting_text": ["Drugs with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of nocturia due to nocturnal polyuria in males."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c29d050-edea-5100-9416-9d787230328f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ffbda877-34eb-5a68-9f76-dbdfc348ce3b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "HP:0005261", "object_location_in_text": [576, 588], "original_object": "hemarthroses", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0854057", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:334f6125-8028-508e-aa3c-f6d18bdae6e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120330", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0854057"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:409ab308-e06e-5e0d-8863-15bd4cf1c9b1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:aa466ec9-95db-5a76-889e-ea27ef57571d", "object": "MONDO:0000022", "object_location_in_text": [72, 90], "original_object": "nocturnal enuresis", "original_subject": "DESMOPRESSIN ACETATE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DESMOPRESSIN ACETATE HYDRATE#149-20120330", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:4450", "supporting_text": ["Drugs with a new route of administration indicated for the treatment of nocturnal enuresis associated with decreased urine osmolality or urinary specific gravity."], "temporal_context_qualifier": "nocturnal"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b58b615c-9f4c-5bfa-82ae-dc0071508c84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8ea46acf-19fd-5a01-83e1-2387f192b6bf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0240412", "object_location_in_text": [590, 613], "original_object": "intramuscular hematomas", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3981b4ca-1f3a-5d06-bb89-bd2b51c4d525", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52680415-52a0-61c2-e063-6294a90ae27e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:509bbab3-be01-5a9f-8bbb-9913c0d77c1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate disease with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2e21331-4d54-4fa7-8f0d-31fe23a981aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2e21331-4d54-4fa7-8f0d-31fe23a981aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2e21331-4d54-4fa7-8f0d-31fe23a981aa"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:738ed5b8-d5ea-5c13-a63c-66dc29ce4c86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate disease with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87168b9-f103-4ba5-b0b3-0656d1c81da2"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74902731-d726-5175-9967-be43bdb2750c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84dbb392-4535-4cbc-af60-75abb494f26e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84dbb392-4535-4cbc-af60-75abb494f26e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84dbb392-4535-4cbc-af60-75abb494f26e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8910efb-4649-5c0d-b9e3-cdde39810c82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate disease with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=673cd9ab-b714-49ee-9ce7-c99be605c30e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c399857a-af7a-59f9-aa5b-bae52086d8b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "object_location_in_text": [440, 450], "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=539d7da2-72b8-45f9-836c-4e3351dd488e"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcf0bf04-9189-544b-bcb3-572e95314ce6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b6a640d-eb9d-5f5c-adea-b870a366fa0b", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C0740166", "original_object": "hemostasis", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"], "temporal_context_qualifier": "during surgical procedures and postoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "von Willebrand's disease (Type I)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2dbe4ef1-ee0c-5ee1-a09f-abd8368fe820", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:46dd987c-dc7c-5281-9c1d-027a193fb880", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c41e24d-59b6-5287-b73c-b17b1907515f", "object": "UMLS:C2748540", "object_location_in_text": [618, 634], "original_object": "mucosal bleeding", "original_subject": "DESMOPRESSIN", "population_context_qualifier": "patients with mild to moderate von Willebrand's disease (Type I) with factor VIII levels greater than 5%", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5"]}], "subject": "CHEBI:4450", "supporting_text": ["1 INDICATIONS AND USAGE Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2e190b5-65db-5084-884f-53fbe33eda2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042009a-6ac8-544e-97fb-5554540b2ba9", "object": "HP:0012735", "original_object": "cough", "original_subject": "DEXCHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c7c6756-abb2-c10c-e063-6394a90a9863", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c7c6756-abb2-c10c-e063-6394a90a9863", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c7c6756-abb2-c10c-e063-6394a90a9863"]}], "subject": "CHEBI:4464", "supporting_text": ["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3669761-52e7-5f98-b89c-c4ab0e845b46", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042009a-6ac8-544e-97fb-5554540b2ba9", "object": "HP:0012735", "object_location_in_text": [254, 259], "original_object": "cough", "original_subject": "DEXCHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf3886ab-62b3-497a-a587-18cbfbaf3634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf3886ab-62b3-497a-a587-18cbfbaf3634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf3886ab-62b3-497a-a587-18cbfbaf3634"]}], "subject": "CHEBI:4464", "supporting_text": ["Uses temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: runny nose sneezing itching of the nose or throat itchy, watery eyes nasal congestion reduces swelling of nasal passages cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54404f84-855e-5f3f-9117-2b8a324bf355", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042009a-6ac8-544e-97fb-5554540b2ba9", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "DEXCHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa4f80c9-e600-4bc0-8528-02a8162a36f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa4f80c9-e600-4bc0-8528-02a8162a36f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa4f80c9-e600-4bc0-8528-02a8162a36f0"]}], "subject": "CHEBI:4464", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb828bc9-611b-5b98-959c-9dd1092a5981", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9042009a-6ac8-544e-97fb-5554540b2ba9", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "DEXCHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4694616b-4ef4-28a4-e063-6394a90ac5f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4694616b-4ef4-28a4-e063-6394a90ac5f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4694616b-4ef4-28a4-e063-6394a90ac5f6"]}], "subject": "CHEBI:4464", "supporting_text": ["Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "taking monoamine oxidase inhibitors (MAOI), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue)", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3331e7d-930c-5809-9f79-6065ecc15133", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors (MAOI)", "linezolid", "intravenous methylene blue"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b07c3cbb-48b9-5a88-b524-a350d5ba6a87", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "HP:0100735", "original_object": "hypertensive crisis", "original_subject": "DEXTROAMPHETAMINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0862f02a-72a8-41cc-8845-57cf4974bb6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0862f02a-72a8-41cc-8845-57cf4974bb6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0862f02a-72a8-41cc-8845-57cf4974bb6f"]}], "subject": "CHEBI:4469", "supporting_text": ["4 CONTRAINDICATIONS XELSTRYM is contraindicated in patients: with known hypersensitivity to amphetamine products or other components of XELSTRYM. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see ADVERSE REACTIONS (6.2) ] taking monoamine oxidase inhibitors (MAOI), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS AND PRECAUTIONS (5.7) and DRUG INTERACTIONS (7.1) ] Known hypersensitivity to amphetamine products or other ingredients in XELSTRYM ( 4 ) Use with monoamine oxidase inhibitor (MAOI), or within 14 days of the last MAOI dose ( 4 , 7.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1de6a14a-2595-5990-ad1e-eb898bc24179", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9346ff55-b751-4919-ae63-eb58b69e3f0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9346ff55-b751-4919-ae63-eb58b69e3f0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9346ff55-b751-4919-ae63-eb58b69e3f0f"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets, USP are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:223495de-4575-578a-b2e1-a824a3f4698f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b3a40f-b7ac-4047-8ff5-3e34c2d75193", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b3a40f-b7ac-4047-8ff5-3e34c2d75193", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b3a40f-b7ac-4047-8ff5-3e34c2d75193"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b867f40-9d34-5459-a434-286007e62cc9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b40c9a90-7e2e-48d6-adb6-2351c0ca621d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b40c9a90-7e2e-48d6-adb6-2351c0ca621d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b40c9a90-7e2e-48d6-adb6-2351c0ca621d"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets, USP are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:490a5926-5021-5da7-90f8-070e38e823e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ef920a9-c5b9-4d31-a478-ee18d22a3c5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ef920a9-c5b9-4d31-a478-ee18d22a3c5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ef920a9-c5b9-4d31-a478-ee18d22a3c5b"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:716cda44-3a8c-5a5e-8053-32eeef980917", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2d13f3-d14f-47e4-abe9-7763f95a8e94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2d13f3-d14f-47e4-abe9-7763f95a8e94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2d13f3-d14f-47e4-abe9-7763f95a8e94"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Tablets are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8034d863-cc51-54d1-9a45-b4f1f2aebfb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca1a8890-0675-4c9c-9716-6c28f975d827", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca1a8890-0675-4c9c-9716-6c28f975d827", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca1a8890-0675-4c9c-9716-6c28f975d827"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:850b9954-6532-5537-9530-f09aa83156b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54b122b0-2ec8-43c9-86e8-a3538a83c776", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54b122b0-2ec8-43c9-86e8-a3538a83c776", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54b122b0-2ec8-43c9-86e8-a3538a83c776"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets, USP are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab2b27fe-9c58-5d37-9a6f-5e1d9df64bd5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc164327-dd48-4851-b613-71d957ee6066", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc164327-dd48-4851-b613-71d957ee6066", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc164327-dd48-4851-b613-71d957ee6066"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets, USP are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotionally lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cee49c84-2b4a-5d97-af3f-f31830063fee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 years to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1548cce2-fb6b-4f17-8a3b-868933f6c9d6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1548cce2-fb6b-4f17-8a3b-868933f6c9d6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1548cce2-fb6b-4f17-8a3b-868933f6c9d6"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Oral Solution is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotionally lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0fc479c-f09b-554c-8cec-c54b1ef188f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "object_location_in_text": [65, 110], "original_object": "Attention Deficit Disorder with Hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e05cf690-d45a-4696-a1bf-40c9350cc084", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e05cf690-d45a-4696-a1bf-40c9350cc084", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e05cf690-d45a-4696-a1bf-40c9350cc084"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3125f12-bedc-5383-bdf1-b7c1553154b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:466cbae8-4f67-4a65-b670-ada6a953d550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=466cbae8-4f67-4a65-b670-ada6a953d550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=466cbae8-4f67-4a65-b670-ada6a953d550"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e299c5d6-90a5-5f30-90a8-401d5575bf53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9f1c9cb0-7752-40cc-8ed1-5e79b8dc9da2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9f1c9cb0-7752-40cc-8ed1-5e79b8dc9da2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f1c9cb0-7752-40cc-8ed1-5e79b8dc9da2"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets, USP are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f73dcdf8-4da0-5d67-9be3-fbebd225a20b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 years to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7658071e-ee2c-4d23-94ce-1906959ec036", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7658071e-ee2c-4d23-94ce-1906959ec036", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7658071e-ee2c-4d23-94ce-1906959ec036"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate oral solution is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotionally lability, and impulsivity", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f86f6b1c-dea5-5d9e-9422-0a487decb8bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31d47bcc-e52e-55bb-984f-bdacaadb621c", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit hyperactivity disorder", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 years to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94674695-aa8a-3150-e053-2995a90a445f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94674695-aa8a-3150-e053-2995a90a445f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94674695-aa8a-3150-e053-2995a90a445f"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine Sulfate Oral Solution is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotionally lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe2d25d2-96f5-53a1-bbf9-eff465b167ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f9a2e53b-d819-57f1-ae6a-cb0df7c83438", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "DEXTROAMPHETAMINE", "population_context_qualifier": "pediatric patients (ages 3 to 16 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b8c97ac-c83c-4a1f-a33c-121239253abf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b8c97ac-c83c-4a1f-a33c-121239253abf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b8c97ac-c83c-4a1f-a33c-121239253abf"]}], "subject": "CHEBI:4469", "supporting_text": ["Dextroamphetamine sulfate tablets, USP are indicated for: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12bed86c-3bb0-5889-9e90-01b84d993ae8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "MONDO:0004979", "object_location_in_text": [402, 408], "original_object": "asthma", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01ea6357-24dc-4056-9fd2-9e643650b91f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01ea6357-24dc-4056-9fd2-9e643650b91f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01ea6357-24dc-4056-9fd2-9e643650b91f"]}], "subject": "CHEBI:4470", "supporting_text": ["Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (MAOI) (see PRECAUTIONS - Drug Interactions ). Antihistamines should not be used to treat lower respiratory tract conditions including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea7153cb-e9cd-57d8-aa21-62ddcd40a537", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "MONDO:0004979", "object_location_in_text": [425, 431], "original_object": "asthma", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3983d6d3-8bf4-4a88-962f-9bf72fd6e685", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3983d6d3-8bf4-4a88-962f-9bf72fd6e685", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3983d6d3-8bf4-4a88-962f-9bf72fd6e685"]}], "subject": "CHEBI:4470", "supporting_text": ["Dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (MAOI) (see PRECAUTIONS , Drug Interactions ). Promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665464", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c2fb36a-91e8-5f84-9c08-550ff3c995c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665464"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5f52d329-c1c2-563a-a88d-77435d0db00b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0000713", "object_location_in_text": [322, 331], "original_object": "agitation", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcefda7c-9a68-278e-e053-2995a90aec79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79"]}], "subject": "CHEBI:4470", "supporting_text": ["1 INDICATIONS AND USAGE AUVELITY is a combination of dextromethorphan, an uncompetitive N -methyl D -aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults ( 1.1 ) the treatment of agitation associated with dementia due to Alzheimer’s disease ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02869b74-75fd-522c-ad90-99dafb3b288d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [101, 106], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation minor aches &amp; pains headache fever sore throat reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ddb26fb-4f7b-58fd-b836-54b249ceb9b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [43, 48], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d66b1a2e-49b6-473b-acec-2694c73ce8b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d66b1a2e-49b6-473b-acec-2694c73ce8b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d66b1a2e-49b6-473b-acec-2694c73ce8b4"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves cold symptoms: ▪ cough due to minor throat &amp; bronchial irritation ▪ sneezing ▪ runny nose"], "temporal_context_qualifier": "temporarily"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f518575-751e-57a3-a011-24d49724fc40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0b3eb8c3-9b9e-861b-e063-6294a90a4a0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0b3eb8c3-9b9e-861b-e063-6294a90a4a0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b3eb8c3-9b9e-861b-e063-6294a90a4a0f"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses Temporarily relieves common cold/flu symptoms: Nasal congestion Cough due to minor throat &amp; bronchial irritation Sore throat Headache Minor aches &amp; pains Fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45a7369a-20bb-5349-9f44-2ac413dc41bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4d38921-ec90-0658-e053-2a95a90a848a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4d38921-ec90-0658-e053-2a95a90a848a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4d38921-ec90-0658-e053-2a95a90a848a"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves cold symptoms: • nasal congestion • sinus congestion &amp; pressure • cough due to minor throat &amp; bronchial irritation • cough to help you sleep • runny nose &amp; sneezing • reduces swelling of nasal passages • temporarily restores freer breathing through the nose • promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53d8764c-7e49-5c8f-b961-10f722e773a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [26, 31], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f496c61-41a6-41ba-80f5-7a5309c4d18b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f496c61-41a6-41ba-80f5-7a5309c4d18b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f496c61-41a6-41ba-80f5-7a5309c4d18b"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes"], "temporal_context_qualifier": "as may occur with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:608be9d9-9b64-52b4-b68c-5192666480c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [25, 30], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:baf9e8c3-804e-43d6-837f-37d1246c035f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=baf9e8c3-804e-43d6-837f-37d1246c035f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=baf9e8c3-804e-43d6-837f-37d1246c035f"]}], "subject": "CHEBI:4470", "supporting_text": ["Use temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold."], "temporal_context_qualifier": "as may occur with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f93c487-5793-549c-b257-d383fd7f17ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation cough to help you sleep minor aches &amp; pains headache fever sore throat runny nose &amp; sneezing reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c187fc42-32a2-5dd2-89b2-838eb87ea736", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [112, 117], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18f3d694-9dff-407e-a264-916dbd201f9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses For the temporary relief of the following cold symptoms minor aches and pains headache sneezing runny nose cough due to minor throat and bronchial irritation temporarily reduces fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce0c0562-0fb8-5511-bf76-026f17719f8b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [41, 46], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f913fcd6-a2b8-df5e-e053-6394a90ac988", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f913fcd6-a2b8-df5e-e053-6394a90ac988", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f913fcd6-a2b8-df5e-e053-6394a90ac988"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf925b27-5a68-5789-973e-3cf5273eef10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "MONDO:0005002"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [138, 143], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses Nighttime temporarily relieves these symptoms occuring with a cold, hay fever, or other upper respiratory allergies nasal congestion cough runny nose sneezing itchy, watery eyes itching of the nose or throat Daytime temporaily relieves cough due to minor throat and bronchial irritation occuring with a cold, and nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy, watery eyes sneezing itching of the nose or throat temporarily restores freer breathing through the nose"], "temporal_context_qualifier": "occuring with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9177c7a-25e5-56b0-8101-1805b06bb034", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [25, 30], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aeb26c0e-4efe-4099-9b68-47824f4506c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aeb26c0e-4efe-4099-9b68-47824f4506c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aeb26c0e-4efe-4099-9b68-47824f4506c0"]}], "subject": "CHEBI:4470", "supporting_text": ["Use temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold."], "temporal_context_qualifier": "as may occur with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e131adb3-b652-5288-84be-908ee07b9f71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [48, 53], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fdc9e1b7-3aef-5c56-99a1-0329dcd09533", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "HP:0012735", "object_location_in_text": [25, 30], "original_object": "cough", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:20f7c1a9-fc4d-1f51-e063-6394a90a8be3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=20f7c1a9-fc4d-1f51-e063-6394a90a8be3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=20f7c1a9-fc4d-1f51-e063-6394a90a8be3"]}], "subject": "CHEBI:4470", "supporting_text": ["Use temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold."], "temporal_context_qualifier": "as may occur with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031245", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:904229f5-9faa-50a7-83b6-90048c091871", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031245"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "MONDO:0003781", "original_object": "bronchitis", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e"]}], "subject": "CHEBI:4470", "supporting_text": ["DAY Uses ■ temporarily relieves these common cold and flu symptoms: ■ minor aches and pains ■ headache ■ sore throat ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily reduces fever NIGHT Uses ■ temporarily relieves these common cold and flu symptoms: ■ cough ■ minor aches and pains ■ sore throat ■ headache ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes due to hay fever ■ temporarily reduces fever ■ controls cough to help you get to sleep SPRAY Uses temporarily relieves nasal congestion due to: a cold hay fever or other upper respiratory allergies promotes nasal and sinus drainage temporarily relieves sinus congestion and pressure helps clear nasal passages; shrinks swollen membranes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8d9b230-10fc-5ea2-842a-7ebebbec52dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840402", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4e149e09-e503-5c85-b5a1-28b3c9154733", "object": "MONDO:0005709", "object_location_in_text": [26, 37], "original_object": "common cold", "original_subject": "DEXTROMETHORPHAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:4470", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021708", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d08daf5-961c-54e2-83ed-d33c8b367b57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891002", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021708"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:75fb028b-05a1-508e-8675-ff9895cc8284", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b81149fb-9eb1-55ab-ad8a-6010ffd858bc", "object": "UMLS:C1528732", "object_location_in_text": [85, 93], "original_object": "sedation", "original_subject": "PROPOFOL", "population_context_qualifier": "intubated, mechanically ventilated adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99af9e0a-c268-84ca-e053-2a95a90a0a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99af9e0a-c268-84ca-e053-2a95a90a0a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99af9e0a-c268-84ca-e053-2a95a90a0a3e"]}], "subject": "CHEBI:44915", "supporting_text": ["INDICATIONS &amp; USAGE Propofol injectable emulsion is an IV general anesthetic and sedation drug that can be used as described in the table below. TABLE 3. INDICATIONS FOR PROPOFOL INJECTABLE EMULSION Safety, effectiveness and dosing guidelines for propofol injectable emulsion have not been established for MAC Sedation in the pediatric population; therefore, it is not recommended for this use (see PRECAUTIONS , Pediatric Use). Propofol injectable emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations. In the Intensive Care Unit (ICU), propofol injectable emulsion can be administered to intubated, mechanically ventilated adult patients to provide continuous sedation and control of stress responses only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management. Propofol injectable emulsion is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established (see PRECAUTIONS , Pediatric Use). Propofol injectable emulsion is not recommended for obstetrics, including Cesarean section deliveries. Propofol injectable emulsion crosses the placenta, and as with other general anesthetic agents, the administration of propofol injectable emulsion may be associated with neonatal depression (see PRECAUTIONS ). Propofol is not recommended for use in nursing mothers because propofol injectable emulsion has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of propofol are not known (see PRECAUTIONS ). INDICATIONS &amp; USAGE"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021708", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8dbb700-941f-52d0-869b-b3d938fc851b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891002", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021708"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:75fb028b-05a1-508e-8675-ff9895cc8284", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b81149fb-9eb1-55ab-ad8a-6010ffd858bc", "object": "UMLS:C1528732", "object_location_in_text": [85, 93], "original_object": "sedation", "original_subject": "PROPOFOL", "population_context_qualifier": "intubated, mechanically ventilated adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99c8438a-2b3c-796e-e053-2a95a90a0200", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99c8438a-2b3c-796e-e053-2a95a90a0200", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99c8438a-2b3c-796e-e053-2a95a90a0200"]}], "subject": "CHEBI:44915", "supporting_text": ["INDICATIONS &amp; USAGE Propofol injectable emulsion is an IV general anesthetic and sedation drug that can be used as described in the table below. TABLE 3. INDICATIONS FOR PROPOFOL INJECTABLE EMULSION Safety, effectiveness and dosing guidelines for propofol injectable emulsion have not been established for MAC Sedation in the pediatric population; therefore, it is not recommended for this use (see PRECAUTIONS , Pediatric Use). Propofol injectable emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations. In the Intensive Care Unit (ICU), propofol injectable emulsion can be administered to intubated, mechanically ventilated adult patients to provide continuous sedation and control of stress responses only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management. Propofol injectable emulsion is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established (see PRECAUTIONS , Pediatric Use). Propofol injectable emulsion is not recommended for obstetrics, including Cesarean section deliveries. Propofol injectable emulsion crosses the placenta, and as with other general anesthetic agents, the administration of propofol injectable emulsion may be associated with neonatal depression (see PRECAUTIONS ). Propofol is not recommended for use in nursing mothers because propofol injectable emulsion has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of propofol are not known (see PRECAUTIONS ). INDICATIONS &amp; USAGE"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "proven or strongly suspected susceptible bacteria infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73a6162f-3b59-5eee-af10-a50a1f41652c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39406e44-0ed2-5ea0-a8ec-f119eb87a036", "object": "UMLS:C3714514", "object_location_in_text": [226, 236], "original_object": "infections", "original_subject": "DICLOXACILLIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2861a407-7898-489d-a43c-1e316341863e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2861a407-7898-489d-a43c-1e316341863e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2861a407-7898-489d-a43c-1e316341863e"]}], "subject": "CHEBI:4511", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules USP and other antibacterial drugs, dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing ) . Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "proven or strongly suspected susceptible bacteria infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77bcc729-7850-559f-8293-d48842c1e3ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39406e44-0ed2-5ea0-a8ec-f119eb87a036", "object": "UMLS:C3714514", "object_location_in_text": [226, 236], "original_object": "infections", "original_subject": "DICLOXACILLIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:939f13c5-c394-49c1-ae57-edc44438a9de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=939f13c5-c394-49c1-ae57-edc44438a9de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=939f13c5-c394-49c1-ae57-edc44438a9de"]}], "subject": "CHEBI:4511", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules USP and other antibacterial drugs, dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing ) . Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "proven or strongly suspected susceptible bacteria infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fee1c648-3868-5d58-abee-60869f6c3381", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39406e44-0ed2-5ea0-a8ec-f119eb87a036", "object": "UMLS:C3714514", "object_location_in_text": [226, 236], "original_object": "infections", "original_subject": "DICLOXACILLIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e12a13dd-b93d-452c-8671-aec751ddaa4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e12a13dd-b93d-452c-8671-aec751ddaa4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e12a13dd-b93d-452c-8671-aec751ddaa4d"]}], "subject": "CHEBI:4511", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules USP and other antibacterial drugs, dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing ) . Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "proven or strongly suspected susceptible bacteria infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff7bd86e-64ea-5f58-a225-4a59d3132c15", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39406e44-0ed2-5ea0-a8ec-f119eb87a036", "object": "UMLS:C3714514", "object_location_in_text": [226, 236], "original_object": "infections", "original_subject": "DICLOXACILLIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3393668f-ea58-442e-b293-c7107b69d1af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3393668f-ea58-442e-b293-c7107b69d1af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3393668f-ea58-442e-b293-c7107b69d1af"]}], "subject": "CHEBI:4511", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules USP and other antibacterial drugs, dicloxacillin sodium capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see CLINICAL PHARMACOLOGY – Susceptibility Plate Testing ) . Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "infection caused by larva of pork tapeworm in the central nervous system", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09a25e69-847a-51bc-8a2b-78daba6e2f05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19810101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:8a1cf688-dc2f-5bbb-a101-aae6035105e7", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:a7a7f9f0-3489-5e5c-84ad-c759f3b58848", "object": "UMLS:C0338437", "original_object": "neurocysticercosis", "original_subject": "Praziquantel Tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:45267", "supporting_text": ["Neurocysticercosis- In the treatment of infections brought about the larvas of the pork tapeworm in the central nervous system."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "concomitant HIV infection", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f410449-29b2-5bb1-a47f-11ab37a8e9df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["other antituberculous agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ccc48b1f-7f06-5ffa-b049-44fe27da9602", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b4bca79-e53a-51dd-a79c-bfd0a19d429b", "object": "MONDO:0100481", "object_location_in_text": [55, 74], "original_object": "active tuberculosis", "original_subject": "PYRAZINAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1d97cb1-8072-4503-84c6-fe7f2fd3fd48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1d97cb1-8072-4503-84c6-fe7f2fd3fd48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1d97cb1-8072-4503-84c6-fe7f2fd3fd48"]}], "subject": "CHEBI:45285", "supporting_text": ["Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "monoamine oxidase inhibitor administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d67e66d-bf6a-518f-8ad5-c485f63a5fdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase inhibitors"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d438eb03-444f-5f85-9466-dd17d533c262", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a494b4d0-2064-5283-a1f3-b3324766c35b", "object": "UMLS:C0020546", "original_object": "hypertensive crises", "original_subject": "DIETHYLPROPION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31b58e5e-60af-4466-bd20-4b648e867e64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31b58e5e-60af-4466-bd20-4b648e867e64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31b58e5e-60af-4466-bd20-4b648e867e64"]}], "subject": "CHEBI:4530", "supporting_text": ["Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension. (See .) PRECAUTIONS Agitated states. Patients with a history of drug abuse. Use in combination with other anorectic agents is contraindicated. During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006837", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f260be6-9fbc-55b5-aaaa-bf01849dfb0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006837"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76918077-e29b-532e-9151-77c9c6f73d1e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0000879", "original_object": "cutaneous candidiasis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:246585a0-e53e-4f54-8f8b-76536011ab23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=246585a0-e53e-4f54-8f8b-76536011ab23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=246585a0-e53e-4f54-8f8b-76536011ab23"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006837", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eb21769-c721-592a-8bb1-f749282a9553", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006837"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76918077-e29b-532e-9151-77c9c6f73d1e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0000879", "original_object": "cutaneous candidiasis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eadbd29d-5990-4987-833f-40cd0b2d2868", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eadbd29d-5990-4987-833f-40cd0b2d2868", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eadbd29d-5990-4987-833f-40cd0b2d2868"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox Olamine Topical Suspension USP, 1.0% is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:446f5157-9242-51a9-8b9f-41ddc37b5af2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0001461", "object_location_in_text": [122, 136], "original_object": "tinea corporis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c22416e-4293-4ba5-a983-137cbc6022db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c22416e-4293-4ba5-a983-137cbc6022db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c22416e-4293-4ba5-a983-137cbc6022db"]}], "subject": "CHEBI:453011", "supporting_text": ["Superficial Dermatophyte Infections Ciclopirox gel is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum . Seborrheic Dermatitis Ciclopirox gel is indicated for the topical treatment of seborrheic dermatitis of the scalp."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c443b23-1603-5798-a3b6-572a5ca0aa05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0001461", "object_location_in_text": [131, 145], "original_object": "tinea corporis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a74ed86-997a-4b86-b54a-b2b2c94e8abb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a74ed86-997a-4b86-b54a-b2b2c94e8abb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a74ed86-997a-4b86-b54a-b2b2c94e8abb"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4f3cf1a-7734-5582-b0e3-015fa38c0c34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0001461", "object_location_in_text": [153, 167], "original_object": "tinea corporis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eadbd29d-5990-4987-833f-40cd0b2d2868", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eadbd29d-5990-4987-833f-40cd0b2d2868", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eadbd29d-5990-4987-833f-40cd0b2d2868"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox Olamine Topical Suspension USP, 1.0% is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2e733b2-93bf-50d8-ae2c-1ef391bc3519", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0001461", "object_location_in_text": [161, 175], "original_object": "tinea corporis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:246585a0-e53e-4f54-8f8b-76536011ab23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=246585a0-e53e-4f54-8f8b-76536011ab23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=246585a0-e53e-4f54-8f8b-76536011ab23"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:039999a9-53c5-50b4-adf8-188448c209b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca11318c-9396-55ca-8256-223b08d07e2d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "MONDO:0001628", "object_location_in_text": [311, 324], "original_object": "onychomycosis", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ce98020-5615-4332-bf57-72777e2ce038", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ce98020-5615-4332-bf57-72777e2ce038", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ce98020-5615-4332-bf57-72777e2ce038"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (Nail Lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (Nail Lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (Nail Lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (Nail Lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (Nail Lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data : The results of use of ciclopirox topical solution, 8% (Nail La"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1da36946-a049-528a-aeaf-147ae64c39d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca11318c-9396-55ca-8256-223b08d07e2d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "MONDO:0001628", "object_location_in_text": [311, 324], "original_object": "onychomycosis", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3e0ea78-42c0-4430-b299-fffee9e09c16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3e0ea78-42c0-4430-b299-fffee9e09c16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3e0ea78-42c0-4430-b299-fffee9e09c16"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of ciclopirox topical solution, 8% (nail lacquer) and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solutio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4acd5d94-f036-59e5-9093-6b1ab0b2f9d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca11318c-9396-55ca-8256-223b08d07e2d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "MONDO:0001628", "object_location_in_text": [311, 324], "original_object": "onychomycosis", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79084b47-7481-4926-9837-e08f633b1ddf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79084b47-7481-4926-9837-e08f633b1ddf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79084b47-7481-4926-9837-e08f633b1ddf"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of ciclopirox topical solution, 8% (nail lacquer) and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solutio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7fb46086-454d-5ffc-8d5e-bdca1da92c05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca11318c-9396-55ca-8256-223b08d07e2d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0001628", "object_location_in_text": [310, 323], "original_object": "onychomycosis", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c67dd09-ab1f-4ccf-97b5-421356f64f22", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c67dd09-ab1f-4ccf-97b5-421356f64f22", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c67dd09-ab1f-4ccf-97b5-421356f64f22"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entireINDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis.Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied. The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d8a1a6c-cf07-5d84-b84d-b4321b966092", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca11318c-9396-55ca-8256-223b08d07e2d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "MONDO:0001628", "object_location_in_text": [311, 324], "original_object": "onychomycosis", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:efcd78c0-2426-4fcc-a1c8-527e4e6f99d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=efcd78c0-2426-4fcc-a1c8-527e4e6f99d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=efcd78c0-2426-4fcc-a1c8-527e4e6f99d3"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire Error! Hyperlink reference not valid. section of the labeling.) Ciclopirox Topical Solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. • No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. • Ciclopirox Topical Solution, 8% should be used only under medical supervision as described above. • The effectiveness and safety of ciclopirox topical solution, 8% in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. • The safety and efficacy of using Ciclopirox Topical Solution, 8% daily for greater than 48 weeks have not been established. Clinical Trials Data - The results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula invo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2011a94-428f-5f38-a194-bc76b0b19d49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca11318c-9396-55ca-8256-223b08d07e2d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "MONDO:0001628", "object_location_in_text": [311, 324], "original_object": "onychomycosis", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1548af93-0dc1-4606-865f-6201b2bb7de1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1548af93-0dc1-4606-865f-6201b2bb7de1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1548af93-0dc1-4606-865f-6201b2bb7de1"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of ciclopirox topical solution, 8% (nail lacquer) and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solutio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006837", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6bdc8457-c9cd-5c83-b47f-6608adf37b62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006837"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0002026", "original_object": "candidiasis", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a74ed86-997a-4b86-b54a-b2b2c94e8abb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a74ed86-997a-4b86-b54a-b2b2c94e8abb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a74ed86-997a-4b86-b54a-b2b2c94e8abb"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032030", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10beeffb-535a-5af5-af0a-5ca285e4304f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032030"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:807f572f-abe5-5ab0-9756-61a614b1e489", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0005915", "original_object": "tinea versicolor", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eadbd29d-5990-4987-833f-40cd0b2d2868", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eadbd29d-5990-4987-833f-40cd0b2d2868", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eadbd29d-5990-4987-833f-40cd0b2d2868"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox Olamine Topical Suspension USP, 1.0% is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032030", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:541caf34-20ff-5fa1-81e0-75028390c396", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032030"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:807f572f-abe5-5ab0-9756-61a614b1e489", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0005915", "original_object": "tinea versicolor", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:246585a0-e53e-4f54-8f8b-76536011ab23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=246585a0-e53e-4f54-8f8b-76536011ab23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=246585a0-e53e-4f54-8f8b-76536011ab23"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032030", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5727fdd8-cfbd-5996-9160-7384ca0fe0c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032030"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:807f572f-abe5-5ab0-9756-61a614b1e489", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "object": "MONDO:0005915", "original_object": "tinea versicolor", "original_subject": "CICLOPIROX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a74ed86-997a-4b86-b54a-b2b2c94e8abb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a74ed86-997a-4b86-b54a-b2b2c94e8abb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a74ed86-997a-4b86-b54a-b2b2c94e8abb"]}], "subject": "CHEBI:453011", "supporting_text": ["Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02249902-7e4c-5dfc-8547-ad3f4de34f19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5dc96f7-e293-5f17-83a6-8e01b27054b4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "UMLS:C1274469", "object_location_in_text": [295, 336], "original_object": "onychomycosis of fingernails and toenails", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02f46b6e-b424-4210-83bf-e79618df4344", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02f46b6e-b424-4210-83bf-e79618df4344", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02f46b6e-b424-4210-83bf-e79618df4344"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. • No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. • Ciclopirox Topical Solution, 8% should be used only under medical supervision as described above. • The effectiveness and safety of ciclopirox topical solution, 8% in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. • The safety and efficacy of using Ciclopirox Topical Solution, 8% daily for greater than 48 weeks have not been established. Clinical Trials Data - The results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obt"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e41c834-ae9c-5a89-95c9-5c47960a3b70", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5dc96f7-e293-5f17-83a6-8e01b27054b4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "UMLS:C1274469", "object_location_in_text": [310, 351], "original_object": "onychomycosis of fingernails and toenails", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb7b7163-2ee7-447a-b585-7a240070f84b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb7b7163-2ee7-447a-b585-7a240070f84b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb7b7163-2ee7-447a-b585-7a240070f84b"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of thelabeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. • No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of ciclopirox topical solution, 8% (nail lacquer) and systemic antifungal agents for onychomycosis, is not recommended. • Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. • The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. • The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ccc0177-268a-5f41-9768-42f1ce19072d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5dc96f7-e293-5f17-83a6-8e01b27054b4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "UMLS:C1274469", "object_location_in_text": [298, 339], "original_object": "onychomycosis of fingernails and toenails", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b281493f-ce8c-42f8-95c7-2eb1c9712157", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b281493f-ce8c-42f8-95c7-2eb1c9712157", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b281493f-ce8c-42f8-95c7-2eb1c9712157"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATION AND USAGE section of the labeling.) Ciclopirox topical solution, USP 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of ciclopirox topical solution, 8% and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obtained "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:312da9d9-c0b8-5c72-adb5-72cc01b50019", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5dc96f7-e293-5f17-83a6-8e01b27054b4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "UMLS:C1274469", "object_location_in_text": [298, 339], "original_object": "onychomycosis of fingernails and toenails", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a08137a9-331f-4615-9752-e2cb52b3d8fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a08137a9-331f-4615-9752-e2cb52b3d8fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a08137a9-331f-4615-9752-e2cb52b3d8fc"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATION AND USAGE section of the labeling.) Ciclopirox topical solution, USP 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of ciclopirox topical solution, 8% and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obtained "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50bb62f8-f8ec-5647-aa25-6eaa5fcab235", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19821230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f5dc96f7-e293-5f17-83a6-8e01b27054b4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:83366363-cd07-5a04-ab90-acc50901ca56", "medic_supporting_text_truncated": true, "object": "UMLS:C1274469", "object_location_in_text": [295, 336], "original_object": "onychomycosis of fingernails and toenails", "original_subject": "CICLOPIROX", "population_context_qualifier": "immunocompetent patients with mild to moderate onychomycosis without lunula involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7e22682-1485-47e5-b6ae-94534bd3d889", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7e22682-1485-47e5-b6ae-94534bd3d889", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7e22682-1485-47e5-b6ae-94534bd3d889"]}], "subject": "CHEBI:453011", "supporting_text": ["(To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. • No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. • Ciclopirox Topical Solution, 8% should be used only under medical supervision as described above. • The effectiveness and safety of ciclopirox topical solution, 8% in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. • The safety and efficacy of using Ciclopirox Topical Solution, 8% daily for greater than 48 weeks have not been established. Clinical Trials Data - The results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obt"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026926", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4fa7ab8d-80d9-59e2-b4d6-c4e8d1bcfd3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980622", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["one or more antituberculosis (anti-TB) drugs"], "medic_disease_context_ids": ["UMLS:C0026926"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:28b4d884-b18b-55df-b69f-cb4300a1bf95", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1729b7b0-224f-5bc6-9fd9-44be98672a08", "object": "MONDO:0006052", "object_location_in_text": [139, 168], "original_object": "active pulmonary tuberculosis", "original_subject": "RIFAPENTINE", "population_context_qualifier": "adults and children 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3882444-18ca-4708-a51b-6c089664c10c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3882444-18ca-4708-a51b-6c089664c10c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3882444-18ca-4708-a51b-6c089664c10c"]}], "subject": "CHEBI:45304", "supporting_text": ["1 INDICATIONS AND USAGE PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0026926", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:487c6a03-28d3-5bb4-aa81-4f63ce4065af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980622", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["isoniazid"], "medic_disease_context_ids": ["UMLS:C0026926"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:442f98b4-b672-50f7-ae83-9b45704af308", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1729b7b0-224f-5bc6-9fd9-44be98672a08", "object": "MONDO:0040753", "object_location_in_text": [363, 392], "original_object": "latent tuberculosis infection", "original_subject": "RIFAPENTINE", "population_context_qualifier": "adults and children 2 years and older at high risk of progression to tuberculosis disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3882444-18ca-4708-a51b-6c089664c10c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3882444-18ca-4708-a51b-6c089664c10c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3882444-18ca-4708-a51b-6c089664c10c"]}], "subject": "CHEBI:45304", "supporting_text": ["1 INDICATIONS AND USAGE PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0694539", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b332c82-202a-5de8-aa53-1e767c71f126", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694539"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b0fba24-e527-5cb0-ad51-cece25ff9d69", "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "DIGOXIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dfac7f13-28be-423d-9389-9089da29da17", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dfac7f13-28be-423d-9389-9089da29da17", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dfac7f13-28be-423d-9389-9089da29da17"]}], "subject": "CHEBI:4551", "supporting_text": ["1 INDICATIONS AND USAGE Digoxin tablets are a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin tablets are indicated for the treatment of mild to moderate heart failure in adults. Digoxin tablets increase left ventricular ejection fraction and improve heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin tablets should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients Digoxin tablets increase myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin tablets are indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0694539", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ce02b08-ea30-511b-a5b0-a5d6412b644e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694539"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b0fba24-e527-5cb0-ad51-cece25ff9d69", "object": "MONDO:0004981", "object_location_in_text": [637, 656], "original_object": "atrial fibrillation", "original_subject": "DIGOXIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:75c99fc4-33b6-c3ce-e053-2991aa0a4d88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=75c99fc4-33b6-c3ce-e053-2991aa0a4d88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75c99fc4-33b6-c3ce-e053-2991aa0a4d88"]}], "subject": "CHEBI:4551", "supporting_text": ["1. INDICATIONS &amp; USAGE 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0694539", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddcf7296-b6d5-5dbe-8fd1-649e3efbabc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694539"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b0fba24-e527-5cb0-ad51-cece25ff9d69", "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "DIGOXIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcf907d9-0f0e-4ecc-a555-7e6dcc08c166", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcf907d9-0f0e-4ecc-a555-7e6dcc08c166", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcf907d9-0f0e-4ecc-a555-7e6dcc08c166"]}], "subject": "CHEBI:4551", "supporting_text": ["1 INDICATIONS AND USAGE In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1) In pediatric patients with heart failure, digoxin increases myocardial contractility. 1.1 Heart Failure Digoxin Oral Solution, USP is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin Oral Solution, USP is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. Digoxin should not be used for the treatment of multifocal atrial tachycardia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0694539", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1135d115-507d-5b7d-8e88-514b605aee7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694539"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2d142d8-6376-5525-b72f-434d8e91de10", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b0fba24-e527-5cb0-ad51-cece25ff9d69", "object": "UMLS:C0694539", "object_location_in_text": [274, 301], "original_object": "chronic atrial fibrillation", "original_subject": "DIGOXIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcf9b23b-5840-46ff-bb61-c57a02831a03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcf9b23b-5840-46ff-bb61-c57a02831a03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcf9b23b-5840-46ff-bb61-c57a02831a03"]}], "subject": "CHEBI:4551", "supporting_text": ["1 INDICATIONS &amp; USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0694539", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:986f000a-36cb-5681-95b5-ba7291972946", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694539"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2d142d8-6376-5525-b72f-434d8e91de10", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b0fba24-e527-5cb0-ad51-cece25ff9d69", "object": "UMLS:C0694539", "object_location_in_text": [274, 301], "original_object": "chronic atrial fibrillation", "original_subject": "DIGOXIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e61d2108-d871-44c0-b12a-2e61fbb56967", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e61d2108-d871-44c0-b12a-2e61fbb56967", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e61d2108-d871-44c0-b12a-2e61fbb56967"]}], "subject": "CHEBI:4551", "supporting_text": ["1 INDICATIONS &amp; USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0694539", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:debda0b7-608e-5074-be85-4fb6ce38f08e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0694539"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2d142d8-6376-5525-b72f-434d8e91de10", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2b0fba24-e527-5cb0-ad51-cece25ff9d69", "object": "UMLS:C0694539", "object_location_in_text": [274, 301], "original_object": "chronic atrial fibrillation", "original_subject": "DIGOXIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e23bf2a6-1c24-44c4-8135-e469900f84b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e23bf2a6-1c24-44c4-8135-e469900f84b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e23bf2a6-1c24-44c4-8135-e469900f84b2"]}], "subject": "CHEBI:4551", "supporting_text": ["1 INDICATIONS &amp; USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3125c575-0deb-5a53-8bc0-f3f673833ba3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b31fbfe9-2391-525a-8aca-36ca1f388446", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d25b6756-3c6a-5e63-b132-316d41019b2e", "object": "MONDO:0000745", "original_object": "hyperkalemia and cardiac arrest", "original_subject": "SUCCINYLCHOLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e235eb7d-5ce2-4884-9d16-493c90d7beba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e235eb7d-5ce2-4884-9d16-493c90d7beba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e235eb7d-5ce2-4884-9d16-493c90d7beba"]}], "subject": "CHEBI:45652", "supporting_text": ["4 CONTRAINDICATIONS SUCCINYLCHOLINE CHLORIDE INJECTION, USP is contraindicated: in patients with skeletal muscle myopathies [see Warnings and Precautions (5.1) ] in patients with known hypersensitivity to succinylcholine. Severe anaphylactic reactions to succinylcholine have been reported [see Warnings and Precautions (5.2) ] after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, which may result in severe hyperkalemia and cardiac arrest [see Warnings and Precautions (5.4) ] in patients with known or suspected genetic susceptibility to malignant hyperthermia [see Warnings and Precautions (5.5) , Clinical Pharmacology (12.5) ] Skeletal muscle myopathies. (4) Known hypersensitivity to succinylcholine. (4) After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury. (4) Known or suspected genetic susceptibility to malignant hyperthermia. (4)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10d64676-37b0-5c58-8d1e-58fa96ea1698", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:79dd7e82-4c76-586f-8581-99325e2c9d05", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "HP:0005506", "original_object": "chronic myeloid leukaemia", "original_subject": "imatinib", "population_context_qualifier": "adult and paediatric patients in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imatinib-accord", "https://www.ema.europa.eu/en/documents/product-information/imatinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord"]}], "subject": "CHEBI:45783", "supporting_text": ["Imatinib Accord is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.&nbsp; adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.&nbsp; adult patients with relapsed or refractory Ph+ ALL as monotherapy.&nbsp; adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.&nbsp; adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.&nbsp; adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).&nbsp; the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.&nbsp;  Patients who have a low or very low risk of recurrence should not receive adjuvant treatment The effect of imatinib on the outcome of bone marrow transplantation has not been determined. In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de3c0d59-de20-5860-b9ca-abb156fc1022", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:99b9bb22-5bb9-51d1-9eec-f1134c206235", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukaemia", "original_subject": "imatinib", "population_context_qualifier": "adult patients with relapsed or refractory", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imatinib-accord", "https://www.ema.europa.eu/en/documents/product-information/imatinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord"]}], "subject": "CHEBI:45783", "supporting_text": ["Imatinib Accord is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.&nbsp; adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.&nbsp; adult patients with relapsed or refractory Ph+ ALL as monotherapy.&nbsp; adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.&nbsp; adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.&nbsp; adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).&nbsp; the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.&nbsp;  Patients who have a low or very low risk of recurrence should not receive adjuvant treatment The effect of imatinib on the outcome of bone marrow transplantation has not been determined. In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1518321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:364e7bb5-fc1f-5b36-8a20-9314c28517e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C1518321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "IMATINIB", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c037022-7fc8-4b6e-9db3-427206c572b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c037022-7fc8-4b6e-9db3-427206c572b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c037022-7fc8-4b6e-9db3-427206c572b4"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy ( 1.4 ) • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown ( 1.6 ) • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1518321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c862f83-f0de-57c0-9b75-3b7099d5a7cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C1518321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "IMATINIB", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0291eca5-7a1d-4a79-30be-252224d96509", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy ( 1.4 ) • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown ( 1.6 ) • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1518321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:685616fe-075f-51a6-8c25-9176b09f10d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C1518321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "IMATINIB", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e7ed4ef-24e3-4545-9a99-2e34c946e8e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e7ed4ef-24e3-4545-9a99-2e34c946e8e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e7ed4ef-24e3-4545-9a99-2e34c946e8e7"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) . Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1518321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef83f919-5d84-5843-b15c-20a5df7cf1b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C1518321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "IMATINIB", "population_context_qualifier": "Pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d07ac08-962e-41a8-8a3c-50febc8c5f34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d07ac08-962e-41a8-8a3c-50febc8c5f34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d07ac08-962e-41a8-8a3c-50febc8c5f34"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d39db2c-4c59-56ce-9f0e-c493d0451024", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:fb3c8e2d-6f01-521d-b426-3a4221d0d3c5", "medic_pair_confidence": 0.9639, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0006311", "original_object": "myelodysplastic/myeloproliferative diseases", "original_subject": "imatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:glivec", "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"]}], "subject": "CHEBI:45783", "supporting_text": ["Glivec is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment; adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis; adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy; adult patients with relapsed or refractory Ph+ ALL as monotherapy; adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.  The effect of Glivec on the outcome of bone-marrow transplantation has not been determined. Glivec is indicated for:  the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST); the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment; the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery.  In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2ddda4b-0a36-55d3-882e-8f766ccaa581", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:fb3c8e2d-6f01-521d-b426-3a4221d0d3c5", "medic_pair_confidence": 0.9639, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0006311", "original_object": "myelodysplastic/myeloproliferative diseases", "original_subject": "imatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imatinib-accord", "https://www.ema.europa.eu/en/documents/product-information/imatinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord"]}], "subject": "CHEBI:45783", "supporting_text": ["Imatinib Accord is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.&nbsp; adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.&nbsp; adult patients with relapsed or refractory Ph+ ALL as monotherapy.&nbsp; adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.&nbsp; adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.&nbsp; adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).&nbsp; the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.&nbsp;  Patients who have a low or very low risk of recurrence should not receive adjuvant treatment The effect of imatinib on the outcome of bone marrow transplantation has not been determined. In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de9e2f86-3c3f-5a35-9ab8-40bd5665c1a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:fb3c8e2d-6f01-521d-b426-3a4221d0d3c5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0006311", "original_object": "myelodysplastic/myeloproliferative diseases", "original_subject": "imatinib", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imatinib-teva", "https://www.ema.europa.eu/en/documents/product-information/imatinib-teva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva"]}], "subject": "CHEBI:45783", "supporting_text": ["Imatinib Teva is indicated for the treatment of  Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr?abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon?alpha therapy, or in accelerated phase or blast crisis. Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph+ ALL as monotherapy. Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.  The effect of imatinib on the outcome of bone marrow transplantation has not been determined. Imatinib Teva is indicated for  the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.  In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recur"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:012a12e4-6e99-563a-af92-3dae64366cf1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fb3c8e2d-6f01-521d-b426-3a4221d0d3c5", "medic_pair_confidence": 0.9639, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0006311", "original_object": "myelodysplastic/myeloproliferative diseases", "original_subject": "IMATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1787fad-3612-43e1-98fa-ce62361e0b3c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1787fad-3612-43e1-98fa-ce62361e0b3c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1787fad-3612-43e1-98fa-ce62361e0b3c"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platelet-derived growth factor receptor (PDGFR) gene re-arrangements", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea732e7d-7d0a-5a70-8b75-65a73dd71365", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fb3c8e2d-6f01-521d-b426-3a4221d0d3c5", "medic_pair_confidence": 0.9639, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0006311", "original_object": "myelodysplastic/myeloproliferative diseases", "original_subject": "IMATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0611fc0-b217-4988-acd4-b8c629ce489b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0611fc0-b217-4988-acd4-b8c629ce489b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0611fc0-b217-4988-acd4-b8c629ce489b"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) Af"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:016cdffb-c6d5-526b-8de5-98f05e935faa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1debf3a0-7587-47d7-8ea6-e739698d7297", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1debf3a0-7587-47d7-8ea6-e739698d7297", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1debf3a0-7587-47d7-8ea6-e739698d7297"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3881d405-7335-5fb4-b81a-4a7f4e8b2ddd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9131b2ce-752d-3a30-e053-2a95a90adaab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9131b2ce-752d-3a30-e053-2a95a90adaab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9131b2ce-752d-3a30-e053-2a95a90adaab"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53ad4692-d4b1-5283-a270-950e80934891", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:211ef2da-2868-4a77-8055-1cb2cd78e24b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interf"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b3448e7-44dd-51b3-ad0c-e6a4e63bec52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:07764bf9-21b4-4e32-9d7e-e348f8e4291f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=07764bf9-21b4-4e32-9d7e-e348f8e4291f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07764bf9-21b4-4e32-9d7e-e348f8e4291f"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1­-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After I"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c7c21a6-3f5b-54de-be7d-c3f988a2507e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82eb01e0-8685-4f06-8a72-7663e8ded38f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82eb01e0-8685-4f06-8a72-7663e8ded38f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82eb01e0-8685-4f06-8a72-7663e8ded38f"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c74a6f7-33cd-5b37-8189-84d65bfe69ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0611fc0-b217-4988-acd4-b8c629ce489b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0611fc0-b217-4988-acd4-b8c629ce489b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0611fc0-b217-4988-acd4-b8c629ce489b"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) Af"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ddcb5a5-ad6f-5b83-b5a7-83c18d0b2750", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be5b9047-155b-59ca-e053-2995a90ad3dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be5b9047-155b-59ca-e053-2995a90ad3dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be5b9047-155b-59ca-e053-2995a90ad3dc"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1‑-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After I"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8631df1-6951-5c33-a926-d9076f70d370", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9cfc301-3c7f-4910-8813-41dcb0b4ca69", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9cfc301-3c7f-4910-8813-41dcb0b4ca69", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9cfc301-3c7f-4910-8813-41dcb0b4ca69"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d364545a-e1c6-561f-92c4-86084d71e5c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a819a954-41c9-4d49-a74e-c8c4b338b22a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interfer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d89f9de9-31fe-5aea-b899-7aaf6253a1d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4e409f7-20b4-4c80-8a6a-f95995ffad78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4e409f7-20b4-4c80-8a6a-f95995ffad78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4e409f7-20b4-4c80-8a6a-f95995ffad78"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interfer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9a5160e-f984-5f56-85c4-4d80548de34c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4acacbd-13f8-4a46-b615-b639a17f331f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4acacbd-13f8-4a46-b615-b639a17f331f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4acacbd-13f8-4a46-b615-b639a17f331f"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, recurrent and/or metastatic", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe4174c9-ff42-57b0-a2ca-d16ecfd9e156", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58d8811-d0cc-5661-bfb9-d731be22b480", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0011934", "original_object": "dermatofibrosarcoma protuberans", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) Af"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFRa rearrangement", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:409bacef-16f5-5a25-ace4-58c140e5f58a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9b5b3082-ea1c-5ac5-9725-6340353c941d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015687", "original_object": "chronic eosinophilic leukaemia", "original_subject": "imatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:glivec", "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"]}], "subject": "CHEBI:45783", "supporting_text": ["Glivec is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment; adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis; adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy; adult patients with relapsed or refractory Ph+ ALL as monotherapy; adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.  The effect of Glivec on the outcome of bone-marrow transplantation has not been determined. Glivec is indicated for:  the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST); the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment; the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery.  In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFR? rearrangement", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:649f03bb-40ae-5254-b9d5-2b815dd9cbb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9b5b3082-ea1c-5ac5-9725-6340353c941d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015687", "original_object": "chronic eosinophilic leukaemia", "original_subject": "imatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imatinib-accord", "https://www.ema.europa.eu/en/documents/product-information/imatinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord"]}], "subject": "CHEBI:45783", "supporting_text": ["Imatinib Accord is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.&nbsp; adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.&nbsp; adult patients with relapsed or refractory Ph+ ALL as monotherapy.&nbsp; adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.&nbsp; adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.&nbsp; adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).&nbsp; the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.&nbsp;  Patients who have a low or very low risk of recurrence should not receive adjuvant treatment The effect of imatinib on the outcome of bone marrow transplantation has not been determined. In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFRα fusion kinase positive", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39d0d1ac-ee78-50f0-9fad-d1265a5acd44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecd3f371-41b1-561a-b5be-a2245f8fad35", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015687", "original_object": "chronic eosinophilic leukemia", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4e409f7-20b4-4c80-8a6a-f95995ffad78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4e409f7-20b4-4c80-8a6a-f95995ffad78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4e409f7-20b4-4c80-8a6a-f95995ffad78"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interfer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFRα fusion kinase positive", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef0efd6f-f610-576b-9d86-af0419a0b8c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecd3f371-41b1-561a-b5be-a2245f8fad35", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015687", "original_object": "chronic eosinophilic leukemia", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a819a954-41c9-4d49-a74e-c8c4b338b22a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interfer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:604636eb-af67-5fc8-9c33-62132cbb2ae9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:56df3583-f964-52fe-bcaa-01cdab185c83", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015691", "original_object": "hypereosinophilic syndrome", "original_subject": "imatinib", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imatinib-teva", "https://www.ema.europa.eu/en/documents/product-information/imatinib-teva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva"]}], "subject": "CHEBI:45783", "supporting_text": ["Imatinib Teva is indicated for the treatment of  Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr?abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon?alpha therapy, or in accelerated phase or blast crisis. Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. Adult patients with relapsed or refractory Ph+ ALL as monotherapy. Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR? rearrangement.  The effect of imatinib on the outcome of bone marrow transplantation has not been determined. Imatinib Teva is indicated for  the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.  In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recur"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFRa rearrangement", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c56ad3e0-4cc0-5e71-92c8-3aab99813a1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011107", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:56df3583-f964-52fe-bcaa-01cdab185c83", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015691", "original_object": "hypereosinophilic syndrome", "original_subject": "imatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:glivec", "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"]}], "subject": "CHEBI:45783", "supporting_text": ["Glivec is indicated for the treatment of  adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment; adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis; adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy; adult patients with relapsed or refractory Ph+ ALL as monotherapy; adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.  The effect of Glivec on the outcome of bone-marrow transplantation has not been determined. Glivec is indicated for:  the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST); the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment; the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery.  In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFRα fusion kinase positive", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18b8db60-cef2-50cd-8802-9c043a1c3e6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56df3583-f964-52fe-bcaa-01cdab185c83", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015691", "original_object": "hypereosinophilic syndrome", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4e409f7-20b4-4c80-8a6a-f95995ffad78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4e409f7-20b4-4c80-8a6a-f95995ffad78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4e409f7-20b4-4c80-8a6a-f95995ffad78"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interfer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "FIP1L1-PDGFRα fusion kinase positive", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39126b48-380b-56d6-8e6a-3c4647c5b43d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56df3583-f964-52fe-bcaa-01cdab185c83", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8bc46413-79e5-59d7-8a3a-90792ce5f5fb", "medic_supporting_text_truncated": true, "object": "MONDO:0015691", "original_object": "hypereosinophilic syndrome", "original_subject": "IMATINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a819a954-41c9-4d49-a74e-c8c4b338b22a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a"]}], "subject": "CHEBI:45783", "supporting_text": ["1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interfer"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d99ec2a-d58e-5c3b-b371-c9a9b6dfd8f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "MONDO:0001475", "original_object": "severe neutropenia", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c12c77c-5fd4-48dc-a318-e96892233992", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c12c77c-5fd4-48dc-a318-e96892233992", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c12c77c-5fd4-48dc-a318-e96892233992"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyl 35 castor oil. Paclitaxel should not be used in patients with solid tumors who have baseline neutrophil counts of &lt;1,500 cells/mm 3 or in patients with AIDS-related Kaposi's sarcoma with baseline neutrophil counts of &lt;1,000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:359dec73-9744-519a-8766-d7762aa327ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "MONDO:0001475", "original_object": "severe neutropenia", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4c5d08a-e0f5-4af1-97d6-213705adedf1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4c5d08a-e0f5-4af1-97d6-213705adedf1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4c5d08a-e0f5-4af1-97d6-213705adedf1"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel Injection, USP is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Polyoxyl 35 Castor Oil, NF. Paclitaxel Injection, USP should not be used in patients with solid tumors who have baseline neutrophil counts of &lt;1,500 cells/mm 3 or in patients with AIDS-related kaposi’s sarcoma with baseline neutrophil counts of &lt;1,000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55664813-056b-586e-a416-6a4f36fe4087", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "MONDO:0001475", "original_object": "severe neutropenia", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6c24189-293f-42ca-b969-75870bb55af0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyl 35 castor oil. Paclitaxel should not be used in patients with solid tumors who have baseline neutrophil counts of &lt;1,500 cells/mm 3 or in patients with AIDS-related Kaposi's sarcoma with baseline neutrophil counts of &lt;1,000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d160950-1fb7-5197-9414-94fbff52680d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "MONDO:0001475", "original_object": "severe neutropenia", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e7bc2c2-a369-4c6f-9dd9-ee98ddaae833", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e7bc2c2-a369-4c6f-9dd9-ee98ddaae833", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e7bc2c2-a369-4c6f-9dd9-ee98ddaae833"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel is contraindicated in patients who have a history of hypersensitivity reactions to Paclitaxel or other drugs formulated in polyoxyl 35 castor oil. Paclitaxel should not be used in patients with solid tumors who have baseline neutrophil counts of &lt;1,500 cells/mm 3 or in patients with AIDS-related Kaposi's sarcoma with baseline neutrophil counts of &lt;1,000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bea48da1-26f6-5ecf-af8a-67f24bc0d7e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "MONDO:0001475", "original_object": "severe neutropenia", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:30384708-1fcd-4a75-94d7-9d5d617a37b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=30384708-1fcd-4a75-94d7-9d5d617a37b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30384708-1fcd-4a75-94d7-9d5d617a37b6"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel is contraindicated in patients who have a history of hypersensitivity reactions to Paclitaxel or other drugs formulated in polyoxyl 35 castor oil. Paclitaxel should not be used in patients with solid tumors who have baseline neutrophil counts of &lt;1,500 cells/mm 3 or in patients with AIDS-related Kaposi's sarcoma with baseline neutrophil counts of &lt;1,000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d85e9bd6-510e-5b72-8759-17fe0ddd3e62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "MONDO:0001475", "original_object": "severe neutropenia", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59906bd2-8337-4cd8-9288-65b90eac2a7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59906bd2-8337-4cd8-9288-65b90eac2a7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59906bd2-8337-4cd8-9288-65b90eac2a7a"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in polyoxyl 35 castor oil. Paclitaxel should not be used in patients with solid tumors who have baseline neutrophil counts of &lt;1,500 cells/mm 3 or in patients with AIDS-related Kaposi's sarcoma with baseline neutrophil counts of &lt;1,000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "baseline neutrophil counts of < 1000 cells/mm3, 1000 cells/mm 3", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61a8afc1-e590-5013-a35f-e23cce2a120b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:934e2d1c-9bca-57c0-8795-ffcfe3df26b9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "UMLS:C0276535", "original_object": "AIDS-related Kaposi's sarcoma", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbd32bd2-9685-41cb-bee2-730a45526b65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbd32bd2-9685-41cb-bee2-730a45526b65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbd32bd2-9685-41cb-bee2-730a45526b65"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel injection is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel injection or other drugs formulated in polyoxyl 35 castor oil, NF. Paclitaxel injection should not be used in patients with solid tumors who have baseline neutrophil counts of &lt; 1500 cells/mm 3 or in patients with AIDS-related Kaposi’s sarcoma with baseline neutrophil counts of &lt; 1000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "baseline neutrophil counts of < 1000 cells/mm3, 1000 cells/mm 3", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2b3618e-3b9c-514a-917d-c390192ec5d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:934e2d1c-9bca-57c0-8795-ffcfe3df26b9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "UMLS:C0276535", "original_object": "AIDS-related Kaposi's sarcoma", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4be6cbf-72b9-4f7f-9b1b-459b2d35961a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4be6cbf-72b9-4f7f-9b1b-459b2d35961a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4be6cbf-72b9-4f7f-9b1b-459b2d35961a"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel injection is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel injection or other drugs formulated in polyoxyl 35 castor oil, NF. Paclitaxel injection should not be used in patients with solid tumors who have baseline neutrophil counts of &lt; 1500 cells/mm 3 or in patients with AIDS-related Kaposi’s sarcoma with baseline neutrophil counts of &lt; 1000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "baseline neutrophil counts of < 1500 cells/mm3, 1500 cells/mm 3", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:930e7564-2183-5c80-8d22-aab0eab8570e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c09d50f2-5522-5394-8bab-61cdacd994d3", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "UMLS:C0280100", "object_location_in_text": [239, 251], "original_object": "solid tumors", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4be6cbf-72b9-4f7f-9b1b-459b2d35961a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4be6cbf-72b9-4f7f-9b1b-459b2d35961a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4be6cbf-72b9-4f7f-9b1b-459b2d35961a"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel injection is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel injection or other drugs formulated in polyoxyl 35 castor oil, NF. Paclitaxel injection should not be used in patients with solid tumors who have baseline neutrophil counts of &lt; 1500 cells/mm 3 or in patients with AIDS-related Kaposi’s sarcoma with baseline neutrophil counts of &lt; 1000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "baseline neutrophil counts of < 1500 cells/mm3, 1500 cells/mm 3", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93dc18a9-44f6-5685-8ed6-97dda12a2733", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c09d50f2-5522-5394-8bab-61cdacd994d3", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a705cb6d-c662-5c7c-8a51-8e79f8dad0f2", "object": "UMLS:C0280100", "object_location_in_text": [239, 251], "original_object": "solid tumors", "original_subject": "PACLITAXEL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbd32bd2-9685-41cb-bee2-730a45526b65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbd32bd2-9685-41cb-bee2-730a45526b65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbd32bd2-9685-41cb-bee2-730a45526b65"]}], "subject": "CHEBI:45863", "supporting_text": ["Paclitaxel injection is contraindicated in patients who have a history of hypersensitivity reactions to paclitaxel injection or other drugs formulated in polyoxyl 35 castor oil, NF. Paclitaxel injection should not be used in patients with solid tumors who have baseline neutrophil counts of &lt; 1500 cells/mm 3 or in patients with AIDS-related Kaposi’s sarcoma with baseline neutrophil counts of &lt; 1000 cells/mm 3 ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "inability to monitor renal function", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afba9a91-9d39-5bc8-9c77-9eb8001d3b55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2869cec-4d7d-5906-92d8-319f52753490", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "object": "MONDO:0001106", "original_object": "severe renal insufficiency", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69af86b4-9c9f-4a70-b448-97b36698f3cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69af86b4-9c9f-4a70-b448-97b36698f3cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69af86b4-9c9f-4a70-b448-97b36698f3cd"]}], "subject": "CHEBI:45924", "supporting_text": ["Sulfamethoxazole and trimethoprim oral suspension is contraindicated in the following situations: known hypersensitivity to trimethoprim or sulfonamides history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides documented megaloblastic anemia due to folate deficiency pediatric patients less than 2 months of age marked hepatic damage severe renal insufficiency when renal function status cannot be monitored concomitant administration with dofetilide (see PRECAUTIONS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "surface ocular bacterial infections", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:524f1f0d-a54b-5d55-a29a-75ab0fc07acf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4da4d7e-4579-5344-a2ff-0a15d8e749a1", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "object": "MONDO:0002307", "object_location_in_text": [178, 200], "original_object": "blepharoconjunctivitis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac"]}], "subject": "CHEBI:45924", "supporting_text": ["Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * * Efficacy for this organism in this organ system was studied in fewer than 10 infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "surface ocular bacterial infections", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ab49647-d1be-5473-ab2b-bfb803d0f87c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:16232c6e-0732-543d-91b1-5f82e5b94e82", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "object": "MONDO:0006668", "object_location_in_text": [142, 172], "original_object": "acute bacterial conjunctivitis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac"]}], "subject": "CHEBI:45924", "supporting_text": ["Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * * Efficacy for this organism in this organ system was studied in fewer than 10 infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0275791", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:301586ba-9da8-543e-b538-a5db090b84ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0275791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:30c30e07-475c-51a5-bcde-c6a38ce22f28", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "object": "MONDO:0019345", "object_location_in_text": [1209, 1220], "original_object": "Shigellosis", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults and pediatric patients two months of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebb570bb-6e5e-489e-875c-9e7b3a6d716a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebb570bb-6e5e-489e-875c-9e7b3a6d716a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebb570bb-6e5e-489e-875c-9e7b3a6d716a"]}], "subject": "CHEBI:45924", "supporting_text": ["1 INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: Pneumocystis jirovecii Pneumonia (1.1) Shigellosis (1.2) Urinary Tract Infections (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and trimethoprim injection and other antibacterial drugs, Sulfamethoxazole and trimethoprim injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.4) 1.1 Pneumocystis jirovecii Pneumonia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22378b97-46c8-5939-9f55-5d87db42fd2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cdc4169-bb5b-5f5a-b7bc-7ae498686a50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40bc69a7-4d86-5277-8c24-a3f486c4e136", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d085fb8e-bb68-5063-9439-bf4c50ffec21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3336b49-979f-5222-a4be-da3a02a032ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3244edf3-94be-5eed-800c-1fbb67fc9fc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c19f9a8-e945-56b2-8aae-667d6b397875", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7bcd649-7837-5ffa-ab77-d85e5eced078", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc5dab92-c6d2-5a40-b013-6660ad54d2e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0275791", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4a43d38-80d2-56be-88c2-2418a61d7f4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0275791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1966, 1975], "original_object": "enteritis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3a49508-0ebe-1334-e053-2a95a90ae173", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3a49508-0ebe-1334-e053-2a95a90ae173", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3a49508-0ebe-1334-e053-2a95a90ae173"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim tablets offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible st"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c988ee12-c89f-5d03-b8e3-94721884a1dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "TRIMETHOPRIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b2ae58a-684f-5165-8a07-2026130bbebf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d1d3ee1-efba-5ee8-93a2-e5ee51912781", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763883", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4bed2c6d-7d6f-5af9-9c6a-bb2f534a74d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:562e2547-db2d-e2d2-e063-6294a90a1f5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=562e2547-db2d-e2d2-e063-6294a90a1f5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=562e2547-db2d-e2d2-e063-6294a90a1f5d"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:565f6c36-2d29-5cfe-9963-8d23d925bb17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763883", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:717b7b7b-e0e4-5bc7-bae7-9a7879b9b5fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ef62512-0dc3-4821-9b60-6b375841c4c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ef62512-0dc3-4821-9b60-6b375841c4c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ef62512-0dc3-4821-9b60-6b375841c4c0"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78ba6e44-b184-57f5-83a6-6189aaffd0b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8acc5864-ab2f-565a-869b-b3ec60255f86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763883", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2d0257e-8222-546e-b414-ab6db9e4fbd2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4da9c4f-0704-4ed5-9d19-5c949f37f726", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4da9c4f-0704-4ed5-9d19-5c949f37f726", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4da9c4f-0704-4ed5-9d19-5c949f37f726"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d340604-b539-5fff-b133-977f41f664f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c15d3779-1171-5129-afea-2756a59d98e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e53a594d-3293-527b-9b9c-f9ace5791b04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e90b1fc8-e5b2-5020-89c9-ce68065b572d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.51, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2fb467e-6bb0-5c2c-9895-a33036637866", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.51, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:63e97b61-ece3-5d7c-ba3c-e10874ca640b", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "TRIMETHOPRIM", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:45924", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Alzheimer's", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8736a7e-90aa-51bd-8d4d-a945f5366661", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960214", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:86f359e5-6529-5b96-a7fb-d3fe32db7d1c", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:7abd8692-dc9c-5246-acb0-64a8f3602d2a", "object": "MONDO:0001627", "object_location_in_text": [21, 29], "original_object": "dementia", "original_subject": "Tacrine Hcl 10mg/20mg/30mg/40mg", "population_context_qualifier": "patients with Alzheimer's", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:45980", "supporting_text": ["For the treatment of dementia in patients with Alzheimer's"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0472699", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f360401-b868-5454-be2d-0089fc0ac7b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111125", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0472699"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:43793720-8af8-5f56-801a-e1b2af1ae6d9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "UMLS:C0948382", "object_location_in_text": [99, 111], "original_object": "deep mycosis", "original_subject": "FLUCONAZOLE", "population_context_qualifier": "pediatric", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FLUCONAZOLE#148-20111125", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:46081", "supporting_text": ["Drugs with a new additional pediatric dosage and a new additional indication for the prevention of deep mycosis in patients with hematopoietic stem cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:415ca779-8eac-5396-863c-e0a9a3d26803", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c89c3bbd-1170-4170-e053-2a95a90a8e41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c89c3bbd-1170-4170-e053-2a95a90a8e41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c89c3bbd-1170-4170-e053-2a95a90a8e41"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a4d78f8-6506-56c5-8741-2841b4fdf0c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7961c029-746c-48c3-888b-8f8344102873", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7961c029-746c-48c3-888b-8f8344102873", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7961c029-746c-48c3-888b-8f8344102873"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d40ed1c-d1f7-5c54-90ed-7cf1b65bc49f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:982d8641-4a12-5fb7-9109-b4b70b3e8fce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaf9e5f8-048e-407c-bc11-ad4edff85c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaf9e5f8-048e-407c-bc11-ad4edff85c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaf9e5f8-048e-407c-bc11-ad4edff85c05"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd25d847-3481-5113-b1e2-49b2b97ff31d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0de7211d-b8ce-214d-e063-6294a90aec41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0de7211d-b8ce-214d-e063-6294a90aec41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0de7211d-b8ce-214d-e063-6294a90aec41"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfd78f84-6e6c-5a28-82ee-fc6934b2d679", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7259671f-a703-4a2a-81db-9a4839b34072", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7259671f-a703-4a2a-81db-9a4839b34072", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7259671f-a703-4a2a-81db-9a4839b34072"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e863c6d1-3152-501d-8451-a21343b667fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:67af604c-928f-468b-ba27-ad45e95d3e7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=67af604c-928f-468b-ba27-ad45e95d3e7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=67af604c-928f-468b-ba27-ad45e95d3e7e"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:164664cb-392a-5288-a25d-58b3ebb28cfd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c89c3bbd-1170-4170-e053-2a95a90a8e41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c89c3bbd-1170-4170-e053-2a95a90a8e41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c89c3bbd-1170-4170-e053-2a95a90a8e41"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26e0ab91-bdb8-56a5-a095-642251a621c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:67af604c-928f-468b-ba27-ad45e95d3e7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=67af604c-928f-468b-ba27-ad45e95d3e7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=67af604c-928f-468b-ba27-ad45e95d3e7e"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:773e72d2-f90d-53b4-84f2-453c6f6f2594", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0de7211d-b8ce-214d-e063-6294a90aec41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0de7211d-b8ce-214d-e063-6294a90aec41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0de7211d-b8ce-214d-e063-6294a90aec41"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9071e087-6850-5033-87f1-ad8d54c81731", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaf9e5f8-048e-407c-bc11-ad4edff85c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaf9e5f8-048e-407c-bc11-ad4edff85c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaf9e5f8-048e-407c-bc11-ad4edff85c05"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c81cb7df-fa14-5a72-bf3b-610c74c9065f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7961c029-746c-48c3-888b-8f8344102873", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7961c029-746c-48c3-888b-8f8344102873", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7961c029-746c-48c3-888b-8f8344102873"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebb31b19-c472-5382-871d-e8e0f18fa3aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7259671f-a703-4a2a-81db-9a4839b34072", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7259671f-a703-4a2a-81db-9a4839b34072", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7259671f-a703-4a2a-81db-9a4839b34072"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8a8bbbc-a75f-581a-81e7-184c169ac514", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:0005249", "object_location_in_text": [426, 435], "original_object": "pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:096f2c21-0eb8-5daf-8c97-7e12bf3c9ad5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [335, 346], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:16b6fba0-b96f-4252-a70d-31dc61400298", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=16b6fba0-b96f-4252-a70d-31dc61400298", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16b6fba0-b96f-4252-a70d-31dc61400298"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida ). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:140149b4-e4af-5925-a95a-ffd03e45a455", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7961c029-746c-48c3-888b-8f8344102873", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7961c029-746c-48c3-888b-8f8344102873", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7961c029-746c-48c3-888b-8f8344102873"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49b6945b-787e-501b-9361-a32c635a2ef6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c89c3bbd-1170-4170-e053-2a95a90a8e41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c89c3bbd-1170-4170-e053-2a95a90a8e41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c89c3bbd-1170-4170-e053-2a95a90a8e41"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b5137c2-4672-5a86-80f4-c0e6e3a25141", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0de7211d-b8ce-214d-e063-6294a90aec41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0de7211d-b8ce-214d-e063-6294a90aec41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0de7211d-b8ce-214d-e063-6294a90aec41"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ec90732-2bb6-5a0f-ae8c-49923558e6ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:67af604c-928f-468b-ba27-ad45e95d3e7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=67af604c-928f-468b-ba27-ad45e95d3e7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=67af604c-928f-468b-ba27-ad45e95d3e7e"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9907ab0-4761-5ac7-a840-fcfc2ca8c48c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5cfe0a1-f55c-41b1-8ad6-d1d0134a4d1d"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6691d64-3e98-53f6-96db-062a40183bfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7259671f-a703-4a2a-81db-9a4839b34072", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7259671f-a703-4a2a-81db-9a4839b34072", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7259671f-a703-4a2a-81db-9a4839b34072"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec884f45-98d9-5138-a355-60d2c7a19390", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "MONDO:1010128", "object_location_in_text": [329, 340], "original_object": "peritonitis", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaf9e5f8-048e-407c-bc11-ad4edff85c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaf9e5f8-048e-407c-bc11-ad4edff85c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaf9e5f8-048e-407c-bc11-ad4edff85c05"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3c0feca-4635-5da8-bcff-87a05e45183f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19900129", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e6d5896-21bf-5231-88d6-210ccaeff475", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6c6a9088-ea66-5b8b-8278-57306fc903e2", "object": "UMLS:C0948599", "original_object": "Candida pneumonia", "original_subject": "FLUCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:16b6fba0-b96f-4252-a70d-31dc61400298", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=16b6fba0-b96f-4252-a70d-31dc61400298", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16b6fba0-b96f-4252-a70d-31dc61400298"]}], "subject": "CHEBI:46081", "supporting_text": ["Fluconazole tablets are indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida ). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:239c8c17-07ee-53c9-82a8-24ed8dbbc0f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31786929-e958-55ac-9ac2-c04004fb1c90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:450be540-3058-567c-b884-55b90ffed369", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012531", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11a2db3f-1477-5f51-92ab-ea3d7063cce7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4f4807b-962f-5c69-9457-8a0df0bd64ed", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0001945", "object_location_in_text": [182, 187], "original_object": "fever", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4"]}], "subject": "CHEBI:46195", "supporting_text": ["Propoxyphene napsylate and acetaminophen tablets, 100 mg/650 mg are indicated for the relief of mild to moderate pain, either when pain is present alone or when it is accompanied by fever."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21ef1145-0385-52ad-992a-9565a0f9104c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2448e28c-6ef8-52a0-8e33-a82832bb22cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2690be5b-2903-584a-bca0-5cadad18ce55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [92, 100], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f9451b1-c0c4-5681-ae92-729646eaddfe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c6f37d7-39d5-5e7a-a6fb-ec2e97c5443d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f3345ff-bf99-5cb1-af90-94bb91c78d25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [92, 100], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a78813ca-d1e9-5095-8c57-4213c4846132", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7570753-c1ab-5107-8728-e1d14193f711", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21abb28b-a997-5b3f-acb1-41d70fac6566", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5501efc8-f4ae-55fa-a8a3-de7fd5fdd7cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f8ecc06-a85e-5893-bf89-bcf937c14069", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [83, 91], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88ecec3b-e3e7-516f-bc7d-af28371e8161", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98e15f0f-2eef-5983-8817-c05e099f6ecd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [83, 91], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d290ae96-61ab-531d-bf9f-0dadc23ff963", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6971461-4731-50f2-af10-12457b2264aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7d0dd30-5ce3-5e5d-be5c-a053896dc27f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d640416-9393-5562-85d2-d575f54ff584", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:144cd38f-43d9-5dc8-8267-9f07f53ad9a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d2426dd-7641-55e2-92f5-a0c8fc675b61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012378", "object_location_in_text": [130, 137], "original_object": "fatigue", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f315dc4-f318-5c17-b7af-d3ca8967c9eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012378", "object_location_in_text": [130, 137], "original_object": "fatigue", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae3fc2e6-0ddf-578c-9f03-32289cd3d21b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38a969dc-1894-5c82-9a19-c1dff59da828", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012735", "original_object": "cough", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation cough to help you sleep minor aches &amp; pains headache fever sore throat runny nose &amp; sneezing reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44488dc4-d2f6-551e-a236-fb6c1cecffaf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012735", "object_location_in_text": [101, 106], "original_object": "cough", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation minor aches &amp; pains headache fever sore throat reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49aa442d-3b89-51e0-8de3-fbe78b5a8037", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012735", "original_object": "cough", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0b3eb8c3-9b9e-861b-e063-6294a90a4a0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0b3eb8c3-9b9e-861b-e063-6294a90a4a0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b3eb8c3-9b9e-861b-e063-6294a90a4a0f"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses Temporarily relieves common cold/flu symptoms: Nasal congestion Cough due to minor throat &amp; bronchial irritation Sore throat Headache Minor aches &amp; pains Fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:624947f2-90d7-5501-81be-0ad708ded7e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012735", "object_location_in_text": [214, 219], "original_object": "cough", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90cc8dca-b448-402c-bb48-407039a62616", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90cc8dca-b448-402c-bb48-407039a62616", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90cc8dca-b448-402c-bb48-407039a62616"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses temporarily relieves these symptoms due to a cold: minor aches and pains minor sore throat pain headache nasal and sinus congestion runny nose sneezing itchy nose or throat itchy, watery eyes due to hay fever cough due to minor throat and bronchial irritation temporarily reduces fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67d52835-db52-5fd8-a466-9973fd465793", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "HP:0012735", "object_location_in_text": [112, 117], "original_object": "cough", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18f3d694-9dff-407e-a264-916dbd201f9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses For the temporary relief of the following cold symptoms minor aches and pains headache sneezing runny nose cough due to minor throat and bronchial irritation temporarily reduces fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031245", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbe23f15-eba1-5df7-aece-1751cb8c1593", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031245"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "MONDO:0003781", "original_object": "bronchitis", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e"]}], "subject": "CHEBI:46195", "supporting_text": ["DAY Uses ■ temporarily relieves these common cold and flu symptoms: ■ minor aches and pains ■ headache ■ sore throat ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily reduces fever NIGHT Uses ■ temporarily relieves these common cold and flu symptoms: ■ cough ■ minor aches and pains ■ sore throat ■ headache ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes due to hay fever ■ temporarily reduces fever ■ controls cough to help you get to sleep SPRAY Uses temporarily relieves nasal congestion due to: a cold hay fever or other upper respiratory allergies promotes nasal and sinus drainage temporarily relieves sinus congestion and pressure helps clear nasal passages; shrinks swollen membranes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a81e941a-7601-58d6-9630-6416f66c6708", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3de91d1-8645-546b-be31-a68a86b77183", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4cb5443-8434-5456-9a7d-312860e42a11", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d0fc9fd-2130-544a-9355-6fcb3511097d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e0c15db-6e07-5f1b-832b-1b53aff4481b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27e97169-f596-5605-93f8-c1be86106f72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [121, 129], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d5e19a6-399b-5f3e-b000-05cf4e00153b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:513249bf-1595-59d7-8205-ec8f3e0e6b34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72e823ad-68ed-5390-965c-c46ef5446390", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [121, 129], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7336029b-a6d8-5d59-9f4b-25d410407d8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b37fda70-d379-583c-8748-1af4eb5a7c1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:695577e4-2cad-5ee4-ac2b-4e9076532dd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0026821", "object_location_in_text": [114, 120], "original_object": "cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3f4b250-8b28-54d6-8d98-0f8b5dd7031a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6bcad33-1e93-545b-8133-6db2181c0a33", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db00e37e-1810-5b12-b1d2-2f8b62844f53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6f66c10-996b-595f-9419-09e6dc8389b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0026821", "object_location_in_text": [114, 120], "original_object": "cramps", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:076520eb-0a6b-5f0c-adbb-a5996881accc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4573f056-4baa-5d8a-8239-74fd8acd345e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62468118-8ff8-5006-9509-bf07cf5238ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0231528", "object_location_in_text": [101, 113], "original_object": "muscle aches", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b899da4-83d9-5776-b9c9-40d352d092ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f5dc65d-962b-58b8-80a4-0ede1612e2ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7eb360d5-51fe-5556-afe0-e5806ecbc519", "object": "UMLS:C0231528", "object_location_in_text": [101, 113], "original_object": "muscle aches", "original_subject": "ACETAMINOPHEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:46195", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05b3c774-2efc-5a4a-a7b6-50cb4b8bbd48", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [38, 45], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4ef917b-a9a8-4102-97d3-d7233393e622", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4ef917b-a9a8-4102-97d3-d7233393e622", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4ef917b-a9a8-4102-97d3-d7233393e622"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:530749e1-64e0-5774-8747-cc6d40bf8374", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564", "MONDO:0005326", "UMLS:C0684339", "UMLS:C0446292", "UMLS:C0330962"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [37, 44], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05ee2662-6a51-6e49-e063-6294a90a4ed7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05ee2662-6a51-6e49-e063-6294a90a4ed7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05ee2662-6a51-6e49-e063-6294a90a4ed7"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses ■ temporarily relieves pain and itching associated with ■ insect bites ■ minor burns ■ sunburn ■ minor skin irritations ■ minor cuts ■ scrapes ■ rashes due to poison ivy, poison oak, and poison sumac ■ dries the oozing and weeping of poison ivy, poison oak, and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5df215b8-beb6-50a8-8a7f-f7195444b3d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564", "MONDO:0005326"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [37, 44], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97a12fef-d5eb-453c-8c0d-6642f873ec82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97a12fef-d5eb-453c-8c0d-6642f873ec82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97a12fef-d5eb-453c-8c0d-6642f873ec82"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses • temporarily relieves pain and itching associated with: • insect bites • minor burns • sunburn • minor skin irritations • minor cuts • scrapes • rashes due to poison ivy, poison oak and poison sumac • dries the oozing and weeping of poison ivy, poison oak and poison sumac"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b7042ed-1e59-596e-a7d2-55171d1dc33e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [38, 45], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e9c0f5b-cb76-475b-9a2b-39afa1eeb9ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e9c0f5b-cb76-475b-9a2b-39afa1eeb9ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e9c0f5b-cb76-475b-9a2b-39afa1eeb9ff"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:883e84b3-b40c-5315-a4c3-c14a9fc8f6a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [38, 45], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aedbf1d-c8b7-4d5d-83ee-e38872c37d4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aedbf1d-c8b7-4d5d-83ee-e38872c37d4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aedbf1d-c8b7-4d5d-83ee-e38872c37d4f"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95392f73-ef30-5ae9-9a05-ed7c72d5139a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [38, 45], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6057b4ff-6adc-4688-893c-62d237d7d1ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6057b4ff-6adc-4688-893c-62d237d7d1ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6057b4ff-6adc-4688-893c-62d237d7d1ae"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritations", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f5d854c-7789-5c4c-a5cf-578cd04e21ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [42, 49], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:106a2968-444a-e77d-e063-6394a90aa8c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=106a2968-444a-e77d-e063-6394a90aa8c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=106a2968-444a-e77d-e063-6394a90aa8c3"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for the temporary relief of pain and itching associated with minor skin irritations dries the oozing and weeping of poison: ivy, oak and sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f100692b-3d90-530b-897f-6dfe309bd4a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [43, 50], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:709c3bb8-5b36-4823-941a-45ddb3e431c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=709c3bb8-5b36-4823-941a-45ddb3e431c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=709c3bb8-5b36-4823-941a-45ddb3e431c4"]}], "subject": "CHEBI:4636", "supporting_text": ["​Uses for the temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd981266-1a0f-5532-82ae-0987ca786c97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0000989", "object_location_in_text": [42, 49], "original_object": "itching", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22b8b83e-66d6-0caa-e063-6394a90ad6fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22b8b83e-66d6-0caa-e063-6394a90ad6fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22b8b83e-66d6-0caa-e063-6394a90ad6fd"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses For the temporary relief of pain and itching associated with minor burns minor cuts oscrapes insect bite minor skin irritations rashes due to poison ivy, poison oak, and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0458082", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67b58525-dcd6-5bf0-b68e-8b7c324c61e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["centrally acting anticholinergic agents"], "medic_disease_context_ids": ["UMLS:C0458082"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0001300", "object_location_in_text": [521, 533], "original_object": "parkinsonism", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8944f3c-acef-4ebe-9633-7d641ae95edf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8944f3c-acef-4ebe-9633-7d641ae95edf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8944f3c-acef-4ebe-9633-7d641ae95edf"]}], "subject": "CHEBI:4636", "supporting_text": ["Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0458082", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eedd3ed5-114f-5cc1-941a-5a210b46f5f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["centrally acting anticholinergic agents"], "medic_disease_context_ids": ["UMLS:C0458082"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d7de7e-6b4d-55c4-b6b0-1c6d77fc7a11", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0001300", "object_location_in_text": [521, 533], "original_object": "parkinsonism", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f808ee14-fccf-4abe-b53a-a40b0b3bba03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f808ee14-fccf-4abe-b53a-a40b0b3bba03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f808ee14-fccf-4abe-b53a-a40b0b3bba03"]}], "subject": "CHEBI:4636", "supporting_text": ["Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:525cc996-a856-57ae-a49c-505af82a9de6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [33, 37], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22b8b83e-66d6-0caa-e063-6394a90ad6fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22b8b83e-66d6-0caa-e063-6394a90ad6fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22b8b83e-66d6-0caa-e063-6394a90ad6fd"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses For the temporary relief of pain and itching associated with minor burns minor cuts oscrapes insect bite minor skin irritations rashes due to poison ivy, poison oak, and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52a85577-d47c-52be-99d9-007c4c27213d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564", "MONDO:0005326"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [28, 32], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97a12fef-d5eb-453c-8c0d-6642f873ec82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97a12fef-d5eb-453c-8c0d-6642f873ec82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97a12fef-d5eb-453c-8c0d-6642f873ec82"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses • temporarily relieves pain and itching associated with: • insect bites • minor burns • sunburn • minor skin irritations • minor cuts • scrapes • rashes due to poison ivy, poison oak and poison sumac • dries the oozing and weeping of poison ivy, poison oak and poison sumac"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d4fd270-4a9b-5644-ae4d-19420dee264c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [29, 33], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aedbf1d-c8b7-4d5d-83ee-e38872c37d4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aedbf1d-c8b7-4d5d-83ee-e38872c37d4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aedbf1d-c8b7-4d5d-83ee-e38872c37d4f"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9eba0f12-8c00-5804-ad24-f36169af01ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [29, 33], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e9c0f5b-cb76-475b-9a2b-39afa1eeb9ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e9c0f5b-cb76-475b-9a2b-39afa1eeb9ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e9c0f5b-cb76-475b-9a2b-39afa1eeb9ff"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1306b83-3780-5275-9aaf-d4e99f34cff8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [29, 33], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4ef917b-a9a8-4102-97d3-d7233393e622", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4ef917b-a9a8-4102-97d3-d7233393e622", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4ef917b-a9a8-4102-97d3-d7233393e622"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba49c166-cf62-55e9-9b3e-6bc9f20e91ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [33, 37], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:106a2968-444a-e77d-e063-6394a90aa8c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=106a2968-444a-e77d-e063-6394a90aa8c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=106a2968-444a-e77d-e063-6394a90aa8c3"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for the temporary relief of pain and itching associated with minor skin irritations dries the oozing and weeping of poison: ivy, oak and sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcb60f00-e968-50d7-8af6-53f38aed31e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [34, 38], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:709c3bb8-5b36-4823-941a-45ddb3e431c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=709c3bb8-5b36-4823-941a-45ddb3e431c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=709c3bb8-5b36-4823-941a-45ddb3e431c4"]}], "subject": "CHEBI:4636", "supporting_text": ["​Uses for the temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038814", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d44bdb5f-9aa9-5428-9de4-f71bfc133c9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038814", "UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [29, 33], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6057b4ff-6adc-4688-893c-62d237d7d1ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6057b4ff-6adc-4688-893c-62d237d7d1ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6057b4ff-6adc-4688-893c-62d237d7d1ae"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e89afc5e-ec57-5055-8fea-ac9bc8618a0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564", "MONDO:0005326", "UMLS:C0684339", "UMLS:C0446292", "UMLS:C0330962"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012531", "object_location_in_text": [28, 32], "original_object": "pain", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05ee2662-6a51-6e49-e063-6294a90a4ed7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05ee2662-6a51-6e49-e063-6294a90a4ed7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05ee2662-6a51-6e49-e063-6294a90a4ed7"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses ■ temporarily relieves pain and itching associated with ■ insect bites ■ minor burns ■ sunburn ■ minor skin irritations ■ minor cuts ■ scrapes ■ rashes due to poison ivy, poison oak, and poison sumac ■ dries the oozing and weeping of poison ivy, poison oak, and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01e78ed2-7246-5b34-afa5-a000c18bac1e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "MONDO:0005002"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012735", "object_location_in_text": [138, 143], "original_object": "cough", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses Nighttime temporarily relieves these symptoms occuring with a cold, hay fever, or other upper respiratory allergies nasal congestion cough runny nose sneezing itchy, watery eyes itching of the nose or throat Daytime temporaily relieves cough due to minor throat and bronchial irritation occuring with a cold, and nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy, watery eyes sneezing itching of the nose or throat temporarily restores freer breathing through the nose"], "temporal_context_qualifier": "occuring with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66b558b8-e7e4-5089-8b70-c01ebe265a81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "HP:0012735", "object_location_in_text": [214, 219], "original_object": "cough", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90cc8dca-b448-402c-bb48-407039a62616", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90cc8dca-b448-402c-bb48-407039a62616", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90cc8dca-b448-402c-bb48-407039a62616"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses temporarily relieves these symptoms due to a cold: minor aches and pains minor sore throat pain headache nasal and sinus congestion runny nose sneezing itchy nose or throat itchy, watery eyes due to hay fever cough due to minor throat and bronchial irritation temporarily reduces fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6426f01-f599-5d95-8de0-adc86eea455a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "MONDO:0005642", "object_location_in_text": [110, 133], "original_object": "allergic conjunctivitis", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8944f3c-acef-4ebe-9633-7d641ae95edf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8944f3c-acef-4ebe-9633-7d641ae95edf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8944f3c-acef-4ebe-9633-7d641ae95edf"]}], "subject": "CHEBI:4636", "supporting_text": ["Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3475af3-dc1e-52b5-bb0d-ab908d048336", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3be33a2-b7eb-4826-9c0c-9de24d54c173", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3be33a2-b7eb-4826-9c0c-9de24d54c173", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3be33a2-b7eb-4826-9c0c-9de24d54c173"]}], "subject": "CHEBI:4636", "supporting_text": [": Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic: For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness: For active and prophylactic treatment of motion sickness. Antiparkinsonism: For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016452", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eeda89c9-7d08-5684-94a0-7c5aa833a589", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016452"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "MONDO:0005642", "object_location_in_text": [110, 133], "original_object": "allergic conjunctivitis", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f808ee14-fccf-4abe-b53a-a40b0b3bba03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f808ee14-fccf-4abe-b53a-a40b0b3bba03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f808ee14-fccf-4abe-b53a-a40b0b3bba03"]}], "subject": "CHEBI:4636", "supporting_text": ["Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0684339", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48874e3d-59ed-5daf-93f8-290dc5b214c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0684339", "UMLS:C0446292", "UMLS:C0330962"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c58bdc0-a444-5dee-a358-e5d7866d437c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "MONDO:0006547", "object_location_in_text": [133, 139], "original_object": "rashes", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22b8b83e-66d6-0caa-e063-6394a90ad6fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22b8b83e-66d6-0caa-e063-6394a90ad6fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22b8b83e-66d6-0caa-e063-6394a90ad6fd"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses For the temporary relief of pain and itching associated with minor burns minor cuts oscrapes insect bite minor skin irritations rashes due to poison ivy, poison oak, and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "poison ivy, poison oak and poison sumac", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66628d19-9933-59a0-a36d-746a3e3a18ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d920e44-9326-58c8-9413-be0c98773889", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "UMLS:C1446325", "object_location_in_text": [208, 226], "original_object": "oozing and weeping", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:709c3bb8-5b36-4823-941a-45ddb3e431c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=709c3bb8-5b36-4823-941a-45ddb3e431c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=709c3bb8-5b36-4823-941a-45ddb3e431c4"]}], "subject": "CHEBI:4636", "supporting_text": ["​Uses for the temporary relief of pain and itching associated with: minor burns sunburns minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0684339", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b491a162-1194-5e27-8d31-68809d0542bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0684339", "UMLS:C0446292", "UMLS:C0330962"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d920e44-9326-58c8-9413-be0c98773889", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "UMLS:C1446325", "object_location_in_text": [217, 235], "original_object": "oozing and weeping", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05ee2662-6a51-6e49-e063-6294a90a4ed7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05ee2662-6a51-6e49-e063-6294a90a4ed7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05ee2662-6a51-6e49-e063-6294a90a4ed7"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses ■ temporarily relieves pain and itching associated with ■ insect bites ■ minor burns ■ sunburn ■ minor skin irritations ■ minor cuts ■ scrapes ■ rashes due to poison ivy, poison oak, and poison sumac ■ dries the oozing and weeping of poison ivy, poison oak, and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "poison ivy, poison oak and poison sumac", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d084478f-954f-5ec1-84f0-137dcdd476b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d920e44-9326-58c8-9413-be0c98773889", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "UMLS:C1446325", "object_location_in_text": [206, 224], "original_object": "oozing and weeping", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8026c7dd-eb7b-ebea-e053-2991aa0a1b0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8026c7dd-eb7b-ebea-e053-2991aa0a1b0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8026c7dd-eb7b-ebea-e053-2991aa0a1b0f"]}], "subject": "CHEBI:4636", "supporting_text": ["Uses for the temporary relief of pain and itching associated with: minor burns sunburn minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood or plasma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:963713a5-fe2b-5585-b584-c09f4984af31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "UMLS:C1527304", "object_location_in_text": [242, 260], "original_object": "allergic reactions", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f808ee14-fccf-4abe-b53a-a40b0b3bba03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f808ee14-fccf-4abe-b53a-a40b0b3bba03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f808ee14-fccf-4abe-b53a-a40b0b3bba03"]}], "subject": "CHEBI:4636", "supporting_text": ["Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood or plasma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b23641f-af13-57ca-bfb0-7aad87669963", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:936e0d28-0c8a-59e9-bf38-869a80f68532", "object": "UMLS:C1527304", "object_location_in_text": [242, 260], "original_object": "allergic reactions", "original_subject": "DIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8944f3c-acef-4ebe-9633-7d641ae95edf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8944f3c-acef-4ebe-9633-7d641ae95edf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8944f3c-acef-4ebe-9633-7d641ae95edf"]}], "subject": "CHEBI:4636", "supporting_text": ["Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Motion Sickness For active and prophylactic treatment of motion sickness. Antiparkinsonism For parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. Nighttime Sleep-aid."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1cc5d28f-0596-5cad-af83-262519a8ee2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861222", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c68688b-e730-52ef-a441-4e6106123c75", "object": "MONDO:0005098", "object_location_in_text": [68, 74], "original_object": "stroke", "original_subject": "DIPYRIDAMOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e729d829-4bd0-4074-85ea-e0f9f5d7cdb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5"]}], "subject": "CHEBI:4653", "supporting_text": ["1 INDICATIONS AND USAGE AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (1)"], "temporal_context_qualifier": "following transient ischemia of the brain or completed ischemic stroke due to thrombosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a7c2334-025b-5aa0-abbe-aaa8c2820dd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861222", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c68688b-e730-52ef-a441-4e6106123c75", "object": "MONDO:0005098", "object_location_in_text": [111, 117], "original_object": "stroke", "original_subject": "DIPYRIDAMOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:467d6ce3-bc05-4aa1-87cc-3214fd628d39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=467d6ce3-bc05-4aa1-87cc-3214fd628d39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=467d6ce3-bc05-4aa1-87cc-3214fd628d39"]}], "subject": "CHEBI:4653", "supporting_text": ["1 INDICATIONS AND USAGE Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. • Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7944f17e-b2be-5692-a2f0-bba13101f096", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861222", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c68688b-e730-52ef-a441-4e6106123c75", "object": "MONDO:0005098", "object_location_in_text": [111, 117], "original_object": "stroke", "original_subject": "DIPYRIDAMOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:465bbdac-a483-689a-811f-32923ea99fa7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=465bbdac-a483-689a-811f-32923ea99fa7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=465bbdac-a483-689a-811f-32923ea99fa7"]}], "subject": "CHEBI:4653", "supporting_text": ["1 INDICATIONS AND USAGE Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79dee0f4-6c61-5c8c-b1e4-ad9784cb42b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861222", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c68688b-e730-52ef-a441-4e6106123c75", "object": "MONDO:0005098", "object_location_in_text": [68, 74], "original_object": "stroke", "original_subject": "DIPYRIDAMOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6473563d-b4df-4434-a74e-f8fa3cb9994f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6473563d-b4df-4434-a74e-f8fa3cb9994f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6473563d-b4df-4434-a74e-f8fa3cb9994f"]}], "subject": "CHEBI:4653", "supporting_text": ["1 INDICATIONS AND USAGE AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (1)"], "temporal_context_qualifier": "following transient ischemia of the brain or completed ischemic stroke due to thrombosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93152fab-3f52-5548-a95e-217824fdd730", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861222", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c68688b-e730-52ef-a441-4e6106123c75", "object": "MONDO:0005098", "object_location_in_text": [68, 74], "original_object": "stroke", "original_subject": "DIPYRIDAMOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f07c8535-f9fb-4697-9b63-1ab22210efc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f07c8535-f9fb-4697-9b63-1ab22210efc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f07c8535-f9fb-4697-9b63-1ab22210efc9"]}], "subject": "CHEBI:4653", "supporting_text": ["1 INDICATIONS AND USAGE AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (1)"], "temporal_context_qualifier": "following transient ischemia of the brain or completed ischemic stroke due to thrombosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "transient ischemia of the brain, completed ischemic stroke due to thrombosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0a4b99c-7599-5ccb-baee-5934dc766d39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861222", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c68688b-e730-52ef-a441-4e6106123c75", "object": "MONDO:0005098", "object_location_in_text": [111, 117], "original_object": "stroke", "original_subject": "DIPYRIDAMOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92222dd3-7802-2a03-7d30-58cf192cc33e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92222dd3-7802-2a03-7d30-58cf192cc33e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92222dd3-7802-2a03-7d30-58cf192cc33e"]}], "subject": "CHEBI:4653", "supporting_text": ["1 INDICATIONS AND USAGE Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and extended-release dipyridamole capsules are a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e898c7b-460a-5f0b-9d91-ec320a08dbae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80006f10-85a3-4390-b5dc-3b2097134f3d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80006f10-85a3-4390-b5dc-3b2097134f3d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80006f10-85a3-4390-b5dc-3b2097134f3d"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic acid injection is contraindicated in patients with the following conditions: • Hypocalcemia [see Warnings and Precautions (5.2) ] • Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions (5.3) ] . • Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2) ] . • Hypocalcemia ( 4 ) • Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) • Hypersensitivity to any component of zoledronic acid injection ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ea20a98-650a-5f55-a42e-a7c3e615f38b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d761011b-edd6-4d3f-bacd-8607dc2414fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d761011b-edd6-4d3f-bacd-8607dc2414fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d761011b-edd6-4d3f-bacd-8607dc2414fc"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic acid injection is contraindicated in patients with the following conditions: • Hypocalcemia [see Warnings and Precautions ( 5.2 )] • Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions ( 5.3 )]. • Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions ( 6.2 )] . • Hypocalcemia ( 4 ) • Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) • Hypersensitivity to any component of zoledronic acid injection ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18c8477d-eda2-515f-bd77-b4114b20ff0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:164500d7-51cf-438a-8bee-7a7dce76ad7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=164500d7-51cf-438a-8bee-7a7dce76ad7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=164500d7-51cf-438a-8bee-7a7dce76ad7a"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic Acid Injection is contraindicated in patients with the following conditions: Hypocalcemia [see Warnings and Precautions ( 5.2 )]. Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions ( 5.3 )]. Known hypersensitivity to zoledronic acid or any components of Zoledronic Acid Injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions ( 6.2 )]. Hypocalcemia ( 4 ) Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) Hypersensitivity to any component of Zoledronic Acid Injection ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:270dc9b3-ce08-5322-bb73-31119055a9e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f94a5c9e-74bc-d09e-cd65-394b2a5de2ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f94a5c9e-74bc-d09e-cd65-394b2a5de2ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f94a5c9e-74bc-d09e-cd65-394b2a5de2ad"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic acid injection is contraindicated in patients with the following conditions: Hypocalcemia [see Warnings and Precautions ( 5.2 )] Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Preacutions ( 5.3 )]. Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions ( 6.2 )]. Hypocalcemia (4) Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) Hypersensitivity to any component of zoledronic acid injection ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d79c6b1-aa7f-5d50-beff-596b09305761", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1977d713-4cc7-405e-b4c1-a9a91635eff6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1977d713-4cc7-405e-b4c1-a9a91635eff6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1977d713-4cc7-405e-b4c1-a9a91635eff6"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic acid injection is contraindicated in patients with the following conditions: • Hypocalcemia [see Warnings and Precautions (5.2) ] • Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions (5.3) ] . • Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2) ] . • Hypocalcemia ( 4 ) • Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) • Hypersensitivity to any component of zoledronic acid injection ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4534d677-e9c1-5a7d-8a10-2d51b716cb7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:824eaeee-6b3d-4d62-b268-77f8bd8e7f10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=824eaeee-6b3d-4d62-b268-77f8bd8e7f10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=824eaeee-6b3d-4d62-b268-77f8bd8e7f10"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic acid injection is contraindicated in patients with the following conditions: • Hypocalcemia [see Warnings and Precautions (5.2) ] • Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions (5.3) ]. • Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2) ]. Hypocalcemia ( 4 ) Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) Hypersensitivity to any component of zoledronic acid injection ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:892492d5-0d0c-5a21-84f9-e2ad725f0714", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf5f96d4-f87c-4968-bed0-a4b5e77f4162", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf5f96d4-f87c-4968-bed0-a4b5e77f4162", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf5f96d4-f87c-4968-bed0-a4b5e77f4162"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Zoledronic acid is contraindicated in patients with the following conditions: Hypocalcemia [see Warnings and Precautions (5.2) ] Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions (5.3) ] . Known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2) ] . Hypocalcemia (4) Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment (4 , 5.3) Hypersensitivity to any component of zoledronic acid injection (4 , 6.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "Creatinine clearance less than 35 mL/min", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9f850fa-f3a7-5c31-95d0-7b57edba2a9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:348c5cf2-867c-5d68-b6e3-6c7a8857099a", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C1565662", "original_object": "acute renal impairment", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a9b3737-9ce6-4a89-b76e-6aab79eba9cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a9b3737-9ce6-4a89-b76e-6aab79eba9cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9b3737-9ce6-4a89-b76e-6aab79eba9cf"]}], "subject": "CHEBI:46557", "supporting_text": ["4 CONTRAINDICATIONS Reclast is contraindicated in patients with the following conditions: • Hypocalcemia [see Warnings and Precautions ( 5.2 )] • Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Warnings and Precautions ( 5.3 )] . • Known hypersensitivity to zoledronic acid or any components of Reclast. Hypersensitivity reactions, including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see Adverse Reactions ( 6.2 )]. • Hypocalcemia ( 4 ) • Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment ( 4 , 5.3 ) • Hypersensitivity to any component of Reclast ( 4 , 6.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:061abf33-5275-57aa-aea7-1979faff0bdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010320", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6618ea28-272d-5f79-a234-2cb8fcd0abdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C0016663", "object_location_in_text": [39, 61], "original_object": "pathological fractures", "original_subject": "zoledronic acid", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zoledronic-acid-accord", "https://www.ema.europa.eu/en/documents/product-information/zoledronic-acid-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-accord"]}], "subject": "CHEBI:46557", "supporting_text": ["Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1fbdd318-73a0-55ca-8ba2-bda28be21a34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010320", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6618ea28-272d-5f79-a234-2cb8fcd0abdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C0016663", "object_location_in_text": [39, 61], "original_object": "pathological fractures", "original_subject": "zoledronic acid", "population_context_qualifier": "adult patients with advanced malignancies involving bone", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zometa", "https://www.ema.europa.eu/en/documents/product-information/zometa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zometa"]}], "subject": "CHEBI:46557", "supporting_text": ["Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia (TIH); prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia (TIH); prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone; treatment of adult patients with tumour-induced hypercalcaemia (TIH)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8f19b5f-98f9-5dca-90a5-e1a13dcb7438", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010320", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6618ea28-272d-5f79-a234-2cb8fcd0abdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C0016663", "object_location_in_text": [39, 61], "original_object": "pathological fractures", "original_subject": "zoledronic acid", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zoledronic-acid-medac", "https://www.ema.europa.eu/en/documents/product-information/zoledronic-acid-medac-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-medac"]}], "subject": "CHEBI:46557", "supporting_text": ["Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d78ee0b5-fe6f-530c-97a8-f102a4d428d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010320", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6618ea28-272d-5f79-a234-2cb8fcd0abdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C0016663", "object_location_in_text": [39, 61], "original_object": "pathological fractures", "original_subject": "zoledronic acid", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zoledronic-acid-mylan", "https://www.ema.europa.eu/en/documents/product-information/zoledronic-acid-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-mylan"]}], "subject": "CHEBI:46557", "supporting_text": ["Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone; treatment of adult patients with tumour-induced hypercalcaemia (TIH)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfecc1c8-40cf-53d7-9910-d20ef7c51a42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010320", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6618ea28-272d-5f79-a234-2cb8fcd0abdc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C0016663", "object_location_in_text": [71, 93], "original_object": "pathological fractures", "original_subject": "zoledronic acid", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zoledronic-acid-hospira", "https://www.ema.europa.eu/en/documents/product-information/zoledronic-acid-hospira-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-hospira"]}], "subject": "CHEBI:46557", "supporting_text": ["4 mg / 5 ml and 4 mg / 100 ml:  Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).  5 mg / 100 ml: Treatment of osteoporosis:  in post-menopausal women; in men;  at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:  in post-menopausal women; in men;  at increased risk of fracture. Treatment of Paget's disease of the bone in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbea1aa5-0ea1-599d-8dc8-6477460e6dac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["standard antineoplastic therapy"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1383048-7b51-54ef-be3f-d2b5dea9a01b", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "HP:0006775", "object_location_in_text": [157, 173], "original_object": "multiple myeloma", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46c3a880-3723-45cf-979e-57ef6391662e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46c3a880-3723-45cf-979e-57ef6391662e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46c3a880-3723-45cf-979e-57ef6391662e"]}], "subject": "CHEBI:46557", "supporting_text": ["1 INDICATIONS AND USAGE Zoledronic acid injection is a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbf14d55-4fda-54e3-aefe-ff8d089847e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["standard antineoplastic therapy"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1383048-7b51-54ef-be3f-d2b5dea9a01b", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "HP:0006775", "object_location_in_text": [151, 167], "original_object": "multiple myeloma", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f433c13c-dd8c-4dca-834e-a4ecf09d1eab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f433c13c-dd8c-4dca-834e-a4ecf09d1eab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f433c13c-dd8c-4dca-834e-a4ecf09d1eab"]}], "subject": "CHEBI:46557", "supporting_text": ["1 INDICATIONS AND USAGE Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "long-term systemic glucocorticoid therapy", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:883f35c5-0ace-52ba-8fdd-6f34795e821c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010320", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:54ef8438-9c82-5810-9f64-b343688bf460", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "MONDO:0005298", "object_location_in_text": [13, 25], "original_object": "osteoporosis", "original_subject": "zoledronic acid", "population_context_qualifier": "men at increased risk of fracture", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aclasta", "https://www.ema.europa.eu/en/documents/product-information/aclasta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aclasta"]}], "subject": "CHEBI:46557", "supporting_text": ["Treatment of osteoporosis:  in post-menopausal women; in men;  at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. Treatment of Paget's disease of the bone."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0280100", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f3190a3-60a1-52ea-9993-46e7f4e3f4b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010820", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["standard antineoplastic therapy"], "medic_disease_context_ids": ["UMLS:C0280100"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40acbf59-5a13-5a02-9223-505021776ab2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36867161-7957-50a1-92b1-73e9c5e08599", "object": "UMLS:C0153690", "original_object": "bone metastases", "original_subject": "ZOLEDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f433c13c-dd8c-4dca-834e-a4ecf09d1eab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f433c13c-dd8c-4dca-834e-a4ecf09d1eab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f433c13c-dd8c-4dca-834e-a4ecf09d1eab"]}], "subject": "CHEBI:46557", "supporting_text": ["1 INDICATIONS AND USAGE Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6dcc9d97-c4bc-585d-9345-8bd235449565", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "HP:0004308", "object_location_in_text": [68, 91], "original_object": "ventricular arrhythmias", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients where the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31e79459-107f-4d69-a163-90014f1c4772", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31e79459-107f-4d69-a163-90014f1c4772", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31e79459-107f-4d69-a163-90014f1c4772"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae15e918-fccc-5fa5-b0ca-a3037ae1cf53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "HP:0004308", "object_location_in_text": [68, 91], "original_object": "ventricular arrhythmias", "original_subject": "DISOPYRAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11a68e26-d2e4-48f6-ba0f-9bdd5778f25a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3fd692d-b828-568f-9473-c382a6a427d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "HP:0004308", "object_location_in_text": [78, 101], "original_object": "ventricular arrhythmias", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3acbcef2-04ec-1ab1-b855-d1244b0e8006", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3acbcef2-04ec-1ab1-b855-d1244b0e8006", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3acbcef2-04ec-1ab1-b855-d1244b0e8006"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide phosphate capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:134ea08b-90a4-586f-8147-bbeea895fac2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [100, 133], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with documented life-threatening ventricular arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ee7d47d9-1900-4040-92ca-04fe1078defb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ee7d47d9-1900-4040-92ca-04fe1078defb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee7d47d9-1900-4040-92ca-04fe1078defb"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide Phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Disopyramide Phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Disopyramide Phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:254c4512-26b0-5184-89c3-ef997ed3169f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [102, 135], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with documented ventricular arrhythmias that are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5e0c230-db38-4476-8357-9a227ccff1bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5e0c230-db38-4476-8357-9a227ccff1bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5e0c230-db38-4476-8357-9a227ccff1bc"]}], "subject": "CHEBI:4657", "supporting_text": ["Norpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ad1a6c1-fe3b-50e9-9c83-6fd72ce84cf2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [100, 133], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with documented life-threatening ventricular arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdf8d8a6-b524-491f-b7c1-0d23c77abbcd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdf8d8a6-b524-491f-b7c1-0d23c77abbcd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdf8d8a6-b524-491f-b7c1-0d23c77abbcd"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide Phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Disopyramide Phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Disopyramide Phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6501d50b-28a7-54f7-b41f-5653ca0b6951", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [132, 165], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b95acd8-1cce-4b76-9cb2-6e9ea40e54b1"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9757938b-b59b-579f-9a11-2a5bdfe88327", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [102, 135], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with documented ventricular arrhythmias that are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c02f1b8-4493-429c-b9f7-21f364e330f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c02f1b8-4493-429c-b9f7-21f364e330f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c02f1b8-4493-429c-b9f7-21f364e330f8"]}], "subject": "CHEBI:4657", "supporting_text": ["Norpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a496ffc0-0f2b-55a1-9aa0-84e86fec542d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [102, 135], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with documented ventricular arrhythmias that are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2aa1642-d262-4520-bc6a-9fd3ad795677", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677"]}], "subject": "CHEBI:4657", "supporting_text": ["Norpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c375627f-2d3d-5cc4-8472-c1ce22017ad8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:131c125b-ea4a-5256-ba43-2caf00be5f8f", "object": "UMLS:C0750197", "object_location_in_text": [100, 133], "original_object": "sustained ventricular tachycardia", "original_subject": "DISOPYRAMIDE", "population_context_qualifier": "patients with documented life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11a68e26-d2e4-48f6-ba0f-9bdd5778f25a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a"]}], "subject": "CHEBI:4657", "supporting_text": ["Disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:326cc55e-035b-5d7c-969a-6af07383e14e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b9c9f8d6-467e-5bf6-ad78-2622d08e8f9c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "CLONIDINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:826de1dc-378e-4c90-86d1-e33f7a4248cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=826de1dc-378e-4c90-86d1-e33f7a4248cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=826de1dc-378e-4c90-86d1-e33f7a4248cd"]}], "subject": "CHEBI:46631", "supporting_text": ["1 INDICATIONS AND USAGE QLONILIK TM (clonidine hydrochloride) oral solution is indicated for the treatment of hypertension, to lower blood pressure in adults. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the American College of Cardiology/American Heart Association (ACC/AHA). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyper"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b2e8f98-3b40-53d6-8748-4e7f0273ef8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b9c9f8d6-467e-5bf6-ad78-2622d08e8f9c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "CLONIDINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:826de1dc-378e-4c90-86d1-e33f7a4248cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=826de1dc-378e-4c90-86d1-e33f7a4248cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=826de1dc-378e-4c90-86d1-e33f7a4248cd"]}], "subject": "CHEBI:46631", "supporting_text": ["1 INDICATIONS AND USAGE QLONILIK TM (clonidine hydrochloride) oral solution is indicated for the treatment of hypertension, to lower blood pressure in adults. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the American College of Cardiology/American Heart Association (ACC/AHA). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyper"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bf2abff-c643-5889-801e-430b7f85e771", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970911", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ae6906ba-829c-5161-8419-5e0a3f2f8e73", "object": "HP:0002017", "object_location_in_text": [52, 71], "original_object": "nausea and vomiting", "original_subject": "DOLASETRON", "population_context_qualifier": "adults and children 2 years and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:201b0eb8-4a1e-4e22-ab4b-addb642710d6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=201b0eb8-4a1e-4e22-ab4b-addb642710d6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=201b0eb8-4a1e-4e22-ab4b-addb642710d6"]}], "subject": "CHEBI:4682", "supporting_text": ["ANZEMET Tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older."], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:105adecc-4a76-5fd3-9145-36e1e67109dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2110eec5-949d-4718-ad6d-3629e5db8a07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2110eec5-949d-4718-ad6d-3629e5db8a07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2110eec5-949d-4718-ad6d-3629e5db8a07"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:149b8a6a-db9a-5269-81b3-ef3b0d03461c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e046e0b7-f510-4318-9884-034d683864d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e046e0b7-f510-4318-9884-034d683864d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e046e0b7-f510-4318-9884-034d683864d4"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27e189f2-58ce-52a9-a047-c4c5c5c72513", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "Myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eefc47bc-c10f-49bb-8ef7-5999f798ab39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eefc47bc-c10f-49bb-8ef7-5999f798ab39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eefc47bc-c10f-49bb-8ef7-5999f798ab39"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE CARDURA is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) CARDURA is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension CARDURA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bde4c68-eac1-501a-9334-3af64ea89e6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3354196f-bbcf-4bc5-94f6-e6e8e132acb1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3354196f-bbcf-4bc5-94f6-e6e8e132acb1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3354196f-bbcf-4bc5-94f6-e6e8e132acb1"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37b16480-f48f-591d-8b17-babe1592d1ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54eeef3d-c906-37e7-e063-6294a90afca2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54eeef3d-c906-37e7-e063-6294a90afca2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54eeef3d-c906-37e7-e063-6294a90afca2"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:730a8167-e391-5ca1-98d2-9467f183a6f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e2f83a4-e800-4533-9d9a-15ea10d1cf92", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e2f83a4-e800-4533-9d9a-15ea10d1cf92", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e2f83a4-e800-4533-9d9a-15ea10d1cf92"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73373a00-f603-5eb0-9898-efd27d94bc94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:277c3278-4fe2-47ac-9115-15b417325ffd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=277c3278-4fe2-47ac-9115-15b417325ffd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277c3278-4fe2-47ac-9115-15b417325ffd"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: ( 1 ) Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b33c798-616f-5efb-ac8a-30d78fa3f175", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [542, 564], "original_object": "myocardial infarctions", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a697a36-14c1-5f44-8548-79c29fa8ec9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b887aa5-5edf-48c5-a480-dea8c35afa9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b887aa5-5edf-48c5-a480-dea8c35afa9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b887aa5-5edf-48c5-a480-dea8c35afa9d"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93d6bc32-28f0-5867-a91d-a95520423abf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e524986-7903-416f-b2b8-d27295103e75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e524986-7903-416f-b2b8-d27295103e75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e524986-7903-416f-b2b8-d27295103e75"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) • Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a4b5cc0-50c4-5ecf-9725-e4bbc80b4281", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec06f008-37a1-4757-a3ee-0b4720912bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec06f008-37a1-4757-a3ee-0b4720912bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec06f008-37a1-4757-a3ee-0b4720912bc4"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that eve"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae1265d8-7a40-5c0c-8a36-5ea7066021fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [542, 564], "original_object": "myocardial infarctions", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfea0b5b-9354-490f-88ff-008134077d24", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfea0b5b-9354-490f-88ff-008134077d24", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfea0b5b-9354-490f-88ff-008134077d24"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5239c0f-ea6f-54f6-9dc9-59476ed7a680", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [542, 564], "original_object": "myocardial infarctions", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6f30259-0332-5c2e-bdff-c1dabb89c170", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [542, 564], "original_object": "myocardial infarctions", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ea9bb6b-a4f0-496a-b27b-4454167a4b70", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ea9bb6b-a4f0-496a-b27b-4454167a4b70", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ea9bb6b-a4f0-496a-b27b-4454167a4b70"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7f351ab-85c0-5d1b-bbe0-f6e6800192b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08521333-ff21-45ad-b99e-1f43d945d24d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08521333-ff21-45ad-b99e-1f43d945d24d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08521333-ff21-45ad-b99e-1f43d945d24d"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d756d174-1b4a-56a6-a50a-b34230545af9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcaf1417-8849-47f3-b400-e41dd8e9ba18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcaf1417-8849-47f3-b400-e41dd8e9ba18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcaf1417-8849-47f3-b400-e41dd8e9ba18"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eec491c4-18ce-59d3-a3b4-5dcb7c94787d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5e1f5e49-2da1-43ab-9795-228a8bcc5a82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5e1f5e49-2da1-43ab-9795-228a8bcc5a82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e1f5e49-2da1-43ab-9795-228a8bcc5a82"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE CARDURA is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) • Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) CARDURA is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension CARDURA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest red"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f93f138e-94d1-5635-ac58-f423dbf50fe0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [542, 564], "original_object": "myocardial infarctions", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:30a6bb83-f91b-4c4f-a849-4f2be3735a0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=30a6bb83-f91b-4c4f-a849-4f2be3735a0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30a6bb83-f91b-4c4f-a849-4f2be3735a0e"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0207997f-aa80-550b-ad55-73baa1268eb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [530, 537], "original_object": "strokes", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ea9bb6b-a4f0-496a-b27b-4454167a4b70", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ea9bb6b-a4f0-496a-b27b-4454167a4b70", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ea9bb6b-a4f0-496a-b27b-4454167a4b70"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14b88250-6f99-58cd-b21d-40720e7fd285", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e046e0b7-f510-4318-9884-034d683864d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e046e0b7-f510-4318-9884-034d683864d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e046e0b7-f510-4318-9884-034d683864d4"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21ebc1b7-fabe-5935-84b7-8a55265715bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "Stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eefc47bc-c10f-49bb-8ef7-5999f798ab39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eefc47bc-c10f-49bb-8ef7-5999f798ab39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eefc47bc-c10f-49bb-8ef7-5999f798ab39"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE CARDURA is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) CARDURA is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension CARDURA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d1970a7-bf6a-5419-9697-331a03d6c19a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec06f008-37a1-4757-a3ee-0b4720912bc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec06f008-37a1-4757-a3ee-0b4720912bc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec06f008-37a1-4757-a3ee-0b4720912bc4"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that eve"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31874969-c8e8-50de-99bd-5d0e91028b21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [530, 537], "original_object": "strokes", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37b5964e-4a10-5630-a9b7-398a06a24b9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b887aa5-5edf-48c5-a480-dea8c35afa9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b887aa5-5edf-48c5-a480-dea8c35afa9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b887aa5-5edf-48c5-a480-dea8c35afa9d"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49f6b22b-e2e6-5e85-af78-3b6656c0097d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcaf1417-8849-47f3-b400-e41dd8e9ba18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcaf1417-8849-47f3-b400-e41dd8e9ba18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcaf1417-8849-47f3-b400-e41dd8e9ba18"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a7ddd99-002f-573e-ac50-5fac2baf1ff2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e2f83a4-e800-4533-9d9a-15ea10d1cf92", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e2f83a4-e800-4533-9d9a-15ea10d1cf92", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e2f83a4-e800-4533-9d9a-15ea10d1cf92"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52a72cae-36ba-5d07-8694-f96ea794e64a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5e1f5e49-2da1-43ab-9795-228a8bcc5a82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5e1f5e49-2da1-43ab-9795-228a8bcc5a82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e1f5e49-2da1-43ab-9795-228a8bcc5a82"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE CARDURA is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) • Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) CARDURA is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension CARDURA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest red"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62b49456-0879-5ec4-b46c-c99ae9b8d56a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54eeef3d-c906-37e7-e063-6294a90afca2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54eeef3d-c906-37e7-e063-6294a90afca2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54eeef3d-c906-37e7-e063-6294a90afca2"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a2e0ddf-d46b-5b49-be38-2e028f4734f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2110eec5-949d-4718-ad6d-3629e5db8a07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2110eec5-949d-4718-ad6d-3629e5db8a07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2110eec5-949d-4718-ad6d-3629e5db8a07"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d4faca9-98d4-5e88-81be-e10b8b61e3e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e524986-7903-416f-b2b8-d27295103e75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e524986-7903-416f-b2b8-d27295103e75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e524986-7903-416f-b2b8-d27295103e75"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin is an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) ( 1.1 ) • Treatment of Hypertension ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablet is indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72bd33ea-dc52-5816-bd1e-972845358d10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [530, 537], "original_object": "strokes", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:30a6bb83-f91b-4c4f-a849-4f2be3735a0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=30a6bb83-f91b-4c4f-a849-4f2be3735a0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30a6bb83-f91b-4c4f-a849-4f2be3735a0e"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96d747a2-abab-5ea8-ac3b-d28223da68d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3354196f-bbcf-4bc5-94f6-e6e8e132acb1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3354196f-bbcf-4bc5-94f6-e6e8e132acb1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3354196f-bbcf-4bc5-94f6-e6e8e132acb1"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a38b751-ac48-59bf-844e-839da2aae405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [530, 537], "original_object": "strokes", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfea0b5b-9354-490f-88ff-008134077d24", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfea0b5b-9354-490f-88ff-008134077d24", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfea0b5b-9354-490f-88ff-008134077d24"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbc82542-5410-5f9b-8f89-3278b555449a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [530, 537], "original_object": "strokes", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8cf0dc6-4cb2-54c0-bc37-44204c28918a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08521333-ff21-45ad-b99e-1f43d945d24d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08521333-ff21-45ad-b99e-1f43d945d24d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08521333-ff21-45ad-b99e-1f43d945d24d"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb636852-bcec-5a9a-a04d-2353336572c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901102", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5af96f3-da78-5d13-ae69-cfde76c4936c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "DOXAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:277c3278-4fe2-47ac-9115-15b417325ffd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=277c3278-4fe2-47ac-9115-15b417325ffd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277c3278-4fe2-47ac-9115-15b417325ffd"]}], "subject": "CHEBI:4708", "supporting_text": ["1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: ( 1 ) Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0543467", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8e92604-744f-5148-8d0b-f510bd1e5322", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0543467"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ca3f2ae-6477-5f0a-9fd2-e0d905705306", "object": "HP:0002013", "object_location_in_text": [72, 80], "original_object": "vomiting", "original_subject": "DROPERIDOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:147e033d-d997-4ef6-8bb5-a9ba372590b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2"]}], "subject": "CHEBI:4717", "supporting_text": ["Droperidol Injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0543467", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73a241de-04c0-5309-8671-7c3137a58ab0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0543467"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ca3f2ae-6477-5f0a-9fd2-e0d905705306", "object": "HP:0002018", "object_location_in_text": [61, 67], "original_object": "nausea", "original_subject": "DROPERIDOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:147e033d-d997-4ef6-8bb5-a9ba372590b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=147e033d-d997-4ef6-8bb5-a9ba372590b2"]}], "subject": "CHEBI:4717", "supporting_text": ["Droperidol Injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0949083", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:171855be-425f-5dd5-bbae-922b3f7549c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200213", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0949083", "UMLS:C1701940"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5f91158d-2ca0-59db-8ad8-9832a5cce733", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e691de41-29dd-5b7a-bf0a-2dcc695a08f2", "object": "MONDO:0005229", "object_location_in_text": [178, 189], "original_object": "bacteraemia", "original_subject": "imipenem;cilastatin;relebactam", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:recarbrio", "https://www.ema.europa.eu/en/documents/product-information/recarbrio-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/recarbrio"]}], "subject": "CHEBI:471744", "supporting_text": ["Recarbrio is indicated for:- Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.- Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30fc6322-874b-5869-864e-de3e9d4dd95e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e79810e7-a124-57af-8b40-2b58b7ef78b0", "object": "MONDO:0005550", "object_location_in_text": [39, 48], "original_object": "infection", "original_subject": "DYCLONINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45"]}], "subject": "CHEBI:4724", "supporting_text": ["Uses first aid to help protect against infection and for the temporary relief of pain and itching associated with minor burns, minor cuts, scrapes, insect bites, or minor skin irritations."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb1428c3-e2c9-58fd-a36f-74232dfda080", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e79810e7-a124-57af-8b40-2b58b7ef78b0", "object": "HP:0000989", "object_location_in_text": [90, 97], "original_object": "itching", "original_subject": "DYCLONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45"]}], "subject": "CHEBI:4724", "supporting_text": ["Uses first aid to help protect against infection and for the temporary relief of pain and itching associated with minor burns, minor cuts, scrapes, insect bites, or minor skin irritations."], "temporal_context_qualifier": "temporary relief"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8828981-047f-5c4a-bb76-97aa2e5e9dc3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e79810e7-a124-57af-8b40-2b58b7ef78b0", "object": "HP:0012531", "object_location_in_text": [81, 85], "original_object": "pain", "original_subject": "DYCLONINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575989be-b9f2-4778-a92d-4ec8e1325c45"]}], "subject": "CHEBI:4724", "supporting_text": ["Uses first aid to help protect against infection and for the temporary relief of pain and itching associated with minor burns, minor cuts, scrapes, insect bites, or minor skin irritations."], "temporal_context_qualifier": "temporary relief"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:938006e5-41de-5c89-bb39-b3d66483b95e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "EDETIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05"]}], "subject": "CHEBI:4735", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fabe4c14-ec01-52f5-a3fd-293a2ec0d407", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "EDETIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4"]}], "subject": "CHEBI:4735", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc77d277-6e52-59ae-a205-bec1e8ec4c82", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:defa5ba2-3195-5bcf-8c70-83d469598b3b", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "HP:0002516", "original_object": "intracranial pressure elevation", "original_subject": "EDETIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05"]}], "subject": "CHEBI:4735", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc80edf1-b2d9-5fff-ac50-d69955bfffc3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:defa5ba2-3195-5bcf-8c70-83d469598b3b", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "HP:0002516", "original_object": "intracranial pressure elevation", "original_subject": "EDETIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4"]}], "subject": "CHEBI:4735", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3825525a-1acf-5816-928a-fc326c19b870", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "EDETIC ACID", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6998949-e1cb-4c86-a480-c0dfd9cb75b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6998949-e1cb-4c86-a480-c0dfd9cb75b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6998949-e1cb-4c86-a480-c0dfd9cb75b5"]}], "subject": "CHEBI:4735", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97a21a10-e6fe-5364-adbf-36c5168fba6c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "EDETIC ACID", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56cb1f4b-ddf4-0661-e063-6394a90a9c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56cb1f4b-ddf4-0661-e063-6394a90a9c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56cb1f4b-ddf4-0661-e063-6394a90a9c45"]}], "subject": "CHEBI:4735", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b1660fa-21fc-5e92-8acb-dd38d4d15b46", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33b265d0-c624-5928-8086-f5bb0b267076", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "UMLS:C0235266", "original_object": "eye irritation", "original_subject": "EDETIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:4735", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e20e1e4-d67f-5f22-ba4b-39e4233b41c3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "EDETIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1ff0cdc-ac5d-30ca-e053-2a95a90a5066", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1ff0cdc-ac5d-30ca-e053-2a95a90a5066", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1ff0cdc-ac5d-30ca-e053-2a95a90a5066"]}], "subject": "CHEBI:4735", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e8150e3-ab7a-5d8a-bda2-454d8424cf8a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "UMLS:C0014724", "object_location_in_text": [99, 106], "original_object": "burning", "original_subject": "EDETIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:4735", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "benzodiazepines", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:591a3da9-56a2-5954-9de5-83559a10958b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:daf8f6fe-49b7-563f-bead-270465c1ece3", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "UMLS:C0079159", "object_location_in_text": [466, 484], "original_object": "conscious sedation", "original_subject": "EDETIC ACID", "population_context_qualifier": "pediatric patients aged 1 to 17", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05"]}], "subject": "CHEBI:4735", "supporting_text": ["Adult Patients Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17) Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (see Precautions: Pediatric Use )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "benzodiazepines", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7409cf3-e06e-5943-920c-7b744eb01b02", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:daf8f6fe-49b7-563f-bead-270465c1ece3", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "UMLS:C0079159", "object_location_in_text": [490, 508], "original_object": "conscious sedation", "original_subject": "EDETIC ACID", "population_context_qualifier": "Pediatric Patients (aged 1 to 17)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5da455f-3213-ab11-e053-2995a90a54ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5da455f-3213-ab11-e053-2995a90a54ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5da455f-3213-ab11-e053-2995a90a54ee"]}], "subject": "CHEBI:4735", "supporting_text": ["INDICATIONS &amp; USAGE Adult Patients Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17) Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (see PRECAUTIONS, PEDIATRIC USE )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8de0377-774c-5196-b1c9-0cf3021bec03", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1214457e-4603-5425-8edc-d9e2f238829c", "object": "UMLS:C0441723", "object_location_in_text": [59, 69], "original_object": "irritation", "original_subject": "EDETIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:4735", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d346d9de-ffaf-5ab2-949b-a5d6be32bcdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "MONDO:0016586", "object_location_in_text": [545, 566], "original_object": "systemic mastocytosis", "original_subject": "DICLOFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c"]}], "subject": "CHEBI:47381", "supporting_text": ["Ranitdine Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01ea0b09-b301-50c9-8418-07fc5bc14856", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "MONDO:0019610", "object_location_in_text": [514, 540], "original_object": "Zollinger-Ellison syndrome", "original_subject": "DICLOFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c"]}], "subject": "CHEBI:47381", "supporting_text": ["Ranitdine Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0003419", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c657c9f-6384-582c-98de-7a7357367002", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220620", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003419", "UMLS:C0877557", "MONDO:0004855"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3099d411-2f72-555c-8d25-c64c9a5e101e", "object": "UMLS:C0021368", "original_object": "inflammation", "original_subject": "DICLOFENAC SODIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DICLOFENAC SODIUM#37-20220620", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:47381", "supporting_text": ["A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07026d94-668c-5ccc-8b40-62c19aa842f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4146abc-814d-4d55-b51d-a3cb57603325", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4146abc-814d-4d55-b51d-a3cb57603325", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4146abc-814d-4d55-b51d-a3cb57603325"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:076245e6-f8c7-5e47-ae15-4b581af8334e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73182d59-97ad-44d4-ad9e-680dc575ab86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73182d59-97ad-44d4-ad9e-680dc575ab86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73182d59-97ad-44d4-ad9e-680dc575ab86"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0967c4ff-af74-5c93-bcf7-3e19c182f282", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4471245-83d0-49f5-9cd5-3f7e76c799c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4471245-83d0-49f5-9cd5-3f7e76c799c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4471245-83d0-49f5-9cd5-3f7e76c799c4"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10e6f286-3911-57b2-89ea-70ed328f4d34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45e191b6-c6c9-45f9-96d5-cf30f8aa910c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45e191b6-c6c9-45f9-96d5-cf30f8aa910c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45e191b6-c6c9-45f9-96d5-cf30f8aa910c"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:186e61e5-2c6a-5d1a-b464-0f07ee0aff2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fa49554-d85f-a1d5-e063-6294a90a8baf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fa49554-d85f-a1d5-e063-6294a90a8baf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fa49554-d85f-a1d5-e063-6294a90a8baf"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2497d482-9818-5f49-9ca6-33a4de26955e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:861907f7-a338-41c4-899e-48bd9a7e4749", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=861907f7-a338-41c4-899e-48bd9a7e4749", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=861907f7-a338-41c4-899e-48bd9a7e4749"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29e5e75d-bae7-5ce5-a964-ac2bcfd2eed2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08b8737f-b6d2-77da-e063-6294a90a1a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08b8737f-b6d2-77da-e063-6294a90a1a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08b8737f-b6d2-77da-e063-6294a90a1a3e"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3de56c84-39fd-5956-a4a1-dbf535fc7605", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [73, 83], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:851c8b39-6056-4bbc-812e-b9b13977c1ac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=851c8b39-6056-4bbc-812e-b9b13977c1ac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=851c8b39-6056-4bbc-812e-b9b13977c1ac"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE LICART is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years of age and older. LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50d42fae-0466-5c97-931c-8d3a002b9f5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [82, 92], "original_object": "acute pain", "original_subject": "DICLOFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9729cbd-fe89-4b88-b059-b93ccaaf4da4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9729cbd-fe89-4b88-b059-b93ccaaf4da4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9729cbd-fe89-4b88-b059-b93ccaaf4da4"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE FLECTOR ® PATCH is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. FLECTOR PATCH contains diclofenac epolamine, a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:614184d2-4b22-5885-8468-266c46520bda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [76, 86], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1f19a016-c4fc-43c5-9990-e5f2e2776a82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1f19a016-c4fc-43c5-9990-e5f2e2776a82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f19a016-c4fc-43c5-9990-e5f2e2776a82"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE FLECTOR ® is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. FLECTOR is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65d30fd9-6672-58a9-8843-2c4269f82901", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb512554-c37e-4fd2-b06d-eadf7ab62442", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb512554-c37e-4fd2-b06d-eadf7ab62442", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb512554-c37e-4fd2-b06d-eadf7ab62442"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c902585-3324-5e0b-8025-bb8d7d2fd9d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b563e42-3b06-5320-e063-6294a90a30e5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b563e42-3b06-5320-e063-6294a90a30e5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b563e42-3b06-5320-e063-6294a90a30e5"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be736508-71ef-59cc-9b27-dd52b1942274", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [73, 83], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e555ade-00db-5613-e063-6394a90afd45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e555ade-00db-5613-e063-6394a90afd45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e555ade-00db-5613-e063-6394a90afd45"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE LICART is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c543793f-2980-5be8-b987-c0f7558efa81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [82, 92], "original_object": "acute pain", "original_subject": "DICLOFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8b489ee-b48f-41b6-a759-c910e531576f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8b489ee-b48f-41b6-a759-c910e531576f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8b489ee-b48f-41b6-a759-c910e531576f"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE FLECTOR ® PATCH is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. FLECTOR PATCH contains diclofenac epolamine, a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfb3ea50-e526-5c83-8a22-96352341f024", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d9bfacc-1b0c-4fab-b949-cd0c914089f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d9bfacc-1b0c-4fab-b949-cd0c914089f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d9bfacc-1b0c-4fab-b949-cd0c914089f9"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d20480d9-164b-5f23-81bb-1b2acb4aa876", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7bfe17d-e88e-4792-bfba-cea56ed96c3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7bfe17d-e88e-4792-bfba-cea56ed96c3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7bfe17d-e88e-4792-bfba-cea56ed96c3b"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f06e12ea-4a7c-57b7-b364-1b3a8038b773", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18593350-32df-4562-8bfe-e38de53e2b93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18593350-32df-4562-8bfe-e38de53e2b93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18593350-32df-4562-8bfe-e38de53e2b93"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc4a3dbe-c4c6-55e0-8337-779c29ea5772", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880728", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038045", "UMLS:C0009938"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f2ea4d1-fa9c-590e-b947-5ce021b24eef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e293c837-06dd-5716-9f3e-e16c64bd7b9f", "object": "UMLS:C0184567", "object_location_in_text": [107, 117], "original_object": "acute pain", "original_subject": "DICLOFENAC", "population_context_qualifier": "adults and pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a5c4d2d-a819-4749-b4d4-7f2c099175a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a5c4d2d-a819-4749-b4d4-7f2c099175a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a5c4d2d-a819-4749-b4d4-7f2c099175a4"]}], "subject": "CHEBI:47381", "supporting_text": ["1 INDICATIONS AND USAGE DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. • DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0729552", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df22b32c-5bd2-5d62-b7b4-f86b120c1429", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0729552"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e04dab61-2208-5f63-b3ac-d4b7cf8b80d9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:320e4a88-aa46-58a9-aca2-56549d0361f0", "medic_supporting_text_truncated": true, "object": "MONDO:0004779", "object_location_in_text": [1245, 1257], "original_object": "epididymitis", "original_subject": "CEFAZOLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f17160d4-fc42-4f9c-abb8-d04f01ae6dd1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f17160d4-fc42-4f9c-abb8-d04f01ae6dd1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f17160d4-fc42-4f9c-abb8-d04f01ae6dd1"]}], "subject": "CHEBI:474053", "supporting_text": ["Cefazolin for Injection, USP is indicated for the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella species , H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections: Due to S. aureus (penicillin‑sensitive and penicillin-resistant), group A beta‑hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections: Due to E. coli , various strains of streptococci, P. mirabilis , Klebsiella species, and S. aureus . Bone and Joint Infections: Due to S. aureus . Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli , P. mirabilis , Klebsiella species, and some strains of enterococci. Septicemia: Due to S. pneumoniae , S. aureus (penicillin‑sensitive and penicillin‑resistant), P. mirabilis , E. coli , and Klebsiella species. Endocarditis: Due to S. aureus (penicillin‑sensitive and penicillin‑resistant) and group A beta‑hemolytic streptococci. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high‑risk patients such as "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0729552", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad965430-4f87-56cc-8a81-0d75eaa00bb2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0729552"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a07c29f9-4d8b-5e02-8be9-766d7463a316", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:320e4a88-aa46-58a9-aca2-56549d0361f0", "medic_supporting_text_truncated": true, "object": "MONDO:0005280", "object_location_in_text": [1232, 1243], "original_object": "prostatitis", "original_subject": "CEFAZOLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f17160d4-fc42-4f9c-abb8-d04f01ae6dd1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f17160d4-fc42-4f9c-abb8-d04f01ae6dd1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f17160d4-fc42-4f9c-abb8-d04f01ae6dd1"]}], "subject": "CHEBI:474053", "supporting_text": ["Cefazolin for Injection, USP is indicated for the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella species , H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections: Due to S. aureus (penicillin‑sensitive and penicillin-resistant), group A beta‑hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections: Due to E. coli , various strains of streptococci, P. mirabilis , Klebsiella species, and S. aureus . Bone and Joint Infections: Due to S. aureus . Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli , P. mirabilis , Klebsiella species, and some strains of enterococci. Septicemia: Due to S. pneumoniae , S. aureus (penicillin‑sensitive and penicillin‑resistant), P. mirabilis , E. coli , and Klebsiella species. Endocarditis: Due to S. aureus (penicillin‑sensitive and penicillin‑resistant) and group A beta‑hemolytic streptococci. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high‑risk patients such as "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "candidiasis caused by Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af3ee3cf-b125-5739-b4ac-888ab15b8476", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141218", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:969efe9f-cf6a-596b-8d8c-107d9021f278", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f361d51a-fc35-512a-8eb8-8bdf99e6596d", "object": "MONDO:0001648", "object_location_in_text": [129, 151], "original_object": "esophageal candidiasis", "original_subject": "CASPOFUNGIN ACETATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CASPOFUNGIN ACETATE#116-20141218", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:474180", "supporting_text": ["Drugs with a new additional pediatric dosage indicated for the treatment of febrile neutropenia with suspected fungal infection, esophageal candidiasis, invasive candidiasis, and aspergillosis caused by Candida or Aspergillus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbaac76e-0538-5576-ad76-f934976e6c0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011023", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836", "UMLS:C0004034"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9a3eed73-cc7a-58c7-b161-ebbc82269fea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0fdb6c44-67f2-559f-b82f-ea768eba3276", "object": "MONDO:0002041", "original_object": "fungal infections", "original_subject": "caspofungin", "population_context_qualifier": "febrile, neutropaenic adult or paediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cancidas", "https://www.ema.europa.eu/en/documents/product-information/cancidas-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cancidas"]}], "subject": "CHEBI:474180", "supporting_text": ["Treatment of invasive candidiasis in adult or paediatric patients; treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy; empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "aspergillosis caused by Aspergillus", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3f4ea1f-b6b0-50e1-a678-c1fb890b3213", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141218", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:e2f57153-05ee-58dd-8030-8c31ceca7d82", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f361d51a-fc35-512a-8eb8-8bdf99e6596d", "object": "MONDO:0005657", "object_location_in_text": [179, 192], "original_object": "aspergillosis", "original_subject": "CASPOFUNGIN ACETATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CASPOFUNGIN ACETATE#116-20141218", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:474180", "supporting_text": ["Drugs with a new additional pediatric dosage indicated for the treatment of febrile neutropenia with suspected fungal infection, esophageal candidiasis, invasive candidiasis, and aspergillosis caused by Candida or Aspergillus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "candidiasis caused by Candida", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3097ef43-d1fd-55ef-ae41-9029c023d92b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141218", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d49cb2cf-7ce9-50a3-ae9f-4260d528fe35", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f361d51a-fc35-512a-8eb8-8bdf99e6596d", "object": "MONDO:0044067", "object_location_in_text": [153, 173], "original_object": "invasive candidiasis", "original_subject": "CASPOFUNGIN ACETATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CASPOFUNGIN ACETATE#116-20141218", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:474180", "supporting_text": ["Drugs with a new additional pediatric dosage indicated for the treatment of febrile neutropenia with suspected fungal infection, esophageal candidiasis, invasive candidiasis, and aspergillosis caused by Candida or Aspergillus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "suspected fungal infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff1d5a99-ee72-5331-9896-820016bb7aab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141218", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f361d51a-fc35-512a-8eb8-8bdf99e6596d", "object": "UMLS:C0746883", "object_location_in_text": [76, 95], "original_object": "febrile neutropenia", "original_subject": "CASPOFUNGIN ACETATE", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CASPOFUNGIN ACETATE#116-20141218", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:474180", "supporting_text": ["Drugs with a new additional pediatric dosage indicated for the treatment of febrile neutropenia with suspected fungal infection, esophageal candidiasis, invasive candidiasis, and aspergillosis caused by Candida or Aspergillus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Candida spp.", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4609184d-20a8-5c9e-a9bd-a0c4ef6eb192", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76918077-e29b-532e-9151-77c9c6f73d1e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ff723ad0-9dce-5b3f-b204-b123c1a629e7", "object": "MONDO:0000879", "object_location_in_text": [314, 335], "original_object": "cutaneous candidiasis", "original_subject": "KETOCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b"]}], "subject": "CHEBI:47519", "supporting_text": ["Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c50b9ea1-3008-55ce-8263-ae24e54f0a2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ff723ad0-9dce-5b3f-b204-b123c1a629e7", "object": "MONDO:0001461", "object_location_in_text": [65, 79], "original_object": "tinea corporis", "original_subject": "KETOCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b"]}], "subject": "CHEBI:47519", "supporting_text": ["Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0032030", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61f17874-a093-5ef9-b63d-729cbad8453c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0032030", "UMLS:C0032030"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:807f572f-abe5-5ab0-9756-61a614b1e489", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ff723ad0-9dce-5b3f-b204-b123c1a629e7", "object": "MONDO:0005915", "original_object": "tinea versicolor", "original_subject": "KETOCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b"]}], "subject": "CHEBI:47519", "supporting_text": ["Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31666e0a-5b14-589f-b206-0c8277863425", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ff723ad0-9dce-5b3f-b204-b123c1a629e7", "object": "MONDO:0005984", "object_location_in_text": [98, 109], "original_object": "tinea pedis", "original_subject": "KETOCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b"]}], "subject": "CHEBI:47519", "supporting_text": ["Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:715dcfa1-b0a1-51c3-b907-f6e6c9e8541e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ff723ad0-9dce-5b3f-b204-b123c1a629e7", "object": "UMLS:C1384589", "object_location_in_text": [81, 93], "original_object": "tinea cruris", "original_subject": "KETOCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51363e79-8681-4b68-aebf-09323c95809b"]}], "subject": "CHEBI:47519", "supporting_text": ["Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "concomitant esotropias with a significant accommodative component", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4108c12f-9ceb-5f71-a6b7-e34dc6c5debc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a0e997c-e22d-50ae-9fbc-54b76d8b08d0", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e11e2f09-8a6d-5654-b288-fa9307cc36e1", "object": "MONDO:0004895", "original_object": "accommodative esotropia", "original_subject": "ECHOTHIOPHATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8afc8951-db76-4f27-8752-7c0d6aa47244", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8afc8951-db76-4f27-8752-7c0d6aa47244", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8afc8951-db76-4f27-8752-7c0d6aa47244"]}], "subject": "CHEBI:4753", "supporting_text": ["Reduction of Elevated IOP Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. Accommodative Esotropia Concomitant esotropias with a significant accommodative component."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0233697", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14a37afa-822c-5685-b3ae-c71328c5ee13", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0233697"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c7e9d67-17ef-5384-b3e5-797ea74f9566", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75d9a58b-da68-5d23-bd0a-c1d6d57aad9c", "medic_supporting_text_truncated": true, "object": "MONDO:0008114", "original_object": "Obsessive-Compulsive Disorder", "original_subject": "CLOMIPRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff9ed80e-d692-494f-9741-a9af30fa5000", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff9ed80e-d692-494f-9741-a9af30fa5000", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff9ed80e-d692-494f-9741-a9af30fa5000"]}], "subject": "CHEBI:47780", "supporting_text": ["Clomipramine Hydrochloride capsules, USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are egodystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of Clomipramine hydrochloride capsules, USP for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of Clomipramine hydrochloride capsules, USP for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to use Clomipramine hydrochloride for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0233697", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c30b2a2c-f9b1-530b-b5f2-9be6aa512be7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0233697", "UMLS:C0600104"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c7e9d67-17ef-5384-b3e5-797ea74f9566", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75d9a58b-da68-5d23-bd0a-c1d6d57aad9c", "medic_supporting_text_truncated": true, "object": "MONDO:0008114", "original_object": "Obsessive-Compulsive Disorder", "original_subject": "CLOMIPRAMINE", "population_context_qualifier": "patients with obsessions and compulsions meeting DSM-III-R criteria", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a8dc192b-3334-4ca4-8862-3f320014dfb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a8dc192b-3334-4ca4-8862-3f320014dfb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8dc192b-3334-4ca4-8862-3f320014dfb0"]}], "subject": "CHEBI:47780", "supporting_text": ["Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of clomipramine hydrochloride capsules for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of clomipramine hydrochloride capsules for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to use clomipramine hydrochloride capsules for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0233697", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec12e22d-ce9d-5329-afb0-3a42572ab71c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0233697"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c7e9d67-17ef-5384-b3e5-797ea74f9566", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75d9a58b-da68-5d23-bd0a-c1d6d57aad9c", "medic_supporting_text_truncated": true, "object": "MONDO:0008114", "original_object": "Obsessive-Compulsive Disorder", "original_subject": "CLOMIPRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa0d4de8-c96e-429d-a65c-928afbf46863", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa0d4de8-c96e-429d-a65c-928afbf46863", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa0d4de8-c96e-429d-a65c-928afbf46863"]}], "subject": "CHEBI:47780", "supporting_text": ["Clomipramine Hydrochloride capsules, USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are egodystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of Clomipramine hydrochloride capsules, USP for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of Clomipramine hydrochloride capsules, USP for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to use Clomipramine hydrochloride for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0233697", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc6fb6b7-d88a-53a6-adc1-00ae96e73066", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0233697", "UMLS:C0600104"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c7e9d67-17ef-5384-b3e5-797ea74f9566", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75d9a58b-da68-5d23-bd0a-c1d6d57aad9c", "medic_supporting_text_truncated": true, "object": "MONDO:0008114", "original_object": "Obsessive-Compulsive Disorder", "original_subject": "CLOMIPRAMINE", "population_context_qualifier": "patients with obsessions and compulsions meeting DSM-III-R criteria", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be907f61-d918-45f1-89d7-ab61086c83a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be907f61-d918-45f1-89d7-ab61086c83a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be907f61-d918-45f1-89d7-ab61086c83a7"]}], "subject": "CHEBI:47780", "supporting_text": ["Clomipramine hydrochloride capsules USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of clomipramine hydrochloride capsules for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of clomipramine hydrochloride capsules for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to use clomipramine hydrochloride capsules for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6db2d3ed-d736-5aca-b97e-85bd072ce481", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960118", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C2712605", "UMLS:C0033701"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa7ed193-538f-52f2-8aae-277bf7986e90", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CEFEPIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15"]}], "subject": "CHEBI:478164", "supporting_text": ["Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19ac983b-38f9-50d0-9052-967e1daca2a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960118", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa7ed193-538f-52f2-8aae-277bf7986e90", "medic_supporting_text_truncated": true, "object": "HP:0031864", "original_object": "bacteremia", "original_subject": "CEFEPIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15"]}], "subject": "CHEBI:478164", "supporting_text": ["Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4552431", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f74f68ac-ccec-53d1-846c-7f70d6995f6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240321", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552431", "MONDO:0006939", "UMLS:C0949083", "UMLS:C1701940"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5f91158d-2ca0-59db-8ad8-9832a5cce733", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:64b440f0-abc5-5df1-86d5-b34949839912", "object": "MONDO:0005229", "object_location_in_text": [290, 301], "original_object": "bacteraemia", "original_subject": "cefepime;enmetazobactam", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:exblifep", "https://www.ema.europa.eu/en/documents/product-information/exblifep-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/exblifep"]}], "subject": "CHEBI:478164", "supporting_text": ["Exblifep is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1): - Complicated urinary tract infections (cUTI), including pyelonephritis - Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25a2456c-1fd9-5db4-9c98-96644b93934b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960118", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410", "UMLS:C0033809", "UMLS:C2712605", "UMLS:C0014344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa7ed193-538f-52f2-8aae-277bf7986e90", "medic_supporting_text_truncated": true, "object": "MONDO:0005249", "original_object": "pneumonia", "original_subject": "CEFEPIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15"]}], "subject": "CHEBI:478164", "supporting_text": ["Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to"], "temporal_context_qualifier": "concurrent bacteremia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26cc6d07-f4b1-5ea8-9622-5bc53d7e274f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960118", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:59be1928-64f0-5f57-baea-0f6a422cce8b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa7ed193-538f-52f2-8aae-277bf7986e90", "medic_supporting_text_truncated": true, "object": "MONDO:0006939", "object_location_in_text": [1028, 1042], "original_object": "pyelonephritis", "original_subject": "CEFEPIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15"]}], "subject": "CHEBI:478164", "supporting_text": ["Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:411f7aec-5713-5c01-88e1-c603d350d815", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960118", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["metronidazole"], "medic_disease_context_ids": ["UMLS:C0014834", "UMLS:C0033809", "UMLS:C2712605", "UMLS:C0014344", "UMLS:C1456246"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a09b3c8-d93e-5d0d-8de2-214913dd1108", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa7ed193-538f-52f2-8aae-277bf7986e90", "medic_supporting_text_truncated": true, "object": "UMLS:C1112209", "original_object": "intra-abdominal infections", "original_subject": "CEFEPIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eb8794e-2502-43cc-8a32-dcba78031f15"]}], "subject": "CHEBI:478164", "supporting_text": ["Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13a8d5ea-94f6-5a01-9eb5-f21444f9a0e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7077d32e-4b06-4d48-ba0c-6db2f8ebe08c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7077d32e-4b06-4d48-ba0c-6db2f8ebe08c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7077d32e-4b06-4d48-ba0c-6db2f8ebe08c"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets USP are indicated for the treatment of hypertension. Enalapril maleate tablets USP are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of enalapril maleate tablets USP and thiazides are approximately additive. Heart Failure Enalapril maleate tablets USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets USP improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets USP consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets USP does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis). In considering use of enalapril maleate tablets USP, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a8aa34f-c8fd-59ea-85b6-f9e5b6002f87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fdc2d8a-9b5d-43c4-b32f-6f2505aee33c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fdc2d8a-9b5d-43c4-b32f-6f2505aee33c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fdc2d8a-9b5d-43c4-b32f-6f2505aee33c"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ac39ccd-4704-5ad4-b49c-c88691818fc9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb3c7066-76cb-4e8e-b98b-bcb41a3631df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb3c7066-76cb-4e8e-b98b-bcb41a3631df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb3c7066-76cb-4e8e-b98b-bcb41a3631df"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59666d43-c247-5c92-bb41-4f81f6515252", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bdb34c96-1532-4ce5-93a7-3cc90904c910", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bdb34c96-1532-4ce5-93a7-3cc90904c910", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdb34c96-1532-4ce5-93a7-3cc90904c910"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f4198b8-c6a4-5452-be30-49ed8ec362d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:074fe718-88d8-365c-e063-6394a90a299d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=074fe718-88d8-365c-e063-6394a90a299d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=074fe718-88d8-365c-e063-6394a90a299d"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:702005b3-da55-5f2f-ac09-d60ae786a01c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a88902bd-742f-4ea6-b625-cc9df1709efc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a88902bd-742f-4ea6-b625-cc9df1709efc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a88902bd-742f-4ea6-b625-cc9df1709efc"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76ab8066-a643-5b64-8575-eb3f1575c6b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fbc6cce-7ad5-49d5-9705-5f66ef92d544", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fbc6cce-7ad5-49d5-9705-5f66ef92d544", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fbc6cce-7ad5-49d5-9705-5f66ef92d544"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0651eb9-6572-5db2-9839-09bde6ebb177", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a12343f-5733-40cc-93b4-a02f5147fb91", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a12343f-5733-40cc-93b4-a02f5147fb91", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a12343f-5733-40cc-93b4-a02f5147fb91"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005162", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7efc3fe-5e89-5a24-b6f9-144276aeeea5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005162"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [394, 407], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with ejection fraction ≤35 percent", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4b7b936-4a62-4991-8d3c-03bb37f044c1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4b7b936-4a62-4991-8d3c-03bb37f044c1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4b7b936-4a62-4991-8d3c-03bb37f044c1"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."], "temporal_context_qualifier": "development of overt heart failure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ea7f67d-198c-5178-bc7b-b0c733272f89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cbaaa849-0f9d-4294-b122-090ff17fdcc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cbaaa849-0f9d-4294-b122-090ff17fdcc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbaaa849-0f9d-4294-b122-090ff17fdcc7"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fc487aa-0740-5920-9722-10249b38af2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59f44ba0-a323-493f-e063-6394a90a1c3c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59f44ba0-a323-493f-e063-6394a90a1c3c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59f44ba0-a323-493f-e063-6394a90a1c3c"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6696420a-b2b2-5a53-bef5-4507f6f89adf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b464099-491d-473b-836e-9d86b2b1eeec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b464099-491d-473b-836e-9d86b2b1eeec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b464099-491d-473b-836e-9d86b2b1eeec"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:706d70a6-2cd4-527f-ad6a-6e80b81aa1f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5118eb9f-1466-4318-b17e-cf5898edbeef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5118eb9f-1466-4318-b17e-cf5898edbeef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5118eb9f-1466-4318-b17e-cf5898edbeef"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f33ee37-ef56-5437-b571-4f1d69d89274", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe303f6a-4a9f-259e-e053-6394a90af16b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe303f6a-4a9f-259e-e053-6394a90af16b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe303f6a-4a9f-259e-e053-6394a90af16b"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e258c52a-9339-5b13-bdde-dcbdffa7bb58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5c6e64c-a3ed-44f2-83e7-f4b62b6cd622", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5c6e64c-a3ed-44f2-83e7-f4b62b6cd622", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5c6e64c-a3ed-44f2-83e7-f4b62b6cd622"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asymptomatic left ventricular dysfunction", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7db5de4-82e5-5823-866d-a3942acea735", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851224", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e82ec2ba-9d28-56cb-9dcb-6b54c32fc315", "object": "MONDO:0005252", "object_location_in_text": [428, 441], "original_object": "heart failure", "original_subject": "ENALAPRIL", "population_context_qualifier": "clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e47afc0d-afc4-4972-a28a-5d3c640390ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e47afc0d-afc4-4972-a28a-5d3c640390ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e47afc0d-afc4-4972-a28a-5d3c640390ab"]}], "subject": "CHEBI:4784", "supporting_text": ["Hypertension Enalapril maleate tablets are indicated for the treatment of hypertension. Enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. The blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. Heart Failure Enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate tablets consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets do not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis ). In considering use of enalapril maleate tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "axillary node tumor involvement", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5e8e16d-1ac4-504b-ab86-1d5ad8250acd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990915", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:60cad7e0-d899-591b-9bfd-20f693fc2ed3", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "EPIRUBICIN", "population_context_qualifier": "patients with evidence of axillary node tumor involvement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:F7EC5EC1-FB05-4C78-B821-9AEA638CF144", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=F7EC5EC1-FB05-4C78-B821-9AEA638CF144", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=F7EC5EC1-FB05-4C78-B821-9AEA638CF144"]}], "subject": "CHEBI:47898", "supporting_text": ["Epirubicin Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer."], "temporal_context_qualifier": "following resection of primary breast cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "end-of-dose \"wearing-off\"", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:962e4cf6-0a0b-5236-b7ee-e340bb314c6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991019", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["levodopa/carbidopa"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ad044f6-bbb2-5a36-b0d9-995a79044b32", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf066094-a007-598e-9a00-85e838eff575", "object": "MONDO:0005180", "original_object": "idiopathic Parkinson's Disease", "original_subject": "ENTACAPONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9ac99ad-7e82-4064-8c66-214ac6d1776b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9ac99ad-7e82-4064-8c66-214ac6d1776b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9ac99ad-7e82-4064-8c66-214ac6d1776b"]}], "subject": "CHEBI:4798", "supporting_text": ["INDICATIONS Entacapone tablets are indicated as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose \"wearing-off\" (see CLINICAL PHARMACOLOGY, Clinical Studies ). Entacapone tablets effectiveness has not been systematically evaluated in patients with idiopathic Parkinson’s Disease who do not experience end-of-dose \"wearing-off\"."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "(not indicated - this is a limitation stating it is NOT indicated for prevention)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95e8acb3-9187-5a3f-a581-ee91f6487589", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:291198cb-ef21-5f69-9da3-a0f430513ea4", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f8a33c3-5729-5355-9786-e0893f644839", "object": "MONDO:0005277", "object_location_in_text": [94, 102], "original_object": "migraine", "original_subject": "RIZATRIPTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7414f2d-d7cf-41e5-b457-f5850e8bb7a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7414f2d-d7cf-41e5-b457-f5850e8bb7a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7414f2d-d7cf-41e5-b457-f5850e8bb7a7"]}], "subject": "CHEBI:48273", "supporting_text": ["1 INDICATIONS AND USAGE Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "(not indicated - this is a limitation stating safety and effectiveness have not been established)", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a05d9dd0-1ffa-50ea-9527-2addad2ccd5e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c941bbd9-0583-54d5-ba0f-8d79f35f7854", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f8a33c3-5729-5355-9786-e0893f644839", "object": "MONDO:0043537", "original_object": "cluster headache", "original_subject": "RIZATRIPTAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7414f2d-d7cf-41e5-b457-f5850e8bb7a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7414f2d-d7cf-41e5-b457-f5850e8bb7a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7414f2d-d7cf-41e5-b457-f5850e8bb7a7"]}], "subject": "CHEBI:48273", "supporting_text": ["1 INDICATIONS AND USAGE Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:016bc737-cb29-573c-aac4-4841722b538e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e96cfada-3763-4af7-b323-1256926a797c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e96cfada-3763-4af7-b323-1256926a797c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e96cfada-3763-4af7-b323-1256926a797c"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:079fd567-24c8-5726-af41-922ea4665acf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ce36f6b-d5d7-5409-9465-017248a45636", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:200390f2-7dad-4ecc-a086-c29e18525c01", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=200390f2-7dad-4ecc-a086-c29e18525c01", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=200390f2-7dad-4ecc-a086-c29e18525c01"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS AND USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a38acd2-fa15-5362-a953-adc142d2c504", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60e6264c-723c-49b2-a246-827b15ff219c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60e6264c-723c-49b2-a246-827b15ff219c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60e6264c-723c-49b2-a246-827b15ff219c"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26cef0e0-5f8a-5087-8e77-d2e8d76499bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c288922b-3258-4c1c-bd8a-32a41dd43a63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c288922b-3258-4c1c-bd8a-32a41dd43a63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c288922b-3258-4c1c-bd8a-32a41dd43a63"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51ea9ec1-fc00-5aa0-b977-dfea530cd485", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ce36f6b-d5d7-5409-9465-017248a45636", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6bad4e06-c0a1-4123-83c2-67d3b081e8a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6bad4e06-c0a1-4123-83c2-67d3b081e8a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6bad4e06-c0a1-4123-83c2-67d3b081e8a9"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS AND USAGE Cinacalcet is a positive modulator of the calcium-sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:701731d9-06aa-56e3-9624-eddb71b93848", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79b64bbb-3682-4b31-9bb6-03e2c5ac5a2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79b64bbb-3682-4b31-9bb6-03e2c5ac5a2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79b64bbb-3682-4b31-9bb6-03e2c5ac5a2c"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70fbc49c-5767-51f1-ab62-51e90f2b53eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b920a91f-309f-4f83-a123-525b3bdd55b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b920a91f-309f-4f83-a123-525b3bdd55b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b920a91f-309f-4f83-a123-525b3bdd55b7"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f521988-38ca-5fa4-8bc6-a9341b7683e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ce36f6b-d5d7-5409-9465-017248a45636", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02b8c11b-99e8-4039-b6fa-a9c38d2f48fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02b8c11b-99e8-4039-b6fa-a9c38d2f48fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02b8c11b-99e8-4039-b6fa-a9c38d2f48fa"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS AND USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84067db3-ebc1-5220-aee8-7ee7bf987059", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ce36f6b-d5d7-5409-9465-017248a45636", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4a561936-494f-4320-bf6e-c36481f1518c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4a561936-494f-4320-bf6e-c36481f1518c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a561936-494f-4320-bf6e-c36481f1518c"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS AND USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:996b5ed7-97ce-5cb2-b055-a8fe3d519ad1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1cfc943-5b70-4451-a1fc-61e45e669d84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1cfc943-5b70-4451-a1fc-61e45e669d84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1cfc943-5b70-4451-a1fc-61e45e669d84"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a345cc1a-9ccc-59c6-b8eb-9d4169256399", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44b548ef-1679-4d15-86ad-0d9636b48a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44b548ef-1679-4d15-86ad-0d9636b48a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44b548ef-1679-4d15-86ad-0d9636b48a45"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS AND USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd6b28e8-b342-58d0-bd94-f6aa41d391bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7ce36f6b-d5d7-5409-9465-017248a45636", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0604423-af02-46dd-b38b-8e0937517304", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0604423-af02-46dd-b38b-8e0937517304", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0604423-af02-46dd-b38b-8e0937517304"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS AND USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f182bd50-76ac-55ab-9ee0-e53b3a529fda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:330b4214-dba7-468c-a67e-b1057f4628da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=330b4214-dba7-468c-a67e-b1057f4628da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=330b4214-dba7-468c-a67e-b1057f4628da"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary HPT", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f560a434-df3a-53c7-9bf7-e1b32d1343e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040308", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2c518e9b-ae3e-513c-a255-3ca6696f5571", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0001566", "original_object": "severe hypercalcemia", "original_subject": "CINACALCET", "population_context_qualifier": "adult patients with primary HPT who are unable to undergo parathyroidectomy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86fe67f9-d4e0-4966-a80b-c04bf6bb0ef9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86fe67f9-d4e0-4966-a80b-c04bf6bb0ef9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86fe67f9-d4e0-4966-a80b-c04bf6bb0ef9"]}], "subject": "CHEBI:48390", "supporting_text": ["1 INDICATIONS &amp; USAGE Cinacalcet is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33c8a112-a43e-5d65-84c6-c49ad52de2ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:13dc9a4f-4722-5b44-8c4e-1cfc1f71375d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0006964", "original_object": "secondary hyperparathyroidism", "original_subject": "cinacalcet", "population_context_qualifier": "children aged 3 years and older with end-stage renal disease on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cinacalcet-accordpharma", "https://www.ema.europa.eu/en/documents/product-information/cinacalcet-accordpharma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-accordpharma"]}], "subject": "CHEBI:48390", "supporting_text": ["Secondary hyperparathyroidism AdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4). Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1). Parathyroid carcinoma and primary hyperparathyroidism in adults Reduction of hypercalcaemia in adult patients with:  parathyroid carcinoma. primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b92d464e-73fa-5fee-b92b-a8761be4c28a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:13dc9a4f-4722-5b44-8c4e-1cfc1f71375d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e1c30ce6-7806-51ff-b1d5-a99d4b8923f5", "object": "MONDO:0006964", "original_object": "secondary hyperparathyroidism", "original_subject": "cinacalcet", "population_context_qualifier": "patients on maintenance dialysis therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cinacalcet-viatris", "https://www.ema.europa.eu/en/documents/product-information/cinacalcet-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-viatris"]}], "subject": "CHEBI:48390", "supporting_text": ["Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with:  parathyroid carcinoma primary HPT for whom parathyroidectomy  would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:100e30be-c3c9-520b-bf84-fc9ef84bdfde", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [372, 394], "original_object": "myocardial infarctions", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c6c4edd-bf92-525c-9c0f-d77285a50d83", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [276, 298], "original_object": "myocardial infarctions", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e73a977-c548-5b1b-9f95-1b86b6f2b7ae", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8acdc142-aa38-4fcb-bd15-fbba9635a4c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8acdc142-aa38-4fcb-bd15-fbba9635a4c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8acdc142-aa38-4fcb-bd15-fbba9635a4c6"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33a58781-a876-59fc-8774-d5f973b26de9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:24e308cc-7cec-4054-9627-66f743ed71b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=24e308cc-7cec-4054-9627-66f743ed71b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24e308cc-7cec-4054-9627-66f743ed71b0"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS &amp; USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:375b9257-4ef4-5ca0-bdaf-4c8675873ae3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85a24657-583b-4776-98c9-b30285cb3058", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85a24657-583b-4776-98c9-b30285cb3058", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85a24657-583b-4776-98c9-b30285cb3058"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS &amp; USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ea1865f-fc3f-56f1-a8bb-22905d83d587", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57dc737b-01e2-4b22-991f-d4710950dcf3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57dc737b-01e2-4b22-991f-d4710950dcf3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57dc737b-01e2-4b22-991f-d4710950dcf3"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41e6297c-5ca5-57c0-8368-17943fe4b76a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5972c6fd-08e3-4189-a894-1ba220b57e80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5972c6fd-08e3-4189-a894-1ba220b57e80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5972c6fd-08e3-4189-a894-1ba220b57e80"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b43674c-d594-5d2d-9c9c-ccf088239be0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79e2620d-6554-4e03-8087-59ec2e4dd75b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79e2620d-6554-4e03-8087-59ec2e4dd75b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79e2620d-6554-4e03-8087-59ec2e4dd75b"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:688ed255-c249-508d-a4bb-40de2bbbde87", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b8585a2-22e0-4a4f-a1c3-24bcdec01834", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b8585a2-22e0-4a4f-a1c3-24bcdec01834", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b8585a2-22e0-4a4f-a1c3-24bcdec01834"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7541b64f-ec72-57aa-8515-3c67b35c154b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1df1ff60-6be5-4018-a28c-0d23e5867eba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1df1ff60-6be5-4018-a28c-0d23e5867eba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1df1ff60-6be5-4018-a28c-0d23e5867eba"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablet are indicated for the treatment of hypertension, in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78f251df-6c02-563b-903f-6cfaee92a60f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:812d2d57-14d6-48a9-9687-85c2d125197e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=812d2d57-14d6-48a9-9687-85c2d125197e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=812d2d57-14d6-48a9-9687-85c2d125197e"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS &amp; USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b729d77-bfca-52b6-bc7d-7a558d3bcd82", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c49a7f23-2af0-4607-9f21-114970f8630d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c49a7f23-2af0-4607-9f21-114970f8630d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c49a7f23-2af0-4607-9f21-114970f8630d"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b30eacd6-2e41-52c9-93ce-c4b25c746cdb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:67aa498d-edf6-45b8-a3fd-019c3fb76960", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=67aa498d-edf6-45b8-a3fd-019c3fb76960", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=67aa498d-edf6-45b8-a3fd-019c3fb76960"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4bda091-ab51-5cca-8109-aeaf04510a0c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [276, 298], "original_object": "myocardial infarctions", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f59e7192-6461-57e3-b886-6c61437aaed6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f4d89ab-58c8-27ea-e063-6394a90a8723", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f4d89ab-58c8-27ea-e063-6394a90a8723", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f4d89ab-58c8-27ea-e063-6394a90a8723"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f814c220-3c7b-52d8-8b37-ffd50486c6c5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [372, 394], "original_object": "myocardial infarctions", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0abdde1c-65ad-56a6-bb6d-8667bc9d06b5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f4d89ab-58c8-27ea-e063-6394a90a8723", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f4d89ab-58c8-27ea-e063-6394a90a8723", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f4d89ab-58c8-27ea-e063-6394a90a8723"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2683878e-f786-5adc-8444-588ea6c8e988", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57dc737b-01e2-4b22-991f-d4710950dcf3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57dc737b-01e2-4b22-991f-d4710950dcf3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57dc737b-01e2-4b22-991f-d4710950dcf3"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:349ed6dc-1e1d-57cb-8fc0-978dceb4d732", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:67aa498d-edf6-45b8-a3fd-019c3fb76960", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=67aa498d-edf6-45b8-a3fd-019c3fb76960", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=67aa498d-edf6-45b8-a3fd-019c3fb76960"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3dae5ef5-8d20-5eb2-9eb0-538b49b10b58", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [264, 271], "original_object": "strokes", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d74a740-ccde-5e17-bac2-f82e53d504a9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5972c6fd-08e3-4189-a894-1ba220b57e80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5972c6fd-08e3-4189-a894-1ba220b57e80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5972c6fd-08e3-4189-a894-1ba220b57e80"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72d5e049-2a17-5452-bb8b-305d58d2e9f6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85a24657-583b-4776-98c9-b30285cb3058", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85a24657-583b-4776-98c9-b30285cb3058", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85a24657-583b-4776-98c9-b30285cb3058"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS &amp; USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:750855d0-c7c4-533e-b9f4-fe69944c02eb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8acdc142-aa38-4fcb-bd15-fbba9635a4c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8acdc142-aa38-4fcb-bd15-fbba9635a4c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8acdc142-aa38-4fcb-bd15-fbba9635a4c6"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:750d187e-ae2d-58d7-9c05-4457a6fbab51", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:812d2d57-14d6-48a9-9687-85c2d125197e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=812d2d57-14d6-48a9-9687-85c2d125197e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=812d2d57-14d6-48a9-9687-85c2d125197e"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS &amp; USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:893f7ccb-9e91-57b6-9ec6-3a453f7f932e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c49a7f23-2af0-4607-9f21-114970f8630d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c49a7f23-2af0-4607-9f21-114970f8630d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c49a7f23-2af0-4607-9f21-114970f8630d"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93535daa-d601-5702-8d3f-56970f2479e3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79e2620d-6554-4e03-8087-59ec2e4dd75b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79e2620d-6554-4e03-8087-59ec2e4dd75b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79e2620d-6554-4e03-8087-59ec2e4dd75b"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a874a791-679b-5900-a42b-467def9b7616", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:24e308cc-7cec-4054-9627-66f743ed71b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=24e308cc-7cec-4054-9627-66f743ed71b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24e308cc-7cec-4054-9627-66f743ed71b0"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS &amp; USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8bfc9ad-b0e4-590f-be52-972c5fff5271", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [360, 367], "original_object": "strokes", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c70f5550-e56a-5723-801b-f5e299870773", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1df1ff60-6be5-4018-a28c-0d23e5867eba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1df1ff60-6be5-4018-a28c-0d23e5867eba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1df1ff60-6be5-4018-a28c-0d23e5867eba"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablet are indicated for the treatment of hypertension, in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6ae2784-350d-5152-abdb-a54e8e6b8171", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [264, 271], "original_object": "strokes", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from bl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e184ab9f-7f73-5f7b-b2d8-7dffffeabfe1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b8585a2-22e0-4a4f-a1c3-24bcdec01834", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b8585a2-22e0-4a4f-a1c3-24bcdec01834", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b8585a2-22e0-4a4f-a1c3-24bcdec01834"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE Olmesartan medoxomil tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5273daa-7150-5009-8fb5-17cf5d06aea6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2e7c5c22-8deb-5dac-87d2-065a9a9273eb", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [360, 367], "original_object": "strokes", "original_subject": "OLMESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521"]}], "subject": "CHEBI:48416", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0036983", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72b0c0e0-7a2f-5118-ada0-c1ae1ab0f886", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190823", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0036983", "HP:0031275"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2c028f3e-b92a-5601-bf01-7f500bc90092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a55b6a0e-efb6-5179-b25a-495c1f8a0527", "object": "UMLS:C4304283", "object_location_in_text": [43, 65], "original_object": "refractory hypotension", "original_subject": "angiotensin II", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:giapreza", "https://www.ema.europa.eu/en/documents/product-information/giapreza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza"]}], "subject": "CHEBI:48432", "supporting_text": ["Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies."], "temporal_context_qualifier": "despite adequate volume restitution and application of catecholamines and other available vasopressor therapies"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "noncompensatory sinus tachycardia", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba96202f-e77d-56bd-ba0e-bc72ee2bf1cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880815", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4d138f41-3e82-5c80-abbd-b9f5a1487262", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:121ed57e-13ff-522a-bb5b-5818edbb4e82", "object": "UMLS:C0018810", "object_location_in_text": [242, 252], "original_object": "heart rate", "original_subject": "ESMOLOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595cc3d5-1306-4828-aefa-5595219ffd62", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595cc3d5-1306-4828-aefa-5595219ffd62"]}], "subject": "CHEBI:4856", "supporting_text": ["1 INDICATIONS AND USAGE BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 ) 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of BREVIBLOC injection to prevent such events is not recommended."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "noncompensatory sinus tachycardia", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb6f1130-9dc6-5cb1-b328-d3c0cf568b3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880815", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4d138f41-3e82-5c80-abbd-b9f5a1487262", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:121ed57e-13ff-522a-bb5b-5818edbb4e82", "object": "UMLS:C0018810", "object_location_in_text": [242, 252], "original_object": "heart rate", "original_subject": "ESMOLOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c593cdb-cdfe-4492-8862-9b05116aa25e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c593cdb-cdfe-4492-8862-9b05116aa25e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c593cdb-cdfe-4492-8862-9b05116aa25e"]}], "subject": "CHEBI:4856", "supporting_text": ["1 INDICATIONS AND USAGE BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 ) 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of BREVIBLOC injection to prevent such events is not recommended."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "noncompensatory sinus tachycardia", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd9c4445-b82b-50bb-9709-b1d678365195", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880815", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4d138f41-3e82-5c80-abbd-b9f5a1487262", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:121ed57e-13ff-522a-bb5b-5818edbb4e82", "object": "UMLS:C0018810", "object_location_in_text": [242, 252], "original_object": "heart rate", "original_subject": "ESMOLOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:220a07b8-5c68-41a3-8705-fd91f14c50b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=220a07b8-5c68-41a3-8705-fd91f14c50b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=220a07b8-5c68-41a3-8705-fd91f14c50b4"]}], "subject": "CHEBI:4856", "supporting_text": ["1 INDICATIONS AND USAGE BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 ) 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of BREVIBLOC injection to prevent such events is not recommended."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031356", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b85ef79-3a67-57b8-ae21-a05cb56d759a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901226", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031356"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:05f85dc6-0b72-5a05-bfb6-45256ab9f99c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57314dac-b984-5819-b512-98a3f2395b42", "object": "MONDO:0013600", "object_location_in_text": [70, 78], "original_object": "insomnia", "original_subject": "ESTAZOLAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1e3b4bf-22e9-430a-a768-4d86ae886c9e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1e3b4bf-22e9-430a-a768-4d86ae886c9e"]}], "subject": "CHEBI:4858", "supporting_text": ["Estazolam tablets, USP are indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Both outpatient studies and a sleep laboratory study have shown that estazolam administered at bedtime improved sleep induction and sleep maintenance (see CLINICAL PHARMACOLOGY ). Because insomnia is often transient and intermittent, the prolonged administration of estazolam is generally neither necessary nor recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. There is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY )."], "temporal_context_qualifier": "short-term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "heparin-induced thrombocytopenia (HIT) type II", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98b5c1a2-39fe-5c21-a6cd-e89fc260c8a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080716", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:44c079af-0a26-5282-9971-84d90155ad24", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1eb6c838-f46a-5eb7-bbe6-132d84cc963b", "object": "MONDO:0000831", "object_location_in_text": [64, 74], "original_object": "thrombosis", "original_subject": "ARGATROBAN HYDRATE", "population_context_qualifier": "patients with heparin-induced thrombocytopenia (HIT) type II", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ARGATROBAN HYDRATE#171-20080716", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:48720", "supporting_text": ["Drugs with a new indication and a new dosage for prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia (HIT) type II."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HIT type II", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5b71c5f-dce0-5ab4-9ed4-88056d05fd70", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9c6e72b8-ed22-5855-bc9c-da1468bfc351", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1eb6c838-f46a-5eb7-bbe6-132d84cc963b", "object": "UMLS:C0005778", "object_location_in_text": [86, 103], "original_object": "blood coagulation", "original_subject": "ARGATROBAN HYDRATE", "population_context_qualifier": "HIT type II patients (including the patients who have the risk for HIT)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ARGATROBAN HYDRATE#145-20110520", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:48720", "supporting_text": ["Drugs with new additional indications and new dosages for the prevention of perfusion blood coagulation during blood extracorporeal circulation (hemodialysis) in patients with heparin-induced thrombocytopenia (HIT) type II and in addition for the prevention of blood coagulation during percutaneous coronary intervention in HIT type II patients (including the patients who have the risk for HIT)."], "temporal_context_qualifier": "during percutaneous coronary intervention"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80abd054-da57-5c40-848d-a60f3f48789c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "object_location_in_text": [1936, 1958], "original_object": "ankylosing spondylitis", "original_subject": "etanercept", "population_context_qualifier": "adults with severe active ankylosing spondylitis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "active and progressive psoriatic arthritis with inadequate response to previous disease-modifying antirheumatic drug therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f087a07e-ff8e-5308-93a6-73092ea9013f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "object_location_in_text": [1027, 1046], "original_object": "psoriatic arthritis", "original_subject": "etanercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15e7e2ba-d7bb-504a-8c70-799fda986121", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b9313d76-9078-5e32-93fe-37c4eba691c8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "MONDO:0019437", "object_location_in_text": [1183, 1211], "original_object": "enthesitis-related arthritis", "original_subject": "etanercept", "population_context_qualifier": "adolescents from the age of 12 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:enbrel", "https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than two years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis (AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to, or intolerance of, conventional therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62dcc620-0a4d-5dfd-bae1-a93547a94dd2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b9313d76-9078-5e32-93fe-37c4eba691c8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "MONDO:0019437", "object_location_in_text": [1188, 1216], "original_object": "enthesitis-related arthritis", "original_subject": "etanercept", "population_context_qualifier": "adolescents from the age of 12 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to methotrexate, intolerance to methotrexate", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87ef6c35-d54b-554c-a9a0-548fa88c1240", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4d2e98f7-25c6-5d1a-a40a-b636b264fe55", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "MONDO:0024280", "original_object": "polyarthritis", "original_subject": "etanercept", "population_context_qualifier": "children and adolescents from the age of two years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:enbrel", "https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than two years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis (AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to, or intolerance of, methotrexate", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1ffee86-7dec-5541-99ed-f338131a34f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4d2e98f7-25c6-5d1a-a40a-b636b264fe55", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "MONDO:0024280", "object_location_in_text": [791, 804], "original_object": "polyarthritis", "original_subject": "etanercept", "population_context_qualifier": "children and adolescents from the age of 2 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic severe plaque psoriasis inadequately controlled by, or intolerant to, other systemic therapies or phototherapies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:845b500b-0749-51e0-b533-f214da430b0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:0e6ca689-757d-58ce-aef2-6bd45c549b64", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "UMLS:C0406317", "original_object": "plaque psoriasis", "original_subject": "etanercept", "population_context_qualifier": "children and adolescents from the age of 6 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96ee3a6c-9acb-5083-8986-6e8577237b66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:42ba7dbd-ad67-5020-b472-308afe9106db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "UMLS:C3889038", "original_object": "non-radiographic axial spondyloarthritis", "original_subject": "etanercept", "population_context_qualifier": "adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to methotrexate, intolerance to methotrexate", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6472f82c-7395-5236-b7e9-ac056f667a77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:07605dc0-486e-5a77-8179-665279f8c25d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "UMLS:C4049572", "object_location_in_text": [843, 866], "original_object": "extended oligoarthritis", "original_subject": "etanercept", "population_context_qualifier": "children and adolescents from the age of two years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:enbrel", "https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than two years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis (AS) Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to, or intolerance of, methotrexate", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1d0f5c5-acee-52b4-a206-118d85ebd28b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:07605dc0-486e-5a77-8179-665279f8c25d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a7089190-5c63-55f6-9a44-3630c06c2ecf", "medic_supporting_text_truncated": true, "object": "UMLS:C4049572", "object_location_in_text": [850, 873], "original_object": "extended oligoarthritis", "original_subject": "etanercept", "population_context_qualifier": "children and adolescents from the age of 2 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:benepali", "https://www.ema.europa.eu/en/documents/product-information/benepali-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/benepali"]}], "subject": "CHEBI:4875", "supporting_text": ["Rheumatoid arthritis Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years. Psoriatic arthritis Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. Axial spondyloarthritis Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to co"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal absorption impaired", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:987d5788-9e67-5aa4-b0d5-13c2442e5a81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:86ad2255-adb5-5fbb-8be3-71fe590a3088", "object": "HP:0000969", "object_location_in_text": [55, 60], "original_object": "edema", "original_subject": "ETHACRYNIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9bc3907-bfa7-4d9f-90d9-c2097230f7e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9bc3907-bfa7-4d9f-90d9-c2097230f7e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9bc3907-bfa7-4d9f-90d9-c2097230f7e4"]}], "subject": "CHEBI:4876", "supporting_text": ["Ethacrynic acid tablets are indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Escherichia coli, beta-lactamase–producing Klebsiella species, beta-lactamase–producing Enterobacter species", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b9fdbae-51d9-589b-b85c-89938d7b3e8a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Escherichia coli, beta-lactamase–producing Klebsiella species, beta-lactamase–producing Enterobacter species", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e4aa5e6-6850-52c0-a814-39af3cbd1358", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6e91044-c8fb-5d22-9752-90745e58a2bb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d72ec24a-b107-5e55-8c3b-8c4d67f855af", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:57dbe806-8e07-5f0a-afc7-b9fbc1da98d2", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "HP:0002783", "original_object": "lower respiratory tract infections", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "S. pneumoniae infection, H. influenzae infection, M. catarrhalis infection", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdf4d652-5e00-5538-9af3-841be2624c03", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49b41f71-3324-5b2b-ad04-ad6d835e7323", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "MONDO:0005441", "original_object": "recurrent or persistent acute otitis media", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "pediatric patients aged 3 months to 12 years weighing less than or equal to 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59979859-8c9b-4173-a5e3-2e6312fd9d79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59979859-8c9b-4173-a5e3-2e6312fd9d79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59979859-8c9b-4173-a5e3-2e6312fd9d79"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE AUGMENTIN ES-600 is indicated for the treatment of pediatric patients aged 3 months to 12 years weighing less than or equal to 40 kg with: Recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs less than or equal to 2 mcg/mL), H. influenzae (including beta-lactamase-producing strains), or M. catarrhalis (including beta-lactamase-producing strains) characterized by the following risk factors: - Antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) day care attendance [see Microbiology (12.4)] ."], "temporal_context_qualifier": "characterized by antibacterial exposure for acute otitis media within the preceding 3 months, and either age 2 years, or younger or day care attendance"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96b9c60a-c092-5606-9941-f5d9f55f48b2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15d9c229-0d23-52ff-bfb2-0fd72199aa8c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "MONDO:0005961", "original_object": "sinusitis", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb0bbac8-2eb3-5b7f-8776-d8e92bfc9e59", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15d9c229-0d23-52ff-bfb2-0fd72199aa8c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "MONDO:0005961", "original_object": "sinusitis", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase-producing pathogens, S. pneumoniae with reduced susceptibility to penicillin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20f317dd-deb4-5962-937f-e71026d46ea2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:67eb57d0-058f-509e-b435-b2978472c1c6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "UMLS:C0275556", "object_location_in_text": [275, 300], "original_object": "acute bacterial sinusitis", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium Extended Release Tablets is indicated for the treatment of infections in adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets with: community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected beta-lactamase-producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs equal to 2 mcg/mL)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "S. pneumoniae with reduced susceptibility to penicillin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2a0c681-68f7-5793-a5e8-ef91784c1e08", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "UMLS:C0694549", "object_location_in_text": [243, 271], "original_object": "community-acquired pneumonia", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45c60b69-1b65-01ed-e063-6294a90a57be"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium Extended Release Tablets is indicated for the treatment of infections in adults and pediatric patients weighing greater than or equal to 40 kg who are able to swallow tablets with: community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected beta-lactamase-producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs equal to 2 mcg/mL)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d668607-a4ca-5a70-aed3-8c31a0aa74b2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4a6deb5-0bcd-4fa3-b19b-a82fa1dd14f3"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "beta-lactamase–producing Haemophilus influenzae, beta-lactamase–producing Moraxella catarrhalis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8b3e6ba-88da-5fbc-8519-70d76ba825b6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ecdd475f-87b3-5162-a9be-65a870eb87be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4635e7ee-4643-5258-9c3a-78bfd9223947", "object": "UMLS:C1698510", "original_object": "acute bacterial otitis media", "original_subject": "CLAVULANIC ACID", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c857fb6-9c7d-4192-9f28-38d8dd57508b"]}], "subject": "CHEBI:48947", "supporting_text": ["1 INDICATIONS AND USAGE Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. Amoxicillin and Clavulanate Potassium is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassaemia syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35951522-020f-5e2c-957b-49738e6f8ebc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060828", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["deferoxamine"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [53, 74], "original_object": "chronic iron overload", "original_subject": "deferasirox", "population_context_qualifier": "patients aged 10 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:deferasirox-accord", "https://www.ema.europa.eu/en/documents/product-information/deferasirox-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/deferasirox-accord"]}], "subject": "CHEBI:49005", "supporting_text": ["Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:  in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) aged 2 to 5 years, in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (&lt;7 ml/kg/month of packed red blood cells) aged 2 years and older, in adult and paediatric patients with other anaemias aged 2 years and older.  Deferasirox Accord is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassaemia syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:512eabf5-886c-5bb8-873e-d9459ef4164e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060828", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [41, 62], "original_object": "chronic iron overload", "original_subject": "deferasirox", "population_context_qualifier": "patients aged 10 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:exjade", "https://www.ema.europa.eu/en/documents/product-information/exjade-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/exjade"]}], "subject": "CHEBI:49005", "supporting_text": ["Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (? 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older. Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:  in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (? 7 ml/kg/month of packed red blood cells) aged two to five years; in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (&lt; 7 ml/kg/month of packed red blood cells) aged two years and older; in patients with other anaemias aged two years and older.  Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older."], "temporal_context_qualifier": "requiring chelation therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-transfusion dependent thalassaemia syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be2328c5-1d60-5e55-93b4-2e00171653f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060828", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["deferoxamine therapy is contraindicated or inadequate"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [53, 74], "original_object": "chronic iron overload", "original_subject": "deferasirox", "population_context_qualifier": "patients aged 10 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:deferasirox-mylan", "https://www.ema.europa.eu/en/documents/product-information/deferasirox-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/deferasirox-mylan"]}], "subject": "CHEBI:49005", "supporting_text": ["Deferasirox Mylan is indicated for  the treatment of chronic iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:  in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) aged 2 to 5 years, in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (&lt;7 ml/kg/month of packed red blood cells) aged 2 years and older, in adult and paediatric patients with other anaemias aged 2 years and older.   the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion dependent thalassaemia syndromes aged 10 years and older."], "temporal_context_qualifier": "requiring chelation therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d8066bd-859c-5997-9d32-fcb945e9fbed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [87, 108], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a2e1bd2-9f3a-40ec-94a2-bc76350d6d4b"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. (1.2)"], "temporal_context_qualifier": "with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f99f1c2-0a04-5a8e-afd3-5daf090d3b64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [96, 117], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7f14819-1abc-4abf-b55b-cf89beaf124e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7f14819-1abc-4abf-b55b-cf89beaf124e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7f14819-1abc-4abf-b55b-cf89beaf124e"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:379026ed-a567-50ad-b98e-92d197502c91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [82, 103], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fee89140-fff1-4443-9f42-24ac004fcda1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58b73f53-5281-534b-ba0c-94129e306841", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [96, 117], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:485c4834-7bec-2018-e063-6294a90ab4e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=485c4834-7bec-2018-e063-6294a90ab4e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=485c4834-7bec-2018-e063-6294a90ab4e3"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:666d7415-11d7-55bc-9c04-a5ff44710bb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [101, 122], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7eda83c3-a282-47f6-9f06-d2f9612f5c5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7eda83c3-a282-47f6-9f06-d2f9612f5c5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7eda83c3-a282-47f6-9f06-d2f9612f5c5b"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox oral granules is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox oral granules is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion- dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6927928f-f7a3-5736-bc3d-7e49bced79f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [96, 117], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65453013-c360-4835-8358-2a278a4a32db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65453013-c360-4835-8358-2a278a4a32db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65453013-c360-4835-8358-2a278a4a32db"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e1e22aa-c7c5-56fa-8531-555ac7e8835f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [96, 117], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:350dfc39-d03d-e221-22e9-3880728c955c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=350dfc39-d03d-e221-22e9-3880728c955c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=350dfc39-d03d-e221-22e9-3880728c955c"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. (1. 2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:836b27fe-8bcb-501b-a6fe-1d1b381ab90d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [89, 110], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c36bb5a-2552-46c1-8500-4ae783cffef1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c36bb5a-2552-46c1-8500-4ae783cffef1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c36bb5a-2552-46c1-8500-4ae783cffef1"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS &amp; USAGE Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:889f699e-6722-584f-9177-adad2af6d5b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [96, 117], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:57cf1650-88f9-474e-9e19-df451a15619d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=57cf1650-88f9-474e-9e19-df451a15619d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57cf1650-88f9-474e-9e19-df451a15619d"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b3d2f9e-d616-59b0-aa64-680c8341227d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [116, 137], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a03c7657-fdca-4acb-ad82-c24680e90eae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a03c7657-fdca-4acb-ad82-c24680e90eae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a03c7657-fdca-4acb-ad82-c24680e90eae"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99ac6355-12a3-5d0e-824b-ed02aabf350c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [82, 103], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3495a70c-870c-4968-940e-8baea152cf85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3495a70c-870c-4968-940e-8baea152cf85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3495a70c-870c-4968-940e-8baea152cf85"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 )"], "temporal_context_qualifier": "with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L :: with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b3d6415-1647-561b-a46f-7d16ac706164", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [102, 123], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eded6687-ba78-4117-a316-eec56d46a08a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eded6687-ba78-4117-a316-eec56d46a08a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eded6687-ba78-4117-a316-eec56d46a08a"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox oral granules are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox oral granules are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad584cff-20c6-5aa5-b8cb-461104b77d40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [116, 137], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da3295fc-5210-46a3-a5cc-7b9ec9265eca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da3295fc-5210-46a3-a5cc-7b9ec9265eca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da3295fc-5210-46a3-a5cc-7b9ec9265eca"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. (1.1) Deferasirox tablets for oral suspension is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 )"], "temporal_context_qualifier": "with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L :: with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd6ad0fd-ad6d-5b01-b4c9-46abb83e78aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [95, 116], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0fb210b3-6a3d-4313-83ce-52012e384f9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0fb210b3-6a3d-4313-83ce-52012e384f9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fb210b3-6a3d-4313-83ce-52012e384f9b"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d31dc3c8-100e-5af0-9089-1327d19cde66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [116, 137], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9054806-2721-4736-9aef-81ffb8db75d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9054806-2721-4736-9aef-81ffb8db75d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9054806-2721-4736-9aef-81ffb8db75d1"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. (1.1) Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db3e8f05-97d2-5547-8032-cad55533609a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [100, 121], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c220484e-1e6a-4a0c-a221-60223f3bc24c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c220484e-1e6a-4a0c-a221-60223f3bc24c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c220484e-1e6a-4a0c-a221-60223f3bc24c"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox oral granules are iron chelators indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox oral granules are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0920be5-825d-5fa4-b515-debac5ed7a27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [116, 137], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older with liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e37fe330-f5c1-56de-93c4-02b27b2b1f5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [87, 108], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7ae9c31-e14f-4cf9-9ab3-850519f1a87c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7ae9c31-e14f-4cf9-9ab3-850519f1a87c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7ae9c31-e14f-4cf9-9ab3-850519f1a87c"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"], "temporal_context_qualifier": "with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L :: with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eceadbab-66f0-568c-8536-a07d7361ce8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [87, 108], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc690f20-533e-490e-b13d-143382e02351", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc690f20-533e-490e-b13d-143382e02351", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc690f20-533e-490e-b13d-143382e02351"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non‑transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 )"], "temporal_context_qualifier": "with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L :: with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-transfusion-dependent thalassemia (NTDT) syndromes", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f126c42c-8f63-5498-8c1a-0734a9335eed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051102", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [87, 108], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c2842a0-7781-4047-84cd-88bd018e10c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c2842a0-7781-4047-84cd-88bd018e10c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c2842a0-7781-4047-84cd-88bd018e10c7"]}], "subject": "CHEBI:49005", "supporting_text": ["1 INDICATIONS AND USAGE Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 )"], "temporal_context_qualifier": "with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ba43581-331a-5d44-ad85-717936d94eca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170703", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005841"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [58, 79], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients for whom injection of iron chelating agents is inappropriate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DEFERASIROX#86-20170703", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:49005", "supporting_text": ["Drugs in a new dosage form indicated for the treatment of chronic iron overload due to blood transfusions (in patients for whom injection of iron chelating agents is inappropriate)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0005841", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57101e32-f06a-5122-8bac-d1ff291b41e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080416", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0005841"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:251ee7e8-787a-5108-b308-03f862f2abf1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:d1395504-f222-5d33-b6df-5c8f62dbfa10", "object": "UMLS:C1739382", "object_location_in_text": [66, 87], "original_object": "chronic iron overload", "original_subject": "DEFERASIROX", "population_context_qualifier": "patients for whom injection of iron chelating agents is inappropriate", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DEFERASIROX#171-20080416", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:49005", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of chronic iron overload due to blood transfusions (in patients for whom injection of iron chelating agents is inappropriate). [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hormone-sensitive breast cancer", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:553c79dd-28e5-5a4f-b5c2-c090d29dea6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "object": "MONDO:0004989", "original_object": "Breast cancer", "original_subject": "ETHINYL ESTRADIOL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84a20017-344b-4684-a915-c85a55fcbbcb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84a20017-344b-4684-a915-c85a55fcbbcb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84a20017-344b-4684-a915-c85a55fcbbcb"]}], "subject": "CHEBI:4903", "supporting_text": ["4 CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Mono-Linyah is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.7) ] Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [ see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hormone-sensitive breast cancer", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80327e7e-1caa-585e-9e11-6767b50f339c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "object": "MONDO:0004989", "original_object": "Breast cancer", "original_subject": "ETHINYL ESTRADIOL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ec8f18f-297c-405f-b191-a40767366bad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ec8f18f-297c-405f-b191-a40767366bad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ec8f18f-297c-405f-b191-a40767366bad"]}], "subject": "CHEBI:4903", "supporting_text": ["4 CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Mono-Linyah is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.7) ] Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [ see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hormone-sensitive breast cancer", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:892eff91-fdc5-5d25-9046-acbdacb21c49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "object": "MONDO:0004989", "original_object": "Breast cancer", "original_subject": "ETHINYL ESTRADIOL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b2e4bf2-73e5-15b0-e063-6394a90a42fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b2e4bf2-73e5-15b0-e063-6394a90a42fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b2e4bf2-73e5-15b0-e063-6394a90a42fc"]}], "subject": "CHEBI:4903", "supporting_text": ["4 CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Mono-Linyah is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.7) ] Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [ see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of arterial or venous thrombotic diseases", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:208c99af-ef1d-560b-8525-991e5d5d859d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ba6d2ce-1c41-599d-bbb7-bd4b8351d697", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "medic_supporting_text_truncated": true, "object": "MONDO:0005015", "original_object": "Diabetes mellitus", "original_subject": "ETHINYL ESTRADIOL", "population_context_qualifier": "females who smoke, if over age 35", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58cd12d3-39b1-4375-b7e0-09ba2378a52b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58cd12d3-39b1-4375-b7e0-09ba2378a52b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58cd12d3-39b1-4375-b7e0-09ba2378a52b"]}], "subject": "CHEBI:4903", "supporting_text": ["4 CONTRAINDICATIONS Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium is contraindicated in females who are known to have or develop the following conditions: • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: • Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] • Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 )] • Have cerebrovascular disease [see Warnings and Precautions ( 5.1 )] • Have coronary artery disease [see Warnings and Precautions ( 5.1 )] • Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 )] • Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 )] • Have uncontrolled hypertension [see Warnings and Precautions ( 5.6 )] • Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.8 )] • Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings and Precautions ( 5.9 )] • Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.10 )] • Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions ( 5.3 )] • Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions ( 5.4 ) and Use in Specific Populations ( 8.7 )] • Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings and Precautions ( 5.5 ) and Drug Interactions ( 7.3 )] . • Renal impairment ( 4 ) • Adrenal insufficiency ( 4 ) • A high risk of arterial or venous thrombotic diseases ( 4 ) • Undiagnosed abnormal uterine bleeding ( 4 ) • Breast cancer ("]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0549184", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f330456-0f64-513c-a61b-3aabb234bc55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir, paritaprevir/ritonavir, dasabuvir"], "medic_disease_context_ids": ["UMLS:C0549184"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cad7760b-f94e-5d4b-bdb5-dd7b7d147f34", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "medic_supporting_text_truncated": true, "object": "UMLS:C0220847", "original_object": "hepatitis C", "original_subject": "ETHINYL ESTRADIOL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9187a357-e95d-4733-9627-f19522b86373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9187a357-e95d-4733-9627-f19522b86373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9187a357-e95d-4733-9627-f19522b86373"]}], "subject": "CHEBI:4903", "supporting_text": ["4 CONTRAINDICATIONS Renal impairment ( 4 ) Adrenal insufficiency ( 4 ) A high risk of arterial or venous thrombotic diseases ( 4 ) Undiagnosed abnormal uterine bleeding ( 4 ) Breast cancer ( 4 ) Liver tumors or liver disease ( 4 ) Co-administration with Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Drospirenone and Ethinyl Estradiol Tablets is contraindicated in females who are known to have or develop the following conditions: • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: ○ Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 ) ] ○ Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 ) ] ○ Have cerebrovascular disease [see Warnings and Precautions ( 5.1 ) ] ○ Have coronary artery disease [ see Warnings and Precautions ( 5.1 ) ] ○ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 ) ] ○ Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 ) ] ○ Have uncontrolled hypertension [see Warnings and Precautions ( 5.6 ) ] ○ Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.8 ) ] ○ Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings And Precautions ( 5.9 ) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.10 ) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings And Precautions ( 5.3 ) ] Liver tumor (benign or malignant) or liver disease [see Warnings And Precautions ( 5.4 ) and Use In Specific Populations ( 8.7 ) ] Use of Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, wit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Note: text states product \"may be less effective\" in this population", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:477a73ca-9cb9-54c1-a7f5-2b68512f0de6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "object": "UMLS:C0032961", "object_location_in_text": [115, 124], "original_object": "pregnancy", "original_subject": "ETHINYL ESTRADIOL", "population_context_qualifier": "women at or above 198 lbs (90 kg)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36445b6a-e0f2-42f7-a8f3-5b80c90b87dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36445b6a-e0f2-42f7-a8f3-5b80c90b87dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36445b6a-e0f2-42f7-a8f3-5b80c90b87dd"]}], "subject": "CHEBI:4903", "supporting_text": ["1 INDICATIONS AND USAGE Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) &lt; 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0556482", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3090fc7-1c7c-54c1-a7bc-2d4e2772ea28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0556482"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac2484c9-20b0-5da6-8c31-1a0886351ade", "medic_supporting_text_truncated": true, "object": "UMLS:C0032961", "object_location_in_text": [99, 108], "original_object": "pregnancy", "original_subject": "ETHINYL ESTRADIOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8f91d0c-014f-4c1c-a472-1b1947ab96a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8f91d0c-014f-4c1c-a472-1b1947ab96a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8f91d0c-014f-4c1c-a472-1b1947ab96a6"]}], "subject": "CHEBI:4903", "supporting_text": ["Norethindrone and ethinyl estradiol tablets, USP 1 mg/0.035 mg are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT ® System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. Method (1) Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (2) Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (3) (4) Adapted from Hatcher et al., 1998, Ref. # 1. Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency"], "temporal_context_qualifier": "within 72 hours after unprotected intercourse"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24076f28-528d-520f-8a04-ee9e19617f50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021025", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["statin"], "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c14a2c54-3355-51bb-be66-fc550c197e5b", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3ceeb8b9-2d10-5a1c-8a13-f8cc9c854bac", "medic_supporting_text_truncated": true, "object": "MONDO:0021187", "object_location_in_text": [251, 273], "original_object": "primary hyperlipidemia", "original_subject": "EZETIMIBE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e9a9eda-1b2a-4475-8483-0f410a17c524", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e9a9eda-1b2a-4475-8483-0f410a17c524", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e9a9eda-1b2a-4475-8483-0f410a17c524"]}], "subject": "CHEBI:49040", "supporting_text": ["1 INDICATIONS AND USAGE Ezetimibe Tablets is indicated: In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe tablets is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use. EZETIMIBE Tablets is indicated (1) : In combination with a statin, or alone when additional low density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to d"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5931e4f7-2e9c-569f-9885-da9483894a7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021025", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["statin"], "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c14a2c54-3355-51bb-be66-fc550c197e5b", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3ceeb8b9-2d10-5a1c-8a13-f8cc9c854bac", "medic_supporting_text_truncated": true, "object": "MONDO:0021187", "object_location_in_text": [254, 276], "original_object": "primary hyperlipidemia", "original_subject": "EZETIMIBE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac539a72-77e4-419c-b1d9-42002e9cecf7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac539a72-77e4-419c-b1d9-42002e9cecf7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac539a72-77e4-419c-b1d9-42002e9cecf7"]}], "subject": "CHEBI:49040", "supporting_text": ["1 INDICATIONS AND USAGE Ezetimibe tablets are indicated: • In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe tablet is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use. Ezetimibe tablets are indicated ( 1 ): • In combination with a statin, or alone when additional low density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2f16595-371e-5dd3-a152-4f6f119f58df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021025", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["statin"], "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c14a2c54-3355-51bb-be66-fc550c197e5b", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3ceeb8b9-2d10-5a1c-8a13-f8cc9c854bac", "medic_supporting_text_truncated": true, "object": "MONDO:0021187", "object_location_in_text": [254, 276], "original_object": "primary hyperlipidemia", "original_subject": "EZETIMIBE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55b18d8f-40e0-48ba-baf1-79a0d1bb2ee2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55b18d8f-40e0-48ba-baf1-79a0d1bb2ee2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55b18d8f-40e0-48ba-baf1-79a0d1bb2ee2"]}], "subject": "CHEBI:49040", "supporting_text": ["1 INDICATIONS AND USAGE Ezetimibe tablets are indicated: • In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe tablet is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use. Ezetimibe tablets are indicated ( 1 ): • In combination with a statin, or alone when additional low density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0021368", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b18780e2-81e1-5234-9072-fa93ff47d943", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970410", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021368"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:9fd63059-4af9-5221-86ad-b3a5bc0d6d65", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8cb6ede0-d485-56a1-8224-192c95292fad", "object": "MONDO:0005178", "object_location_in_text": [39, 53], "original_object": "osteoarthritis", "original_subject": "Etodolac BP 200mg/400mg Tablet and Etodolac 300mg Capsule", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:4909", "supporting_text": ["Inflammation and painful conditions in osteoarthritis, acute attacks of gout and pseudogout, pain following dental extraction, post operative and post episiotomy pain dysmenorrhoea acute musculoskeletal pain."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "ovarian cancer which has progressed after cancer chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86787a8d-a797-56fb-8081-fba8aeeeb092", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120222", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:151af2de-1718-5c6b-97d3-0c791bffb052", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a8918761-15b4-5334-8617-06d5e823d0e9", "object": "MONDO:0008170", "object_location_in_text": [77, 91], "original_object": "ovarian cancer", "original_subject": "ETOPOSIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ETOPOSIDE#153-20120222", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:4911", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Public knowledge-based application after PAFSC's preliminary assessment]"], "temporal_context_qualifier": "after cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:404a518f-3c97-5257-9a6c-7ad714c0bf4f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15e11379-e681-4f2b-bdd6-dbbe56e563b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15e11379-e681-4f2b-bdd6-dbbe56e563b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15e11379-e681-4f2b-bdd6-dbbe56e563b0"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women Exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies ( 14.1 )] . 1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies ( 14.2 )] ."], "temporal_context_qualifier": "following two to three years of tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d653983-7ae5-526a-85eb-49912e4ace73", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf066b7a-032a-416c-8d40-15ba581423e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE AROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ]."], "temporal_context_qualifier": "following two to three years of tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76b1f644-2729-5111-8b76-fcf65c69c6d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:392b5b4f-3fb4-4ba7-a15a-6022298db719", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=392b5b4f-3fb4-4ba7-a15a-6022298db719", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=392b5b4f-3fb4-4ba7-a15a-6022298db719"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy. ( 14.1 ). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women Exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies ( 14.1 )]. 1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies ( 14.2 )]."], "temporal_context_qualifier": "following two to three years of tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7dd10d2d-ba64-52e2-9430-f006663d5437", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [101, 120], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0b31daa-0792-43d5-af08-8b6a864dc90a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0b31daa-0792-43d5-af08-8b6a864dc90a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0b31daa-0792-43d5-af08-8b6a864dc90a"]}], "subject": "CHEBI:4953", "supporting_text": ["AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy."], "temporal_context_qualifier": "who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bad5559-fea1-5b72-940a-c9b7714676d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1bbe1bd-fa92-4fdd-88df-31ebcb200d37", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1bbe1bd-fa92-4fdd-88df-31ebcb200d37", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1bbe1bd-fa92-4fdd-88df-31ebcb200d37"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women Exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies ( 14.1 )] . 1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [ see Clinical Studies ( 14.2 ) ]."], "temporal_context_qualifier": "who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ccc697c-d2d4-5add-a3b9-a0c528d5383b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [151, 170], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women with estrogen-receptor positive disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:abde1ccd-0ec9-40d4-b205-fbc00f5878b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=abde1ccd-0ec9-40d4-b205-fbc00f5878b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abde1ccd-0ec9-40d4-b205-fbc00f5878b9"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE Exemestane is an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets, USP for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women Exemestane tablets, USP are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets, USP for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies ( 14.1 )]. 1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane tablets, USP are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies ( 14.2 )]."], "temporal_context_qualifier": "following two to three years of tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e71b3a1c-4b6f-5b06-ac03-44e45ccd15fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tamoxifen"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8bd17b4-5289-45bb-8095-de89dc8d39ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8bd17b4-5289-45bb-8095-de89dc8d39ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8bd17b4-5289-45bb-8095-de89dc8d39ed"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women Exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ]."], "temporal_context_qualifier": "who have received two to three years of tamoxifen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c97d5ef-0226-5710-b147-b905d0037ea2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "UMLS:C3495917", "object_location_in_text": [356, 378], "original_object": "advanced breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9354d1a1-8e8c-4c6a-b7ad-d4fe14b10a8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9354d1a1-8e8c-4c6a-b7ad-d4fe14b10a8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9354d1a1-8e8c-4c6a-b7ad-d4fe14b10a8b"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE Exemestane is an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women Exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women Exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ]."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0755434-2a3d-5ac2-af65-2eeb373aea00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991021", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5898d05-df63-5930-b56d-2a16dc5f0d88", "object": "UMLS:C3495917", "object_location_in_text": [360, 382], "original_object": "advanced breast cancer", "original_subject": "EXEMESTANE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69abd0ff-b200-4d1a-b14a-80e980a8e781", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69abd0ff-b200-4d1a-b14a-80e980a8e781", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69abd0ff-b200-4d1a-b14a-80e980a8e781"]}], "subject": "CHEBI:4953", "supporting_text": ["1 INDICATIONS AND USAGE EXEMESTANE is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women EXEMESTANE is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women EXEMESTANE is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ]."], "temporal_context_qualifier": "following tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless patients are receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:236d1cf7-b847-569b-8228-85bcba4a959a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [117, 136], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4a045e4-d6ce-475d-abe4-590941bd3815", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4a045e4-d6ce-475d-abe4-590941bd3815", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4a045e4-d6ce-475d-abe4-590941bd3815"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "not receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4de8f9c0-420a-5f0f-b575-024d2c4e6a2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [127, 146], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam Injection is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless patients are receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5443c687-611d-5a7b-82f9-d1944576359e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [117, 136], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c57af2a2-aa9a-4dac-a200-e0d845005d05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c57af2a2-aa9a-4dac-a200-e0d845005d05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57af2a2-aa9a-4dac-a200-e0d845005d05"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless patients are receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0b4cb02-04dc-5156-85e9-2927ac0dfbb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [117, 136], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a633cef-6dfc-4186-b595-174db2d8330e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a633cef-6dfc-4186-b595-174db2d8330e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a633cef-6dfc-4186-b595-174db2d8330e"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless patients are receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e49f74fd-9880-515d-8fcf-5db7f4850691", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [117, 136], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf7bd9ba-5030-479a-8448-3a99395b0d0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf7bd9ba-5030-479a-8448-3a99395b0d0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf7bd9ba-5030-479a-8448-3a99395b0d0c"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless patients are receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4bd4a15-cac7-5b49-8535-b7e86145040d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [117, 136], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f466f8a3-f31c-44f4-b0e8-444464f20f66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f466f8a3-f31c-44f4-b0e8-444464f20f66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f466f8a3-f31c-44f4-b0e8-444464f20f66"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless patients are receiving appropriate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7a5bc59-aea1-558f-883c-c53ca238dc74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5d6b5b-bf3c-59b1-9dae-de05f65a8158", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "MONDO:0005338", "object_location_in_text": [117, 136], "original_object": "open angle glaucoma", "original_subject": "DIAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0813073-d0b0-4fd7-b307-56f69c910c82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0813073-d0b0-4fd7-b307-56f69c910c82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0813073-d0b0-4fd7-b307-56f69c910c82"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper motor neuron disorders", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:00aee83b-8d7c-5d93-babd-7ba0c8e532cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "HP:0001257", "object_location_in_text": [759, 769], "original_object": "spasticity", "original_subject": "DIAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0813073-d0b0-4fd7-b307-56f69c910c82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0813073-d0b0-4fd7-b307-56f69c910c82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0813073-d0b0-4fd7-b307-56f69c910c82"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures (See WARNINGS ). Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus. Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper motor neuron disorders", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e54ca20-6c64-5607-964d-521622c382e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "HP:0001257", "object_location_in_text": [760, 770], "original_object": "spasticity", "original_subject": "DIAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e7dd743-a87b-4ab3-b6ae-f116cd0c8b0f"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures. (See WARNINGS .) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam Injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper motor neuron disorders", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:904a34fc-566d-574a-abd0-5976b41cb788", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "HP:0001257", "object_location_in_text": [760, 770], "original_object": "spasticity", "original_subject": "DIAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4a045e4-d6ce-475d-abe4-590941bd3815", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4a045e4-d6ce-475d-abe4-590941bd3815", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4a045e4-d6ce-475d-abe4-590941bd3815"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures. (See WARNINGS .) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus. Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper motor neuron disorders", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a828e683-9296-5542-9ca6-2e995ef0141b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "HP:0001257", "object_location_in_text": [759, 769], "original_object": "spasticity", "original_subject": "DIAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a633cef-6dfc-4186-b595-174db2d8330e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a633cef-6dfc-4186-b595-174db2d8330e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a633cef-6dfc-4186-b595-174db2d8330e"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures (See WARNINGS ). Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus. Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper motor neuron disorders", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c23c236a-85ef-5e8c-9b68-e97f92421130", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:25650f7f-ba72-583e-8dc5-3c9d4a0ae0d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5cdd672c-7522-5270-889f-56a4ef677a56", "object": "HP:0001257", "object_location_in_text": [759, 769], "original_object": "spasticity", "original_subject": "DIAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c57af2a2-aa9a-4dac-a200-e0d845005d05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c57af2a2-aa9a-4dac-a200-e0d845005d05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57af2a2-aa9a-4dac-a200-e0d845005d05"]}], "subject": "CHEBI:49575", "supporting_text": ["Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures (See WARNINGS ). Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus. Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4727711", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeb07075-7794-5016-a8e4-d7ead4a94ca7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080610", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aromatase inhibitor"], "medic_disease_context_ids": ["UMLS:C4727711"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:51cbc5bd-fc11-59b6-9c2b-7e2c4e6a4830", "object": "MONDO:0007254", "object_location_in_text": [55, 68], "original_object": "breast cancer", "original_subject": "lapatinib", "population_context_qualifier": "post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tyverb", "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb"]}], "subject": "CHEBI:49603", "supporting_text": ["Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):  in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting; in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy; in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study had not previously been treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hemodynamically significant patent ductus arteriosus", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e04d908f-14ba-5a42-8a5a-014870ae5902", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:d09aeaa6-1ee8-5e4d-ab06-3c8efb04c523", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:b570f3ec-5a7c-5e2a-be1b-6c618783c30e", "object": "MONDO:0011827", "original_object": "patent ductus arteriosus", "original_subject": "Indomethacin Injection 1mg/vial (additional Dosage form)", "population_context_qualifier": "premature infants weighing between 500g and 1750g", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:49662", "supporting_text": ["To close a hemodynamically significant patent ductus arteriosus (PDA) in premature infants weighing between 500g and 1750g when after 48 hrs. usual medical management (e.g. fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of hemodynamically significant patent ductus arteriosus should be present, such as respratory distress, a continous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest X-ray."], "temporal_context_qualifier": "when after 48 hrs. usual medical management (e.g. fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3266992", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:453d41e9-bd9f-512a-be83-e68da5390e29", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111125", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3266992"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a43c5274-06d6-50a0-9f7d-047eecd801be", "object": "MONDO:0005233", "object_location_in_text": [89, 115], "original_object": "non-small cell lung cancer", "original_subject": "GEFITINIB", "population_context_qualifier": "patients with EGFR gene mutation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:GEFITINIB#152-20111125", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:49668", "supporting_text": ["A drug with a revised indication for the treatment of unresectable advanced or recurrent non-small cell lung cancer in patients with EGFR gene mutation."], "temporal_context_qualifier": "unresectable advanced or recurrent"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:110a78f0-9d35-5754-810b-6f9c839ebe7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [450, 479], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4421ceb7-a114-436c-871a-7bc5444f8154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4421ceb7-a114-436c-871a-7bc5444f8154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4421ceb7-a114-436c-871a-7bc5444f8154"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:147affd7-ca47-56eb-bf98-d8fe150bdbcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [442, 471], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0f38398-4d34-4ecc-8a6a-37732adaaad3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0f38398-4d34-4ecc-8a6a-37732adaaad3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0f38398-4d34-4ecc-8a6a-37732adaaad3"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS &amp; USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H2) receptor antagonist indicated (1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1996a046-f679-5bd9-b1f9-42c326fc9665", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [450, 479], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5648ca13-1add-56ec-e063-6294a90a6f29", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5648ca13-1add-56ec-e063-6294a90a6f29", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5648ca13-1add-56ec-e063-6294a90a6f29"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22fa6ca4-443a-59d9-86ac-1e9ba53d0dbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [442, 471], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c5dce17-1865-4aa6-89f6-24dd55b5f06c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c5dce17-1865-4aa6-89f6-24dd55b5f06c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c5dce17-1865-4aa6-89f6-24dd55b5f06c"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS &amp; USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H2) receptor antagonist indicated (1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ddc0fcd-a575-5e6e-9375-d4d674784a62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [450, 479], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e6d167f-91e4-4122-911d-d3da66386f44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e6d167f-91e4-4122-911d-d3da66386f44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e6d167f-91e4-4122-911d-d3da66386f44"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46abf526-c9f8-532e-9665-b6e16f10c41b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [450, 479], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd95271c-cf39-47fb-97a6-f6ee1e619e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd95271c-cf39-47fb-97a6-f6ee1e619e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd95271c-cf39-47fb-97a6-f6ee1e619e4a"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7954ec91-55bc-5358-8457-055e610128fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [442, 471], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eec89230-47fc-4139-a370-b4f9e225e8c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eec89230-47fc-4139-a370-b4f9e225e8c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eec89230-47fc-4139-a370-b4f9e225e8c0"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS &amp; USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H2) receptor antagonist indicated (1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0ae0eed-9b86-54f5-b4c4-0dfac752473b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae33e9e-93ed-5493-82e2-cdd089c85b92", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0017169", "object_location_in_text": [450, 479], "original_object": "multiple endocrine neoplasias", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:669fbd46-cae5-4477-884e-8eca893d2e05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=669fbd46-cae5-4477-884e-8eca893d2e05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=669fbd46-cae5-4477-884e-8eca893d2e05"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21e78361-0932-51c8-8074-4198d830cee6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [422, 448], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e6d167f-91e4-4122-911d-d3da66386f44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e6d167f-91e4-4122-911d-d3da66386f44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e6d167f-91e4-4122-911d-d3da66386f44"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4336bd0c-88ae-5851-9e6e-b68f68f85ce2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [422, 448], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5648ca13-1add-56ec-e063-6294a90a6f29", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5648ca13-1add-56ec-e063-6294a90a6f29", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5648ca13-1add-56ec-e063-6294a90a6f29"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54f7a589-3362-5ce8-ab80-465a9d4f225e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [422, 448], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4421ceb7-a114-436c-871a-7bc5444f8154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4421ceb7-a114-436c-871a-7bc5444f8154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4421ceb7-a114-436c-871a-7bc5444f8154"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:742f2f6c-0427-5bcc-8ac7-fa70be0ad171", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [414, 440], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eec89230-47fc-4139-a370-b4f9e225e8c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eec89230-47fc-4139-a370-b4f9e225e8c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eec89230-47fc-4139-a370-b4f9e225e8c0"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS &amp; USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H2) receptor antagonist indicated (1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8398e486-25d6-5c19-9db3-06772dd821e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [414, 440], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0f38398-4d34-4ecc-8a6a-37732adaaad3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0f38398-4d34-4ecc-8a6a-37732adaaad3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0f38398-4d34-4ecc-8a6a-37732adaaad3"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS &amp; USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H2) receptor antagonist indicated (1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9565ecb4-2026-59dd-8f04-8fd64738e271", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [414, 440], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c5dce17-1865-4aa6-89f6-24dd55b5f06c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c5dce17-1865-4aa6-89f6-24dd55b5f06c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c5dce17-1865-4aa6-89f6-24dd55b5f06c"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS &amp; USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H2) receptor antagonist indicated (1) : In adult and pediatric patients 40 kg and greater for the treatment of: active duodenal ulcer (DU). active gastric ulcer. symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:974b42b8-19e1-5cf7-aeb6-b8234c7b0ce4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [422, 448], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd95271c-cf39-47fb-97a6-f6ee1e619e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd95271c-cf39-47fb-97a6-f6ee1e619e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd95271c-cf39-47fb-97a6-f6ee1e619e4a"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb368a01-e7f5-5394-befb-b1733b836935", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:59a05326-f364-52de-9352-de058d5c7ec1", "object": "MONDO:0019610", "object_location_in_text": [422, 448], "original_object": "Zollinger-Ellison syndrome", "original_subject": "FAMOTIDINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:669fbd46-cae5-4477-884e-8eca893d2e05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=669fbd46-cae5-4477-884e-8eca893d2e05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=669fbd46-cae5-4477-884e-8eca893d2e05"]}], "subject": "CHEBI:4975", "supporting_text": ["1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine is a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0549184", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b834aff-bdbb-5b40-9a88-c6cd71ff1c6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pimozide"], "medic_disease_context_ids": ["UMLS:C0549184"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a701aee-4250-566d-838e-eea7a5818cf5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "MONDO:0100053", "original_object": "anaphylaxis", "original_subject": "APREPITANT", "population_context_qualifier": "None", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1b111eb-659a-496b-a86a-8f0fa370f147", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1b111eb-659a-496b-a86a-8f0fa370f147", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1b111eb-659a-496b-a86a-8f0fa370f147"]}], "subject": "CHEBI:499361", "supporting_text": ["4 CONTRAINDICATIONS APONVIE is contraindicated in patients: with a history of hypersensitivity to aprepitant or any component of the product [see Description (11) ] . Hypersensitivity reactions have included anaphylaxis [see Warnings and Precautions (5.1) ] . taking pimozide. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of pimozide, which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide [see Drug Interactions (7.1) ] . Known hypersensitivity to any component of this product. ( 4 , 5.1 ) Concurrent use with pimozide. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly and moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ed7dacd-c04a-5dc1-866e-7eb921f1b8ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20031111", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [75, 94], "original_object": "nausea and vomiting", "original_subject": "aprepitant", "population_context_qualifier": "children, toddlers and infants from the age of 6 months to less than 12 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emend", "https://www.ema.europa.eu/en/documents/product-information/emend-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emend"]}], "subject": "CHEBI:499361", "supporting_text": ["Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27eca4bd-b1b0-5849-b54b-58f16d025f74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [190, 209], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:696f9e80-9cae-403b-de9e-078343ce4713", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=696f9e80-9cae-403b-de9e-078343ce4713", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=696f9e80-9cae-403b-de9e-078343ce4713"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 ) EMEND capsules is indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ae1ebbb-0a0e-51f7-9d3a-42af5925def0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [251, 270], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f58b8944-93ee-4be1-a238-cc0061ddd93a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules is indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ae1ebbb-0a0e-51f7-9d3a-42af5925def0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f58b8944-93ee-4be1-a238-cc0061ddd93a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules is indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e638737-da7b-5fa1-a962-18ece9a4e64a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [250, 269], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:377c3ecb-fdec-dde4-e063-6294a90a29bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=377c3ecb-fdec-dde4-e063-6294a90a29bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=377c3ecb-fdec-dde4-e063-6294a90a29bd"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f5bb36e-48db-576a-b488-4c4dc345995f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c218d3a-a508-4abc-9ed8-a6e8e191d1b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. ( 1 ) delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. ( 1 ) nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f5bb36e-48db-576a-b488-4c4dc345995f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [143, 162], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c218d3a-a508-4abc-9ed8-a6e8e191d1b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. ( 1 ) delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. ( 1 ) nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses, 3-day regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b25ff6e-c531-5881-8a63-7a6c626eca3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [252, 271], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d72e0e10-4557-41b0-b65d-d395468cad19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d72e0e10-4557-41b0-b65d-d395468cad19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d72e0e10-4557-41b0-b65d-d395468cad19"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b2802d3-d862-5317-98e2-68dfbfd87808", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db16d6b9-3b89-431d-97f9-9b4a8300e913", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db16d6b9-3b89-431d-97f9-9b4a8300e913", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db16d6b9-3b89-431d-97f9-9b4a8300e913"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, indicated: in combination with other antiemetic agents for the: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for the prevention of postoperative nausea and vomiting (PONV) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b2802d3-d862-5317-98e2-68dfbfd87808", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [187, 206], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db16d6b9-3b89-431d-97f9-9b4a8300e913", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db16d6b9-3b89-431d-97f9-9b4a8300e913", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db16d6b9-3b89-431d-97f9-9b4a8300e913"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, indicated: in combination with other antiemetic agents for the: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for the prevention of postoperative nausea and vomiting (PONV) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68d94c47-ac9e-5fc4-b2db-b31d072d2061", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:19919480-960b-4741-9611-c133d68512f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=19919480-960b-4741-9611-c133d68512f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19919480-960b-4741-9611-c133d68512f5"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72b7db98-82cd-58c6-bba1-09170e2c6f43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a7d2f44-b578-4d99-a4ff-f267626064d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a7d2f44-b578-4d99-a4ff-f267626064d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a7d2f44-b578-4d99-a4ff-f267626064d0"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73e55ace-e70c-5599-aad5-92cd9f6f2b54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7375ab3f-a6fc-4601-9415-07b4f681cdef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7375ab3f-a6fc-4601-9415-07b4f681cdef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7375ab3f-a6fc-4601-9415-07b4f681cdef"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Fosaprepitant for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8105ac5a-9add-597d-a3a4-f99506051f6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18a60093-cec8-1b8c-e063-6394a90a8902", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18a60093-cec8-1b8c-e063-6394a90a8902", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18a60093-cec8-1b8c-e063-6394a90a8902"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE FOCINVEZ, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8375891f-fabd-54e8-af27-a0774fce2601", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f942e4c-e26a-4155-9e14-344b2970b189", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f942e4c-e26a-4155-9e14-344b2970b189", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f942e4c-e26a-4155-9e14-344b2970b189"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4cd8486-8330-5dba-92e6-cd2de65fb231", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec44482e-6194-4829-a3f7-ebe8d48a41a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, indicated: in combination with other antiemetic agents for the: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for the prevention of postoperative nausea and vomiting (PONV) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4cd8486-8330-5dba-92e6-cd2de65fb231", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [187, 206], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec44482e-6194-4829-a3f7-ebe8d48a41a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, indicated: in combination with other antiemetic agents for the: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for the prevention of postoperative nausea and vomiting (PONV) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8597328-f202-5710-a26b-c5c640a9e144", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [248, 267], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules are indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8597328-f202-5710-a26b-c5c640a9e144", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules are indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b78afea6-1ef7-5f28-9925-268019658f99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44f634f4-b794-4d55-8ab7-037fdef8ff0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44f634f4-b794-4d55-8ab7-037fdef8ff0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44f634f4-b794-4d55-8ab7-037fdef8ff0f"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy, high-dose cisplatin", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd306dbb-8063-5978-80e4-117e1c8ed525", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d66803a-6811-4c29-9c57-e16acfa87f21", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d66803a-6811-4c29-9c57-e16acfa87f21", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d66803a-6811-4c29-9c57-e16acfa87f21"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0212fb7-e7f6-5ba1-bf9f-89870a4677a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "object_location_in_text": [250, 269], "original_object": "nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af9b6086-4bf2-472c-8740-4134eaaebace", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af9b6086-4bf2-472c-8740-4134eaaebace", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af9b6086-4bf2-472c-8740-4134eaaebace"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0212fb7-e7f6-5ba1-bf9f-89870a4677a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af9b6086-4bf2-472c-8740-4134eaaebace", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af9b6086-4bf2-472c-8740-4134eaaebace", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af9b6086-4bf2-472c-8740-4134eaaebace"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4e01b9b-0097-5de1-a50c-1431a65e135a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ed3e0a9-a0a8-4555-9f73-2043e79e3398", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ed3e0a9-a0a8-4555-9f73-2043e79e3398", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ed3e0a9-a0a8-4555-9f73-2043e79e3398"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4eb29c5-c92c-54f5-9698-5dc008b6f7cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5bb41bcb-c775-4447-9bd0-d4c55ad110ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5bb41bcb-c775-4447-9bd0-d4c55ad110ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5bb41bcb-c775-4447-9bd0-d4c55ad110ea"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed019f72-35b4-5a41-86c6-211e02b05b78", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7afe33d8-5416-465a-b98b-f4eedc327a94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7afe33d8-5416-465a-b98b-f4eedc327a94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7afe33d8-5416-465a-b98b-f4eedc327a94"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE FOCINVEZ, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa0863d0-6e3e-55bf-8b5d-60f46dac8397", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1cc7d482-5d45-4621-9ffc-cd3f7c54614d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1cc7d482-5d45-4621-9ffc-cd3f7c54614d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1cc7d482-5d45-4621-9ffc-cd3f7c54614d"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly emetogenic cisplatin based cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3933ee02-d309-5780-97c5-183e1b4eaf7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20031111", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [448, 485], "original_object": "acute and delayed nausea and vomiting", "original_subject": "aprepitant", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:emend", "https://www.ema.europa.eu/en/documents/product-information/emend-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/emend"]}], "subject": "CHEBI:499361", "supporting_text": ["Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:067f53ef-5a2e-5b0d-8086-9e16d2172c6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [203, 230], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5bb41bcb-c775-4447-9bd0-d4c55ad110ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5bb41bcb-c775-4447-9bd0-d4c55ad110ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5bb41bcb-c775-4447-9bd0-d4c55ad110ea"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d30a8cb-a12b-50be-ad95-9ef36e16aaa6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a78aaa00-a46b-4f9e-a415-2fca9e9a4fb4"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules are indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25426a05-43d9-5a01-8ce9-c1715de60f0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7afe33d8-5416-465a-b98b-f4eedc327a94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7afe33d8-5416-465a-b98b-f4eedc327a94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7afe33d8-5416-465a-b98b-f4eedc327a94"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE FOCINVEZ, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fdff930-a46a-57c4-8590-ada04953195d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [205, 232], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df341f63-0fef-4411-a89b-6df6b9e792be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df341f63-0fef-4411-a89b-6df6b9e792be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df341f63-0fef-4411-a89b-6df6b9e792be"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fdff930-a46a-57c4-8590-ada04953195d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [195, 232], "original_object": "acute and delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df341f63-0fef-4411-a89b-6df6b9e792be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df341f63-0fef-4411-a89b-6df6b9e792be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df341f63-0fef-4411-a89b-6df6b9e792be"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:326eaaf1-b9c6-5b45-bd98-53a7f5ef6bb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [203, 230], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1cc7d482-5d45-4621-9ffc-cd3f7c54614d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1cc7d482-5d45-4621-9ffc-cd3f7c54614d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1cc7d482-5d45-4621-9ffc-cd3f7c54614d"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f9b22d2-cc85-5d34-9ddb-b87c9e13fc47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [232, 269], "original_object": "acute and delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:377c3ecb-fdec-dde4-e063-6294a90a29bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=377c3ecb-fdec-dde4-e063-6294a90a29bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=377c3ecb-fdec-dde4-e063-6294a90a29bd"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45fc47ee-2cd4-5c62-a669-55821e853359", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [205, 232], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d30d839-bb88-46ce-a9ed-66fe32a12a7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d30d839-bb88-46ce-a9ed-66fe32a12a7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d30d839-bb88-46ce-a9ed-66fe32a12a7a"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45fc47ee-2cd4-5c62-a669-55821e853359", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [195, 232], "original_object": "acute and delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d30d839-bb88-46ce-a9ed-66fe32a12a7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d30d839-bb88-46ce-a9ed-66fe32a12a7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d30d839-bb88-46ce-a9ed-66fe32a12a7a"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b5984d0-ab25-5955-939c-52bc1acdeae2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18a60093-cec8-1b8c-e063-6394a90a8902", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18a60093-cec8-1b8c-e063-6394a90a8902", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18a60093-cec8-1b8c-e063-6394a90a8902"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE FOCINVEZ, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6bdda74e-34dd-5d80-b5fa-0b3733d7ee12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [148, 175], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44f634f4-b794-4d55-8ab7-037fdef8ff0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44f634f4-b794-4d55-8ab7-037fdef8ff0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44f634f4-b794-4d55-8ab7-037fdef8ff0f"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73336bdd-3040-5f4a-b946-a98e30a65b12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db16d6b9-3b89-431d-97f9-9b4a8300e913", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db16d6b9-3b89-431d-97f9-9b4a8300e913", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db16d6b9-3b89-431d-97f9-9b4a8300e913"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, indicated: in combination with other antiemetic agents for the: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for the prevention of postoperative nausea and vomiting (PONV) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76f79fe1-34cc-5ec7-942f-2cc44ff3255e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [203, 230], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a7d2f44-b578-4d99-a4ff-f267626064d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a7d2f44-b578-4d99-a4ff-f267626064d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a7d2f44-b578-4d99-a4ff-f267626064d0"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ddd7377-d987-52e4-bc9e-5539d2a197e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [234, 271], "original_object": "acute and delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d72e0e10-4557-41b0-b65d-d395468cad19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d72e0e10-4557-41b0-b65d-d395468cad19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d72e0e10-4557-41b0-b65d-d395468cad19"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:874f34de-bffc-5dfc-95e6-3be8a3f6148e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [203, 230], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f942e4c-e26a-4155-9e14-344b2970b189", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f942e4c-e26a-4155-9e14-344b2970b189", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f942e4c-e26a-4155-9e14-344b2970b189"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fd7afb5-ee6b-5475-9cd7-ed0b95dbb1be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [203, 230], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:19919480-960b-4741-9611-c133d68512f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=19919480-960b-4741-9611-c133d68512f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19919480-960b-4741-9611-c133d68512f5"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:970e8d93-2371-5d3a-96cd-dc1c62cd12be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec44482e-6194-4829-a3f7-ebe8d48a41a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec44482e-6194-4829-a3f7-ebe8d48a41a5"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, indicated: in combination with other antiemetic agents for the: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) for the prevention of postoperative nausea and vomiting (PONV) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a571165d-3763-5933-a01d-530cf3690106", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [172, 209], "original_object": "acute and delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:696f9e80-9cae-403b-de9e-078343ce4713", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=696f9e80-9cae-403b-de9e-078343ce4713", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=696f9e80-9cae-403b-de9e-078343ce4713"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 ) EMEND capsules is indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7bdb396-51fe-51d7-abd9-d933c257927c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af9b6086-4bf2-472c-8740-4134eaaebace", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af9b6086-4bf2-472c-8740-4134eaaebace", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af9b6086-4bf2-472c-8740-4134eaaebace"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb40f45a-f633-5943-80ef-6be36a00f425", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [135, 162], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c218d3a-a508-4abc-9ed8-a6e8e191d1b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c218d3a-a508-4abc-9ed8-a6e8e191d1b4"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen. ( 1 ) delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. ( 1 ) nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses, single-dose regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c848d96b-a42f-5a27-bdbb-1bf74b49befe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [205, 232], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ed3e0a9-a0a8-4555-9f73-2043e79e3398", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ed3e0a9-a0a8-4555-9f73-2043e79e3398", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ed3e0a9-a0a8-4555-9f73-2043e79e3398"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cddcb8f6-bd65-5f3a-ab88-afc7524ef4a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [205, 232], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dbdf8f5-6936-4143-b52d-96774b799a7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dbdf8f5-6936-4143-b52d-96774b799a7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dbdf8f5-6936-4143-b52d-96774b799a7d"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cddcb8f6-bd65-5f3a-ab88-afc7524ef4a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [195, 232], "original_object": "acute and delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dbdf8f5-6936-4143-b52d-96774b799a7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dbdf8f5-6936-4143-b52d-96774b799a7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dbdf8f5-6936-4143-b52d-96774b799a7d"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2940318-8007-587f-9623-639f06ea17cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [197, 224], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d66803a-6811-4c29-9c57-e16acfa87f21", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d66803a-6811-4c29-9c57-e16acfa87f21", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d66803a-6811-4c29-9c57-e16acfa87f21"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e118f3ab-f204-5353-b3b1-052a870e2a6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "object_location_in_text": [203, 230], "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "adults and pediatric patients 6 months of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7375ab3f-a6fc-4601-9415-07b4f681cdef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7375ab3f-a6fc-4601-9415-07b4f681cdef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7375ab3f-a6fc-4601-9415-07b4f681cdef"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Fosaprepitant for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of ( 1 ): acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)."], "temporal_context_qualifier": "associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f65065c7-4b65-5dc4-aab9-adc80bea12ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients 12 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f58b8944-93ee-4be1-a238-cc0061ddd93a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f58b8944-93ee-4be1-a238-cc0061ddd93a"]}], "subject": "CHEBI:499361", "supporting_text": ["1 INDICATIONS AND USAGE Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. Aprepitant capsules is indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic agent administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36482a4d-cdb8-5572-b80b-e37962957384", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002013", "object_location_in_text": [97, 105], "original_object": "vomiting", "original_subject": "APREPITANT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APREPITANT#164-20091016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:499361", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f44f25c0-80e7-5e30-8e17-f2e8cb19d987", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120622", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002013", "object_location_in_text": [165, 173], "original_object": "vomiting", "original_subject": "APREPITANT", "population_context_qualifier": "patients of 12 years or older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APREPITANT#132-20120622", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:499361", "supporting_text": ["Drugs with a new additional pediatric dosage for patients of 12 years or older. These drugs are indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase)."], "temporal_context_qualifier": "including delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic agent administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30449167-7254-5ac8-8d49-c91999b8e297", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002018", "object_location_in_text": [86, 92], "original_object": "nausea", "original_subject": "APREPITANT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APREPITANT#164-20091016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:499361", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c5b2557-fdda-508e-828a-90cd0f4d5a72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120622", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:c254fdfa-a67a-574a-b854-a1e5303f28d5", "object": "HP:0002018", "object_location_in_text": [154, 160], "original_object": "nausea", "original_subject": "APREPITANT", "population_context_qualifier": "patients of 12 years or older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APREPITANT#132-20120622", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:499361", "supporting_text": ["Drugs with a new additional pediatric dosage for patients of 12 years or older. These drugs are indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase)."], "temporal_context_qualifier": "including delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "aggressive and symptomatic medullary thyroid cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d32dbd2-8eef-5fa4-94b5-fb75d8c3645c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120216", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:92f1060b-9d24-5976-b4a6-002808bfd153", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50ae043e-6f6a-5001-9eec-fd07775c76b3", "object": "MONDO:0015277", "object_location_in_text": [70, 94], "original_object": "medullary thyroid cancer", "original_subject": "vandetanib", "population_context_qualifier": "patients with unresectable locally advanced or metastatic disease; adults, children and adolescents aged 5 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:caprelsa", "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"]}], "subject": "CHEBI:49960", "supporting_text": ["Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "mixed dyslipidemia", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a7d4b15-5345-58a7-8476-834317bb65eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:0d9602db-dfaa-5690-b197-280e24fc1abe", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:e73275f3-94ef-5102-bd95-e60b3772e17c", "object": "MONDO:0005148", "original_object": "type 2 diabetes mellitus", "original_subject": "Metformin HCl ER 500mg + Fenofibrate 80mg/160mg tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:5001", "supporting_text": ["For the treatment of Type- II diabetes associated with mixed dyslipidemia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "familial hyperlipemia", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1292dc53-2db3-55fd-9aaa-a8b6e29c9954", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110330", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:6a22020d-2e09-567f-b963-f2c4159d945a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e8ae5110-32b1-53b4-9dc0-32be36ba7e75", "object": "MONDO:0021187", "object_location_in_text": [78, 90], "original_object": "hyperlipemia", "original_subject": "FENOFIBRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FENOFIBRATE#156-20110330", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:5001", "supporting_text": ["Drugs in new dosage forms and with new dosages indicated for the treatment of hyperlipemia (including familial hyperlipemia)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd452188-ea46-5d6b-bbe7-680bfd506f1e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:60f4b311-84a8-54cb-a0e1-aea813827816", "object": "MONDO:0002050", "object_location_in_text": [280, 290], "original_object": "depression", "original_subject": "ESTROGENS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae"]}], "subject": "CHEBI:50114", "supporting_text": ["Indications &amp; Usage COVARYXT® and COVARYX® H.S. are indicated in the treatment of Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) COVARYXT® and COVARYX® H.S. HAVE NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (See BOXED WARNINGS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72c890a7-a062-53fd-9f9a-7a1e5fb0ae2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9cbd2987-10bb-eceb-153d-ee7be1ed0c84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9cbd2987-10bb-eceb-153d-ee7be1ed0c84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9cbd2987-10bb-eceb-153d-ee7be1ed0c84"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for Injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions ( 5.2 )] . Dexrazoxane for Injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use Dexrazoxane for Injection with doxorubicin initiation. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7601a4d0-f7e2-5b94-a037-0b33eea01335", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9c625fc-8852-4ed4-bcf2-63f46a706782", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9c625fc-8852-4ed4-bcf2-63f46a706782", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9c625fc-8852-4ed4-bcf2-63f46a706782"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ]. Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. ( 1 )"], "temporal_context_qualifier": "associated with doxorubicin administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9652936e-e6b6-5afe-abf0-c47c9771555c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb72203a-0b09-42d5-bf51-7f479feb3adb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb72203a-0b09-42d5-bf51-7f479feb3adb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb72203a-0b09-42d5-bf51-7f479feb3adb"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ] . Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation."], "temporal_context_qualifier": "associated with doxorubicin administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5e143b4-5ad6-5b85-8f5f-9a7496b4a668", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a7c01089-85f5-40aa-b679-f53a425b4d68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a7c01089-85f5-40aa-b679-f53a425b4d68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a7c01089-85f5-40aa-b679-f53a425b4d68"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ]. Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. ( 1 )"], "temporal_context_qualifier": "associated with doxorubicin administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad39c7e6-4587-558c-a241-14d596e0f576", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9550d22-6069-a6de-9968-6a18c9e0448f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9550d22-6069-a6de-9968-6a18c9e0448f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9550d22-6069-a6de-9968-6a18c9e0448f"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for Injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions ( 5.2 )] . Dexrazoxane for Injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use Dexrazoxane for Injection with doxorubicin initiation. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae57c30d-60a4-5539-b8d3-4250f614746a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be9ac1e9-21a9-439a-9029-9f03513220ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be9ac1e9-21a9-439a-9029-9f03513220ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be9ac1e9-21a9-439a-9029-9f03513220ea"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ] . Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation."], "temporal_context_qualifier": "associated with doxorubicin administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c40beb94-2332-5b01-b9c9-376e53c9a973", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1d98fbe-5fd9-4518-b1a5-fac92e32928f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1d98fbe-5fd9-4518-b1a5-fac92e32928f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1d98fbe-5fd9-4518-b1a5-fac92e32928f"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions ( 5.2 )] . Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. ( 1 )"], "temporal_context_qualifier": "associated with doxorubicin administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcbc1207-8154-58d4-bf1d-d25ef7ccfaef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["doxorubicin"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56469d78-6e5c-530e-bc54-c5d15cf91c36", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f99e8b4f-41ef-56d4-857a-c3b0d07140e6", "object": "MONDO:0004994", "object_location_in_text": [106, 120], "original_object": "cardiomyopathy", "original_subject": "DEXRAZOXANE", "population_context_qualifier": "women", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68089182-d4a2-4053-8d0d-fc97a901515d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68089182-d4a2-4053-8d0d-fc97a901515d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68089182-d4a2-4053-8d0d-fc97a901515d"]}], "subject": "CHEBI:50223", "supporting_text": ["1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2 )] . Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. (1)"], "temporal_context_qualifier": "associated with doxorubicin administration"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0601e20f-7ad0-5db8-b06f-7408a2e45e0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [570, 583], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4853677-1622-4037-688b-fdf533a11d96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE NEXIUM is a proton pump inhibitor (PPI). NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) NEXIUM for delayed-release oral suspension is indicated for the: • Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) • Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of NEXIUM may be considered. Pediatric Patients 12 Years to 17 Years of Age NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bd15d0a-28a6-52a2-af89-e4f7d09d5fad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["NSAID"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers (age 60 years and older and/or documented history of gastric ulcers)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:277ce748-2809-4be0-81e7-6a4d604f2c6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=277ce748-2809-4be0-81e7-6a4d604f2c6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277ce748-2809-4be0-81e7-6a4d604f2c6f"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. (1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8-week course of esomeprazole magnesium may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. Pediatric Patients 1"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2750d8af-6c1c-5404-bbe3-ac6acf262507", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e04e7c84-59c8-4a1d-8dfc-d72588b97b59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e04e7c84-59c8-4a1d-8dfc-d72588b97b59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e04e7c84-59c8-4a1d-8dfc-d72588b97b59"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated with GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8-week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartbur"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:322a3b25-30bc-5eae-acf7-da7bdb71a05b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [573, 586], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71a4fa85-032b-4f50-a2ee-fd9642ae8b15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71a4fa85-032b-4f50-a2ee-fd9642ae8b15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71a4fa85-032b-4f50-a2ee-fd9642ae8b15"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "continuous NSAID therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4706a1ef-3537-5ab9-a3b8-faa6fdf75d38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "patients at risk for developing gastric ulcers; age ≥60; patients with documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c916d32-f9e9-1d15-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c916d32-f9e9-1d15-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c916d32-f9e9-1d15-e054-00144ff88e88"]}], "subject": "CHEBI:50275", "supporting_text": ["1.INDICATIONS &amp; USAGE SECTION 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Dosage and Administration (2) and Clinical Studies (14)]. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "continuous NSAID therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c274adc-6d03-5889-b6b1-f9407810aeff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "patients at risk for developing gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e30823f-c435-4abf-8f2f-5e6d6fa4ab86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e30823f-c435-4abf-8f2f-5e6d6fa4ab86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e30823f-c435-4abf-8f2f-5e6d6fa4ab86"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole strontium is a proton pump inhibitor indicated for adults for: Treatment of gastroesophageal reflux disease (GERD) ( 1.1 ) Risk reduction of NSAID-associated gastric ulcer ( 1.2 ) H. pylori eradication to reduce the risk of duodenal ulcer recurrence ( 1.3 ) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome ( 1.4 ) 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . Eradica"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e10b5a4-dbb4-5f65-b303-55d6d1d50848", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [555, 568], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:651cfdb1-d7c7-45e6-add0-f40eea7722f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=651cfdb1-d7c7-45e6-add0-f40eea7722f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=651cfdb1-d7c7-45e6-add0-f40eea7722f7"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4fc214fe-7977-52da-a5f7-4a8afc3a8150", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43cf2754-3ec7-75f7-e063-6394a90adfeb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43cf2754-3ec7-75f7-e063-6394a90adfeb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43cf2754-3ec7-75f7-e063-6394a90adfeb"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. (1.1) Maintenance of healing of EE in adults. (1.2) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. (1.3) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. (1.4) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. (1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. (1.6) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. Ped"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b3c645e-7e5c-5d9c-8d1f-e343a1a4e063", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [581, 594], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a02051ae-8e0c-4188-8a76-fcdf8b532a93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a02051ae-8e0c-4188-8a76-fcdf8b532a93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a02051ae-8e0c-4188-8a76-fcdf8b532a93"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole Magnesium Delayed-Release Capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8-week course of Esomeprazole Magnesium Delayed-Release Capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole Magnesium Delayed-Release Capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole Magnesium Delayed-Release Capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole Magnesium Delayed-Release Capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92afcc83-c6d9-54ff-95b2-ed5565723d38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [581, 594], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81f5f7d9-14bb-4804-975e-65d96f91785f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81f5f7d9-14bb-4804-975e-65d96f91785f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81f5f7d9-14bb-4804-975e-65d96f91785f"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole Magnesium Delayed-Release Capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8-week course of Esomeprazole Magnesium Delayed-Release Capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole Magnesium Delayed-Release Capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole Magnesium Delayed-Release Capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole Magnesium Delayed-Release Capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "continuous NSAID therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d49f664-79b8-5fd9-b200-afe3deaad46c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "patients at risk for developing gastric ulcers; patients ≥60 years of age and/or with documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2e18e10-6f02-4ccc-842d-1962a3838b74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2e18e10-6f02-4ccc-842d-1962a3838b74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2e18e10-6f02-4ccc-842d-1962a3838b74"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole strontium is a proton pump inhibitor indicated for adults for: Treatment of gastroesophageal reflux disease (GERD) (1.1) Risk reduction of NSAID-associated gastric ulcer (1.2) H. pylori eradication to reduce the risk of duodenal ulcer recurrence (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4) 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . Eradication of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1d7df61-2557-58dd-932d-d85386777607", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [591, 604], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e89589f1-945e-429a-819e-61755cba77fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e89589f1-945e-429a-819e-61755cba77fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e89589f1-945e-429a-819e-61755cba77fa"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 1 year to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed release oral suspension are indicated for the short-term treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4fa140b-8ed0-50c0-a1db-e5309392d201", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [593, 606], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:992b1830-55cc-4e95-8d6d-e7f796d5b373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=992b1830-55cc-4e95-8d6d-e7f796d5b373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=992b1830-55cc-4e95-8d6d-e7f796d5b373"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4-to 8-week course of esomeprazole magnesium for delayed-release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d53c8ac4-3a50-5847-ad99-da832da65c44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [573, 586], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6ad71713-39da-460b-81fc-e5fba103b215", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6ad71713-39da-460b-81fc-e5fba103b215", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ad71713-39da-460b-81fc-e5fba103b215"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symp"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7d88e0c-caee-5c89-a355-870522eb2be0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a3df29e-dc44-4dfe-a26f-4bbbf18e31eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a3df29e-dc44-4dfe-a26f-4bbbf18e31eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a3df29e-dc44-4dfe-a26f-4bbbf18e31eb"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. (1.1) Maintenance of healing of EE in adults. (1.2) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. (1.3) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. (1.4) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. (1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. (1.6) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbe2c91c-0d0e-5b76-ae01-95520eff2bd5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [593, 606], "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f907e633-4080-44ae-829f-141497876922", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f907e633-4080-44ae-829f-141497876922", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f907e633-4080-44ae-829f-141497876922"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed-release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6873b6e-b4d4-5780-900f-9a5316a368d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5baf88c3-eda4-8aa6-e063-6294a90a68b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5baf88c3-eda4-8aa6-e063-6294a90a68b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5baf88c3-eda4-8aa6-e063-6294a90a68b4"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: · Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) · Maintenance of healing of EE in adults. ( 1.2 ) · Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) · Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) · Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) · Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "continuous NSAID therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6e1f6c5-ca08-57b1-9b9a-f3aa93a15e08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "patients at risk for developing gastric ulcers; patients ≥60 years of age and/or with documented history of gastric ulcers", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:61a5a84e-0194-4f11-91f8-83d7ac404932", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=61a5a84e-0194-4f11-91f8-83d7ac404932", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=61a5a84e-0194-4f11-91f8-83d7ac404932"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole strontium is a proton pump inhibitor indicated for adults for: Treatment of gastroesophageal reflux disease (GERD) (1.1) Risk reduction of NSAID-associated gastric ulcer (1.2) H. pylori eradication to reduce the risk of duodenal ulcer recurrence (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4) 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . Eradication of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0374997", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3269fa23-b60e-55c6-95b0-7c9aee73b2ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["UMLS:C0374997"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [812, 826], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f907e633-4080-44ae-829f-141497876922", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f907e633-4080-44ae-829f-141497876922", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f907e633-4080-44ae-829f-141497876922"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed-release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatm"], "temporal_context_qualifier": "following Helicobacter pylori eradication"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3562d89d-6453-5930-98e4-345e99573791", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [812, 826], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:992b1830-55cc-4e95-8d6d-e7f796d5b373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=992b1830-55cc-4e95-8d6d-e7f796d5b373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=992b1830-55cc-4e95-8d6d-e7f796d5b373"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4-to 8-week course of esomeprazole magnesium for delayed-release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0374997", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f622700-d9ce-5b06-ac45-523bda38c0fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["UMLS:C0374997"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [802, 816], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5baf88c3-eda4-8aa6-e063-6294a90a68b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5baf88c3-eda4-8aa6-e063-6294a90a68b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5baf88c3-eda4-8aa6-e063-6294a90a68b4"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: · Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) · Maintenance of healing of EE in adults. ( 1.2 ) · Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) · Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) · Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) · Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0374997", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98317753-c4f5-5930-9d54-942dfc8eefba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["UMLS:C0374997"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1319da6-bf0d-4dd6-a713-1677bfbfbdae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1319da6-bf0d-4dd6-a713-1677bfbfbdae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1319da6-bf0d-4dd6-a713-1677bfbfbdae"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 1 year to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed release oral suspension is indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. Pediatric Patients 1 Year to 11 Years of Age Esomeprazole magnesium for delayed release oral suspension is indicated for the short-term treatment (8 weeks) for the healing of EE in pediatric patients 1 year to 11 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium for delayed release oral suspens"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1cdbe01-dcec-511b-afeb-2f932beb703a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [776, 790], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:651cfdb1-d7c7-45e6-add0-f40eea7722f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=651cfdb1-d7c7-45e6-add0-f40eea7722f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=651cfdb1-d7c7-45e6-add0-f40eea7722f7"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associate"], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bca761e4-046d-5a9b-8956-cd6f3a3f40ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [791, 805], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4853677-1622-4037-688b-fdf533a11d96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE NEXIUM is a proton pump inhibitor (PPI). NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) NEXIUM for delayed-release oral suspension is indicated for the: • Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) • Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of NEXIUM may be considered. Pediatric Patients 12 Years to 17 Years of Age NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c59ae66d-660c-586c-a5a1-3f1f171ce974", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:277ce748-2809-4be0-81e7-6a4d604f2c6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=277ce748-2809-4be0-81e7-6a4d604f2c6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277ce748-2809-4be0-81e7-6a4d604f2c6f"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. (1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8-week course of esomeprazole magnesium may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. Pediatric Patients 1"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0374997", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfc4c8f0-29e1-510c-b994-e86948c80f2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["UMLS:C0374997"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [784, 798], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a3df29e-dc44-4dfe-a26f-4bbbf18e31eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a3df29e-dc44-4dfe-a26f-4bbbf18e31eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a3df29e-dc44-4dfe-a26f-4bbbf18e31eb"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsules are a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. (1.1) Maintenance of healing of EE in adults. (1.2) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. (1.3) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. (1.4) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. (1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. (1.6) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6dfa146-520a-50e8-a15f-122f1325ed96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [810, 824], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e89589f1-945e-429a-819e-61755cba77fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e89589f1-945e-429a-819e-61755cba77fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e89589f1-945e-429a-819e-61755cba77fa"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 1 year to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed release oral suspension are indicated for the short-term treatmen"], "temporal_context_qualifier": "following Helicobacter pylori eradication"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850666", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb7422a7-032d-5be3-b635-97eb46d713a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["amoxicillin", "clarithromycin"], "medic_disease_context_ids": ["UMLS:C0850666"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [261, 275], "original_object": "duodenal ulcer", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e30823f-c435-4abf-8f2f-5e6d6fa4ab86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e30823f-c435-4abf-8f2f-5e6d6fa4ab86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e30823f-c435-4abf-8f2f-5e6d6fa4ab86"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole strontium is a proton pump inhibitor indicated for adults for: Treatment of gastroesophageal reflux disease (GERD) ( 1.1 ) Risk reduction of NSAID-associated gastric ulcer ( 1.2 ) H. pylori eradication to reduce the risk of duodenal ulcer recurrence ( 1.3 ) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome ( 1.4 ) 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . Eradica"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "heartburn and other symptoms associated with GERD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f426c06-c065-5834-9b72-ca46f25efbf1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "adults and pediatric patients 12 years to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:277ce748-2809-4be0-81e7-6a4d604f2c6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=277ce748-2809-4be0-81e7-6a4d604f2c6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=277ce748-2809-4be0-81e7-6a4d604f2c6f"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. (1.6 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8-week course of esomeprazole magnesium may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium delayed-release capsules indicated for the short-term treatment (4 to 8 weeks) for the healing of EE in pediatric patients 12 years to 17 years of age. 1.2 Maintenance of Healing of EE Esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of EE in adults. Controlled studies do not extend beyond 6 months. 1.3 Treatment of Symptomatic GERD Adults Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. Pediatric Patients 1"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f9dec3e-4ee4-50d8-a511-3f519eba350c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "pediatric patients 1 month to less than 1 year of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f907e633-4080-44ae-829f-141497876922", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f907e633-4080-44ae-829f-141497876922", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f907e633-4080-44ae-829f-141497876922"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed-release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatm"], "temporal_context_qualifier": "short-term treatment (up to 6 weeks)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab847e07-3ade-5c74-b562-d6246ad35ba7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "pediatric patients 1 month to less than 1 year of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:992b1830-55cc-4e95-8d6d-e7f796d5b373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=992b1830-55cc-4e95-8d6d-e7f796d5b373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=992b1830-55cc-4e95-8d6d-e7f796d5b373"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4-to 8-week course of esomeprazole magnesium for delayed-release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed-release oral suspension is indicated for the short-term treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd9f0bcc-daa1-5f22-9352-2408be268a56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "pediatric patients 1 month to less than 1 year of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e89589f1-945e-429a-819e-61755cba77fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e89589f1-945e-429a-819e-61755cba77fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e89589f1-945e-429a-819e-61755cba77fa"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE Esomeprazole magnesium for delayed release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed release oral suspension is indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 1 year to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) Esomeprazole magnesium for delayed-release oral suspension is indicated for the: Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults Esomeprazole magnesium for delayed release oral suspension is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium for delayed release oral suspension may be considered. Pediatric Patients 12 Years to 17 Years of Age Esomeprazole magnesium for delayed release oral suspension are indicated for the short-term treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc1472f6-9ac6-5fe8-8124-c04f52ddff33", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ff2c9c4-1e95-5729-acd2-fafa336600e4", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "ESOMEPRAZOLE", "population_context_qualifier": "pediatric patients 1 month to less than 1 year of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4853677-1622-4037-688b-fdf533a11d96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4853677-1622-4037-688b-fdf533a11d96"]}], "subject": "CHEBI:50275", "supporting_text": ["1 INDICATIONS AND USAGE NEXIUM is a proton pump inhibitor (PPI). NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) NEXIUM for delayed-release oral suspension is indicated for the: • Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) • Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of NEXIUM may be considered. Pediatric Patients 12 Years to 17 Years of Age NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) for the healing of EE "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NSAID use", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b87ee4e-9db2-534d-8598-7d107d1786b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110406", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fb53fd7f-d428-530f-a3d9-b9f10dbbdd02", "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "Esomeprazole magnesium Delayed Release Tablets 20mg/40mg (Additional Indication)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:50309", "supporting_text": ["1. Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Ulcer. 2. Risk Reduction of NSAID Associated Gastric Ulcer. 3. Prolonged Treatment after IV Induced Prevention of Rebleeding of Peptic Ulcer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca3ed77f-f42b-5cad-9012-fb4373764c08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960725", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec052dff-f081-5cd9-ac49-74554830869a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dd77c915-0b98-50ac-abeb-b421db815cf3", "object": "MONDO:0011786", "original_object": "allergic rhinitis", "original_subject": "FEXOFENADINE", "population_context_qualifier": "patients with hay fever or other upper respiratory allergies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9ccd673-c65f-45c6-9863-26136eb816db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9ccd673-c65f-45c6-9863-26136eb816db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9ccd673-c65f-45c6-9863-26136eb816db"]}], "subject": "CHEBI:5050", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ■ runny nose ■ itchy, watery eyes ■ sneezing ■ utching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276535", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2a7b383-e3b9-5c7f-a9a8-30c9810fa28b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276535"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd3f0de3-a8ef-51aa-9505-3073b16ae315", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1ce97896-e6e8-55c4-94b5-957cb960b607", "object": "MONDO:0005055", "original_object": "Kaposi's sarcoma", "original_subject": "ALITRETINOIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49c16717-7d86-4257-80c9-baa1417e5555", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49c16717-7d86-4257-80c9-baa1417e5555", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49c16717-7d86-4257-80c9-baa1417e5555"]}], "subject": "CHEBI:50648", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Kaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "paroxysmal or persistent atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c860b87-e6c2-5050-b00c-424d679cc3b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091125", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4077e79b-32f6-5d7f-82e9-7b11c876e21d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:62021724-413b-5c8c-8aa3-abbe0a08592f", "object": "UMLS:C0232201", "object_location_in_text": [43, 55], "original_object": "sinus rhythm", "original_subject": "dronedarone", "population_context_qualifier": "adult clinically stable patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:multaq", "https://www.ema.europa.eu/en/documents/product-information/multaq-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/multaq"]}], "subject": "CHEBI:50659", "supporting_text": ["Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered. Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure."], "temporal_context_qualifier": "after successful cardioversion"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance to anti-influenza medicinal products other than zanamivir", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7f09d61-42a9-5bd8-a681-c0c28fbb3b28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f651ec65-77fb-57c0-9de6-984a056deb82", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3d27a2ab-b896-55f2-8226-c707c38b0f20", "object": "UMLS:C0858004", "original_object": "influenza A virus infection", "original_subject": "zanamivir", "population_context_qualifier": "adult and paediatric patients (aged ≥6 months)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:dectova", "https://www.ema.europa.eu/en/documents/product-information/dectova-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/dectova"]}], "subject": "CHEBI:50663", "supporting_text": ["Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when:  The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.  Dectova should be used in accordance with official guidance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance to anti-influenza medicinal products other than zanamivir", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d34b5286-3c35-5019-9c23-bdcc54e2fd34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190426", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:66ac8c6d-6493-5297-a886-8eed685c1fe2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3d27a2ab-b896-55f2-8226-c707c38b0f20", "object": "UMLS:C0858005", "original_object": "influenza B virus infection", "original_subject": "zanamivir", "population_context_qualifier": "adult and paediatric patients (aged ≥6 months)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:dectova", "https://www.ema.europa.eu/en/documents/product-information/dectova-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/dectova"]}], "subject": "CHEBI:50663", "supporting_text": ["Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when:  The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.  Dectova should be used in accordance with official guidance."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3022849-7898-55b3-8007-75c2a1670b55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990917", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:42875e3b-5514-515c-9d56-a05cbcf68a39", "object": "HP:0003124", "object_location_in_text": [29, 55], "original_object": "elevated total cholesterol", "original_subject": "Atorvastatin Calcium 10mg/20mg/40mg Film Coated Tablet", "population_context_qualifier": "patients with primary hypercholesterolemia and mixed dyslipidemia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:50686", "supporting_text": ["As an adjunct diet to reduce elevated total cholesterol and triglyceride levels in patients with primary hypercholesterolemia and mixed dyslipidemia (type IIa & IIb)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3022849-7898-55b3-8007-75c2a1670b55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110420", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:723a183d-3701-5bb7-81dc-36e37c2ece05", "object": "HP:0003124", "original_object": "elevated total cholesterol", "original_subject": "42. 5mg/10mg/20mg/40mg/80mg Atorvastatin calcium (Additional Dosage Form)", "population_context_qualifier": "patients with Primary HyperCholesterolemia and Mixed Dyalipidemia (Type IIa and IIIb)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:50686", "supporting_text": ["1) As an Adjunct to Diet to Reduce Elevated Total Cholesterol and Triglyceride Levels in Patients with Primary HyperCholesterolemia and Mixed Dyalipidemia (Type IIa and IIIb). 2) In adult patients with type II diabetes and without clinically evident coronary heart disease to reduce the risk of myocardial infarction and stroke. 3) To reduce the risk of stroke in adult patients without clinically evident coronary heart disease but multiple risk factors for coronary heart disease"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003118", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6756862c-df10-5c09-886a-eb96eaf40a38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000928", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003118"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:93f1128d-a293-5006-822e-31f5e23aab53", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d287dae9-6f2b-5f16-a266-fc0a646814c5", "object": "MONDO:0001076", "object_location_in_text": [232, 251], "original_object": "glucose intolerance", "original_subject": "MIFEPRISTONE", "population_context_qualifier": "adult patients who have failed surgery or are not candidates for surgery", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:542f3fae-8bc8-4f00-9228-e4b66c9ad6a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9"]}], "subject": "CHEBI:50692", "supporting_text": ["1 INDICATIONS AND USAGE KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "endogenous Cushing's syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f16b253-f871-58cd-b01f-2e9b8ba4208a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50f27bca-3115-54b8-b779-6353b55e0477", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d287dae9-6f2b-5f16-a266-fc0a646814c5", "object": "MONDO:0002909", "object_location_in_text": [98, 111], "original_object": "hyperglycemia", "original_subject": "MIFEPRISTONE", "population_context_qualifier": "adult patients with type 2 diabetes mellitus or glucose intolerance who have failed surgery or are not candidates for surgery", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:542f3fae-8bc8-4f00-9228-e4b66c9ad6a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9"]}], "subject": "CHEBI:50692", "supporting_text": ["1 INDICATIONS AND USAGE KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003118", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85e4d8b2-4bf1-52fc-b14b-b1b1d0890be6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000928", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003118", "MONDO:0001076"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:50f27bca-3115-54b8-b779-6353b55e0477", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d287dae9-6f2b-5f16-a266-fc0a646814c5", "object": "MONDO:0002909", "object_location_in_text": [89, 102], "original_object": "hyperglycemia", "original_subject": "MIFEPRISTONE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5e09acc0-fd26-4722-b8b3-46e560390d47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5e09acc0-fd26-4722-b8b3-46e560390d47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e09acc0-fd26-4722-b8b3-46e560390d47"]}], "subject": "CHEBI:50692", "supporting_text": ["1 INDICATIONS AND USAGE Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important"], "temporal_context_qualifier": "who have failed surgery or are not candidates for surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003118", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8f71b2b-18fb-563d-a0d7-fce725fe4b60", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000928", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003118"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0d9602db-dfaa-5690-b197-280e24fc1abe", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d287dae9-6f2b-5f16-a266-fc0a646814c5", "object": "MONDO:0005148", "object_location_in_text": [204, 228], "original_object": "type 2 diabetes mellitus", "original_subject": "MIFEPRISTONE", "population_context_qualifier": "adult patients who have failed surgery or are not candidates for surgery", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:542f3fae-8bc8-4f00-9228-e4b66c9ad6a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9"]}], "subject": "CHEBI:50692", "supporting_text": ["1 INDICATIONS AND USAGE KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01662659-3aed-5f4d-ab7e-3024ef9d36eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06b7e829-c272-5361-9c43-aa7640a4cabd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d0066c2-86c0-58ac-a898-db1c8ce14a09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f7f17bf-248c-5034-ab4e-0d858edbb754", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43343afa-13e0-54d5-b1bf-0cbb2e7f91fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43b46dae-d1f7-5d2f-ba85-69155cb527ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c113eda2-1deb-5e64-8018-c3945b015171", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c177c42a-6af0-5394-bc26-e58d578c4160", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c25d9d8-0c13-5f1c-a898-406161eddd6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49856703-25f4-5cca-a233-f633c4ff36d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b2604ca-c257-59d7-a05c-f5d0da035eb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f891e467-947d-5397-a832-0895e9881f30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24d6a2c6-1fb6-5df0-920e-38ef502830ef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0002788", "original_object": "upper respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2215092f-0632-59f2-89dc-afd5b29a5117", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:552c6052-eafc-58f2-853f-e23cef636b2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5851e2a9-32a1-5ac8-8ba5-919958f60026", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a4e9e70-694d-50ff-93f6-4fa2ce2b8a8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022729", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d1c13d1-3215-5c5b-b007-518045eee774", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022729"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bae17358-1180-4ca8-b163-f9a6f4f83a3d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bae17358-1180-4ca8-b163-f9a6f4f83a3d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bae17358-1180-4ca8-b163-f9a6f4f83a3d"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Minocycline "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022729", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6c77eef-9236-59c6-b717-7176e5aeb28e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022729"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3539f84e-b489-4914-96c1-ac3731032971", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3539f84e-b489-4914-96c1-ac3731032971", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3539f84e-b489-4914-96c1-ac3731032971"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Minocycline "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f61649a3-88ec-5063-a876-7d1c852e0493", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:065ccb12-0437-5d8c-aa00-6f18afd09852", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06b45583-7cd6-56f3-9995-00490b7955ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08c075c7-ab91-5748-ad83-8bab294f08a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a5a80c6-d316-5e2d-b59c-b1686b0d6967", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0df023a4-8a08-51b4-b827-8ee901f4dcbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16b3d445-e075-5c9d-89ce-c0a5c7c19ce8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2edd16d7-5373-5abe-be9f-ac82fcba878f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ad09c18-0650-5d16-b570-6e6370b3ef89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:853d3549-64c5-5a79-ae48-9ee8bd80e926", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bca8e517-2923-5192-b056-d2e092c02564", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e57bc4ac-5a8b-50cd-93e2-908cc0d87dfc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7ccda19-0201-511e-be30-226f933060e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcbaafb3-d928-581d-8d94-22e15abd6c4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff5246a2-13a8-560a-a0b5-c63611cfa309", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d899d8f-3f31-539f-88f2-0ab382e2c0bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8935e5ba-14eb-5068-8206-417ceef96fe1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92351244-439c-51ef-82bc-828b79d62b99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a733cda7-c836-50e1-8cfa-741f6afa25fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05de94a7-3df1-5206-a60f-2db82f1b7c59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23a4067b-5497-5e21-96ed-aae9bfcd4d80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29fb02d9-fc42-50e5-b101-15de9bff1560", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35045889-1b3f-5729-8b76-e00e52d8e54f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35c8d160-5ba8-51e9-8ea5-31fc3c1b6369", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:443ce15a-331b-5b94-a3ef-ab3f7ab39eec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8aace7ed-ab05-5578-9cab-d92d9bc363a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:938f64db-430a-56ff-872e-8eefe116006e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9546eb07-7285-5326-91f3-63b44c471a1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7f9bd9e-c81e-5143-ba06-e50aa6226df9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8719347-1753-52e0-89d9-41f455cc9cef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbe93cc2-edc3-544d-ac9e-935f539a9eab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3fb3383-c831-5ee7-baed-db28f5157f26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc02cb88-fce2-574e-8afd-52de98bf1ec7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:070684f9-2a4d-5ba2-8f00-51d76f26ec43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13dec23d-1aec-5089-8b62-2db1e80202c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3657d7ee-1bd6-5c0b-b56f-c8b019ee36c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ce71221-14f0-5660-aaa6-5767bb226c3e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6dc899a0-4974-5f92-9265-77284248f028", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76673405-6235-58b2-a797-9f98caa74319", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8115ac5d-4e5d-5ef6-aaa4-516ee824525c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84951dca-8675-5b3a-ba49-1891756bcea5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92b66f34-c591-5a1f-9f4a-383e9c3cd947", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6df7cc3-f0de-5127-a52b-3aa8ea12b7fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd5df7d4-9572-5b2d-b969-ebf7724cf51b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd772dd6-4a32-5be4-a1b7-22ba184111a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e29ccaba-82dd-533e-9f48-c6b0709a5a28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa36adee-c264-5998-a63e-5528b50b92e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ccfa39f-2fae-540b-a47c-c60a38a13841", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:341d70d9-0aa2-5708-8415-0be9d05b4184", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:425997bd-41d0-51d4-84eb-28a24d5bd377", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4682067c-4b8b-5cfe-91dc-fad5771fe058", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d146f75-2865-5aba-96f0-1ef094d2b0be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:607ef475-ba49-5b9b-8994-74a59b7e2ff4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:655c2804-f995-5cf1-92ca-073fb82b4d85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b81e7bb-00f1-5379-861b-73c0a64a0e18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d847c4b-f491-5ac3-8102-732b2542dc84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b057c73-1b42-5451-9065-d49bd570966e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cce77e75-f14f-5851-903b-f0ce2556b6d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1901153-ac3a-5934-afc7-bd652ff4b560", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfc7d014-d293-52cd-b487-8c124b75d420", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3e2984d-2fb6-5698-84a7-552aa4f19972", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e1e4f6e-891f-5a1d-b452-2f4edef8cfa0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27259cb1-4cbf-515b-8b6b-01f891b2cf9c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a68dce7-a455-5b40-b54d-b1233d80f641", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:303cde03-206e-55ee-adfb-b1b00e5058cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d10ee4a-6b59-56f5-96b4-5b5bbe70d10f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ccbd4ab-3862-5230-8437-96858d53858b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a663b0f8-3044-5f66-a362-82283a0bf485", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aec62d4b-a1ac-5afb-b690-7639e7d6dab9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3f93914-9c16-58fd-8fc6-155f6c937a03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba214d64-0a75-50cb-b7fa-fc9293149f36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7ef7d96-1eb6-5b85-943a-6d32c2ce5676", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df6d8a1a-d133-53ee-bdd7-515057ce9827", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1eebaf3-7360-512e-b792-366d271023ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9102c7f-eaf9-5944-ba4d-b90b876daf82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3be70b88-9588-537a-ba4d-f2cc4147ef4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3db4e01e-e73d-5064-a702-fbc7bfb04e0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40476e0e-304b-5793-9ca6-c0124494897f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62270fcb-9e25-56c4-bf2e-7c8300f65940", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a2c13a0-14a8-54bc-89c5-74bda82326a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77c1f22c-676e-57c2-af47-9808a90c875a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8059b2ee-fc5b-557f-90e7-2ab8987dab09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1502869-90e4-5beb-b43d-4887feabf2e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7e33d81-8177-5d11-b5b6-25e245af50a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be947f38-cde9-54f3-9492-7524cb34e770", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c11a21ba-d409-53a7-b7f4-514b92470447", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1edacbc-5b5e-5199-9804-cbbe00742a1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce6649ae-a67b-5418-9f67-612f7a8950cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8ae49ad-ae98-5c84-9cf2-e1209eea62a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:059955a5-3d56-5a89-b4a1-297559ba92c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c8848ac-52d3-5bf9-aec2-e56f521d17d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e1947e5-afa9-5ce9-8427-2c65fbb0e791", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29203ef0-e8ef-557c-9ae4-a12d357e289e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ab40f01-7432-5435-9fd4-d1a97923a8fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77262cb7-4415-5555-b7ce-84604e2c63a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82c0932a-c037-58b2-b851-8efd4854455d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8904dc3e-481e-5539-9d36-99ae2264b2e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7e63532-4577-52e0-9ff5-da046754cd5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad2550e5-0105-5e0a-9450-789a0848f893", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d711733f-779b-5ca0-8ba0-42cf470f6c35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de3d9cd8-9e66-589d-bb47-aca69b6fbd8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6345a4b-1d0d-5fd5-9d6a-9c16b6e28e41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef19d3f5-ee94-5ddb-8fcc-0d221afcefe0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Treponema pallidum subspecies pallidum infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2728a24d-d714-5bb4-a38f-ec3c7d276572", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fee7e3b0-928d-5182-a15e-e542f1f834f2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0005976", "original_object": "syphilis", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31dcc04d-2658-501d-9117-e9c3c62a8ada", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f90062a-cce3-5225-9ab0-4bb228fe5ab3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e32bab6e-ef03-5f5b-9d2b-2301c5382838", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb8c116b-3b82-5647-81fb-0ffcd436da30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27fb4db0-6848-5c73-9756-5b9c7c47020f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35eba086-7651-5af1-841d-1dfceef63ef1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf4483a0-bc59-502b-b0a1-d5a566e8c14d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddf7521f-ffbf-5a6b-8726-468a63ac5840", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ddc14ad-1ab2-517c-9605-f81dc3262180", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19197a64-e08e-5236-adff-04c3d640caaf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:316b9a3f-7b39-5d6f-890f-ef2a9e21c327", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2c3230c-c56a-5054-9a3d-b9a3374cff3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13de88cf-88ee-5e3d-9e76-9ba9bec4e29e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022729", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:370331fd-dc1f-544f-bb4c-1ba18fb4b680", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022729"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bae17358-1180-4ca8-b163-f9a6f4f83a3d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bae17358-1180-4ca8-b163-f9a6f4f83a3d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bae17358-1180-4ca8-b163-f9a6f4f83a3d"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Minocycline "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56ccd00e-611d-5b96-8658-edcd6af6ecdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a65d6b6-531e-5dec-9682-995279780f80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5263051-f9ca-5d75-8bcf-633b0bcfc42e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d71b32dc-3521-5f31-9313-d6c12d5720a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022729", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f86cce94-f17e-5c27-8bbc-977ba85d8eac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022729"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3539f84e-b489-4914-96c1-ac3731032971", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3539f84e-b489-4914-96c1-ac3731032971", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3539f84e-b489-4914-96c1-ac3731032971"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Minocycline "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:270b1d43-e427-5acf-80a4-c704392675d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [1832, 1860], "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5eae69f3-7ab0-5969-a43b-b4716501c014", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d855f4f-c5f2-5979-97d0-63a0e7253294", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [1832, 1860], "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e2bfc93-038d-5041-9eb3-b41d952a9a1e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "object_location_in_text": [1832, 1860], "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2ea36af-08ee-5abb-8955-49672da94ced", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9aa177a-539f-5088-aee6-082e83d9e35c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94d941e3-d3d8-4414-bd5c-4a92848e738f"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Klebsiella aerogenes . Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Min"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4159082-9cf5-5086-ae8e-3657376a72f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f04f64e5-6448-5c9e-8667-9ab1130e95b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0cfef11-b123-524f-9344-98217051bc61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1121d2f7-405f-5c44-a275-732e59d1d586", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501", "UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:208f63d3-935b-511a-a1d6-59ca3fdc9a2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501", "UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31760650-3cbb-5c82-9949-305f00b092f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd86ff45-37d0-4501-b9fb-e1836e4a8be4"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bb22e34-5b4d-5ff7-9d5a-0c0d373cf698", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=093ff3c7-3ecc-47b4-9ae6-5218bcd262b2"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:485827ae-dc63-5c3e-9f15-c644d5bbf9d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0becbde8-6ec5-4830-a0d9-cfdb7b15eb84"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (NOTE: Mi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:563c7d2c-cdb9-5601-95f6-96be85c6bc9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5901f09b-0ed1-5b1f-a31d-e0d9bcf44c58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501", "UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:779c8cd3-0008-51cb-85af-9b71723d8e62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501", "UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7db12572-6729-5f8a-beef-803f31de3990", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3b9a7e-6724-4c2a-b3cb-236f522b31a8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7db4ecae-c0ad-5e51-9441-2a1758404a21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55df55fb-18ec-4e00-9ed0-10bba0da513b"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cdff2b0-7e7e-509f-9ba8-4ada9c73ad57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2390b7-242c-43ff-afb3-b0a5e79351d3"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: M"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4e2df05-d30e-5028-8cd1-1529e49736b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65767ae3-b1ed-4492-90f2-703b2c7e0f38"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus (NOTE: Mino"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8a23a13-7cd0-5668-a880-2e9ea06488db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903", "UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "MINOCYCLINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa"]}], "subject": "CHEBI:50694", "supporting_text": ["MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34d404b3-140a-5c68-8c1d-80c4bb95ac2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [83, 93], "original_object": "infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec20539-0421-4eac-95ed-e9acc6329fd0"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75167e73-b638-52e2-aa88-9919b7e53af2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [83, 93], "original_object": "infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87a137c6-dd53-44d3-ab49-ef78ebed35c8"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9871cec6-8b7e-55ec-b65e-cf5a53c74362", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [88, 98], "original_object": "infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caa99901-467c-4e99-b7e9-fbabdf5d118c"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minoc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbb34acb-1507-516a-aa1d-4a7d15ca0587", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c0565b7b-3178-5940-a142-723397512b9a", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [83, 93], "original_object": "infections", "original_subject": "MINOCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"]}], "subject": "CHEBI:50694", "supporting_text": ["Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hormone-sensitive breast cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02c8d65e-7ff0-5bc9-b468-4cdd7c273725", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a555d8e-6010-5957-a070-9def23518edb", "object": "MONDO:0004989", "original_object": "Breast cancer", "original_subject": "NORGESTIMATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ec8f18f-297c-405f-b191-a40767366bad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ec8f18f-297c-405f-b191-a40767366bad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ec8f18f-297c-405f-b191-a40767366bad"]}], "subject": "CHEBI:50815", "supporting_text": ["4 CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Mono-Linyah is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.7) ] Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [ see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hormone-sensitive breast cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4929efa-6d89-57d2-8db7-c819af6ce71e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a555d8e-6010-5957-a070-9def23518edb", "object": "MONDO:0004989", "original_object": "Breast cancer", "original_subject": "NORGESTIMATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84a20017-344b-4684-a915-c85a55fcbbcb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84a20017-344b-4684-a915-c85a55fcbbcb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84a20017-344b-4684-a915-c85a55fcbbcb"]}], "subject": "CHEBI:50815", "supporting_text": ["4 CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Mono-Linyah is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.7) ] Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [ see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hormone-sensitive breast cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e59ceef7-d0f1-50c1-869c-b13e99bcad3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a555d8e-6010-5957-a070-9def23518edb", "object": "MONDO:0004989", "original_object": "Breast cancer", "original_subject": "NORGESTIMATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b2e4bf2-73e5-15b0-e063-6394a90a42fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b2e4bf2-73e5-15b0-e063-6394a90a42fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b2e4bf2-73e5-15b0-e063-6394a90a42fc"]}], "subject": "CHEBI:50815", "supporting_text": ["4 CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Breast cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Mono-Linyah is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1) ] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1) ] Have cerebrovascular disease [see Warnings and Precautions (5.1) ] Have coronary artery disease [see Warnings and Precautions (5.1) ] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1) ] Have uncontrolled hypertension [see Warnings and Precautions (5.4) ] Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.6) ] Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.7) ] Women over age 35 with any migraine headaches [see Warnings and Precautions ( 5.7 )] Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.8) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [ see Warnings and Precautions (5.10) ] Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions (5.3) ]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of arterial or venous thrombotic diseases", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aef47923-3c65-5d77-987f-ad8ae7aca265", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010511", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir/paritaprevir/ritonavir", "dasabuvir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ba6d2ce-1c41-599d-bbb7-bd4b8351d697", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75357b8f-85ab-588a-a59f-a110eb735419", "medic_supporting_text_truncated": true, "object": "MONDO:0005015", "original_object": "Diabetes mellitus", "original_subject": "DROSPIRENONE", "population_context_qualifier": "females who smoke, if over age 35", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58cd12d3-39b1-4375-b7e0-09ba2378a52b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58cd12d3-39b1-4375-b7e0-09ba2378a52b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58cd12d3-39b1-4375-b7e0-09ba2378a52b"]}], "subject": "CHEBI:50838", "supporting_text": ["4 CONTRAINDICATIONS Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium is contraindicated in females who are known to have or develop the following conditions: • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: • Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 )] • Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 )] • Have cerebrovascular disease [see Warnings and Precautions ( 5.1 )] • Have coronary artery disease [see Warnings and Precautions ( 5.1 )] • Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 )] • Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 )] • Have uncontrolled hypertension [see Warnings and Precautions ( 5.6 )] • Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.8 )] • Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings and Precautions ( 5.9 )] • Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.10 )] • Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions ( 5.3 )] • Liver tumors, benign or malignant, or liver disease [see Warnings and Precautions ( 5.4 ) and Use in Specific Populations ( 8.7 )] • Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings and Precautions ( 5.5 ) and Drug Interactions ( 7.3 )] . • Renal impairment ( 4 ) • Adrenal insufficiency ( 4 ) • A high risk of arterial or venous thrombotic diseases ( 4 ) • Undiagnosed abnormal uterine bleeding ( 4 ) • Breast cancer ("]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0549184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f0d6f3a-956e-5918-939f-fa33ef18803e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010511", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ombitasvir, paritaprevir/ritonavir, dasabuvir"], "medic_disease_context_ids": ["UMLS:C0549184"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cad7760b-f94e-5d4b-bdb5-dd7b7d147f34", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75357b8f-85ab-588a-a59f-a110eb735419", "medic_supporting_text_truncated": true, "object": "UMLS:C0220847", "original_object": "hepatitis C", "original_subject": "DROSPIRENONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9187a357-e95d-4733-9627-f19522b86373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9187a357-e95d-4733-9627-f19522b86373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9187a357-e95d-4733-9627-f19522b86373"]}], "subject": "CHEBI:50838", "supporting_text": ["4 CONTRAINDICATIONS Renal impairment ( 4 ) Adrenal insufficiency ( 4 ) A high risk of arterial or venous thrombotic diseases ( 4 ) Undiagnosed abnormal uterine bleeding ( 4 ) Breast cancer ( 4 ) Liver tumors or liver disease ( 4 ) Co-administration with Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir ( 4 ) Drospirenone and Ethinyl Estradiol Tablets is contraindicated in females who are known to have or develop the following conditions: • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: ○ Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions ( 5.1 ) ] ○ Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions ( 5.1 ) ] ○ Have cerebrovascular disease [see Warnings and Precautions ( 5.1 ) ] ○ Have coronary artery disease [ see Warnings and Precautions ( 5.1 ) ] ○ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions ( 5.1 ) ] ○ Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ( 5.1 ) ] ○ Have uncontrolled hypertension [see Warnings and Precautions ( 5.6 ) ] ○ Have diabetes mellitus with vascular disease [see Warnings and Precautions ( 5.8 ) ] ○ Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings And Precautions ( 5.9 ) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.10 ) ] Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings And Precautions ( 5.3 ) ] Liver tumor (benign or malignant) or liver disease [see Warnings And Precautions ( 5.4 ) and Use In Specific Populations ( 8.7 ) ] Use of Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, wit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2126838b-b68b-5df1-bacb-eadb278b6164", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c5e3a51-651f-518f-ac29-afa453050401", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6cbfd7d2-7025-5a6e-9fbf-d69d39bdcc29", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99b88b09-4c9d-50ef-9b1e-9fec24666daf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bea8379e-f76f-5977-a4c1-d2a07121777f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c16ac4ed-5966-510e-81a0-bc88e0d14240", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf93620d-bf4b-5895-9b39-e31a6f433f64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Bacillus anthracis exposure", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b11e7b6a-2ca0-5edd-97f7-fb90b84cc421", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1bf6447d-f09d-5847-b4be-becf8ec0c833", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0016595", "original_object": "inhalational anthrax", "original_subject": "DOXYCYCLINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe8dd6d2-46b6-4987-8441-1b5a16b15bb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe8dd6d2-46b6-4987-8441-1b5a16b15bb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe8dd6d2-46b6-4987-8441-1b5a16b15bb4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline i"], "temporal_context_qualifier": "post-exposure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:025a34c7-80ab-5350-96e7-6670c2348cbc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b198be9-f9e8-517e-b47b-af4d2c14fc49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e7ae717-7897-5afb-a18a-234a9ac7d5bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5132fadb-2fb1-586b-beb5-88ce933aa216", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:562de2ff-7d3f-5eb5-b235-49cc3893aa60", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75c7bde3-17e8-5e1f-895e-fd59d5ab9c5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76ba8781-86fd-5fcf-ad29-a51328dc589b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79e39765-b207-56a6-a9c6-ca76c034daf7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f7553fc-3dba-54ce-b32d-7201689d5066", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99b2b690-4475-5c65-8ab2-0d699d7a6c1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcb69f64-e6f0-518b-a4eb-c8adc11c5f68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef5111b4-875a-537c-b1ee-599db09ae4a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "urinary tract infections", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f558fa46-7faf-5699-bd5d-81fe25247a25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a43b022c-fe62-560a-b714-76c6d1616f87", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0000010", "original_object": "respiratory tract and urinary tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa674772-14c5-541a-b711-b5cc57dc0377", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3ecbb2a-5450-5138-8fea-c7b5c78639ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "HP:0011947", "original_object": "respiratory tract infection", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06acbe0f-7d5b-58d8-b42d-65b8281ca594", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07626d2e-cf17-5755-843e-435c54d43da3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:121d3bd6-f5f4-534b-ac3c-c58b8a33a49f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19b1ce7d-0d30-52d0-84ad-2a71138acef0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a1fae3e-8ec8-537a-a204-43d9b5d2135c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49bd948b-1dcd-5f8d-924e-e08c4eee5a96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ecb9c0b-cba6-5124-a2cb-896edd174a42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64073707-fe25-5c02-9a44-5c9fb1322f62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:789ca930-fb1d-56f0-b1b3-1a35781cb0c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81b6fda9-4e2b-5b2d-804a-4b1449a5a7f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8663425c-2bdf-5757-a8c4-9377342ca0d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8786acf0-a6a6-54d0-9140-1483d8d0c912", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e082b71-336c-5f44-a61e-8c35758aad1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0583f0a-ad06-5c24-956c-74d79e44d76f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb1c55a9-be66-58eb-90eb-b190eb7de69a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d25fb1eb-ee1f-5436-aea9-9279d85962ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7defec2-54cf-5da7-8d1b-8169f71a72e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e077dcf1-4412-53a9-8354-d08e514089f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f27f6d96-4a24-549d-b81f-c0dd0333b619", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4bb507d-76e7-56cc-9074-74f6a978daa6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c1ce66f-64b9-5ac0-9553-461141549de9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001249", "original_object": "trachoma", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e2ae852-b288-551a-8eb9-798dd827e16d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27239a81-53f3-5430-8c80-bddb13676a63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:296d9e42-df96-5d72-9f2a-a1893e7a5bb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:360a43dd-181a-5026-bf52-bf57a7e4f1a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57d864b8-d640-556a-8e91-c8b23a29e527", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58b56037-7ba1-5088-a8b6-b6448942baa4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75528353-57e7-5182-8b46-833385f5a930", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b130613b-09ac-5036-8906-fc70539ee456", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4cde253-1635-5db8-ade4-7636827202cc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcb925c1-38b6-52f3-8452-75ef2d800999", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018481", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4365ee6-8bf0-5cdd-8f25-929792d99298", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018481"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:72ed0523-41c0-502c-b81d-c9821f1b061c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0001797", "original_object": "chancroid", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0004589", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a0ad934-1f5e-5bc0-ac0d-6cf30348fcda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0004589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Bacillus anth", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2bae939-9cb1-50fe-adf4-892e2bfd46ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2a9f916d-3fc2-57c3-9825-29792ed2700c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005119", "original_object": "anthrax", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b97dc9b-4e90-5bc4-a61a-7f439a667b1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:120e93ae-340c-5224-8371-9189d7548fe7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:147695d8-1db3-5d0a-a5f9-836b925dd23a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19f4d8f6-c772-5181-b880-2bad0d60d4c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49c0df8f-5741-57e8-bec0-1ef4660ab5af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ca6d352-7a14-5bcf-b000-ab9e202f47e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5239af1b-12c4-5e16-84d9-845b3e5d4641", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d35191f-4f39-5bda-8ef5-c637a18409b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e120972-86c2-5a56-a117-7fd5dc412859", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69bc51c1-891c-5e79-859a-84444e0bada6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77010a17-d1d4-5513-a6ef-bceadddf32fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:799f12cc-f39b-522b-9df9-dc2099a88be1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7de6c3cd-d2e2-5a43-9819-8b371e5e571b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91ab076f-7404-5d02-a480-3b21d3159f99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98a82f7d-0b1f-5697-b547-df184e921af0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3032f9d-1d36-5abd-94bf-7cf622653b4f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc3cf6f4-d3bd-59cf-a785-6f94f11a76e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d53056dd-c528-50a8-b661-d5442163ecc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552012", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eee52c17-55e9-5f84-a908-ae93479ebdef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552012"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f63f8b56-4f06-5a1e-a765-75406aface7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0318324", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f69dc430-250b-510a-a07f-43be0098d3f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0318324"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a8a37de7-c040-5778-b2ea-f5e36912e0ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005664", "original_object": "bartonellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10194723-4950-5830-be0a-6aaccec1f843", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:135d62fb-a585-508d-a539-1e0bf0207ac3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a11ccd4-87a0-5bd1-8641-24dbd514eeb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1adfdeac-5f4a-513d-8233-3c9f045af679", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e6655b5-82fa-516d-be0a-f9212a19466f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36c6f4c0-5177-5749-ae3e-53be2863656d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:383397fa-7bb1-5a85-9276-87484f1e7cc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41c976d5-9eda-5432-be31-6da6205124b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4763fc6a-0c82-5f62-8c96-b67b8933fa36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b1d919e-245f-5484-a6f8-86752bb4c506", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51157056-b1fb-5bf4-99e1-f24121bd9591", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65c7bf56-dd2d-5990-9d8c-9b30a167b7eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a4f31d2-4871-589b-a2f9-4735298da9e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91047c71-3281-5889-9df2-ff7e0817b27e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e1e94a1-77c8-5d59-a034-0f2516d6926f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0a494be-6351-5ded-ab52-a5562dd30fda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1509e00-2ed3-5904-b630-0b701f183f09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2e79fef-14c0-5314-8344-3bce088ad6ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cffec1c5-9aa7-5433-9d1a-e35449ea3388", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Brucella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d20ed3d6-343c-533a-91bd-3736832c27d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006303", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d621de01-59a7-51aa-9fb1-ac43c32ecb31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["streptomycin"], "medic_disease_context_ids": ["UMLS:C0006303"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b12291f-4cd6-514c-9d79-a4e7d12def65", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005683", "original_object": "brucellosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15a6d6ed-613c-58da-ae5c-b5fda7afe242", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18c5dfad-9178-5f75-bcd4-32cbe4f7cd1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:597282ee-893d-52fd-873d-f246b1c7c758", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:629e2e82-c061-5b1a-a2b0-d6693a3c6d7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:851b92fc-7391-58d7-8cff-f054406d4290", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c6bb1e6-baa7-5034-a288-d0f62b84b0e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:925818be-6b3e-50f8-ae6e-304ca6896389", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fa14e50-80d5-5efb-9e4a-e34429fab6e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fe70b6a-18bf-5955-8f30-bcd1b7d6910e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa3e046c-9486-5ade-a0ff-2849335e7c10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad277e6b-4e62-5e0b-9e2e-fe6f7cb99c2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0aa0546-0f83-5832-b639-a2abd73c0569", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b876c14a-e2d9-5189-a8c6-1d207fbde6f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1e9b7ee-4406-5d1f-bc34-32033ac41b10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0be1d84-92e8-57ea-9b08-a0acd02c057e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d775a866-b977-51d8-b15d-9a56da855842", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7802c3d-6c9b-501c-a61a-54aab2a7d0bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9157ae3-2557-5cd8-bf94-e789bb4d085a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006792"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e800a925-b88f-5584-9544-ab5bfaf0596b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee970dd3-053e-507f-b0d6-b62cb862547a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella granulomatis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f26d142f-574d-518d-86bd-957e6f47333c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9a49c2d-a0f9-5aae-81a7-3c02daf97962", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "MEDIUM", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005777", "original_object": "granuloma inguinale", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08b5e128-11d8-5de8-8d16-e2123187998f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c35c84c-8f52-51f3-b15d-2cf71926822b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d787bf5-40fd-5c0c-8085-80d197525118", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14fa2a5a-5d47-5d24-9ff8-9ca532dbcd65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:227e50ec-3da8-53ca-96cb-f5a0f166b239", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bfc1d4b-5291-5c8f-877f-fadf67c84041", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7296af89-718c-5116-9171-10f43ce99864", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7cd2033c-7a56-5f98-b90b-2a364b124309", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82404f62-72fa-55f0-9cc2-d78c6206ab83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c951b85-76c8-5824-9421-8614a2cda0e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cfc1d5c-ec23-5858-8e5a-f7e47e776bcb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a07da742-a254-5ede-8d4b-5649ba74ae42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a659b785-4fc5-5d6a-95ac-11e94bf8bbb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0549627-8e61-5db3-bbbf-87af3de08682", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b11470a4-d5b8-5529-8840-cfedb171b4ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5d22400-9102-557e-ab77-15eb37d5064a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0445aa6-6c02-54a6-8ca7-9a85eb66b310", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e927a753-c286-52ee-8ede-f08dfd8d3c79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7c8ab33-4737-5e5e-bf3f-b2bd1509a861", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa92008f-6947-50b3-a34a-e3330970bbc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5377ac45-6918-5e67-9b66-81167b337849", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005808", "original_object": "inclusion conjunctivitis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:183ea4f1-d12b-55ff-97c5-ef8553f07ea6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:189ebb04-937a-5650-8757-59d0374de6bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:269a254c-626f-5250-8045-19d14f8eebf9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2feaefc8-912d-539c-9849-7ea3d1e86275", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a67869d-9496-5153-9111-8c5d35bfa3a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69ecd1bf-7f97-55de-a57a-d0dfb6c265d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a0cbfc9-cc3a-55f5-b0e8-3c6aab8f9b46", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8406bfa4-2ee5-5734-975a-95a6d5c3e1a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:856ade15-3ec9-5d63-96ef-9e48a241edc9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85cca952-ce44-5c3a-a9c7-a2fbf91cafe9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e973f0e-9c39-59d4-a02d-c30839884665", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a7f1de7-f8bd-5ead-875e-5cb6fdd39cec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9eeeed4a-7cde-5a8d-a8b5-f0aa7b66089a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3eaeae8-141b-5c68-8afa-940748b6cb44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae8723fd-63b8-5898-8a29-ad7b30446982", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6f4f4aa-f292-5c5c-b9cc-b738c83a4d38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c742169a-629f-52bc-a006-208b42a1e095", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf29dbe3-5cab-5750-ad0c-f7b9d09d1d40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1782094-8d87-5969-8af3-fed0223b43e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f618143d-2b18-5bab-a710-99ff2533970c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008151", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa9c4882-343c-5639-8f3c-f6cde9e09a3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008151"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4efc45ec-2fb9-5ce8-94d1-23760fbd442c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005834", "original_object": "lymphogranuloma venereum", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0cb89570-ccc2-5286-b4b8-9d4e731f4ecd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f83ffa9-3809-5d51-800b-32b7d1385f50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24f8fb34-e78c-5183-bb6d-ffdd59260e7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:274adb5f-0fd1-51ad-9221-1b8f4e3fd3e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4849f42b-9f69-5c84-bd43-6611504887f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ac2041c-1c94-5cde-b553-974c20979af5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:590e98f1-3964-5efd-a477-387aee42f3b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:622f0dcd-8fe0-5747-b21d-81ece0a22eac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68560060-ec97-57ae-ae22-242bc04b7317", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6859da9f-8e32-55f9-b99c-d3ef8b0b9b69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76eff348-ae23-5c82-b349-ea8ee6f57cde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90f42db5-8138-5311-8bac-279742c6e887", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4b08556-5ee7-55bb-bd3f-d88a895f2ecf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b325c8a7-f9cc-59a4-8a64-26dcc80da610", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb408cb0-f8f5-54e6-a7ed-96ec8c70d8ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0ff168f-d9bd-53e4-89ca-46c10b9fc1b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca06b726-74ef-57e1-9774-8e262057dc27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d919ef72-7feb-5aba-bc3a-c54c0e417445", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9bac251-94db-5a09-8c41-cb4e181616fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008150", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e99c6d41-4a2b-5c5c-916c-8cbd22de5405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0008150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276108", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f40cb842-3ef4-534a-8327-a34e041a9c62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be0cf54f-d6db-540b-9587-29721d95554d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0005888", "original_object": "psittacosis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0358bca7-8d25-53a2-a758-73d653a82be3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:658652f5-6329-55c5-9fdc-ecb421b90488", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79951b73-0355-5d5c-b06e-1d9f142bfda3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ad26ad6-6a2f-5dde-9f3e-581eb3fa1ed6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8532e800-86f9-57ec-a2b1-c0d1acd4a8ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9be7512d-0421-5087-9561-eca2fb5e6e65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e30a78c-9cbe-5f18-acb1-97d277dd3d1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9523ace-44d2-5df1-8f77-36f95e0c1f15", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd7f7dce-5e02-5b36-9e6d-186c8579260a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:deee5803-1d89-5253-9303-6aaf5fac60eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016677", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efddab83-64ab-55d3-ac17-fd47cb216d64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016677"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6110eb4c-3618-5efd-be03-295191904043", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0018077", "original_object": "tularemia", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c4aca56-0136-52b7-a53f-eae0dd7d8dad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28da959a-68df-5d6c-8293-cb8c3ebc5059", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29972f5c-3d0a-5550-a834-611bbdf0c267", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29f2b644-a925-5c23-98f9-16ba4cbbd45f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6364ad25-892e-5529-a3e2-de20a6374efc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2193d22-26e7-5faa-8d1f-ce26e327e793", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8ba2ec1-0124-57ff-b961-c7584c2ab69b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba326dd1-e68c-55f6-b9bf-c73d6442fc8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c15ad59b-865f-5d0b-861d-a7df54c28261", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8255acf-eedc-5460-928c-d0a9f759aec0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0043408", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb128cc8-3b1d-5396-a520-65dfc35cb98d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043408"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23b47549-b415-5400-8c95-0e022eb3d028", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019095", "original_object": "plague", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07aae649-99bd-530a-9f28-1e658bb47e98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0df78cad-48f8-51ba-9a87-d01ce752a7f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3427ccce-999e-5e4c-9b52-972eb30660b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d0ff635-2148-54af-a6d3-8bba74583527", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:748f9125-58a0-5a4f-836b-e2ee06d7e5de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84ca0ff4-7a3a-527a-b1e1-cf07b634074e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85c4c9e7-f921-5d12-b541-16bc8278dd71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae1ec401-881b-54da-93d6-5df803c39bbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbb5d540-2edc-59fb-b6ab-2d8719d57fd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4c17088-e0a2-5ade-b313-6f4383b60dfc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0315000", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e60c6988-a665-5905-acd7-c3329f45bc15", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0315000"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003b6994-1c30-5dc7-a72f-41b040620ed7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0019633", "original_object": "relapsing fever", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10846d9d-20c1-5f37-a63d-14a41f06d167", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19f901e8-275d-54b2-ba9f-992fb3b51090", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20f3d93d-1e0d-5967-b247-3a051c7a3379", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3073168d-2058-5fbe-90af-27e5c2c7cc57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d92f882-c39c-5048-819a-c1a9cea3bebb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f7ab441-9fc0-56ea-ac57-cbad78ebd78f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68250249-1e08-5472-838a-a2dd12f2a9de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7850f672-d4b3-576b-8368-6024b0d59c80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82a17469-2693-55bb-a748-3d74ff1dff4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0022727", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86406e8b-61dc-5046-b5bd-a678134f1968", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0022727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8764e9bc-9b95-596b-aa63-38697ebd9e41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a18a884e-ca5b-5a95-86b8-f11a7ad67a67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1f7bb0e-ffc1-50ad-a4d4-d3b3edc84843", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a252a8aa-46fc-5360-bd59-76f38c61b72d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b20c8492-15ec-5a2e-8c6e-c0e4c28802bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4049372-7acf-55fd-b8e9-d0b9b6a38e9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4933e73-c75a-5b26-9838-1d49b8049984", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Klebsiella species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa7b014b-0705-58cf-a60d-76cfe76db4c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06253b87-7ec9-5f01-bb7d-3652457ec224", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d08dae8-094c-58c1-a49d-2da0f23bd5ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e144da0-926d-57e6-8e22-68dd8c7cfc3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d78b5d9-54c9-5ff7-8e14-0d4f178349d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8dc437af-abb2-5065-ad03-1d1a3f15011b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dcf0d4f-d5d7-5142-9d5f-5dcf565fece0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac2c3b80-8f92-5518-827e-0efa1e2a5eec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9eed64d-27a3-50fc-a620-7f8db67a42a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038410", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e72fdb40-1f7b-5b12-8d4b-7116455222f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de5db33a-eef9-500b-8c77-2cbb89f32b08", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C0041912", "original_object": "upper respiratory infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:001bf48b-3de0-5a8d-b4e5-b1d64108d228", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09c0514b-4861-59b0-8778-313c109ecc19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ecadbc8-3087-4692-916a-b7f392d8e8da"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:278c3cb5-5b55-5990-a3f8-986cdfd341aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7c14a8e-c713-4f03-94e8-1ec9ae077d4d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . • Respiratory tract infections caused by Mycoplasma pneumoniae . • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:376ace60-d6dd-573e-88f3-ad52e969a894", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbc1924f-d647-465a-b8b2-25de332c5896"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophil a psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducrey i . Plague due to Y ersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d8261c4-a09a-5747-a389-62258d53566b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cff08863-7156-49d0-abbd-8f9274302886"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets, USP and other antibacterial drugs, doxycycline hyclate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: · Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . · Respiratory tract infections caused by Mycoplasma pneumoniae . · Lymphogranuloma venereum caused by Chlamydia trachomatis . · Psittacosis (ornithosis) caused by Chlamydophila psittaci . · Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. · Inclusion conjunctivitis caused by Chlamydia trachomatis . · Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . · Nongonococcal urethritis caused by Ureaplasma urealyticum . · Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: · Chancroid caused by Haemophilus ducreyi . · Plague due to Yersinia pestis . · Tularemia due to Francisella tularensis . · Cholera caused by Vibrio cholerae . · Campylobacter fetus infections caused by Campylobacter fetus . · Brucellosis due to Brucella species (in conjunction with streptomycin). · Bartonellosis due to Bartonella bacilliformis . · Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58661f9c-e547-522a-8f74-69d9d6aded06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=051654c7-8ba6-44f2-842c-72f515e9b32d"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6cc617f6-b1f2-52f4-a98e-843376537584", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddd8208-c297-af5c-e063-6294a90a7b3b"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7382770b-db0b-5c84-8ce6-e6e33bbd54b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c29f716-bdb0-437d-92a4-d856b87db976"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78808217-bda5-572d-aabb-680a7cf539e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7a5fa4b-ed6c-55a8-b6e7-80744e4ad355", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab896923-6e7b-5cf4-9ef7-336dc67f0df2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0686eca-8bef-4e0d-a160-7b2c265f1b44"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus . • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c331e8f2-b6d1-5371-9f0c-50ea7aeefbed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fb9f5ad-90a2-4858-bc34-f800d8b2fa90"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfed05e5-ae66-56bd-9be5-25d0fbd9aaff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0d4cc3b-ec71-565e-a532-beb55e0362bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2305ab4a-7d08-41f6-9c39-c9b6835be389"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycyc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d168fb85-1cf9-5e1e-a3a3-cce2c8579237", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=656ccfe8-dd25-474a-9306-e44e511d7acd"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility tes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d665cbfc-24a2-5e3c-b606-405dcbfe70c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddc8395f-dbc4-5910-b6d7-40cc6e77e889", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0085501", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2b7e19e-d39f-5d21-81f7-065025190051", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0085501"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4b441d7-7bfb-5309-9af5-856f2444f112", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df44c686-de34-487a-8741-a0a12993cab2"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb867ef7-6fc1-507e-990c-ff7f186fe0b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f02f5358-dd42-44d7-802d-a3001e0d4f13"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline capsules, USP are indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline capsules, USP are also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4760903", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5ae3c20-0f96-55b6-ba39-af7f34ec6995", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4760903"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b08332-3256-4658-965a-ede3d973a388"]}], "subject": "CHEBI:50845", "supporting_text": ["1 INDICATIONS AND USAGE Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy in acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae. Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be resistant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12816ee8-ab5c-58e7-b86d-a5a095e07649", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [178, 188], "original_object": "infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fdc01c3-c62f-40cf-8351-91cbcc43d379"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35d0f60f-0e0b-507b-880d-9e7d60404673", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [178, 188], "original_object": "infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88c429a1-351d-432e-b69b-d7a0afca482a"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c1b7b97-a311-57d2-b580-5a72246aa661", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3699cf47-a960-5c46-9747-e2eeea4402c3", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [178, 188], "original_object": "infections", "original_subject": "DOXYCYCLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e7cf78f-3b48-4614-9fa4-c6d1e0c05a35"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b0a818c-bd61-5b7c-b787-c76272867aaa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [210, 220], "original_object": "infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db53637e-16ac-41b0-b9d5-553471405d64"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility te"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86931492-6536-50a3-8d34-6bbe014fc0a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [178, 188], "original_object": "infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0106a3d3-db4d-f6ee-e063-6294a90a25e9"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Acinetobacter species infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88359dbd-c6d8-5528-ba53-2c373162ea1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [194, 204], "original_object": "infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8194d6e-c407-465e-a342-4d2d9756dfc4"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recomm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1264774", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d201f4d4-8cc4-53e6-8a9e-f5e91c465502", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1264774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:19c21e45-eaf0-5a0f-9c57-799ff0413f7c", "medic_supporting_text_truncated": true, "object": "UMLS:C3714514", "object_location_in_text": [178, 188], "original_object": "infections", "original_subject": "DOXYCYCLINE ANHYDROUS", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d421b771-de88-4769-949f-8a24baa69c25"]}], "subject": "CHEBI:50845", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0334abee-8975-59f8-b561-024a775551ee", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0005642", "object_location_in_text": [213, 236], "original_object": "allergic conjunctivitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ca837f1-ff58-5bea-a0ee-4bde2ad900f6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0005642", "object_location_in_text": [212, 235], "original_object": "allergic conjunctivitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a506712-b032-463a-9a17-480558445808"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9898311e-6766-5092-907f-3ea27ead6099", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0005642", "object_location_in_text": [175, 198], "original_object": "allergic conjunctivitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe"]}], "subject": "CHEBI:50848", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9ba39fd-d749-557a-917a-044a3c82283e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0005642", "object_location_in_text": [189, 212], "original_object": "allergic conjunctivitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d35422a3-c287-51ba-a964-f1d648b2662e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0005642", "object_location_in_text": [213, 236], "original_object": "allergic conjunctivitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:095c0ca5-a7f1-55d6-b45c-93d841292884", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006604", "object_location_in_text": [237, 249], "original_object": "acne rosacea", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a506712-b032-463a-9a17-480558445808"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ed97b82-b0f2-53ee-9ff9-f713cfa2428a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006604", "object_location_in_text": [238, 250], "original_object": "acne rosacea", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad7e46fb-09fb-5bc6-a85d-e0c2c893d2ef", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006604", "object_location_in_text": [238, 250], "original_object": "acne rosacea", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f17eeceb-9596-5888-bafe-34ecda9bf483", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006604", "object_location_in_text": [200, 212], "original_object": "acne rosacea", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe"]}], "subject": "CHEBI:50848", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd2db4c9-d2a3-57a8-a126-bc835b832047", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006604", "object_location_in_text": [214, 226], "original_object": "acne rosacea", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c2dc5d0-fbfc-5554-aaec-1fc631c45dca", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006814", "object_location_in_text": [308, 314], "original_object": "iritis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a506712-b032-463a-9a17-480558445808"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62bd49b3-9c60-5265-8e13-22c7b82ad9de", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006814", "object_location_in_text": [309, 315], "original_object": "iritis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81edeb83-d933-5aba-aafd-d7df5e32b918", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006814", "object_location_in_text": [309, 315], "original_object": "iritis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2cfd862-feec-52c7-b3aa-d774babc9d24", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006814", "object_location_in_text": [271, 277], "original_object": "iritis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe"]}], "subject": "CHEBI:50848", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc0d9869-c237-5dbe-a7f4-fa676864f06f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "MONDO:0006814", "object_location_in_text": [285, 291], "original_object": "iritis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c37f6e2-b245-548d-b867-c12b62c3452e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0010543", "object_location_in_text": [293, 301], "original_object": "cyclitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5340c92a-5acb-52c0-9fed-c0df28767160", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0010543", "object_location_in_text": [279, 287], "original_object": "cyclitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe"]}], "subject": "CHEBI:50848", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75d41967-5514-5cef-81de-460060ee0c03", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0010543", "object_location_in_text": [316, 324], "original_object": "cyclitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a506712-b032-463a-9a17-480558445808"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94e9d825-ac9e-5418-a6b9-2ecea6877231", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0010543", "object_location_in_text": [317, 325], "original_object": "cyclitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc91c004-7921-5019-99ee-4d9cec52007f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0010543", "object_location_in_text": [317, 325], "original_object": "cyclitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54b4fd0f-3bf8-581d-9d0f-b76869585a26", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0153027", "object_location_in_text": [284, 307], "original_object": "herpes zoster keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6726e993-6845-57d7-9124-5a9ff93da50d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0153027", "object_location_in_text": [260, 283], "original_object": "herpes zoster keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0f1db49-e170-5ac7-bcf2-66acb8524f2c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0153027", "object_location_in_text": [284, 307], "original_object": "herpes zoster keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf8b7b4e-3cef-558a-9266-deb09433d977", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0153027", "object_location_in_text": [283, 306], "original_object": "herpes zoster keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a506712-b032-463a-9a17-480558445808"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efb637ab-b3ed-5c1f-b85f-0401b470865a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0153027", "object_location_in_text": [246, 269], "original_object": "herpes zoster keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe"]}], "subject": "CHEBI:50848", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4017b810-9172-5f13-8d6e-a1b4ebc5ab82", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0259799", "object_location_in_text": [252, 282], "original_object": "superficial punctate keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed9f004b-f910-4d75-b205-e96b6254946e"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68756947-f4c8-50de-b87d-763128ed83a1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0259799", "object_location_in_text": [228, 258], "original_object": "superficial punctate keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4faa8cbe-2004-e8b5-e063-6394a90a3550"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76a98196-5e5d-5b8d-bd38-f3613cdf64be", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0259799", "object_location_in_text": [252, 282], "original_object": "superficial punctate keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36cfd5b8-c892-44e1-aaed-fb32d7aeca7c"]}], "subject": "CHEBI:50848", "supporting_text": [": Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf2d6ad3-7a2f-5a98-a135-8ec4744bd294", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0259799", "object_location_in_text": [251, 281], "original_object": "superficial punctate keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a506712-b032-463a-9a17-480558445808", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a506712-b032-463a-9a17-480558445808"]}], "subject": "CHEBI:50848", "supporting_text": ["Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid- responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa7a0915-1abd-5673-8c50-410e7a2768ed", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ce368e23-00f1-595f-ab24-ded5163b374d", "object": "UMLS:C0259799", "object_location_in_text": [214, 244], "original_object": "superficial punctate keratitis", "original_subject": "LOTEPREDNOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f37d74ac-5f9c-40a8-b43b-35148fc66bbe"]}], "subject": "CHEBI:50848", "supporting_text": ["LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced stage cutaneous T-cell lymphoma", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc3525e8-4718-556d-9d21-efcd213d015e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010329", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:97f4c971-5db7-5542-bfce-c372ea5a56c0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:33d9fbd7-d9f9-5a42-b65e-ab0cdbe48da0", "object": "MONDO:0000607", "original_object": "cutaneous T-cell lymphoma", "original_subject": "bexarotene", "population_context_qualifier": "patients refractory to at least one systemic treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:targretin", "https://www.ema.europa.eu/en/documents/product-information/targretin-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/targretin"]}], "subject": "CHEBI:50859", "supporting_text": ["Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0037284", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90c3ae6c-e456-5fe9-ab97-8e611b3acd9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240624", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0037284"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b1673fd1-9afe-5d5e-a679-8d3ddac161bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:33d9fbd7-d9f9-5a42-b65e-ab0cdbe48da0", "object": "MONDO:0019471", "original_object": "adult T-cell leukemia/lymphoma", "original_subject": "BEXAROTENE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BEXAROTENE#15-20240624", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:50859", "supporting_text": ["A drug with a new indication for the treatment of adult T- cell leukemia/lymphoma with skin lesions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2363973", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0689f29-6877-505e-b7c7-38b4e497cb05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200403", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2363973"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:965c8f82-d060-592e-96e7-7cb199f9e201", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0a384780-14c1-587a-8472-b7388b5ebd5d", "object": "MONDO:0013024", "original_object": "chronic thromboembolic pulmonary hypertension", "original_subject": "treprostinil", "population_context_qualifier": "adult patients with WHO Functional Class (FC) III or IV", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:trepulmix", "https://www.ema.europa.eu/en/documents/product-information/trepulmix-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/trepulmix"]}], "subject": "CHEBI:50861", "supporting_text": ["Treatment of adult patients with WHO Functional Class (FC) III or IV and:  inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment  to improve exercise capacity."], "temporal_context_qualifier": "persistent or recurrent CTEPH after surgical treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "radioactive iodine refractoriness", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6699c5d5-7632-54e6-9fc9-a201b93b95f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060719", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9ecc0c5a-a1fc-5580-bace-765da84bab8e", "object": "MONDO:0015447", "original_object": "differentiated thyroid carcinoma", "original_subject": "sorafenib", "population_context_qualifier": "patients with progressive, locally advanced or metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nexavar", "https://www.ema.europa.eu/en/documents/product-information/nexavar-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar"]}], "subject": "CHEBI:50924", "supporting_text": ["Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radioactive iodine treatment refractoriness", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f72a1e9-8833-5cd2-b000-d7bacd9ba535", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ecc0c5a-a1fc-5580-bace-765da84bab8e", "object": "MONDO:0015447", "original_object": "differentiated thyroid carcinoma", "original_subject": "SORAFENIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dae598f7-823f-405c-ae31-f924594187b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dae598f7-823f-405c-ae31-f924594187b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dae598f7-823f-405c-ae31-f924594187b9"]}], "subject": "CHEBI:50924", "supporting_text": ["1 INDICATIONS AND USAGE Sorafenib is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma ( 1.1 ) Advanced renal cell carcinoma ( 1.2 ) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma Sorafenib tablets are indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radioactive iodine treatment refractory disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a12eb3d7-4403-57a6-9223-f9fc7a9240ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ecc0c5a-a1fc-5580-bace-765da84bab8e", "object": "MONDO:0015447", "original_object": "differentiated thyroid carcinoma", "original_subject": "SORAFENIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68aa4b7f-3f13-4e73-b572-aa6c11a8429c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68aa4b7f-3f13-4e73-b572-aa6c11a8429c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68aa4b7f-3f13-4e73-b572-aa6c11a8429c"]}], "subject": "CHEBI:50924", "supporting_text": ["Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radioactive iodine treatment refractory disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cda92afd-0e34-501c-bf6d-67e9f9412317", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ecc0c5a-a1fc-5580-bace-765da84bab8e", "object": "MONDO:0015447", "original_object": "differentiated thyroid carcinoma", "original_subject": "SORAFENIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06f442d6-071e-4081-b7f7-40f3b803ab3f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06f442d6-071e-4081-b7f7-40f3b803ab3f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06f442d6-071e-4081-b7f7-40f3b803ab3f"]}], "subject": "CHEBI:50924", "supporting_text": ["Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radioactive iodine treatment refractory disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecc958ea-dfc9-5555-88f8-be455913e552", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ecc0c5a-a1fc-5580-bace-765da84bab8e", "object": "MONDO:0015447", "original_object": "differentiated thyroid carcinoma", "original_subject": "SORAFENIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faa9d847-2cd5-6538-e053-6394a90aa92b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faa9d847-2cd5-6538-e053-6394a90aa92b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faa9d847-2cd5-6538-e053-6394a90aa92b"]}], "subject": "CHEBI:50924", "supporting_text": ["Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "radioactive iodine-refractory disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edf81e59-c84d-5ce1-ae51-c89b4c52202f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ecc0c5a-a1fc-5580-bace-765da84bab8e", "object": "MONDO:0015447", "object_location_in_text": [223, 255], "original_object": "differentiated thyroid carcinoma", "original_subject": "SORAFENIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93f9c3b2-d4c5-80d3-5421-8b4c29fbf8a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93f9c3b2-d4c5-80d3-5421-8b4c29fbf8a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93f9c3b2-d4c5-80d3-5421-8b4c29fbf8a6"]}], "subject": "CHEBI:50924", "supporting_text": ["1 INDICATIONS AND USAGE Sorafenib is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma Sorafenib tablets are indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment."], "temporal_context_qualifier": "locally recurrent or metastatic, progressive"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010415", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7cccc104-296f-5203-985a-7f7c0b1ac710", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010415"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce2d5006-6985-5b35-a8f4-4b0101bedf77", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "MONDO:0005723", "original_object": "cryptococcal meningitis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b1c40b2-e0fb-47d5-b821-889b3090cebe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b1c40b2-e0fb-47d5-b821-889b3090cebe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b1c40b2-e0fb-47d5-b821-889b3090cebe"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010415", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cfcd18d-3cfc-509a-8967-342dfb2f42b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010415"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce2d5006-6985-5b35-a8f4-4b0101bedf77", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "MONDO:0005723", "original_object": "cryptococcal meningitis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine Capsules, USP are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules, USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules, USP (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010415", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0f68bdd-eb03-58bc-a789-c87ea618220f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010415"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce2d5006-6985-5b35-a8f4-4b0101bedf77", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "MONDO:0005723", "original_object": "cryptococcal meningitis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b55832c-6771-4f5b-9aef-f88a1d22795e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b55832c-6771-4f5b-9aef-f88a1d22795e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b55832c-6771-4f5b-9aef-f88a1d22795e"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010415", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf0e03ae-e1f3-5328-990f-e61ae1248b2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010415"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce2d5006-6985-5b35-a8f4-4b0101bedf77", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "MONDO:0005723", "original_object": "cryptococcal meningitis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aaf23f5-9b8f-4c5a-8c90-5c83765ad889", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aaf23f5-9b8f-4c5a-8c90-5c83765ad889", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aaf23f5-9b8f-4c5a-8c90-5c83765ad889"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0010415", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd777aa9-0809-572a-bf98-5f54930b194b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0010415"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce2d5006-6985-5b35-a8f4-4b0101bedf77", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "MONDO:0005723", "original_object": "cryptococcal meningitis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59f0bf8c-21a8-4932-85b2-2fe017a2a486", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59f0bf8c-21a8-4932-85b2-2fe017a2a486", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59f0bf8c-21a8-4932-85b2-2fe017a2a486"]}], "subject": "CHEBI:5100", "supporting_text": ["INDICATIONS &amp; USAGE Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41bc4a90-284d-51d5-a2b5-d43600e1dfb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61691cea-7f27-5b14-a8d3-c7ab1627fbd2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0153254", "original_object": "candidal endocarditis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b1c40b2-e0fb-47d5-b821-889b3090cebe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b1c40b2-e0fb-47d5-b821-889b3090cebe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b1c40b2-e0fb-47d5-b821-889b3090cebe"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:431873e5-b375-55dc-923b-286cd6a7c6e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e1f8378-390d-5a5b-afee-7ec57cee0b59", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0153254", "original_object": "candida endocarditis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59f0bf8c-21a8-4932-85b2-2fe017a2a486", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59f0bf8c-21a8-4932-85b2-2fe017a2a486", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59f0bf8c-21a8-4932-85b2-2fe017a2a486"]}], "subject": "CHEBI:5100", "supporting_text": ["INDICATIONS &amp; USAGE Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96f659e5-435f-5fa4-85c4-768772b0dc66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61691cea-7f27-5b14-a8d3-c7ab1627fbd2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0153254", "original_object": "candidal endocarditis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aaf23f5-9b8f-4c5a-8c90-5c83765ad889", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aaf23f5-9b8f-4c5a-8c90-5c83765ad889", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aaf23f5-9b8f-4c5a-8c90-5c83765ad889"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9c3460a-8c89-56a8-ab13-fa8f4931c5d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61691cea-7f27-5b14-a8d3-c7ab1627fbd2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0153254", "original_object": "candidal endocarditis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b55832c-6771-4f5b-9aef-f88a1d22795e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b55832c-6771-4f5b-9aef-f88a1d22795e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b55832c-6771-4f5b-9aef-f88a1d22795e"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f00dad56-4fb4-562b-a187-d6151c1a6a6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e1f8378-390d-5a5b-afee-7ec57cee0b59", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0153254", "original_object": "candida endocarditis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c63d98-f03f-43f5-8c1f-e9ac6087312b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c63d98-f03f-43f5-8c1f-e9ac6087312b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c63d98-f03f-43f5-8c1f-e9ac6087312b"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine capsules (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9355eb8-666c-51f3-8603-736f0667982a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61691cea-7f27-5b14-a8d3-c7ab1627fbd2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0153254", "original_object": "candidal endocarditis", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine Capsules, USP are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules, USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules, USP (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36b02d95-7d22-5ad7-a6f0-0fa1401a41f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:04e9cd38-2097-5195-a5af-a0a8f4679604", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0349009", "original_object": "candida septicemia", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59f0bf8c-21a8-4932-85b2-2fe017a2a486", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59f0bf8c-21a8-4932-85b2-2fe017a2a486", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59f0bf8c-21a8-4932-85b2-2fe017a2a486"]}], "subject": "CHEBI:5100", "supporting_text": ["INDICATIONS &amp; USAGE Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:373ec6e9-6283-57d8-8bd2-b9493d25d76e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:04e9cd38-2097-5195-a5af-a0a8f4679604", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0349009", "original_object": "candida septicemia", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4c63d98-f03f-43f5-8c1f-e9ac6087312b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4c63d98-f03f-43f5-8c1f-e9ac6087312b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4c63d98-f03f-43f5-8c1f-e9ac6087312b"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine capsules (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:773ceb70-b299-52b0-a626-eeb1349cbba0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e08f258-05ea-5724-9a50-179bf641d062", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0349009", "original_object": "candidal septicemia", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b55832c-6771-4f5b-9aef-f88a1d22795e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b55832c-6771-4f5b-9aef-f88a1d22795e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b55832c-6771-4f5b-9aef-f88a1d22795e"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a640fc7f-aea8-5941-977b-9a7b84ad3109", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e08f258-05ea-5724-9a50-179bf641d062", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0349009", "original_object": "candidal septicemia", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b1c40b2-e0fb-47d5-b821-889b3090cebe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b1c40b2-e0fb-47d5-b821-889b3090cebe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b1c40b2-e0fb-47d5-b821-889b3090cebe"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9b90e2c-03d2-57de-ba72-1f392109e774", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e08f258-05ea-5724-9a50-179bf641d062", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0349009", "original_object": "candidal septicemia", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f2f67a8-2d13-4a7c-8e90-8b625c6ed98e"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine Capsules, USP are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules, USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules, USP (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa94dbed-898d-5cbb-8c1f-c216104978b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8e08f258-05ea-5724-9a50-179bf641d062", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9bcffe76-9044-5bb0-a2fa-be4ab96e46f1", "object": "UMLS:C0349009", "original_object": "candidal septicemia", "original_subject": "FLUCYTOSINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aaf23f5-9b8f-4c5a-8c90-5c83765ad889", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aaf23f5-9b8f-4c5a-8c90-5c83765ad889", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aaf23f5-9b8f-4c5a-8c90-5c83765ad889"]}], "subject": "CHEBI:5100", "supporting_text": ["Flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine (see MICROBIOLOGY )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1eb5f39c-aa90-55cd-89a7-240a2fd1d380", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436f5616-9626-4b6a-9deb-2986444179d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436f5616-9626-4b6a-9deb-2986444179d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436f5616-9626-4b6a-9deb-2986444179d0"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21e22392-6909-5de2-bb22-35255caa24bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6673efde-057a-a889-e053-2a91aa0a517b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6673efde-057a-a889-e053-2a91aa0a517b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6673efde-057a-a889-e053-2a91aa0a517b"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fd531dd-adf5-59ec-ba81-907c2cf903bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f7a30b5-2728-0c82-e063-6394a90a92dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f7a30b5-2728-0c82-e063-6394a90a92dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f7a30b5-2728-0c82-e063-6394a90a92dd"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35b0bf44-fae8-5ac8-a39e-61b7e30c1dfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6671d89f-cc82-c03c-e053-2a91aa0aa5fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6671d89f-cc82-c03c-e053-2a91aa0aa5fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6671d89f-cc82-c03c-e053-2a91aa0aa5fa"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:433025e7-6210-5e89-9eb8-18c79789ccd0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2190e8d0-d7ca-4f53-b243-0d2c31979aa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2190e8d0-d7ca-4f53-b243-0d2c31979aa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2190e8d0-d7ca-4f53-b243-0d2c31979aa8"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f75e35e-8e09-5338-a2e8-0f15e628b9d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:442ed32b-b508-40cc-9915-ff05674566da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=442ed32b-b508-40cc-9915-ff05674566da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=442ed32b-b508-40cc-9915-ff05674566da"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:669aa925-fff5-543d-b991-9989e5278da5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1855bb03-392f-4a0d-8361-24fc2a0e635e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1855bb03-392f-4a0d-8361-24fc2a0e635e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1855bb03-392f-4a0d-8361-24fc2a0e635e"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b425057-9be3-51cb-bec0-4d27ba695b38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3eefb01b-3d6a-a3eb-e063-6394a90a4829", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3eefb01b-3d6a-a3eb-e063-6394a90a4829", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3eefb01b-3d6a-a3eb-e063-6394a90a4829"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7acc3069-c30b-5ed0-bf01-366e165b0617", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc7f2af-1eba-3d01-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc7f2af-1eba-3d01-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc7f2af-1eba-3d01-e054-00144ff88e88"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b78adc2-e2dd-51f0-a91e-ffb3d1170f32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8117cab2-65ff-326b-e053-2991aa0abb9c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8117cab2-65ff-326b-e053-2991aa0abb9c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8117cab2-65ff-326b-e053-2991aa0abb9c"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8b0369e-077f-527c-b3d6-9d9daaac1188", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ea41cbe-bc07-4c95-8bb2-7dfc2e96a874", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ea41cbe-bc07-4c95-8bb2-7dfc2e96a874", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ea41cbe-bc07-4c95-8bb2-7dfc2e96a874"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df099af5-7eb1-520b-bdbc-a1598b3fb40c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e67a9e4f-05bf-5ffe-9b17-938e1ce0fa0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15f1360d-95d3-5cd4-9edd-0d5cc32c951b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002133", "object_location_in_text": [255, 273], "original_object": "status epilepticus", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f1c915f-0c15-5885-a688-97940a30738b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:defa5ba2-3195-5bcf-8c70-83d469598b3b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002516", "original_object": "intracranial pressure elevation", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74d007e9-9604-0941-e053-2a91aa0a29c4"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "benzodiazepine-controlled condition", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70348519-f41b-5a47-93d0-5906890f4d77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:defa5ba2-3195-5bcf-8c70-83d469598b3b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "HP:0002516", "original_object": "intracranial pressure elevation", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see Warnings )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:725fc173-7737-5bf7-aa69-2efe98239b71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436f5616-9626-4b6a-9deb-2986444179d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436f5616-9626-4b6a-9deb-2986444179d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436f5616-9626-4b6a-9deb-2986444179d0"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72e2f930-d567-55d0-89a1-e5d55591de92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6671d89f-cc82-c03c-e053-2a91aa0aa5fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6671d89f-cc82-c03c-e053-2a91aa0aa5fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6671d89f-cc82-c03c-e053-2a91aa0aa5fa"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80c39b85-f0f1-5c37-9707-f0045ce7d764", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:442ed32b-b508-40cc-9915-ff05674566da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=442ed32b-b508-40cc-9915-ff05674566da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=442ed32b-b508-40cc-9915-ff05674566da"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86a27ed2-006b-521b-b857-d358cbc95389", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f7a30b5-2728-0c82-e063-6394a90a92dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f7a30b5-2728-0c82-e063-6394a90a92dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f7a30b5-2728-0c82-e063-6394a90a92dd"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ea81faa-92e0-5090-bc44-1e179dc8ce22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1855bb03-392f-4a0d-8361-24fc2a0e635e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1855bb03-392f-4a0d-8361-24fc2a0e635e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1855bb03-392f-4a0d-8361-24fc2a0e635e"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:904871c2-7901-5153-a26a-7644489ce109", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3eefb01b-3d6a-a3eb-e063-6394a90a4829", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3eefb01b-3d6a-a3eb-e063-6394a90a4829", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3eefb01b-3d6a-a3eb-e063-6394a90a4829"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a17ea12f-a420-52db-a471-cd573b13364a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ea41cbe-bc07-4c95-8bb2-7dfc2e96a874", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ea41cbe-bc07-4c95-8bb2-7dfc2e96a874", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ea41cbe-bc07-4c95-8bb2-7dfc2e96a874"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bff7495a-91cf-50c6-a714-2db37a9badd3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2190e8d0-d7ca-4f53-b243-0d2c31979aa8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2190e8d0-d7ca-4f53-b243-0d2c31979aa8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2190e8d0-d7ca-4f53-b243-0d2c31979aa8"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0c39dc0-2aa6-5354-aa60-033f0dba1df9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc7f2af-1eba-3d01-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc7f2af-1eba-3d01-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc7f2af-1eba-3d01-e054-00144ff88e88"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc641da5-df1b-5887-bb70-1527974e969f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6673efde-057a-a889-e053-2a91aa0a517b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6673efde-057a-a889-e053-2a91aa0a517b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6673efde-057a-a889-e053-2a91aa0a517b"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potentially life-threatening condition", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e00a46fd-1c90-5c48-8542-db30648f8ac8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:405b0602-3bb5-531d-b11d-749fbca720d5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "MONDO:0006810", "original_object": "intracranial hypertension", "original_subject": "FLUMAZENIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8117cab2-65ff-326b-e053-2991aa0abb9c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8117cab2-65ff-326b-e053-2991aa0abb9c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8117cab2-65ff-326b-e053-2991aa0abb9c"]}], "subject": "CHEBI:5103", "supporting_text": ["Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "benzodiazepines", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fbc76db-7946-5b75-8efe-b78fbce438bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:daf8f6fe-49b7-563f-bead-270465c1ece3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "UMLS:C0079159", "object_location_in_text": [466, 484], "original_object": "conscious sedation", "original_subject": "FLUMAZENIL", "population_context_qualifier": "Pediatric Patients (aged 1 to 17)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56452ba8-521d-1f84-e063-6294a90af6fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56452ba8-521d-1f84-e063-6294a90af6fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56452ba8-521d-1f84-e063-6294a90af6fc"]}], "subject": "CHEBI:5103", "supporting_text": ["Adult Patients Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17) Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (see PRECAUTIONS, Pediatric Use)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "benzodiazepines", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5a3375e-0973-59f9-8807-9aac4b965ddb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:daf8f6fe-49b7-563f-bead-270465c1ece3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "UMLS:C0079159", "object_location_in_text": [466, 484], "original_object": "conscious sedation", "original_subject": "FLUMAZENIL", "population_context_qualifier": "pediatric patients aged 1 to 17", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=744ef484-ef46-8d62-e053-2a91aa0a0c05"]}], "subject": "CHEBI:5103", "supporting_text": ["Adult Patients Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17) Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (see Precautions: Pediatric Use )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "benzodiazepines", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f301f619-07ed-57c9-9dcb-a883115587d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:daf8f6fe-49b7-563f-bead-270465c1ece3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c511d29-df87-5249-8273-ba7a58c17a26", "object": "UMLS:C0079159", "object_location_in_text": [490, 508], "original_object": "conscious sedation", "original_subject": "FLUMAZENIL", "population_context_qualifier": "Pediatric Patients (aged 1 to 17)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5da455f-3213-ab11-e053-2995a90a54ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5da455f-3213-ab11-e053-2995a90a54ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5da455f-3213-ab11-e053-2995a90a54ee"]}], "subject": "CHEBI:5103", "supporting_text": ["INDICATIONS &amp; USAGE Adult Patients Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17) Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (see PRECAUTIONS, PEDIATRIC USE )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Panic Disorder with or without agoraphobia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25e57c1a-6cdc-5aed-a862-fb327ea01382", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:75230a74-f80c-5f44-8c24-83356ac7e539", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "medic_supporting_text_truncated": true, "object": "MONDO:0005383", "object_location_in_text": [450, 464], "original_object": "Panic Disorder", "original_subject": "FLUOXETINE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58b39e6a-3aae-4551-b081-586a4506aef2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58b39e6a-3aae-4551-b081-586a4506aef2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58b39e6a-3aae-4551-b081-586a4506aef2"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years. ( 1.1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adults and pediatric patients aged 7 to 17 years. ( 1.2 ) Acute and maintenance treatment of Bulimia Nervosa in adult patients. ( 1.3 ) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients. ( 1.4 ) 1.1 Major Depressive Disorder Fluoxetine tablets are indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to 18 years [see Clinical Studies (14.1) ] . The usefulness of the drug in adult and pediatric patients receiving fluoxetine tablets for extended periods should periodically be re-evaluated [see Dosage and Administration (2.1) ] . 1.2 Obsessive Compulsive Disorder Fluoxetine tablets are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . The effectiveness of fluoxetine tablets in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2) ] . 1.3 Bulimia Nervosa Fluoxetine tablets are indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . The physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Adminis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Panic Disorder with or without agoraphobia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e05b7cf-0a4e-554c-936b-9caa64a15490", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:75230a74-f80c-5f44-8c24-83356ac7e539", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "medic_supporting_text_truncated": true, "object": "MONDO:0005383", "object_location_in_text": [450, 464], "original_object": "Panic Disorder", "original_subject": "FLUOXETINE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac1651cc-4a2e-47cf-8a7e-be7ddcaf9f31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac1651cc-4a2e-47cf-8a7e-be7ddcaf9f31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac1651cc-4a2e-47cf-8a7e-be7ddcaf9f31"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years. ( 1.1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adults and pediatric patients aged 7 to 17 years. ( 1.2 ) Acute and maintenance treatment of Bulimia Nervosa in adult patients. ( 1.3 ) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients. ( 1.4 ) 1.1 Major Depressive Disorder Fluoxetine tablets are indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to 18 years [see Clinical Studies (14.1) ] . The usefulness of the drug in adult and pediatric patients receiving fluoxetine tablets for extended periods should periodically be re-evaluated [see Dosage and Administration (2.1) ] . 1.2 Obsessive Compulsive Disorder Fluoxetine tablets are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . The effectiveness of fluoxetine tablets in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2) ] . 1.3 Bulimia Nervosa Fluoxetine tablets are indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . The physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Adminis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0225f5b4-d911-5b2a-bba2-47f19b2b673c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f89a5800-6fdb-4938-a28e-3bf1aeb1c21a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f89a5800-6fdb-4938-a28e-3bf1aeb1c21a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f89a5800-6fdb-4938-a28e-3bf1aeb1c21a"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68f5671b-1ea9-582d-a6c3-df1b4061ccd8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f6ceda3-3edc-4427-98a6-23e3c930c44d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1)] . Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2)] . Olanzapine and fluoxetine capsules combines olanzapine, an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor, indicated for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e894364-03ff-5c93-89d8-05f625cd54c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9d2a503-6ec1-4817-9c8b-235b6f037a19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9d2a503-6ec1-4817-9c8b-235b6f037a19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9d2a503-6ec1-4817-9c8b-235b6f037a19"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:770dad31-13c5-5af7-b50e-e320102f44dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5cdb0d6d-d0cc-4fd9-e063-6394a90a9e0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5cdb0d6d-d0cc-4fd9-e063-6394a90a9e0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5cdb0d6d-d0cc-4fd9-e063-6394a90a9e0f"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:919692fb-d140-5620-9334-6fcd8cea2289", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5fa64a6-3de3-4e2e-8b92-6d507fb8eee9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5fa64a6-3de3-4e2e-8b92-6d507fb8eee9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5fa64a6-3de3-4e2e-8b92-6d507fb8eee9"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7ffffc8-3b79-50d3-9994-79c754c6a53d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7b102f0-17a2-49f7-b898-cb2e0fc71b4d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7b102f0-17a2-49f7-b898-cb2e0fc71b4d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7b102f0-17a2-49f7-b898-cb2e0fc71b4d"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d175f902-5185-5666-8eb6-a56f9ff076c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8666383-462d-4a21-8f49-1d572da386d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8666383-462d-4a21-8f49-1d572da386d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8666383-462d-4a21-8f49-1d572da386d1"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db71c131-2306-5a00-8ae8-7aaa869eb996", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871229", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Olanzapine"], "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f435c67-4e31-55c2-82b3-4f467a9d6d9c", "object": "UMLS:C2063866", "object_location_in_text": [1075, 1105], "original_object": "treatment resistant depression", "original_subject": "FLUOXETINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:851c4cfb-e1f0-4087-b13d-c07c25fea37d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=851c4cfb-e1f0-4087-b13d-c07c25fea37d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=851c4cfb-e1f0-4087-b13d-c07c25fea37d"]}], "subject": "CHEBI:5118", "supporting_text": ["1 INDICATIONS AND USAGE Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . Fluoxetine capsules are a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000815", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4cd07561-703d-56eb-baa5-6e3de07ce3e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000815", "MONDO:0009421"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f9a369c-9c9c-5dd7-a251-592bd0753ee3", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1574b86a-0076-539a-9f3a-27ae347ddd29", "object": "UMLS:C1963961", "original_object": "testosterone deficiency", "original_subject": "FLUOXYMESTERONE", "population_context_qualifier": "male", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09BAFC2D-1893-4618-86DC-E9403407CD41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09BAFC2D-1893-4618-86DC-E9403407CD41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09BAFC2D-1893-4618-86DC-E9403407CD41"]}], "subject": "CHEBI:5120", "supporting_text": ["In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d075b6c-6754-5d71-8029-9ba9146204b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "MONDO:0004979", "object_location_in_text": [402, 408], "original_object": "asthma", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01ea6357-24dc-4056-9fd2-9e643650b91f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01ea6357-24dc-4056-9fd2-9e643650b91f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01ea6357-24dc-4056-9fd2-9e643650b91f"]}], "subject": "CHEBI:51209", "supporting_text": ["Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (MAOI) (see PRECAUTIONS - Drug Interactions ). Antihistamines should not be used to treat lower respiratory tract conditions including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "patients on monoamine oxidase (MAO) inhibitor therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e27aec9-e28d-5dcd-bb19-5fc60c422bda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase (MAO) inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa9d225d-ca19-57d9-8294-28fad9d538b7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "MONDO:0005010", "object_location_in_text": [590, 620], "original_object": "severe coronary artery disease", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10"]}], "subject": "CHEBI:51209", "supporting_text": ["Pseudodine™ C Cough Syrup is contraindicated under the following conditions: Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. Hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS, Drug Interactions )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "patients on monoamine oxidase (MAO) inhibitor therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42a44325-4295-565e-aeee-f396515c67e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase (MAO) inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d036fe90-e61c-585c-868a-ee042b01d8e7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "MONDO:0005044", "object_location_in_text": [569, 588], "original_object": "severe hypertension", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10"]}], "subject": "CHEBI:51209", "supporting_text": ["Pseudodine™ C Cough Syrup is contraindicated under the following conditions: Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. Hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS, Drug Interactions )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68d65910-33bd-5e63-ae57-40f02c545352", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "HP:0012735", "object_location_in_text": [254, 259], "original_object": "cough", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf3886ab-62b3-497a-a587-18cbfbaf3634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf3886ab-62b3-497a-a587-18cbfbaf3634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf3886ab-62b3-497a-a587-18cbfbaf3634"]}], "subject": "CHEBI:51209", "supporting_text": ["Uses temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: runny nose sneezing itching of the nose or throat itchy, watery eyes nasal congestion reduces swelling of nasal passages cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ccaf9cb7-00a7-5ab6-9668-12aca2d6c31b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "HP:0012735", "object_location_in_text": [101, 106], "original_object": "cough", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6"]}], "subject": "CHEBI:51209", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation minor aches &amp; pains headache fever sore throat reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012735", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5299f84a-9cfb-50eb-9342-6abdbfd116dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:01ab355d-f1c2-563d-8bb3-590576c130de", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "HP:0031245", "original_object": "productive cough", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:657aeccc-4f6a-496b-9a69-e64a81e4c91e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=657aeccc-4f6a-496b-9a69-e64a81e4c91e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=657aeccc-4f6a-496b-9a69-e64a81e4c91e"]}], "subject": "CHEBI:51209", "supporting_text": ["Uses • helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive • temporarily relieves nasal congestion due to: • common cold • hay fever • upper respiratory allergies • temporarily restores freer breathing through the nose • promotes nasal and/or sinus drainage • temporarily relieves sinus congestion and pressure"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:081b9746-86b6-544c-8fae-0712b346d11d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "MONDO:0005324", "object_location_in_text": [48, 57], "original_object": "hay fever", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26f2c3c1-a2f2-474a-950a-8cfe07f289fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26f2c3c1-a2f2-474a-950a-8cfe07f289fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26f2c3c1-a2f2-474a-950a-8cfe07f289fa"]}], "subject": "CHEBI:51209", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat nasal congestion reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1d435d2-6546-5ae6-8ca6-6139d6cb561e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "MONDO:0005324", "object_location_in_text": [50, 59], "original_object": "hay fever", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2"]}], "subject": "CHEBI:51209", "supporting_text": ["Uses • temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • sneezing • itchy, watery eyes • runny nose • itching of the nose or throat • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies • reduces swelling of nasal passages • temporarily relieves sinus congestion and pressure • temporarily restores freer breathing through the nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001742", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03623c5b-0dd9-5b45-8363-2e60a1cc511d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001742"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:69b8fdec-ba2c-536a-a04a-4a4652f2b40b", "object": "MONDO:0005709", "object_location_in_text": [226, 237], "original_object": "common cold", "original_subject": "PSEUDOEPHEDRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2"]}], "subject": "CHEBI:51209", "supporting_text": ["Uses • temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • sneezing • itchy, watery eyes • runny nose • itching of the nose or throat • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies • reduces swelling of nasal passages • temporarily relieves sinus congestion and pressure • temporarily restores freer breathing through the nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2be4c81a-7347-554c-a4f1-c141202f6d52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c9fa4aa7-bc0f-565c-b362-92992d8833b1", "object": "HP:0012735", "original_object": "cough", "original_subject": "DOXYLAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4d38921-ec90-0658-e053-2a95a90a848a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4d38921-ec90-0658-e053-2a95a90a848a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4d38921-ec90-0658-e053-2a95a90a848a"]}], "subject": "CHEBI:51380", "supporting_text": ["Uses temporarily relieves cold symptoms: • nasal congestion • sinus congestion &amp; pressure • cough due to minor throat &amp; bronchial irritation • cough to help you sleep • runny nose &amp; sneezing • reduces swelling of nasal passages • temporarily restores freer breathing through the nose • promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fb45c3a-a1b6-5cb7-ae92-11a8dfa74726", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c9fa4aa7-bc0f-565c-b362-92992d8833b1", "object": "HP:0012735", "object_location_in_text": [101, 106], "original_object": "cough", "original_subject": "DOXYLAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6"]}], "subject": "CHEBI:51380", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation minor aches &amp; pains headache fever sore throat reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a906a653-b6d6-5417-aaaf-a4ebe481b679", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c9fa4aa7-bc0f-565c-b362-92992d8833b1", "object": "HP:0012735", "original_object": "cough", "original_subject": "DOXYLAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1"]}], "subject": "CHEBI:51380", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation cough to help you sleep minor aches &amp; pains headache fever sore throat runny nose &amp; sneezing reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "idiopathic or congenital PAH", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afaf9b9a-54a3-5282-b2b9-661e87bd792e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b1109275-038c-5c39-9ef9-2c05d0575bb6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92a4080e-e526-5ff7-afef-bb39932ad1c6", "object": "UMLS:C0456261", "original_object": "pulmonary vascular resistance", "original_subject": "BOSENTAN", "population_context_qualifier": "pediatric patients aged 3 years and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c006d8ef-8cb7-4fb3-88eb-b2debc302a20", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c006d8ef-8cb7-4fb3-88eb-b2debc302a20", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c006d8ef-8cb7-4fb3-88eb-b2debc302a20"]}], "subject": "CHEBI:51450", "supporting_text": ["1 INDICATIONS AND USAGE Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1)] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) (1). in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability (1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "idiopathic or congenital PAH", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7587d85-716f-5ff2-96a1-7028a5648814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b1109275-038c-5c39-9ef9-2c05d0575bb6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92a4080e-e526-5ff7-afef-bb39932ad1c6", "object": "UMLS:C0456261", "original_object": "pulmonary vascular resistance", "original_subject": "BOSENTAN", "population_context_qualifier": "pediatric patients aged 3 years and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:749e42fb-2fe0-45dd-9268-b43bb3f4081c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=749e42fb-2fe0-45dd-9268-b43bb3f4081c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=749e42fb-2fe0-45dd-9268-b43bb3f4081c"]}], "subject": "CHEBI:51450", "supporting_text": ["1 INDICATIONS AND USAGE TRACLEER is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) ] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. TRACLEER is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) ( 1 ). in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "idiopathic or congenital PAH", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ccae6612-880a-5f86-9b8e-60bbfe87df47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b1109275-038c-5c39-9ef9-2c05d0575bb6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92a4080e-e526-5ff7-afef-bb39932ad1c6", "object": "UMLS:C0456261", "original_object": "pulmonary vascular resistance", "original_subject": "BOSENTAN", "population_context_qualifier": "pediatric patients aged 3 years and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:540b6f6a-79f3-4681-8c2a-268cf7cecbc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=540b6f6a-79f3-4681-8c2a-268cf7cecbc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=540b6f6a-79f3-4681-8c2a-268cf7cecbc9"]}], "subject": "CHEBI:51450", "supporting_text": ["1. INDICATIONS AND USAGE Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) ] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) ( 1 ). in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "idiopathic or congenital PAH", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9918d05-cac1-54f9-90d9-2a6fa75cb9f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ed0b935-c4f7-55f6-b02d-1c97780cfa6b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92a4080e-e526-5ff7-afef-bb39932ad1c6", "object": "MONDO:0015924", "original_object": "pulmonary arterial hypertension", "original_subject": "BOSENTAN", "population_context_qualifier": "pediatric patients aged 3 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c006d8ef-8cb7-4fb3-88eb-b2debc302a20", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c006d8ef-8cb7-4fb3-88eb-b2debc302a20", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c006d8ef-8cb7-4fb3-88eb-b2debc302a20"]}], "subject": "CHEBI:51450", "supporting_text": ["1 INDICATIONS AND USAGE Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1)] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) (1). in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability (1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "Use without an inhaled corticosteroid", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12e52576-199c-5039-8e3b-f25bd2828656", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010216", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ec71b57d-7b69-51ed-9ac3-659078260da3", "object": "MONDO:0004979", "original_object": "asthma", "original_subject": "FORMOTEROL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:303479a7-80fb-1f6d-e063-6394a90abbda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=303479a7-80fb-1f6d-e063-6394a90abbda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=303479a7-80fb-1f6d-e063-6394a90abbda"]}], "subject": "CHEBI:5147", "supporting_text": ["4 CONTRAINDICATIONS Use of a long-acting beta 2 -adrenergic agonists (LABA), including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see WARNINGS and PRECAUTIONS ( 5.1 )] . Formoterol fumarate inhalation solution is not indicated for the treatment of asthma. Use of a long-acting beta 2 -agonist (LABA), including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3808875", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:998f7c85-9f2c-5056-900b-d2ff7a77fe75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3808875"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:291198cb-ef21-5f69-9da3-a0f430513ea4", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:4c374d1f-9c8a-5d70-8128-148d6c2a3c71", "object": "MONDO:0005277", "original_object": "migraine", "original_subject": "Almotriptan Tablet 6.25mg/12.5mg", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:520985", "supporting_text": ["For acute treatment of migraine attacks with a history of migraine with or without aura in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to dutasteride or other 5 alpha-reductase inhibitors", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fc79429-12f7-55b4-9bb5-2ef096f13674", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b41cae8-5d84-5b8c-9add-bcf60ddeb998", "object": "MONDO:0010481", "object_location_in_text": [217, 227], "original_object": "angioedema", "original_subject": "DUTASTERIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c78d18cf-05df-4154-b2f9-39cc374ca9e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c78d18cf-05df-4154-b2f9-39cc374ca9e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c78d18cf-05df-4154-b2f9-39cc374ca9e3"]}], "subject": "CHEBI:521033", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy. Dutasteride use is contraindicated in women who are pregnant. (4, 5.4, 8.1) Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride capsules or other 5 alpha-reductase inhibitors. (4) Dutasteride is contraindicated for use in: Pregnancy. Dutasteride use is contraindicated in women who are pregnant. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, dutasteride may cause fetal harm when administered to a pregnant woman [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)] . Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2)] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "clinically significant hypersensitivity to dutasteride or other 5 alpha-reductase inhibitors", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9ea8b36-8517-5f86-a864-a4c816a171f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011120", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b41cae8-5d84-5b8c-9add-bcf60ddeb998", "object": "MONDO:0010481", "object_location_in_text": [887, 897], "original_object": "angioedema", "original_subject": "DUTASTERIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:908832b2-21d6-48ae-89cb-f06687321f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=908832b2-21d6-48ae-89cb-f06687321f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=908832b2-21d6-48ae-89cb-f06687321f74"]}], "subject": "CHEBI:521033", "supporting_text": ["4 CONTRAINDICATIONS Dutasteride is contraindicated for use in: • Pregnancy. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, dutasteride may cause fetal harm when administered to a pregnant woman. If dutasteride is used during pregnancy or if the patient becomes pregnant while taking dutasteride, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.4), Use in Specific Populations ( Error! Hyperlink reference not valid. )] . • Women of childbearing potential [see Warnings and Precautions ( 5.4 ), Use in Specific Populations ( Error! Hyperlink reference not valid. )] . • Pediatric patients [see Use in Specific Populations ( 8.4 )] . • Patients with previously demonstrated clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions ( 6.2 )] . • Pregnancy and women of childbearing potential. ( 4 , 5.4 , 8.1 ) • Pediatric patients. ( 4 ) • Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior therapy including imatinib", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81904d77-d6ab-5151-9b53-293c0862ebe2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071119", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7effd00e-340f-518c-9824-e33e5f09be51", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c8a2e99d-d755-50bc-9b54-75a6ab6e23f9", "object": "MONDO:0011996", "original_object": "Philadelphia chromosome positive chronic myelogenous leukaemia", "original_subject": "nilotinib", "population_context_qualifier": "paediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nilotinib-accord", "https://www.ema.europa.eu/en/documents/product-information/nilotinib-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nilotinib-accord"]}], "subject": "CHEBI:52172", "supporting_text": ["Nilotinib Accord is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, - adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, - paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior therapy including imatinib", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b113ee84-debe-598e-9b25-55e993c64d33", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071119", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7effd00e-340f-518c-9824-e33e5f09be51", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c8a2e99d-d755-50bc-9b54-75a6ab6e23f9", "object": "MONDO:0011996", "original_object": "Philadelphia chromosome positive chronic myelogenous leukaemia", "original_subject": "nilotinib", "population_context_qualifier": "paediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tasigna", "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna"]}], "subject": "CHEBI:52172", "supporting_text": ["Tasigna is indicated for the treatment of:  adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.  Tasigna is indicated for the treatment of:  adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase, adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available, paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bc948ce-582e-5910-9864-4727aabdcd56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071029", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c8a2e99d-d755-50bc-9b54-75a6ab6e23f9", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "NILOTINIB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288d165-3505-49bb-9b2e-124490d65f49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288d165-3505-49bb-9b2e-124490d65f49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288d165-3505-49bb-9b2e-124490d65f49"]}], "subject": "CHEBI:52172", "supporting_text": ["1 INDICATIONS AND USAGE DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) 1.1 Adult Patients with Newly Diagnosed Ph+ CML-CP DANZITEN is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Adult Patients with Resistant or Intolerant Ph+ CML-CP and CML-AP DANZITEN is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "resistant or intolerant to prior tyrosine-kinase inhibitor therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa30aae7-052e-595e-83bd-ea11c84a5519", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071029", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c8a2e99d-d755-50bc-9b54-75a6ab6e23f9", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "NILOTINIB", "population_context_qualifier": "Pediatric patients greater than or equal to 1 year of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e"]}], "subject": "CHEBI:52172", "supporting_text": ["1 INDICATIONS AND USAGE Nilotinib is a kinase inhibitor indicated for the treatment of: • Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) • Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. ( 1.3 ) 1.1 Adult and Pediatric Patients With Newly Diagnosed Ph+ CML-CP Nilotinib capsules are indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Adult Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Nilotinib capsules are indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. 1.3 Pediatric Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Nilotinib capsules are indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "imatinib resistance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59d25486-2f73-5427-a4d9-6a28c4a97cfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090121", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:43933201-b655-54a7-89ce-79bd5342013a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a743d99a-61c6-5ad1-827d-c8a83de0f363", "object": "MONDO:0011996", "object_location_in_text": [129, 157], "original_object": "chronic myelogenous leukemia", "original_subject": "NILOTINIB HYDROCHLORIDE HYDRATE", "population_context_qualifier": "patients with chronic phase and accelerated phase disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NILOTINIB HYDROCHLORIDE HYDRATE#175-20090121", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:52172", "supporting_text": ["A drug containing a new active ingredient indicated for the treatment of imatinib-resistant, chronic phase and accelerated phase chronic myelogenous leukemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0020480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:335153db-6998-566a-8a00-b4fb14d42d81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0020480", "MONDO:0007762"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b3f4ef8e-3454-5bb5-8884-af63f1b6982a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2445d78-74a1-5936-a062-b1f92ee80ef6", "medic_supporting_text_truncated": true, "object": "MONDO:0004982", "object_location_in_text": [211, 223], "original_object": "pancreatitis", "original_subject": "GEMFIBROZIL", "population_context_qualifier": "subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e9e08da-9700-4934-a2b1-4f64c70ea8a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e9e08da-9700-4934-a2b1-4f64c70ea8a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e9e08da-9700-4934-a2b1-4f64c70ea8a2"]}], "subject": "CHEBI:5296", "supporting_text": ["Gemfibrozil Tablets, USP are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated trig"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0020480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:777dac1c-8de5-5572-b86d-a6351b041c31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0020480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b3f4ef8e-3454-5bb5-8884-af63f1b6982a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2445d78-74a1-5936-a062-b1f92ee80ef6", "medic_supporting_text_truncated": true, "object": "MONDO:0004982", "object_location_in_text": [209, 221], "original_object": "pancreatitis", "original_subject": "GEMFIBROZIL", "population_context_qualifier": "subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a95264ab-eb86-7699-e053-2995a90a3d1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a95264ab-eb86-7699-e053-2995a90a3d1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a95264ab-eb86-7699-e053-2995a90a3d1f"]}], "subject": "CHEBI:5296", "supporting_text": ["Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated tri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0020480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77ef3f6e-5eb6-5c46-b386-73f5efd30779", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0020480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b3f4ef8e-3454-5bb5-8884-af63f1b6982a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2445d78-74a1-5936-a062-b1f92ee80ef6", "medic_supporting_text_truncated": true, "object": "MONDO:0004982", "object_location_in_text": [209, 221], "original_object": "pancreatitis", "original_subject": "GEMFIBROZIL", "population_context_qualifier": "subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5501438d-5247-4f2a-8e15-085276d01725", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5501438d-5247-4f2a-8e15-085276d01725", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5501438d-5247-4f2a-8e15-085276d01725"]}], "subject": "CHEBI:5296", "supporting_text": ["Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated tri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0020480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be0e5487-65f2-5e77-a8ea-0039b4b75629", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0020480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b3f4ef8e-3454-5bb5-8884-af63f1b6982a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2445d78-74a1-5936-a062-b1f92ee80ef6", "medic_supporting_text_truncated": true, "object": "MONDO:0004982", "object_location_in_text": [209, 221], "original_object": "pancreatitis", "original_subject": "GEMFIBROZIL", "population_context_qualifier": "subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4260d746-bb58-4e10-9ffe-fc414f22b591", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4260d746-bb58-4e10-9ffe-fc414f22b591", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4260d746-bb58-4e10-9ffe-fc414f22b591"]}], "subject": "CHEBI:5296", "supporting_text": ["Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated tri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0020480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eeea75ae-4571-5bd7-8d98-b068218c34fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0020480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b3f4ef8e-3454-5bb5-8884-af63f1b6982a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2445d78-74a1-5936-a062-b1f92ee80ef6", "medic_supporting_text_truncated": true, "object": "MONDO:0004982", "object_location_in_text": [209, 221], "original_object": "pancreatitis", "original_subject": "GEMFIBROZIL", "population_context_qualifier": "subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:509e6e7c-bb54-f135-e063-6294a90a5279", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=509e6e7c-bb54-f135-e063-6294a90a5279", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=509e6e7c-bb54-f135-e063-6294a90a5279"]}], "subject": "CHEBI:5296", "supporting_text": ["Gemfibrozil Tablets are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated tri"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "low HDL-cholesterol levels, elevated LDL-cholesterol, elevated triglycerides", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1679863-24db-5363-9856-6ef7ef32ec8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ac3210c-1617-53fa-a341-8c047a7e672d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2445d78-74a1-5936-a062-b1f92ee80ef6", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1530, 1552], "original_object": "coronary heart disease", "original_subject": "GEMFIBROZIL", "population_context_qualifier": "Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c48855b7-215e-453b-b3b1-a0f9dee7221f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c48855b7-215e-453b-b3b1-a0f9dee7221f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c48855b7-215e-453b-b3b1-a0f9dee7221f"]}], "subject": "CHEBI:5296", "supporting_text": ["LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. LOPID therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of LOPID therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglyce"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002157", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:893a7886-547e-503b-9311-66a5b0f412e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002157"], "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c1a7f82-9ca4-58a0-9961-72a0f1b7b8ac", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62ddc123-b447-51b6-a7f5-ce2fad54f3e5", "object": "HP:0001944", "original_object": "dehydration", "original_subject": "DIATRIZOATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0AAAA03E-B258-45EC-89C8-06E1353F57EF", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0AAAA03E-B258-45EC-89C8-06E1353F57EF", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0AAAA03E-B258-45EC-89C8-06E1353F57EF"]}], "subject": "CHEBI:53691", "supporting_text": ["—General HYPAQUE-76 has no absolute contraindications in its recommended uses (see general WARNINGS and PRECAUTIONS ). Do not use HYPAQUE-76 for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. Even a small amount in the subarachnoid space may produce convulsions and result in fatality. (See also AORTOGRAPHY, Warnings. ) Epidural injection is also contraindicated. HYPAQUE-76 should not be injected directly into the carotid, vertebral, or spinal arteries. HYPAQUE-76 is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid. Urography is contraindicated in patients with anuria. Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also PRECAUTIONS—General. )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0001944", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a9b81e3-ba99-5b88-84bc-20018db0b65a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001944"], "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b008eb06-4d70-5285-9b91-b13064630436", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62ddc123-b447-51b6-a7f5-ce2fad54f3e5", "object": "HP:0002157", "original_object": "azotemia", "original_subject": "DIATRIZOATE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0AAAA03E-B258-45EC-89C8-06E1353F57EF", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0AAAA03E-B258-45EC-89C8-06E1353F57EF", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0AAAA03E-B258-45EC-89C8-06E1353F57EF"]}], "subject": "CHEBI:53691", "supporting_text": ["—General HYPAQUE-76 has no absolute contraindications in its recommended uses (see general WARNINGS and PRECAUTIONS ). Do not use HYPAQUE-76 for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. Even a small amount in the subarachnoid space may produce convulsions and result in fatality. (See also AORTOGRAPHY, Warnings. ) Epidural injection is also contraindicated. HYPAQUE-76 should not be injected directly into the carotid, vertebral, or spinal arteries. HYPAQUE-76 is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid. Urography is contraindicated in patients with anuria. Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also PRECAUTIONS—General. )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0242339", "has_confidence_score": 0.49, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08fb4ebd-577c-5c03-9455-3be01e9a678c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091217", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242339"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:913ab761-6c00-5cb1-bf9d-cd0f5cd875e9", "medic_pair_confidence": 0.49, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:46b12bd5-12da-5510-8b92-569b97976c0b", "object": "MONDO:0005148", "object_location_in_text": [21, 46], "original_object": "type II diabetes mellitus", "original_subject": "Glimepiride 1/2 mg + Metformin 500 mg + Atorvastatin 10 mg tablets", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:5383", "supporting_text": ["For the treatment of type II diabetes mellitus associated with dyslipidemia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C3495917", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b6c30ff-dbd0-5da0-af8b-630be0102058", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3495917"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28659be0-c5e8-5cb7-9830-fe38dabc726f", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "GOSERELIN", "population_context_qualifier": "pregnant women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a906a5bd-d2ec-4e35-8962-c0c86c637630", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a906a5bd-d2ec-4e35-8962-c0c86c637630", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a906a5bd-d2ec-4e35-8962-c0c86c637630"]}], "subject": "CHEBI:5523", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity ( 4.1 ) Pregnancy unless used for treatment of advanced breast cancer ( 4.2 ) 4.1 Hypersensitivity Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in those patients who have a known hypersensitivity to GnRH, GnRH agonist analogues or any of the components in ZOLADEX [see Warnings and Precautions ( 5.6 )]. 4.2 Pregnancy ZOLADEX is contraindicated during pregnancy unless ZOLADEX is being used for palliative treatment of advanced breast cancer. ZOLADEX can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormone changes that occur with ZOLADEX treatment [see Use in Specific Populations ( 8.1 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C3495917", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ca5dae3-5f04-58b4-a719-9d92ba4480cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3495917"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28659be0-c5e8-5cb7-9830-fe38dabc726f", "object": "UMLS:C0032961", "original_object": "pregnancy", "original_subject": "GOSERELIN", "population_context_qualifier": "pregnant women", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:294b168b-6e5f-4db9-bf70-d599271458b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3"]}], "subject": "CHEBI:5523", "supporting_text": ["4 CONTRAINDICATIONS Hypersensitivity ( 4.1 ) Pregnancy unless used for treatment of advanced breast cancer ( 4.2 ) 4.1 Hypersensitivity Anaphylactic reactions to ZOLADEX have been reported in the medical literature. ZOLADEX is contraindicated in those patients who have a known hypersensitivity to GnRH, GnRH agonist analogues or any of the components in ZOLADEX [see Warnings and Precautions ( 5.6 )]. 4.2 Pregnancy ZOLADEX is contraindicated during pregnancy unless ZOLADEX is being used for palliative treatment of advanced breast cancer. ZOLADEX can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, the patient should be apprised of the potential hazard to the fetus. There is an increased risk for pregnancy loss due to expected hormone changes that occur with ZOLADEX treatment [see Use in Specific Populations ( 8.1 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3495917", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2661ec5a-7c55-512c-9a9d-1d3758de6f07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3495917"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28659be0-c5e8-5cb7-9830-fe38dabc726f", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [466, 479], "original_object": "breast cancer", "original_subject": "GOSERELIN", "population_context_qualifier": "pre- and perimenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a906a5bd-d2ec-4e35-8962-c0c86c637630", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a906a5bd-d2ec-4e35-8962-c0c86c637630", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a906a5bd-d2ec-4e35-8962-c0c86c637630"]}], "subject": "CHEBI:5523", "supporting_text": ["1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pha"], "temporal_context_qualifier": "palliative treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3495917", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2d2bd03-9a30-5d48-8c28-8ee4af52ef89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3495917"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:28659be0-c5e8-5cb7-9830-fe38dabc726f", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [466, 479], "original_object": "breast cancer", "original_subject": "GOSERELIN", "population_context_qualifier": "pre- and perimenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:294b168b-6e5f-4db9-bf70-d599271458b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3"]}], "subject": "CHEBI:5523", "supporting_text": ["1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women. The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial [see Dosage and Administration ( 2.5 ), Clinical Pha"], "temporal_context_qualifier": "palliative treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8dbda438-5ce9-5365-9221-cb82f4ce016f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830915", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483", "UMLS:C0038410"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fc2cbb0f-c8ad-541f-bed3-a57d9f116eff", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "CEFTIZOXIME", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0013824B-6AEE-4DA4-AFFD-35BC6BF19D91", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0013824B-6AEE-4DA4-AFFD-35BC6BF19D91", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0013824B-6AEE-4DA4-AFFD-35BC6BF19D91"]}], "subject": "CHEBI:553473", "supporting_text": ["Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphyloco"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0013217", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1474d638-7a79-5258-92cd-327a6e6f16d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120420", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0013217"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [25, 33], "original_object": "vomiting", "original_subject": "granisetron", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sancuso", "https://www.ema.europa.eu/en/documents/product-information/sancuso-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso"]}], "subject": "CHEBI:5537", "supporting_text": ["Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy."], "temporal_context_qualifier": "for up to five consecutive days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b18e723-9dcc-5362-acc6-b7ea8ede6253", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [154, 162], "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af68579f-c863-4535-94af-a4126b43c182", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af68579f-c863-4535-94af-a4126b43c182", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af68579f-c863-4535-94af-a4126b43c182"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:494d04c4-9705-550a-b4a0-7122609f494a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [155, 163], "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:783e9d68-2371-4fd4-8d7a-a5e36f8718d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=783e9d68-2371-4fd4-8d7a-a5e36f8718d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=783e9d68-2371-4fd4-8d7a-a5e36f8718d0"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection, is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Granisetron hydrochloride injection, is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 ) Prevention and treatment of postoperative nausea and vomiting in adults. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5066fa1a-7ffe-5ef7-aafb-bb3ace4b3470", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [154, 162], "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a43da9a3-1997-40d9-8622-97490a5c0642", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a43da9a3-1997-40d9-8622-97490a5c0642", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a43da9a3-1997-40d9-8622-97490a5c0642"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f4f36d9-8a0f-56e9-92e9-b80b36914785", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [154, 162], "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb723c47-002e-4243-9c5e-448f5cfd6d68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb723c47-002e-4243-9c5e-448f5cfd6d68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb723c47-002e-4243-9c5e-448f5cfd6d68"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac7ec377-6fdc-5d48-8d71-87568f789728", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["high-dose cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d88adba-7f5e-4e97-84b3-6ca8ec98c023", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d88adba-7f5e-4e97-84b3-6ca8ec98c023", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d88adba-7f5e-4e97-84b3-6ca8ec98c023"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: • The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. • The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Granisetron hydrochloride injection is a serotonin-3 (5-HT3) receptor antagonist indicated for: • Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 ) • Prevention and treatment of postoperative nausea and vomiting in adults. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d976ccc1-0d59-5118-8add-be34485ba4d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [159, 167], "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02f350c9-b7d2-4906-af28-70ed4461ff23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02f350c9-b7d2-4906-af28-70ed4461ff23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02f350c9-b7d2-4906-af28-70ed4461ff23"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc6380c5-7bf2-599f-904a-5e82e00d1a32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002013", "object_location_in_text": [159, 167], "original_object": "vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e07862df-f324-4575-a1ef-f7e1cbab4c7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e07862df-f324-4575-a1ef-f7e1cbab4c7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e07862df-f324-4575-a1ef-f7e1cbab4c7a"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851346", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11fcc5ea-37b3-591a-8067-1b8d2f431730", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0851346"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65d31bc7-c6a6-4515-8e3a-93e0754540b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65d31bc7-c6a6-4515-8e3a-93e0754540b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65d31bc7-c6a6-4515-8e3a-93e0754540b2"]}], "subject": "CHEBI:5537", "supporting_text": ["INDICATIONS &amp; USAGE Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic chemotherapy, anthracycline and cyclophosphamide combination chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:569570d1-706f-571a-8e79-92f41ba0f21c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetics"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "GRANISETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7c7ffdd-8270-4030-bc1e-a1cb28a6de56", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7c7ffdd-8270-4030-bc1e-a1cb28a6de56", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7c7ffdd-8270-4030-bc1e-a1cb28a6de56"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851346", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b3aaa59-cc3c-5009-8d47-9dc18f64aa7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0851346"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2758eb4d-2fe0-4f74-b3f5-b4903009e97c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2758eb4d-2fe0-4f74-b3f5-b4903009e97c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2758eb4d-2fe0-4f74-b3f5-b4903009e97c"]}], "subject": "CHEBI:5537", "supporting_text": ["Granisetron is indicated for the prevention of: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0013217", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07242082-d7ff-5384-a43d-0e3250abef39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120420", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0013217"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [14, 20], "original_object": "nausea", "original_subject": "granisetron", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sancuso", "https://www.ema.europa.eu/en/documents/product-information/sancuso-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso"]}], "subject": "CHEBI:5537", "supporting_text": ["Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy."], "temporal_context_qualifier": "for up to five consecutive days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:184987e6-8b03-5acc-8962-ae5b5e913246", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [141, 147], "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:783e9d68-2371-4fd4-8d7a-a5e36f8718d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=783e9d68-2371-4fd4-8d7a-a5e36f8718d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=783e9d68-2371-4fd4-8d7a-a5e36f8718d0"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection, is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Granisetron hydrochloride injection, is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 ) Prevention and treatment of postoperative nausea and vomiting in adults. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e74ce58-4c43-5384-b30d-10b5df719915", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [140, 146], "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a43da9a3-1997-40d9-8622-97490a5c0642", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a43da9a3-1997-40d9-8622-97490a5c0642", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a43da9a3-1997-40d9-8622-97490a5c0642"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:562e94d0-8d63-5680-9d30-c63442810f6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [145, 151], "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e07862df-f324-4575-a1ef-f7e1cbab4c7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e07862df-f324-4575-a1ef-f7e1cbab4c7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e07862df-f324-4575-a1ef-f7e1cbab4c7a"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6579f997-204c-5356-94ab-00bf316ff02a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [145, 151], "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02f350c9-b7d2-4906-af28-70ed4461ff23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02f350c9-b7d2-4906-af28-70ed4461ff23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02f350c9-b7d2-4906-af28-70ed4461ff23"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c364f50-ac41-5cab-ab91-1fbd46ea3c05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["high-dose cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d88adba-7f5e-4e97-84b3-6ca8ec98c023", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d88adba-7f5e-4e97-84b3-6ca8ec98c023", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d88adba-7f5e-4e97-84b3-6ca8ec98c023"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: • The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. • The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Granisetron hydrochloride injection is a serotonin-3 (5-HT3) receptor antagonist indicated for: • Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. ( 1 ) • Prevention and treatment of postoperative nausea and vomiting in adults. ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a727909c-af45-5e7e-9a6d-bbff014fdc66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [140, 146], "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb723c47-002e-4243-9c5e-448f5cfd6d68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb723c47-002e-4243-9c5e-448f5cfd6d68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb723c47-002e-4243-9c5e-448f5cfd6d68"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8f04cf6-21ea-52c5-8502-a6b9aa16a4e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "HP:0002018", "object_location_in_text": [140, 146], "original_object": "nausea", "original_subject": "GRANISETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af68579f-c863-4535-94af-a4126b43c182", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af68579f-c863-4535-94af-a4126b43c182", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af68579f-c863-4535-94af-a4126b43c182"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE Granisetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic chemotherapy, anthracycline and cyclophosphamide combination chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a412ed22-3b65-5273-b4c7-4c9ef113dd5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931229", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetics"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5a216f75-9fc2-5f4a-a05d-3c42e5fce369", "object": "UMLS:C3830545", "object_location_in_text": [124, 151], "original_object": "delayed nausea and vomiting", "original_subject": "GRANISETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7c7ffdd-8270-4030-bc1e-a1cb28a6de56", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7c7ffdd-8270-4030-bc1e-a1cb28a6de56", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7c7ffdd-8270-4030-bc1e-a1cb28a6de56"]}], "subject": "CHEBI:5537", "supporting_text": ["1 INDICATIONS AND USAGE SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0015333", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:987a1836-d18e-5d88-b13f-58c371b86e20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0015333"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:686d9d32-63e7-5e2f-8c51-08b761bded56", "object": "HP:0002013", "object_location_in_text": [98, 106], "original_object": "vomiting", "original_subject": "GRANISETRON HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:GRANISETRON HYDROCHLORIDE#144-20111222", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:5537", "supporting_text": ["Drugs with a new additional indication for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with radiation. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0015333", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ae2f42b-d179-5450-ae3c-7cb40d93dac7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111222", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0015333"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:686d9d32-63e7-5e2f-8c51-08b761bded56", "object": "HP:0002018", "object_location_in_text": [87, 93], "original_object": "nausea", "original_subject": "GRANISETRON HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:GRANISETRON HYDROCHLORIDE#144-20111222", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:5537", "supporting_text": ["Drugs with a new additional indication for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with radiation. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5639ccc9-6017-55f6-a188-2605127bc4f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "HP:0012735", "object_location_in_text": [26, 31], "original_object": "cough", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f496c61-41a6-41ba-80f5-7a5309c4d18b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f496c61-41a6-41ba-80f5-7a5309c4d18b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f496c61-41a6-41ba-80f5-7a5309c4d18b"]}], "subject": "CHEBI:5551", "supporting_text": ["Uses temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes"], "temporal_context_qualifier": "as may occur with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dba1150-0b3a-5b5d-b280-ef7c30594638", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "HP:0012735", "object_location_in_text": [27, 32], "original_object": "cough", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:98f8bf79-825d-c04d-0edd-826d4752736d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=98f8bf79-825d-c04d-0edd-826d4752736d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=98f8bf79-825d-c04d-0edd-826d4752736d"]}], "subject": "CHEBI:5551", "supporting_text": ["Uses Temporarily relieves: cough due to minor throat and bronchial irritation helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes and make coughs more productive"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8190e19-b2d3-542a-b994-c2f9d04d3c3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "HP:0012735", "object_location_in_text": [48, 53], "original_object": "cough", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:5551", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549313", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffa7347f-21e4-5668-9707-4639122470be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "HP:0012735", "object_location_in_text": [101, 106], "original_object": "cough", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1cbe58-f5a2-c96e-e063-6294a90a74e6"]}], "subject": "CHEBI:5551", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation minor aches &amp; pains headache fever sore throat reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "phlegm accumulation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:767712a5-7c3b-5466-91b9-6f4c4d4708fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090516", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:01ab355d-f1c2-563d-8bb3-590576c130de", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:badb6c70-a3a2-513c-8c4a-9cb0a454495e", "object": "HP:0031245", "object_location_in_text": [21, 37], "original_object": "productive cough", "original_subject": "Guaiphenesin ER Tablet 1200mg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:5551", "supporting_text": ["For the treatment of productive cough accompanied by Phlegm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012735", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf8996a2-1dd8-5bdc-8d17-1f23d3940147", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012735"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:01ab355d-f1c2-563d-8bb3-590576c130de", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "HP:0031245", "original_object": "productive cough", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:657aeccc-4f6a-496b-9a69-e64a81e4c91e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=657aeccc-4f6a-496b-9a69-e64a81e4c91e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=657aeccc-4f6a-496b-9a69-e64a81e4c91e"]}], "subject": "CHEBI:5551", "supporting_text": ["Uses • helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive • temporarily relieves nasal congestion due to: • common cold • hay fever • upper respiratory allergies • temporarily restores freer breathing through the nose • promotes nasal and/or sinus drainage • temporarily relieves sinus congestion and pressure"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031245", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff8ede39-029e-5c5e-adc5-60d59e0b9f2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031245"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "MONDO:0003781", "original_object": "bronchitis", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e"]}], "subject": "CHEBI:5551", "supporting_text": ["DAY Uses ■ temporarily relieves these common cold and flu symptoms: ■ minor aches and pains ■ headache ■ sore throat ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily reduces fever NIGHT Uses ■ temporarily relieves these common cold and flu symptoms: ■ cough ■ minor aches and pains ■ sore throat ■ headache ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes due to hay fever ■ temporarily reduces fever ■ controls cough to help you get to sleep SPRAY Uses temporarily relieves nasal congestion due to: a cold hay fever or other upper respiratory allergies promotes nasal and sinus drainage temporarily relieves sinus congestion and pressure helps clear nasal passages; shrinks swollen membranes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e1c31b1d-2917-5539-80c4-86a9f9bf48b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "MONDO:0005709", "object_location_in_text": [26, 37], "original_object": "common cold", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:5551", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stable chronic bronchitis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5bf0ce9-c5c1-5e11-8c80-92ba8819670f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020712", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5e07d483-e931-5a34-a78e-fb7a1046e84c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:faf8716c-35b7-5d2d-942d-6909113527d5", "object": "UMLS:C0225378", "original_object": "phlegm", "original_subject": "GUAIFENESIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:78987a51-82f7-4ca6-80ad-fa22d1f3e11a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=78987a51-82f7-4ca6-80ad-fa22d1f3e11a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=78987a51-82f7-4ca6-80ad-fa22d1f3e11a"]}], "subject": "CHEBI:5551", "supporting_text": ["Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes and make coughs more productive. Helps loosen phlegm and thin bronchial secretions in patients with stable chronic bronchitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0677725", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29c86535-e46d-5665-8898-18576546e6bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090324", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0677725"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:52c3545b-19eb-570e-a165-4ad61ea894d4", "object": "MONDO:0018876", "object_location_in_text": [177, 197], "original_object": "mantle cell lymphoma", "original_subject": "CLADRIBINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CLADRIBINE#175-20090324", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:567361", "supporting_text": ["A drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including follicular lymphoma, and mantle cell lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1335701", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90a671fe-fe93-5573-8b22-a4c143334c4b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090324", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1335701"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:52c3545b-19eb-570e-a165-4ad61ea894d4", "object": "MONDO:0018906", "object_location_in_text": [152, 171], "original_object": "follicular lymphoma", "original_subject": "CLADRIBINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CLADRIBINE#175-20090324", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:567361", "supporting_text": ["A drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including follicular lymphoma, and mantle cell lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "P. falciparum malaria", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:277bca39-689d-58e2-9fe4-e19390eb975c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921125", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39ea084f-b766-57bd-89df-45a34bb2809a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73907cdb-f9d6-5ae4-8d77-f29889a511a3", "object": "UMLS:C1565489", "original_object": "severe renal impairment", "original_subject": "ATOVAQUONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:152433eb-1341-9cc0-e063-6394a90a1481", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=152433eb-1341-9cc0-e063-6394a90a1481", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=152433eb-1341-9cc0-e063-6394a90a1481"]}], "subject": "CHEBI:575568", "supporting_text": ["4 CONTRAINDICATIONS Atovaquone and proguanil hydrochloride tablets are contraindicated in individuals with known hypersensitivity reactions to atovaquone or proguanil hydrochloride or any component of the formulation [see Warnings and Precautions (5.4) , Adverse Reactions (6.2) ] . Atovaquone and proguanil hydrochloride tablets are contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) because of pancytopenia in patients with severe renal impairment treated with proguanil [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] . Known serious hypersensitivity reactions to atovaquone or proguanil hydrochloride or any component of the formulation. ( 4 ) Prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min). ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mild-to-moderate PCP", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25ea7e56-e3c8-5099-b947-5e7975d39e30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921125", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4b05df9c-16cd-540d-baad-2deb6eba8c74", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73907cdb-f9d6-5ae4-8d77-f29889a511a3", "object": "MONDO:0019121", "original_object": "Pneumocystis jirovecii pneumonia", "original_subject": "ATOVAQUONE", "population_context_qualifier": "adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9045ba6f-938e-4717-bfa2-a3efe52f04cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9045ba6f-938e-4717-bfa2-a3efe52f04cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9045ba6f-938e-4717-bfa2-a3efe52f04cd"]}], "subject": "CHEBI:575568", "supporting_text": ["1 INDICATIONS AND USAGE Atovaquone oral suspension is a quinone antimicrobial drug indicated for: • Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) • Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15fba672-5e8f-5520-9f39-01c189316999", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0000822", "MONDO:0005009"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2fe957a7-4f06-541e-963d-8c8f0cfd01e0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "object": "MONDO:0003019", "object_location_in_text": [151, 162], "original_object": "hypokalemia", "original_subject": "HYDROCHLOROTHIAZIDE", "population_context_qualifier": "digitalized patients; patients with significant cardiac arrhythmias", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71f5c703-94d4-49b0-9c2d-374b9cbcab85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71f5c703-94d4-49b0-9c2d-374b9cbcab85"]}], "subject": "CHEBI:5778", "supporting_text": ["Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:467f6861-8f3c-5c83-8a26-f72147a6909e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee"]}], "subject": "CHEBI:5778", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48544cc9-aabc-5d8b-a96e-10acab2cc1c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de"]}], "subject": "CHEBI:5778", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ec5a3af-8a92-52c2-a291-819eb172afca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [372, 394], "original_object": "myocardial infarctions", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521"]}], "subject": "CHEBI:5778", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4096bdb-25aa-59e1-81d2-988f91599778", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d"]}], "subject": "CHEBI:5778", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4f4c938-b331-5350-a2e5-5e2efda3a491", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [372, 394], "original_object": "myocardial infarctions", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1"]}], "subject": "CHEBI:5778", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c4f8f59-524a-5310-b5bb-807310dd8e6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [360, 367], "original_object": "strokes", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=569596a2-98f0-116a-e063-6294a90a3fa1"]}], "subject": "CHEBI:5778", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55f4322b-e97c-5be4-adec-f75edafcbe0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=543b9806-ccfa-4144-a2a2-d0e35eaceeee"]}], "subject": "CHEBI:5778", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84caa9ce-cc4a-5351-a2fc-20b40502434c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3c4f7ed-e667-4528-a675-b032c2a4425d"]}], "subject": "CHEBI:5778", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba644a1e-7f7f-55f2-b6b5-ce7a54715990", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd8d318d-167a-4b26-935d-265dde3193de"]}], "subject": "CHEBI:5778", "supporting_text": ["Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure r"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb72fe93-bc25-566a-983d-1a7162e7563e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [360, 367], "original_object": "strokes", "original_subject": "HYDROCHLOROTHIAZIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a90915ca-f9d3-4fff-8370-d5dc4cdfc521"]}], "subject": "CHEBI:5778", "supporting_text": ["1 INDICATIONS AND USAGE BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of sever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d35c439-859d-5805-905f-568c8f0086dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "object": "HP:0000969", "object_location_in_text": [862, 867], "original_object": "edema", "original_subject": "HYDROCHLOROTHIAZIDE", "population_context_qualifier": "pregnant women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0789baef-3424-43ab-a3fb-4908172da565", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0789baef-3424-43ab-a3fb-4908172da565", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0789baef-3424-43ab-a3fb-4908172da565"]}], "subject": "CHEBI:5778", "supporting_text": ["Hydrochlorothiazide capsules, USP are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules, USP may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate."], "temporal_context_qualifier": "during pregnancy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0011675", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de298636-81d5-54bf-b9fa-9f28129e9527", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["digitalis preparations"], "medic_disease_context_ids": ["HP:0011675"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:afe537fd-770f-5112-967c-279ac2a51eff", "medic_supporting_text_truncated": true, "object": "MONDO:0005044", "object_location_in_text": [81, 93], "original_object": "hypertension", "original_subject": "HYDROCHLOROTHIAZIDE", "population_context_qualifier": "patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43425ec7-a2c0-41d8-b759-b7b5918949ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43425ec7-a2c0-41d8-b759-b7b5918949ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43425ec7-a2c0-41d8-b759-b7b5918949ce"]}], "subject": "CHEBI:5778", "supporting_text": ["This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide tablets are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumb"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086209", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5cf8855-c09e-541c-b666-3fcdcbfe60f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1547512a-4788-5362-a8df-47def0ba92d9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "medic_supporting_text_truncated": true, "object": "HP:0000713", "object_location_in_text": [46, 67], "original_object": "psychomotor agitation", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7279ad5a-0a49-432d-8fa2-17e4c6ecbadc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7279ad5a-0a49-432d-8fa2-17e4c6ecbadc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7279ad5a-0a49-432d-8fa2-17e4c6ecbadc"]}], "subject": "CHEBI:5818", "supporting_text": ["The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre- and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS ) . In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d36c5eb-646f-5db8-a5ef-bad79e7f28f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444", "MONDO:0850230"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [181, 189], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c2c4d8e-c3d1-48c7-8f99-ffa159667465", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c2c4d8e-c3d1-48c7-8f99-ffa159667465", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c2c4d8e-c3d1-48c7-8f99-ffa159667465"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d889927-9740-5895-9747-44d31fbf6ecc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [181, 189], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0de7a377-7a8f-4119-b172-1eadb4b7e1be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0de7a377-7a8f-4119-b172-1eadb4b7e1be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0de7a377-7a8f-4119-b172-1eadb4b7e1be"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1df0ae9a-8b3c-5548-bab2-236f22cbe000", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444", "MONDO:0850230"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [181, 189], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a586fc0-e4e0-5621-e063-6294a90a222b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a586fc0-e4e0-5621-e063-6294a90a222b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a586fc0-e4e0-5621-e063-6294a90a222b"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc1ed164-b2db-54d3-9ef3-f52b7533619f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444", "MONDO:0850230"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [193, 201], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c9101ee-0746-4833-83cf-d0d09e52c0a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c9101ee-0746-4833-83cf-d0d09e52c0a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c9101ee-0746-4833-83cf-d0d09e52c0a9"]}], "subject": "CHEBI:5818", "supporting_text": ["INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3e49aa3-fddc-540c-808a-b4eb66539a64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444", "MONDO:0850230"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [181, 189], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48daaa55-be60-40bd-8772-ea2650305fc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48daaa55-be60-40bd-8772-ea2650305fc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48daaa55-be60-40bd-8772-ea2650305fc6"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis .Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9288521-11cb-5d99-8175-fa6e4470dd96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444", "MONDO:0850230"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [193, 201], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:98a1c161-5728-4626-a6b0-5414935e4eef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=98a1c161-5728-4626-a6b0-5414935e4eef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=98a1c161-5728-4626-a6b0-5414935e4eef"]}], "subject": "CHEBI:5818", "supporting_text": ["INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0851444", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fbdcfbd2-e5c8-5458-b45c-544388b58f38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0851444", "MONDO:0850230"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "HP:0000989", "object_location_in_text": [181, 189], "original_object": "pruritus", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87d4bbff-0498-4c26-86cb-7ce173afa0b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87d4bbff-0498-4c26-86cb-7ce173afa0b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87d4bbff-0498-4c26-86cb-7ce173afa0b6"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used in premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "organic disease states", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27637e72-27ec-599f-b86b-61787c31a4ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "MONDO:0011918", "object_location_in_text": [26, 33], "original_object": "anxiety", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58d99cf6-2319-410b-b8be-de9c304541b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58d99cf6-2319-410b-b8be-de9c304541b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58d99cf6-2319-410b-b8be-de9c304541b6"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydrOXYzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "organic disease states", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:762bf325-1c40-5951-aa7d-59f18788aeeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "MONDO:0011918", "object_location_in_text": [26, 33], "original_object": "anxiety", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0de7a377-7a8f-4119-b172-1eadb4b7e1be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0de7a377-7a8f-4119-b172-1eadb4b7e1be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0de7a377-7a8f-4119-b172-1eadb4b7e1be"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "organic disease states", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae840c91-bd94-5286-b079-c08a7faed033", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "MONDO:0011918", "object_location_in_text": [26, 33], "original_object": "anxiety", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:acc99b8f-87f0-eb3a-e053-2995a90aaaed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=acc99b8f-87f0-eb3a-e053-2995a90aaaed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acc99b8f-87f0-eb3a-e053-2995a90aaaed"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydrOXYzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "organic disease states", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3e6664e-0447-5117-9501-f6872362d9b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "MONDO:0011918", "object_location_in_text": [26, 33], "original_object": "anxiety", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87d4bbff-0498-4c26-86cb-7ce173afa0b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87d4bbff-0498-4c26-86cb-7ce173afa0b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87d4bbff-0498-4c26-86cb-7ce173afa0b6"]}], "subject": "CHEBI:5818", "supporting_text": ["For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used in premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "organic disease states", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecdd8f26-98dc-593d-8cb2-3fcbb4ff7d2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "object": "MONDO:0011918", "object_location_in_text": [38, 45], "original_object": "anxiety", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0f7f48d-e39c-4981-9c0e-5c2eccaba424", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0f7f48d-e39c-4981-9c0e-5c2eccaba424", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0f7f48d-e39c-4981-9c0e-5c2eccaba424"]}], "subject": "CHEBI:5818", "supporting_text": ["INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086209", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20f6d48e-35c9-56bb-9a29-9cd178bd5548", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086209"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6cc7cf0c-df2a-59ba-aaee-9b6cc3a9c8fb", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ecd83f1f-490c-502d-bf2c-0e4bfb3a82b0", "medic_supporting_text_truncated": true, "object": "UMLS:C0233494", "object_location_in_text": [33, 40], "original_object": "tension", "original_subject": "HYDROXYZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7279ad5a-0a49-432d-8fa2-17e4c6ecbadc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7279ad5a-0a49-432d-8fa2-17e4c6ecbadc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7279ad5a-0a49-432d-8fa2-17e4c6ecbadc"]}], "subject": "CHEBI:5818", "supporting_text": ["The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre- and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS ) . In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "haemodynamically significant patent ductus arteriosus", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c26b1fdd-e55b-51d2-9963-4700ef18e79b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040728", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d09aeaa6-1ee8-5e4d-ab06-3c8efb04c523", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:146671bb-5aa7-5a54-9467-ec08edd03159", "object": "MONDO:0011827", "object_location_in_text": [44, 68], "original_object": "patent ductus arteriosus", "original_subject": "ibuprofen", "population_context_qualifier": "preterm newborn infants less than 34 weeks of gestational age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ibuprofen-genorph", "https://www.ema.europa.eu/en/documents/product-information/ibuprofen-genorph-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ibuprofen-genorph"]}], "subject": "CHEBI:5855", "supporting_text": ["Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd580140-b5e3-5011-ac3c-320794fbbf15", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2889b20e-5a03-55f3-bd5a-8a06d02b4525", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "FELODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7990a581-3e0f-5d8c-e053-2991aa0aa6a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7990a581-3e0f-5d8c-e053-2991aa0aa6a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7990a581-3e0f-5d8c-e053-2991aa0aa6a7"]}], "subject": "CHEBI:585948", "supporting_text": ["Felodipine Extended-release Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (fo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.8075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9302033c-ca9e-58b6-b6e5-79ffd9ff1430", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.8075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2889b20e-5a03-55f3-bd5a-8a06d02b4525", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "FELODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7990a581-3e0f-5d8c-e053-2991aa0aa6a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7990a581-3e0f-5d8c-e053-2991aa0aa6a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7990a581-3e0f-5d8c-e053-2991aa0aa6a7"]}], "subject": "CHEBI:585948", "supporting_text": ["Felodipine Extended-release Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (fo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab93e493-0b44-5814-bd23-b941bf587736", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830706", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dd5c420-bae9-5285-8f9e-6bef70101e29", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "INDAPAMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff"]}], "subject": "CHEBI:5893", "supporting_text": ["1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83c3bdab-c883-54ae-a666-cf49657b86e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830706", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dd5c420-bae9-5285-8f9e-6bef70101e29", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "INDAPAMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff"]}], "subject": "CHEBI:5893", "supporting_text": ["1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0042135", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfd8be3d-16d4-5028-8bb1-06b833891666", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200921", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0042135"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:3bcace3c-6fc5-5f84-ae42-749ae4736f22", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:4678b29a-2676-5cac-b9cc-ad2694105a1b", "object": "UMLS:C0032797", "object_location_in_text": [14, 36], "original_object": "postpartum haemorrhage", "original_subject": "Carbetocin bulk and Carbetocin injection 100 mcg/ml", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:59204", "supporting_text": ["Prevention of postpartum haemorrhage due to uterine atony"], "temporal_context_qualifier": "postpartum"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:141f2a0f-fcd6-5288-a4b2-0fb6a645ad4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:450f29b6-833a-5157-86cd-4b128a03363b", "object": "HP:0012735", "object_location_in_text": [20, 25], "original_object": "cough", "original_subject": "DEXBROMPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bca1807a-6040-4001-bce4-57c48e647ded", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bca1807a-6040-4001-bce4-57c48e647ded", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bca1807a-6040-4001-bce4-57c48e647ded"]}], "subject": "CHEBI:59269", "supporting_text": ["Uses A nonnaracotic cough suppressant and antihistamine for the temporary relief of: cough due to minor throat and bronchial irritation runny nose sneezing itching of the nose or throat itchy, watery eyes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad3caf15-adbc-5a8d-9fa1-332b0cb24c65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:450f29b6-833a-5157-86cd-4b128a03363b", "object": "HP:0012735", "object_location_in_text": [20, 25], "original_object": "cough", "original_subject": "DEXBROMPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d046f4ba-5753-4ed5-a924-0b66fd116781", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d046f4ba-5753-4ed5-a924-0b66fd116781", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d046f4ba-5753-4ed5-a924-0b66fd116781"]}], "subject": "CHEBI:59269", "supporting_text": ["Uses A nonnaracotic cough suppressant and antihistamine for the temporary relief of: cough due to minor throat and bronchial irritation runny nose sneezing itching of the nose or throat itchy, watery eyes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "allergic perennial rhinitis, nonallergic perennial rhinitis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cee38846-910e-57e9-93a3-185a5d76235b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d703b0fe-4e37-5abc-8bbe-ac410b2cd63e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc418084-fa3f-5823-94bc-e4f068c42873", "object": "HP:0031417", "object_location_in_text": [85, 95], "original_object": "rhinorrhea", "original_subject": "IPRATROPIUM", "population_context_qualifier": "adults and children age 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac641027-929e-694d-80cd-bf770dc51aa6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac641027-929e-694d-80cd-bf770dc51aa6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac641027-929e-694d-80cd-bf770dc51aa6"]}], "subject": "CHEBI:5956", "supporting_text": ["Ipratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution, 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0004923", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46439fbe-5b54-5b79-907e-191b55a80fce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080716", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0004923"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:cafc4459-bee7-5d11-89f7-e05a129f2d1f", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8fc803d2-2bbf-5254-9b1f-38fd093b55cc", "object": "UMLS:C1278087", "object_location_in_text": [63, 89], "original_object": "serum phenylalanine levels", "original_subject": "SAPROPTERIN HYDROCHLORIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SAPROPTERIN HYDROCHLORIDE#174-20080716", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:59560", "supporting_text": ["A drug with a new indication and a new dosage for reduction of serum phenylalanine levels in patients with hyperphenylalaninemia (tetrahydrobiopterin-responsive hyperphenylalaninemia) caused by tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004923", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2809366-b118-5830-8f5a-ca562ab7337d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071213", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Phe-restricted diet"], "medic_disease_context_ids": ["HP:0004923"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ab94df1-bd0b-5fbe-bdb0-8e6448d892ce", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7699896-3ccd-59d1-9f3f-f17d9b13eaae", "object": "MONDO:0009861", "original_object": "Phenylketonuria", "original_subject": "SAPROPTERIN", "population_context_qualifier": "adult and pediatric patients one month of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:907e24c4-3337-4aee-b789-276e37a85cd8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=907e24c4-3337-4aee-b789-276e37a85cd8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=907e24c4-3337-4aee-b789-276e37a85cd8"]}], "subject": "CHEBI:59560", "supporting_text": ["1 INDICATIONS AND USAGE Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet. Sapropterin dihydrochloride powder for oral solution is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe‑restricted diet. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004923", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7921305-1fe7-5ecc-9d64-f357370cfe2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071213", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Phe‑restricted diet"], "medic_disease_context_ids": ["HP:0004923"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ab94df1-bd0b-5fbe-bdb0-8e6448d892ce", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7699896-3ccd-59d1-9f3f-f17d9b13eaae", "object": "MONDO:0009861", "original_object": "Phenylketonuria", "original_subject": "SAPROPTERIN", "population_context_qualifier": "adult and pediatric patients one month of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8de84882-dd24-46f2-8416-5e492d4275d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8de84882-dd24-46f2-8416-5e492d4275d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8de84882-dd24-46f2-8416-5e492d4275d1"]}], "subject": "CHEBI:59560", "supporting_text": ["1 INDICATIONS AND USAGE Zelvysia is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Zelvysia is to be used in conjunction with a Phe-restricted diet. Zelvysia is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). Zelvysia is to be used in conjunction with a Phe‑restricted diet. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "tetrahydrobiopterin (BH4) deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57a47448-f12f-5ae1-9f20-a31ff0b061ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d5d81d50-bcef-5644-8159-3f41c714eb5a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c7699896-3ccd-59d1-9f3f-f17d9b13eaae", "object": "UMLS:C0751435", "original_object": "hyperphenylalaninaemia", "original_subject": "sapropterin", "population_context_qualifier": "adults and paediatric patients of all ages", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kuvan", "https://www.ema.europa.eu/en/documents/product-information/kuvan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan"]}], "subject": "CHEBI:59560", "supporting_text": ["Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "tetrahydrobiopterin (BH4) deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2e70c44-04f6-564e-a980-6dfe6c074313", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d5d81d50-bcef-5644-8159-3f41c714eb5a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c7699896-3ccd-59d1-9f3f-f17d9b13eaae", "object": "UMLS:C0751435", "original_object": "hyperphenylalaninaemia", "original_subject": "sapropterin", "population_context_qualifier": "adults and paediatric patients of all ages", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sapropterin-dipharma", "https://www.ema.europa.eu/en/documents/product-information/sapropterin-dipharma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sapropterin-dipharma"]}], "subject": "CHEBI:59560", "supporting_text": ["Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment. Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fe65047-08fe-5ce5-a43f-d9b171d3f888", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f816d649-e636-58b0-8c4b-1f043888af75", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "CLOCORTOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:88d9a7cf-31b5-4b85-9827-0ecce328e6a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=88d9a7cf-31b5-4b85-9827-0ecce328e6a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=88d9a7cf-31b5-4b85-9827-0ecce328e6a0"]}], "subject": "CHEBI:59582", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92c6cd6a-119c-5f39-9951-3b1cc9ab46ee", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f816d649-e636-58b0-8c4b-1f043888af75", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "CLOCORTOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1eae193c-5cfd-5db1-344a-c951e2c9eff8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1eae193c-5cfd-5db1-344a-c951e2c9eff8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1eae193c-5cfd-5db1-344a-c951e2c9eff8"]}], "subject": "CHEBI:59582", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3648696-7e5b-5480-a208-36a8953bd36b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f816d649-e636-58b0-8c4b-1f043888af75", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "CLOCORTOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a8f6ef34-471c-4f30-961b-08cb777a7cd8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a8f6ef34-471c-4f30-961b-08cb777a7cd8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8f6ef34-471c-4f30-961b-08cb777a7cd8"]}], "subject": "CHEBI:59582", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4310448a-3670-580e-815b-d26bf28a4ae4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:197871da-e0c5-49a9-8dd0-34a8c2685c6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=197871da-e0c5-49a9-8dd0-34a8c2685c6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=197871da-e0c5-49a9-8dd0-34a8c2685c6b"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c21ac62-24a2-5a9e-84de-71805f66379e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9adacfa2-2814-4deb-9e34-c3b3c8dcd41a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9adacfa2-2814-4deb-9e34-c3b3c8dcd41a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9adacfa2-2814-4deb-9e34-c3b3c8dcd41a"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e4fde31-23f0-50e7-ae03-4b84fcd39690", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:029a90b6-0722-49be-8400-3ec29526aafd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=029a90b6-0722-49be-8400-3ec29526aafd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=029a90b6-0722-49be-8400-3ec29526aafd"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2bccf91-1744-59df-a86d-0675ab386a3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:21dd9a41-93c7-470c-94ed-f4c24e3d5633", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=21dd9a41-93c7-470c-94ed-f4c24e3d5633", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21dd9a41-93c7-470c-94ed-f4c24e3d5633"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS &amp; USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastoli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aec5e265-0587-5141-b98a-f32b065c0dae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e0ddb7b-80c5-47ab-afee-c74bb735e829", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e0ddb7b-80c5-47ab-afee-c74bb735e829", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e0ddb7b-80c5-47ab-afee-c74bb735e829"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2fc85ed-c768-58fc-8a51-5ccce4f04191", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [260, 281], "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:068224c4-a34d-32d7-bb2a-7eed44ccf7d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=068224c4-a34d-32d7-bb2a-7eed44ccf7d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=068224c4-a34d-32d7-bb2a-7eed44ccf7d3"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablets are angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. (1.2) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6e4ede3-3a08-5bf5-9745-4f544830de4f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7885b2a8-be4e-48ab-8113-4e6ab791eb98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension AVAPRO ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05ae9ed3-295f-56a8-b3f4-6a246856ec84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:029a90b6-0722-49be-8400-3ec29526aafd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=029a90b6-0722-49be-8400-3ec29526aafd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=029a90b6-0722-49be-8400-3ec29526aafd"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20ae8093-a56f-53c0-87e6-3c99dda5a7a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7885b2a8-be4e-48ab-8113-4e6ab791eb98", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension AVAPRO ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:443f7055-7dbb-5f8a-86a6-421c703d06c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:21dd9a41-93c7-470c-94ed-f4c24e3d5633", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=21dd9a41-93c7-470c-94ed-f4c24e3d5633", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21dd9a41-93c7-470c-94ed-f4c24e3d5633"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS &amp; USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastoli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b9b678e-7931-52f6-8884-6dbbc0f800bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:068224c4-a34d-32d7-bb2a-7eed44ccf7d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=068224c4-a34d-32d7-bb2a-7eed44ccf7d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=068224c4-a34d-32d7-bb2a-7eed44ccf7d3"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablets are angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. (1.2) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afadaa25-ebea-5fed-a532-dcc96e32b9ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9adacfa2-2814-4deb-9e34-c3b3c8dcd41a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9adacfa2-2814-4deb-9e34-c3b3c8dcd41a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9adacfa2-2814-4deb-9e34-c3b3c8dcd41a"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d558776a-fea9-5404-ab7a-2a4ac166cfea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e0ddb7b-80c5-47ab-afee-c74bb735e829", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e0ddb7b-80c5-47ab-afee-c74bb735e829", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e0ddb7b-80c5-47ab-afee-c74bb735e829"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd48235a-7b63-55b2-b735-c4fe1ed45aea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "IRBESARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:197871da-e0c5-49a9-8dd0-34a8c2685c6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=197871da-e0c5-49a9-8dd0-34a8c2685c6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=197871da-e0c5-49a9-8dd0-34a8c2685c6b"]}], "subject": "CHEBI:5959", "supporting_text": ["1 INDICATIONS AND USAGE Irbesartan tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23d8c277-5a29-54f2-b2ec-f316f254674c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970826", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["antihypertensive medicinal-product"], "medic_disease_context_ids": ["HP:0000822", "MONDO:0005148"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4fc4cd40-cd52-5c90-853c-c2eaf27e3075", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "object": "MONDO:0005240", "object_location_in_text": [50, 63], "original_object": "renal disease", "original_subject": "irbesartan", "population_context_qualifier": "patients with hypertension and type-2 diabetes mellitus", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aprovel", "https://www.ema.europa.eu/en/documents/product-information/aprovel-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aprovel"]}], "subject": "CHEBI:5959", "supporting_text": ["Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fe9c3b9-d87d-501f-b4f7-bec817789669", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970826", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["antihypertensive medicinal-product"], "medic_disease_context_ids": ["HP:0000822", "MONDO:0005148"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4fc4cd40-cd52-5c90-853c-c2eaf27e3075", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "object": "MONDO:0005240", "object_location_in_text": [50, 63], "original_object": "renal disease", "original_subject": "irbesartan", "population_context_qualifier": "patients with hypertension and type-2 diabetes mellitus", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:irbesartan-zentiva", "https://www.ema.europa.eu/en/documents/product-information/irbesartan-zentiva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-zentiva"]}], "subject": "CHEBI:5959", "supporting_text": ["Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ff4fb10-c544-5dc4-b022-043331c81c47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970826", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "MONDO:0005148"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4fc4cd40-cd52-5c90-853c-c2eaf27e3075", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:48bff0c7-54b7-54b4-9ff8-22ec5e206e5f", "object": "MONDO:0005240", "object_location_in_text": [50, 63], "original_object": "renal disease", "original_subject": "irbesartan", "population_context_qualifier": "patients with hypertension and type-2 diabetes mellitus", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:karvea", "https://www.ema.europa.eu/en/documents/product-information/karvea-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/karvea"]}], "subject": "CHEBI:5959", "supporting_text": ["Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal product regimen."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:477d8ffb-5907-59db-9361-bc5f44a00202", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040309", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c4b294f8-e72c-560e-901d-b1cdd5beb0f5", "object": "HP:0003124", "object_location_in_text": [438, 464], "original_object": "elevated total cholesterol", "original_subject": "colesevelam", "population_context_qualifier": "adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cholestagel", "https://www.ema.europa.eu/en/documents/product-information/cholestagel-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel"]}], "subject": "CHEBI:59594", "supporting_text": ["Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated. Cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94754b01-3647-52bc-90e6-d591786b747a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e58c492-a05a-5317-bd70-96e46c9b0db8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4b294f8-e72c-560e-901d-b1cdd5beb0f5", "object": "UMLS:C0342882", "original_object": "heterozygous familial hypercholesterolemia", "original_subject": "COLESEVELAM", "population_context_qualifier": "boys and postmenarchal girls, 10 to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5e50cc0c-03bc-444b-9d15-ea112bc0f91c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5e50cc0c-03bc-444b-9d15-ea112bc0f91c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e50cc0c-03bc-444b-9d15-ea112bc0f91c"]}], "subject": "CHEBI:59594", "supporting_text": ["1 INDICATIONS AND USAGE Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a13df041-fd0a-522c-838a-87715ec19371", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e58c492-a05a-5317-bd70-96e46c9b0db8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4b294f8-e72c-560e-901d-b1cdd5beb0f5", "object": "UMLS:C0342882", "original_object": "heterozygous familial hypercholesterolemia", "original_subject": "COLESEVELAM", "population_context_qualifier": "boys and postmenarchal girls, 10 to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7058806-ad4f-6d5f-e053-2a95a90a35e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7058806-ad4f-6d5f-e053-2a95a90a35e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7058806-ad4f-6d5f-e053-2a95a90a35e8"]}], "subject": "CHEBI:59594", "supporting_text": ["1 INDICATIONS AND USAGE Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cae0550b-1ef0-590e-9e14-d7171659e391", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e58c492-a05a-5317-bd70-96e46c9b0db8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4b294f8-e72c-560e-901d-b1cdd5beb0f5", "object": "UMLS:C0342882", "original_object": "heterozygous familial hypercholesterolemia", "original_subject": "COLESEVELAM", "population_context_qualifier": "boys and postmenarchal girls, 10 to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b48a7426-b513-4790-99a4-4f07d83318d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b48a7426-b513-4790-99a4-4f07d83318d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b48a7426-b513-4790-99a4-4f07d83318d7"]}], "subject": "CHEBI:59594", "supporting_text": ["1 INDICATIONS AND USAGE Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d523c8bd-f311-50ad-8980-3c1a8404fb81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e58c492-a05a-5317-bd70-96e46c9b0db8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4b294f8-e72c-560e-901d-b1cdd5beb0f5", "object": "UMLS:C0342882", "original_object": "heterozygous familial hypercholesterolemia", "original_subject": "COLESEVELAM", "population_context_qualifier": "boys and postmenarchal girls, 10 to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f235408-e28d-4cce-b7f1-66bbe0e4534c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f235408-e28d-4cce-b7f1-66bbe0e4534c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f235408-e28d-4cce-b7f1-66bbe0e4534c"]}], "subject": "CHEBI:59594", "supporting_text": ["1 INDICATIONS AND USAGE Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88e1595b-c4aa-5f7a-b0cb-037d3e5a5823", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5697556d-666c-5105-89a4-80ff6e86f625", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "MONDO:0000565", "original_object": "infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4ad8613-f25e-4b82-9621-cc5ff9525d3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4ad8613-f25e-4b82-9621-cc5ff9525d3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4ad8613-f25e-4b82-9621-cc5ff9525d3e"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aacf75db-6f84-545e-a31e-8cafa9a7af67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5697556d-666c-5105-89a4-80ff6e86f625", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "MONDO:0000565", "original_object": "infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:548f3559-0531-4c95-9e1d-81f81a3801f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=548f3559-0531-4c95-9e1d-81f81a3801f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=548f3559-0531-4c95-9e1d-81f81a3801f1"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc881180-40c1-55ae-b427-c71151ad9015", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5697556d-666c-5105-89a4-80ff6e86f625", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "MONDO:0000565", "original_object": "infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191f0224-67b7-4945-bdcd-38d60645e38c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191f0224-67b7-4945-bdcd-38d60645e38c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191f0224-67b7-4945-bdcd-38d60645e38c"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f312ae6c-4b44-50a9-baf6-a3c2d92cea5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5697556d-666c-5105-89a4-80ff6e86f625", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "MONDO:0000565", "original_object": "infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4a0ad110-e55e-4d3b-84f8-dd0b924fe2f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4a0ad110-e55e-4d3b-84f8-dd0b924fe2f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a0ad110-e55e-4d3b-84f8-dd0b924fe2f6"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17701469-9164-50aa-bd61-23e2e53058f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec2be24-3169-536f-a9eb-ef347e9163e1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "UMLS:C1827573", "object_location_in_text": [333, 367], "original_object": "right-sided infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:278ad91e-2141-4bc1-b142-a9caca65f1bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=278ad91e-2141-4bc1-b142-a9caca65f1bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=278ad91e-2141-4bc1-b142-a9caca65f1bf"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6bab0bc-37ee-53e9-88d8-cd4a43da49d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec2be24-3169-536f-a9eb-ef347e9163e1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "UMLS:C1827573", "object_location_in_text": [333, 367], "original_object": "right-sided infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74176769-b22e-4e41-8c56-051e15ec5fea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74176769-b22e-4e41-8c56-051e15ec5fea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74176769-b22e-4e41-8c56-051e15ec5fea"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:add28722-283e-5efd-8617-c27de9d8d9e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec2be24-3169-536f-a9eb-ef347e9163e1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "UMLS:C1827573", "object_location_in_text": [333, 367], "original_object": "right-sided infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ae55ae0-d20f-4e15-b4dc-7e45c33f3152", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ae55ae0-d20f-4e15-b4dc-7e45c33f3152", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ae55ae0-d20f-4e15-b4dc-7e45c33f3152"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbe17cef-0d6f-57b4-8f7e-de3d739ad622", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec2be24-3169-536f-a9eb-ef347e9163e1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "UMLS:C1827573", "object_location_in_text": [333, 367], "original_object": "right-sided infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5736d54-5bc2-48c6-97c6-65f7422725f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5736d54-5bc2-48c6-97c6-65f7422725f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5736d54-5bc2-48c6-97c6-65f7422725f0"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5342785-48e0-549e-abc8-de5ef967df2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec2be24-3169-536f-a9eb-ef347e9163e1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "UMLS:C1827573", "object_location_in_text": [441, 475], "original_object": "right-sided infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ed4d986-2aa9-43cd-9a8a-fbd11cb5ecef"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin in Sodium Chloride Injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) for whom appropriate dosing can be achieved ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients for whom appropriate dosing can be achieved, including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age) for whom appropriate dosing can be achieved. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Staphylococcus aureus bloodstream infections", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f14457eb-670d-5abe-909e-f738134b5ec5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec2be24-3169-536f-a9eb-ef347e9163e1", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8c7d0f7e-2c86-5724-986b-45f9e2c9796e", "object": "UMLS:C1827573", "object_location_in_text": [300, 334], "original_object": "right-sided infective endocarditis", "original_subject": "DAPTOMYCIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1957b6ce-7382-4a7b-bf02-3595948d09c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1957b6ce-7382-4a7b-bf02-3595948d09c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1957b6ce-7382-4a7b-bf02-3595948d09c6"]}], "subject": "CHEBI:600103", "supporting_text": ["1 INDICATIONS AND USAGE Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult patients ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "intravenous therapy is appropriate", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86cdb261-6696-577f-9519-67c4544d3a6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4fb91cdf-cb4a-514c-961c-ca932c1cf1dc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1526aeb3-2e2e-5874-8460-b8440ae2dead", "object": "MONDO:0001648", "object_location_in_text": [126, 149], "original_object": "oesophageal candidiasis", "original_subject": "micafungin", "population_context_qualifier": "Adults, adolescents ≥ 16 years of age and elderly", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mycamine", "https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine"]}], "subject": "CHEBI:600520", "supporting_text": ["Mycamine is indicated for: Adults, adolescents ≥ 16 years of age and elderly  treatment of invasive candidiasis; treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate; prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count &lt; 500 cells/µl) for 10 or more days.  Children (including neonates) and adolescents &lt; 16 years of age  treatment of invasive candidiasis. prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count &lt; 500 cells/µl) for 10 or more days.  The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25a1d7c7-ee0f-53ba-8dbf-d9e30cdd2662", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dccd8d6-3f48-5808-9edc-fd6eb3da163b", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [341, 363], "original_object": "myocardial infarctions", "original_subject": "ALISKIREN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3fd2503-25ef-4660-a29a-f62c491e28fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3fd2503-25ef-4660-a29a-f62c491e28fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3fd2503-25ef-4660-a29a-f62c491e28fb"]}], "subject": "CHEBI:601027", "supporting_text": ["1 INDICATIONS AND USAGE Aliskiren tablets are a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension Aliskiren tablets are indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with aliskiren tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarcti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7348266f-2e33-54c5-8880-11e04ddcb101", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dccd8d6-3f48-5808-9edc-fd6eb3da163b", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [332, 354], "original_object": "myocardial infarctions", "original_subject": "ALISKIREN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db"]}], "subject": "CHEBI:601027", "supporting_text": ["1 INDICATIONS AND USAGE Aliskiren is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Aliskiren is indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with Aliskiren. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascu"], "temporal_context_qualifier": "lowering blood pressure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3f3e5e7-ce9f-5763-8882-b8c82dd30ec5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dccd8d6-3f48-5808-9edc-fd6eb3da163b", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [243, 265], "original_object": "myocardial infarctions", "original_subject": "ALISKIREN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c222831-90af-4336-8bf6-5628ddf24326", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c222831-90af-4336-8bf6-5628ddf24326", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c222831-90af-4336-8bf6-5628ddf24326"]}], "subject": "CHEBI:601027", "supporting_text": ["1 INDICATIONS AND USAGE Tekturna is a renin inhibitor (RI) indicated for: The treatment of hypertension, to lower blood pressure (1.1) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension Tekturna is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with Tekturna. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:200ab3ff-26da-506b-af8a-2c09c82697b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dccd8d6-3f48-5808-9edc-fd6eb3da163b", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [231, 238], "original_object": "strokes", "original_subject": "ALISKIREN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c222831-90af-4336-8bf6-5628ddf24326", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c222831-90af-4336-8bf6-5628ddf24326", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c222831-90af-4336-8bf6-5628ddf24326"]}], "subject": "CHEBI:601027", "supporting_text": ["1 INDICATIONS AND USAGE Tekturna is a renin inhibitor (RI) indicated for: The treatment of hypertension, to lower blood pressure (1.1) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension Tekturna is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with Tekturna. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28bcbc91-b9fe-5f3d-8b40-2c9d48f63a28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dccd8d6-3f48-5808-9edc-fd6eb3da163b", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [320, 327], "original_object": "strokes", "original_subject": "ALISKIREN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41c0e5e0-eb26-4d9e-bcd2-d0f2cc8fc6db"]}], "subject": "CHEBI:601027", "supporting_text": ["1 INDICATIONS AND USAGE Aliskiren is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Aliskiren is indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with Aliskiren. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascu"], "temporal_context_qualifier": "lowering blood pressure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:984d347f-14c1-5aa6-86fe-eef2d1a05745", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2dccd8d6-3f48-5808-9edc-fd6eb3da163b", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [329, 336], "original_object": "strokes", "original_subject": "ALISKIREN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3fd2503-25ef-4660-a29a-f62c491e28fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3fd2503-25ef-4660-a29a-f62c491e28fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3fd2503-25ef-4660-a29a-f62c491e28fb"]}], "subject": "CHEBI:601027", "supporting_text": ["1 INDICATIONS AND USAGE Aliskiren tablets are a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension Aliskiren tablets are indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating risk reduction with aliskiren tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarcti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6af1f29b-6873-5187-9a35-50c5760ec5ab", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:773f6776-5236-5fe1-9f6f-85b73ae3c3f9", "object": "UMLS:C1141927", "object_location_in_text": [150, 162], "original_object": "wound sepsis", "original_subject": "SILVER CATION", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ef0cf79-e960-44a6-acac-797913b71c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ef0cf79-e960-44a6-acac-797913b71c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ef0cf79-e960-44a6-acac-797913b71c97"]}], "subject": "CHEBI:60253", "supporting_text": ["INDICATIONS &amp; USAGE SECTION Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b06cfcf5-6e1c-53b4-a47e-028d0f3c3869", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:773f6776-5236-5fe1-9f6f-85b73ae3c3f9", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SILVER CATION", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42c3ece4-0df0-4ed8-ac0f-a65fad19eed7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42c3ece4-0df0-4ed8-ac0f-a65fad19eed7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42c3ece4-0df0-4ed8-ac0f-a65fad19eed7"]}], "subject": "CHEBI:60253", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "endobronchial non-small-cell lung cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ccf56a68-6f06-5dda-89d6-fa360cb9010a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:adb502cd-b0bb-5a5b-a5b3-ccc2a8be083c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1227efb3-d8d0-5b36-a500-47da00f4c03a", "object": "UMLS:C4744843", "original_object": "endobronchial obstruction", "original_subject": "PORFIMER", "population_context_qualifier": "patients with completely or partially obstructing endobronchial NSCLC", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c4841b4-fbc0-4163-8ee1-cb28629cbfbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c4841b4-fbc0-4163-8ee1-cb28629cbfbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c4841b4-fbc0-4163-8ee1-cb28629cbfbf"]}], "subject": "CHEBI:60652", "supporting_text": ["1 INDICATIONS AND USAGE PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy 1.1 Esophageal Cancer PHOTOFRIN ® is indicated for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their healthcare provider, cannot be satisfactorily treated with Nd:YAG laser therapy. 1.2 Endobronchial Cancer PHOTOFRIN is indicated for the treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated. PHOTOFRIN is indicated for the reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC. 1.3 High-Grade Dysplasia in Barrett’s Esophagus PHOTOFRIN is indicated for the ablation of high-grade dysplasia in Barrett’s esophagus patients who do not undergo esophagectomy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "during the dose initiation and ramp-up phase of venetoclax", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02eea14e-3ff6-59c8-b574-be75d17fe444", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_section"], "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c5684204-feb5-5d3e-acf8-631a5e226d20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "MONDO:0003864", "original_object": "chronic lymphocytic leukemia/small lymphocytic lymphoma", "original_subject": "ITRACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ab38a8a-3708-4b97-9f7f-8e554a15348d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ab38a8a-3708-4b97-9f7f-8e554a15348d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ab38a8a-3708-4b97-9f7f-8e554a15348d"]}], "subject": "CHEBI:6076", "supporting_text": ["Congestive Heart Failure: Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF (see BOXED WARNING , WARNINGS , PRECAUTIONS : Drug Interactions-Calcium Channel Blockers, ADVERSE REACTIONS : Post-marketing Experience, and CLINICAL PHARMACOLOGY : Special Populations) . Drug Interactions: Co-administration of a number of CYP3A4 substrates are contraindicated with itraconazole. Some examples of drugs for which plasma concentrations increase are: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, finerenone, voclosporin. In addition, co-administration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors (see PRECAUTIONS : Drug Interactions Section for specific examples). This increase in drug concentrations caused by co-administration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Some specific examples are listed in PRECAUTIONS : Drug Interactions. Co-administration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up ph"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "potential for an increased risk of tumor lysis syndrome", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e25a305-a67e-5118-bb8d-754209061960", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_section"], "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f156d1a-9f93-52d3-8cd8-1f9b220a5e41", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "MONDO:0003864", "original_object": "CLL/SLL", "original_subject": "ITRACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:349ffcf4-b2cd-4c93-9411-13c39275b8f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=349ffcf4-b2cd-4c93-9411-13c39275b8f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=349ffcf4-b2cd-4c93-9411-13c39275b8f3"]}], "subject": "CHEBI:6076", "supporting_text": ["Congestive Heart Failure: Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. (See BOXED WARNING , WARNINGS, PRECAUTIONS : Drug Interactions-Calcium Channel Blockers , ADVERSE REACTIONS : Postmarketing Experience , and CLINICAL PHARMACOLOGY : Special Populations .) Drug Interactions: Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole capsules. Some examples of drugs for which plasma concentrations increase are: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, finerenone, voclosporin. In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Some specific examples are listed in PRECAUTIONS: Drug Interactions. Coadministration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "during the dose initiation and ramp-up phase of venetoclax", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:852a4467-72fc-5e6a-99c5-390f8cd891a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_section"], "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4f156d1a-9f93-52d3-8cd8-1f9b220a5e41", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "MONDO:0003864", "object_location_in_text": [1953, 1960], "original_object": "CLL/SLL", "original_subject": "ITRACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4d555fa-787c-40fb-bb7d-b0d4f7318fd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4d555fa-787c-40fb-bb7d-b0d4f7318fd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4d555fa-787c-40fb-bb7d-b0d4f7318fd0"]}], "subject": "CHEBI:6076", "supporting_text": ["Congestive Heart Failure SPORANOX ® (itraconazole) Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. (See BOXED WARNING , WARNINGS , PRECAUTIONS: Drug Interactions-Calcium Channel Blockers, ADVERSE REACTIONS: Postmarketing Experience , and CLINICAL PHARMACOLOGY: Special Populations .) Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with SPORANOX ® . Some examples of drugs for which plasma concentrations increase are: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, finerenone, voclosporin. In addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Some specific examples are listed in PRECAUTIONS: Drug Interactions. Coadministration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "during the dose initiation and ramp-up phase of venetoclax", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cacd58db-b375-53a5-b21a-639c949228f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_section"], "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c5684204-feb5-5d3e-acf8-631a5e226d20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "MONDO:0003864", "original_object": "chronic lymphocytic leukemia/small lymphocytic lymphoma", "original_subject": "ITRACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46732a10-1f0d-4022-9689-256c44683e96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46732a10-1f0d-4022-9689-256c44683e96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46732a10-1f0d-4022-9689-256c44683e96"]}], "subject": "CHEBI:6076", "supporting_text": ["Congestive Heart Failure Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. (See BOXED WARNING , WARNINGS , PRECAUTIONS : Drug Interactions -Calcium Channel Blockers, ADVERSE REACTIONS : Post-marketing Experience, and CLINICAL PHARMACOLOGY : Special Populations.) Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole capsules. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (See PRECAUTIONS : Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Specific examples are listed in PRECAUTIONS : Drug Interactions. Coadministration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up phase of venetoclax due to the potential f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035020", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:776591c7-d087-557e-92d1-8f14030d0408", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0035020"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:781e4d9e-877d-53a3-8632-eded32e5e329", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "HP:0032256", "object_location_in_text": [190, 204], "original_object": "Histoplasmosis", "original_subject": "ITRACONAZOLE", "population_context_qualifier": "HIV-infected patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ab38a8a-3708-4b97-9f7f-8e554a15348d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ab38a8a-3708-4b97-9f7f-8e554a15348d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ab38a8a-3708-4b97-9f7f-8e554a15348d"]}], "subject": "CHEBI:6076", "supporting_text": ["Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis (see CLINICAL PHARMACOLOGY : Special Populations, CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS : Post-marketing Experience for more information). Description of Clinical Studies: Blastomycosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0035020", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a50e7b59-3c25-5ae0-b6e0-5c33ea6114f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0035020"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:781e4d9e-877d-53a3-8632-eded32e5e329", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "HP:0032256", "object_location_in_text": [190, 204], "original_object": "Histoplasmosis", "original_subject": "ITRACONAZOLE", "population_context_qualifier": "HIV-infected patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e564067e-e469-4c51-9076-75f89f5c5cdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e564067e-e469-4c51-9076-75f89f5c5cdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e564067e-e469-4c51-9076-75f89f5c5cdf"]}], "subject": "CHEBI:6076", "supporting_text": ["Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis (see CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information). Description of Clinical Studies: Blastomycosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the n"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic cavitary pulmonary disease, disseminated, non-meningeal histoplasmosis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a97ddc98-2a96-547f-b401-6c12c366c971", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:781e4d9e-877d-53a3-8632-eded32e5e329", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "object": "HP:0032256", "object_location_in_text": [205, 219], "original_object": "Histoplasmosis", "original_subject": "ITRACONAZOLE", "population_context_qualifier": "immunocompromised and non-immunocompromised adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:306352d1-9d5a-49ad-b72d-893b99546861", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861"]}], "subject": "CHEBI:6076", "supporting_text": ["1 INDICATIONS AND USAGE TOLSURA is indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-fungal therapy should be adjusted accordingly TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients ( 1 ): Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pulmonary and extrapulmonary aspergillosis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eac4ca96-5969-597d-923f-9dc3e3c8040b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19920911", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["amphotericin B"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e2f57153-05ee-58dd-8030-8c31ceca7d82", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "medic_supporting_text_truncated": true, "object": "MONDO:0005657", "original_object": "aspergillosis", "original_subject": "ITRACONAZOLE", "population_context_qualifier": "immunocompromised and non-immunocompromised patients; patients who are intolerant of or who are refractory to amphotericin B therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68165d90-953c-e2f5-e053-2a91aa0ada25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68165d90-953c-e2f5-e053-2a91aa0ada25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68165d90-953c-e2f5-e053-2a91aa0ada25"]}], "subject": "CHEBI:6076", "supporting_text": ["Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis (see CLINICAL PHARMACOLOGY : Special Populations, CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS : Post-marketing Experience for more information). Description of Clinical Studies: Blastomycosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "suspected fungal infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d340c994-f3a3-5e2c-97fa-43b035eb0d92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110926", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bb7e53fb-10b0-5fb6-8910-505f6781941b", "object": "UMLS:C0746883", "object_location_in_text": [92, 111], "original_object": "febrile neutropenia", "original_subject": "ITRACONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ITRACONAZOLE#148-20110926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6076", "supporting_text": ["A drug with new indications for (1) the treatment of fungal infection, (2) the treatment of febrile neutropenia with suspected fungal infection, and (3) the prevention of deep mycosis in patients with hematologic malignancy or hematopoietic stem cell transplantation in whom neutropenia is anticipated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory lesions of rosacea", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c20f5076-ed99-5705-adf0-7c4666885e92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:407b3ccf-8c84-5855-831c-9a31db06c46f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "MONDO:0006604", "object_location_in_text": [98, 105], "original_object": "rosacea", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1d5b166-ab06-4ab5-b0c6-31126238118a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1d5b166-ab06-4ab5-b0c6-31126238118a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1d5b166-ab06-4ab5-b0c6-31126238118a"]}], "subject": "CHEBI:6078", "supporting_text": ["1 INDICATIONS AND USAGE SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea. SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22003e4e-1712-528e-8ece-93bfd27954bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1fb17bc2-9192-4a0b-a3ee-fda9db035daa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1fb17bc2-9192-4a0b-a3ee-fda9db035daa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fb17bc2-9192-4a0b-a3ee-fda9db035daa"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin tablets, USP are indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. Ivermectin tablets are indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64% to 100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis. Ivermectin tablets are indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1,427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin tablets has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27e555a1-bd16-5eb9-802b-7d639ef3abcf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:104a5045-94b1-4022-bc49-719521f30f0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=104a5045-94b1-4022-bc49-719521f30f0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=104a5045-94b1-4022-bc49-719521f30f0d"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e36ca4e-66e8-5805-a70b-13c15378d646", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:681888c9-af79-4b7d-ae80-c3f4f6f1effd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=681888c9-af79-4b7d-ae80-c3f4f6f1effd"]}], "subject": "CHEBI:6078", "supporting_text": ["STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:568f602a-93fb-5d35-b48a-38f8e4a1d29b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23bb1ccf-1a35-438d-a0df-3ecc4fa30033", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23bb1ccf-1a35-438d-a0df-3ecc4fa30033", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23bb1ccf-1a35-438d-a0df-3ecc4fa30033"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d0b3eb3-3f5f-5229-9430-93a89dbdbd5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:847a1dd7-d65b-4a0e-a67d-d90392059dac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=847a1dd7-d65b-4a0e-a67d-d90392059dac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=847a1dd7-d65b-4a0e-a67d-d90392059dac"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b135ebae-bbcb-5adb-bd16-77dac1ec2865", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad6539f2-94de-1bc5-e053-2a95a90a4cf2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad6539f2-94de-1bc5-e053-2a95a90a4cf2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad6539f2-94de-1bc5-e053-2a95a90a4cf2"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6a807dc-4d94-509d-8b90-914e8c044c01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:014e33e7-c07d-4feb-a2cf-7cd160b1facd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=014e33e7-c07d-4feb-a2cf-7cd160b1facd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=014e33e7-c07d-4feb-a2cf-7cd160b1facd"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbb7b10e-5b0b-567d-a2c6-7ff1bd3abe44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d140f06-e46b-4cdd-97e4-37b6cf4ade13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d140f06-e46b-4cdd-97e4-37b6cf4ade13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d140f06-e46b-4cdd-97e4-37b6cf4ade13"]}], "subject": "CHEBI:6078", "supporting_text": ["STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf376830-f5bb-5460-b191-ffad06599ae1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cb062d7-0597-4e92-b2f6-7129a95e9500", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cb062d7-0597-4e92-b2f6-7129a95e9500", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cb062d7-0597-4e92-b2f6-7129a95e9500"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae- producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da6b1d9d-7d39-5933-804f-921fb585f3b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2de5ee45-0465-4996-ac00-5bdd352b4ed7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2de5ee45-0465-4996-ac00-5bdd352b4ed7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2de5ee45-0465-4996-ac00-5bdd352b4ed7"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin tablets are indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin tablets are indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64% to 100% of infected patients were cured following a single 200 mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies ). Onchocerciasis Ivermectin tablets are indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1,427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277302", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6777131-97d6-53ac-b87a-c93e7b4e39f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961122", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277302"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c9076ade-2662-5c55-a518-c5f147f2855b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ad6138a-de41-5562-a8c2-240a870d869b", "object": "UMLS:C0348997", "original_object": "intestinal strongyloidiasis", "original_subject": "IVERMECTIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8005642-3bf0-41b9-8a53-8b933c68c073", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8005642-3bf0-41b9-8a53-8b933c68c073", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8005642-3bf0-41b9-8a53-8b933c68c073"]}], "subject": "CHEBI:6078", "supporting_text": ["Ivermectin tablets are indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract. Ivermectin tablets are indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies ) Onchocerciasis. Ivermectin tablets are indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1,427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: Ivermectin has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute suicidal ideation or behavior", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeca196a-448b-5aa9-8217-363601e3829d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190305", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["oral antidepressant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3eddc2a7-18a4-5a85-baf4-64b71e61c5e8", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "ESKETAMINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d81a6a79-a74a-44b7-822c-0dfa3036eaed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed"]}], "subject": "CHEBI:60799", "supporting_text": ["1 INDICATIONS AND USAGE SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant SPRAVATO is a non-competitive N -methyl D -aspartate (NMDA) receptor antagonist indicated for the treatment of: Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant. ( 1 ) Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002625", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d21dd31-c666-5f6d-b95b-ba375d45e089", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20011207", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0002625"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ffd19906-2cd5-5180-86ef-068b6387a1b4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7d7f4414-e842-5bf7-b006-cafd94aeb216", "object": "MONDO:0005279", "original_object": "pulmonary embolism", "original_subject": "FONDAPARINUX", "population_context_qualifier": "adult patients undergoing hip fracture surgery", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:baa50757-a927-4d56-a933-5d7798fe6ab0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=baa50757-a927-4d56-a933-5d7798fe6ab0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=baa50757-a927-4d56-a933-5d7798fe6ab0"]}], "subject": "CHEBI:61033", "supporting_text": ["1 INDICATIONS AND USAGE Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) in adult patients when administered in conjunction with warfarin. ( 1.2 , 1.3 ) Treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg. (1.4) 1.1 Prophylaxis of Deep Vein Thrombosis in Adult Patients Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT in adults), which may lead to pulmonary embolism (PE): in patients undergoing hip fracture surgery, including extended prophylaxis; in patients undergoing hip replacement surgery; in patients undergoing knee replacement surgery; in patients undergoing abdominal surgery who are at risk for thromboembolic complications. 1.2 Treatment of Acute Deep Vein Thrombosis in Adult Patients Fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis in adults when administered in conjunction with warfarin sodium. 1.3 Treatment of Acute Pulmonary Embolism in Adult Patients Fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism in adults when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. 1.4 Treatment of Venous Thromboembolism in Pediatric Patients Fondaparinux sodium injection is indicated for the treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0149871", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62e90668-8dd2-5fe3-acaf-4a348cb44229", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020320", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0149871"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5c5604c8-204e-5f13-ac27-c83d943aed72", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3942d102-a4ba-57a7-bc68-9a88531e1c63", "object": "UMLS:C0235511", "original_object": "superficial-vein thrombosis", "original_subject": "fondaparinux sodium", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:arixtra", "https://www.ema.europa.eu/en/documents/product-information/arixtra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra"]}], "subject": "CHEBI:61033", "supporting_text": ["1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injection Prevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery. Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery. Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease. Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis. 2.5-mg/0.5-ml solution for injection Treatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (&lt; 120 mins) invasive management (PCI) is not indicated. infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy. 5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injection Treatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "musculoskeletal painful and inflammatory condition", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:540bd2bd-e870-5ab0-80e3-ce86455a3527", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:cc51ab42-27e7-57aa-9c90-79d6ad66c362", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:c7061077-8bbc-51d7-84d6-0c2463a4b580", "object": "UMLS:C0457950", "object_location_in_text": [4, 23], "original_object": "acute low back pain", "original_subject": "Thiocolchicoside 4mg/8mg + Ketoprofen 50mg/100mg tablets", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:6128", "supporting_text": ["For acute low back pain & other musculoskeletal painful and inflammatory condition in adults"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0339164", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20eede31-b0ec-5a46-ad62-d80a574d5177", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0339164"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ed02d62-4b49-5ac8-bbe5-cd16cbfc08cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c15c4aea-21bc-5ab4-bf15-381c2e6de44b", "object": "UMLS:C0022281", "object_location_in_text": [72, 86], "original_object": "ocular itching", "original_subject": "KETOROLAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c94644d3-7b64-4f3d-a0c7-12c77466a0fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c94644d3-7b64-4f3d-a0c7-12c77466a0fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c94644d3-7b64-4f3d-a0c7-12c77466a0fc"]}], "subject": "CHEBI:6129", "supporting_text": ["1 INDICATIONS AND USAGE ACULAR is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. ACULAR is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. ACULAR is a nonsteroidal anti-inflammatory drug (NSAID) indicated for: The temporary relief of ocular itching due to seasonal allergic conjunctivitis. ( 1 ) The treatment of inflammation following cataract surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0339164", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efcf50c5-40ee-5a25-b502-7eab174914cf", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0339164"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ed02d62-4b49-5ac8-bbe5-cd16cbfc08cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c15c4aea-21bc-5ab4-bf15-381c2e6de44b", "object": "UMLS:C0022281", "object_location_in_text": [113, 127], "original_object": "ocular itching", "original_subject": "KETOROLAC", "population_context_qualifier": "patients with seasonal allergic conjunctivitis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6905c57a-5c9a-414d-8034-c3598726a044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6905c57a-5c9a-414d-8034-c3598726a044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6905c57a-5c9a-414d-8034-c3598726a044"]}], "subject": "CHEBI:6129", "supporting_text": ["1 INDICATIONS AND USAGE Ketorolac tromethamine ophthalmic solution 0.5% is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution 0.5% is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Ketorolac tromethamine ophthalmic solution 0.5% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for: The temporary relief of ocular itching due to seasonal allergic conjunctivitis. ( 1 ) The treatment of inflammation following cataract surgery. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "locally advanced or metastatic NSCLC of squamous histology", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77848c45-c0fa-5948-b29c-6d02b52e832a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b2e05551-ccfe-5e9d-b734-09a6a7c91e0c", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "afatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:giotrif", "https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif"]}], "subject": "CHEBI:61390", "supporting_text": ["Giotrif as monotherapy is indicated for the treatment of  Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy."], "temporal_context_qualifier": "progressing on or after platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor positive HER2-overexpressed/amplified breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33f95c8e-3bfc-51c4-ac7b-ec861e8d47a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180831", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c7b815f4-5c3e-54ca-a154-3c35fdbdf1d3", "object": "MONDO:0007254", "object_location_in_text": [147, 160], "original_object": "breast cancer", "original_subject": "neratinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nerlynx", "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx"]}], "subject": "CHEBI:61397", "supporting_text": ["Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy."], "temporal_context_qualifier": "less than one year from the completion of prior adjuvant trastuzumab based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c2bf20e-7915-5f8c-bff7-156fb93abc27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "MONDO:0000001", "object_location_in_text": [197, 233], "original_object": "active secondary progressive disease", "original_subject": "FINGOLIMOD", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd981e18-1766-4a2d-9a9b-965ec960aa06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd981e18-1766-4a2d-9a9b-965ec960aa06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd981e18-1766-4a2d-9a9b-965ec960aa06"]}], "subject": "CHEBI:63115", "supporting_text": ["1 INDICATIONS AND USAGE Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4db7a0eb-390e-5b6a-9556-41278b962213", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "MONDO:0000001", "object_location_in_text": [184, 220], "original_object": "active secondary progressive disease", "original_subject": "FINGOLIMOD", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cc9e1c8c-0e2b-44e2-878b-27057f786be9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9"]}], "subject": "CHEBI:63115", "supporting_text": ["1 INDICATIONS AND USAGE GILENYA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93ed49fc-fb73-534b-8a2a-320759720a8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "MONDO:0000001", "object_location_in_text": [197, 233], "original_object": "active secondary progressive disease", "original_subject": "FINGOLIMOD", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a545c6fc-7006-52c2-f476-34e9801ac04f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a545c6fc-7006-52c2-f476-34e9801ac04f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a545c6fc-7006-52c2-f476-34e9801ac04f"]}], "subject": "CHEBI:63115", "supporting_text": ["1 INDICATIONS AND USAGE Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy, rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e76d3cc-1efe-50af-a869-175272d1d494", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110317", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:007a20ca-1ef4-5d5b-ac3b-aa379b2b5321", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "MONDO:0005314", "object_location_in_text": [63, 101], "original_object": "relapsing remitting multiple sclerosis", "original_subject": "fingolimod", "population_context_qualifier": "adult and paediatric patients aged 10 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:fingolimod-mylan", "https://www.ema.europa.eu/en/documents/product-information/fingolimod-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/fingolimod-mylan"]}], "subject": "CHEBI:63115", "supporting_text": ["Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e6b8145-2f62-5ac3-9647-9cbd578c4415", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "UMLS:C2921627", "object_location_in_text": [121, 149], "original_object": "clinically isolated syndrome", "original_subject": "FINGOLIMOD", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cc9e1c8c-0e2b-44e2-878b-27057f786be9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9"]}], "subject": "CHEBI:63115", "supporting_text": ["1 INDICATIONS AND USAGE GILENYA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:599d8cd6-b23e-549b-bc12-e936b79b48da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "UMLS:C2921627", "object_location_in_text": [134, 162], "original_object": "clinically isolated syndrome", "original_subject": "FINGOLIMOD", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd981e18-1766-4a2d-9a9b-965ec960aa06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd981e18-1766-4a2d-9a9b-965ec960aa06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd981e18-1766-4a2d-9a9b-965ec960aa06"]}], "subject": "CHEBI:63115", "supporting_text": ["1 INDICATIONS AND USAGE Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef6745e1-38bd-5abe-be6e-76c9ab4c81b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3e45760-8782-55b6-8e9d-2262e8e6d632", "object": "UMLS:C2921627", "object_location_in_text": [134, 162], "original_object": "clinically isolated syndrome", "original_subject": "FINGOLIMOD", "population_context_qualifier": "patients 10 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a545c6fc-7006-52c2-f476-34e9801ac04f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a545c6fc-7006-52c2-f476-34e9801ac04f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a545c6fc-7006-52c2-f476-34e9801ac04f"]}], "subject": "CHEBI:63115", "supporting_text": ["1 INDICATIONS AND USAGE Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15d51485-50f9-51ea-8e15-5c8631eaea51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840801", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a7b43d0e-9687-5a69-aa15-5782583394a9", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LABETALOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2e50571-d8c1-43e7-b90f-877ba1c35c9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2e50571-d8c1-43e7-b90f-877ba1c35c9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2e50571-d8c1-43e7-b90f-877ba1c35c9b"]}], "subject": "CHEBI:6343", "supporting_text": ["1 INDICATIONS AND USAGE Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8da0c90d-6bb4-5a57-96ce-fb7aba64d187", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840801", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a7b43d0e-9687-5a69-aa15-5782583394a9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "LABETALOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2e50571-d8c1-43e7-b90f-877ba1c35c9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2e50571-d8c1-43e7-b90f-877ba1c35c9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2e50571-d8c1-43e7-b90f-877ba1c35c9b"]}], "subject": "CHEBI:6343", "supporting_text": ["1 INDICATIONS AND USAGE Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4075847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e4431ef-713a-5ef4-862d-d48656f3b9de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960808", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["a second agent without cross-resistance to lamivudine"], "medic_disease_context_ids": ["UMLS:C4075847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:99d8a2a1-d6e0-5f58-984b-ad89864996d4", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1e944d32-7b2b-53a4-8cfe-382ce4ab4909", "object": "MONDO:0005366", "object_location_in_text": [41, 60], "original_object": "chronic hepatitis B", "original_subject": "lamivudine", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zeffix", "https://www.ema.europa.eu/en/documents/product-information/zeffix-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zeffix"]}], "subject": "CHEBI:63577", "supporting_text": ["Zeffix is indicated for the treatment of chronic hepatitis B in adults with:  compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate; decompensated liver disease in combination with a second agent without cross-resistance to lamivudine."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "preparatory dehydration", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e012174-a0fe-5e95-b8b7-421a98a8a7c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:15893534-1f9d-5cde-b2f3-de0c6ae9a458", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b26d41bf-aaed-56ac-bfa9-9392d2721bfe", "object": "MONDO:0001106", "original_object": "renal failure", "original_subject": "IOPROMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d96a7883-d160-40a1-bdbd-2e8d7877cd18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d96a7883-d160-40a1-bdbd-2e8d7877cd18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d96a7883-d160-40a1-bdbd-2e8d7877cd18"]}], "subject": "CHEBI:63578", "supporting_text": ["4 CONTRAINDICATIONS • Do not administer ULTRAVIST Injection intrathecally. Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. • Preparatory dehydration (for example, prolonged fasting and the administration of a laxative) before ULTRAVIST Injection is contraindicated in pediatric patients because of risk of acute renal failure. • ULTRAVIST Injection is contraindicated for intrathecal use. ( 4 ) • Preparatory dehydration (for example, prolonged fasting and the administration of a laxative before ULTRAVIST Injection) is contraindicated in pediatric patients because of risk of renal failure. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "preparatory dehydration", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44eaf00f-e060-53f0-8663-5ab2daf599c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c90d3b66-77cd-50c8-933e-8fbbe43545a7", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b26d41bf-aaed-56ac-bfa9-9392d2721bfe", "object": "MONDO:0002492", "original_object": "acute renal failure", "original_subject": "IOPROMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65647318-27e4-4f37-bd68-50eea52d6c5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65647318-27e4-4f37-bd68-50eea52d6c5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65647318-27e4-4f37-bd68-50eea52d6c5b"]}], "subject": "CHEBI:63578", "supporting_text": ["4 CONTRAINDICATIONS • Do not administer ULTRAVIST injection intrathecally. Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. • Preparatory dehydration (for example, prolonged fasting and the administration of a laxative) before ULTRAVIST injection is contraindicated in pediatric patients because of risk of acute renal failure. • ULTRAVIST injection is contraindicated for intrathecal use. ( 4 ) • Preparatory dehydration (for example, prolonged fasting and the administration of a laxative before ULTRAVIST injection) is contraindicated in pediatric patients because of risk of renal failure. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "preparatory dehydration", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b7c67d2-bec4-5171-8b12-a6039997c5ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c90d3b66-77cd-50c8-933e-8fbbe43545a7", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b26d41bf-aaed-56ac-bfa9-9392d2721bfe", "object": "MONDO:0002492", "original_object": "acute renal failure", "original_subject": "IOPROMIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d96a7883-d160-40a1-bdbd-2e8d7877cd18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d96a7883-d160-40a1-bdbd-2e8d7877cd18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d96a7883-d160-40a1-bdbd-2e8d7877cd18"]}], "subject": "CHEBI:63578", "supporting_text": ["4 CONTRAINDICATIONS • Do not administer ULTRAVIST Injection intrathecally. Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. • Preparatory dehydration (for example, prolonged fasting and the administration of a laxative) before ULTRAVIST Injection is contraindicated in pediatric patients because of risk of acute renal failure. • ULTRAVIST Injection is contraindicated for intrathecal use. ( 4 ) • Preparatory dehydration (for example, prolonged fasting and the administration of a laxative before ULTRAVIST Injection) is contraindicated in pediatric patients because of risk of renal failure. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cirrhotic CHC patients coinfected with HIV", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78e6e911-e087-5f57-a7cb-9e32adc512fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:34510680-24ae-5d07-81e6-f35fde1e56f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7b4662fa-bdb0-5b7d-98d2-a97d6a1c032a", "object": "UMLS:C1394798", "original_object": "hepatic decompensation", "original_subject": "RIBAVIRIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eee304d0-c2ea-44f4-97d9-92a414d31b6c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eee304d0-c2ea-44f4-97d9-92a414d31b6c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eee304d0-c2ea-44f4-97d9-92a414d31b6c"]}], "subject": "CHEBI:63580", "supporting_text": ["4 CONTRAINDICATIONS Ribavirin tablets are contraindicated in: Women who are pregnant. Ribavirin tablets may cause fetal harm when administered to a pregnant woman. Ribavirin tablets are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1) , and Patient Counseling Information (17) ] . Men whose female partners are pregnant. Patients with hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia). In combination with didanosine. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials [see Drug Interactions (7.1) ] . Ribavirin tablets and PEGASYS ® combination therapy are contraindicated in patients with: Autoimmune hepatitis. Hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before treatment [see Warnings and Precautions (5.3) ] . Hepatic decompensation (Child-Pugh score greater than or equal to 6) in cirrhotic CHC patients coinfected with HIV before treatment [see Warnings and Precautions (5.3) ] . Pregnant women and men whose female partners are pregnant (4 , 5.1 , 8.1 ) Hemoglobinopathies (4) Coadministration with didanosine (4 , 7.1) Ribavirin tablets in combination with PEGASYS ® are contraindicated in patients with: Autoimmune hepatitis (4) Hepatic decompensation in cirrhotic patients (4 , 5.3)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cirrhotic CHC patients coinfected with HIV", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac7e9a4c-a8fe-56c8-9b6b-33828160a266", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851231", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["peginterferon alfa-2a"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:34510680-24ae-5d07-81e6-f35fde1e56f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7b4662fa-bdb0-5b7d-98d2-a97d6a1c032a", "object": "UMLS:C1394798", "original_object": "hepatic decompensation", "original_subject": "RIBAVIRIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14d74b63-34ca-4897-bfdd-3e3952ab6088", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14d74b63-34ca-4897-bfdd-3e3952ab6088", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14d74b63-34ca-4897-bfdd-3e3952ab6088"]}], "subject": "CHEBI:63580", "supporting_text": ["Ribavirin tablet is contraindicated in: Patients with known hypersensitivity to ribavirin tablets or to any component of the tablet. Women who are pregnant. Men whose female partners are pregnant. Patients with hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia). Ribavirin tablets and peginterferon alfa-2a combination therapy is contraindicated in patients with: Autoimmune hepatitis. Hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment. Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4505456", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:757b6d00-36c2-5661-b55e-43d1482c8e00", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091224", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["peg interferon alpha-2b"], "medic_disease_context_ids": ["UMLS:C4505456"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:807fab91-6f0e-57bb-ac49-c890b9d8e521", "object": "MONDO:0005354", "object_location_in_text": [101, 120], "original_object": "chronic hepatitis C", "original_subject": "Ribavirin Capsules 200mg (Addl. Strength)", "population_context_qualifier": "naïve adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:63580", "supporting_text": ["Indicated in combination with peg interferon alpha-2b for the treatment of naïve adult patients with chronic hepatitis C with clinically stable HIV co-infection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "serogroup 2 (genotype 2)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66e821e0-881c-5632-9e7f-5ba7eb29e21d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7b4662fa-bdb0-5b7d-98d2-a97d6a1c032a", "object": "MONDO:0005354", "object_location_in_text": [105, 124], "original_object": "chronic hepatitis C", "original_subject": "RIBAVIRIN", "population_context_qualifier": "patients with chronic hepatitis C in serogroup 2 (genotype 2)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RIBAVIRIN#100-20160928", "https://www.pmda.go.jp/files/000227562.pdf"]}], "subject": "CHEBI:63580", "supporting_text": ["A drug with a new additional indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C in serogroup 2 (genotype 2), for a combination use of ombitasvir hydrate, paritaprevir hydrate, and ritonavir."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bff911c5-4462-5d92-b4a1-6a50a76d5d4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100617", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:944682f0-a69f-5723-89bf-3612c67533f6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f64c226f-f5ab-582d-984d-cd05d6fb59b2", "object": "UMLS:C4721208", "object_location_in_text": [113, 160], "original_object": "metastatic castration-resistant prostate cancer", "original_subject": "CABAZITAXEL", "population_context_qualifier": "patients previously treated with a docetaxel-containing treatment regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa"]}], "subject": "CHEBI:63584", "supporting_text": ["1 INDICATIONS AND USAGE JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:00900bdf-ca5a-5c10-859d-1c2b621f640f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20101115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f38e45f-5f93-528a-b3ee-8d43c0d02dac", "object": "UMLS:C0278488", "object_location_in_text": [590, 614], "original_object": "metastatic breast cancer", "original_subject": "ERIBULIN", "population_context_qualifier": "patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9bfd8ac7-57e2-4c9d-add8-26502cfb54a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9bfd8ac7-57e2-4c9d-add8-26502cfb54a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bfd8ac7-57e2-4c9d-add8-26502cfb54a8"]}], "subject": "CHEBI:63587", "supporting_text": ["1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) 1.1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies (14.1) ] . 1.2 Liposarcoma Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies (14.2) ] ."], "temporal_context_qualifier": "prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2a20adb-2765-5266-8ea4-273cb81c83a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20101115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f38e45f-5f93-528a-b3ee-8d43c0d02dac", "object": "UMLS:C0278488", "object_location_in_text": [590, 614], "original_object": "metastatic breast cancer", "original_subject": "ERIBULIN", "population_context_qualifier": "patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d3a9ac3-10e9-cad5-e063-6394a90a461f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d3a9ac3-10e9-cad5-e063-6394a90a461f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d3a9ac3-10e9-cad5-e063-6394a90a461f"]}], "subject": "CHEBI:63587", "supporting_text": ["1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) 1.1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies (14.1) ] . 1.2 Liposarcoma Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies (14.2) ] ."], "temporal_context_qualifier": "prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d06de909-8575-5e56-9d46-a62e8b2d450d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20101115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f38e45f-5f93-528a-b3ee-8d43c0d02dac", "object": "UMLS:C0278488", "object_location_in_text": [590, 614], "original_object": "metastatic breast cancer", "original_subject": "ERIBULIN", "population_context_qualifier": "patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:62690292-b1de-46f1-b6e8-012a725f8c63", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=62690292-b1de-46f1-b6e8-012a725f8c63", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=62690292-b1de-46f1-b6e8-012a725f8c63"]}], "subject": "CHEBI:63587", "supporting_text": ["1 INDICATIONS AND USAGE Eribulin Mesylate Injection is a microtubule inhibitor indicated for the treatment of patients with: • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (1.1) • Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (1.2) 1.1 Metastatic Breast Cancer Eribulin Mesylate Injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [ see Clinical Studies (14.1) ] . 1.2 Liposarcoma Eribulin Mesylate Injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [ see Clinical Studies (14.2) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e505992c-a786-5393-8397-89ec80d145b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20101115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f38e45f-5f93-528a-b3ee-8d43c0d02dac", "object": "UMLS:C0278488", "object_location_in_text": [590, 614], "original_object": "metastatic breast cancer", "original_subject": "ERIBULIN", "population_context_qualifier": "patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa69e7a5-fa82-4984-b9d2-653c772b80e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa69e7a5-fa82-4984-b9d2-653c772b80e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa69e7a5-fa82-4984-b9d2-653c772b80e3"]}], "subject": "CHEBI:63587", "supporting_text": ["1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) 1.1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies (14.1) ] . 1.2 Liposarcoma Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies (14.2) ] ."], "temporal_context_qualifier": "prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278488", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6cbc353-ffb5-5c0b-b5a7-774e0042d384", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20101115", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["anthracycline", "taxane"], "medic_disease_context_ids": ["UMLS:C0278488"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9f38e45f-5f93-528a-b3ee-8d43c0d02dac", "object": "UMLS:C0278488", "object_location_in_text": [591, 615], "original_object": "metastatic breast cancer", "original_subject": "ERIBULIN", "population_context_qualifier": "patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a81f3e9-ac52-4f98-bf62-da7974d012b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a81f3e9-ac52-4f98-bf62-da7974d012b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a81f3e9-ac52-4f98-bf62-da7974d012b3"]}], "subject": "CHEBI:63587", "supporting_text": ["1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) 1.1 Me tastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies (14.1) ] . 1.2 Liposarcoma Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies (14.2) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012450", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23a1c7de-b1ef-5daf-9e87-60dcfb322ede", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0012450"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:429beb09-cb71-5623-a61d-2d603b97e2b1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a075760-af3c-51c2-bf07-1333c7950152", "object": "MONDO:0002203", "object_location_in_text": [62, 74], "original_object": "constipation", "original_subject": "LACTULOSE", "population_context_qualifier": "patients with a history of chronic constipation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3363bdbd-f0d1-45b3-8193-7fdb0a310cc2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3363bdbd-f0d1-45b3-8193-7fdb0a310cc2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3363bdbd-f0d1-45b3-8193-7fdb0a310cc2"]}], "subject": "CHEBI:6359", "supporting_text": ["LACTULOSE For Oral Solution is indicated for the treatment of constipation. In patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012450", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bc4818e-6512-585f-9d1b-6bbbce867733", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0012450"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:429beb09-cb71-5623-a61d-2d603b97e2b1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9a075760-af3c-51c2-bf07-1333c7950152", "object": "MONDO:0002203", "object_location_in_text": [62, 74], "original_object": "constipation", "original_subject": "LACTULOSE", "population_context_qualifier": "patients with a history of chronic constipation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59e75426-42ae-4904-941f-009181101a8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59e75426-42ae-4904-941f-009181101a8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59e75426-42ae-4904-941f-009181101a8a"]}], "subject": "CHEBI:6359", "supporting_text": ["LACTULOSE For Oral Solution is indicated for the treatment of constipation. In patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "none specified", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41a4b580-b079-5ace-a2b6-633b1b746c5e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071016", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["capecitabine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:29ab6358-7a4f-50c1-bc28-1f3b3256fb2f", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4a151df7-0d06-5679-b122-58f1c3916ff3", "object": "HP:0002910", "original_object": "elevated transaminases", "original_subject": "IXABEPILONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:241f0b1e-8b95-470d-876f-bf1804daaf18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18"]}], "subject": "CHEBI:63605", "supporting_text": ["4 CONTRAINDICATIONS IXEMPRA is contraindicated in patients who have: a neutrophil count &lt;1500 cells/mm 3 or a platelet count &lt;100,000 cells/mm 3 [see Warnings and Precautions ( 5.2 )]. a history of severe hypersensitivity to agents containing Cremophor ® EL or its derivatives (e.g., polyoxyethylated castor oil) [see Warnings and Precautions ( 5.4 )]. IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT &gt;2.5 x ULN or bilirubin &gt;1 x ULN [see Boxed Warning and Warnings and Precautions ( 5.3 )]. Baseline neutrophil count &lt;1500 cells/mm 3 or a platelet count &lt;100,000 cells/mm 3 ( 4 ). Hypersensitivity to drugs formulated with Cremophor ® EL ( 4 ). IXEMPRA in combination with capecitabine is contraindicated for use in patients with AST or ALT &gt;2.5 x ULN or bilirubin &gt;1 x ULN.( 4 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "none specified", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7648706b-5554-516e-99fc-01e2aa37773a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071016", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["capecitabine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cecbfe2b-554c-581e-9453-b852d9502ccf", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4a151df7-0d06-5679-b122-58f1c3916ff3", "object": "MONDO:0024288", "original_object": "hyperbilirubinemia", "original_subject": "IXABEPILONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:241f0b1e-8b95-470d-876f-bf1804daaf18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18"]}], "subject": "CHEBI:63605", "supporting_text": ["4 CONTRAINDICATIONS IXEMPRA is contraindicated in patients who have: a neutrophil count &lt;1500 cells/mm 3 or a platelet count &lt;100,000 cells/mm 3 [see Warnings and Precautions ( 5.2 )]. a history of severe hypersensitivity to agents containing Cremophor ® EL or its derivatives (e.g., polyoxyethylated castor oil) [see Warnings and Precautions ( 5.4 )]. IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT &gt;2.5 x ULN or bilirubin &gt;1 x ULN [see Boxed Warning and Warnings and Precautions ( 5.3 )]. Baseline neutrophil count &lt;1500 cells/mm 3 or a platelet count &lt;100,000 cells/mm 3 ( 4 ). Hypersensitivity to drugs formulated with Cremophor ® EL ( 4 ). IXEMPRA in combination with capecitabine is contraindicated for use in patients with AST or ALT &gt;2.5 x ULN or bilirubin &gt;1 x ULN.( 4 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anthracycline-resistant breast cancer, taxane-resistant breast cancer, capecitabine-resistant breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c29d8f67-141c-5e2c-b20e-874cf099e037", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bbeb3367-787b-524a-8786-d75fc80f84a5", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4a151df7-0d06-5679-b122-58f1c3916ff3", "object": "MONDO:0007254", "object_location_in_text": [113, 157], "original_object": "metastatic or locally advanced breast cancer", "original_subject": "IXABEPILONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:241f0b1e-8b95-470d-876f-bf1804daaf18", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18"]}], "subject": "CHEBI:63605", "supporting_text": ["1 INDICATIONS AND USAGE IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14 )]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14 )]. IXEMPRA is a microtubule inhibitor indicated for treatment: In combination with capecitabine for patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. ( 1 ). As a single agent for patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine. ( 1 )."], "temporal_context_qualifier": "after failure of an anthracycline, a taxane, and capecitabine"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4552480", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62e384bd-43e7-5f04-a4cf-fee3ecf5c1ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4552480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ff6c05ec-4ac9-59bd-ae31-5c5bf4fe202d", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C0744130", "object_location_in_text": [335, 359], "original_object": "diabetic foot infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:95b8fd63-d018-8062-e053-2995a90ab96d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=95b8fd63-d018-8062-e053-2995a90ab96d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=95b8fd63-d018-8062-e053-2995a90ab96d"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid Injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30540095-d5b1-5728-8502-b3b96396135e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [392, 438], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e70e63b-bfd5-478d-a8ee-8ba22c9efabd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e70e63b-bfd5-478d-a8ee-8ba22c9efabd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e70e63b-bfd5-478d-a8ee-8ba22c9efabd"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE ZYVOX is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39ea862f-3905-55ba-a5f6-bb4cf7f2d3fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [406, 452], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d05541c6-fd63-cc99-e053-2995a90a4ec7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d05541c6-fd63-cc99-e053-2995a90a4ec7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d05541c6-fd63-cc99-e053-2995a90a4ec7"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid Injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52853d2b-9bbb-5ff6-bc12-5dd16d71ba94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [407, 453], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:561abed1-c0f9-40ee-98a8-7c710bcde822", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=561abed1-c0f9-40ee-98a8-7c710bcde822", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=561abed1-c0f9-40ee-98a8-7c710bcde822"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS &amp; USAGE Linezolid tablets are an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:599a6d56-fff0-57e8-be8b-68c2da3b9baa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [392, 438], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e5e9975-6f36-42e4-ab46-0e75dda83592", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e5e9975-6f36-42e4-ab46-0e75dda83592", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e5e9975-6f36-42e4-ab46-0e75dda83592"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE ZYVOX is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d70dbdb-6747-5b7d-b3d9-1ff901b570ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [406, 452], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:870c9600-04d5-4b44-a5b5-02252a310f22", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=870c9600-04d5-4b44-a5b5-02252a310f22", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=870c9600-04d5-4b44-a5b5-02252a310f22"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ddfaf7f-dca4-5c8e-9a03-98f57db56ca7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [396, 442], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b721756c-3b5e-456d-a2f6-0d8a56cc7f35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b721756c-3b5e-456d-a2f6-0d8a56cc7f35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b721756c-3b5e-456d-a2f6-0d8a56cc7f35"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a440f5c-e6f3-5937-9c56-629a2550118c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [396, 442], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:83a84897-ccca-42a1-ab1a-bbf1d43a982b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=83a84897-ccca-42a1-ab1a-bbf1d43a982b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=83a84897-ccca-42a1-ab1a-bbf1d43a982b"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f746155-5c0b-5e86-9cad-a967be3a7787", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [416, 462], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a89a37ec-a736-464b-a83a-84bef6ccd702", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a89a37ec-a736-464b-a83a-84bef6ccd702", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a89a37ec-a736-464b-a83a-84bef6ccd702"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid for oral suspension is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a990665-ad27-587a-bd12-560d027ccb01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [405, 451], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90dd8c13-c428-4472-91e5-5b1fcdc4fce3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90dd8c13-c428-4472-91e5-5b1fcdc4fce3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90dd8c13-c428-4472-91e5-5b1fcdc4fce3"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid tablets are an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f840438-cf6a-5cd6-91a6-a79996660cb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "medic_supporting_text_truncated": true, "object": "UMLS:C4552480", "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d1b4d0a-0fd9-448b-a28f-51ed05a5a0cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d1b4d0a-0fd9-448b-a28f-51ed05a5a0cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d1b4d0a-0fd9-448b-a28f-51ed05a5a0cf"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [ see Warnings and Precautions (5.4) ]. Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.1 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.2 ); Uncomplicated skin and skin structure infections ( 1.2 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs, linezolid should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) 1.1 Pneumonia Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [ see Clinical Studies (14) ]. Community-acquired pneumonia caused by Streptococcus pneumoniae , including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [ see Clinical Studies (14) ]. 1.2 Skin and Skin Structure Infections Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , or Streptococcus agalactiae . Linezolid has not been studied in the treatment of decubitus ulcers [ see Clinical Studies (14) ]. Uncomplicated skin and skin s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b83e22f6-7015-5191-9763-b43d0670eea9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [416, 462], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:16007ca5-7956-4414-af38-406a6623400e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=16007ca5-7956-4414-af38-406a6623400e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16007ca5-7956-4414-af38-406a6623400e"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS AND USAGE Linezolid for Oral Suspension is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1. 2); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1. 3); Uncomplicated skin and skin structure infections ( 1. 4); Vancomycin-resistant Enterococcus faecium infections. ( 1. 5)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0744130", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d91c4c7d-6e54-5efb-8724-08b3a1a3ecbc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000418", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744130"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b510c6b2-6149-5651-b584-02fd2ddb1801", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 11, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01e076d4-32eb-5a98-8a00-f5e0b76b07b6", "object": "UMLS:C4552480", "object_location_in_text": [407, 453], "original_object": "complicated skin and skin structure infections", "original_subject": "LINEZOLID", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf4fa35d-93c9-41c3-a2ae-0298014b8a9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf4fa35d-93c9-41c3-a2ae-0298014b8a9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf4fa35d-93c9-41c3-a2ae-0298014b8a9f"]}], "subject": "CHEBI:63607", "supporting_text": ["1 INDICATIONS &amp; USAGE Linezolid tablets are an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "CCR5-tropic HIV-1", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f2a9725-6d91-5a90-9c20-dbc88c87367d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070806", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["other antiretroviral agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d0c668b7-4d36-574c-8db0-e8b910f04fb7", "medic_supporting_text_truncated": true, "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "MARAVIROC", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2b5e5c5d-852a-413b-825c-8491d4539e67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2b5e5c5d-852a-413b-825c-8491d4539e67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b5e5c5d-852a-413b-825c-8491d4539e67"]}], "subject": "CHEBI:63608", "supporting_text": ["1 INDICATIONS AND USAGE SELZENTRY, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of SELZENTRY in treatment-experienced subjects and one study in treatment-naïve subjects. Both studies in treatment-experienced subjects were conducted in clinically advanced, 3-class antiretroviral-experienced (NRTI, NNRTI, PI, or enfuvirtide) adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with SELZENTRY: Adult patients infected with only CCR5-tropic HIV-1 should use SELZENTRY. Tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for SELZENTRY use. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on SELZENTRY. [see Microbiology (12.4) Clinical Studies (14.3) ] . Use of SELZENTRY is not recommended in subjects with dual/mixed or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a phase 2 study of this patient group. The safety and efficacy of SELZENTRY have not been established in pediatric patients. In treatment-naïve subjects, more subjects treated with SELZENTRY experienced virologic failure and developed lamivudine resistance compared to efavirenz. [see Microbiology (12.4) Clinical Studies (14.3) ] SELZENTRY is a CCR5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1. In treatment-naïve subjects, more subjects treated with SELZENTRY experienced virologic failure and developed lamivudine resistance compared to efavirenz [see Microbiology (12.4) Clinical Studies (14.3) ]. Tropism testing with a highly sensitive tropism assay is required for the appropriate use"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "CCR5-tropic HIV-1", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6098bc8d-128e-5664-90ba-06a9e84287c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070806", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d0c668b7-4d36-574c-8db0-e8b910f04fb7", "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "MARAVIROC", "population_context_qualifier": "adult and pediatric patients 2 years of age and older weighing at least 10 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7b9c67b-10c6-45b5-b2a8-952cd350b0b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7b9c67b-10c6-45b5-b2a8-952cd350b0b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b9c67b-10c6-45b5-b2a8-952cd350b0b1"]}], "subject": "CHEBI:63608", "supporting_text": ["1 INDICATIONS AND USAGE Maraviroc is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "CCR5-tropic HIV-1", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b964dd61-b4e2-5e0f-a076-807afc2f2686", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070806", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d0c668b7-4d36-574c-8db0-e8b910f04fb7", "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "MARAVIROC", "population_context_qualifier": "adult and pediatric patients 2 years of age and older weighing at least 10 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c4a1da5-a8e1-4038-970d-fb15c189c35e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c4a1da5-a8e1-4038-970d-fb15c189c35e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c4a1da5-a8e1-4038-970d-fb15c189c35e"]}], "subject": "CHEBI:63608", "supporting_text": ["1 INDICATIONS AND USAGE Maraviroc is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine-resistant strains of P. falciparum", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fd3918b-9a44-5d6c-b2be-3e37892945a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "MONDO:0005136", "original_object": "malaria", "original_subject": "MEFLOQUINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c47fd79-c0ca-42d6-9910-774272b25bc1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c47fd79-c0ca-42d6-9910-774272b25bc1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c47fd79-c0ca-42d6-9910-774272b25bc1"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "P. falciparum malaria, P. vivax malaria, chloroquine-resistant P. falciparum", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33f65116-d0b9-5cf9-b87f-c9b3a161aa1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "MONDO:0005136", "original_object": "malaria", "original_subject": "MEFLOQUINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4ed49c5-2a8b-4d2b-b8fb-a69a556a48cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4ed49c5-2a8b-4d2b-b8fb-a69a556a48cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4ed49c5-2a8b-4d2b-b8fb-a69a556a48cc"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with Mefloquine Hydrochloride Tablets, are at high risk of relapse because Mefloquine Hydrochloride Tablets do not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0858318", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8eaf15a4-222f-5c7d-b085-dd6aa033000b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0858318", "UMLS:C0858321"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "MONDO:0005136", "object_location_in_text": [129, 136], "original_object": "malaria", "original_subject": "MEFLOQUINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9cbe26c7-7313-4cd6-9514-9190af1de763", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9cbe26c7-7313-4cd6-9514-9190af1de763", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9cbe26c7-7313-4cd6-9514-9190af1de763"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae. Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "P. falciparum malaria, P. vivax malaria", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9093ffe-ced7-5dce-9809-090cff604b05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "MONDO:0005136", "object_location_in_text": [129, 136], "original_object": "malaria", "original_subject": "MEFLOQUINE", "population_context_qualifier": "prophylaxis of chloroquine-resistant strains of P. falciparum", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09716a24-d7da-42b2-af29-c03a1b6670bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09716a24-d7da-42b2-af29-c03a1b6670bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09716a24-d7da-42b2-af29-c03a1b6670bd"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae. Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "P. falciparum malaria, P. vivax malaria, chloroquine-resistant P. falciparum", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e19b7fea-b38d-5877-a20c-6ea8d96bd0ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "MONDO:0005136", "original_object": "malaria", "original_subject": "MEFLOQUINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ccbb82-3804-4f02-bf17-f07e22a8b02a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ccbb82-3804-4f02-bf17-f07e22a8b02a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ccbb82-3804-4f02-bf17-f07e22a8b02a"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with Mefloquine Hydrochloride Tablets, are at high risk of relapse because Mefloquine Hydrochloride Tablets do not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "P. falciparum malaria, P. vivax malaria", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e4a8ec4-93b9-5ad3-9c3b-feab7ed91191", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3dc95598-f0b1-54be-a64e-55af8d67fa3a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "UMLS:C2930826", "object_location_in_text": [123, 136], "original_object": "acute malaria", "original_subject": "MEFLOQUINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6ccbb82-3804-4f02-bf17-f07e22a8b02a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6ccbb82-3804-4f02-bf17-f07e22a8b02a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6ccbb82-3804-4f02-bf17-f07e22a8b02a"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with Mefloquine Hydrochloride Tablets, are at high risk of relapse because Mefloquine Hydrochloride Tablets do not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "P. falciparum malaria, P. vivax malaria", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b28d8584-f11a-5095-8e1f-4487b99f86f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890502", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3dc95598-f0b1-54be-a64e-55af8d67fa3a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f596834d-7e24-5228-82dd-8b098e906a4b", "object": "UMLS:C2930826", "object_location_in_text": [123, 136], "original_object": "acute malaria", "original_subject": "MEFLOQUINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4ed49c5-2a8b-4d2b-b8fb-a69a556a48cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4ed49c5-2a8b-4d2b-b8fb-a69a556a48cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4ed49c5-2a8b-4d2b-b8fb-a69a556a48cc"]}], "subject": "CHEBI:63609", "supporting_text": ["Treatment of Acute Malaria Infections Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with Mefloquine Hydrochloride Tablets, are at high risk of relapse because Mefloquine Hydrochloride Tablets do not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemotherapy-refractory or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d46f28f-2e53-5b05-8563-709a844b68f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:869ac7ef-f16d-47d9-8897-29add0679dd7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=869ac7ef-f16d-47d9-8897-29add0679dd7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=869ac7ef-f16d-47d9-8897-29add0679dd7"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. NELARABINE INJECTION is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "treatment-refractory or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e43f71b-c279-5b3b-86d3-6ff3a816e0d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:03ad6056-0e71-4e7c-842a-a5f87649bdcd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=03ad6056-0e71-4e7c-842a-a5f87649bdcd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03ad6056-0e71-4e7c-842a-a5f87649bdcd"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Nelarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease that has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68008650-0767-5c29-afcc-f82e984740d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e425731e-626b-4141-a997-fb85e077c2a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e425731e-626b-4141-a997-fb85e077c2a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e425731e-626b-4141-a997-fb85e077c2a4"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease that has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:811baac7-4fab-5abe-9b9b-3cf153f69af1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8cb23281-93ca-40b8-b8e0-c57dd4298322", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8cb23281-93ca-40b8-b8e0-c57dd4298322", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8cb23281-93ca-40b8-b8e0-c57dd4298322"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemotherapy-refractory or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82341932-8796-5e87-90d6-9c5b377d857d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc401b06-4e3b-413e-a854-3e031c433862", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc401b06-4e3b-413e-a854-3e031c433862", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc401b06-4e3b-413e-a854-3e031c433862"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemotherapy-refractory or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abb393d8-1b45-5699-b84b-d4ec110be730", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f9051de-5c4d-4c0f-8c19-e15214498cca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f9051de-5c4d-4c0f-8c19-e15214498cca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f9051de-5c4d-4c0f-8c19-e15214498cca"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemotherapy-refractory or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4f1c244-f720-5b70-87eb-66474f102959", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2a08758-9a9d-49a2-a498-9da109045ee9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2a08758-9a9d-49a2-a498-9da109045ee9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2a08758-9a9d-49a2-a498-9da109045ee9"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemotherapy-resistant or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfe5d746-0fa0-5c40-b3bb-bc8171eb950a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d0e1b59-bd1e-4c6e-9a95-e8143ee076bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d0e1b59-bd1e-4c6e-9a95-e8143ee076bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d0e1b59-bd1e-4c6e-9a95-e8143ee076bf"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chemotherapy-refractory or relapsed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9ace551-a057-513c-b2f3-a261b40a818b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1cc1580-50d9-4b9b-a002-1fc6686a9515", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1cc1580-50d9-4b9b-a002-1fc6686a9515", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1cc1580-50d9-4b9b-a002-1fc6686a9515"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS &amp; USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. Nelarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4a91bee-1bd8-50a7-a63f-f994fc431cf6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051028", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c3241031-b300-52b3-9a96-1f99b55e92bb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:bf2fd2ee-05dc-5857-ba84-2dfdd2e2c4a8", "object": "MONDO:0004963", "original_object": "T-cell acute lymphoblastic leukemia", "original_subject": "NELARABINE", "population_context_qualifier": "adult and pediatric patients age 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f60da70f-2f9e-421d-a277-95b1edb57a71", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f60da70f-2f9e-421d-a277-95b1edb57a71", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f60da70f-2f9e-421d-a277-95b1edb57a71"]}], "subject": "CHEBI:63612", "supporting_text": ["1 INDICATIONS AND USAGE Nelarabine is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease is unresectable or who are otherwise not candidates for curative surgery", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53f63996-591b-5b1e-bc77-fb66e446d84b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:be78ffac-5f99-515a-9d03-9b27ecfd123c", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "MONDO:0005112", "original_object": "malignant pleural mesothelioma", "original_subject": "PEMETREXED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe432994-e61b-4a87-8c98-cc20b847d0fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe432994-e61b-4a87-8c98-cc20b847d0fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe432994-e61b-4a87-8c98-cc20b847d0fe"]}], "subject": "CHEBI:63616", "supporting_text": ["1 INDICATIONS AND USAGE Pemetrexed Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (1.1) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. (1.1) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.1) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (1.1)"], "temporal_context_qualifier": "initial treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-small cell lung cancer other than predominantly squamous cell histology", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09c4718b-e49c-5469-8146-c69b472c0780", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040920", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "MONDO:0005233", "object_location_in_text": [356, 382], "original_object": "non-small cell lung cancer", "original_subject": "pemetrexed", "population_context_qualifier": "patients with locally advanced or metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pemetrexed-accord", "https://www.ema.europa.eu/en/documents/product-information/pemetrexed-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-accord"]}], "subject": "CHEBI:63616", "supporting_text": ["Malignant pleural mesothelioma Pemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology."], "temporal_context_qualifier": "second line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-small cell lung cancer other than predominantly squamous cell histology", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecf5503b-631b-5d15-9976-531513e0a8a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040920", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "MONDO:0005233", "object_location_in_text": [356, 382], "original_object": "non-small cell lung cancer", "original_subject": "pemetrexed", "population_context_qualifier": "patients with locally advanced or metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pemetrexed-pfizer", "https://www.ema.europa.eu/en/documents/product-information/pemetrexed-pfizer-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer"]}], "subject": "CHEBI:63616", "supporting_text": ["Malignant pleural mesothelioma Pemetrexed Pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology."], "temporal_context_qualifier": "second-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "no EGFR or ALK genomic tumor aberrations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83bca728-9229-5e44-93fe-5bf986a90af6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pembrolizumab", "platinum chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "UMLS:C0278987", "object_location_in_text": [203, 240], "original_object": "metastatic non-small cell lung cancer", "original_subject": "PEMETREXED", "population_context_qualifier": "patients with metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dfd19e67-54cb-c062-e053-2995a90a294a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dfd19e67-54cb-c062-e053-2995a90a294a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dfd19e67-54cb-c062-e053-2995a90a294a"]}], "subject": "CHEBI:63616", "supporting_text": ["1 INDICATIONS AND USAGE Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fd8304f-bdbd-5436-84f3-07710373d17f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pembrolizumab", "platinum chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:010adf15-d619-5ba3-9610-6059c2ce6328", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "UMLS:C4288755", "object_location_in_text": [199, 249], "original_object": "metastatic non-squamous non-small cell lung cancer", "original_subject": "PEMETREXED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b660f68-b770-4e0a-b2f9-25e663deecc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b660f68-b770-4e0a-b2f9-25e663deecc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b660f68-b770-4e0a-b2f9-25e663deecc3"]}], "subject": "CHEBI:63616", "supporting_text": ["1 INDICATIONS AND USAGE Pemetrexed Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "no EGFR or ALK genomic tumor aberrations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38f7abc7-da0c-5ea9-bb30-d91cdcc63405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pembrolizumab", "platinum chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:010adf15-d619-5ba3-9610-6059c2ce6328", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "UMLS:C4288755", "object_location_in_text": [193, 243], "original_object": "metastatic non-squamous non-small cell lung cancer", "original_subject": "PEMETREXED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f006b06-ab85-423d-ba0c-dfc3fc25844e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f006b06-ab85-423d-ba0c-dfc3fc25844e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f006b06-ab85-423d-ba0c-dfc3fc25844e"]}], "subject": "CHEBI:63616", "supporting_text": ["1. INDICATIONS AND USAGE PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 )"], "temporal_context_qualifier": "initial treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "EGFR or ALK genomic tumor aberrations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92f16983-d2bb-5db3-a6f9-592ffd4c360d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pembrolizumab", "platinum chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:010adf15-d619-5ba3-9610-6059c2ce6328", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "UMLS:C4288755", "object_location_in_text": [204, 254], "original_object": "metastatic non-squamous non-small cell lung cancer", "original_subject": "PEMETREXED", "population_context_qualifier": "patients with no EGFR or ALK genomic tumor aberrations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:21a607a6-1ec3-e61b-7d89-c71e3bdc2e3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=21a607a6-1ec3-e61b-7d89-c71e3bdc2e3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21a607a6-1ec3-e61b-7d89-c71e3bdc2e3b"]}], "subject": "CHEBI:63616", "supporting_text": ["1 INDICATIONS AND USAGE Pemetrexed for injection is a folate analog metabolic inhibitor indicated: • in combination with pembrolizumab and platinum chemotherapy,for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. (1.1) • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.1) • as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "no EGFR or ALK genomic tumor aberrations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d30133fc-94c1-5674-8ea5-cc3b92446edf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pembrolizumab", "platinum chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:010adf15-d619-5ba3-9610-6059c2ce6328", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "UMLS:C4288755", "object_location_in_text": [199, 249], "original_object": "metastatic non-squamous non-small cell lung cancer", "original_subject": "PEMETREXED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe432994-e61b-4a87-8c98-cc20b847d0fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe432994-e61b-4a87-8c98-cc20b847d0fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe432994-e61b-4a87-8c98-cc20b847d0fe"]}], "subject": "CHEBI:63616", "supporting_text": ["1 INDICATIONS AND USAGE Pemetrexed Injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (1.1) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. (1.1) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.1) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (1.1)"], "temporal_context_qualifier": "initial treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4324656", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ca0d545-eaec-5df5-83f6-bde4344c8764", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040204", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4324656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11d111d1-4ab4-5151-b1d7-b7c1dbe50d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:324e82b3-ee9b-5fc4-ae3b-fbfdbbe4a9c2", "object": "UMLS:C4324656", "original_object": "locally advanced or metastatic non-squamous non-small cell lung cancer", "original_subject": "PEMETREXED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3"]}], "subject": "CHEBI:63616", "supporting_text": ["1 INDICATIONS AND USAGE Pemetrexed Injection is a folate analog metabolic inhibitor indicated: • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) • as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 )"], "temporal_context_qualifier": "after four cycles of platinum-based first-line chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12aed0ef-4d2c-5425-82c4-b5b7bc199fe8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [91, 112], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16a29055-8d66-5054-8070-c9317876e6e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [90, 111], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16c43757-f195-545b-a32e-f79b176571ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [91, 112], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:228dc0f0-7f58-57d6-8309-83c12f6e1f8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24d93f28-9271-54f5-8d31-c9534bc62407", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [178, 199], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: • Primary dysbetalipoproteinemia. • Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bea4541-2d42-5d5e-b4cf-1e005a9821ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [90, 111], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient is chemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f2a327f-f51c-5f73-8815-03117e6e16e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [90, 111], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:427f7e15-6eea-50f0-a05e-604d01d8d78f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7102a793-9572-5b2a-acdb-68ce40a6d8ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72cc6e3d-fd95-54cd-8ee3-83b6d4867c85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97897352-f15c-537b-b2fc-7c8ddc75eb1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1f3869a-e881-5f70-b5b8-324e228b7688", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [90, 111], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9454f04-f52f-573f-bc77-7339e0f67812", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9e5a5b4-3d06-5776-a40b-614b9fe362e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [91, 112], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1d2d339-43ab-5dd5-97f7-c954461593a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9a24605-4547-5b23-93b9-9e70db3aecb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebf3b858-7293-5711-b922-a1c5b00d3477", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee679ded-d5cb-576c-ab5c-20b15698edc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff01b3b7-0ed7-5364-b37b-a6397bce39ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005068", "object_location_in_text": [88, 109], "original_object": "myocardial infarction", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11b9d8ca-34a3-5aec-bd76-5adcf53f43e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19630688-7f63-5ee7-9d4c-8056bc6155cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34f56772-ed69-57bc-b618-c20e5e0d9561", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35233a3c-3843-5709-a546-9f80c35df629", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [414, 420], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d02c570-2cdb-53a7-92e6-33d611e3e842", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [412, 418], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e95e46b-d769-5959-a2d5-4f22bbc17953", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [412, 418], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient is chemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44e5c214-97fe-5648-88cd-7a5ef267798c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [414, 420], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50995d1e-95ee-5292-9764-0746a81a1e61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [414, 420], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d7667aa-56e6-5dec-b519-544e17f403e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fb059ec-ea68-5f3f-bb44-c898586e6eeb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73ade71e-9151-52f2-8477-fb90e10f92d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [412, 418], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87d0a19d-9363-5a70-b7ae-9e630a4ada64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b274ebb9-092c-520b-9f84-5b86a2b1e950", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdad624f-899c-5de4-a9c5-5458b2d8ede7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [413, 419], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4008695-f92d-505f-9181-4be018dd5792", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdb52a22-b726-5afa-8ab4-051245d527e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3c9a7f0-bb7d-5e8a-abe8-f169c94b054b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea1aeb6d-e769-5144-9776-be1c59540383", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [500, 506], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: • Primary dysbetalipoproteinemia. • Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f066369a-7a72-586c-802c-458888188573", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005098", "object_location_in_text": [408, 414], "original_object": "stroke", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d4d0c1d-b51a-5f45-b278-07a9c9defc80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:199356ee-86fd-55cc-8380-8ec96345f4ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a5c3f7d-fc87-573e-9941-11eede573c47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient is chemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72fd6f69-b6b7-549e-bed4-71ba51dd8978", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [422, 447], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84bfee9c-2ada-5f0b-9c75-9ff4bb340f49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87ffc960-f51e-52af-ab96-e3326528e32e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:889ca70f-c807-5a80-8317-cbbf250165a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d5da8c4-0009-5375-8706-84e75fc5a0c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92b95af4-6f2f-5ff0-a18e-291b37a5c9ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [424, 449], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9503a078-2a12-5f10-a109-11305359a0c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [422, 447], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96267d24-9654-5c20-bac4-0d2255f401ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96aa177b-7fe9-5ec2-a030-f3bf732ed97f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [424, 449], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:992bead1-4cc2-5605-8af1-2c0b73682119", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b57f909e-7010-545a-a317-a99b6712cf1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5d229e5-ab48-5e35-a8ad-d0cabe13d7aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8e9a556-21b6-5b40-8944-86bece1c4159", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [418, 443], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d96a2cbd-e3bc-5b29-b5a3-43e85aa93a1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [510, 535], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: • Primary dysbetalipoproteinemia. • Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df039902-f42a-55ee-a857-5c14d0537b77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [424, 449], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5c92e28-0baf-542c-b6b0-035d9756ae22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d76a9f50-ccaf-5fde-8ce5-aa2b14699461", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0005264", "object_location_in_text": [423, 448], "original_object": "transient ischemic attack", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:466f709a-3fb7-51e5-9424-1b8ddf70c0c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5f611aa-9974-422e-a353-5d834a33937c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:481aaeb0-1b62-5539-b935-797f781cee01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "object_location_in_text": [565, 589], "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095ac6fd-fdfb-4207-b15d-8e93bee378c3"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: • Primary dysbetalipoproteinemia. • Hypertriglyceridemia."], "temporal_context_qualifier": "progression"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ee5ddf4-00ec-5493-9918-a716cdd74c38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42ccbca7-fa52-4df9-8f1a-ea7da7312883"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85bbc81d-ec31-559c-8f84-065e37c320e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dbdc80d-9d8c-4e22-9108-d87a77e07a6b"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:870209f3-6049-5e37-848d-c1a17f907f2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4dbaa72-7b3e-4aef-983b-90efb2b343cd"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9133f0ad-62f5-5967-acf1-4cd2ff8cd091", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b06ed801-ddee-4f56-924a-59fcb451eae6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a16d3990-6701-5b9b-8d1f-0e0f84d2ea10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cef5e92-26b7-435c-878f-72a05a624560"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0d81fa8-cda0-511e-ae18-2e0eb22369a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "object_location_in_text": [479, 503], "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebd794ba-90c3-4d81-9c45-4aa9d9454359"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."], "temporal_context_qualifier": "progression of coronary atherosclerosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dcb2e294-2d9c-5567-9e2d-63c3c53672ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dcdea97f-029e-5c5b-a893-f3790a49cf53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "object_location_in_text": [479, 503], "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46cdd32d-a022-4acf-ba2b-10e7877d56c6"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."], "temporal_context_qualifier": "progression of coronary atherosclerosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0f463c2-afdc-500f-bb43-473850324e9b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ae196a4-be3d-4cd8-9ff2-68aeb91b8678"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5e357b6-7085-5195-b3eb-92571b75a30e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa152ce7-6c07-4aaf-9374-932ce81d0cf9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee0744b9-ffdb-5616-8901-078389680909", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "object_location_in_text": [479, 503], "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d42bd30-1f09-49f4-9ec8-31366df1b4b4"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: 1. To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). 2. To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. 3. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. 4. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). 5. As an adjunct to diet for the treatment of adults with: 1. Primary dysbetalipoproteinemia. 2. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."], "temporal_context_qualifier": "progression of coronary atherosclerosis"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee111341-9f7d-5255-8b91-ee977b49b16a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76e5fdf8-bd03-4cd5-9361-e61678cb3de9"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efca7d01-9e6f-5a98-a4bf-e03a994dc311", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ecd9fd1-7662-412d-99c5-13c77188748c"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2676a03c-5301-5913-bf69-428026ad1564", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d5bce9c-a788-4c52-a69e-c53174b8d061"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41bf754b-786f-5567-b96c-c023b61d10f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "object_location_in_text": [478, 502], "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce15ad07-3286-478f-9f30-1db6a45ed402"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient is chemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d773ea9-1f75-52d1-a2ad-2e5265c470c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e218ad6-5b47-4cca-81be-ebaea5795964"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "clinically evident coronary heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:daa1708f-e4e9-5d0b-8df1-c6a015ebd9ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b744d66d-ca80-500a-9786-855214aabeed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:583821fa-5e49-57d3-af62-d09cf791847f", "object": "MONDO:0021661", "object_location_in_text": [478, 502], "original_object": "coronary atherosclerosis", "original_subject": "PRAVASTATIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=678dfe58-3200-4c3d-9718-365aa47d070f"]}], "subject": "CHEBI:63618", "supporting_text": ["1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low- density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). • To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18aa2ec5-3c59-5acd-9044-9fc8cbac8eaa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c65253ab-937f-4982-b841-69c2b9f9ccdb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c65253ab-937f-4982-b841-69c2b9f9ccdb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c65253ab-937f-4982-b841-69c2b9f9ccdb"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning] . Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18f41dc8-0c51-5e49-90cf-619ab06994bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41b4e503-60a6-4662-a6f9-46ecf93d930a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41b4e503-60a6-4662-a6f9-46ecf93d930a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41b4e503-60a6-4662-a6f9-46ecf93d930a"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c5a9416-f1fb-5cb2-882a-d353ac6ebb89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28a3c4af-5819-5e71-981d-4d726167733e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28e31482-4fce-5b08-a312-563e56d6b2f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d3ba484-0c0d-5935-895f-b5fb57638f86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9da7e6d2-64da-43cd-9575-b2b0d5d412dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9da7e6d2-64da-43cd-9575-b2b0d5d412dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9da7e6d2-64da-43cd-9575-b2b0d5d412dc"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:320fdbd4-250c-5c85-a029-7c73a5d852cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da08c286-b930-463a-858a-efc54f12019f"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympt"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34fe33fe-2e7b-5c22-9acf-7c29c1564cdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a96f9c6f-4c9c-4406-bca8-08bf9a4af1f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a96f9c6f-4c9c-4406-bca8-08bf9a4af1f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a96f9c6f-4c9c-4406-bca8-08bf9a4af1f4"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning] . Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b4a74d6-739b-51c9-80f3-e64cbee0a218", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2492317c-8b04-477e-a5d2-53e791fface9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2492317c-8b04-477e-a5d2-53e791fface9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2492317c-8b04-477e-a5d2-53e791fface9"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6bf52e26-60be-5390-beb5-2eb5e95c1215", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:617faff7-d9e4-477d-ab2c-aded5c129a86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=617faff7-d9e4-477d-ab2c-aded5c129a86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=617faff7-d9e4-477d-ab2c-aded5c129a86"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e6dfb10-3746-55a3-9ff6-17c733219f80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:343e4ad7-05e2-4e6c-8f8e-91c07739cae2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=343e4ad7-05e2-4e6c-8f8e-91c07739cae2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=343e4ad7-05e2-4e6c-8f8e-91c07739cae2"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ]. Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b4d8425-6d39-507b-8d58-834e749fdc36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ed5dba7-ef28-575e-86a7-e3e9f80c1e46", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6ac2a70-e0ec-4fcd-8732-5f1637be1e60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6ac2a70-e0ec-4fcd-8732-5f1637be1e60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6ac2a70-e0ec-4fcd-8732-5f1637be1e60"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:926aa985-1fad-564c-925a-5cbc0d91d840", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7bcc5d3b-b2c9-4753-9eef-b5360538f5ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7bcc5d3b-b2c9-4753-9eef-b5360538f5ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7bcc5d3b-b2c9-4753-9eef-b5360538f5ee"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dac71694-1edd-5b5c-88e3-eca9c9055324", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e38962a2-68c6-5f75-9d0d-d2eedab52b66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d1be333-be2b-4064-86a4-c2ad9ad07b83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d1be333-be2b-4064-86a4-c2ad9ad07b83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d1be333-be2b-4064-86a4-c2ad9ad07b83"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed9b0e57-fe16-56ee-b95a-57d97f69b460", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f174e1-f249-4f34-806d-20e643084429"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f11375b4-f407-558a-b203-c0874576c0c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8407044-0c8c-5e68-a8a1-6f8f6d9be293", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "HP:0004763", "object_location_in_text": [270, 309], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=739b7624-952d-4343-b720-974d30e284d9"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18698d4d-07ea-5efc-a2a8-2ddcb3bfe8ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2492317c-8b04-477e-a5d2-53e791fface9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2492317c-8b04-477e-a5d2-53e791fface9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2492317c-8b04-477e-a5d2-53e791fface9"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:196bcd3a-c3ee-5f8b-a662-c96363ecbcbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:617faff7-d9e4-477d-ab2c-aded5c129a86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=617faff7-d9e4-477d-ab2c-aded5c129a86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=617faff7-d9e4-477d-ab2c-aded5c129a86"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62c7224b-3ffe-5c6e-8670-7cedacf11420", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6ac2a70-e0ec-4fcd-8732-5f1637be1e60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6ac2a70-e0ec-4fcd-8732-5f1637be1e60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6ac2a70-e0ec-4fcd-8732-5f1637be1e60"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "structural heart disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82c989ac-136e-578d-9bc2-01d3d957923b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ecd6452-ccc3-493f-9a4a-69f0fbf67a42", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ecd6452-ccc3-493f-9a4a-69f0fbf67a42", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ecd6452-ccc3-493f-9a4a-69f0fbf67a42"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride extended-release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Usage Considerations: • The use of propafenone hydrochloride extended-release capsules in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use propafenone hydrochloride extended-release capsules to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride extended-release capsules are an antiarrhythmic indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) Usage Considerations: • Use in patients with permanent atrial fibrillation or with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use to control ventricular rate during atrial fibrillation. ( 1 ) • In patients with atrial fibrillation and atrial flutter, use propafenone hydrochloride extended-release capsules with drugs that increase the atrioventricular nodal refractory period. ( 1 ) • The effect of propafenone on mortality has not been determined. ( 1 )"], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0fc4d71-5493-5f32-a6d7-526d83a86a05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7bcc5d3b-b2c9-4753-9eef-b5360538f5ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7bcc5d3b-b2c9-4753-9eef-b5360538f5ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7bcc5d3b-b2c9-4753-9eef-b5360538f5ee"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dba0cf9e-9db9-5565-8a92-351ea57a3789", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41b4e503-60a6-4662-a6f9-46ecf93d930a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41b4e503-60a6-4662-a6f9-46ecf93d930a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41b4e503-60a6-4662-a6f9-46ecf93d930a"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc26228d-908c-50fb-a0bb-83a49b746a2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d1be333-be2b-4064-86a4-c2ad9ad07b83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d1be333-be2b-4064-86a4-c2ad9ad07b83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d1be333-be2b-4064-86a4-c2ad9ad07b83"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "episodic AF", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc6f97d1-9fe3-5406-9ed4-e7bed53a1e59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:0004981", "original_object": "atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients with episodic AF who do not have structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9da7e6d2-64da-43cd-9575-b2b0d5d412dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9da7e6d2-64da-43cd-9575-b2b0d5d412dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9da7e6d2-64da-43cd-9575-b2b0d5d412dc"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: • prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. • treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: • The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. • Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. • Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. • The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: • prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) • prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associate"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ea6bda4-0065-57ce-bfe3-63ebd713adb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da08c286-b930-463a-858a-efc54f12019f"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympt"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43bca80b-7826-5efd-9831-e9a5393d92f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:343e4ad7-05e2-4e6c-8f8e-91c07739cae2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=343e4ad7-05e2-4e6c-8f8e-91c07739cae2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=343e4ad7-05e2-4e6c-8f8e-91c07739cae2"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ]. Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49033450-e5da-524f-8371-cd269317752b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=739b7624-952d-4343-b720-974d30e284d9"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d81f887-f198-5118-b68d-c0a5d50dfaba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f174e1-f249-4f34-806d-20e643084429"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a5a9692-a4ee-5895-b988-2f22634be9ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75668829-8c5e-5e08-9e61-24ac75804bff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:864321b6-da11-5b2d-8da0-10bd5cb12414", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1b11acb-da0c-5aa5-b424-a473d47da29d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cee11da9-9b78-521e-97c7-c467f3b99bfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddfa8a45-65c8-512a-b4fd-85c960c34da7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:281e66cd-64e4-5f93-9c01-44fa6184e343", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "MONDO:1030011", "object_location_in_text": [110, 140], "original_object": "paroxysmal atrial fibrillation", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38411c8e-4b6a-53c1-90de-6c9fae9bd9d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da08c286-b930-463a-858a-efc54f12019f"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympt"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:481b50bd-0417-5047-8a96-13b94ff6623e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ac1db49-8502-58eb-b433-6a6adca0b660", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b5fbf7d-071c-5ec4-8885-0c2800764dd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5427cce-05db-5bc9-a633-7d58b8be73a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:add68d1d-8ff5-5284-b7a7-05e615502f7a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:343e4ad7-05e2-4e6c-8f8e-91c07739cae2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=343e4ad7-05e2-4e6c-8f8e-91c07739cae2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=343e4ad7-05e2-4e6c-8f8e-91c07739cae2"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ]. Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c32969af-4506-5a6d-9702-c8786e1f3b6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=739b7624-952d-4343-b720-974d30e284d9"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da12b9c1-34a4-53b9-a320-48c58b9aeeec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f86b41a3-78b6-5f1e-a798-237454a2a42d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f174e1-f249-4f34-806d-20e643084429"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disabling symptoms", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fea98397-b198-52b5-94f5-59f03e2a46c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b10d37e-380e-5d04-8053-5cb12903b433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0741292", "original_object": "paroxysmal atrial flutter", "original_subject": "PROPAFENONE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2826244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02fa0d8e-87b9-5564-b6ea-5f70aabbf9c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2826244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=faa8e971-4b4f-43db-be97-33acc16dcdc7"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:382dc2a7-dcbf-5912-8b45-341281d6aa0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=739b7624-952d-4343-b720-974d30e284d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=739b7624-952d-4343-b720-974d30e284d9"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2826244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4aab8e88-c918-5404-bd18-ce2198bb4d59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2826244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8ad1f0f-0e95-4868-a2af-e193c1833841"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:801e0b70-ba58-5cbe-842b-9db50339dd40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c8cebcd-699f-4c4c-900b-94e0fe519345"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2826244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83f5300c-5bec-5752-ae38-dbfcf71f6a42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2826244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=80f174e1-f249-4f34-806d-20e643084429", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80f174e1-f249-4f34-806d-20e643084429"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2826244", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:856dddf9-eab1-58a1-b9b1-1e0f85b4e655", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2826244"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c887381-42fe-4f37-858a-d9ffb218dd1c"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride is an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8a45463-bf71-5f90-b165-0862882073a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7202aed6-40a9-2bff-e053-2a95a90ae752"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5ccf426-d836-56db-96c5-ffa4cf1a7702", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da08c286-b930-463a-858a-efc54f12019f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da08c286-b930-463a-858a-efc54f12019f"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone hydrochloride tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone hydrochloride tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. (1) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sympt"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1a91508-e208-5bca-913e-7a39fe64eb16", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19891127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71f5f659-467f-57a4-bc6d-abcee4a0fe53", "medic_supporting_text_truncated": true, "object": "UMLS:C0750197", "object_location_in_text": [448, 481], "original_object": "sustained ventricular tachycardia", "original_subject": "PROPAFENONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=680a803d-3d4d-4ca3-b1ce-7d7e3ff8a626"]}], "subject": "CHEBI:63619", "supporting_text": ["1 INDICATIONS AND USAGE Propafenone Hydrochloride Tablets are indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of Propafenone Hydrochloride Tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use Propafenone Hydrochloride Tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of Propafenone Hydrochloride Tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of Propafenone Hydrochloride Tablets, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ] . Propafenone Hydrochloride Tablets are an antiarrhythmic indicated to: prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atrial fibrillation or flutter", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0544b633-9fe5-5460-b2c0-430b91c063de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c538a08-c421-58d0-b754-9ec00b9086e0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0232202", "object_location_in_text": [176, 195], "original_object": "normal sinus rhythm", "original_subject": "SOTALOL", "population_context_qualifier": "patients with atrial fibrillation or flutter", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6ea445d-4d7c-4c32-83a7-e7683a56075b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6ea445d-4d7c-4c32-83a7-e7683a56075b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6ea445d-4d7c-4c32-83a7-e7683a56075b"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atrial fibrillation or flutter", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f34109b-4bce-56e0-af1e-a48c62785e5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c538a08-c421-58d0-b754-9ec00b9086e0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0232202", "object_location_in_text": [176, 195], "original_object": "normal sinus rhythm", "original_subject": "SOTALOL", "population_context_qualifier": "patients with atrial fibrillation or flutter", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bbeaba9f-0513-4980-bc29-7f9259a53ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bbeaba9f-0513-4980-bc29-7f9259a53ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bbeaba9f-0513-4980-bc29-7f9259a53ecc"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atrial fibrillation or flutter", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a1a004e-fa75-5f61-b7c9-4d125125534b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c538a08-c421-58d0-b754-9ec00b9086e0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0232202", "object_location_in_text": [201, 220], "original_object": "normal sinus rhythm", "original_subject": "SOTALOL", "population_context_qualifier": "patients with atrial fibrillation or flutter", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bcbc1624-283e-732f-e053-2995a90a8f11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bcbc1624-283e-732f-e053-2995a90a8f11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bcbc1624-283e-732f-e053-2995a90a8f11"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride/Sotalol hydrochloride AF tablets are an antiarrhythmic indicated for: the treatment of life threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.09, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:035d511d-8aa0-5233-8217-1bf82213b491", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.09, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0750197", "original_object": "sustained ventricular tachycardia", "original_subject": "SOTALOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:667fc1f2-6ccf-4373-89d8-6a064ee7509e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=667fc1f2-6ccf-4373-89d8-6a064ee7509e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=667fc1f2-6ccf-4373-89d8-6a064ee7509e"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.09, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b4c285a-a663-5e37-a107-93b05f48492b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.09, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0750197", "original_object": "sustained ventricular tachycardia", "original_subject": "SOTALOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7cb4879f-31e7-4862-bc0c-d439e592d81c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7cb4879f-31e7-4862-bc0c-d439e592d81c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7cb4879f-31e7-4862-bc0c-d439e592d81c"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride/Sotalol hydrochloride AF tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.09, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f3f4788-f479-5d61-b15c-9bf0fe25d803", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.09, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0750197", "original_object": "sustained ventricular tachycardia", "original_subject": "SOTALOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a36d95c-6e93-4e57-befe-b5274f359244", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a36d95c-6e93-4e57-befe-b5274f359244", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a36d95c-6e93-4e57-befe-b5274f359244"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.09, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f5db98a-56cb-5a17-a7dc-94a7203e0f7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.09, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0750197", "original_object": "sustained ventricular tachycardia", "original_subject": "SOTALOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a56c82e-7ecd-43b0-2899-f89e47adf7db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a56c82e-7ecd-43b0-2899-f89e47adf7db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a56c82e-7ecd-43b0-2899-f89e47adf7db"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride/Sotalol hydrochloride AF tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening ventricular arrhythmias", "has_confidence_score": 0.09, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6aa231f4-5d56-5cf8-ac19-686691e92f37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921030", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.09, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78f53e3c-4eea-58fb-83db-47896ec5f3d1", "object": "UMLS:C0750197", "original_object": "sustained ventricular tachycardia", "original_subject": "SOTALOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe82c866-03d4-e07b-e053-6394a90a8b1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe82c866-03d4-e07b-e053-6394a90a8b1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe82c866-03d4-e07b-e053-6394a90a8b1e"]}], "subject": "CHEBI:63622", "supporting_text": ["1 INDICATIONS AND USAGE Sotalol hydrochloride/Sotalol hydrochloride AF tablets are an antiarrhythmic indicated for: the treatment of life-threatening ventricular arrhythmias ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27c61a5a-4c05-5da3-802b-d1c15c864861", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [1009, 1019], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebe89ab6-24c0-4214-853f-67e2e0c7daa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebe89ab6-24c0-4214-853f-67e2e0c7daa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebe89ab6-24c0-4214-853f-67e2e0c7daa9"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.6 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e078f8c-9bc8-528b-a8c5-9db332d9999b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [1009, 1019], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:704c8f86-9098-5f42-aa4d-c4abacbf1b8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [752, 762], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Enter section text here Tindamax is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4, 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3, 14.4 )]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89427954-0dc7-58d3-8cdc-2dba815b30bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [489, 499], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )] . 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3 , 14.4 )] . 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as vaginitis, vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as and virus should be ruled out. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1209e96-7473-57b8-8a6b-1acd3fb6157e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [1009, 1019], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae0cc2f3-9f9a-5a99-ad6b-c5e835dd448d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [742, 752], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS &amp; USAGE Tinidazole Tablets is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non- pregnant, adult women ( 1.4 , 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies ( 14.2 ) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies ( 14.3 , 14.4 ) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [ see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 ) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tinidazole Tablets and other antibacterial drugs, Tinidazole Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible ba"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4505386", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c12c8c4d-1ede-5d04-9214-aae40d37cbc1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505386"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73c03601-af9d-520d-a02c-5b4be81894aa", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0001103", "object_location_in_text": [488, 498], "original_object": "giardiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tinidazole is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33f395ad-9211-515c-90b5-186b1dc2467b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:09ab2070-3504-5b61-b19f-68d7344721f8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0002154", "object_location_in_text": [607, 621], "original_object": "trichomoniasis", "original_subject": "TINIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ee65308-60e9-54e2-8329-3bf15336b1f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:09ab2070-3504-5b61-b19f-68d7344721f8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0002154", "object_location_in_text": [351, 365], "original_object": "trichomoniasis", "original_subject": "TINIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Enter section text here Tindamax is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4, 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3, 14.4 )]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4118eb8e-da92-5364-be81-7985032ffe09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:09ab2070-3504-5b61-b19f-68d7344721f8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0002154", "object_location_in_text": [341, 355], "original_object": "trichomoniasis", "original_subject": "TINIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS &amp; USAGE Tinidazole Tablets is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non- pregnant, adult women ( 1.4 , 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies ( 14.2 ) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies ( 14.3 , 14.4 ) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [ see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 ) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tinidazole Tablets and other antibacterial drugs, Tinidazole Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible ba"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e3c9dd0-9a22-5897-b7a2-5b5a51ff4e4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:09ab2070-3504-5b61-b19f-68d7344721f8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0002154", "object_location_in_text": [607, 621], "original_object": "trichomoniasis", "original_subject": "TINIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:948e9c44-e6e8-55c2-8daa-d91525ad5610", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:09ab2070-3504-5b61-b19f-68d7344721f8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0002154", "object_location_in_text": [88, 102], "original_object": "trichomoniasis", "original_subject": "TINIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tinidazole is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d805dc51-caed-5cb0-8eb0-9a91b2873499", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:09ab2070-3504-5b61-b19f-68d7344721f8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0002154", "object_location_in_text": [88, 102], "original_object": "trichomoniasis", "original_subject": "TINIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )] . 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3 , 14.4 )] . 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as vaginitis, vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as and virus should be ruled out. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1622505", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da6517ca-9403-52b9-8817-2e6c7cc09760", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1622505", "MONDO:0005316"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b95be0d-190b-5604-b141-60b5f6af1f1b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0005316", "object_location_in_text": [1030, 1049], "original_object": "bacterial vaginosis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adult women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tinidazole is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bf1b6d1-3c45-5871-83ea-d1c85e861aaa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [716, 736], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )] . 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3 , 14.4 )] . 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as vaginitis, vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as and virus should be ruled out. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b3ef3d9-8b3c-5e6c-bf72-f5a6b723e789", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [1235, 1255], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebe89ab6-24c0-4214-853f-67e2e0c7daa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebe89ab6-24c0-4214-853f-67e2e0c7daa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebe89ab6-24c0-4214-853f-67e2e0c7daa9"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.6 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3dd4ce1d-aece-54fc-80fd-b77c3580538e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [970, 990], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS &amp; USAGE Tinidazole Tablets is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non- pregnant, adult women ( 1.4 , 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies ( 14.2 ) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies ( 14.3 , 14.4 ) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [ see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 ) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tinidazole Tablets and other antibacterial drugs, Tinidazole Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible ba"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a30cd25-71f4-55f1-aa05-e7d1c4037372", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [978, 998], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Enter section text here Tindamax is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4, 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3, 14.4 )]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:842a1d76-a221-5f98-8634-56bed0a103e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [1235, 1255], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a13e1302-dd23-5d1f-b07f-b6bee7cbf28a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [711, 731], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tinidazole is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4afa86b-d928-5324-a0d2-69b5252325e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0127e91-3ce0-55a3-b19c-af169d3ff092", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "MONDO:0024275", "object_location_in_text": [1235, 1255], "original_object": "intestinal amebiasis", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10abbe8e-4416-55fc-802c-2714ad8cd429", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [995, 1015], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e03b4ac-c88a-4044-9d58-0cfcda3db53c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS &amp; USAGE Tinidazole Tablets is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non- pregnant, adult women ( 1.4 , 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies ( 14.2 ) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies ( 14.3 , 14.4 ) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [ see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 ) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tinidazole Tablets and other antibacterial drugs, Tinidazole Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible ba"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014323", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29ec1016-8de4-5ec2-a311-5e3ebab78122", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014323"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [759, 779], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0d01539-8413-4703-94cc-d221918630a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0d01539-8413-4703-94cc-d221918630a1"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of the"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:922b09c8-7e72-5e37-b189-23d94cb099fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [1260, 1280], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebe89ab6-24c0-4214-853f-67e2e0c7daa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebe89ab6-24c0-4214-853f-67e2e0c7daa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebe89ab6-24c0-4214-853f-67e2e0c7daa9"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.6 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9db78c15-5525-5d96-9213-b543bed1b45a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [736, 756], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f55bcc41-2e8d-4ee5-9993-05c7d86f2d2c"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tinidazole is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be89c964-0bf0-58f3-b669-f156756f84ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [1260, 1280], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f3ce597-64c1-4204-a67a-8b6f6e7e8bca"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c48cc31b-f4bd-5c80-9361-7e640d2d0289", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [741, 761], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9719883b-496d-42bb-e053-2995a90a1ab1"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )] . 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3 , 14.4 )] . 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as vaginitis, vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as and virus should be ruled out. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole and other antibacterial drugs, tinidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb8b3e53-b94d-56b1-ae90-8597db72d500", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [1003, 1023], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "adults and pediatric patients older than three years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc5aaeb2-a7c3-4ff5-a2be-4eaf162453fb"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Enter section text here Tindamax is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4, 8.1 ) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies ( 14.1 )]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [see Clinical Studies ( 14.2 )]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies ( 14.3, 14.4 )]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations ( 8.1 ) and Clinical Studies ( 14.5 )]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When cult"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4316791", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4d68afa-03de-5917-93ad-1dae5a2063e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040517", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4316791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a40bd6d5-f0ab-5493-9f04-f66b3d1cb5e4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fd5c5d-7a23-5bca-90e6-bd73c2b0b667", "medic_supporting_text_truncated": true, "object": "UMLS:C0023886", "object_location_in_text": [1260, 1280], "original_object": "amebic liver abscess", "original_subject": "TINIDAZOLE", "population_context_qualifier": "patients age 3 and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f552a9b-3190-4301-8352-36451a73b956"]}], "subject": "CHEBI:63627", "supporting_text": ["1 INDICATIONS AND USAGE Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis . The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [ see Clinical Studies (14.1) ]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia ) in both adults and pediatric patients older than three years of age [ see Clinical Studies (14.2) ]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [ see Clinical Studies (14.3 , 14.4) ]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations (8.1) and Clinical Studies (14.5) ]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HIV-1 strains resistant to more than one protease inhibitor", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2375a1ec-bccc-5cc2-8839-9ed9deb48802", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050622", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ritonavir"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42ef957b-5635-5a2d-b59c-806e571c0326", "medic_supporting_text_truncated": true, "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "TIPRANAVIR", "population_context_qualifier": "treatment-experienced adult and pediatric patients weighing 36 kg or higher", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08982e49-d2eb-4b25-b01a-1be52fd669ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08982e49-d2eb-4b25-b01a-1be52fd669ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08982e49-d2eb-4b25-b01a-1be52fd669ef"]}], "subject": "CHEBI:63628", "supporting_text": ["1 INDICATIONS AND USAGE APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug I"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Stage IV-B, recurrent, or persistent cervical cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a63154c3-e224-5ffd-85fb-7cc46d0f055a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3668116b-2cf1-58e7-8960-d2a4af01fef7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0002974", "original_object": "cervical cancer", "original_subject": "TOPOTECAN", "population_context_qualifier": "patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:729b2b22-1344-44f3-b614-14f6ec3c263e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=729b2b22-1344-44f3-b614-14f6ec3c263e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=729b2b22-1344-44f3-b614-14f6ec3c263e"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan Hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) 1.1 Ovarian Cancer Topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer Topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. 1.3 Cervical Cancer Topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Stage IV-B, recurrent, or persistent cervical cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f65b1bce-6009-52c8-b2f5-19418d05d6a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3668116b-2cf1-58e7-8960-d2a4af01fef7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0002974", "original_object": "cervical cancer", "original_subject": "TOPOTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eeee060c-a9ec-423e-a374-8484009f8524", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eeee060c-a9ec-423e-a374-8484009f8524", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eeee060c-a9ec-423e-a374-8484009f8524"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE HYCAMTIN for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) 1.1 Ovarian Cancer HYCAMTIN ® for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer HYCAMTIN for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first‑line chemotherapy. 1.3 Cervical Cancer HYCAMTIN for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "stage IVB disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07998cf1-01b1-5385-8429-deb89fcd2cde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961112", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:cffa6e99-49ea-5d75-9a8d-7ffb3b5ae988", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0005131", "object_location_in_text": [261, 284], "original_object": "carcinoma of the cervix", "original_subject": "topotecan", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:topotecan-hospira", "https://www.ema.europa.eu/en/documents/product-information/topotecan-hospira-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/topotecan-hospira"]}], "subject": "CHEBI:63632", "supporting_text": ["Topotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf556fd4-ac5e-5aea-a801-325028d0a057", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cffa6e99-49ea-5d75-9a8d-7ffb3b5ae988", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0005131", "object_location_in_text": [569, 592], "original_object": "carcinoma of the cervix", "original_subject": "TOPOTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7636bc1e-77b6-46ad-9df0-c8bb1c5e503f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7636bc1e-77b6-46ad-9df0-c8bb1c5e503f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7636bc1e-77b6-46ad-9df0-c8bb1c5e503f"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies ( 14 ) ] . Topotecan Injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. Topotecan is a topoisomerase inhibitor indicated for: small cell lung cancer sensitive disease after failure of first-line chemotherapy. ( 1 ) combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. ( 1 )"], "temporal_context_qualifier": "which is not amenable to curative treatment with surgery and/or radiation therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stage IV-B, recurrent, or persistent carcinoma of the cervix", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4b6266b-b972-5eac-b372-8be8b07dd46f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cffa6e99-49ea-5d75-9a8d-7ffb3b5ae988", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0005131", "object_location_in_text": [603, 626], "original_object": "carcinoma of the cervix", "original_subject": "TOPOTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a439bf07-53db-0352-846a-99d9da772f9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a439bf07-53db-0352-846a-99d9da772f9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a439bf07-53db-0352-846a-99d9da772f9b"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan hydrochloride for injection is indicated for the treatment of: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies (14 ) ]. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. Topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. (1) Combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. (1)"], "temporal_context_qualifier": "which is not amenable to curative treatment with surgery and/or radiation therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "failure of first-line or subsequent therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7bdf2183-8784-5110-bfc6-7c879350ce3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961112", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:75167ca0-1af1-57f6-8993-32956239d856", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0005140", "object_location_in_text": [266, 299], "original_object": "metastatic carcinoma of the ovary", "original_subject": "topotecan", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hycamtin", "https://www.ema.europa.eu/en/documents/product-information/hycamtin-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin"]}], "subject": "CHEBI:63632", "supporting_text": ["Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-sensitive disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17b7ed02-c00c-5b33-b1f5-4b881e61cde9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4c786f4-0154-529d-94d9-1dcfe1fbffc9", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0008433", "original_object": "small cell lung cancer", "original_subject": "TOPOTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:207ee628-1a7a-4949-bab2-07b9d79b72a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=207ee628-1a7a-4949-bab2-07b9d79b72a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=207ee628-1a7a-4949-bab2-07b9d79b72a3"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) 1.1 Ovarian Cancer Topotecan Hydrochloride for Injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer Topotecan Hydrochloride for Injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. 1.3 Cervical Cancer Topotecan Hydrochloride for Injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment."], "temporal_context_qualifier": "who progressed at least 60 days after initiation of first-line chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sensitive disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b5b6563-a787-51cc-83df-3830d4dc5f21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4c786f4-0154-529d-94d9-1dcfe1fbffc9", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0008433", "original_object": "small cell lung cancer", "original_subject": "TOPOTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a439bf07-53db-0352-846a-99d9da772f9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a439bf07-53db-0352-846a-99d9da772f9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a439bf07-53db-0352-846a-99d9da772f9b"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan hydrochloride for injection is indicated for the treatment of: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies (14 ) ]. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. Topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. (1) Combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. (1)"], "temporal_context_qualifier": "after failure of first-line chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-sensitive disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63450eec-5bd2-5c53-8dd0-f1280a12bfd8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4c786f4-0154-529d-94d9-1dcfe1fbffc9", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0008433", "original_object": "small cell lung cancer", "original_subject": "TOPOTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d4e1cce-c57e-4a8b-be96-f95a2778e221", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d4e1cce-c57e-4a8b-be96-f95a2778e221", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d4e1cce-c57e-4a8b-be96-f95a2778e221"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan Injection is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. Topotecan Injection is a topoisomerase inhibitor indicated for treatment of small cell lung cancer (SCLC) platinum-sensitive disease in patients who progressed at least 60 days after initiation of first-line chemotherapy. ( 1 )"], "temporal_context_qualifier": "progressed at least 60 days after initiation of first-line chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-sensitive disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:910fc2ad-8462-5829-8cf5-63316969fc87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960528", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4c786f4-0154-529d-94d9-1dcfe1fbffc9", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:57709cdd-ab3b-5af3-b2ee-4739ef232ff2", "object": "MONDO:0008433", "original_object": "small cell lung cancer", "original_subject": "TOPOTECAN", "population_context_qualifier": "Patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:996430c0-ee26-4ed9-82b8-a8b645becba6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=996430c0-ee26-4ed9-82b8-a8b645becba6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=996430c0-ee26-4ed9-82b8-a8b645becba6"]}], "subject": "CHEBI:63632", "supporting_text": ["1 INDICATIONS AND USAGE Topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) 1.1 Ovarian Cancer Topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer Topotecan hydrochloride for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. 1.3 Cervical Cancer Topotecan hydrochloride for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment."], "temporal_context_qualifier": "who progressed at least 60 days after initiation of first-line chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3273990", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4f71ea4-6768-5df9-ad51-7856ed997b09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3273990"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:36fd8efe-e038-5235-b659-0260430edb9c", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:18782e4f-dfd5-52df-8b84-38d59f64b0e4", "object": "MONDO:0005191", "original_object": "metastatic melanoma", "original_subject": "Vemurafenib Tablet 240mg", "population_context_qualifier": "patients with BRAFV600E mutation as detected by an FDA-approved test", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:63637", "supporting_text": ["For the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test. Vemurafenib is not recommended for use in patients with wild-type BRAF melanoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3273990", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a22700a-3336-560c-8fd7-d300f7cab90e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3273990"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:219fe20c-9480-5ca2-9ea0-628fd0dc4df1", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:18782e4f-dfd5-52df-8b84-38d59f64b0e4", "object": "UMLS:C4725093", "original_object": "unresectable melanoma", "original_subject": "Vemurafenib Tablet 240mg", "population_context_qualifier": "patients with BRAFV600E mutation as detected by an FDA-approved test", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:63637", "supporting_text": ["For the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test. Vemurafenib is not recommended for use in patients with wild-type BRAF melanoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002384", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2acbaefc-1119-5f8f-9b9b-9dffdcaef05c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090821", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002384"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8373600d-d08f-53f8-94fe-70e08293d85b", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:14818bc8-eab0-5179-95fd-2fdf4f23f020", "object": "HP:0002384", "original_object": "refractory complex partial seizures", "original_subject": "VIGABATRIN", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7cbc0a5-8c28-4451-9176-b608e228ba66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7cbc0a5-8c28-4451-9176-b608e228ba66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7cbc0a5-8c28-4451-9176-b608e228ba66"]}], "subject": "CHEBI:63638", "supporting_text": ["1 INDICATIONS AND USAGE Vigabatrin for oral solution is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; vigabatrin for oral solution is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) 1.1 Refractory Complex Partial Seizures (CPS) Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions ( 5.1 )] . Vigabatrin for oral solution is not indicated as a first line agent for complex partial seizures. 1.2 Infantile Spasms (IS) Vigabatrin for oral solution is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions ( 5.1 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:026e563e-15a6-5ee3-95dc-a2e5503773d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [552, 570], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:022b0913-f683-4af8-a862-f81b315909b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=022b0913-f683-4af8-a862-f81b315909b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=022b0913-f683-4af8-a862-f81b315909b2"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE SUBVENITE is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures primary generalized tonic-clonic (PGTC) seizures generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15ae618c-1b42-5ebe-9115-2937e4ccd760", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [556, 574], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54ea1ec3-876b-4d3a-a92b-1a6d70951de0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54ea1ec3-876b-4d3a-a92b-1a6d70951de0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54ea1ec3-876b-4d3a-a92b-1a6d70951de0"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b88b21d-7748-5d6f-8ca3-4baaffd4e2c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [562, 580], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:beb24a4f-ab0b-435a-b60b-2b8d565ecd75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=beb24a4f-ab0b-435a-b60b-2b8d565ecd75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=beb24a4f-ab0b-435a-b60b-2b8d565ecd75"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy — adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bec4c32-1154-5c83-a5d5-27fc0f3d1ecf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [563, 581], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "population_context_qualifier": "patients treated for acute mood episodes with standard therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f31e1854-6068-4e45-b1e5-6def862fc466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f31e1854-6068-4e45-b1e5-6def862fc466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f31e1854-6068-4e45-b1e5-6def862fc466"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine tablet is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d235dec-426e-5560-9115-88e56167f030", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [563, 581], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "population_context_qualifier": "patients treated for acute mood episodes with standard therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50d46278-636a-470e-afcc-d3c8bd844e46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50d46278-636a-470e-afcc-d3c8bd844e46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50d46278-636a-470e-afcc-d3c8bd844e46"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine tablet is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33907106-67d1-5639-9c81-9016edd155b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [561, 579], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60958229-5b5f-49e2-97f4-a8722138f7ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60958229-5b5f-49e2-97f4-a8722138f7ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60958229-5b5f-49e2-97f4-a8722138f7ce"]}], "subject": "CHEBI:6367", "supporting_text": ["1. INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy - adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome.( 1.1 ) Epilepsy - monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a129f4d-27c4-5577-a72c-1cf609bffdd5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [556, 574], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4d89cd9-c5d8-490f-996d-fc15b47c7b21", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4d89cd9-c5d8-490f-996d-fc15b47c7b21", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4d89cd9-c5d8-490f-996d-fc15b47c7b21"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy — adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55248693-1a84-5834-93de-73f14134aaaa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [559, 577], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7e3572d-56fe-4727-2bb4-013ccca22678", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7e3572d-56fe-4727-2bb4-013ccca22678"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE LAMICTAL is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:565e62b0-be06-52be-95db-f0de0f0872f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [558, 576], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:811188be-d231-4b58-8d7a-b01b236fab51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=811188be-d231-4b58-8d7a-b01b236fab51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=811188be-d231-4b58-8d7a-b01b236fab51"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6114e4f1-6a36-59c8-a005-fba9dfbc12fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [563, 581], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "population_context_qualifier": "patients treated for acute mood episodes with standard therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c638ab70-05dd-4f8b-9a11-b33a75f8c504", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c638ab70-05dd-4f8b-9a11-b33a75f8c504", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c638ab70-05dd-4f8b-9a11-b33a75f8c504"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine tablet is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b02f6ccb-f247-5a43-98fb-c10157438fce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [563, 581], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "population_context_qualifier": "patients treated for acute mood episodes with standard therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d7c2d52-a78e-4508-8853-ba306cdeeaba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d7c2d52-a78e-4508-8853-ba306cdeeaba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d7c2d52-a78e-4508-8853-ba306cdeeaba"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine tablet is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b24ecd2a-46be-5f64-8e07-1e1b25c52d07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [558, 576], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc6e6735-d49a-44d8-936d-7c33437bc59e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc6e6735-d49a-44d8-936d-7c33437bc59e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc6e6735-d49a-44d8-936d-7c33437bc59e"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acute mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbdcd886-dc94-5ece-ad0d-ad80368be9f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [558, 576], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6139a858-700c-4eb9-9f84-99d280bde326", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6139a858-700c-4eb9-9f84-99d280bde326", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6139a858-700c-4eb9-9f84-99d280bde326"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mood episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6d25f4d-7876-5dc1-a796-732fe6ff76e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19941227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9ef01533-db32-5839-b3b4-8160d01e1dbf", "object": "MONDO:0001866", "object_location_in_text": [554, 572], "original_object": "bipolar I disorder", "original_subject": "LAMOTRIGINE", "population_context_qualifier": "patients treated for acute mood episodes with standard therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=35aa48a2-2ce6-4a6e-bf5a-1bc6111d1234"]}], "subject": "CHEBI:6367", "supporting_text": ["1 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy — adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. (1.1) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3839044", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ee88c65-e42b-55a5-8020-e1d71078b5bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3839044", "UMLS:C0042774"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:99d8a2a1-d6e0-5f58-984b-ad89864996d4", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:407e3df5-59c0-5575-ab5f-3150e41657a4", "object": "MONDO:0005366", "object_location_in_text": [1178, 1197], "original_object": "chronic hepatitis B", "original_subject": "tenofovir disoproxil", "population_context_qualifier": "adolescents 12 to < 18 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tenofovir-disoproxil-viatris", "https://www.ema.europa.eu/en/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-viatris"]}], "subject": "CHEBI:63717", "supporting_text": ["HIV-1 infection Tenofovir disoproxil 245 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults. In adults, the demonstration of the benefit of tenofovir disoproxil in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (&gt; 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (&lt; 10,000 copies/ml, with the majority of patients having &lt; 5,000 copies/ml). Tenofovir disoproxil 245 mg film-coated tablets are also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years. The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with:  compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. evidence of lamivudine-resistant hepatitis B virus. decompensated liver disease.  Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to &lt; 18 years of age with:  compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3839044", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90812022-5b4c-529f-bef7-d36db6db4d68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020204", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3839044", "UMLS:C0042774", "UMLS:C0333361", "UMLS:C0016059"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:99d8a2a1-d6e0-5f58-984b-ad89864996d4", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:407e3df5-59c0-5575-ab5f-3150e41657a4", "object": "MONDO:0005366", "object_location_in_text": [1171, 1190], "original_object": "chronic hepatitis B", "original_subject": "tenofovir disoproxil", "population_context_qualifier": "adolescents 12 to < 18 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tenofovir-disoproxil-zentiva", "https://www.ema.europa.eu/en/documents/product-information/tenofovir-disoproxil-zentiva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-zentiva"]}], "subject": "CHEBI:63717", "supporting_text": ["HIV?1 infection Tenofovir disoproxil Zentiva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV?1 infected adults. In adults, the demonstration of the benefit of tenofovir disoproxil in HIV?1 infection is based on results of one study in treatment?naïve patients, including patients with a high viral load (&gt; 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre?treated patients experiencing early virological failure (&lt; 10,000 copies/ml, with the majority of patients having &lt; 5,000 copies/ml). Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV?1 infected adolescents, with NRTI (nucleotide reverse transcriptase inhibitor) resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years. The choice of Tenofovir disoproxil Zentiva to treat antiretroviral?experienced patients with HIV?1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adults with:  compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1); evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1); decompensated liver disease (see sections 4.4, 4.8 and 5.1).  Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adolescents 12 to &lt; 18 years of age with:  compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NRTI resistance, toxicities precluding the use of first line agents", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28c3a06d-28e1-594e-9fb8-a5fbe8ec31e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020204", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:407e3df5-59c0-5575-ab5f-3150e41657a4", "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "tenofovir disoproxil", "population_context_qualifier": "HIV-1 infected adolescents, aged 12 to < 18 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tenofovir-disoproxil-zentiva", "https://www.ema.europa.eu/en/documents/product-information/tenofovir-disoproxil-zentiva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-zentiva"]}], "subject": "CHEBI:63717", "supporting_text": ["HIV?1 infection Tenofovir disoproxil Zentiva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV?1 infected adults. In adults, the demonstration of the benefit of tenofovir disoproxil in HIV?1 infection is based on results of one study in treatment?naïve patients, including patients with a high viral load (&gt; 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre?treated patients experiencing early virological failure (&lt; 10,000 copies/ml, with the majority of patients having &lt; 5,000 copies/ml). Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV?1 infected adolescents, with NRTI (nucleotide reverse transcriptase inhibitor) resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years. The choice of Tenofovir disoproxil Zentiva to treat antiretroviral?experienced patients with HIV?1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adults with:  compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1); evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1); decompensated liver disease (see sections 4.4, 4.8 and 5.1).  Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adolescents 12 to &lt; 18 years of age with:  compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "NRTI resistance, toxicities precluding the use of first line agents", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dddc2704-5a52-56d5-b806-0782902e8b1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020204", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:407e3df5-59c0-5575-ab5f-3150e41657a4", "object": "UMLS:C2363741", "object_location_in_text": [0, 15], "original_object": "HIV-1 infection", "original_subject": "tenofovir disoproxil", "population_context_qualifier": "adolescents aged 12 to < 18 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tenofovir-disoproxil-viatris", "https://www.ema.europa.eu/en/documents/product-information/tenofovir-disoproxil-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-viatris"]}], "subject": "CHEBI:63717", "supporting_text": ["HIV-1 infection Tenofovir disoproxil 245 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults. In adults, the demonstration of the benefit of tenofovir disoproxil in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (&gt; 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (&lt; 10,000 copies/ml, with the majority of patients having &lt; 5,000 copies/ml). Tenofovir disoproxil 245 mg film-coated tablets are also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years. The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients. Hepatitis B infection Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with:  compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. evidence of lamivudine-resistant hepatitis B virus. decompensated liver disease.  Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to &lt; 18 years of age with:  compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NSAID-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:077223fe-c2a0-5b94-9f08-5a9457db031b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "object_location_in_text": [373, 386], "original_object": "gastric ulcer", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7daa1721-f92b-4096-b19e-4d27fc8acb51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7daa1721-f92b-4096-b19e-4d27fc8acb51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7daa1721-f92b-4096-b19e-4d27fc8acb51"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release orally disintegrating tablets are proton pump inhibitors (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)‑-associated gastric ulcer in adults. (1.5) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. (1.7) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. (1.8) • Maintenance of healing of EE in adults. (1.9) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. (1.10) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies (14.1) ]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release orally disintegrating tablets /amoxicillin/clarithromycin Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14.2) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release orally disintegrating tablets/amoxicillin Lansoprazo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d8ec0f0-b7b3-591b-96c2-1031ab47a88a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9a43df0-efab-4486-860f-92afdb258c8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9a43df0-efab-4486-860f-92afdb258c8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9a43df0-efab-4486-860f-92afdb258c8b"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release orally disintegrating tablets are a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release orally disintegrating tablets are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 )] . 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release orally disintegrating tablets/amoxicillin/clarithromycin Lansoprazole delayed-release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 )] . Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release orally disintegrating tablets/amoxici"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:410d8975-1981-51de-9c34-96ffee0e784e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:960d6601-aec5-4900-a400-385b6687a4bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=960d6601-aec5-4900-a400-385b6687a4bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=960d6601-aec5-4900-a400-385b6687a4bc"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f3d9c9e-0b1c-561a-8a37-998ed58a5469", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56cafcf5-ce3d-a312-e063-6294a90a3db1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56cafcf5-ce3d-a312-e063-6294a90a3db1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56cafcf5-ce3d-a312-e063-6294a90a3db1"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f026780-c511-5e53-9301-8b2a4f72f00f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:854e4235-4815-4461-9b9b-d3d783fb775d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=854e4235-4815-4461-9b9b-d3d783fb775d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=854e4235-4815-4461-9b9b-d3d783fb775d"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a48c9718-e401-507e-a149-33407000c91f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6ec5e9b1-f55b-50ba-b3c9-884bfeb105f5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0001126", "original_object": "gastric ulcer", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86685cba-c889-5c9f-94db-dd201643527f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "object": "MONDO:0005412", "object_location_in_text": [249, 263], "original_object": "duodenal ulcer", "original_subject": "LANSOPRAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40adc1d3-7ce7-4698-aa7f-b5dbaaecec00", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40adc1d3-7ce7-4698-aa7f-b5dbaaecec00", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40adc1d3-7ce7-4698-aa7f-b5dbaaecec00"]}], "subject": "CHEBI:6375", "supporting_text": ["H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence The components in lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets and other antibacterial drugs, lansoprazole delayed-release capsules, amoxicillin capsules, and clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:042ed577-5228-534d-8957-4ab55b3b4520", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71ba78cb-7e46-43eb-9425-fa130f537f84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71ba78cb-7e46-43eb-9425-fa130f537f84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71ba78cb-7e46-43eb-9425-fa130f537f84"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE PREVACID and PREVACID SoluTab are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults. ( 1.1 ) Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) Maintenance of healed duodenal ulcers in adults. ( 1.3 ) Treatment of active benign gastric ulcer in adults. ( 1.4 ) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) Maintenance of healing of EE in adults. ( 1.9 ) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer PREVACID and PREVACID SoluTab are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies (14.1) ] . 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: PREVACID or PREVACID SoluTab/amoxicillin/clarithromycin PREVACID or PREVACID SoluTab in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14.2) ] . Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: PREVACID or PREVACID SoluTab/amoxicillin PREVACID or PREVACID SoluTab in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with H. pylori infection and duodena"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a9ea5c8-5ef2-5806-b128-b043f1a6117b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:960d6601-aec5-4900-a400-385b6687a4bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=960d6601-aec5-4900-a400-385b6687a4bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=960d6601-aec5-4900-a400-385b6687a4bc"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5be9f6c0-776d-5ddd-8378-28428ac100fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18b4020f-d7e6-42f8-838d-2b5da152530e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18b4020f-d7e6-42f8-838d-2b5da152530e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18b4020f-d7e6-42f8-838d-2b5da152530e"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsules is a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults. ( 1.1 ) Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) Maintenance of healed duodenal ulcers in adults. ( 1.3 ) Treatment of active benign gastric ulcer in adults. ( 1.4 ) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) Maintenance of healing of EE in adults. ( 1.9 ) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [ see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [ see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules/ amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b61c589-a3d4-519b-ae1c-7ef83bdb9f95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db42468a-450c-4b12-b2f2-e9a76e976d45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db42468a-450c-4b12-b2f2-e9a76e976d45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db42468a-450c-4b12-b2f2-e9a76e976d45"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Maintenance of healed duodenal ulcers in adults ( 1.3 ) • Treatment of active benign gastric ulcer in adults ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (ZES) in adults ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 )]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: lansoprazole/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 )]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: lansoprazole/amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcc57c17-8f1b-5fe1-acd2-f67d3a8e9c9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56cafcf5-ce3d-a312-e063-6294a90a3db1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56cafcf5-ce3d-a312-e063-6294a90a3db1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56cafcf5-ce3d-a312-e063-6294a90a3db1"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c87b0511-3a26-5ac5-8d0d-cfc0fd1afc23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7286d6a5-611b-4993-ab93-4899d599435d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7286d6a5-611b-4993-ab93-4899d599435d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7286d6a5-611b-4993-ab93-4899d599435d"]}], "subject": "CHEBI:6375", "supporting_text": ["1. INDICATIONS AND USAGE Lansoprazole delayed-release capsules are proton pump inhibitors (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Maintenance of healed duodenal ulcers in adults ( 1.3 ) • Treatment of active benign gastric ulcer in adults ( 1.4 ) • Healing of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older ( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older ( 1.8 ) • Maintenance of healing of EE in adults.( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks ) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ]. 1.2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole /amoxicillin /clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 )]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with H. pylori infect"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df2db5cc-1e99-552a-85db-24b831d2af6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:854e4235-4815-4461-9b9b-d3d783fb775d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=854e4235-4815-4461-9b9b-d3d783fb775d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=854e4235-4815-4461-9b9b-d3d783fb775d"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb18b836-1073-5275-8118-2b4b24d07322", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950510", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8f3b1e34-ec82-5d6d-865c-02053d1c80c9", "medic_supporting_text_truncated": true, "object": "MONDO:0019610", "original_object": "Zollinger-Ellison syndrome", "original_subject": "LANSOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7a3aa37-9c9b-43fe-92be-6e0fdc8d1c92"]}], "subject": "CHEBI:6375", "supporting_text": ["1 INDICATIONS AND USAGE Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) 1.1 Treatment of Active Duodenal Ulcer Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies ( 14.1 ) ]. 1.2 Eradication of H.pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies ( 14.2 ) ]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole delayed-release capsules /amoxicillin Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15832b17-f9e5-57a5-bff5-8900dc474d14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0010481", "object_location_in_text": [1003, 1013], "original_object": "angioedema", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96df285d-dd13-4083-b2c6-e5c799e7587b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96df285d-dd13-4083-b2c6-e5c799e7587b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96df285d-dd13-4083-b2c6-e5c799e7587b"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [ see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions ( 5.1 , 5.2 ), Use in Special Populations ( 8.1 , 8.3 )] . 4.2 Severe Hypersensitivity Reactions Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions 5.9 , 5.15 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f07975d-4446-51b8-a983-9ed4c940bc19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0010481", "object_location_in_text": [989, 999], "original_object": "angioedema", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2166bbdf-eb12-4564-b9e4-b63ca21312bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2166bbdf-eb12-4564-b9e4-b63ca21312bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2166bbdf-eb12-4564-b9e4-b63ca21312bc"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( BOXED WARNING , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1 , 5.2 ), Use in Special Populations (8.1 , 8.3) ]. 4.2 Severe Hypersensitivity Reactions Lenalidomide is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9 , 5.15 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b3d3a76-0b02-5066-ad6c-2f8bfd0b70f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0010481", "object_location_in_text": [1005, 1015], "original_object": "angioedema", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dffe719b-4f61-47e2-b71c-673322d487f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dffe719b-4f61-47e2-b71c-673322d487f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dffe719b-4f61-47e2-b71c-673322d487f5"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS • Pregnancy (Boxed Warning, 4.1 , 5.1 , 8.1 ). • Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide capsules can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide’s structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning]. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1, 5.2), Use in Special Populations (8.1, 8.3)] . 4.2 Severe Hypersensitivity Reactions Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9, 5.15)]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d4a3eab-7b31-57a6-888c-6d178e5835f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0010481", "object_location_in_text": [993, 1003], "original_object": "angioedema", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c98fb504-76d0-4c25-9c0b-412885828a7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c98fb504-76d0-4c25-9c0b-412885828a7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c98fb504-76d0-4c25-9c0b-412885828a7a"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [ see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions ( 5.1 , 5.2 ), Use in Special Populations ( 8.1 , 8.3 )] . 4.2 Severe Hypersensitivity Reactions Lenalidomide is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions ( 5.9 , 5.15 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a8d7087-8c11-5626-a455-6920fd4268d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018229", "object_location_in_text": [1017, 1041], "original_object": "Stevens-Johnson syndrome", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dffe719b-4f61-47e2-b71c-673322d487f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dffe719b-4f61-47e2-b71c-673322d487f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dffe719b-4f61-47e2-b71c-673322d487f5"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS • Pregnancy (Boxed Warning, 4.1 , 5.1 , 8.1 ). • Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide capsules can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide’s structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning]. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1, 5.2), Use in Special Populations (8.1, 8.3)] . 4.2 Severe Hypersensitivity Reactions Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9, 5.15)]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77b2637b-d2d7-5862-b02d-40196cb78ffc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018229", "object_location_in_text": [1001, 1025], "original_object": "Stevens-Johnson syndrome", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2166bbdf-eb12-4564-b9e4-b63ca21312bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2166bbdf-eb12-4564-b9e4-b63ca21312bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2166bbdf-eb12-4564-b9e4-b63ca21312bc"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( BOXED WARNING , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1 , 5.2 ), Use in Special Populations (8.1 , 8.3) ]. 4.2 Severe Hypersensitivity Reactions Lenalidomide is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9 , 5.15 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c71ee76d-3b52-517d-bbfd-e427d787a701", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018229", "object_location_in_text": [1005, 1029], "original_object": "Stevens-Johnson syndrome", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c98fb504-76d0-4c25-9c0b-412885828a7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c98fb504-76d0-4c25-9c0b-412885828a7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c98fb504-76d0-4c25-9c0b-412885828a7a"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [ see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions ( 5.1 , 5.2 ), Use in Special Populations ( 8.1 , 8.3 )] . 4.2 Severe Hypersensitivity Reactions Lenalidomide is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions ( 5.9 , 5.15 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcab95e8-436b-5e5c-a32e-ea7e87c2165b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2119aa2-5c91-5be5-8247-667bdcfb426a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018229", "object_location_in_text": [1015, 1039], "original_object": "Stevens-Johnson syndrome", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96df285d-dd13-4083-b2c6-e5c799e7587b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96df285d-dd13-4083-b2c6-e5c799e7587b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96df285d-dd13-4083-b2c6-e5c799e7587b"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [ see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions ( 5.1 , 5.2 ), Use in Special Populations ( 8.1 , 8.3 )] . 4.2 Severe Hypersensitivity Reactions Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions 5.9 , 5.15 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06e03a5b-c9d8-54bb-9775-818a8841412d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:545614a9-7a22-583c-b095-583d894aa056", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0019810", "object_location_in_text": [1043, 1069], "original_object": "toxic epidermal necrolysis", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dffe719b-4f61-47e2-b71c-673322d487f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dffe719b-4f61-47e2-b71c-673322d487f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dffe719b-4f61-47e2-b71c-673322d487f5"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS • Pregnancy (Boxed Warning, 4.1 , 5.1 , 8.1 ). • Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide capsules can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide’s structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning]. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1, 5.2), Use in Special Populations (8.1, 8.3)] . 4.2 Severe Hypersensitivity Reactions Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9, 5.15)]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53a9f897-073c-542e-8cfc-c11c0310bee1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:545614a9-7a22-583c-b095-583d894aa056", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0019810", "object_location_in_text": [1027, 1053], "original_object": "toxic epidermal necrolysis", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2166bbdf-eb12-4564-b9e4-b63ca21312bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2166bbdf-eb12-4564-b9e4-b63ca21312bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2166bbdf-eb12-4564-b9e4-b63ca21312bc"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( BOXED WARNING , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions (5.1 , 5.2 ), Use in Special Populations (8.1 , 8.3) ]. 4.2 Severe Hypersensitivity Reactions Lenalidomide is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions (5.9 , 5.15 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b46f741e-8729-5001-ac3a-a6055bf56457", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:545614a9-7a22-583c-b095-583d894aa056", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0019810", "object_location_in_text": [1041, 1067], "original_object": "toxic epidermal necrolysis", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96df285d-dd13-4083-b2c6-e5c799e7587b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96df285d-dd13-4083-b2c6-e5c799e7587b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96df285d-dd13-4083-b2c6-e5c799e7587b"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [ see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions ( 5.1 , 5.2 ), Use in Special Populations ( 8.1 , 8.3 )] . 4.2 Severe Hypersensitivity Reactions Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions 5.9 , 5.15 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "severe hypersensitivity to lenalidomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7326ca7-d7d1-5961-a2d4-2ed1301ea01d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:545614a9-7a22-583c-b095-583d894aa056", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0019810", "object_location_in_text": [1031, 1057], "original_object": "toxic epidermal necrolysis", "original_subject": "LENALIDOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c98fb504-76d0-4c25-9c0b-412885828a7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c98fb504-76d0-4c25-9c0b-412885828a7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c98fb504-76d0-4c25-9c0b-412885828a7a"]}], "subject": "CHEBI:63791", "supporting_text": ["4 CONTRAINDICATIONS Pregnancy ( Boxed Warning , 4.1 , 5.1 , 8.1 ). Demonstrated severe hypersensitivity to lenalidomide ( 4.2 , 5.9 , 5.15 ). 4.1 Pregnancy Lenalidomide can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide's structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant [ see Boxed Warning ] . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus [see Warnings and Precautions ( 5.1 , 5.2 ), Use in Special Populations ( 8.1 , 8.3 )] . 4.2 Severe Hypersensitivity Reactions Lenalidomide is contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide [see Warnings and Precautions ( 5.9 , 5.15 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated marginal zone lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:742d7865-2896-53bf-9362-64a0668fc286", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f829255d-e3b7-5ac8-9a89-5f660844813f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0017604", "object_location_in_text": [740, 762], "original_object": "marginal zone lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fa97bf5-28a2-48f1-8955-f56012d296be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated marginal zone lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b119e24d-4d7a-5859-90a6-35c0614d77f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f829255d-e3b7-5ac8-9a89-5f660844813f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0017604", "object_location_in_text": [742, 764], "original_object": "marginal zone lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c414531-a3bf-455a-aca7-9e716f42099a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c414531-a3bf-455a-aca7-9e716f42099a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c414531-a3bf-455a-aca7-9e716f42099a"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c70ca8ef-2f60-53fa-8073-c0c28a7bb4bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f829255d-e3b7-5ac8-9a89-5f660844813f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0017604", "object_location_in_text": [744, 766], "original_object": "marginal zone lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f27092f3-3977-4f4a-b214-45309e136e46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f27092f3-3977-4f4a-b214-45309e136e46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f27092f3-3977-4f4a-b214-45309e136e46"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated marginal zone lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa3b6e71-d8e5-5af9-a70e-cbbcc2343be7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f829255d-e3b7-5ac8-9a89-5f660844813f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0017604", "object_location_in_text": [740, 762], "original_object": "marginal zone lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9943e098-20b0-dbb3-af12-7816eedd3f70", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9943e098-20b0-dbb3-af12-7816eedd3f70", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9943e098-20b0-dbb3-af12-7816eedd3f70"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or progressed mantle cell lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23d61850-d86f-5be5-913a-66828d3d56aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9943e098-20b0-dbb3-af12-7816eedd3f70", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9943e098-20b0-dbb3-af12-7816eedd3f70", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9943e098-20b0-dbb3-af12-7816eedd3f70"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "mantle cell lymphoma (MCL) whose disease has relapsed or progressed", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2978dc2d-5c01-5aa0-94d2-a116415ddb68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fa97bf5-28a2-48f1-8955-f56012d296be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or progressed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34c267f8-0e99-57bb-929c-3b0c54818d59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76f6c1e7-985b-43d9-892c-849df50ae80e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76f6c1e7-985b-43d9-892c-849df50ae80e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76f6c1e7-985b-43d9-892c-849df50ae80e"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or progressed mantle cell lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4bcd7167-f0fe-5a60-b05d-25adb1e6513f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c414531-a3bf-455a-aca7-9e716f42099a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c414531-a3bf-455a-aca7-9e716f42099a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c414531-a3bf-455a-aca7-9e716f42099a"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or progressed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c32c877-49f8-5174-b070-a518172133e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba2a07fd-ca60-40bc-b79b-9caf81900fa3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba2a07fd-ca60-40bc-b79b-9caf81900fa3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba2a07fd-ca60-40bc-b79b-9caf81900fa3"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or progressed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db54f0ed-c280-5087-8124-5a78bfb9bf5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["bortezomib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f27092f3-3977-4f4a-b214-45309e136e46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f27092f3-3977-4f4a-b214-45309e136e46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f27092f3-3977-4f4a-b214-45309e136e46"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or progressed disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa589a7d-95ad-5c60-8e8d-5b9faf353fd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["bortezomib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0cf00928-a4a3-5fef-876e-cf3b06e0a0c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018876", "original_object": "mantle cell lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca8cc2cc-c856-e676-4f60-1e46d7b53d73", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca8cc2cc-c856-e676-4f60-1e46d7b53d73", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca8cc2cc-c856-e676-4f60-1e46d7b53d73"]}], "subject": "CHEBI:63791", "supporting_text": ["1 IND ICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "deletion 5q cytogenetic abnormality", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b4264a1-23f6-531d-b6fb-4ad12250809a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100820", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9ee3db05-7ca4-52b4-9cc3-40a70026b303", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f6b272b3-eb6e-56c9-a701-bb1c44ce24e3", "object": "MONDO:0018881", "object_location_in_text": [78, 102], "original_object": "myelodysplastic syndrome", "original_subject": "LENALIDOMIDE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LENALIDOMIDE HYDRATE#162-20100820", "https://www.pmda.go.jp/files/000228384.pdf"]}], "subject": "CHEBI:63791", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated follicular lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33046384-b94d-5a49-895e-7dcc9df47907", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018906", "object_location_in_text": [648, 667], "original_object": "follicular lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c414531-a3bf-455a-aca7-9e716f42099a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c414531-a3bf-455a-aca7-9e716f42099a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c414531-a3bf-455a-aca7-9e716f42099a"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated follicular lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eb21ab1-0ea2-5921-8aa4-d72e0584570f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018906", "object_location_in_text": [644, 663], "original_object": "follicular lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fa97bf5-28a2-48f1-8955-f56012d296be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6715251-8abf-58cb-9c10-5906d1929d26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018906", "object_location_in_text": [648, 667], "original_object": "follicular lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f27092f3-3977-4f4a-b214-45309e136e46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f27092f3-3977-4f4a-b214-45309e136e46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f27092f3-3977-4f4a-b214-45309e136e46"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously treated follicular lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2bfaa58-9a9f-52c7-8504-a718ad5948a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab product"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "MONDO:0018906", "object_location_in_text": [646, 665], "original_object": "follicular lymphoma", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9943e098-20b0-dbb3-af12-7816eedd3f70", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9943e098-20b0-dbb3-af12-7816eedd3f70", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9943e098-20b0-dbb3-af12-7816eedd3f70"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "low- or intermediate-1-risk myelodysplastic syndromes", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:488489bd-fd3c-596f-9beb-951f77086464", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23d44ae0-bbbb-5f40-9a81-b1d28419eb82", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "UMLS:C3666003", "original_object": "transfusion-dependent anemia", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84d9dec7-9250-4dbd-9a0d-23e75f111892", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84d9dec7-9250-4dbd-9a0d-23e75f111892", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84d9dec7-9250-4dbd-9a0d-23e75f111892"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Previously treated follicular lymphoma (FL), in combination with a rituximab product (1.4). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product (1.5)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "low- or intermediate-1-risk myelodysplastic syndromes, deletion 5q abnormality", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e650548-99fd-50f1-8271-1a20b1ea97e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:23d44ae0-bbbb-5f40-9a81-b1d28419eb82", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2db83a9-fb84-5710-b6a4-6380946f8894", "object": "UMLS:C3666003", "original_object": "transfusion-dependent anemia", "original_subject": "LENALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76f6c1e7-985b-43d9-892c-849df50ae80e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76f6c1e7-985b-43d9-892c-849df50ae80e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76f6c1e7-985b-43d9-892c-849df50ae80e"]}], "subject": "CHEBI:63791", "supporting_text": ["1 INDICATIONS AND USAGE Lenalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients with: • Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). • MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). • Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). • Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). • Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). • Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001087", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1cb26c62-a0a0-501b-b529-b831b6b72691", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20231115", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0001087"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ad2bd3b8-fdc6-5d6b-b391-89eb41695a0e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:190b819f-3fd3-5df1-a0df-a3c309bd8672", "object": "HP:0007906", "original_object": "elevated intraocular pressure", "original_subject": "latanoprost", "population_context_qualifier": "children from 4 years of age and adolescents", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:catiolanze", "https://www.ema.europa.eu/en/documents/product-information/catiolanze-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/catiolanze"]}], "subject": "CHEBI:6384", "supporting_text": ["Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma. &nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5911cdff-2781-58be-8094-05566807b8be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071217", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:41a36799-eea5-5636-8733-27431c04fcaa", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [257, 279], "original_object": "myocardial infarctions", "original_subject": "NEBIVOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ebcc539-efe0-4545-bd83-37c20de7efb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ebcc539-efe0-4545-bd83-37c20de7efb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ebcc539-efe0-4545-bd83-37c20de7efb0"]}], "subject": "CHEBI:64022", "supporting_text": ["1 INDICATIONS AND USAGE Nebivolol Tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdce322c-2e34-5789-bd33-7928692a248c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071217", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:41a36799-eea5-5636-8733-27431c04fcaa", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [255, 277], "original_object": "myocardial infarctions", "original_subject": "NEBIVOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489"]}], "subject": "CHEBI:64022", "supporting_text": ["1 INDICATIONS AND USAGE Nebivolol tablet is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, bu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fca40645-fe85-52d6-b593-566837b36ba6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071217", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:41a36799-eea5-5636-8733-27431c04fcaa", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [257, 279], "original_object": "myocardial infarctions", "original_subject": "NEBIVOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9d8edb5-5312-ad38-e053-2995a90a7154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9d8edb5-5312-ad38-e053-2995a90a7154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9d8edb5-5312-ad38-e053-2995a90a7154"]}], "subject": "CHEBI:64022", "supporting_text": ["1 INDICATIONS AND USAGE Nebivolol Tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:068b6943-f88c-539a-bf64-f5b38d427f65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071217", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:41a36799-eea5-5636-8733-27431c04fcaa", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [245, 252], "original_object": "strokes", "original_subject": "NEBIVOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9d8edb5-5312-ad38-e053-2995a90a7154", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9d8edb5-5312-ad38-e053-2995a90a7154", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9d8edb5-5312-ad38-e053-2995a90a7154"]}], "subject": "CHEBI:64022", "supporting_text": ["1 INDICATIONS AND USAGE Nebivolol Tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08b6e303-6652-5c34-8547-752f528abb3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071217", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:41a36799-eea5-5636-8733-27431c04fcaa", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [245, 252], "original_object": "strokes", "original_subject": "NEBIVOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ebcc539-efe0-4545-bd83-37c20de7efb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ebcc539-efe0-4545-bd83-37c20de7efb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ebcc539-efe0-4545-bd83-37c20de7efb0"]}], "subject": "CHEBI:64022", "supporting_text": ["1 INDICATIONS AND USAGE Nebivolol Tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but redu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a30b3f1-0a75-5b43-83e2-4bec81e5e634", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071217", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:41a36799-eea5-5636-8733-27431c04fcaa", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [243, 250], "original_object": "strokes", "original_subject": "NEBIVOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9f0bd0b4-ee17-46bb-b4e2-8ca0ea0e0489"]}], "subject": "CHEBI:64022", "supporting_text": ["1 INDICATIONS AND USAGE Nebivolol tablet is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nebivolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, bu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0520909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29a47f02-15ed-56dc-87d5-6745fb3d64a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200226", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0520909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:64980092-d601-567a-92dc-4e675c1aed10", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2af4e647-b83a-5a50-9e42-2c76fffcbb89", "object": "UMLS:C0520909", "original_object": "postoperative nausea and vomiting", "original_subject": "AMISULPRIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab23bc6e-b6a8-165f-e053-2a95a90ab144", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab23bc6e-b6a8-165f-e053-2a95a90ab144"]}], "subject": "CHEBI:64045", "supporting_text": ["1 INDICATIONS AND USAGE BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. BARHEMSYS is a dopamine-2 (D 2 ) antagonist indicated in adults for: Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. ( 1 ) Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:026d6755-0d7c-5327-ae94-076dbcf10708", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [162, 181], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa2d40a5-3504-44ef-8f5c-aa4c06308074", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa2d40a5-3504-44ef-8f5c-aa4c06308074", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa2d40a5-3504-44ef-8f5c-aa4c06308074"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole Tablets, USP are aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) • Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) • First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole Tablets, USP are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole Tablets, USP are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "extended adjuvant treatment; following 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e3ecb53-4f5d-57db-a32c-e5fd4eafdf85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [156, 175], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c10bf97f-f9cf-468a-8a1f-7637f41022e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c10bf97f-f9cf-468a-8a1f-7637f41022e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c10bf97f-f9cf-468a-8a1f-7637f41022e4"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "extended adjuvant treatment following prior standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1cc98c06-6876-5f52-a93d-aa454238d1b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6fd92634-c9c5-457e-808c-a4614e8db7db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6fd92634-c9c5-457e-808c-a4614e8db7db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6fd92634-c9c5-457e-808c-a4614e8db7db"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole Tablets, USP are aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets, are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets, are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets, are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole tablets, are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "who have received 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1de9e633-f939-5c27-bc5c-266911bcf4bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [155, 174], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe0e4d4b-436d-a36d-e053-6294a90a973d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe0e4d4b-436d-a36d-e053-6294a90a973d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe0e4d4b-436d-a36d-e053-6294a90a973d"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole Tablets are aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets, are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets, are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets, are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole tablets, are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2738044c-a06d-5e4e-b1bc-e6d3e7123a2c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [156, 175], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a707ec4b-8d26-55c2-e053-2a95a90a2e07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a707ec4b-8d26-55c2-e053-2a95a90a2e07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a707ec4b-8d26-55c2-e053-2a95a90a2e07"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "extended adjuvant treatment following prior standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ed9ebe6-bdf1-5cfc-ac9f-f4caccfa8145", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32d7dd83-a3ef-41fe-e063-6394a90ae62a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32d7dd83-a3ef-41fe-e063-6394a90ae62a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32d7dd83-a3ef-41fe-e063-6394a90ae62a"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole Tablets, USP are aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole Tablets, USP are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole Tablets, USP are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:715a132a-f5f9-5b45-b87b-f0722259b6a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [156, 175], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following prior standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:890b7827-2a91-5e7e-95de-8fe6c457a85e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [156, 175], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c391fe11-fd47-4a35-af6d-c823ab7b8838", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c391fe11-fd47-4a35-af6d-c823ab7b8838", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c391fe11-fd47-4a35-af6d-c823ab7b8838"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following prior standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0191317-3730-589e-a23e-5a3447653a55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [146, 165], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82b77d74-085f-45ac-a7dd-1f5c038bf406", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)]."], "temporal_context_qualifier": "following standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a51b90d7-4e12-5e55-961c-6795b8de7cb2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d1f18f0-2c77-407c-b702-2d1b07f92510", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d1f18f0-2c77-407c-b702-2d1b07f92510", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d1f18f0-2c77-407c-b702-2d1b07f92510"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole Tablets, USP are aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole Tablets, USP are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole Tablets, USP are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c22797e9-fbe8-51fa-a2b5-27341d7c1155", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [149, 168], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff7325d2-3383-4ff9-a187-9350e3538640", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff7325d2-3383-4ff9-a187-9350e3538640", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff7325d2-3383-4ff9-a187-9350e3538640"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies (14.2 , 14.3) ] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4 , 14.5) ]."], "temporal_context_qualifier": "following 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d112e6fb-777d-58fc-9140-76d57ee1cd3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [160, 179], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b00e08c-9a1c-09e0-e053-2a91aa0a7638", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b00e08c-9a1c-09e0-e053-2a91aa0a7638", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b00e08c-9a1c-09e0-e053-2a91aa0a7638"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole Tablets, USP are aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole Tablets, USP are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole Tablets, USP are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole Tablets, USP are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following 5 years of adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4745239", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc5f31dd-9742-5b71-a4f9-1f07958d513f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4745239"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [156, 175], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26dcb6ee-74d8-4804-b151-79a41484979b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26dcb6ee-74d8-4804-b151-79a41484979b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26dcb6ee-74d8-4804-b151-79a41484979b"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "extended adjuvant treatment following prior standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd5c0188-e08b-5fe1-98f6-a6d8b174e7d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "MONDO:0007254", "object_location_in_text": [158, 177], "original_object": "early breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1524730f-e37d-478c-1956-b113b3ca42a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1524730f-e37d-478c-1956-b113b3ca42a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1524730f-e37d-478c-1956-b113b3ca42a8"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer (1.3) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [ see Clinical Studies (14.2 , 14.3) ]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [ see Clinical Studies (14.4 , 14.5) ]."], "temporal_context_qualifier": "following prior standard adjuvant tamoxifen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression following antiestrogen therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3738e1c7-a122-5d02-910f-510ccd6dec86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "UMLS:C3495917", "object_location_in_text": [427, 449], "original_object": "advanced breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c10bf97f-f9cf-468a-8a1f-7637f41022e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c10bf97f-f9cf-468a-8a1f-7637f41022e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c10bf97f-f9cf-468a-8a1f-7637f41022e4"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression following antiestrogen therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d1e462f-627e-53a4-837f-72ac4a3b554d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "UMLS:C3495917", "object_location_in_text": [419, 441], "original_object": "advanced breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82b77d74-085f-45ac-a7dd-1f5c038bf406", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression following antiestrogen therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7d81104-c33a-5fe8-a93b-f3fe03806868", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "UMLS:C3495917", "object_location_in_text": [427, 449], "original_object": "advanced breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26dcb6ee-74d8-4804-b151-79a41484979b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26dcb6ee-74d8-4804-b151-79a41484979b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26dcb6ee-74d8-4804-b151-79a41484979b"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression following antiestrogen therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb7a8145-cb2b-5039-9b18-9f6e3e3a175c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "UMLS:C3495917", "object_location_in_text": [427, 449], "original_object": "advanced breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a707ec4b-8d26-55c2-e053-2a95a90a2e07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a707ec4b-8d26-55c2-e053-2a95a90a2e07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a707ec4b-8d26-55c2-e053-2a95a90a2e07"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bedf5bf3-006f-527b-aa57-fbb2ea61f698", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "UMLS:C3495917", "object_location_in_text": [427, 449], "original_object": "advanced breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c391fe11-fd47-4a35-af6d-c823ab7b8838", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c391fe11-fd47-4a35-af6d-c823ab7b8838", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c391fe11-fd47-4a35-af6d-c823ab7b8838"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following antiestrogen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0242656", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3e304d7-d756-5023-8bf7-580ad1fe43ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970725", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0242656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f6f1abb-ff7b-5fc3-846e-912be930ee44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:95784c90-9f4e-563c-9884-a06c4582ba1a", "object": "UMLS:C3495917", "object_location_in_text": [427, 449], "original_object": "advanced breast cancer", "original_subject": "LETROZOLE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=065cc89f-3a3f-4d78-b9f6-1c32a77ceb1c"]}], "subject": "CHEBI:6413", "supporting_text": ["1 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2 , 14.3 )] . 1.3 First and Second-Line Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies ( 14.4 , 14.5 )]."], "temporal_context_qualifier": "following antiestrogen therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "postarsenical jaundice", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:390265bc-db50-5592-82c0-023cd1d3ce71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:545c09d6-21fe-5d97-a054-f4e7589e6a6b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b647ae7b-0faa-5063-8da3-4f77feb7a7d2", "object": "HP:0001399", "object_location_in_text": [79, 100], "original_object": "hepatic insufficiency", "original_subject": "DIMERCAPROL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ED1FC15-CA74-400E-BFDB-64483B2C590B", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ED1FC15-CA74-400E-BFDB-64483B2C590B", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ED1FC15-CA74-400E-BFDB-64483B2C590B"]}], "subject": "CHEBI:64198", "supporting_text": ["BAL in Oil (Dimercaprol Injection USP) is contraindicated in most instances of hepatic insufficiency with the exception of postarsenical jaundice. The drug should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "postarsenical jaundice", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b00d3c58-fe5f-552d-a5d3-769b5da0e476", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:545c09d6-21fe-5d97-a054-f4e7589e6a6b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b647ae7b-0faa-5063-8da3-4f77feb7a7d2", "object": "HP:0001399", "object_location_in_text": [79, 100], "original_object": "hepatic insufficiency", "original_subject": "DIMERCAPROL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bee9a137-160f-47e8-a551-ca461ae4f51e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bee9a137-160f-47e8-a551-ca461ae4f51e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bee9a137-160f-47e8-a551-ca461ae4f51e"]}], "subject": "CHEBI:64198", "supporting_text": ["BAL in Oil (Dimercaprol Injection USP) is contraindicated in most instances of hepatic insufficiency with the exception of postarsenical jaundice. The drug should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4290023", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c28c5dd-5740-588f-861d-1d53a9ebc8a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110826", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C4290023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eef138a1-24d1-5858-aa5d-b9081086df72", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d85eb2a6-e1f4-5f83-b863-5b3a1b22928f", "object": "MONDO:0015798", "original_object": "inflammatory myofibroblastic tumor", "original_subject": "CRIZOTINIB", "population_context_qualifier": "adult and pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a51b0de-47d6-455e-a94c-d2c737b04ff7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7"]}], "subject": "CHEBI:64310", "supporting_text": ["1 INDICATIONS AND USAGE XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0205373", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90116293-23a5-539e-b888-95ab21c78ee1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110826", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0205373", "UMLS:C4290023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:41b17f65-38ef-5f46-97bb-2b53c97f023b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d85eb2a6-e1f4-5f83-b863-5b3a1b22928f", "object": "MONDO:0020325", "original_object": "anaplastic large cell lymphoma", "original_subject": "CRIZOTINIB", "population_context_qualifier": "pediatric patients 1 year of age and older and young adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a51b0de-47d6-455e-a94c-d2c737b04ff7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7"]}], "subject": "CHEBI:64310", "supporting_text": ["1 INDICATIONS AND USAGE XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4744493", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:237e1d4b-dae6-585f-bee0-959da64ca0e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110826", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4744493"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d85eb2a6-e1f4-5f83-b863-5b3a1b22928f", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "CRIZOTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a51b0de-47d6-455e-a94c-d2c737b04ff7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7"]}], "subject": "CHEBI:64310", "supporting_text": ["1 INDICATIONS AND USAGE XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:853a1c81-2cc8-5cf4-bfcf-9c610c639530", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b03ee9ee-1b8c-5671-86b3-7ac5624c6ba3", "object": "HP:0002013", "object_location_in_text": [114, 122], "original_object": "vomiting", "original_subject": "FOSAPREPITANT MEGLUMINE", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FOSAPREPITANT MEGLUMINE#105-20160318", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:64311", "supporting_text": ["A drug with new additional pediatric dosages indicated for the treatment of gastrointestinal symptoms (nausea and vomiting, including delayed phase) associated with administration of antineoplastic drugs (cisplatin, etc.)."], "temporal_context_qualifier": "delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df2615c6-1703-5031-aa23-ddc2223c4820", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110926", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b03ee9ee-1b8c-5671-86b3-7ac5624c6ba3", "object": "HP:0002013", "object_location_in_text": [105, 113], "original_object": "vomiting", "original_subject": "FOSAPREPITANT MEGLUMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FOSAPREPITANT MEGLUMINE#144-20110926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:64311", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase)."], "temporal_context_qualifier": "delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fd11c24-4041-501d-bcfe-142be59fda8b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110926", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b03ee9ee-1b8c-5671-86b3-7ac5624c6ba3", "object": "HP:0002018", "object_location_in_text": [94, 100], "original_object": "nausea", "original_subject": "FOSAPREPITANT MEGLUMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FOSAPREPITANT MEGLUMINE#144-20110926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:64311", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase)."], "temporal_context_qualifier": "delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96e79c96-b828-545c-ac5c-51a9f27bdc2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b03ee9ee-1b8c-5671-86b3-7ac5624c6ba3", "object": "HP:0002018", "object_location_in_text": [103, 109], "original_object": "nausea", "original_subject": "FOSAPREPITANT MEGLUMINE", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FOSAPREPITANT MEGLUMINE#105-20160318", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:64311", "supporting_text": ["A drug with new additional pediatric dosages indicated for the treatment of gastrointestinal symptoms (nausea and vomiting, including delayed phase) associated with administration of antineoplastic drugs (cisplatin, etc.)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fcbd54a-5396-5cfc-acb2-04ed41392e9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d298a3e2-26b6-5de5-a915-583a4930064b", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b03ee9ee-1b8c-5671-86b3-7ac5624c6ba3", "object": "UMLS:C0426576", "object_location_in_text": [76, 101], "original_object": "gastrointestinal symptoms", "original_subject": "FOSAPREPITANT MEGLUMINE", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FOSAPREPITANT MEGLUMINE#105-20160318", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:64311", "supporting_text": ["A drug with new additional pediatric dosages indicated for the treatment of gastrointestinal symptoms (nausea and vomiting, including delayed phase) associated with administration of antineoplastic drugs (cisplatin, etc.)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly emetogenic cisplatin based cancer chemotherapy", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3234ecf6-c73c-598f-bf09-5a1f9014fcf8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d8037ea9-59b1-53fb-9298-d8ed7d3a2c8b", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "Fosaprepitant (as Dimeglumine) for Injection 150mg.", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:64321", "supporting_text": ["1. Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults. 2. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3234ecf6-c73c-598f-bf09-5a1f9014fcf8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d8037ea9-59b1-53fb-9298-d8ed7d3a2c8b", "object": "HP:0002017", "object_location_in_text": [35, 54], "original_object": "nausea and vomiting", "original_subject": "Fosaprepitant (as Dimeglumine) for Injection 150mg.", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:64321", "supporting_text": ["1. Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults. 2. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy, moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ee02db1-479e-5a20-bd1d-199e1de6556f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080111", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["combination therapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6fb38943-c820-5828-99f3-1b7873a93fe7", "object": "HP:0002017", "object_location_in_text": [14, 33], "original_object": "nausea and vomiting", "original_subject": "fosaprepitant", "population_context_qualifier": "adults and paediatric patients aged 6 months and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ivemend", "https://www.ema.europa.eu/en/documents/product-information/ivemend-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend"]}], "subject": "CHEBI:64321", "supporting_text": ["Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly emetogenic cisplatin based cancer chemotherapy", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1428d5b9-5ebd-5936-92e3-650fcd72c361", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:d8037ea9-59b1-53fb-9298-d8ed7d3a2c8b", "object": "UMLS:C3830545", "original_object": "delayed nausea and vomiting", "original_subject": "Fosaprepitant (as Dimeglumine) for Injection 150mg.", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:64321", "supporting_text": ["1. Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults. 2. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "at initiation and during the ramp-up phase", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0964e66f-28bc-5fe8-99e2-af1efecf1347", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52193a9d-3012-5c75-b134-2254d553791d", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0004948", "object_location_in_text": [529, 563], "original_object": "chronic lymphocytic leukemia (CLL)", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b073b082-7b57-4423-8c06-4fd4263d6f84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b073b082-7b57-4423-8c06-4fd4263d6f84"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) Coadministration of Noxafil with the following drugs is contraindicated; Noxafil increases concentrations and toxicities of: Sirolimus ( 4.2 , 7.2 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) Ergot alkaloids ( 4.5 , 7.2 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.2 ) Noxafil PowderMix for delayed-release oral suspension is contraindicated in patients with known or suspected Hereditary Fructose Intolerance (HFI). ( 4.7 , 5.9 , 8.4 ) 4.1 Hypersensitivity Noxafil is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Noxafil is contraindicated with sirolimus. Concomitant administration of Noxafil with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Noxafil is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of Noxafil with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ] . 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolys"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HMG-CoA reductase inhibitor use", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bf9b865-0274-54b5-aa07-5b063ce24fe3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["posaconazole"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aab231a7-5d85-55df-a952-b0c503d5f463", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0005290", "original_object": "rhabdomyolysis", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4032672e-1bb0-427d-a3b3-09cda4beaf34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4032672e-1bb0-427d-a3b3-09cda4beaf34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4032672e-1bb0-427d-a3b3-09cda4beaf34"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: Sirolimus ( 4.2 , 5.1 , 7.1 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.3 ) Ergot alkaloids ( 4.5 , 7.4 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.16 ) 4.1 Hypersensitivity Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole is contraindicated with sirolimus. Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ] . 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [see Drug Interactions (7.3) and Clinical Pharmacology (12.3) ] . 4.5 Use with Ergot Alkaloids Posaconazole may increase th"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HMG-CoA reductase inhibitor use", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:435bc121-8f62-56a8-ad05-fcd2220aede6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["posaconazole"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aab231a7-5d85-55df-a952-b0c503d5f463", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0005290", "original_object": "rhabdomyolysis", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0bdf77ae-3639-49c1-b7c7-533f9d073084", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0bdf77ae-3639-49c1-b7c7-533f9d073084", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0bdf77ae-3639-49c1-b7c7-533f9d073084"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: Sirolimus ( 4.2 , 5.1 , 7.1 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.3 ) Ergot alkaloids ( 4.5 , 7.4 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.16 ) 4.1 Hypersensitivity Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole is contraindicated with sirolimus. Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [ see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ]. 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [ see Warnings and Precautions (5.2) and Drug Interactions (7.2) ]. 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [ see Drug Interactions (7.3) and Clinical Pharmacology (12.3) ]. 4.5 Use with Ergot Alkaloids Posaconazole may increase th"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:369b9130-6164-5a89-a628-c113768d53ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ebbd88b-547b-4b49-ab73-98094a2d5a79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ebbd88b-547b-4b49-ab73-98094a2d5a79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ebbd88b-547b-4b49-ab73-98094a2d5a79"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS • Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) • Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: • Sirolimus: ( 4.2 , 7.2 ) • CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) • HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) • Ergot alkaloids ( 4.5 , 7.2 ) • Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.2 ) 4.1 Hypersensitivity Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole is contraindicated with sirolimus. Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ] . 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . 4.5 Use with Ergot Alkaloids Posaconazole may inc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:401f4518-5c75-54ea-b591-99003f8a6f95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91f89a3b-2479-4d05-9997-7b0cfaa496ec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91f89a3b-2479-4d05-9997-7b0cfaa496ec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91f89a3b-2479-4d05-9997-7b0cfaa496ec"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS • Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) • Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: • Sirolimus ( 4.2 , 5.1 , 7.1 ) • CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3, 5.2 , 7.2 ) • HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4, 7.3 ) • Ergot alkaloids ( 4.5 , 7.4 ) • Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6, 5.11 , 7.16 ) 4.1 Hypersensitivity Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole is contraindicated with sirolimus. Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [ see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 ) ]. 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [ see Warnings and Precautions (5.2) and Drug Interactions ( 7.2 ) ]. 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [ see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.3 ) ]. 4.5 Use with Ergot Alkaloids Posacon"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41fd2898-57c6-5154-bd66-ed637b66174b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2ba0343-cd17-4b23-8356-005a1dfd0b35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2ba0343-cd17-4b23-8356-005a1dfd0b35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2ba0343-cd17-4b23-8356-005a1dfd0b35"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS • Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) • Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: • Sirolimus ( 4.2 , 5.1 , 7.1 ) • CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3, 5.2 , 7.2 ) • HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4, 7.3 ) • Ergot alkaloids ( 4.5 , 7.4 ) • Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6, 5.11 , 7.16 ) 4.1 Hypersensitivity Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole is contraindicated with sirolimus. Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [ see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 ) ]. 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [ see Warnings and Precautions (5.2) and Drug Interactions ( 7.2 ) ]. 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [ see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.3 ) ]. 4.5 Use with Ergot Alkaloids Posacon"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53f4fd59-7bd3-5589-8fe4-b2ecac70fad1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e883b495-d7e7-6d58-e053-2a95a90a1cd3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e883b495-d7e7-6d58-e053-2a95a90a1cd3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e883b495-d7e7-6d58-e053-2a95a90a1cd3"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) Coadministration of posaconazole delayed-release tablets with the following drugs is contraindicated; posaconazole delayed-release tablets increase concentrations and toxicities of: Sirolimus ( 4.2 , 7.2 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) Ergot alkaloids ( 4.5 , 7.2 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.2 ) 4.1 Hypersensitivity Posaconazole delayed-release tablets are contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole delayed-release tablets are contraindicated with sirolimus. Concomitant administration of posaconazole delayed-release tablets with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole delayed-release tablets are contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole delayed-release tablets with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ] . 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:588564bc-c9d9-54da-8340-684a70285b9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8d8dd03-46b5-bd26-bb27-7ca31d8c3326", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8d8dd03-46b5-bd26-bb27-7ca31d8c3326", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8d8dd03-46b5-bd26-bb27-7ca31d8c3326"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS • Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) • Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: Sirolimus ( 4.2 , 5.1 , 7.2 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) Ergot alkaloids ( 4.5 , 7.2 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp up phase ( 4.6 , 5.11 , 7.2 ) 4.1 Hypersensitivity Posaconazole delayed-release tablets are contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole delayed-release tablets are contraindicated with sirolimus. Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )] . 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole delayed-release tablets are contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions ( 5.2 ) and Drug Interactions ( 7.2 )]. 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [see Drug Interactions ( 7.2 ) and Clini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d6a297a-2640-5c68-a907-58e2f609716f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["venetoclax"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9e4b74ef-376f-5337-b6aa-8dfce4455b7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0043875", "original_object": "tumor lysis syndrome", "original_subject": "POSACONAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8412398b-c696-4f12-ba3a-da74dc8dadaf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8412398b-c696-4f12-ba3a-da74dc8dadaf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8412398b-c696-4f12-ba3a-da74dc8dadaf"]}], "subject": "CHEBI:64355", "supporting_text": ["4 CONTRAINDICATIONS Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) Coadministration of posaconazole delayed-release tablets with the following drugs is contraindicated; posaconazole delayed-release tablets increase concentrations and toxicities of: Sirolimus ( 4.2 , 7.2 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.2 ) Ergot alkaloids ( 4.5 , 7.2 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.2 ) 4.1 Hypersensitivity Posaconazole delayed-release tablets are contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. 4.2 Use with Sirolimus Posaconazole delayed-release tablets are contraindicated with sirolimus. Concomitant administration of posaconazole delayed-release tablets with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . 4.3 QT Prolongation with Concomitant Use with CYP3A4 Substrates Posaconazole delayed-release tablets are contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole delayed-release tablets with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes [see Warnings and Precautions (5.2) and Drug Interactions (7.2) ] . 4.4 HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4 Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hematopoietic stem cell transplant recipients with graft-versus-host disease, hematologic malignancies with prolonged neutropenia from chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79dc173e-4136-542b-8f67-7e53bb510cd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:795c1e68-d610-547d-85af-0e4a7e530110", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "object": "MONDO:0000240", "original_object": "invasive aspergillosis", "original_subject": "POSACONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older who weigh 10 kg or greater ; severely immunocompromised patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ebbd88b-547b-4b49-ab73-98094a2d5a79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ebbd88b-547b-4b49-ab73-98094a2d5a79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ebbd88b-547b-4b49-ab73-98094a2d5a79"]}], "subject": "CHEBI:64355", "supporting_text": ["1 INDICATIONS AND USAGE Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the treatment of invasive aspergillosis as follows: ( 1.1 ) o Posaconazole injection : adults and pediatric patients 2 years of age and older who weigh 10 kg or greater. • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) o Posaconazole injection : adults and pediatric patients 2 years of age and older who weigh 10 kg or greater. 1.1 Treatment of Invasive Aspergillosis Posaconazole injection is indicated for the treatment of invasive aspergillosis as follows : • Posaconazole injection: adults and pediatric patients 2 years of age and older who weigh 10 kg or greater 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole injection is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: • Posaconazole injection: adults and pediatric patients 2 years of age and older who weigh 10 kg or grea ter"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hematopoietic stem cell transplant recipients with graft-versus-host disease, hematologic malignancies with prolonged neutropenia from chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19ac627a-614d-5692-a4ca-8bc967186105", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0a350837-7f17-50f7-bb33-b5974092d507", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0002026", "object_location_in_text": [347, 365], "original_object": "Candida infections", "original_subject": "POSACONAZOLE", "population_context_qualifier": "severely immunocompromised patients; adults and pediatric patients 2 years of age and older who weigh greater than 40 kg (delayed-release tablets) or 13 years of age and older (oral suspension)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e031b632-8e57-4359-87bd-a5da02bdc55f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e031b632-8e57-4359-87bd-a5da02bdc55f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e031b632-8e57-4359-87bd-a5da02bdc55f"]}], "subject": "CHEBI:64355", "supporting_text": ["1 INDICATIONS AND USAGE Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets : adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Posaconazole oral suspension: adults and pediatric patients 13 years of age and older Posaconazole oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adults and pediatric patients 13 years of age and older. ( 1.3 ) 1.1 Treatment of Invasive Aspergillosis Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg. 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy [see Clinical Studies (14.1) ] as follows: Posaconazole delayed-release tablets : adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Posaconazole oral suspension: adults and pediatric pa"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hematopoietic stem cell transplant recipients with graft-versus-host disease, hematologic malignancies with prolonged neutropenia from chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2273ce8-d31c-5f59-8c53-1fb29ef43dfe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060915", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "object": "MONDO:0002026", "original_object": "candidiasis", "original_subject": "POSACONAZOLE", "population_context_qualifier": "adults and pediatric patients 2 years of age and older who weigh 10 kg or greater ; severely immunocompromised patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ebbd88b-547b-4b49-ab73-98094a2d5a79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ebbd88b-547b-4b49-ab73-98094a2d5a79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ebbd88b-547b-4b49-ab73-98094a2d5a79"]}], "subject": "CHEBI:64355", "supporting_text": ["1 INDICATIONS AND USAGE Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the treatment of invasive aspergillosis as follows: ( 1.1 ) o Posaconazole injection : adults and pediatric patients 2 years of age and older who weigh 10 kg or greater. • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) o Posaconazole injection : adults and pediatric patients 2 years of age and older who weigh 10 kg or greater. 1.1 Treatment of Invasive Aspergillosis Posaconazole injection is indicated for the treatment of invasive aspergillosis as follows : • Posaconazole injection: adults and pediatric patients 2 years of age and older who weigh 10 kg or greater 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole injection is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: • Posaconazole injection: adults and pediatric patients 2 years of age and older who weigh 10 kg or grea ter"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to amphotericin B, itraconazole or fluconazole, intolerance to amphotericin B, itraconazole or fluconazole", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e1cc9e0-b590-5524-b0a6-ffcf6287bc0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a24221db-f04e-54b8-9a76-00fba72160e3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "object": "MONDO:0005706", "original_object": "coccidioidomycosis", "original_subject": "posaconazole", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:posaconazole-accord", "https://www.ema.europa.eu/en/documents/product-information/posaconazole-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-accord"]}], "subject": "CHEBI:64355", "supporting_text": ["Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:  Invasive aspergillosis; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to amphotericin B, disease refractory to itraconazole, disease refractory to fluconazole, amphotericin B intolerance, itraconazole intolerance, fluconazole intolerance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd57b6fc-6b36-5119-ab11-b116f3809290", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a24221db-f04e-54b8-9a76-00fba72160e3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0005706", "original_object": "coccidioidomycosis", "original_subject": "posaconazole", "population_context_qualifier": "adults and paediatric patients from 2 years of age weighing more than 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:noxafil", "https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil"]}], "subject": "CHEBI:64355", "supporting_text": ["Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following invasive fungal infections in adult and paediatric patients from 2 years of age:&nbsp;  Invasive aspergillosis&nbsp; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;  Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.&nbsp;&nbsp;  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.&nbsp; Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in adults and paediatric patients from 2 years of age:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;&nbsp;  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.&nbsp;&nbsp;  Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in adults with oropharyngeal candidiasis. Noxafil gastro-resistant tablets are indicated for use in the treatment of the following invasive fungal infections in adults and paediatric patients from 2 years of age weighing more than 40 kg:&nbsp;  Invasive aspergillosis  Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and myceto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to itraconazole, intolerance to itraconazole", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c0421ef-42b5-5acf-87c6-e13ec5665732", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:90cd4bdf-fc85-5fb2-80d4-a2d3caa7adf5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "object": "MONDO:0015908", "original_object": "chromoblastomycosis", "original_subject": "posaconazole", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:posaconazole-accord", "https://www.ema.europa.eu/en/documents/product-information/posaconazole-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-accord"]}], "subject": "CHEBI:64355", "supporting_text": ["Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:  Invasive aspergillosis; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to itraconazole, itraconazole intolerance", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c7cc3ad-a2a6-528b-a41b-1b3c92a57a1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:90cd4bdf-fc85-5fb2-80d4-a2d3caa7adf5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0015908", "original_object": "chromoblastomycosis", "original_subject": "posaconazole", "population_context_qualifier": "adults and paediatric patients from 2 years of age weighing more than 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:noxafil", "https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil"]}], "subject": "CHEBI:64355", "supporting_text": ["Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following invasive fungal infections in adult and paediatric patients from 2 years of age:&nbsp;  Invasive aspergillosis&nbsp; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;  Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.&nbsp;&nbsp;  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.&nbsp; Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in adults and paediatric patients from 2 years of age:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;&nbsp;  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.&nbsp;&nbsp;  Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in adults with oropharyngeal candidiasis. Noxafil gastro-resistant tablets are indicated for use in the treatment of the following invasive fungal infections in adults and paediatric patients from 2 years of age weighing more than 40 kg:&nbsp;  Invasive aspergillosis  Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and myceto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to amphotericin B, amphotericin B intolerance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7e9a86d-46d1-5ae3-aca2-2dcf72e44944", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:29725125-4775-5307-89a1-6f57d027b210", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0016426", "original_object": "fusariosis", "original_subject": "posaconazole", "population_context_qualifier": "adults and paediatric patients from 2 years of age weighing more than 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:noxafil", "https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil"]}], "subject": "CHEBI:64355", "supporting_text": ["Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following invasive fungal infections in adult and paediatric patients from 2 years of age:&nbsp;  Invasive aspergillosis&nbsp; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;  Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.&nbsp;&nbsp;  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.&nbsp; Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in adults and paediatric patients from 2 years of age:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;&nbsp;  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.&nbsp;&nbsp;  Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in adults with oropharyngeal candidiasis. Noxafil gastro-resistant tablets are indicated for use in the treatment of the following invasive fungal infections in adults and paediatric patients from 2 years of age weighing more than 40 kg:&nbsp;  Invasive aspergillosis  Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and myceto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to amphotericin B, intolerance to amphotericin B", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc2bff0d-f7fb-5bde-bbe8-50bd9d70f18c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:29725125-4775-5307-89a1-6f57d027b210", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "object": "MONDO:0016426", "original_object": "fusariosis", "original_subject": "posaconazole", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:posaconazole-accord", "https://www.ema.europa.eu/en/documents/product-information/posaconazole-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-accord"]}], "subject": "CHEBI:64355", "supporting_text": ["Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:  Invasive aspergillosis; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to itraconazole, itraconazole intolerance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32fef5e6-8279-5f91-97ff-f711cab6586b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:512dae2c-81d9-5947-b1a5-b4a12147f49b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "medic_supporting_text_truncated": true, "object": "MONDO:0016823", "object_location_in_text": [369, 377], "original_object": "mycetoma", "original_subject": "posaconazole", "population_context_qualifier": "adults and paediatric patients from 2 years of age weighing more than 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:noxafil", "https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/noxafil"]}], "subject": "CHEBI:64355", "supporting_text": ["Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following invasive fungal infections in adult and paediatric patients from 2 years of age:&nbsp;  Invasive aspergillosis&nbsp; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;  Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.&nbsp;&nbsp;  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.&nbsp; Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in adults and paediatric patients from 2 years of age:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;&nbsp;  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.&nbsp;&nbsp;  Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in adults with oropharyngeal candidiasis. Noxafil gastro-resistant tablets are indicated for use in the treatment of the following invasive fungal infections in adults and paediatric patients from 2 years of age weighing more than 40 kg:&nbsp;  Invasive aspergillosis  Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;  Chromoblastomycosis and myceto"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "disease refractory to itraconazole, intolerance to itraconazole", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f53ef21b-415e-53cf-a53c-5c2707c75e5a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:512dae2c-81d9-5947-b1a5-b4a12147f49b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ea3ae480-f65d-5dfb-8466-22300dfd9244", "object": "MONDO:0016823", "object_location_in_text": [279, 287], "original_object": "mycetoma", "original_subject": "posaconazole", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:posaconazole-accord", "https://www.ema.europa.eu/en/documents/product-information/posaconazole-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-accord"]}], "subject": "CHEBI:64355", "supporting_text": ["Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:  Invasive aspergillosis; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.  Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients:&nbsp;  Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections; Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "suspected coronary artery disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8c816e5-1649-5091-818b-760722fa5c1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1020, 1043], "original_object": "coronary artery disease", "original_subject": "LIDOCAINE", "population_context_qualifier": "Adults and pediatric patients 12 years of age and over", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50"]}], "subject": "CHEBI:6456", "supporting_text": ["1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) CT imaging of the head and body. (270 mg Iodine/mL and 320 mg Iodine/mL) excretory urography. (270 mg Iodine/mL) peripheral venography. (320 mg Iodine/mL) coronary computed tomography"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8912caa8-ba32-578f-9ec0-5815abfe0d91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "HP:0012531", "object_location_in_text": [47, 51], "original_object": "pain", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e"]}], "subject": "CHEBI:6456", "supporting_text": ["Uses: Temporarily relieves local discomfort or pain or burning associated with anorectal disorders."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:985955fe-6ae9-55a2-9aa8-9f34d03c12ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "HP:0012531", "original_object": "pain", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58793581-8826-9a74-e063-6294a90a2465"]}], "subject": "CHEBI:6456", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hemorrhoidal tissues", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2043402-b355-5e9d-98d9-3e651bb770c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd435476-e26f-5006-b0a5-a0cf6c17ebad", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "HP:0012531", "object_location_in_text": [119, 135], "original_object": "pain and burning", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb5de395-e104-ce2b-e053-6394a90af802", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb5de395-e104-ce2b-e053-6394a90af802", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb5de395-e104-ce2b-e053-6394a90af802"]}], "subject": "CHEBI:6456", "supporting_text": ["Uses helps relieve the local itching and discomfort associated with inflamed hemorrhoidal tissues temporarily relieves pain and burning"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba7ec60f-6893-5347-87fc-3ff5d2efeae7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "HP:0012531", "original_object": "pain", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2"]}], "subject": "CHEBI:6456", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016167", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03bf826e-1227-501a-8366-52bc940e5df0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016167", "UMLS:C0033775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cbbac17-5f77-587b-8828-e5c679598c28", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "MONDO:0004872", "object_location_in_text": [120, 131], "original_object": "hemorrhoids", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3881327f-c3fc-7df2-e063-6294a90a468d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3881327f-c3fc-7df2-e063-6294a90a468d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3881327f-c3fc-7df2-e063-6294a90a468d"]}], "subject": "CHEBI:6456", "supporting_text": ["INDICATIONS: Indicated for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d89c5422-436b-57a4-b852-17cad38579f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cbbac17-5f77-587b-8828-e5c679598c28", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "MONDO:0004872", "object_location_in_text": [66, 77], "original_object": "hemorrhoids", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70eb750e-fa78-4e01-b32a-0e2ff48d0a8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70eb750e-fa78-4e01-b32a-0e2ff48d0a8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70eb750e-fa78-4e01-b32a-0e2ff48d0a8b"]}], "subject": "CHEBI:6456", "supporting_text": ["Uses: Helps relieve the pain, itching and burning associated with hemorrhoids and other anorectal disorders."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012531", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65f17106-171c-5d6e-8aad-78b2847299c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b6a4459-e2f4-5e6b-8013-127cd1f37599", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "MONDO:0041052", "object_location_in_text": [88, 111], "original_object": "post-herpetic neuralgia", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3de6bb95-3673-45c4-bf11-90ec858c37d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3de6bb95-3673-45c4-bf11-90ec858c37d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3de6bb95-3673-45c4-bf11-90ec858c37d9"]}], "subject": "CHEBI:6456", "supporting_text": ["INDICATION AND USAGE Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6beeb61-b498-50d2-96cc-889ad2b06a8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "UMLS:C0014724", "object_location_in_text": [55, 62], "original_object": "burning", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f64cbd3-6745-4397-9767-3adc3b301e0e"]}], "subject": "CHEBI:6456", "supporting_text": ["Uses: Temporarily relieves local discomfort or pain or burning associated with anorectal disorders."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1fc60681-6fae-544b-a441-f0c35a3f455b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:436d4e04-ca59-508a-8100-86bee47fd0ad", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "UMLS:C0234215", "original_object": "discomfort", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df51623c-e0b6-8e86-e053-2995a90a59b2"]}], "subject": "CHEBI:6456", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0687707", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3119dabb-6c16-57c3-88a4-3313a47cc237", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0687707"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:436d4e04-ca59-508a-8100-86bee47fd0ad", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1544160-b420-53c4-a8fe-40fc452ead93", "object": "UMLS:C0234215", "original_object": "discomfort", "original_subject": "LIDOCAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58793581-8826-9a74-e063-6294a90a2465", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58793581-8826-9a74-e063-6294a90a2465"]}], "subject": "CHEBI:6456", "supporting_text": ["USES FOR THE TEMPORARY RELIEF OF LOCAL AND ANORECTAL ITCHING, DISCOMFORT, AND PAIN ASSOCIATED WITH ANORECTAL DISORDERS OR ANORECTAL INFLAMMATION."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic or mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0470fffc-c8ae-5951-b897-d1c0eef5b2b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090506", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ec8dae6c-4f34-5d2f-a638-511e28f0d3dc", "object": "MONDO:0001866", "object_location_in_text": [179, 197], "original_object": "bipolar I disorder", "original_subject": "ILOPERIDONE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33f60b40-3fca-11de-8f56-0002a5d5c51b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b"]}], "subject": "CHEBI:65173", "supporting_text": ["1 INDICATIONS AND USAGE FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with the use of broad-spectrum antibiotics", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08f24d6f-3183-59ab-8b6f-a8c6fd23c4ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "LOPERAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518bb0f0-88f2-1c95-e063-6294a90a722f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518bb0f0-88f2-1c95-e063-6294a90a722f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518bb0f0-88f2-1c95-e063-6294a90a722f"]}], "subject": "CHEBI:6532", "supporting_text": ["Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS ). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella , Shigella, and Campylobacter . patients with pseudomembranous colitis (e.g., Clostridium difficle ) associated with the use of broad-spectrum antibiotics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with the use of broad-spectrum antibiotics", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fb2a56e-108d-5aa6-8ed3-86353dec8420", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "LOPERAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59e1c4cf-17cc-13c9-e063-6294a90af61c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59e1c4cf-17cc-13c9-e063-6294a90af61c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59e1c4cf-17cc-13c9-e063-6294a90af61c"]}], "subject": "CHEBI:6532", "supporting_text": ["Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter. patients with pseudomembranous colitis (e.g., Clostridium difficle) associated with the use of broad-spectrum antibiotics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with the use of broad-spectrum antibiotics", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6beffa3d-6383-5581-8c00-f3de0a13b665", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "LOPERAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3b0ac1a9-ffa6-9af6-e063-6294a90a2678", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3b0ac1a9-ffa6-9af6-e063-6294a90a2678", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b0ac1a9-ffa6-9af6-e063-6294a90a2678"]}], "subject": "CHEBI:6532", "supporting_text": ["Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS ). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella , Shigella, and Campylobacter . patients with pseudomembranous colitis (e.g., Clostridium difficle ) associated with the use of broad-spectrum antibiotics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with the use of broad-spectrum antibiotics", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6eda54e5-66fd-5139-8743-f9754935e465", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "LOPERAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3fdfc0e5-56a2-48a0-8ee6-390a194a29f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3fdfc0e5-56a2-48a0-8ee6-390a194a29f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fdfc0e5-56a2-48a0-8ee6-390a194a29f3"]}], "subject": "CHEBI:6532", "supporting_text": ["Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS ). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella , Shigella, and Campylobacter . patients with pseudomembranous colitis (e.g., Clostridium difficle ) associated with the use of broad-spectrum antibiotics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with the use of broad-spectrum antibiotics", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c809e91e-4ed8-5b26-8eab-c9cd26ae6897", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "LOPERAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5daab489-eb3f-eca1-e063-6394a90a99d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5daab489-eb3f-eca1-e063-6394a90a99d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5daab489-eb3f-eca1-e063-6394a90a99d5"]}], "subject": "CHEBI:6532", "supporting_text": ["Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS ). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella , Shigella, and Campylobacter . patients with pseudomembranous colitis (e.g., Clostridium difficle ) associated with the use of broad-spectrum antibiotics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "associated with the use of broad-spectrum antibiotics", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea7c6f26-0d0f-5827-bab8-6fecd1dab6df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000705", "original_object": "pseudomembranous colitis", "original_subject": "LOPERAMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:45a1e6b0-1e2b-958a-e063-6394a90a261d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=45a1e6b0-1e2b-958a-e063-6394a90a261d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=45a1e6b0-1e2b-958a-e063-6394a90a261d"]}], "subject": "CHEBI:6532", "supporting_text": ["Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS ). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella , Shigella , and Campylobacter . patients with pseudomembranous colitis (e.g., Clostridium difficile ) associated with the use of broad-spectrum antibiotics."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0042769", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6ee1b98-7768-5c0d-8bf3-d0c35c0cb29c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19710101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042769"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a99f23fe-3f84-5457-a258-3dd2783fec0f", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0000257", "object_location_in_text": [53, 68], "original_object": "acute diarrhoea", "original_subject": "Loperamide", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:6532", "supporting_text": ["Anti diarrhoeal agent- indicated in the treatment of acute diarrhoea due to food poisoning, viral infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277528", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e48ab198-8d3c-566f-a4f3-74f74a8ea96c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277528"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:faaff3a3-79ce-59ce-bd2a-422b36c624f2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f01e6dc2-b1b6-5987-9a55-43fad79c96d1", "object": "MONDO:0001673", "object_location_in_text": [25, 33], "original_object": "diarrhea", "original_subject": "LOPERAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d3ccda2-3886-4ff7-ad10-6440fc4da6bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d3ccda2-3886-4ff7-ad10-6440fc4da6bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d3ccda2-3886-4ff7-ad10-6440fc4da6bf"]}], "subject": "CHEBI:6532", "supporting_text": ["Use controls symptoms of diarrhea, including Travelers' Diarrhea"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:078679d5-6431-5f2e-92d8-0d1171e5568f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170518", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a1383048-7b51-54ef-be3f-d2b5dea9a01b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:55eb9c92-3d1a-5d01-baeb-1bf67808ac7f", "object": "HP:0006775", "object_location_in_text": [104, 120], "original_object": "multiple myeloma", "original_subject": "CARFILZOMIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CARFILZOMIB#93-20170518", "https://www.pmda.go.jp/files/000224115.pdf"]}], "subject": "CHEBI:65347", "supporting_text": ["Drugs with a new dosage and other characteristics indicated for the treatment of relapsed or refractory multiple myeloma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:183aecd1-2fd9-595a-8895-8f955f2d850e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b71b939e-8cb1-492c-8311-28f75dc4c682", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b71b939e-8cb1-492c-8311-28f75dc4c682", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b71b939e-8cb1-492c-8311-28f75dc4c682"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4483136c-f1d7-5bec-8e4f-e9531cd1bde7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:461b2b94-205a-4860-9cb4-d30267ada9df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=461b2b94-205a-4860-9cb4-d30267ada9df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=461b2b94-205a-4860-9cb4-d30267ada9df"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. (1.2) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81d65fc0-512c-5f1f-8baa-3b7e4c4d0591", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f7a1758-8691-4e53-96d6-a01626ee8140", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f7a1758-8691-4e53-96d6-a01626ee8140", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f7a1758-8691-4e53-96d6-a01626ee8140"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:864205fa-dc27-52b1-a1a4-14cb8e495b18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e597023d-6dcc-4d9e-8ce0-2d28a5d862f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e597023d-6dcc-4d9e-8ce0-2d28a5d862f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e597023d-6dcc-4d9e-8ce0-2d28a5d862f3"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron Mirabegron is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6e02288-2881-503b-87ad-a182f0df1ffc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["solifenacin succinate"], "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba9e9e15-e666-4c56-9271-2e24739cfa2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) MYRBETRIQ Monotherapy MYRBETRIQ ® is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. MYRBETRIQ Combination Therapy with Solifenacin Succinate MYRBETRIQ, in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) MYRBETRIQ Granules MYRBETRIQ ® Granules is indicated for the treatment of NDO in pediatric patients aged 3 years and older. MYRBETRIQ MYRBETRIQ is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebcf152a-4874-5341-b873-2b4f19709dfd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e40eb74-3b2a-47f7-bf31-fe27484f9bd2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e40eb74-3b2a-47f7-bf31-fe27484f9bd2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e40eb74-3b2a-47f7-bf31-fe27484f9bd2"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed2f8abd-8b3d-5f01-9d40-13598d6adea4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0042023"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "MONDO:0006624", "original_object": "overactive bladder", "original_subject": "MIRABEGRON", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:98247602-29b9-4621-8eeb-519e40b883b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=98247602-29b9-4621-8eeb-519e40b883b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=98247602-29b9-4621-8eeb-519e40b883b9"]}], "subject": "CHEBI:65349", "supporting_text": ["1 INDICATIONS AND USAGE Mirabegron extended-release tablets are beta-3 adrenergic agonists indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Extended-Release Tablets Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0439609", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b84c338-f3b3-590d-b52c-e114c7efe0cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0439609"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c2bbba16-462e-5a83-9048-4c4f088eb51f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d16cc60e-d72b-57af-b257-684aa512732a", "object": "UMLS:C4020898", "original_object": "overactive bladder syndrome", "original_subject": "mirabegron", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:betmiga", "https://www.ema.europa.eu/en/documents/product-information/betmiga-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga"]}], "subject": "CHEBI:65349", "supporting_text": ["Overactive bladder in adults&nbsp;  Betmiga prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.&nbsp;  Neurogenic detrusor overactivity in the paediatric population&nbsp;  Betmiga prolonged release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de96e0dd-a9db-5a95-9529-b352f3b0bedc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181022", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "UMLS:C0242339", "MONDO:0005148"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6aa16ad4-19e7-5b90-8779-6141a79adf0d", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ab3fa9ed-1925-5161-8e3f-1bc94ab37ed0", "object": "UMLS:C0920298", "object_location_in_text": [73, 98], "original_object": "chronic weight management", "original_subject": "Lorcaserin Hydrochloride Bulk and 10 mg tablets", "population_context_qualifier": "adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at one weight related comorbid condition", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:65350", "supporting_text": ["An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at one weight related comorbid condition (e.g. Hypertension, dyslipidaemia, type 2 diabetes)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b361f2f-e3e9-5bbf-bc61-c6e96d79f309", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37f34a57-6419-5704-8cc0-bf1a3f449b14", "object": "MONDO:0005324", "object_location_in_text": [48, 57], "original_object": "hay fever", "original_subject": "LORATADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b43e5a5-30a8-46ca-a44d-1e1abf567b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b43e5a5-30a8-46ca-a44d-1e1abf567b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b43e5a5-30a8-46ca-a44d-1e1abf567b51"]}], "subject": "CHEBI:6538", "supporting_text": ["Uses temporatily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing iching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2dbcbab-dead-5858-8bb2-79925677749e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021127", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37f34a57-6419-5704-8cc0-bf1a3f449b14", "object": "MONDO:0005324", "object_location_in_text": [50, 59], "original_object": "hay fever", "original_subject": "LORATADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2"]}], "subject": "CHEBI:6538", "supporting_text": ["Uses • temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • sneezing • itchy, watery eyes • runny nose • itching of the nose or throat • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies • reduces swelling of nasal passages • temporarily relieves sinus congestion and pressure • temporarily restores freer breathing through the nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001742", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2af750df-2025-518e-b3ad-d8dc9c67c534", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021127", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001742"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37f34a57-6419-5704-8cc0-bf1a3f449b14", "object": "MONDO:0005709", "object_location_in_text": [226, 237], "original_object": "common cold", "original_subject": "LORATADINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=934dda74-7995-46f1-b6f2-f4b928a2eeb2"]}], "subject": "CHEBI:6538", "supporting_text": ["Uses • temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • sneezing • itchy, watery eyes • runny nose • itching of the nose or throat • temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies • reduces swelling of nasal passages • temporarily relieves sinus congestion and pressure • temporarily restores freer breathing through the nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "not requiring relief of anxiety and/or diminished recall of events while being mechanically ventilated", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37010e4e-2b5d-5eae-a629-c7ad632eacf0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68ba5c01-9698-5dbc-81b3-a705b21870a4", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "HP:0002093", "object_location_in_text": [300, 332], "original_object": "severe respiratory insufficiency", "original_subject": "LORAZEPAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fc0e987-61c9-40c4-b0d5-fcea07c8733e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fc0e987-61c9-40c4-b0d5-fcea07c8733e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fc0e987-61c9-40c4-b0d5-fcea07c8733e"]}], "subject": "CHEBI:6539", "supporting_text": ["ATIVAN Injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle (polyethylene glycol, propylene glycol, and benzyl alcohol), in patients with acute narrow-angle glaucoma, or in patients with sleep apnea syndrome. It is also contraindicated in patients with severe respiratory insufficiency, except in those patients requiring relief of anxiety and/or diminished recall of events while being mechanically ventilated. The use of ATIVAN Injection intra-arterially is contraindicated because, as with other injectable benzodiazepines, inadvertent intra-arterial injection may produce arteriospasm resulting in gangrene which may require amputation (see WARNINGS ). ATIVAN Injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see WARNINGS and PRECAUTIONS, Pediatric Use )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88ad7a4c-3357-5798-829b-df87c80ca94f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:b3c5b3e6-9184-540d-96f8-d477d1fe6ee1", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "Lorazepam Orodispersible Tablet 1mg/2mg (additional Dosage form)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:6539", "supporting_text": ["For the management of anxiety disorders or for the short term relief of symptoms of anxiety or anxiety associated with depressive symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:00750110-65c9-5b2a-baa9-8f6b719f7996", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:787240e9-67b5-4af3-b16d-7cf314e3f2e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=787240e9-67b5-4af3-b16d-7cf314e3f2e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=787240e9-67b5-4af3-b16d-7cf314e3f2e3"]}], "subject": "CHEBI:6539", "supporting_text": ["INDICATIONS &amp; USAGE Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:056679bb-7e58-5e57-bd95-bac15bf1cc7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bf22e97-9425-484d-bac6-519c6bae6a37", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bf22e97-9425-484d-bac6-519c6bae6a37", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bf22e97-9425-484d-bac6-519c6bae6a37"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c23d5a8-d44d-58d6-a481-cb488f034765", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [53, 60], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:903351ae-1bb0-4ac0-8430-df24cf2eee76", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=903351ae-1bb0-4ac0-8430-df24cf2eee76", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=903351ae-1bb0-4ac0-8430-df24cf2eee76"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets areindicated for the management of anxietydisorders or for theshort-termrelief of the symptoms of anxiety or anxietyassociatedwithdepressivesymptoms.Anxiety or tensionassociatedwith the stress of everyday life usuallydoesnotrequiretreatmentwith an anxiolytic. The effectiveness of lorazepam tablets in long-termuse,thatis,morethan 4 months,has not been assessed by systematicclinicalstudies. The physicianshouldperiodicallyreassess the usefulness of the drug for the individualpatient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:172b6566-f216-53ff-ae9a-b8bf9a93af53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6c5356b1-c199-49ad-bb00-fd67c6691f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6c5356b1-c199-49ad-bb00-fd67c6691f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6c5356b1-c199-49ad-bb00-fd67c6691f74"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28cbbdd9-1c78-5d1c-a398-9cd05510ad44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ed37d304-04cf-43ec-a58d-d72002ff889b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ed37d304-04cf-43ec-a58d-d72002ff889b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed37d304-04cf-43ec-a58d-d72002ff889b"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:294dc7ba-b41b-5cff-91c2-2e6b3190e748", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c2cc4eb-cc84-f08c-e063-6394a90a605b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c2cc4eb-cc84-f08c-e063-6394a90a605b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c2cc4eb-cc84-f08c-e063-6394a90a605b"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b256c76-938b-5dd5-b8e9-e11c9ad18678", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [45, 52], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0681c8db-ff09-4258-a5e0-76a26b0ea0af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0681c8db-ff09-4258-a5e0-76a26b0ea0af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0681c8db-ff09-4258-a5e0-76a26b0ea0af"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:440edf10-49f0-54ac-b46f-805deb02fc6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [66, 73], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f44ebe9-c94d-47cc-8933-ce02009d81a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f44ebe9-c94d-47cc-8933-ce02009d81a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f44ebe9-c94d-47cc-8933-ce02009d81a1"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam Oral Concentrate USP is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:811ee41f-1466-5417-a333-00e4c6e699db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac1f88c2-2cf2-47de-a612-946cd4503090", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac1f88c2-2cf2-47de-a612-946cd4503090", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac1f88c2-2cf2-47de-a612-946cd4503090"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8eb50569-6687-592d-9fcc-9908dd6eccb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0810422-b732-4c04-97d8-c1521c401ef4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0810422-b732-4c04-97d8-c1521c401ef4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0810422-b732-4c04-97d8-c1521c401ef4"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b87fb34-14a0-565e-b226-e946c79a9d74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:569e8a5a-ddf7-ebbc-e063-6294a90ab7a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=569e8a5a-ddf7-ebbc-e063-6294a90ab7a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=569e8a5a-ddf7-ebbc-e063-6294a90ab7a4"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b15a0585-f9cf-5547-809e-533d4cce7df0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [45, 52], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1009c870-fd98-4e3b-81c8-4184036fb8c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1009c870-fd98-4e3b-81c8-4184036fb8c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1009c870-fd98-4e3b-81c8-4184036fb8c2"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stress of everyday life", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbea6bbd-8e86-5d47-9ab7-19f6f754ee91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86630bdd-13ad-4ab5-9e94-fcf2ea2113e1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86630bdd-13ad-4ab5-9e94-fcf2ea2113e1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86630bdd-13ad-4ab5-9e94-fcf2ea2113e1"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e64bf094-9d61-552d-8d1a-a9f8a69c333c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [45, 52], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6dfbe8be-168c-44e9-acfa-fa838b92d3b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6dfbe8be-168c-44e9-acfa-fa838b92d3b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6dfbe8be-168c-44e9-acfa-fa838b92d3b7"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f525ce52-aebc-5197-b3c1-0ccb25f8ce77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [45, 52], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be9f8bda-1cd9-40a6-a4da-b5961389fb5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be9f8bda-1cd9-40a6-a4da-b5961389fb5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be9f8bda-1cd9-40a6-a4da-b5961389fb5b"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0086132", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6084733-7663-5894-985f-7bb064e4cd1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0086132"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:45674d8c-f70c-5ee4-a60d-2c4eab902a0d", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8734c678-4961-5f6f-8b00-fc1544fd4949", "object": "MONDO:0011918", "object_location_in_text": [45, 52], "original_object": "anxiety", "original_subject": "LORAZEPAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf265c2e-ab2f-42e5-96cf-3998eb5a644d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf265c2e-ab2f-42e5-96cf-3998eb5a644d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf265c2e-ab2f-42e5-96cf-3998eb5a644d"]}], "subject": "CHEBI:6539", "supporting_text": ["Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06d4f634-10e8-578f-b92e-c0b5f514ff66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [328, 350], "original_object": "myocardial infarctions", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a397502e-abe7-49cf-97c7-d53a616947eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a397502e-abe7-49cf-97c7-d53a616947eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a397502e-abe7-49cf-97c7-d53a616947eb"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS &amp; USAGE Losartan potassium tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some othe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ac572ca-4d64-5da0-82c1-2a9032fa6267", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:498f26a1-5030-4f9b-9599-07d50e912d41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=498f26a1-5030-4f9b-9599-07d50e912d41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=498f26a1-5030-4f9b-9599-07d50e912d41"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. (1.3) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic pro"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13d6a8f5-bcad-51b3-a082-fe50925c3650", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [321, 342], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:021cd76a-b093-4704-8410-5e7d01e20a54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=021cd76a-b093-4704-8410-5e7d01e20a54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=021cd76a-b093-4704-8410-5e7d01e20a54"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. (1.3) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ce20b82-3f84-5de5-8b47-5edc4057ab44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [317, 338], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca012edc-923d-4ada-a261-db82b71b3c4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca012edc-923d-4ada-a261-db82b71b3c4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca012edc-923d-4ada-a261-db82b71b3c4f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:226fbc4b-b5d4-5b9c-a9cd-95d1370dc0ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [317, 338], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a959c71b-d658-4871-b303-073234b9fa84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a959c71b-d658-4871-b303-073234b9fa84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a959c71b-d658-4871-b303-073234b9fa84"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26193f55-1f92-5d39-a24e-03a154a205d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bf520a2-a50e-a6ae-0fdf-9be4e69729c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bf520a2-a50e-a6ae-0fdf-9be4e69729c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bf520a2-a50e-a6ae-0fdf-9be4e69729c0"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44154138-c50e-5b1f-86c9-c13f8fddff0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [321, 343], "original_object": "myocardial infarctions", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c15387df-87a4-4784-acb5-7dd550498f8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c15387df-87a4-4784-acb5-7dd550498f8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c15387df-87a4-4784-acb5-7dd550498f8f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49493f76-faf0-5156-b6e4-5e7fdea243db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [319, 340], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9501dfaa-c8cf-46d6-8bec-936c4fd8fe03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9501dfaa-c8cf-46d6-8bec-936c4fd8fe03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9501dfaa-c8cf-46d6-8bec-936c4fd8fe03"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d460853-27c2-52ab-9d97-26da48edd3ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [310, 331], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e136356b-e4d2-4e00-a409-35825c5637c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e136356b-e4d2-4e00-a409-35825c5637c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e136356b-e4d2-4e00-a409-35825c5637c9"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic proper"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e628a26-fdda-5cbc-aad1-f0b39fbc2965", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [321, 342], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5833c02c-9957-a069-e063-6294a90ad3e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5833c02c-9957-a069-e063-6294a90ad3e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5833c02c-9957-a069-e063-6294a90ad3e4"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dfe6306-12bc-588f-86ae-e7dfa7f7805e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [319, 340], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3233c707-70b6-4c29-8210-913eeb2a38ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3233c707-70b6-4c29-8210-913eeb2a38ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3233c707-70b6-4c29-8210-913eeb2a38ed"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adafd562-eb8c-5a8f-889e-42521ad8abc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [319, 340], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c565e7ba-97aa-4a65-80e6-543e9af6e1c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c565e7ba-97aa-4a65-80e6-543e9af6e1c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c565e7ba-97aa-4a65-80e6-543e9af6e1c4"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1c99323-ddcb-5833-8422-eb3b3805fd8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [317, 338], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9953f51-f30a-952d-e053-6394a90abf5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9953f51-f30a-952d-e053-6394a90abf5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9953f51-f30a-952d-e053-6394a90abf5f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1e0eb0b-6dbc-56c8-bf09-78e58784aa24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [321, 342], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f39f7f9-edac-45ca-9ee2-c2ecad0915ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f39f7f9-edac-45ca-9ee2-c2ecad0915ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f39f7f9-edac-45ca-9ee2-c2ecad0915ab"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f515ec9d-8ff3-58a9-8f32-d1de8b89dabe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [321, 342], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1843ee4b-1afc-4992-993a-4b0e03e785fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1843ee4b-1afc-4992-993a-4b0e03e785fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1843ee4b-1afc-4992-993a-4b0e03e785fc"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa61463a-f63d-534a-90c2-f94ce9080f28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [316, 337], "original_object": "myocardial infarction", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92691768-b5e6-4527-98dc-d86c58f6f13e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92691768-b5e6-4527-98dc-d86c58f6f13e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92691768-b5e6-4527-98dc-d86c58f6f13e"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05fd7154-697e-536e-87d1-fc62c9c69fb3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7cf8a7d-90f1-46a3-abff-1eb316aa7d72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7cf8a7d-90f1-46a3-abff-1eb316aa7d72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7cf8a7d-90f1-46a3-abff-1eb316aa7d72"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0962b01a-25c6-574c-bb38-75a52ede1d80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [316, 322], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients are excluded from this benefit", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a397502e-abe7-49cf-97c7-d53a616947eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a397502e-abe7-49cf-97c7-d53a616947eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a397502e-abe7-49cf-97c7-d53a616947eb"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS &amp; USAGE Losartan potassium tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some othe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0962b01a-25c6-574c-bb38-75a52ede1d80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [316, 323], "original_object": "strokes", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a397502e-abe7-49cf-97c7-d53a616947eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a397502e-abe7-49cf-97c7-d53a616947eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a397502e-abe7-49cf-97c7-d53a616947eb"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS &amp; USAGE Losartan potassium tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some othe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:101d604a-5318-5199-88db-54a343dd3cc3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients excluded per label text", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3233c707-70b6-4c29-8210-913eeb2a38ed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3233c707-70b6-4c29-8210-913eeb2a38ed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3233c707-70b6-4c29-8210-913eeb2a38ed"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18aac4f6-1b59-59bb-a7f7-f05c6157310e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c43e9dc6-2c8a-47d7-b40d-eb55dfe11a51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c43e9dc6-2c8a-47d7-b40d-eb55dfe11a51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c43e9dc6-2c8a-47d7-b40d-eb55dfe11a51"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27eba036-ce34-5222-a1ff-29d06f54ce39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [309, 315], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c15387df-87a4-4784-acb5-7dd550498f8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c15387df-87a4-4784-acb5-7dd550498f8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c15387df-87a4-4784-acb5-7dd550498f8f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27eba036-ce34-5222-a1ff-29d06f54ce39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [309, 316], "original_object": "strokes", "original_subject": "LOSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c15387df-87a4-4784-acb5-7dd550498f8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c15387df-87a4-4784-acb5-7dd550498f8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c15387df-87a4-4784-acb5-7dd550498f8f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32222e09-6752-5751-8af5-322266efad12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [298, 304], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bf520a2-a50e-a6ae-0fdf-9be4e69729c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bf520a2-a50e-a6ae-0fdf-9be4e69729c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bf520a2-a50e-a6ae-0fdf-9be4e69729c0"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:461449dd-6475-5979-9466-87753287c2c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a945396-dd71-4b16-bfab-947982407f36", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a945396-dd71-4b16-bfab-947982407f36", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a945396-dd71-4b16-bfab-947982407f36"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b14740c-e34d-5429-99fa-c557a3e2ac8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients are excluded from this benefit", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9953f51-f30a-952d-e053-6394a90abf5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9953f51-f30a-952d-e053-6394a90abf5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9953f51-f30a-952d-e053-6394a90abf5f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1177bb2-e840-5fde-aae2-c8e74826caf9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df4f55f0-fb11-4f6f-a7ed-127b50f955fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df4f55f0-fb11-4f6f-a7ed-127b50f955fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df4f55f0-fb11-4f6f-a7ed-127b50f955fc"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4afed81-d1ea-5a3b-9d93-ffb51e488cb6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients excluded per label text", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c565e7ba-97aa-4a65-80e6-543e9af6e1c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c565e7ba-97aa-4a65-80e6-543e9af6e1c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c565e7ba-97aa-4a65-80e6-543e9af6e1c4"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5096245-3f89-5f72-99a9-0cf0cec7060b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "patients with hypertension and left ventricular hypertrophy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a959c71b-d658-4871-b303-073234b9fa84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a959c71b-d658-4871-b303-073234b9fa84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a959c71b-d658-4871-b303-073234b9fa84"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5b5d125-d719-560f-b880-d608627b0945", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [304, 310], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients are excluded from this benefit", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92691768-b5e6-4527-98dc-d86c58f6f13e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92691768-b5e6-4527-98dc-d86c58f6f13e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92691768-b5e6-4527-98dc-d86c58f6f13e"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b600cf88-d874-5f75-bf74-b071ba7ede27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients are excluded from this benefit", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9501dfaa-c8cf-46d6-8bec-936c4fd8fe03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9501dfaa-c8cf-46d6-8bec-936c4fd8fe03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9501dfaa-c8cf-46d6-8bec-936c4fd8fe03"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da9587fa-4d95-5fe0-bfc1-1cc3172deea3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [309, 315], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "patients with hypertension and left ventricular hypertrophy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5833c02c-9957-a069-e063-6294a90ad3e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5833c02c-9957-a069-e063-6294a90ad3e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5833c02c-9957-a069-e063-6294a90ad3e4"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e015ff5d-7805-5617-b6de-6bbccaab2df4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [309, 315], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "patients with hypertension and left ventricular hypertrophy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:021cd76a-b093-4704-8410-5e7d01e20a54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=021cd76a-b093-4704-8410-5e7d01e20a54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=021cd76a-b093-4704-8410-5e7d01e20a54"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. (1.3) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacolog"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e270d6bd-d08a-59be-9c89-43fa194f2741", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [307, 313], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:498f26a1-5030-4f9b-9599-07d50e912d41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=498f26a1-5030-4f9b-9599-07d50e912d41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=498f26a1-5030-4f9b-9599-07d50e912d41"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. (1.3) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic pro"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1fc1080-3ebf-518f-8368-700ef4bf4805", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [298, 304], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e136356b-e4d2-4e00-a409-35825c5637c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e136356b-e4d2-4e00-a409-35825c5637c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e136356b-e4d2-4e00-a409-35825c5637c9"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic proper"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2f413de-4a2c-5cc1-abfa-c52912299b3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [309, 315], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "patients with hypertension and left ventricular hypertrophy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1843ee4b-1afc-4992-993a-4b0e03e785fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1843ee4b-1afc-4992-993a-4b0e03e785fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1843ee4b-1afc-4992-993a-4b0e03e785fc"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc6a1232-6d0a-5f32-a52f-0efd97fa905c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [305, 311], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "Black patients are excluded from this benefit", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ca012edc-923d-4ada-a261-db82b71b3c4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ca012edc-923d-4ada-a261-db82b71b3c4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca012edc-923d-4ada-a261-db82b71b3c4f"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd3e74bf-aeab-5b41-a7f2-1c76ca743698", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950414", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822", "HP:0001712"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:78510928-3cfc-54fc-9260-f9c5aff5c240", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [309, 315], "original_object": "stroke", "original_subject": "LOSARTAN", "population_context_qualifier": "patients with hypertension and left ventricular hypertrophy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f39f7f9-edac-45ca-9ee2-c2ecad0915ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f39f7f9-edac-45ca-9ee2-c2ecad0915ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f39f7f9-edac-45ca-9ee2-c2ecad0915ab"]}], "subject": "CHEBI:6541", "supporting_text": ["1 INDICATIONS AND USAGE Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-Class I mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a410fb8-bb5c-5db9-b718-811e588019ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120723", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ivacaftor/tezacaftor/elexacaftor"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:72eeda02-cc0f-50ff-9dd5-833ebd9d5745", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:baeaa20e-7fc4-5f8c-8c03-8ec39efe09a4", "object": "MONDO:0009061", "original_object": "cystic fibrosis", "original_subject": "ivacaftor", "population_context_qualifier": "paediatric patients aged 2 to less than 6 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kalydeco", "https://www.ema.europa.eu/en/documents/product-information/kalydeco-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco"]}], "subject": "CHEBI:66901", "supporting_text": ["Kalydeco tablets are indicated:&nbsp;&nbsp;- As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (Class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.&nbsp;- In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.&nbsp;- In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one non-Class I mutation in the CFTR gene. Kalydeco granules are indicated:&nbsp;- As monotherapy for the treatment of infants aged at least 1 month, toddlers and children weighing 3 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (Class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.&nbsp;- In a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one non-Class I mutation in the CFTR gene."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "steroid drug insufficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26199241-2321-52bb-bc0c-8834d5106299", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230823", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:e218636e-c036-5634-9444-3c1f36fe33e1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:de8d6e44-ca25-50cc-805e-fe9bf8dba625", "object": "MONDO:0013730", "object_location_in_text": [66, 91], "original_object": "graft-versus-host disease", "original_subject": "RUXOLITINIB PHOSPHATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RUXOLITINIB PHOSPHATE#20-20230823", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:66919", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective)."], "temporal_context_qualifier": "after hematopoietic stem cell transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "steroid drug insufficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7fc65cc5-ae25-5e11-afbd-6fec9f3be9e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:e218636e-c036-5634-9444-3c1f36fe33e1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:de8d6e44-ca25-50cc-805e-fe9bf8dba625", "object": "MONDO:0013730", "object_location_in_text": [187, 212], "original_object": "graft-versus-host disease", "original_subject": "RUXOLITINIB PHOSPHATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RUXOLITINIB PHOSPHATE#9-20240924", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:66919", "supporting_text": ["Drugs with a new indication and a new additional pediatric dosage and a drug with a new indication and a new additional pediatric dosage in an additional dosage form for the treatment of graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective)."], "temporal_context_qualifier": "after hematopoietic stem cell transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665472", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10eec44f-5e57-5172-b5b6-a7c0b363ce2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850531", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665472"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53ef6c4f-47ba-56f7-8499-5ed2ddd315c1", "object": "HP:0002017", "object_location_in_text": [188, 207], "original_object": "nausea and vomiting", "original_subject": "DRONABINOL", "population_context_qualifier": "adults; patients who have failed to respond adequately to conventional antiemetic treatments", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:adb1801c-0fb5-4e16-b969-1db91230e0b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=adb1801c-0fb5-4e16-b969-1db91230e0b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=adb1801c-0fb5-4e16-b969-1db91230e0b9"]}], "subject": "CHEBI:66964", "supporting_text": ["1 INDICATIONS AND USAGE Dronabinol capsules are indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol capsules is a cannabinoid indicated in adults for the treatment of: Anorexia associated with weight loss in patients with AIDS. ( 1 ) Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665472", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bec7987-920a-58f2-abaa-4258d4ccd621", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850531", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665472"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53ef6c4f-47ba-56f7-8499-5ed2ddd315c1", "object": "HP:0002017", "object_location_in_text": [192, 211], "original_object": "nausea and vomiting", "original_subject": "DRONABINOL", "population_context_qualifier": "adults who have failed to respond adequately to conventional antiemetic treatments", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:495aabae-3597-49dc-a5af-e328bcd937b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=495aabae-3597-49dc-a5af-e328bcd937b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=495aabae-3597-49dc-a5af-e328bcd937b7"]}], "subject": "CHEBI:66964", "supporting_text": ["1 INDICATIONS AND USAGE Dronabinol oral solution is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol oral solution is a cannabinoid indicated in adults for the treatment of: anorexia associated with weight loss in patients with AIDS. ( 1 ) nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665472", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e130bf40-f659-5399-9d01-7c835dc1d14b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850531", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665472"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53ef6c4f-47ba-56f7-8499-5ed2ddd315c1", "object": "HP:0002017", "object_location_in_text": [120, 139], "original_object": "nausea and vomiting", "original_subject": "DRONABINOL", "population_context_qualifier": "patients who have failed to respond adequately to conventional antiemetic treatments", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5050ed63-c6bc-4761-9a81-ef8e5f3f378e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5050ed63-c6bc-4761-9a81-ef8e5f3f378e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5050ed63-c6bc-4761-9a81-ef8e5f3f378e"]}], "subject": "CHEBI:66964", "supporting_text": ["Dronabinol capsules are indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665472", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3fd30d9-a79f-5d54-90e8-c5190cc04029", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850531", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665472"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53ef6c4f-47ba-56f7-8499-5ed2ddd315c1", "object": "HP:0002017", "object_location_in_text": [192, 211], "original_object": "nausea and vomiting", "original_subject": "DRONABINOL", "population_context_qualifier": "adults who have failed to respond adequately to conventional antiemetic treatments", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44205ae6-b86a-485c-baf6-233a2c878640", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44205ae6-b86a-485c-baf6-233a2c878640", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44205ae6-b86a-485c-baf6-233a2c878640"]}], "subject": "CHEBI:66964", "supporting_text": ["1 INDICATIONS AND USAGE Dronabinol oral solution is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol oral solution is a cannabinoid indicated in adults for the treatment of: anorexia associated with weight loss in patients with AIDS. ( 1 ) nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3665472", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6ff3e17-e628-52b1-86f9-ff4c758a4693", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850531", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665472"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53ef6c4f-47ba-56f7-8499-5ed2ddd315c1", "object": "HP:0002017", "object_location_in_text": [192, 211], "original_object": "nausea and vomiting", "original_subject": "DRONABINOL", "population_context_qualifier": "adults; patients who have failed to respond adequately to conventional antiemetic treatments", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd8c5d57-0173-4f62-8ff0-d8147986a976", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd8c5d57-0173-4f62-8ff0-d8147986a976", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd8c5d57-0173-4f62-8ff0-d8147986a976"]}], "subject": "CHEBI:66964", "supporting_text": ["1 INDICATIONS AND USAGE Dronabinol capsules are indicated in adults for the treatment of: • anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). • nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol capsules is a cannabinoid indicated in adults for the treatment of: • Anorexia associated with weight loss in patients with AIDS. ( 1 ) • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38d71624-566e-5426-bd6a-e26514708e7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [82, 89], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7d31433-8f39-4fe6-b542-1b4410122db7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7d31433-8f39-4fe6-b542-1b4410122db7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7d31433-8f39-4fe6-b542-1b4410122db7"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a2c2df0-125c-5d7c-9ec0-3896e9701785", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [96, 103], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b11c10b9-f40e-4ea7-9c5d-118517049f9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b11c10b9-f40e-4ea7-9c5d-118517049f9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b11c10b9-f40e-4ea7-9c5d-118517049f9d"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets, USP are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets, USP are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults (1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5cfaf49b-5141-5a83-a568-5fbb4a23cf2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f755f8f3-7645-433c-b502-c1f15b700299", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f755f8f3-7645-433c-b502-c1f15b700299", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f755f8f3-7645-433c-b502-c1f15b700299"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:617966a0-0724-5824-a739-c120b889dbcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [82, 89], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:598eb392-1dfe-c08c-e063-6394a90a4c7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=598eb392-1dfe-c08c-e063-6394a90a4c7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=598eb392-1dfe-c08c-e063-6394a90a4c7d"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67191555-4515-5c86-ac1d-d87c5bf0334f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d2ff762-041d-74ed-e063-6394a90ac588", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d2ff762-041d-74ed-e063-6394a90ac588", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d2ff762-041d-74ed-e063-6394a90ac588"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78171328-92ac-5ee1-957b-fa05220baf9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dab43efd-bec6-472f-b13a-1c043914dcd1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dab43efd-bec6-472f-b13a-1c043914dcd1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dab43efd-bec6-472f-b13a-1c043914dcd1"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79301b41-2f73-532a-9772-746cb1b8f44c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52ee9258-8311-e6bd-e063-6294a90a567f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52ee9258-8311-e6bd-e063-6294a90a567f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52ee9258-8311-e6bd-e063-6294a90a567f"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a51cf25-413b-509c-a0d3-eb0138ae1925", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1079db3f-d8ad-4c25-aa91-8ac8054ee4f2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1079db3f-d8ad-4c25-aa91-8ac8054ee4f2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1079db3f-d8ad-4c25-aa91-8ac8054ee4f2"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80ade47a-dfe7-51d4-b2cf-95677839bf47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [82, 89], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d53bf04e-5cfc-4974-9b24-2cce545d1bd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d53bf04e-5cfc-4974-9b24-2cce545d1bd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d53bf04e-5cfc-4974-9b24-2cce545d1bd0"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cf4e447-8ba1-5d36-a0ba-1de16957eb4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53df5b1b-64da-e805-e063-6294a90a0a55", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53df5b1b-64da-e805-e063-6294a90a0a55", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53df5b1b-64da-e805-e063-6294a90a0a55"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6efc837-ca1c-5197-a480-e657778ad9cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f99f13ab-33c0-4304-8dc5-3a75f3909377", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f99f13ab-33c0-4304-8dc5-3a75f3909377", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f99f13ab-33c0-4304-8dc5-3a75f3909377"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8eda94f-4e89-5594-b78d-5dc5dc56d4bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [82, 89], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:21d4a6ee-0a66-45d7-bab9-c5eef399713d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=21d4a6ee-0a66-45d7-bab9-c5eef399713d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21d4a6ee-0a66-45d7-bab9-c5eef399713d"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adc196c3-70ad-5f7e-ae86-23c2126349ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [82, 89], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba2fb6de-af86-4c05-9018-135e1f8594f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba2fb6de-af86-4c05-9018-135e1f8594f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba2fb6de-af86-4c05-9018-135e1f8594f9"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1e603a9-8afe-5012-b892-73810a782e21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [91, 98], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b541252-e8a7-b678-e063-6394a90a34dc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b541252-e8a7-b678-e063-6394a90a34dc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b541252-e8a7-b678-e063-6394a90a34dc"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "diseases affecting the vestibular system", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c91dad1d-e6c6-50ac-b507-94ca47c33591", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4d86a05-d2f3-51bc-b0b3-3959975ec433", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 15, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1af2600-e805-5a48-9388-6855db62337c", "object": "HP:0002321", "object_location_in_text": [82, 89], "original_object": "vertigo", "original_subject": "MECLIZINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6b3f4d8-5fcf-2278-e053-2a95a90ab139", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6b3f4d8-5fcf-2278-e053-2a95a90ab139", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6b3f4d8-5fcf-2278-e053-2a95a90ab139"]}], "subject": "CHEBI:6709", "supporting_text": ["1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d949f83f-aada-5977-9df4-bf57bf777c93", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52a41f05-1f3b-5633-9972-af7fb56ad7bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "MONDO:1060209", "object_location_in_text": [100, 120], "original_object": "secondary amenorrhea", "original_subject": "MEDROXYPROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1020bb60-4f13-4cd7-aaa1-c556752c84b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1020bb60-4f13-4cd7-aaa1-c556752c84b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1020bb60-4f13-4cd7-aaa1-c556752c84b7"]}], "subject": "CHEBI:6715", "supporting_text": ["INDICATIONS &amp; USAGE Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:034b7ec9-ca8f-53ac-acc2-61f065d1c83f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [76, 101], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a586be28-96af-4fed-a13f-9b94fd4c7405", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a586be28-96af-4fed-a13f-9b94fd4c7405", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a586be28-96af-4fed-a13f-9b94fd4c7405"]}], "subject": "CHEBI:6715", "supporting_text": ["PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39a2e94c-ff48-5053-a6be-5f3da9edcb19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0de6142f-a78e-ae58-e063-6394a90adff0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0de6142f-a78e-ae58-e063-6394a90adff0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0de6142f-a78e-ae58-e063-6394a90adff0"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f1245c9-b2f6-5746-89c1-ee0251557c82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [125, 150], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "population_context_qualifier": "nonhysterectomized postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1020bb60-4f13-4cd7-aaa1-c556752c84b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1020bb60-4f13-4cd7-aaa1-c556752c84b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1020bb60-4f13-4cd7-aaa1-c556752c84b7"]}], "subject": "CHEBI:6715", "supporting_text": ["INDICATIONS &amp; USAGE Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51ca7263-dba8-5f78-99a4-608b65d66714", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cbf142f9-9af3-4d79-9343-0ab42d6dbe9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cbf142f9-9af3-4d79-9343-0ab42d6dbe9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbf142f9-9af3-4d79-9343-0ab42d6dbe9f"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56480c48-bbdf-5fa5-bd47-93e8999621c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [96, 121], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2627eb11-06bf-4a45-9172-094468e3ca07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2627eb11-06bf-4a45-9172-094468e3ca07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2627eb11-06bf-4a45-9172-094468e3ca07"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e9a4048-3811-5d61-b00c-eb4053fd6cb6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3dfd683-d44e-427b-af06-70b9b698e016", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3dfd683-d44e-427b-af06-70b9b698e016", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3dfd683-d44e-427b-af06-70b9b698e016"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a87b87a3-dd01-569c-9077-0eefc66e331a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9e05272-aa4e-4df8-b08b-481abca3e8fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9e05272-aa4e-4df8-b08b-481abca3e8fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9e05272-aa4e-4df8-b08b-481abca3e8fd"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb919140-fec1-5270-84ce-763e70af9405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37275fd0-eb24-40a4-a93f-b818bb98414e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37275fd0-eb24-40a4-a93f-b818bb98414e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37275fd0-eb24-40a4-a93f-b818bb98414e"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc6fc5b9-e3e5-55bb-a76d-a1b30989d1fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a541749-5d14-44aa-a409-5e51f5bbf929", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a541749-5d14-44aa-a409-5e51f5bbf929", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a541749-5d14-44aa-a409-5e51f5bbf929"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4491448-8e2c-59c7-8d11-fdeebcc00aed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be69a43-7daf-55ed-bbd9-ba443c8d40bc", "object": "UMLS:C3650625", "object_location_in_text": [101, 126], "original_object": "abnormal uterine bleeding", "original_subject": "MEDROXYPROGESTERONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2a3e692-3477-4c8d-8f2a-7cea3c64cf8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2a3e692-3477-4c8d-8f2a-7cea3c64cf8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2a3e692-3477-4c8d-8f2a-7cea3c64cf8b"]}], "subject": "CHEBI:6715", "supporting_text": ["Medroxyprogesterone acetate tablets, USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d70a239c-6a60-5a8f-9fe9-0c2fbfd9cbde", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19810101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:52a41f05-1f3b-5633-9972-af7fb56ad7bd", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:03ed7664-b224-5ea3-af61-a62fc7a3873e", "object": "MONDO:1060209", "original_object": "secondary amenorrhea", "original_subject": "Medroxy Progesterone Acetate Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:6716", "supporting_text": ["Gynaecological disorders- Indicated in the treatment of secondry amenorrhea and functional uterine bleeding of hormonal imbalance only."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09b4d2b6-c0c7-5b76-8c5a-f4cfc556e55e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e56b6410-0b01-5427-82c6-2e3bec0d36ba", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0002447", "original_object": "advanced carcinoma of the endometrium", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c755c6b-32e9-4029-8b70-855007f7375b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c755c6b-32e9-4029-8b70-855007f7375b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c755c6b-32e9-4029-8b70-855007f7375b"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277556", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25e03370-3f71-5e61-a3e2-ff2867689c98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277556", "UMLS:C4684950", "MONDO:0024883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e56b6410-0b01-5427-82c6-2e3bec0d36ba", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0002447", "original_object": "advanced carcinoma of the endometrium", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b764cf3-4756-4f0e-b747-421d71674313", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b764cf3-4756-4f0e-b747-421d71674313", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b764cf3-4756-4f0e-b747-421d71674313"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol Acetate Tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32d1e9a8-17a8-54f6-ab1d-90fc37c0d31b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e56b6410-0b01-5427-82c6-2e3bec0d36ba", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0002447", "original_object": "advanced carcinoma of the endometrium", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd6617df-0876-4fc5-8435-b53d29ccc1ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd6617df-0876-4fc5-8435-b53d29ccc1ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd6617df-0876-4fc5-8435-b53d29ccc1ae"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6eb1d164-da6a-58ab-a0a7-8f3aba5cb281", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e56b6410-0b01-5427-82c6-2e3bec0d36ba", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0002447", "original_object": "advanced carcinoma of the endometrium", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d74ac91-5fe3-4e21-81f2-e484e2a18548", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d74ac91-5fe3-4e21-81f2-e484e2a18548", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d74ac91-5fe3-4e21-81f2-e484e2a18548"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83e256cc-0d66-5477-ae51-c3b85a070f6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e56b6410-0b01-5427-82c6-2e3bec0d36ba", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0002447", "original_object": "advanced carcinoma of the endometrium", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ec70070-da70-4a38-9d58-cf2278517661", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ec70070-da70-4a38-9d58-cf2278517661", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ec70070-da70-4a38-9d58-cf2278517661"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278802", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b335478a-1a19-5497-9d71-5e6b5ac5f7da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278802", "MONDO:0002447", "UMLS:C0813148"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e56b6410-0b01-5427-82c6-2e3bec0d36ba", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0002447", "original_object": "advanced carcinoma of the endometrium", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66573d39-f2a7-49fd-9ed2-97ac8f6e8456", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66573d39-f2a7-49fd-9ed2-97ac8f6e8456", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66573d39-f2a7-49fd-9ed2-97ac8f6e8456"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:088de7bb-b4e6-53f1-ba0c-e15e81e8bc42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf60d43e-8bef-5f13-b37f-89db713180a7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0004989", "object_location_in_text": [72, 104], "original_object": "advanced carcinoma of the breast", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd6617df-0876-4fc5-8435-b53d29ccc1ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd6617df-0876-4fc5-8435-b53d29ccc1ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd6617df-0876-4fc5-8435-b53d29ccc1ae"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0277556", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c43bfb0-68fc-5ef9-ae8e-b57a13879ff5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0277556", "UMLS:C4684950", "MONDO:0024883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf60d43e-8bef-5f13-b37f-89db713180a7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0004989", "object_location_in_text": [72, 104], "original_object": "advanced carcinoma of the breast", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b764cf3-4756-4f0e-b747-421d71674313", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b764cf3-4756-4f0e-b747-421d71674313", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b764cf3-4756-4f0e-b747-421d71674313"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol Acetate Tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afedf335-1b4f-55c2-9d11-19f1ee146aea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf60d43e-8bef-5f13-b37f-89db713180a7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0004989", "object_location_in_text": [72, 104], "original_object": "advanced carcinoma of the breast", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c755c6b-32e9-4029-8b70-855007f7375b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c755c6b-32e9-4029-8b70-855007f7375b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c755c6b-32e9-4029-8b70-855007f7375b"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0278493", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c75cccf4-dba8-517e-b682-3a1341a9f27f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278493", "MONDO:0004989", "UMLS:C4723838"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf60d43e-8bef-5f13-b37f-89db713180a7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0004989", "object_location_in_text": [72, 104], "original_object": "advanced carcinoma of the breast", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66573d39-f2a7-49fd-9ed2-97ac8f6e8456", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66573d39-f2a7-49fd-9ed2-97ac8f6e8456", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66573d39-f2a7-49fd-9ed2-97ac8f6e8456"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2b0f37c-248d-5afd-aa7d-559aa7158275", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf60d43e-8bef-5f13-b37f-89db713180a7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0004989", "object_location_in_text": [72, 104], "original_object": "advanced carcinoma of the breast", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ec70070-da70-4a38-9d58-cf2278517661", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ec70070-da70-4a38-9d58-cf2278517661", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ec70070-da70-4a38-9d58-cf2278517661"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0549379", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe66c7b5-9b2a-5cd4-b425-a87c998d18f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0549379", "MONDO:0004993", "MONDO:0024879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf60d43e-8bef-5f13-b37f-89db713180a7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:42979685-fb58-5f12-8463-704ec6e72ba9", "object": "MONDO:0004989", "object_location_in_text": [72, 104], "original_object": "advanced carcinoma of the breast", "original_subject": "MEGESTROL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d74ac91-5fe3-4e21-81f2-e484e2a18548", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d74ac91-5fe3-4e21-81f2-e484e2a18548", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d74ac91-5fe3-4e21-81f2-e484e2a18548"]}], "subject": "CHEBI:6722", "supporting_text": ["Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "at risk for renal failure due to volume depletion", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36db993e-10cb-5523-a7fd-b9faa722b693", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:778c000e-a55f-5234-9860-fde136af6647", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "MONDO:0001106", "original_object": "moderate to severe renal insufficiency", "original_subject": "MELOXICAM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:385fd779-1be1-49ae-8213-750b96ecc997", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=385fd779-1be1-49ae-8213-750b96ecc997", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=385fd779-1be1-49ae-8213-750b96ecc997"]}], "subject": "CHEBI:6741", "supporting_text": ["4 CONTRAINDICATIONS QAMZOVA is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [ see Warnings and Precautions ( 5.7 ) ]. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal anaphylactic-like reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions ( 5.8 ) ]. In the setting of coronary artery bypass graft (CABG) surgery [ see Warnings and Precautions ( 5.1 ) ]. Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion [ see Warnings and Precautions ( 5.6 ) ]. Known hypersensitivity to meloxicam or any components of the drug product. ( 4 ) History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. ( 4 ) In the setting of coronary artery bypass graft (CABG) surgery. ( 4 ) Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion. ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ff69393-7047-5364-a368-fb1bd9272c39", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "MONDO:0011429", "original_object": "juvenile rheumatoid arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ddf5a4d-8e84-419d-8e3a-c91b85501885", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ddf5a4d-8e84-419d-8e3a-c91b85501885", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ddf5a4d-8e84-419d-8e3a-c91b85501885"]}], "subject": "CHEBI:6741", "supporting_text": ["1 INDICATIONS AND USAGE Meloxicam oral suspension is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older ( 1.3 ) 1.1 Osteoarthritis (OA) Meloxicam oral suspension is indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1) ]. 1.2 Rheumatoid Arthritis (RA) Meloxicam oral suspension is indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam oral suspension is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older [see Clinical Studies (14.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a17c8aa-1c44-5006-a8eb-a01989b89475", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [304, 333], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients who weigh ≥60 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58dcbc65-d126-7b48-e063-6294a90a52e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58dcbc65-d126-7b48-e063-6294a90a52e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58dcbc65-d126-7b48-e063-6294a90a52e9"]}], "subject": "CHEBI:6741", "supporting_text": [". 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)] . 1.2 Rheumatoid Arthritis (RA) Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)] . 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥60 kg [see Dosage and Administration (2.4)and Clinical Studies (14.2)] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f89e111-e38e-57c0-8bab-330942709aa6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [304, 333], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients who weigh ≥60 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58dbce26-b2ac-2ce4-e063-6294a90a5727", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58dbce26-b2ac-2ce4-e063-6294a90a5727", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58dbce26-b2ac-2ce4-e063-6294a90a5727"]}], "subject": "CHEBI:6741", "supporting_text": [". 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)] . 1.2 Rheumatoid Arthritis (RA) Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)] . 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥60 kg [see Dosage and Administration (2.4)and Clinical Studies (14.2)] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86422a34-f0a1-54cd-907c-6336dafaea09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [149, 178], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients who weigh ≥60 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:385b7cf4-976a-4a58-9ebc-def8b6e78b75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=385b7cf4-976a-4a58-9ebc-def8b6e78b75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=385b7cf4-976a-4a58-9ebc-def8b6e78b75"]}], "subject": "CHEBI:6741", "supporting_text": ["1 INDICATIONS AND USAGE Meloxicam is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1.1) Rheumatoid Arthritis (RA) (1.2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3) 1.1 Osteoarthritis (OA) Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis [ see Clinical Studies (14.1)]. 1.2 Rheumatoid Arthritis (RA) Meloxicam is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see Clinical Studies (14.1) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥ 60 kg [ see Dosage and Administration ( 2.4 ) and Clinical Studies (14.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8956e6e-2c4b-5568-a709-c43c703c51ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [149, 178], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients who weigh ≥60 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdd282df-572f-42a7-a1c6-a00e1bb4573d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdd282df-572f-42a7-a1c6-a00e1bb4573d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdd282df-572f-42a7-a1c6-a00e1bb4573d"]}], "subject": "CHEBI:6741", "supporting_text": ["1 INDICATIONS AND USAGE Meloxicam is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1.1) Rheumatoid Arthritis (RA) (1.2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3) 1.1 Osteoarthritis (OA) Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis [ see Clinical Studies (14.1)]. 1.2 Rheumatoid Arthritis (RA) Meloxicam is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see Clinical Studies (14.1) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥ 60 kg [ see Dosage and Administration ( 2.4 ) and Clinical Studies (14.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb9ff1dc-0c9f-5a1e-8452-6b64c894c97e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [150, 179], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1c2d65f-ebb1-48bf-8fa1-c216f7d570ec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1c2d65f-ebb1-48bf-8fa1-c216f7d570ec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1c2d65f-ebb1-48bf-8fa1-c216f7d570ec"]}], "subject": "CHEBI:6741", "supporting_text": ["1 INDICATIONS AND USAGE Zybic™ is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older ( 1.3 ) 1.1 Osteoarthritis (OA) Zybic™ is indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1) ]. 1.2 Rheumatoid Arthritis (RA) Zybic™ is indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Zybic™ is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older [see Clinical Studies (14.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd4c75c8-fc85-5160-89bb-c07e33cc9fe9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [149, 178], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients who weigh ≥60 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8c35ea4-d6ac-40c7-8f35-864fd1ec75d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8c35ea4-d6ac-40c7-8f35-864fd1ec75d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8c35ea4-d6ac-40c7-8f35-864fd1ec75d2"]}], "subject": "CHEBI:6741", "supporting_text": ["1 INDICATIONS AND USAGE Meloxicam is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) (1.1) Rheumatoid Arthritis (RA) (1.2) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3) 1.1 Osteoarthritis (OA) Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis [ see Clinical Studies (14.1)]. 1.2 Rheumatoid Arthritis (RA) Meloxicam is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see Clinical Studies (14.1) ]. 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥ 60 kg [ see Dosage and Administration ( 2.4 ) and Clinical Studies (14.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pauciarticular course, polyarticular course", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e745de4b-9bb7-56de-a441-d04f30514571", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000413", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c41234d6-3a36-55f5-b238-e338fab3ccaf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:776d485e-854c-5819-bb5a-44936dcb8d51", "object": "UMLS:C3714757", "object_location_in_text": [164, 193], "original_object": "Juvenile Rheumatoid Arthritis", "original_subject": "MELOXICAM", "population_context_qualifier": "patients who weigh ≥60 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b603255e-1fcf-42ec-ab62-9aa321cb7ac6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b603255e-1fcf-42ec-ab62-9aa321cb7ac6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b603255e-1fcf-42ec-ab62-9aa321cb7ac6"]}], "subject": "CHEBI:6741", "supporting_text": ["1 INDICATIONS AND USAGE . Meloxicam tablets are a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) ( 1.1 ) Rheumatoid Arthritis (RA) ( 1.2 ) Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg ( 1.3 ) 1.1 Osteoarthritis (OA) Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1) ] . 1.2 Rheumatoid Arthritis (RA) Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1) ] . 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh ≥60 kg [see Dosage and Administration (2.4) and Clinical Studies (14.2) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:151b2972-c63e-5971-9863-d7706bc8e8cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f1181a6-be57-5ece-ba0f-9034cfb47f37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd04edac-a6f5-5fee-bcae-84ab86f6d6bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16dead83-436b-575a-83ad-ae87a49a0430", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:413e7b4d-25b9-54bc-bc2e-23270ae8c297", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8287af46-d2b5-5894-b2d8-9526aa202eae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:84e39b5e-61e1-56d8-aeb6-4b8ce22960fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [133, 141], "original_object": "headache", "original_subject": "PYRILAMINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad29832e-0ea8-571a-9525-ee9c2a5f7571", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [92, 100], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0da483d-2292-533a-ab7c-86ed92d824a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [117, 125], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c356d37e-7ce6-5e46-b5dc-4552ec15c186", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c39b640f-a44b-5301-9527-d21e61068314", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [92, 100], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffc1a2d0-ab47-5f6d-bb9c-5341bfd20d5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:348954e2-f821-59db-a7bf-976fc8cc6306", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35f30791-0993-5c0d-a67d-040af4b8c556", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e53a970-52b5-56a2-bb13-fc44c902280a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:479ba800-b565-5f01-9e3a-8f215b438021", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48669f82-9c3d-56ae-994a-0be3c2c8c959", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [83, 91], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b998219-aebe-52b0-b9fe-bd9ef3e901c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [90, 98], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6caf1193-bc84-50ad-ae3a-36d55689802b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [102, 110], "original_object": "bloating", "original_subject": "PYRILAMINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:778e3d70-2c36-529f-8dc2-c56ca2a3ca6f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa35833f-f208-5cc9-afac-9e1090dff0a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0003270", "object_location_in_text": [83, 91], "original_object": "bloating", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06ceecfb-2961-5208-b666-d7e972dbf05d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b25c74d-3e55-5157-9a1e-d1ad671c4e35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:475c4d4a-d23c-5453-a0e9-904accec1f57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012378", "object_location_in_text": [170, 177], "original_object": "fatigue", "original_subject": "PYRILAMINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48bd12d1-3973-56d8-bb2f-08c084b8818d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012378", "object_location_in_text": [148, 155], "original_object": "fatigue", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95eadb94-0b2a-570a-ba25-195ca79b41fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012378", "object_location_in_text": [130, 137], "original_object": "fatigue", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca55ea46-c0bb-5f1d-a638-d3391347b8d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48d3f6e2-aa90-5619-a602-d059ad961636", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012378", "object_location_in_text": [130, 137], "original_object": "fatigue", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54b02b78-5d9b-56d8-841e-81a79d8282cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012735", "original_object": "cough", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:17a2f643-fa98-21ee-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=17a2f643-fa98-21ee-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17a2f643-fa98-21ee-e054-00144ff88e88"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:709cac3f-515f-5b2c-b8e0-e198548b7a6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012735", "object_location_in_text": [193, 198], "original_object": "cough", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3b8a686f-d8e8-56db-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3b8a686f-d8e8-56db-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b8a686f-d8e8-56db-e054-00144ff8d46c"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: itchy nose or throat sneezing itchy, watery eyes runny nose cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80a1578e-c959-56fc-b4c2-5ae5a4b44cba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "HP:0012735", "object_location_in_text": [194, 199], "original_object": "cough", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0bdea30a-39da-6611-e063-6394a90aa4cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0bdea30a-39da-6611-e063-6394a90aa4cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0bdea30a-39da-6611-e063-6394a90aa4cf"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever or other upper respiratory allergies: ■ runny nose ■ itching of the nose or throat ■ sneezing ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bceff462-4437-56b9-a03b-be8934a50e9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:237e9d6b-3c51-50d8-a29b-cf613abe4adc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "MONDO:0005324", "object_location_in_text": [125, 134], "original_object": "hay fever", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e524967-d01c-4c93-9198-c42f15fe3fe0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e524967-d01c-4c93-9198-c42f15fe3fe0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e524967-d01c-4c93-9198-c42f15fe3fe0"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses ■ temporarily relieves runny nose and alleviates sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20da4bc2-44c6-5d86-82dc-1e9f3f27b6bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "PYRILAMINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4cc016ed-bd7c-53a3-a682-db7f2e1e6401", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba44180d-c2d1-58fa-9f96-a246182cf96f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c258f70e-62d7-5782-a672-ba54fed753bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1fa4a0ea-5db6-50b9-b96b-3981b207c6ea", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "MONDO:1060205", "original_object": "menstrual cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0be7a3bb-412c-5afb-b4e8-faab6fbb9866", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41f7cc3a-c923-51da-8214-e5dc23628c52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:709d1dfd-b3c1-50b8-9ccb-7d3d317eb85f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:719caa9e-11cc-51fd-a403-0f0dec780ebe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [121, 129], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82579f0c-adf1-527e-9188-40ae5ba03205", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89ebfece-a127-546d-91b6-97fe071fb81f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [144, 152], "original_object": "backache", "original_subject": "PYRILAMINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:affd5ad8-c61d-5c60-bf0f-f320f1fe353a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [121, 129], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8373deb-150d-59f0-9710-f051b63ffd2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ccb7cb0c-e53d-50ef-9de6-a7de30a7eecf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 8, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0004604", "object_location_in_text": [126, 134], "original_object": "backache", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e3ed340-fd55-560a-896c-5e84e852085a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0026821", "object_location_in_text": [114, 120], "original_object": "cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:373bcdd3-694e-5deb-911d-b3c81c9d580b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0026821", "object_location_in_text": [114, 120], "original_object": "cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90190807-f5e0-5b13-abd2-608319539a24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6764315-6458-50c2-9796-52abc0dda50a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbfaa982-93b5-5428-a7a3-3636d53dfc19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1905dc8b-a804-5d5d-83b7-b4e3c9efd685", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=514a9340-b88c-2167-e063-6294a90a4165"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21f57798-cff4-5e8a-8e5c-bd6b00eb8da8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0231528", "object_location_in_text": [101, 113], "original_object": "muscle aches", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f823e8b2-bf38-409e-8197-4ddba16d3149"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6004a20e-97d7-5aa6-8ab9-ee0b3950d276", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cc4b39a-39d5-a2bb-e063-6394a90a2e95"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c98d818-d5ca-58f2-b4f7-94aa47cd5247", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0231528", "object_location_in_text": [135, 147], "original_object": "muscle aches", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=436b3716-1c87-bfba-e063-6394a90a1e12"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: cramps bloating water-weight gain headache backache muscle aches fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f736d547-fd9d-5c69-9bdf-1f04840c9d3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0231528", "object_location_in_text": [155, 167], "original_object": "muscle aches", "original_subject": "PYRILAMINE", "population_context_qualifier": "menstruating individuals", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34eb8a9b-d0ee-13e8-e063-6294a90a2fef"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses Uses: ■ for the temporary relief of these symptoms associated with menstrual periods: ■ cramps ■ bloating ■ water-weight gain ■ headache ■ backache ■ muscle aches ■ fatigue"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc05e31a-479b-5de0-acbd-bcf4a62242d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b225369-24c8-569e-9e79-35277a341320", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:888a2d38-5fea-5cf5-baf2-2acff78cbe59", "object": "UMLS:C0231528", "object_location_in_text": [101, 113], "original_object": "muscle aches", "original_subject": "PYRILAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d288db7e-6754-4c49-be98-f501f805fbed"]}], "subject": "CHEBI:6762", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: bloating headache muscle aches cramps backache fatigue water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "remission of ulcerative colitis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05a5bb6a-31ea-5524-b88d-66805e6451aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871224", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0697b5fa-a2a7-5702-89a8-6ba6ab2a1450", "object": "MONDO:0005101", "object_location_in_text": [139, 157], "original_object": "ulcerative colitis", "original_subject": "MESALAMINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1ed6fcc-7fd4-4b8a-9ddb-e772ea930e9e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1ed6fcc-7fd4-4b8a-9ddb-e772ea930e9e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1ed6fcc-7fd4-4b8a-9ddb-e772ea930e9e"]}], "subject": "CHEBI:6775", "supporting_text": ["1 INDICATIONS AND USAGE Mesalamine delayed-release capsules are an aminosalicylate indicated for: Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. ( 1.1 ) Maintenance of remission of ulcerative colitis in adults. ( 1.2 ) 1.1 Treatment of Mildly to Moderately Active Ulcerative Colitis Mesalamine delayed-release capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. 1.2 Maintenance of Remission of Ulcerative Colitis Mesalamine delayed-release capsules are indicated for the maintenance of remission of ulcerative colitis in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0033515", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f4c8e15-1b84-57d3-8aae-fa48a2106410", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0033515"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.192375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0e6a966-179a-45e0-8444-4c1b8523f8d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0e6a966-179a-45e0-8444-4c1b8523f8d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0e6a966-179a-45e0-8444-4c1b8523f8d2"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone Hydrochloride Oral Concentrate ( Intensol ™) contains methadone, an opioid agonist indicated for the: • Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "heroin or other morphine-like drugs", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27717ff2-2f22-5100-aaaf-5538cfe71a5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_claim_relation": "maintenance", "medic_co_administered_with": ["appropriate social and medical services"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.192375, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:540edd43-165d-4257-b989-3bccc8f54afb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=540edd43-165d-4257-b989-3bccc8f54afb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=540edd43-165d-4257-b989-3bccc8f54afb"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone hydrochloride tablets are indicated for the: 1. Management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid addiction (heroin or other morphine-like drugs)", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61f148d5-2b51-5f07-acba-8f6dfc9220b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5baef1bf-8bf0-429c-a4ce-1c93171f3f15", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5baef1bf-8bf0-429c-a4ce-1c93171f3f15", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5baef1bf-8bf0-429c-a4ce-1c93171f3f15"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone hydrochloride oral solution is indicated for the: Management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "heroin or other morphine-like drugs", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8411151c-644f-5997-a31a-4890bfab96e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.192375, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0366917-f745-4b01-a662-a98a7d80b4a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0366917-f745-4b01-a662-a98a7d80b4a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0366917-f745-4b01-a662-a98a7d80b4a0"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone hydrochloride tablet is indicated for the: 1. Management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid addiction (heroin or other morphine-like drugs)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afd86a0e-3df0-5188-a7ac-4d94e1c5af87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "object_location_in_text": [133, 149], "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9dad5d5-3417-4992-99ee-6550f81add6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9dad5d5-3417-4992-99ee-6550f81add6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9dad5d5-3417-4992-99ee-6550f81add6b"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone Hydrochloride contains methadone, an opioid agonist indicated for the: detoxification treatment of opioid addiction (heroin or other morphine-like drugs). maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "heroin or other morphine-like drugs", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1a511a0-70a1-582e-b5b2-11fc73052029", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.192375, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c8b541c-33e8-4969-b258-af150808d46e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c8b541c-33e8-4969-b258-af150808d46e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c8b541c-33e8-4969-b258-af150808d46e"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone hydrochloride tablets are indicated for the: 1. Management of severe and persistent pain that requires an extended treatment with a daily opioid analgesic that cannot be adequately treated with alternative options, including immediate-release opioids"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid addiction (heroin or other morphine-like drugs)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea3979f6-62c5-50a0-b8b2-b9d700c67da5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ae4a977-53f4-5fa7-b7a4-21b534e1fe03", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a14c55e-4326-5d67-9c0c-b8cf77c15ca4", "object": "HP:0033515", "object_location_in_text": [133, 149], "original_object": "opioid addiction", "original_subject": "METHADONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:714e5adb-bdce-4dff-99aa-4ac3a2f3a0fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=714e5adb-bdce-4dff-99aa-4ac3a2f3a0fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=714e5adb-bdce-4dff-99aa-4ac3a2f3a0fe"]}], "subject": "CHEBI:6807", "supporting_text": ["1 INDICATIONS AND USAGE Methadone Hydrochloride contains methadone, an opioid agonist indicated for the: detoxification treatment of opioid addiction (heroin or other morphine-like drugs). maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:469fa0e3-b31c-5bf8-9967-ea13f5e945ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:831f9c1c-52e5-5935-9c1c-b39cea518c47", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8b7e9557-6cdb-50b9-b55a-8c449a1ec287", "object": "MONDO:0007743", "original_object": "attention deficit disorder with hyperactivity", "original_subject": "METHAMPHETAMINE", "population_context_qualifier": "children over 6 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f31f580f-1f08-4a0f-b078-0b9e3308f712", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f31f580f-1f08-4a0f-b078-0b9e3308f712", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f31f580f-1f08-4a0f-b078-0b9e3308f712"]}], "subject": "CHEBI:6809", "supporting_text": ["Attention Deficit Disorder with Hyperactivity Methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22e023aa-72dc-5688-95cb-90e483c221ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe6ff0f9-7610-4a69-9b75-da7ec4bb7744", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe6ff0f9-7610-4a69-9b75-da7ec4bb7744", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe6ff0f9-7610-4a69-9b75-da7ec4bb7744"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine Injection. Clofarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine Injection. ( 1 )"], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2907208d-031a-5a4a-9a7b-518493bcf519", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18adf4af-63ed-41e6-ab59-87085ce3e5fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18adf4af-63ed-41e6-ab59-87085ce3e5fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18adf4af-63ed-41e6-ab59-87085ce3e5fb"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. ( 1 )"], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32684f96-2f62-532d-bc40-acd66e7a90a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26b2de66-6518-49ab-820e-492454cbc873", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26b2de66-6518-49ab-820e-492454cbc873", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26b2de66-6518-49ab-820e-492454cbc873"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens."], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4afdfabe-8663-546f-a601-2f9384e90612", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0da6764d-5fac-7e0f-ea3e-a5aee55a8b2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0da6764d-5fac-7e0f-ea3e-a5aee55a8b2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0da6764d-5fac-7e0f-ea3e-a5aee55a8b2d"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. ( 1 )"], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c1d43e1-7886-5d9f-ab86-0cc03db4616b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7d3a96e-0280-4f14-b921-795996f75950", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7d3a96e-0280-4f14-b921-795996f75950", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7d3a96e-0280-4f14-b921-795996f75950"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. ( 1 )"], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b5660c1-9ee8-58e8-9762-6b8352babe9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a273a2d-a1ff-412a-925e-696648730dae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a273a2d-a1ff-412a-925e-696648730dae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a273a2d-a1ff-412a-925e-696648730dae"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. (1)"], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdb9b3ca-7ede-515b-b542-590ab70913e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54436453-882e-406b-87a3-049d150101c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54436453-882e-406b-87a3-049d150101c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54436453-882e-406b-87a3-049d150101c6"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. ( 1 )"], "temporal_context_qualifier": "after at least two prior regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e724d57c-33e7-52e3-a624-dbdaa0a24fed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3b7cf57-4212-51bf-bcf8-2f36c1295663", "object": "MONDO:0004967", "object_location_in_text": [145, 173], "original_object": "acute lymphoblastic leukemia", "original_subject": "CLOFARABINE", "population_context_qualifier": "pediatric patients 1 to 21 years old", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a2cb5e3-08a5-4d50-95e6-23440e0b7490", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a2cb5e3-08a5-4d50-95e6-23440e0b7490", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a2cb5e3-08a5-4d50-95e6-23440e0b7490"]}], "subject": "CHEBI:681569", "supporting_text": ["1 INDICATIONS AND USAGE Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with clofarabine injection. Clofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with clofarabine injection. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced postanesthesia apnea", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed7e2cd9-0da6-54fc-9331-0ad009fb729c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5fbb04d7-8be3-5f2c-bc9c-a61f5e603895", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f742e79-2447-58cc-ac93-ee4608ade481", "object": "MONDO:0000106", "object_location_in_text": [212, 217], "original_object": "apnea", "original_subject": "DOXAPRAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8eb330a-a75b-46cb-b694-5be9327ed2eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb"]}], "subject": "CHEBI:681848", "supporting_text": ["Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE AND ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO 2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation."], "temporal_context_qualifier": "postanesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug overdosage", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a11c887e-5da2-54f5-b4b1-dbd84fd15fe9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:64a52456-9d02-5ab8-bb2b-c68cf3005cf0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f742e79-2447-58cc-ac93-ee4608ade481", "object": "UMLS:C0151559", "original_object": "central nervous system depression", "original_subject": "DOXAPRAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:954859c0-a121-34d6-e053-2a95a90a1e19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19"]}], "subject": "CHEBI:681848", "supporting_text": ["INDICATIONS &amp; USAGE Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE &amp; ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced CNS depression", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be099910-3a6b-5ffe-bf98-0fde2d8b3c33", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4741b0bf-486f-5946-8e64-415b596c8a1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f742e79-2447-58cc-ac93-ee4608ade481", "object": "UMLS:C0151559", "object_location_in_text": [700, 714], "original_object": "CNS depression", "original_subject": "DOXAPRAM", "population_context_qualifier": "patients with mild to moderate respiratory and CNS depression", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8eb330a-a75b-46cb-b694-5be9327ed2eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb"]}], "subject": "CHEBI:681848", "supporting_text": ["Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE AND ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO 2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug-induced CNS depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b80c728b-a4e9-5e00-9ccb-68344ad0bf62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f742e79-2447-58cc-ac93-ee4608ade481", "object": "UMLS:C0235063", "object_location_in_text": [186, 208], "original_object": "respiratory depression", "original_subject": "DOXAPRAM", "population_context_qualifier": "patients with mild to moderate respiratory and CNS depression", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8eb330a-a75b-46cb-b694-5be9327ed2eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb"]}], "subject": "CHEBI:681848", "supporting_text": ["Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE AND ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO 2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "drug overdosage", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c25d0530-0de1-59db-a236-42eb04976fe4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f742e79-2447-58cc-ac93-ee4608ade481", "object": "UMLS:C0235063", "original_object": "respiratory depression", "original_subject": "DOXAPRAM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:954859c0-a121-34d6-e053-2a95a90a1e19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19"]}], "subject": "CHEBI:681848", "supporting_text": ["INDICATIONS &amp; USAGE Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE &amp; ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66246c6e-5602-53d6-a104-774f4a825edd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:48c13c91-2bdc-5b18-9416-82d47a21b214", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d5afc560-74ae-5982-9f73-60f2abbbf552", "object": "MONDO:0001817", "object_location_in_text": [220, 248], "original_object": "acute angle-closure glaucoma", "original_subject": "METHAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec5e2032-3273-4364-be63-44766750650d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec5e2032-3273-4364-be63-44766750650d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec5e2032-3273-4364-be63-44766750650d"]}], "subject": "CHEBI:6822", "supporting_text": ["Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery."], "temporal_context_qualifier": "preoperatively"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4247eb9-f6f4-589d-8df1-4c96c1b7085e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dfb98198-a010-5e14-b742-3080ba247daa", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d5afc560-74ae-5982-9f73-60f2abbbf552", "object": "MONDO:0005338", "object_location_in_text": [149, 176], "original_object": "chronic open-angle glaucoma", "original_subject": "METHAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec5e2032-3273-4364-be63-44766750650d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec5e2032-3273-4364-be63-44766750650d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec5e2032-3273-4364-be63-44766750650d"]}], "subject": "CHEBI:6822", "supporting_text": ["Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83ca5a68-1cbd-5398-88d8-8c99b2f6d3a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:296e8990-4693-5bf4-bd59-1917350ae069", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d5afc560-74ae-5982-9f73-60f2abbbf552", "object": "UMLS:C0149893", "object_location_in_text": [178, 196], "original_object": "secondary glaucoma", "original_subject": "METHAZOLAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec5e2032-3273-4364-be63-44766750650d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec5e2032-3273-4364-be63-44766750650d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec5e2032-3273-4364-be63-44766750650d"]}], "subject": "CHEBI:6822", "supporting_text": ["Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:278faa19-5078-5ef3-9e48-c0bcc4a99722", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "HP:0012531", "object_location_in_text": [164, 168], "original_object": "pain", "original_subject": "METHENAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:6824", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:331da4f8-264e-5357-89d1-992ee0948392", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "HP:0012531", "object_location_in_text": [168, 172], "original_object": "pain", "original_subject": "METHENAMINE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:6824", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6c16b4c-f68d-5ff0-8285-e29e1d489de5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "HP:0012531", "object_location_in_text": [166, 170], "original_object": "pain", "original_subject": "METHENAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:6824", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c59d775-006a-531f-8db7-d866545091fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "UMLS:C0021368", "object_location_in_text": [133, 145], "original_object": "inflammation", "original_subject": "METHENAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:6824", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:435d8393-6008-53c8-afc0-dd0ff4026094", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "UMLS:C0021368", "object_location_in_text": [135, 147], "original_object": "inflammation", "original_subject": "METHENAMINE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:6824", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c3e357b-ca67-5b0e-912c-f2e0778456c5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "UMLS:C0021368", "object_location_in_text": [131, 143], "original_object": "inflammation", "original_subject": "METHENAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:6824", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4418d931-9692-5866-9337-ff060681a656", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "UMLS:C0549185", "object_location_in_text": [149, 162], "original_object": "hypermotility", "original_subject": "METHENAMINE", "population_context_qualifier": "patients with local symptoms accompanying lower urinary tract infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b0dee-1a3b-4846-a212-c9febb3fc17d"]}], "subject": "CHEBI:6824", "supporting_text": ["Uro-MP Capsules are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:763e4a4f-949c-5cef-a446-62f37aaa2233", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "UMLS:C0549185", "object_location_in_text": [147, 160], "original_object": "hypermotility", "original_subject": "METHENAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ccadff1-461a-335a-e063-6394a90ad5d7"]}], "subject": "CHEBI:6824", "supporting_text": [": Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268821", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae0236a0-76df-506d-9b70-9de210cf0076", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268821"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5937eb32-efef-548e-810a-ed8f31a3a6b1", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:66c4a1b2-98f6-5440-8ab7-a40450232ba7", "object": "UMLS:C0549185", "object_location_in_text": [145, 158], "original_object": "hypermotility", "original_subject": "METHENAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09821e01-1135-e75c-e063-6294a90a3451"]}], "subject": "CHEBI:6824", "supporting_text": ["Uribel Tabs are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "tuberous sclerosis complex (TSC)", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4725bb71-13b1-5d11-9e5b-e460f726ff22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090330", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dc50b93a-6858-5f12-a51a-b1da0c5debbb", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ec7ef87-af97-5221-b73d-6708f6a9c72f", "object": "MONDO:0004555", "original_object": "renal angiomyolipoma", "original_subject": "EVEROLIMUS", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2150f73a-179b-4afc-b8ce-67c85cc72f04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04"]}], "subject": "CHEBI:68478", "supporting_text": ["1 INDICATIONS AND USAGE AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "none specified", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a78b646-0b77-5d7e-8bde-f37f4866578c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090330", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["exemestane"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ec7ef87-af97-5221-b73d-6708f6a9c72f", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "EVEROLIMUS", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5cfca904-b75c-5a39-8cb9-b99bb421bceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5cfca904-b75c-5a39-8cb9-b99bb421bceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5cfca904-b75c-5a39-8cb9-b99bb421bceb"]}], "subject": "CHEBI:68478", "supporting_text": ["1 INDICATIONS AND USAGE Everolimus tablets are kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer Everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. 1.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma Everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery. 1.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) Everolimus tablets are indicated in adult and pediatric patients aged 1 year and older with TSC for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected."], "temporal_context_qualifier": "after failure of treatment with letrozole or anastrozole"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "none specified", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab5dce38-41be-5496-8da2-788f2bef972a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090330", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["exemestane"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ec7ef87-af97-5221-b73d-6708f6a9c72f", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "EVEROLIMUS", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fb55800-f322-6bb6-9dde-622925ef28bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fb55800-f322-6bb6-9dde-622925ef28bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fb55800-f322-6bb6-9dde-622925ef28bd"]}], "subject": "CHEBI:68478", "supporting_text": ["1 INDICATIONS AND USAGE Everolimus tablets are kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer Everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. 1.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma Everolimus tablets are indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery. 1.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) Everolimus tablets are indicated in adult and pediatric patients aged 1 year and older with TSC for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected."], "temporal_context_qualifier": "after failure of treatment with letrozole or anastrozole"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide tablets", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b5aed77-6a48-5520-ab4d-df6d5167912e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0010481", "object_location_in_text": [553, 563], "original_object": "angioedema", "original_subject": "TERIFLUNOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8"]}], "subject": "CHEBI:68540", "supporting_text": ["4 CONTRAINDICATIONS Teriflunomide tablets are contraindicated in/with: Patients with severe hepatic impairment [see Warnings and Precautions (5.1) ] . Pregnant women and females of reproductive potential not using effective contraception. Teriflunomide tablets may cause fetal harm [see Warnings and Precautions (5.2 , 5.3) and Use in Specific Populations (8.1) ] . Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide tablets. Reactions have included anaphylaxis, angioedema, and serious skin reactions [see Warnings and Precautions (5.5) ]. Coadministration with leflunomide [see Clinical Pharmacology (12.3) ]. Severe hepatic impairment ( 4 , 5.1 ) Pregnancy ( 4 , 5.2 , 8.1 ) Hypersensitivity ( 4 , 5.5 ) Current leflunomide treatment ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d37c3a13-258d-56ce-90c9-afaf20e44354", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0010481", "object_location_in_text": [529, 539], "original_object": "angioedema", "original_subject": "TERIFLUNOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63ba28ef-5055-461a-99ef-c49e8ece4b54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63ba28ef-5055-461a-99ef-c49e8ece4b54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63ba28ef-5055-461a-99ef-c49e8ece4b54"]}], "subject": "CHEBI:68540", "supporting_text": ["4 CONTRAINDICATIONS Teriflunomide is contraindicated in/with: Patients with severe hepatic impairment [see Warnings and Precautions (5.1) ] . Pregnant women and females of reproductive potential not using effective contraception. Teriflunomide may cause fetal harm [see Warnings and Precautions (5.2 , 5.3 ) and Use in Specific Populations (8.1) ] . Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide. Reactions have included anaphylaxis, angioedema, and serious skin reactions [see Warnings and Precautions (5.5) ] . Coadministration with leflunomide [see Clinical Pharmacology (12.3) ]. Severe hepatic impairment ( 4 , 5.1 ) Pregnancy ( 4 , 5.2 , 8.1 ) Hypersensitivity ( 4 , 5.5 ) Current leflunomide treatment ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide tablets", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01be755a-8616-5533-9fb0-91a030a790e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a701aee-4250-566d-838e-eea7a5818cf5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0100053", "object_location_in_text": [540, 551], "original_object": "anaphylaxis", "original_subject": "TERIFLUNOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8"]}], "subject": "CHEBI:68540", "supporting_text": ["4 CONTRAINDICATIONS Teriflunomide tablets are contraindicated in/with: Patients with severe hepatic impairment [see Warnings and Precautions (5.1) ] . Pregnant women and females of reproductive potential not using effective contraception. Teriflunomide tablets may cause fetal harm [see Warnings and Precautions (5.2 , 5.3) and Use in Specific Populations (8.1) ] . Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide tablets. Reactions have included anaphylaxis, angioedema, and serious skin reactions [see Warnings and Precautions (5.5) ]. Coadministration with leflunomide [see Clinical Pharmacology (12.3) ]. Severe hepatic impairment ( 4 , 5.1 ) Pregnancy ( 4 , 5.2 , 8.1 ) Hypersensitivity ( 4 , 5.5 ) Current leflunomide treatment ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c85d85a7-ff26-5297-9ae9-77f6999b34c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a701aee-4250-566d-838e-eea7a5818cf5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0100053", "object_location_in_text": [516, 527], "original_object": "anaphylaxis", "original_subject": "TERIFLUNOMIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63ba28ef-5055-461a-99ef-c49e8ece4b54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63ba28ef-5055-461a-99ef-c49e8ece4b54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63ba28ef-5055-461a-99ef-c49e8ece4b54"]}], "subject": "CHEBI:68540", "supporting_text": ["4 CONTRAINDICATIONS Teriflunomide is contraindicated in/with: Patients with severe hepatic impairment [see Warnings and Precautions (5.1) ] . Pregnant women and females of reproductive potential not using effective contraception. Teriflunomide may cause fetal harm [see Warnings and Precautions (5.2 , 5.3 ) and Use in Specific Populations (8.1) ] . Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide. Reactions have included anaphylaxis, angioedema, and serious skin reactions [see Warnings and Precautions (5.5) ] . Coadministration with leflunomide [see Clinical Pharmacology (12.3) ]. Severe hepatic impairment ( 4 , 5.1 ) Pregnancy ( 4 , 5.2 , 8.1 ) Hypersensitivity ( 4 , 5.5 ) Current leflunomide treatment ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19de593d-da82-5aba-bac5-a9473eb3821f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0000001", "object_location_in_text": [186, 222], "original_object": "active secondary progressive disease", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4650d12c-b9c8-4525-b07f-a2d773eca155", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE AUBAGIO ® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AUBAGIO is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:936af5ee-4733-5d64-b3c8-6e5705e44fff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0000001", "object_location_in_text": [199, 235], "original_object": "active secondary progressive disease", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8219b4a2-fb9d-4387-ba33-96d28aad71dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8219b4a2-fb9d-4387-ba33-96d28aad71dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8219b4a2-fb9d-4387-ba33-96d28aad71dd"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5fd35cd-d85a-529d-bce9-2c851096cc75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0000001", "object_location_in_text": [199, 235], "original_object": "active secondary progressive disease", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1824aae5-58af-43da-8231-435c8f118bc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1824aae5-58af-43da-8231-435c8f118bc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1824aae5-58af-43da-8231-435c8f118bc0"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4f9006a-dbdf-5f08-9160-62ec2e80b3df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "MONDO:0000001", "object_location_in_text": [199, 235], "original_object": "active secondary progressive disease", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bae19c8-ce93-52fb-b3d5-c91a66b49480", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "UMLS:C2921627", "object_location_in_text": [123, 151], "original_object": "clinically isolated syndrome", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4650d12c-b9c8-4525-b07f-a2d773eca155", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4650d12c-b9c8-4525-b07f-a2d773eca155"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE AUBAGIO ® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AUBAGIO is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fd5877a-f2c1-5917-baf9-69b9e45cccd5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "UMLS:C2921627", "object_location_in_text": [136, 164], "original_object": "clinically isolated syndrome", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1824aae5-58af-43da-8231-435c8f118bc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1824aae5-58af-43da-8231-435c8f118bc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1824aae5-58af-43da-8231-435c8f118bc0"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fe9a0c0-6a54-54b3-a55e-8cbbdeae7b71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "UMLS:C2921627", "object_location_in_text": [136, 164], "original_object": "clinically isolated syndrome", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8219b4a2-fb9d-4387-ba33-96d28aad71dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8219b4a2-fb9d-4387-ba33-96d28aad71dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8219b4a2-fb9d-4387-ba33-96d28aad71dd"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f48b5aae-a132-5a54-bf52-2e779d3ccf63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120912", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ac394f81-7c81-5dde-b814-d14d0f71acb6", "object": "UMLS:C2921627", "object_location_in_text": [136, 164], "original_object": "clinically isolated syndrome", "original_subject": "TERIFLUNOMIDE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fd80242-c607-4c50-b497-8259abb4a2f8"]}], "subject": "CHEBI:68540", "supporting_text": ["1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:287d1164-bd05-5a48-a107-f7d116721d88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d68b79ab-3104-410e-a63f-9919a23625af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d68b79ab-3104-410e-a63f-9919a23625af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d68b79ab-3104-410e-a63f-9919a23625af"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablet is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablet was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablet also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1)] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablet is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2)]. While use is not limited to this setting, the efficacy of ticagrelor tablet was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablet is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical S"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28ac9949-425a-59ec-9ba9-3e298c24d346", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [157, 163], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f9bd52a-99a7-4606-92b4-456a917aabef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f9bd52a-99a7-4606-92b4-456a917aabef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f9bd52a-99a7-4606-92b4-456a917aabef"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) BRILINTA is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies (14.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:301c5df9-7b61-5259-98a5-bf30a6e0431b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [168, 174], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc333c4a-ad63-4d67-a3f7-431ac469d116", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc333c4a-ad63-4d67-a3f7-431ac469d116", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc333c4a-ad63-4d67-a3f7-431ac469d116"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack (TIA) [se"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3757d8c0-bca3-5745-ad3d-4df79152804d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "TICAGRELOR", "population_context_qualifier": "acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ecb82df-fad2-1f6c-e063-6294a90a9d19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ecb82df-fad2-1f6c-e063-6294a90a9d19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ecb82df-fad2-1f6c-e063-6294a90a9d19"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies (14.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46140d46-5ae1-5603-88b2-58f36aea624f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c59ea45-6113-6e9e-70b5-3b8c8b3d89b6"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ]. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical S"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:559cf858-7db8-54fe-a345-a442bd76fcfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [157, 163], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7b3f443-e83d-4bf2-0e96-023448fed9a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) BRILINTA is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies (14.3) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d839df5-a1f1-5bb8-826d-88feadf4eb85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:557351f1-47b7-216d-e063-6394a90afb51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=557351f1-47b7-216d-e063-6394a90afb51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=557351f1-47b7-216d-e063-6394a90afb51"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablet is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablet was established in a population with type 2 diabetes mellitus (T2DM). (1.2) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablet also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1)] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablet is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2)]. While use is not limited to this setting, the efficacy of ticagrelor tablet was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablet is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e7802a6-b3ec-500a-b4a7-a39a192914d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [112, 118], "original_object": "stroke", "original_subject": "TICAGRELOR", "population_context_qualifier": "patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of Ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies ( 14.2 )] . While use is not limited to this setting, the efficacy of Ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:720ca509-7f79-5dcb-9e2a-dde8a25aa6c5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5955a5f5-fbc7-8f67-e063-6394a90ada36", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5955a5f5-fbc7-8f67-e063-6394a90ada36", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5955a5f5-fbc7-8f67-e063-6394a90ada36"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ]. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77e249a6-ccbe-509a-9371-ae7508265de1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40ac26dc-2570-de7e-e063-6294a90ade72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40ac26dc-2570-de7e-e063-6294a90ade72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40ac26dc-2570-de7e-e063-6294a90ade72"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack (TIA) [see Clin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ac5d9ca-4e9b-514b-a207-5877a8f800e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f73a4db-2c7f-4e42-a914-87aedc2780fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f73a4db-2c7f-4e42-a914-87aedc2780fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f73a4db-2c7f-4e42-a914-87aedc2780fb"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablet was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies ( 14.1 )] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2)]. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinica"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:935136ab-04ca-564f-bffd-990613d2a75a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [174, 180], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:789606e3-9efa-440c-84f1-f1c56fcbf0cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=789606e3-9efa-440c-84f1-f1c56fcbf0cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=789606e3-9efa-440c-84f1-f1c56fcbf0cd"]}], "subject": "CHEBI:68558", "supporting_text": ["1. INDICATIONS AND USAGE SECTION Ticagrelor tablets are a P2Y12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies ( 14.1 )]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies ( 14.2 )] . While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1556bab-0dbd-58bb-a23d-8afb18367feb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [157, 163], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32769721-c1dd-4bd3-90aa-a6cab59d3cd6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32769721-c1dd-4bd3-90aa-a6cab59d3cd6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32769721-c1dd-4bd3-90aa-a6cab59d3cd6"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of Ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies ( 14.1 )]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies ( 14.2 )]. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablet is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies ( 14.3 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2bb3ae8-0495-54a8-b3d9-8bb19161ff01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [159, 165], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:555d4e44-9bb2-474e-9bea-c549e3261dbb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=555d4e44-9bb2-474e-9bea-c549e3261dbb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=555d4e44-9bb2-474e-9bea-c549e3261dbb"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies (14.3) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc5a8021-cff2-5a72-a2b4-1b0b15f3bfa5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "TICAGRELOR", "population_context_qualifier": "patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7efe86fa-5d19-413a-8b15-e51279b62f3f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7efe86fa-5d19-413a-8b15-e51279b62f3f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7efe86fa-5d19-413a-8b15-e51279b62f3f"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are P2Y 12 platelet inhibitor indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies ( 14.2 )] . While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc9d5cdd-bc4b-564b-9a8f-08386339ff63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a50eb0b4-1bee-4781-8eba-75e324540d36", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a50eb0b4-1bee-4781-8eba-75e324540d36", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a50eb0b4-1bee-4781-8eba-75e324540d36"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ]. While use is not limited to this setting, the efficacy of ticagrelor tablets was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Stu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e67e12f3-f6e6-5b10-b9dc-b9799d2029b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [166, 172], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37f1d3d7-030f-180a-e063-6294a90a89da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37f1d3d7-030f-180a-e063-6294a90a89da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37f1d3d7-030f-180a-e063-6294a90a89da"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ]. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical S"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ead6e473-fd64-5717-b78b-db08c32b67df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0005098", "object_location_in_text": [157, 163], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c89c29c9-d2c0-4605-b74f-059e0b104977", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c89c29c9-d2c0-4605-b74f-059e0b104977", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c89c29c9-d2c0-4605-b74f-059e0b104977"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of Ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies ( 14.1 )]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies ( 14.2 )]. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablet is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies ( 14.3 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6c7e36d-9f03-514b-8f08-0db956614e05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [157, 163], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bbdc202-bbe4-4aec-b4e9-1f1feb41d819", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bbdc202-bbe4-4aec-b4e9-1f1feb41d819", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bbdc202-bbe4-4aec-b4e9-1f1feb41d819"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies ( 14.1 )] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [ see Clinical Studies ( 14.2 )] . While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [ see Clinical Studies ( 14.3 )] "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7313b53-3a9d-5659-885a-4bb795067d3a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110720", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C5392833", "MONDO:0005264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 17, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [157, 163], "original_object": "stroke", "original_subject": "TICAGRELOR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1225fd45-9b56-1671-ee77-cd0c9f2174a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1225fd45-9b56-1671-ee77-cd0c9f2174a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1225fd45-9b56-1671-ee77-cd0c9f2174a5"]}], "subject": "CHEBI:68558", "supporting_text": ["1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). ( 1.3 ) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies ( 14.1 )]. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies ( 14.2 )]. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clini"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0155668", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31eb1155-5f52-5a5a-9cb2-d5cc609bb817", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0155668"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:9de9416c-a421-5dee-a009-216ebe8d0935", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "UMLS:C1963943", "object_location_in_text": [135, 151], "original_object": "atherothrombosis", "original_subject": "TICAGRELOR", "population_context_qualifier": "especially high risk patients; age of 65 years or older; with diabetes mellitus requiring drug therapy; history of two or more episodes of myocardial infarction; angiography-confirmed multivessel coronary artery disease; or non-end-stage chronic renal dysfunction", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TICAGRELOR#98-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:68558", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of: (1) Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. (2) Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0033678", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b50fdf5-819a-5922-adc6-bfc70854e836", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aspirin"], "medic_disease_context_ids": ["HP:0033678"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:4405405f-10d1-53c0-b9bc-5940a672ed09", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0006805", "object_location_in_text": [465, 480], "original_object": "unstable angina", "original_subject": "TICAGRELOR", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TICAGRELOR#98-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:68558", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of: (1) Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. (2) Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.)"], "temporal_context_qualifier": "for which percutaneous coronary intervention (PCI) is indicated"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0033678", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ba31ade-5def-5e41-98cc-8946d6f88469", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aspirin"], "medic_disease_context_ids": ["HP:0033678"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:442e237d-76f8-5884-b7c5-eea83b83909f", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:03fc5f00-065a-51f1-abbc-4a7113bf9cd9", "object": "MONDO:0041656", "object_location_in_text": [486, 528], "original_object": "ST-segment elevation myocardial infarction", "original_subject": "TICAGRELOR", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TICAGRELOR#98-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:68558", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of: (1) Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. (2) Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.)"], "temporal_context_qualifier": "for which percutaneous coronary intervention (PCI) is indicated"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "airflow obstruction", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b93961e-a74e-512a-945b-50fd11cdd0a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091129", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:21d2e90f-d938-511f-9a9d-5a078bf97ee4", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6c34b515-3e83-5f49-8c6f-ed613ceb8333", "object": "MONDO:0005002", "object_location_in_text": [117, 154], "original_object": "chronic obstructive pulmonary disease", "original_subject": "indacaterol", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:oslif-breezhaler", "https://www.ema.europa.eu/en/documents/product-information/oslif-breezhaler-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/oslif-breezhaler"]}], "subject": "CHEBI:68575", "supporting_text": ["Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "airflow obstruction", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7bc7034-06d1-50b0-811d-4e6037c851b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091129", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:21d2e90f-d938-511f-9a9d-5a078bf97ee4", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6c34b515-3e83-5f49-8c6f-ed613ceb8333", "object": "MONDO:0005002", "object_location_in_text": [118, 155], "original_object": "chronic obstructive pulmonary disease", "original_subject": "indacaterol", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:onbrez-breezhaler", "https://www.ema.europa.eu/en/documents/product-information/onbrez-breezhaler-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler"]}], "subject": "CHEBI:68575", "supporting_text": ["Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe236a3b-cda4-5f98-b839-eb01f6edf159", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "object": "MONDO:0005098", "object_location_in_text": [763, 769], "original_object": "stroke", "original_subject": "rivaroxaban", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xarelto", "https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto"]}], "subject": "CHEBI:68579", "supporting_text": ["Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e6d3cc7-2e26-5a62-88c1-c9b9783f4b30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [86, 92], "original_object": "stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10db92f9-2300-4a80-836b-673e1ae91610", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at l"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58790980-17ce-543f-95be-e8f7a8a50780", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [88, 94], "original_object": "stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0e105f6-28f3-45ee-83bd-7d458835242b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE XARELTO is a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial tr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6708107e-65f1-5a0b-8407-15271304f836", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [90, 96], "original_object": "stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9178947d-9d58-4c1a-b158-6030e17556af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9178947d-9d58-4c1a-b158-6030e17556af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9178947d-9d58-4c1a-b158-6030e17556af"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE Rivaroxaban is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablets are indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablets are indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablets are indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e3a7040-4b21-59a4-8827-ef0654908453", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [99, 105], "original_object": "stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9fee7136-c8fd-4bea-ab15-7a0e7292396d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9fee7136-c8fd-4bea-ab15-7a0e7292396d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9fee7136-c8fd-4bea-ab15-7a0e7292396d"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS &amp; USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablet is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [ see Clinical Studies ( 14.1 )]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablet is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablet is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablet is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for rec"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78a87f80-b830-5157-a0e8-9e36d2ddf9a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [99, 105], "original_object": "stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5524f30f-789d-4f5c-8f7c-d03a475b6d34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5524f30f-789d-4f5c-8f7c-d03a475b6d34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5524f30f-789d-4f5c-8f7c-d03a475b6d34"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablets are indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablets are indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablets are indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b82220b3-425b-553e-b8e1-8b0db8acc67d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [99, 105], "original_object": "stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e62f23c6-89f2-4179-95dc-5732401b3f93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e62f23c6-89f2-4179-95dc-5732401b3f93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e62f23c6-89f2-4179-95dc-5732401b3f93"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablets are indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablets are indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablets are indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002625", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b19dcbfe-e29c-5447-983e-0cb3e9ba2181", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0002625"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ffd19906-2cd5-5180-86ef-068b6387a1b4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "MONDO:0005279", "original_object": "pulmonary embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients undergoing knee or hip replacement surgery", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9fee7136-c8fd-4bea-ab15-7a0e7292396d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9fee7136-c8fd-4bea-ab15-7a0e7292396d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9fee7136-c8fd-4bea-ab15-7a0e7292396d"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS &amp; USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablet is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [ see Clinical Studies ( 14.1 )]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablet is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablet is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablet is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for rec"], "temporal_context_qualifier": "Following Hip or Knee Replacement Surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dea585f4-c3c3-5290-9e3f-ee9a5f29aa2c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120118", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:022f02f4-23ac-50b9-a831-9b6e56b1d7d7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "object": "MONDO:1060198", "object_location_in_text": [67, 82], "original_object": "ischemic stroke", "original_subject": "RIVAROXABAN", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RIVAROXABAN#145-20120118", "https://www.pmda.go.jp/files/000247811.pdf"]}], "subject": "CHEBI:68579", "supporting_text": ["Drugs with a new active ingredient indicated for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5e8d0bd-6d95-5e77-9341-d19a49e48e8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080930", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "object": "UMLS:C5400523", "object_location_in_text": [774, 791], "original_object": "systemic embolism", "original_subject": "rivaroxaban", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xarelto", "https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto"]}], "subject": "CHEBI:68579", "supporting_text": ["Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19ffcc8e-f279-556f-9882-4b83490f05c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [99, 116], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0e105f6-28f3-45ee-83bd-7d458835242b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0e105f6-28f3-45ee-83bd-7d458835242b"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE XARELTO is a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial tr"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2326690a-7b50-536e-a9b1-daeb6ef1f8ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [110, 127], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e62f23c6-89f2-4179-95dc-5732401b3f93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e62f23c6-89f2-4179-95dc-5732401b3f93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e62f23c6-89f2-4179-95dc-5732401b3f93"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablets are indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablets are indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablets are indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c5dcbbc-9b8d-5f6c-ab1d-b1f72d8ffca8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [110, 127], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5524f30f-789d-4f5c-8f7c-d03a475b6d34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5524f30f-789d-4f5c-8f7c-d03a475b6d34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5524f30f-789d-4f5c-8f7c-d03a475b6d34"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) • for treatment of deep vein thrombosis (DVT) ( 1.2 ) • for treatment of pulmonary embolism (PE) ( 1.3 ) • for reduction in the risk of recurrence of DVT or PE ( 1.4 ) • for prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) • for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) • for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablets are indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablets are indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablets are indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at con"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f05cda3-fee8-5877-880b-e0997ef2f34c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [101, 118], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9178947d-9d58-4c1a-b158-6030e17556af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9178947d-9d58-4c1a-b158-6030e17556af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9178947d-9d58-4c1a-b158-6030e17556af"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE Rivaroxaban is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablets are indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablets are indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablets are indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablets are indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98bb2102-c5ba-55f1-9813-be8f53a657e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [97, 114], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10db92f9-2300-4a80-836b-673e1ae91610", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS AND USAGE XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at l"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebb48718-c989-5d11-ba11-f00da3ca15e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110701", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [110, 127], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9fee7136-c8fd-4bea-ab15-7a0e7292396d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9fee7136-c8fd-4bea-ab15-7a0e7292396d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9fee7136-c8fd-4bea-ab15-7a0e7292396d"]}], "subject": "CHEBI:68579", "supporting_text": ["1 INDICATIONS &amp; USAGE Rivaroxaban tablet is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Rivaroxaban tablet is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of rivaroxaban tablets and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [ see Clinical Studies ( 14.1 )]. 1.2 Treatment of Deep Vein Thrombosis Rivaroxaban tablet is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism Rivaroxaban tablet is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism Rivaroxaban tablet is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for rec"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:246ce4ce-46e7-5891-9378-f6af7dcb894d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120118", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fcb1c5a9-981d-5cce-9df9-4c07da1ee062", "object": "UMLS:C5400523", "object_location_in_text": [87, 104], "original_object": "systemic embolism", "original_subject": "RIVAROXABAN", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RIVAROXABAN#145-20120118", "https://www.pmda.go.jp/files/000247811.pdf"]}], "subject": "CHEBI:68579", "supporting_text": ["Drugs with a new active ingredient indicated for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0021342", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8706a1f9-3a65-5a9e-9ff6-4aa44e0a0a99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180702", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021342"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:bd0945d9-9ce0-5b43-8aac-19194a8f80f5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:da85f553-a3d3-5843-89b0-3ff4d8e70496", "object": "MONDO:0000705", "object_location_in_text": [99, 123], "original_object": "pseudomembranous colitis", "original_subject": "FIDAXOMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FIDAXOMICIN#79-20180702", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:68590", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of infectious enteritis (including pseudomembranous colitis) caused by C. difficile."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "C. difficile-associated diarrhoea", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f453d9c5-d059-5a40-b167-d169edc74b37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111205", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:865d534f-6f87-5ef4-9a1d-51060243f57b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:da85f553-a3d3-5843-89b0-3ff4d8e70496", "object": "UMLS:C0343386", "original_object": "Clostridioides difficile infections", "original_subject": "fidaxomicin", "population_context_qualifier": "adults and paediatric patients from birth to < 18 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:dificlir", "https://www.ema.europa.eu/en/documents/product-information/dificlir-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir"]}], "subject": "CHEBI:68590", "supporting_text": ["Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg. Consideration should be given to official guidelines on the appropriate use of antibacterial agents. Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to &lt; 18 years of age. Consideration should be given to official guidelines on the appropriate use of antibacterial agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "serogroup 1 (genotype I [1a] or II [1b])", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05b31904-6553-5a9f-899e-c6b4cf8adcd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110926", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["interferon", "ribavirin"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e80112ae-079b-5222-b3a6-7239e87ef519", "object": "MONDO:0005354", "object_location_in_text": [121, 140], "original_object": "chronic hepatitis C", "original_subject": "TELAPREVIR", "population_context_qualifier": "patients who did not respond to interferon monotherapy or interferon-ribavirin combination therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TELAPREVIR#148-20110926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:68595", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of viremia in serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C in: (1) untreated patients with high blood HCV RNA; or (2) patients who did not respond to, or in whom the symptom relapsed with, interferon monotherapy or interferon-ribavirin combination therapy. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "serogroup 2 (genotype III [2a] or IV [2b]) chronic hepatitis C", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d6a3494-3850-530c-8e78-14ef11f1cee8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140919", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["interferon monotherapy", "interferon-ribavirin combination therapy"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e80112ae-079b-5222-b3a6-7239e87ef519", "object": "MONDO:0005354", "object_location_in_text": [117, 136], "original_object": "chronic hepatitis C", "original_subject": "TELAPREVIR", "population_context_qualifier": "patients who did not respond to, or in whom the symptom relapsed with, interferon monotherapy or interferon-ribavirin combination therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TELAPREVIR#116-20140919", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:68595", "supporting_text": ["A drug with a new additional indication for the improvement of viremia in serogroup 2 (genotype III [2a] or IV [2b]) chronic hepatitis C in patients who did not respond to, or in whom the symptom relapsed with, interferon monotherapy or interferon-ribavirin combination therapy. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "virologically suppressed (HIV-1 RNA less than 50 copies/mL), no history of treatment failure, no known or suspected resistance to either cabotegravir or rilpivirine", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13850539-e066-5b6e-9f38-7e7bbbc2be94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["VOCABRIA (cabotegravir)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:158af584-f0e4-5d62-857b-5eafdd2d96f8", "object": "UMLS:C2363741", "object_location_in_text": [238, 253], "original_object": "HIV-1 infection", "original_subject": "RILPIVIRINE", "population_context_qualifier": "adults and adolescents 12 years and older and weighing at least 35 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb109de9-d88d-4405-8dd6-d458cbc387d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb109de9-d88d-4405-8dd6-d458cbc387d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb109de9-d88d-4405-8dd6-d458cbc387d1"]}], "subject": "CHEBI:68606", "supporting_text": ["1 INDICATIONS AND USAGE Rilpivirine tablets are a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 12 years of age and older and weighing at least 35 kg with HIV-1 RNA less than or equal to 100,000 copies/mL ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a46f662-ed4e-5416-b495-40399fb03f41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["VOCABRIA (cabotegravir)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:158af584-f0e4-5d62-857b-5eafdd2d96f8", "object": "UMLS:C2363741", "object_location_in_text": [238, 253], "original_object": "HIV-1 infection", "original_subject": "RILPIVIRINE", "population_context_qualifier": "adults and adolescents 12 years and older and weighing at least 35 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dadbf50d-6b7d-4fb5-bd9f-7769b048e764", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dadbf50d-6b7d-4fb5-bd9f-7769b048e764", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dadbf50d-6b7d-4fb5-bd9f-7769b048e764"]}], "subject": "CHEBI:68606", "supporting_text": ["1 INDICATIONS AND USAGE Rilpivirine tablets are a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 12 years of age and older and weighing at least 35 kg with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "newly diagnosed high risk metastatic hormone sensitive prostate cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4f5e3a2-0e9a-5f3e-89d0-4f4f3625aebd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110905", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone", "prednisolone", "androgen deprivation therapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:788f805f-8e37-533e-9b5c-91eac8b13f39", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:30fab7f7-855d-56e5-a96e-67813bc55511", "object": "UMLS:C4302896", "object_location_in_text": [113, 157], "original_object": "metastatic hormone sensitive prostate cancer", "original_subject": "abiraterone", "population_context_qualifier": "adult men", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:abiraterone-accord", "https://www.ema.europa.eu/en/documents/product-information/abiraterone-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-accord"]}], "subject": "CHEBI:68642", "supporting_text": ["Abiraterone Accord is indicated with prednisone or prednisolone for:  the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hepatocellular carcinoma progression after cancer chemotherapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1812bc4c-bbee-5c2e-b3a7-3a4c4d091aa1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170626", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:fadc6882-9dc2-59c9-bec9-5e02d1f74700", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:465a0724-090a-56d5-b2e1-8974b3796bde", "object": "UMLS:C1112459", "object_location_in_text": [61, 98], "original_object": "unresectable hepatocellular carcinoma", "original_subject": "REGORAFENIB HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:REGORAFENIB HYDRATE#93-20170626", "https://www.pmda.go.jp/files/000227545.pdf"]}], "subject": "CHEBI:68647", "supporting_text": ["A drug with a new additional indication for the treatment of unresectable hepatocellular carcinoma which has progressed after cancer chemotherapy. [Priority review]"], "temporal_context_qualifier": "following cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "medicinal and chemical products-induced methaemoglobinaemia", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9739bdc6-9ac2-584a-8040-27a47ea09ea6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110506", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4d0c1053-8960-59e4-828a-aa82f4d03409", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:efa2a973-bc3b-5e57-af3a-2efce88027b6", "object": "MONDO:0001117", "object_location_in_text": [72, 91], "original_object": "methaemoglobinaemia", "original_subject": "methylthioninium chloride", "population_context_qualifier": "adults, children and adolescents (aged 0 to 17 years old)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:methylthioninium-chloride-proveblue", "https://www.ema.europa.eu/en/documents/product-information/methylthioninium-chloride-proveblue-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/methylthioninium-chloride-proveblue"]}], "subject": "CHEBI:6872", "supporting_text": ["Acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia. Methylthioninium chloride Proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old)."], "temporal_context_qualifier": "acute symptomatic"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "except when administered as an intra-articular injection for localized joint conditions", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:382c1b37-a53e-5f43-9ec7-bbe9d3824345", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e7baf1b4-995b-567b-bfcf-86ef09c3d143", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "object": "MONDO:0000256", "object_location_in_text": [706, 732], "original_object": "systemic fungal infections", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96"]}], "subject": "CHEBI:6888", "supporting_text": ["Methylprednisolone acetate injectable suspension is contraindicated in patients with known hypersensitivity to the product and its constituents. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Methylprednisolone acetate Sterile Aqueous Suspension is contraindicated for intrathecal administration. Reports of severe medical events have been associated with this route of administration. Methylprednisolone acetate injectable suspension is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see WARNINGS and PRECAUTIONS: Pediatric Use ). Methylprednisolone acetate injectable suspension is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions (see WARNINGS: Immunosuppression and Increased Risk of Infection , Fungal Infections )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2458ea2b-8c48-5029-acb5-d6d5f63cf7eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "HP:0002181", "original_object": "cerebral edema", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96"]}], "subject": "CHEBI:6888", "supporting_text": ["A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone acetate Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Di"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "treatment-resistant rheumatic diseases", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9cc0dfe-d113-5a06-8f6a-73d63377d1f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140829", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c9060584-bc03-5d7b-a63c-da21035f1841", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fe00c61e-a20e-5a48-ba6f-6999008e062e", "object": "MONDO:0005854", "object_location_in_text": [355, 386], "original_object": "mixed connective tissue disease", "original_subject": "METHYLPREDNISOLONE SODIUM SUCCINATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHYLPREDNISOLONE SODIUM SUCCINATE#118-20140829", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6888", "supporting_text": ["Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69031196-69fe-597b-866d-b2eff35fcf74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1626, 1648], "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e38b09c-da41-4ee3-8f99-812d3276d551", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e38b09c-da41-4ee3-8f99-812d3276d551", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e38b09c-da41-4ee3-8f99-812d3276d551"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69fb8fa7-65f4-51a6-89aa-a09202c70829", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1626, 1648], "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2af28649-2553-4bcc-9cb1-c73f7cec76d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2af28649-2553-4bcc-9cb1-c73f7cec76d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2af28649-2553-4bcc-9cb1-c73f7cec76d5"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7378ab42-ac35-5325-92b7-e7179b277a63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1536, 1558], "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96"]}], "subject": "CHEBI:6888", "supporting_text": ["A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone acetate Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Di"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d715d7a-4742-51a2-a9e3-9b4856bdf856", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1626, 1648], "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb0ba76-067f-46c4-a5d8-b585d5ecafe3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb0ba76-067f-46c4-a5d8-b585d5ecafe3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb0ba76-067f-46c4-a5d8-b585d5ecafe3"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0002928", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab4aa058-6dc3-58d4-9a89-3517f7dc3066", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_disease_context_ids": ["UMLS:C0002928"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7271310c-7764-4812-aa30-a5e90987c7a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c715763e-e4ab-5ad3-8a69-4459aeecfd6e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1626, 1648], "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68ef8ec4-16de-4a8c-8696-b09359660380", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68ef8ec4-16de-4a8c-8696-b09359660380", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68ef8ec4-16de-4a8c-8696-b09359660380"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff86d086-c53e-5e2c-ab90-8ed44f3e903a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1626, 1648], "original_object": "tuberculous meningitis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e5997ed-f4a5-43f7-abbd-c8e2219fe0e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e5997ed-f4a5-43f7-abbd-c8e2219fe0e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e5997ed-f4a5-43f7-abbd-c8e2219fe0e9"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "treatment-resistant rheumatic diseases", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13c9777d-3b2c-53b2-a29e-81425ea435ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140829", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:52c321fa-f8ee-5649-b8a1-f4f88547841b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fe00c61e-a20e-5a48-ba6f-6999008e062e", "object": "MONDO:0007915", "object_location_in_text": [281, 309], "original_object": "systemic lupus erythematosus", "original_subject": "METHYLPREDNISOLONE SODIUM SUCCINATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHYLPREDNISOLONE SODIUM SUCCINATE#118-20140829", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6888", "supporting_text": ["Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "treatment-resistant rheumatic diseases", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba840527-768b-5dc8-888f-b67600e37828", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140829", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a8e4a814-d837-5343-afd4-51a50580300f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fe00c61e-a20e-5a48-ba6f-6999008e062e", "object": "MONDO:0016367", "object_location_in_text": [325, 340], "original_object": "dermatomyositis", "original_subject": "METHYLPREDNISOLONE SODIUM SUCCINATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHYLPREDNISOLONE SODIUM SUCCINATE#118-20140829", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6888", "supporting_text": ["Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "treatment-resistant rheumatic diseases", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:517f6963-11a4-5a8d-9822-5511ec2ac566", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140829", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:713de7b7-9bbc-5f5a-9473-f798e34928bf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fe00c61e-a20e-5a48-ba6f-6999008e062e", "object": "MONDO:0019127", "object_location_in_text": [311, 323], "original_object": "polymyositis", "original_subject": "METHYLPREDNISOLONE SODIUM SUCCINATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHYLPREDNISOLONE SODIUM SUCCINATE#118-20140829", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6888", "supporting_text": ["Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "treatment-resistant rheumatic diseases", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d23abcc-cad8-58d3-8b74-988d4ce6318a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140829", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3285cc26-11e4-53ae-b859-7ad82ce58984", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fe00c61e-a20e-5a48-ba6f-6999008e062e", "object": "MONDO:0019340", "object_location_in_text": [342, 353], "original_object": "scleroderma", "original_subject": "METHYLPREDNISOLONE SODIUM SUCCINATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHYLPREDNISOLONE SODIUM SUCCINATE#118-20140829", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6888", "supporting_text": ["Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f1aa74a-2742-5e32-bee8-52f5b22343f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2af28649-2553-4bcc-9cb1-c73f7cec76d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2af28649-2553-4bcc-9cb1-c73f7cec76d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2af28649-2553-4bcc-9cb1-c73f7cec76d5"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3275580", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6926c501-0cd4-570d-b33e-3e819f0e1d0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3275580"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7271310c-7764-4812-aa30-a5e90987c7a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:748431b5-f7b0-5975-8c9e-7638a7bde79e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e5997ed-f4a5-43f7-abbd-c8e2219fe0e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e5997ed-f4a5-43f7-abbd-c8e2219fe0e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e5997ed-f4a5-43f7-abbd-c8e2219fe0e9"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7be8761d-bf32-5382-ace4-c2c48845e9b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a363f0cd-9c8e-4622-9271-171706846b96"]}], "subject": "CHEBI:6888", "supporting_text": ["A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone acetate Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Di"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d5ceb83-1a73-5199-b2ad-e341aef41bb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e38b09c-da41-4ee3-8f99-812d3276d551", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e38b09c-da41-4ee3-8f99-812d3276d551", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e38b09c-da41-4ee3-8f99-812d3276d551"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3275580", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e8d9eca-9f2b-5922-87b8-fdbc5e4ee7ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3275580"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:decceb81-e922-4b72-a278-3ed80f4adb04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=decceb81-e922-4b72-a278-3ed80f4adb04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=decceb81-e922-4b72-a278-3ed80f4adb04"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sym"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91b89407-a1f6-5b98-9eb2-4de34d1ab753", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68ef8ec4-16de-4a8c-8696-b09359660380", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68ef8ec4-16de-4a8c-8696-b09359660380", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68ef8ec4-16de-4a8c-8696-b09359660380"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4d6f8a3-c224-534b-abd9-6eaa8b6e66be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67d36d92-3df4-5435-bd1f-507bef0b4fe2", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "METHYLPREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cb0ba76-067f-46c4-a5d8-b585d5ecafe3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cb0ba76-067f-46c4-a5d8-b585d5ecafe3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cb0ba76-067f-46c4-a5d8-b585d5ecafe3"]}], "subject": "CHEBI:6888", "supporting_text": ["When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "treatment-resistant rheumatic diseases", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa0f2850-fec2-55ce-9aa4-ddb5e0a20814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140829", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:4526ddb9-1c78-5d57-98fc-ef4b87dadcef", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fe00c61e-a20e-5a48-ba6f-6999008e062e", "object": "MONDO:0800113", "object_location_in_text": [131, 150], "original_object": "systemic vasculitis", "original_subject": "METHYLPREDNISOLONE SODIUM SUCCINATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:METHYLPREDNISOLONE SODIUM SUCCINATE#118-20140829", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6888", "supporting_text": ["Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f1bb257-aef2-5bc4-9d19-46cbcc5a3eb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58239cf1-53b4-4ef7-e063-6394a90a65bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58239cf1-53b4-4ef7-e063-6394a90a65bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58239cf1-53b4-4ef7-e063-6394a90a65bd"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31e5a3db-6787-59c9-ae51-f16457c0c4f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cbcec1e7-7eac-456e-a253-aaf6761b4883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cbcec1e7-7eac-456e-a253-aaf6761b4883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbcec1e7-7eac-456e-a253-aaf6761b4883"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f15d19c-0915-5502-838a-d2bf60c8479c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b0b19b1-4c3c-4ecb-8153-8c58ba29e5ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b0b19b1-4c3c-4ecb-8153-8c58ba29e5ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b0b19b1-4c3c-4ecb-8153-8c58ba29e5ee"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45d3b501-0869-51c0-bc68-a9374d3516fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b867129-3b85-f12c-e063-6294a90ac407", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b867129-3b85-f12c-e063-6294a90ac407", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b867129-3b85-f12c-e063-6294a90ac407"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f4a9f2f-62e0-52c1-b8b2-f909053978b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59ed27b8-32b5-60c0-e063-6394a90a8a23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59ed27b8-32b5-60c0-e063-6394a90a8a23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59ed27b8-32b5-60c0-e063-6394a90a8a23"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:802c48f5-ba13-5780-9939-43c45f6c59a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59ed1885-cc00-5325-e063-6294a90a50c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59ed1885-cc00-5325-e063-6294a90a50c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59ed1885-cc00-5325-e063-6294a90a50c2"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81c1331b-6754-5c9f-9e67-0bb273fa744e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:106b7a0c-af7f-2565-e063-6294a90a34e0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=106b7a0c-af7f-2565-e063-6294a90a34e0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=106b7a0c-af7f-2565-e063-6294a90a34e0"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83370c84-8cc2-5006-b6dd-a327ab93ea20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:621249c4-531b-4138-9bde-77a06ad7816b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=621249c4-531b-4138-9bde-77a06ad7816b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=621249c4-531b-4138-9bde-77a06ad7816b"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a58c9ce1-0a30-5936-b780-21da4070ca92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58d493d3-b69c-422a-b6a8-0f8fa1e55545", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58d493d3-b69c-422a-b6a8-0f8fa1e55545", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58d493d3-b69c-422a-b6a8-0f8fa1e55545"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b34f33a1-0d6e-57b2-bfc7-48c5f5e1a212", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [264, 286], "original_object": "myocardial infarctions", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6399f2c3-7799-4f8b-b8b7-8d2137b1f852", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6399f2c3-7799-4f8b-b8b7-8d2137b1f852", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6399f2c3-7799-4f8b-b8b7-8d2137b1f852"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b49d11a1-72cc-5e87-9641-81077ae1b6f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4871791a-7679-4345-8fd6-fdb9c9217352", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4871791a-7679-4345-8fd6-fdb9c9217352", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4871791a-7679-4345-8fd6-fdb9c9217352"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b85dac29-5008-5481-9542-ecaa9840446d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39d822df-0fa4-4f06-a6f1-d313824c62df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39d822df-0fa4-4f06-a6f1-d313824c62df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d822df-0fa4-4f06-a6f1-d313824c62df"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba3d5541-315d-5161-9391-ae22271914b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a236293-35c1-4083-9805-ab40df535083", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a236293-35c1-4083-9805-ab40df535083", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a236293-35c1-4083-9805-ab40df535083"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf121254-2fc2-5775-b204-29257a05d38a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ca72c89-82c5-4b31-b515-1a8b8e82ec59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ca72c89-82c5-4b31-b515-1a8b8e82ec59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ca72c89-82c5-4b31-b515-1a8b8e82ec59"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d374b9ab-fbce-5148-aeb3-a6d0f421781d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9ccdbc0-0e4e-40c4-aacf-de60deda9fd5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9ccdbc0-0e4e-40c4-aacf-de60deda9fd5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9ccdbc0-0e4e-40c4-aacf-de60deda9fd5"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e97539b5-f624-5a72-a50b-1ff96580d932", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:485f1fdb-6543-4f47-e063-6394a90a2459", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=485f1fdb-6543-4f47-e063-6394a90a2459", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=485f1fdb-6543-4f47-e063-6394a90a2459"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e975dbc1-f32d-5b30-8a1f-d54611cea797", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ecff825-34ea-4535-b935-627bf2c13d93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ecff825-34ea-4535-b935-627bf2c13d93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ecff825-34ea-4535-b935-627bf2c13d93"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4805dbc-a7ba-550c-b7c0-330b399271ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff180ca2-7490-a571-e053-6394a90a97b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff180ca2-7490-a571-e053-6394a90a97b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff180ca2-7490-a571-e053-6394a90a97b1"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol succinate is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Angina Pectoris. (1.2) • Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bad318c-338f-5451-a2a5-c479b7dddf64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [243, 250], "original_object": "strokes", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4871791a-7679-4345-8fd6-fdb9c9217352", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4871791a-7679-4345-8fd6-fdb9c9217352", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4871791a-7679-4345-8fd6-fdb9c9217352"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3447a029-3074-5ed6-a7e0-959404f6d1fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [252, 259], "original_object": "strokes", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6399f2c3-7799-4f8b-b8b7-8d2137b1f852", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6399f2c3-7799-4f8b-b8b7-8d2137b1f852", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6399f2c3-7799-4f8b-b8b7-8d2137b1f852"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduct"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3580c64a-d291-54f4-855f-d93983a0e40f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39d822df-0fa4-4f06-a6f1-d313824c62df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39d822df-0fa4-4f06-a6f1-d313824c62df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d822df-0fa4-4f06-a6f1-d313824c62df"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e622fc6-1a5e-55f5-afcb-805e39424e08", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:485f1fdb-6543-4f47-e063-6394a90a2459", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=485f1fdb-6543-4f47-e063-6394a90a2459", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=485f1fdb-6543-4f47-e063-6394a90a2459"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59582246-050f-5cd0-bcad-8a3448319a64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b867129-3b85-f12c-e063-6294a90ac407", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b867129-3b85-f12c-e063-6294a90ac407", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b867129-3b85-f12c-e063-6294a90ac407"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f9c3ee8-1d70-54c4-ac46-2aeb6aea2cb3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:621249c4-531b-4138-9bde-77a06ad7816b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=621249c4-531b-4138-9bde-77a06ad7816b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=621249c4-531b-4138-9bde-77a06ad7816b"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fab43ca-e0d3-5e52-8e9a-3fa98a7f67ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58d493d3-b69c-422a-b6a8-0f8fa1e55545", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58d493d3-b69c-422a-b6a8-0f8fa1e55545", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58d493d3-b69c-422a-b6a8-0f8fa1e55545"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ff2d897-4f91-5ce1-b2c5-d613f6196112", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c9ccdbc0-0e4e-40c4-aacf-de60deda9fd5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c9ccdbc0-0e4e-40c4-aacf-de60deda9fd5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9ccdbc0-0e4e-40c4-aacf-de60deda9fd5"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:996702f9-9c33-5933-b486-aa5af98bd12a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59ed27b8-32b5-60c0-e063-6394a90a8a23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59ed27b8-32b5-60c0-e063-6394a90a8a23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59ed27b8-32b5-60c0-e063-6394a90a8a23"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c40e72eb-2c0b-55e4-b52b-42d888c05004", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b0b19b1-4c3c-4ecb-8153-8c58ba29e5ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b0b19b1-4c3c-4ecb-8153-8c58ba29e5ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b0b19b1-4c3c-4ecb-8153-8c58ba29e5ee"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c66039ea-2a47-5a7b-b726-fed9c4755a40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cbcec1e7-7eac-456e-a253-aaf6761b4883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cbcec1e7-7eac-456e-a253-aaf6761b4883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbcec1e7-7eac-456e-a253-aaf6761b4883"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1922867-d0f9-55d0-8958-94793419dac7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ecff825-34ea-4535-b935-627bf2c13d93", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ecff825-34ea-4535-b935-627bf2c13d93", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ecff825-34ea-4535-b935-627bf2c13d93"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db960485-be6c-5eb3-b605-7fa581372301", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58239cf1-53b4-4ef7-e063-6394a90a65bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58239cf1-53b4-4ef7-e063-6394a90a65bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58239cf1-53b4-4ef7-e063-6394a90a65bd"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e24d9c06-2f6e-5104-b4b7-62e1b8897039", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59ed1885-cc00-5325-e063-6294a90a50c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59ed1885-cc00-5325-e063-6294a90a50c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59ed1885-cc00-5325-e063-6294a90a50c2"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2d4965c-9228-5012-b439-3b1b868ce98d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff180ca2-7490-a571-e053-6394a90a97b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff180ca2-7490-a571-e053-6394a90a97b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff180ca2-7490-a571-e053-6394a90a97b1"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol succinate is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Angina Pectoris. (1.2) • Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef7bbfc6-198c-51b7-9c1d-2ba4947dc231", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ca72c89-82c5-4b31-b515-1a8b8e82ec59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ca72c89-82c5-4b31-b515-1a8b8e82ec59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ca72c89-82c5-4b31-b515-1a8b8e82ec59"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of strok"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fed2d3a7-5c1b-5985-9557-d0b4f2e89c83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a236293-35c1-4083-9805-ab40df535083", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a236293-35c1-4083-9805-ab40df535083", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a236293-35c1-4083-9805-ab40df535083"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff46ff55-c71b-59ff-b6e9-c4feb336f0e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e77baae6-94ff-59fe-9d8c-91ac82862f97", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "METOPROLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:106b7a0c-af7f-2565-e063-6294a90a34e0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=106b7a0c-af7f-2565-e063-6294a90a34e0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=106b7a0c-af7f-2565-e063-6294a90a34e0"]}], "subject": "CHEBI:6904", "supporting_text": ["1 INDICATIONS AND USAGE Metoprolol tartrate tablet is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Angina Pectoris. ( 1.2 ) • Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5453b3b-88ea-5a50-b751-b05cfdfa0c49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "object": "MONDO:0005412", "object_location_in_text": [302, 316], "original_object": "duodenal ulcer", "original_subject": "METRONIDAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5cdacbf5-67be-42eb-bd54-8acc32ea1abc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5cdacbf5-67be-42eb-bd54-8acc32ea1abc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5cdacbf5-67be-42eb-bd54-8acc32ea1abc"]}], "subject": "CHEBI:6909", "supporting_text": ["1 INDICATIONS AND USAGE PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2641507-2966-504a-82a6-d6456e0be135", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "object": "MONDO:0005412", "object_location_in_text": [662, 676], "original_object": "duodenal ulcer", "original_subject": "METRONIDAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fe5d2db-c59d-4e15-acd7-f9df8eca45aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fe5d2db-c59d-4e15-acd7-f9df8eca45aa"]}], "subject": "CHEBI:6909", "supporting_text": ["1 INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PYLERA is a combination antibacterial indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . (1.1) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence."], "temporal_context_qualifier": "recurrence"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe2e7075-3865-5a73-bd10-6e067e7b5fb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "object": "MONDO:0005412", "object_location_in_text": [302, 316], "original_object": "duodenal ulcer", "original_subject": "METRONIDAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c50626a2-5969-490b-a88a-a4ee45e79615", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c50626a2-5969-490b-a88a-a4ee45e79615", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c50626a2-5969-490b-a88a-a4ee45e79615"]}], "subject": "CHEBI:6909", "supporting_text": ["1 INDICATIONS AND USAGE PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40ef22cc-68ba-537c-984b-4786b8e67ccc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0df89815-985a-571a-913c-f647668c205b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "medic_supporting_text_truncated": true, "object": "MONDO:0002345", "object_location_in_text": [435, 445], "original_object": "cervicitis", "original_subject": "METRONIDAZOLE", "population_context_qualifier": "females", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f1de4ca-a005-4ca9-a43a-380429c80d6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f1de4ca-a005-4ca9-a43a-380429c80d6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f1de4ca-a005-4ca9-a43a-380429c80d6f"]}], "subject": "CHEBI:6909", "supporting_text": ["Symptomatic Trichomoniasis. Metronidazole tablets, USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets, USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets, USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bb4c216-8f78-511c-9870-04e29660d40d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8be65546-1eae-5974-8938-aec98a654750", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "medic_supporting_text_truncated": true, "object": "MONDO:0003632", "object_location_in_text": [431, 445], "original_object": "endocervicitis", "original_subject": "METRONIDAZOLE", "population_context_qualifier": "females", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f1de4ca-a005-4ca9-a43a-380429c80d6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f1de4ca-a005-4ca9-a43a-380429c80d6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f1de4ca-a005-4ca9-a43a-380429c80d6f"]}], "subject": "CHEBI:6909", "supporting_text": ["Symptomatic Trichomoniasis. Metronidazole tablets, USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets, USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets, USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1622505", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67b65a8b-e61c-5eba-9431-6c6575a97ae5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1622505", "MONDO:0005316"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b95be0d-190b-5604-b141-60b5f6af1f1b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "object": "MONDO:0005316", "object_location_in_text": [61, 80], "original_object": "bacterial vaginosis", "original_subject": "METRONIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ced2460-a003-4314-897b-f4ae0ff72edf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ced2460-a003-4314-897b-f4ae0ff72edf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ced2460-a003-4314-897b-f4ae0ff72edf"]}], "subject": "CHEBI:6909", "supporting_text": [": Metronidazole vaginal gel is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19b2751b-386c-5413-9ab9-f2a7a5831990", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["omeprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:112be0b9-19ff-5d84-8593-22e5b09509d6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [379, 401], "original_object": "duodenal ulcer disease", "original_subject": "METRONIDAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c29bfde9-5eb4-422a-bd30-4bce45e73dc0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c29bfde9-5eb4-422a-bd30-4bce45e73dc0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c29bfde9-5eb4-422a-bd30-4bce45e73dc0"]}], "subject": "CHEBI:6909", "supporting_text": ["1 INDICATIONS AND USAGE Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850666", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73f3c7e5-69e5-5800-b071-92191cb28bbc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0850666"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "object": "MONDO:0005412", "object_location_in_text": [331, 345], "original_object": "duodenal ulcer", "original_subject": "METRONIDAZOLE", "population_context_qualifier": "patients with active duodenal ulcer disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c809fa5-c630-4bf1-a0fc-5ee875008807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c809fa5-c630-4bf1-a0fc-5ee875008807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c809fa5-c630-4bf1-a0fc-5ee875008807"]}], "subject": "CHEBI:6909", "supporting_text": [": The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af75a2e4-5fea-5b26-af1b-4298c64fc3b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["omeprazole"], "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [380, 394], "original_object": "duodenal ulcer", "original_subject": "METRONIDAZOLE", "population_context_qualifier": "patients with active duodenal ulcer or history of duodenal ulcer disease within the past 5 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4d66e80-f0bc-4e64-a0f0-630ef673da1b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4d66e80-f0bc-4e64-a0f0-630ef673da1b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4d66e80-f0bc-4e64-a0f0-630ef673da1b"]}], "subject": "CHEBI:6909", "supporting_text": ["1 INDICATIONS AND USAGE Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules are a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidem"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trichomonas vaginalis infection", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a5e6b72-7651-5646-91b9-84fb264a76b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f21bdad9-41a8-57df-a51f-a8b6ef029f30", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e16d652c-db32-50a7-866d-b4e9b53880ec", "medic_supporting_text_truncated": true, "object": "UMLS:C0007869", "object_location_in_text": [462, 478], "original_object": "cervical erosion", "original_subject": "METRONIDAZOLE", "population_context_qualifier": "females", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f1de4ca-a005-4ca9-a43a-380429c80d6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f1de4ca-a005-4ca9-a43a-380429c80d6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f1de4ca-a005-4ca9-a43a-380429c80d6f"]}], "subject": "CHEBI:6909", "supporting_text": ["Symptomatic Trichomoniasis. Metronidazole tablets, USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets, USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets, USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablets therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0033120", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fb8944e-3a51-5fd9-9808-9ab0be485b03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19710101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0033120"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:bf5f9e5f-3d56-5c7f-8a16-55a03ea83458", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:e4c204fe-1ffb-567a-be07-cd1ef08273d7", "object": "HP:0033120", "object_location_in_text": [104, 119], "original_object": "nummular eczema", "original_subject": "Desoximetasone", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:691037", "supporting_text": ["Topical corticosteroid- Indicated in the management of various acute and chronic dermatoses viz eczema, nummular eczema, infantile eczema, atopical dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001047", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8de63f63-6687-54b1-b15b-2bf5a217d962", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19710101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001047"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:91607e8e-b17c-5bc6-a6ee-a1ea35b7f5ce", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:e4c204fe-1ffb-567a-be07-cd1ef08273d7", "object": "MONDO:0004980", "object_location_in_text": [121, 137], "original_object": "infantile eczema", "original_subject": "Desoximetasone", "population_context_qualifier": "infants", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:691037", "supporting_text": ["Topical corticosteroid- Indicated in the management of various acute and chronic dermatoses viz eczema, nummular eczema, infantile eczema, atopical dermatitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-dystrophic myotonic disorders", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3b95bdc-1887-5575-8b1b-3c5f8a616311", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181218", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:866d9be9-ad09-59ef-a18e-a3b2129c1496", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:03dde32a-d6e7-5b21-814f-ee7c8e86a48b", "object": "HP:0002486", "object_location_in_text": [55, 63], "original_object": "myotonia", "original_subject": "mexiletine hcl", "population_context_qualifier": "adult patients with non-dystrophic myotonic disorders", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:namuscla", "https://www.ema.europa.eu/en/documents/product-information/namuscla-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/namuscla"]}], "subject": "CHEBI:6916", "supporting_text": ["Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a794632a-a8c9-5e37-b94b-fd474f346496", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "HP:0004308", "object_location_in_text": [109, 132], "original_object": "ventricular arrhythmias", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:17c65cba-f56f-4cad-a9e2-d31f62e95849", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=17c65cba-f56f-4cad-a9e2-d31f62e95849", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17c65cba-f56f-4cad-a9e2-d31f62e95849"]}], "subject": "CHEBI:6916", "supporting_text": ["INDICATIONS &amp; USAGE Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb972d69-78cc-590b-8fc1-837ff2001a88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "HP:0004308", "object_location_in_text": [109, 132], "original_object": "ventricular arrhythmias", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c6024e9-760b-40a4-9ef1-b75b269c582a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c6024e9-760b-40a4-9ef1-b75b269c582a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c6024e9-760b-40a4-9ef1-b75b269c582a"]}], "subject": "CHEBI:6916", "supporting_text": ["INDICATIONS &amp; USAGE Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:247ca4f1-d649-598b-9541-da0368417f16", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [118, 151], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58b7a7f5-5ae0-2f60-e063-6394a90a37dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58b7a7f5-5ae0-2f60-e063-6394a90a37dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58b7a7f5-5ae0-2f60-e063-6394a90a37dd"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:443f5a96-ec67-505a-884b-24a0e2c66140", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1cb1e35-9586-41c4-b43f-c517f2d42f31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1cb1e35-9586-41c4-b43f-c517f2d42f31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1cb1e35-9586-41c4-b43f-c517f2d42f31"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7566bbe0-96aa-5df9-8b6f-5ce2badb573e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b192b46-e69f-4031-b843-8b28fa85f07b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b192b46-e69f-4031-b843-8b28fa85f07b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b192b46-e69f-4031-b843-8b28fa85f07b"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75689601-6341-55ac-bd73-dac622792e35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [118, 151], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68987377-c7c2-493b-be42-30379ec432bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68987377-c7c2-493b-be42-30379ec432bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68987377-c7c2-493b-be42-30379ec432bc"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bdaa4d3-d20b-5c24-b813-92ce7725c11f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [137, 170], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a61a07f6-0b48-4dcd-ad42-5d90f6e69ab1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a61a07f6-0b48-4dcd-ad42-5d90f6e69ab1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a61a07f6-0b48-4dcd-ad42-5d90f6e69ab1"]}], "subject": "CHEBI:6916", "supporting_text": ["INDICATIONS &amp; USAGE Mexiletine hydrochloride capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d1b5039-76b1-5aa2-a5fd-055413fb224f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2c0430d-35ee-460c-b0d5-f117d43430c5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2c0430d-35ee-460c-b0d5-f117d43430c5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2c0430d-35ee-460c-b0d5-f117d43430c5"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9da4c0d9-3fe7-509e-91e4-787c2886d37f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [118, 151], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cd564bd-24e3-481b-b998-f69f65d67fbe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cd564bd-24e3-481b-b998-f69f65d67fbe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cd564bd-24e3-481b-b998-f69f65d67fbe"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e9f1ef2-e580-5bbd-a267-98bd6b7507a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfe2b847-e18d-cef2-e053-2995a90a42af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfe2b847-e18d-cef2-e053-2995a90a42af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfe2b847-e18d-cef2-e053-2995a90a42af"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4934603-fa9e-5d57-bb08-e2ecf7705653", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [118, 151], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ff45dbf-b555-4f55-a286-98bfaea9ea29", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ff45dbf-b555-4f55-a286-98bfaea9ea29", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ff45dbf-b555-4f55-a286-98bfaea9ea29"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7276be2-8889-535d-99f3-7d6ad9d0642f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b3a807f-368a-42dc-8266-ddf8347a8826", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b3a807f-368a-42dc-8266-ddf8347a8826", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b3a807f-368a-42dc-8266-ddf8347a8826"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1834b9c-d6a3-5d22-aaba-462ccf135c73", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [118, 151], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3aec79aa-9dfb-495f-9280-2b830dc7eae9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3aec79aa-9dfb-495f-9280-2b830dc7eae9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3aec79aa-9dfb-495f-9280-2b830dc7eae9"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdbd8f97-d3e1-5c1f-8d84-a694d31ca6aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0bd3f2c-44e5-4ad0-9b76-c2028f0cae11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0bd3f2c-44e5-4ad0-9b76-c2028f0cae11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0bd3f2c-44e5-4ad0-9b76-c2028f0cae11"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5424bec-dff0-5f6f-aad8-d736107d6627", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [118, 151], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f4239ef-a28a-40d3-9617-2029d492829d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f4239ef-a28a-40d3-9617-2029d492829d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f4239ef-a28a-40d3-9617-2029d492829d"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d79939fb-c97c-5078-a657-9f1e6b4f27f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c2e1055-2fa1-462c-90f3-6d77e89ea38a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c2e1055-2fa1-462c-90f3-6d77e89ea38a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c2e1055-2fa1-462c-90f3-6d77e89ea38a"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e785225b-9165-5772-88ef-fde37a9c0c4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c528aae3-ff51-b9e4-a401-4ef5910e4b43", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c528aae3-ff51-b9e4-a401-4ef5910e4b43", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c528aae3-ff51-b9e4-a401-4ef5910e4b43"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine hydrochloride capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "documented ventricular arrhythmias", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0da2f46-ce25-52e5-bdba-8e6c0d9a62de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851230", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f463a191-c7c9-5da9-85ff-a9685ae0c102", "object": "UMLS:C0750197", "object_location_in_text": [117, 150], "original_object": "sustained ventricular tachycardia", "original_subject": "MEXILETINE", "population_context_qualifier": "patients in whom the arrhythmias are life-threatening", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c09f68fa-759e-4772-9f6b-11005d8f83d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c09f68fa-759e-4772-9f6b-11005d8f83d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c09f68fa-759e-4772-9f6b-11005d8f83d5"]}], "subject": "CHEBI:6916", "supporting_text": ["Mexiletine Hydrochloride Capsules USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life- threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2f1a67c-a8cf-5d79-a058-129521ae3c02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "HP:0000989", "object_location_in_text": [82, 89], "original_object": "itching", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4354b71e-6268-440d-b916-0403c6fc3ddb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4354b71e-6268-440d-b916-0403c6fc3ddb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4354b71e-6268-440d-b916-0403c6fc3ddb"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses cures most jock itch (tinea cruris) relieves symptoms of jock itch including itching, burning and chafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adeac4a1-98c5-532c-94db-ea509b56fc59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0014724", "object_location_in_text": [91, 98], "original_object": "burning", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4354b71e-6268-440d-b916-0403c6fc3ddb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4354b71e-6268-440d-b916-0403c6fc3ddb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4354b71e-6268-440d-b916-0403c6fc3ddb"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses cures most jock itch (tinea cruris) relieves symptoms of jock itch including itching, burning and chafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcd885bd-0f45-5a47-9cf2-3a41a4126631", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:878aaebf-9e22-57fc-9efe-e5374ff58a20", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0041834", "object_location_in_text": [103, 110], "original_object": "redness", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses treats most athlete's foot, jock itch and ringworm. Relieves itching, scaling, cracking, burning, redness, soreness, irritation, discomfort, and chafing associated with jock itch. Relieves itchy, scaly skin between the toes or itching, burning feet associated with athlete's foot. Ask your health professional regarding additional uses"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65e5cea3-1cdb-59bf-904b-7a13eb5e35d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:436d4e04-ca59-508a-8100-86bee47fd0ad", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0234215", "object_location_in_text": [134, 144], "original_object": "discomfort", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses treats most athlete's foot, jock itch and ringworm. Relieves itching, scaling, cracking, burning, redness, soreness, irritation, discomfort, and chafing associated with jock itch. Relieves itchy, scaly skin between the toes or itching, burning feet associated with athlete's foot. Ask your health professional regarding additional uses"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bbff462-1a42-5830-8909-dfaa7cf29bb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d5995f4-1e33-5d4c-8e9c-2b102173bdb8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0234233", "object_location_in_text": [112, 120], "original_object": "soreness", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses treats most athlete's foot, jock itch and ringworm. Relieves itching, scaling, cracking, burning, redness, soreness, irritation, discomfort, and chafing associated with jock itch. Relieves itchy, scaly skin between the toes or itching, burning feet associated with athlete's foot. Ask your health professional regarding additional uses"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4855a29-2657-54cd-85e4-abfbd1c6fb5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4537e5e-6bba-5cc6-b0d6-9af57480b179", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0237849", "object_location_in_text": [75, 82], "original_object": "scaling", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses treats most athlete's foot, jock itch and ringworm. Relieves itching, scaling, cracking, burning, redness, soreness, irritation, discomfort, and chafing associated with jock itch. Relieves itchy, scaly skin between the toes or itching, burning feet associated with athlete's foot. Ask your health professional regarding additional uses"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91e50b9f-fcbc-52c7-b2e6-c12b1fbb46f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0441723", "object_location_in_text": [122, 132], "original_object": "irritation", "original_subject": "MICONAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4de96ed4-7506-4acd-8e8d-ea74bfd18e4a"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses treats most athlete's foot, jock itch and ringworm. Relieves itching, scaling, cracking, burning, redness, soreness, irritation, discomfort, and chafing associated with jock itch. Relieves itchy, scaly skin between the toes or itching, burning feet associated with athlete's foot. Ask your health professional regarding additional uses"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07bba193-f85b-59a3-b99c-fff9f521e6ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2489f21e-f07f-5672-ab92-2e7d4f2391a0", "object": "MONDO:0001461", "object_location_in_text": [105, 119], "original_object": "tinea corporis", "original_subject": "MICONAZOLE NITRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb161d23-bc41-4cec-9e42-dfeef861d161", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb161d23-bc41-4cec-9e42-dfeef861d161", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb161d23-bc41-4cec-9e42-dfeef861d161"]}], "subject": "CHEBI:6923", "supporting_text": ["Indications: For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "candidiasis caused by Candida", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f5547b3-8d0a-5d72-8376-30afb4332518", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:890c06eb-120e-5f08-b6c4-332ba132a3bc", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C0919659", "object_location_in_text": [59, 84], "original_object": "oropharyngeal candidiasis", "original_subject": "MICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MICONAZOLE#79-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:6923", "supporting_text": ["A drug in a new dosage form indicated for the treatment of oropharyngeal candidiasis caused by Candida."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chafing", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14db6bba-587a-5598-9ec9-160abad118fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C1384589", "object_location_in_text": [79, 88], "original_object": "jock itch", "original_subject": "MICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1fcf072b-cf12-967a-e063-6294a90acfc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1fcf072b-cf12-967a-e063-6294a90acfc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1fcf072b-cf12-967a-e063-6294a90acfc7"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses for the cure of most athlete's foot, ringworm and chafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d936b9b-3594-576c-91ab-6157fcdf3457", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C1384589", "object_location_in_text": [76, 85], "original_object": "jock itch", "original_subject": "MICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edc2da26-ae46-4175-86ed-83e1a65f6d14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edc2da26-ae46-4175-86ed-83e1a65f6d14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edc2da26-ae46-4175-86ed-83e1a65f6d14"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses cures most athlete's foot (linea pedis), ringworm (linea corporis) and jock itch (linea cruris) relieves symptoms of athlete's foot, including itching burning and cracking"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2cfc384-6613-5ab7-8c7c-b4e479aec405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C1384589", "object_location_in_text": [76, 85], "original_object": "jock itch", "original_subject": "MICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a64c9371-0ac7-4c47-bc12-7bc77162b244", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a64c9371-0ac7-4c47-bc12-7bc77162b244", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a64c9371-0ac7-4c47-bc12-7bc77162b244"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses cures most athlete's foot (linea pedis), ringworm (linea corporis) and jock itch (linea cruris) relieves symptoms of athlete's foot, including itching burning and cracking"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5bb30d3-8515-5877-af8f-9d34ef89eb8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b44f00f3-24cc-5bc2-ae5f-35f06090e3c0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2636b93a-3e36-5c95-9899-d8a582bfbd0a", "object": "UMLS:C1384589", "object_location_in_text": [76, 85], "original_object": "jock itch", "original_subject": "MICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97334166-1dff-4ed2-ad31-f524b22097f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97334166-1dff-4ed2-ad31-f524b22097f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97334166-1dff-4ed2-ad31-f524b22097f9"]}], "subject": "CHEBI:6923", "supporting_text": ["Uses cures most athlete's foot (linea pedis), ringworm (linea corporis) and jock itch (linea cruris) relieves symptoms of athlete's foot, including itching burning and cracking"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "absent hair follicles", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9a0f4a3-8f4a-52b4-8c04-3d1469fac520", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b1c8b9a7-884d-5471-9add-dfee3c49a42b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f461f5df-0c22-555d-bb10-c5f134cf079f", "object": "MONDO:0004907", "object_location_in_text": [236, 245], "original_object": "hair loss", "original_subject": "MINOXIDIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d55f726-9bd7-c198-e063-6394a90ae3d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d55f726-9bd7-c198-e063-6394a90ae3d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d55f726-9bd7-c198-e063-6394a90ae3d7"]}], "subject": "CHEBI:6942", "supporting_text": ["For hairline recession at the temples, a receding hairline, thinning at the crown, a widening part on the top of the scalp, and overall hair thinning. Growater may not be effective if hair follicles are no longer present in the area of hair loss."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypertension refractory to other drugs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3be8c6d7-8e1b-58da-9ac6-68b232da4737", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f461f5df-0c22-555d-bb10-c5f134cf079f", "object": "MONDO:0005044", "object_location_in_text": [111, 123], "original_object": "hypertension", "original_subject": "MINOXIDIL", "population_context_qualifier": "patients with symptomatic hypertension or hypertension associated with target organ damage", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fea137a-bc88-4b24-85db-538c90ad1870", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fea137a-bc88-4b24-85db-538c90ad1870", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fea137a-bc88-4b24-85db-538c90ad1870"]}], "subject": "CHEBI:6942", "supporting_text": ["Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypertension refractory to other drugs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4bf094f5-bb80-5d20-9ac7-6586aae84cd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f461f5df-0c22-555d-bb10-c5f134cf079f", "object": "MONDO:0005044", "object_location_in_text": [111, 123], "original_object": "hypertension", "original_subject": "MINOXIDIL", "population_context_qualifier": "patients with symptomatic hypertension or hypertension associated with target organ damage", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ccd07ab-07ed-4b42-b182-3d22b98abca7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ccd07ab-07ed-4b42-b182-3d22b98abca7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ccd07ab-07ed-4b42-b182-3d22b98abca7"]}], "subject": "CHEBI:6942", "supporting_text": ["Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypertension refractory to other drugs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f41c8b2-4369-508d-82a4-b6a2048e2706", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f461f5df-0c22-555d-bb10-c5f134cf079f", "object": "MONDO:0005044", "object_location_in_text": [111, 123], "original_object": "hypertension", "original_subject": "MINOXIDIL", "population_context_qualifier": "patients with symptomatic hypertension or hypertension associated with target organ damage", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0dae476-8d0b-4d0c-a505-ad51bf27a1c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0dae476-8d0b-4d0c-a505-ad51bf27a1c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0dae476-8d0b-4d0c-a505-ad51bf27a1c8"]}], "subject": "CHEBI:6942", "supporting_text": ["Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypertension refractory to other drugs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c202de7-b45c-5c88-affe-93cb3a8c29b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f461f5df-0c22-555d-bb10-c5f134cf079f", "object": "MONDO:0005044", "object_location_in_text": [111, 123], "original_object": "hypertension", "original_subject": "MINOXIDIL", "population_context_qualifier": "patients with symptomatic hypertension or hypertension associated with target organ damage", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5bc9f21d-c959-89ee-e063-6294a90a0a62", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5bc9f21d-c959-89ee-e063-6294a90a0a62", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5bc9f21d-c959-89ee-e063-6294a90a0a62"]}], "subject": "CHEBI:6942", "supporting_text": ["Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypertension refractory to other drugs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3293b8d-f03f-52d9-b6ea-1e495a04600d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f461f5df-0c22-555d-bb10-c5f134cf079f", "object": "MONDO:0005044", "object_location_in_text": [111, 123], "original_object": "hypertension", "original_subject": "MINOXIDIL", "population_context_qualifier": "patients with symptomatic hypertension or hypertension associated with target organ damage", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0b4fc036-9497-442b-b629-c4b386932789", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0b4fc036-9497-442b-b629-c4b386932789", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b4fc036-9497-442b-b629-c4b386932789"]}], "subject": "CHEBI:6942", "supporting_text": ["Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6742fce-4f15-5d5f-89f5-de9d7168cd0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110121", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:022f02f4-23ac-50b9-a831-9b6e56b1d7d7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0a8d925d-fac7-597d-87bc-5c8a178f11fa", "object": "MONDO:1060198", "object_location_in_text": [63, 78], "original_object": "ischemic stroke", "original_subject": "DABIGATRAN ETEXILATE METHANESULFONATE", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DABIGATRAN ETEXILATE METHANESULFONATE#156-20110121", "https://www.pmda.go.jp/files/000207341.pdf"]}], "subject": "CHEBI:70743", "supporting_text": ["Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df7b1296-d818-5a70-8c79-ea7660fe6f5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110121", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0a8d925d-fac7-597d-87bc-5c8a178f11fa", "object": "UMLS:C5400523", "object_location_in_text": [83, 100], "original_object": "systemic embolism", "original_subject": "DABIGATRAN ETEXILATE METHANESULFONATE", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DABIGATRAN ETEXILATE METHANESULFONATE#156-20110121", "https://www.pmda.go.jp/files/000207341.pdf"]}], "subject": "CHEBI:70743", "supporting_text": ["Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ce314b4-da4b-57ed-915f-3401d01b5569", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080317", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:01393fc8-9a87-5ae8-9578-d9657fca62b4", "object": "MONDO:0005098", "object_location_in_text": [540, 546], "original_object": "stroke", "original_subject": "dabigatran etexilate", "population_context_qualifier": "adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:dabigatran-etexilate-teva", "https://www.ema.europa.eu/en/documents/product-information/dabigatran-etexilate-teva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/dabigatran-etexilate-teva"]}], "subject": "CHEBI:70746", "supporting_text": ["Dabigatran etexilate Leon Farma 75 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 110 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥&nbsp;75 years; heart failure (NYHA Class ≥&nbsp;II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 150 mg Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥&nbsp;75 years; heart failure (NYHA Class ≥&nbsp;II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18&nbsp;years of age."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60fffc22-0962-5933-a685-5f609752f688", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080317", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:01393fc8-9a87-5ae8-9578-d9657fca62b4", "object": "UMLS:C5400523", "object_location_in_text": [551, 568], "original_object": "systemic embolism", "original_subject": "dabigatran etexilate", "population_context_qualifier": "adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:dabigatran-etexilate-teva", "https://www.ema.europa.eu/en/documents/product-information/dabigatran-etexilate-teva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/dabigatran-etexilate-teva"]}], "subject": "CHEBI:70746", "supporting_text": ["Dabigatran etexilate Leon Farma 75 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 110 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥&nbsp;75 years; heart failure (NYHA Class ≥&nbsp;II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 150 mg Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥&nbsp;75 years; heart failure (NYHA Class ≥&nbsp;II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18&nbsp;years of age."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07c19917-e8c4-5d43-94a3-0e974c38f919", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39ac558a-b375-f3c1-e063-6394a90aa901", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39ac558a-b375-f3c1-e063-6394a90aa901", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39ac558a-b375-f3c1-e063-6394a90aa901"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08ff57af-82f2-5417-8030-04ed54b8a41b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:834a3c5f-b723-4bcb-a560-dc305dd0d829", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=834a3c5f-b723-4bcb-a560-dc305dd0d829", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=834a3c5f-b723-4bcb-a560-dc305dd0d829"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult PatientsFollowing Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c394fc4-4b52-5a60-876f-79be1d9a43b1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [118, 124], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b31d27e9-5502-43c5-83fa-89608c014b7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b31d27e9-5502-43c5-83fa-89608c014b7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b31d27e9-5502-43c5-83fa-89608c014b7a"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b1a27d2-377f-5eef-8177-db8f266cf054", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0379093-3e19-45ae-a616-0f24a1d255f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0379093-3e19-45ae-a616-0f24a1d255f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0379093-3e19-45ae-a616-0f24a1d255f4"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f7ab0e8-2baf-5a35-93bb-f5a951d716ab", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25c82ba1-5dec-56f4-9277-bb1fe1f71e0a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c24e235-218b-438e-9456-42c18ff01913", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c24e235-218b-438e-9456-42c18ff01913", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c24e235-218b-438e-9456-42c18ff01913"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27ef6da3-8550-523b-a6bf-872935bf7191", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [118, 124], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:369b945d-5bda-4773-910a-d0adef7f0f39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=369b945d-5bda-4773-910a-d0adef7f0f39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=369b945d-5bda-4773-910a-d0adef7f0f39"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31301d3c-802b-56c0-a528-da68d2019952", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [120, 126], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a608e019-db9a-d6fb-cd0d-cecc1351a2b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a608e019-db9a-d6fb-cd0d-cecc1351a2b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a608e019-db9a-d6fb-cd0d-cecc1351a2b1"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules is a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:400761e1-8a0d-59bc-946c-dad6af1c5d8f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [117, 123], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd47a015-ff90-d7a7-8dcb-4e6e31a68071", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd47a015-ff90-d7a7-8dcb-4e6e31a68071", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd47a015-ff90-d7a7-8dcb-4e6e31a68071"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have u"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e58ab2d-2e49-5eab-9849-9d7cbf0460c2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b196b1f-408e-4615-b980-9f822adff835", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b196b1f-408e-4615-b980-9f822adff835", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b196b1f-408e-4615-b980-9f822adff835"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:674240f7-c7dc-580e-a6fe-37271d5a0ee0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:baafb5be-ffe6-4755-a7ab-817b3c9b222d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=baafb5be-ffe6-4755-a7ab-817b3c9b222d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=baafb5be-ffe6-4755-a7ab-817b3c9b222d"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients wh"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82871658-5748-558a-acac-4921e69222dc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27e95caf-7938-ef8e-e063-6394a90a6a1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27e95caf-7938-ef8e-e063-6394a90a6a1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27e95caf-7938-ef8e-e063-6394a90a6a1a"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae772888-a86c-5c32-8d55-b792e2177e9a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5937f27-88c7-4c4a-801e-4c8945008982", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5937f27-88c7-4c4a-801e-4c8945008982", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5937f27-88c7-4c4a-801e-4c8945008982"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4d4fb35-481f-5246-8ab6-b17236d3c39c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [118, 124], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a8ec82a-c367-40dc-9302-e1896fcb05ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a8ec82a-c367-40dc-9302-e1896fcb05ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a8ec82a-c367-40dc-9302-e1896fcb05ea"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have unde"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b96a2271-71b2-5aad-b7a2-3a565cb2b27d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f79088b-b353-485a-9df4-6f5088f5bd0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f79088b-b353-485a-9df4-6f5088f5bd0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f79088b-b353-485a-9df4-6f5088f5bd0f"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c01c17d9-360a-5d8b-bbd2-60343957052c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [118, 124], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b76b79ce-b7dd-4390-b40e-71ae6c477d10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b76b79ce-b7dd-4390-b40e-71ae6c477d10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b76b79ce-b7dd-4390-b40e-71ae6c477d10"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have unde"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0d4d328-74f6-5b90-86be-70165922dccb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [105, 111], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE PRADAXA Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients PRADAXA Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery PRADAXA Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. 1.5 Treatment of Venous Thromboembolic E"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9a06304-790b-58a4-a878-40acb9188f83", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [121, 127], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13649035-a498-4e31-a7ea-8b18cedceca7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13649035-a498-4e31-a7ea-8b18cedceca7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13649035-a498-4e31-a7ea-8b18cedceca7"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult PatientsFollowing Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb3dad18-ffa0-5c83-9250-58aab8f3a069", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "MONDO:0005098", "object_location_in_text": [119, 125], "original_object": "stroke", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery (1.4) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0db79db1-c55b-58f9-9bee-9c2da632e97a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [128, 145], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd47a015-ff90-d7a7-8dcb-4e6e31a68071", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd47a015-ff90-d7a7-8dcb-4e6e31a68071", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd47a015-ff90-d7a7-8dcb-4e6e31a68071"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have u"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:226eb696-ab45-5f11-bcf2-ed6341a43752", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [132, 149], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c24e235-218b-438e-9456-42c18ff01913", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c24e235-218b-438e-9456-42c18ff01913", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c24e235-218b-438e-9456-42c18ff01913"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:237c3321-de08-5b56-8077-50bd08d89460", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [130, 147], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bee57f1b-ee5f-4f81-ae6f-ea65ddf9a174"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d8874dd-dbb0-53ab-8d3d-5f22f6888745", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [129, 146], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a8ec82a-c367-40dc-9302-e1896fcb05ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a8ec82a-c367-40dc-9302-e1896fcb05ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a8ec82a-c367-40dc-9302-e1896fcb05ea"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have unde"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:555fb740-b5a0-5cbf-acfa-10e4659ce370", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [130, 147], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7ea7e2c-ca54-4ecc-9fc7-bd3571b0ebc2"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery (1.4) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e22c05b-7a24-5b51-aa68-7d8346fcd4f2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [130, 147], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39ac558a-b375-f3c1-e063-6394a90aa901", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39ac558a-b375-f3c1-e063-6394a90aa901", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39ac558a-b375-f3c1-e063-6394a90aa901"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e64677c-c3b2-5361-8314-ccb4174d159f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [130, 147], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27e95caf-7938-ef8e-e063-6394a90a6a1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27e95caf-7938-ef8e-e063-6394a90a6a1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27e95caf-7938-ef8e-e063-6394a90a6a1a"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:754b9315-f1dd-5ba3-bacc-f1d81db1ca0d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [132, 149], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13649035-a498-4e31-a7ea-8b18cedceca7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13649035-a498-4e31-a7ea-8b18cedceca7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13649035-a498-4e31-a7ea-8b18cedceca7"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult PatientsFollowing Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1cfe63c-be5d-587a-bfcf-bafeb1434b58", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [129, 146], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:369b945d-5bda-4773-910a-d0adef7f0f39", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=369b945d-5bda-4773-910a-d0adef7f0f39", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=369b945d-5bda-4773-910a-d0adef7f0f39"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa48080e-273e-5985-8992-93f8f3df3251", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [132, 149], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:baafb5be-ffe6-4755-a7ab-817b3c9b222d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=baafb5be-ffe6-4755-a7ab-817b3c9b222d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=baafb5be-ffe6-4755-a7ab-817b3c9b222d"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients wh"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1900f85-5e64-506a-9003-3703319585f5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [130, 147], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f79088b-b353-485a-9df4-6f5088f5bd0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f79088b-b353-485a-9df4-6f5088f5bd0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f79088b-b353-485a-9df4-6f5088f5bd0f"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b930dc34-6d3c-586f-a747-ce8d674a4c99", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [131, 148], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a608e019-db9a-d6fb-cd0d-cecc1351a2b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a608e019-db9a-d6fb-cd0d-cecc1351a2b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a608e019-db9a-d6fb-cd0d-cecc1351a2b1"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules is a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:babe3cf7-ac0b-5a5b-9687-8e14c4b26666", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [132, 149], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:834a3c5f-b723-4bcb-a560-dc305dd0d829", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=834a3c5f-b723-4bcb-a560-dc305dd0d829", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=834a3c5f-b723-4bcb-a560-dc305dd0d829"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult PatientsFollowing Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7bee98e-249e-5dae-af2b-95d16879678b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [132, 149], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0379093-3e19-45ae-a616-0f24a1d255f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0379093-3e19-45ae-a616-0f24a1d255f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0379093-3e19-45ae-a616-0f24a1d255f4"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7297812-8064-5dff-bb5d-dbc2ad9ed543", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [130, 147], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b196b1f-408e-4615-b980-9f822adff835", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b196b1f-408e-4615-b980-9f822adff835", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b196b1f-408e-4615-b980-9f822adff835"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd1cb353-286d-5df2-9f0b-2a192eeafac8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [129, 146], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b76b79ce-b7dd-4390-b40e-71ae6c477d10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b76b79ce-b7dd-4390-b40e-71ae6c477d10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b76b79ce-b7dd-4390-b40e-71ae6c477d10"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have unde"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee168301-2a9a-5ced-a79d-3a08bd1b55e1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [132, 149], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5937f27-88c7-4c4a-801e-4c8945008982", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5937f27-88c7-4c4a-801e-4c8945008982", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5937f27-88c7-4c4a-801e-4c8945008982"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3913ce0-819c-5d53-8620-ec3667de1909", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "object": "UMLS:C5400523", "object_location_in_text": [129, 146], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b31d27e9-5502-43c5-83fa-89608c014b7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b31d27e9-5502-43c5-83fa-89608c014b7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b31d27e9-5502-43c5-83fa-89608c014b7a"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Dabigatran Etexilate Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Dabigatran Etexilate Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb73b8e4-06d6-5eda-8faa-2e3517c4711b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 19, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:428f7219-921d-5e01-adf2-ffb7b3fcf759", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [116, 133], "original_object": "systemic embolism", "original_subject": "DABIGATRAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9"]}], "subject": "CHEBI:70752", "supporting_text": ["1 INDICATIONS AND USAGE PRADAXA Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients PRADAXA Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery PRADAXA Capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. 1.5 Treatment of Venous Thromboembolic E"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:435c7c0f-12d1-57b7-b6f5-1b0a31c6f38f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6fdcefd2-fcb5-5e76-b060-0c7a390a8d1a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0001987", "object_location_in_text": [352, 374], "original_object": "chronic hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59e73eb8-edf8-4fad-93c2-deb6b23497f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59e73eb8-edf8-4fad-93c2-deb6b23497f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59e73eb8-edf8-4fad-93c2-deb6b23497f8"]}], "subject": "CHEBI:71028", "supporting_text": ["1 INDICATIONS AND USAGE Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) 1.1 Acute and Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency Carglumic acid tablets for oral suspension is indicated in adult and pediatric patients as: • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. • Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51c00b9e-b26b-5a21-99de-2d95ba8e6795", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6fdcefd2-fcb5-5e76-b060-0c7a390a8d1a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0001987", "object_location_in_text": [352, 374], "original_object": "chronic hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:591f95ca-3d99-4fb6-a402-e5a383a746d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=591f95ca-3d99-4fb6-a402-e5a383a746d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=591f95ca-3d99-4fb6-a402-e5a383a746d0"]}], "subject": "CHEBI:71028", "supporting_text": ["1 INDICATIONS &amp; USAGE Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. (1.1) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. (1.1) 1.1 Acute and Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency Carglumic acid tablets for oral suspension are indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c59385e6-8ca0-52ed-8cef-bccac96c77cc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6fdcefd2-fcb5-5e76-b060-0c7a390a8d1a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0001987", "object_location_in_text": [352, 374], "original_object": "chronic hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aee4281-402b-4cd6-9e6a-08945262e1a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aee4281-402b-4cd6-9e6a-08945262e1a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aee4281-402b-4cd6-9e6a-08945262e1a1"]}], "subject": "CHEBI:71028", "supporting_text": ["1 INDICATIONS AND USAGE Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) 1.1 Acute and Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency Carglumic acid tablets for oral suspension is indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa4c0728-0893-56e2-880a-88f1a85ecf50", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6fdcefd2-fcb5-5e76-b060-0c7a390a8d1a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0001987", "object_location_in_text": [319, 341], "original_object": "chronic hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10175e73-5172-4dde-a508-8a88b7afc0a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10175e73-5172-4dde-a508-8a88b7afc0a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10175e73-5172-4dde-a508-8a88b7afc0a1"]}], "subject": "CHEBI:71028", "supporting_text": ["1. INDICATIONS AND USAGE CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 ) 1.1 Acute and Chronic Hyperammonemia due to N‑acetylglutamate Synthase (NAGS) Deficiency CARBAGLU is indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. 1.2 Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) CARBAGLU is indicated in adult and pediatric patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to PA or MMA."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:365170be-9aee-564a-ae1e-9991dd1f64df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0008281", "object_location_in_text": [229, 249], "original_object": "acute hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2aee4281-402b-4cd6-9e6a-08945262e1a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2aee4281-402b-4cd6-9e6a-08945262e1a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2aee4281-402b-4cd6-9e6a-08945262e1a1"]}], "subject": "CHEBI:71028", "supporting_text": ["1 INDICATIONS AND USAGE Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) 1.1 Acute and Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency Carglumic acid tablets for oral suspension is indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b4caf9a-9689-571d-b451-c702e80dcb3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0008281", "object_location_in_text": [231, 251], "original_object": "acute hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:591f95ca-3d99-4fb6-a402-e5a383a746d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=591f95ca-3d99-4fb6-a402-e5a383a746d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=591f95ca-3d99-4fb6-a402-e5a383a746d0"]}], "subject": "CHEBI:71028", "supporting_text": ["1 INDICATIONS &amp; USAGE Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. (1.1) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. (1.1) 1.1 Acute and Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency Carglumic acid tablets for oral suspension are indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "propionic acidemia (PA), methylmalonic acidemia (MMA)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba8209db-48d4-53bf-bde7-7f778c8177b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0008281", "object_location_in_text": [196, 216], "original_object": "acute hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10175e73-5172-4dde-a508-8a88b7afc0a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10175e73-5172-4dde-a508-8a88b7afc0a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10175e73-5172-4dde-a508-8a88b7afc0a1"]}], "subject": "CHEBI:71028", "supporting_text": ["1. INDICATIONS AND USAGE CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 ) 1.1 Acute and Chronic Hyperammonemia due to N‑acetylglutamate Synthase (NAGS) Deficiency CARBAGLU is indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. 1.2 Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) CARBAGLU is indicated in adult and pediatric patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to PA or MMA."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "N-acetylglutamate synthase (NAGS) deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d626c913-ea5c-5b4e-99e9-18639dc61ccc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100318", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d57c64a4-482e-5e6d-affa-3aa4814d6e21", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73328f81-8962-5da3-b2e5-babd792c1224", "object": "HP:0008281", "object_location_in_text": [229, 249], "original_object": "acute hyperammonemia", "original_subject": "CARGLUMIC ACID", "population_context_qualifier": "pediatric and adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59e73eb8-edf8-4fad-93c2-deb6b23497f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59e73eb8-edf8-4fad-93c2-deb6b23497f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59e73eb8-edf8-4fad-93c2-deb6b23497f8"]}], "subject": "CHEBI:71028", "supporting_text": ["1 INDICATIONS AND USAGE Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) 1.1 Acute and Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency Carglumic acid tablets for oral suspension is indicated in adult and pediatric patients as: • Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. • Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d40763d-b1c8-5cb2-acde-68edb47e83be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090630", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822", "UMLS:C0242339", "MONDO:0007147"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:77623047-4956-530f-b080-9a8b1b169d08", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:978eddb0-0230-55c4-81f8-2dfa2aadf344", "object": "HP:0025502", "object_location_in_text": [229, 239], "original_object": "overweight", "original_subject": "liraglutide", "population_context_qualifier": "adult patients with an initial Body Mass Index (BMI) of ≥ 27 kg/m² to < 30 kg/m² in the presence of at least one weight-related comorbidity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:saxenda", "https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda"]}], "subject": "CHEBI:71193", "supporting_text": ["Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of • ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to &lt; 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. Adolescents (≥12 years) Saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with:  obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points)* and body weight above 60 kg. Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose.  *IOTF BMI cut-off points for obesity by sex between 12-18 years, in accordance with study design of the Trial 4180, see section 5.1. Children (6 to &lt;12 years)Saxenda is indicated as an adjunct to healthy nutrition and increased physical activity for weight management in children from the age of 6 to &lt;12 years with&nbsp;- obesity (BMI ≥95th percentile)* and- body weight ≥45 kgTreatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. *CDC BMI cut-off points for obesity (≥95th percentile) by sex between 6 to &lt;12 years, in accordance with study design of the Trial 4392, see section 5.1."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "weight-related comorbid condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0faece2-9d0c-552b-a0bf-515a2c893eac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100125", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:77623047-4956-530f-b080-9a8b1b169d08", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:978eddb0-0230-55c4-81f8-2dfa2aadf344", "object": "HP:0025502", "object_location_in_text": [322, 332], "original_object": "overweight", "original_subject": "LIRAGLUTIDE", "population_context_qualifier": "Adults with at least one weight-related comorbid condition", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:625ac780-70a9-41e4-a892-bcba0f803f1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=625ac780-70a9-41e4-a892-bcba0f803f1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=625ac780-70a9-41e4-a892-bcba0f803f1c"]}], "subject": "CHEBI:71193", "supporting_text": ["1 INDICATIONS AND USAGE Liraglutide injection is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response or intolerance to TNF blockers", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28741059-0dc1-5f8e-9611-184301125466", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121106", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:04a2b2fc-9e88-5ed3-a98c-8f9a1d4a8ad3", "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "TOFACITINIB", "population_context_qualifier": "adult", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6c033ff-bce0-4d1c-a182-3b13191686e1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6c033ff-bce0-4d1c-a182-3b13191686e1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6c033ff-bce0-4d1c-a182-3b13191686e1"]}], "subject": "CHEBI:71200", "supporting_text": ["1 INDICATIONS AND USAGE Tofacitinib oral solution is a Janus kinase (JAK) inhibitor. Tofacitinib oral solution is indicated for the treatment of pediatric patients 2 years of age and older with: • Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response or intolerance to one or more TNF blockers", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:289fcf1b-68c2-5eb5-adaa-6b4c5e17ac6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121106", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:04a2b2fc-9e88-5ed3-a98c-8f9a1d4a8ad3", "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "TOFACITINIB", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d9cf18a9-e825-49ac-b080-68957c0e79ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d9cf18a9-e825-49ac-b080-68957c0e79ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9cf18a9-e825-49ac-b080-68957c0e79ae"]}], "subject": "CHEBI:71200", "supporting_text": ["1 INDICATIONS AND USAGE Tofacitinib is a Janus kinase (JAK) inhibitor. Tofacitinib oral solution is indicated for the treatment of pediatric patients 2 years of age and older with: • Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response or intolerance to TNF blockers", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af5a91d4-39de-5357-afa6-239d685c5c6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121106", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:04a2b2fc-9e88-5ed3-a98c-8f9a1d4a8ad3", "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "TOFACITINIB", "population_context_qualifier": "pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd1b61bf-de03-4198-89f6-f3952b79d2c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd1b61bf-de03-4198-89f6-f3952b79d2c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd1b61bf-de03-4198-89f6-f3952b79d2c2"]}], "subject": "CHEBI:71200", "supporting_text": ["1 INDICATIONS AND USAGE Tofacitinib oral solution is a Janus kinase (JAK) inhibitor. Tofacitinib oral solution is indicated for the treatment of pediatric patients 2 years of age and older with: Active psoriatic arthritis ( PsA), who have had an inadequate response or intolerance to one or more TNF blockers. Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response or intolerance to TNF blockers", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3f6593f-662b-5a43-8c5b-32a1146dd757", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121106", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:04a2b2fc-9e88-5ed3-a98c-8f9a1d4a8ad3", "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "TOFACITINIB", "population_context_qualifier": "pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:327f6b60-1a5d-49e6-acff-18603d0ee9d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=327f6b60-1a5d-49e6-acff-18603d0ee9d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=327f6b60-1a5d-49e6-acff-18603d0ee9d0"]}], "subject": "CHEBI:71200", "supporting_text": ["1 INDICATIONS AND USAGE Tofacitinib oral solution is Janus kinase (JAK) inhibitors. Tofacitinib oral solution is indicated for the treatment of pediatric patients 2 years of age and older with: Active psoriatic arthritis PsA, who have had an inadequate response or intolerance to one or more TNF blockers. Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response or intolerance to TNF blockers", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5c6f582-ebdb-5deb-8e6b-d407bcbeff7c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121106", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:04a2b2fc-9e88-5ed3-a98c-8f9a1d4a8ad3", "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "TOFACITINIB", "population_context_qualifier": "pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a764a133-b870-4514-bbee-24d43f8cb7fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a764a133-b870-4514-bbee-24d43f8cb7fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a764a133-b870-4514-bbee-24d43f8cb7fd"]}], "subject": "CHEBI:71200", "supporting_text": ["1 INDICATIONS AND USAGE Tofacitinib oral solution is a Janus kinase (JAK) inhibitor. Tofacitinib oral solution is indicated for the treatment of pediatric patients 2 years of age and older with: Active psoriatic arthritis ( PsA), who have had an inadequate response or intolerance to one or more TNF blockers. Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1514457", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ca27b27-fd32-59ed-90bb-66887e2fb09a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091019", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1514457"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c2afbc56-f73c-57f4-823e-9103bd58f29c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a9cc6189-9b31-5d53-bfdd-b9b5f5f53dae", "object": "UMLS:C5206410", "original_object": "advanced soft tissue sarcoma", "original_subject": "PAZOPANIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25575cc6-5757-4f9b-9c09-0c4deb61ba12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25575cc6-5757-4f9b-9c09-0c4deb61ba12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25575cc6-5757-4f9b-9c09-0c4deb61ba12"]}], "subject": "CHEBI:71219", "supporting_text": ["1 INDICATIONS AND USAGE Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: Advanced renal cell carcinoma (RCC). ( 1.1 ) Advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0171e378-21ca-58a1-9179-7810c7767361", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See DOSAGE AND ADMINISTRATION.)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2189b7f2-4c4d-5fe4-9c8c-c8d48d9ce62d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51164bbb-1338-54a8-9e74-29aed2b07d4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59304774-2794-58b8-b156-64756c310e7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ce15bdd-02c3-5e7b-ade5-88ef69d523d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cdb5611-4f6e-5e96-8643-20248fdc5562", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4c9047a-d9c4-5803-b570-2d6de40f399f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e1c08439-4f77-5743-a1e4-a319f0c96159", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1745dfd-f326-52ef-93a5-ffbabeabfa37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "HP:0012531", "object_location_in_text": [73, 77], "original_object": "pain", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dca603a2-66a3-5e91-8be9-2bef248988f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a6ac3754-13a7-5682-9f2c-ca072c062da0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "MONDO:0006624", "original_object": "urinary urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4354dcce-6d85-4584-e063-6294a90a5616", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4354dcce-6d85-4584-e063-6294a90a5616", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4354dcce-6d85-4584-e063-6294a90a5616"]}], "subject": "CHEBI:71416", "supporting_text": ["Use Fast relief from urinary pain, burning, urgency and frequency associated with urinary tract infections. Treatment should not exceed 2 days; see Directions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16a48976-2c03-57a2-a7c3-a6ed801886a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e5ad9be-c411-5439-a157-9958e611c920", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See DOSAGE AND ADMINISTRATION.)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c84ba32-82cb-5c23-b4df-71fca1f432c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:585d3baf-0bf3-5d6b-bda8-fd3d448322a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5dd7ed19-321c-57bc-9c50-b7b9e69e1b28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8851589a-d652-57bb-b5df-06175274a212", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [35, 42], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4354dcce-6d85-4584-e063-6294a90a5616", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4354dcce-6d85-4584-e063-6294a90a5616", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4354dcce-6d85-4584-e063-6294a90a5616"]}], "subject": "CHEBI:71416", "supporting_text": ["Use Fast relief from urinary pain, burning, urgency and frequency associated with urinary tract infections. Treatment should not exceed 2 days; see Directions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac3643d6-129d-5493-b440-a2247e142405", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b930c0e3-dba2-5bd2-8e2f-90779dfd90a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cde0ddad-26f3-5778-8603-e843c9084437", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e362066f-ada8-54ca-a46b-51693cd336e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 9, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0014724", "object_location_in_text": [79, 86], "original_object": "burning", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000010", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cec0e802-e2dc-5a51-b493-42479c0196a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000010"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e7c96e55-d7a9-583d-89b9-7ad4a496f2c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0042023", "original_object": "urinary frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4354dcce-6d85-4584-e063-6294a90a5616", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4354dcce-6d85-4584-e063-6294a90a5616", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4354dcce-6d85-4584-e063-6294a90a5616"]}], "subject": "CHEBI:71416", "supporting_text": ["Use Fast relief from urinary pain, burning, urgency and frequency associated with urinary tract infections. Treatment should not exceed 2 days; see Directions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:341b36a8-f1b0-5fd5-8102-f1d106ee8737", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43b7721a-afcb-50b0-9805-5fc57041c29d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44abf274-e878-5330-9653-5519d945b930", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73aa583c-60e1-5859-87d1-24329e70dfae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f92ac47-e5ab-54bc-a052-5d1afc168d7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fb641dd-68f6-5e3b-a78c-e262324a6e88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa6471ff-8df1-5f5c-aef4-1e61627f607f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1a66026-c395-5171-8e77-cda089493db3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eaec141b-482f-57c4-984e-95eee4b57181", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0376249", "object_location_in_text": [96, 105], "original_object": "frequency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See DOSAGE AND ADMINISTRATION.)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:020c1a40-bb81-5d38-b05a-fe96c83bdb03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56ad921f-0b6e-aa2b-e063-6394a90aec6b"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06f39c22-b0d1-5a70-a159-1b1940d16f21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=548edf26-c81e-f982-e063-6394a90af9da"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:392118c6-3d53-553c-a480-4c40563fd6ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4972da43-5ed3-d210-e063-6394a90acb87"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40d5768d-4e8f-5e98-9d4a-9d2e878242bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1e5aa-df98-8482-e063-6294a90a878d"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:666a0ae8-1bd5-5dfc-9f81-b0939f9153f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2a6e59c-1c26-53d5-893e-9ca07c2dd35f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce702be2-eec2-4346-965e-f1f6ba342fc9"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3c778ac-f7e8-53d4-8599-274180961291", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96308f8c-66e7-486a-a5c0-ee9a133ad051"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8a6949a-9b1d-5c5b-9f2d-bbfa532896f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10cd6fad-1923-ad00-e063-6394a90a9554"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See DOSAGE AND ADMINISTRATION.)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "irritation of the mucosa of the lower urinary tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd2be120-42e2-55cf-ace2-f970dac3cd77", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19870910", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:441aedd5-d013-5a81-98e3-216a4923521a", "object": "UMLS:C0439609", "object_location_in_text": [88, 95], "original_object": "urgency", "original_subject": "PHENAZOPYRIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49baf6e5-133a-4e1a-9740-506673d27caf"]}], "subject": "CHEBI:71416", "supporting_text": ["Phenazopyridine Hydrochloride is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine Hydrochloride for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy. Phenazopyridine Hydrochloride is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine Hydrochloride should not exceed 2 days. There is no evidence that the combined administration of Phenazopyridine Hydrochloride and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See Dosage and Administration .)"], "temporal_context_qualifier": "caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0153792", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70817b55-8895-58e5-889c-1a9035f66d8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["other anticancer drugs"], "medic_disease_context_ids": ["UMLS:C0153792", "UMLS:C0677954"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7b50ef0-e67d-5f22-963d-632d29d77daf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:43232cc8-d0a0-526e-bfb6-7896690e06ce", "object": "MONDO:0009348", "object_location_in_text": [140, 156], "original_object": "Hodgkin Lymphoma", "original_subject": "PROCARBAZINE", "population_context_qualifier": "patients with Stage III or Stage IV disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1aa75a3a-18c9-49e1-91a6-293d0b7da756", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1aa75a3a-18c9-49e1-91a6-293d0b7da756", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1aa75a3a-18c9-49e1-91a6-293d0b7da756"]}], "subject": "CHEBI:71417", "supporting_text": ["1 INDICATIONS AND USAGE MATULANE is indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. MATULANE is an alkylating drug indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "corticosteroid-responsive dermatoses", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4c9b42e-8a57-5793-83b5-2cb8428fb6f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bfa97d5b-582e-5cb1-9d88-21d0cc65c3b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "object": "HP:0000989", "original_object": "pruritus", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93041e9c-3320-4617-b1c1-68c95bf6b770", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93041e9c-3320-4617-b1c1-68c95bf6b770", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93041e9c-3320-4617-b1c1-68c95bf6b770"]}], "subject": "CHEBI:71418", "supporting_text": ["Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f595b50-4fd1-5c78-b93c-681e4292499d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b6eed06-ff96-4ceb-bb0c-a67a149987a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b6eed06-ff96-4ceb-bb0c-a67a149987a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b6eed06-ff96-4ceb-bb0c-a67a149987a4"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f2199c2-062d-573f-9898-3b537d94fbd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d11aee3-b66e-439b-9188-7d91219a59cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d11aee3-b66e-439b-9188-7d91219a59cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d11aee3-b66e-439b-9188-7d91219a59cf"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e0f28ea-06fb-5454-9520-99fe2b0c58b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e55f3f0f-bd52-47e4-b77d-73ede1b41466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e55f3f0f-bd52-47e4-b77d-73ede1b41466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e55f3f0f-bd52-47e4-b77d-73ede1b41466"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48a216df-0762-5adc-a2e0-fdefb90926ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cfae0704-e754-419b-bbdc-69e7867a8a5a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cfae0704-e754-419b-bbdc-69e7867a8a5a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfae0704-e754-419b-bbdc-69e7867a8a5a"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:723170cd-65e7-592a-8d32-5b5fd667a969", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1659, 1673], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e48eec7-7cd5-4174-8b3f-07c96f4ef115", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e48eec7-7cd5-4174-8b3f-07c96f4ef115", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e48eec7-7cd5-4174-8b3f-07c96f4ef115"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension, USP is indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87a8aaec-8b80-5079-8e0e-9db1eaeb3b8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8983976-39ff-59f0-aa79-d0e57545f2e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd81ea61-7e0f-5349-ba20-5dbe399b51c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dbee70b-bd11-4430-b626-97fbb8f01b49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dbee70b-bd11-4430-b626-97fbb8f01b49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dbee70b-bd11-4430-b626-97fbb8f01b49"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "primary or metastatic brain tumor or craniotomy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f072e0ae-1017-573a-99c7-b9b573fb84b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6b55922e-19e1-5b77-b2cf-d1f67bc0378c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "HP:0002181", "object_location_in_text": [1652, 1666], "original_object": "cerebral edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af498d0a-c2a4-da25-3636-a1b45628e9e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af498d0a-c2a4-da25-3636-a1b45628e9e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af498d0a-c2a4-da25-3636-a1b45628e9e7"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-infectious uveitis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b13c0f7-779b-583b-b363-04af20bddefa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170302", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:26c4951a-3944-5d92-ac45-19c9d0513de4", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "object": "MONDO:0003005", "object_location_in_text": [80, 93], "original_object": "macular edema", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TRIAMCINOLONE ACETONIDE#99-20170302", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:71418", "supporting_text": ["A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f64b49d-e886-51ef-9b27-8ccf6e56cc82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d11aee3-b66e-439b-9188-7d91219a59cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d11aee3-b66e-439b-9188-7d91219a59cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d11aee3-b66e-439b-9188-7d91219a59cf"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c8c93f6-bec1-5ba8-964f-7259e4320fa1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dbee70b-bd11-4430-b626-97fbb8f01b49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dbee70b-bd11-4430-b626-97fbb8f01b49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dbee70b-bd11-4430-b626-97fbb8f01b49"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d61620e-641f-5d02-990b-9fcb0006de9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1398, 1420], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e48eec7-7cd5-4174-8b3f-07c96f4ef115", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e48eec7-7cd5-4174-8b3f-07c96f4ef115", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e48eec7-7cd5-4174-8b3f-07c96f4ef115"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension, USP is indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:932759c3-560e-5b76-ac6a-2767d949ebd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b6eed06-ff96-4ceb-bb0c-a67a149987a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b6eed06-ff96-4ceb-bb0c-a67a149987a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b6eed06-ff96-4ceb-bb0c-a67a149987a4"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fac2868-a0f5-5390-b126-150974abef8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af498d0a-c2a4-da25-3636-a1b45628e9e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af498d0a-c2a4-da25-3636-a1b45628e9e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af498d0a-c2a4-da25-3636-a1b45628e9e7"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1020ae9-0da1-5e68-a816-ef3ccf1efbd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e55f3f0f-bd52-47e4-b77d-73ede1b41466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e55f3f0f-bd52-47e4-b77d-73ede1b41466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e55f3f0f-bd52-47e4-b77d-73ede1b41466"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb1ff15c-76cf-54db-bc6b-80e9e247ca88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cfae0704-e754-419b-bbdc-69e7867a8a5a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cfae0704-e754-419b-bbdc-69e7867a8a5a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfae0704-e754-419b-bbdc-69e7867a8a5a"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e943c4ed-4c63-5d5b-a982-4837ee15caa9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "subarachnoid block or impending block", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd0a2470-6bd5-5ad5-8b6b-b2de40c56d0a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["appropriate antituberculous chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d75b611-d0c1-5814-a348-d40d0a1f9f28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0006042", "object_location_in_text": [1391, 1413], "original_object": "tuberculous meningitis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05bc2cc6-85b5-5359-933f-b329578e8f5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f3aaf3a-cc66-4d4f-b9b7-2c50c325d477"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:135154a1-098b-5195-86d0-a6a9b1fc5c41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dbee70b-bd11-4430-b626-97fbb8f01b49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dbee70b-bd11-4430-b626-97fbb8f01b49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dbee70b-bd11-4430-b626-97fbb8f01b49"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b8d552b-2705-5ce7-83fa-0dcc0f255a94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cfae0704-e754-419b-bbdc-69e7867a8a5a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cfae0704-e754-419b-bbdc-69e7867a8a5a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfae0704-e754-419b-bbdc-69e7867a8a5a"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4eeb8ad2-943a-5f3a-8d00-adfc8c74c374", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b6eed06-ff96-4ceb-bb0c-a67a149987a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b6eed06-ff96-4ceb-bb0c-a67a149987a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b6eed06-ff96-4ceb-bb0c-a67a149987a4"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64c53ad0-b4fe-510d-9da2-9b5b51f95939", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af498d0a-c2a4-da25-3636-a1b45628e9e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af498d0a-c2a4-da25-3636-a1b45628e9e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af498d0a-c2a4-da25-3636-a1b45628e9e7"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c908583-4479-5e27-adb3-662d617bd302", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8d11aee3-b66e-439b-9188-7d91219a59cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8d11aee3-b66e-439b-9188-7d91219a59cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d11aee3-b66e-439b-9188-7d91219a59cf"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:893633fc-73c9-5a92-9cf5-fe4e6cc495a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e55f3f0f-bd52-47e4-b77d-73ede1b41466", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e55f3f0f-bd52-47e4-b77d-73ede1b41466", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e55f3f0f-bd52-47e4-b77d-73ede1b41466"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8abd838b-5e4a-5119-b22a-9b7b3900e547", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf0b4d32-c8b7-48c9-a29b-3e7c2afc6cbf"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurologic or myocardial involvement", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d17b1e47-4f36-56ae-b259-34f8d060c3e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5484f23f-07f3-529b-a6b5-60db0b386070", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:18cb07f4-c9b9-5bc8-b3d7-7bf4ec0f93a0", "medic_supporting_text_truncated": true, "object": "MONDO:0019444", "original_object": "trichinosis", "original_subject": "TRIAMCINOLONE ACETONIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e48eec7-7cd5-4174-8b3f-07c96f4ef115", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e48eec7-7cd5-4174-8b3f-07c96f4ef115", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e48eec7-7cd5-4174-8b3f-07c96f4ef115"]}], "subject": "CHEBI:71418", "supporting_text": ["Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension, USP is indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "collagen vascular disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:498346aa-a4d2-5eb3-aded-dc1e499a4557", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021112", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6ed0b935-c4f7-55f6-b02d-1c97780cfa6b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bd32ff1e-d959-55da-8b6a-3c0e28aee839", "object": "MONDO:0015924", "original_object": "pulmonary arterial hypertension", "original_subject": "tadalafil", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:talmanco", "https://www.ema.europa.eu/en/documents/product-information/talmanco-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/talmanco"]}], "subject": "CHEBI:71940", "supporting_text": ["Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "WHO functional class II, WHO functional class III", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9957e01-72b5-5465-90a6-e80dddafff51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021112", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6ed0b935-c4f7-55f6-b02d-1c97780cfa6b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bd32ff1e-d959-55da-8b6a-3c0e28aee839", "object": "MONDO:0015924", "original_object": "pulmonary arterial hypertension", "original_subject": "tadalafil", "population_context_qualifier": "paediatric patients aged 2 years and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:adcirca", "https://www.ema.europa.eu/en/documents/product-information/adcirca-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/adcirca"]}], "subject": "CHEBI:71940", "supporting_text": ["AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease. Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance to integrase inhibitor class, emtricitabine resistance, tenofovir resistance", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5095c984-53f3-5dd2-8d87-72f2f8034dc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151119", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f1475649-ce35-5d0b-a657-2c38aa869dc9", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a814f970-4ac3-5a0d-a2bb-e1b8c3daa41b", "object": "UMLS:C0276500", "original_object": "human immunodeficiency virus 1 infection", "original_subject": "elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide", "population_context_qualifier": "adults and adolescents aged 12 years and older with body weight at least 35 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:genvoya", "https://www.ema.europa.eu/en/documents/product-information/genvoya-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya"]}], "subject": "CHEBI:72289", "supporting_text": ["Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "rifampicin and isoniazid resistance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:908bdbb3-f82d-5538-ba03-8d35970cc731", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140305", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1d009e26-e6d9-5bee-ba83-04470bf4d7c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:7696f51e-d3de-5be1-b2cf-1d88431af7b8", "object": "MONDO:0006052", "original_object": "pulmonary tuberculosis", "original_subject": "bedaquiline", "population_context_qualifier": "adult and paediatric patients (2 years to less than 18 years of age and weighing at least 7 kg)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:sirturo", "https://www.ema.europa.eu/en/documents/product-information/sirturo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo"]}], "subject": "CHEBI:72292", "supporting_text": ["&nbsp;Sirturo is indicated for use as part of an appropriate combination regimen in adult and paediatric patients (2 years to less than 18 years of age and weighing at least 7 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid. Consideration should be given to official guidance on the appropriate use of antibacterial agents. &nbsp;"], "temporal_context_qualifier": "(none)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Mycobacterium tuberculosis resistant to at least rifampin and isoniazid", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed252079-e279-5098-a215-a831a8002946", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["combination therapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d009e26-e6d9-5bee-ba83-04470bf4d7c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7696f51e-d3de-5be1-b2cf-1d88431af7b8", "object": "MONDO:0006052", "object_location_in_text": [218, 240], "original_object": "pulmonary tuberculosis", "original_subject": "BEDAQUILINE", "population_context_qualifier": "adult and pediatric patients (2 years and older and weighing at least 8 kg)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1534c9ae-4948-4cf4-9f66-222a99db6d0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1534c9ae-4948-4cf4-9f66-222a99db6d0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1534c9ae-4948-4cf4-9f66-222a99db6d0e"]}], "subject": "CHEBI:72292", "supporting_text": ["1 INDICATIONS AND USAGE SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "multi-drug resistant Mycobacterium tuberculosis", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f925542a-ac6c-5785-b4a1-551b86338a64", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:583a7dca-e7e6-565f-ad3a-47f7fe127ab8", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8bbc75a3-a845-5ef5-87d0-b397da48e0db", "object": "MONDO:0018076", "object_location_in_text": [0, 12], "original_object": "tuberculosis", "original_subject": "Bedaquiline Tablet 100", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:72292", "supporting_text": ["tuberculosis due to multi-drug resistant Mycobacterium tuberculosis"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:212bbd72-95a8-5a17-a917-81d575f5c2cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110518", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [26, 32], "original_object": "stroke", "original_subject": "apixaban", "population_context_qualifier": "adult patients with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:apixaban-accord", "https://www.ema.europa.eu/en/documents/product-information/apixaban-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/apixaban-accord"]}], "subject": "CHEBI:72296", "supporting_text": ["Adults&nbsp;Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). &nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). &nbsp; Paediatric population &nbsp;Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. Adults &nbsp;Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. &nbsp; Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). &nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). &nbsp; Paediatric population&nbsp;Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non valvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be8beec5-66c2-53a5-a973-d8442e2663bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110518", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [288, 294], "original_object": "stroke", "original_subject": "apixaban", "population_context_qualifier": "adult patients with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eliquis", "https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis"]}], "subject": "CHEBI:72296", "supporting_text": ["Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric population Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age.&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0063d70c-41c4-5927-b384-cd6b7bc6ecb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [100, 106], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:19a60552-374d-4b8b-a8ce-ceae252ea5ba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=19a60552-374d-4b8b-a8ce-ceae252ea5ba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19a60552-374d-4b8b-a8ce-ceae252ea5ba"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE Apixaban tablets are a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis Apixaban tablets are indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism Apixaban tablets are indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE Apixaban tablets are indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:084fe326-161d-5399-bc44-e4a877d83305", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [92, 98], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f47aa0e-0235-4220-85dd-dfcb8ad0d009", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f47aa0e-0235-4220-85dd-dfcb8ad0d009", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f47aa0e-0235-4220-85dd-dfcb8ad0d009"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:177d52fa-a500-53be-9074-61dcf2484324", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [169, 175], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8917e527-990a-17c0-e053-2a95a90a4631", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8917e527-990a-17c0-e053-2a95a90a4631", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8917e527-990a-17c0-e053-2a95a90a4631"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS ® (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b506be1-5b86-5c1d-a448-ee1ef7306791", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [92, 98], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd383ae7-1e34-44ef-b8f1-ca6906dfbcef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd383ae7-1e34-44ef-b8f1-ca6906dfbcef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd383ae7-1e34-44ef-b8f1-ca6906dfbcef"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:421268bd-fe65-5ef2-b4e3-8aa486b10363", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [92, 98], "original_object": "stroke", "original_subject": "APIXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9481622-7cc6-418a-acb6-c5450daae9b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ccbfde0-5ff6-50ec-ac51-a3471a5f091b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [90, 96], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1523ab32-2c2c-6501-e063-6394a90aa0b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1523ab32-2c2c-6501-e063-6394a90aa0b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1523ab32-2c2c-6501-e063-6394a90aa0b3"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73037a08-012f-5dd0-b900-1507ae5a2e5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [92, 98], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33a9046a-41cc-46c1-becc-2ff4d7d71538", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33a9046a-41cc-46c1-becc-2ff4d7d71538", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33a9046a-41cc-46c1-becc-2ff4d7d71538"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:738acb3e-92f5-511f-87d7-1459ef90dd51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [90, 96], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41a133ef-e461-48ad-8221-b735bdd0ec25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41a133ef-e461-48ad-8221-b735bdd0ec25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41a133ef-e461-48ad-8221-b735bdd0ec25"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bf0b10d-2c4e-5437-982a-05e3f3143dda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [93, 99], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:095a08ac-cf0e-497e-a682-ddef38d6b29c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=095a08ac-cf0e-497e-a682-ddef38d6b29c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095a08ac-cf0e-497e-a682-ddef38d6b29c"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS &amp; USAGE Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis Apixaban tablets are indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism Apixaban tablets are indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE Apixaban tablets are indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c81b4dac-b4f9-585c-80e7-bab914ccb515", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [92, 98], "original_object": "stroke", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33752f5d-2ca7-45c0-8292-b54742219b97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33752f5d-2ca7-45c0-8292-b54742219b97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33752f5d-2ca7-45c0-8292-b54742219b97"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2e8fa18-6f8f-55ce-981c-ac8a1931cfa2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [92, 98], "original_object": "stroke", "original_subject": "APIXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a454cd24-0c6d-46e8-b1e4-197388606175", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff1d23c4-77a8-5354-b488-215ad9d82c28", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005098", "object_location_in_text": [90, 96], "original_object": "stroke", "original_subject": "APIXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002625", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e4bfd98-383c-58b3-8eec-647db7918235", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151221", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["HP:0002625", "HP:0034192"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:277448d8-f6d7-591b-b763-c1248c4d5c18", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:0005399", "object_location_in_text": [110, 132], "original_object": "venous thromboembolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APIXABAN#106-20151221", "https://www.pmda.go.jp/files/000208682.pdf"]}], "subject": "CHEBI:72296", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98049b32-932a-5ec5-8d4a-dfc8d0f3812e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121225", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:022f02f4-23ac-50b9-a831-9b6e56b1d7d7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "MONDO:1060198", "object_location_in_text": [63, 78], "original_object": "ischemic stroke", "original_subject": "APIXABAN", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APIXABAN#133-20121225", "https://www.pmda.go.jp/files/000208682.pdf"]}], "subject": "CHEBI:72296", "supporting_text": ["Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6f38c39-0f76-591c-971d-964f5adfe6d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110518", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [37, 54], "original_object": "systemic embolism", "original_subject": "apixaban", "population_context_qualifier": "adult patients with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:apixaban-accord", "https://www.ema.europa.eu/en/documents/product-information/apixaban-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/apixaban-accord"]}], "subject": "CHEBI:72296", "supporting_text": ["Adults&nbsp;Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). &nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). &nbsp; Paediatric population &nbsp;Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. Adults &nbsp;Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. &nbsp; Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). &nbsp; Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). &nbsp; Paediatric population&nbsp;Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df7bdd82-fbac-5b93-a758-8359e701db6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110518", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [299, 316], "original_object": "systemic embolism", "original_subject": "apixaban", "population_context_qualifier": "adult patients with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eliquis", "https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis"]}], "subject": "CHEBI:72296", "supporting_text": ["Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric population Treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age. AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age.&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:036cd356-a663-5f9f-b6ac-3c15f336172b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [103, 120], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f47aa0e-0235-4220-85dd-dfcb8ad0d009", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f47aa0e-0235-4220-85dd-dfcb8ad0d009", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f47aa0e-0235-4220-85dd-dfcb8ad0d009"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b7779df-29a2-5791-a6f2-f951fc680ed7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [103, 120], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33752f5d-2ca7-45c0-8292-b54742219b97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33752f5d-2ca7-45c0-8292-b54742219b97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33752f5d-2ca7-45c0-8292-b54742219b97"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19d89bfb-f7c6-5df8-9996-5d6f8c138ca3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [101, 118], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41a133ef-e461-48ad-8221-b735bdd0ec25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41a133ef-e461-48ad-8221-b735bdd0ec25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41a133ef-e461-48ad-8221-b735bdd0ec25"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3375da9e-3d12-517e-9a49-33456f57e759", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [111, 128], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:19a60552-374d-4b8b-a8ce-ceae252ea5ba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=19a60552-374d-4b8b-a8ce-ceae252ea5ba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=19a60552-374d-4b8b-a8ce-ceae252ea5ba"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE Apixaban tablets are a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis Apixaban tablets are indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism Apixaban tablets are indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE Apixaban tablets are indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64963a66-24cd-520d-bf37-53236049980b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [180, 197], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8917e527-990a-17c0-e053-2a95a90a4631", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8917e527-990a-17c0-e053-2a95a90a4631", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8917e527-990a-17c0-e053-2a95a90a4631"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS ® (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85c5d957-e099-5274-ad89-d0db99d95178", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [101, 118], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1523ab32-2c2c-6501-e063-6394a90aa0b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1523ab32-2c2c-6501-e063-6394a90aa0b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1523ab32-2c2c-6501-e063-6394a90aa0b3"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90272833-66d2-5e85-bde2-9a35aadbc23d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [103, 120], "original_object": "systemic embolism", "original_subject": "APIXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a454cd24-0c6d-46e8-b1e4-197388606175", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a23fac6-152f-56e3-8db2-6e3f05ce1abc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [103, 120], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33a9046a-41cc-46c1-becc-2ff4d7d71538", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33a9046a-41cc-46c1-becc-2ff4d7d71538", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33a9046a-41cc-46c1-becc-2ff4d7d71538"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be33dc18-f9fe-5421-bf11-6b3b56507414", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [101, 118], "original_object": "systemic embolism", "original_subject": "APIXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7be1f4c1-bb2f-4ded-ae9a-515d2a22f93e"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1123797-e2c8-59f0-9570-32e25398dbf9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [103, 120], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd383ae7-1e34-44ef-b8f1-ca6906dfbcef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd383ae7-1e34-44ef-b8f1-ca6906dfbcef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd383ae7-1e34-44ef-b8f1-ca6906dfbcef"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecd50b43-b4d4-5189-a900-5d81cf71dbd5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "medic_supporting_text_truncated": true, "object": "UMLS:C5400523", "object_location_in_text": [103, 120], "original_object": "systemic embolism", "original_subject": "APIXABAN", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9481622-7cc6-418a-acb6-c5450daae9b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fecc2dd3-b537-50e6-9943-1f01c91ff83a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [104, 121], "original_object": "systemic embolism", "original_subject": "APIXABAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:095a08ac-cf0e-497e-a682-ddef38d6b29c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=095a08ac-cf0e-497e-a682-ddef38d6b29c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095a08ac-cf0e-497e-a682-ddef38d6b29c"]}], "subject": "CHEBI:72296", "supporting_text": ["1 INDICATIONS &amp; USAGE Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis Apixaban tablets are indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism Apixaban tablets are indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE Apixaban tablets are indicated to reduce the risk of recurrent DVT and PE following initial therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a32b07dd-744e-5e91-ab90-2da05243b0a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121225", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:563e39a2-0151-54df-8be3-243499964f06", "object": "UMLS:C5400523", "object_location_in_text": [83, 100], "original_object": "systemic embolism", "original_subject": "APIXABAN", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:APIXABAN#133-20121225", "https://www.pmda.go.jp/files/000208682.pdf"]}], "subject": "CHEBI:72296", "supporting_text": ["Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "parenteral support dependence", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c10b624e-5cf5-5e58-8f99-880ba3ff2e57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3cd36ca3-f417-5990-9701-7846454677b8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:588f8753-16ec-5fe2-9c22-5564a16603eb", "object": "MONDO:0015183", "original_object": "Short Bowel Syndrome", "original_subject": "TEDUGLUTIDE", "population_context_qualifier": "adults and pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66b69c1e-b25c-44d3-b5ff-1c1de9a516fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa"]}], "subject": "CHEBI:72305", "supporting_text": ["1 INDICATIONS AND USAGE GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "refractory or not eligible to radioactive iodine", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9afc8338-698b-50ac-a810-96e525edc868", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140321", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c1fff3c9-51b5-515b-9e81-1a531cc73458", "object": "MONDO:0015447", "object_location_in_text": [715, 747], "original_object": "differentiated thyroid carcinoma", "original_subject": "cabozantinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cabometyx", "https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx"]}], "subject": "CHEBI:72317", "supporting_text": ["Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell carcinoma  as first-line treatment of adult patients with intermediate or poor risk, in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.  Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Hepatocellular carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.Differentiated thyroid carcinoma (DTC)Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.Neuroendocrine Tumours (NET)Cabometyx is indicated for the treatment of adult&nbsp;patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues."], "temporal_context_qualifier": "progressed during or after prior systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0030274", "has_confidence_score": 0.97, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:801ccee5-bcf3-5b5b-9f7c-3c88ac65b2ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140321", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0030274"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:48e4dc9a-e268-5ea9-8c92-a447f8e8d858", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c1fff3c9-51b5-515b-9e81-1a531cc73458", "object": "MONDO:0019496", "object_location_in_text": [1061, 1083], "original_object": "neuroendocrine tumours", "original_subject": "cabozantinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cabometyx", "https://www.ema.europa.eu/en/documents/product-information/cabometyx-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx"]}], "subject": "CHEBI:72317", "supporting_text": ["Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell carcinoma  as first-line treatment of adult patients with intermediate or poor risk, in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.  Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Hepatocellular carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.Differentiated thyroid carcinoma (DTC)Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.Neuroendocrine Tumours (NET)Cabometyx is indicated for the treatment of adult&nbsp;patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues."], "temporal_context_qualifier": "progressed following at least one prior systemic therapy other than somatostatin analogues"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-hyperkeratotic actinic keratoses", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d0553e92-5909-549b-be50-f07b2e32aab5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040727", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3d929b51-e528-5d9e-8d2d-ba7b87187b56", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a41a3bfd-f21f-5ada-a721-55d9918c165a", "object": "MONDO:0005173", "object_location_in_text": [186, 203], "original_object": "actinic keratoses", "original_subject": "METHYL AMINOLEVULINATE", "population_context_qualifier": "immunocompetent patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d02af310-d097-4886-86e5-adcf6bca0533", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d02af310-d097-4886-86e5-adcf6bca0533", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d02af310-d097-4886-86e5-adcf6bca0533"]}], "subject": "CHEBI:724125", "supporting_text": ["Metvixia Cream in combination with 570 to 670 nm wavelength red light illumination using the CureLight BroadBand Model CureLight 01 lamp is indicated for treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette) in the physician’s office when other therapies are unacceptable or considered medically less appropriate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:351696a8-99f7-521f-8805-26fa512fce68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:021b97cc-a76f-44b6-b7be-670d2ae83690", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=021b97cc-a76f-44b6-b7be-670d2ae83690", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=021b97cc-a76f-44b6-b7be-670d2ae83690"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52b023f7-25fa-5ecd-8df1-a79ed09096ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a147b361-262c-49c6-9b8e-7e454f755721", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a147b361-262c-49c6-9b8e-7e454f755721", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a147b361-262c-49c6-9b8e-7e454f755721"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55cc14dc-f6be-5b5e-bed4-1f8e100b8a81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79766855-2533-43b1-b60e-1e9daecadad5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79766855-2533-43b1-b60e-1e9daecadad5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79766855-2533-43b1-b60e-1e9daecadad5"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58baa25d-4a18-571c-86f3-df7e5087e8cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:38f17780-8037-44a0-9e84-b7150c9bde12", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=38f17780-8037-44a0-9e84-b7150c9bde12", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38f17780-8037-44a0-9e84-b7150c9bde12"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e22debe-6242-52f3-917d-21067584fd25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6eb0bd33-582f-43a6-a607-e72b4390c6d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6eb0bd33-582f-43a6-a607-e72b4390c6d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6eb0bd33-582f-43a6-a607-e72b4390c6d3"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a9cdfa3-d10b-5338-91d7-5bc0127a81b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0f2077c-48e6-452e-9f88-e1f2c89df0a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0f2077c-48e6-452e-9f88-e1f2c89df0a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0f2077c-48e6-452e-9f88-e1f2c89df0a2"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7dd10f7-094d-598d-82f9-10611b0acf59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b263fe0-5f06-4889-bf14-4aa185470810", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b263fe0-5f06-4889-bf14-4aa185470810", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b263fe0-5f06-4889-bf14-4aa185470810"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5239366", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc25444b-cea5-5ade-b80c-35001ac10296", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990811", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5239366"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bc6fa7ff-e899-527e-a533-dfd87d01aeee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:39c8f2e8-b0ad-5e02-993a-1529a331ec2a", "object": "MONDO:0016684", "object_location_in_text": [307, 329], "original_object": "anaplastic astrocytoma", "original_subject": "TEMOZOLOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56245d21-4a42-471e-bbdc-80b129336e2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56245d21-4a42-471e-bbdc-80b129336e2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56245d21-4a42-471e-bbdc-80b129336e2f"]}], "subject": "CHEBI:72564", "supporting_text": ["1. INDICATIONS AND USAGE TEMOZOLOMIDE Capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. ( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 ) 1.1 Newly Diagnosed Glioblastoma TEMOZOLOMIDE Capsules is indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.2 Anaplastic Astrocytoma TEMOZOLOMIDE Capsules is indicated for the: adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0141230f-ea7f-58e1-8e8d-bd20c0258e5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130208", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["dexamethasone"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1383048-7b51-54ef-be3f-d2b5dea9a01b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1635a3d-1e55-57b7-b6d5-f2acbfe706ce", "object": "HP:0006775", "object_location_in_text": [175, 191], "original_object": "multiple myeloma", "original_subject": "POMALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8c3b7f3-7e72-47af-be23-133e7bb3db59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8c3b7f3-7e72-47af-be23-133e7bb3db59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8c3b7f3-7e72-47af-be23-133e7bb3db59"]}], "subject": "CHEBI:72690", "supporting_text": ["1 INDICATIONS AND USAGE Pomalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). 1.1 Multiple Myeloma Pomalidomide capsules, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy."], "temporal_context_qualifier": "disease progression on or within 60 days of completion of the last therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c483f39-c4dd-5164-9338-41659f89acf6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130208", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["dexamethasone"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1383048-7b51-54ef-be3f-d2b5dea9a01b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e1635a3d-1e55-57b7-b6d5-f2acbfe706ce", "object": "HP:0006775", "object_location_in_text": [175, 191], "original_object": "multiple myeloma", "original_subject": "POMALIDOMIDE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fcd4978-b2d1-4d1a-b239-717cddb8be1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fcd4978-b2d1-4d1a-b239-717cddb8be1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fcd4978-b2d1-4d1a-b239-717cddb8be1f"]}], "subject": "CHEBI:72690", "supporting_text": ["1 INDICATIONS AND USAGE Pomalidomide capsules are a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). 1.1 Multiple Myeloma Pomalidomide capsules, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy."], "temporal_context_qualifier": "disease progression on or within 60 days of completion of the last therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25d272ca-46c2-5341-8bd5-a304dc21fb7a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130226", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4468bcb9-0b2c-5f45-b010-bfbd72173d88", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9eacdb30-e965-59d5-8563-ce3bcb103130", "object": "HP:0030016", "original_object": "dyspareunia", "original_subject": "OSPEMIFENE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9accbcc9-78ee-4f84-9b7e-704f2ab1c413", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413"]}], "subject": "CHEBI:73275", "supporting_text": ["1 INDICATIONS AND USAGE OSPHENA is indicated for: OSPHENA is an estrogen agonist/antagonist indicated for: The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1.1 ) The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1.2 ) 1.1 The Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause. 1.2 The Treatment of Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27f4ccf5-2849-53cf-830e-3b713e74f951", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130226", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b5a2ff2-c38e-5f33-8b00-7402af2f2c3c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9eacdb30-e965-59d5-8563-ce3bcb103130", "object": "HP:0031088", "original_object": "vaginal dryness", "original_subject": "OSPEMIFENE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9accbcc9-78ee-4f84-9b7e-704f2ab1c413", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9accbcc9-78ee-4f84-9b7e-704f2ab1c413"]}], "subject": "CHEBI:73275", "supporting_text": ["1 INDICATIONS AND USAGE OSPHENA is indicated for: OSPHENA is an estrogen agonist/antagonist indicated for: The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1.1 ) The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1.2 ) 1.1 The Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause. 1.2 The Treatment of Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a5627f7-6ab8-5cf7-9156-10448255249a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [316, 338], "original_object": "myocardial infarctions", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e8e129d-cb17-45fc-b3e2-2600c0166463", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e8e129d-cb17-45fc-b3e2-2600c0166463", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e8e129d-cb17-45fc-b3e2-2600c0166463"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative ris"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f2e5fd7-e0d6-5c31-ad1b-b13d180b2cb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6ab029aa-dfe0-4abb-8c7f-2692fe6a2368", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6ab029aa-dfe0-4abb-8c7f-2692fe6a2368", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ab029aa-dfe0-4abb-8c7f-2692fe6a2368"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:153d19ed-76c9-5fde-988d-bae1f0698120", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c154d99c-e4fb-41d0-8fac-e1982672e8d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c154d99c-e4fb-41d0-8fac-e1982672e8d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c154d99c-e4fb-41d0-8fac-e1982672e8d7"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42bb76f1-59f1-5825-a492-47aa4d22ff52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9acc0c81-4145-43cc-b31a-7b1e3313259d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9acc0c81-4145-43cc-b31a-7b1e3313259d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9acc0c81-4145-43cc-b31a-7b1e3313259d"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4db2bece-301a-5043-ad6f-24e1603d6889", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33dcfdb9-1741-71e1-e063-6294a90afdff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33dcfdb9-1741-71e1-e063-6294a90afdff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33dcfdb9-1741-71e1-e063-6294a90afdff"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4dfb7b95-e537-5b01-a703-1261a0d86db9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26b94a64-ec95-817a-e063-6394a90ac5f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26b94a64-ec95-817a-e063-6394a90ac5f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26b94a64-ec95-817a-e063-6394a90ac5f1"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:528efc99-c4c8-55a1-adee-4e3fbb987493", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a788d0-b7f0-4f39-8adb-ab68870ecfa5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a788d0-b7f0-4f39-8adb-ab68870ecfa5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a788d0-b7f0-4f39-8adb-ab68870ecfa5"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64bd86bc-ce25-5f2e-bf9c-1a12b561c154", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a8014fb-9b65-4457-bfd5-0ab7e6de330e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a8014fb-9b65-4457-bfd5-0ab7e6de330e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a8014fb-9b65-4457-bfd5-0ab7e6de330e"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ced07a6-f1de-5236-9324-62452828afa5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85cb81c8-9019-51d5-b510-a1f182633016", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15822faf-6924-4a63-a4e1-6058b308708c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15822faf-6924-4a63-a4e1-6058b308708c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15822faf-6924-4a63-a4e1-6058b308708c"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88a6a891-3217-514b-a0ce-cecc2d371990", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d66548a-231e-4104-be0c-c6ce1586b46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d66548a-231e-4104-be0c-c6ce1586b46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d66548a-231e-4104-be0c-c6ce1586b46c"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9048b74e-96d0-5a13-9050-b19a31bbacb7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a224f90-24a5-411e-ac26-6496a1930f3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a224f90-24a5-411e-ac26-6496a1930f3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a224f90-24a5-411e-ac26-6496a1930f3a"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94d7e3a5-a710-57b1-aa47-20ec1b7501e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44c5352d-89f8-4bd3-9479-1069304562ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44c5352d-89f8-4bd3-9479-1069304562ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44c5352d-89f8-4bd3-9479-1069304562ca"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96a17384-b417-5c69-8d73-6850eccd04ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4580b85b-437c-4c52-bf31-5976968ecd5c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4580b85b-437c-4c52-bf31-5976968ecd5c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4580b85b-437c-4c52-bf31-5976968ecd5c"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b74e73bb-0786-57de-8f1e-e0d009fee7ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c899eedb-4113-45da-acc3-8e181250a7d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c899eedb-4113-45da-acc3-8e181250a7d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c899eedb-4113-45da-acc3-8e181250a7d8"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c319fd6b-3a2f-5b9e-82f8-1bfe58a3b2fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2e24b14-0169-4028-828a-894ad3c2ba55", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2e24b14-0169-4028-828a-894ad3c2ba55", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2e24b14-0169-4028-828a-894ad3c2ba55"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d08c6953-e237-59c6-9b75-5e7e0fb0e09f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [316, 338], "original_object": "myocardial infarctions", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fc1f850-9653-4082-929a-926b644810e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fc1f850-9653-4082-929a-926b644810e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fc1f850-9653-4082-929a-926b644810e7"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative ris"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d32c4b23-53e1-5f68-a2eb-a4154705528c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5ed8220-fb49-50d3-b3c7-6710e6236afb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f"]}], "subject": "CHEBI:7444", "supporting_text": ["INDICATIONS Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is sim"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e62e2021-25f5-5c83-8a3b-e1828857de38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d126308-c58d-4950-9dcb-eaadb1a2054f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d126308-c58d-4950-9dcb-eaadb1a2054f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d126308-c58d-4950-9dcb-eaadb1a2054f"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0273af64-1fc3-5f48-a506-302ae58e8326", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d126308-c58d-4950-9dcb-eaadb1a2054f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d126308-c58d-4950-9dcb-eaadb1a2054f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d126308-c58d-4950-9dcb-eaadb1a2054f"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:130d2ff1-1057-5c31-8467-7d4a7517a798", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c154d99c-e4fb-41d0-8fac-e1982672e8d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c154d99c-e4fb-41d0-8fac-e1982672e8d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c154d99c-e4fb-41d0-8fac-e1982672e8d7"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:188eb5d4-e756-5118-bcad-95a0eb7446d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29db1aac-6866-5bbf-809e-ed9395ccf2fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a8014fb-9b65-4457-bfd5-0ab7e6de330e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a8014fb-9b65-4457-bfd5-0ab7e6de330e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a8014fb-9b65-4457-bfd5-0ab7e6de330e"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d5ee502-cde9-5ced-9b61-2b5b441a83b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0d66548a-231e-4104-be0c-c6ce1586b46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0d66548a-231e-4104-be0c-c6ce1586b46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d66548a-231e-4104-be0c-c6ce1586b46c"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38415416-0578-5e10-9c43-f76be31c9c97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:15822faf-6924-4a63-a4e1-6058b308708c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=15822faf-6924-4a63-a4e1-6058b308708c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15822faf-6924-4a63-a4e1-6058b308708c"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c308e6b-e002-52f2-9fe5-78a686fee46c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4580b85b-437c-4c52-bf31-5976968ecd5c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4580b85b-437c-4c52-bf31-5976968ecd5c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4580b85b-437c-4c52-bf31-5976968ecd5c"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:654e1e19-a09e-516a-bfdb-1f10c813b210", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c899eedb-4113-45da-acc3-8e181250a7d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c899eedb-4113-45da-acc3-8e181250a7d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c899eedb-4113-45da-acc3-8e181250a7d8"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:940ac99a-acda-576f-8407-c0794db5aedf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d226ea-1624-47ee-82bf-e9660b75029f"]}], "subject": "CHEBI:7444", "supporting_text": ["INDICATIONS Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is sim"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9881b2bb-1ba0-5a30-a5a2-adb740d98642", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [304, 311], "original_object": "strokes", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e8e129d-cb17-45fc-b3e2-2600c0166463", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e8e129d-cb17-45fc-b3e2-2600c0166463", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e8e129d-cb17-45fc-b3e2-2600c0166463"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative ris"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e8ea104-57c3-5156-81aa-f7b6cfccb019", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e2e24b14-0169-4028-828a-894ad3c2ba55", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e2e24b14-0169-4028-828a-894ad3c2ba55", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2e24b14-0169-4028-828a-894ad3c2ba55"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a42f23e9-f766-502c-bff9-977001ea2401", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9acc0c81-4145-43cc-b31a-7b1e3313259d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9acc0c81-4145-43cc-b31a-7b1e3313259d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9acc0c81-4145-43cc-b31a-7b1e3313259d"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3f7b8b1-372b-5d1f-9517-d66eb81664a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:33dcfdb9-1741-71e1-e063-6294a90afdff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=33dcfdb9-1741-71e1-e063-6294a90afdff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33dcfdb9-1741-71e1-e063-6294a90afdff"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP is indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdd56f6c-0643-5673-a260-90dcf20323ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64a788d0-b7f0-4f39-8adb-ab68870ecfa5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64a788d0-b7f0-4f39-8adb-ab68870ecfa5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a788d0-b7f0-4f39-8adb-ab68870ecfa5"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7a0764b-933e-565f-9f95-ecb3a7a8b307", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6ab029aa-dfe0-4abb-8c7f-2692fe6a2368", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6ab029aa-dfe0-4abb-8c7f-2692fe6a2368", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ab029aa-dfe0-4abb-8c7f-2692fe6a2368"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8697b5c-2f51-519e-8f9b-d2fd8bdcf918", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26b94a64-ec95-817a-e063-6394a90ac5f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26b94a64-ec95-817a-e063-6394a90ac5f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26b94a64-ec95-817a-e063-6394a90ac5f1"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f23a4d43-3685-550e-83ea-d84c7130b803", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [304, 311], "original_object": "strokes", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fc1f850-9653-4082-929a-926b644810e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fc1f850-9653-4082-929a-926b644810e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fc1f850-9653-4082-929a-926b644810e7"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative ris"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3e772c2-bee2-55b9-b442-0184d5627ad2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44c5352d-89f8-4bd3-9479-1069304562ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44c5352d-89f8-4bd3-9479-1069304562ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44c5352d-89f8-4bd3-9479-1069304562ca"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7ca9a45-b223-5328-bf7a-17967df1fa59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c6737f8-8fd8-4d8f-a66a-e99d3b64e1dd"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets, USP is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fca58c90-322b-51aa-9e14-bfc78149fe45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 20, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2308f30c-4ed0-58be-817e-dd6878409437", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "NADOLOL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8a224f90-24a5-411e-ac26-6496a1930f3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8a224f90-24a5-411e-ac26-6496a1930f3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a224f90-24a5-411e-ac26-6496a1930f3a"]}], "subject": "CHEBI:7444", "supporting_text": ["Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "infections proven or strongly suspected to be caused by susceptible bacteria", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1dcb01a6-07a0-5562-90a3-ab3b51ffd115", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96160c5a-94fe-5e66-ad67-e649ebd80af5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:092e0a8a-efd8-5125-934b-73c777aa25c0", "object": "UMLS:C3714514", "object_location_in_text": [43, 53], "original_object": "infections", "original_subject": "NAFCILLIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d271b9a-a667-0fd2-e063-6294a90a3b4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d271b9a-a667-0fd2-e063-6294a90a3b4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d271b9a-a667-0fd2-e063-6294a90a3b4a"]}], "subject": "CHEBI:7447", "supporting_text": ["Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY-Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to a methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9137c48e-8b31-5daf-b6ad-0d2f535bbfbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2c3c8746-70f6-5282-b11d-18d7c805d0aa", "object": "MONDO:0001461", "object_location_in_text": [132, 146], "original_object": "tinea corporis", "original_subject": "NAFTIFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:567f7418-e65c-740f-6233-741f5274fe1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=567f7418-e65c-740f-6233-741f5274fe1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=567f7418-e65c-740f-6233-741f5274fe1c"]}], "subject": "CHEBI:7451", "supporting_text": ["1 INDICATIONS AND USAGE Naftifine hydrochloride cream is indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum . Naftifine hydrochloride cream is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:acdf865e-14c7-58f8-9d15-15e329fa2a38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19880229", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2c3c8746-70f6-5282-b11d-18d7c805d0aa", "object": "UMLS:C1384589", "object_location_in_text": [114, 126], "original_object": "tinea cruris", "original_subject": "NAFTIFINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:567f7418-e65c-740f-6233-741f5274fe1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=567f7418-e65c-740f-6233-741f5274fe1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=567f7418-e65c-740f-6233-741f5274fe1c"]}], "subject": "CHEBI:7451", "supporting_text": ["1 INDICATIONS AND USAGE Naftifine hydrochloride cream is indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum . Naftifine hydrochloride cream is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum . ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid drug effects", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ecd64f2-552f-596f-868e-cee96c0e444c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950417", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa53bcb7-6bc1-511b-a40f-84d58b99323f", "object": "UMLS:C0235063", "object_location_in_text": [118, 140], "original_object": "respiratory depression", "original_subject": "NALMEFENE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3abfbffc-9e52-4fc6-ae92-6e0a97f4afe7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3abfbffc-9e52-4fc6-ae92-6e0a97f4afe7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3abfbffc-9e52-4fc6-ae92-6e0a97f4afe7"]}], "subject": "CHEBI:7457", "supporting_text": ["Nalmefene hydrochloride injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. Nalmefene hydrochloride injection is indicated in the management of known or suspected opioid overdose."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid drug effects", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f6ea205-02a9-518e-8364-9ecba54ac727", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950417", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa53bcb7-6bc1-511b-a40f-84d58b99323f", "object": "UMLS:C0235063", "object_location_in_text": [118, 140], "original_object": "respiratory depression", "original_subject": "NALMEFENE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22d67228-6c24-47ca-afc7-52ef279520a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22d67228-6c24-47ca-afc7-52ef279520a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22d67228-6c24-47ca-afc7-52ef279520a0"]}], "subject": "CHEBI:7457", "supporting_text": ["Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235063", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fe0ffc4-d641-5248-ab13-0af6c4b94a41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950417", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235063", "UMLS:C0151559"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:971d0d60-d7c5-527f-a729-620da29ddab0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa53bcb7-6bc1-511b-a40f-84d58b99323f", "object": "UMLS:C0579142", "object_location_in_text": [94, 109], "original_object": "opioid overdose", "original_subject": "NALMEFENE", "population_context_qualifier": "adults and pediatric patients aged 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a59a5847-9fe4-4341-a203-be0a5e6d3e36", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a59a5847-9fe4-4341-a203-be0a5e6d3e36", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a59a5847-9fe4-4341-a203-be0a5e6d3e36"]}], "subject": "CHEBI:7457", "supporting_text": ["1 INDICATIONS AND USAGE ZURNAI is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZURNAI is not a substitute for emergency medical care. ZURNAI is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. ( 1 ) ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) ZURNAI is not a substitute for emergency medical care. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235063", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fac300f-92d2-50c5-ae70-3da88f23ff82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19950417", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235063", "UMLS:C0151559"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:971d0d60-d7c5-527f-a729-620da29ddab0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fa53bcb7-6bc1-511b-a40f-84d58b99323f", "object": "UMLS:C0579142", "original_object": "opioid overdose", "original_subject": "NALMEFENE", "population_context_qualifier": "adults and pediatric patients aged 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:999a4269-9e54-4801-b2ac-2a7276f0b94f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=999a4269-9e54-4801-b2ac-2a7276f0b94f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=999a4269-9e54-4801-b2ac-2a7276f0b94f"]}], "subject": "CHEBI:7457", "supporting_text": ["1 INDICATIONS AND USAGE OPVEE nasal spray is indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. OPVEE nasal spray is not a substitute for emergency medical care. OPVEE nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. OPVEE nasal spray is not a substitute for emergency medical care."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b7c0067-1d99-5d61-8876-e70dfd6c706b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d04ae2d7-01b9-405d-bb7a-bf2d876ce26a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d04ae2d7-01b9-405d-bb7a-bf2d876ce26a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d04ae2d7-01b9-405d-bb7a-bf2d876ce26a"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52077f81-c3de-5ca2-92e4-18d8aaec721d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8535cc84-ad4a-4d67-8480-fb5a2e3406f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8535cc84-ad4a-4d67-8480-fb5a2e3406f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8535cc84-ad4a-4d67-8480-fb5a2e3406f8"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY, Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52441321-b269-57a8-b3d3-8de41c6432fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b59ee3cc-9604-4abc-81be-897e2f42aa67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b59ee3cc-9604-4abc-81be-897e2f42aa67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b59ee3cc-9604-4abc-81be-897e2f42aa67"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY, Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033493", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:552a0fd7-87ad-5d32-a893-28fb3543a1c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033493", "UMLS:C0025605", "UMLS:C0027348", "UMLS:C0030873", "UMLS:C0006491", "UMLS:C0010526"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53ed164c-dd09-4ea4-e063-6294a90a2434", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53ed164c-dd09-4ea4-e063-6294a90a2434", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53ed164c-dd09-4ea4-e063-6294a90a2434"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6df55c0e-fbdf-5f6b-a56c-4d4e3cd72d4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68df290c-d776-4cfc-9565-332eb56c4723", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68df290c-d776-4cfc-9565-332eb56c4723", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68df290c-d776-4cfc-9565-332eb56c4723"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock. (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f2c43a8-6663-5875-8612-a8d570075191", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d8813be-6d22-46f1-ac25-0d8a817a521c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d8813be-6d22-46f1-ac25-0d8a817a521c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d8813be-6d22-46f1-ac25-0d8a817a521c"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0579142", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9aabf49f-652e-51a0-a8c3-cca0dc4732b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0579142"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dfa48492-d83b-48cc-9ad1-bdc0c2ac9931", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dfa48492-d83b-48cc-9ad1-bdc0c2ac9931", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dfa48492-d83b-48cc-9ad1-bdc0c2ac9931"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e3e23df-9d0f-5664-8f15-ccb307a1411b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7faaedb3-227b-408d-b772-6b326638b00e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7faaedb3-227b-408d-b772-6b326638b00e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7faaedb3-227b-408d-b772-6b326638b00e"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a31ecd00-2559-5dcd-95c1-b57957167534", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1303f15-c48b-a44d-b28a-72f370094e02", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1303f15-c48b-a44d-b28a-72f370094e02", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1303f15-c48b-a44d-b28a-72f370094e02"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0579142", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af3c4f91-0eb4-5183-bd3f-c0dded063168", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0579142"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2879294f-9af9-459e-e063-6394a90a0820", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2879294f-9af9-459e-e063-6394a90a0820", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2879294f-9af9-459e-e063-6394a90a0820"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b895cd40-d3eb-5b69-bd59-6df99e79dbfd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aef6719c-cd71-46ee-b7b1-1806b939bf3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aef6719c-cd71-46ee-b7b1-1806b939bf3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aef6719c-cd71-46ee-b7b1-1806b939bf3e"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6338e46-fcd3-5db5-9ef6-516896563add", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd65e3fe-cd7a-4855-8f55-8cc3a0921ccc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd65e3fe-cd7a-4855-8f55-8cc3a0921ccc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd65e3fe-cd7a-4855-8f55-8cc3a0921ccc"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock. (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4cc509c-f4c7-515a-9ede-295168bfacbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d66b96a-acbb-2292-e063-6294a90af788", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d66b96a-acbb-2292-e063-6294a90af788", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d66b96a-acbb-2292-e063-6294a90af788"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef73022e-a77f-5bf6-8f9b-f23380a70f32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ae08e26-223b-4971-b2f1-f1e183a3f930", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ae08e26-223b-4971-b2f1-f1e183a3f930", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ae08e26-223b-4971-b2f1-f1e183a3f930"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "opioid depression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f19d24c9-45a7-5204-af2b-4bcfedf84fca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 12, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5de44ee7-6525-4857-9a67-8882e96dbeb5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5de44ee7-6525-4857-9a67-8882e96dbeb5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5de44ee7-6525-4857-9a67-8882e96dbeb5"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride injection is also indicated for diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0579142", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb71072a-127d-5277-ba4d-1c10122f3064", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0579142"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0235063", "object_location_in_text": [115, 137], "original_object": "respiratory depression", "original_subject": "NALOXONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5906381c-81f4-4635-867a-e56e4d629692", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5906381c-81f4-4635-867a-e56e4d629692", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5906381c-81f4-4635-867a-e56e4d629692"]}], "subject": "CHEBI:7459", "supporting_text": ["Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY ; Adjunctive Use in Septic Shock )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235063", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ab6eddc-0857-57be-9376-c4a7e4c20d7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235063", "UMLS:C0151559"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:971d0d60-d7c5-527f-a729-620da29ddab0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0579142", "object_location_in_text": [103, 118], "original_object": "opioid overdose", "original_subject": "NALOXONE", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe9735db-c57e-44a8-bffb-b87a84c2a6f3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe9735db-c57e-44a8-bffb-b87a84c2a6f3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe9735db-c57e-44a8-bffb-b87a84c2a6f3"]}], "subject": "CHEBI:7459", "supporting_text": ["1 INDICATIONS AND USAGE REXTOVY Nasal Spray is indicated for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. REXTOVY Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. REXTOVY Nasal Spray is not a substitute for emergency medical care. REXTOVY Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adults and pediatric patients. ( 1 ) REXTOVY Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) REXTOVY Nasal Spray is not a substitute for emergency medical care. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235063", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be0f0cae-6c6f-5c38-ac0e-3907bf0cf27e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235063", "UMLS:C0151559"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:971d0d60-d7c5-527f-a729-620da29ddab0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ddcfc5d-cf2b-51e0-8cf9-4710ded217cf", "object": "UMLS:C0579142", "object_location_in_text": [112, 127], "original_object": "opioid overdose", "original_subject": "NALOXONE", "population_context_qualifier": "known or suspected opioid overdose", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4517afa1-4b17-4a15-b91b-65b18bd0558f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4517afa1-4b17-4a15-b91b-65b18bd0558f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4517afa1-4b17-4a15-b91b-65b18bd0558f"]}], "subject": "CHEBI:7459", "supporting_text": ["1 INDICATIONS AND USAGE Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. Naloxone HCl Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. ( 1 ) Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) Naloxone HCl Nasal Spray is not a substitute for emergency medical care. ( 1 )"], "temporal_context_qualifier": "emergency"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98eaed54-9229-5a15-bad3-8d8430dbab8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33b265d0-c624-5928-8086-f5bb0b267076", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0235266", "original_object": "eye irritation", "original_subject": "NAPHAZOLINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16e48766-48f5-5ac3-839d-1043d0b5a33a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0014724", "object_location_in_text": [180, 187], "original_object": "burning", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ef71c89-a194-5c98-8791-39b6fd27e93d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0014724", "object_location_in_text": [180, 187], "original_object": "burning", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b6ac8de-9870-524a-b3a9-fb060b48e256", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0014724", "object_location_in_text": [99, 106], "original_object": "burning", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c393c63-2280-5602-b207-c6c0e44ba619", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e3bec2a-ef29-5a26-8a4c-5e70eed8bbf1", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0441723", "object_location_in_text": [99, 121], "original_object": "burning and irritation", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9cb261ed-b708-1189-e053-2a95a90a547d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9cb261ed-b708-1189-e053-2a95a90a547d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9cb261ed-b708-1189-e053-2a95a90a547d"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses For the relief of redness of the eye due to minor eye irritations For the temporary relief of burning and irritation due to dryness of the eye For use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37496aa6-1db9-5814-8276-ca5d787809d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e3bec2a-ef29-5a26-8a4c-5e70eed8bbf1", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0441723", "original_object": "burning and irritation", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:326a1462-78d1-42d6-8257-7e4f00d1f215", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=326a1462-78d1-42d6-8257-7e4f00d1f215", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=326a1462-78d1-42d6-8257-7e4f00d1f215"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses for use as a protectant against further irritation or to relieve dryness of the eye for the temporary relief of burning &amp; irritation due to dryness of the eye relieves redness of the eye due to minor eye irritations"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4968ad44-cdbb-5776-9d18-d0ee9a144ea8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0441723", "object_location_in_text": [52, 62], "original_object": "irritation", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4682f68d-6bdd-d860-e063-6394a90a2b52"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5be6d85b-f055-58e5-a49c-73b2d5a2961b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0441723", "object_location_in_text": [52, 62], "original_object": "irritation", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44155cf8-6fd9-d16f-e063-6394a90ac731"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses ■ relieves redness of the eye due to minor eye irritations ■ for use as a protectant against further irritation or to relieve dryness of the eye ■ for the temporary relief of burning and irritation due to dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "dryness of the eye", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4b2a68c-aaa6-5177-88da-2b33e556d9db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:333c2544-108b-5f05-9386-74e039207fa8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:654459ab-c822-54c2-bb27-593b3c353698", "object": "UMLS:C0441723", "object_location_in_text": [59, 69], "original_object": "irritation", "original_subject": "NAPHAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b37250f-9bdf-574e-e053-2a95a90a013e"]}], "subject": "CHEBI:7470", "supporting_text": ["Uses for the relief of redness of the eye due to minor eye irritations for the temporary relief of burning and irritation due to dryness of the eye for use as a protectant against further irritation or dryness of the eye"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "house dust mite antigen-induced bronchial asthma", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5ce6cf0-8c4b-5fde-91e7-f5dcc69e0ebd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141226", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:622b5bbc-9b53-5f84-81e2-4e499dfc0011", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1b3b7dba-bf2d-59f8-a472-d52c4fb73e90", "object": "MONDO:0004979", "object_location_in_text": [133, 149], "original_object": "bronchial asthma", "original_subject": "ML", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ML#118-20141226", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:74705", "supporting_text": ["Drugs with new active ingredients indicated for the allergen immunotherapy for house dust mite antigen-induced allergic rhinitis and bronchial asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "house dust mite antigen-induced allergic rhinitis", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66f376e9-8ff1-55c4-9eaa-52c837b7bdc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141226", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ec052dff-f081-5cd9-ac49-74554830869a", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1b3b7dba-bf2d-59f8-a472-d52c4fb73e90", "object": "MONDO:0011786", "object_location_in_text": [111, 128], "original_object": "allergic rhinitis", "original_subject": "ML", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ML#118-20141226", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:74705", "supporting_text": ["Drugs with new active ingredients indicated for the allergen immunotherapy for house dust mite antigen-induced allergic rhinitis and bronchial asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic or mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c9cc497-8217-5f97-a9a6-703964dd92bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20260220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5f1e938-bca5-528f-9066-152973540785", "object": "MONDO:0001866", "object_location_in_text": [185, 203], "original_object": "bipolar I disorder", "original_subject": "MILSAPERIDONE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:254a1c01-4a4c-4bdd-85d6-1f23f2e4e6f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=254a1c01-4a4c-4bdd-85d6-1f23f2e4e6f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=254a1c01-4a4c-4bdd-85d6-1f23f2e4e6f8"]}], "subject": "CHEBI:747406", "supporting_text": ["1 INDICATIONS AND USAGE BYSANTI ™ is indicated for the: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . BYSANTI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58f61799-2b94-5ddc-a37a-5f19a27dfd72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250925", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["abemaciclib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e174531f-4e71-56e6-8df3-d9eadd914547", "object": "MONDO:0007254", "object_location_in_text": [223, 259], "original_object": "advanced or metastatic breast cancer", "original_subject": "IMLUNESTRANT", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5bc172e4-e8a2-441a-be52-279a7f890196", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5bc172e4-e8a2-441a-be52-279a7f890196", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5bc172e4-e8a2-441a-be52-279a7f890196"]}], "subject": "CHEBI:747442", "supporting_text": ["1 INDICATIONS AND USAGE INLURIYO is indicated: as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1 )-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy [see Dosage and Administration ( 2.1 )] . in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy [see Dosage and Administration ( 2.1 )] . INLURIYO ® is an estrogen receptor antagonist indicated: as monotherapy for the treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy ( 1 ) in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy ( 1 )"], "temporal_context_qualifier": "with disease progression following at least one line of endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reduced cardiac output", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d60960ba-b2a5-546e-a205-c29fc2df729b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0f28e72c-daca-52a3-80ae-812fc000b0ae", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f04ff708-ecbe-51cc-908f-0f8ec95f9b25", "object": "HP:0031275", "object_location_in_text": [112, 130], "original_object": "distributive shock", "original_subject": "ISOPROTERENOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dfb97590-dcbf-47e7-bbfe-f01580eb6ed0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dfb97590-dcbf-47e7-bbfe-f01580eb6ed0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dfb97590-dcbf-47e7-bbfe-f01580eb6ed0"]}], "subject": "CHEBI:747921", "supporting_text": ["1. INDICATIONS AND USAGE Isoproterenol hydrochloride is indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output For bronchospasm occurring during anesthesia Isoproterenol hydrochloride is a beta-adrenergic agonist indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output ( 1 ) For treatment of bronchospasm occurring during anesthesia ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06fc00b2-e05a-5d2b-92e2-b3401af6744d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "HP:0012735", "object_location_in_text": [112, 117], "original_object": "cough", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18f3d694-9dff-407e-a264-916dbd201f9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18f3d694-9dff-407e-a264-916dbd201f9a"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses For the temporary relief of the following cold symptoms minor aches and pains headache sneezing runny nose cough due to minor throat and bronchial irritation temporarily reduces fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27f2b516-1f5f-5f66-833d-f72857aca7f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "HP:0012735", "object_location_in_text": [43, 48], "original_object": "cough", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d66b1a2e-49b6-473b-acec-2694c73ce8b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d66b1a2e-49b6-473b-acec-2694c73ce8b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d66b1a2e-49b6-473b-acec-2694c73ce8b4"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses temporarily relieves cold symptoms: ▪ cough due to minor throat &amp; bronchial irritation ▪ sneezing ▪ runny nose"], "temporal_context_qualifier": "temporarily"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8c4bc2d-981e-5d82-a926-242f399c4426", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "HP:0012735", "object_location_in_text": [41, 46], "original_object": "cough", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f913fcd6-a2b8-df5e-e053-6394a90ac988", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f913fcd6-a2b8-df5e-e053-6394a90ac988", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f913fcd6-a2b8-df5e-e053-6394a90ac988"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses temporarily relieves cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6038df2-bc9a-59e1-b5d4-220b304586b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "HP:0012735", "object_location_in_text": [48, 53], "original_object": "cough", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f98e0a7-4aac-589c-b85e-c79daa188504", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "MONDO:0005709", "object_location_in_text": [26, 37], "original_object": "common cold", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002315", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50a97a2a-5cf2-5196-906b-0690c83d372e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002315"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "UMLS:C0235309", "object_location_in_text": [125, 138], "original_object": "upset stomach", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses for the relief of: heartburn, acid indigestion, and sour stomach when accompanied with headache or body aches and pains upset stomach with headache from overindulgence in food or drink headache, body aches, and pain alone"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002315", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28fd4306-afdf-59c7-a27b-5cfce784d29f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002315"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a569b57e-af37-5880-a6ef-d749dbda9aba", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4dc5b69e-7fcd-507e-b6e3-1f7999d0288e", "object": "UMLS:C0860277", "object_location_in_text": [57, 69], "original_object": "sour stomach", "original_subject": "CHLORPHENIRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7"]}], "subject": "CHEBI:747960", "supporting_text": ["Uses for the relief of: heartburn, acid indigestion, and sour stomach when accompanied with headache or body aches and pains upset stomach with headache from overindulgence in food or drink headache, body aches, and pain alone"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16036475-0215-569a-9545-3ccf1eadbac7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [218, 241], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaf79e72-26bf-4152-9cd1-10d8c30fa4fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaf79e72-26bf-4152-9cd1-10d8c30fa4fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaf79e72-26bf-4152-9cd1-10d8c30fa4fe"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:169d0802-86fb-55b1-8708-d05cb8b2dbfa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [245, 268], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e896cbfe-4745-4088-82a3-8dc10b75c41f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e896cbfe-4745-4088-82a3-8dc10b75c41f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e896cbfe-4745-4088-82a3-8dc10b75c41f"]}], "subject": "CHEBI:748220", "supporting_text": ["General Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]). Psoriasis Psoriasis patients who are treated with Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf ® ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42b0bfb0-988b-514b-bfdc-27ec5e49e430", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [217, 240], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1952d4c7-a40e-4924-b669-c41400774cb9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1952d4c7-a40e-4924-b669-c41400774cb9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1952d4c7-a40e-4924-b669-c41400774cb9"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43909d3f-5848-5273-a736-20d5afbcbf05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [220, 243], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:893508f4-d20a-4511-94bb-b8f120734904", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=893508f4-d20a-4511-94bb-b8f120734904", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=893508f4-d20a-4511-94bb-b8f120734904"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine Capsules USP MODIFIED are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Cyclosporine Capsules USP MODIFIED. Psoriasis Psoriasis patients who are treated with Cyclosporine Capsules USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Cyclosporine Capsules USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87ddf28c-d6af-5f8c-b72f-91ee08592592", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [217, 240], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c36132b2-3ec7-4c43-a25e-75cbdbe3d88d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c36132b2-3ec7-4c43-a25e-75cbdbe3d88d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c36132b2-3ec7-4c43-a25e-75cbdbe3d88d"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ace5d4f-1a8f-571d-a897-2ddc88a077c5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [208, 231], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ec430a-e930-145c-e766-13fb49b64644", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine [MODIFIED] is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine [MODIFIED]. Psoriasis Psoriasis patients who are treated with cyclosporine [MODIFIED] should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine [MODIFIED]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fd48d1b-9cf9-596f-98f3-55a39909d8d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [221, 244], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2de1e8b1-625f-43ce-a1d5-d543be208b11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2de1e8b1-625f-43ce-a1d5-d543be208b11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2de1e8b1-625f-43ce-a1d5-d543be208b11"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules, USP MODIFIED are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, USP MODIFIED. Psoriasis Psoriasis patients who are treated with cyclosporine capsules, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf8f93cb-a87f-5b2a-83a1-b756641bb606", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [217, 240], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5baaf78c-90f6-abcf-52c8-814490f3cf9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3cdaa13-8787-5b57-a3aa-ac6a0e64149f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [191, 214], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94461af3-11f1-4670-95d4-2965b9538ae3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3"]}], "subject": "CHEBI:748220", "supporting_text": ["General Neoral is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Neoral. Psoriasis Psoriasis patients who are treated with Neoral should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Neoral."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa688ef1-4ec4-5b47-ac50-f8e4899baf8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3eb33787-3123-575d-af1f-3de5b65b9302", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "HP:0012211", "object_location_in_text": [225, 248], "original_object": "abnormal renal function", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3dc2a50-1084-4190-a6f3-37034a04db86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3dc2a50-1084-4190-a6f3-37034a04db86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3dc2a50-1084-4190-a6f3-37034a04db86"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine oral solution, USP MODIFIED is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED. Psoriasis Psoriasis patients who are treated with cyclosporine oral solution, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e2749d0-f8c9-5508-a720-27732443003c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [300, 312], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e896cbfe-4745-4088-82a3-8dc10b75c41f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e896cbfe-4745-4088-82a3-8dc10b75c41f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e896cbfe-4745-4088-82a3-8dc10b75c41f"]}], "subject": "CHEBI:748220", "supporting_text": ["General Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]). Psoriasis Psoriasis patients who are treated with Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf ® ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ebd9b3d-8175-5552-8888-8578a01e5037", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [276, 288], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2de1e8b1-625f-43ce-a1d5-d543be208b11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2de1e8b1-625f-43ce-a1d5-d543be208b11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2de1e8b1-625f-43ce-a1d5-d543be208b11"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules, USP MODIFIED are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, USP MODIFIED. Psoriasis Psoriasis patients who are treated with cyclosporine capsules, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3509c287-3c8c-5ade-a89c-42d070c821c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [275, 287], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:893508f4-d20a-4511-94bb-b8f120734904", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=893508f4-d20a-4511-94bb-b8f120734904", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=893508f4-d20a-4511-94bb-b8f120734904"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine Capsules USP MODIFIED are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Cyclosporine Capsules USP MODIFIED. Psoriasis Psoriasis patients who are treated with Cyclosporine Capsules USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Cyclosporine Capsules USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:375c7e7f-46b5-5874-9c3c-e9bde9e92fa0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [272, 284], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5baaf78c-90f6-abcf-52c8-814490f3cf9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65335dc9-1102-5a50-ad6d-44ca83a09a1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [280, 292], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3dc2a50-1084-4190-a6f3-37034a04db86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3dc2a50-1084-4190-a6f3-37034a04db86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3dc2a50-1084-4190-a6f3-37034a04db86"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine oral solution, USP MODIFIED is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED. Psoriasis Psoriasis patients who are treated with cyclosporine oral solution, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:667b4513-8148-5a56-9f18-9a8648ce1e71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [273, 285], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaf79e72-26bf-4152-9cd1-10d8c30fa4fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaf79e72-26bf-4152-9cd1-10d8c30fa4fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaf79e72-26bf-4152-9cd1-10d8c30fa4fe"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f7de219-ed02-542a-8968-bbef535849d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [272, 284], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c36132b2-3ec7-4c43-a25e-75cbdbe3d88d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c36132b2-3ec7-4c43-a25e-75cbdbe3d88d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c36132b2-3ec7-4c43-a25e-75cbdbe3d88d"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5de09d3-92f2-52a1-a7c3-1f987413e6c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [246, 258], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94461af3-11f1-4670-95d4-2965b9538ae3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3"]}], "subject": "CHEBI:748220", "supporting_text": ["General Neoral is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Neoral. Psoriasis Psoriasis patients who are treated with Neoral should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Neoral."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f68efc5f-4780-556c-a4fd-a34bedae9e6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [272, 284], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1952d4c7-a40e-4924-b669-c41400774cb9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1952d4c7-a40e-4924-b669-c41400774cb9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1952d4c7-a40e-4924-b669-c41400774cb9"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb49be6d-d27f-56fa-9553-3f2561328aba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f92c4797-0037-5f5d-b900-9c9673e6b5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "MONDO:0004992", "object_location_in_text": [263, 275], "original_object": "malignancies", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ec430a-e930-145c-e766-13fb49b64644", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine [MODIFIED] is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine [MODIFIED]. Psoriasis Psoriasis patients who are treated with cyclosporine [MODIFIED] should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine [MODIFIED]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08d2d2e4-eb48-5c08-9c28-dfb86575073f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [242, 267], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5baaf78c-90f6-abcf-52c8-814490f3cf9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5baaf78c-90f6-abcf-52c8-814490f3cf9f"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0cb6c42b-3c1b-51d4-b0eb-45bfce88cd42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [242, 267], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1952d4c7-a40e-4924-b669-c41400774cb9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1952d4c7-a40e-4924-b669-c41400774cb9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1952d4c7-a40e-4924-b669-c41400774cb9"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0cfdcd58-77c2-5145-8d87-88ed155348f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [270, 295], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e896cbfe-4745-4088-82a3-8dc10b75c41f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e896cbfe-4745-4088-82a3-8dc10b75c41f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e896cbfe-4745-4088-82a3-8dc10b75c41f"]}], "subject": "CHEBI:748220", "supporting_text": ["General Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]). Psoriasis Psoriasis patients who are treated with Gengraf ® Capsules (cyclosporine capsules, USP [ MODIFIED ]) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Gengraf ® ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bf1573c-2768-5f7d-8e05-70c57874968a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [242, 267], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c36132b2-3ec7-4c43-a25e-75cbdbe3d88d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c36132b2-3ec7-4c43-a25e-75cbdbe3d88d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c36132b2-3ec7-4c43-a25e-75cbdbe3d88d"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4340f82e-fb42-5444-8390-1f70ca999c07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [250, 275], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3dc2a50-1084-4190-a6f3-37034a04db86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3dc2a50-1084-4190-a6f3-37034a04db86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3dc2a50-1084-4190-a6f3-37034a04db86"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine oral solution, USP MODIFIED is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED. Psoriasis Psoriasis patients who are treated with cyclosporine oral solution, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine oral solution, USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64414d79-5a0d-5579-9506-9b6a9210ba55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [233, 258], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ec430a-e930-145c-e766-13fb49b64644", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ec430a-e930-145c-e766-13fb49b64644"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine [MODIFIED] is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine [MODIFIED]. Psoriasis Psoriasis patients who are treated with cyclosporine [MODIFIED] should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine [MODIFIED]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99208c29-a7b9-59af-ad96-69bff60f48b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [216, 241], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:94461af3-11f1-4670-95d4-2965b9538ae3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3"]}], "subject": "CHEBI:748220", "supporting_text": ["General Neoral is contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Neoral. Psoriasis Psoriasis patients who are treated with Neoral should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Neoral."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd065bd9-93c1-5250-948f-9a80174aa07f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [246, 271], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2de1e8b1-625f-43ce-a1d5-d543be208b11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2de1e8b1-625f-43ce-a1d5-d543be208b11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2de1e8b1-625f-43ce-a1d5-d543be208b11"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules, USP MODIFIED are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, USP MODIFIED. Psoriasis Psoriasis patients who are treated with cyclosporine capsules, USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules, USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2a40494-0ec9-5410-bd60-ece507eaee24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [245, 270], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:893508f4-d20a-4511-94bb-b8f120734904", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=893508f4-d20a-4511-94bb-b8f120734904", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=893508f4-d20a-4511-94bb-b8f120734904"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine Capsules USP MODIFIED are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Cyclosporine Capsules USP MODIFIED. Psoriasis Psoriasis patients who are treated with Cyclosporine Capsules USP MODIFIED should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive Cyclosporine Capsules USP MODIFIED."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0003765", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff68f58e-df06-5cfb-87f5-46c7402e0a63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19831114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003765"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:903cfb62-6ef5-5009-93cc-7389f895533e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9afba22d-3e7f-5fca-bdd5-e1ee890eb81f", "object": "UMLS:C1868885", "object_location_in_text": [243, 268], "original_object": "uncontrolled hypertension", "original_subject": "CYCLOSPORINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aaf79e72-26bf-4152-9cd1-10d8c30fa4fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aaf79e72-26bf-4152-9cd1-10d8c30fa4fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaf79e72-26bf-4152-9cd1-10d8c30fa4fe"]}], "subject": "CHEBI:748220", "supporting_text": ["General Cyclosporine capsules (modified) are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. Rheumatoid Arthritis Rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified). Psoriasis Psoriasis patients who are treated with cyclosporine capsules (modified) should not receive concomitant PUVA or UVB therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. Psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules (modified)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "altered osteogenic activity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:189dfddd-cddc-57a6-a604-6b1dc03424c6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:726d3da3-4cc9-5aaf-95bb-52fca676ad71", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb5df029-d6df-5d3a-a9ab-fbb2ab62eb67", "object": "UMLS:C0203668", "original_object": "bone imaging", "original_subject": "FLUORIDE ION F-18", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8afb06c-f4c3-46f0-8f8b-0bc9e072ce47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8afb06c-f4c3-46f0-8f8b-0bc9e072ce47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8afb06c-f4c3-46f0-8f8b-0bc9e072ce47"]}], "subject": "CHEBI:748569", "supporting_text": ["1 INDICATIONS AND USAGE Sodium Fluoride F 18 Injection, USP is indicated for diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity. Sodium Fluoride F 18 Injection, USP is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "exposure to wind or sun", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47ea7b65-79d0-5bf5-b267-2c1a2071a214", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e3bec2a-ef29-5a26-8a4c-5e70eed8bbf1", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af6f4991-b8e2-5869-8921-6c14a680cf1f", "object": "UMLS:C0441723", "object_location_in_text": [152, 174], "original_object": "burning and irritation", "original_subject": "TETRAHYDROZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0bc0d6e7-9195-db6b-e063-6294a90aef04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0bc0d6e7-9195-db6b-e063-6294a90aef04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0bc0d6e7-9195-db6b-e063-6294a90aef04"]}], "subject": "CHEBI:748590", "supporting_text": ["Uses for the temporary relief of discomfort and redness of the eye due to minor eye irritations relieves dryness of the eye for the temporary relief of burning and irritation due to exposure to wind or sun for protection against further irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d29f768-ddea-5549-9306-fadac00abb35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0000989", "object_location_in_text": [41, 48], "original_object": "itching", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724"]}], "subject": "CHEBI:748835", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritations", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83283db4-a11f-5dfc-9293-330e2eb6b431", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0000989", "object_location_in_text": [41, 48], "original_object": "itching", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:365fca57-2107-727d-e063-6394a90a070d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=365fca57-2107-727d-e063-6394a90a070d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=365fca57-2107-727d-e063-6394a90a070d"]}], "subject": "CHEBI:748835", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritations"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritations", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7cfa35e-5193-575a-8d5b-cbe862a7931e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0000989", "object_location_in_text": [41, 48], "original_object": "itching", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb3548c8-f202-dc50-e053-6394a90a5b30", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb3548c8-f202-dc50-e053-6394a90a5b30", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb3548c8-f202-dc50-e053-6394a90a5b30"]}], "subject": "CHEBI:748835", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritations"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2dd3a050-f673-5c19-bf60-e45d0fe5382e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0012531", "object_location_in_text": [32, 36], "original_object": "pain", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724"]}], "subject": "CHEBI:748835", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor irritation or injury of the mouth and gums, occasional sore mouth and sore throat", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6871b9b8-af5b-5e5a-884a-577669611fda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0012531", "object_location_in_text": [93, 97], "original_object": "pain", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a1b4133-0eac-2f8f-e063-6394a90af8f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a1b4133-0eac-2f8f-e063-6394a90af8f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a1b4133-0eac-2f8f-e063-6394a90af8f6"]}], "subject": "CHEBI:748835", "supporting_text": ["Use first aid to help prevent infection in minor oral irritation for the temporary relief of pain due to minor irritation or injury of the mouth and gums occasional sore mouth and sore throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bd8bc79-6dc6-5c47-a8c2-b6a7e6fecdd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0012531", "object_location_in_text": [152, 156], "original_object": "pain", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2089c28b-98fd-4797-8940-b0749d8b5df7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2089c28b-98fd-4797-8940-b0749d8b5df7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2089c28b-98fd-4797-8940-b0749d8b5df7"]}], "subject": "CHEBI:748835", "supporting_text": ["Uses • On chest and throat, helps temporarily relieve cough as may occur with common cold and minor bronchial irritation. • For the temporary relief of pain associated with minor skin irritation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7028de2-05c2-5d2e-8d7a-53ce692793bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0012531", "object_location_in_text": [32, 36], "original_object": "pain", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fb3548c8-f202-dc50-e053-6394a90a5b30", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fb3548c8-f202-dc50-e053-6394a90a5b30", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb3548c8-f202-dc50-e053-6394a90a5b30"]}], "subject": "CHEBI:748835", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritations"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd9d2d49-a38c-5a63-ab04-2d7f7d8264e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0012531", "object_location_in_text": [32, 36], "original_object": "pain", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:365fca57-2107-727d-e063-6394a90a070d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=365fca57-2107-727d-e063-6394a90a070d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=365fca57-2107-727d-e063-6394a90a070d"]}], "subject": "CHEBI:748835", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritations"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor irritation or injury of the mouth and gums, occasional sore mouth and sore throat", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd241aee-9ab0-57ca-83ab-0c06db9c50c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "HP:0012531", "object_location_in_text": [94, 98], "original_object": "pain", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a1c82b4-02b3-d456-e063-6294a90a16bb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a1c82b4-02b3-d456-e063-6294a90a16bb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a1c82b4-02b3-d456-e063-6294a90a16bb"]}], "subject": "CHEBI:748835", "supporting_text": ["Uses first aid to help prevent infection in minor oral irritation for the temporary relief of pain due to minor irritation or injury of the mouth and gums occasional sore mouth and sore throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains of muscles and joints", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:776e09dc-7d18-5342-b3d9-333a1aeceee1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:247045da-2eee-5588-96e8-0b2dec379881", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "MONDO:0005578", "object_location_in_text": [110, 119], "original_object": "arthritis", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609"]}], "subject": "CHEBI:748835", "supporting_text": ["Uses For the temporary relief of minor aches and pains of muscles and joints associated with: simple backache arthritis strains bruises sprains"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012531", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7369e697-4ef5-5203-973b-248a885e96cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b6a4459-e2f4-5e6b-8013-127cd1f37599", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "MONDO:0041052", "object_location_in_text": [88, 111], "original_object": "post-herpetic neuralgia", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3de6bb95-3673-45c4-bf11-90ec858c37d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3de6bb95-3673-45c4-bf11-90ec858c37d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3de6bb95-3673-45c4-bf11-90ec858c37d9"]}], "subject": "CHEBI:748835", "supporting_text": ["INDICATION AND USAGE Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains of muscles and joints", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3c01d72-d072-5a03-9bba-3e1db9f7d1ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b8d8849c-9639-5b9a-b95e-d8d1e6d8be44", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "UMLS:C0009938", "object_location_in_text": [128, 135], "original_object": "bruises", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609"]}], "subject": "CHEBI:748835", "supporting_text": ["Uses For the temporary relief of minor aches and pains of muscles and joints associated with: simple backache arthritis strains bruises sprains"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains of muscles and joints", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0524f44e-96d9-592e-ac7d-02ff3d7b8616", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b561352c-9ffd-5832-aadc-11a3447d1d1e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "UMLS:C0038045", "object_location_in_text": [136, 143], "original_object": "sprains", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609"]}], "subject": "CHEBI:748835", "supporting_text": ["Uses For the temporary relief of minor aches and pains of muscles and joints associated with: simple backache arthritis strains bruises sprains"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor aches and pains of muscles and joints", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9cfc0aa-d1f6-501b-918a-400c3b8d770b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b2b1a28b-af8c-5e70-8917-cce1ba98d47a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eb45a602-84f1-5f8f-a96f-296fe7af851a", "object": "UMLS:C0080194", "object_location_in_text": [120, 127], "original_object": "strains", "original_subject": "MENTHOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe1f1408-b0cb-67a4-e053-6394a90ad609"]}], "subject": "CHEBI:748835", "supporting_text": ["Uses For the temporary relief of minor aches and pains of muscles and joints associated with: simple backache arthritis strains bruises sprains"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24aebb35-13b6-58d4-8963-fb8983f5fd5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "adult and pediatric patients when oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d122b875-435e-4e00-b945-7a0546df95c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d122b875-435e-4e00-b945-7a0546df95c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d122b875-435e-4e00-b945-7a0546df95c2"]}], "subject": "CHEBI:748997", "supporting_text": ["1 INDICATIONS AND USAGE VYKOURA is indicated for: 1.1 Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients. 1.2 Reducing the toxicity of: Methotrexate in adult and pediatric patients with impaired methotrexate elimination or Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients. 1.3 Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible. 1.4 Treatment of patients with metastatic colorectal cancer in combination with fluorouracil."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29148430-ae49-57d5-ab28-e779f563d1a4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f579879c-7d53-4663-8ad8-84b8b645cda5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f579879c-7d53-4663-8ad8-84b8b645cda5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f579879c-7d53-4663-8ad8-84b8b645cda5"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin Calcium for Injection rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3aeba616-194a-5e00-ad63-cace1e1373a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9df20901-6980-4d4e-89ec-40f3c1f91852", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9df20901-6980-4d4e-89ec-40f3c1f91852", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9df20901-6980-4d4e-89ec-40f3c1f91852"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin Calcium for Injection rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5253fd7f-2a79-596c-9969-8a9416d9c28b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c31f29d-4ecd-599b-b625-af423aeb01b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82c445f5-4cb7-4457-af19-3b5b8a121b4f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82c445f5-4cb7-4457-af19-3b5b8a121b4f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82c445f5-4cb7-4457-af19-3b5b8a121b4f"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88a91b9c-f026-5f36-b0ba-6bd88ddad1a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8bdd60c-9a1c-4ef4-ba6b-b911849128f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8bdd60c-9a1c-4ef4-ba6b-b911849128f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8bdd60c-9a1c-4ef4-ba6b-b911849128f1"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92255030-5737-5f69-8445-59feb44f2d0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b72d1fd-f389-45d9-b43b-510b45c92263", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b72d1fd-f389-45d9-b43b-510b45c92263", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b72d1fd-f389-45d9-b43b-510b45c92263"]}], "subject": "CHEBI:748997", "supporting_text": ["INDICATIONS &amp; USAGE Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad8b039b-3668-50b5-b682-5c6430e5fa19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c"]}], "subject": "CHEBI:748997", "supporting_text": [": Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b07c02b1-59fb-5fe3-a973-3e140659df51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee"]}], "subject": "CHEBI:748997", "supporting_text": ["INDICATIONS &amp; USAGE Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0fca337-089c-526d-b413-64c389c31d81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:968b192b-72f3-41b0-a1f5-bab8a96d3419", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=968b192b-72f3-41b0-a1f5-bab8a96d3419", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=968b192b-72f3-41b0-a1f5-bab8a96d3419"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin Calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3ed4774-a815-5862-9e87-7ca823f13445", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d0e5356-ff39-4a8e-944c-e808a21ef4b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d0e5356-ff39-4a8e-944c-e808a21ef4b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d0e5356-ff39-4a8e-944c-e808a21ef4b2"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec7f40c6-3b90-58b7-8f50-774758e931c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0001700", "original_object": "megaloblastic anemia", "original_subject": "LEUCOVORIN", "population_context_qualifier": "patients for whom oral therapy is not feasible", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:79d023ab-7d77-48c1-8f47-ea322fd58c2b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=79d023ab-7d77-48c1-8f47-ea322fd58c2b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79d023ab-7d77-48c1-8f47-ea322fd58c2b"]}], "subject": "CHEBI:748997", "supporting_text": ["Leucovorin Calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d52412b-ca4f-5249-9720-7201b97356fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5c937d4b-ee8e-5ca7-95c2-5b52f52323dd", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "LEUCOVORIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:748997", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "prior therapies refractory to ganciclovir, valganciclovir, cidofovir or foscarnet", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b569829-afba-5d8e-8d4c-276d7bb91814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20221109", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:efa59ba8-35bf-5423-93ca-d107d929c7bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:26625a1a-5308-5180-a5f7-03adadd355e9", "object": "MONDO:0005132", "original_object": "cytomegalovirus infection", "original_subject": "maribavir", "population_context_qualifier": "adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:livtencity", "https://www.ema.europa.eu/en/documents/product-information/livtencity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/livtencity"]}], "subject": "CHEBI:749006", "supporting_text": ["LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0029216", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69f4bba1-5e98-5e04-8f01-7882c0854f9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240624", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0029216", "UMLS:C0472699"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:8e1bbbf1-262b-5d3c-83e4-eef603976d47", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:26625a1a-5308-5180-a5f7-03adadd355e9", "object": "MONDO:0005132", "object_location_in_text": [67, 90], "original_object": "cytomegalovirus disease", "original_subject": "MARIBAVIR", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MARIBAVIR#13-20240624", "https://www.pmda.go.jp/files/000276092.pdf"]}], "subject": "CHEBI:749006", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of cytomegalovirus disease in organ transplantation (including hematopoietic stem cell transplantation) that is refractory to conventional anti- cytomegalovirus therapy."], "temporal_context_qualifier": "refractory to conventional anti-cytomegalovirus therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3279003", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25655c54-96da-5ed7-8596-b531df7cce4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3279003", "UMLS:C3279003", "UMLS:C0159075", "MONDO:0008829", "HP:0010310"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:698299e9-585e-5f02-86b9-a8993273d413", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36a9ea73-0369-5227-9bbe-609d7b4d2e25", "object": "UMLS:C0229889", "original_object": "lymphatic vessels", "original_subject": "ISOSULFAN BLUE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1878964e-5220-48c8-a872-dcadbc451aff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1878964e-5220-48c8-a872-dcadbc451aff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1878964e-5220-48c8-a872-dcadbc451aff"]}], "subject": "CHEBI:749330", "supporting_text": ["1 INDICATIONS AND USAGE Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3279003", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d50019d-50c6-528e-9d7f-69626facf030", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3279003", "UMLS:C3279003", "UMLS:C0159075", "MONDO:0008829", "HP:0010310"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:698299e9-585e-5f02-86b9-a8993273d413", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36a9ea73-0369-5227-9bbe-609d7b4d2e25", "object": "UMLS:C0229889", "original_object": "lymphatic vessels", "original_subject": "ISOSULFAN BLUE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0391e544-3633-48df-9f3a-ed16183125b1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0391e544-3633-48df-9f3a-ed16183125b1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0391e544-3633-48df-9f3a-ed16183125b1"]}], "subject": "CHEBI:749330", "supporting_text": ["1 INDICATIONS AND USAGE Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3279003", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9df11018-e90d-5db8-878d-374ed850fc95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3279003", "UMLS:C3279003", "UMLS:C0159075", "MONDO:0008829", "HP:0010310"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:698299e9-585e-5f02-86b9-a8993273d413", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36a9ea73-0369-5227-9bbe-609d7b4d2e25", "object": "UMLS:C0229889", "original_object": "lymphatic vessels", "original_subject": "ISOSULFAN BLUE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4b7e84ee-f3ba-4b80-86d3-f4debe6a2eca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4b7e84ee-f3ba-4b80-86d3-f4debe6a2eca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b7e84ee-f3ba-4b80-86d3-f4debe6a2eca"]}], "subject": "CHEBI:749330", "supporting_text": ["1 INDICATIONS AND USAGE Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3279003", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f25936d-dc6c-595c-bf8f-ec0bad9f3b22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3279003", "UMLS:C3279003", "UMLS:C0159075", "MONDO:0008829", "HP:0010310"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:698299e9-585e-5f02-86b9-a8993273d413", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36a9ea73-0369-5227-9bbe-609d7b4d2e25", "object": "UMLS:C0229889", "object_location_in_text": [98, 115], "original_object": "lymphatic vessels", "original_subject": "ISOSULFAN BLUE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa6260da-0acd-4552-a215-07df8da1031c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa6260da-0acd-4552-a215-07df8da1031c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa6260da-0acd-4552-a215-07df8da1031c"]}], "subject": "CHEBI:749330", "supporting_text": ["1 INDICATIONS AND USAGE Isosulfan blue injection upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3279003", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab186909-f4ba-53ed-a632-ee456dac9598", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3279003", "UMLS:C3279003", "UMLS:C0159075", "MONDO:0008829", "HP:0010310"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:698299e9-585e-5f02-86b9-a8993273d413", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36a9ea73-0369-5227-9bbe-609d7b4d2e25", "object": "UMLS:C0229889", "object_location_in_text": [106, 123], "original_object": "lymphatic vessels", "original_subject": "ISOSULFAN BLUE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cbee4532-238b-4f91-86ae-f8c0c1b6d7da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cbee4532-238b-4f91-86ae-f8c0c1b6d7da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbee4532-238b-4f91-86ae-f8c0c1b6d7da"]}], "subject": "CHEBI:749330", "supporting_text": ["1 INDICATIONS AND USAGE Lymphazurin™ 1% (isosulfan blue) upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). 1.1 Lymphatic Vessel Delineation Lymphazuirn™ 1% (isosulfan blue) upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3279003", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de8cdb17-49ed-5ac0-80c7-2a02dedf1b0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3279003", "UMLS:C3279003", "UMLS:C0159075", "MONDO:0008829", "HP:0010310"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:698299e9-585e-5f02-86b9-a8993273d413", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:36a9ea73-0369-5227-9bbe-609d7b4d2e25", "object": "UMLS:C0229889", "object_location_in_text": [101, 118], "original_object": "lymphatic vessels", "original_subject": "ISOSULFAN BLUE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d36ae5af-6351-497a-9151-82bcb2c62fa0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d36ae5af-6351-497a-9151-82bcb2c62fa0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d36ae5af-6351-497a-9151-82bcb2c62fa0"]}], "subject": "CHEBI:749330", "supporting_text": ["1 INDICATIONS AND USAGE Isosulfan Blue Injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). 1.1 Lymphatic Vessel Delineation Isosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "de novo or secondary acute myeloid leukemia", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07737d8e-1786-5272-98aa-dd7d9d098e64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:f4f3b68f-e6a5-5f26-90be-8451db92d483", "object": "MONDO:0018874", "object_location_in_text": [572, 594], "original_object": "acute myeloid leukemia", "original_subject": "Decitabine Injection 30mg/vial (Additional pack size)", "population_context_qualifier": "adult patients aged 65 yrs and above, not candidates for standard induction chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:749378", "supporting_text": ["1. For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French- American-British subtypes(refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk international Prognostic Scoring System groups. 2. For the treatment of adult patients aged 65 yrs and above with newly diagnosed de novo or secondary acute myeloid leukemia, according to WHO classification, who are not candidates for standard induction chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:155c9875-481b-5d1a-8aae-21291f0a1d97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f2121338-9586-161d-e053-2995a90af908", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f2121338-9586-161d-e053-2995a90af908", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f2121338-9586-161d-e053-2995a90af908"]}], "subject": "CHEBI:749380", "supporting_text": ["1.1 Chronic Idiopathic Constipation in Adults Lubiprostone capsules are indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone capsules are indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26593b3e-6067-5d03-908a-b0e7d120a2ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5653f3b-c3c8-487c-bc00-3770985aa5ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5653f3b-c3c8-487c-bc00-3770985aa5ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5653f3b-c3c8-487c-bc00-3770985aa5ee"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:556b3dd1-5f65-5296-8fb4-998ec9de654d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4d506e0-1322-4fc4-e053-2995a90ac880", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4d506e0-1322-4fc4-e053-2995a90ac880", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4d506e0-1322-4fc4-e053-2995a90ac880"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60e1c04a-7294-52da-80db-abd84d94aad7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fd683a5-87ff-42b8-a8c8-fff81625f67f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fd683a5-87ff-42b8-a8c8-fff81625f67f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fd683a5-87ff-42b8-a8c8-fff81625f67f"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone capsules are a chloride channel activator indicated for the treatment of: • chronic idiopathic constipation (CIC) in adults. ( 1.1 ) • opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic, non-cancer pain, chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:686d6723-cc6c-530b-887f-98b6bfa080e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5797e57c-4e87-48d9-b16d-992f64db594f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5797e57c-4e87-48d9-b16d-992f64db594f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5797e57c-4e87-48d9-b16d-992f64db594f"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain, prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d85be5f-d301-5219-a2eb-939ea1e76e45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:164a2b47-0a52-4bb4-9e71-5342c2e951f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=164a2b47-0a52-4bb4-9e71-5342c2e951f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=164a2b47-0a52-4bb4-9e71-5342c2e951f4"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Amitiza is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75b4f0ef-8f2e-5e0b-9590-b26a4ce30dfe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:031170a4-5f7d-b371-e063-6394a90ae21d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=031170a4-5f7d-b371-e063-6394a90ae21d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=031170a4-5f7d-b371-e063-6394a90ae21d"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7fc66580-61a2-51ed-9be4-56bbc31c791e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f06d76d2-028a-629f-e053-2995a90a80f5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f06d76d2-028a-629f-e053-2995a90a80f5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f06d76d2-028a-629f-e053-2995a90a80f5"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain, prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94482ff7-f5a9-5f48-a581-11459bac5532", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d474ac6a-444d-4aa6-9986-24be6fcf811d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d474ac6a-444d-4aa6-9986-24be6fcf811d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d474ac6a-444d-4aa6-9986-24be6fcf811d"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Amitiza is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fb7f63d-f897-50d5-af49-9bfafdab4409", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2bd6f613-64d0-0291-e063-6294a90a0238", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2bd6f613-64d0-0291-e063-6294a90a0238", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2bd6f613-64d0-0291-e063-6294a90a0238"]}], "subject": "CHEBI:749380", "supporting_text": ["1.1 Chronic Idiopathic Constipation in Adults Lubiprostone is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 1.2 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain Lubiprostone is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a356e0de-154a-57df-b674-7e8204b873b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:006b8b6c-f0eb-4246-87da-67582984b0e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=006b8b6c-f0eb-4246-87da-67582984b0e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=006b8b6c-f0eb-4246-87da-67582984b0e4"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8873aef-e650-565e-8ad2-80a2d55b4043", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9d958b58-6c4f-4bb1-8660-cf5eac256440", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9d958b58-6c4f-4bb1-8660-cf5eac256440", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9d958b58-6c4f-4bb1-8660-cf5eac256440"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain, chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa7677e7-6d67-5adb-9bd7-4979f2bcef60", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic, non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3014dd6d-9c05-479d-b79d-7a49f78a1ce5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3014dd6d-9c05-479d-b79d-7a49f78a1ce5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3014dd6d-9c05-479d-b79d-7a49f78a1ce5"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone capsules are a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. (1.1) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afc69350-d89e-505f-b940-8908eb9f64a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:031149b9-c709-de1f-e063-6394a90a6d81", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=031149b9-c709-de1f-e063-6394a90a6d81", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=031149b9-c709-de1f-e063-6394a90a6d81"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain, chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1436087-c8e3-532b-a968-8630abc2b892", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic, non-cancer pain", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4aed57d0-99d8-424e-a1c7-0cd8a31a66cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4aed57d0-99d8-424e-a1c7-0cd8a31a66cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4aed57d0-99d8-424e-a1c7-0cd8a31a66cf"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: • chronic idiopathic constipation (CIC) in adults. ( 1.1 ) • opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6442f2c-1215-5236-a2bb-9bbab8ddf335", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060131", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:71454e73-a146-5cb1-9dd1-57fa4decab45", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "LUBIPROSTONE", "population_context_qualifier": "adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdf79a5a-6857-4a32-8c54-8c435d1a7535", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdf79a5a-6857-4a32-8c54-8c435d1a7535", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdf79a5a-6857-4a32-8c54-8c435d1a7535"]}], "subject": "CHEBI:749380", "supporting_text": ["1 INDICATIONS AND USAGE Lubiprostone is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08d48fcb-512a-5d96-ade0-518cfaffc1bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["neuroleptic drugs", "phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [145, 169], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01688e6f-7b22-41bf-9a85-1c88d90f99b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01688e6f-7b22-41bf-9a85-1c88d90f99b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01688e6f-7b22-41bf-9a85-1c88d90f99b6"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets, USP are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20218040-6e7a-563a-83de-9a5ed27d1185", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [140, 164], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50c61b1d-49d6-37f2-e063-6294a90a0590", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50c61b1d-49d6-37f2-e063-6294a90a0590", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50c61b1d-49d6-37f2-e063-6294a90a0590"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bb42793-beb6-5382-839d-5fcfa7e6eff9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52bd605a-6a28-c2ec-e063-6294a90a8371", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52bd605a-6a28-c2ec-e063-6294a90a8371", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52bd605a-6a28-c2ec-e063-6294a90a8371"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30847113-2912-5395-bd3c-ddd0819b64e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [140, 164], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ead16a7-88ed-407d-b25a-0d9a1d9da5ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ead16a7-88ed-407d-b25a-0d9a1d9da5ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ead16a7-88ed-407d-b25a-0d9a1d9da5ef"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33697c90-fa50-5272-8fba-55c4fc7c55e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["neuroleptic drugs", "phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [145, 169], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7430b584-2812-4af5-994a-33dd1afed476", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7430b584-2812-4af5-994a-33dd1afed476", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7430b584-2812-4af5-994a-33dd1afed476"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets, USP are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ede9380-d3e0-5629-af98-c17e486ee33b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5035534e-e15c-8f06-e063-6294a90a5003", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5035534e-e15c-8f06-e063-6294a90a5003", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5035534e-e15c-8f06-e063-6294a90a5003"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:489fc8e6-f7c2-53a0-805c-4a42894c7b63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:512ada3e-4b85-d989-e063-6394a90a9d54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=512ada3e-4b85-d989-e063-6394a90a9d54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=512ada3e-4b85-d989-e063-6394a90a9d54"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d208065-55e7-5fcc-b983-8efc39feea79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [140, 164], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae749a71-d253-474d-a26c-bec780c5b09c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae749a71-d253-474d-a26c-bec780c5b09c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae749a71-d253-474d-a26c-bec780c5b09c"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders [except tardive dyskinesia - see PRECAUTIONS ] due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d90c647-4c62-52a0-ad86-4b66798d99eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["neuroleptic drugs", "phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [145, 169], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:241479dd-91bf-455a-80a1-1bb2d1c8156d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=241479dd-91bf-455a-80a1-1bb2d1c8156d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=241479dd-91bf-455a-80a1-1bb2d1c8156d"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets, USP are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f52f3a0-9223-5a2c-8437-9ea82393dc19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bac9dfb7-aa09-4841-9e8f-cc41bb438fe2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bac9dfb7-aa09-4841-9e8f-cc41bb438fe2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bac9dfb7-aa09-4841-9e8f-cc41bb438fe2"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:603c4610-3b85-59bf-963f-cb8ed49afc60", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [140, 164], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:513b1f4c-d253-6ad7-e063-6394a90a1dab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=513b1f4c-d253-6ad7-e063-6394a90a1dab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=513b1f4c-d253-6ad7-e063-6394a90a1dab"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c17637b-dcfa-5120-bacf-8377f1193252", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["neuroleptic drugs", "phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [142, 166], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f92fbafa-314d-4449-831f-26108339e6b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f92fbafa-314d-4449-831f-26108339e6b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f92fbafa-314d-4449-831f-26108339e6b2"]}], "subject": "CHEBI:749396", "supporting_text": ["INDICATIONS For use as an adjunct in the therapy of all forms of parkinsonism (see DOSAGE AND ADMINISTRATION ). Useful also in the control of extrapyramidal disorders (except tardive dyskinesia — see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e99d136-82d8-5545-a94a-1a65ee3d5ed8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53c02a89-012c-e724-e063-6294a90acc75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53c02a89-012c-e724-e063-6294a90acc75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53c02a89-012c-e724-e063-6294a90acc75"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8ce9fbd-b40b-5116-8705-46bbb8fb7415", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df0647b8-2aa7-4aa4-9ba3-82c28698e7c5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df0647b8-2aa7-4aa4-9ba3-82c28698e7c5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df0647b8-2aa7-4aa4-9ba3-82c28698e7c5"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0a8c15d-c714-53a5-8afa-5155160d5723", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09e3e099-0b29-4ab5-bf35-5e41355dd454", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09e3e099-0b29-4ab5-bf35-5e41355dd454", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09e3e099-0b29-4ab5-bf35-5e41355dd454"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorder", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1a30485-828f-5d15-a70b-d64f69e48ef9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [97, 121], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c19664aa-a797-4192-b5f3-e906a7cac048", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c19664aa-a797-4192-b5f3-e906a7cac048", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c19664aa-a797-4192-b5f3-e906a7cac048"]}], "subject": "CHEBI:749396", "supporting_text": ["For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug exposure", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2d0ba4a-ea9a-5827-a386-d6fa81f420ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [129, 153], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b93035b-34d6-4084-ba73-5dea72f9d124", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b93035b-34d6-4084-ba73-5dea72f9d124", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b93035b-34d6-4084-ba73-5dea72f9d124"]}], "subject": "CHEBI:749396", "supporting_text": ["INDICATIONS &amp; USAGE SECTION For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e050eba1-0e2c-5cde-b543-69125882f916", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [140, 164], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:284e78af-7544-4c4a-8081-74e45501dc76", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=284e78af-7544-4c4a-8081-74e45501dc76", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=284e78af-7544-4c4a-8081-74e45501dc76"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders [except tardive dyskinesia - see PRECAUTIONS ] due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e753d302-917f-55d9-bf52-96430207be41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["phenothiazines"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [140, 164], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9270d14c-b885-4679-8871-6f2547450398", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9270d14c-b885-4679-8871-6f2547450398", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9270d14c-b885-4679-8871-6f2547450398"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders [except tardive dyskinesia - see PRECAUTIONS ] due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuroleptic drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee7b3809-435e-51d6-8af7-a7a2db9dd62c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a42e3e-f44a-5928-b375-fdfe64885968", "object": "UMLS:C0015371", "object_location_in_text": [145, 169], "original_object": "extrapyramidal disorders", "original_subject": "BENZTROPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c002005d-a478-48d4-b345-cb87edcb061f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c002005d-a478-48d4-b345-cb87edcb061f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c002005d-a478-48d4-b345-cb87edcb061f"]}], "subject": "CHEBI:749396", "supporting_text": ["Benztropine Mesylate Tablets, USP are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia-see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "poison ivy, poison oak and poison sumac", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d398708f-cc10-5344-8e9d-e5231397620c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8d920e44-9326-58c8-9413-be0c98773889", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7c0b1470-c58e-59db-abdf-e96c000dc93b", "object": "UMLS:C1446325", "object_location_in_text": [206, 224], "original_object": "oozing and weeping", "original_subject": "BROMODIPHENHYDRAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:415f2c69-388f-07a0-e063-6294a90a80d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=415f2c69-388f-07a0-e063-6294a90a80d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=415f2c69-388f-07a0-e063-6294a90a80d9"]}], "subject": "CHEBI:749400", "supporting_text": ["Uses for the temporary relief of pain and itching associated with: minor burns sunburn minor cuts scrapes insect bites minor skin irritations rashes due to poison ivy, poison oak and poison sumac dries the oozing and weeping of poison ivy, poison oak and poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5932543c-4904-5a3f-9912-7e01f5ecf813", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:17a2f643-fa98-21ee-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=17a2f643-fa98-21ee-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17a2f643-fa98-21ee-e054-00144ff88e88"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad3c369d-5bba-516e-93de-8a112a4f627b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "object_location_in_text": [20, 25], "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bca1807a-6040-4001-bce4-57c48e647ded", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bca1807a-6040-4001-bce4-57c48e647ded", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bca1807a-6040-4001-bce4-57c48e647ded"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses A nonnaracotic cough suppressant and antihistamine for the temporary relief of: cough due to minor throat and bronchial irritation runny nose sneezing itching of the nose or throat itchy, watery eyes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4cf1292-2e5c-567f-95d2-789230f329b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "object_location_in_text": [194, 199], "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0bdea30a-39da-6611-e063-6394a90aa4cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0bdea30a-39da-6611-e063-6394a90aa4cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0bdea30a-39da-6611-e063-6394a90aa4cf"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever or other upper respiratory allergies: ■ runny nose ■ itching of the nose or throat ■ sneezing ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd56549e-fd99-55e0-8e14-1ade0e0495f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c7c6756-abb2-c10c-e063-6394a90a9863", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c7c6756-abb2-c10c-e063-6394a90a9863", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c7c6756-abb2-c10c-e063-6394a90a9863"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9016bff-71eb-5b75-bb1e-ccc5826871e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "object_location_in_text": [254, 259], "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf3886ab-62b3-497a-a587-18cbfbaf3634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf3886ab-62b3-497a-a587-18cbfbaf3634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf3886ab-62b3-497a-a587-18cbfbaf3634"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: runny nose sneezing itching of the nose or throat itchy, watery eyes nasal congestion reduces swelling of nasal passages cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb13db24-cac8-5c4d-9201-efba40d9ff6c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "object_location_in_text": [20, 25], "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d046f4ba-5753-4ed5-a924-0b66fd116781", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d046f4ba-5753-4ed5-a924-0b66fd116781", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d046f4ba-5753-4ed5-a924-0b66fd116781"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses A nonnaracotic cough suppressant and antihistamine for the temporary relief of: cough due to minor throat and bronchial irritation runny nose sneezing itching of the nose or throat itchy, watery eyes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1f05f48-bea9-532c-855c-ccd725e82056", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a19f609-159c-5ae3-a9f8-4e70dabb205b", "object": "HP:0012735", "object_location_in_text": [193, 198], "original_object": "cough", "original_subject": "CHLOPHEDIANOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3b8a686f-d8e8-56db-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3b8a686f-d8e8-56db-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b8a686f-d8e8-56db-e054-00144ff8d46c"]}], "subject": "CHEBI:749409", "supporting_text": ["Uses Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: itchy nose or throat sneezing itchy, watery eyes runny nose cough due to minor throat and bronchial irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuromuscular blockade", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04d2404d-8030-56dc-9bc0-8809672d4956", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["neostigmine", "pyridostigmine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f604db16-a909-51a6-b4fd-ddd5acfb8abd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75e7f7c0-8bbe-5c93-81da-331b4726a7b2", "object": "HP:0001662", "object_location_in_text": [540, 551], "original_object": "bradycardia", "original_subject": "GLYCOPYRRONIUM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:62267afe-1a73-4623-984e-646db590ec5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=62267afe-1a73-4623-984e-646db590ec5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=62267afe-1a73-4623-984e-646db590ec5b"]}], "subject": "CHEBI:749411", "supporting_text": ["In Anesthesia: Glycopyrrolate injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, glycopyrrolate injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer : For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "cholinergic agents use", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11bdc2a6-a8de-5b00-a7e8-18d44f53c0f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f604db16-a909-51a6-b4fd-ddd5acfb8abd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75e7f7c0-8bbe-5c93-81da-331b4726a7b2", "object": "HP:0001662", "original_object": "bradycardia", "original_subject": "GLYCOPYRRONIUM", "population_context_qualifier": "patients undergoing anesthesia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:65688bed-0d70-4b51-8301-1948b1deade1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=65688bed-0d70-4b51-8301-1948b1deade1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65688bed-0d70-4b51-8301-1948b1deade1"]}], "subject": "CHEBI:749411", "supporting_text": ["In Anesthesia Glycopyrrolate Injection, USP is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection, USP may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neuromuscular blockade", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32dfe721-3a74-5cee-b094-1654afab9d55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["neostigmine", "pyridostigmine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f604db16-a909-51a6-b4fd-ddd5acfb8abd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75e7f7c0-8bbe-5c93-81da-331b4726a7b2", "object": "HP:0001662", "object_location_in_text": [573, 584], "original_object": "bradycardia", "original_subject": "GLYCOPYRRONIUM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ecb3435-58e5-46cb-b8c2-85b5fd955f83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ecb3435-58e5-46cb-b8c2-85b5fd955f83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ecb3435-58e5-46cb-b8c2-85b5fd955f83"]}], "subject": "CHEBI:749411", "supporting_text": ["INDICATIONS &amp; USAGE In Anesthesia Glycopyrrolate Injection, USP is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection, USP may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. •"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "cholinergic agent toxicity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e40178a1-7c61-5231-9903-015771df849c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["neostigmine", "pyridostigmine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f604db16-a909-51a6-b4fd-ddd5acfb8abd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75e7f7c0-8bbe-5c93-81da-331b4726a7b2", "object": "HP:0001662", "object_location_in_text": [549, 560], "original_object": "bradycardia", "original_subject": "GLYCOPYRRONIUM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:83602e34-7a8c-4606-b43e-23ab909b6c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=83602e34-7a8c-4606-b43e-23ab909b6c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=83602e34-7a8c-4606-b43e-23ab909b6c1a"]}], "subject": "CHEBI:749411", "supporting_text": ["In Anesthesia Glycopyrrolate Injection, USP is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection, USP may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. •"], "temporal_context_qualifier": "following neuromuscular blockade reversal"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0280100", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3889deb4-6f5c-5ad7-bd24-888095427a42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070827", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0280100", "MONDO:0005062", "HP:0006775"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:acabe93f-9e14-56c2-8fbe-c6d07260253e", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fd11318d-e8e1-5c2f-b2d4-2e83a24da742", "object": "MONDO:0002280", "object_location_in_text": [25, 32], "original_object": "anaemia", "original_subject": "epoetin alfa", "population_context_qualifier": "adult patients receiving chemotherapy and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:epoetin-alfa-hexal", "https://www.ema.europa.eu/en/documents/product-information/epoetin-alfa-hexal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal"]}], "subject": "CHEBI:749425", "supporting_text": ["Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:  treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis; Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.  Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1827687", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c54a51e2-fdb0-5ede-a34a-1c62689e20c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020822", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1827687"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0001475", "object_location_in_text": [26, 37], "original_object": "neutropenia", "original_subject": "pegfilgrastim", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pelmeg", "https://www.ema.europa.eu/en/documents/product-information/pelmeg-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pelmeg"]}], "subject": "CHEBI:749426", "supporting_text": ["To reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:143218a9-4bdd-5730-9a62-25f176d87d8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0005550", "object_location_in_text": [100, 109], "original_object": "infection", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a8c290ee-b699-4395-a596-1453d4a4b4eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a8c290ee-b699-4395-a596-1453d4a4b4eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8c290ee-b699-4395-a596-1453d4a4b4eb"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE UDENYCA is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7cf4d8d2-e4fb-51f3-9542-060e5d544f69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0005550", "object_location_in_text": [101, 110], "original_object": "infection", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eeadd641-573d-47fe-897a-61006e5f9e03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eeadd641-573d-47fe-897a-61006e5f9e03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eeadd641-573d-47fe-897a-61006e5f9e03"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e40c953-b248-595d-b4a0-10e5c4b15848", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0005550", "object_location_in_text": [192, 201], "original_object": "infection", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "adults and pediatric patients aged newborn and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99d30b99-2743-446b-98f3-0430bf4ea869", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99d30b99-2743-446b-98f3-0430bf4ea869", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99d30b99-2743-446b-98f3-0430bf4ea869"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Patients with Cancer Receiving Myelosuppressive Chemotherapy NYVEPRIA is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . NYVEPRIA is a leukocyte growth factor indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )"], "temporal_context_qualifier": "receiving myelosuppressive anti-cancer drugs"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8551cc66-cff4-5287-8dba-148310750dc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0005550", "object_location_in_text": [100, 109], "original_object": "infection", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:77a8576f-b91e-42ce-b613-2fa3c3d4a571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=77a8576f-b91e-42ce-b613-2fa3c3d4a571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77a8576f-b91e-42ce-b613-2fa3c3d4a571"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE UDENYCA is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b79322f3-e9df-5b52-bab1-5edc9adfab0c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0005550", "object_location_in_text": [103, 112], "original_object": "infection", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9bfc4d3e-6120-7fec-f1d6-0b3743752034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9bfc4d3e-6120-7fec-f1d6-0b3743752034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bfc4d3e-6120-7fec-f1d6-0b3743752034"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Fulphila is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f926f8ee-4be8-54d5-83de-4f8afa3cecea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "MONDO:0005550", "object_location_in_text": [101, 110], "original_object": "infection", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; adults and pediatric patients aged newborn and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c48fe1a7-63d7-4dce-bb53-a913cb0ade83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c48fe1a7-63d7-4dce-bb53-a913cb0ade83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c48fe1a7-63d7-4dce-bb53-a913cb0ade83"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Armlupeg is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3658261", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:baa9c863-7cee-5219-b6a9-bf44a86fbf5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020822", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C3658261"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [59, 78], "original_object": "febrile neutropenia", "original_subject": "pegfilgrastim", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pelmeg", "https://www.ema.europa.eu/en/documents/product-information/pelmeg-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pelmeg"]}], "subject": "CHEBI:749426", "supporting_text": ["To reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04f1c727-ed22-5f44-a073-34cc56b01c69", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [131, 150], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9bfc4d3e-6120-7fec-f1d6-0b3743752034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9bfc4d3e-6120-7fec-f1d6-0b3743752034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bfc4d3e-6120-7fec-f1d6-0b3743752034"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Fulphila is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a0e849e-0030-5eff-9aae-9040bb06c47c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [129, 148], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; adults and pediatric patients aged newborn and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c48fe1a7-63d7-4dce-bb53-a913cb0ade83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c48fe1a7-63d7-4dce-bb53-a913cb0ade83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c48fe1a7-63d7-4dce-bb53-a913cb0ade83"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Armlupeg is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f2c3f89-43a4-5114-8bbd-80cc4f5e6ef3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [129, 148], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eeadd641-573d-47fe-897a-61006e5f9e03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eeadd641-573d-47fe-897a-61006e5f9e03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eeadd641-573d-47fe-897a-61006e5f9e03"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a9fae54-8c04-501e-b45b-294f420aa4d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [128, 147], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:77a8576f-b91e-42ce-b613-2fa3c3d4a571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=77a8576f-b91e-42ce-b613-2fa3c3d4a571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77a8576f-b91e-42ce-b613-2fa3c3d4a571"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE UDENYCA is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76957843-0623-5808-bb7f-be45cf6d4266", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [220, 239], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "adults and pediatric patients aged newborn and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99d30b99-2743-446b-98f3-0430bf4ea869", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99d30b99-2743-446b-98f3-0430bf4ea869", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99d30b99-2743-446b-98f3-0430bf4ea869"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Patients with Cancer Receiving Myelosuppressive Chemotherapy NYVEPRIA is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . NYVEPRIA is a leukocyte growth factor indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )"], "temporal_context_qualifier": "receiving myelosuppressive anti-cancer drugs"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87c3e006-ccde-5c42-867c-787e925cc8ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [161, 180], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "adult and pediatric patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fdfe5d72-6b80-435a-afa4-c5d74dd852ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fdfe5d72-6b80-435a-afa4-c5d74dd852ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdfe5d72-6b80-435a-afa4-c5d74dd852ce"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE Neulasta is a leukocyte growth factor indicated in adult and pediatric patients to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 )"], "temporal_context_qualifier": "receiving myelosuppressive anti-cancer drugs"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8004648-c116-5edd-b52a-f80abc37e5c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [128, 147], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a8c290ee-b699-4395-a596-1453d4a4b4eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a8c290ee-b699-4395-a596-1453d4a4b4eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8c290ee-b699-4395-a596-1453d4a4b4eb"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE UDENYCA is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fca1795e-1d4f-5e69-8d0e-f618028b8ce1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020131", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b51e477d-110a-5603-a894-2f77f6c33f0a", "object": "UMLS:C0746883", "object_location_in_text": [132, 151], "original_object": "febrile neutropenia", "original_subject": "PEGFILGRASTIM", "population_context_qualifier": "adults and pediatric patients aged newborn and older with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dada041-6528-4acf-809c-62d271538c9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dada041-6528-4acf-809c-62d271538c9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dada041-6528-4acf-809c-62d271538c9a"]}], "subject": "CHEBI:749426", "supporting_text": ["1 INDICATIONS AND USAGE ZIEXTENZO is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 )"], "temporal_context_qualifier": "receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0376545", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cedabe4e-0019-57f7-be03-0d9df9a2ba17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0376545"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c90d3b66-77cd-50c8-933e-8fbbe43545a7", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6d9cfaf6-67f7-55e0-b907-853c85ece6a0", "object": "MONDO:0002492", "object_location_in_text": [71, 90], "original_object": "acute renal failure", "original_subject": "rasburicase", "population_context_qualifier": "adults, children and adolescents (aged 0 to 17 years); at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:fasturtec", "https://www.ema.europa.eu/en/documents/product-information/fasturtec-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec"]}], "subject": "CHEBI:749439", "supporting_text": ["Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy."], "temporal_context_qualifier": "at initiation of chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0376545", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2a86c6a-2b4c-5bf6-804f-0982cc98da14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010223", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0376545"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:781a3601-0fea-5cce-b6fb-c2e93c15ead9", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6d9cfaf6-67f7-55e0-b907-853c85ece6a0", "object": "HP:0002149", "object_location_in_text": [29, 49], "original_object": "acute hyperuricaemia", "original_subject": "rasburicase", "population_context_qualifier": "adults, children and adolescents (aged 0 to 17 years); at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:fasturtec", "https://www.ema.europa.eu/en/documents/product-information/fasturtec-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec"]}], "subject": "CHEBI:749439", "supporting_text": ["Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy."], "temporal_context_qualifier": "at initiation of chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system manifestations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11a2d32f-a69b-543a-881f-ddd203780a04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19940523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6f50ecc7-d42d-5ca3-bdcf-278125bfafc4", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e85303bf-befa-5b79-b9b2-cafbc25f32bd", "object": "MONDO:0009265", "original_object": "Type 1 Gaucher disease", "original_subject": "IMIGLUCERASE", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df60f030-866b-4374-a31f-8ae3f6b45c38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df60f030-866b-4374-a31f-8ae3f6b45c38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df60f030-866b-4374-a31f-8ae3f6b45c38"]}], "subject": "CHEBI:749442", "supporting_text": ["1 INDICATIONS AND USAGE CEREZYME is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. CEREZYME is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system manifestations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:664c1084-6d8a-5a96-98c2-617888ca4de0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19940523", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ac318f4-4a93-5428-aeb6-645b7e838fb7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e85303bf-befa-5b79-b9b2-cafbc25f32bd", "object": "MONDO:0009267", "object_location_in_text": [128, 150], "original_object": "Type 3 Gaucher disease", "original_subject": "IMIGLUCERASE", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df60f030-866b-4374-a31f-8ae3f6b45c38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df60f030-866b-4374-a31f-8ae3f6b45c38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df60f030-866b-4374-a31f-8ae3f6b45c38"]}], "subject": "CHEBI:749442", "supporting_text": ["1 INDICATIONS AND USAGE CEREZYME is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. CEREZYME is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "normal or increased intravascular volume", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ad17283-95ca-54a2-8bc6-8bda13fb0d92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19760723", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3fd3c0f-dffe-5055-946d-f48a4384a5d8", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9e140c-f5ce-55e6-bc1a-e798d1d0640f", "object": "MONDO:0002280", "object_location_in_text": [130, 143], "original_object": "Severe anemia", "original_subject": "ALBUMIN HUMAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:167f48d0-8ae5-4f7e-b050-9673dad78acc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=167f48d0-8ae5-4f7e-b050-9673dad78acc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=167f48d0-8ae5-4f7e-b050-9673dad78acc"]}], "subject": "CHEBI:749447", "supporting_text": ["4 CONTRAINDICATIONS ALBUMINEX 25% is contraindicated in patients with: Hypersensitivity to human albumin or any of the excipients Severe anemia or cardiac failure with normal or increased intravascular volume Hypersensitivity to human albumin or the excipients Severe anemia or cardiac failure with normal or increased intravascular volume"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "with normal or increased intravascular volume", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1e77ed4-8ddc-5ce3-b2ce-71ded29f8ae0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19760723", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3fd3c0f-dffe-5055-946d-f48a4384a5d8", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9e140c-f5ce-55e6-bc1a-e798d1d0640f", "object": "MONDO:0002280", "object_location_in_text": [129, 142], "original_object": "Severe anemia", "original_subject": "ALBUMIN HUMAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8428d373-f4b1-4e3b-bb19-ea89048f7c79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8428d373-f4b1-4e3b-bb19-ea89048f7c79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8428d373-f4b1-4e3b-bb19-ea89048f7c79"]}], "subject": "CHEBI:749447", "supporting_text": ["4 CONTRAINDICATIONS ALBUMINEX 5% is contraindicated in patients with: Hypersensitivity to human albumin or any of the excipients Severe anemia or cardiac failure with normal or increased intravascular volume Hypersensitivity to human albumin or the excipients Severe anemia or cardiac failure with normal or increased intravascular volume"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "normal or increased intravascular volume", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9a43eff-5807-576b-9a4f-cf1bc4e9418a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19760723", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:71b2b4a4-bf42-5f71-9ef4-7f6ecea21315", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9e140c-f5ce-55e6-bc1a-e798d1d0640f", "object": "MONDO:0005009", "original_object": "Cardiac failure", "original_subject": "ALBUMIN HUMAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:167f48d0-8ae5-4f7e-b050-9673dad78acc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=167f48d0-8ae5-4f7e-b050-9673dad78acc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=167f48d0-8ae5-4f7e-b050-9673dad78acc"]}], "subject": "CHEBI:749447", "supporting_text": ["4 CONTRAINDICATIONS ALBUMINEX 25% is contraindicated in patients with: Hypersensitivity to human albumin or any of the excipients Severe anemia or cardiac failure with normal or increased intravascular volume Hypersensitivity to human albumin or the excipients Severe anemia or cardiac failure with normal or increased intravascular volume"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "with normal or increased intravascular volume", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:531bbaaa-850d-5e1e-b60d-8d6f2400b83c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19760723", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:71b2b4a4-bf42-5f71-9ef4-7f6ecea21315", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:de9e140c-f5ce-55e6-bc1a-e798d1d0640f", "object": "MONDO:0005252", "object_location_in_text": [146, 161], "original_object": "cardiac failure", "original_subject": "ALBUMIN HUMAN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8428d373-f4b1-4e3b-bb19-ea89048f7c79", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8428d373-f4b1-4e3b-bb19-ea89048f7c79", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8428d373-f4b1-4e3b-bb19-ea89048f7c79"]}], "subject": "CHEBI:749447", "supporting_text": ["4 CONTRAINDICATIONS ALBUMINEX 5% is contraindicated in patients with: Hypersensitivity to human albumin or any of the excipients Severe anemia or cardiac failure with normal or increased intravascular volume Hypersensitivity to human albumin or the excipients Severe anemia or cardiac failure with normal or increased intravascular volume"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C5392833", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83fac1ce-5504-5bc2-9450-70935e908d34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871113", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5392833"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:630c9f40-dd19-5cfa-b23f-38d5fd821740", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2656f85-16c4-5546-88dd-9f3f2456a6cb", "object": "MONDO:0005099", "object_location_in_text": [380, 403], "original_object": "Subarachnoid hemorrhage", "original_subject": "ALTEPLASE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c669f77c-fa48-478b-a14b-80b20a0139c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2"]}], "subject": "CHEBI:749459", "supporting_text": ["4 CONTRAINDICATIONS General Active internal bleeding. ( 4.1 , 4.2 ) Recent intracranial or intraspinal surgery or serious head trauma. ( 4.1 , 4.2 ) Intracranial conditions that may increase the risk of bleeding. ( 4.1 , 4.2 ) Bleeding diathesis. ( 4.1 , 4.2 ) Current severe uncontrolled hypertension. ( 4.1 , 4.2 ) Acute Ischemic Stroke Current intracranial hemorrhage. ( 4.1 ) Subarachnoid hemorrhage. ( 4.1 ) Acute Myocardial Infarction or Pulmonary Embolism History of recent stroke. ( 4.2 ) 4.1 Acute Ischemic Stroke Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit [see Warnings and Precautions (5.1) ] : Current intracranial hemorrhage Subarachnoid hemorrhage Active internal bleeding Recent (within 3 months) intracranial or intraspinal surgery or serious head trauma Presence of intracranial conditions that may increase the risk of bleeding (e.g., some neoplasms, arteriovenous malformations, or aneurysms) Bleeding diathesis Current severe uncontrolled hypertension. 4.2 Acute Myocardial Infarction or Pulmonary Embolism Do not administer Activase for treatment of AMI or PE in the following situations in which the risk of bleeding is greater than the potential benefit [see Warnings and Precautions (5.1) ]: Active internal bleeding History of recent stroke Recent (within 3 months) intracranial or intraspinal surgery or serious head trauma Presence of intracranial conditions that may increase the risk of bleeding (e.g. some neoplasms, arteriovenous malformations, or aneurysms) Bleeding diathesis Current severe uncontrolled hypertension."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:052af363-7b75-5483-a347-b1b56eda2d0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0001475", "original_object": "neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575d164d-45fa-4e3e-81e4-2652d96673d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575d164d-45fa-4e3e-81e4-2652d96673d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575d164d-45fa-4e3e-81e4-2652d96673d1"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NYPOZI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ]. 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NYPOZI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ]. 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NYPOZI is indicated to reduce the duratio"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:82549152-d24d-5a96-a5ab-aa384f44d5e0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3c45f0f-88e0-5234-9f82-78a8a57bc5da", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "object": "MONDO:0001475", "object_location_in_text": [70, 88], "original_object": "severe neutropenia", "original_subject": "FILGRASTIM", "population_context_qualifier": "adult and pediatric patients 1 month and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df918ec2-0907-443f-a52a-b72866959644", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df918ec2-0907-443f-a52a-b72866959644", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df918ec2-0907-443f-a52a-b72866959644"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )"], "temporal_context_qualifier": "receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ea5aec1-cd23-5374-bae3-78c03cef29f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0001475", "original_object": "neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0d1c22b-566b-4776-bdbf-00f96dad0cae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZARXIO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies ( 14.1 )] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy ZARXIO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies ( 14.2 )] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation ZARXIO is indicated to red"], "temporal_context_qualifier": "following myeloablative chemotherapy and bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92e83feb-de4d-52ce-9382-d73412e08972", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0001475", "object_location_in_text": [136, 147], "original_object": "neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89092bb8-6a20-e23e-e053-2a95a90aa750", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89092bb8-6a20-e23e-e053-2a95a90aa750", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89092bb8-6a20-e23e-e053-2a95a90aa750"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NYPOZI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NYPOZI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NYPOZI is indicated to reduce the durat"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b941c716-ab39-545b-a010-211465119882", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0001475", "object_location_in_text": [145, 156], "original_object": "neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3bc802bd-76b4-4f45-8571-a436ec26228e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3bc802bd-76b4-4f45-8571-a436ec26228e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3bc802bd-76b4-4f45-8571-a436ec26228e"]}], "subject": "CHEBI:749461", "supporting_text": ["Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can le"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d26cf8bc-993c-5889-9e98-8919078b8dd0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0001475", "object_location_in_text": [137, 148], "original_object": "neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74e1ec6e-1630-4654-895c-2bd355f939e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74e1ec6e-1630-4654-895c-2bd355f939e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74e1ec6e-1630-4654-895c-2bd355f939e7"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE RELEUKO is a leukocyte growth factor indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy RELEUKO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies ( 14.1 )]. 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy RELEUKO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies ( 14.2 )]. 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation RELEUKO is indicated to reduce "], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d511236f-738a-5a38-a8c7-6326fce37cb8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0001475", "object_location_in_text": [135, 146], "original_object": "neutropenia", "original_subject": "FILGRASTIM", "population_context_qualifier": "patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c2f9573-08fd-43be-a489-8a5e5d8ab2ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c2f9573-08fd-43be-a489-8a5e5d8ab2ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c2f9573-08fd-43be-a489-8a5e5d8ab2ff"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE FILKRI is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy FILKRI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy FILKRI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation FILKRI is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid m"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b35d3bd-5371-51cf-a2e0-b4d611073cc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "MONDO:0005550", "object_location_in_text": [99, 108], "original_object": "infection", "original_subject": "FILGRASTIM", "population_context_qualifier": "patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c2f9573-08fd-43be-a489-8a5e5d8ab2ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c2f9573-08fd-43be-a489-8a5e5d8ab2ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c2f9573-08fd-43be-a489-8a5e5d8ab2ff"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE FILKRI is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy FILKRI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy FILKRI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation FILKRI is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid m"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26c086d8-d568-56ac-9cf7-7f5b4b96444f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [131, 150], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d23ab39c-b6ec-41cf-a529-9dd2852c9d9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d23ab39c-b6ec-41cf-a529-9dd2852c9d9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d23ab39c-b6ec-41cf-a529-9dd2852c9d9a"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid maligna"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3be1f054-a55f-5bf9-9624-5090de43a5b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [128, 147], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89092bb8-6a20-e23e-e053-2a95a90aa750", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89092bb8-6a20-e23e-e053-2a95a90aa750", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89092bb8-6a20-e23e-e053-2a95a90aa750"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NYPOZI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NYPOZI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NYPOZI is indicated to reduce the durat"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:798ef03a-bcaf-59fb-a9a3-8e62f76ae9ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [129, 148], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0d1c22b-566b-4776-bdbf-00f96dad0cae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZARXIO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies ( 14.1 )] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy ZARXIO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies ( 14.2 )] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation ZARXIO is indicated to red"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8614fefc-35d0-5fec-aca5-92ca8d1a2cf2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [127, 146], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "population_context_qualifier": "patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c2f9573-08fd-43be-a489-8a5e5d8ab2ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c2f9573-08fd-43be-a489-8a5e5d8ab2ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c2f9573-08fd-43be-a489-8a5e5d8ab2ff"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE FILKRI is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy FILKRI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy FILKRI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation FILKRI is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid m"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6148f9f-dfd0-5cc6-acc1-d87b367a77cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [128, 147], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:575d164d-45fa-4e3e-81e4-2652d96673d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=575d164d-45fa-4e3e-81e4-2652d96673d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=575d164d-45fa-4e3e-81e4-2652d96673d1"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NYPOZI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ]. 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NYPOZI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ]. 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NYPOZI is indicated to reduce the duratio"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dcd7954a-a8e1-54a2-bcc6-ac2d1a8fcb8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [137, 156], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3bc802bd-76b4-4f45-8571-a436ec26228e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3bc802bd-76b4-4f45-8571-a436ec26228e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3bc802bd-76b4-4f45-8571-a436ec26228e"]}], "subject": "CHEBI:749461", "supporting_text": ["Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can le"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmyeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e00802a0-2d84-5133-bda2-fafc7ea7688a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0746883", "object_location_in_text": [129, 148], "original_object": "febrile neutropenia", "original_subject": "FILGRASTIM", "population_context_qualifier": "patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97cc73cc-b5b7-458a-a933-77b00523e193", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NEUPOGEN is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NEUPOGEN is indicated to reduce th"], "temporal_context_qualifier": "undergoing myeloablative chemotherapy followed by bone marrow transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hematopoietic Syndrome of Acute Radiation Syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a47e9b6-4c30-52ed-9996-a5372b9bf2cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c5f207e-fcdb-5f3c-9650-683ba3ed1e68", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0220921", "object_location_in_text": [1084, 1092], "original_object": "survival", "original_subject": "FILGRASTIM", "population_context_qualifier": "patients acutely exposed to myelosuppressive doses of radiation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97cc73cc-b5b7-458a-a933-77b00523e193", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NEUPOGEN is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NEUPOGEN is indicated to reduce th"], "temporal_context_qualifier": "acutely exposed to myelosuppressive doses of radiation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Hematopoietic Syndrome of Acute Radiation Syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b67d1d18-cecf-5b34-ac7f-7dc2ad2aae97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6c5f207e-fcdb-5f3c-9650-683ba3ed1e68", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f2a64c9a-ee18-5b9c-927f-9658fee570f8", "medic_supporting_text_truncated": true, "object": "UMLS:C0220921", "object_location_in_text": [1094, 1102], "original_object": "survival", "original_subject": "FILGRASTIM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0d1c22b-566b-4776-bdbf-00f96dad0cae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae"]}], "subject": "CHEBI:749461", "supporting_text": ["1 INDICATIONS AND USAGE ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZARXIO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies ( 14.1 )] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy ZARXIO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies ( 14.2 )] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation ZARXIO is indicated to red"], "temporal_context_qualifier": "acutely exposed to myelosuppressive doses of radiation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active rheumatoid arthritis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:159183c0-27bd-5681-a338-852a56a0c9b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["methotrexate", "non-biologic disease-modifying anti-rheumatic drugs (DMARDs)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0008383", "object_location_in_text": [294, 314], "original_object": "rheumatoid arthritis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c24655e5-796e-4127-b716-92f08d649c83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c24655e5-796e-4127-b716-92f08d649c83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c24655e5-796e-4127-b716-92f08d649c83"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE Adalimumab-bwwd is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ) . • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ) . • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ) . • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active Crohn's disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f664817f-a948-5fbd-82b2-61e873f64dcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a82e12e2-e9e6-5717-a5f3-b8af061469fe", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0005011", "original_object": "Crohn's disease", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active ulcerative colitis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbce4851-1ad3-5772-97d6-6ba5614edc56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0005101", "object_location_in_text": [898, 916], "original_object": "ulcerative colitis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe active ankylosing spondylitis with inadequate response to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:349376f9-8179-5839-97e9-5f118ca76228", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "object_location_in_text": [1619, 1641], "original_object": "ankylosing spondylitis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:amsparity", "https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Amsparity in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis  Amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis  Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis (AS)  Amsparity is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS  Amsparity is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fcabf72-2a00-57b9-bcae-0fed7fbc755b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "original_object": "ankylosing spondylitis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hukyndra", "https://www.ema.europa.eu/en/documents/product-information/hukyndra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis \t\t\tHukyndra in combination with methotrexate, is indicated for: \t\t\t- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate. \t\t\t- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis \t\t\tPolyarticular juvenile idiopathic arthritis \t\t\tHukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more DMARD. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis \t\t\tHukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis \t\t\tAnkylosing spondylitis (AS) \t\t\tHukyndra is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS \t\t\tHukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe active ankylosing spondylitis with inadequate response to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ccdb76ae-e852-5af0-867e-6bd766627704", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "object_location_in_text": [1674, 1696], "original_object": "ankylosing spondylitis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yuflyma", "https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Yuflyma in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "not previously treated with methotrexate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:403c8926-b9ab-5ab2-9205-b8cf2ff21d8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "object_location_in_text": [126, 146], "original_object": "rheumatoid arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imraldi", "https://www.ema.europa.eu/en/documents/product-information/imraldi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Imraldi in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis  Polyarticular juvenile idiopathic arthritis  Imraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.  Enthesitis-related arthritis  Imraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis  Ankylosing spondylitis (AS)  Imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.  Axial spondyloarthritis without radiographic evidence of AS  Imraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CR"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe, active and progressive rheumatoid arthritis not previously treated with methotrexate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1c5821f-2689-5260-baa6-a77b827c9f94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "object_location_in_text": [128, 148], "original_object": "rheumatoid arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:amsparity", "https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Amsparity in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis  Amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis  Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis (AS)  Amsparity is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS  Amsparity is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe, active and progressive rheumatoid arthritis not previously treated with methotrexate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0dd86af-5e2a-55b6-b19d-1ea621fd3c5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "object_location_in_text": [127, 147], "original_object": "rheumatoid arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yuflyma", "https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Yuflyma in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe, active and progressive rheumatoid arthritis not previously treated with methotrexate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8eb0cbd-bd53-5a85-a351-e42dea4343aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "object_location_in_text": [134, 154], "original_object": "rheumatoid arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hukyndra", "https://www.ema.europa.eu/en/documents/product-information/hukyndra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis \t\t\tHukyndra in combination with methotrexate, is indicated for: \t\t\t- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate. \t\t\t- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis \t\t\tPolyarticular juvenile idiopathic arthritis \t\t\tHukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more DMARD. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis \t\t\tHukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis \t\t\tAnkylosing spondylitis (AS) \t\t\tHukyndra is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS \t\t\tHukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active rheumatoid arthritis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a94a75df-2cac-57fe-9055-69d078b4cb34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate", "non-biologic disease-modifying anti-rheumatic drugs (DMARDs)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0008383", "object_location_in_text": [286, 306], "original_object": "rheumatoid arthritis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous disease-modifying anti-rheumatic drug therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:003a0340-cf9e-555f-b09b-a183b35fc076", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imraldi", "https://www.ema.europa.eu/en/documents/product-information/imraldi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Imraldi in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis  Polyarticular juvenile idiopathic arthritis  Imraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.  Enthesitis-related arthritis  Imraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis  Ankylosing spondylitis (AS)  Imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.  Axial spondyloarthritis without radiographic evidence of AS  Imraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CR"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "active and progressive psoriatic arthritis with inadequate response to previous disease-modifying anti-rheumatic drug therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03d5cb5d-c2f1-531b-8cbc-cb59a6886f66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yuflyma", "https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Yuflyma in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "active and progressive psoriatic arthritis with inadequate response to previous disease-modifying anti-rheumatic drug therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7754cca1-1049-5984-a8a0-9da2039eefe9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:amsparity", "https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Amsparity in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis  Amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis  Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis (AS)  Amsparity is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS  Amsparity is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous DMARD therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0c75070-ba4f-5ba6-9efe-a1ca1be43e3a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hukyndra", "https://www.ema.europa.eu/en/documents/product-information/hukyndra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis \t\t\tHukyndra in combination with methotrexate, is indicated for: \t\t\t- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate. \t\t\t- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis \t\t\tPolyarticular juvenile idiopathic arthritis \t\t\tHukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more DMARD. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis \t\t\tHukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis \t\t\tAnkylosing spondylitis (AS) \t\t\tHukyndra is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS \t\t\tHukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4beaba36-c996-596c-8c77-90bb36b2b8a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0018456", "object_location_in_text": [864, 907], "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "patients from the age of 2 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yuflyma", "https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Yuflyma in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to one or more DMARD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8eea6cf-ddfe-50d7-b286-a97c96c3175b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0018456", "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "patients from the age of 2 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hukyndra", "https://www.ema.europa.eu/en/documents/product-information/hukyndra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis \t\t\tHukyndra in combination with methotrexate, is indicated for: \t\t\t- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate. \t\t\t- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis \t\t\tPolyarticular juvenile idiopathic arthritis \t\t\tHukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more DMARD. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis \t\t\tHukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis \t\t\tAnkylosing spondylitis (AS) \t\t\tHukyndra is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS \t\t\tHukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4594b1b-694d-5621-8124-6a49f6de3d58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0018456", "object_location_in_text": [869, 912], "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "adalimumab", "population_context_qualifier": "patients from the age of 2 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:amsparity", "https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Amsparity in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis  Amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis  Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis (AS)  Amsparity is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS  Amsparity is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active polyarticular juvenile idiopathic arthritis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a8d1bc7-8265-5c05-a10e-bb074a92290d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0018456", "object_location_in_text": [378, 421], "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to, or intolerant of, conventional therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:00d488cf-2dc4-5e69-9e2b-38079d6e3763", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b9313d76-9078-5e32-93fe-37c4eba691c8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0019437", "original_object": "enthesitis-related arthritis", "original_subject": "adalimumab", "population_context_qualifier": "patients, 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hukyndra", "https://www.ema.europa.eu/en/documents/product-information/hukyndra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis \t\t\tHukyndra in combination with methotrexate, is indicated for: \t\t\t- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate. \t\t\t- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis \t\t\tPolyarticular juvenile idiopathic arthritis \t\t\tHukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more DMARD. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis \t\t\tHukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis \t\t\tAnkylosing spondylitis (AS) \t\t\tHukyndra is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS \t\t\tHukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to, or intolerance of, conventional therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a11e6ea8-b12c-57cb-bf68-b65bcc4f8efd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b9313d76-9078-5e32-93fe-37c4eba691c8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0019437", "object_location_in_text": [1340, 1368], "original_object": "enthesitis-related arthritis", "original_subject": "adalimumab", "population_context_qualifier": "patients, 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:amsparity", "https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Amsparity in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis  Amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis  Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis (AS)  Amsparity is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS  Amsparity is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to, or intolerance of, conventional therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8b3e67a-e59f-5655-bfbd-898b8c9e69ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b9313d76-9078-5e32-93fe-37c4eba691c8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "MONDO:0019437", "object_location_in_text": [1380, 1408], "original_object": "enthesitis-related arthritis", "original_subject": "adalimumab", "population_context_qualifier": "patients, 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yuflyma", "https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Yuflyma in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-infectious intermediate, posterior, and panuveitis", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2630dfc3-9170-59db-a3ef-6ec9889fc384", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7345f276-102e-4175-b7ef-ff1706b05472", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7345f276-102e-4175-b7ef-ff1706b05472", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7345f276-102e-4175-b7ef-ff1706b05472"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-infectious intermediate, posterior, and panuveitis", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ba911ef-7b11-5e2c-9504-cb4d460decb2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef25af7e-6267-409a-8d68-de51eb48812a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef25af7e-6267-409a-8d68-de51eb48812a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef25af7e-6267-409a-8d68-de51eb48812a"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe chronic plaque psoriasis with inadequate response to or inappropriate candidacy for topical therapy and phototherapies", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:17561522-af0f-5bd3-b6f8-edd0df5ff6ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:e9560931-c961-5226-86dc-27ddc31ab723", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "UMLS:C0406317", "original_object": "chronic plaque psoriasis", "original_subject": "adalimumab", "population_context_qualifier": "children and adolescents from 4 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yuflyma", "https://www.ema.europa.eu/en/documents/product-information/yuflyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yuflyma"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Yuflyma in combination with methotrexate, is indicated for: - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to or inappropriate candidates for topical therapy and phototherapies", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75e4a964-40d7-576a-86c1-aa8facda328b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:e9560931-c961-5226-86dc-27ddc31ab723", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "UMLS:C0406317", "original_object": "chronic plaque psoriasis", "original_subject": "adalimumab", "population_context_qualifier": "children and adolescents from 4 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:amsparity", "https://www.ema.europa.eu/en/documents/product-information/amsparity-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis Amsparity in combination with methotrexate, is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis  Amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis  Amsparity is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis Ankylosing spondylitis (AS)  Amsparity is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS  Amsparity is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to or inappropriate candidates for topical therapy and phototherapies", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b08ddbed-e444-5baf-92ff-b71b7d5624f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030908", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ee93ee5f-e83d-55f7-af27-50276dc72620", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "medic_supporting_text_truncated": true, "object": "UMLS:C0406317", "original_object": "severe chronic plaque psoriasis", "original_subject": "adalimumab", "population_context_qualifier": "children and adolescents from 4 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:hukyndra", "https://www.ema.europa.eu/en/documents/product-information/hukyndra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/hukyndra"]}], "subject": "CHEBI:749494", "supporting_text": ["Rheumatoid arthritis \t\t\tHukyndra in combination with methotrexate, is indicated for: \t\t\t- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate has been inadequate. \t\t\t- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis \t\t\tPolyarticular juvenile idiopathic arthritis \t\t\tHukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more DMARD. Hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis \t\t\tHukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). Axial spondyloarthritis \t\t\tAnkylosing spondylitis (AS) \t\t\tHukyndra is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS \t\t\tHukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have ha"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b39938c-5a74-5d34-a02e-f97a7b30dab7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9560931-c961-5226-86dc-27ddc31ab723", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "UMLS:C0406317", "original_object": "chronic plaque psoriasis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients who are candidates for systemic therapy or phototherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f609c9-2088-bb05-e063-6394a90a9ecc"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc2a8dbd-b701-5aff-add6-02071608cc8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021231", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e9560931-c961-5226-86dc-27ddc31ab723", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "UMLS:C0406317", "original_object": "chronic plaque psoriasis", "original_subject": "ADALIMUMAB", "population_context_qualifier": "adult patients who are candidates for systemic therapy or phototherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:608d4f0d-b19f-46d3-749a-7159aa5f933d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d"]}], "subject": "CHEBI:749494", "supporting_text": ["1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "insufficient response to conventional therapies", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b83d843-bb14-5ec1-a93b-985de49a9702", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:07773804-25ba-5688-aed3-1302a65d38c3", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "UMLS:C4518725", "original_object": "non-infectious panuveitis", "original_subject": "ADALIMUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ADALIMUMAB#101-20160928", "https://www.pmda.go.jp/files/000224547.pdf"]}], "subject": "CHEBI:749494", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of non-infectious intermediate, posterior, and panuveitis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "insufficient response to conventional therapies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d5c7e43-f4f7-561e-84f3-6faeee476e0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:614837d0-7c73-5ce1-bbfd-c6bd2619570f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf393db8-a321-54e5-9b04-7fc8e7e1347d", "object": "UMLS:C5396634", "original_object": "non-infectious posterior uveitis", "original_subject": "ADALIMUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ADALIMUMAB#101-20160928", "https://www.pmda.go.jp/files/000224547.pdf"]}], "subject": "CHEBI:749494", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of non-infectious intermediate, posterior, and panuveitis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-resistant recurrent disease", "has_confidence_score": 0.095, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d124ff2-f2ac-554b-93ae-131c354481ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040226", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel", "pegylated liposomal doxorubicin", "topotecan"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6baec09c-c6b1-517f-88ee-6894ac2e3db6", "medic_pair_confidence": 0.095, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ef107c27-9e80-5e3d-ba5c-ccfd1a954edf", "object": "MONDO:0005140", "original_object": "epithelial ovarian cancer", "original_subject": "BEVACIZUMAB", "population_context_qualifier": "patients who received no more than 2 prior chemotherapy regimens", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b4040a2-a5c5-4ff0-ab45-935d7e49cf78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b4040a2-a5c5-4ff0-ab45-935d7e49cf78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b4040a2-a5c5-4ff0-ab45-935d7e49cf78"]}], "subject": "CHEBI:749495", "supporting_text": ["1 INDICATIONS AND USAGE Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "platinum-resistant recurrent disease", "has_confidence_score": 0.08075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c143ba73-2e11-599f-9bf9-23f880f86f58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040226", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["paclitaxel", "pegylated liposomal doxorubicin", "topotecan"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6baec09c-c6b1-517f-88ee-6894ac2e3db6", "medic_pair_confidence": 0.095, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97354a23-ad24-5145-a110-127a56339c52", "object": "MONDO:0005140", "original_object": "epithelial ovarian cancer", "original_subject": "BEVACIZUMAB-MALY", "population_context_qualifier": "patients who received no more than 2 prior chemotherapy regimens", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42b4f96e-1f70-2126-e063-6294a90a93e3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42b4f96e-1f70-2126-e063-6294a90a93e3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42b4f96e-1f70-2126-e063-6294a90a93e3"]}], "subject": "CHEBI:749495", "supporting_text": ["1 INDICATIONS AND USAGE Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "symptomatic despite H1 antihistamine treatment", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92a5d839-6dd4-5f50-ad64-5ef7e5080101", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32052b22-b110-5392-a66b-e9dd59068c5b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e670d4f8-b57e-5d01-b1ae-74cc0ab93d74", "object": "HP:0410133", "original_object": "chronic spontaneous urticaria", "original_subject": "OMALIZUMAB", "population_context_qualifier": "adults and adolescents 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f6a2191-adfb-48b9-9bfa-0d9920479f0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d"]}], "subject": "CHEBI:749497", "supporting_text": ["1 INDICATIONS AND USAGE XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "perennial aeroallergen reactivity", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d73cc826-bdb1-5753-b89b-680ab2045a0c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:951ebaf4-04d5-5b19-bfe9-8a3d2e8e67f0", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e670d4f8-b57e-5d01-b1ae-74cc0ab93d74", "object": "MONDO:0004979", "original_object": "moderate to severe persistent asthma", "original_subject": "OMALIZUMAB", "population_context_qualifier": "adults and pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f6a2191-adfb-48b9-9bfa-0d9920479f0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d"]}], "subject": "CHEBI:749497", "supporting_text": ["1 INDICATIONS AND USAGE XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "perennial aeroallergen reactivity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10f16f90-729c-550c-a669-c96a6aa9864b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7a7eadb5-2dd8-538f-893a-15059f9200db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e670d4f8-b57e-5d01-b1ae-74cc0ab93d74", "object": "UMLS:C4041248", "object_location_in_text": [371, 404], "original_object": "severe persistent allergic asthma", "original_subject": "omalizumab", "population_context_qualifier": "children (6 to <12 years of age)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:omlyclo", "https://www.ema.europa.eu/en/documents/product-information/omlyclo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/omlyclo"]}], "subject": "CHEBI:749497", "supporting_text": ["Allergic asthma Omlyclo is indicated in adults, adolescents and children (6 to &lt;12 years of age).&nbsp; Omlyclo treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2). Adults and adolescents (12 years of age and older) Omlyclo is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 &lt;80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Children (6 to &lt;12 years of age) Omlyclo is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Chronic rhinosinusitis with nasal polyps (CRSwNP) Omlyclo is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control. Chronic spontaneous urticaria (CSU) Omlyclo is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "perennial aeroallergen reactivity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c60c0931-0972-5048-87be-4721f60b100e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7a7eadb5-2dd8-538f-893a-15059f9200db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e670d4f8-b57e-5d01-b1ae-74cc0ab93d74", "object": "UMLS:C4041248", "object_location_in_text": [354, 387], "original_object": "severe persistent allergic asthma", "original_subject": "omalizumab", "population_context_qualifier": "children (6 to <12 years of age)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xolair", "https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xolair"]}], "subject": "CHEBI:749497", "supporting_text": ["Allergic asthma Xolair is indicated in adults, adolescents and children (6 to &lt;12&nbsp;years of age). Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. Adults and adolescents (12&nbsp;years of age and older) Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 &lt;80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Children (6 to &lt;12&nbsp;years of age) Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Chronic rhinosinusitis with nasal polyps (CRSwNP) Xolair is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18&nbsp;years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control. Chronic spontaneous urticaria (CSU) Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response to nasal corticosteroids", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f0fe45f-8bd6-5771-979b-622e0b471049", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030620", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d46f369-9d63-5674-a16b-e8d2232e756b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e670d4f8-b57e-5d01-b1ae-74cc0ab93d74", "object": "UMLS:C4524092", "original_object": "chronic rhinosinusitis with nasal polyps", "original_subject": "OMALIZUMAB", "population_context_qualifier": "adult patients 18 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f6a2191-adfb-48b9-9bfa-0d9920479f0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d"]}], "subject": "CHEBI:749497", "supporting_text": ["1 INDICATIONS AND USAGE XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "plateau-phase-multiple-myeloma", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ec08285-5c39-5f4c-95b5-1bfb25d00896", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080424", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7e17d71e-9b5b-5857-80ee-caabd1eb496e", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:eb5f1704-7fe1-55a3-a1ca-b5514ff90e8f", "object": "HP:0002718", "object_location_in_text": [181, 211], "original_object": "recurrent bacterial infections", "original_subject": "human normal immunoglobulin (IVIg)", "population_context_qualifier": "plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:privigen", "https://www.ema.europa.eu/en/documents/product-information/privigen-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/privigen"]}], "subject": "CHEBI:749498", "supporting_text": ["Replacement therapy in adults, and children and adolescents (0-18 years) in:  primary immunodeficiency (PID) syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT); congenital AIDS with recurrent bacterial infections.  Immunomodulation in adults, and children and adolescents (0-18 years) in:  primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain-Barré syndrome; Kawasaki disease; chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "plateau-phase-multiple-myeloma", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8346e8c9-1d71-5535-b24f-840d4e50f0cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060119", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7e17d71e-9b5b-5857-80ee-caabd1eb496e", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:57afc241-4624-5a70-94b4-16e6b577f089", "object": "HP:0002718", "object_location_in_text": [171, 201], "original_object": "recurrent bacterial infections", "original_subject": "human normal immunoglobulin", "population_context_qualifier": "adults, children and adolescents (0-18 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:flebogamma-dif", "https://www.ema.europa.eu/en/documents/product-information/flebogamma-dif-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif"]}], "subject": "CHEBI:749498", "supporting_text": ["Replacement therapy in adults, children and adolescents (0-18 years) in:  primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT); congenital AIDS with recurrent bacterial infections.  Immunomodulation in adults, children and adolescents (0-18 years) in:  primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease."], "temporal_context_qualifier": "who failed to respond to pneumococcal immunisation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital AIDS", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e595d699-242d-5fb7-ae7a-452075afe083", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060119", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7e17d71e-9b5b-5857-80ee-caabd1eb496e", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:57afc241-4624-5a70-94b4-16e6b577f089", "object": "HP:0002718", "object_location_in_text": [175, 205], "original_object": "recurrent bacterial infections", "original_subject": "human normal immunoglobulin", "population_context_qualifier": "adults, and children and adolescents (0-18 years)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kiovig", "https://www.ema.europa.eu/en/documents/product-information/kiovig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kiovig"]}], "subject": "CHEBI:749498", "supporting_text": ["Replacement therapy in adults, and children and adolescents (0-18 years) in:  primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT); congenital AIDS and recurrent bacterial infections.  Immunomodulation in adults, and children and adolescents (0-18 years) in:  primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease; multifocal motor neuropathy (MMN)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2921627", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fce49bb-cbb1-5e10-8225-b58b7ecb3c40", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20041123", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2921627", "MONDO:0000001"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1436c4ca-b6eb-55a4-975a-a5dcdb58ed4e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4967f645-6aba-5ce8-9718-ad0913e4fc71", "medic_supporting_text_truncated": true, "object": "MONDO:0005301", "original_object": "multiple sclerosis", "original_subject": "NATALIZUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ef653c36-dd4b-4e71-9d2d-40b8fea24b67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ef653c36-dd4b-4e71-9d2d-40b8fea24b67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ef653c36-dd4b-4e71-9d2d-40b8fea24b67"]}], "subject": "CHEBI:749500", "supporting_text": ["1 INDICATIONS AND USAGE TYRUKO is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYRUKO is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Natalizumab products increase the risk of PML [see Warnings and Precautions ( 5.1 )] . When initiating and continuing treatment with TYRUKO, physicians should consider whether the expected benefit of TYRUKO is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) • TYRUKO is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: • In CD, TYRUKO should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) 1.1 Multiple Sclerosis (MS) TYRUKO is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Natalizumab products increase the risk of PML [see Warnings and Precautions ( 5.1 )] . When initiating and continuing treatment with TYRUKO, physicians should consider whether the expected benefit of TYRUKO is sufficient to offset this risk. 1.2 Crohn's Disease (CD) TYRUKO is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. TYRUKO should not be used in combination with immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08ba3f2e-a5e5-5e43-88bd-f76eacfe708c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [106, 132], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0c65058-22c3-4f57-9b61-9bc6fcd6e240", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0c65058-22c3-4f57-9b61-9bc6fcd6e240", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0c65058-22c3-4f57-9b61-9bc6fcd6e240"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels &gt;400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21176144-077f-5b31-a8fe-85af749582c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [114, 140], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5238dc45-a2b7-4208-b1a7-cc695b6cd1f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5238dc45-a2b7-4208-b1a7-cc695b6cd1f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5238dc45-a2b7-4208-b1a7-cc695b6cd1f0"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e12b139-67a9-5c81-9992-27efef95f48a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [114, 140], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:408ad775-9a1b-43cc-b122-226ade73e0c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=408ad775-9a1b-43cc-b122-226ade73e0c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=408ad775-9a1b-43cc-b122-226ade73e0c2"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73348994-76db-5f04-a33a-897b358e0ddd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [106, 132], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cc447b99-e654-42dd-8cf1-f9e7952a25cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cc447b99-e654-42dd-8cf1-f9e7952a25cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc447b99-e654-42dd-8cf1-f9e7952a25cd"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels &gt;400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86129596-ff1d-54c8-81fc-40319ba314d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [114, 140], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d02eca8c-18d4-4b11-bb16-08748543b04d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d02eca8c-18d4-4b11-bb16-08748543b04d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d02eca8c-18d4-4b11-bb16-08748543b04d"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:987aca74-b4a2-58bf-a1b1-7cc014ce5806", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [131, 157], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0b64dfe-49bc-45d7-9281-9e9d6e296c40", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0b64dfe-49bc-45d7-9281-9e9d6e296c40", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0b64dfe-49bc-45d7-9281-9e9d6e296c40"]}], "subject": "CHEBI:749501", "supporting_text": ["INDICATIONS &amp; USAGE 1) Cholestyramine for oral suspension, USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension, USP may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt; 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1300070-270f-53d2-b8ae-3263440c289f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [114, 140], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:430ac07e-8524-4dec-a599-b7ebc56d9563", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=430ac07e-8524-4dec-a599-b7ebc56d9563", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=430ac07e-8524-4dec-a599-b7ebc56d9563"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "elevated low density lipoprotein [LDL] cholesterol", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af0559cd-f3ae-54ff-9483-69a0c51e6a83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "original_object": "hypercholesterolemia", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00990dec-7618-4cc8-9387-48c2cea8df1c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00990dec-7618-4cc8-9387-48c2cea8df1c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00990dec-7618-4cc8-9387-48c2cea8df1c"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension, USP Light powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP Light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3f42122-b146-5dc3-88f6-90a3cf98b2e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [106, 132], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2998a314-deb2-4a02-afab-7e8c868888e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2998a314-deb2-4a02-afab-7e8c868888e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2998a314-deb2-4a02-afab-7e8c868888e2"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels &gt;400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eec1b2bd-ac52-5084-8690-a07789071bf5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [114, 140], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31d04422-f159-42ba-8eb5-b0ec1dbc52f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31d04422-f159-42ba-8eb5-b0ec1dbc52f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31d04422-f159-42ba-8eb5-b0ec1dbc52f9"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for oral suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6d6d933-36f7-5d2f-bfc7-4222a1782507", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [118, 144], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:362ddd91-a63f-4ec6-841a-75785dd208c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=362ddd91-a63f-4ec6-841a-75785dd208c8"]}], "subject": "CHEBI:749501", "supporting_text": ["1) QUESTRAN (Cholestyramine for Oral Suspension USP), is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. QUESTRAN may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with QUESTRAN secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels &gt;400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases QUESTRAN may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of QUESTRA"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f813aefd-9cba-504c-885d-7ba343026a3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [102, 128], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09420793-7357-4194-8172-0b1cddb167fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09420793-7357-4194-8172-0b1cddb167fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09420793-7357-4194-8172-0b1cddb167fe"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for oral suspension is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation:- LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should oc"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff86b7a9-1182-5399-8a8f-2860f3fc3761", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0c071f40-11c4-5b00-9f51-1f10f2178f7b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "HP:0003124", "object_location_in_text": [106, 132], "original_object": "elevated serum cholesterol", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b26a13e9-42a2-4869-a00a-672bb1ac4742", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b26a13e9-42a2-4869-a00a-672bb1ac4742", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b26a13e9-42a2-4869-a00a-672bb1ac4742"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels &gt;400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "elevated low density lipoprotein [LDL] cholesterol", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ef39651-25a3-5e61-9086-3692bdbed99f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "UMLS:C0342879", "object_location_in_text": [158, 186], "original_object": "primary hypercholesterolemia", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d931e372-2477-4554-912e-9d4d7d538ce2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d931e372-2477-4554-912e-9d4d7d538ce2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d931e372-2477-4554-912e-9d4d7d538ce2"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "elevated low density lipoprotein [LDL] cholesterol", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54bc37bd-c67a-5668-9abf-09fac2923b8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b33851d2-b2ce-5fbd-97dd-a4569c2ac1ae", "medic_supporting_text_truncated": true, "object": "UMLS:C0342879", "object_location_in_text": [158, 186], "original_object": "primary hypercholesterolemia", "original_subject": "CHOLESTYRAMINE", "population_context_qualifier": "patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c65e556a-3b6a-4466-a7ce-5b24103ed8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c65e556a-3b6a-4466-a7ce-5b24103ed8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c65e556a-3b6a-4466-a7ce-5b24103ed8ad"]}], "subject": "CHEBI:749501", "supporting_text": ["1) Cholestyramine for Oral Suspension, USP powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (&lt;4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels &gt; 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholestero"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0de42a0d-304b-5a34-9ba3-c55c20b5c879", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010917", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["myelosuppressive chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38ffae54-4686-5d06-a0ec-c1f56bfa0bc4", "object": "MONDO:0002280", "object_location_in_text": [108, 114], "original_object": "anemia", "original_subject": "DARBEPOETIN ALFA", "population_context_qualifier": "patients with cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0fd36cb9-c4f6-4167-93c9-8530865db3f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9"]}], "subject": "CHEBI:749503", "supporting_text": ["1 INDICATIONS AND USAGE Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 )."], "temporal_context_qualifier": "receiving concomitant myelosuppressive chemotherapy with a minimum of two additional months of planned chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "belzutifan administration", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:060fb506-8303-5209-b6d4-67aee4b8a54c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250624", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:38ffae54-4686-5d06-a0ec-c1f56bfa0bc4", "object": "MONDO:0002280", "object_location_in_text": [66, 72], "original_object": "anemia", "original_subject": "DARBEPOETIN ALFA", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DARBEPOETIN ALFA#4-20250624", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:749503", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of anemia resulting from the administration of belzutifan."], "temporal_context_qualifier": "resulting from the administration of belzutifan"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hypothalamic-pituitary dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ab7a7e4-ec12-5912-abbb-cfb2e532b80e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2d6aec33-8b9e-5716-9f6f-ab36c62a156c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e6f4ba7c-9fba-5074-9462-3bcaa867cf46", "object": "MONDO:0002775", "object_location_in_text": [111, 122], "original_object": "anovulation", "original_subject": "CHORIOGONADOTROPIN ALFA", "population_context_qualifier": "patients with anovulation or oligoovulation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CHORIOGONADOTROPIN ALFA#101-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:749511", "supporting_text": ["A drug with a new active ingredient indicated for: • Induction of ovulation and luteinization in patients with anovulation or oligoovulation associated with hypothalamic-pituitary dysfunction • Induction of final follicular maturation and luteinization as part of assisted reproductive technology for infertile women."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypogonadism secondary to a pituitary deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a795525-7c57-5fad-806d-20ca97179d23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000920", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6f4ba7c-9fba-5074-9462-3bcaa867cf46", "object": "MONDO:0018555", "object_location_in_text": [826, 855], "original_object": "hypogonadotropic hypogonadism", "original_subject": "CHORIOGONADOTROPIN ALFA", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f803acfc-06ea-4841-be9e-10d49fa5caec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f803acfc-06ea-4841-be9e-10d49fa5caec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f803acfc-06ea-4841-be9e-10d49fa5caec"]}], "subject": "CHEBI:749511", "supporting_text": ["HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL” DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomical obstruction. In general, hCG is thought to induce testicular descent in situations when descent would have occurred at puberty. hCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following hCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted in children between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypogonadism secondary to a pituitary deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbe0712d-2630-5c8b-9f29-f8c71330f2ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000920", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11ce65b4-7bc5-55ea-bf95-44d4f0467c41", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6f4ba7c-9fba-5074-9462-3bcaa867cf46", "object": "MONDO:0018555", "object_location_in_text": [826, 855], "original_object": "hypogonadotropic hypogonadism", "original_subject": "CHORIOGONADOTROPIN ALFA", "population_context_qualifier": "males", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e94155f-19be-4944-b197-be4edbb4faf9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e94155f-19be-4944-b197-be4edbb4faf9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e94155f-19be-4944-b197-be4edbb4faf9"]}], "subject": "CHEBI:749511", "supporting_text": ["HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL” DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomical obstruction. In general, hCG is thought to induce testicular descent in situations when descent would have occurred at puberty. hCG thus may help predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following hCG administration is permanent, in most cases, the response is temporary. Therapy is usually instituted in children between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hypothalamic-pituitary dysfunction", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f4feae1-97de-5dd8-967a-2627b1be35bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:07bbe3a2-2fc1-5059-b756-fc8f75f295ef", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e6f4ba7c-9fba-5074-9462-3bcaa867cf46", "object": "UMLS:C1699041", "object_location_in_text": [126, 140], "original_object": "oligoovulation", "original_subject": "CHORIOGONADOTROPIN ALFA", "population_context_qualifier": "patients with anovulation or oligoovulation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CHORIOGONADOTROPIN ALFA#101-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:749511", "supporting_text": ["A drug with a new active ingredient indicated for: • Induction of ovulation and luteinization in patients with anovulation or oligoovulation associated with hypothalamic-pituitary dysfunction • Induction of final follicular maturation and luteinization as part of assisted reproductive technology for infertile women."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0002625", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c29324c-bc6c-579a-8cf3-b578104091fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19810101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002625"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:22d38a64-2eee-56e9-bab7-cba1787c4acf", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:c5c0c408-7e36-519b-9af3-77b5d88fd2b0", "object": "HP:0001907", "original_object": "thromboembolism", "original_subject": "Urokinase for Injection", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:749515", "supporting_text": ["Thrombolytic agent- Indicated in the treatment of pulmonary embolism and thrombo embolic disorders involving deep veins."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0856120", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d372d273-7776-5de3-84f8-c19434d8f721", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970313", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0856120"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ed2c788d-f61a-50ae-8378-6754073368a1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:92f3b75f-bbeb-5fe1-a543-9624e86dad72", "object": "UMLS:C0035020", "original_object": "relapses", "original_subject": "interferon beta-1a", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:avonex", "https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/avonex"]}], "subject": "CHEBI:749518", "supporting_text": ["Avonex is indicated for the treatment of:  patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; Avonex slows the progression of disability and decreases the frequency of relapses; patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite MS.  Avonex should be discontinued in patients who develop progressive MS."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0004836", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57a9c210-aee6-571c-90d3-a730a7b7ce4d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180419", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["daunorubicin (DNR)", "cytarabine (AraC)"], "medic_disease_context_ids": ["HP:0004836"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:23c7513c-2155-5506-95db-7add9099d035", "object": "HP:0004808", "original_object": "acute myeloid leukaemia", "original_subject": "gemtuzumab ozogamicin", "population_context_qualifier": "age 15 years and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:mylotarg", "https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg"]}], "subject": "CHEBI:749520", "supporting_text": ["Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL)."], "temporal_context_qualifier": "previously untreated, de novo"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory CD33-positive", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0b4a385-3c7a-59b5-bed2-67d01b80e4db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170901", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:23c7513c-2155-5506-95db-7add9099d035", "object": "MONDO:0018874", "object_location_in_text": [150, 172], "original_object": "acute myeloid leukemia", "original_subject": "GEMTUZUMAB OZOGAMICIN", "population_context_qualifier": "adults and pediatric patients 2 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:32fd2bb2-1cfa-4250-feb8-d7956c794e05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=32fd2bb2-1cfa-4250-feb8-d7956c794e05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32fd2bb2-1cfa-4250-feb8-d7956c794e05"]}], "subject": "CHEBI:749520", "supporting_text": ["1 INDICATIONS AND USAGE MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older ( 1.2 ). 1.1 Newly-Diagnosed CD33-positive Acute Myeloid Leukemia (AML) MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older. 1.2 Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33de6106-6384-550b-822e-ec6c08f84d08", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:202d823c-7564-5f2c-8f2b-5d866835cc6b", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1455, 1481], "original_object": "non-small cell lung cancer", "original_subject": "HYALURONIDASE (HUMAN RECOMBINANT)", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e58b045-e352-4f62-99bf-77fae1bebc69", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69"]}], "subject": "CHEBI:749530", "supporting_text": ["1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose "], "temporal_context_qualifier": "disease has progressed on or after platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "EGFR mutation, ALK mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a1058213-ada5-5015-9adb-73802d34bd86", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:202d823c-7564-5f2c-8f2b-5d866835cc6b", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "HYALURONIDASE (HUMAN RECOMBINANT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a617b089-ce66-464b-987b-b45d029b4d6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f"]}], "subject": "CHEBI:749530", "supporting_text": ["1 INDICATIONS AND USAGE TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. ( 1.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.1 ) Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) in combination with lurbinectedin, for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ HYBREZA or intravenous atezolizumab, and carboplatin plus etoposide. ( 1.2 ) Hepatocellular Carcinoma (HCC) "], "temporal_context_qualifier": "during or following platinum-containing chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:567b5e7a-e35b-5422-8949-46d4dd52f82d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4f46f08-eddb-5bd4-8ef8-3db22259806f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:202d823c-7564-5f2c-8f2b-5d866835cc6b", "object": "MONDO:0006804", "original_object": "inflammatory breast cancer", "original_subject": "HYALURONIDASE (HUMAN RECOMBINANT)", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:749530", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "neoadjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af77daf8-94a1-53f2-8a87-330f9048b735", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:202d823c-7564-5f2c-8f2b-5d866835cc6b", "object": "MONDO:0007254", "object_location_in_text": [420, 439], "original_object": "early breast cancer", "original_subject": "HYALURONIDASE (HUMAN RECOMBINANT)", "population_context_qualifier": "adult patients at high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:749530", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9b7f716-c80f-5b56-b952-f707e985271f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:202d823c-7564-5f2c-8f2b-5d866835cc6b", "object": "UMLS:C0278488", "object_location_in_text": [633, 657], "original_object": "metastatic breast cancer", "original_subject": "HYALURONIDASE (HUMAN RECOMBINANT)", "population_context_qualifier": "adult patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:749530", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cec04aba-2312-5ade-b41e-bd52c1084c7d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:202d823c-7564-5f2c-8f2b-5d866835cc6b", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "HYALURONIDASE (HUMAN RECOMBINANT)", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:749530", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "neoadjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C4505456", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3413386-b167-5464-b261-b63ed46be937", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4505456"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:34510680-24ae-5d07-81e6-f35fde1e56f3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:528e1236-4892-5e8c-ab9f-64de4a0ea74d", "object": "UMLS:C1394798", "original_object": "Hepatic decompensation", "original_subject": "PEGINTERFERON ALFA-2A", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d9290e5b-6d40-2318-e053-2995a90a9916", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d9290e5b-6d40-2318-e053-2995a90a9916", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9290e5b-6d40-2318-e053-2995a90a9916"]}], "subject": "CHEBI:749533", "supporting_text": ["4 CONTRAINDICATIONS PEGASYS is contraindicated in patients with: Known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, or Stevens-Johnson syndrome to alpha interferons, including PEGASYS, or any of its components. Autoimmune hepatitis Hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic patients before treatment Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before treatment PEGASYS is contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurologic and other complications which are sometimes fatal in neonates and infants. When PEGASYS is used in combination with other HCV antiviral drugs, the contraindications applicable to those agents are applicable to combination therapies. PEGASYS combination treatment with ribavirin is contraindicated in women who are pregnant and men whose female partners are pregnant [See Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Refer to the prescribing information of the other HCV antiviral drugs, including ribavirin, for a list of their contraindications. Autoimmune hepatitis ( 4 ) Hepatic decompensation in patients with cirrhosis ( 4 ) Use in neonates/infants ( 4 ) Known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction and anaphylaxis to alpha interferons or any component of the product ( 4 ) Additional contraindications for use with other HCV antiviral drugs: When used in combination with other HCV antiviral drugs, all contraindications also apply to PEGASYS combination therapy ( 4 ) Ribavirin is contraindicated in pregnant women and men whose female partners are pregnant ( 4 , 8.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f719d8da-2227-5b73-a276-19d91dad0d49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:99d8a2a1-d6e0-5f58-984b-ad89864996d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:528e1236-4892-5e8c-ab9f-64de4a0ea74d", "object": "MONDO:0005366", "original_object": "Chronic Hepatitis B", "original_subject": "PEGINTERFERON ALFA-2A", "population_context_qualifier": "non-cirrhotic pediatric patients 3 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d9290e5b-6d40-2318-e053-2995a90a9916", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d9290e5b-6d40-2318-e053-2995a90a9916", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9290e5b-6d40-2318-e053-2995a90a9916"]}], "subject": "CHEBI:749533", "supporting_text": ["1 INDICATIONS AND USAGE PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT) 1.1 Chronic Hepatitis C (CHC) Adult Patients: PEGASYS, as part of a combination regimen with other hepatitis C virus (HCV) antiviral drugs, is indicated for the treatment of adults with CHC and compensated liver disease. For information about the safe and effective use of other HCV antiviral drugs to be used in combination with PEGASYS, refer to their prescribing information. PEGASYS monotherapy is only indicated for the treatment of patients with CHC and compensated liver disease if there are contraindications or significant intolerance to other HCV antiviral drugs. Pediatric Patients: PEGASYS in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with CHC and compensated liver disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3839044", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfa4bd1d-6b3f-541c-8b13-82a4ab1fb29d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20021016", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_disease_context_ids": ["UMLS:C3839044"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:528e1236-4892-5e8c-ab9f-64de4a0ea74d", "object": "UMLS:C0524910", "original_object": "Chronic Hepatitis C", "original_subject": "PEGINTERFERON ALFA-2A", "population_context_qualifier": "pediatric patients 5 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d9290e5b-6d40-2318-e053-2995a90a9916", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d9290e5b-6d40-2318-e053-2995a90a9916", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9290e5b-6d40-2318-e053-2995a90a9916"]}], "subject": "CHEBI:749533", "supporting_text": ["1 INDICATIONS AND USAGE PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT) 1.1 Chronic Hepatitis C (CHC) Adult Patients: PEGASYS, as part of a combination regimen with other hepatitis C virus (HCV) antiviral drugs, is indicated for the treatment of adults with CHC and compensated liver disease. For information about the safe and effective use of other HCV antiviral drugs to be used in combination with PEGASYS, refer to their prescribing information. PEGASYS monotherapy is only indicated for the treatment of patients with CHC and compensated liver disease if there are contraindications or significant intolerance to other HCV antiviral drugs. Pediatric Patients: PEGASYS in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with CHC and compensated liver disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0744831", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d34f34df-1869-5d1a-bca8-85712e749481", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110926", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0744831"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d97f4a89-b218-5827-88ff-79728d5488bb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:528e1236-4892-5e8c-ab9f-64de4a0ea74d", "object": "UMLS:C0744831", "object_location_in_text": [104, 130], "original_object": "chronic active hepatitis B", "original_subject": "PEGINTERFERON ALFA-2A", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PEGINTERFERON ALFA-2A#144-20110926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:749533", "supporting_text": ["Drugs with a new additional indication and a new dosage for the improvement of viremia in patients with chronic active hepatitis B. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b5623ef-5524-50fe-bea4-37b57effbb17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f282583c-5772-546f-8189-3b358f39985c", "object": "MONDO:0002050", "object_location_in_text": [304, 314], "original_object": "depression", "original_subject": "ESTROGENS, ESTERIFIED", "population_context_qualifier": "patients not improved by estrogens alone", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:759907a1-2da7-47df-bf7f-e642f60b998f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=759907a1-2da7-47df-bf7f-e642f60b998f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=759907a1-2da7-47df-bf7f-e642f60b998f"]}], "subject": "CHEBI:749546", "supporting_text": ["Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe4ab314-e3a7-54f1-9eb6-f89133dd2859", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f282583c-5772-546f-8189-3b358f39985c", "object": "MONDO:0002050", "object_location_in_text": [304, 314], "original_object": "depression", "original_subject": "ESTROGENS, ESTERIFIED", "population_context_qualifier": "patients not improved by estrogens alone", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39355c9a-509a-4918-8a9c-ae155950df3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39355c9a-509a-4918-8a9c-ae155950df3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39355c9a-509a-4918-8a9c-ae155950df3e"]}], "subject": "CHEBI:749546", "supporting_text": ["Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR-expressing", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:067779a2-1868-5e4b-8eda-f48cde16a7a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080716", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:6b46823a-8932-57fe-9ed5-7fe2a2f719d1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:95d1bd1e-c730-565b-bd16-31226b1bbaeb", "object": "MONDO:0024331", "object_location_in_text": [90, 147], "original_object": "unresectable and advanced/recurrent colorectal carcinomas", "original_subject": "CETUXIMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CETUXIMAB#175-20080716", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:749550", "supporting_text": ["A drug containing a new active ingredient indicated for the treatment of EGFR-expressing, unresectable and advanced/recurrent colorectal carcinomas. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR-expressing, RAS wild-type metastatic colorectal cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dde64aa6-52fb-537d-94cf-1916e6d6ec8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040629", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7883379b-4d29-511d-963a-a4eb81b67307", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:95d1bd1e-c730-565b-bd16-31226b1bbaeb", "object": "UMLS:C4721579", "object_location_in_text": [122, 150], "original_object": "metastatic colorectal cancer", "original_subject": "cetuximab", "population_context_qualifier": "patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:erbitux", "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux"]}], "subject": "CHEBI:749550", "supporting_text": ["Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer:  in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.  For details, see section 5.1. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:  in combination with radiation therapy for locally advanced disease; in combination with platinum-based chemotherapy for recurrent and/or metastatic disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "prolonged reductions of CD4+ lymphocyte counts", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7313128b-0ac3-5bde-8a5d-10ac0cd2fd1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010507", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d834131f-22e0-52b5-a502-4ded16fd3f5a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a317878d-676b-533d-be07-34a17efcb449", "object": "MONDO:0005109", "original_object": "HIV infection", "original_subject": "ALEMTUZUMAB", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6236b0bc-82e9-4447-9a78-f57d94770269", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269"]}], "subject": "CHEBI:749551", "supporting_text": ["4 CONTRAINDICATIONS LEMTRADA is contraindicated in patients: with known hypersensitivity or anaphylactic reactions to alemtuzumab or any of the excipients in LEMTRADA who are infected with human immunodeficiency virus (HIV) because LEMTRADA causes prolonged reductions of CD4+ lymphocyte counts with active infection Known hypersensitivity or anaphylactic reactions to alemtuzumab or any of the excipients in LEMTRADA ( 4 ) Infection with Human Immunodeficiency Virus ( 4 ) Active infection ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9b8bd21-ea70-5665-8d32-94d80fc6215d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010507", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a317878d-676b-533d-be07-34a17efcb449", "object": "MONDO:0000001", "object_location_in_text": [154, 190], "original_object": "active secondary progressive disease", "original_subject": "ALEMTUZUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6236b0bc-82e9-4447-9a78-f57d94770269", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269"]}], "subject": "CHEBI:749551", "supporting_text": ["1 INDICATIONS AND USAGE LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. (1.5)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1340ec8-bf3a-57c5-867e-f4e2919d17c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d30422cc-a05a-5edb-81fa-9b185297797b", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "medic_supporting_text_truncated": true, "object": "UMLS:C0010340", "original_object": "acute critical illness", "original_subject": "SOMATROPIN", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58d84ffa-4056-4e36-ad67-7bd4aef444a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5"]}], "subject": "CHEBI:749556", "supporting_text": ["4 CONTRAINDICATIONS OMNITROPE is contraindicated in patients with: • Acute Critical Illness Treatment with pharmacologic amounts of somatropin is contraindicated in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions ( 5.1 )] . • Prader-Willi Syndrome in Children Somatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients [see Warnings and Precautions ( 5.2 )] . • Active Malignancy In general, somatropin is contraindicated in the presence of active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Somatropin should be discontinued if there is evidence of recurrent activity. Since GHD may be an early sign of the presence of a pituitary tumor (or, rarely, other brain tumors), the presence of such tumors should be ruled out prior to initiation of treatment. Somatropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial tumor [see Warnings and Precautions ( 5.3 )] . • Hypersensitivity OMNITROPE is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported with postmarketing use of somatropins [see Warnings and Precautions ( 5.6 )]. • Diabetic Retinopathy Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy. • Closed Epiphyses Somatropin should not be used for growth promotion in pediatric patients with closed epiphyses. • Acute Critical Illness ( 4 ) • Children with Prader-Willi Syndrome who are severely obese or have s"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate secretion of normal endogenous growth hormone", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd6a072c-3967-581b-be2d-4548c3dddcdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20001220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:696b931c-7dae-58fd-8ac6-eaadddf86483", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:c16adc9b-30c2-52f0-83b4-fe29c5b461ce", "object": "HP:0001510", "object_location_in_text": [20, 34], "original_object": "growth failure", "original_subject": "Somatropin (r human growth hormone) 24IU/8mg", "population_context_qualifier": "endocrinologists", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:749556", "supporting_text": ["By endorinologists- growth failure due to in adequate secretion of normal endogenous growth hormone."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "born small for gestational age", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d92a6312-e236-55a3-a12d-1486703f9041", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:696b931c-7dae-58fd-8ac6-eaadddf86483", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "HP:0001510", "object_location_in_text": [134, 148], "original_object": "growth failure", "original_subject": "SOMATROPIN", "population_context_qualifier": "pediatric patients; age 2 years to 4 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 ) 1.1 Pediatric Patients ZOMACTON is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), height standard deviation score (HSDS) ≤-2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range, short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. 1.2 Adult Patients ZOMACTON is indicated for the replacement of endogenous GH in adults with GH deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "born small for gestational age", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2eeb19be-1177-5bf6-b7b5-c792099664bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe06fb3b-5679-54fb-835c-3aef0eb74416", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "HP:0004322", "object_location_in_text": [212, 225], "original_object": "short stature", "original_subject": "SOMATROPIN", "population_context_qualifier": "pediatric patients; age 2 years to 4 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85ba081b-bee0-4a9a-aa0f-ae5b5e9a0886"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 ) 1.1 Pediatric Patients ZOMACTON is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), height standard deviation score (HSDS) ≤-2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range, short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. 1.2 Adult Patients ZOMACTON is indicated for the replacement of endogenous GH in adults with GH deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001518", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e3756a7-b33c-54c5-a646-e0b48249a93b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001518"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe06fb3b-5679-54fb-835c-3aef0eb74416", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "medic_supporting_text_truncated": true, "object": "HP:0004322", "object_location_in_text": [183, 196], "original_object": "short stature", "original_subject": "SOMATROPIN", "population_context_qualifier": "children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa9d3467-a450-4b06-885a-7d834dcbddff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa9d3467-a450-4b06-885a-7d834dcbddff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa9d3467-a450-4b06-885a-7d834dcbddff"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE Norditropin is a recombinant human growth hormone indicated for: Pediatric : Treatment of children with growth failure due to growth hormone deficiency (GHD), short stature associated with Noonan syndrome, short stature associated with Turner syndrome and short stature born SGA with no catch-up growth by age 2-4 years ( 1.1 ) Adult : Treatment of adults with either adult onset or childhood onset GHD ( 1.2 ) 1.1 Pediatric Patients Norditropin [somatropin (rDNA origin) injection] is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH). Norditropin [somatropin (rDNA origin) injection] is indicated for the treatment of children with short stature associated with Noonan syndrome. Norditropin [somatropin (rDNA origin) injection] is indicated for the treatment of children with short stature associated with Turner syndrome. Norditropin [somatropin (rDNA origin) injection] is indicated for the treatment of children with short stature born small for gestational age (SGA) with no catch-up growth by age 2-4 years. 1.2 Adult Patients Norditropin [somatropin (rDNA origin) injection] is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD) who meet either of the following two criteria: Adult Onset (AO): Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or Childhood Onset (CO): Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients who were treated with somatropin for GHD in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for GHD adults. According to current standards, confirmation of the diagnosis of adult GHD in both groups involves an appro"], "temporal_context_qualifier": "with no catch-up growth by age 2-4 years"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001518", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:772e267f-9dcc-5703-bd8b-b33d092ab304", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001518"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe06fb3b-5679-54fb-835c-3aef0eb74416", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "HP:0004322", "object_location_in_text": [218, 231], "original_object": "short stature", "original_subject": "SOMATROPIN", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1058e17c-9261-459c-a3e6-fae38d196c14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE NORDITROPIN is a recombinant human growth hormone indicated for: • Pediatric : Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Noonan syndrome, short stature associated with Turner syndrome, short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years, Idiopathic Short Stature (ISS), and growth failure due to Prader-Willi Syndrome ( 1.1 ) • Adult : Replacement of endogenous GH in adults with growth hormone deficiency ( 1.2 ) 1.1 Pediatric Patients NORDITROPIN is indicated for the treatment of pediatric patients with: • growth failure due to inadequate secretion of endogenous growth hormone (GH), • short stature associated with Noonan syndrome, • short stature associated with Turner syndrome, • short stature born small for gestational age (SGA) with no catch-up growth by age 2 years to 4 years of age, • Idiopathic Short Stature (ISS), height standard deviation score (SDS) &lt;-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, • growth failure due to Prader-Willi syndrome (PWS). 1.2 Adult Patients NORDITROPIN is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)"], "temporal_context_qualifier": "with no catch-up growth by age 2 to 4 years"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3897045", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af064b69-2c43-59b5-a69d-b96247329816", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3897045"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe06fb3b-5679-54fb-835c-3aef0eb74416", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "HP:0004322", "original_object": "short stature", "original_subject": "SOMATROPIN", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a774e1ae-3997-49ee-8b0e-99a2b315d409", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a774e1ae-3997-49ee-8b0e-99a2b315d409", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a774e1ae-3997-49ee-8b0e-99a2b315d409"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE HUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH); short stature associated with Turner syndrome; Idiopathic Short Stature (ISS), height standard deviation score (SDS) &lt;-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. ( 1.1 ) Adult Patients: replacement of endogenous GH in adults with GH deficiency. ( 1.2 ) 1.1 Pediatric Patients HUMATROPE is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, Idiopathic Short Stature (ISS), height standard deviation score (SDS) &lt;-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. 1.2 Adult Patients HUMATROPE is indicated for the replacement of endogenous GH in adults with GH deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0019682", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02dd8453-e18f-5154-b1c4-160a543ea33f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0019682"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a266569b-afc8-5eaf-b01c-3b8c66633988", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "HP:0004325", "original_object": "decreased body weight", "original_subject": "SOMATROPIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:62b01d29-90f0-45b2-a0c4-3a750ba36c8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE SEROSTIM (somatropin) is indicated for the treatment of adults with HIV and wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. SEROSTIM is a human growth hormone (somatropin) indicated for the treatment of adults with HIV and wasting or cachexia to increase lean body mass and body weight, and improve physical endurance ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "growth hormone deficiency of either childhood or adult-onset etiology", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20d16b60-0a5a-5234-921b-6a1505d0e6ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010215", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2c8d2d07-01d5-593a-a89c-62c2920993f9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "HP:0034323", "object_location_in_text": [373, 398], "original_object": "growth hormone deficiency", "original_subject": "somatropin", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nutropinaq", "https://www.ema.europa.eu/en/documents/product-information/nutropinaq-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nutropinaq"]}], "subject": "CHEBI:749556", "supporting_text": ["Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome. Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment."], "temporal_context_qualifier": "replacement of endogenous growth hormone"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0019682", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3667ec4c-7536-55b7-afd9-f33692a8769e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19861016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0019682"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2b251cf-8e28-5f3c-8449-e0577cc4b8f7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dbd79e05-4702-5813-b4a7-207b3be822cc", "object": "UMLS:C5195214", "original_object": "increased lean body mass", "original_subject": "SOMATROPIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:62b01d29-90f0-45b2-a0c4-3a750ba36c8a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a"]}], "subject": "CHEBI:749556", "supporting_text": ["1 INDICATIONS AND USAGE SEROSTIM (somatropin) is indicated for the treatment of adults with HIV and wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. SEROSTIM is a human growth hormone (somatropin) indicated for the treatment of adults with HIV and wasting or cachexia to increase lean body mass and body weight, and improve physical endurance ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "fistulizing disease", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67a51348-846e-535f-aaf5-1abce91d59ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980824", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:afe6a8d3-5506-5c13-b11d-c1705b67ba0f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "HP:0000143", "original_object": "rectovaginal fistula", "original_subject": "INFLIXIMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f"]}], "subject": "CHEBI:749571", "supporting_text": ["1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "fistulizing disease", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1334884-2992-5a53-b657-af21b08ba85e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980824", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ebb156e3-4682-51aa-b815-38c495de4eec", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "HP:0033279", "original_object": "enterocutaneous fistula", "original_subject": "INFLIXIMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f"]}], "subject": "CHEBI:749571", "supporting_text": ["1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy including corticosteroid, immunomodulator and primary nutrition therapy, or intolerance to or contraindications for such therapies, or who are intolerant to or have contraindications for such therapies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db5a5ff3-3a15-5916-9931-c7c5b74d4690", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a82e12e2-e9e6-5717-a5f3-b8af061469fe", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0005011", "original_object": "Crohn's disease", "original_subject": "infliximab", "population_context_qualifier": "children and adolescents aged 6 to 17 years with severe, active disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:flixabi", "https://www.ema.europa.eu/en/documents/product-information/flixabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi"]}], "subject": "CHEBI:749571", "supporting_text": ["Rheumatoid arthritis Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:  adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. dult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.  In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1). Adult Crohn’s disease Flixabi is indicated for:  reatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. reatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).  Paediatric Crohn’s disease Flixabi is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Flixabi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis Flixabi is indicated for treatment of severely active"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active CD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdae5254-1457-5261-b219-922dbd147010", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980824", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a82e12e2-e9e6-5717-a5f3-b8af061469fe", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0005011", "original_object": "Crohn's Disease", "original_subject": "INFLIXIMAB", "population_context_qualifier": "pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f"]}], "subject": "CHEBI:749571", "supporting_text": ["1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies a"], "temporal_context_qualifier": "inadequate response to conventional therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or intolerance to or medical contraindications for such therapies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8963904-3aca-59cc-a89e-fea289fef54a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0005101", "object_location_in_text": [1664, 1682], "original_object": "ulcerative colitis", "original_subject": "infliximab", "population_context_qualifier": "children and adolescents aged 6 to 17 years with severely active disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:flixabi", "https://www.ema.europa.eu/en/documents/product-information/flixabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi"]}], "subject": "CHEBI:749571", "supporting_text": ["Rheumatoid arthritis Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:  adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. dult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.  In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1). Adult Crohn’s disease Flixabi is indicated for:  reatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. reatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).  Paediatric Crohn’s disease Flixabi is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Flixabi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis Flixabi is indicated for treatment of severely active"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c32ff01-6d43-5506-be1d-5ec141fdac8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980824", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0005101", "object_location_in_text": [731, 749], "original_object": "Ulcerative Colitis", "original_subject": "INFLIXIMAB", "population_context_qualifier": "pediatric patients 6 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f"]}], "subject": "CHEBI:749571", "supporting_text": ["1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies a"], "temporal_context_qualifier": "inadequate response to conventional therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:685d0dca-94a2-595f-93b2-bfc1a43493c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "original_object": "ankylosing spondylitis", "original_subject": "infliximab", "population_context_qualifier": "adult patients with severe, active disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:flixabi", "https://www.ema.europa.eu/en/documents/product-information/flixabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi"]}], "subject": "CHEBI:749571", "supporting_text": ["Rheumatoid arthritis Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:  adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. dult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.  In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1). Adult Crohn’s disease Flixabi is indicated for:  reatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. reatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).  Paediatric Crohn’s disease Flixabi is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Flixabi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis Flixabi is indicated for treatment of severely active"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d972d04-551a-545b-b808-1f77b9945f41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980824", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "original_object": "Rheumatoid Arthritis", "original_subject": "INFLIXIMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f"]}], "subject": "CHEBI:749571", "supporting_text": ["1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous DMARD therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56c3d97b-0ec1-54be-8370-b5cb1c011197", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "original_object": "psoriatic arthritis", "original_subject": "infliximab", "population_context_qualifier": "adult patients with active and progressive disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:flixabi", "https://www.ema.europa.eu/en/documents/product-information/flixabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi"]}], "subject": "CHEBI:749571", "supporting_text": ["Rheumatoid arthritis Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:  adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. dult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.  In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1). Adult Crohn’s disease Flixabi is indicated for:  reatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. reatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).  Paediatric Crohn’s disease Flixabi is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Flixabi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis Flixabi is indicated for treatment of severely active"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately to severely active disease", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db3d5ba5-a1e4-53ac-b245-cf7d9a3cb8d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980824", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ff722628-fd7f-52bf-be83-9c34f48a70a1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "UMLS:C0236053", "original_object": "mucosal ulceration", "original_subject": "INFLIXIMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f"]}], "subject": "CHEBI:749571", "supporting_text": ["1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies a"], "temporal_context_qualifier": "inadequate response to conventional therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response despite full and adequate course of conventional therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:116aa39f-be84-5975-b177-232907429c8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:aedc49e0-f85d-5f90-ad73-7e314c581c83", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:97cb85bf-3571-5e4f-b916-828a5937c493", "medic_supporting_text_truncated": true, "object": "UMLS:C3888864", "original_object": "fistulising Crohn's disease", "original_subject": "infliximab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:flixabi", "https://www.ema.europa.eu/en/documents/product-information/flixabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi"]}], "subject": "CHEBI:749571", "supporting_text": ["Rheumatoid arthritis Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:  adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. dult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.  In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1). Adult Crohn’s disease Flixabi is indicated for:  reatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. reatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).  Paediatric Crohn’s disease Flixabi is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Flixabi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Paediatric ulcerative colitis Flixabi is indicated for treatment of severely active"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvar and vaginal atrophy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4db9b5df-c70a-533f-90d5-00b68003479b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4468bcb9-0b2c-5f45-b010-bfbd72173d88", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5a8d55b-a0ba-5045-b880-ed94ec05f83d", "object": "HP:0030016", "original_object": "dyspareunia", "original_subject": "ESTROGENS, CONJUGATED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96609623-528e-4aba-cabe-7254aed816d5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96609623-528e-4aba-cabe-7254aed816d5"]}], "subject": "CHEBI:749574", "supporting_text": ["1 INDICATIONS AND USAGE PREMARIN (conjugated estrogens) vaginal cream is a mixture of estrogens indicated for: • Treatment of Atrophic Vaginitis and Kraurosis Vulvae ( 1.1 ) • Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause ( 1.2 ) 1.1 Treatment of Atrophic Vaginitis and Kraurosis Vulvae 1.2 Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause"], "temporal_context_qualifier": "due to Menopause"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5912d39a-08ef-5a0e-9869-e87176ba41e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5a8d55b-a0ba-5045-b880-ed94ec05f83d", "object": "UMLS:C3650625", "object_location_in_text": [96, 121], "original_object": "abnormal uterine bleeding", "original_subject": "ESTROGENS, CONJUGATED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87e2da8d-432c-4ed5-67a1-dc26294b2295", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87e2da8d-432c-4ed5-67a1-dc26294b2295", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87e2da8d-432c-4ed5-67a1-dc26294b2295"]}], "subject": "CHEBI:749574", "supporting_text": ["Premarin Intravenous (conjugated estrogens, USP) for injection is indicated in the treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels."], "temporal_context_qualifier": "short-term use only"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0011974", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6a59879-e870-5008-acf9-e2416bf40447", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0011974"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a3f1b8a-36e5-5a62-ad87-671f1553bda0", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:17048ad2-e660-5a7b-867c-e2bed70b2275", "object": "UMLS:C0406175", "object_location_in_text": [21, 32], "original_object": "chafed skin", "original_subject": "WHITE PETROLATUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb00264f-e73d-771b-e053-2a95a90a85e5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb00264f-e73d-771b-e053-2a95a90a85e5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb00264f-e73d-771b-e053-2a95a90a85e5"]}], "subject": "CHEBI:749575", "supporting_text": ["Use(s) • Helps treat chafed skin associated with diaper rash • Helps seal out wetness • Temporarily protects minor • Cuts • Scrapes • Burns • Temporarily helps protect and relieve chapped and cracked skin and lips • Helps prevent and protect from the drying effects of wind and cold weather"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe primary insulin-like-growth-factor-1 deficiency", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cbcd628-4745-5b95-9b2b-4d7d71cffc95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070802", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:696b931c-7dae-58fd-8ac6-eaadddf86483", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bb41e802-6cf3-552b-ab20-c467da1c9d7b", "object": "HP:0001510", "object_location_in_text": [31, 45], "original_object": "growth failure", "original_subject": "mecasermin", "population_context_qualifier": "children and adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:increlex", "https://www.ema.europa.eu/en/documents/product-information/increlex-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/increlex"]}], "subject": "CHEBI:749581", "supporting_text": ["For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD). Severe primary IGFD is defined by:  height standard deviation score ? -3.0 and; basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and; growth hormone (GH) sufficiency; exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.  Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital or acquired hypogonadotrophic hypogonadism", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ade69309-5969-5a4b-a872-a105335ab98c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951020", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["human chorionic gonadotrophin (hCG)"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:41619f1c-4232-5a93-8a0f-505a710019b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fbc609a7-283e-522d-96d3-e152144afa12", "object": "UMLS:C0037864", "object_location_in_text": [687, 702], "original_object": "spermatogenesis", "original_subject": "follitropin alfa", "population_context_qualifier": "men", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gonal-f", "https://www.ema.europa.eu/en/documents/product-information/gonal-f-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f"]}], "subject": "CHEBI:749583", "supporting_text": ["Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate. Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT). GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level &lt;1.2 IU/l. GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hCG) therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital or acquired hypogonadotropic hypogonadism", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fdba6428-d903-571e-9d23-e0c688120db3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951020", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["human chorionic gonadotropin (hCG)"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:41619f1c-4232-5a93-8a0f-505a710019b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fbc609a7-283e-522d-96d3-e152144afa12", "object": "UMLS:C0037864", "original_object": "spermatogenesis", "original_subject": "follitropin alfa", "population_context_qualifier": "adult men", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ovaleap", "https://www.ema.europa.eu/en/documents/product-information/ovaleap-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ovaleap"]}], "subject": "CHEBI:749583", "supporting_text": ["In adult women  Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate; Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer; Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level &lt; 1.2 IU/L.  In adult men  Ovaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid α-glucosidase [GAA] deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1330c5a-dce3-580a-88ec-b6db29404be1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060428", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:260d126e-1183-59b8-86f3-f7f8c425a7a1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0ebb4196-a74b-5df8-baa7-77b2d4b0445b", "object": "MONDO:0009290", "object_location_in_text": [114, 127], "original_object": "Pompe disease", "original_subject": "ALGLUCOSIDASE ALFA", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6bfbc45-2d34-439e-8aad-59ee2d53d4df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6bfbc45-2d34-439e-8aad-59ee2d53d4df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6bfbc45-2d34-439e-8aad-59ee2d53d4df"]}], "subject": "CHEBI:749600", "supporting_text": ["1 INDICATIONS AND USAGE LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency). LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "macular oedema secondary to retinal vein occlusion", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07615e42-fdc2-5823-892d-6ee490543cd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070122", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2f2c94ce-d5d0-52ff-ade5-06f035d193dc", "object": "HP:0000505", "object_location_in_text": [129, 146], "original_object": "visual impairment", "original_subject": "ranibizumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lucentis", "https://www.ema.europa.eu/en/documents/product-information/lucentis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis"]}], "subject": "CHEBI:749601", "supporting_text": ["Lucentis is indicated in adults for:  The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000819", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e11bbb1f-ecd1-565a-9c77-cbb79de798e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060630", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000819"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:97d81a8d-051a-54e5-b009-f878ddb1ce61", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f2c94ce-d5d0-52ff-ade5-06f035d193dc", "object": "MONDO:0004728", "original_object": "Diabetic Macular Edema", "original_subject": "RANIBIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0e23118-1490-a554-e053-2995a90ab90c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c"]}], "subject": "CHEBI:749601", "supporting_text": ["1 INDICATIONS AND USAGE CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000819", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bec5da5d-c42f-5df8-9bdb-ad9aee744f33", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060630", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000819"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e13e81d2-41e1-580d-9048-ab2226cd41f7", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f2c94ce-d5d0-52ff-ade5-06f035d193dc", "object": "MONDO:0005266", "original_object": "Diabetic Retinopathy", "original_subject": "RANIBIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0e23118-1490-a554-e053-2995a90ab90c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c"]}], "subject": "CHEBI:749601", "supporting_text": ["1 INDICATIONS AND USAGE CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3537442", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92a25b18-7ba4-5c33-800c-a3f98c57e095", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130820", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3537442"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:08663ffc-206e-5604-b6f8-73eda467a224", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:2f2c94ce-d5d0-52ff-ade5-06f035d193dc", "object": "MONDO:0810000", "original_object": "choroidal neovascularization", "original_subject": "RANIBIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RANIBIZUMAB#126-20130820", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:749601", "supporting_text": ["A drug with new additional indications and a new dosage for the treatment of macular edema following retinal vein occlusion and choroidal neovascularisasion in pathologic myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000545", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:409e8f60-f829-5176-9f39-0ebb604bf517", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060630", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:680b2c63-6eb2-54ee-86d9-3efc1498ca6a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2f2c94ce-d5d0-52ff-ade5-06f035d193dc", "object": "UMLS:C3665926", "original_object": "Myopic Choroidal Neovascularization", "original_subject": "RANIBIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0e23118-1490-a554-e053-2995a90ab90c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c"]}], "subject": "CHEBI:749601", "supporting_text": ["1 INDICATIONS AND USAGE CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "wild-type RAS metastatic colorectal cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ada24540-3d65-5cb2-9e60-47333a2034b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071203", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7883379b-4d29-511d-963a-a4eb81b67307", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50014783-2668-5d10-83a0-035627b5b31f", "object": "UMLS:C4721579", "object_location_in_text": [77, 105], "original_object": "metastatic colorectal cancer", "original_subject": "panitumumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vectibix", "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix"]}], "subject": "CHEBI:749603", "supporting_text": ["Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):  in first-line in combination with Folfox or Folfiri. in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens."], "temporal_context_qualifier": "after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "complement-mediated thrombotic microangiopathy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53d1e046-0c87-5765-aafe-5b49585425c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130913", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:45e616c1-d3c2-573b-b31d-80830ab12de0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5d86abf4-784b-524a-81d0-b1ccdc0d71fa", "object": "MONDO:0016244", "original_object": "atypical hemolytic uremic syndrome", "original_subject": "ECULIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ECULIZUMAB#123-20130913", "https://www.pmda.go.jp/files/000231967.pdf"]}], "subject": "CHEBI:749604", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "haemolysis", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6b2115c-3187-505f-a298-a74e4e7bcc37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c3bf2c21-c492-5c7a-81a4-8ba4ad50b7a6", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:5d86abf4-784b-524a-81d0-b1ccdc0d71fa", "object": "MONDO:0100244", "original_object": "paroxysmal nocturnal haemoglobinuria", "original_subject": "eculizumab", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:epysqli", "https://www.ema.europa.eu/en/documents/product-information/epysqli-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/epysqli"]}], "subject": "CHEBI:749604", "supporting_text": ["Epysqli is indicated in adults and children for the treatment of:- Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.- Atypical haemolytic uremic syndrome (aHUS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately to severely active ulcerative colitis with inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or intolerance to or medical contraindications for such therapies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5ea4c045-3e1b-559b-99c5-5e75f55906e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0005101", "original_object": "ulcerative colitis", "original_subject": "golimumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gobivaz", "https://www.ema.europa.eu/en/documents/product-information/gobivaz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gobivaz"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative coliti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), intolerance to or medical contraindications for such therapies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bde3d1aa-3cd3-5dee-9f6d-8c5998308278", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0005101", "object_location_in_text": [1682, 1700], "original_object": "ulcerative colitis", "original_subject": "golimumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gotenfia", "https://www.ema.europa.eu/en/documents/product-information/gotenfia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gotenfia"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA)Gotenfia, in combination with methotrexate (MTX), is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Psoriatic arthritis (PsA)Gotenfia, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritisAnkylosing spondylitis (AS)Gotenfia is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-Axial SpA)Gotenfia is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Gotenfia is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Juvenile idiopathic arthritisPolyarticular juvenile idiopathic ar"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy, including corticosteroids and 6‑mercaptopurine (6‑MP) or azathioprine (AZA), intolerant to or have medical contraindications for such therapies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef316aa5-a28c-5fad-a261-7f6f313e5571", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0005101", "object_location_in_text": [1822, 1840], "original_object": "ulcerative colitis", "original_subject": "golimumab", "population_context_qualifier": "paediatric patients 2 years of age and older with a body weight of at least 15 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:simponi", "https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC. Psoriatic arthritis (PsA) Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non radiographic axial spondyloarthritis (nr Axial SpA) Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or w"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b0d1d39-8345-5ee9-b828-f86b56788173", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "object_location_in_text": [1091, 1113], "original_object": "ankylosing spondylitis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gotenfia", "https://www.ema.europa.eu/en/documents/product-information/gotenfia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gotenfia"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA)Gotenfia, in combination with methotrexate (MTX), is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Psoriatic arthritis (PsA)Gotenfia, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritisAnkylosing spondylitis (AS)Gotenfia is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-Axial SpA)Gotenfia is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Gotenfia is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Juvenile idiopathic arthritisPolyarticular juvenile idiopathic ar"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "responded inadequately to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbb39bf1-2eac-5de8-8c58-6f8368b06889", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "object_location_in_text": [1390, 1412], "original_object": "ankylosing spondylitis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gobivaz", "https://www.ema.europa.eu/en/documents/product-information/gobivaz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gobivaz"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative coliti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "responded inadequately to conventional therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff672c79-89a8-5646-8ce8-e9bc35cccf13", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef44fec7-9475-592e-8bac-25d0989f8f1d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0005306", "object_location_in_text": [1229, 1251], "original_object": "ankylosing spondylitis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:simponi", "https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC. Psoriatic arthritis (PsA) Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non radiographic axial spondyloarthritis (nr Axial SpA) Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or w"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "not previously treated with MTX", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e941340-cce6-5da4-b3e9-03778672a225", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "object_location_in_text": [138, 158], "original_object": "rheumatoid arthritis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gobivaz", "https://www.ema.europa.eu/en/documents/product-information/gobivaz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gobivaz"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative coliti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "not previously treated with MTX", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7841a2e8-986b-5669-b30d-f74afa302830", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate (MTX)"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "object_location_in_text": [138, 158], "original_object": "rheumatoid arthritis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:simponi", "https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC. Psoriatic arthritis (PsA) Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non radiographic axial spondyloarthritis (nr Axial SpA) Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or w"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous DMARD therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:90f58de5-efc0-5c7f-b52f-57e37bbe610d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "object_location_in_text": [965, 984], "original_object": "psoriatic arthritis", "original_subject": "golimumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gobivaz", "https://www.ema.europa.eu/en/documents/product-information/gobivaz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gobivaz"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative coliti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous DMARD therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6eb1964-f0f5-5b0d-ac89-0fa228c6f3a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "object_location_in_text": [793, 812], "original_object": "psoriatic arthritis", "original_subject": "golimumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:simponi", "https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC. Psoriatic arthritis (PsA) Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non radiographic axial spondyloarthritis (nr Axial SpA) Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or w"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous DMARD therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e367a13b-49c1-57ac-9def-3160c9a2404a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MTX"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0011849", "object_location_in_text": [672, 691], "original_object": "psoriatic arthritis", "original_subject": "golimumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gotenfia", "https://www.ema.europa.eu/en/documents/product-information/gotenfia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gotenfia"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA)Gotenfia, in combination with methotrexate (MTX), is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Psoriatic arthritis (PsA)Gotenfia, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritisAnkylosing spondylitis (AS)Gotenfia is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-Axial SpA)Gotenfia is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Gotenfia is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Juvenile idiopathic arthritisPolyarticular juvenile idiopathic ar"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "responded inadequately to previous therapy with MTX", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f1b039c-d3a6-52a3-831c-e69bb5a0eec8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MTX"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0018456", "object_location_in_text": [695, 738], "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "golimumab", "population_context_qualifier": "children 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gobivaz", "https://www.ema.europa.eu/en/documents/product-information/gobivaz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gobivaz"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative coliti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "responded inadequately to previous therapy with MTX", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e979199-39f0-500e-ae09-d158f6e7cb29", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate (MTX)"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0018456", "object_location_in_text": [576, 619], "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "golimumab", "population_context_qualifier": "children 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:simponi", "https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/simponi"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC. Psoriatic arthritis (PsA) Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non radiographic axial spondyloarthritis (nr Axial SpA) Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or w"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate response to previous therapy with MTX", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a895ed3d-462c-5f52-986a-8e6b68ed2147", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["MTX"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8f55d9d8-a26f-53ff-b2dd-2858ef6d6933", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "MONDO:0018456", "original_object": "polyarticular juvenile idiopathic arthritis", "original_subject": "golimumab", "population_context_qualifier": "children 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gotenfia", "https://www.ema.europa.eu/en/documents/product-information/gotenfia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gotenfia"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA)Gotenfia, in combination with methotrexate (MTX), is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Psoriatic arthritis (PsA)Gotenfia, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritisAnkylosing spondylitis (AS)Gotenfia is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-Axial SpA)Gotenfia is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Gotenfia is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Juvenile idiopathic arthritisPolyarticular juvenile idiopathic ar"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs), inadequate response to, or intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e640fb1-c015-5b56-a6b6-4c0b30b1804e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:42ba7dbd-ad67-5020-b472-308afe9106db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "UMLS:C3889038", "object_location_in_text": [1305, 1345], "original_object": "non-radiographic axial spondyloarthritis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gotenfia", "https://www.ema.europa.eu/en/documents/product-information/gotenfia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gotenfia"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA)Gotenfia, in combination with methotrexate (MTX), is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Psoriatic arthritis (PsA)Gotenfia, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritisAnkylosing spondylitis (AS)Gotenfia is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-Axial SpA)Gotenfia is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Gotenfia is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Juvenile idiopathic arthritisPolyarticular juvenile idiopathic ar"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, and inadequate response to, or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e64a7783-a08f-587f-86dd-f4db638e25cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091001", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:42ba7dbd-ad67-5020-b472-308afe9106db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6bd26ba6-bd19-5e27-a3ef-6e23b28e1747", "medic_supporting_text_truncated": true, "object": "UMLS:C3889038", "object_location_in_text": [1605, 1645], "original_object": "non-radiographic axial spondyloarthritis", "original_subject": "golimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:gobivaz", "https://www.ema.europa.eu/en/documents/product-information/gobivaz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/gobivaz"]}], "subject": "CHEBI:749607", "supporting_text": ["Rheumatoid arthritis (RA) Gobivaz, in combination with methotrexate (MTX), is indicated for:  the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.  Golimumab, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. Juvenile idiopathic arthritis Polyarticular juvenile idiopathic arthritis (pJIA) Gobivaz in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. Psoriatic arthritis (PsA) Gobivaz, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.&nbsp;Golimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Axial spondyloarthritis Ankylosing spondylitis (AS) Gobivaz is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis (nr-Axial SpA) Gobivaz is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). Ulcerative colitis (UC) Gobivaz is indicated for treatment of moderately to severely active ulcerative coliti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c91c4d1-0149-532e-9683-67d6f38d7bb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:0e6ca689-757d-58ce-aef2-6bd45c549b64", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8e315662-8150-5a40-a44c-d5c97e0398a5", "object": "UMLS:C0406317", "object_location_in_text": [917, 933], "original_object": "plaque psoriasis", "original_subject": "ustekinumab", "population_context_qualifier": "children and adolescent patients from the age of 6 years and older who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:qoyvolma", "https://www.ema.europa.eu/en/documents/product-information/qoyvolma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/qoyvolma"]}], "subject": "CHEBI:749609", "supporting_text": ["Adult Crohn’s Disease&nbsp;Qoyvolma is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.&nbsp;&nbsp;Paediatric Crohn's Disease &nbsp;Qoyvolma is indicated for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy. &nbsp;&nbsp;Ulcerative colitis&nbsp;Qoyvolma is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic.&nbsp;   Plaque psoriasis&nbsp;Qoyvolma is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A).&nbsp;&nbsp;Paediatric plaque psoriasis&nbsp;Qoyvolma is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.&nbsp;&nbsp;Psoriatic arthritis (PsA)&nbsp;Qoyvolma, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50f3a3fe-0c5f-58e7-a983-a49a9e4d8502", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:0e6ca689-757d-58ce-aef2-6bd45c549b64", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8e315662-8150-5a40-a44c-d5c97e0398a5", "object": "UMLS:C0406317", "object_location_in_text": [676, 692], "original_object": "plaque psoriasis", "original_subject": "ustekinumab", "population_context_qualifier": "children and adolescent patients from the age of 6 years and older who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imuldosa", "https://www.ema.europa.eu/en/documents/product-information/imuldosa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imuldosa"]}], "subject": "CHEBI:749609", "supporting_text": ["Adult Crohn’s Disease&nbsp;Imuldosa is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. Paediatric Crohn’s Disease&nbsp;Imuldosa is indicated for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy. Plaque psoriasis&nbsp;Imuldosa is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A). Paediatric plaque psoriasis&nbsp;Imuldosa is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. Psoriatic arthritis (PsA)&nbsp;Imuldosa, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease- modifying anti-rheumatic drug (DMARD) therapy has been inadequate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e62f80f0-a4a2-5369-a182-0dd0e8ca43cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090115", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0406317"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:0e6ca689-757d-58ce-aef2-6bd45c549b64", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8e315662-8150-5a40-a44c-d5c97e0398a5", "object": "UMLS:C0406317", "object_location_in_text": [391, 407], "original_object": "plaque psoriasis", "original_subject": "ustekinumab", "population_context_qualifier": "children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:steqeyma", "https://www.ema.europa.eu/en/documents/product-information/steqeyma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/steqeyma"]}], "subject": "CHEBI:749609", "supporting_text": ["Crohn’s Disease  Steqeyma is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.  Plaque psoriasis  Steqeyma is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1).  Paediatric plaque psoriasis  Steqeyma is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1).  Psoriatic arthritis (PsA)  Steqeyma, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "candidates for phototherapy or systemic therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5d5c087-edb2-57e0-be0d-c81191ebd01c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:632cb7db-1c29-5340-a9f8-47258a0d185d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8e315662-8150-5a40-a44c-d5c97e0398a5", "object": "UMLS:C0406317", "object_location_in_text": [132, 167], "original_object": "moderate to severe plaque psoriasis", "original_subject": "USTEKINUMAB", "population_context_qualifier": "Adult patients; Pediatric patients 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b72aa27-82cc-4c1b-be43-8b50e5e3d737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b72aa27-82cc-4c1b-be43-8b50e5e3d737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b72aa27-82cc-4c1b-be43-8b50e5e3d737"]}], "subject": "CHEBI:749609", "supporting_text": ["1 INDICATIONS AND USAGE STARJEMZA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn’s disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) STARJEMZA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) STARJEMZA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn’s Disease (CD) STARJEMZA is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease. 1.4 Ulcerative Colitis STARJEMZA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2940aad6-42ba-54fa-b9d5-1ca7211c27e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091026", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:be860169-1034-527d-aad6-b1ad4e1de15e", "object": "MONDO:0000001", "object_location_in_text": [185, 221], "original_object": "active secondary progressive disease", "original_subject": "OFATUMUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a8a3f53-2062-48ff-9dbe-b939df133ca3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3"]}], "subject": "CHEBI:749610", "supporting_text": ["1 INDICATIONS AND USAGE KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b9d70e0-6c84-5079-a33c-0ce4b54bc166", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091026", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:be860169-1034-527d-aad6-b1ad4e1de15e", "object": "UMLS:C2921627", "object_location_in_text": [122, 150], "original_object": "clinically isolated syndrome", "original_subject": "OFATUMUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a8a3f53-2062-48ff-9dbe-b939df133ca3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3"]}], "subject": "CHEBI:749610", "supporting_text": ["1 INDICATIONS AND USAGE KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0195775", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:059ea031-058e-552e-8277-6b475fedebdc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0195775"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:ec367a28-cb67-52b7-b7d7-127f7a887f22", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:02c2c8b7-21e4-52e4-92b6-c2d48aed4a0d", "object": "UMLS:C0234428", "object_location_in_text": [21, 49], "original_object": "disturbance of consciousness", "original_subject": "Citicoline Oral Drops", "population_context_qualifier": "adult", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:749658", "supporting_text": ["For the treatment of disturbance of consciousness resulting from head injuries, brain operation & acute stage of cerebral infraction in adult."], "temporal_context_qualifier": "resulting from brain operation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5368f989-9751-586b-b91b-c02b3c22d690", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eca2bb8a-24c5-53fa-9d73-43af033686a4", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "COCARBOXYLASE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "CHEBI:749677", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41f2780b-236f-510a-98f3-46972da6945d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dc24fc4e-7249-5dd9-a509-512966f9e8dd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002176", "object_location_in_text": [81, 104], "original_object": "spinal cord compression", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yaxwer", "https://www.ema.europa.eu/en/documents/product-information/yaxwer-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yaxwer"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:463465c0-e0bc-5a06-935b-e52b4117a865", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dc24fc4e-7249-5dd9-a509-512966f9e8dd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002176", "object_location_in_text": [81, 104], "original_object": "spinal cord compression", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:degevma", "https://www.ema.europa.eu/en/documents/product-information/degevma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/degevma"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f03425c-2f04-5c56-a0af-cdf5b4612395", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dc24fc4e-7249-5dd9-a509-512966f9e8dd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002176", "object_location_in_text": [81, 104], "original_object": "spinal cord compression", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xbonzy", "https://www.ema.europa.eu/en/documents/product-information/xbonzy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xbonzy"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c8323cb-cb55-5f75-881f-189618da7381", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dc24fc4e-7249-5dd9-a509-512966f9e8dd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002176", "object_location_in_text": [81, 104], "original_object": "spinal cord compression", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xgeva", "https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.&nbsp;&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b19982c-e1d3-50d1-817c-17fc2e1ce7a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dc24fc4e-7249-5dd9-a509-512966f9e8dd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002176", "object_location_in_text": [88, 111], "original_object": "spinal cord compression", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:wyost", "https://www.ema.europa.eu/en/documents/product-information/wyost-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/wyost"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.&nbsp; Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c0e79a8-221d-52a7-aee0-2d9c48ad6730", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9d3014f1-c1c6-5080-a5f4-b001f53eaf4b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002756", "object_location_in_text": [39, 60], "original_object": "pathological fracture", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xgeva", "https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xgeva"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.&nbsp;&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:112ac6f7-066e-585e-856c-a4181f7a9747", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9d3014f1-c1c6-5080-a5f4-b001f53eaf4b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002756", "object_location_in_text": [39, 60], "original_object": "pathological fracture", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xbonzy", "https://www.ema.europa.eu/en/documents/product-information/xbonzy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xbonzy"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:160fc938-1433-553f-8b12-8967dced9c47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9d3014f1-c1c6-5080-a5f4-b001f53eaf4b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002756", "object_location_in_text": [46, 67], "original_object": "pathological fracture", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:wyost", "https://www.ema.europa.eu/en/documents/product-information/wyost-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/wyost"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.&nbsp; Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:292905a9-bda6-5364-bb36-327876bd4b23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9d3014f1-c1c6-5080-a5f4-b001f53eaf4b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002756", "object_location_in_text": [39, 60], "original_object": "pathological fracture", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yaxwer", "https://www.ema.europa.eu/en/documents/product-information/yaxwer-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yaxwer"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced malignancies involving bone", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b8eb3ad-03d8-55f5-8c8b-02acf06b1ad9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9d3014f1-c1c6-5080-a5f4-b001f53eaf4b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "HP:0002756", "object_location_in_text": [39, 60], "original_object": "pathological fracture", "original_subject": "denosumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:degevma", "https://www.ema.europa.eu/en/documents/product-information/degevma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/degevma"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6dd2ef32-890e-5c6a-b952-3d26e979c352", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "MONDO:0005315", "original_object": "fracture", "original_subject": "DENOSUMAB", "population_context_qualifier": "men at high risk for fracture", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39a0a789-778f-4695-b3a9-61643e6396cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39a0a789-778f-4695-b3a9-61643e6396cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39a0a789-778f-4695-b3a9-61643e6396cd"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Conexxence is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )]. 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Conexxence is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )]. 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Conexxence is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who "], "temporal_context_qualifier": "receiving androgen deprivation therapy for nonmetastatic prostate cancer"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e1e2230-a574-57b2-a5a2-e35728d68b76", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["androgen deprivation therapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "MONDO:0005315", "original_object": "fracture", "original_subject": "DENOSUMAB", "population_context_qualifier": "men", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:49e5afe9-a0c7-40c4-af9f-f287a80c5c88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Prolia is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3317725-e4e0-542f-b86d-8add2ee65433", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "MONDO:0005315", "original_object": "fracture", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy for nonmetastatic prostate cancer", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9e32bf7-d70a-4083-8577-c15751c7f769", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9e32bf7-d70a-4083-8577-c15751c7f769", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9e32bf7-d70a-4083-8577-c15751c7f769"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Bildyos is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Bildyos is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Bildyos is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Bildyos is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6e12803-f9d0-57b7-b752-ca403930f772", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "MONDO:0005315", "original_object": "fracture", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy for nonmetastatic prostate cancer", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:815d3ba4-27a1-4a06-925a-a87f35442bdb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=815d3ba4-27a1-4a06-925a-a87f35442bdb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=815d3ba4-27a1-4a06-925a-a87f35442bdb"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Enoby is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Enoby is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Enoby is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e09a106f-496d-5664-bdd0-ab304f444549", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2f819cb-e859-5074-821e-308ad9717a89", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "MONDO:0005315", "original_object": "fracture", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy for nonmetastatic prostate cancer", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:29140df2-24a3-4a6f-a8e3-065521448d61", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=29140df2-24a3-4a6f-a8e3-065521448d61", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29140df2-24a3-4a6f-a8e3-065521448d61"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Boncresa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Boncresa is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Boncresa is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25484075-1411-5499-86d5-303b1239d631", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d3a7554e-b7b8-5f9b-ab29-3635b2a3cf6c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "UMLS:C0016658", "original_object": "fractures", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e1d80a82-de52-4a34-9df3-609e50667ffb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e1d80a82-de52-4a34-9df3-609e50667ffb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1d80a82-de52-4a34-9df3-609e50667ffb"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Ospomyv is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Ospomyv is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Ospomyv is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:290da3ad-ccf7-51b5-9f1f-1afc5c2beed4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56b04329-9473-52f6-850a-b29a5339fb99", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "UMLS:C0080179", "original_object": "vertebral fractures", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy for nonmetastatic prostate cancer", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4bf239bb-c467-4add-b7cf-ea666e4fc693", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4bf239bb-c467-4add-b7cf-ea666e4fc693", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bf239bb-c467-4add-b7cf-ea666e4fc693"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Jubbonti is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies ( 14.1 )] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Jubbonti is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies ( 14.2 )] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Jubbonti is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or pati"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6dc40f4e-208d-540c-9f76-bd1e623bd822", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56b04329-9473-52f6-850a-b29a5339fb99", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "UMLS:C0080179", "original_object": "vertebral fractures", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f3be096-5100-4d0e-b765-481bbb2672e1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f3be096-5100-4d0e-b765-481bbb2672e1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f3be096-5100-4d0e-b765-481bbb2672e1"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture OSVYRTI is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis OSVYRTI is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis OSVYRTI is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are int"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmetastatic prostate cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3d4e399-be7e-54ac-a449-d2bd65226341", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["androgen deprivation therapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56b04329-9473-52f6-850a-b29a5339fb99", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "medic_supporting_text_truncated": true, "object": "UMLS:C0080179", "original_object": "vertebral fractures", "original_subject": "DENOSUMAB", "population_context_qualifier": "men receiving androgen deprivation therapy for nonmetastatic prostate cancer", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7a449553-105c-46a1-bb72-849d8f5b81bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7a449553-105c-46a1-bb72-849d8f5b81bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7a449553-105c-46a1-bb72-849d8f5b81bd"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:070db7f3-e836-5faf-8771-90cf4248ce94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [254, 279], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:enwylma", "https://www.ema.europa.eu/en/documents/product-information/enwylma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/enwylma"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2832a287-a327-580a-9da8-00837d82d6a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [236, 261], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yaxwer", "https://www.ema.europa.eu/en/documents/product-information/yaxwer-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yaxwer"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51eb1133-da58-5816-9c74-d9f0b952835e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [254, 279], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:osenvelt", "https://www.ema.europa.eu/en/documents/product-information/osenvelt-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/osenvelt"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6993e36f-d288-587f-abe6-9f675f121822", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [242, 267], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:jubereq", "https://www.ema.europa.eu/en/documents/product-information/jubereq-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/jubereq"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.&nbsp;Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85b485eb-41e1-5bed-9d27-02a4964eb17b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [254, 279], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vevzuo", "https://www.ema.europa.eu/en/documents/product-information/vevzuo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vevzuo"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e09e348-1da7-5c42-9d81-f221bc025d11", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [255, 280], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zvogra", "https://www.ema.europa.eu/en/documents/product-information/zvogra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zvogra"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aec4b869-df1b-5385-9172-4c7c3e45fcb1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [236, 261], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xbonzy", "https://www.ema.europa.eu/en/documents/product-information/xbonzy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xbonzy"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c42cfa87-94ae-58ef-b001-33a585b4f81b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [236, 261], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:bilprevda", "https://www.ema.europa.eu/en/documents/product-information/bilprevda-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/bilprevda"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc3e597b-64d5-56de-bdd9-fca2536c7b16", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [255, 280], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:xbryk", "https://www.ema.europa.eu/en/documents/product-information/xbryk-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/xbryk"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1). Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4d9864b-98bb-50e9-b5cb-fee8b006d1eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [237, 262], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:bomyntra", "https://www.ema.europa.eu/en/documents/product-information/bomyntra-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/bomyntra"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f53a5987-3605-556e-ac1b-b09db52d6332", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [254, 279], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:denbrayce", "https://www.ema.europa.eu/en/documents/product-information/denbrayce-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/denbrayce"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0011847", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fec6634d-4317-547e-9833-d74bdd84464a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100526", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011847"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7602b0a2-3ce2-5bf4-9f15-7378aae6a9e5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0005674", "object_location_in_text": [236, 261], "original_object": "giant cell tumour of bone", "original_subject": "denosumab", "population_context_qualifier": "adults and skeletally mature adolescents", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:degevma", "https://www.ema.europa.eu/en/documents/product-information/degevma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/degevma"]}], "subject": "CHEBI:749681", "supporting_text": ["Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4510264", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23c39070-e38f-545a-9595-ef1622df7ae4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4510264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bb1ffbf-16fe-5415-ab12-ec336376c177", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0043455", "object_location_in_text": [420, 447], "original_object": "hypercalcemia of malignancy", "original_subject": "DENOSUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f040a245-1be4-4962-a8b7-a13ee7fac707", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f040a245-1be4-4962-a8b7-a13ee7fac707", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f040a245-1be4-4962-a8b7-a13ee7fac707"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Oziltus is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Oziltus is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Oziltus is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials (14.2) ] . 1.3 Hypercalcemia of Malignancy Oziltus is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4510264", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0ac7fbb-448a-56da-8465-4c0540afa8a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4510264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bb1ffbf-16fe-5415-ab12-ec336376c177", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0043455", "object_location_in_text": [422, 449], "original_object": "hypercalcemia of malignancy", "original_subject": "DENOSUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1f0590e-f5bb-44ac-99a0-4aa4596c7e54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1f0590e-f5bb-44ac-99a0-4aa4596c7e54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1f0590e-f5bb-44ac-99a0-4aa4596c7e54"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Bilprevda is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Bilprevda is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Bilprevda is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Bilprevda is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4510264", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd0b669f-09c2-5853-ada3-dcc19f9a1fd2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4510264"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bb1ffbf-16fe-5415-ab12-ec336376c177", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0043455", "object_location_in_text": [420, 447], "original_object": "hypercalcemia of malignancy", "original_subject": "DENOSUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:547cb095-f7f5-f933-75ce-5e6abf2ad5bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=547cb095-f7f5-f933-75ce-5e6abf2ad5bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=547cb095-f7f5-f933-75ce-5e6abf2ad5bc"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Aukelso is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Aukelso is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Aukelso is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials (14.2) ] . 1.3 Hypercalcemia of Malignancy Aukelso is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypercalcemia of malignancy refractory to bisphosphonate therapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e063adec-2079-549f-beb4-dd4459471a1e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100601", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9bb1ffbf-16fe-5415-ab12-ec336376c177", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "MONDO:0043455", "object_location_in_text": [418, 445], "original_object": "hypercalcemia of malignancy", "original_subject": "DENOSUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:628f0998-1206-4001-aeee-18133aa9f3bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=628f0998-1206-4001-aeee-18133aa9f3bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=628f0998-1206-4001-aeee-18133aa9f3bf"]}], "subject": "CHEBI:749681", "supporting_text": ["1 INDICATIONS AND USAGE Xgeva is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Xgeva is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Xgeva is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Xgeva is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "bone metastasis of solid tumor", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d425f51-ec41-5883-84b3-4313d5c194c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3f6792e4-38cb-51e3-bf23-553cab3a3e5f", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:50315b55-155c-5052-8b36-6729b6d9f871", "object": "UMLS:C0238792", "object_location_in_text": [67, 79], "original_object": "bone lesions", "original_subject": "DENOSUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DENOSUMAB#153-20120118", "https://www.pmda.go.jp/files/000228530.pdf"]}], "subject": "CHEBI:749681", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gout refractory to conventional therapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5827c6f5-836b-5139-820c-e3d4465ff43d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a6408f3c-e28b-5791-a9e4-6cfcc9e45ef6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4b7a2165-041f-5818-85cd-83b8aa7fea63", "object": "UMLS:C0268108", "object_location_in_text": [121, 133], "original_object": "chronic gout", "original_subject": "PEGLOTICASE", "population_context_qualifier": "adult patients refractory to conventional therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f4574d1-401f-4647-83e5-28c0f4a122a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f4574d1-401f-4647-83e5-28c0f4a122a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f4574d1-401f-4647-83e5-28c0f4a122a7"]}], "subject": "CHEBI:749683", "supporting_text": ["1 INDICATIONS AND USAGE KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "allogeneic haematopoietic stem cell transplant", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2a45276-9b5b-5321-aaab-b7a7a03f1e81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180108", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8e1bbbf1-262b-5d3c-83e4-eef603976d47", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2f637f6c-dda7-597a-9cf6-e141375e8aff", "object": "MONDO:0005132", "original_object": "cytomegalovirus disease", "original_subject": "letermovir", "population_context_qualifier": "adult and paediatric patients weighing at least 15 kg who are CMV-seropositive recipients [R+]", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:prevymis", "https://www.ema.europa.eu/en/documents/product-information/prevymis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis"]}], "subject": "CHEBI:749693", "supporting_text": ["Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult and paediatric patients weighing at least 5 kg who are CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).Prevymis is indicated for prophylaxis of CMV disease in CMV-seronegative adult and paediatric patients weighing at least 40 kg who have received a kidney transplant from a CMV-seropositive donor [D+/R-].Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult and paediatric patients weighing at least 15 kg who are CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). Consideration should be given to official guidance on the appropriate use of antiviral agents.&nbsp;"], "temporal_context_qualifier": "allogeneic haematopoietic stem cell transplant (HSCT)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "allogeneic haematopoietic stem cell transplant", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10886beb-d193-5419-b02f-40fedc46097b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180108", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a70c2d66-d7cc-56f3-93c7-ab7c0086a89e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2f637f6c-dda7-597a-9cf6-e141375e8aff", "object": "UMLS:C4554665", "original_object": "cytomegalovirus reactivation", "original_subject": "letermovir", "population_context_qualifier": "adult and paediatric patients weighing at least 15 kg who are CMV-seropositive recipients [R+]", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:prevymis", "https://www.ema.europa.eu/en/documents/product-information/prevymis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis"]}], "subject": "CHEBI:749693", "supporting_text": ["Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult and paediatric patients weighing at least 5 kg who are CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).Prevymis is indicated for prophylaxis of CMV disease in CMV-seronegative adult and paediatric patients weighing at least 40 kg who have received a kidney transplant from a CMV-seropositive donor [D+/R-].Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult and paediatric patients weighing at least 15 kg who are CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). Consideration should be given to official guidance on the appropriate use of antiviral agents.&nbsp;"], "temporal_context_qualifier": "allogeneic haematopoietic stem cell transplant (HSCT)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa0cb941-8f98-5900-b700-04c852cbaf33", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:192ea008-896c-5805-b98a-5c63ff326cc5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses  Helps prevent sunburn.  If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4285d6f6-fbcc-5c03-b014-eb64cc586a6b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aeebe7be-b87f-5605-8184-d82bcbf0f19b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3787ba3-8679-5a4b-a5a1-058dceba2590", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5de9ca1a-3026-258c-e063-6394a90a1c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5de9ca1a-3026-258c-e063-6394a90a1c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5de9ca1a-3026-258c-e063-6394a90a1c1a"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses • Helps prevent sunburn • If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce2ff2fa-931e-5124-8d75-d28bdf5f0801", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses • helps prevent sunburn • if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed3a3b2b-8911-5d76-a206-ed9cf7c87383", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dc3aae6c-f2a2-5200-ba26-367bf08d0b31", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "OCTISALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a5a35be-9e24-18dd-e063-6394a90a097f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a5a35be-9e24-18dd-e063-6394a90a097f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a5a35be-9e24-18dd-e063-6394a90a097f"]}], "subject": "CHEBI:749764", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:786e01ce-974a-5d32-b544-2f4c983d87a1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68da0f3d-13e9-5122-9995-81a61a4f0ade", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:70879b9e-2c69-53a1-a5fe-72d58b86d649", "object": "MONDO:0002898", "object_location_in_text": [123, 134], "original_object": "skin cancer", "original_subject": "HOMOSALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:749790", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bc92e7b-b91b-5ccb-b5d3-8d1d87986395", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:70879b9e-2c69-53a1-a5fe-72d58b86d649", "object": "UMLS:C0037271", "object_location_in_text": [139, 155], "original_object": "early skin aging", "original_subject": "HOMOSALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=636e38d8-f83b-4000-9174-1015a56f6292"]}], "subject": "CHEBI:749790", "supporting_text": ["Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "caused by the sun", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27f088d7-ca69-5e3a-9e3c-0609a305b148", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:70879b9e-2c69-53a1-a5fe-72d58b86d649", "object": "UMLS:C0037271", "object_location_in_text": [142, 158], "original_object": "early skin aging", "original_subject": "HOMOSALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dde7a00-33a6-fad3-e063-6294a90a1fbb"]}], "subject": "CHEBI:749790", "supporting_text": ["Uses • helps prevent sunburn • if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun"], "temporal_context_qualifier": "if used as directed with other sun protection measures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "sun damage", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c74403ac-c3d5-582c-9d85-dc0d42a5ef65", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:70879b9e-2c69-53a1-a5fe-72d58b86d649", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "HOMOSALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dd1da6c-4a2c-7a37-e063-6294a90aa92e"]}], "subject": "CHEBI:749790", "supporting_text": ["Uses  Helps prevent sunburn.  If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1456711", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cde461ac-8d77-52fa-b2f4-c6357bcc9269", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1456711"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f8106f28-ccf7-59dd-af8e-acc77c1f753d", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:70879b9e-2c69-53a1-a5fe-72d58b86d649", "object": "UMLS:C0037271", "object_location_in_text": [143, 159], "original_object": "early skin aging", "original_subject": "HOMOSALATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53ee9b7d-9dff-7121-e063-6394a90ad38f"]}], "subject": "CHEBI:749790", "supporting_text": ["Uses ■ helps prevent sunburn ■ if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Trypanosoma brucei gambiense infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:928d4c77-523b-5ebf-aa0c-5b9cb5321cae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210716", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1781b620-658c-506d-9da8-c7a03c2d9f13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2ab0e21e-301e-579e-92ed-b0a4005505e9", "object": "MONDO:0005459", "original_object": "human African trypanosomiasis", "original_subject": "FEXINIDAZOLE", "population_context_qualifier": "patients 6 years of age and older and weighing at least 20 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74a611bc-9977-46bb-b626-0370b3031628", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74a611bc-9977-46bb-b626-0370b3031628", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74a611bc-9977-46bb-b626-0370b3031628"]}], "subject": "CHEBI:749938", "supporting_text": ["1 INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Fexinidazole Tablets is a nitroimidazole antimicrobial, indicated for the treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e695ad0-dc83-5457-969c-c78334cf865a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [135, 152], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ahzantive", "https://www.ema.europa.eu/en/documents/product-information/ahzantive-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ahzantive"]}], "subject": "CHEBI:750062", "supporting_text": ["Ahzantive is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), • visual impairment due to diabetic macular oedema (DME) (see section 5.1), • visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f61a78a-90e1-5e02-b4a6-9ba31defc17c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [127, 144], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:afiveg", "https://www.ema.europa.eu/en/documents/product-information/afiveg-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/afiveg"]}], "subject": "CHEBI:750062", "supporting_text": ["Afiveg is indicated for adults for the treatment of  neovascular (wet) age-related macular degeneration (AMD) (see section 1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6fe4f1c0-912d-5e23-9486-19441686d829", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [113, 130], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:afqlir", "https://www.ema.europa.eu/en/documents/product-information/afqlir-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/afqlir"]}], "subject": "CHEBI:750062", "supporting_text": ["Afqlir is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a52591a6-ede1-50ed-b164-8ba04622439f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [113, 130], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vgenfli", "https://www.ema.europa.eu/en/documents/product-information/vgenfli-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vgenfli"]}], "subject": "CHEBI:750062", "supporting_text": ["Vgenfli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbbe5097-e425-50b6-aa2c-d565fb3f645f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [134, 151], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pavblu", "https://www.ema.europa.eu/en/documents/product-information/pavblu-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pavblu"]}], "subject": "CHEBI:750062", "supporting_text": ["Pavblu is indicated for adults for the treatment of  neovascular (wet) age-related macular degeneration (AMD)&nbsp;(see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)&nbsp;(see section 5.1), visual impairment due to diabetic macular oedema (DME)&nbsp;(see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV)&nbsp;(see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1a390c0-5fda-51a9-b82f-fe37a3d3ff9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [131, 148], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eyluxvi", "https://www.ema.europa.eu/en/documents/product-information/eyluxvi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eyluxvi"]}], "subject": "CHEBI:750062", "supporting_text": ["Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665926", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd5b8fe1-f09b-58fb-8a57-4e3fd52b1bc0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121121", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3665926"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ac96f895-e499-5c2c-bdf5-03039bf376a6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "HP:0000505", "object_location_in_text": [130, 147], "original_object": "visual impairment", "original_subject": "aflibercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eiyzey", "https://www.ema.europa.eu/en/documents/product-information/eiyzey-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eiyzey"]}], "subject": "CHEBI:750062", "supporting_text": ["Eiyzey is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1)s."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0031241", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:108cb27b-9064-5222-809a-c262060fcc22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250919", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031241"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f7e5bceb-3209-5ac3-bb8e-563d14978269", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3a0bfb22-6b88-5ed5-a3bd-64aab60ad979", "object": "MONDO:0005150", "object_location_in_text": [43, 75], "original_object": "age-related macular degeneration", "original_subject": "AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 3]", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 3]#7-20250919", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["Biosimilars indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization, macular edema following retinal vein occlusion, and choroidal neovascularization in patients with pathologic myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0031241", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ec9bb59-5ad9-5548-8f48-7da9b06a4e82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240118", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031241"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f7e5bceb-3209-5ac3-bb8e-563d14978269", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "MONDO:0005150", "object_location_in_text": [59, 91], "original_object": "age-related macular degeneration", "original_subject": "AFLIBERCEPT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT#24-20240118", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["A drug in a new dosage form indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0031241", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92ab522d-63e7-584b-86a0-8c9aec1d8ab9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120928", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031241"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f7e5bceb-3209-5ac3-bb8e-563d14978269", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "MONDO:0005150", "object_location_in_text": [66, 98], "original_object": "age-related macular degeneration", "original_subject": "AFLIBERCEPT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT#135-20120928", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0031241", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db08f3a4-3001-5109-badc-99e52fcd3814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250919", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031241"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f7e5bceb-3209-5ac3-bb8e-563d14978269", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3a9a7a9f-274a-58ec-98fc-44fd81963bae", "object": "MONDO:0005150", "object_location_in_text": [43, 75], "original_object": "age-related macular degeneration", "original_subject": "AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 2]", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 2]#7-20250919", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["Biosimilars indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization, macular edema following retinal vein occlusion, and choroidal neovascularization in patients with pathologic myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3537442", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12f365d2-59bb-584b-a804-59d907720e65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140919", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3537442"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:08663ffc-206e-5604-b6f8-73eda467a224", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "MONDO:0810000", "object_location_in_text": [60, 88], "original_object": "choroidal neovascularization", "original_subject": "AFLIBERCEPT", "population_context_qualifier": "patients with pathologic myopia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT#115-20140919", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["Drugs with a new additional indication for the treatment of choroidal neovascularization in patients with pathologic myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3537442", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:248ff383-e936-5dca-a419-99471a2b7a67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240624", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3537442"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:08663ffc-206e-5604-b6f8-73eda467a224", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0221d183-0ece-567b-972e-4a175af36335", "object": "MONDO:0810000", "object_location_in_text": [92, 120], "original_object": "choroidal neovascularization", "original_subject": "AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 1]", "population_context_qualifier": "patients with pathologic myopia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 1]#18-20240624", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["A biosimilar indicated for the treatment of macular edema following retinal vein occlusion, choroidal neovascularization in patients with pathologic myopia, and diabetic macular edema."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3537442", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cca8163c-b815-58ce-9ad2-602aa382c6a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250919", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3537442"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:08663ffc-206e-5604-b6f8-73eda467a224", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3a0bfb22-6b88-5ed5-a3bd-64aab60ad979", "object": "MONDO:0810000", "object_location_in_text": [102, 130], "original_object": "choroidal neovascularization", "original_subject": "AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 3]", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 3]#7-20250919", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["Biosimilars indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization, macular edema following retinal vein occlusion, and choroidal neovascularization in patients with pathologic myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3537442", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3cdc96d-9adc-5917-b24d-e14b4cb5602e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250919", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3537442"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:08663ffc-206e-5604-b6f8-73eda467a224", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3a9a7a9f-274a-58ec-98fc-44fd81963bae", "object": "MONDO:0810000", "object_location_in_text": [102, 130], "original_object": "choroidal neovascularization", "original_subject": "AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 2]", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AFLIBERCEPT [AFLIBERCEPT BIOSIMILAR 2]#7-20250919", "https://www.pmda.go.jp/files/000264250.pdf"]}], "subject": "CHEBI:750062", "supporting_text": ["Biosimilars indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization, macular edema following retinal vein occlusion, and choroidal neovascularization in patients with pathologic myopia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "oxaliplatin-containing regimen resistance or progression", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23d3909f-2373-5484-b6d5-098588e8501e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20111118", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluorouracil", "leucovorin", "irinotecan"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7883379b-4d29-511d-963a-a4eb81b67307", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3315869f-0adb-5b75-b702-8c509ae78a7a", "object": "UMLS:C4721579", "object_location_in_text": [149, 177], "original_object": "metastatic colorectal cancer", "original_subject": "AFLIBERCEPT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6725df6-50ee-4b0a-b900-d02ba634395d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6725df6-50ee-4b0a-b900-d02ba634395d"]}], "subject": "CHEBI:750062", "supporting_text": ["1 INDICATIONS AND USAGE ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "EBV seronegative or with unknown EBV serostatus", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e10ba72e-149b-5ff9-987d-af97ed8a3bc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110615", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6166c796-90a9-5baa-94e5-6dfe0c8527e2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f2e480f-37f8-57a4-be73-5a392289c58b", "object": "MONDO:0019088", "object_location_in_text": [168, 219], "original_object": "post-transplant lymphoproliferative disorder (PTLD)", "original_subject": "BELATACEPT", "population_context_qualifier": "transplant recipients", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c16ac648-d5d2-9f7d-8637-e2328572754e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c16ac648-d5d2-9f7d-8637-e2328572754e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c16ac648-d5d2-9f7d-8637-e2328572754e"]}], "subject": "CHEBI:750070", "supporting_text": ["4 CONTRAINDICATIONS NULOJIX is contraindicated in transplant recipients who are Epstein-Barr virus (EBV) seronegative or with unknown EBV serostatus due to the risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS) [see Boxed Warning and Warnings and Precautions (5.1) ] . Patients who are EBV seronegative or with unknown EBV serostatus. (4)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "eosinophilic phenotype", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:835be4d5-a592-51c9-af0b-6482a6be448c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171114", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d303baeb-1476-5fc8-9853-28946163135a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:dcdacfc0-af45-5bc4-a9b9-5e805468bf28", "object": "UMLS:C0581126", "object_location_in_text": [226, 239], "original_object": "severe asthma", "original_subject": "BENRALIZUMAB", "population_context_qualifier": "adult and pediatric patients aged 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da6aca1a-19ed-44a4-abb7-696c7d58b784", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784"]}], "subject": "CHEBI:750071", "supporting_text": ["1 INDICATIONS AND USAGE FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. ( 1.1 ) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.2 ) • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "relapsed or refractory", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4975fb0-866c-568a-a2f7-5cdc5f409586", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:cb66b1eb-e84b-52af-9b61-77ea671163ce", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:7e574e1c-ca4a-5b9e-b8d0-a98fa77433ff", "object": "MONDO:0000430", "object_location_in_text": [84, 110], "original_object": "peripheral T-cell lymphoma", "original_subject": "BRENTUXIMAB VEDOTIN", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BRENTUXIMAB VEDOTIN#74-20191220", "https://www.pmda.go.jp/files/000243154.pdf"]}], "subject": "CHEBI:750074", "supporting_text": ["1) A drug with a new indication and a new dosage for the treatment of CD30-positive peripheral T-cell lymphoma. 2) A drug with a new additional pediatric dosage indicated for the treatment of relapsed or refractory CD30-positive Hodgkin’s lymphoma and peripheral T-cell lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2610f180-4506-59ac-ace3-66d727d1d6d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160704", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0406317", "MONDO:0022205", "UMLS:C0748052"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "MONDO:0011849", "object_location_in_text": [84, 103], "original_object": "psoriatic arthritis", "original_subject": "IXEKIZUMAB", "population_context_qualifier": "patients who have not responded sufficiently to conventional therapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#101-20160704", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "conventional therapy failure", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb2773c5-1056-51c2-a66f-5138b59ef71b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180821", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:501808c5-d7ac-5687-b766-abcac6bc81d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "MONDO:0011849", "object_location_in_text": [73, 92], "original_object": "psoriatic arthritis", "original_subject": "IXEKIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#80-20180821", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new dosage indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "conventional therapy failure", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3345d440-7df3-5c39-a324-ad9d7db01880", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180821", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:734d710b-6a03-5fdb-a089-dfa27ddb70ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "MONDO:0022205", "object_location_in_text": [94, 112], "original_object": "pustular psoriasis", "original_subject": "IXEKIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#80-20180821", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new dosage indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc6550e9-3b2c-5419-8040-0f5f0a1db080", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160704", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0406317", "MONDO:0011849", "UMLS:C0748052"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:734d710b-6a03-5fdb-a089-dfa27ddb70ae", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "MONDO:0022205", "object_location_in_text": [105, 123], "original_object": "pustular psoriasis", "original_subject": "IXEKIZUMAB", "population_context_qualifier": "patients who have not responded sufficiently to conventional therapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#101-20160704", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "conventional therapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47975883-918b-595c-860f-5b5c1a8f7fd8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180821", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:0e6ca689-757d-58ce-aef2-6bd45c549b64", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "UMLS:C0406317", "object_location_in_text": [55, 71], "original_object": "plaque psoriasis", "original_subject": "IXEKIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#80-20180821", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new dosage indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "conventional therapy failure", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27e35e63-3ba0-56fb-8bbb-95c3023eb7ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180821", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:462f57f5-37b0-5038-bb2b-b83b564ed07e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "UMLS:C0748052", "object_location_in_text": [118, 141], "original_object": "erythrodermic psoriasis", "original_subject": "IXEKIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#80-20180821", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new dosage indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0406317", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f385e690-1aab-5873-943e-200eae536538", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160704", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0406317", "MONDO:0011849", "MONDO:0022205"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:462f57f5-37b0-5038-bb2b-b83b564ed07e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "UMLS:C0748052", "object_location_in_text": [129, 152], "original_object": "erythrodermic psoriasis", "original_subject": "IXEKIZUMAB", "population_context_qualifier": "patients who have not responded sufficiently to conventional therapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IXEKIZUMAB#101-20160704", "https://www.pmda.go.jp/files/000224346.pdf"]}], "subject": "CHEBI:750112", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "objective signs of inflammation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:28794e66-7892-5a45-b2bb-cd9a66a6d9a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160322", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42ba7dbd-ad67-5020-b472-308afe9106db", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cf5cf2a1-6346-5d2c-9aa6-792bbef5f2b2", "object": "UMLS:C3889038", "original_object": "non-radiographic axial spondyloarthritis", "original_subject": "IXEKIZUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac96658a-d7dc-4c7c-8928-2adcdf4318b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac96658a-d7dc-4c7c-8928-2adcdf4318b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac96658a-d7dc-4c7c-8928-2adcdf4318b2"]}], "subject": "CHEBI:750112", "supporting_text": ["1 INDICATIONS AND USAGE TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 ) 1.1 Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis. 1.3 Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Non-radiographic Axial Spondyloarthritis TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "childhood-onset idiopathic nephrotic syndrome", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb6f4e73-df13-5d69-9e5e-3250b9686c31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9b079520-c24f-5851-9b89-b8fa6bf226c0", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48df519e-9b49-5a5f-9474-09515a4ac7d6", "medic_supporting_text_truncated": true, "object": "UMLS:C0035020", "object_location_in_text": [347, 354], "original_object": "relapse", "original_subject": "OBINUTUZUMAB", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda"]}], "subject": "CHEBI:750126", "supporting_text": ["1 INDICATIONS AND USAGE GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). ( 1.1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma (FL)who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1.2 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1.2 , 14 ) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy ( 1.3 , 14 ) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. ( 1.4 , 14 ) 1.1 Chronic Lymphocytic Leukemia (CLL) GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. 1.2 Follicular Lymphoma (FL) GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen . GAZYVA, in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, is indicated for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma . 1.3 Lupus Nephritis (LN) GAZYVA is indicated for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. 1.4 Childhood-Onset Idiopathic Nephrotic Syndrome (INS) GAZYVA is indicated to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with freque"], "temporal_context_qualifier": "in complete remission"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36f9cc05-f693-5267-a3c6-37dcb9ef38ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140421", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d21d7cee-0d76-53a6-99dc-ba6d422cda1f", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "RAMUCIRUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6080942-dee6-423e-b688-1272c2ae90d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4"]}], "subject": "CHEBI:750139", "supporting_text": ["1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on or after platinum-based chemotherapy", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36719d63-5999-5da5-b0a2-77ad60ea7663", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140421", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d21d7cee-0d76-53a6-99dc-ba6d422cda1f", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "RAMUCIRUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6080942-dee6-423e-b688-1272c2ae90d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4"]}], "subject": "CHEBI:750139", "supporting_text": ["1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4721579", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3763dd39-eff5-5ed5-97ba-89478aa6f68c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141219", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["irinotecan", "folinic acid", "5-fluorouracil"], "medic_disease_context_ids": ["UMLS:C4721579"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4db18fd6-759e-58ad-bde9-03459dacc042", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d21d7cee-0d76-53a6-99dc-ba6d422cda1f", "object": "MONDO:0005575", "object_location_in_text": [721, 738], "original_object": "colorectal cancer", "original_subject": "ramucirumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cyramza", "https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza"]}], "subject": "CHEBI:750139", "supporting_text": ["Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. Colorectal cancer Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5?fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. Non-small cell lung cancer Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. Hepatocellular carcinoma Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ?&nbsp;400&nbsp;ng/ml and who have been previously treated with sorafenib."], "temporal_context_qualifier": "with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09ef3d99-2b9b-55d9-9e9e-00a5705145aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140421", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["FOLFIRI"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4db18fd6-759e-58ad-bde9-03459dacc042", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d21d7cee-0d76-53a6-99dc-ba6d422cda1f", "medic_supporting_text_truncated": true, "object": "MONDO:0005575", "original_object": "colorectal cancer", "original_subject": "RAMUCIRUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6080942-dee6-423e-b688-1272c2ae90d4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6080942-dee6-423e-b688-1272c2ae90d4"]}], "subject": "CHEBI:750139", "supporting_text": ["1 INDICATIONS AND USAGE CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. CYRAMZA, in combination with docetaxel, is indicated for the treatment of adults with "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HER2-positive early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f8e0840-61c4-58d0-ad9d-f0f5a5b11bed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131115", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:48843129-3a6c-5532-8984-99201b5ba0b5", "object": "MONDO:0007254", "original_object": "early breast cancer", "original_subject": "trastuzumab emtansine", "population_context_qualifier": "adult patients with residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kadcyla", "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla"]}], "subject": "CHEBI:750159", "supporting_text": ["Early Breast Cancer (EBC) Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Metastatic Breast Cancer (MBC) Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:  Received prior therapy for locally advanced or metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy."], "temporal_context_qualifier": "after neoadjuvant taxane-based and HER2-targeted therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-positive early breast cancer, residual invasive disease", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:219bee96-7731-500f-b16b-f7d1658c41e4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48843129-3a6c-5532-8984-99201b5ba0b5", "object": "MONDO:0007254", "object_location_in_text": [512, 531], "original_object": "early breast cancer", "original_subject": "TRASTUZUMAB EMTANSINE", "population_context_qualifier": "patients who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:23f3c1f4-0fc8-4804-a9e3-04cf25dd302e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e"]}], "subject": "CHEBI:750159", "supporting_text": ["1 INDICATIONS AND USAGE KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-authorized test for KADCYLA [see Dosage and Administration (2.1) ] 1.1 Metastatic Breast Cancer (MBC) KADCYLA ® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-authorized test for KADCYLA [ see Dosage and Administration (2.1) ]. 1.2 Early Breast Cancer (EBC) KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment. Select patients for therapy based on an FDA-authorized test for KADCYLA [ see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "after neoadjuvant taxane and trastuzumab-based treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HER2-positive, unresectable locally advanced or metastatic breast cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d20f3ae-16ab-5ec6-a7d5-653182dfb052", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131115", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trastuzumab", "taxane"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:48843129-3a6c-5532-8984-99201b5ba0b5", "object": "UMLS:C0278488", "original_object": "metastatic breast cancer", "original_subject": "trastuzumab emtansine", "population_context_qualifier": "adult patients who previously received trastuzumab and a taxane, separately or in combination", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kadcyla", "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla"]}], "subject": "CHEBI:750159", "supporting_text": ["Early Breast Cancer (EBC) Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Metastatic Breast Cancer (MBC) Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:  Received prior therapy for locally advanced or metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1565489", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:190564ea-58aa-5c48-b244-6833b79cd176", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C1565489"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:917058c3-c74d-531c-b369-8c60e3579128", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c00b991a-748c-5877-be5d-5a0bc98625e9", "object": "MONDO:0034212", "original_object": "methotrexate toxicity", "original_subject": "GLUCARPIDASE", "population_context_qualifier": "adult and pediatric patients with delayed methotrexate clearance", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:acaef5a6-b740-40e3-8ffe-74a75c74745c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=acaef5a6-b740-40e3-8ffe-74a75c74745c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acaef5a6-b740-40e3-8ffe-74a75c74745c"]}], "subject": "CHEBI:750223", "supporting_text": ["1 INDICATIONS AND USAGE VORAXAZE is indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0033141", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:824a416e-130f-5b3b-b515-b6d7602081e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220429", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0033141"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b47f456a-920e-5a5d-ac67-309419159655", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:877d5829-4d04-554d-841e-a086bec2cfcd", "object": "MONDO:0100130", "object_location_in_text": [52, 87], "original_object": "Acute Respiratory Distress Syndrome", "original_subject": "Aviptadil bulk and Aviptadil injection (Each ml vial contains Aviptadil 15 mcg)", "population_context_qualifier": "patients with severe COVID-19 with Acute Respiratory Distress Syndrome (ARDS)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:750343", "supporting_text": ["For treatment of patients with severe COVID-19 with Acute Respiratory Distress Syndrome (ARDS), in light of Covid 19 outbreak for restricted emergency use in the countr0079"], "temporal_context_qualifier": "in light of Covid 19 outbreak"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afca882d-67cc-56c1-bd16-a185d13bb2a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120608", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b4f46f08-eddb-5bd4-8ef8-3db22259806f", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b72322b3-3beb-5808-b3e4-8c8a085ea7d7", "object": "MONDO:0006804", "original_object": "inflammatory breast cancer", "original_subject": "PERTUZUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:750362", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "neoadjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34340aee-a9c4-576b-9b4f-ec88cf7ee186", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120608", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b72322b3-3beb-5808-b3e4-8c8a085ea7d7", "object": "MONDO:0007254", "object_location_in_text": [420, 439], "original_object": "early breast cancer", "original_subject": "PERTUZUMAB", "population_context_qualifier": "adult patients at high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:750362", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:caa6fb1f-61b3-58b1-93e4-98554e165bf8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120608", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["docetaxel"], "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b72322b3-3beb-5808-b3e4-8c8a085ea7d7", "object": "UMLS:C0278488", "object_location_in_text": [633, 657], "original_object": "metastatic breast cancer", "original_subject": "PERTUZUMAB", "population_context_qualifier": "adult patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:750362", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d87729d0-5e9a-52b0-8c0c-886b22170e21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120608", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b72322b3-3beb-5808-b3e4-8c8a085ea7d7", "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "PERTUZUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da"]}], "subject": "CHEBI:750362", "supporting_text": ["1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) 1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]. 1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] . Select patients for therapy based on an FDA-authorized companion diagnostic test [see Dosage and Administration (2.1) ]."], "temporal_context_qualifier": "neoadjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FGFR inhibitor administration", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60c76d1d-9463-52a8-a156-b86ec2156d7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210323", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bdb61e8e-be87-5096-9ade-7fe509fbee9d", "object": "MONDO:0000328", "object_location_in_text": [51, 68], "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CARBONATE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LANTHANUM CARBONATE HYDRATE#65-20210323", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:750449", "supporting_text": ["Drugs with a new indication for the improvement of hyperphosphatemia associated with administration of FGFR inhibitor. [Expedited review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "melanoma with a BRAF V600 mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eec43281-7871-53ee-8763-6978eb9d7aa3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130826", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trametinib"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:69f8c6a8-386d-51fd-b56f-5b916cef0816", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:76d21a4a-9b6a-5fe6-9bf9-6b574e9e0d18", "object": "MONDO:0005105", "object_location_in_text": [150, 158], "original_object": "melanoma", "original_subject": "dabrafenib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tafinlar", "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"]}], "subject": "CHEBI:75045", "supporting_text": ["Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation."], "temporal_context_qualifier": "following complete resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-small cell lung cancer with a BRAF V600 mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99f6433d-c00d-53cc-844d-97b3ca704fd9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130826", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trametinib"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:76d21a4a-9b6a-5fe6-9bf9-6b574e9e0d18", "object": "MONDO:0005233", "object_location_in_text": [565, 591], "original_object": "non-small cell lung cancer", "original_subject": "dabrafenib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tafinlar", "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"]}], "subject": "CHEBI:75045", "supporting_text": ["Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3273990", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f321cf20-da6b-5b99-bb0a-d78371d94f4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130826", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trametinib"], "medic_disease_context_ids": ["UMLS:C3273990"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a9a831d6-1951-52b4-8187-ff0a9caac48a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:76d21a4a-9b6a-5fe6-9bf9-6b574e9e0d18", "object": "MONDO:0021637", "original_object": "low-grade glioma", "original_subject": "dabrafenib", "population_context_qualifier": "paediatric patients aged 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:finlee", "https://www.ema.europa.eu/en/documents/product-information/finlee-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/finlee"]}], "subject": "CHEBI:75045", "supporting_text": ["Low-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. High-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3273990", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09d3ca12-53fc-5328-8572-7841d872d9b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130826", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trametinib"], "medic_disease_context_ids": ["UMLS:C3273990"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9da18895-9186-556d-80be-33ba16c43a19", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:76d21a4a-9b6a-5fe6-9bf9-6b574e9e0d18", "object": "MONDO:0100342", "original_object": "high-grade glioma", "original_subject": "dabrafenib", "population_context_qualifier": "paediatric patients aged 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:finlee", "https://www.ema.europa.eu/en/documents/product-information/finlee-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/finlee"]}], "subject": "CHEBI:75045", "supporting_text": ["Low-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. High-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment."], "temporal_context_qualifier": "following at least one prior radiation and/or chemotherapy treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7051d1cf-f2cb-5393-8e9d-90ee24a0ed35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190620", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2cf95943-86b8-5af5-b9d1-ac4c0ed8a598", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0cd50c03-15e1-5fa0-b790-f5f15332a8d1", "object": "MONDO:0002049", "object_location_in_text": [43, 66], "original_object": "severe thrombocytopenia", "original_subject": "avatrombopag", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:doptelet", "https://www.ema.europa.eu/en/documents/product-information/doptelet-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet"]}], "subject": "CHEBI:750510", "supporting_text": ["Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)."], "temporal_context_qualifier": "scheduled to undergo an invasive procedure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0341439", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:915b9fcb-c972-5ebe-b093-322e0b1c9663", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230327", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0341439"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:fc95f468-42a1-53f8-ad40-cb60011322ab", "object": "MONDO:0002049", "object_location_in_text": [69, 85], "original_object": "thrombocytopenia", "original_subject": "AVATROMBOPAG MALEATE", "population_context_qualifier": "patients for whom an elective invasive procedure is planned", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:AVATROMBOPAG MALEATE#34-20230327", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:750510", "supporting_text": ["A drug with a new active ingredient indicated for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9899a55-fbef-5c53-a05c-c34218f90efa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a51a8c55-9c96-552d-93bc-33009ab6b0e3", "object": "HP:0000969", "object_location_in_text": [435, 440], "original_object": "edema", "original_subject": "NEOMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83"]}], "subject": "CHEBI:7507", "supporting_text": ["For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae , Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . This product does not provide adequate coverage against: Serratia marcescens and S treptococci , including Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indwelling catheter use", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49b27f3a-d3a9-5546-8eae-7a5b6e10cd0e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f0c7cff9-e4ce-59be-8966-a55ba176ade4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a51a8c55-9c96-552d-93bc-33009ab6b0e3", "object": "MONDO:0001882", "object_location_in_text": [204, 215], "original_object": "bacteriuria", "original_subject": "NEOMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb"]}], "subject": "CHEBI:7507", "supporting_text": ["Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters. If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated."], "temporal_context_qualifier": "short-term use (up to 10 days)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indwelling catheter use", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b159e492-f0ab-58eb-ba22-1a60da54e3a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a51a8c55-9c96-552d-93bc-33009ab6b0e3", "object": "MONDO:0005550", "original_object": "infection", "original_subject": "NEOMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb"]}], "subject": "CHEBI:7507", "supporting_text": ["Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters. If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indwelling catheter use", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f1d65e74-1635-5a23-88b3-cdad15ce2c65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a51a8c55-9c96-552d-93bc-33009ab6b0e3", "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "NEOMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb"]}], "subject": "CHEBI:7507", "supporting_text": ["Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters. If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48e16f2e-49ea-5f42-a3ae-79ef7a9748c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a51a8c55-9c96-552d-93bc-33009ab6b0e3", "object": "UMLS:C0021368", "object_location_in_text": [445, 457], "original_object": "inflammation", "original_subject": "NEOMYCIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83"]}], "subject": "CHEBI:7507", "supporting_text": ["For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae , Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . This product does not provide adequate coverage against: Serratia marcescens and S treptococci , including Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic non-cancer pain, chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:713d6dd9-cf19-5ee8-8bcb-44d3152335dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170323", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6f8f76f9-14b9-515f-a109-1aead88eef1e", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "NALDEMEDINE", "population_context_qualifier": "adult patients with chronic non-cancer pain; patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1a1256c-a1eb-4abe-ab1e-30e4711afd16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16"]}], "subject": "CHEBI:751608", "supporting_text": ["1 INDICATIONS AND USAGE SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. SYMPROIC is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, anti-EGFR agents", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecef68f5-f4b6-516c-888d-f5d15681d082", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160425", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7883379b-4d29-511d-963a-a4eb81b67307", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:843226b8-0efd-5b8c-8b5d-6a0c5f6fcb6b", "object": "UMLS:C4721579", "object_location_in_text": [112, 140], "original_object": "metastatic colorectal cancer", "original_subject": "trifluridine;tipiracil", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lonsurf", "https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf"]}], "subject": "CHEBI:75179", "supporting_text": ["Colorectal cancer Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents Gastric cancer Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3714514", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f24552ce-2fde-5c94-9c3a-53d743d6a140", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20091126", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3714514"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:3c8fa03f-735a-5f6e-886c-13e26ca87c91", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:1f79c429-1ae1-5106-b258-4bb3fca55aea", "object": "MONDO:0001673", "object_location_in_text": [15, 24], "original_object": "diarrhoea", "original_subject": "Rifaximin Dispersible Tablet 200mg", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:75246", "supporting_text": ["For infections diarrhoea in adults"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3666003", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d4ab3f0-3e22-5f7b-a356-90a757d345c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240606", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3666003"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec8cded8-1479-5266-9e4e-d2e08bafb8df", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1b2046f2-44f7-55fd-9c98-a5a4b2420073", "object": "MONDO:0018881", "original_object": "myelodysplastic syndromes", "original_subject": "IMETELSTAT", "population_context_qualifier": "adult patients with low- to intermediate-1 risk MDS; patients who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0fab7ca-e578-43c5-9df6-bdaff4182257", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0fab7ca-e578-43c5-9df6-bdaff4182257", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0fab7ca-e578-43c5-9df6-bdaff4182257"]}], "subject": "CHEBI:752899", "supporting_text": ["1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inability to receive oral or enteral nutrition", "has_confidence_score": 0.2025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da026672-033a-5c44-bace-9b1ca2920277", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131003", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dac96cdf-ee94-5afc-9ef3-ad65df111db3", "medic_pair_confidence": 0.2025, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ac12473-c5a0-5ae3-8dff-6eda2f8fe5a4", "object": "UMLS:C0342919", "original_object": "essential fatty acid deficiency", "original_subject": "OLIVE OIL", "population_context_qualifier": "adults and pediatric patients, including term and preterm neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e"]}], "subject": "CHEBI:752944", "supporting_text": ["1 INDICATIONS AND USAGE CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inability to receive oral or enteral nutrition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd7d2490-52fc-55ba-a36b-aa316a709e74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131003", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:87c2b028-e0e7-53bd-9ee5-1392df3da9bf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8ac12473-c5a0-5ae3-8dff-6eda2f8fe5a4", "object": "UMLS:C3544299", "original_object": "caloric supplementation", "original_subject": "OLIVE OIL", "population_context_qualifier": "adults and pediatric patients, including term and preterm neonates", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae98eb03-c0e7-49d1-b024-77968e3d9d6e"]}], "subject": "CHEBI:752944", "supporting_text": ["1 INDICATIONS AND USAGE CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINOLIPID is indicated in adults and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inflammatory activity", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96b83ac8-70fe-5463-86d9-68499199b3cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:aa393085-a4bc-5284-8d18-c02b76f2d1c4", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1c474555-69e1-50a7-8eb9-905c2fa5d6a0", "object": "MONDO:0005301", "original_object": "early primary progressive multiple sclerosis", "original_subject": "ocrelizumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ocrevus", "https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus"]}], "subject": "CHEBI:753057", "supporting_text": ["Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital chronic cholestasis, hereditary chronic cholestasis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:911e85a7-4bcd-54f0-8c13-bc76f34efe1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090723", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:348178ad-d2e4-5c2b-a96f-fb21bb93b88a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:07a6f0c7-1604-518e-97ff-f45251e38f6c", "object": "HP:0100513", "original_object": "vitamin E deficiency", "original_subject": "tocofersolan", "population_context_qualifier": "paediatric patients from birth (in term newborns) to 16 or 18 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vedrop", "https://www.ema.europa.eu/en/documents/product-information/vedrop-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop"]}], "subject": "CHEBI:753119", "supporting_text": ["Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36ad06d5-b963-5ab3-8fdb-2f5de8ebcccf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19991207", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:fbbf669e-20c4-557a-840e-11f94aab5ad0", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cd8fd7c0-c982-5421-8e54-800d1da5ab6a", "object": "MONDO:0004739", "object_location_in_text": [73, 93], "original_object": "urea cycle disorders", "original_subject": "sodium phenylbutyrate", "population_context_qualifier": "patients with late-onset disease who have a history of hyperammonaemic encephalopathy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ammonaps", "https://www.ema.europa.eu/en/documents/product-information/ammonaps-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps"]}], "subject": "CHEBI:75316", "supporting_text": ["Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase. It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy."], "temporal_context_qualifier": "partial enzyme deficiencies, presenting after the first month of life"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gas", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bec1a9e-14f1-578b-8f3e-905114c9cf2c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:40237dae-6d8f-582c-ac31-9f4917eee7f4", "object": "HP:0003270", "object_location_in_text": [123, 131], "original_object": "bloating", "original_subject": "DIMETHICONE, UNSPECIFIED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7"]}], "subject": "CHEBI:753206", "supporting_text": ["Uses for the relief of: • acid indigestion • heartburn • sour stomach • upset stomach due to these symptoms • pressure and bloating commonly referred to as gas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gas", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa28ba3e-8d3d-536e-bcbb-985b7e6f833d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa1480d6-f195-51e8-a80f-8154860c0376", "object": "HP:0003270", "object_location_in_text": [116, 124], "original_object": "bloating", "original_subject": "DIMETHICONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8e5dc0a-5a2d-4b9c-8639-5c909be3a321", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8e5dc0a-5a2d-4b9c-8639-5c909be3a321", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8e5dc0a-5a2d-4b9c-8639-5c909be3a321"]}], "subject": "CHEBI:753206", "supporting_text": ["Uses ▪ relieves: ▪ heartburn ▪ acid indigestion ▪ sour stomach ▪ upset stomach due to these symptoms ▪ pressure and bloating commonly referred to as gas ▪ overindulgence in food and drink"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gas", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d295f5b-f402-5968-aff9-944c50d048a5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0e821828-3b9e-5c4b-8463-cc0c0fe073c9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa1480d6-f195-51e8-a80f-8154860c0376", "object": "UMLS:C0033095", "object_location_in_text": [103, 111], "original_object": "pressure", "original_subject": "DIMETHICONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8e5dc0a-5a2d-4b9c-8639-5c909be3a321", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8e5dc0a-5a2d-4b9c-8639-5c909be3a321", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8e5dc0a-5a2d-4b9c-8639-5c909be3a321"]}], "subject": "CHEBI:753206", "supporting_text": ["Uses ▪ relieves: ▪ heartburn ▪ acid indigestion ▪ sour stomach ▪ upset stomach due to these symptoms ▪ pressure and bloating commonly referred to as gas ▪ overindulgence in food and drink"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "overindulgence in food and drink", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b2cda91-837d-52ad-9323-738e234189ac", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aa1480d6-f195-51e8-a80f-8154860c0376", "object": "UMLS:C0235309", "object_location_in_text": [65, 78], "original_object": "upset stomach", "original_subject": "DIMETHICONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d8e5dc0a-5a2d-4b9c-8639-5c909be3a321", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d8e5dc0a-5a2d-4b9c-8639-5c909be3a321", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8e5dc0a-5a2d-4b9c-8639-5c909be3a321"]}], "subject": "CHEBI:753206", "supporting_text": ["Uses ▪ relieves: ▪ heartburn ▪ acid indigestion ▪ sour stomach ▪ upset stomach due to these symptoms ▪ pressure and bloating commonly referred to as gas ▪ overindulgence in food and drink"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235304", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46381825-88ad-503b-8e67-ed8644eb3f93", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235304", "HP:0002020", "UMLS:C0860277"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:40237dae-6d8f-582c-ac31-9f4917eee7f4", "object": "UMLS:C0235309", "object_location_in_text": [72, 85], "original_object": "upset stomach", "original_subject": "DIMETHICONE, UNSPECIFIED", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ea0287c-2264-4b5d-8f37-2cf3733936c7"]}], "subject": "CHEBI:753206", "supporting_text": ["Uses for the relief of: • acid indigestion • heartburn • sour stomach • upset stomach due to these symptoms • pressure and bloating commonly referred to as gas"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "α-galactosidase-A deficiency", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0571d4df-c58d-5617-bb79-073502ac766d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010803", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:33957469-7630-5616-9190-dcdbd552017e", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:710d672d-120a-56a5-b329-3a3f7d2d9197", "object": "MONDO:0010526", "object_location_in_text": [105, 118], "original_object": "Fabry disease", "original_subject": "agalsidase alfa", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:replagal", "https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/replagal"]}], "subject": "CHEBI:753217", "supporting_text": ["Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency)."], "temporal_context_qualifier": "long-term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital factor-XIII-A-subunit deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54c62802-e501-52c8-8c90-ca7922504f2f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20120903", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e558148d-541a-58ec-ba41-287cda4154b5", "object": "UMLS:C0019080", "object_location_in_text": [36, 44], "original_object": "bleeding", "original_subject": "catridecacog", "population_context_qualifier": "adult and paediatric patients 6 years and above", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:novothirteen", "https://www.ema.europa.eu/en/documents/product-information/novothirteen-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/novothirteen"]}], "subject": "CHEBI:753274", "supporting_text": ["Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency."], "temporal_context_qualifier": "long-term prophylactic treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital blood coagulation factor XIII A-subunit deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22a997e6-78d6-5c56-957c-7d9ba9620f0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e558148d-541a-58ec-ba41-287cda4154b5", "object": "MONDO:0002243", "object_location_in_text": [65, 82], "original_object": "bleeding tendency", "original_subject": "CATRIDECACOG", "population_context_qualifier": "patients with congenital blood coagulation factor XIII A-subunit deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CATRIDECACOG#122-20150326", "https://www.pmda.go.jp/files/000213204.pdf"]}], "subject": "CHEBI:753274", "supporting_text": ["A drug with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor XIII A-subunit deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blood coagulation factor VIII deficiency", "has_confidence_score": 0.836, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86a6ad16-6783-5aa6-a519-792633134aea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140117", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.836, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0684327b-fc19-579c-b87b-5a5df11f7aa9", "object": "MONDO:0002243", "object_location_in_text": [63, 80], "original_object": "bleeding tendency", "original_subject": "TUROCTOCOG ALPHA", "population_context_qualifier": "patients with blood coagulation factor VIII deficiency", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TUROCTOCOG ALPHA#131-20140117", "https://www.pmda.go.jp/files/000203945.pdf"]}], "subject": "CHEBI:753278", "supporting_text": ["Drugs with a new active ingredient indicated for inhibition of bleeding tendency in patients with blood coagulation factor VIII deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital hemophilia", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcb38d9a-1285-5c3f-aab0-ab885bc67f91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130516", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:bc10934a-ce67-5d28-bf9d-28ae29f771d1", "object": "UMLS:C0019080", "object_location_in_text": [80, 88], "original_object": "bleeding", "original_subject": "EPTACOG ALFA (ACTIVATED)", "population_context_qualifier": "patients with congenital hemophilia who have inhibitors against blood coagulation factor VIII or IX", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EPTACOG ALFA (ACTIVATED)#131-20130516", "https://www.pmda.go.jp/files/000277929.pdf"]}], "subject": "CHEBI:753315", "supporting_text": ["Drugs with a new dosage to add single-dose administration for the prevention of bleeding in patients with congenital hemophilia who have inhibitors against blood coagulation factor VIII or IX. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "coagulation factor IX deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b7d09ae-ca54-5a86-9788-75f871aa6ba3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180702", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:80eba96d-a8ea-50a0-a971-fd454fea3c7f", "object": "MONDO:0002243", "object_location_in_text": [64, 81], "original_object": "bleeding tendency", "original_subject": "NONACOG BETA PEGOL", "population_context_qualifier": "patients with coagulation factor IX deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NONACOG BETA PEGOL#85-20180702", "https://www.pmda.go.jp/files/000238159.pdf"]}], "subject": "CHEBI:753327", "supporting_text": ["Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with coagulation factor IX deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "laryngeal attacks", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e969504a-8414-530d-9390-7299fdbb5f31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170622", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba71935d-291b-500e-a659-46d70a35b26a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fa90818-c18e-5451-aa5b-69b14320fbef", "object": "MONDO:0019623", "original_object": "hereditary angioedema", "original_subject": "CONESTAT ALFA", "population_context_qualifier": "adult and adolescent patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66d3fecb-32a4-7781-e053-2a91aa0a83ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66d3fecb-32a4-7781-e053-2a91aa0a83ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66d3fecb-32a4-7781-e053-2a91aa0a83ca"]}], "subject": "CHEBI:753329", "supporting_text": ["1 INDICATIONS AND USAGE RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0011974", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca0cd441-5ea8-5e76-a994-c6ee13c7c5c9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0011974"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a3f1b8a-36e5-5a62-ad87-671f1553bda0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a7f55f6f-ca2b-517d-8f41-ee15f121fa3c", "object": "UMLS:C0406175", "original_object": "chafed skin", "original_subject": "LANOLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b9377a6-8dc3-1f69-e063-6294a90acec4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b9377a6-8dc3-1f69-e063-6294a90acec4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b9377a6-8dc3-1f69-e063-6294a90acec4"]}], "subject": "CHEBI:753362", "supporting_text": ["Uses helps treat and prevent diaper rash temporarily protects minor cuts, scrapes and burns temporarily protects and relieve chapped,chafed or cracked skin or lips protects chafed skin due to diaper rash and helps seal out wetness"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:318f2e6d-ffff-51d8-abcd-d0121f872ef2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:919c01d5-a90e-59de-8bde-ba1f64f8cb07", "object": "HP:0012531", "object_location_in_text": [152, 156], "original_object": "pain", "original_subject": "EUCALYPTUS GLOBULUS LEAF OIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2089c28b-98fd-4797-8940-b0749d8b5df7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2089c28b-98fd-4797-8940-b0749d8b5df7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2089c28b-98fd-4797-8940-b0749d8b5df7"]}], "subject": "CHEBI:753379", "supporting_text": ["Uses • On chest and throat, helps temporarily relieve cough as may occur with common cold and minor bronchial irritation. • For the temporary relief of pain associated with minor skin irritation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequately controlled chronic obstructive pulmonary disease, eosinophilic phenotype", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6d89a7f-38b1-56fd-a12c-732ade28ba87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:21d2e90f-d938-511f-9a9d-5a078bf97ee4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6eb5d6b5-d419-5456-b866-ebc9c381bccb", "object": "MONDO:0005002", "original_object": "chronic obstructive pulmonary disease", "original_subject": "MEPOLIZUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fefb887c-e4ac-431e-8893-e9d1a5a63fea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea"]}], "subject": "CHEBI:753401", "supporting_text": ["1 INDICATIONS AND USAGE NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations ( 8.4 ), Clinical Studies ( 14.1 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bca6aaf-2d01-56b7-aef3-550ada6a63d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151201", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:56df3583-f964-52fe-bcaa-01cdab185c83", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6eb5d6b5-d419-5456-b866-ebc9c381bccb", "object": "MONDO:0015691", "object_location_in_text": [791, 817], "original_object": "hypereosinophilic syndrome", "original_subject": "mepolizumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nucala", "https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nucala"]}], "subject": "CHEBI:753401", "supporting_text": ["Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older . Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe4b2297-a768-50b4-83c7-7901b83854a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151201", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7c2597a2-247f-55b9-b436-40715383fa63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6eb5d6b5-d419-5456-b866-ebc9c381bccb", "object": "MONDO:0015943", "original_object": "eosinophilic granulomatosis with polyangiitis", "original_subject": "mepolizumab", "population_context_qualifier": "patients aged 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nucala", "https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nucala"]}], "subject": "CHEBI:753401", "supporting_text": ["Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older . Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "eosinophilic phenotype", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc56ce25-3b24-57a0-95c3-1b6634a80af1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d303baeb-1476-5fc8-9853-28946163135a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6eb5d6b5-d419-5456-b866-ebc9c381bccb", "object": "UMLS:C0581126", "object_location_in_text": [208, 221], "original_object": "severe asthma", "original_subject": "MEPOLIZUMAB", "population_context_qualifier": "adult and pediatric patients aged 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fefb887c-e4ac-431e-8893-e9d1a5a63fea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea"]}], "subject": "CHEBI:753401", "supporting_text": ["1 INDICATIONS AND USAGE NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations ( 8.4 ), Clinical Studies ( 14.1 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4524092", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7d02102-632a-55ed-b490-b14abaa4e4df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151201", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["intranasal corticosteroids"], "medic_disease_context_ids": ["UMLS:C4524092"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7d46f369-9d63-5674-a16b-e8d2232e756b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6eb5d6b5-d419-5456-b866-ebc9c381bccb", "object": "UMLS:C4524092", "original_object": "chronic rhinosinusitis with nasal polyps", "original_subject": "mepolizumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nucala", "https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nucala"]}], "subject": "CHEBI:753401", "supporting_text": ["Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older . Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate response to nasal corticosteroids", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3646143b-cf59-5c2f-9c2c-1a6d44bf59f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d46f369-9d63-5674-a16b-e8d2232e756b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6eb5d6b5-d419-5456-b866-ebc9c381bccb", "object": "UMLS:C4524092", "original_object": "chronic rhinosinusitis with nasal polyps", "original_subject": "MEPOLIZUMAB", "population_context_qualifier": "adult patients aged 18 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fefb887c-e4ac-431e-8893-e9d1a5a63fea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea"]}], "subject": "CHEBI:753401", "supporting_text": ["1 INDICATIONS AND USAGE NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations ( 8.4 ), Clinical Studies ( 14.1 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "compensated cirrhosis type C", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a4fcf51-914d-5c68-9bfa-e8c6793df257", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081016", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:8f14421e-67ac-50bb-8b40-92a682ccde1f", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0acc09e7-0ec7-5911-98fd-471447fd1dd5", "object": "HP:0020071", "object_location_in_text": [66, 73], "original_object": "viremia", "original_subject": "INTERFERON ALFA (NAMALWA)", "population_context_qualifier": "patients with compensated cirrhosis type C excluding patients with high blood levels of serogroup 1 HCV-RNA", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:INTERFERON ALFA (NAMALWA)#171-20081016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:753470", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of viremia in patients with compensated cirrhosis type C (excluding patients with high blood levels of serogroup 1 HCV-RNA)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hypersensitivity to asparaginase", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec277831-9ffa-5a6e-ab00-18f11c365c80", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19940201", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3695b86e-c99d-5186-9f82-e80c7d1923f1", "object": "MONDO:0004967", "object_location_in_text": [196, 224], "original_object": "acute lymphoblastic leukemia", "original_subject": "PEGASPARGASE", "population_context_qualifier": "pediatric and adult patients with hypersensitivity to asparaginase", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac7b6a6f-6ddb-48c6-8088-d8a8e3fea6ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac7b6a6f-6ddb-48c6-8088-d8a8e3fea6ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac7b6a6f-6ddb-48c6-8088-d8a8e3fea6ce"]}], "subject": "CHEBI:753505", "supporting_text": ["1 INDICATIONS AND USAGE ONCASPAR is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for treatment of pediatric and adult patients with: First-line acute lymphoblastic leukemia ( 1.1 ) Acute lymphoblastic leukemia and hypersensitivity to asparaginase ( 1.2 ) 1.1 First Line Acute Lymphoblastic Leukemia (ALL) ONCASPAR ® is indicated as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of pediatric and adult patients with ALL. 1.2 Acute Lymphoblastic Leukemia and Hypersensitivity to Asparaginase ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with ALL and hypersensitivity to native forms of L-asparaginase."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46ab7819-9322-5f32-ba87-bc764f1255d0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8372c6c0-315d-5a17-9372-e216b8877c6a", "object": "HP:0000989", "object_location_in_text": [41, 48], "original_object": "itching", "original_subject": "PEPPERMINT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724"]}], "subject": "CHEBI:753511", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:585b0ac2-3eb1-5f6a-a5fe-372578e648e9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8372c6c0-315d-5a17-9372-e216b8877c6a", "object": "HP:0012531", "object_location_in_text": [32, 36], "original_object": "pain", "original_subject": "PEPPERMINT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7caef8db-a07a-6705-e053-2991aa0aa724"]}], "subject": "CHEBI:753511", "supporting_text": ["Use for the temporary relief of pain and itching associated with minor skin irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0011974", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d959c4f0-1f65-564c-a1af-703142e76a44", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0011974"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a3f1b8a-36e5-5a62-ad87-671f1553bda0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3f27bbc-c001-5cc0-9d2a-57be08458cd7", "object": "UMLS:C0406175", "original_object": "chafed skin", "original_subject": "PETROLATUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b9377a6-8dc3-1f69-e063-6294a90acec4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b9377a6-8dc3-1f69-e063-6294a90acec4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b9377a6-8dc3-1f69-e063-6294a90acec4"]}], "subject": "CHEBI:753513", "supporting_text": ["Uses helps treat and prevent diaper rash temporarily protects minor cuts, scrapes and burns temporarily protects and relieve chapped,chafed or cracked skin or lips protects chafed skin due to diaper rash and helps seal out wetness"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "epithelial cellular adhesion molecule (EpCAM)-positive carcinomas", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e848135d-cc14-5f38-9931-4e948979fea0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250210", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5e2dbb21-b1c7-5cae-81e6-2dfc3435ab17", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c91b8492-3993-539f-b61e-847ba7a4bc1c", "object": "UMLS:C0220656", "object_location_in_text": [58, 75], "original_object": "malignant ascites", "original_subject": "catumaxomab", "population_context_qualifier": "adults; adults not eligible for further systemic anticancer therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:korjuny", "https://www.ema.europa.eu/en/documents/product-information/korjuny-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny"]}], "subject": "CHEBI:753535", "supporting_text": ["Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "CD22-positive B-cell precursor acute lymphoblastic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5292488d-834f-534f-b6bf-92d36c00f07d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170817", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6ef690aa-0f87-5878-8c87-0cf74ca1977e", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "INOTUZUMAB OZOGAMICIN", "population_context_qualifier": "adult and pediatric patients 1 year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cc7014b1-c775-411d-b374-8113248b4077", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077"]}], "subject": "CHEBI:753564", "supporting_text": ["1. INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "when alternative therapies are not available or are not appropriate", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db9f5695-4afe-518d-b7d2-9acd059c8bd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20121214", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1bf6447d-f09d-5847-b4be-becf8ec0c833", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8b98d814-0af7-5bce-a4f6-627a383ae10f", "object": "MONDO:0016595", "object_location_in_text": [104, 124], "original_object": "inhalational anthrax", "original_subject": "RAXIBACUMAB", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6927e91-bb46-47b3-ab66-f9d8a9d7b12a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6927e91-bb46-47b3-ab66-f9d8a9d7b12a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6927e91-bb46-47b3-ab66-f9d8a9d7b12a"]}], "subject": "CHEBI:753589", "supporting_text": ["1 INDICATIONS AND USAGE Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0278987", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39417629-dd99-5636-96ae-6fd61f42e61c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230220", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["durvalumab", "platinum-based chemotherapy"], "medic_disease_context_ids": ["UMLS:C0278987"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:bbc2f863-a49a-59dc-b37c-f86fbf284f27", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "tremelimumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imjudo", "https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo"]}], "subject": "CHEBI:753608", "supporting_text": ["Imjudo&nbsp;in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo&nbsp;in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "H1 antihistamine treatment failure", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d2654fa-06c7-582b-b1d9-73ead92ce592", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170328", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32052b22-b110-5392-a66b-e9dd59068c5b", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7de095fa-5868-5e53-bce5-144512e8eb92", "object": "HP:0410133", "original_object": "chronic spontaneous urticaria", "original_subject": "DUPILUMAB", "population_context_qualifier": "adult and pediatric patients aged 2 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595f437d-2729-40bb-9c62-c8ece1f82780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780"]}], "subject": "CHEBI:753623", "supporting_text": ["1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "eosinophilic phenotype, oral corticosteroid dependent asthma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93ec208b-3308-5eca-a066-ac98500a3925", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170328", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7de095fa-5868-5e53-bce5-144512e8eb92", "object": "MONDO:0004979", "original_object": "asthma", "original_subject": "DUPILUMAB", "population_context_qualifier": "adult and pediatric patients aged 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595f437d-2729-40bb-9c62-c8ece1f82780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780"]}], "subject": "CHEBI:753623", "supporting_text": ["1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "eosinophilic phenotype", "has_confidence_score": 0.05625, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df559d80-64cd-5b8c-8117-724da9bc077e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170328", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:21d2e90f-d938-511f-9a9d-5a078bf97ee4", "medic_pair_confidence": 0.05625, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7de095fa-5868-5e53-bce5-144512e8eb92", "object": "MONDO:0005002", "original_object": "chronic obstructive pulmonary disease", "original_subject": "DUPILUMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595f437d-2729-40bb-9c62-c8ece1f82780", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780"]}], "subject": "CHEBI:753623", "supporting_text": ["1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic diseases", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1545b1a9-5fa0-53dc-a9b8-46ff30e06413", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:2653599a-a680-5938-92c3-aa47d423f9ef", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:41f03e3a-90e7-5b8a-835c-5048eb19afc5", "object": "HP:0012450", "object_location_in_text": [54, 74], "original_object": "chronic constipation", "original_subject": "MACROGOL 4000", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MACROGOL 4000#77-20180921", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:753709", "supporting_text": ["A new combination drug indicated for the treatment of chronic constipation (excluding constipation due to organic diseases)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "death", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98671e2b-7103-5dae-aacb-c25a7f064c62", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000602", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a1967e36-e1c3-51fd-81c7-0f7d4e6339bc", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d4184d0c-18e3-531f-bdfc-877e10dce3b8", "object": "UMLS:C1536220", "original_object": "acute ST elevation myocardial infarction", "original_subject": "TENECTEPLASE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:739a3c53-caf6-40d6-a6af-84ce733a948b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=739a3c53-caf6-40d6-a6af-84ce733a948b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=739a3c53-caf6-40d6-a6af-84ce733a948b"]}], "subject": "CHEBI:753718", "supporting_text": ["1 INDICATIONS AND USAGE TNKase ® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). TNKase is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "suspected myocardial infarction with persistent ST elevation, recent left-bundle-branch block", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:092201b1-638e-5b90-9a8d-4ba721beb195", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d4184d0c-18e3-531f-bdfc-877e10dce3b8", "object": "MONDO:0005068", "object_location_in_text": [66, 87], "original_object": "myocardial infarction", "original_subject": "tenecteplase", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:metalyse", "https://www.ema.europa.eu/en/documents/product-information/metalyse-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/metalyse"]}], "subject": "CHEBI:753718", "supporting_text": ["Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left-bundle-branch block within six hours after the onset of acute-myocardial-infarction symptoms. Metalyse is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage."], "temporal_context_qualifier": "within six hours after the onset of acute-myocardial-infarction symptoms"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blast crisis of chronic leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27578ee4-5554-52d1-9154-b98ffad78f36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20161219", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:339f0029-196c-5efd-948d-249d6e885188", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:2ea3dedd-161c-59a5-8165-22d3702d7fff", "object": "MONDO:0010643", "object_location_in_text": [67, 81], "original_object": "acute leukemia", "original_subject": "CRISANTASPASE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CRISANTASPASE#104-20161219", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:753844", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blast crisis of chronic leukemia", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df6a6df2-a0f4-55cf-88ce-572e546a8a85", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:339f0029-196c-5efd-948d-249d6e885188", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6ac1c7a2-e02e-55af-8ebe-21bb9afaa181", "object": "MONDO:0010643", "object_location_in_text": [72, 86], "original_object": "acute leukemia", "original_subject": "L-ASPARAGINASE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:L-ASPARAGINASE#140-20130221", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:753896", "supporting_text": ["Drugs with a new route of administration. These drugs are indicated for acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3714645", "has_confidence_score": 0.74205, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2d460ef-92a9-5757-9f4a-eab0ab7f425d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040608", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3714645"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:86261939-f825-5e2a-b847-ec72dce3881a", "medic_pair_confidence": 0.74205, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:7957e2dd-2a75-5ea3-b262-260e762106dc", "object": "MONDO:0003159", "original_object": "haemostatic disorders", "original_subject": "human fibrinogen;human thrombin", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:veraseal", "https://www.ema.europa.eu/en/documents/product-information/veraseal-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/veraseal"]}], "subject": "CHEBI:753967", "supporting_text": ["Supportive treatment in adults where standard surgical techniques are insufficient:  for improvement of haemostasis as suture support in vascular surgery"], "temporal_context_qualifier": "where standard surgical techniques are insufficient"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8acf8a1b-878d-5a67-9386-3ef009b4757d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240919", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluoropyrimidine- and platinum-containing chemotherapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:fa442ec2-cd62-5e79-9a60-5f8f4c5fc8ed", "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "zolbetuximab", "population_context_qualifier": "adult patients whose tumours are Claudin (CLDN) 18.2 positive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vyloy", "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vyloy"]}], "subject": "CHEBI:754224", "supporting_text": ["Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first line treatment of adult patients with locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive (see section 4.2)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "established atherosclerotic cardiovascular disease", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8fb1a25c-f082-5815-9461-2775dc035e49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150923", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:81ae23a7-af52-5883-995f-2f4417122904", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:f891c91c-474b-5dff-82c2-a92efbdf3d4c", "object": "UMLS:C4324389", "original_object": "cardiovascular risk", "original_subject": "alirocumab", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:praluent", "https://www.ema.europa.eu/en/documents/product-information/praluent-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/praluent"]}], "subject": "CHEBI:754310", "supporting_text": ["Primary hypercholesterolaemia and mixed dyslipidaemia Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients 8 years of age and older with heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Established atherosclerotic cardiovascular disease Praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: - in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "multiple painful osteoblastic skeletal metastases", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:74ace135-3a9c-5a7b-84d2-a3182b01d80f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980204", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3b4fe075-e70f-53a8-a298-a37876f20817", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c81be8ff-5672-587d-b5e3-5e105f527124", "object": "HP:0002653", "object_location_in_text": [41, 50], "original_object": "bone pain", "original_subject": "samarium [153Sm] lexidronam pentasodium", "population_context_qualifier": "patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:quadramet", "https://www.ema.europa.eu/en/documents/product-information/quadramet-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet"]}], "subject": "CHEBI:754404", "supporting_text": ["Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan. The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b98375fe-10e3-53c7-8670-e294ca192c78", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "CHEBI:754405", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b8ce74dc-de3b-5d10-9008-95ab76325fa6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "CYANOCOBALAMIN", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "CHEBI:754405", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ef008b8-22ee-5f0d-bbd2-6d883d362cb5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9172ca9d-6419-41de-829c-4f9a16220b46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9172ca9d-6419-41de-829c-4f9a16220b46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9172ca9d-6419-41de-829c-4f9a16220b46"]}], "subject": "CHEBI:754405", "supporting_text": ["Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2338c914-199c-51ac-84ce-9fe87e451b81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1e35c97-2157-454e-967f-53a4300827de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1e35c97-2157-454e-967f-53a4300827de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1e35c97-2157-454e-967f-53a4300827de"]}], "subject": "CHEBI:754405", "supporting_text": ["Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin injection is also suitable for the vitamin B 12 absorption test (Schilling test)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:270a924d-8f66-5be7-96df-f6e893213a42", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a66eb3c4-3e1d-4d49-b963-4fa2334cc9b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a66eb3c4-3e1d-4d49-b963-4fa2334cc9b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a66eb3c4-3e1d-4d49-b963-4fa2334cc9b6"]}], "subject": "CHEBI:754405", "supporting_text": ["Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44e6dbbe-1ddb-58c4-9ade-053e81fd89db", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a61181f5-7e2d-45f9-929a-cb8bc70c992e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a61181f5-7e2d-45f9-929a-cb8bc70c992e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a61181f5-7e2d-45f9-929a-cb8bc70c992e"]}], "subject": "CHEBI:754405", "supporting_text": ["Cyanocobalamin is indicated for vitamin B12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B12 absorption test (Schilling test)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6e662ed-9504-5dc9-a86b-4141409ebc26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:579bd1fe-51a1-403f-a422-0fb701aab57d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=579bd1fe-51a1-403f-a422-0fb701aab57d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=579bd1fe-51a1-403f-a422-0fb701aab57d"]}], "subject": "CHEBI:754405", "supporting_text": ["Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0016412", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c85d9212-d85f-53ef-a857-334fb5c70520", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0016412"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:54e5a304-5133-5e44-9c11-66cc491e3fb9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:92f28736-0466-57cb-acfa-a6b1cc855858", "object": "MONDO:0020696", "original_object": "vitamin B12 deficiency", "original_subject": "CYANOCOBALAMIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cdd4fd12-e214-43a6-b560-d56fc0d87190", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cdd4fd12-e214-43a6-b560-d56fc0d87190", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdd4fd12-e214-43a6-b560-d56fc0d87190"]}], "subject": "CHEBI:754405", "supporting_text": [": Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asthma requiring systemic corticosteroid administration", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:31381be6-1480-5274-84d4-de80dc81b4a1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3aab3099-ba00-5d70-97aa-342f96900113", "object": "MONDO:0004979", "object_location_in_text": [50, 56], "original_object": "asthma", "original_subject": "BECLOMETHASONE 17-MONOPROPIONATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0e6af3a-e2ef-4dfa-947a-e511cc5b5828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0e6af3a-e2ef-4dfa-947a-e511cc5b5828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0e6af3a-e2ef-4dfa-947a-e511cc5b5828"]}], "subject": "CHEBI:754770", "supporting_text": ["QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "asthma requiring systemic corticosteroid administration", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4830b78b-26b2-57e9-84b0-988906dffaa1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3aab3099-ba00-5d70-97aa-342f96900113", "object": "MONDO:0004979", "object_location_in_text": [50, 56], "original_object": "asthma", "original_subject": "BECLOMETHASONE 17-MONOPROPIONATE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:20682605-557b-4586-9d98-829a63091ddf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=20682605-557b-4586-9d98-829a63091ddf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=20682605-557b-4586-9d98-829a63091ddf"]}], "subject": "CHEBI:754770", "supporting_text": ["QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d9b2077-f902-59e1-862b-a86a91befc9c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3f360a9-ac6d-589b-ba8e-5e88de94de18", "object": "MONDO:0000001", "object_location_in_text": [184, 220], "original_object": "active secondary progressive disease", "original_subject": "SIPONIMOD", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44492772-5aed-4627-bd85-e8e89f308bb3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3"]}], "subject": "CHEBI:754951", "supporting_text": ["1 INDICATIONS AND USAGE MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de7f3fa3-1677-5552-93dc-84c8120082c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b3f360a9-ac6d-589b-ba8e-5e88de94de18", "object": "UMLS:C2921627", "object_location_in_text": [121, 149], "original_object": "clinically isolated syndrome", "original_subject": "SIPONIMOD", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44492772-5aed-4627-bd85-e8e89f308bb3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3"]}], "subject": "CHEBI:754951", "supporting_text": ["1 INDICATIONS AND USAGE MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MAYZENT is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HIV-1 resistance to the NNRTI class", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d38c1e9d-383b-5dfe-8fa8-44f6f9eff468", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181122", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["other antiretroviral medicinal products"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:35eefdc6-cef0-5961-8f24-f938ff7c689b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:71d38913-0138-5992-a55c-288ce769bfe7", "object": "UMLS:C2363741", "original_object": "HIV-1 infection", "original_subject": "doravirine", "population_context_qualifier": "adults, and adolescents aged 12 years and older weighing at least 35 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pifeltro", "https://www.ema.europa.eu/en/documents/product-information/pifeltro-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro"]}], "subject": "CHEBI:754975", "supporting_text": ["Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic diseases", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a852c938-34f2-5f96-8c5b-81eb5cf1a676", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240715", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:2653599a-a680-5938-92c3-aa47d423f9ef", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0ebb26a6-2ecb-5993-b821-9072d9a2d494", "object": "HP:0012450", "object_location_in_text": [17, 37], "original_object": "chronic constipation", "original_subject": "Elobixibat Hydrate Bulk Drug and Elobixibat Tablets 5 mg", "population_context_qualifier": "patients without constipation associated with organic diseases", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:755066", "supporting_text": ["For treatment of chronic constipation (except for constipation associated with organic diseases)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "very low, low and intermediate-risk myelodysplastic syndromes", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3578235c-03cd-5bb0-b0d9-a30f1539d4e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200625", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a1bcdb1-eae9-5658-9bfd-db952d05db68", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cb880b6e-9f79-5883-a5b4-013deb79a31c", "object": "UMLS:C3666003", "object_location_in_text": [53, 82], "original_object": "transfusion-dependent anaemia", "original_subject": "luspatercept", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:reblozyl", "https://www.ema.europa.eu/en/documents/product-information/reblozyl-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl"]}], "subject": "CHEBI:755086", "supporting_text": ["Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia.&nbsp; Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia.&nbsp;"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "BRCA mutation-positive, HER2-negative", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:608326ce-6297-59e6-b369-28d93012e132", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:da818536-d69e-5105-976f-6e7c38bdbdc6", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6637f9e6-e8d5-5d03-9e1a-0aa6d744c1ce", "object": "MONDO:0007254", "original_object": "unresectable or recurrent breast cancer", "original_subject": "TALAZOPARIB TOSILATE", "population_context_qualifier": "patients who have previously been treated with chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TALAZOPARIB TOSILATE#28-20240118", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:755149", "supporting_text": ["(1) A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. (2) A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer and unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. (3) A drug with a new active ingredient indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "BRCA mutation-positive", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd16060f-e611-5fb3-a621-96ac89832236", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240118", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:944682f0-a69f-5723-89bf-3612c67533f6", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6637f9e6-e8d5-5d03-9e1a-0aa6d744c1ce", "object": "UMLS:C4721208", "object_location_in_text": [95, 142], "original_object": "metastatic castration-resistant prostate cancer", "original_subject": "TALAZOPARIB TOSILATE", "population_context_qualifier": "BRCA mutation-positive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TALAZOPARIB TOSILATE#28-20240118", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:755149", "supporting_text": ["(1) A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. (2) A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer and unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. (3) A drug with a new active ingredient indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001395", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97a6d361-dcfc-50e7-97e6-0d34aa915c2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240314", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001395"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:14d44230-5ee8-5c62-b542-30ebbf8ad527", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1be77d8b-f69e-50cf-8e31-1c1c32af41ad", "object": "MONDO:0007027", "original_object": "metabolic dysfunction-associated steatohepatitis", "original_subject": "RESMETIROM", "population_context_qualifier": "adults with noncirrhotic MASH", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e67ea09f-a840-439c-86c8-f98585f978b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e67ea09f-a840-439c-86c8-f98585f978b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e67ea09f-a840-439c-86c8-f98585f978b2"]}], "subject": "CHEBI:755243", "supporting_text": ["1 INDICATIONS AND USAGE REZDIFFRA ® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "refractory B cell acute lymphoblastic leukaemia, relapsed post transplant B cell acute lymphoblastic leukaemia, second or later relapse B cell acute lymphoblastic leukaemia", "has_confidence_score": 0.97, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80f61cbb-80ee-50c5-a6ec-993edcaf4571", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180823", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:980d9818-b625-5f3b-99f1-4382a5ef5662", "medic_pair_confidence": 0.97, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1ad2034e-d388-52bc-8ba9-5fb97de9c8f0", "object": "UMLS:C4721444", "original_object": "B cell acute lymphoblastic leukaemia", "original_subject": "tisagenlecleucel", "population_context_qualifier": "Paediatric and young adult patients up to and including 25 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kymriah", "https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah"]}], "subject": "CHEBI:755258", "supporting_text": ["Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR mutations, ALK positive mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ffad0960-6eef-5b63-b569-79bf26e04061", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180921", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["tremelimumab", "platinum-based chemotherapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6aa4f8db-ca8d-5622-98b2-3b113030d99b", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "durvalumab", "population_context_qualifier": "adults with no sensitising EGFR mutations or ALK positive mutations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imfinzi", "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi"]}], "subject": "CHEBI:755270", "supporting_text": ["Non-Small Cell Lung Cancer (NSCLC)IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements (for selection criteria, see section 5.1). IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations. Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC). Hepatocellular Carcinoma (HCC)IMFINZI as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).&nbsp; IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Endometrial Cancer&nbsp;IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:&nbsp;- IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)&nbsp;- IMFINZI in combination with olaparib in endometrial canc"], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "unresectable or metastatic melanoma with a BRAF V600 mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a570a5e-db27-54f1-a8a1-985d4e450632", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180919", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["binimetinib"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:69f8c6a8-386d-51fd-b56f-5b916cef0816", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:35ff9282-2e97-52d3-97bc-24d8d7879675", "object": "MONDO:0005105", "object_location_in_text": [133, 141], "original_object": "melanoma", "original_subject": "encorafenib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:braftovi", "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"]}], "subject": "CHEBI:755294", "supporting_text": ["MelanomaEncorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Colorectal cancer (CRC)Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) &nbsp;with a BRAF V600E mutation, who have received prior systemic therapy.Non-small cell lung cancer (NSCLC)Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced non-small cell lung cancer with a BRAF V600E mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:412188b8-4ec8-5a3a-bd10-520a389abe03", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180919", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["binimetinib"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:35ff9282-2e97-52d3-97bc-24d8d7879675", "object": "MONDO:0005233", "object_location_in_text": [538, 564], "original_object": "non-small cell lung cancer", "original_subject": "encorafenib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:braftovi", "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"]}], "subject": "CHEBI:755294", "supporting_text": ["MelanomaEncorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Colorectal cancer (CRC)Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) &nbsp;with a BRAF V600E mutation, who have received prior systemic therapy.Non-small cell lung cancer (NSCLC)Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "metastatic colorectal cancer (CRC) with a BRAF V600E mutation, with a BRAF V600E mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc06536d-8a96-5b3c-a31e-7ff48c539a66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180919", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cetuximab"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4db18fd6-759e-58ad-bde9-03459dacc042", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:35ff9282-2e97-52d3-97bc-24d8d7879675", "object": "MONDO:0005575", "original_object": "colorectal cancer", "original_subject": "encorafenib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:braftovi", "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"]}], "subject": "CHEBI:755294", "supporting_text": ["MelanomaEncorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Colorectal cancer (CRC)Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) &nbsp;with a BRAF V600E mutation, who have received prior systemic therapy.Non-small cell lung cancer (NSCLC)Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation."], "temporal_context_qualifier": "who have received prior systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1511021", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33c258c7-56c9-5f4e-931e-b25cc066c7c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190108", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1511021"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:219fe20c-9480-5ca2-9ea0-628fd0dc4df1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:35ff9282-2e97-52d3-97bc-24d8d7879675", "object": "UMLS:C4725093", "object_location_in_text": [67, 88], "original_object": "unresectable melanoma", "original_subject": "ENCORAFENIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ENCORAFENIB#83-20190108", "https://www.pmda.go.jp/files/000240840.pdf"]}], "subject": "CHEBI:755294", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of unresectable melanoma with BRAF gene mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "genetically confirmed Bardet Biedl syndrome, loss-of-function biallelic pro-opiomelanocortin deficiency, biallelic leptin receptor deficiency", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c6d0e04-1161-5e9a-98a9-e6819f55d8fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210716", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:844b71a2-9a89-5d5b-b20b-96851d2286ca", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3bde05c9-f28c-5e3e-ad0b-e4508066d56a", "object": "UMLS:C0020175", "object_location_in_text": [70, 76], "original_object": "hunger", "original_subject": "setmelanotide", "population_context_qualifier": "adults and children 2 years of age and above", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imcivree", "https://www.ema.europa.eu/en/documents/product-information/imcivree-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree"]}], "subject": "CHEBI:755301", "supporting_text": ["IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 2 years of age and above."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "genetically confirmed Bardet Biedl syndrome, loss-of-function biallelic pro-opiomelanocortin deficiency, biallelic leptin receptor deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11cd23a7-1084-5a0c-b56e-c59d6f6360c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210716", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:87e64efc-0059-50f9-8c1f-2c0a8f033dcf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3bde05c9-f28c-5e3e-ad0b-e4508066d56a", "object": "MONDO:0011122", "object_location_in_text": [43, 50], "original_object": "obesity", "original_subject": "setmelanotide", "population_context_qualifier": "adults and children 2 years of age and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:imcivree", "https://www.ema.europa.eu/en/documents/product-information/imcivree-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree"]}], "subject": "CHEBI:755301", "supporting_text": ["IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 2 years of age and above."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4054152", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1dfdff0b-5624-54c9-807b-37dd649a27eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20201125", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C4054152", "MONDO:0013992"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6da0138c-212f-54a8-b20d-3f2ccee17044", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3bde05c9-f28c-5e3e-ad0b-e4508066d56a", "object": "UMLS:C1262477", "object_location_in_text": [88, 104], "original_object": "weight reduction", "original_subject": "SETMELANOTIDE", "population_context_qualifier": "pediatric patients aged 2 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70c3ccf7-4df0-4c75-ba07-fede9970c8d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9"]}], "subject": "CHEBI:755301", "supporting_text": ["1 INDICATIONS AND USAGE IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged [ see Dosage and Administration (2.1) ]: 4 years and older with acquired hypothalamic obesity (HO) 2 years and older with syndromic or monogenic obesity due to: o Bardet-Biedl syndrome (BBS) o Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged (1): 4 years and older with acquired hypothalamic obsesity (HO). 2 years and older with Bardet-Biedl syndrome (BBS). 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by an genetic test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "bipolar I or II disorder", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14742f18-d64a-557a-adeb-fee6a60f0f35", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191220", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["lithium", "valproate"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b33c7d25-fe6c-5cd5-ac0e-c7797512a645", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:01fa6e03-73d6-51eb-b190-30935fa34f9d", "object": "HP:0000716", "original_object": "depressive episodes", "original_subject": "LUMATEPERONE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db730b06-6351-47fd-8183-e61e61bbead5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5"]}], "subject": "CHEBI:755315", "supporting_text": ["1 INDICATIONS AND USAGE CAPLYTA is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate [see Clinical Studies (14.2) ] . Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.3 ) ]. CAPLYTA is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 ) Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. ( 1 ) Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4688007", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e63ee20-6567-5c52-b589-06171eed29e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4688007"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5de0d314-475c-5f61-8191-eac348e21c0e", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:89845860-fd3a-55aa-b291-b0d1523e8722", "object": "MONDO:0002158", "original_object": "fallopian tube cancer", "original_subject": "mirvetuximab soravtansine", "population_context_qualifier": "adult patients with folate receptor-alpha (FRα) positive high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:elahere", "https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/elahere"]}], "subject": "CHEBI:755477", "supporting_text": ["Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4688007", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4d3372a-dc01-5191-a1ab-434c70886de6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241114", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4688007"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:49c0251c-38aa-58bd-8959-7d40767c064b", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:89845860-fd3a-55aa-b291-b0d1523e8722", "object": "MONDO:0015686", "object_location_in_text": [191, 216], "original_object": "primary peritoneal cancer", "original_subject": "mirvetuximab soravtansine", "population_context_qualifier": "adult patients with folate receptor-alpha (FRα) positive high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:elahere", "https://www.ema.europa.eu/en/documents/product-information/elahere-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/elahere"]}], "subject": "CHEBI:755477", "supporting_text": ["Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7992c22c-ce9d-5e30-8af6-5b0c0d0f728e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951127", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "5-fluorouracil"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "docetaxel", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:taxotere", "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere"]}], "subject": "CHEBI:755540", "supporting_text": ["Breast cancer Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:  operable node-positive breast cancer; operable node-negative breast cancer.  For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Taxotere in combination with cisplatin and 5-fluorouracil"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5237824", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0542c2fe-357d-57bc-9b88-3536d13cba1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_disease_context_ids": ["UMLS:C5237824"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive for advanced disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5237824", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fb13ee1-2e26-5a50-a07e-2dd759d71de0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_disease_context_ids": ["UMLS:C5237824"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive for advanced disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5237824", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1caa85d1-c9d3-53b7-84ee-2e830c910ed5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_disease_context_ids": ["UMLS:C5237824"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive for advanced disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5237824", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f7a2c6c-001c-5185-abf0-11a51dbed1f7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_disease_context_ids": ["UMLS:C5237824"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive for advanced disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5237824", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d9ce9d0-9243-50ce-9901-040162723056", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_disease_context_ids": ["UMLS:C5237824"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive for advanced disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5237824", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76924dd4-fa3b-522a-8270-9eebd37e29e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_disease_context_ids": ["UMLS:C5237824"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive for advanced disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac09532b-c62d-5ba6-bf46-c59d1b179962", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "object_location_in_text": [1935, 1957], "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3538b979-8cac-49ed-b8dc-50f73ce38c72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3538b979-8cac-49ed-b8dc-50f73ce38c72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3538b979-8cac-49ed-b8dc-50f73ce38c72"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer BEIZRAY as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. BEIZRAY in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer BEIZRAY in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma BEIZRAY in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroeso"], "temporal_context_qualifier": "who have not received prior chemotherapy for advanced disease"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4aea0d8-d240-5da3-8611-57c70e750030", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e03d1378-6889-43d5-a34c-f96132cffa88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88"]}], "subject": "CHEBI:755540", "supporting_text": ["1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eadab870-8fbf-5156-b9df-6c8681cf38ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81686d37-a13f-46e2-b439-a84eb1433634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81686d37-a13f-46e2-b439-a84eb1433634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81686d37-a13f-46e2-b439-a84eb1433634"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Br e a st Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) N o n- small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) C a stration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer (1.3) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squ a m o u s Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5e721eb-d8e9-5382-adae-57a904d6351f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e0f06bd-d190-45da-be8b-062e8de01970", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970"]}], "subject": "CHEBI:755540", "supporting_text": ["1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic non-small-cell lung cancer", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a7c5047-1b47-5fb3-9b33-7dda77fc1dd3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951127", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c28e843a-099c-5171-9434-1b60e1fa6ce6", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1451, 1477], "original_object": "non-small-cell lung cancer", "original_subject": "docetaxel", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:taxotere", "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere"]}], "subject": "CHEBI:755540", "supporting_text": ["Breast cancer Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:  operable node-positive breast cancer; operable node-negative breast cancer.  For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Taxotere in combination with cisplatin and 5-fluorouracil"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:026bc42e-347c-5bd1-b1b5-a4f56d1a58e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1395, 1421], "original_object": "non-small cell lung cancer", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39730592-9bb2-5605-bca8-3f5e3d8c1457", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1395, 1421], "original_object": "non-small cell lung cancer", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:445eea28-7dfb-52e5-9e27-b8226251baa4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1395, 1421], "original_object": "non-small cell lung cancer", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5eb48785-139e-5f49-8e74-f6e28898e5ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1395, 1421], "original_object": "non-small cell lung cancer", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:624bd44f-02d9-56c3-8852-3e507d4ba33a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1395, 1421], "original_object": "non-small cell lung cancer", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "unresectable, locally advanced or metastatic", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf9bfd40-cf9f-5b63-a831-c62b52607c78", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1395, 1421], "original_object": "non-small cell lung cancer", "original_subject": "DOCETAXEL", "population_context_qualifier": "treatment-naive", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "operable node-positive breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11b0b362-748c-5180-a3e5-02c5f89ccc1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["doxorubicin", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [1026, 1039], "original_object": "breast cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81686d37-a13f-46e2-b439-a84eb1433634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81686d37-a13f-46e2-b439-a84eb1433634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81686d37-a13f-46e2-b439-a84eb1433634"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Br e a st Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) N o n- small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) C a stration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer (1.3) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squ a m o u s Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "operable node-positive breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39e3f968-ab06-51be-ae49-788c42cde6d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["doxorubicin", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [1029, 1042], "original_object": "breast cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e0f06bd-d190-45da-be8b-062e8de01970", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970"]}], "subject": "CHEBI:755540", "supporting_text": ["1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatm"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "operable node-positive breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b79e05a4-54a5-5889-b784-0c99e16baddf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["doxorubicin", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [994, 1007], "original_object": "breast cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3538b979-8cac-49ed-b8dc-50f73ce38c72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3538b979-8cac-49ed-b8dc-50f73ce38c72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3538b979-8cac-49ed-b8dc-50f73ce38c72"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer BEIZRAY as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. BEIZRAY in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer BEIZRAY in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma BEIZRAY in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroeso"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "operable node-positive breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2ab9531-dd4a-5d48-8287-958485ee755d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["doxorubicin", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [1029, 1042], "original_object": "breast cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e03d1378-6889-43d5-a34c-f96132cffa88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88"]}], "subject": "CHEBI:755540", "supporting_text": ["1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatm"], "temporal_context_qualifier": "adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone refractory metastatic prostate cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f96d1116-3732-57e0-b410-54cb4fa40fe4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19951127", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone", "prednisolone"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:f7f2f0f5-acc0-52e9-a8d7-309e8eaf599b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0008315", "object_location_in_text": [1903, 1918], "original_object": "prostate cancer", "original_subject": "docetaxel", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:taxotere", "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere"]}], "subject": "CHEBI:755540", "supporting_text": ["Breast cancer Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:  operable node-positive breast cancer; operable node-negative breast cancer.  For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Non-small-cell lung cancer Taxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. Prostate cancer Taxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Taxotere in combination with cisplatin and 5-fluorouracil"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33aad3b3-b2e9-59a1-a81d-9df34e8a8236", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:120b764e-690f-51eb-8e65-647d5c23bff1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0010150", "original_object": "squamous cell carcinoma of the head and neck", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"], "temporal_context_qualifier": "induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5aa2e2d1-b3fe-580e-acd7-f119069371e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:120b764e-690f-51eb-8e65-647d5c23bff1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0010150", "original_object": "squamous cell carcinoma of the head and neck", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"], "temporal_context_qualifier": "induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a25b0a94-e606-58ab-a678-b1695fd98c87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:120b764e-690f-51eb-8e65-647d5c23bff1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0010150", "original_object": "squamous cell carcinoma of the head and neck", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"], "temporal_context_qualifier": "induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4289992-bfea-5120-a731-2924919daa8f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:120b764e-690f-51eb-8e65-647d5c23bff1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0010150", "original_object": "squamous cell carcinoma of the head and neck", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"], "temporal_context_qualifier": "induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c477b263-047a-53fb-aeed-28d6d6b35475", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:120b764e-690f-51eb-8e65-647d5c23bff1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0010150", "original_object": "squamous cell carcinoma of the head and neck", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"], "temporal_context_qualifier": "induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db929039-5bbc-58f3-8fb0-4bca34a3af36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin", "fluorouracil"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:120b764e-690f-51eb-8e65-647d5c23bff1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0010150", "original_object": "squamous cell carcinoma of the head and neck", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"], "temporal_context_qualifier": "induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f3f4892-d425-579a-8915-94f4790b7654", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [581, 617], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3104aab1-cd6e-4ad2-8e0a-286a0c5d1940"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88ed6525-c722-5c3f-9a9d-c6a923ea5082", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [563, 599], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3538b979-8cac-49ed-b8dc-50f73ce38c72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3538b979-8cac-49ed-b8dc-50f73ce38c72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3538b979-8cac-49ed-b8dc-50f73ce38c72"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer BEIZRAY as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. BEIZRAY in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer BEIZRAY in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma BEIZRAY in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroeso"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5fb0a6e-e6ec-5747-8a1c-e1d17221c2c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [581, 617], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00c61d11-d6b7-4618-b6f6-2592dbcc8af7"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a958b010-9210-5e26-895e-69892bf49d05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [582, 618], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e0f06bd-d190-45da-be8b-062e8de01970", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e0f06bd-d190-45da-be8b-062e8de01970"]}], "subject": "CHEBI:755540", "supporting_text": ["1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa137703-f247-5021-b2c6-ac553fe5578d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [581, 617], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=644c5035-20d2-4686-beaa-bef08e99051c"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad4a161b-3f41-519d-9e4c-f8b9a31f63a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [582, 618], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81686d37-a13f-46e2-b439-a84eb1433634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81686d37-a13f-46e2-b439-a84eb1433634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81686d37-a13f-46e2-b439-a84eb1433634"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: Br e a st Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) N o n- small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) C a stration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer (1.3) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squ a m o u s Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b23555a3-ff29-5e8e-be0c-12e72e63cb41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [581, 617], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:caad7fb3-59fd-5943-a800-26842b267645", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [581, 617], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b9999bb-869e-4d25-838c-23c3ab280044"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d00fbf16-abf7-5b5e-874e-93c58fa92ac9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [582, 618], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e03d1378-6889-43d5-a34c-f96132cffa88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88"]}], "subject": "CHEBI:755540", "supporting_text": ["1. INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e8aae603-5c72-5dc1-8385-58b602f9d20c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960514", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["prednisone"], "medic_disease_context_ids": ["UMLS:C4721208"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:225402a7-ed48-5c01-8cad-40844791e315", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:043d57ec-ce98-5f81-a771-5e20161e0d53", "medic_supporting_text_truncated": true, "object": "MONDO:0850353", "object_location_in_text": [581, 617], "original_object": "castration-resistant prostate cancer", "original_subject": "DOCETAXEL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=654319ae-e5f9-4a6a-b566-201923153b6e"]}], "subject": "CHEBI:755540", "supporting_text": ["1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatme"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3665464", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd0eea2e-93bc-58dd-b893-054ccc4e6421", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["UMLS:C3665464"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9e7703-3f17-5ead-930f-8809c54ff1aa", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:621fa3fc-7ef2-5327-a31c-31af42a49c74", "object": "UMLS:C1270972", "object_location_in_text": [92, 117], "original_object": "mild cognitive impairment", "original_subject": "FLORTAUCIPIR (18F)", "population_context_qualifier": "patients for whom donanemab (genetical recombination) is indicated", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:FLORTAUCIPIR (18F)#12-20241227", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:755541", "supporting_text": ["A drug with a new active ingredient indicated for the support of selection of patients with mild cognitive impairment and mild dementia due to Alzheimer's disease, for whom donanemab (genetical recombination) is indicated. [Expedited review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor-negative breast cancer, human epidermal growth factor receptor 2 (HER2)-negative breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ffd7f13-f106-5c9b-a10f-090977a8805e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:da818536-d69e-5105-976f-6e7c38bdbdc6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a341ccfe-5723-5020-a439-fac40bb41f4d", "object": "MONDO:0007254", "object_location_in_text": [154, 193], "original_object": "unresectable or recurrent breast cancer", "original_subject": "SACITUZUMAB GOVITECAN", "population_context_qualifier": "patients who have previously been treated with chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SACITUZUMAB GOVITECAN#16-20240924", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:755547", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative unresectable or recurrent breast cancer in patients who have previously been treated with chemotherapy. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "EGFR mutation, ALK mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:648cffc5-1a05-56ab-83ca-d6fb266ee016", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160518", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4fde2b1f-c9c8-58c2-bc6a-912518ff5099", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "ATEZOLIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a617b089-ce66-464b-987b-b45d029b4d6f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f"]}], "subject": "CHEBI:755740", "supporting_text": ["1 INDICATIONS AND USAGE TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. ( 1.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.1 ) Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) in combination with lurbinectedin, for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ HYBREZA or intravenous atezolizumab, and carboplatin plus etoposide. ( 1.2 ) Hepatocellular Carcinoma (HCC) "], "temporal_context_qualifier": "during or following platinum-containing chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "unresectable advanced or recurrent non-small-cell lung cancer", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a49c3074-8977-59a4-a5df-370bdb6c0033", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191122", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c28e843a-099c-5171-9434-1b60e1fa6ce6", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:4fde2b1f-c9c8-58c2-bc6a-912518ff5099", "object": "MONDO:0005233", "object_location_in_text": [91, 117], "original_object": "non-small-cell lung cancer", "original_subject": "ATEZOLIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ATEZOLIZUMAB#73-20191122", "https://www.pmda.go.jp/files/000234772.pdf"]}], "subject": "CHEBI:755740", "supporting_text": ["A drug with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small-cell lung cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C5237421", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ed89f94-8fb6-5da7-bbf9-a1642afda63a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190920", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5237421"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:4fde2b1f-c9c8-58c2-bc6a-912518ff5099", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "ATEZOLIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ATEZOLIZUMAB#73-20190920", "https://www.pmda.go.jp/files/000234772.pdf"]}], "subject": "CHEBI:755740", "supporting_text": ["A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of PD-L1-positive, hormone receptor- negative and HER2-negative inoperable or recurrent breast cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0581126", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4def814-4cfb-5558-bdf1-36a771eda8a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220919", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0581126"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c4b0d336-1bcf-5de8-9861-39b4d0736bb0", "object": "MONDO:0004979", "object_location_in_text": [120, 126], "original_object": "asthma", "original_subject": "tezepelumab", "population_context_qualifier": "adults and adolescents 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tezspire", "https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire"]}], "subject": "CHEBI:755742", "supporting_text": ["AsthmaTezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. Chronic rhinosinusitis with nasal polyps (CRSwNP)&nbsp;Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe CRSwNP", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3616e949-cc0e-52b1-a7b6-95c371be126e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220919", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["intranasal corticosteroids"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7d46f369-9d63-5674-a16b-e8d2232e756b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c4b0d336-1bcf-5de8-9861-39b4d0736bb0", "object": "UMLS:C4524092", "original_object": "chronic rhinosinusitis with nasal polyps", "original_subject": "tezepelumab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tezspire", "https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire"]}], "subject": "CHEBI:755742", "supporting_text": ["AsthmaTezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. Chronic rhinosinusitis with nasal polyps (CRSwNP)&nbsp;Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequately controlled chronic rhinosinusitis with nasal polyps", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d5c80c2-8207-5c89-835f-db082f551fce", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d46f369-9d63-5674-a16b-e8d2232e756b", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4b0d336-1bcf-5de8-9861-39b4d0736bb0", "object": "UMLS:C4524092", "original_object": "chronic rhinosinusitis with nasal polyps", "original_subject": "TEZEPELUMAB", "population_context_qualifier": "adult and pediatric patients aged 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60f0aa03-ad25-4d48-80ce-7fcfa76f325f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60f0aa03-ad25-4d48-80ce-7fcfa76f325f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60f0aa03-ad25-4d48-80ce-7fcfa76f325f"]}], "subject": "CHEBI:755742", "supporting_text": ["1 INDICATIONS AND USAGE TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "RPE65 mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98093a1c-4cd7-5263-9a03-0d4964ebd7fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171219", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:26ad44a4-9823-5ceb-b710-539847d53d19", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f01a2fc-882c-5f26-9991-fbecb9cb8edf", "object": "MONDO:0019118", "original_object": "retinal dystrophy", "original_subject": "VORETIGENE NEPARVOVEC", "population_context_qualifier": "patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy with viable retinal cells", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08313a24-e7ce-457a-bb3f-161bc45517ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee"]}], "subject": "CHEBI:755766", "supporting_text": ["1 INDICATIONS AND USAGE LUXTURNA (voretigene neparvovec-rzyl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s). LUXTURNA is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0001518", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cec33c60-e0b6-540c-aac5-f848a5482fc9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001518"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe06fb3b-5679-54fb-835c-3aef0eb74416", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:33712640-f47c-5260-903a-c82a8719e5eb", "object": "HP:0004322", "original_object": "short stature", "original_subject": "SOMAPACITAN", "population_context_qualifier": "pediatric patients aged 2.5 years and older with no catch-up growth by 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eadd03b4-adc3-4b88-8a24-9d205c5b85aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eadd03b4-adc3-4b88-8a24-9d205c5b85aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eadd03b4-adc3-4b88-8a24-9d205c5b85aa"]}], "subject": "CHEBI:755778", "supporting_text": ["1 INDICATIONS AND USAGE SOGROYA is indicated for the treatment of pediatric patients aged 2.5 years and older with: • Growth failure due to inadequate secretion of endogenous growth hormone (GH). • Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age. • Growth failure associated with Noonan syndrome (NS). • Idiopathic Short Stature (ISS). SOGROYA is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD). SOGROYA is a human growth hormone analog indicated for: Pediatric Patients: Treatment of pediatric patients aged 2.5 years and older with: • Growth failure due to inadequate secretion of endogenous growth hormone (GH). ( 1 ) • Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age. ( 1 ) • Growth failure associated with Noonan syndrome (NS). ( 1 ) • Idiopathic Short Stature (ISS). ( 1 ) Adults: Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0034323", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66e9921d-7e76-54b5-942f-242379aa2153", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230626", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0034323"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:fe06fb3b-5679-54fb-835c-3aef0eb74416", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:33712640-f47c-5260-903a-c82a8719e5eb", "object": "HP:0004322", "object_location_in_text": [94, 107], "original_object": "short stature", "original_subject": "SOMAPACITAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SOMAPACITAN#21-20230626", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:755778", "supporting_text": ["(1) Drugs with a new indication, a new dosage, and other characteristics for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. (2) A drug with a new indication and a new dosage in an additional dosage form for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure."], "temporal_context_qualifier": "prior to epiphyseal closure"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0031241", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d834d336-1575-5423-80db-ca98d7759ca4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031241"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f7e5bceb-3209-5ac3-bb8e-563d14978269", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3d9be86c-9537-5a96-83f2-fa73980a0f57", "object": "MONDO:0005150", "object_location_in_text": [67, 99], "original_object": "age-related macular degeneration", "original_subject": "BROLUCIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BROLUCIZUMAB#70-20200325", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:755824", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "SOD1 gene mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edfa3130-57bf-5925-8cbe-5c499d43a89d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240529", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:565da63f-c80e-5075-aac5-760df3580469", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:21a6736c-786c-571e-9e67-64c1727a0d0f", "object": "MONDO:0004976", "original_object": "amyotrophic lateral sclerosis", "original_subject": "tofersen", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:qalsody", "https://www.ema.europa.eu/en/documents/product-information/qalsody-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/qalsody"]}], "subject": "CHEBI:755937", "supporting_text": ["Qalsody is indicated for the treatment of adults with&nbsp;amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69d26570-8c10-53ef-a1e5-22b569527617", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8daef316-3694-58d1-947d-c7c0b4fbb6b7", "object": "MONDO:0005550", "object_location_in_text": [75, 84], "original_object": "infection", "original_subject": "EFLAPEGRASTIM", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e436115-62e7-4729-aeb0-ff78ea685206", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206"]}], "subject": "CHEBI:755956", "supporting_text": ["1 INDICATIONS AND USAGE Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d5a6749-ed81-51e1-a014-8c9fa5f97450", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8daef316-3694-58d1-947d-c7c0b4fbb6b7", "object": "MONDO:0005550", "object_location_in_text": [75, 84], "original_object": "infection", "original_subject": "EFLAPEGRASTIM", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dc62c46-bb10-4a62-a459-d3eeeb6dd82f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dc62c46-bb10-4a62-a459-d3eeeb6dd82f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dc62c46-bb10-4a62-a459-d3eeeb6dd82f"]}], "subject": "CHEBI:755956", "supporting_text": ["1 INDICATIONS AND USAGE Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97cc2514-18ef-5970-a539-d580b6f76508", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8daef316-3694-58d1-947d-c7c0b4fbb6b7", "object": "UMLS:C0746883", "object_location_in_text": [103, 122], "original_object": "febrile neutropenia", "original_subject": "EFLAPEGRASTIM", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e436115-62e7-4729-aeb0-ff78ea685206", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206"]}], "subject": "CHEBI:755956", "supporting_text": ["1 INDICATIONS AND USAGE Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fea03681-a208-57ce-855f-d90fb925033e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8daef316-3694-58d1-947d-c7c0b4fbb6b7", "object": "UMLS:C0746883", "object_location_in_text": [103, 122], "original_object": "febrile neutropenia", "original_subject": "EFLAPEGRASTIM", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2dc62c46-bb10-4a62-a459-d3eeeb6dd82f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2dc62c46-bb10-4a62-a459-d3eeeb6dd82f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2dc62c46-bb10-4a62-a459-d3eeeb6dd82f"]}], "subject": "CHEBI:755956", "supporting_text": ["1 INDICATIONS AND USAGE Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital blood coagulation factor VIII deficiency, blood coagulation factor VIII inhibitors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d4b1add-25e9-58b4-b829-8503a2e6f620", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180323", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e9f582dd-1dda-5f94-ae3f-eaadc05a5053", "object": "MONDO:0002243", "object_location_in_text": [64, 81], "original_object": "bleeding tendency", "original_subject": "EMICIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EMICIZUMAB#95-20180323", "https://www.pmda.go.jp/files/000236236.pdf"]}], "subject": "CHEBI:755960", "supporting_text": ["Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor VIII deficiency with blood coagulation factor VIII inhibitors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital blood coagulation factor VIII deficiency, blood coagulation factor VIII inhibitors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8aa155d4-c6dc-533b-8a10-d3150e09799f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e9f582dd-1dda-5f94-ae3f-eaadc05a5053", "object": "MONDO:0002243", "object_location_in_text": [53, 70], "original_object": "bleeding tendency", "original_subject": "EMICIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EMICIZUMAB#85-20181221", "https://www.pmda.go.jp/files/000236236.pdf"]}], "subject": "CHEBI:755960", "supporting_text": ["Drugs with a new dosage indicated for the control of bleeding tendency in patients with congenital blood coagulation factor VIII deficiency with blood coagulation factor VIII inhibitors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blood coagulation factor VIII deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8aa155d4-c6dc-533b-8a10-d3150e09799f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20181221", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:e9f582dd-1dda-5f94-ae3f-eaadc05a5053", "object": "MONDO:0002243", "object_location_in_text": [75, 92], "original_object": "bleeding tendency", "original_subject": "EMICIZUMAB", "population_context_qualifier": "patients without blood coagulation factor VIII inhibitors", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EMICIZUMAB#85-20181221", "https://www.pmda.go.jp/files/000236236.pdf"]}], "subject": "CHEBI:755960", "supporting_text": ["Drugs with a new additional indication and a new dosage for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency without blood coagulation factor VIII inhibitors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f67a3852-dfed-5ebf-ae2d-a7af09cc137e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191114", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["obinutuzumab"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3dae876-8451-5f09-a914-c141f89e43e6", "medic_supporting_text_truncated": true, "object": "HP:0033125", "original_object": "Follicular lymphoma", "original_subject": "ZANUBRUTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e08fe23-d70e-424c-bc51-1222e320f902", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902"]}], "subject": "CHEBI:755996", "supporting_text": ["1 INDICATIONS AND USAGE BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.1 Mantle Cell Lymphoma BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Waldenström's Macroglobulinemia BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) [see Clinical Studies (14.2) ] . 1.3 Marginal Zone Lymphoma BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received a"], "temporal_context_qualifier": "after two or more lines of systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsed or refractory", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21de1266-b81b-5fa8-bb1b-8796487ce9c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191114", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f829255d-e3b7-5ac8-9a89-5f660844813f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3dae876-8451-5f09-a914-c141f89e43e6", "medic_supporting_text_truncated": true, "object": "MONDO:0017604", "original_object": "Marginal zone lymphoma", "original_subject": "ZANUBRUTINIB", "population_context_qualifier": "adult patients who have received at least one anti–CD20-based regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e08fe23-d70e-424c-bc51-1222e320f902", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902"]}], "subject": "CHEBI:755996", "supporting_text": ["1 INDICATIONS AND USAGE BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.1 Mantle Cell Lymphoma BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Waldenström's Macroglobulinemia BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) [see Clinical Studies (14.2) ] . 1.3 Marginal Zone Lymphoma BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "RAS wild-type HER2-positive unresectable or metastatic colorectal cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f865f9a-cf1b-5095-afc0-d32307916007", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trastuzumab"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4db18fd6-759e-58ad-bde9-03459dacc042", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:374a3994-cec3-5c97-9bf8-7c1ed3f0a203", "medic_supporting_text_truncated": true, "object": "MONDO:0005575", "object_location_in_text": [698, 715], "original_object": "colorectal cancer", "original_subject": "TUCATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f27eb1b9-b7fc-424e-988f-84dd7bb195a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3"]}], "subject": "CHEBI:756373", "supporting_text": ["1 INDICATIONS AND USAGE TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. ( 1.1 ) • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.1 Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. 1.2 Unresectable or Metastatic Colorectal Cancer TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed"], "temporal_context_qualifier": "that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced unresectable or metastatic HER2-positive breast cancer", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b62a9eb1-18c9-5ae3-b9d6-2306e666736a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["trastuzumab", "capecitabine"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b691e086-854f-58df-80bb-52a7d24b2d21", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:374a3994-cec3-5c97-9bf8-7c1ed3f0a203", "medic_supporting_text_truncated": true, "object": "MONDO:0006244", "object_location_in_text": [210, 237], "original_object": "HER2-positive breast cancer", "original_subject": "TUCATINIB", "population_context_qualifier": "adult patients, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f27eb1b9-b7fc-424e-988f-84dd7bb195a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3"]}], "subject": "CHEBI:756373", "supporting_text": ["1 INDICATIONS AND USAGE TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. ( 1.1 ) • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.1 Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. 1.2 Unresectable or Metastatic Colorectal Cancer TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0278689", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c76cc81-dcdb-5480-9af4-3b0db65c803c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200925", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278689"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:5644b704-971f-5f76-9eaf-2f48ad09e417", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:227297de-148b-535b-80ad-6534dd4036e0", "object": "UMLS:C0278689", "object_location_in_text": [173, 197], "original_object": "recurrent ovarian cancer", "original_subject": "NIRAPARIB TOSILATE HYDRATE", "population_context_qualifier": "patients who are in a complete or partial response to platinum-based chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NIRAPARIB TOSILATE HYDRATE#62-20200925", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:756415", "supporting_text": ["A drug with a new active ingredient indicated for the maintenance treatment of ovarian cancer in patients who have received first chemotherapy, the maintenance treatment of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy, and the treatment of homologous recombination deficiency (HRD)-positive recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384600", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f9cefec-5028-5d16-92f9-f52a48a192fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384600"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a5850430-2a8c-5f8f-8d23-3ab95f0a1a19", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3470ce02-fd94-5b1f-8520-f0b996bcf3ab", "object": "MONDO:0015545", "original_object": "hemophagocytic lymphohistiocytosis/macrophage activation syndrome", "original_subject": "EMAPALUMAB", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a865e0ef-8685-4f69-8838-648c4f3bab47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a865e0ef-8685-4f69-8838-648c4f3bab47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a865e0ef-8685-4f69-8838-648c4f3bab47"]}], "subject": "CHEBI:756460", "supporting_text": ["1 INDICATIONS AND USAGE GAMIFANT is indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. GAMIFANT is an interferon gamma (IFNγ) neutralizing antibody indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. ( 1 ) adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "relapsed or refractory (r/r) DLBCL", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97c23f46-f3d9-5b18-bd2e-5dc1eeda80a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180823", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2c7a3e49-386f-52ef-bb75-67aed6ca9421", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c94cc2f3-f183-54d0-8247-ef3d46d2b89a", "object": "MONDO:0018905", "original_object": "diffuse large B cell lymphoma", "original_subject": "axicabtagene ciloleucel", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:yescarta", "https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta"]}], "subject": "CHEBI:756472", "supporting_text": ["Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy."], "temporal_context_qualifier": "after two or more lines of systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c3699b3-cae6-5a65-b092-2755586531bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarctions", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee466dc-5a4e-4c77-8e94-8b510cafd61b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee466dc-5a4e-4c77-8e94-8b510cafd61b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee466dc-5a4e-4c77-8e94-8b510cafd61b"]}], "subject": "CHEBI:7565", "supporting_text": ["I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II.Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5de4b82e-03ae-50da-a65f-93d228248e9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarctions", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cda16a27-f029-40a6-a0e8-2bed0de71169", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cda16a27-f029-40a6-a0e8-2bed0de71169", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cda16a27-f029-40a6-a0e8-2bed0de71169"]}], "subject": "CHEBI:7565", "supporting_text": ["I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II.Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6efc7edc-3b65-5fde-b61c-296c8e1be1eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarctions", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ebcb33c-f43b-4b36-9f94-9774b2a59e06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06"]}], "subject": "CHEBI:7565", "supporting_text": ["Vasospastic Angina PROCARDIA XL is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA XL may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. Chronic Stable Angina (Classical Effort-Associated Angina) PROCARDIA XL is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to moni"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:089cdd94-9709-5c2c-988c-4c486169258d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "strokes", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ebcb33c-f43b-4b36-9f94-9774b2a59e06", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ebcb33c-f43b-4b36-9f94-9774b2a59e06"]}], "subject": "CHEBI:7565", "supporting_text": ["Vasospastic Angina PROCARDIA XL is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA XL may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. Chronic Stable Angina (Classical Effort-Associated Angina) PROCARDIA XL is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to moni"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d06d02f-023b-5375-b97c-b23097a3a818", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "strokes", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cda16a27-f029-40a6-a0e8-2bed0de71169", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cda16a27-f029-40a6-a0e8-2bed0de71169", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cda16a27-f029-40a6-a0e8-2bed0de71169"]}], "subject": "CHEBI:7565", "supporting_text": ["I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II.Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dd1ad81-46f6-5da9-8d5b-29881392f722", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "strokes", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee466dc-5a4e-4c77-8e94-8b510cafd61b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee466dc-5a4e-4c77-8e94-8b510cafd61b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee466dc-5a4e-4c77-8e94-8b510cafd61b"]}], "subject": "CHEBI:7565", "supporting_text": ["I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II.Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0340288", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5437871c-260e-560b-9910-b88827b75180", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0340288"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cc7ef117-f91f-56bb-8aeb-cd218f7d7f3b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "UMLS:C0002962", "object_location_in_text": [80, 86], "original_object": "angina", "original_subject": "NIFEDIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5014847e-389d-48c1-8350-b9b24ca8d2a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5014847e-389d-48c1-8350-b9b24ca8d2a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5014847e-389d-48c1-8350-b9b24ca8d2a4"]}], "subject": "CHEBI:7565", "supporting_text": ["I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0741032", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0abe6d47-c5a8-598a-9d15-4f0875362bbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0741032"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7bea912-a802-599b-b0a6-a72db0fd5420", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "MONDO:0006021", "object_location_in_text": [68, 86], "original_object": "vasospastic angina", "original_subject": "NIFEDIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5014847e-389d-48c1-8350-b9b24ca8d2a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5014847e-389d-48c1-8350-b9b24ca8d2a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5014847e-389d-48c1-8350-b9b24ca8d2a4"]}], "subject": "CHEBI:7565", "supporting_text": ["I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0340288", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f38a675-e803-55b3-8ee6-ed4fdd364e9d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0340288"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:deb8e931-b9a6-5609-af3c-98301ddfff3f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "UMLS:C0162521", "object_location_in_text": [1495, 1513], "original_object": "exercise tolerance", "original_subject": "NIFEDIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cda16a27-f029-40a6-a0e8-2bed0de71169", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cda16a27-f029-40a6-a0e8-2bed0de71169", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cda16a27-f029-40a6-a0e8-2bed0de71169"]}], "subject": "CHEBI:7565", "supporting_text": ["I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II.Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0340288", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6eaa7fff-9778-56b6-8c6b-52e52ab26ec2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0340288"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:deb8e931-b9a6-5609-af3c-98301ddfff3f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "UMLS:C0162521", "object_location_in_text": [1495, 1513], "original_object": "exercise tolerance", "original_subject": "NIFEDIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ee466dc-5a4e-4c77-8e94-8b510cafd61b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ee466dc-5a4e-4c77-8e94-8b510cafd61b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ee466dc-5a4e-4c77-8e94-8b510cafd61b"]}], "subject": "CHEBI:7565", "supporting_text": ["I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II.Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormal"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0340288", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db176756-97eb-5893-a63c-f3924cc8fe89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0340288"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:deb8e931-b9a6-5609-af3c-98301ddfff3f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "UMLS:C0162521", "original_object": "exercise tolerance", "original_subject": "NIFEDIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b0263a7-c492-40ea-e053-2a95a90a561e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b0263a7-c492-40ea-e053-2a95a90a561e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b0263a7-c492-40ea-e053-2a95a90a561e"]}], "subject": "CHEBI:7565", "supporting_text": ["I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (S"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0340288", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd16b82e-cc31-5389-b82e-c1d5ec449042", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0340288"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:deb8e931-b9a6-5609-af3c-98301ddfff3f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "UMLS:C0162521", "original_object": "exercise tolerance", "original_subject": "NIFEDIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a3daa0fc-7ec3-42c2-91b2-8418331dd0fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a3daa0fc-7ec3-42c2-91b2-8418331dd0fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a3daa0fc-7ec3-42c2-91b2-8418331dd0fc"]}], "subject": "CHEBI:7565", "supporting_text": ["I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (S"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic stable angina (effort-associated angina)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e793b9ac-d212-5866-9ea4-f274baaa9835", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:deb8e931-b9a6-5609-af3c-98301ddfff3f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b8994878-0ee8-5ef0-84d9-69ad38eb416c", "medic_supporting_text_truncated": true, "object": "UMLS:C0162521", "original_object": "exercise tolerance", "original_subject": "NIFEDIPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f43889f-3e6a-6a5c-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f43889f-3e6a-6a5c-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f43889f-3e6a-6a5c-e054-00144ff8d46c"]}], "subject": "CHEBI:7565", "supporting_text": ["I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (S"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4324656", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32b7d0c9-ac05-5f76-b40c-94b87565a244", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4324656"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:addbfeba-56f9-503c-b85b-808f51a44c4a", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "TELISOTUZUMAB VEDOTIN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc04f980-3957-4e35-ab81-8ec2ffe87215", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215"]}], "subject": "CHEBI:756513", "supporting_text": ["1 INDICATIONS AND USAGE EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration ( 2.1 )] , who have received a prior systemic therapy . This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. ( 1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )"], "temporal_context_qualifier": "who have received a prior systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital haemophilia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:390ab74b-ac09-5726-a116-7a6206ca1f05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241227", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:ce06a768-a9d2-59dd-81ff-21c9addd22aa", "object": "MONDO:0002243", "object_location_in_text": [65, 82], "original_object": "bleeding tendency", "original_subject": "MARSTACIMAB", "population_context_qualifier": "patients who do not have inhibitors against blood coagulation factor VIII or IX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MARSTACIMAB#19-20241227", "https://www.pmda.go.jp/files/000278381.pdf"]}], "subject": "CHEBI:756519", "supporting_text": ["A drug with a new active ingredient indicated for the control of bleeding tendency in patients with congenital haemophilia who do not have inhibitors against blood coagulation factor VIII or IX."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-muscle invasive bladder cancer, Bacillus Calmette-Guérin (BCG)-unresponsiveness", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27703933-6d8e-5d2e-9e30-258e1527168b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d8b93f88-1197-5e37-810a-662ef4e8f4b2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5f3caee-94d4-5d32-ba86-855431971c93", "object": "MONDO:0004647", "original_object": "carcinoma in situ", "original_subject": "NADOFARAGENE FIRADENOVEC", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ca20ed4-da4f-463c-ac2a-ccd6ab3774fa"]}], "subject": "CHEBI:756521", "supporting_text": ["1 INDICATIONS AND USAGE ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anaplastic lymphoma kinase (ALK)-positive", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:44fdc603-22c0-5b4b-8efe-74a2d2fdda9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241218", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:199df86f-156b-52fc-b91b-fe6665711f0c", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "ENSARTINIB", "population_context_qualifier": "adult patients who have not previously received an ALK-inhibitor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e1b2f79-678a-472a-b924-66909c8a4b2e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e"]}], "subject": "CHEBI:756608", "supporting_text": ["1 INDICATIONS AND USAGE ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] who have not previously received an ALK-inhibitor. ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test who have not previously received an ALK-inhibitor. ( 1 , 2.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3827240", "has_confidence_score": 0.873, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a81adf8-6be5-5c41-ac3d-54b0a203bcf7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200924", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3827240"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d66a283a-ba7b-54ca-8e26-26b3409de16a", "medic_pair_confidence": 0.873, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:52dcdc65-b983-597b-b6e8-50a47e10380f", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumours", "original_subject": "avapritinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ayvakyt", "https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt"]}], "subject": "CHEBI:756628", "supporting_text": ["Unresectable or metastatic gastrointestinal stromal tumour (GIST) AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. Advanced systemic mastocytosis (AdvSM) AYVAKYT is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. Indolent systemic mastocytosis (ISM) AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment (see section 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3898046", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a7635b0-63d5-57f7-99a0-ac8a18e7fa48", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200109", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3898046"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475ddfb6-d159-590b-b099-651c0b387b33", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:52dcdc65-b983-597b-b6e8-50a47e10380f", "object": "MONDO:0011719", "original_object": "gastrointestinal stromal tumor", "original_subject": "AVAPRITINIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:645c887c-8cd4-4623-8da9-ac223d71a8b9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9"]}], "subject": "CHEBI:756628", "supporting_text": ["1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C5420237", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa1afb66-2ef5-5de1-98b2-65dc32018721", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20211118", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5420237"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3da58aab-cd57-5c90-80d0-e7bf79a66ef9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4ea1e745-b1bb-5751-ae3f-f407b603ce53", "object": "HP:0100723", "original_object": "gastrointestinal stromal tumour", "original_subject": "ripretinib", "population_context_qualifier": "adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:qinlock", "https://www.ema.europa.eu/en/documents/product-information/qinlock-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock"]}], "subject": "CHEBI:756647", "supporting_text": ["Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6780e6c-86cf-582a-8024-644925c7b37f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a2af572a-d61c-501c-8d67-bd08bd1abaf4", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8ee883dc-bd1f-5ebd-8cf0-363a491dd781", "object": "MONDO:0016686", "object_location_in_text": [99, 118], "original_object": "Grade 2 astrocytoma", "original_subject": "Vorasidenib Tablets 10 mg/ 40 mg", "population_context_qualifier": "adult and pediatric patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:756658", "supporting_text": ["Vorasidenib is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, subtotal resection, or gross total resection."], "temporal_context_qualifier": "following surgery including biopsy, subtotal resection, or gross total resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b5bf283-8fb3-52f9-a972-9f0c9c42b437", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240806", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a2af572a-d61c-501c-8d67-bd08bd1abaf4", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:004ec9c8-2203-5e1a-8c05-d7781806edaf", "object": "MONDO:0016686", "object_location_in_text": [120, 139], "original_object": "Grade 2 astrocytoma", "original_subject": "VORASIDENIB", "population_context_qualifier": "adult and pediatric patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31405fee-55b7-4857-987e-2724ee76be84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84"]}], "subject": "CHEBI:756658", "supporting_text": ["1 INDICATIONS AND USAGE VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ]. VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection. ( 1 )"], "temporal_context_qualifier": "following surgery including biopsy, sub-total resection, or gross total resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6662d9df-d769-5c87-a12f-919fc0718cb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251015", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:8fb9768c-7084-5516-a3b5-0e524a6d9891", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8ee883dc-bd1f-5ebd-8cf0-363a491dd781", "object": "MONDO:0016695", "object_location_in_text": [122, 139], "original_object": "oligodendroglioma", "original_subject": "Vorasidenib Tablets 10 mg/ 40 mg", "population_context_qualifier": "adult and pediatric patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:756658", "supporting_text": ["Vorasidenib is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, subtotal resection, or gross total resection."], "temporal_context_qualifier": "following surgery including biopsy, subtotal resection, or gross total resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3898826", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:878d7353-c95b-5ab7-b749-6cac560f4a5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250917", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3898826"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8fb9768c-7084-5516-a3b5-0e524a6d9891", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:004ec9c8-2203-5e1a-8c05-d7781806edaf", "object": "MONDO:0016695", "object_location_in_text": [114, 131], "original_object": "oligodendroglioma", "original_subject": "vorasidenib", "population_context_qualifier": "adult and adolescent patients aged 12 years and older and weighing at least 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:voranigo", "https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo"]}], "subject": "CHEBI:756658", "supporting_text": ["Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade&nbsp;2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12&nbsp;years and older and weighing at least 40&nbsp;kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section&nbsp;5.1)."], "temporal_context_qualifier": "who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63ef6449-e2ed-5298-8e15-8ed3f3c5709a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240806", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8fb9768c-7084-5516-a3b5-0e524a6d9891", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:004ec9c8-2203-5e1a-8c05-d7781806edaf", "object": "MONDO:0016695", "object_location_in_text": [143, 160], "original_object": "oligodendroglioma", "original_subject": "VORASIDENIB", "population_context_qualifier": "adult and pediatric patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31405fee-55b7-4857-987e-2724ee76be84", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31405fee-55b7-4857-987e-2724ee76be84"]}], "subject": "CHEBI:756658", "supporting_text": ["1 INDICATIONS AND USAGE VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ]. VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection. ( 1 )"], "temporal_context_qualifier": "following surgery including biopsy, sub-total resection, or gross total resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3898826", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2aad30d9-6cce-58ee-888f-38e8646cf23f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250917", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3898826"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:14f29ae6-8c76-58b8-8b0a-05cc1c10a706", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:004ec9c8-2203-5e1a-8c05-d7781806edaf", "object": "MONDO:0019781", "object_location_in_text": [99, 110], "original_object": "astrocytoma", "original_subject": "vorasidenib", "population_context_qualifier": "adult and adolescent patients aged 12 years and older and weighing at least 40 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:voranigo", "https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo"]}], "subject": "CHEBI:756658", "supporting_text": ["Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade&nbsp;2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12&nbsp;years and older and weighing at least 40&nbsp;kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section&nbsp;5.1)."], "temporal_context_qualifier": "who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "somatostatin receptor positive neuroendocrine tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:454df732-a50c-5c29-982c-15bd8b0a2c11", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200903", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2f43c76c-f315-5df8-9873-b2627b6cfe34", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4cf7bd30-a5f7-5576-9c58-465e68cfa0c7", "object": "MONDO:0019496", "original_object": "neuroendocrine tumors", "original_subject": "COPPER OXODOTREOTIDE CU-64", "population_context_qualifier": "adult patients", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f898c8a7-beb7-4318-a8ea-6f058d69342b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f898c8a7-beb7-4318-a8ea-6f058d69342b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f898c8a7-beb7-4318-a8ea-6f058d69342b"]}], "subject": "CHEBI:756834", "supporting_text": ["1 INDICATIONS AND USAGE Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Detectnet is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78f3ff04-7bb7-5ed5-b741-f7d64b50cedf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:232064e1-0391-5217-83f3-38bc4197a5bf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1cb22330-378b-5f6f-8388-bab0fdd0e5b3", "object": "MONDO:0019087", "object_location_in_text": [98, 116], "original_object": "cholangiocarcinoma", "original_subject": "pemigatinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pemazyre", "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre"]}], "subject": "CHEBI:757002", "supporting_text": ["Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed &nbsp;after at least one prior line of systemic therapy."], "temporal_context_qualifier": "after at least one prior line of systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "FGFR1 rearrangement", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e06090e-313b-5e62-9e99-24eb508bf460", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200417", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c98a4c55-b110-57d7-8723-7e355096a070", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1cb22330-378b-5f6f-8388-bab0fdd0e5b3", "object": "UMLS:C0439677", "original_object": "myeloid/lymphoid neoplasms", "original_subject": "PEMIGATINIB", "population_context_qualifier": "adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e1f2222-1d89-4e63-989c-ccebe2ab1eb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4"]}], "subject": "CHEBI:757002", "supporting_text": ["1 INDICATIONS AND USAGE PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. ( 1 , 2.1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 , 2.1 ) For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. ( 1 , 2.1 ) 1.1 Cholangiocarcinoma PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement PEMAZYRE is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5238463", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a91a55e5-2457-5252-a454-288c096772f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180126", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5238463"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1488c335-8b73-5506-ba7e-03d938918699", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62603299-9fc1-535c-a259-fb7bea31b23c", "object": "MONDO:0000386", "original_object": "gastroenteropancreatic neuroendocrine tumors", "original_subject": "LUTETIUM OXODOTREOTIDE LU-177", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7642094-9ec6-4927-8582-bbe60e5e74cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7642094-9ec6-4927-8582-bbe60e5e74cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7642094-9ec6-4927-8582-bbe60e5e74cc"]}], "subject": "CHEBI:757020", "supporting_text": ["1 INDICATIONS AND USAGE BEXLUTRY is indicated for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Pediatric use information is approved for Advanced Accelerator Applications USA INC’s LUTATHERA (lutetium Lu 177 dotatate) injection for intravenous use. However, due to Advanced Accelerator Applications USA Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. BEXLUTRY is a radiolabeled somatostatin analog indicated for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "insomnia characterized by difficulties with sleep onset and/or sleep maintenance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f499223-0f69-58a3-b9ee-f927e0325618", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220407", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:05f85dc6-0b72-5a05-bfb6-45256ab9f99c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3df7ad76-dfe5-52cb-a6c8-431d20f90eea", "object": "MONDO:0013600", "object_location_in_text": [86, 94], "original_object": "insomnia", "original_subject": "DARIDOREXANT", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3a2d1503-b816-40c9-9fac-7e03c5a3bcef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3a2d1503-b816-40c9-9fac-7e03c5a3bcef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a2d1503-b816-40c9-9fac-7e03c5a3bcef"]}], "subject": "CHEBI:757065", "supporting_text": ["1 INDICATIONS AND USAGE QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14.1) ] . QUVIVIQ is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "maintenance dialysis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4511d2d3-d452-5d10-a7bd-9eb18009754e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180323", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:13dc9a4f-4722-5b44-8c4e-1cfc1f71375d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6aec3f9c-e97c-51f4-8029-3e453b0fbc2c", "object": "MONDO:0006964", "object_location_in_text": [66, 95], "original_object": "secondary hyperparathyroidism", "original_subject": "EVOCALCET", "population_context_qualifier": "patients on maintenance dialysis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EVOCALCET#87-20180323", "https://www.pmda.go.jp/files/000241166.pdf"]}], "subject": "CHEBI:757091", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0278579", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da367106-25c4-5143-9c78-d4f4aa7eeb3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0278579", "MONDO:0002974"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3668116b-2cf1-58e7-8960-d2a4af01fef7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ade2ada4-d8d9-5577-ad5d-7f7ff10a7888", "object": "MONDO:0002974", "object_location_in_text": [1488, 1503], "original_object": "cervical cancer", "original_subject": "cemiplimab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:libtayo", "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo"]}], "subject": "CHEBI:757176", "supporting_text": ["Cutaneous Squamous Cell Carcinoma  Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation (see section 5.1 for selection criteria).&nbsp;  Basal Cell Carcinoma  Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).  Non-Small Cell Lung Cancer  Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ? 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:  locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.   Libtayo in combination with platinum?based chemotherapy is indicated for the first?line treatment of adult patients with NSCLC expressing PD-L1 (in ? 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:  locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.    Cervical Cancer  Libtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy."], "temporal_context_qualifier": "disease progression on or after platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4745056", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9de46b6-f954-5057-a0b1-0f37f52757ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4745056", "UMLS:C1304306"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:13037d22-6a9f-58fe-9c47-26cae16d74ef", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ade2ada4-d8d9-5577-ad5d-7f7ff10a7888", "object": "MONDO:0020804", "original_object": "basal cell carcinoma", "original_subject": "cemiplimab", "population_context_qualifier": "adult patients who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:libtayo", "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo"]}], "subject": "CHEBI:757176", "supporting_text": ["Cutaneous Squamous Cell Carcinoma  Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation (see section 5.1 for selection criteria).&nbsp;  Basal Cell Carcinoma  Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).  Non-Small Cell Lung Cancer  Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ? 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:  locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.   Libtayo in combination with platinum?based chemotherapy is indicated for the first?line treatment of adult patients with NSCLC expressing PD-L1 (in ? 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:  locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.    Cervical Cancer  Libtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital haemophilia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0152bfd8-9544-58e6-9119-7a8d89433bec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230925", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5975eeae-fa24-5358-8935-4b7839f90702", "object": "MONDO:0002243", "object_location_in_text": [64, 81], "original_object": "bleeding tendency", "original_subject": "CONCIZUMAB", "population_context_qualifier": "patients with inhibitors against blood coagulation factor VIII or IX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CONCIZUMAB#30-20230925", "https://www.pmda.go.jp/files/000279143.pdf"]}], "subject": "CHEBI:757182", "supporting_text": ["Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital haemophilia who have inhibitors against blood coagulation factor VIII or IX."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital haemophilia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3e57b78-19e4-5f94-93f8-2034a49dd7ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240624", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5975eeae-fa24-5358-8935-4b7839f90702", "object": "MONDO:0002243", "object_location_in_text": [47, 64], "original_object": "bleeding tendency", "original_subject": "CONCIZUMAB", "population_context_qualifier": "patients who do not have inhibitors against blood coagulation factor VIII or IX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:CONCIZUMAB#19-20240624", "https://www.pmda.go.jp/files/000279143.pdf"]}], "subject": "CHEBI:757182", "supporting_text": ["Drugs with a new indication for the control of bleeding tendency in patients with congenital haemophilia who do not have inhibitors against blood coagulation factor VIII or IX."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "activating EGFR Exon 20 insertion mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:574e9f3b-c0b0-538b-a82c-1f6f79ef5963", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20211209", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:f92eb018-e2ac-593a-8f4e-610224d0fb7e", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "amivantamab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:rybrevant", "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant"]}], "subject": "CHEBI:757222", "supporting_text": ["Rybrevant is indicated:  in combination with lazertinib for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations. in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon&nbsp;19 deletions or Exon&nbsp;21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI). in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations. as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum based therapy."], "temporal_context_qualifier": "after failure of platinum based therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7d5ddae-e3a7-5e0b-b61a-82c42e79a40f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f92eb018-e2ac-593a-8f4e-610224d0fb7e", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "object_location_in_text": [1455, 1481], "original_object": "non-small cell lung cancer", "original_subject": "AMIVANTAMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e58b045-e352-4f62-99bf-77fae1bebc69", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69"]}], "subject": "CHEBI:757222", "supporting_text": ["1 INDICATIONS AND USAGE RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 ) 1.1 First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT FASPRO, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose "], "temporal_context_qualifier": "disease has progressed on or after platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Arginase 1 Deficiency (ARG1-D)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0b131ea-d342-5b91-8324-af84583e7225", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20260223", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["dietary protein restriction"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:afae7d4e-3fa2-57f2-8232-dfd37f9239cf", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cd3186a-1422-5029-819c-3a066888cbaf", "object": "MONDO:0008814", "object_location_in_text": [66, 82], "original_object": "hyperargininemia", "original_subject": "PEGZILARGINASE", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5ceabf2-43a0-4746-9371-d98a39cf6cfc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5ceabf2-43a0-4746-9371-d98a39cf6cfc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5ceabf2-43a0-4746-9371-d98a39cf6cfc"]}], "subject": "CHEBI:757248", "supporting_text": ["1 INDICATIONS AND USAGE LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LOARGYS is an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. ( 1 ) This indication is approved under accelerated approval based on reduction of plasma arginine. ( 14 ) Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "polycythaemia vera without symptomatic splenomegaly", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:327b7350-b98e-5615-9619-88e0393c6821", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190215", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4e70fd06-2331-5ed9-a3fe-7785101743d5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:60bd6658-039e-5365-b0ca-4e53f200c022", "object": "MONDO:0009891", "object_location_in_text": [67, 85], "original_object": "polycythaemia vera", "original_subject": "ropeginterferon alfa-2b", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:besremi", "https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/besremi"]}], "subject": "CHEBI:757263", "supporting_text": ["Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate secretion of endogenous growth hormone", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bc4cbe5-ac47-5a22-a3fa-fde0afdbed15", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:696b931c-7dae-58fd-8ac6-eaadddf86483", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:747c57e2-7957-53e1-a6a9-f32ae764de43", "object": "HP:0001510", "object_location_in_text": [116, 130], "original_object": "growth failure", "original_subject": "SOMATROGON", "population_context_qualifier": "pediatric patients aged 3 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:06dce529-b741-4a1b-8842-3ad77be6e308", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=06dce529-b741-4a1b-8842-3ad77be6e308", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=06dce529-b741-4a1b-8842-3ad77be6e308"]}], "subject": "CHEBI:757274", "supporting_text": ["1 INDICATIONS AND USAGE NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone. NGENLA is a human growth hormone analog indicated for treatment of pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-positive status", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e121947e-0311-534f-89a1-58ea59507437", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["zanidatamab-hrii", "fluoropyrimidine- and platinum-containing chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7414e7c0-a2d9-5e09-ab7c-45adfe7c2039", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a5238c0-783a-5b5d-a74f-dfddbe037f03", "medic_supporting_text_truncated": true, "object": "MONDO:0003219", "original_object": "gastroesophageal junction adenocarcinoma", "original_subject": "TISLELIZUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08ef1e3e-496f-4b0b-94ee-fbba3cc1985a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a"]}], "subject": "CHEBI:757282", "supporting_text": ["1 INDICATIONS AND USAGE TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy in adults for the first line treatment of HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. ( 1.3 ) 1.1 Esophageal Cancer First-Line Treatment of Esophageal Squamous Cell Carcinoma TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). Previously Treated Esophageal Squamous Cell Carcinoma TEVIMBRA, as a single agent, is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. 1.2 Gastric Cancer TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) whose tumors express PD-L1 (≥"], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-positive status", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbd198dd-089f-52a5-963e-8cde004f5bf7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["zanidatamab-hrii", "fluoropyrimidine- and platinum-containing chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:665ef0ad-0b2c-5686-b682-c2daf7ce6ff7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a5238c0-783a-5b5d-a74f-dfddbe037f03", "medic_supporting_text_truncated": true, "object": "MONDO:0005028", "original_object": "esophageal adenocarcinoma", "original_subject": "TISLELIZUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08ef1e3e-496f-4b0b-94ee-fbba3cc1985a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a"]}], "subject": "CHEBI:757282", "supporting_text": ["1 INDICATIONS AND USAGE TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy in adults for the first line treatment of HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. ( 1.3 ) 1.1 Esophageal Cancer First-Line Treatment of Esophageal Squamous Cell Carcinoma TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). Previously Treated Esophageal Squamous Cell Carcinoma TEVIMBRA, as a single agent, is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. 1.2 Gastric Cancer TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) whose tumors express PD-L1 (≥"], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-negative status, PD-L1 expression", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b709620a-7c57-5f94-aaa5-c233ec16e574", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["platinum and fluoropyrimidine-based chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b896a5b2-89b6-5c33-8248-4f240557ba1c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a5238c0-783a-5b5d-a74f-dfddbe037f03", "medic_supporting_text_truncated": true, "object": "MONDO:0005036", "original_object": "gastric adenocarcinoma", "original_subject": "TISLELIZUMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08ef1e3e-496f-4b0b-94ee-fbba3cc1985a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a"]}], "subject": "CHEBI:757282", "supporting_text": ["1 INDICATIONS AND USAGE TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy in adults for the first line treatment of HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. ( 1.3 ) 1.1 Esophageal Cancer First-Line Treatment of Esophageal Squamous Cell Carcinoma TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). Previously Treated Esophageal Squamous Cell Carcinoma TEVIMBRA, as a single agent, is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. 1.2 Gastric Cancer TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) whose tumors express PD-L1 (≥"], "temporal_context_qualifier": "first-line treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1522484", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:786bfecc-7e98-5ad1-aae3-9dbf7851f2c1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1522484"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2057d27c-e402-5e26-88f4-84cefb91e26b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:878dd0d2-df4f-5bbc-9e83-967f363870fa", "object": "MONDO:0015459", "original_object": "nasopharyngeal carcinoma", "original_subject": "TORIPALIMAB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82e7921a-1e84-4988-9799-0ad7d19b2a75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82e7921a-1e84-4988-9799-0ad7d19b2a75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82e7921a-1e84-4988-9799-0ad7d19b2a75"]}], "subject": "CHEBI:757285", "supporting_text": ["1 INDICATIONS AND USAGE LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) 1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). 1.2 Previously Treated Unresectable or Metastatic NPC LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy."], "temporal_context_qualifier": "disease progression on or after a platinum-containing chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-low or -ultralow", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1e64ddf-79ba-50db-bc89-c61b5deea132", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250825", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:33f9b8a8-c4e2-5244-9a1d-1893a61ff062", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "TRASTUZUMAB DERUXTECAN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TRASTUZUMAB DERUXTECAN#5-20250825", "https://www.pmda.go.jp/files/000238706.pdf"]}], "subject": "CHEBI:757286", "supporting_text": ["A drug with a new indication for the treatment of hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-low or -ultralow inoperable or recurrent breast cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe alpha1-proteinase inhibitor deficiency", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb04f049-8e3e-57ae-855d-cd223c630bb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150820", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:88cd02f7-37e5-5ef0-a595-24cfb48c5f53", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:51a15f17-82a5-57f6-8207-b4055ab1165c", "object": "MONDO:0004849", "object_location_in_text": [77, 86], "original_object": "emphysema", "original_subject": "alpha1-proteinase inhibitor (human)", "population_context_qualifier": "adults with documented severe alpha1-proteinase inhibitor deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:respreeza", "https://www.ema.europa.eu/en/documents/product-information/respreeza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza"]}], "subject": "CHEBI:757317", "supporting_text": ["Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency."], "temporal_context_qualifier": "with evidence of progressive lung disease"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR)-mutated", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1ff1c062-63b1-5048-b289-40d78d4482e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250117", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25c39abe-1a96-5430-9ffb-f8cd48942a4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "DATOPOTAMAB DERUXTECAN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2950227c-6230-4ca4-a135-46e44d9424a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0"]}], "subject": "CHEBI:757370", "supporting_text": ["1 INDICATIONS AND USAGE DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ] . ( 1.2 ) adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.3 ) 1.1 Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. 1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinica"], "temporal_context_qualifier": "who have received prior EGFR-directed therapy and platinum-based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e43ecf7d-3564-5980-92a0-75823fac5122", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250117", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25c39abe-1a96-5430-9ffb-f8cd48942a4e", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [701, 714], "original_object": "breast cancer", "original_subject": "DATOPOTAMAB DERUXTECAN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2950227c-6230-4ca4-a135-46e44d9424a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2950227c-6230-4ca4-a135-46e44d9424a0"]}], "subject": "CHEBI:757370", "supporting_text": ["1 INDICATIONS AND USAGE DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ] . ( 1.2 ) adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.3 ) 1.1 Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. 1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinica"], "temporal_context_qualifier": "unresectable or metastatic; who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0005506", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2d128215-8c3e-5254-b9dd-d312b06ec2b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240321", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005506", "MONDO:0018881"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:90774e5b-37a1-5d1f-a8ef-a993b2cc6910", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b4590c5f-1276-5e81-9390-600d7a028c9b", "object": "MONDO:0001475", "object_location_in_text": [59, 70], "original_object": "neutropenia", "original_subject": "efbemalenograstim alfa", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ryzneuta", "https://www.ema.europa.eu/en/documents/product-information/ryzneuta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ryzneuta"]}], "subject": "CHEBI:757380", "supporting_text": ["Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)."], "temporal_context_qualifier": "treated with cytotoxic chemotherapy for malignancy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0005506", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55b3393d-5fe9-51bb-abdc-a0cfb5ec7df5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240321", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005506", "MONDO:0018881"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b4590c5f-1276-5e81-9390-600d7a028c9b", "object": "UMLS:C0746883", "object_location_in_text": [92, 111], "original_object": "febrile neutropenia", "original_subject": "efbemalenograstim alfa", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ryzneuta", "https://www.ema.europa.eu/en/documents/product-information/ryzneuta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ryzneuta"]}], "subject": "CHEBI:757380", "supporting_text": ["Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)."], "temporal_context_qualifier": "treated with cytotoxic chemotherapy for malignancy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff7273f0-1200-54d6-820c-aae0694c5d73", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["myelosuppressive anti-cancer drugs"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a930bbb-f91b-5967-82b3-5a7b42d70364", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b4590c5f-1276-5e81-9390-600d7a028c9b", "object": "UMLS:C0746883", "object_location_in_text": [104, 123], "original_object": "febrile neutropenia", "original_subject": "EFBEMALENOGRASTIM ALFA", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:290ed754-758c-9cae-e063-6294a90ae68b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=290ed754-758c-9cae-e063-6294a90ae68b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290ed754-758c-9cae-e063-6294a90ae68b"]}], "subject": "CHEBI:757380", "supporting_text": ["1. INDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inhibitors to blood coagulation factor VIII or factor IX", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:580988b5-5b49-5d3c-8ef5-b7b78d57d87e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140620", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:0b10912f-f947-5592-a32d-65050748fce5", "object": "MONDO:0002243", "object_location_in_text": [67, 84], "original_object": "bleeding tendency", "original_subject": "ANTI-INHIBITOR COAGULANT COMPLEX", "population_context_qualifier": "patients with inhibitors to blood coagulation factor VIII or factor IX", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ANTI-INHIBITOR COAGULANT COMPLEX#122-20140620", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:757383", "supporting_text": ["Drugs with a revised indication and a new dosage for inhibition of bleeding tendency by promoting the blood coagulation in the plasma in patients with inhibitors to blood coagulation factor VIII or factor IX."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000789", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c910100-657c-5b3c-9de2-7c1e900b04e8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000789"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0d3e26e7-ae3a-5c3a-a5ec-921ce19866c6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2c93446-d329-5eb8-85fd-1c35cc68cb74", "object": "HP:0000789", "original_object": "infertility", "original_subject": "FOLLITROPIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae85b9c3-e7eb-4981-a5d9-346050e8f189", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae85b9c3-e7eb-4981-a5d9-346050e8f189", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae85b9c3-e7eb-4981-a5d9-346050e8f189"]}], "subject": "CHEBI:757385", "supporting_text": ["1 INDICATIONS AND USAGE GONAL-f is indicated for: GONAL-f is a gonadotropin indicated for: Women: Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. ( 1.1 ) Development of multiple follicles in ovulatory infertile women as part of Assisted Reproductive Technology (ART) cycles. ( 1.2 ) Men: Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure. ( 1.3 ) 1.1 Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. 1.2 Development of multiple follicles in ovulatory infertile women as part of an assisted reproductive technology (ART) cycle. 1.3 Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure."], "temporal_context_qualifier": "as part of Assisted Reproductive Technology (ART) cycles"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "oligo-anovulatory infertility", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d761ebf-fb29-5fe0-86e2-3f52e2f16237", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5994c64e-43c7-5fd9-b8ea-af562c86adfe", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c2c93446-d329-5eb8-85fd-1c35cc68cb74", "object": "UMLS:C0029965", "original_object": "ovulation", "original_subject": "FOLLITROPIN", "population_context_qualifier": "women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ae85b9c3-e7eb-4981-a5d9-346050e8f189", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ae85b9c3-e7eb-4981-a5d9-346050e8f189", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae85b9c3-e7eb-4981-a5d9-346050e8f189"]}], "subject": "CHEBI:757385", "supporting_text": ["1 INDICATIONS AND USAGE GONAL-f is indicated for: GONAL-f is a gonadotropin indicated for: Women: Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. ( 1.1 ) Development of multiple follicles in ovulatory infertile women as part of Assisted Reproductive Technology (ART) cycles. ( 1.2 ) Men: Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure. ( 1.3 ) 1.1 Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. 1.2 Development of multiple follicles in ovulatory infertile women as part of an assisted reproductive technology (ART) cycle. 1.3 Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C5206655", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4403d832-6caa-51c5-bbfd-1dc6f011c2cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240419", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5206655", "MONDO:0019210"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ed390d4a-aae1-5aa0-9492-cbef6f8e45ab", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:f63f9107-cc9a-5ad2-8cff-be89efeff810", "object": "MONDO:0019210", "original_object": "Merkel cell carcinoma", "original_subject": "retifanlimab", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zynyz", "https://www.ema.europa.eu/en/documents/product-information/zynyz-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zynyz"]}], "subject": "CHEBI:757460", "supporting_text": ["Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC)&nbsp; Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy."], "temporal_context_qualifier": "not amenable to curative surgery or radiation therapy :: not amenable to curative surgery or radiation therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "deep partial thickness thermal burns, full thickness thermal burns", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7577e0b-db1a-5cce-94a7-8a04728cfe12", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e784c141-ff15-57ed-b242-8777e62b2c6f", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:717853d5-a464-5e99-8ddd-87541d36b2eb", "object": "HP:6000793", "original_object": "eschar", "original_subject": "ANACAULASE-BCDB", "population_context_qualifier": "adults and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a2f23ad-78ef-43fa-9864-6bd77aac9e57", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a2f23ad-78ef-43fa-9864-6bd77aac9e57", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a2f23ad-78ef-43fa-9864-6bd77aac9e57"]}], "subject": "CHEBI:757477", "supporting_text": ["1 INDICATIONS AND USAGE NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "dystrophin gene deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:788bfafe-3e56-5cf5-8335-5fd68cbea6b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200325", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d5793552-462d-5b5a-a70d-7ab5a7d1ade7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8a156782-e522-50f0-b5f6-b27502728c82", "object": "MONDO:0010679", "original_object": "Duchenne muscular dystrophy", "original_subject": "VILTOLARSEN", "population_context_qualifier": "patients with confirmed deficiency of the dystrophin gene amenable to exon 53 skipping therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VILTOLARSEN#70-20200325", "https://www.pmda.go.jp/files/000237467.pdf"]}], "subject": "CHEBI:757485", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of Duchenne muscular dystrophy (DMD) with a confirmed deficiency of the dystrophin gene amenable to exon 53 skipping therapy. [SAKIGAKE designation] [Conditional early approval]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inadequate secretion of endogenous growth hormone", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b943da1-db5d-54ed-8d80-87ff079ed647", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:696b931c-7dae-58fd-8ac6-eaadddf86483", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9c1c476d-7cca-5f01-803c-35b8a4989abb", "object": "HP:0001510", "object_location_in_text": [188, 202], "original_object": "growth failure", "original_subject": "LONAPEGSOMATROPIN", "population_context_qualifier": "pediatric patients 1 year and older who weigh at least 11.5 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9229f871-bc61-4ddc-8122-d126d40e36ac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9229f871-bc61-4ddc-8122-d126d40e36ac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9229f871-bc61-4ddc-8122-d126d40e36ac"]}], "subject": "CHEBI:757592", "supporting_text": ["1 INDICATIONS AND USAGE SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH). Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). SKYTROFA is a human growth hormone indicated for: Pediatric Patients: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH) ( 1 ). Adults: Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001510", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57edb978-3179-57e2-8910-91f20706aa7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220111", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001510"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2c8d2d07-01d5-593a-a89c-62c2920993f9", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9c1c476d-7cca-5f01-803c-35b8a4989abb", "object": "HP:0034323", "original_object": "growth hormone deficiency", "original_subject": "lonapegsomatropin", "population_context_qualifier": "children and adolescents aged from 3 years up to 18 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:skytrofa", "https://www.ema.europa.eu/en/documents/product-information/skytrofa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa"]}], "subject": "CHEBI:757592", "supporting_text": ["Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-hemodialysis dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3259d9bb-07ee-5b4d-813f-af1c7fdd16e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200116", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b8a7e39-d7f6-5422-8b7d-ba770505f2f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0080953a-44c3-572c-bba1-648d329a768f", "object": "MONDO:0001356", "object_location_in_text": [69, 91], "original_object": "iron deficiency anemia", "original_subject": "FERRIC DERISOMALTOSE", "population_context_qualifier": "adult patients who have non-hemodialysis dependent chronic kidney disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55859d2d-0456-4fa9-b41f-f535accc97db", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55859d2d-0456-4fa9-b41f-f535accc97db", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55859d2d-0456-4fa9-b41f-f535accc97db"]}], "subject": "CHEBI:757594", "supporting_text": ["1 INDICATIONS AND USAGE Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD) MONOFERRIC is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron. ( 1 ) who have non-hemodialysis dependent chronic kidney disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001878", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:976284c8-a3c5-5273-bd73-ef7b4372e408", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20211213", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001878"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c3bf2c21-c492-5c7a-81a4-8ba4ad50b7a6", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:02fd909d-8fb1-5e11-9743-c1ab0d398215", "object": "MONDO:0100244", "object_location_in_text": [77, 113], "original_object": "paroxysmal nocturnal haemoglobinuria", "original_subject": "pegcetacoplan", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aspaveli", "https://www.ema.europa.eu/en/documents/product-information/aspaveli-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli"]}], "subject": "CHEBI:757617", "supporting_text": ["Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pyruvate kinase (PK) deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50d37f8c-ab15-55a5-a164-adb09ae40ddc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:439464e0-4172-5d7b-a1a2-33b0d5454c08", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:38fa4cb6-8e26-5755-b145-d9d68b3e8793", "object": "MONDO:0003664", "object_location_in_text": [67, 83], "original_object": "hemolytic anemia", "original_subject": "MITAPIVAT", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ccee896-e313-4c6c-9674-b4746ada0a90", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ccee896-e313-4c6c-9674-b4746ada0a90", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ccee896-e313-4c6c-9674-b4746ada0a90"]}], "subject": "CHEBI:757622", "supporting_text": ["1 INDICATIONS AND USAGE PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR exon 19 deletions or exon 21 L858R substitution mutations", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f414b562-e126-5b88-b92e-5d823887469d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250120", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["amivantamab"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1714358f-f7ba-5d82-a059-2d4f4f999d48", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:e6eb975a-a666-590f-9612-238d5948cf3b", "object": "MONDO:0005233", "original_object": "advanced non-small cell lung cancer", "original_subject": "lazertinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lazcluze", "https://www.ema.europa.eu/en/documents/product-information/lazcluze-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze"]}], "subject": "CHEBI:757712", "supporting_text": ["Lazcluze in combination with amivantamab is indicated for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11b360bf-cd78-5dff-9fde-27d56c49375d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240819", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["amivantamab"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6eb975a-a666-590f-9612-238d5948cf3b", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "LAZERTINIB", "population_context_qualifier": "adult patients with locally advanced or metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c417f9ee-2027-4ed5-92ad-3c19266de16c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c417f9ee-2027-4ed5-92ad-3c19266de16c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c417f9ee-2027-4ed5-92ad-3c19266de16c"]}], "subject": "CHEBI:757712", "supporting_text": ["1 INDICATIONS AND USAGE LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced or metastatic RET fusion-positive thyroid cancer, radioactive iodine refractory", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d6fa84b-68dd-51bd-82ca-aee62196acd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240516", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:ed4ffe7a-c2c4-5332-a158-787596a0c7ab", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0431bc25-3036-5784-8864-e0c3a49d2dab", "object": "MONDO:0002108", "object_location_in_text": [193, 207], "original_object": "thyroid cancer", "original_subject": "Selpercatinib Capsules 40 mg & 80mg", "population_context_qualifier": "Adult and pediatric patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:757714", "supporting_text": [" Adult patients with metastatic RET fusion-positive non-small cell lung cancer(NSCLC)  Adult and pediatric patients 12 years of age and older with advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy.  Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory(if radioative iodine is appropriate)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "radioactive iodine-refractory status", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2206a5d-dcec-5079-976c-8cdfa8a69057", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210211", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ed4ffe7a-c2c4-5332-a158-787596a0c7ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "object": "MONDO:0002108", "original_object": "thyroid cancer", "original_subject": "selpercatinib", "population_context_qualifier": "adults and adolescents 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:retsevmo", "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"]}], "subject": "CHEBI:757714", "supporting_text": ["Retsevmo as monotherapy is indicated for the treatment of adults with:&nbsp;  advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)  Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with:  advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) advanced RET mutant medullary thyroid cancer (MTC)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4526511", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd1f0bf4-7af4-59b1-be2c-273a6a166a34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200508", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4526511"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ed4ffe7a-c2c4-5332-a158-787596a0c7ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "medic_supporting_text_truncated": true, "object": "MONDO:0002108", "object_location_in_text": [367, 381], "original_object": "thyroid cancer", "original_subject": "SELPERCATINIB", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828"]}], "subject": "CHEBI:757714", "supporting_text": ["1 INDICATIONS AND USAGE RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options ( 1.4 ) 1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. 1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. 1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). 1.4 Other RET Fusion-Positive Solid Tumo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "metastatic RET fusion-positive non-small cell lung cancer", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04aa4e25-7a18-5ae4-8b6d-fae19e3afa24", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240516", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0431bc25-3036-5784-8864-e0c3a49d2dab", "object": "MONDO:0005233", "object_location_in_text": [53, 79], "original_object": "non-small cell lung cancer", "original_subject": "Selpercatinib Capsules 40 mg & 80mg", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:757714", "supporting_text": [" Adult patients with metastatic RET fusion-positive non-small cell lung cancer(NSCLC)  Adult and pediatric patients 12 years of age and older with advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy.  Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory(if radioative iodine is appropriate)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RET fusion positive status", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:674d59c0-7965-567d-afbe-05bd8bf4f433", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210211", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "selpercatinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:retsevmo", "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"]}], "subject": "CHEBI:757714", "supporting_text": ["Retsevmo as monotherapy is indicated for the treatment of adults with:&nbsp;  advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)  Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with:  advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) advanced RET mutant medullary thyroid cancer (MTC)"], "temporal_context_qualifier": "not previously treated with a RET inhibitor"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4526511", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4a14a82-1d86-5ea0-a4ff-bcf533e16319", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200508", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4526511"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "SELPERCATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828"]}], "subject": "CHEBI:757714", "supporting_text": ["1 INDICATIONS AND USAGE RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options ( 1.4 ) 1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. 1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. 1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). 1.4 Other RET Fusion-Positive Solid Tumo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced or metastatic RET mutant medullary thyroid cancer", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33d0f329-afbc-533a-bc84-27c19ab319ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240516", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:92f1060b-9d24-5976-b4a6-002808bfd153", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0431bc25-3036-5784-8864-e0c3a49d2dab", "object": "MONDO:0015277", "object_location_in_text": [183, 207], "original_object": "medullary thyroid cancer", "original_subject": "Selpercatinib Capsules 40 mg & 80mg", "population_context_qualifier": "Adult and pediatric patients 12 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:757714", "supporting_text": [" Adult patients with metastatic RET fusion-positive non-small cell lung cancer(NSCLC)  Adult and pediatric patients 12 years of age and older with advanced or metastatic RET mutant medullary thyroid cancer (MTC) who require systemic therapy.  Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory(if radioative iodine is appropriate)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RET mutant status", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7d62cca-417d-56f5-bad4-9d20468170ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210211", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:92f1060b-9d24-5976-b4a6-002808bfd153", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "object": "MONDO:0015277", "original_object": "medullary thyroid cancer", "original_subject": "selpercatinib", "population_context_qualifier": "adults and adolescents 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:retsevmo", "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"]}], "subject": "CHEBI:757714", "supporting_text": ["Retsevmo as monotherapy is indicated for the treatment of adults with:&nbsp;  advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)  Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with:  advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) advanced RET mutant medullary thyroid cancer (MTC)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "RET mutation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b38ae2dc-b4c3-5782-8bd3-35b742ba1619", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200508", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92f1060b-9d24-5976-b4a6-002808bfd153", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "medic_supporting_text_truncated": true, "object": "MONDO:0015277", "original_object": "medullary thyroid cancer", "original_subject": "SELPERCATINIB", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828"]}], "subject": "CHEBI:757714", "supporting_text": ["1 INDICATIONS AND USAGE RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options ( 1.4 ) 1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. 1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. 1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). 1.4 Other RET Fusion-Positive Solid Tumo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RET fusion positive status", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bd718ef-70f9-5cb6-b06e-ff727e6e571f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210211", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c09d50f2-5522-5394-8bab-61cdacd994d3", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "object": "UMLS:C0280100", "original_object": "solid tumors", "original_subject": "selpercatinib", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:retsevmo", "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"]}], "subject": "CHEBI:757714", "supporting_text": ["Retsevmo as monotherapy is indicated for the treatment of adults with:&nbsp;  advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)  Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with:  advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) advanced RET mutant medullary thyroid cancer (MTC)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4526511", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1911277-8598-5822-9a94-f109496f2c75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200508", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4526511"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c09d50f2-5522-5394-8bab-61cdacd994d3", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a85e6511-4060-57e1-ad70-d80413ac8c34", "medic_supporting_text_truncated": true, "object": "UMLS:C0280100", "object_location_in_text": [849, 861], "original_object": "solid tumors", "original_subject": "SELPERCATINIB", "population_context_qualifier": "adult and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828"]}], "subject": "CHEBI:757714", "supporting_text": ["1 INDICATIONS AND USAGE RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options ( 1.4 ) 1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. 1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. 1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). 1.4 Other RET Fusion-Positive Solid Tumo"], "temporal_context_qualifier": "progressed on or following prior systemic treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "RET fusion-positive status", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f25adfb-9f49-5c71-8fb2-c30d2b897935", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:399c88ff-8f2f-5599-aae2-041956270e3b", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fe942f24-7fff-5cd8-a135-0e2dfd35c8cc", "object": "UMLS:C0278987", "original_object": "metastatic non-small cell lung cancer", "original_subject": "Pralsetinib Capsule 100mg", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:757728", "supporting_text": ["• Indicated for the treatment of adult patients with metastatic rearranged during transfection (RET)fusion-positive non- small cell lung cancer.,."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Clinical stage T1c or T2a, Gleason Score ≤ 6, PSA ≤ 10 ng/mL", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:863d52a0-9fed-5b32-b039-d6c094ca34c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171110", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ef67221a-1ee2-57eb-a8bf-25db75156761", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:19c75a95-213a-5e4c-8469-f6fde5fef03c", "object": "MONDO:0005082", "object_location_in_text": [103, 133], "original_object": "adenocarcinoma of the prostate", "original_subject": "padeliporfin", "population_context_qualifier": "adult patients with previously untreated, unilateral, low risk adenocarcinoma of the prostate with a life expectancy ≥ 10 years", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tookad", "https://www.ema.europa.eu/en/documents/product-information/tookad-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tookad"]}], "subject": "CHEBI:757787", "supporting_text": ["Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ? 10 years and:  Clinical stage T1c or T2a; Gleason Score ? 6, based on high-resolution biopsy strategies; PSA ? 10 ng/mL; 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ? 50 % cancer involvement in any one core or a PSA density ? 0.15 ng/mL/cm³."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0004818", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fa3f73a-434a-50b0-aeec-b33b6472dc1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240822", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["complement component 5 (C5) inhibitor"], "medic_disease_context_ids": ["HP:0004818"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c3bf2c21-c492-5c7a-81a4-8ba4ad50b7a6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:3b95e92c-eae1-5b7d-ac2a-d4af792fca8d", "object": "MONDO:0100244", "original_object": "paroxysmal nocturnal haemoglobinuria", "original_subject": "crovalimab", "population_context_qualifier": "adult and paediatric patients 12 years of age or older with a weight of 40 kg and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:piasky", "https://www.ema.europa.eu/en/documents/product-information/piasky-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/piasky"]}], "subject": "CHEBI:757815", "supporting_text": ["Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):  In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months."], "temporal_context_qualifier": "after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acid α-glucosidase deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8c9d6a6-c6d2-5f67-a988-2fc16e32bd89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220624", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:260d126e-1183-59b8-86f3-f7f8c425a7a1", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:07594760-fb9e-5447-8732-be9e48548f67", "object": "MONDO:0009290", "object_location_in_text": [123, 136], "original_object": "Pompe disease", "original_subject": "avalglucosidase alfa", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:nexviadyme", "https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/nexviadyme"]}], "subject": "CHEBI:757819", "supporting_text": ["Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency)."], "temporal_context_qualifier": "long-term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "MET exon 14 skipping mutation-positive, unresectable advanced or recurrent", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ff3530e-7e7a-52f9-9918-a8f5e80ca293", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240624", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:4924faf7-ec2e-5404-b587-1a6ae39ec66c", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "GUMARONTINIB HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:GUMARONTINIB HYDRATE#15-20240624", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:757889", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent MET exon 14 (METex14) skipping mutation-positive non- small cell lung cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4721208", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ba5e797-1edf-5c62-b5c0-a7c0bf27d899", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20221209", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["androgen deprivation therapy (ADT)", "androgen receptor (AR) pathway inhibition"], "medic_disease_context_ids": ["UMLS:C4721208", "UMLS:C4727274"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:944682f0-a69f-5723-89bf-3612c67533f6", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6f870ccc-56ae-5112-9c94-5034f46ebda2", "object": "UMLS:C4721208", "original_object": "metastatic castration-resistant prostate cancer", "original_subject": "lutetium (177Lu) vipivotide tetraxetan", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pluvicto", "https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto"]}], "subject": "CHEBI:757895", "supporting_text": ["Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy."], "temporal_context_qualifier": "who have been treated with AR pathway inhibition and taxane based chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital antithrombin deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05b050e9-c104-588e-ad97-30d40e7fe202", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150703", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:745d34e0-904d-5eeb-a2fd-598905fe3b36", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5669651c-bff0-545c-857c-adac2eba58c4", "object": "MONDO:0001243", "original_object": "disseminated intravascular coagulation", "original_subject": "ANTITHROMBIN GAMMA", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ANTITHROMBIN GAMMA#113-20150703", "https://www.pmda.go.jp/files/000216795.pdf"]}], "subject": "CHEBI:757939", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of thrombophilia due to congenital antithrombin (AT) deficiency (CAD) and disseminated intravascular coagulation (DIC) accompanied by a decrease in AT."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hereditary transthyretin-mediated amyloidosis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff0a86c5-8965-546e-9e85-8c8ab96d5ea5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220613", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:999a156d-ae6a-50f3-be83-33d95aa4d116", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fe44f32e-5786-5682-8d1e-5aea61bd38b1", "object": "MONDO:0001824", "original_object": "polyneuropathy", "original_subject": "VUTRISIRAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8db0facb-81b6-4006-9239-27dc6409c5d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8db0facb-81b6-4006-9239-27dc6409c5d3"]}], "subject": "CHEBI:757985", "supporting_text": ["1 INDICATIONS AND USAGE AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) 1.1 Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. 1.2 Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blood coagulation factor VIII deficiency", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10062774-762a-5319-90ca-7d0d2e20d89b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171130", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3d81ba55-cc59-5a45-9e4c-dfb9d1310e79", "object": "MONDO:0002243", "object_location_in_text": [74, 91], "original_object": "bleeding tendency", "original_subject": "RURIOCTOCOG ALFA PEGOL", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RURIOCTOCOG ALFA PEGOL#96-20171130", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:758057", "supporting_text": ["Drugs with a new additional pediatric dosage indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blood coagulation factor VIII deficiency", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1dc3d055-0fe5-5f54-a7b2-52509d85a0f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230626", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3d81ba55-cc59-5a45-9e4c-dfb9d1310e79", "object": "MONDO:0002243", "object_location_in_text": [53, 70], "original_object": "bleeding tendency", "original_subject": "RURIOCTOCOG ALFA PEGOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RURIOCTOCOG ALFA PEGOL#30-20230626", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:758057", "supporting_text": ["Drugs with a new dosage indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C5418984", "has_confidence_score": 0.85, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c3272ee-f664-559f-8f97-4587df3e98de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240801", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5418984"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d0809921-a87e-55d4-bb0a-845c0340bfb0", "medic_pair_confidence": 0.85, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:cc84ca24-822f-5839-a08a-d353bdd88348", "object": "MONDO:0010122", "object_location_in_text": [13, 59], "original_object": "congenital thrombotic thrombocytopenic purpura", "original_subject": "rADAMTS13", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:adzynma", "https://www.ema.europa.eu/en/documents/product-information/adzynma-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/adzynma"]}], "subject": "CHEBI:758079", "supporting_text": ["Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3161650", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a164ee7-f65d-52b4-b826-c3375c705212", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251125", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C3161650"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b92669c6-1a55-5a06-85d7-4b8291589e19", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:993bfd03-e923-5e0a-ba3d-49f10f065385", "object": "MONDO:0003634", "object_location_in_text": [55, 66], "original_object": "proteinuria", "original_subject": "SIBEPRENLIMAB", "population_context_qualifier": "adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8a93b32-0676-4704-86dc-cb65f425c6e5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8a93b32-0676-4704-86dc-cb65f425c6e5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8a93b32-0676-4704-86dc-cb65f425c6e5"]}], "subject": "CHEBI:758086", "supporting_text": ["1 INDICATIONS AND USAGE VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. VOYXACT is an A Proliferation Inducing Ligand (APRIL) blocker, indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. ( 1 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "relapsed or refractory B-cell precursor acute lymphoblastic leukaemia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f41a5f32-3db3-5eb0-8a9c-2ba72aa1da72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20201214", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:99b9bb22-5bb9-51d1-9eec-f1134c206235", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:9897ef89-b426-5899-9b69-f8f8339f33f7", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukaemia", "original_subject": "brexucabtagene autoleucel", "population_context_qualifier": "adult patients 26 years of age and above", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tecartus", "https://www.ema.europa.eu/en/documents/product-information/tecartus-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus"]}], "subject": "CHEBI:758090", "supporting_text": ["Mantle cell lymphoma Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Acute lymphoblastic leukaemia Tecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b78b1004-20df-5593-bb8b-8d2b9d20c7f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250718", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "fulvestrant"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:56ad3e13-b8f1-59e0-b14b-78dbd189b4b2", "object": "MONDO:0007254", "object_location_in_text": [208, 221], "original_object": "breast cancer", "original_subject": "inavolisib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:itovebi", "https://www.ema.europa.eu/en/documents/product-information/itovebi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/itovebi"]}], "subject": "CHEBI:758122", "supporting_text": ["Itovebi, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment (see section 5.1).&nbsp;Patients previously treated with a CDK 4/6 inhibitor in the (neo)adjuvant setting should have had an interval of at least 12 months between termination of CDK 4/6 inhibitor treatment and the detection of recurrence. In pre/perimenopausal women and in men, endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist."], "temporal_context_qualifier": "following recurrence on or within 12 months of completing adjuvant endocrine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f54764f-85eb-54d6-96f1-bec73c215f83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241010", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["palbociclib", "fulvestrant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:56ad3e13-b8f1-59e0-b14b-78dbd189b4b2", "object": "MONDO:0007254", "object_location_in_text": [256, 300], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "INAVOLISIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5de59f5b-e5db-410f-b692-658686ef4107", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107"]}], "subject": "CHEBI:758122", "supporting_text": ["1 INDICATIONS AND USAGE ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1) ] . ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. ( 1 , 14.1 )"], "temporal_context_qualifier": "following recurrence on or after completing adjuvant endocrine therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HER2-positive biliary tract cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dae0a8a8-1e28-5adb-9edb-c361ee1feac7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250627", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4a4cfcdb-7c87-5997-9b5b-d8541c93b342", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:79522f86-123c-56f6-b0d4-715e1ea54fbe", "object": "MONDO:0003060", "original_object": "biliary tract cancer", "original_subject": "zanidatamab", "population_context_qualifier": "adults; previously treated with at least one prior line of systemic therapy; unresectable locally advanced or metastatic disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ziihera", "https://www.ema.europa.eu/en/documents/product-information/ziihera-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ziihera"]}], "subject": "CHEBI:758162", "supporting_text": ["Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indolent lymphoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c16d1995-a8e2-55df-91cb-be658806a475", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:833318d1-4cbf-5317-aa83-6bba2a5b4720", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2c877c03-2445-5fc3-8b5d-254a628691b5", "object": "MONDO:0018905", "original_object": "diffuse large B-cell lymphoma", "original_subject": "EPCORITAMAB", "population_context_qualifier": "adult patients with relapsed or refractory disease after two or more lines of systemic therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7836711-b677-412d-bf2d-0f7c8444103a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a"]}], "subject": "CHEBI:758284", "supporting_text": ["1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "follicular lymphoma (Grade 1 to Grade 3 A)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2b75e85-6f25-5379-b797-32d9b5839ce3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:2c877c03-2445-5fc3-8b5d-254a628691b5", "object": "MONDO:0018906", "object_location_in_text": [78, 97], "original_object": "follicular lymphoma", "original_subject": "EPCORITAMAB", "population_context_qualifier": "patients with relapsed or refractory disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EPCORITAMAB#18-20250220", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:758284", "supporting_text": ["Drugs with a new dosage indicated for the treatment of relapsed or refractory follicular lymphoma (Grade 1 to Grade 3 A)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR exon 19 deletions or exon 21 (L858R) substitution mutations", "has_confidence_score": 0.6375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbafc5dc-3015-5721-bc14-486de2b0719c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20260212", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1714358f-f7ba-5d82-a059-2d4f4f999d48", "medic_pair_confidence": 0.6375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d0c6cb05-51b9-54d5-ba41-d59f66607d52", "object": "MONDO:0005233", "original_object": "advanced non-small cell lung cancer", "original_subject": "Aumolertinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aumseqa", "https://www.ema.europa.eu/en/documents/product-information/aumseqa-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aumseqa"]}], "subject": "CHEBI:758431", "supporting_text": ["Aumseqa as monotherapy is indicated for:- the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC)whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (forbiomarker-based patient selection, see section 4.2).- the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC (forbiomarker-based patient selection, see section 4.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0472699", "has_confidence_score": 0.513, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:081cd0d4-86e2-53af-9059-84410a62d4e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240326", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0472699"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:4e1dbbe6-be2b-5b07-b7e5-3f9b2f042c38", "medic_pair_confidence": 0.513, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6360b974-9758-538e-8ef3-9cb902e4b2a4", "object": "MONDO:0020547", "object_location_in_text": [67, 100], "original_object": "chronic graft-versus-host disease", "original_subject": "BELUMOSUDIL MESILATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:BELUMOSUDIL MESILATE#21-20240326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:758454", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective)."], "temporal_context_qualifier": "after hematopoietic stem cell transplantation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0062fb86-5563-5808-9906-7aa148e0fd91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250423", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a1383048-7b51-54ef-be3f-d2b5dea9a01b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:91581571-7d7d-5359-a52b-ea7f7e5f6701", "object": "HP:0006775", "object_location_in_text": [76, 92], "original_object": "multiple myeloma", "original_subject": "linvoseltamab", "population_context_qualifier": "adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynozyfic", "https://www.ema.europa.eu/en/documents/product-information/lynozyfic-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynozyfic"]}], "subject": "CHEBI:758940", "supporting_text": ["Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f713d7dd-1f34-57b9-9fef-accc081a58d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250702", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2db0fb84-7ac6-5e5d-b435-05b336e4a3be", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:91581571-7d7d-5359-a52b-ea7f7e5f6701", "object": "HP:0006775", "object_location_in_text": [88, 127], "original_object": "relapsed or refractory multiple myeloma", "original_subject": "LINVOSELTAMAB", "population_context_qualifier": "adult patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9fd0739-1b3f-4b8b-824a-1f0a902384d3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9fd0739-1b3f-4b8b-824a-1f0a902384d3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9fd0739-1b3f-4b8b-824a-1f0a902384d3"]}], "subject": "CHEBI:758940", "supporting_text": ["1 INDICATIONS AND USAGE LYNOZYFIC is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). LYNOZYFIC is a bispecific B-cell maturation antigen (BCMA)‑directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b03d3d9b-d42d-5c2a-b672-e4b4fe3aba26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000969", "object_location_in_text": [435, 440], "original_object": "edema", "original_subject": "POLYMYXIN B", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83"]}], "subject": "CHEBI:759086", "supporting_text": ["For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae , Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . This product does not provide adequate coverage against: Serratia marcescens and S treptococci , including Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indwelling catheter use", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3205e35a-fc68-5ffe-89f8-0785284119ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f0c7cff9-e4ce-59be-8966-a55ba176ade4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0001882", "object_location_in_text": [204, 215], "original_object": "bacteriuria", "original_subject": "POLYMYXIN B", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb"]}], "subject": "CHEBI:759086", "supporting_text": ["Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters. If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated."], "temporal_context_qualifier": "short-term use (up to 10 days)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indwelling catheter use", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32c2c834-ed42-5670-8e32-450cd7ac268a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4bce3326-12d0-5efe-9c3d-f71535cc2cc2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0005550", "original_object": "infection", "original_subject": "POLYMYXIN B", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb"]}], "subject": "CHEBI:759086", "supporting_text": ["Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters. If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "indwelling catheter use", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a260e41-da72-5a27-93be-4caadaaef17b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:158b5a8b-e255-57a3-acd1-510c567d33ab", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0100338", "original_object": "urinary tract infection", "original_subject": "POLYMYXIN B", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2f47d77-efd3-4c84-a364-08fb6d9978eb"]}], "subject": "CHEBI:759086", "supporting_text": ["Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters. Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters. If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13be9c4e-51f8-5088-8f87-376640d01b78", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "UMLS:C0021368", "object_location_in_text": [445, 457], "original_object": "inflammation", "original_subject": "POLYMYXIN B", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=191c1a56-194f-4876-b501-2f8aee447d83"]}], "subject": "CHEBI:759086", "supporting_text": ["For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae , Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . This product does not provide adequate coverage against: Serratia marcescens and S treptococci , including Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0673b08-a925-5239-be84-e138bf25feae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200330", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:7e401fc1-c75e-505e-a12e-ce22cb111a4a", "object": "HP:0000010", "object_location_in_text": [495, 519], "original_object": "urinary tract infections", "original_subject": "Polymyxin B for injection 500000 IU", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:759086", "supporting_text": ["Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Ps. Aeruginosa. It may also be used as subconjuctival infection in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa. It may be indicated in serious infections caused by susceptibel strains of the following organisms, 1. H. influenzae, specifically meningeal infections 2. Escherichia coli, specifically urinary tract infections 3. Aerobacter aerogenes, specifically bacteremia 4. Klebsiella pneumoniae, specifically bacteremia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02641eef-74b6-50b5-88ac-394b27cb1eec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [638, 662], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a6e0431-fc98-5037-9fcd-92af5b558c5c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [639, 663], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia. Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bf195c2-6226-50c2-bb12-5b853d2c28cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [638, 662], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30691725-cdd2-5caf-bc23-1205cbb9ccbc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [638, 662], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1f1c158-5267-5a39-a3c5-03e9f6c68d64", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [638, 662], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d702c430-8df5-56be-b643-9a24b361efd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [639, 663], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0014834", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:def129a8-1604-504c-a978-ba2e3bb8a344", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0014834"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56fbba81-5ee2-5398-91b0-f838e5cd4718", "medic_pair_confidence": 0.927162, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0000010", "object_location_in_text": [639, 663], "original_object": "urinary tract infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:881f5703-97a4-5303-9c14-8038dfec8d81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200330", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:7e401fc1-c75e-505e-a12e-ce22cb111a4a", "object": "HP:0031864", "object_location_in_text": [558, 568], "original_object": "bacteremia", "original_subject": "Polymyxin B for injection 500000 IU", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:759086", "supporting_text": ["Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Ps. Aeruginosa. It may also be used as subconjuctival infection in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa. It may be indicated in serious infections caused by susceptibel strains of the following organisms, 1. H. influenzae, specifically meningeal infections 2. Escherichia coli, specifically urinary tract infections 3. Aerobacter aerogenes, specifically bacteremia 4. Klebsiella pneumoniae, specifically bacteremia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36d82442-c2b1-5421-a5aa-c2dce6daf52c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [699, 709], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46a3aff6-f412-5531-bec6-6962f1498c12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [701, 711], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e1aff87-0878-5efd-ae6e-88da47bc45dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [700, 710], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91412c23-1fc8-5ba6-a4e6-af81fae91879", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [700, 710], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc87a422-bff1-5641-8470-236b2bafc762", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [699, 709], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd7f5c04-a723-5f8b-b6e2-a4a6b3c07e17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [700, 710], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia. Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2712605", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7fe7614-da6a-577f-b947-d01d3a4b8320", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2712605"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9d235261-faa1-5664-a363-f8acc5da431d", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "HP:0031864", "object_location_in_text": [701, 711], "original_object": "bacteremia", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "surface ocular bacterial infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f7c6de1-25f2-5d08-9c81-0f430817d515", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4da4d7e-4579-5344-a2ff-0a15d8e749a1", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0002307", "object_location_in_text": [178, 200], "original_object": "blepharoconjunctivitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac"]}], "subject": "CHEBI:759086", "supporting_text": ["Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * * Efficacy for this organism in this organ system was studied in fewer than 10 infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "surface ocular bacterial infections", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98a815e4-e699-5ca3-8807-cca8460e31dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:16232c6e-0732-543d-91b1-5f82e5b94e82", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0006668", "object_location_in_text": [142, 172], "original_object": "acute bacterial conjunctivitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c68818b2-d849-41d2-be07-731244afbbac"]}], "subject": "CHEBI:759086", "supporting_text": ["Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * * Efficacy for this organism in this organ system was studied in fewer than 10 infections."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6929e937-b477-5a57-968b-37d5995d258c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200330", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:7e401fc1-c75e-505e-a12e-ce22cb111a4a", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "Polymyxin B for injection 500000 IU", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:759086", "supporting_text": ["Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Ps. Aeruginosa. It may also be used as subconjuctival infection in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa. It may be indicated in serious infections caused by susceptibel strains of the following organisms, 1. H. influenzae, specifically meningeal infections 2. Escherichia coli, specifically urinary tract infections 3. Aerobacter aerogenes, specifically bacteremia 4. Klebsiella pneumoniae, specifically bacteremia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:082f6173-86d9-5ffb-ad69-ac9cd96a4c22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ffe71a6-c7a4-57ee-8bdc-d6e6160db456", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14eb16ce-49ce-58f1-8138-bdaa33413331", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia. Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34cf587f-0755-58dc-8d9e-c274cf17f8b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87d253fe-15de-52c9-bc7d-0ba281a92e7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af0dab65-6422-5fb4-b0a8-82b596244c6a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c721c87c-dcc0-55d6-b9ab-826cc5debbb2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.98, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0021108", "original_object": "meningitis", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59c68a97-3a95-573f-ba1b-a5ffc018a118", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200330", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:7e401fc1-c75e-505e-a12e-ce22cb111a4a", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "Polymyxin B for injection 500000 IU", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:759086", "supporting_text": ["Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Ps. Aeruginosa. It may also be used as subconjuctival infection in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa. It may be indicated in serious infections caused by susceptibel strains of the following organisms, 1. H. influenzae, specifically meningeal infections 2. Escherichia coli, specifically urinary tract infections 3. Aerobacter aerogenes, specifically bacteremia 4. Klebsiella pneumoniae, specifically bacteremia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b110d0a-ddf6-5633-9c11-8df50cbbe013", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd664927-db58-a1af-e053-6294a90a9048"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b4fb666-66a7-591e-89b2-fbd3baf3a92f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72dd6de6-31d6-4a8f-881b-91af91ed9314"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia. Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5759bdc8-4959-53e4-9f31-b373fb41de5e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2bf65f6-2763-4859-a665-ad5e6cde71ee"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:647fe2d5-06c0-51df-896b-1652a0172ecd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia . Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89af9556-9e0b-5560-a91d-14168b2b6197", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18daf0d1-b6f5-46f4-ab2f-01a594f3959c"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aabc912a-631d-5175-be06-cf1cc502e4ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a974c557-e88f-451b-a1bd-d2c656be226e"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0033809", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c670b510-76ec-5df9-8d29-27de1656e6e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce43afea-a8b7-5a10-a4f4-71485d79ecfa", "medic_pair_confidence": 0.9468, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5f43cf95-eaf9-5ae7-a6bf-fd86d52dd4ea", "object": "MONDO:0043885", "original_object": "eye infections", "original_subject": "POLYMYXIN B", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7dc505aa-64b0-4b7f-8ee3-2945bde40a34"]}], "subject": "CHEBI:759086", "supporting_text": ["Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2 (ERBB2) tyrosine kinase domain activating mutations", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24fc4f0b-77bd-5326-bdfd-62788cde5b8d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250808", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53c694df-6603-5a50-9e5b-18be84ae3f04", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "ZONGERTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d3fabf12-354e-4e5c-b5de-20fdb579b783", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d3fabf12-354e-4e5c-b5de-20fdb579b783", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d3fabf12-354e-4e5c-b5de-20fdb579b783"]}], "subject": "CHEBI:759202", "supporting_text": ["1 INDICATIONS AND USAGE HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. HERNEXEOS is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. ( 1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )"], "temporal_context_qualifier": "unresectable or metastatic"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2939459", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c6ee710-13de-59ff-b597-162abb3165fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050819", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2939459"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:058a5110-9a8b-57db-8939-8076298ae1fd", "object": "HP:0012531", "object_location_in_text": [90, 94], "original_object": "pain", "original_subject": "NEPAFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52fe0332-388a-451c-b759-97e760883837", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52fe0332-388a-451c-b759-97e760883837", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52fe0332-388a-451c-b759-97e760883837"]}], "subject": "CHEBI:75922", "supporting_text": ["1 INDICATIONS AND USAGE NEVANAC ® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC ® ophthalmic suspension is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2939459", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f4a857b-72f2-5d28-8780-f8fb0dee23cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050819", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2939459"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7cf7c8da-96fc-5942-a632-5901934a3dbf", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:058a5110-9a8b-57db-8939-8076298ae1fd", "object": "HP:0100533", "original_object": "ocular inflammation", "original_subject": "NEPAFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2909252-c5f1-421f-9073-b7be90b45b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2909252-c5f1-421f-9073-b7be90b45b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2909252-c5f1-421f-9073-b7be90b45b51"]}], "subject": "CHEBI:75922", "supporting_text": ["1 INDICATIONS AND USAGE NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2939459", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f14d8341-e45a-570e-b88f-03764cee59ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050819", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2939459"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f086a2a5-0de4-52ca-819b-1acb8e263e5c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:058a5110-9a8b-57db-8939-8076298ae1fd", "object": "HP:0200026", "original_object": "ocular pain", "original_subject": "NEPAFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a2909252-c5f1-421f-9073-b7be90b45b51", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a2909252-c5f1-421f-9073-b7be90b45b51", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a2909252-c5f1-421f-9073-b7be90b45b51"]}], "subject": "CHEBI:75922", "supporting_text": ["1 INDICATIONS AND USAGE NEVANAC ® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2939459", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:945c1e07-5b89-5374-930e-43a41656dbb2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050819", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2939459"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b921bee-bf42-56dd-9ae9-45b7b1221928", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:058a5110-9a8b-57db-8939-8076298ae1fd", "object": "UMLS:C0021368", "object_location_in_text": [99, 111], "original_object": "inflammation", "original_subject": "NEPAFENAC", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52fe0332-388a-451c-b759-97e760883837", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52fe0332-388a-451c-b759-97e760883837", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52fe0332-388a-451c-b759-97e760883837"]}], "subject": "CHEBI:75922", "supporting_text": ["1 INDICATIONS AND USAGE NEVANAC ® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. NEVANAC ® ophthalmic suspension is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Neisseria meningitidis (serogroups A, C, W and Y)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72c2bff0-7e2c-5422-ab1c-a794d762e55d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220926", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3eb8226f-6448-56a6-a416-5cde50cff2f8", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:6e701113-a7a4-595a-849f-bf5dd2493972", "object": "HP:5210068", "object_location_in_text": [69, 99], "original_object": "invasive meningococcal disease", "original_subject": "C", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:C#41-20220926", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:75948", "supporting_text": ["A drug with a new active ingredient indicated for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis (serogroups A, C, W and Y)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "Diseases with compensatory hypertension", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34d2c6e7-e6dd-5586-bfce-bdb43bd1f0cb", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f682b970-ce98-5cb5-9557-c0833ac8d47c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a3e21b-0dd7-5c2b-a7ab-7b8b57d1e46f", "object": "HP:0001680", "object_location_in_text": [67, 91], "original_object": "coarctation of the aorta", "original_subject": "NITROPRUSSIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72a9b7df-3a2f-4c16-93a9-b645bc0e8143", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72a9b7df-3a2f-4c16-93a9-b645bc0e8143", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72a9b7df-3a2f-4c16-93a9-b645bc0e8143"]}], "subject": "CHEBI:7596", "supporting_text": ["4 CONTRAINDICATIONS Diseases with compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting). Inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) coming to emergency surgery. Patients with congenital (Leber’s) optic atrophy or with tobacco amblyopia. Acute heart failure associated with reduced peripheral vascular resistance. Concomitant use with sildenafil, tadalafil, vardenifil, or riociguat. Diseases with compensatory hypertension (e.g. coarctation of the aorta, arteriovenous shunting) ( 4 ). Inadequate cerebral circulation or moribund patients (A.S.A. Class 5E) coming to emergency surgery ( 4 ). Congenital (Leber’s) optic atrophy or tobacco amblyopia ( 4 ). Acute heart failure with reduced peripheral vascular resistance ( 4 ). Concomitant use with sildenafil, tadalafil, vardenifil, or riociguat ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0264714", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2fc6e240-6c8b-5cee-9644-ca31a905a516", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0264714"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43e9c152-7d41-5b8d-81a7-9fef31bf396e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a3e21b-0dd7-5c2b-a7ab-7b8b57d1e46f", "object": "UMLS:C4478767", "original_object": "elevated left ventricular end-diastolic pressure", "original_subject": "NITROPRUSSIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f02e4ac-5f7c-4003-b9b7-283f489cddb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f02e4ac-5f7c-4003-b9b7-283f489cddb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f02e4ac-5f7c-4003-b9b7-283f489cddb0"]}], "subject": "CHEBI:7596", "supporting_text": ["1 INDICATIONS AND USAGE Sodium nitroprusside is a direct acting vasodilator indicated for: Immediate reduction of blood pressure ( 1.1 ) Producing controlled hypotension to reduce bleeding during surgery ( 1.2 ) Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure ( 1.3 ) 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.2 Induction and Maintenance of Controlled Hypotension Sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. 1.3 Treatment of Acute Heart Failure Sodium nitroprusside is indicated for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0019080", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d04eadc-1c01-56f3-b63c-258eb6981fe5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0019080"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a3e21b-0dd7-5c2b-a7ab-7b8b57d1e46f", "object": "MONDO:0005044", "original_object": "hypertension", "original_subject": "NITROPRUSSIDE", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72a9b7df-3a2f-4c16-93a9-b645bc0e8143", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72a9b7df-3a2f-4c16-93a9-b645bc0e8143", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72a9b7df-3a2f-4c16-93a9-b645bc0e8143"]}], "subject": "CHEBI:7596", "supporting_text": ["1 INDICATIONS AND USAGE Sodium nitroprusside is a direct acting vasodilator indicated for: •Immediate reduction of blood pressure ( 1.1 ) •Producing controlled hypotension to reduce bleeding during surgery. ( 1.2 ) •Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. ( 1.3 ) 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.2 Induction and Maintenance of Controlled Hypotension Sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. 1.3 Treatment of Acute Heart Failure Sodium nitroprusside is indicated for the treatment of acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure."], "temporal_context_qualifier": "during surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0019080", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed0876b0-4cbc-5a16-9036-90cc88fe201c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0019080"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a3e21b-0dd7-5c2b-a7ab-7b8b57d1e46f", "object": "MONDO:0005044", "original_object": "hypertension", "original_subject": "NITROPRUSSIDE", "population_context_qualifier": "adults and children", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5acf0836-93ff-4064-b888-3f560e8a558d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5acf0836-93ff-4064-b888-3f560e8a558d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5acf0836-93ff-4064-b888-3f560e8a558d"]}], "subject": "CHEBI:7596", "supporting_text": ["1 INDICATIONS AND USAGE Sodium nitroprusside is a direct acting vasodilator indicated for: • Immediate reduction of blood pressure ( 1.1 ) • Producing controlled hypotension to reduce bleeding during surgery. ( 1.2 ) • Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. ( 1.3 ) 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.2 Induction and Maintenance of Controlled Hypotension Sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. 1.3 Treatment of Acute Heart Failure Sodium nitroprusside is indicated for the treatment of acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure."], "temporal_context_qualifier": "during surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0264714", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81e344e4-0d97-5a68-8714-1f2e6c760679", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0264714"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c142b5aa-35a1-5951-881d-3b70d71a1a6c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3a3e21b-0dd7-5c2b-a7ab-7b8b57d1e46f", "object": "UMLS:C0264714", "object_location_in_text": [225, 244], "original_object": "acute heart failure", "original_subject": "NITROPRUSSIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f02e4ac-5f7c-4003-b9b7-283f489cddb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f02e4ac-5f7c-4003-b9b7-283f489cddb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f02e4ac-5f7c-4003-b9b7-283f489cddb0"]}], "subject": "CHEBI:7596", "supporting_text": ["1 INDICATIONS AND USAGE Sodium nitroprusside is a direct acting vasodilator indicated for: Immediate reduction of blood pressure ( 1.1 ) Producing controlled hypotension to reduce bleeding during surgery ( 1.2 ) Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure ( 1.3 ) 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.2 Induction and Maintenance of Controlled Hypotension Sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. 1.3 Treatment of Acute Heart Failure Sodium nitroprusside is indicated for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "immunocompromised state", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01128338-4d65-5db0-9662-bf2aee9e8f06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250120", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dad05504-a34e-5721-8608-a49b489fc454", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:289fd5fd-cabe-55f0-ad3a-0e610d8572e6", "object": "MONDO:0100096", "object_location_in_text": [58, 66], "original_object": "COVID-19", "original_subject": "sipavibart", "population_context_qualifier": "adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kavigale", "https://www.ema.europa.eu/en/documents/product-information/kavigale-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kavigale"]}], "subject": "CHEBI:759701", "supporting_text": ["Kavigale is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments.Kavigale should be used in accordance with official recommendations where available and based on information on the activity of sipavibart against presently circulating viral variants (see sections 4.4 and 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "blood coagulation factor VIII deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:faaac259-eb29-58a6-b56d-eb010eb56cd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250919", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1659e6f0-ce25-58c2-8614-d63e67ce5c5a", "object": "MONDO:0002243", "object_location_in_text": [74, 91], "original_object": "bleeding tendency", "original_subject": "DAMOCTOCOG ALFA PEGOL", "population_context_qualifier": "pediatric", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:DAMOCTOCOG ALFA PEGOL#7-20250919", "https://www.pmda.go.jp/files/000229786.pdf"]}], "subject": "CHEBI:759752", "supporting_text": ["Drugs with a new additional pediatric dosage indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acquired haemophilia caused by antibodies to Factor VIII", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a38e5ae4-17e1-5e8a-b681-1492f2479a45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151111", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a18a0638-18db-5086-9808-187df9910471", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2057e0a0-b1c6-5721-9eab-f65dadca7230", "object": "MONDO:0019139", "object_location_in_text": [48, 68], "original_object": "acquired haemophilia", "original_subject": "susoctocog alfa", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:obizur", "https://www.ema.europa.eu/en/documents/product-information/obizur-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/obizur"]}], "subject": "CHEBI:759758", "supporting_text": ["Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "coagulation factor IX deficiency", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fce92c6-ad1c-5bb4-914b-6fc39e405d06", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:78bff89b-f289-506c-aab8-b0c73acaad66", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:87f5ac71-f5a9-5a13-b531-11fe9a10e9cf", "object": "MONDO:0002243", "object_location_in_text": [64, 81], "original_object": "bleeding tendency", "original_subject": "ALBUTREPENONACOG ALFA", "population_context_qualifier": "patients with coagulation factor IX deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ALBUTREPENONACOG ALFA#104-20160928", "https://www.pmda.go.jp/files/000221483.pdf"]}], "subject": "CHEBI:759759", "supporting_text": ["Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with coagulation factor IX deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX, congenital haemophilia with low titre inhibitors", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a5d6a02-ffdc-512d-8944-8ed8ed157573", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220715", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7cb6cdfb-c5be-50bc-a77a-fee325ceb8bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ab7d8f4f-f15e-5ad2-b4c2-6cc648c96f75", "object": "UMLS:C0019080", "object_location_in_text": [99, 107], "original_object": "bleeding", "original_subject": "eptacog beta (activated)", "population_context_qualifier": "adults and adolescents (12 years of age and older)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cevenfacta", "https://www.ema.europa.eu/en/documents/product-information/cevenfacta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cevenfacta"]}], "subject": "CHEBI:759761", "supporting_text": ["CEVENFACTA is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:  in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ?5 Bethesda Units (BU));  in patients with congenital haemophilia with low titre inhibitors (BU &lt;5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX."], "temporal_context_qualifier": "undergoing surgery or invasive procedures"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX, congenital haemophilia with low titre inhibitors", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e95ef70e-7af6-5085-ba03-0fe852122760", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220715", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3d19ac87-b6ea-5834-b43c-a83bb718e165", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:ab7d8f4f-f15e-5ad2-b4c2-6cc648c96f75", "object": "UMLS:C1970394", "object_location_in_text": [99, 116], "original_object": "bleeding episodes", "original_subject": "eptacog beta (activated)", "population_context_qualifier": "adults and adolescents (12 years of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cevenfacta", "https://www.ema.europa.eu/en/documents/product-information/cevenfacta-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cevenfacta"]}], "subject": "CHEBI:759761", "supporting_text": ["CEVENFACTA is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:  in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ?5 Bethesda Units (BU));  in patients with congenital haemophilia with low titre inhibitors (BU &lt;5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "severe congenital protein C deficiency", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09b125a0-59aa-553e-ad7e-31f7e63b0b74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20010716", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8bbbaad0-366b-53e6-9fa3-e5f2c7969ce8", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:1095eaaa-e943-5053-81b0-b9c25d3c1382", "object": "MONDO:0000809", "object_location_in_text": [56, 73], "original_object": "purpura fulminans", "original_subject": "human protein C", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ceprotin", "https://www.ema.europa.eu/en/documents/product-information/ceprotin-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin"]}], "subject": "CHEBI:759768", "supporting_text": ["CEPROTIN is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital protein C deficiency", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a3d1479-e89b-5b86-985e-7e4f9ad150c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:8bbbaad0-366b-53e6-9fa3-e5f2c7969ce8", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1095eaaa-e943-5053-81b0-b9c25d3c1382", "object": "MONDO:0000809", "object_location_in_text": [94, 111], "original_object": "purpura fulminans", "original_subject": "HUMAN PROTEIN C", "population_context_qualifier": "patients with congenital protein C deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:HUMAN PROTEIN C#30-20240326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:759768", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital protein C deficiency", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3738c48e-f765-5745-9d40-c91ea9b98c44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240326", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:383f8e12-e290-53a8-a212-6280939cb9c8", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1095eaaa-e943-5053-81b0-b9c25d3c1382", "object": "MONDO:0002305", "object_location_in_text": [135, 148], "original_object": "thrombophilia", "original_subject": "HUMAN PROTEIN C", "population_context_qualifier": "patients with congenital protein C deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:HUMAN PROTEIN C#30-20240326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:759768", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "congenital protein C deficiency", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24a0ed8d-5a41-528a-836e-3e8a8e1cb88e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:277448d8-f6d7-591b-b763-c1248c4d5c18", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1095eaaa-e943-5053-81b0-b9c25d3c1382", "object": "MONDO:0005399", "object_location_in_text": [67, 89], "original_object": "venous thromboembolism", "original_subject": "HUMAN PROTEIN C", "population_context_qualifier": "patients with congenital protein C deficiency", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:HUMAN PROTEIN C#30-20240326", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:759768", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "superficial corneal neovascularisation, central corneal involvement, severely impaired visual acuity", "has_confidence_score": 1.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a11241e3-ecfb-5c74-817a-f124dc31b5d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:2b4d5194-4f2a-51fc-a0c2-a22f28520512", "medic_pair_confidence": 1.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:6f975112-934f-57fa-aa51-8110d4695ddc", "object": "MONDO:0025667", "object_location_in_text": [52, 79], "original_object": "limbal stem cell deficiency", "original_subject": "ex vivo expanded autologous human corneal epithelial cells containing stem cells", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:holoclar", "https://www.ema.europa.eu/en/documents/product-information/holoclar-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/holoclar"]}], "subject": "CHEBI:759780", "supporting_text": ["Treatment of adult patients with moderate to severe limbal stem cell deficiency (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity), unilateral or bilateral, due to physical or chemical ocular burns. A minimum of 1-2 mm2 of undamaged limbus is required for biopsy."], "temporal_context_qualifier": "due to physical or chemical ocular burns"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15015d8b-3d2f-57b9-830a-8e5733f2040b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dc86db1-2a09-4625-80eb-ff6ce9de2d7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dc86db1-2a09-4625-80eb-ff6ce9de2d7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dc86db1-2a09-4625-80eb-ff6ce9de2d7a"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ccc111c-3f7f-5d8e-9a97-db28a399a79d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a2a5e08-2697-4a00-94fe-de07148acbd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a2a5e08-2697-4a00-94fe-de07148acbd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a2a5e08-2697-4a00-94fe-de07148acbd9"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35f1f76a-1b3f-5b7b-877c-3d51e3cda162", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9929c166-8ba3-4159-a5f9-4618d5d227b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9929c166-8ba3-4159-a5f9-4618d5d227b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9929c166-8ba3-4159-a5f9-4618d5d227b0"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52b8ad9c-df5e-5763-8035-c2525929d2a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0416c8c-faae-4e31-aa50-1fb7df10abf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0416c8c-faae-4e31-aa50-1fb7df10abf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0416c8c-faae-4e31-aa50-1fb7df10abf0"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7210e3cd-266c-5d97-ad93-df5aaa492ee9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc304b04-9373-4e47-905d-6b3367ad3be7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc304b04-9373-4e47-905d-6b3367ad3be7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc304b04-9373-4e47-905d-6b3367ad3be7"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:890adfde-7792-5d3d-b313-f98f7bcc0188", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d34fae51-3658-4456-b3ea-1217f0f52260", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d34fae51-3658-4456-b3ea-1217f0f52260", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d34fae51-3658-4456-b3ea-1217f0f52260"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f527c15-c31d-5c1b-953e-329294deba14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74355cd2-b50e-0dc2-e053-2a91aa0aa164", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74355cd2-b50e-0dc2-e053-2a91aa0aa164", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74355cd2-b50e-0dc2-e053-2a91aa0aa164"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "right bundle branch block with left hemiblock", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1b80691-da34-505c-a329-e230cb7187f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d461242-13d8-518a-956e-64567841892a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "UMLS:C0264914", "original_object": "bifascicular block", "original_subject": "FLECAINIDE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf143926-439b-4005-be0e-1e049b44c044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf143926-439b-4005-be0e-1e049b44c044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf143926-439b-4005-be0e-1e049b44c044"]}], "subject": "CHEBI:75984", "supporting_text": ["Flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree AV block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. Flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ceaaec5-d725-5438-b28a-504d77507797", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmias", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom the benefits of treatment outweigh the risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74355cd2-b50e-0dc2-e053-2a91aa0aa164", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74355cd2-b50e-0dc2-e053-2a91aa0aa164", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74355cd2-b50e-0dc2-e053-2a91aa0aa164"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a2c806b-b55a-5421-aa0b-178c43511dee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0416c8c-faae-4e31-aa50-1fb7df10abf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0416c8c-faae-4e31-aa50-1fb7df10abf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0416c8c-faae-4e31-aa50-1fb7df10abf0"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55852bb5-9540-50c0-ad40-b95549c76258", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc304b04-9373-4e47-905d-6b3367ad3be7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc304b04-9373-4e47-905d-6b3367ad3be7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc304b04-9373-4e47-905d-6b3367ad3be7"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61bd0569-a6e2-5b80-b79d-25166bdcb2b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf143926-439b-4005-be0e-1e049b44c044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf143926-439b-4005-be0e-1e049b44c044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf143926-439b-4005-be0e-1e049b44c044"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66c91da4-3f02-5957-a74c-794b1795a8f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dc86db1-2a09-4625-80eb-ff6ce9de2d7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dc86db1-2a09-4625-80eb-ff6ce9de2d7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dc86db1-2a09-4625-80eb-ff6ce9de2d7a"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e292d3c-1a75-5d24-bb3e-20d5901f2c44", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a2a5e08-2697-4a00-94fe-de07148acbd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a2a5e08-2697-4a00-94fe-de07148acbd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a2a5e08-2697-4a00-94fe-de07148acbd9"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adad51c8-6daa-5646-b157-e8666448e734", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9929c166-8ba3-4159-a5f9-4618d5d227b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9929c166-8ba3-4159-a5f9-4618d5d227b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9929c166-8ba3-4159-a5f9-4618d5d227b0"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea280e43-4e4b-58ca-8bfc-857255a44aec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e52d7fd-2f0c-5d9d-b53f-1595a2ac3ad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004308", "original_object": "ventricular arrhythmia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients in whom benefits outweigh risks", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d34fae51-3658-4456-b3ea-1217f0f52260", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d34fae51-3658-4456-b3ea-1217f0f52260", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d34fae51-3658-4456-b3ea-1217f0f52260"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:193400ac-e0c4-514d-87bb-1173a2b3191f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bc304b04-9373-4e47-905d-6b3367ad3be7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bc304b04-9373-4e47-905d-6b3367ad3be7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bc304b04-9373-4e47-905d-6b3367ad3be7"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2be72215-e5b9-5f23-8715-7aac88e5aff3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9929c166-8ba3-4159-a5f9-4618d5d227b0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9929c166-8ba3-4159-a5f9-4618d5d227b0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9929c166-8ba3-4159-a5f9-4618d5d227b0"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:826616a6-771f-51aa-8c62-246d15af70cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0416c8c-faae-4e31-aa50-1fb7df10abf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0416c8c-faae-4e31-aa50-1fb7df10abf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0416c8c-faae-4e31-aa50-1fb7df10abf0"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bba1da5-41f3-5353-a5d5-aa7923e60c84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a2a5e08-2697-4a00-94fe-de07148acbd9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a2a5e08-2697-4a00-94fe-de07148acbd9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a2a5e08-2697-4a00-94fe-de07148acbd9"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a38e4a05-bd88-535f-b1e1-0d7d8ae402eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf143926-439b-4005-be0e-1e049b44c044", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf143926-439b-4005-be0e-1e049b44c044", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf143926-439b-4005-be0e-1e049b44c044"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9b6ce07-350d-5db0-bae3-cdda2f65bc72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:74355cd2-b50e-0dc2-e053-2a91aa0aa164", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=74355cd2-b50e-0dc2-e053-2a91aa0aa164", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=74355cd2-b50e-0dc2-e053-2a91aa0aa164"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba27146e-b321-53a0-acc9-46108ce3e02e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8dc86db1-2a09-4625-80eb-ff6ce9de2d7a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8dc86db1-2a09-4625-80eb-ff6ce9de2d7a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8dc86db1-2a09-4625-80eb-ff6ce9de2d7a"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0039232", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d56e77c0-7632-5ecf-8fd7-1c256e114239", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19851031", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0039232", "HP:0011717"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:73b61c2f-05d4-5ba8-8bdf-362e7db9abf1", "object": "HP:0004763", "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "FLECAINIDE", "population_context_qualifier": "patients without structural heart disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d34fae51-3658-4456-b3ea-1217f0f52260", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d34fae51-3658-4456-b3ea-1217f0f52260", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d34fae51-3658-4456-b3ea-1217f0f52260"]}], "subject": "CHEBI:75984", "supporting_text": ["In patients without structural heart disease, Flecainide Acetate Tablets USP are indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms • paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets USP are also indicated for the prevention of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of Flecainide Acetate Tablets USP is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS ). Use of Flecainide Acetate Tablets USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of Flecainide Acetate Tablets USP favorably affects survival or the incidence of sudden death."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0004836", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65f8550a-2792-5442-b3c9-e97443342444", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0004836"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:797e3f25-3429-5149-acb2-e112c1f4c076", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2d4fd55f-a5b1-54a9-898e-c75a59475160", "object": "HP:0004836", "original_object": "acute promyelocytic leukaemia", "original_subject": "arsenic trioxide", "population_context_qualifier": "adult patients with relapsed/refractory acute promyelocytic leukaemia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:trisenox", "https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox"]}], "subject": "CHEBI:759843", "supporting_text": ["Trisenox is indicated for induction of remission, and consolidation in adult patients with:  Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/µl) in combination with all?trans?retinoic acid (ATRA) Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy)  characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0004836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27d202fb-8745-5b31-8ecc-307c62ef4a1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20020305", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["HP:0004836"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6eab79b5-c3fc-55ab-b501-7d3808844a0e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:2d4fd55f-a5b1-54a9-898e-c75a59475160", "object": "UMLS:C0544452", "object_location_in_text": [53, 62], "original_object": "remission", "original_subject": "arsenic trioxide", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:arsenic-trioxide-medac", "https://www.ema.europa.eu/en/documents/product-information/arsenic-trioxide-medac-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-medac"]}], "subject": "CHEBI:759843", "supporting_text": ["Arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:  Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 10³/?l) in combination with all-trans-retinoic acid (ATRA) Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR?) gene.  The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "group D streptococci infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9263493-9f87-545e-b66b-859a4ca134d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["penicillin-type drug"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "original_object": "endocarditis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63413469-c676-48a3-a945-7d2489b535ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63413469-c676-48a3-a945-7d2489b535ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63413469-c676-48a3-a945-7d2489b535ef"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "group D streptococci", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec896e22-e8a4-535e-895d-ee21717b64c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["penicillin-type drug"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f58fc6f7-cc48-54de-8bf3-540f642b7e34", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0005025", "original_object": "endocarditis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:138633ce-07ae-57c6-bae3-ce8ada47ea14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f6eb1c-a287-489a-8c3e-aa5954cf1992", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f6eb1c-a287-489a-8c3e-aa5954cf1992", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f6eb1c-a287-489a-8c3e-aa5954cf1992"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the im"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0011450", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5376f314-5562-5b25-bb36-f3f586c03675", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011450"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:449c9a41-d61e-49fd-b5e3-d76f74b92acf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=449c9a41-d61e-49fd-b5e3-d76f74b92acf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=449c9a41-d61e-49fd-b5e3-d76f74b92acf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Sulfate in 0.9% Sodium Chloride Injection and other antibacterial drugs, Gentamicin Sulfate in 0.9% Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate in 0.9% Sodium Chloride Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter- Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin sulfate to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin Sulfate in 0.9% Sodium Chloride Injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue thera"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:607b9a36-129d-5354-a91d-4a24dbeb106a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:60ca1487-392d-4721-aa45-3de38722896c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=60ca1487-392d-4721-aa45-3de38722896c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60ca1487-392d-4721-aa45-3de38722896c"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important addit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e196d6e1-ad2c-5954-bd96-e00c5478f2d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c5514c2-40ef-4817-8f43-edb3ea3c34b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c5514c2-40ef-4817-8f43-edb3ea3c34b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c5514c2-40ef-4817-8f43-edb3ea3c34b5"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important addit"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7d8914b-903c-53e2-8d8c-2f618a50aede", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1ff0cdc-ac5d-30ca-e053-2a95a90a5066", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1ff0cdc-ac5d-30ca-e053-2a95a90a5066", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1ff0cdc-ac5d-30ca-e053-2a95a90a5066"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ea64d5c-6de7-5294-a18c-95ea7f457397", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1102, 1112], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the central nervous system", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c9c1974-e860-59ce-8318-287148333426", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1106, 1116], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the central nervous system", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25b0c8de-275d-5973-8e08-caed94c603d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1111, 1121], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0011450", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e07008b-278b-5d91-a3ad-33b179e86f27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011450"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1108, 1118], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63413469-c676-48a3-a945-7d2489b535ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63413469-c676-48a3-a945-7d2489b535ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63413469-c676-48a3-a945-7d2489b535ef"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the central nervous system", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f473772-a515-5e8a-9724-1b2e9039fcc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1104, 1114], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:913a36c3-50d6-429a-a8dd-a03126d2ca08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=913a36c3-50d6-429a-a8dd-a03126d2ca08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=913a36c3-50d6-429a-a8dd-a03126d2ca08"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important ad"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the central nervous system", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cba17943-36f0-50cc-a32e-46b06ba17079", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1106, 1116], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=977180b3-a222-4282-d485-4a3217674305"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the central nervous system", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e58ad48f-0ee4-5fba-8328-f218c5292e60", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006fa26a-422b-5087-bd05-5a60ff2e5032", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021108", "object_location_in_text": [1128, 1138], "original_object": "meningitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9fbe619-2afe-f1d7-e053-2a95a90aab29", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9fbe619-2afe-f1d7-e053-2a95a90aab29", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9fbe619-2afe-f1d7-e053-2a95a90aab29"]}], "subject": "CHEBI:759884", "supporting_text": ["INDICATIONS &amp; USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infecti"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the skin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c877649-d685-56d7-897f-5351a3bf2a81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a5534a2-5444-52a8-9633-2ffc3437a9f2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021201", "original_object": "skin infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=977180b3-a222-4282-d485-4a3217674305"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the skin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bc6a3e1-9100-562f-9792-91af37c296e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a5534a2-5444-52a8-9633-2ffc3437a9f2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021201", "original_object": "skin infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af87a324-3bed-5193-9a6a-f1447796b315", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6a5534a2-5444-52a8-9633-2ffc3437a9f2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:0021201", "original_object": "skin infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal tract infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c89b4869-527a-54b8-862d-536ba1fb9738", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [1183, 1194], "original_object": "peritonitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd4b36b0-0183-5318-b2fd-2b8580b60846", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:68f8b569-e246-592c-be6e-a7fd3d589790", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "MONDO:1010128", "object_location_in_text": [1192, 1203], "original_object": "peritonitis", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11bbcd42-9dc4-57bf-af3b-e21d1b1b6198", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the respiratory tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4c41af0-4aad-5d5e-9552-cc2af63a1fad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=977180b3-a222-4282-d485-4a3217674305"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the respiratory tract", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f762042d-4b64-5fe4-9953-b5cfd3577793", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:554d7162-c645-514d-81e7-88865cec839f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0035243", "original_object": "respiratory tract infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f15906b-1bfc-5481-9f26-a7c237bd82f9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9ff452fa-5f41-5413-801c-27412b873cbd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "soft tissue infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of soft tissue (including burns)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:953e09cb-1164-5e3e-b0f3-688c17d6fa8a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9ff452fa-5f41-5413-801c-27412b873cbd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "soft tissue infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=977180b3-a222-4282-d485-4a3217674305"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006434", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9fd3f900-1270-5ea2-8576-d367a935d1cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006434"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9ff452fa-5f41-5413-801c-27412b873cbd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "soft tissue infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8c608b3-50b8-4d5d-9e8a-e92c0d2e3cdc"]}], "subject": "CHEBI:759884", "supporting_text": [": To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of soft tissue (including burns)", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3ef9a13-6d53-564e-ab28-c20d8716658f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9ff452fa-5f41-5413-801c-27412b873cbd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "soft tissue infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006434", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e062bfab-2740-5ed3-b3a2-66948db3f428", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006434"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:745ad91e-2f86-5edd-b057-877047a1e697", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C0149778", "original_object": "soft tissue infection", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63413469-c676-48a3-a945-7d2489b535ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63413469-c676-48a3-a945-7d2489b535ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63413469-c676-48a3-a945-7d2489b535ef"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0aa7a2c6-7e0f-53fe-884d-483e2a4f7c07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:edf91d92-44a2-5103-b01e-28034238d5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C2242472", "original_object": "bone infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections of the bone", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2addc04e-35a8-54d1-b288-0cc6ef876e74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:edf91d92-44a2-5103-b01e-28034238d5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C2242472", "original_object": "bone infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=977180b3-a222-4282-d485-4a3217674305", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=977180b3-a222-4282-d485-4a3217674305"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "serious bacterial infections", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebcf16e3-9d80-5022-832b-ab24f46a57ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:edf91d92-44a2-5103-b01e-28034238d5ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1387985f-892f-511d-b86b-13fed4adc9f3", "medic_supporting_text_truncated": true, "object": "UMLS:C2242472", "original_object": "bone infections", "original_subject": "GENTAMICIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84f5c763-1cd3-4d85-9afb-934db8666fbf"]}], "subject": "CHEBI:759884", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0043241", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf548034-0beb-5c2b-a06f-7b097e6cfb84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19921106", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0043241"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:0a8a2780-5db4-5c10-8687-06d71738c559", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:b0c26759-e5bf-5da6-bb34-7d0c833c99fa", "object": "UMLS:C5200937", "original_object": "impaired wound healing", "original_subject": "Tetrachlorodecaoxide 1.037mg/100ml Solution", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:759905", "supporting_text": ["Immuno modulator (tissue repair) of wounds with impaired healing such as infected wound, delayed post traumatic and post operative wound healing and delayed healing after operation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e44a8e8-86b5-5e94-8870-f0996812c4d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20251119", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b779086d-2e93-52af-b5f7-cb7c6ed4fa12", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee6452ec-0189-5770-98cb-d63f53950e00", "object": "UMLS:C4324656", "original_object": "non-squamous non-small cell lung cancer", "original_subject": "SEVABERTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7a11334-6e7a-445b-9a16-bdcd9acbe61f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7a11334-6e7a-445b-9a16-bdcd9acbe61f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7a11334-6e7a-445b-9a16-bdcd9acbe61f"]}], "subject": "CHEBI:759992", "supporting_text": ["1 INDICATIONS AND USAGE HYRNUO is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. HYRNUO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. ( 1 ) This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2363973", "has_confidence_score": 0.405, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11d25306-3eba-5135-91d0-fb155d341221", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180416", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2363973"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:965c8f82-d060-592e-96e7-7cb199f9e201", "medic_pair_confidence": 0.405, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:48c8218b-3882-5d05-9f47-117d267f8180", "object": "MONDO:0013024", "original_object": "chronic thromboembolic pulmonary hypertension", "original_subject": "Riociguat bulk & 0.5mg/1.0mg/1.5mg/2.0mg/2.5 mg tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:76018", "supporting_text": ["For the treatment of persistent/ recurrent chronic Thromoembolic pulmonary Hypertension (CTEPH) WHO Group 4) After surgical treatment or imoperable CTEPH to improve exercise capacity and WHO function"], "temporal_context_qualifier": "After surgical treatment or imoperable CTEPH"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-muscle invasive bladder cancer", "has_confidence_score": 0.95, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe2e6f91-d438-58bd-a0eb-726c898e477c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20260216", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Bacillus Calmette-Guérin (BCG)"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:d8b93f88-1197-5e37-810a-662ef4e8f4b2", "medic_pair_confidence": 0.95, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:49dfc3d6-d9b8-5699-aad9-0c355d05a730", "object": "MONDO:0004647", "object_location_in_text": [178, 195], "original_object": "carcinoma in situ", "original_subject": "nogapendekin alfa inbakicept", "population_context_qualifier": "adult patients with BCG-unresponsive non-muscle invasive bladder cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:anktiva", "https://www.ema.europa.eu/en/documents/product-information/anktiva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/anktiva"]}], "subject": "CHEBI:760245", "supporting_text": ["Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonmuscle invasive bladder cancer, BCG-unresponsive", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1115bb9-4974-53a0-a12b-65879f606e01", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["Bacillus Calmette-Guérin (BCG)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d8b93f88-1197-5e37-810a-662ef4e8f4b2", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c42829a8-d61d-5b26-9ca5-5e66ce8c7cc1", "object": "MONDO:0004647", "original_object": "carcinoma in situ", "original_subject": "NOGAPENDEKIN ALFA INBAKICEPT-PMLN", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eae31db8-3e7a-d9e0-708d-74419d1b50ff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eae31db8-3e7a-d9e0-708d-74419d1b50ff"]}], "subject": "CHEBI:760245", "supporting_text": ["1 INDICATIONS AND USAGE ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR mutation-positive status", "has_confidence_score": 0.57375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08fb1a7a-711d-5744-8de3-62708df8a696", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250327", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f0c19513-2d73-5e74-bb83-85a2056935e2", "medic_pair_confidence": 0.57375, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8ac03779-1dac-5a8a-afd8-f9dfd2fa5def", "object": "MONDO:0005233", "original_object": "unresectable advanced non-small cell lung cancer", "original_subject": "LAZERTINIB MESILATE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LAZERTINIB MESILATE HYDRATE#18-20250327", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:760389", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent epidermal growth factor receptor (EGFR) mutation- positive non-small cell lung cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR mutation-positive status", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1114f80-1f55-55ad-88a1-378ebe444e3a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250327", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:fcecf477-ee05-5f2f-b156-16530de31634", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:8ac03779-1dac-5a8a-afd8-f9dfd2fa5def", "object": "UMLS:C0278517", "original_object": "recurrent non-small cell lung cancer", "original_subject": "LAZERTINIB MESILATE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:LAZERTINIB MESILATE HYDRATE#18-20250327", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:760389", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent epidermal growth factor receptor (EGFR) mutation- positive non-small cell lung cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0556482", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b00f568b-7eec-53b3-8fb3-a4a79ebce958", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0556482"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:61fa2e1b-9485-57c6-8f7d-5133426ad8d3", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:df8c8431-6f2b-5177-9f04-670cdec6e8fd", "medic_supporting_text_truncated": true, "object": "UMLS:C0032961", "object_location_in_text": [99, 108], "original_object": "pregnancy", "original_subject": "NORETHINDRONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8f91d0c-014f-4c1c-a472-1b1947ab96a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8f91d0c-014f-4c1c-a472-1b1947ab96a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8f91d0c-014f-4c1c-a472-1b1947ab96a6"]}], "subject": "CHEBI:7627", "supporting_text": ["Norethindrone and ethinyl estradiol tablets, USP 1 mg/0.035 mg are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT ® System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. Method (1) Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (2) Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (3) (4) Adapted from Hatcher et al., 1998, Ref. # 1. Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency"], "temporal_context_qualifier": "within 72 hours after unprotected intercourse"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1306878", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2086dbff-59b9-58ff-9ff3-e331f53b5041", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1306878"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c7808cfe-8e33-5097-baf4-6b5264401c3b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:82071924-2f55-5247-8f20-eb60a34bea31", "object": "HP:0000975", "object_location_in_text": [90, 98], "original_object": "sweating", "original_subject": "NORETHISTERONE ACETATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NORETHISTERONE ACETATE#173-20081016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:7627", "supporting_text": ["A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1306878", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1af4a2e6-2335-55df-a587-8bfc426ed617", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081016", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1306878"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7628a165-45ec-5eff-af9f-c3141ff31e8f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:82071924-2f55-5247-8f20-eb60a34bea31", "object": "UMLS:C0600142", "object_location_in_text": [74, 85], "original_object": "hot flushes", "original_subject": "NORETHISTERONE ACETATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:NORETHISTERONE ACETATE#173-20081016", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:7627", "supporting_text": ["A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:007713d7-d9c0-5b11-9a4f-7db005ca7722", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:df8c8431-6f2b-5177-9f04-670cdec6e8fd", "object": "UMLS:C3650625", "object_location_in_text": [138, 163], "original_object": "abnormal uterine bleeding", "original_subject": "NORETHINDRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:26130af6-221b-2349-81b6-0c0132d6e524", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=26130af6-221b-2349-81b6-0c0132d6e524", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26130af6-221b-2349-81b6-0c0132d6e524"]}], "subject": "CHEBI:7627", "supporting_text": ["Gallifrey (Norethindrone Acetate Tablets, USP), 5 mg Gallifrey is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Gallifrey is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:367d459c-2e3b-5f08-9aff-88005e9deab6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:df8c8431-6f2b-5177-9f04-670cdec6e8fd", "object": "UMLS:C3650625", "object_location_in_text": [97, 122], "original_object": "abnormal uterine bleeding", "original_subject": "NORETHINDRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb0b80e0-5b69-4efa-ae8a-62e718a62dc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb0b80e0-5b69-4efa-ae8a-62e718a62dc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb0b80e0-5b69-4efa-ae8a-62e718a62dc3"]}], "subject": "CHEBI:7627", "supporting_text": ["Norethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b4fda15-9326-52b9-a25a-b2d1da58baa1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:df8c8431-6f2b-5177-9f04-670cdec6e8fd", "object": "UMLS:C3650625", "object_location_in_text": [110, 135], "original_object": "abnormal uterine bleeding", "original_subject": "NORETHINDRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:827c7ef1-a8b7-d0c4-b062-c5154b331a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=827c7ef1-a8b7-d0c4-b062-c5154b331a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=827c7ef1-a8b7-d0c4-b062-c5154b331a35"]}], "subject": "CHEBI:7627", "supporting_text": ["Norethindrone acetate tablets, USP is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:791e7319-01e3-5e00-94c2-77db181f7be1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:df8c8431-6f2b-5177-9f04-670cdec6e8fd", "object": "UMLS:C3650625", "object_location_in_text": [111, 136], "original_object": "abnormal uterine bleeding", "original_subject": "NORETHINDRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2bb29135-6e9b-a9e2-e063-6394a90ae9e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2bb29135-6e9b-a9e2-e063-6394a90ae9e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2bb29135-6e9b-a9e2-e063-6394a90ae9e4"]}], "subject": "CHEBI:7627", "supporting_text": ["Norethindrone Acetate Tablets, USP are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone Acetate Tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3263685", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ab5bf52-0529-580e-8d50-36bf99de4447", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3263685"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:270c714f-145e-5557-b0b8-3c650050568e", "medic_pair_confidence": 0.654075, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:df8c8431-6f2b-5177-9f04-670cdec6e8fd", "object": "UMLS:C3650625", "object_location_in_text": [97, 122], "original_object": "abnormal uterine bleeding", "original_subject": "NORETHINDRONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0a94321-eb60-4aa6-a429-f0156f9f8e01", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0a94321-eb60-4aa6-a429-f0156f9f8e01", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0a94321-eb60-4aa6-a429-f0156f9f8e01"]}], "subject": "CHEBI:7627", "supporting_text": ["Norethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73cfc42f-77b9-59d6-9299-26fe46fa6e9c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4852a754-2fc1-4c10-a414-dc8a1dfd66a2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4852a754-2fc1-4c10-a414-dc8a1dfd66a2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4852a754-2fc1-4c10-a414-dc8a1dfd66a2"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94d045a5-33e0-5165-ad97-c93e30e6eed0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e32f284-a5b2-4ebf-9d9e-0e9a40b46ade", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e32f284-a5b2-4ebf-9d9e-0e9a40b46ade", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e32f284-a5b2-4ebf-9d9e-0e9a40b46ade"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab646823-6c82-58b5-81e5-a95ec88d09cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7cce83f-9508-49de-a442-246ad18ddeda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7cce83f-9508-49de-a442-246ad18ddeda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7cce83f-9508-49de-a442-246ad18ddeda"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad2ca361-9432-5c54-b2eb-a5d8e9ca962a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8eef261f-5c78-a88f-37c4-46e6b0e0f0ee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8eef261f-5c78-a88f-37c4-46e6b0e0f0ee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8eef261f-5c78-a88f-37c4-46e6b0e0f0ee"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated ( see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b48723df-dfa0-5bc9-8178-28bd0bb763e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:21770082-7a99-520d-e063-6394a90ab9cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=21770082-7a99-520d-e063-6394a90ab9cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21770082-7a99-520d-e063-6394a90ab9cb"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9d396b3-e0de-5618-b98a-1770b7f82e7d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c57301f-5128-295e-e063-6394a90ad99e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c57301f-5128-295e-e063-6394a90ad99e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c57301f-5128-295e-e063-6394a90ad99e"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d506efdb-ae07-51ef-a66c-61fc7454a3d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ee5d853-db93-46f1-922b-a013f26ab3c6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ee5d853-db93-46f1-922b-a013f26ab3c6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ee5d853-db93-46f1-922b-a013f26ab3c6"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "acute recovery period after myocardial infarction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d84137d0-875a-5a94-be33-583e81e5b553", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:37c004f1-b604-563e-80bc-464288253d13", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "NORTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:27e96d6c-b311-45d2-b879-65c6a4efcfba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=27e96d6c-b311-45d2-b879-65c6a4efcfba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27e96d6c-b311-45d2-b879-65c6a4efcfba"]}], "subject": "CHEBI:7640", "supporting_text": ["Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of nortriptyline hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting nortriptyline hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Myocardial Infarction Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11fd878a-f027-52cc-87d5-1cd0aba925ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f6f59fb-ae7d-48e5-b23e-a1d92160974f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f6f59fb-ae7d-48e5-b23e-a1d92160974f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f6f59fb-ae7d-48e5-b23e-a1d92160974f"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15e12d3a-5755-5c3e-8513-c95a997ee3de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d59098da-1395-49fb-9fd6-947bbbeed56f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d59098da-1395-49fb-9fd6-947bbbeed56f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d59098da-1395-49fb-9fd6-947bbbeed56f"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:302ef00d-ceea-5ddf-9757-1e0e70b7325d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4a670371-d373-1ba6-e063-6394a90a13b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4a670371-d373-1ba6-e063-6394a90a13b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a670371-d373-1ba6-e063-6394a90a13b6"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:45427056-0557-574a-b9c8-b7bfc71d5f25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e4f92e2-dbc6-5e36-b62e-102e1c909393", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:28b4e26e-206a-4e8a-abfe-774b780e91c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=28b4e26e-206a-4e8a-abfe-774b780e91c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28b4e26e-206a-4e8a-abfe-774b780e91c3"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9f36109-87a5-546b-873e-b710fa0fa943", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b25cbae5-eaf5-4501-b013-02c778ca4a4e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b25cbae5-eaf5-4501-b013-02c778ca4a4e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b25cbae5-eaf5-4501-b013-02c778ca4a4e"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5119786-ebf4-5cff-861e-ec138aad992e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:17b9e33d-da9c-467a-bbc4-9e257727f19a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=17b9e33d-da9c-467a-bbc4-9e257727f19a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17b9e33d-da9c-467a-bbc4-9e257727f19a"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0226896", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2162614-8efe-56ae-b8e0-b4924059ad14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0226896"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d7fbcf5-4f57-5279-b056-676710e2b5ce", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b5dbdfa4-9ba7-5bc8-a5c5-cf4791a1fc3c", "object": "MONDO:0002026", "object_location_in_text": [59, 70], "original_object": "candidiasis", "original_subject": "NYSTATIN", "population_context_qualifier": "oral cavity", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50737729-a4a4-e747-e063-6394a90adcc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50737729-a4a4-e747-e063-6394a90adcc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50737729-a4a4-e747-e063-6394a90adcc5"]}], "subject": "CHEBI:7660", "supporting_text": ["Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "17p deletion", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d705384-30c9-5a50-90a0-772c23d0e4ad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131113", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1433a2b9-a840-54ae-8f0d-cd279b045025", "object": "MONDO:0004948", "original_object": "chronic lymphocytic leukemia", "original_subject": "IBRUTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0dfd0279-ff17-4ea9-89be-9803c71bab44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44"]}], "subject": "CHEBI:76612", "supporting_text": ["1 INDICATIONS AND USAGE IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ). 1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1. 2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. 1. 3 Waldenström’s Macroglobulinemia IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 1. 4 Chronic Graft versus Host Disease IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1514815", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b79e4644-60d9-5fe2-a70b-5c38affb888f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160328", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1514815"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1433a2b9-a840-54ae-8f0d-cd279b045025", "object": "MONDO:0004948", "object_location_in_text": [90, 118], "original_object": "chronic lymphocytic leukemia", "original_subject": "IBRUTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IBRUTINIB#112-20160328", "https://www.pmda.go.jp/files/000266405.pdf"]}], "subject": "CHEBI:76612", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "17p deletion", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4dda205e-3486-54ad-8c4b-60cc2c66c132", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131113", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c7c6f36-1658-5144-98f4-434676add777", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1433a2b9-a840-54ae-8f0d-cd279b045025", "object": "UMLS:C0855095", "original_object": "small lymphocytic lymphoma", "original_subject": "IBRUTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0dfd0279-ff17-4ea9-89be-9803c71bab44", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44"]}], "subject": "CHEBI:76612", "supporting_text": ["1 INDICATIONS AND USAGE IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ). 1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 1. 2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. 1. 3 Waldenström’s Macroglobulinemia IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 1. 4 Chronic Graft versus Host Disease IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1514815", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3acd3589-1518-5e0e-bacb-3b85eff80814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160328", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1514815"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:1c7c6f36-1658-5144-98f4-434676add777", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:1433a2b9-a840-54ae-8f0d-cd279b045025", "object": "UMLS:C0855095", "object_location_in_text": [119, 145], "original_object": "small lymphocytic lymphoma", "original_subject": "IBRUTINIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:IBRUTINIB#112-20160328", "https://www.pmda.go.jp/files/000266405.pdf"]}], "subject": "CHEBI:76612", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006434", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f28d0cc-5f27-596d-8bb8-79422979f9a7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0006434"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:772a8710-d3ab-5df7-aaed-c2e96659afe2", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53dfb4d5-c758-5895-9891-bf7364da125a", "object": "MONDO:0021201", "object_location_in_text": [34, 48], "original_object": "skin infection", "original_subject": "GENTIAN VIOLET CATION", "population_context_qualifier": "in minor cuts, scrapes, burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf7824f0-8a4f-a063-e053-2995a90ae9a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf7824f0-8a4f-a063-e053-2995a90ae9a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf7824f0-8a4f-a063-e053-2995a90ae9a1"]}], "subject": "CHEBI:77181", "supporting_text": ["Uses As first aid to help prevent skin infection in minor cuts n scrapes n burns Warnings n For external use only"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05745603-8543-50d7-b430-6d07854ec7e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:04e72cc6-2264-5d8d-9be6-b52fb3a0d42d", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "Rosuvastatin Calcium Tablets 5/10/20mg (Additional Indication)", "population_context_qualifier": "adolescent boys and girls, at least one year post-menarche, 10-17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:77249", "supporting_text": ["1. As adjunct to diet to reduce Total-C, 05/04/2011 LDL-C, and ApoB levels in adolesent boys and girls, who are at least one year post-menarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C> 190mg/dL or > 160mg/dL and there is a positive family history of premature cadiovascular disease (CVD) or two or more other CVD risk factors. 2. As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0342882", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:597ff5b0-e462-54fa-b450-7f60668553e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342882"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:74a17a1f-e22a-5f3f-9bcc-e7c1659d67a7", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:04e72cc6-2264-5d8d-9be6-b52fb3a0d42d", "object": "UMLS:C1445957", "original_object": "total cholesterol", "original_subject": "Rosuvastatin Calcium Tablets 5/10/20mg (Additional Indication)", "population_context_qualifier": "adolescent boys and girls, at least one year post-menarche, 10-17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:77249", "supporting_text": ["1. As adjunct to diet to reduce Total-C, 05/04/2011 LDL-C, and ApoB levels in adolesent boys and girls, who are at least one year post-menarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C> 190mg/dL or > 160mg/dL and there is a positive family history of premature cadiovascular disease (CVD) or two or more other CVD risk factors. 2. As an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vasoactive intestinal peptide tumors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b766ece-a9b5-5771-b23c-41bd5e154e09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881021", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:faaff3a3-79ce-59ce-bd2a-422b36c624f2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7561191-82b9-5319-b14a-173dfc965eb9", "object": "MONDO:0001673", "original_object": "diarrhea", "original_subject": "OCTREOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01962c67-e551-47b6-a276-e1ae1860d2a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01962c67-e551-47b6-a276-e1ae1860d2a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01962c67-e551-47b6-a276-e1ae1860d2a4"]}], "subject": "CHEBI:7726", "supporting_text": ["1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Vasoactive Intestinal Peptide secreting tumors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:610171c1-1d0d-5aad-91ca-9170d104eec8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881021", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:faaff3a3-79ce-59ce-bd2a-422b36c624f2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7561191-82b9-5319-b14a-173dfc965eb9", "object": "MONDO:0001673", "original_object": "diarrhea", "original_subject": "OCTREOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0b7fe9e-7000-4b79-ba3b-291ce92c14f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0b7fe9e-7000-4b79-ba3b-291ce92c14f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0b7fe9e-7000-4b79-ba3b-291ce92c14f9"]}], "subject": "CHEBI:7726", "supporting_text": ["1 INDICATIONS AND USAGE SANDOSTATIN LAR DEPOT 10 mg, 20 mg, and 30 mg is indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated. SANDOSTATIN LAR DEPOT is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for: Acromegaly ( 1.1 ) Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors ( 1.2 ) Profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors ( 1.3 ) 1.1 Acromegaly Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal [see Clinical Studies (14), Dosage and Administration (2)] . 1.2 Carcinoid Tumors Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. 1.3 Vasoactive Intestinal Peptide Tumors (VIPomas) Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors. 1.4 Important"], "temporal_context_qualifier": "in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vasoactive intestinal peptide tumors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0a47a29-27cd-552c-8ea3-722d0c2bc2e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881021", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:faaff3a3-79ce-59ce-bd2a-422b36c624f2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7561191-82b9-5319-b14a-173dfc965eb9", "object": "MONDO:0001673", "original_object": "diarrhea", "original_subject": "OCTREOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ce2fc1e-7520-4d04-be45-2baba32ca24a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ce2fc1e-7520-4d04-be45-2baba32ca24a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ce2fc1e-7520-4d04-be45-2baba32ca24a"]}], "subject": "CHEBI:7726", "supporting_text": ["1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vasoactive intestinal peptide tumors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b7edec46-b389-587e-9d69-6b6ef9dbc634", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881021", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:faaff3a3-79ce-59ce-bd2a-422b36c624f2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7561191-82b9-5319-b14a-173dfc965eb9", "object": "MONDO:0001673", "original_object": "diarrhea", "original_subject": "OCTREOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f278f0d8-4062-420a-97c3-3a8b88253a08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f278f0d8-4062-420a-97c3-3a8b88253a08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f278f0d8-4062-420a-97c3-3a8b88253a08"]}], "subject": "CHEBI:7726", "supporting_text": ["1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vasoactive intestinal peptide tumors", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0c07693-e8fd-5aa1-8b69-3604d1c77a72", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881021", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:faaff3a3-79ce-59ce-bd2a-422b36c624f2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c7561191-82b9-5319-b14a-173dfc965eb9", "object": "MONDO:0001673", "original_object": "diarrhea", "original_subject": "OCTREOTIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6a9a800-889d-417f-b533-1913197d0022", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6a9a800-889d-417f-b533-1913197d0022", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6a9a800-889d-417f-b533-1913197d0022"]}], "subject": "CHEBI:7726", "supporting_text": ["1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0276078", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29dbca0f-96a7-5c39-92d0-d247d945a75d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0276078", "UMLS:C0854135", "MONDO:0005545"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cbeed0c5-ecd4-522d-aff0-4cfd2618192c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0001920", "original_object": "chronic suppurative otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37456656-77c8-d74c-e063-6294a90ab729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37456656-77c8-d74c-e063-6294a90ab729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37456656-77c8-d74c-e063-6294a90ab729"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "perforated tympanic membranes", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33186d84-8878-5111-899e-410483f1d2bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cbeed0c5-ecd4-522d-aff0-4cfd2618192c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0001920", "original_object": "chronic suppurative otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e912ed6-51e8-40c3-bf10-2af092c63be8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e912ed6-51e8-40c3-bf10-2af092c63be8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e912ed6-51e8-40c3-bf10-2af092c63be8"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa Staphylococcus aureus, and Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "perforated tympanic membranes", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad166e28-8b61-5357-8de5-1bab98963c58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cbeed0c5-ecd4-522d-aff0-4cfd2618192c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0001920", "original_object": "chronic suppurative otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7e1903e-5e4a-45b0-ae78-23c2b3c1bcf4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7e1903e-5e4a-45b0-ae78-23c2b3c1bcf4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7e1903e-5e4a-45b0-ae78-23c2b3c1bcf4"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa Staphylococcus aureus, and Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "perforated tympanic membranes", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5de970a-77b6-5841-8bec-3bf84a84996e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cbeed0c5-ecd4-522d-aff0-4cfd2618192c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0001920", "original_object": "chronic suppurative otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "patients 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8db221b1-32f3-f6ca-e404-71f56a860d08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8db221b1-32f3-f6ca-e404-71f56a860d08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8db221b1-32f3-f6ca-e404-71f56a860d08"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis , Pseudomonas aeruginosa, and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis , Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:769fd9a7-26dc-5d6a-9c01-60b2ec4629fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0df89815-985a-571a-913c-f647668c205b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "medic_supporting_text_truncated": true, "object": "MONDO:0002345", "original_object": "cervicitis", "original_subject": "OFLOXACIN", "population_context_qualifier": "adults with mild to moderate infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6"]}], "subject": "CHEBI:7731", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumonia . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumonia . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:47bf3527-d415-596a-a05d-faadc0b881ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0085484", "UMLS:C0038174", "UMLS:C0018483", "UMLS:C0038410", "UMLS:C0033701", "UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:702451eb-c8cc-5839-a350-48dd6995ae70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0006668", "original_object": "bacterial conjunctivitis", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d55b26d-9d12-ca29-e063-6294a90ab237", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d55b26d-9d12-ca29-e063-6294a90ab237", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d55b26d-9d12-ca29-e063-6294a90ab237"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d3f80e4-8c7e-5fdd-96d6-6d16c6c6c82b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0085484", "UMLS:C0038174", "UMLS:C0018483", "UMLS:C0038410", "UMLS:C0033701", "UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:702451eb-c8cc-5839-a350-48dd6995ae70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0006668", "original_object": "bacterial conjunctivitis", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7916bb3-7593-45f8-b9de-98e0f2d57227", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7916bb3-7593-45f8-b9de-98e0f2d57227", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7916bb3-7593-45f8-b9de-98e0f2d57227"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:789abc8c-0ee8-5348-8bf2-1b36b147360d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0085484", "UMLS:C0038174", "UMLS:C0018483", "UMLS:C0038410", "UMLS:C0033701", "UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:702451eb-c8cc-5839-a350-48dd6995ae70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0006668", "original_object": "bacterial conjunctivitis", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab5b0e34-ac5c-4c0c-b104-934b319ae011", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab5b0e34-ac5c-4c0c-b104-934b319ae011", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab5b0e34-ac5c-4c0c-b104-934b319ae011"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:847d8599-8642-5486-ae7c-872a20e11658", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:702451eb-c8cc-5839-a350-48dd6995ae70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0006668", "original_object": "bacterial conjunctivitis", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aab4449-3dda-4e2c-8e40-b3244a548bf5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aab4449-3dda-4e2c-8e40-b3244a548bf5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aab4449-3dda-4e2c-8e40-b3244a548bf5"]}], "subject": "CHEBI:7731", "supporting_text": ["OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8864bb0-b2c7-559a-9155-097e7899b51b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0085484", "UMLS:C0038174", "UMLS:C0018483", "UMLS:C0038410", "UMLS:C0033701", "UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:702451eb-c8cc-5839-a350-48dd6995ae70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0006668", "original_object": "bacterial conjunctivitis", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a9de529-6f85-467a-97b0-8ce124c31173", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a9de529-6f85-467a-97b0-8ce124c31173", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9de529-6f85-467a-97b0-8ce124c31173"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb9f580d-27e0-5ac5-add7-bd5ef8da7702", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0085484", "UMLS:C0038174", "UMLS:C0018483", "UMLS:C0038410", "UMLS:C0033701", "UMLS:C0033809"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:702451eb-c8cc-5839-a350-48dd6995ae70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0006668", "original_object": "bacterial conjunctivitis", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5117d567-2004-c5ed-1391-f8831864696f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5117d567-2004-c5ed-1391-f8831864696f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5117d567-2004-c5ed-1391-f8831864696f"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850121", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97c98334-0bb0-5181-9c1a-becebda1d113", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0850121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "pediatric patients one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8db221b1-32f3-f6ca-e404-71f56a860d08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8db221b1-32f3-f6ca-e404-71f56a860d08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8db221b1-32f3-f6ca-e404-71f56a860d08"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis , Pseudomonas aeruginosa, and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis , Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850121", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:99561655-93b4-5df3-81b7-7d8f81c78a3e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0850121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "pediatric patients one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7e1903e-5e4a-45b0-ae78-23c2b3c1bcf4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7e1903e-5e4a-45b0-ae78-23c2b3c1bcf4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7e1903e-5e4a-45b0-ae78-23c2b3c1bcf4"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa Staphylococcus aureus, and Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0850121", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f336ca16-9e44-564d-985c-142616e6d35b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0850121"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "pediatric patients one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e912ed6-51e8-40c3-bf10-2af092c63be8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e912ed6-51e8-40c3-bf10-2af092c63be8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e912ed6-51e8-40c3-bf10-2af092c63be8"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa Staphylococcus aureus, and Streptococcus pneumoniae ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff59930a-6ea9-5541-93c8-ddcfaea0fe3f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "UMLS:C1096746", "UMLS:C0854135", "MONDO:0005545", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "OFLOXACIN", "population_context_qualifier": "pediatric patients one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37456656-77c8-d74c-e063-6294a90ab729", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37456656-77c8-d74c-e063-6294a90ab729", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37456656-77c8-d74c-e063-6294a90ab729"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pneumoniae."], "temporal_context_qualifier": "with tympanostomy tubes"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:187eccee-cdc9-5aff-ac1c-e543fc695e3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948", "MONDO:0004277"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:07790c0e-8013-5606-adb6-2200fba09373", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "medic_supporting_text_truncated": true, "object": "UMLS:C0149959", "original_object": "acute pelvic inflammatory disease", "original_subject": "OFLOXACIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6"]}], "subject": "CHEBI:7731", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumonia . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumonia . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b641d68-f092-5204-a536-f57991b97e74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0033809", "UMLS:C0038174", "UMLS:C0036766", "UMLS:C0038410", "UMLS:C1522468"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc66800-ad3f-5c7d-a063-775c56466c32", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "UMLS:C0339215", "original_object": "bacterial corneal ulcers", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f7916bb3-7593-45f8-b9de-98e0f2d57227", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f7916bb3-7593-45f8-b9de-98e0f2d57227", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7916bb3-7593-45f8-b9de-98e0f2d57227"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76e8b835-3cea-5c91-888f-6bd6a7fb74f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0033809", "UMLS:C0038174", "UMLS:C0036766", "UMLS:C0038410", "UMLS:C1522468"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc66800-ad3f-5c7d-a063-775c56466c32", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "UMLS:C0339215", "original_object": "bacterial corneal ulcers", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d55b26d-9d12-ca29-e063-6294a90ab237", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d55b26d-9d12-ca29-e063-6294a90ab237", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d55b26d-9d12-ca29-e063-6294a90ab237"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c1fa62d-bb1f-570b-8847-98c52d73c010", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0033809", "UMLS:C0038174", "UMLS:C0036766", "UMLS:C0038410", "UMLS:C1522468"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc66800-ad3f-5c7d-a063-775c56466c32", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "UMLS:C0339215", "original_object": "bacterial corneal ulcers", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a9de529-6f85-467a-97b0-8ce124c31173", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a9de529-6f85-467a-97b0-8ce124c31173", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a9de529-6f85-467a-97b0-8ce124c31173"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.24, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9220aaec-4279-51a3-8007-ec621292172f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc66800-ad3f-5c7d-a063-775c56466c32", "medic_pair_confidence": 0.24, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "UMLS:C0339215", "original_object": "bacterial corneal ulcers", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aab4449-3dda-4e2c-8e40-b3244a548bf5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aab4449-3dda-4e2c-8e40-b3244a548bf5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aab4449-3dda-4e2c-8e40-b3244a548bf5"]}], "subject": "CHEBI:7731", "supporting_text": ["OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c86c7525-3acd-5670-ac02-e98bfb4a2a74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0033809", "UMLS:C0038174", "UMLS:C0036766", "UMLS:C0038410", "UMLS:C1522468"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc66800-ad3f-5c7d-a063-775c56466c32", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "UMLS:C0339215", "original_object": "bacterial corneal ulcers", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5117d567-2004-c5ed-1391-f8831864696f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5117d567-2004-c5ed-1391-f8831864696f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5117d567-2004-c5ed-1391-f8831864696f"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018154", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8418cb4-dad3-5169-9fb6-d9795e97c9c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0018154", "UMLS:C0018150", "MONDO:0005545", "UMLS:C0033809", "UMLS:C0038174", "UMLS:C0036766", "UMLS:C0038410", "UMLS:C1522468"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc66800-ad3f-5c7d-a063-775c56466c32", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "object": "UMLS:C0339215", "original_object": "bacterial corneal ulcers", "original_subject": "OFLOXACIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab5b0e34-ac5c-4c0c-b104-934b319ae011", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab5b0e34-ac5c-4c0c-b104-934b319ae011", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab5b0e34-ac5c-4c0c-b104-934b319ae011"]}], "subject": "CHEBI:7731", "supporting_text": ["Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS Gram-positive bacteria Gram-negative bacteria Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species : Propionibacterium acnes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5e77d1e-6e57-5bd0-a9af-dc2ad9dc9025", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:69852925-5c45-5991-8778-a0c982b2a729", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "medic_supporting_text_truncated": true, "object": "UMLS:C0694549", "original_object": "community-acquired pneumonia", "original_subject": "OFLOXACIN", "population_context_qualifier": "adults with mild to moderate infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6"]}], "subject": "CHEBI:7731", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumonia . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumonia . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0518948", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f353f0e5-bf9e-5df9-82af-21776202f4b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0518948"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0e54410-1f21-57d4-aed8-990affa5c301", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "medic_supporting_text_truncated": true, "object": "UMLS:C1112709", "original_object": "nongonococcal urethritis", "original_subject": "OFLOXACIN", "population_context_qualifier": "adults with mild to moderate infections", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6"]}], "subject": "CHEBI:7731", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumonia . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumonia . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0348321", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:afcf433d-788c-5e13-9ac2-6367f8ea6fa3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19901228", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0348321", "MONDO:0005114"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5d9e2-1103-5061-846c-63b680d3ad49", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f3c1b727-b60e-5fe2-a581-258276f5a4e2", "medic_supporting_text_truncated": true, "object": "UMLS:C1735365", "original_object": "acute bacterial exacerbation of chronic bronchitis", "original_subject": "OFLOXACIN", "population_context_qualifier": "adults with mild to moderate infections; patients who have no alternative treatment options", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6"]}], "subject": "CHEBI:7731", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumonia . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumonia . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy f"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7a734f4-6489-5746-bab8-96276223c2ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171225", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "HP:0002013", "object_location_in_text": [125, 133], "original_object": "vomiting", "original_subject": "OLANZAPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OLANZAPINE#87-20171225", "https://www.pmda.go.jp/files/000224954.pdf"]}], "subject": "CHEBI:7735", "supporting_text": ["Drugs with a new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic drug administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f3f5033-07b4-5032-a2b8-ee87e504d99b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20171225", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisplatin"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "HP:0002018", "object_location_in_text": [114, 120], "original_object": "nausea", "original_subject": "OLANZAPINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OLANZAPINE#87-20171225", "https://www.pmda.go.jp/files/000224954.pdf"]}], "subject": "CHEBI:7735", "supporting_text": ["Drugs with a new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "manic or mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5000c8ec-d7b9-54df-8059-ed21c528894f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960930", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["valproate", "lithium"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "medic_supporting_text_truncated": true, "object": "MONDO:0001866", "object_location_in_text": [648, 666], "original_object": "bipolar I disorder", "original_subject": "OLANZAPINE", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b418946a-1ab4-4d89-a012-d94fc361a3c4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b418946a-1ab4-4d89-a012-d94fc361a3c4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b418946a-1ab4-4d89-a012-d94fc361a3c4"]}], "subject": "CHEBI:7735", "supporting_text": ["1 INDICATIONS AND USAGE ZYPREXA ® (olanzapine) is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As ZYPREXA IntraMuscular for the: Treatment of acute agitation associated with schizophrenia and bipolar I mania. ( 1.4 ) Efficacy was established in three 1-day trials in adults. ( 14.3 ) As ZYPREXA and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:022d3727-8f26-55eb-9c4e-f0fa060c9da9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:olazax", "https://www.ema.europa.eu/en/documents/product-information/olazax-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/olazax"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:252baa14-331c-5b78-920d-9480230af8d9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:olanzapine-teva", "https://www.ema.europa.eu/en/documents/product-information/olanzapine-teva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25b6e6e9-8058-5248-b5e4-48e7e725ec6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:olazax-disperzi", "https://www.ema.europa.eu/en/documents/product-information/olazax-disperzi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/olazax-disperzi"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:485cf6d3-dead-5f45-b508-f32a9a2e16f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:olanzapine-viatris", "https://www.ema.europa.eu/en/documents/product-information/olanzapine-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-viatris"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e6df48c-1cc7-5416-a985-fa86d1471bdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:olanzapine-glenmark", "https://www.ema.europa.eu/en/documents/product-information/olanzapine-glenmark-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-glenmark"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:649c5970-b541-5253-b4a1-f754b1c934ee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:olanzapine-glenmark-europe", "https://www.ema.europa.eu/en/documents/product-information/olanzapine-glenmark-europe-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-glenmark-europe"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0349208", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a505f072-471b-53a7-908a-c2c3a1e4d2bb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960927", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0349208"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:61af91c7-4ca5-50e3-96a2-e116da5214dd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "MONDO:0004985", "object_location_in_text": [441, 457], "original_object": "bipolar disorder", "original_subject": "olanzapine", "population_context_qualifier": "Adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zyprexa-velotab", "https://www.ema.europa.eu/en/documents/product-information/zyprexa-velotab-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zyprexa-velotab"]}], "subject": "CHEBI:7735", "supporting_text": ["Adults Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder."], "temporal_context_qualifier": "in patients whose manic episode has responded to olanzapine treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0041696", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbce65f3-037c-5456-a2ea-9fe02d692ff2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960930", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0041696"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:49c0cd8e-bd83-5e6a-b6d3-57b5d33026ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:31f51db5-dd6c-5b79-ad00-9bbdbde90a6c", "object": "UMLS:C2063866", "original_object": "treatment resistant depression", "original_subject": "OLANZAPINE", "population_context_qualifier": "patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f6ceda3-3edc-4427-98a6-23e3c930c44d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d"]}], "subject": "CHEBI:7735", "supporting_text": ["1 INDICATIONS AND USAGE Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1)] . Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2)] . Olanzapine and fluoxetine capsules combines olanzapine, an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor, indicated for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3824874", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04c25c73-26ff-5b09-958c-bd532073530c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20170302", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3824874"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:15aa12cd-3023-5379-ba3b-8cbc9bed22d6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:98210e76-d330-54f2-966d-2fdc3609173b", "object": "MONDO:0005867", "object_location_in_text": [61, 81], "original_object": "mycoplasma pneumonia", "original_subject": "TOSUFLOXACIN TOSILATE HYDRATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TOSUFLOXACIN TOSILATE HYDRATE#100-20170302", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:77605", "supporting_text": ["A drug with a new additional indication for the treatment of mycoplasma pneumonia caused by Mycoplasma pneumoniae."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78270b06-12bf-5730-b343-a1e1e30e5e4f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "object": "MONDO:0001358", "object_location_in_text": [243, 255], "original_object": "bronchospasm", "original_subject": "OMEPRAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:7772", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:edf7c4b5-064b-5f54-86e0-e40b1d999eb6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:89efb5c9-5434-5ec9-bba2-e17e23171dbb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "object": "MONDO:0005492", "object_location_in_text": [297, 306], "original_object": "urticaria", "original_subject": "OMEPRAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:7772", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5801b76f-9620-55fc-ba37-d8696972fe5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd13a39e-bac7-5466-bb2b-8e9493ed74c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "object": "MONDO:0010481", "object_location_in_text": [231, 241], "original_object": "angioedema", "original_subject": "OMEPRAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:7772", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "hypersensitivity to substituted benzimidazoles or to any components of the formulation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c0fbab5-9503-5860-80d1-b30cd80ecd05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2aea563-aded-590c-b540-d1cb2e140e70", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "object": "MONDO:0800337", "object_location_in_text": [257, 291], "original_object": "acute tubulointerstitial nephritis", "original_subject": "OMEPRAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=688ed6f1-d78a-4006-a682-57021cb38a3e"]}], "subject": "CHEBI:7772", "supporting_text": ["4 CONTRAINDICATIONS KONVOMEP is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Proton pump inhibitors (PPIs), including KONVOMEP, are contraindicated in patients receiving rilpivirine containing products [see Drug Interactions ( 7 )] . Known hypersensitivity to any components of the formulation ( 4 ) Patients receiving rilpivirine‑containing products ( 4 , 7 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:041eb768-3cf8-5caa-bb08-166fb8a6b45d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "object_location_in_text": [137, 151], "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa8fc2ea-3942-453b-bc19-1e4b14ba6926", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa8fc2ea-3942-453b-bc19-1e4b14ba6926", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa8fc2ea-3942-453b-bc19-1e4b14ba6926"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE • Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults () • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults () • Treatment of active benign gastric ulcer in adults () • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older () • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older () • Pathologic hypersecretory conditions in adults () 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology () and the clarithromycin prescribing information, Microbiology sectio n]. 1.3 Treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09f4432a-2117-5393-9c29-9cd6f661593c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5e3a37a-f6e3-43d4-a8a9-54db6c271908", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5e3a37a-f6e3-43d4-a8a9-54db6c271908", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5e3a37a-f6e3-43d4-a8a9-54db6c271908"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b4f9d63-cb09-569d-8ece-bfba145c9878", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:63b3982a-b541-4b0d-99d4-93a673e57d46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=63b3982a-b541-4b0d-99d4-93a673e57d46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63b3982a-b541-4b0d-99d4-93a673e57d46"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2dd4765c-c287-5698-abd6-76c7f7d92699", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c5af5f4b-17be-7245-b281-f27c87831242", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c5af5f4b-17be-7245-b281-f27c87831242", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5af5f4b-17be-7245-b281-f27c87831242"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatmen"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d06d3bd-9f12-59e0-9102-79ec166c001c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54612d26-9e1a-1960-e063-6394a90a5784", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54612d26-9e1a-1960-e063-6394a90a5784", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54612d26-9e1a-1960-e063-6394a90a5784"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:43494df0-7cdd-5372-9bf3-d040152bc989", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a19ce586-59b7-4c2e-9e8d-12e8f0f058e2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a19ce586-59b7-4c2e-9e8d-12e8f0f058e2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a19ce586-59b7-4c2e-9e8d-12e8f0f058e2"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older ( 1.4 ) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older ( 1.6 ) Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology ( 12.4 ) and the clarithromycin prescribing information, Microbiology"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64d8a75d-2749-58b2-8d1f-0f28571a575e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:96104ea6-c08f-40b5-83f5-d840b317f1fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=96104ea6-c08f-40b5-83f5-d840b317f1fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96104ea6-c08f-40b5-83f5-d840b317f1fd"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b24074c-37b1-51ec-aae4-ec5c4f38fd4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0344268f-d8e6-48d5-b1e1-f750ed1d8a52", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0344268f-d8e6-48d5-b1e1-f750ed1d8a52", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0344268f-d8e6-48d5-b1e1-f750ed1d8a52"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcb784fc-d336-50ad-9655-539d7cc28442", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ded0df8b-1813-4595-ac2b-5499704bfd48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ded0df8b-1813-4595-ac2b-5499704bfd48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ded0df8b-1813-4595-ac2b-5499704bfd48"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older ( 1.4 ) Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 2 years of age and older ( 1.5 ) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older ( 1.6 ) Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0005202", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce1c70d3-c27a-5be5-8571-c200157d1da9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0005202"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa58085d-ac10-59b6-ba66-d8eaba4cf968", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "MONDO:0005412", "original_object": "duodenal ulcer", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:062800b1-790a-41c3-a8be-94143d2c7fb6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=062800b1-790a-41c3-a8be-94143d2c7fb6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=062800b1-790a-41c3-a8be-94143d2c7fb6"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment o"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cbf5160-f0a3-51dc-ab19-05d00a14f28b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "object_location_in_text": [455, 474], "original_object": "erosive esophagitis", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f27b3518-d5c1-1229-e053-2a95a90ab56f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f27b3518-d5c1-1229-e053-2a95a90ab56f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f27b3518-d5c1-1229-e053-2a95a90ab56f"]}], "subject": "CHEBI:7772", "supporting_text": ["1. INDICATIONS AND USAGE Omeprazole delayed-release capsules, USP, are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older ( 1.4 ) Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 2 years of age and older ( 1.5 ) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older ( 1.6 ) Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules, USP, are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, Omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial th"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:312f527d-df93-5cc3-af69-c3495a86931b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aa8fc2ea-3942-453b-bc19-1e4b14ba6926", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aa8fc2ea-3942-453b-bc19-1e4b14ba6926", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa8fc2ea-3942-453b-bc19-1e4b14ba6926"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE • Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults () • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults () • Treatment of active benign gastric ulcer in adults () • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older () • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older () • Pathologic hypersecretory conditions in adults () 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology () and the clarithromycin prescribing information, Microbiology sectio n]. 1.3 Treatm"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acid-mediated GERD", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1d774ac-1923-5cc7-bd6a-364d542c4e74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19890914", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e50e4871-23c8-5c14-b9ee-26d5e41eab4e", "medic_supporting_text_truncated": true, "object": "UMLS:C0267055", "original_object": "erosive esophagitis", "original_subject": "OMEPRAZOLE", "population_context_qualifier": "patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6ea9a6f3-b756-4cdf-b3db-f666a2c17d66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6ea9a6f3-b756-4cdf-b3db-f666a2c17d66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6ea9a6f3-b756-4cdf-b3db-f666a2c17d66"]}], "subject": "CHEBI:7772", "supporting_text": ["1 INDICATIONS AND USAGE Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults ( 1.1 ) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) • Treatment of active benign gastric ulcer in adults ( 1.3 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older ( 1.4 ) • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 2 years of age and older ( 1.5 ) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older ( 1.6 ) • Pathologic hypersecretory conditions in adults ( 1.7 ) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5330e644-5702-51ea-a80f-aec1b8cbaf97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [82, 90], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0d827d0-333f-4187-ac75-9dc7d34b6169", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0d827d0-333f-4187-ac75-9dc7d34b6169", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0d827d0-333f-4187-ac75-9dc7d34b6169"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5667e80d-f732-5a2d-b600-713432a65790", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [82, 90], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f175a336-433b-7ab2-e053-2995a90ad5ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f175a336-433b-7ab2-e053-2995a90ad5ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f175a336-433b-7ab2-e053-2995a90ad5ca"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:64536223-962b-541e-805a-eb0a2702989f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [124, 132], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients aged 6 months and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:61758670-91ab-4422-8d9d-e8ca87eecae8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=61758670-91ab-4422-8d9d-e8ca87eecae8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=61758670-91ab-4422-8d9d-e8ca87eecae8"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) • postoperative nausea and/or vomiting. ( 1.2 ) 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and/or vomiting postoperatively, Ondansetron Injection may be given to prevent further episodes. Ondansetron Injection is approved for patients aged 1 month and older."], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66cf2131-9c7b-5b53-ad78-8c5a7086ab8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [113, 121], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66ac9c17-bea7-4f8d-8a27-a1e0f9e65945", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66ac9c17-bea7-4f8d-8a27-a1e0f9e65945", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66ac9c17-bea7-4f8d-8a27-a1e0f9e65945"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3163f79-228f-528e-9c93-50ecb1731f86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [113, 121], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70b48280-ef74-472b-abc3-128962bfcb05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70b48280-ef74-472b-abc3-128962bfcb05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70b48280-ef74-472b-abc3-128962bfcb05"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5d7ac3b-5f57-5ae1-b71b-f57014a9be1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [113, 121], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:269c920c-643a-4eea-9bf9-b1f008915db9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=269c920c-643a-4eea-9bf9-b1f008915db9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=269c920c-643a-4eea-9bf9-b1f008915db9"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen (1) postoperative nausea and/or vomiting (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb030adf-f60d-5eda-88c8-53f1c8f1f02e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002013", "object_location_in_text": [96, 104], "original_object": "vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68a4d845-0c1c-4867-bfca-c0fb11dc93cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68a4d845-0c1c-4867-bfca-c0fb11dc93cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68a4d845-0c1c-4867-bfca-c0fb11dc93cd"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron oral solution is a 5-HT3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05a8093c-e999-5c49-9b58-a7d5905e17a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:674ea285-8f84-4603-9655-82200c523fe5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=674ea285-8f84-4603-9655-82200c523fe5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=674ea285-8f84-4603-9655-82200c523fe5"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12b88bcf-5c1e-5a0d-9ce1-20aab72da863", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:426ba54f-199a-41d1-8c27-f827bea56854", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=426ba54f-199a-41d1-8c27-f827bea56854", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=426ba54f-199a-41d1-8c27-f827bea56854"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d5fa38c-9181-5bcc-a01f-54cca300130f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:416be720-82e8-4a6d-8531-c1a29869daae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=416be720-82e8-4a6d-8531-c1a29869daae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=416be720-82e8-4a6d-8531-c1a29869daae"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:599dd8fa-5308-5a1b-b013-89c25f4cb500", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [196, 215], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients aged 6 months and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a44601b-c31c-4779-a688-28cc4cc75e8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a44601b-c31c-4779-a688-28cc4cc75e8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a44601b-c31c-4779-a688-28cc4cc75e8b"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and/or vomiting postoperatively, Ondansetron Injection may be given to prevent further episodes. Ondansetron Injection is approved for patients aged 1 month and older. Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. (1.1) postoperative nausea and/or vomiting. (1.2)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69d3a33f-d242-5ac1-b0ef-8b532ac8efd8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:00b17a8e-9d38-a8d4-e063-6294a90a153e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=00b17a8e-9d38-a8d4-e063-6294a90a153e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00b17a8e-9d38-a8d4-e063-6294a90a153e"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80786f53-f519-50a3-9ba9-c3e37373b005", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a29b5c18-9884-4c88-8827-65d9ad5f69f6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . initial and repeat courses of moderately emetogenic cancer chemotherapy. radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen (1) postoperative nausea and/or vomiting (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6a61637-8e56-50d1-a2f4-892f24a5860b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5566aebb-d84d-6d6a-e063-6294a90a746f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5566aebb-d84d-6d6a-e063-6294a90a746f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5566aebb-d84d-6d6a-e063-6294a90a746f"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab51e357-b4d1-572c-9d52-bc572c11bde4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:14276805-4e99-4bbe-ad76-ffc06eddb38a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=14276805-4e99-4bbe-ad76-ffc06eddb38a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=14276805-4e99-4bbe-ad76-ffc06eddb38a"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"], "temporal_context_qualifier": "associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2f4cdb8-5deb-5ce0-81bb-2757c4f9b0ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2a30d534-4607-4882-865e-56d2364acaad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2a30d534-4607-4882-865e-56d2364acaad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a30d534-4607-4882-865e-56d2364acaad"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"], "temporal_context_qualifier": "associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfea9d3f-4b22-5d9c-8bee-3342aa3f5426", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [38, 57], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37de0550-a6d1-46a8-a0b8-447b0dcf70ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37de0550-a6d1-46a8-a0b8-447b0dcf70ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37de0550-a6d1-46a8-a0b8-447b0dcf70ad"]}], "subject": "CHEBI:7773", "supporting_text": ["INDICATIONS &amp; USAGE Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5fe0374-69fd-55ef-8f7c-15e96a86eb2e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:960e2104-18c3-4cfa-abf6-f1b30c452918", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=960e2104-18c3-4cfa-abf6-f1b30c452918", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=960e2104-18c3-4cfa-abf6-f1b30c452918"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbf79429-828d-5022-9b9c-a28f313e7203", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 9, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [101, 120], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ab3210e-eed1-479a-afc0-f72b5b776883", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ab3210e-eed1-479a-afc0-f72b5b776883", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ab3210e-eed1-479a-afc0-f72b5b776883"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 ) Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe2a2eb5-5a45-565e-bef9-1c024512f355", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002017", "object_location_in_text": [80, 99], "original_object": "nausea and vomiting", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a14eb9a-0385-40e9-a7ec-71435450ac91", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a14eb9a-0385-40e9-a7ec-71435450ac91", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a14eb9a-0385-40e9-a7ec-71435450ac91"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"], "temporal_context_qualifier": "associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f589791-fe95-5235-91ce-44ecf99ff269", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [113, 119], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients aged 6 months and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:61758670-91ab-4422-8d9d-e8ca87eecae8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=61758670-91ab-4422-8d9d-e8ca87eecae8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=61758670-91ab-4422-8d9d-e8ca87eecae8"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) • postoperative nausea and/or vomiting. ( 1.2 ) 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and/or vomiting postoperatively, Ondansetron Injection may be given to prevent further episodes. Ondansetron Injection is approved for patients aged 1 month and older."], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18aa03c3-4d0f-5783-88ab-085efdedc8cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [71, 77], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0d827d0-333f-4187-ac75-9dc7d34b6169", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0d827d0-333f-4187-ac75-9dc7d34b6169", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0d827d0-333f-4187-ac75-9dc7d34b6169"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:266af4b2-37d2-5149-9c40-4b6b0b69dcca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [102, 108], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:66ac9c17-bea7-4f8d-8a27-a1e0f9e65945", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=66ac9c17-bea7-4f8d-8a27-a1e0f9e65945", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=66ac9c17-bea7-4f8d-8a27-a1e0f9e65945"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:406b15be-b522-5e64-a88b-c21185891b91", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [102, 108], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:269c920c-643a-4eea-9bf9-b1f008915db9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=269c920c-643a-4eea-9bf9-b1f008915db9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=269c920c-643a-4eea-9bf9-b1f008915db9"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 (1) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (1) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen (1) postoperative nausea and/or vomiting (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5764926e-abf4-5830-9055-8db9cf35d41a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [71, 77], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f175a336-433b-7ab2-e053-2995a90ad5ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f175a336-433b-7ab2-e053-2995a90ad5ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f175a336-433b-7ab2-e053-2995a90ad5ca"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ea172b3-bcd3-5cde-935e-f70da18f033d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [102, 108], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70b48280-ef74-472b-abc3-128962bfcb05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70b48280-ef74-472b-abc3-128962bfcb05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70b48280-ef74-472b-abc3-128962bfcb05"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron orally disintegrating tablets also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . (1) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (1) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. (1) • postoperative nausea and/or vomiting. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0034619", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e76e12c1-a13a-5885-a457-4c803a7988f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19910104", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0034619"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:749a25a9-d6df-5262-bdf4-f8913692fa73", "object": "HP:0002018", "object_location_in_text": [85, 91], "original_object": "nausea", "original_subject": "ONDANSETRON", "population_context_qualifier": "patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68a4d845-0c1c-4867-bfca-c0fb11dc93cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68a4d845-0c1c-4867-bfca-c0fb11dc93cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68a4d845-0c1c-4867-bfca-c0fb11dc93cd"]}], "subject": "CHEBI:7773", "supporting_text": ["1 INDICATIONS AND USAGE Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron oral solution is a 5-HT3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63e57fb0-a70e-5530-9581-8fb3e757f5ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cba555b3-366a-52fa-b7f7-08fc406eff9e", "object": "MONDO:0001461", "object_location_in_text": [121, 135], "original_object": "tinea corporis", "original_subject": "OXICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ef2286-0f56-4a8a-b07b-4a597f078ae0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ef2286-0f56-4a8a-b07b-4a597f078ae0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ef2286-0f56-4a8a-b07b-4a597f078ae0"]}], "subject": "CHEBI:7825", "supporting_text": ["OXISTAT Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:301e1aac-6c26-5cfc-b718-14a7c488b966", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cba555b3-366a-52fa-b7f7-08fc406eff9e", "object": "MONDO:0005984", "object_location_in_text": [90, 101], "original_object": "tinea pedis", "original_subject": "OXICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ef2286-0f56-4a8a-b07b-4a597f078ae0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ef2286-0f56-4a8a-b07b-4a597f078ae0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ef2286-0f56-4a8a-b07b-4a597f078ae0"]}], "subject": "CHEBI:7825", "supporting_text": ["OXISTAT Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5433380", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:656014e1-830e-5d1b-9108-eb9ec539fe02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19881230", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5433380", "UMLS:C4505442", "UMLS:C0014531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cba555b3-366a-52fa-b7f7-08fc406eff9e", "object": "UMLS:C1384589", "object_location_in_text": [103, 115], "original_object": "tinea cruris", "original_subject": "OXICONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:64ef2286-0f56-4a8a-b07b-4a597f078ae0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=64ef2286-0f56-4a8a-b07b-4a597f078ae0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64ef2286-0f56-4a8a-b07b-4a597f078ae0"]}], "subject": "CHEBI:7825", "supporting_text": ["OXISTAT Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior drug therapies", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b47bb92-59fe-5900-9b0a-02a766e29d5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:43933201-b655-54a7-89ce-79bd5342013a", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3a3d015b-df2e-58d2-aed0-0470c665ee52", "object": "MONDO:0011996", "object_location_in_text": [67, 95], "original_object": "chronic myelogenous leukemia", "original_subject": "PONATINIB HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PONATINIB HYDROCHLORIDE#103-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:78543", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies, and recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "recurrent or refractory", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:793ff645-eba6-5078-bf4e-40ad6567171f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160928", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:c4eaeeee-e7d7-543e-afcf-a88ad0300715", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3a3d015b-df2e-58d2-aed0-0470c665ee52", "object": "UMLS:C1709527", "object_location_in_text": [180, 241], "original_object": "Philadelphia chromosome-positive acute lymphoblastic leukemia", "original_subject": "PONATINIB HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PONATINIB HYDROCHLORIDE#103-20160928", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:78543", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies, and recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b292f2b-b9fb-5c24-9299-8b460d574ae2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f66d260-f83b-5e36-a3c4-3c6ea78a8f30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13ef7ab0-f31a-5a6c-835a-95df0c09b4e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [245, 252], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride Syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27fccfdd-8781-5cd4-95c1-53c1b2c785dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41f9e662-2942-53a0-a2cb-b533f13f84e5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:484327a5-50e6-563c-87b9-fabb571fe2da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [253, 260], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c527a9e-99cb-52dd-8145-a61077273db9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ed60543-2adb-54c7-b0a5-11b1fe44dbc2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6213cec0-2c18-57f3-bd04-0d098e970607", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62a77dee-afa4-5480-9dca-768238a38568", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [277, 284], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:68c8e6f9-b5f4-5bc2-a245-c66249f82559", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a28f8d4-c52f-5f13-bae1-b0fd383f0aaf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83c387b0-f1f7-5dd6-844d-e95900a99a2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9bc7a971-b971-51a3-86bc-89bffd3016d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [248, 255], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a6c0fc1a-e12e-5ab1-8c1e-e9b260ee791c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3e4ae4e-3d27-508d-a3b9-cb7749be5e86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [277, 284], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e5955e4c-b418-53a2-936c-183dc5f94c51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fcd66cab-07ae-5fda-9ef8-8dae1e53db71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:60276d75-853c-5856-9372-763abb93e40e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "HP:0100518", "object_location_in_text": [239, 246], "original_object": "dysuria", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7cd02b71-ed25-5492-9a92-c1e9542b25b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "MONDO:0006624", "object_location_in_text": [102, 120], "original_object": "overactive bladder", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b432aae-8a9d-8846-e063-6394a90a3b0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b432aae-8a9d-8846-e063-6394a90a3b0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b432aae-8a9d-8846-e063-6394a90a3b0d"]}], "subject": "CHEBI:7856", "supporting_text": ["1 INDICATIONS AND USAGE Oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ( 1 ) Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d46ec1e5-33e5-5ee2-a3ac-3bfda9cb20ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "MONDO:0006624", "object_location_in_text": [90, 108], "original_object": "overactive bladder", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "men", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000384", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:20dee37f-1412-44ed-9e8b-f4379ce23eb0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=20dee37f-1412-44ed-9e8b-f4379ce23eb0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=20dee37f-1412-44ed-9e8b-f4379ce23eb0"]}], "subject": "CHEBI:7856", "supporting_text": ["1 INDICATIONS AND USAGE OXYTROL is a muscarinic antagonist indicated for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency. OXYTROL is a muscarinic antagonist indicated for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:502f0d2e-7eec-5b92-88c2-8c6e9c598ea8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040615", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:0664dc34-b2fc-5be8-ac55-bb7540f0d019", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0042023", "object_location_in_text": [50, 77], "original_object": "increased urinary frequency", "original_subject": "oxybutynin", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kentera", "https://www.ema.europa.eu/en/documents/product-information/kentera-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kentera"]}], "subject": "CHEBI:7856", "supporting_text": ["Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6962d075-72b1-5613-844c-20c16d40422f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e7c96e55-d7a9-583d-89b9-7ad4a496f2c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0042023", "original_object": "urinary frequency", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride Syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a012e745-66f6-5c26-843c-dfe872ccb9cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040615", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [25, 42], "original_object": "urge incontinence", "original_subject": "oxybutynin", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kentera", "https://www.ema.europa.eu/en/documents/product-information/kentera-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kentera"]}], "subject": "CHEBI:7856", "supporting_text": ["Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0052a578-4271-5d06-816e-cdc81f29f8cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b4a756c-1034-5dbc-8469-ee7d89144883", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16d0608f-3ac9-5c0a-bd1e-9bcd7dd482b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3033f7ad-21f9-55f8-b940-58fdeb1e1a90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [258, 275], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32ac1bb1-25fa-517b-a515-99879a7dc07d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d407299-d2f0-5c45-baab-60f4d9a3ed6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:46d287de-074b-5e2d-ac40-a8b25d0637ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4fbcebaf-1b83-526d-87e2-5f752268b82d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79f58dc1-2e60-58c4-9645-31e9bbecaea7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:944dc9ad-9b2c-5291-afd7-393b147553f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [258, 275], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae76bfa6-36d2-5396-9f69-8b61c84950fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b747d261-262e-50e0-bcb3-9c1e46121409", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd81615b-99ab-531f-82b0-fbd80ae3b5a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [220, 237], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db8482a8-7269-59d8-ae86-7a849c9902dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [226, 243], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride Syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd21bc97-d8a6-5f91-a368-a0a23e3c843e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dde106da-a0b1-5ed1-9fcf-6c24c374d767", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df6fb230-406a-5077-a37e-2110fb677334", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [234, 251], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2e31258-59fb-573e-afa2-091a208f21e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:121721ad-06a8-543c-ad54-25b1aafe126c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0150045", "object_location_in_text": [229, 246], "original_object": "urge incontinence", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "neurological condition", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:428734d0-5326-5e2a-98f7-af9d3cd50dbc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5b0009a9-1880-5d1c-b411-93db643db37a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0268849", "object_location_in_text": [339, 360], "original_object": "detrusor overactivity", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "pediatric patients aged 6 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b432aae-8a9d-8846-e063-6394a90a3b0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b432aae-8a9d-8846-e063-6394a90a3b0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b432aae-8a9d-8846-e063-6394a90a3b0d"]}], "subject": "CHEBI:7856", "supporting_text": ["1 INDICATIONS AND USAGE Oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ( 1 ) Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1043c81c-57f1-57b1-91c4-683fe5ae0521", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10fc2eb1-1fdc-502e-81a3-c7a669f0b4b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e42d99b-b61f-5c7d-b876-0d2f5143f823", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2816d522-ee5b-5917-95ea-e01fd4e87076", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49a672db-cc9f-5c96-97a1-d07a9ce91fc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:52af005d-ab61-5d42-9606-abe525f31a02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [206, 215], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c63a94f-9129-585e-9de2-6d689718270f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e6dd1e1-2e62-51f3-8f36-65ed5c40d072", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88da15e8-f53a-54a8-9638-397c1cf97e43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [230, 239], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a209f96-38bd-5e75-8b3c-e5898e1cbd8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e3c1307-488e-5965-a5a1-bc0a46e92887", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad9dd3c3-d357-59af-970d-2f734b2995f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b1723c1a-ae8e-5a9a-9eb0-24e900115b5f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d50f1fb0-b769-5ae8-bf95-2aac790225b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e20a2ebc-99fd-5ed6-abb1-41319a7051b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [201, 210], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee71187f-8515-5875-95da-d06929c45f34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [192, 201], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7edc504-c186-5167-9c5a-a156980e3b83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b52034f2-1e4f-588a-ae0b-cf4553a20f25", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0376249", "object_location_in_text": [230, 239], "original_object": "frequency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f947ca37-8001-5ee4-87d1-ebc5ff5b2942", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20040615", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [82, 89], "original_object": "urgency", "original_subject": "oxybutynin", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kentera", "https://www.ema.europa.eu/en/documents/product-information/kentera-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kentera"]}], "subject": "CHEBI:7856", "supporting_text": ["Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:020bfa3d-d467-5f5a-a2a4-6aaea7f5c3b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10a4e7ad-7d64-55d7-a55e-6f8ce9f806f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22ef8b48-5b1b-5278-a83f-8886833bbcb3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2577931a-64ed-5db7-a6fd-e3926e891895", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a716877-6302-5373-89a7-1e927fc00f1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48dc0680-b20b-5c2d-ac3d-cb6d78a9e38b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:545619ed-2c83-5f26-924e-a00ffce195f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:720bb93a-7219-5d39-ac00-dd9cce59227c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [197, 204], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8525af7d-1d46-536b-b507-f3ff44af6e01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a70b8f76-15de-5ccf-b6ed-be44fa33e846", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9d9d03f-4149-5a1a-9ed0-b6030293276c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [189, 196], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride Syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b22b6df7-0cd3-51eb-b10c-0817c1712e22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8dc7dbd-33e7-5227-81ce-9f3b6015dba9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d53bcd59-0665-5b37-aae6-86e3afcaeeb4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2b9a644-f83e-5798-a3e6-72192903a1e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [192, 199], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f423994b-98a8-53fa-9111-9b63829b93b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [221, 228], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f63c7cd9-6f71-57e8-a23f-eb0a7ed7d747", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [221, 228], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd74839d-c7a6-5037-b774-cf294f278e13", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dbe6232b-6086-51e1-a150-857cb95147cf", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C0439609", "object_location_in_text": [183, 190], "original_object": "urgency", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0aa58d06-ae82-5ba0-9469-c61d198347ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [101, 120], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:33ccb07b-8ed8-58c4-83bc-76e46f0ce1e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39aedee2-13ae-5f32-830b-090753b5f35e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b3f2222-8e4e-5978-94c4-376e8bf904ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fb0c614-a495-5a52-85a5-75c06d085c38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70efc9de-b012-5811-9383-254708cff871", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7b93a3a8-cb0c-5feb-98eb-a9a38b00ee2b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [69, 88], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride Syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c701159-d227-5e8e-aeb9-3ba6e5b47f73", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7da5d6b2-afe0-5e28-a7e0-de1aa0376256", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [101, 120], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c6378e9-5eac-5d59-a550-5d7c7605a7cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c759c275-4b71-5936-a5bc-1518d1c1060b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb50513a-f516-57eb-abbe-320cbcc31073", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [72, 91], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8af0868-c6b0-57a0-8d5f-4ab9d01f5896", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da29efac-aa45-5201-bac9-362beca35ae9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e32295c1-e557-5be1-ad12-ff8cf2ab61ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e658c5da-7e85-54cb-af84-21267b237db6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e665f69b-1543-5083-8f15-513d76d4b77b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [77, 96], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2aa38c4-535a-54b0-836d-884afb7ee580", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6d41e03e-2a60-54bd-819a-c560d054d964", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C2945586", "object_location_in_text": [63, 82], "original_object": "bladder instability", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0010d23e-a817-5369-a388-6ec18b2f95c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [241, 256], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f330b7a0-bbe0-0f00-e053-2a95a90a37b8"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2945586", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10ad31c0-1b45-5be0-97c9-4617c3b4d8d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2945586", "UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [241, 256], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8455b543-81ce-4522-ae9b-8396f944945c"]}], "subject": "CHEBI:7856", "supporting_text": ["INDICATIONS &amp; USAGE Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1834efb8-a33b-5f3b-b605-0e652f081a75", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73d715dc-868d-4194-b668-4c39ababa698"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:341cc082-e05e-543c-9921-e37c529eb114", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [209, 224], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe4ed76b-0009-455f-be30-47e80fc1afdf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride Syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48b251dd-ff15-5fe2-bd64-76fa964275e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4574b227-9726-4798-bac2-83bfb9616f09"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b7a6ee9-2639-5420-bde9-ba8bd29312e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a79659-a181-6a61-e063-6294a90ae034"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a71cebce-4194-544b-8e73-bbc91211ba97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [217, 232], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ee6835a-7a7d-49a9-8460-2f1dd270ead3"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets, USP are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a765ed24-4187-5ad9-aa63-05b2487858fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ede5def-d185-4e40-9c10-8663ac654caf"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6acb338-2588-5481-bd6a-a5a6db21fa18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c497c6c-2448-2c80-e053-2991aa0ab8c7"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:caa510dd-90ea-5e69-8151-b92f7f79eb09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9578b6b8-5b9d-4263-9142-39b2c7216b85"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d118a0d1-71fe-5606-9288-2b7c621865dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0697b3cf-b146-47c0-b5a5-5905ae8d1c97"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2d36585-6d3d-5964-912f-5efb0946e032", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46e78c72-a5a3-472f-9125-b120fa4eee31"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7b4bb72-7123-5dfd-acbb-47ad0676aedc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a551ec5-7e80-47c9-a7b9-f458c1478174"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8216b9e-48d3-5982-bcd8-d7479feba247", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac10c7b7-d0cb-4068-93e2-c0e51f15866e"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfa6ad4b-9548-5384-89d0-01335f1d1c25", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e002fe8-fa3f-4a7d-84df-0c6e031e6ae4"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e10eb4a3-1089-5f89-a260-b9a35d4f0b31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [212, 227], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4463-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efff1ae5-7e49-5eb7-a9c5-ae2eb6d2b660", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a08a16a-f16d-4ef1-95bb-6943bcae0737"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0392115", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f783e5d4-d9f6-51e4-95c6-0a5c77128b09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0392115"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:eb966d42-5d68-5d85-9e3e-db89b6e7a8a3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8651993d-2194-5dff-bf7e-6c8a7e07d3f3", "object": "UMLS:C3897214", "object_location_in_text": [203, 218], "original_object": "urinary leakage", "original_subject": "OXYBUTYNIN", "population_context_qualifier": "patients with uninhibited neurogenic or reflex neurogenic bladder", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1674ddc-44f5-4638-8415-ef02ab6af7cc"]}], "subject": "CHEBI:7856", "supporting_text": ["Oxybutynin Chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031245", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d0533f1-f9bb-56be-80ca-c800c5fac3b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19860530", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031245"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:23c13c62-d7be-53e9-9da0-11563e6bca0b", "object": "MONDO:0003781", "original_object": "bronchitis", "original_subject": "OXYMETAZOLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e"]}], "subject": "CHEBI:7862", "supporting_text": ["DAY Uses ■ temporarily relieves these common cold and flu symptoms: ■ minor aches and pains ■ headache ■ sore throat ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily reduces fever NIGHT Uses ■ temporarily relieves these common cold and flu symptoms: ■ cough ■ minor aches and pains ■ sore throat ■ headache ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes due to hay fever ■ temporarily reduces fever ■ controls cough to help you get to sleep SPRAY Uses temporarily relieves nasal congestion due to: a cold hay fever or other upper respiratory allergies promotes nasal and sinus drainage temporarily relieves sinus congestion and pressure helps clear nasal passages; shrinks swollen membranes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0ee50f07-9ec3-5e22-b03e-f3fa8deb47b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "object_location_in_text": [121, 126], "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d7d1280-f286-4f39-89f3-2b96571810e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d7d1280-f286-4f39-89f3-2b96571810e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d7d1280-f286-4f39-89f3-2b96571810e6"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1427e0b9-f119-5a21-b06b-e00b0df157d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "object_location_in_text": [121, 126], "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7fd585a-99b7-4309-b003-a6cbef05372c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53bae16c-ec4b-59cb-9a9e-f7cd44dc6387", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "object_location_in_text": [120, 125], "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d16a48c5-6b71-40a0-bcda-204f043fe832", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d16a48c5-6b71-40a0-bcda-204f043fe832", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d16a48c5-6b71-40a0-bcda-204f043fe832"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin Injection, USP (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin Injection, USP (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6061e12e-3ae3-50c6-85c7-2dd1012bd574", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "object_location_in_text": [121, 126], "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b6f20a2c-3609-4b09-b8f7-8d8eaeb5c242", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b6f20a2c-3609-4b09-b8f7-8d8eaeb5c242", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b6f20a2c-3609-4b09-b8f7-8d8eaeb5c242"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9cd3fd13-6ca4-5d8a-80cf-fb28ee9778b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dddcdcc3-cd4d-4573-98ac-9468bea23a8b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dddcdcc3-cd4d-4573-98ac-9468bea23a8b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dddcdcc3-cd4d-4573-98ac-9468bea23a8b"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor. Antepartum: Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum: Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2fb8dd7-ae48-5841-8944-39895cbcad10", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:969d5b35-0add-4c23-9605-6a5b6ab65c95", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=969d5b35-0add-4c23-9605-6a5b6ab65c95", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=969d5b35-0add-4c23-9605-6a5b6ab65c95"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor. Antepartum: Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum: Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bab9e667-e1fb-5f3a-bf24-4447a78a65cd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e5a66fc-e507-497c-b5ce-44a8c95898ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor. Antepartum: Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum: Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df890d8c-c285-50ac-af0f-81cacadab32b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "object_location_in_text": [121, 126], "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4c4c4b69-8bf7-472c-aafe-29805ba5c965", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4c4c4b69-8bf7-472c-aafe-29805ba5c965", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c4c4b69-8bf7-472c-aafe-29805ba5c965"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecc150c1-f0e7-54f4-91d7-6f2773ee385b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "pregnant individual", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8fbd0773-6645-4235-9ef2-56edf9c7fb83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8fbd0773-6645-4235-9ef2-56edf9c7fb83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8fbd0773-6645-4235-9ef2-56edf9c7fb83"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, oxytocin is not indicated for elective induction of labor. Antepartum: Oxytocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum: Oxytocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8705f12-dbf8-594d-afde-7f134fb5a5de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "object_location_in_text": [121, 126], "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:18fe8365-86e3-414e-84dc-c98e097a2f36", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=18fe8365-86e3-414e-84dc-c98e097a2f36", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=18fe8365-86e3-414e-84dc-c98e097a2f36"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fb6957bd-be76-52d8-bd8e-bfab6a3d8bc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cd8a9ad0-df9d-5b46-b614-f849f37d3839", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0022864", "original_object": "labor", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d4b2c25-2e5d-49b5-93bc-2ae8a20916d1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d4b2c25-2e5d-49b5-93bc-2ae8a20916d1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d4b2c25-2e5d-49b5-93bc-2ae8a20916d1"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor. Antepartum: Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum: Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."], "temporal_context_qualifier": "at or near term"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0009800", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af009577-fd80-57af-afe2-20f3722740a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0009800", "MONDO:0005081", "HP:0001788"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:33cf47b5-db77-5473-90b5-fc81a3983503", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f50de8a-4f94-53b0-a63e-b99767d81f58", "object": "UMLS:C0259787", "original_object": "labor induction", "original_subject": "OXYTOCIN", "population_context_qualifier": "patients with a medical indication for the initiation of labor", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9b62187-4141-487c-a9da-f42ad7f9b408", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9b62187-4141-487c-a9da-f42ad7f9b408", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9b62187-4141-487c-a9da-f42ad7f9b408"]}], "subject": "CHEBI:7872", "supporting_text": ["IMPORTANT NOTICE Oxytocin is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits-to-risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications. Antepartum Oxytocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve early vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3467c35e-84a5-54ea-b709-81e9262b1f97", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["standard antineoplastic therapy"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95d4d004-8744-57c5-902d-1e3a21577347", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:40132326-832f-5de4-9cfd-c4d530603acd", "object": "MONDO:0043731", "original_object": "osteolytic lesions", "original_subject": "PAMIDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2ca033e-fa5f-4141-b702-11f8b4303da1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2ca033e-fa5f-4141-b702-11f8b4303da1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2ca033e-fa5f-4141-b702-11f8b4303da1"]}], "subject": "CHEBI:7903", "supporting_text": ["1 INDICATIONS AND USAGE Pamidronate disodium is a bisphosphonate indicated for the treatment of: • moderate or severe hypercalcemia associated with malignancy, with or without bone metastases ( 1.1 ) • patients with moderate to severe Paget’s disease of bone ( 1.2 ) • osteolytic bone metastases of breast cancer or osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy ( 1.3 ) Limitations of use Safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. ( 1.4 ) 1.1 Hypercalcemia of Malignancy Pamidronate disodium is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. 1.2 Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. 1.3 Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma [see Clinical Studies (14.3) ] . 1.4"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d3b2aa5c-254b-58c0-bbad-f3759c9004c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95d4d004-8744-57c5-902d-1e3a21577347", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:40132326-832f-5de4-9cfd-c4d530603acd", "medic_supporting_text_truncated": true, "object": "MONDO:0043731", "original_object": "osteolytic lesions", "original_subject": "PAMIDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:176A1E12-A9A1-4901-8900-A530F7937F03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=176A1E12-A9A1-4901-8900-A530F7937F03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=176A1E12-A9A1-4901-8900-A530F7937F03"]}], "subject": "CHEBI:7903", "supporting_text": ["Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efb941db-3cba-54be-9eb1-47b5214847d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["standard antineoplastic therapy"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:95d4d004-8744-57c5-902d-1e3a21577347", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:40132326-832f-5de4-9cfd-c4d530603acd", "medic_supporting_text_truncated": true, "object": "MONDO:0043731", "original_object": "osteolytic lesions", "original_subject": "PAMIDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da574350-be6b-49f3-b2ef-64da06af9b9d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da574350-be6b-49f3-b2ef-64da06af9b9d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da574350-be6b-49f3-b2ef-64da06af9b9d"]}], "subject": "CHEBI:7903", "supporting_text": ["Hypercalcemia of Malignancy Pamidronate disodium in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0006775", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0521b16-e828-59b8-8f06-78f1a0e60584", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911031", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["standard antineoplastic therapy"], "medic_disease_context_ids": ["HP:0006775"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56459d23-2255-5919-a818-b5d831c68133", "medic_pair_confidence": 0.6885, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:40132326-832f-5de4-9cfd-c4d530603acd", "medic_supporting_text_truncated": true, "object": "UMLS:C3898069", "original_object": "osteolytic lesions of multiple myeloma", "original_subject": "PAMIDRONIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23"]}], "subject": "CHEBI:7903", "supporting_text": ["Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metasta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100543", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02dbfb4f-404b-507d-9d63-9bf45ec020ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140319", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_disease_context_ids": ["HP:0100543"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:df43ffd7-3616-5210-8630-015d5bc4abf3", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ab58a02f-9004-502d-aadd-53429b50a1b3", "object": "MONDO:0004975", "original_object": "Alzheimer's disease", "original_subject": "FLORBETABEN F-18", "population_context_qualifier": "adults with cognitive impairment", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0915068-cfd4-4d72-b9f8-7e31fe83cd1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0915068-cfd4-4d72-b9f8-7e31fe83cd1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0915068-cfd4-4d72-b9f8-7e31fe83cd1e"]}], "subject": "CHEBI:79033", "supporting_text": ["1 INDICATIONS AND USAGE NEURACEQ is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f831543-7b05-5743-834a-ec6d793d3429", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "HP:0002020", "original_object": "heartburn", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b422c5eb-9a6d-4f8c-863d-ca515ec780c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b422c5eb-9a6d-4f8c-863d-ca515ec780c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b422c5eb-9a6d-4f8c-863d-ca515ec780c2"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium Delayed-Release Tablets, USP are indicated for: Pantoprazole is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of Pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 Maintenance of Healing of Erosive Esophagitis Pantoprazole is indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome Pantoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07a81f2f-0d5f-5b12-a343-dce76ad91557", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e0c5dac-6832-4692-b012-ca59d5e88987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e0c5dac-6832-4692-b012-ca59d5e88987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e0c5dac-6832-4692-b012-ca59d5e88987"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium for Injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 10 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41a59e38-ef3b-5007-8813-234bd526b437", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "object_location_in_text": [157, 188], "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a476e063-9450-4793-9a22-16b0a0a61cd0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a476e063-9450-4793-9a22-16b0a0a61cd0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a476e063-9450-4793-9a22-16b0a0a61cd0"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium is a proton pump inhibitor (PPI) indicated in adults for the following: • Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of Erosive Esophagitis (EE). ( 1.1 ) • Pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome. ( 1.2 ) 1.1 Gastroesophageal Reflux Disease Associated with a History of Erosive Esophagitis Pantoprazole sodium in 0.9% sodium chloride injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE). Safety and efficacy of pantoprazole sodium in 0.9% sodium chloride injection as a treatment of patients with GERD and a history of EE for more than 10 days have not been demonstrated. 1.2 Pathological Hypersecretion Including Zollinger-Ellison Syndrome Pantoprazole sodium in 0.9% sodium chloride injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "Short-term treatment (7 to 10 days)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a095354-5ecb-51ca-b67c-57716d8c1e31", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "pediatric patients 3 months and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51e4144a-489e-436c-609a-39305f8f56ba", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51e4144a-489e-436c-609a-39305f8f56ba", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51e4144a-489e-436c-609a-39305f8f56ba"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE PROTONIX I.V. is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 7 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7751728d-3064-5113-8f6a-f58db4962028", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22b71a1d-87f8-43ba-b53d-53ca3f70c63e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22b71a1d-87f8-43ba-b53d-53ca3f70c63e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22b71a1d-87f8-43ba-b53d-53ca3f70c63e"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 10 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:822ab534-f25f-5378-a825-3b5bbf2e8ee2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9bed093a-9586-4c82-a2b7-c68f89d0faef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9bed093a-9586-4c82-a2b7-c68f89d0faef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bed093a-9586-4c82-a2b7-c68f89d0faef"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 10 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9183fecf-6848-5922-9c0f-724be47adece", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4ba4c797-3f97-4d85-971e-7b17bdf89221", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4ba4c797-3f97-4d85-971e-7b17bdf89221", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ba4c797-3f97-4d85-971e-7b17bdf89221"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 10 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c620f7a0-55bf-5394-9a74-863585811c63", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "pediatric patients 3 months and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50802e19-72d3-4130-8d14-eb94361b38e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50802e19-72d3-4130-8d14-eb94361b38e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50802e19-72d3-4130-8d14-eb94361b38e7"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE PROTONIX I.V. is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 7 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ccf94af8-afb1-5cbd-aa20-db937b092fce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:362229c5-7b28-4563-aa62-d97d06005480", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=362229c5-7b28-4563-aa62-d97d06005480", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=362229c5-7b28-4563-aa62-d97d06005480"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium for Injection is a proton pump inhibitor (PPI) indicated in adults for the following: • Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of erosive esophagitis (EE). ( 1.1 ) • Pathological hypersecretion conditions, including Zollinger-Ellison (ZE) syndrome. ( 1.2 ) 1.1 Gastroesophageal Reflux Disease Associated with a History of Erosive Esophagitis Pantoprazole Sodium for Injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE). Safety and efficacy of Pantoprazole Sodium for Injection as a treatment of patients with GERD and a history of EE for more than 10 days have not been demonstrated. 1.2 Pathological Hypersecretion Including Zollinger-Ellison Syndrome Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "short-term treatment (7 to 10 days)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d487dac9-0e69-5a8d-82c5-62835a29b9ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "pediatric patients 3 months and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f39b3e7d-39d2-4c8a-9974-4ab885241880", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f39b3e7d-39d2-4c8a-9974-4ab885241880", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f39b3e7d-39d2-4c8a-9974-4ab885241880"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE PROTONIX I.V. is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older . • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 7 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e473df0b-40da-5801-8eb9-f7c7d6e56740", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1bb94d3c-8bc3-4193-9dd8-e9a22066707c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1bb94d3c-8bc3-4193-9dd8-e9a22066707c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bb94d3c-8bc3-4193-9dd8-e9a22066707c"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. • pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."], "temporal_context_qualifier": "for up to 10 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0267055", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecec1d1e-87aa-5f13-b7c5-76f310548fcb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0267055"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:81482a2b-aa6f-52e6-a546-e33c59d69c9b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0007186", "original_object": "gastroesophageal reflux disease", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70378eba-3904-4491-9f6d-00f5d1501c4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70378eba-3904-4491-9f6d-00f5d1501c4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70378eba-3904-4491-9f6d-00f5d1501c4a"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium for Injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Pantoprazole Sodium for Injection is a proton pump inhibitor (PPI) indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. ( 1 ) pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. ( 1 )"], "temporal_context_qualifier": "for up to 10 days"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretion", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7bcdb565-5b3b-5dfc-b0c3-8be08e3bd8b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0696b10c-972b-9dcf-e063-6294a90a1034", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0696b10c-972b-9dcf-e063-6294a90a1034", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0696b10c-972b-9dcf-e063-6294a90a1034"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a0150031-99e0-5316-b8fd-fb1e77e394d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e0c5dac-6832-4692-b012-ca59d5e88987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e0c5dac-6832-4692-b012-ca59d5e88987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e0c5dac-6832-4692-b012-ca59d5e88987"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium for Injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3deab58-2fec-5f73-b955-8326d20d5f23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c39be14b-e881-4586-b77e-4747db494954", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c39be14b-e881-4586-b77e-4747db494954", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c39be14b-e881-4586-b77e-4747db494954"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. ( 1 ) pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretion conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbb2bb5c-456f-5a70-b106-ad3ddfe8c2d8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1ad8f91-3783-4139-8154-e461a53809c1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1ad8f91-3783-4139-8154-e461a53809c1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1ad8f91-3783-4139-8154-e461a53809c1"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium for injection is indicated for treatment of: gas troesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. patho logical hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c302a73c-9527-5aa1-ab81-22607b195579", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70378eba-3904-4491-9f6d-00f5d1501c4a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70378eba-3904-4491-9f6d-00f5d1501c4a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70378eba-3904-4491-9f6d-00f5d1501c4a"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium for Injection is indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults. Pantoprazole Sodium for Injection is a proton pump inhibitor (PPI) indicated for treatment of: gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. ( 1 ) pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretion", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fbc308b3-9a2a-5698-96cf-e94ee9c487b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "MONDO:0019610", "original_object": "Zollinger-Ellison Syndrome", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb3f58d4-0c69-4377-be45-c36099c98d33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb3f58d4-0c69-4377-be45-c36099c98d33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb3f58d4-0c69-4377-be45-c36099c98d33"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for treatment of: • gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. (1) • pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Gastroesophageal Reflux Disease (GERD)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93657c56-cf7a-561b-9a2d-2f1d3becda81", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20000202", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:63e8bef4-ac65-56d3-ab5a-1b803a7674bd", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9fd17f86-0ce8-5545-bc83-e19d9eee160f", "object": "UMLS:C0267055", "object_location_in_text": [693, 712], "original_object": "erosive esophagitis", "original_subject": "PANTOPRAZOLE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b422c5eb-9a6d-4f8c-863d-ca515ec780c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b422c5eb-9a6d-4f8c-863d-ca515ec780c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b422c5eb-9a6d-4f8c-863d-ca515ec780c2"]}], "subject": "CHEBI:7915", "supporting_text": ["1 INDICATIONS AND USAGE Pantoprazole Sodium Delayed-Release Tablets, USP are indicated for: Pantoprazole is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of Pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 Maintenance of Healing of Erosive Esophagitis Pantoprazole is indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome Pantoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic kidney disease (CKD) Stage 5", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be0afe45-c3e6-523a-8e4a-60886ed85c15", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980417", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13dc9a4f-4722-5b44-8c4e-1cfc1f71375d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d07ed965-f0c4-56b9-9705-287a8e454e69", "object": "MONDO:0006964", "object_location_in_text": [127, 156], "original_object": "secondary hyperparathyroidism", "original_subject": "PARICALCITOL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4db985c4-3ba2-4967-898b-35af77f150de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4db985c4-3ba2-4967-898b-35af77f150de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4db985c4-3ba2-4967-898b-35af77f150de"]}], "subject": "CHEBI:7931", "supporting_text": ["1 INDICATIONS AND USAGE Paricalcitol Injection is an active vitamin D 2 analogue indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 5. Paricalcitol Injection is an active vitamin D 2 analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Human Immunodeficiency Virus (HIV) infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e839a9f-91e0-5a7a-92d5-ac90e25ebc67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:075a2d5a-a830-57d0-ae57-95d5a80eaf8e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a5a7d63-5edb-5f63-b28a-0e2b5ff44aa5", "object": "MONDO:0005770", "original_object": "genital herpes", "original_subject": "PENCICLOVIR", "population_context_qualifier": "HIV-infected adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcf0b0fa-bb2c-4f2c-aa9f-1f2da65d8343"]}], "subject": "CHEBI:7956", "supporting_text": ["1 INDICATIONS AND USAGE Famciclovir, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients (1.1) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients (1.2) Treatment of recurrent episodes of orolabial or genital herpes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Human Immunodeficiency Virus (HIV) infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:663b3ce1-41e0-5c2f-a648-6d217ebb6466", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:075a2d5a-a830-57d0-ae57-95d5a80eaf8e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a5a7d63-5edb-5f63-b28a-0e2b5ff44aa5", "object": "MONDO:0005770", "original_object": "genital herpes", "original_subject": "PENCICLOVIR", "population_context_qualifier": "HIV-infected adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d5c46506-a350-44a1-9440-d939da895f16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d5c46506-a350-44a1-9440-d939da895f16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5c46506-a350-44a1-9440-d939da895f16"]}], "subject": "CHEBI:7956", "supporting_text": ["1 INDICATIONS AND USAGE Famciclovir, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients (1.1) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients (1.2) Treatment of recurrent episodes of orolabial or genital herpes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Human Immunodeficiency Virus (HIV)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d7d043f-5696-56ea-97c8-552d99d8a558", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:075a2d5a-a830-57d0-ae57-95d5a80eaf8e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a5a7d63-5edb-5f63-b28a-0e2b5ff44aa5", "object": "MONDO:0005770", "original_object": "genital herpes", "original_subject": "PENCICLOVIR", "population_context_qualifier": "HIV-infected adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2b21ad5-fa83-1fb6-e053-2a95a90a3d0f"]}], "subject": "CHEBI:7956", "supporting_text": ["1 INDICATIONS AND USAGE Famciclovir tablets, a prodrug of penciclovir, are a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV) -Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Human Immunodeficiency Virus (HIV)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca84b31d-f8bb-5d0e-a86b-78474dc20f88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:075a2d5a-a830-57d0-ae57-95d5a80eaf8e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a5a7d63-5edb-5f63-b28a-0e2b5ff44aa5", "object": "MONDO:0005770", "original_object": "genital herpes", "original_subject": "PENCICLOVIR", "population_context_qualifier": "HIV-infected adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c44b8d2-3b70-4e8b-af03-2e917178f761", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c44b8d2-3b70-4e8b-af03-2e917178f761", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c44b8d2-3b70-4e8b-af03-2e917178f761"]}], "subject": "CHEBI:7956", "supporting_text": ["1 INDICATIONS AND USAGE Famciclovir tablets, a prodrug of penciclovir, are a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV) -Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Human Immunodeficiency Virus (HIV)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e08eb909-44d6-5817-91df-4162b0bc491c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960924", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:075a2d5a-a830-57d0-ae57-95d5a80eaf8e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0a5a7d63-5edb-5f63-b28a-0e2b5ff44aa5", "object": "MONDO:0005770", "original_object": "genital herpes", "original_subject": "PENCICLOVIR", "population_context_qualifier": "HIV-infected adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3f02042f-8f51-4ccf-b608-5dcd75d100fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3f02042f-8f51-4ccf-b608-5dcd75d100fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f02042f-8f51-4ccf-b608-5dcd75d100fb"]}], "subject": "CHEBI:7956", "supporting_text": ["1 INDICATIONS AND USAGE Famciclovir tablets, a prodrug of penciclovir, are a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV) -Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13d63833-8a93-5294-b27c-90a5eeb57264", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [94, 119], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "population_context_qualifier": "patients with intermittent claudication", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e09702d1-43d4-47ed-9563-5af3cd667727", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e09702d1-43d4-47ed-9563-5af3cd667727", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e09702d1-43d4-47ed-9563-5af3cd667727"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets, USP are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b199d5b-97e2-5df0-bb63-6ce740b95c65", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:40ae2d9a-0d95-640d-0640-f76e7e1a13cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=40ae2d9a-0d95-640d-0640-f76e7e1a13cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=40ae2d9a-0d95-640d-0640-f76e7e1a13cb"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23b2287a-acb0-5c03-9100-04086cbad324", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [56, 81], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0d1d50f-9023-4e2f-889f-a5febba70fa5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0d1d50f-9023-4e2f-889f-a5febba70fa5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0d1d50f-9023-4e2f-889f-a5febba70fa5"]}], "subject": "CHEBI:7986", "supporting_text": ["TRENTAL is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. TRENTAL can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29cb60d1-cd5c-589b-bfb1-f9ab135d18b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [94, 119], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "population_context_qualifier": "patients with intermittent claudication", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73a76a95-ada5-4707-ab89-fd60e8eda64e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73a76a95-ada5-4707-ab89-fd60e8eda64e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73a76a95-ada5-4707-ab89-fd60e8eda64e"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets, USP are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c3c316a-d2f7-532e-b304-aa70f9855ab2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6c39757-4551-4493-b27f-5b311fd1fc77", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6c39757-4551-4493-b27f-5b311fd1fc77", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6c39757-4551-4493-b27f-5b311fd1fc77"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32477d7c-b892-52e0-8b68-b3470b440ffa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [113, 138], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c3ad4fb4-8995-46ab-86e9-7ec67ef607f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c3ad4fb4-8995-46ab-86e9-7ec67ef607f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3ad4fb4-8995-46ab-86e9-7ec67ef607f9"]}], "subject": "CHEBI:7986", "supporting_text": ["INDICATIONS &amp; USAGE Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c082650-e272-5a35-af20-8313478d7ff6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59c9a583-1f93-480f-879c-457a574374da", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59c9a583-1f93-480f-879c-457a574374da", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59c9a583-1f93-480f-879c-457a574374da"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53bb2459-31df-5aac-894e-2ff8e588b083", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73a6351c-5a8d-abbf-e053-2991aa0a5382", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73a6351c-5a8d-abbf-e053-2991aa0a5382", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73a6351c-5a8d-abbf-e053-2991aa0a5382"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline Extended-Release Tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-Release Tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66c8f0b3-aafa-5860-bc88-91a6090e13e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [87, 112], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73f8cef4-39f3-4f71-b3cc-8da07b8fd65f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73f8cef4-39f3-4f71-b3cc-8da07b8fd65f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73f8cef4-39f3-4f71-b3cc-8da07b8fd65f"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85eaabbb-5a51-54df-b0e3-335f6e64e7e2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [87, 112], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2141f08f-1623-4c88-a157-8dc4aebd3bda", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2141f08f-1623-4c88-a157-8dc4aebd3bda", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2141f08f-1623-4c88-a157-8dc4aebd3bda"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c0bb39c-48ce-58ec-8a10-e37aa79e46aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f247ffa-6df9-36f2-e053-2a95a90a346e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f247ffa-6df9-36f2-e053-2a95a90a346e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f247ffa-6df9-36f2-e053-2a95a90a346e"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9decda92-ccea-5738-a222-cc1552eeebb6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [87, 112], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:edd4dbbc-04ed-4741-9cd9-42e9b744f99e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=edd4dbbc-04ed-4741-9cd9-42e9b744f99e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=edd4dbbc-04ed-4741-9cd9-42e9b744f99e"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline Extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae8b411f-5d87-5d3b-ac33-5a1e453905dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ca79c97-e4e5-4297-85eb-7a9b3d8083b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ca79c97-e4e5-4297-85eb-7a9b3d8083b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ca79c97-e4e5-4297-85eb-7a9b3d8083b5"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline Extended-Release Tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-Release Tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcfc20dd-f31e-554d-ae15-61428aa020ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [87, 112], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:24eb2c70-ca20-490c-837c-9de4f5914225", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=24eb2c70-ca20-490c-837c-9de4f5914225", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24eb2c70-ca20-490c-837c-9de4f5914225"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline Extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c47c0d47-e8c0-5ea6-8225-e48f4288f05a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [113, 138], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37"]}], "subject": "CHEBI:7986", "supporting_text": ["INDICATIONS &amp; USAGE Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c609717c-8dd0-5428-ab62-f1214ee654dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:84816505-9253-41cf-8894-2b2d0e4aff67", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=84816505-9253-41cf-8894-2b2d0e4aff67", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=84816505-9253-41cf-8894-2b2d0e4aff67"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc109bec-35af-5090-abd7-82b3b5ffad1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd2f2672-62cd-4e77-8b0b-782f5d06198b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd2f2672-62cd-4e77-8b0b-782f5d06198b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd2f2672-62cd-4e77-8b0b-782f5d06198b"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline Extended-Release Tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-Release Tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce0a3bd8-659f-5a0d-940b-c5acad5687cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f238969-08bb-9464-e053-2995a90abda3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f238969-08bb-9464-e053-2995a90abda3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f238969-08bb-9464-e053-2995a90abda3"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebd223d9-0dc6-5a8d-bcf7-e592d148b399", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [87, 112], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e95e105c-d2b0-47f8-9c9c-c825d5d85578", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e95e105c-d2b0-47f8-9c9c-c825d5d85578", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e95e105c-d2b0-47f8-9c9c-c825d5d85578"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic occlusive arterial disease of the limbs", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fc9f3109-6843-519c-a94c-f883911eb4fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19840830", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf066f9d-0950-53e2-bdd0-2bf9743638c3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53a5063c-68d9-548b-be26-205dda82e4cc", "object": "HP:0004417", "object_location_in_text": [89, 114], "original_object": "intermittent claudication", "original_subject": "PENTOXIFYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8f24268f-c214-aef0-e053-2995a90a2d62", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8f24268f-c214-aef0-e053-2995a90a2d62", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8f24268f-c214-aef0-e053-2995a90a2d62"]}], "subject": "CHEBI:7986", "supporting_text": ["Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stable coronary artery disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36ae9f80-85d6-5fc1-885a-fba3f7036027", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c3576da-af99-5163-92ff-dd4de2110da5", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PERINDOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fbb31482-9ac8-48c6-b814-5d467f22051b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fbb31482-9ac8-48c6-b814-5d467f22051b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fbb31482-9ac8-48c6-b814-5d467f22051b"]}], "subject": "CHEBI:8024", "supporting_text": ["Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .)"], "temporal_context_qualifier": "stable coronary artery disease"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stable coronary artery disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:80ceeab9-e48b-5ab5-8603-e3ce51054bb6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c3576da-af99-5163-92ff-dd4de2110da5", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PERINDOPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:97a9e8bf-91ed-4256-97d4-f9504bb01373", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=97a9e8bf-91ed-4256-97d4-f9504bb01373", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97a9e8bf-91ed-4256-97d4-f9504bb01373"]}], "subject": "CHEBI:8024", "supporting_text": ["1 INDICATIONS AND USAGE ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) 1.1 Hypertension ACEON is indicated for the treatment of patients with essential hypertension. ACEON may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 1.2 Stable Coronary Artery Disease ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. ACEON can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stable coronary artery disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0cbb45a-1a11-5ad9-b34d-6db346ef619b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c3576da-af99-5163-92ff-dd4de2110da5", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PERINDOPRIL", "population_context_qualifier": "patients with stable coronary artery disease", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87768fbf-7c63-47da-8925-0316f343d6ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87768fbf-7c63-47da-8925-0316f343d6ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87768fbf-7c63-47da-8925-0316f343d6ef"]}], "subject": "CHEBI:8024", "supporting_text": ["1 INDICATIONS AND USAGE Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. (1.1) Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. (1.2) 1.1 Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 1.2 Stable Coronary Artery Disease Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stable coronary artery disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f462c98d-4533-5b38-aac9-5f128383689b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1c3576da-af99-5163-92ff-dd4de2110da5", "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PERINDOPRIL", "population_context_qualifier": "patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fcaefca9-e6ca-4c97-9eb8-7f1c619ce4d0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fcaefca9-e6ca-4c97-9eb8-7f1c619ce4d0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcaefca9-e6ca-4c97-9eb8-7f1c619ce4d0"]}], "subject": "CHEBI:8024", "supporting_text": ["1 INDICATIONS AND USAGE • Perindopril Erbumine Tablets are indicated for the treatment of patients with essential hypertension ( 1.1 ) • Perindopril Erbumine Tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) 1.1 Hypertension Perindopril Erbumine Tablets are indicated for the treatment of patients with essential hypertension. Perindopril Erbumine Tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 1.2 Stable Coronary Artery Disease Perindopril Erbumine Tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. Perindopril Erbumine Tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "functional origin", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f058963-0b29-5110-90a1-fa5b065b4e46", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20221117", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:76102a54-6815-542f-b94d-5d63ea99b8aa", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PHENOBARBITAL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b42d35de-a07a-4db5-998d-d4dbb92342cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b42d35de-a07a-4db5-998d-d4dbb92342cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b42d35de-a07a-4db5-998d-d4dbb92342cf"]}], "subject": "CHEBI:8069", "supporting_text": ["Parenteral Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0235560", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:acdd806b-41d2-564a-8996-494f3a850467", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20221117", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0235560"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c5eca796-e171-502e-a1dc-29423e24112f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:76102a54-6815-542f-b94d-5d63ea99b8aa", "object": "UMLS:C0019080", "original_object": "hemorrhage", "original_subject": "PHENOBARBITAL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b42d35de-a07a-4db5-998d-d4dbb92342cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b42d35de-a07a-4db5-998d-d4dbb92342cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b42d35de-a07a-4db5-998d-d4dbb92342cf"]}], "subject": "CHEBI:8069", "supporting_text": ["Parenteral Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0001945", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32d3d206-7a68-5d66-b305-c791b467e3c5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20080101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001945"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ffba4a3b-e593-5db1-b471-c054541a8603", "object": "HP:0012735", "object_location_in_text": [37, 42], "original_object": "cough", "original_subject": "Phenylephrine 5mg + Chlorpheniramine maleate 0.5mg + Paracetamol 125mg + sodium citrate 60mg + Menthol 1mg (per 5ml) Syrup", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:8093", "supporting_text": ["For the treatment of common cold and cough associated with fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c715c2d-f77b-59de-a11d-2f5a1fa4e567", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "HP:0012735", "object_location_in_text": [48, 53], "original_object": "cough", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f805c01-220c-5d01-804b-eab5169652e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "MONDO:0005002"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "HP:0012735", "object_location_in_text": [138, 143], "original_object": "cough", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea32721-a164-4eed-8eb6-f91a1ced20ef"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses Nighttime temporarily relieves these symptoms occuring with a cold, hay fever, or other upper respiratory allergies nasal congestion cough runny nose sneezing itchy, watery eyes itching of the nose or throat Daytime temporaily relieves cough due to minor throat and bronchial irritation occuring with a cold, and nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy, watery eyes sneezing itching of the nose or throat temporarily restores freer breathing through the nose"], "temporal_context_qualifier": "occuring with a cold"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:761c53f7-650c-5b25-9612-87d81e7fc2e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "HP:0012735", "object_location_in_text": [214, 219], "original_object": "cough", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90cc8dca-b448-402c-bb48-407039a62616", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90cc8dca-b448-402c-bb48-407039a62616", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90cc8dca-b448-402c-bb48-407039a62616"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses temporarily relieves these symptoms due to a cold: minor aches and pains minor sore throat pain headache nasal and sinus congestion runny nose sneezing itchy nose or throat itchy, watery eyes due to hay fever cough due to minor throat and bronchial irritation temporarily reduces fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0700184", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d51e47d3-7f67-50bb-9c09-2216236dbbab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0700184", "UMLS:C0549313"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "HP:0012735", "original_object": "cough", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0b3eb8c3-9b9e-861b-e063-6294a90a4a0f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0b3eb8c3-9b9e-861b-e063-6294a90a4a0f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b3eb8c3-9b9e-861b-e063-6294a90a4a0f"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses Temporarily relieves common cold/flu symptoms: Nasal congestion Cough due to minor throat &amp; bronchial irritation Sore throat Headache Minor aches &amp; pains Fever"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9b480ce-906b-50ed-9556-1269c52873ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "HP:0012735", "original_object": "cough", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4d38921-ec90-0658-e053-2a95a90a848a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4d38921-ec90-0658-e053-2a95a90a848a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4d38921-ec90-0658-e053-2a95a90a848a"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses temporarily relieves cold symptoms: • nasal congestion • sinus congestion &amp; pressure • cough due to minor throat &amp; bronchial irritation • cough to help you sleep • runny nose &amp; sneezing • reduces swelling of nasal passages • temporarily restores freer breathing through the nose • promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat and bronchial irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e2176b82-bbce-5bea-8080-b11c95fff2dc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fae16f1-350f-587e-81b1-1dd52c493d72", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "HP:0012735", "original_object": "cough", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=390d0187-a6f4-4387-a528-9eb70e250db1"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses temporarily relieves common cold/flu symptoms: nasal congestion sinus congestion &amp; pressure cough due to minor throat &amp; bronchial irritation cough to help you sleep minor aches &amp; pains headache fever sore throat runny nose &amp; sneezing reduces swelling of nasal passages temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c833a01-3b31-5879-bb6a-5513888c7fce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d59ee85-08e5-452d-a09a-35fcc2a82b75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d59ee85-08e5-452d-a09a-35fcc2a82b75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d59ee85-08e5-452d-a09a-35fcc2a82b75"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE Phenylephrine hydrochloride injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )"], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21a6b56b-c5b4-5851-b652-fa366b3922f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "object_location_in_text": [135, 146], "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e1a7ab4b-0afe-4463-a039-5be0323cf2f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e1a7ab4b-0afe-4463-a039-5be0323cf2f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1a7ab4b-0afe-4463-a039-5be0323cf2f7"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE IMMPHENTIV injection 100 mcg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock. IMMPHENTIV injection 100 mcg/mL is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection 10 mg/mL is alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock."], "temporal_context_qualifier": "in the settings of anesthesia and septic shock"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6196af84-46f5-5c77-a9f8-62d70a3b4108", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d92631a6-bae8-493b-b4df-c563346607a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d92631a6-bae8-493b-b4df-c563346607a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d92631a6-bae8-493b-b4df-c563346607a8"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE Phenylephrine Hydrochloride Injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )"], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67214dc5-f1cc-5731-a465-794b4ddd3bce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1b9f1d54-ea46-49c8-a33e-c94a61bc0460", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1b9f1d54-ea46-49c8-a33e-c94a61bc0460", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b9f1d54-ea46-49c8-a33e-c94a61bc0460"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS &amp; USAGE Phenylephrine hydrochloride Injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine hydrochloride Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia."], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a94bbaa-cef7-53d2-89da-a90052d7c7b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c7026b15-1228-4acb-beed-4474fcdbb972", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c7026b15-1228-4acb-beed-4474fcdbb972", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c7026b15-1228-4acb-beed-4474fcdbb972"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE Phenylephrine Hydrochloride Injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )"], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:adcc439f-0dd4-53b9-ae6a-0a467822147f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:170e63f1-23f4-4839-ab89-b81832d94a56", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=170e63f1-23f4-4839-ab89-b81832d94a56", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=170e63f1-23f4-4839-ab89-b81832d94a56"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE Phenylephrine hydrochloride injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.( 1 )"], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6be142b-9996-5194-8bb0-1a7d3c7919b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b54a0c59-e5e4-4fd7-ba91-c991ce87b148", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b54a0c59-e5e4-4fd7-ba91-c991ce87b148", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b54a0c59-e5e4-4fd7-ba91-c991ce87b148"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock. Phenylephrine Hydrochloride Injection 10 mg/mL is alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock."], "temporal_context_qualifier": "anesthesia ; septic shock"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cf043f20-e20e-5f8f-ae4c-df70153fba4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4cea0781-2513-4030-8568-62dec253f866", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4cea0781-2513-4030-8568-62dec253f866", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4cea0781-2513-4030-8568-62dec253f866"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE Phenylephrine hydrochloride injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )"], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042401", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d94eb41d-4df1-5f57-8bb2-1702340713a8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042401"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f715e4e-b269-b935-d2c9-003cb29770be", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f715e4e-b269-b935-d2c9-003cb29770be", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f715e4e-b269-b935-d2c9-003cb29770be"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE BIORPHEN is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. BIORPHEN injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )"], "temporal_context_qualifier": "in the setting of anesthesia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor throat & bronchial irritation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:061c6782-dc3e-5f41-9e2b-0d5fe6772233", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a826f97a-8114-5ce4-ba9c-63999388a16b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "MONDO:0005709", "object_location_in_text": [26, 37], "original_object": "common cold", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02fbe8b3-49e2-8712-e063-6294a90add50"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses temporarily relieves common cold symptoms: cough due to minor throat &amp; bronchial irritation sneezing runny nose"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "conditions where short term pupil dilation is desired", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:043a1b97-1afa-50ea-b95c-1522b8805f2c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a84d18c3-1929-5bc5-84ee-5964d473b52b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "UMLS:C0026961", "object_location_in_text": [200, 214], "original_object": "pupil dilation", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dbff7eeb-a16a-4106-ae5e-4effdd33cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dbff7eeb-a16a-4106-ae5e-4effdd33cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dbff7eeb-a16a-4106-ae5e-4effdd33cc45"]}], "subject": "CHEBI:8093", "supporting_text": ["1 INDICATIONS AND USAGE MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1% / 2.5% is indicated to induce mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. MYDCOMBI is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist indicated to induce mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002315", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9e99159-f3a5-5338-8042-7519b4f4c22d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002315"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d23745-88e6-5098-b4a0-8e1b721a79f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "UMLS:C0235309", "object_location_in_text": [125, 138], "original_object": "upset stomach", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses for the relief of: heartburn, acid indigestion, and sour stomach when accompanied with headache or body aches and pains upset stomach with headache from overindulgence in food or drink headache, body aches, and pain alone"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002315", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2047da3d-42b6-5c89-a5df-c33c51257899", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002315"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a569b57e-af37-5880-a6ef-d749dbda9aba", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2610989e-bfcd-5747-8bca-3215f0b964a5", "object": "UMLS:C0860277", "object_location_in_text": [57, 69], "original_object": "sour stomach", "original_subject": "PHENYLEPHRINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0039fee5-35a8-429b-a1cf-7b4bf1f8a6e7"]}], "subject": "CHEBI:8093", "supporting_text": ["Uses for the relief of: heartburn, acid indigestion, and sour stomach when accompanied with headache or body aches and pains upset stomach with headache from overindulgence in food or drink headache, body aches, and pain alone"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1b7660c-533f-5fc6-8c02-d8db82590529", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:da083389-28c5-533a-b9a0-1d95ec62cd5c", "object": "MONDO:0002280", "object_location_in_text": [108, 114], "original_object": "anemia", "original_subject": "ERYTHROPOIETIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3af26b0d-8ad0-44e1-a538-8bdb5ab39374", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3af26b0d-8ad0-44e1-a538-8bdb5ab39374"]}], "subject": "CHEBI:81579", "supporting_text": ["1 INDICATIONS AND USAGE RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 )."], "temporal_context_qualifier": "myelosuppressive chemotherapy planned for minimum two additional months"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2a8316d7-e2b4-52d2-a8f4-f8f80e7ce471", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1035, 1047], "original_object": "appendicitis", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1cb1314-d3e0-4b44-a1df-de14c32e8cc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1cb1314-d3e0-4b44-a1df-de14c32e8cc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1cb1314-d3e0-4b44-a1df-de14c32e8cc6"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) • Skin and skin structure infections in adults ( 1.3 ) • Female pelvic infections in adults ( 1.4 ) • Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.6 ). 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration ( 2 )]. 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and compli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3203359", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39477b49-69c4-5da1-b3b5-7889df959984", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3203359", "MONDO:0005227"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1201, 1213], "original_object": "appendicitis", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a63ca653-27d4-45fe-a744-77e0efe45220", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a63ca653-27d4-45fe-a744-77e0efe45220", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a63ca653-27d4-45fe-a744-77e0efe45220"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and Tazobactam for Injection and Sodium Chloride Injection, is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection and Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycosi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3203359", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e587cac-71c5-5ab9-babd-01d3d50d8575", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3203359", "MONDO:0005227"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [891, 903], "original_object": "appendicitis", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8db6bd91-2106-4bfd-8cc8-38aaf1e18d17", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE ZOSYN is a combination of piperacillin, a penicillin‑class antibacterial and tazobactam, a beta‑lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) • Skin and skin structure infections in adults ( 1.3 ) • Female pelvic infections in adults ( 1.4 ) • Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN and other antibacterial drugs, ZOSYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections ZOSYN is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia ZOSYN is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections ZOSYN is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus . 1.4 Female Pelvic Inf"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:67d67985-ba4b-5c3c-89ea-a1645b503e74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1046, 1058], "original_object": "appendicitis", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2b67a8f-2bbc-5e9d-9db6-bbc1e252f310", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1025, 1037], "original_object": "appendicitis", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [ see Dosage and Administration (2) ]. 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and complicated sk"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd035b53-be67-5205-bc8a-50c0ff31fb96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1046, 1058], "original_object": "appendicitis", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031864", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bbbb400-8af1-5165-8a73-61c4f5e472be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031864"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d4e72bbd-956e-5434-81fe-4fecb29096de", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "UMLS:C0036690", "original_object": "septicemia", "original_subject": "PIPERACILLIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:FAC0C875-111E-4AF2-D186-ED4D4EE9DE59", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=FAC0C875-111E-4AF2-D186-ED4D4EE9DE59", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=FAC0C875-111E-4AF2-D186-ED4D4EE9DE59"]}], "subject": "CHEBI:8232", "supporting_text": ["Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nosocomial pneumonia moderate to severe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4840f52c-8777-5728-b3eb-4941118dd4ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4852b1dd-cd0a-53dc-abd9-6571e1ae3443", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "UMLS:C0949083", "object_location_in_text": [1462, 1482], "original_object": "nosocomial pneumonia", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nosocomial pneumonia moderate to severe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c24f1b8-df7f-555f-a70a-b53fa634102e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4852b1dd-cd0a-53dc-abd9-6571e1ae3443", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7a45ca87-4b20-51d1-9901-a70f6524909f", "medic_supporting_text_truncated": true, "object": "UMLS:C0949083", "object_location_in_text": [1462, 1482], "original_object": "nosocomial pneumonia", "original_subject": "PIPERACILLIN", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496"]}], "subject": "CHEBI:8232", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "insomnia characterized by difficulties with sleep onset and/or sleep maintenance", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87a8c446-f96f-5fd8-a050-68b1ae0207be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:05f85dc6-0b72-5a05-bfb6-45256ab9f99c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bf3a195-e093-57e3-a248-4445f2f75a1b", "object": "MONDO:0013600", "object_location_in_text": [82, 90], "original_object": "insomnia", "original_subject": "SUVOREXANT", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5b72731-1acb-45b7-9c13-290ad12d3951", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951"]}], "subject": "CHEBI:82698", "supporting_text": ["1 INDICATIONS AND USAGE BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. BELSOMRA is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "17p deletion, TP53 mutation", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db170b2f-27b5-5c38-af64-31c20afc542e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140918", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["rituximab", "ofatumumab"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:024df648-8774-55f3-9625-9605566ae4ab", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4952f63f-49ac-53d1-a59c-a7108c9fd4d2", "object": "HP:0005550", "original_object": "chronic lymphocytic leukaemia", "original_subject": "idelalisib", "population_context_qualifier": "adult patients not eligible for any other therapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zydelig", "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig"]}], "subject": "CHEBI:82701", "supporting_text": ["Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):  who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.  Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C1335723", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ac00c74-e7e9-5299-b9c2-33ec8cca6ca1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140918", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1335723"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:76cc24d7-3940-555c-8e1b-22026acd3a97", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4952f63f-49ac-53d1-a59c-a7108c9fd4d2", "object": "MONDO:0018906", "original_object": "follicular lymphoma", "original_subject": "idelalisib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zydelig", "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig"]}], "subject": "CHEBI:82701", "supporting_text": ["Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):  who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.  Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08e0199d-afb5-5e75-b897-4a23a0fed71c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140916", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:469763ff-640f-51cf-93db-1d78f97fee3b", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "NALOXEGOL", "population_context_qualifier": "adult patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:300a6474-ebcd-4404-8040-48fdcfcc1635", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=300a6474-ebcd-4404-8040-48fdcfcc1635"]}], "subject": "CHEBI:82975", "supporting_text": ["1 INDICATIONS AND USAGE MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. MOVANTIK is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chronic pain related to prior cancer or its treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2c91093-de37-5046-b8ea-57e4647481ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140916", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:de26fd82-4b34-57d1-b877-40f05045b0d4", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:469763ff-640f-51cf-93db-1d78f97fee3b", "object": "MONDO:0100187", "original_object": "opioid-induced constipation", "original_subject": "NALOXEGOL", "population_context_qualifier": "adult patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:28596788-b73f-4247-85fc-3105f51fff5a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=28596788-b73f-4247-85fc-3105f51fff5a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28596788-b73f-4247-85fc-3105f51fff5a"]}], "subject": "CHEBI:82975", "supporting_text": ["1 INDICATIONS AND USAGE MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. MOVANTIK is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01b4b767-56b7-54d4-b74d-8763f664404e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "HP:0003124", "object_location_in_text": [247, 273], "original_object": "elevated total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86c49aff-0a4a-46b5-ac6e-26789bf17c9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86c49aff-0a4a-46b5-ac6e-26789bf17c9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c49aff-0a4a-46b5-ac6e-26789bf17c9b"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fbaa37a-4a8d-5cae-b4d9-b52c0be20ff8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "HP:0003124", "original_object": "elevated total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be471aad-d936-48be-8c79-351b56ae9cc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be471aad-d936-48be-8c79-351b56ae9cc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be471aad-d936-48be-8c79-351b56ae9cc7"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets are a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c8c326b-4e9c-53ab-bc1f-bcb939277683", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "HP:0003124", "object_location_in_text": [247, 273], "original_object": "elevated total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:777b0c6b-cd25-454d-a35b-d2df9b44497f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=777b0c6b-cd25-454d-a35b-d2df9b44497f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=777b0c6b-cd25-454d-a35b-d2df9b44497f"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.342, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50e650b1-7253-5bfb-8a50-5ac6603ad7b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "HP:0003124", "original_object": "elevated total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42b1ad55-c449-4250-a666-bb36a6ff5b53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42b1ad55-c449-4250-a666-bb36a6ff5b53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42b1ad55-c449-4250-a666-bb36a6ff5b53"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b84ff218-f4c0-51b2-8d25-512d02767ef7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "HP:0003124", "object_location_in_text": [247, 273], "original_object": "elevated total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31c80f84-0169-4659-b9cf-8f897ed319eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31c80f84-0169-4659-b9cf-8f897ed319eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31c80f84-0169-4659-b9cf-8f897ed319eb"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db1dd831-8511-50a6-8373-0513eed79de6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f52ba5b8-7826-5211-909d-b8b2a990e8e6", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "MONDO:0005347", "original_object": "hypertriglyceridemia", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be471aad-d936-48be-8c79-351b56ae9cc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be471aad-d936-48be-8c79-351b56ae9cc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be471aad-d936-48be-8c79-351b56ae9cc7"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets are a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3466fa2d-47d1-559e-88fc-1b81ec72cf53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31c80f84-0169-4659-b9cf-8f897ed319eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31c80f84-0169-4659-b9cf-8f897ed319eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31c80f84-0169-4659-b9cf-8f897ed319eb"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ded7d6e-7ea1-528b-9d81-afacd7fd2de2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86c49aff-0a4a-46b5-ac6e-26789bf17c9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86c49aff-0a4a-46b5-ac6e-26789bf17c9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c49aff-0a4a-46b5-ac6e-26789bf17c9b"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4b1186d-e2ff-543b-a149-f315a4f466cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:777b0c6b-cd25-454d-a35b-d2df9b44497f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=777b0c6b-cd25-454d-a35b-d2df9b44497f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=777b0c6b-cd25-454d-a35b-d2df9b44497f"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c2ee049-e631-5cbf-8b52-f6faed058e59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "medic_supporting_text_truncated": true, "object": "UMLS:C0342879", "object_location_in_text": [183, 211], "original_object": "primary hypercholesterolemia", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85308d64-921b-48e8-b586-68425d84ee3d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85308d64-921b-48e8-b586-68425d84ee3d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85308d64-921b-48e8-b586-68425d84ee3d"]}], "subject": "CHEBI:83469", "supporting_text": ["Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. &gt; 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is som"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f57d7f48-d610-54bf-80d8-bc9731d62ef8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b864f52c-0876-5ebe-ba82-a635fcb7bcfd", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "medic_supporting_text_truncated": true, "object": "UMLS:C0342879", "object_location_in_text": [183, 211], "original_object": "primary hypercholesterolemia", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce403472-6c0c-4854-bb82-ba6539e1ae07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce403472-6c0c-4854-bb82-ba6539e1ae07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce403472-6c0c-4854-bb82-ba6539e1ae07"]}], "subject": "CHEBI:83469", "supporting_text": ["Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. &gt; 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is som"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2699e2f9-0522-5bc6-b638-c9ac331902a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:777b0c6b-cd25-454d-a35b-d2df9b44497f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=777b0c6b-cd25-454d-a35b-d2df9b44497f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=777b0c6b-cd25-454d-a35b-d2df9b44497f"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8da0d9df-7793-566a-81d9-ebe48072d28c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86c49aff-0a4a-46b5-ac6e-26789bf17c9b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86c49aff-0a4a-46b5-ac6e-26789bf17c9b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c49aff-0a4a-46b5-ac6e-26789bf17c9b"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8df6378-251b-5513-9a9e-9bf8f2ad0a05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:31c80f84-0169-4659-b9cf-8f897ed319eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=31c80f84-0169-4659-b9cf-8f897ed319eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31c80f84-0169-4659-b9cf-8f897ed319eb"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a75b99b-aaa9-563f-8a14-031824c025ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d6a25e69-70a5-5129-93e7-e4af9d513924", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "HP:0003124", "original_object": "elevated total cholesterol", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dbae9f9a-763a-4106-94fb-a7fccbb86a4b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dbae9f9a-763a-4106-94fb-a7fccbb86a4b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dbae9f9a-763a-4106-94fb-a7fccbb86a4b"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsule is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7283f7b-a2d6-5dd3-9ef1-cfb25da569d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f52ba5b8-7826-5211-909d-b8b2a990e8e6", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "MONDO:0005347", "original_object": "hypertriglyceridemia", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dbae9f9a-763a-4106-94fb-a7fccbb86a4b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dbae9f9a-763a-4106-94fb-a7fccbb86a4b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dbae9f9a-763a-4106-94fb-a7fccbb86a4b"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsule is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a1710e8-c750-55a3-8045-0473601bc41f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5ae9125b-7a79-585a-843f-dfab4fdbf6c9", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "MONDO:0017773", "original_object": "low high-density lipoprotein cholesterol", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c880d43a-fa8c-4f7a-a488-419bae7cc311", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c880d43a-fa8c-4f7a-a488-419bae7cc311", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c880d43a-fa8c-4f7a-a488-419bae7cc311"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsules are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: · Reduce TG in patients with severe hypertriglyceridemia (1.1). · Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia (1.2)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:932af1c9-61c6-5502-b19b-0950563a0d60", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5ae9125b-7a79-585a-843f-dfab4fdbf6c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "MONDO:0017773", "original_object": "low high-density lipoprotein cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:be471aad-d936-48be-8c79-351b56ae9cc7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=be471aad-d936-48be-8c79-351b56ae9cc7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be471aad-d936-48be-8c79-351b56ae9cc7"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets are a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6ebe765-7672-5482-a03e-bd330bc2d181", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5ae9125b-7a79-585a-843f-dfab4fdbf6c9", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "MONDO:0017773", "original_object": "low high-density lipoprotein cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42b1ad55-c449-4250-a666-bb36a6ff5b53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42b1ad55-c449-4250-a666-bb36a6ff5b53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42b1ad55-c449-4250-a666-bb36a6ff5b53"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "elevated low-density lipoprotein cholesterol", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3366e735-b4bb-508d-b70f-2ed21cc22bc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:767eebd0-529f-52ce-9647-4f25015cf410", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "MONDO:0021187", "original_object": "hyperlipidemia", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ffcb173-095a-4550-84f2-18959ad2aab8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ffcb173-095a-4550-84f2-18959ad2aab8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ffcb173-095a-4550-84f2-18959ad2aab8"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsules indicated as adjunctive therapy to diet: • to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). • to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d77dc94-3e6f-5613-97fb-d2537982b286", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb559b34-79b1-45a6-a148-38639115cd49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb559b34-79b1-45a6-a148-38639115cd49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb559b34-79b1-45a6-a148-38639115cd49"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70235906-6760-5b0b-96ad-b4297b3b00ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3ad559c-b107-409f-a297-a052765b71ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3ad559c-b107-409f-a297-a052765b71ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3ad559c-b107-409f-a297-a052765b71ab"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed release capsules are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8ab2454-9bce-59b0-8893-d35497ce47bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09310de5-1eaa-44ba-8d9b-2abc1ad1cc33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09310de5-1eaa-44ba-8d9b-2abc1ad1cc33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09310de5-1eaa-44ba-8d9b-2abc1ad1cc33"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8911e6d-269b-5308-afd4-ed32a6f07f6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aec5af02-8dd7-5882-adfc-3c398cc815fa", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0202236", "original_object": "triglycerides", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9a3f97c-9e31-4a5f-822f-c9d45e394493", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9a3f97c-9e31-4a5f-822f-c9d45e394493", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9a3f97c-9e31-4a5f-822f-c9d45e394493"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsule is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a626b80-411a-5e05-a274-fb30ee37c175", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.192375, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3ad559c-b107-409f-a297-a052765b71ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3ad559c-b107-409f-a297-a052765b71ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3ad559c-b107-409f-a297-a052765b71ab"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed release capsules are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3fa4d9d5-3f7c-58d4-82a7-d0d58344ff47", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb559b34-79b1-45a6-a148-38639115cd49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb559b34-79b1-45a6-a148-38639115cd49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb559b34-79b1-45a6-a148-38639115cd49"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.192375, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8ac969b-9a47-5faf-8abf-3a94ce45bef2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.192375, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9a3f97c-9e31-4a5f-822f-c9d45e394493", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9a3f97c-9e31-4a5f-822f-c9d45e394493", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9a3f97c-9e31-4a5f-822f-c9d45e394493"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsule is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea47250e-5724-503a-a49f-d1a3604a6b0d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b764fd8b-a9bf-5342-ad9a-2a541d4625aa", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C0523509", "original_object": "apolipoprotein B", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09310de5-1eaa-44ba-8d9b-2abc1ad1cc33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09310de5-1eaa-44ba-8d9b-2abc1ad1cc33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09310de5-1eaa-44ba-8d9b-2abc1ad1cc33"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:91cf65b0-5456-545c-9dd7-daf5760292e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:74a17a1f-e22a-5f3f-9bcc-e7c1659d67a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C1445957", "original_object": "total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb559b34-79b1-45a6-a148-38639115cd49", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb559b34-79b1-45a6-a148-38639115cd49", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb559b34-79b1-45a6-a148-38639115cd49"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.2025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95b438e3-d02a-5a1c-bc93-f0c908052205", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:74a17a1f-e22a-5f3f-9bcc-e7c1659d67a7", "medic_pair_confidence": 0.2025, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C1445957", "original_object": "total cholesterol", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3ad559c-b107-409f-a297-a052765b71ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3ad559c-b107-409f-a297-a052765b71ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3ad559c-b107-409f-a297-a052765b71ab"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed release capsules are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.2025, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b771c73-de02-5f87-b214-0190a7557964", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:74a17a1f-e22a-5f3f-9bcc-e7c1659d67a7", "medic_pair_confidence": 0.2025, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C1445957", "original_object": "total cholesterol", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9a3f97c-9e31-4a5f-822f-c9d45e394493", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9a3f97c-9e31-4a5f-822f-c9d45e394493", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9a3f97c-9e31-4a5f-822f-c9d45e394493"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsule is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa8533d7-f8a1-5a70-a799-daf6105e3920", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:74a17a1f-e22a-5f3f-9bcc-e7c1659d67a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C1445957", "original_object": "total cholesterol", "original_subject": "FENOFIBRIC ACID", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09310de5-1eaa-44ba-8d9b-2abc1ad1cc33", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09310de5-1eaa-44ba-8d9b-2abc1ad1cc33", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09310de5-1eaa-44ba-8d9b-2abc1ad1cc33"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid tablets is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d169bfdf-f775-55e1-8c5e-0f1b12b45828", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090814", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:32cc1ab9-4a85-52ef-b7fe-7699ae688ec0", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aac629dc-4733-52b8-ab39-37e39e0d0b5e", "object": "UMLS:C3807409", "original_object": "low HDL cholesterol", "original_subject": "FENOFIBRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dbae9f9a-763a-4106-94fb-a7fccbb86a4b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dbae9f9a-763a-4106-94fb-a7fccbb86a4b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dbae9f9a-763a-4106-94fb-a7fccbb86a4b"]}], "subject": "CHEBI:83469", "supporting_text": ["1 INDICATIONS AND USAGE Fenofibric acid delayed-release capsule is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ( 1.1 ). Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC in patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5f1bbc9-45b4-5ec3-afa4-b1344c226ed9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8202658-422f-41db-bdee-7bb95b972b32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8202658-422f-41db-bdee-7bb95b972b32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8202658-422f-41db-bdee-7bb95b972b32"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6228fee-e28c-5dde-8ee9-25ca21ed6f58", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b55790fa-2413-4243-83ec-0391b2effe11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b55790fa-2413-4243-83ec-0391b2effe11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b55790fa-2413-4243-83ec-0391b2effe11"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for exampl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f84fb34b-5894-5e96-8619-089ab9d52c94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:879df2f9-d238-4cde-bbf8-82aef20fde3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=879df2f9-d238-4cde-bbf8-82aef20fde3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=879df2f9-d238-4cde-bbf8-82aef20fde3b"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1a6cd529-392f-51ef-b7d4-f4be653783fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:879df2f9-d238-4cde-bbf8-82aef20fde3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=879df2f9-d238-4cde-bbf8-82aef20fde3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=879df2f9-d238-4cde-bbf8-82aef20fde3b"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3cf04fc4-d3df-5d4f-b1c0-01f4f7a9efff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b55790fa-2413-4243-83ec-0391b2effe11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b55790fa-2413-4243-83ec-0391b2effe11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b55790fa-2413-4243-83ec-0391b2effe11"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for exampl"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:539c9da9-c91f-5ea4-af37-66c7a73e1955", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8202658-422f-41db-bdee-7bb95b972b32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8202658-422f-41db-bdee-7bb95b972b32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8202658-422f-41db-bdee-7bb95b972b32"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da85eb5a-5f47-5eda-b05a-c2432ba64ebb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c8202658-422f-41db-bdee-7bb95b972b32", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c8202658-422f-41db-bdee-7bb95b972b32", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c8202658-422f-41db-bdee-7bb95b972b32"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e545b550-a5de-513b-bb5f-7d6445d1c23a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:fafb4a0e-4a8e-5518-89fd-db7d46677829", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "PRAZOSIN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:879df2f9-d238-4cde-bbf8-82aef20fde3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=879df2f9-d238-4cde-bbf8-82aef20fde3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=879df2f9-d238-4cde-bbf8-82aef20fde3b"]}], "subject": "CHEBI:8364", "supporting_text": ["Prazosin hydrochloride capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for e"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "complete or partial response to platinum-based chemotherapy", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0d865f8-ab81-5240-a484-2ef6e41863b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180813", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:5de0d314-475c-5f61-8191-eac348e21c0e", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:81a8d3d2-ad9c-5677-9494-f8be9e61fda7", "object": "MONDO:0002158", "original_object": "fallopian tube cancer", "original_subject": "Olaparib film coated tablets (100mg, 150 mg)", "population_context_qualifier": "adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer: • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Breast cancer: • In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0877373", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:614bed47-c3b4-5c0d-9330-a2a313ec2ccf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141216", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["bevacizumab"], "medic_disease_context_ids": ["UMLS:C0877373"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5de0d314-475c-5f61-8191-eac348e21c0e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "MONDO:0002158", "original_object": "fallopian tube cancer", "original_subject": "olaparib", "population_context_qualifier": "adult patients who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynparza", "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer Lynparza is indicated as monotherapy for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.  Lynparza in combination with bevacizumab is indicated for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).  Breast cancer Lynparza is indicated as:  monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.  Adenocarcinoma of the pancreas Lynparza is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "complete or partial response to platinum-based chemotherapy", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb3a0877-5cb5-5190-af22-95ad699c56f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180813", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:6baec09c-c6b1-517f-88ee-6894ac2e3db6", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:81a8d3d2-ad9c-5677-9494-f8be9e61fda7", "object": "MONDO:0005140", "original_object": "epithelial ovarian cancer", "original_subject": "Olaparib film coated tablets (100mg, 150 mg)", "population_context_qualifier": "adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer: • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Breast cancer: • In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "germline BRCA1/2-mutations", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b103848-a32b-57bd-a7fc-6f7c787ae36e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141216", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:3691bcb1-2b26-531c-aca6-70b0d8545e55", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "MONDO:0006047", "original_object": "metastatic adenocarcinoma of the pancreas", "original_subject": "olaparib", "population_context_qualifier": "adult patients who have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynparza", "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer Lynparza is indicated as monotherapy for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.  Lynparza in combination with bevacizumab is indicated for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).  Breast cancer Lynparza is indicated as:  monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.  Adenocarcinoma of the pancreas Lynparza is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4319571", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3216a1bd-488a-5407-abd4-f5d4ba06a361", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141216", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4319571"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [1326, 1345], "original_object": "early breast cancer", "original_subject": "olaparib", "population_context_qualifier": "adult patients previously treated with neoadjuvant or adjuvant chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynparza", "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer Lynparza is indicated as monotherapy for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.  Lynparza in combination with bevacizumab is indicated for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).  Breast cancer Lynparza is indicated as:  monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.  Adenocarcinoma of the pancreas Lynparza is"], "temporal_context_qualifier": "adjuvant"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "high risk early breast cancer", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86f0abe1-77bc-5c3d-9634-e68e50e040a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141219", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [1590, 1609], "original_object": "early breast cancer", "original_subject": "OLAPARIB", "population_context_qualifier": "adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:741ff3e3-dc1a-45a6-84e5-2481b27131aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa"]}], "subject": "CHEBI:83766", "supporting_text": ["1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Pat"], "temporal_context_qualifier": "following neoadjuvant or adjuvant chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "BRCA mutation-positive and HER2-negative breast cancer", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a487408a-3784-56b8-97d5-d18559ee5519", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220824", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "object": "MONDO:0007254", "object_location_in_text": [131, 144], "original_object": "breast cancer", "original_subject": "OLAPARIB", "population_context_qualifier": "high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OLAPARIB#39-20220824", "https://www.pmda.go.jp/files/000269956.pdf"]}], "subject": "CHEBI:83766", "supporting_text": ["Drugs with a new indication and a new dosage for the postoperative adjuvant treatment of BRCA mutation- positive and HER2-negative breast cancer with a high risk of recurrence."], "temporal_context_qualifier": "postoperative adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "proficient mismatch repair", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0e396bf-c264-5596-a94a-48618fb12ca5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20241122", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["durvalumab (genetical recombination)"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:1432a819-2634-5491-88c6-449835fca064", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "object": "MONDO:0011962", "original_object": "advanced endometrial cancer", "original_subject": "OLAPARIB", "population_context_qualifier": "patients who have received chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OLAPARIB#17-20241122", "https://www.pmda.go.jp/files/000269956.pdf"]}], "subject": "CHEBI:83766", "supporting_text": ["Drugs with a new indication and a new dosage for the maintenance therapy of advanced or recurrent endometrial cancer with proficient mismatch repair (pMMR) in patients who have received chemotherapy including treatment with durvalumab (genetical recombination)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "complete or partial response to platinum-based chemotherapy", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fcc8b32-fa61-5084-a590-2d716470c0b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180813", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:49c0251c-38aa-58bd-8959-7d40767c064b", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:81a8d3d2-ad9c-5677-9494-f8be9e61fda7", "object": "MONDO:0015686", "object_location_in_text": [119, 144], "original_object": "primary peritoneal cancer", "original_subject": "Olaparib film coated tablets (100mg, 150 mg)", "population_context_qualifier": "adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer: • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Breast cancer: • In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0877373", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c13608e-0d07-5e37-96f4-5132a46db373", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141216", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["bevacizumab"], "medic_disease_context_ids": ["UMLS:C0877373"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:49c0251c-38aa-58bd-8959-7d40767c064b", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "MONDO:0015686", "object_location_in_text": [232, 257], "original_object": "primary peritoneal cancer", "original_subject": "olaparib", "population_context_qualifier": "adult patients who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynparza", "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer Lynparza is indicated as monotherapy for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.  Lynparza in combination with bevacizumab is indicated for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).  Breast cancer Lynparza is indicated as:  monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.  Adenocarcinoma of the pancreas Lynparza is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, hormone receptor (HR)-positive breast cancer", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d8f49b45-f847-56a0-97b9-2f40369160bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180813", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:81a8d3d2-ad9c-5677-9494-f8be9e61fda7", "object": "UMLS:C0278488", "object_location_in_text": [561, 585], "original_object": "metastatic breast cancer", "original_subject": "Olaparib film coated tablets (100mg, 150 mg)", "population_context_qualifier": "patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer: • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. • For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Breast cancer: • In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4087376", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3c58fd1c-9db9-54fe-9474-04f12913ace6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141216", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4087376"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "UMLS:C0278488", "object_location_in_text": [1559, 1583], "original_object": "metastatic breast cancer", "original_subject": "olaparib", "population_context_qualifier": "adult patients who have previously been treated with an anthracycline and a taxane", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynparza", "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer Lynparza is indicated as monotherapy for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.  Lynparza in combination with bevacizumab is indicated for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).  Breast cancer Lynparza is indicated as:  monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.  Adenocarcinoma of the pancreas Lynparza is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HER2-negative metastatic breast cancer", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9879b359-4fd9-5b6f-a6f4-79460dd63b1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141219", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "UMLS:C0278488", "object_location_in_text": [1880, 1904], "original_object": "metastatic breast cancer", "original_subject": "OLAPARIB", "population_context_qualifier": "adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:741ff3e3-dc1a-45a6-84e5-2481b27131aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa"]}], "subject": "CHEBI:83766", "supporting_text": ["1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Pat"], "temporal_context_qualifier": "following chemotherapy in the neoadjuvant, adjuvant or metastatic setting"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "complete or partial response to platinum-based chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:860249e7-87b4-5e76-b08e-ccace020a9d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["platinum-based chemotherapy"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:5644b704-971f-5f76-9eaf-2f48ad09e417", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "object": "UMLS:C0278689", "object_location_in_text": [77, 101], "original_object": "recurrent ovarian cancer", "original_subject": "OLAPARIB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OLAPARIB#94-20180119", "https://www.pmda.go.jp/files/000269956.pdf"]}], "subject": "CHEBI:83766", "supporting_text": ["Drugs with a new active ingredient indicated for the maintenance treament of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4087376", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29101bcd-f9f4-56ad-954a-a06aac713095", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141216", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4087376"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1c988f27-7dc9-52e0-917f-ba607babd2ea", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "medic_supporting_text_truncated": true, "object": "UMLS:C3495949", "original_object": "locally advanced breast cancer", "original_subject": "olaparib", "population_context_qualifier": "adult patients who have previously been treated with an anthracycline and a taxane", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lynparza", "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"]}], "subject": "CHEBI:83766", "supporting_text": ["Ovarian cancer Lynparza is indicated as monotherapy for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.  Lynparza in combination with bevacizumab is indicated for the:  maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).  Breast cancer Lynparza is indicated as:  monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.  Adenocarcinoma of the pancreas Lynparza is"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "BRCA mutation-positive", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e479fc0-1fce-55ca-9d9b-06c2b1becdc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230823", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:944682f0-a69f-5723-89bf-3612c67533f6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a5a16354-6511-50c2-b850-bda7488c16f5", "object": "UMLS:C4721208", "object_location_in_text": [79, 126], "original_object": "metastatic castration-resistant prostate cancer", "original_subject": "OLAPARIB", "population_context_qualifier": "BRCA mutation-positive patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OLAPARIB#27-20230823", "https://www.pmda.go.jp/files/000269956.pdf"]}], "subject": "CHEBI:83766", "supporting_text": ["Drugs with a new dosage indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22fdd587-ac28-512d-9cbd-221f362391f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [300, 306], "original_object": "asthma", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:55653e94-2964-5c61-8d9d-7e403e81799f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [300, 306], "original_object": "asthma", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:719d3418-4b2e-525b-99a7-7acabe502feb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [300, 306], "original_object": "asthma", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcd76ef0-fae0-57fe-b000-529806d71bfc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [300, 306], "original_object": "asthma", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e24133d9-c585-578f-a02e-3d99c34a4453", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004979", "object_location_in_text": [300, 306], "original_object": "asthma", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:288a5f39-c55f-5a73-b4d9-78afae465b74", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [328, 345], "original_object": "atopic dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:474e0182-4702-51ab-90a6-e92a1986fe56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [328, 345], "original_object": "atopic dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:689b42cd-84f0-5fd0-943f-73782765dc57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [328, 345], "original_object": "atopic dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a83ceb2-541e-53f9-9aca-0d732b76f200", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [328, 345], "original_object": "atopic dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bbb5de29-e1a3-5bf5-a016-184a51962be5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:24fa7b6d-4bd6-5c60-9f62-c48555d15005", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0004980", "object_location_in_text": [328, 345], "original_object": "atopic dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ba8d37a-3432-5580-a748-4acf9771b60e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [308, 326], "original_object": "contact dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7dd9a14b-6c04-5f32-84c6-387b0bc043b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [308, 326], "original_object": "contact dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:811dfd7c-fdac-5928-83d9-ac601ea21831", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [308, 326], "original_object": "contact dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bee13d79-513c-538c-8de1-bbe3ec2be474", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [308, 326], "original_object": "contact dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:db96272a-16be-593a-85d6-88dfd13ac7cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ee00c82b-e551-589d-a581-8969836c0ecf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0005480", "object_location_in_text": [308, 326], "original_object": "contact dermatitis", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:485c32ab-192c-5245-9c94-11363872b506", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "MONDO:0005642", "object_location_in_text": [134, 157], "original_object": "allergic conjunctivitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe"]}], "subject": "CHEBI:8378", "supporting_text": ["Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c3016827-a58c-5e3a-ae60-5e28402d1fb0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42dcab72-0809-54f3-ad5f-4f558bad71e6", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "MONDO:0006604", "object_location_in_text": [159, 171], "original_object": "acne rosacea", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe"]}], "subject": "CHEBI:8378", "supporting_text": ["Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd337e06-04e0-525c-be6f-653fa1c7fec7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "MONDO:0006814", "object_location_in_text": [230, 236], "original_object": "iritis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe"]}], "subject": "CHEBI:8378", "supporting_text": ["Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular inflammatory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac829fcf-0329-5594-b5bf-a7e3a4deae67", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular inflammatory conditions unresponsive to topical corticosteroids", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da1dceaf-f749-5bb9-8051-a0af90517cef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ocular inflammatory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5cbf16f-40a1-5902-aaae-304790d4b4af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6079512e-a739-518e-ab59-11ab61b6c3b3", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0020283", "original_object": "uveitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:241a9e06-23d3-59b3-9a16-34b9d4c1553d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [347, 361], "original_object": "serum sickness", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ec401b5-132a-4cd2-8c24-6a5c8b63c2f9"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29222c0d-af17-5ba5-bab5-8e563095e153", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [347, 361], "original_object": "serum sickness", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d8c861d-3756-4b75-aaa9-1b82cf11eb94"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75d2e89a-28f6-56b3-a9d2-7973756d5dbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [347, 361], "original_object": "serum sickness", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b372f7-b811-4c15-85c4-c6dbac342cb4"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d7dd915-1f47-5bc3-8750-175ec1c848aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [347, 361], "original_object": "serum sickness", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f87ce1ba-335e-463d-87d5-9af0206f8f61"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aad661f8-2b8c-5797-b574-a7bc744902ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d5c00be-8689-559e-a7aa-5c6a862653c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "medic_supporting_text_truncated": true, "object": "MONDO:0043789", "object_location_in_text": [347, 361], "original_object": "serum sickness", "original_subject": "PREDNISOLONE", "population_context_qualifier": "adult and pediatric populations", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1f937e7-fed5-4079-bd52-5d930b34ae9f"]}], "subject": "CHEBI:8378", "supporting_text": ["Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ab3319ea-e327-5541-bd0c-6dc53a4ea81c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ddf87f0d-5989-5157-9240-f8e3c4505678", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "UMLS:C0006435", "original_object": "chemical burns", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fcce64a-94ea-4031-ad5a-c4eddc73a910", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fcce64a-94ea-4031-ad5a-c4eddc73a910", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fcce64a-94ea-4031-ad5a-c4eddc73a910"]}], "subject": "CHEBI:8378", "supporting_text": ["PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e4e6f22-2ec7-560a-acce-c8ad96ab8eda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b919c3d-2b4e-552f-9a24-b227cc74e12c", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "UMLS:C0010543", "object_location_in_text": [238, 246], "original_object": "cyclitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe"]}], "subject": "CHEBI:8378", "supporting_text": ["Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0266bb78-c48e-5ff6-87cc-0120506119b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:290f7060-3413-55e4-9983-c7d00dd3a61a", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "UMLS:C0153027", "object_location_in_text": [205, 228], "original_object": "herpes zoster keratitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe"]}], "subject": "CHEBI:8378", "supporting_text": ["Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:72cdac58-461c-5e18-8d1a-d368510c329b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:31076079-f5bc-5832-a71b-03c7d56c627d", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "UMLS:C0259799", "object_location_in_text": [173, 203], "original_object": "superficial punctate keratitis", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b17d2a0e-5f89-4253-9a8a-bb6ec59919fe"]}], "subject": "CHEBI:8378", "supporting_text": ["Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:348e705b-f816-5d02-8256-a5e6cb52e84f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4041d402-97d5-5852-84c9-01eb092cb64f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f8ba3915-16bf-5a83-bee9-997d58966906", "object": "UMLS:C0701836", "object_location_in_text": [181, 194], "original_object": "thermal burns", "original_subject": "PREDNISOLONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4fcce64a-94ea-4031-ad5a-c4eddc73a910", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4fcce64a-94ea-4031-ad5a-c4eddc73a910", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fcce64a-94ea-4031-ad5a-c4eddc73a910"]}], "subject": "CHEBI:8378", "supporting_text": ["PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "UMLS:C0442893", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f60eee1-16d8-5ad0-867b-360836c8f72c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0442893"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e755dc48-6cf4-5e14-b36d-7a54b5e9083e", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:baeb8e91-e8e0-5ab1-93c2-82e71bf453fc", "object": "MONDO:0001609", "original_object": "granulocytopenia", "original_subject": "PRIMAQUINE", "population_context_qualifier": "acutely ill patients", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c920cdf-5c1e-43f7-a275-c72040005715", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c920cdf-5c1e-43f7-a275-c72040005715", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c920cdf-5c1e-43f7-a275-c72040005715"]}], "subject": "CHEBI:8405", "supporting_text": ["Primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. The drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, Primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "systemic disease manifested by tendency to granulocytopenia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ad033f3-93e8-5011-9214-4f7ab325d8ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a80f36b5-c122-5081-b154-711c671f8cdf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:baeb8e91-e8e0-5ab1-93c2-82e71bf453fc", "object": "MONDO:0004670", "object_location_in_text": [302, 321], "original_object": "lupus erythematosus", "original_subject": "PRIMAQUINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82465385-4602-7f46-e053-2991aa0a9fdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82465385-4602-7f46-e053-2991aa0a9fdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82465385-4602-7f46-e053-2991aa0a9fdf"]}], "subject": "CHEBI:8405", "supporting_text": ["Severe glucose-6-phosphate dehydrogenase (G6PD) deficiency (see WARNINGS ). Pregnant women (see WARNINGS , Usage in Pregnancy ). Primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. The drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "systemic disease manifested by tendency to granulocytopenia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62af72b2-e6b7-5998-9b98-45db2524b9cf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a80f36b5-c122-5081-b154-711c671f8cdf", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:baeb8e91-e8e0-5ab1-93c2-82e71bf453fc", "object": "MONDO:0004670", "object_location_in_text": [173, 192], "original_object": "lupus erythematosus", "original_subject": "PRIMAQUINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c920cdf-5c1e-43f7-a275-c72040005715", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c920cdf-5c1e-43f7-a275-c72040005715", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c920cdf-5c1e-43f7-a275-c72040005715"]}], "subject": "CHEBI:8405", "supporting_text": ["Primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. The drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, Primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "systemic disease manifested by tendency to granulocytopenia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:16eea923-64f6-5aba-b9d0-935ee988ffc3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:baeb8e91-e8e0-5ab1-93c2-82e71bf453fc", "object": "MONDO:0008383", "object_location_in_text": [277, 297], "original_object": "rheumatoid arthritis", "original_subject": "PRIMAQUINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82465385-4602-7f46-e053-2991aa0a9fdf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82465385-4602-7f46-e053-2991aa0a9fdf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82465385-4602-7f46-e053-2991aa0a9fdf"]}], "subject": "CHEBI:8405", "supporting_text": ["Severe glucose-6-phosphate dehydrogenase (G6PD) deficiency (see WARNINGS ). Pregnant women (see WARNINGS , Usage in Pregnancy ). Primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. The drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "systemic disease manifested by tendency to granulocytopenia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4dd3e3b-28da-5d0f-b18d-854f75357a8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:baeb8e91-e8e0-5ab1-93c2-82e71bf453fc", "object": "MONDO:0008383", "object_location_in_text": [148, 168], "original_object": "rheumatoid arthritis", "original_subject": "PRIMAQUINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5c920cdf-5c1e-43f7-a275-c72040005715", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5c920cdf-5c1e-43f7-a275-c72040005715", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5c920cdf-5c1e-43f7-a275-c72040005715"]}], "subject": "CHEBI:8405", "supporting_text": ["Primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. The drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, Primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0858321", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e9dccc33-e160-591f-b6f4-e421eca94bae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160328", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0858321", "UMLS:C0858320"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:635e9b80-d941-5339-9f00-5b59c6ccb246", "object": "MONDO:0005136", "object_location_in_text": [67, 74], "original_object": "malaria", "original_subject": "PRIMAQUINE PHOSPHATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PRIMAQUINE PHOSPHATE#108-20160328", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:8405", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "patients on monoamine oxidase (MAO) inhibitor therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c69d04fc-01c6-5c9a-9b36-9ba918362a7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase (MAO) inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:aa9d225d-ca19-57d9-8294-28fad9d538b7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "MONDO:0005010", "object_location_in_text": [590, 620], "original_object": "severe coronary artery disease", "original_subject": "TRIPROLIDINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10"]}], "subject": "CHEBI:84116", "supporting_text": ["Pseudodine™ C Cough Syrup is contraindicated under the following conditions: Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. Hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS, Drug Interactions )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "patients on monoamine oxidase (MAO) inhibitor therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f1e0e03-eebb-5ea2-bcbf-7cc6441e510b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["monoamine oxidase (MAO) inhibitor"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d036fe90-e61c-585c-868a-ee042b01d8e7", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "MONDO:0005044", "object_location_in_text": [569, 588], "original_object": "severe hypertension", "original_subject": "TRIPROLIDINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=DD62A5EB-DD5A-4329-8696-07ACB555AF10"]}], "subject": "CHEBI:84116", "supporting_text": ["Pseudodine™ C Cough Syrup is contraindicated under the following conditions: Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Lower Respiratory Disease Antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. Hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (MAO) inhibitor therapy (see PRECAUTIONS, Drug Interactions )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hay fever (allergic rhinitis), upper respiratory allergies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2486feec-c81f-538e-98db-dd1f2565b228", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d703b0fe-4e37-5abc-8bbe-ac410b2cd63e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "HP:0031417", "original_object": "rhinorrhea", "original_subject": "TRIPROLIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2"]}], "subject": "CHEBI:84116", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other uppser respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hay fever (allergic rhinitis), upper respiratory allergies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76dbcd87-d67b-5b96-89f0-2f2ef4c37bfe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:407c071a-097b-5421-b3c5-99902a04e9eb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "HP:0033841", "original_object": "ocular pruritus", "original_subject": "TRIPROLIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2"]}], "subject": "CHEBI:84116", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other uppser respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0031245", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9419608-490e-56d4-9b55-de02a530729d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0031245"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6566fa06-5b40-5cdc-aa8d-f354b508205f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "MONDO:0003781", "original_object": "bronchitis", "original_subject": "TRIPROLIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37dcb0ed-df56-1bec-e063-6394a90a695e"]}], "subject": "CHEBI:84116", "supporting_text": ["DAY Uses ■ temporarily relieves these common cold and flu symptoms: ■ minor aches and pains ■ headache ■ sore throat ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily reduces fever NIGHT Uses ■ temporarily relieves these common cold and flu symptoms: ■ cough ■ minor aches and pains ■ sore throat ■ headache ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes due to hay fever ■ temporarily reduces fever ■ controls cough to help you get to sleep SPRAY Uses temporarily relieves nasal congestion due to: a cold hay fever or other upper respiratory allergies promotes nasal and sinus drainage temporarily relieves sinus congestion and pressure helps clear nasal passages; shrinks swollen membranes"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "upper respiratory allergies", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:627b2738-a229-5f6f-a600-cbe50555c3c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec052dff-f081-5cd9-ac49-74554830869a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "MONDO:0011786", "original_object": "allergic rhinitis", "original_subject": "TRIPROLIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2"]}], "subject": "CHEBI:84116", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other uppser respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hay fever (allergic rhinitis), upper respiratory allergies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:866ee3c1-e181-5450-88cb-b70361bbe789", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ad218193-78fd-594d-a444-3ca74cc4c797", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "UMLS:C0037383", "object_location_in_text": [147, 155], "original_object": "sneezing", "original_subject": "TRIPROLIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2"]}], "subject": "CHEBI:84116", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other uppser respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hay fever (allergic rhinitis), upper respiratory allergies", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c7553110-e67b-5ea0-84bf-c465d56e6513", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fdc487f7-fabb-5e18-8b8b-89671346cb2e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f5cfcd18-b49d-5f8a-8dab-4f17b5c3d587", "object": "UMLS:C0850060", "original_object": "nasal pruritus", "original_subject": "TRIPROLIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4eeffb6d-fc5e-48bc-95f6-ec4d5cb6e0d2"]}], "subject": "CHEBI:84116", "supporting_text": ["Uses temporarily relieves these symptoms due to hay fever (allergic rhinitis) or other uppser respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "grand mal seizures refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f3120a8-b3e8-564d-8751-1186cd631d9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [166, 184], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af593171-dabb-4ea3-b44c-89ed457b2c46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af593171-dabb-4ea3-b44c-89ed457b2c46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af593171-dabb-4ea3-b44c-89ed457b2c46"]}], "subject": "CHEBI:8412", "supporting_text": ["MYSOLINE, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2676167", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5cec768e-3219-5297-81ca-1a21321856b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2676167"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "population_context_qualifier": "patients refractory to other anticonvulsant therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc018b1d-72d3-45a2-84ff-cf9499c7ae97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc018b1d-72d3-45a2-84ff-cf9499c7ae97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc018b1d-72d3-45a2-84ff-cf9499c7ae97"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:988880b2-b746-5c29-b321-b45d7bd73d53", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:93b4b34c-6dba-4aec-b98e-b2b18feb86a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=93b4b34c-6dba-4aec-b98e-b2b18feb86a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=93b4b34c-6dba-4aec-b98e-b2b18feb86a9"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac244580-12fe-5533-9e8d-c5497c7a7c99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3cdc361a-5558-4341-ad40-f8bc29b4f1ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3cdc361a-5558-4341-ad40-f8bc29b4f1ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3cdc361a-5558-4341-ad40-f8bc29b4f1ce"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac753e5e-5e69-57a9-bcdd-7eb207c64635", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02ba0182-0870-4c0d-a814-a1dc427d47b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02ba0182-0870-4c0d-a814-a1dc427d47b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02ba0182-0870-4c0d-a814-a1dc427d47b8"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf8237c0-f311-590b-bb54-a537036e6e90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a90d5ba6-4170-0b97-5ae3-fc707c9e4f1b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a90d5ba6-4170-0b97-5ae3-fc707c9e4f1b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a90d5ba6-4170-0b97-5ae3-fc707c9e4f1b"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0b17561-5927-55fb-b8a6-12429926f2f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7a50a67-9653-463e-8c85-315b53f460c8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7a50a67-9653-463e-8c85-315b53f460c8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7a50a67-9653-463e-8c85-315b53f460c8"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractory to other anticonvulsant therapy", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da18b8ce-4fc8-5a53-b2b6-a8cc48b6ba3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a18ad0e2-f4f3-57a0-8290-71e0f21715ee", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f7a8e320-e175-5e60-b8fa-084aaa041ba7", "object": "HP:0002069", "object_location_in_text": [175, 193], "original_object": "grand mal seizures", "original_subject": "PRIMIDONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c56d09c-4224-4875-bb22-e8bfd595d378", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c56d09c-4224-4875-bb22-e8bfd595d378", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c56d09c-4224-4875-bb22-e8bfd595d378"]}], "subject": "CHEBI:8412", "supporting_text": ["Primidone tablets used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268108", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1332a115-9eb0-5833-95b9-61f8826f6463", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1941ad84-b5a4-5251-8343-3f708f47dfdb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8feeb93b-1f89-50ed-8cbc-56540ab163e2", "object": "MONDO:0005393", "original_object": "gout", "original_subject": "PROBENECID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:573e61e5-f5e1-4119-9d8e-d9a961a1baa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=573e61e5-f5e1-4119-9d8e-d9a961a1baa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=573e61e5-f5e1-4119-9d8e-d9a961a1baa9"]}], "subject": "CHEBI:8426", "supporting_text": ["INDICATIONS &amp; USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0268108", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:192da7e9-e12e-5bd7-bc1b-63dbd4f83231", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0268108"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1941ad84-b5a4-5251-8343-3f708f47dfdb", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8feeb93b-1f89-50ed-8cbc-56540ab163e2", "object": "MONDO:0005393", "original_object": "gout", "original_subject": "PROBENECID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3"]}], "subject": "CHEBI:8426", "supporting_text": ["INDICATIONS &amp; USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "frequent, recurrent acute attacks of gout", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4254fd5e-f101-540b-9425-c8f86494d5be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37d938ad-d287-5f70-9b7e-502d4f4dfbef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8feeb93b-1f89-50ed-8cbc-56540ab163e2", "object": "UMLS:C0268108", "object_location_in_text": [21, 44], "original_object": "chronic gouty arthritis", "original_subject": "PROBENECID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0567fe6-132b-463b-bc46-9f5a2a2478fb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0567fe6-132b-463b-bc46-9f5a2a2478fb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0567fe6-132b-463b-bc46-9f5a2a2478fb"]}], "subject": "CHEBI:8426", "supporting_text": ["For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "frequent, recurrent acute attacks of gout", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:539f1fb3-e481-5798-bea0-ee36d36cd54e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:37d938ad-d287-5f70-9b7e-502d4f4dfbef", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8feeb93b-1f89-50ed-8cbc-56540ab163e2", "object": "UMLS:C0268108", "object_location_in_text": [21, 44], "original_object": "chronic gouty arthritis", "original_subject": "PROBENECID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b85d3e27-70ff-4533-b463-410e4fb23813", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b85d3e27-70ff-4533-b463-410e4fb23813", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b85d3e27-70ff-4533-b463-410e4fb23813"]}], "subject": "CHEBI:8426", "supporting_text": ["For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:002d7789-7621-5be7-bfae-17c73028cf13", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69365f67-6a14-433b-e053-2991aa0a0ba0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69365f67-6a14-433b-e053-2991aa0a0ba0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69365f67-6a14-433b-e053-2991aa0a0ba0"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning. )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening arrhythmias", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:14366c70-a1ea-50ba-898b-3fe74a299922", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [106, 129], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8192d79d-da2b-2532-e053-2991aa0ae8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8192d79d-da2b-2532-e053-2991aa0ae8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8192d79d-da2b-2532-e053-2991aa0ae8ad"]}], "subject": "CHEBI:8428", "supporting_text": ["INDICATIONS &amp; USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and BOXED WARNING .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30f1e14d-c646-5216-bde0-a31cb197f0c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7cb1594-61cf-41c4-9007-1ee28aa69c50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7cb1594-61cf-41c4-9007-1ee28aa69c50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7cb1594-61cf-41c4-9007-1ee28aa69c50"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening arrhythmias", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:34e8c2e5-8840-57c3-b69c-944f7b5d611d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [106, 129], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9508d1a2-da9a-5480-e053-2a95a90a73c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9508d1a2-da9a-5480-e053-2a95a90a73c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9508d1a2-da9a-5480-e053-2a95a90a73c7"]}], "subject": "CHEBI:8428", "supporting_text": ["INDICATIONS &amp; USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and BOXED WARNING .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3769ba82-6e5f-5e94-8441-048309ca4ed2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:358c956e-8c6c-4bd6-a6bc-194d5b3d6d9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=358c956e-8c6c-4bd6-a6bc-194d5b3d6d9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=358c956e-8c6c-4bd6-a6bc-194d5b3d6d9a"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide Hydrochloride Injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (See WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:738d21bc-46e6-50fd-a2c7-955183ee2ecf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d5d9d6e-1f1c-7565-e063-6394a90a93e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d5d9d6e-1f1c-7565-e063-6394a90a93e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d5d9d6e-1f1c-7565-e063-6394a90a93e7"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81119b82-045c-58a9-a614-81efc5a75682", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [106, 129], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fcaa5e9a-3c8a-4796-aa87-626268b6cf60", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fcaa5e9a-3c8a-4796-aa87-626268b6cf60", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcaa5e9a-3c8a-4796-aa87-626268b6cf60"]}], "subject": "CHEBI:8428", "supporting_text": ["INDICATIONS &amp; USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2956d17-01c3-55e5-9be1-a1eed5bfa663", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ffde440f-7ad7-434c-bcd2-9bd8ff16d204", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ffde440f-7ad7-434c-bcd2-9bd8ff16d204", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ffde440f-7ad7-434c-bcd2-9bd8ff16d204"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide Hydrochloride Injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2e55aa6-95c3-5db9-b471-543901903a3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42405567-3d04-7aec-e063-6294a90aba0a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42405567-3d04-7aec-e063-6294a90aba0a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42405567-3d04-7aec-e063-6294a90aba0a"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide Hydrochloride Injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (See WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0750197", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed3dc858-026c-5e82-ae3b-e22229addfed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0750197"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "HP:0004308", "object_location_in_text": [82, 105], "original_object": "ventricular arrhythmias", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ec3b767-66bb-4634-877e-71f70d501da0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ec3b767-66bb-4634-877e-71f70d501da0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ec3b767-66bb-4634-877e-71f70d501da0"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c3c36ce-d488-5383-b6cb-a43060495553", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "UMLS:C0750197", "object_location_in_text": [115, 148], "original_object": "sustained ventricular tachycardia", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d58751df-cd8b-45a6-8a32-af19e747e23a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d58751df-cd8b-45a6-8a32-af19e747e23a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d58751df-cd8b-45a6-8a32-af19e747e23a"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37c19d08-647c-5818-9e20-04745262cd86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "UMLS:C0750197", "object_location_in_text": [115, 148], "original_object": "sustained ventricular tachycardia", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:17e47845-daad-434c-a784-6d3875b0d704", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:841a0840-d716-547f-9d6b-7a7d7ce1d7c0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "UMLS:C0750197", "object_location_in_text": [115, 148], "original_object": "sustained ventricular tachycardia", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0aac32fa-37b7-5520-e063-6394a90a1fe4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0aac32fa-37b7-5520-e063-6394a90a1fe4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0aac32fa-37b7-5520-e063-6394a90a1fe4"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b79adaa5-8a03-52c5-9f36-f3b8d2367c02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "UMLS:C0750197", "object_location_in_text": [115, 148], "original_object": "sustained ventricular tachycardia", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8effb720-d9f1-2961-e053-2a95a90ac10f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8effb720-d9f1-2961-e053-2a95a90ac10f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8effb720-d9f1-2961-e053-2a95a90ac10f"]}], "subject": "CHEBI:8428", "supporting_text": ["Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0004308", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef2ae41f-ff3b-5c49-a2af-1f455d9eb2f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0004308"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fc8177b5-c2d7-594d-bee4-ebd4b6c65bf5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f73fea68-bc6b-5455-a5f5-5ce70a9e9d9d", "object": "UMLS:C0750197", "object_location_in_text": [139, 172], "original_object": "sustained ventricular tachycardia", "original_subject": "PROCAINAMIDE", "population_context_qualifier": "patients with life-threatening arrhythmias", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fece65c0-fdbc-61d8-e053-6294a90a9a68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fece65c0-fdbc-61d8-e053-6294a90a9a68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fece65c0-fdbc-61d8-e053-6294a90a9a68"]}], "subject": "CHEBI:8428", "supporting_text": ["INDICATIONS &amp; USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "P. falciparum malaria", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a21df3f-7c64-505c-a6c6-18c5c98c5c36", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39ea084f-b766-57bd-89df-45a34bb2809a", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:68d1c99b-92e6-5a86-971f-6fafbcaea8ab", "object": "UMLS:C1565489", "original_object": "severe renal impairment", "original_subject": "PROGUANIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:152433eb-1341-9cc0-e063-6394a90a1481", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=152433eb-1341-9cc0-e063-6394a90a1481", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=152433eb-1341-9cc0-e063-6394a90a1481"]}], "subject": "CHEBI:8455", "supporting_text": ["4 CONTRAINDICATIONS Atovaquone and proguanil hydrochloride tablets are contraindicated in individuals with known hypersensitivity reactions to atovaquone or proguanil hydrochloride or any component of the formulation [see Warnings and Precautions (5.4) , Adverse Reactions (6.2) ] . Atovaquone and proguanil hydrochloride tablets are contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) because of pancytopenia in patients with severe renal impairment treated with proguanil [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] . Known serious hypersensitivity reactions to atovaquone or proguanil hydrochloride or any component of the formulation. ( 4 ) Prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min). ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2606d74e-b679-5935-a1c6-aa546ac848b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0004979", "object_location_in_text": [379, 385], "original_object": "asthma", "original_subject": "PROMETHAZINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine is contraindicated for use in pediatric patients less than two years of age. Promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d894d877-b570-5b3f-9697-82ae8aa52d7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0004979", "object_location_in_text": [425, 431], "original_object": "asthma", "original_subject": "PROMETHAZINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3983d6d3-8bf4-4a88-962f-9bf72fd6e685", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3983d6d3-8bf4-4a88-962f-9bf72fd6e685", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3983d6d3-8bf4-4a88-962f-9bf72fd6e685"]}], "subject": "CHEBI:8461", "supporting_text": ["Dextromethorphan should not be used in patients receiving a monoamine oxidase inhibitor (MAOI) (see PRECAUTIONS , Drug Interactions ). Promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "lower respiratory tract symptoms", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ef0e18c0-e9e7-51ee-9122-c34ea2fbb574", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7bc37424-94ea-5189-9e1e-9e46d5bedfb5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0004979", "object_location_in_text": [391, 397], "original_object": "asthma", "original_subject": "PROMETHAZINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f99bbd5-02f7-2fed-e063-6394a90a6355", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f99bbd5-02f7-2fed-e063-6394a90a6355", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f99bbd5-02f7-2fed-e063-6394a90a6355"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Syrup is contraindicated for use in pediatric patients less than two years of age. Promethazine Syrup is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms including asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bd5e6eb-fb69-57e4-92a3-42eb6637305a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d30e587-6d59-4cf5-ab45-c7639f759df9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d30e587-6d59-4cf5-ab45-c7639f759df9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d30e587-6d59-4cf5-ab45-c7639f759df9"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4660f15b-5297-536c-9de9-95c327ca0401", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4156e780-7ecf-bcae-e063-6394a90a2ae2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4156e780-7ecf-bcae-e063-6394a90a2ae2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4156e780-7ecf-bcae-e063-6394a90a2ae2"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c7e1782-2840-526b-b863-036d4357550b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:974208c8-4aad-4fb9-991b-cf3085034272", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=974208c8-4aad-4fb9-991b-cf3085034272", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=974208c8-4aad-4fb9-991b-cf3085034272"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf1660d7-53ea-57de-a962-1c745bffb80e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e4e57fa-4ce3-4b7b-be5a-381801ed0386", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e4e57fa-4ce3-4b7b-be5a-381801ed0386", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e4e57fa-4ce3-4b7b-be5a-381801ed0386"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anesthesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd68bd2b-7ac4-5656-b433-0ec97b7eed37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anesthesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfdb597e-2f43-5e61-88e0-973f87df193f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine HCl Suppositories are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e183124b-06e4-5f01-a3c2-6e6ec7b77c2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a797d11-19b0-fd33-e063-6394a90a4d58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a797d11-19b0-fd33-e063-6394a90a4d58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a797d11-19b0-fd33-e063-6394a90a4d58"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efa33826-8e1e-5c5f-b7e9-4fd73ba422d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5991de26-891a-153a-e063-6294a90a4633", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5991de26-891a-153a-e063-6294a90a4633", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5991de26-891a-153a-e063-6294a90a4633"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anesthesia-related nausea and vomiting, surgery-related nausea and vomiting", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d87964e-5023-5fdb-92b9-ea142003ad3c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6728bb41-5d50-4abb-bb73-993dcc16ee66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6728bb41-5d50-4abb-bb73-993dcc16ee66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6728bb41-5d50-4abb-bb73-993dcc16ee66"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c8f4bc5-73e3-5727-8365-c58a5fb63ec9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002017", "object_location_in_text": [548, 567], "original_object": "nausea and vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c525cb2c-9a01-4a9b-ad2c-08630719953d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c525cb2c-9a01-4a9b-ad2c-08630719953d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c525cb2c-9a01-4a9b-ad2c-08630719953d"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6218c66c-4aae-5e34-ba1b-f8866f75e5b7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002017", "object_location_in_text": [548, 567], "original_object": "nausea and vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7675718-0a57-41ff-a771-79afc12150aa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7675718-0a57-41ff-a771-79afc12150aa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7675718-0a57-41ff-a771-79afc12150aa"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6e2c5fab-1662-5dd5-8c64-b441e0a4310f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002017", "object_location_in_text": [560, 579], "original_object": "nausea and vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7ce351d8-47be-4937-aad2-153208c93b53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7ce351d8-47be-4937-aad2-153208c93b53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ce351d8-47be-4937-aad2-153208c93b53"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride injection is indicated for the following conditions: • Amelioration of allergic reactions to blood or plasma. • In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. • For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. • For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. • Active treatment of motion sickness. • Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. • As an adjunct to analgesics for the control of postoperative pain. • Preoperative, postoperative, and obstetric (during labor) sedation. • Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anesthesia-related nausea and vomiting, surgery-related nausea and vomiting", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba704385-5315-54ac-b614-3be9f018cd3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5590f356-0904-58f6-e063-6294a90a6ad5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5590f356-0904-58f6-e063-6294a90a6ad5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5590f356-0904-58f6-e063-6294a90a6ad5"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anesthesia-related nausea and vomiting, surgery-related nausea and vomiting", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7699461-fd79-58e5-97a8-4806bd2dfa4f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4466-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4466-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4466-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e7cecbe-cda6-55cc-8bee-c4f36cbfd6c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:974208c8-4aad-4fb9-991b-cf3085034272", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=974208c8-4aad-4fb9-991b-cf3085034272", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=974208c8-4aad-4fb9-991b-cf3085034272"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40ccf45c-694e-53b7-9e67-6497aa203973", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e4e57fa-4ce3-4b7b-be5a-381801ed0386", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e4e57fa-4ce3-4b7b-be5a-381801ed0386", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e4e57fa-4ce3-4b7b-be5a-381801ed0386"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f1ecf5d-ec1d-5c1d-b4a0-f77a05421fac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5991de26-891a-153a-e063-6294a90a4633", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5991de26-891a-153a-e063-6294a90a4633", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5991de26-891a-153a-e063-6294a90a4633"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9865d3cb-6f66-56a7-ac82-57ff5ff6d41a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a797d11-19b0-fd33-e063-6394a90a4d58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a797d11-19b0-fd33-e063-6394a90a4d58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a797d11-19b0-fd33-e063-6394a90a4d58"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2d9c255-0cb8-5a9c-b611-6810cb90318e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d30e587-6d59-4cf5-ab45-c7639f759df9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d30e587-6d59-4cf5-ab45-c7639f759df9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d30e587-6d59-4cf5-ab45-c7639f759df9"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0038895", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6921c87-6da2-5046-902c-e2c164c6ec98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0038895"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4156e780-7ecf-bcae-e063-6394a90a2ae2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4156e780-7ecf-bcae-e063-6394a90a2ae2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4156e780-7ecf-bcae-e063-6394a90a2ae2"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anesthesia and surgery", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce642f84-9063-51ce-9d23-b7bc3063f95e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "HP:0002018", "original_object": "nausea", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine HCl Suppositories are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood or plasma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:683731fa-a856-5fb5-b3f8-d55d026bb283", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergens and foods", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21bfd5f8-e68a-5b67-b03b-913fe9867989", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine HCl Suppositories are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergens and foods", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58175fe3-08c9-5063-bc4f-6d4ca0bbf9ff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bae9c9c1-107f-0fcb-e053-2a95a90a75b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bae9c9c1-107f-0fcb-e053-2a95a90a75b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bae9c9c1-107f-0fcb-e053-2a95a90a75b2"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergens and foods", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:637d9f9e-4d25-52d7-95a3-fa84bffcb521", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f99bbd5-02f7-2fed-e063-6394a90a6355", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f99bbd5-02f7-2fed-e063-6394a90a6355", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f99bbd5-02f7-2fed-e063-6394a90a6355"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "inhalant allergens and foods", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bfcedba-4b41-5e08-8908-d5eb4ca65b18", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9de4476-6e14-5755-b13f-5efdc934a181", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "MONDO:0005642", "original_object": "allergic conjunctivitis", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ca17cd4-460e-4d54-8c53-a58a2b80e5cb"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d23a285-4d65-5dc7-95f4-7544d8e47a2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6d940f8-fa1a-4a75-b4fc-2cbbaf7a0488", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6d940f8-fa1a-4a75-b4fc-2cbbaf7a0488", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6d940f8-fa1a-4a75-b4fc-2cbbaf7a0488"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride tablets, USP are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2811b2ef-e3a8-57ad-b3ac-f04b4818b65e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4156e780-7ecf-bcae-e063-6394a90a2ae2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4156e780-7ecf-bcae-e063-6394a90a2ae2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4156e780-7ecf-bcae-e063-6394a90a2ae2"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48087961-aa6d-5345-9149-997d24e312ab", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9ff2bd5-6464-4c9e-b2ed-dcd2dbe83c47", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9ff2bd5-6464-4c9e-b2ed-dcd2dbe83c47", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9ff2bd5-6464-4c9e-b2ed-dcd2dbe83c47"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride tablets, USP are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:58879c23-e4fc-5192-9e5d-7ab88866f33d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a797d11-19b0-fd33-e063-6394a90a4d58", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a797d11-19b0-fd33-e063-6394a90a4d58", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a797d11-19b0-fd33-e063-6394a90a4d58"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood sensitivity, plasma sensitivity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a860207-a391-54d3-84af-7d76015d4581", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6728bb41-5d50-4abb-bb73-993dcc16ee66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6728bb41-5d50-4abb-bb73-993dcc16ee66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6728bb41-5d50-4abb-bb73-993dcc16ee66"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood or plasma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:89fdb985-fef5-5dbc-8926-05fd8ba72603", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bae9c9c1-107f-0fcb-e053-2a95a90a75b2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bae9c9c1-107f-0fcb-e053-2a95a90a75b2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bae9c9c1-107f-0fcb-e053-2a95a90a75b2"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood or plasma", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96d3b748-1605-5c72-9fb7-a68b978e19ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=047b9a7c-586b-4635-a63e-2c7ce9ec34e7"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine HCl Suppositories are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of postoperative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:acd52be3-16fb-5da0-9618-fe3c2f890d37", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6bcaa89f-5f14-dc45-e053-2a91aa0aac54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6bcaa89f-5f14-dc45-e053-2a91aa0aac54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6bcaa89f-5f14-dc45-e053-2a91aa0aac54"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride tablets, USP are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood sensitivity, plasma sensitivity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b19af291-7925-5aca-8297-16e76aa677f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5590f356-0904-58f6-e063-6294a90a6ad5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5590f356-0904-58f6-e063-6294a90a6ad5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5590f356-0904-58f6-e063-6294a90a6ad5"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2af7d54-0596-5a7c-94e1-a1d09ec2e9eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9e4e57fa-4ce3-4b7b-be5a-381801ed0386", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9e4e57fa-4ce3-4b7b-be5a-381801ed0386", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e4e57fa-4ce3-4b7b-be5a-381801ed0386"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcddfa1d-31dd-5f01-9882-785ffdfffd99", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5991de26-891a-153a-e063-6294a90a4633", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5991de26-891a-153a-e063-6294a90a4633", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5991de26-891a-153a-e063-6294a90a4633"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d953e3d5-510b-501f-99a0-823cbb61d71a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:974208c8-4aad-4fb9-991b-cf3085034272", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=974208c8-4aad-4fb9-991b-cf3085034272", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=974208c8-4aad-4fb9-991b-cf3085034272"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de9e20ae-c484-5e60-917a-b0e8b3d348d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d30e587-6d59-4cf5-ab45-c7639f759df9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d30e587-6d59-4cf5-ab45-c7639f759df9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d30e587-6d59-4cf5-ab45-c7639f759df9"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for. Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0274435", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f43e2afd-e9e7-5ac1-a85b-eeab8252684a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0274435"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:804e2525-d61f-7bed-e053-2991aa0a5daa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=804e2525-d61f-7bed-e053-2991aa0a5daa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=804e2525-d61f-7bed-e053-2991aa0a5daa"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine hydrochloride tablets, USP are useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "blood sensitivity, plasma sensitivity", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f4e6b24c-f8e6-528c-9b5f-57fffb8930fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:592bb337-2224-523a-9d68-747070119656", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7038edb-2523-5327-9eeb-2937e18ae726", "object": "UMLS:C1527304", "original_object": "allergic reactions", "original_subject": "PROMETHAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55f618d1-4466-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55f618d1-4466-3200-e063-6394a90a89a8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55f618d1-4466-3200-e063-6394a90a89a8"]}], "subject": "CHEBI:8461", "supporting_text": ["Promethazine Hydrochloride, is useful orally for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012531", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:669ad19e-92bd-5d28-a72e-e51bd524f8fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012531"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4f4807b-962f-5c69-9457-8a0df0bd64ed", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c4bd3260-0bd4-5a6f-a0a9-010581bf2e1e", "object": "HP:0001945", "object_location_in_text": [182, 187], "original_object": "fever", "original_subject": "PROPOXYPHENE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b3e3fee-b02a-4898-a45e-e4abc1e8d9f4"]}], "subject": "CHEBI:8497", "supporting_text": ["Propoxyphene napsylate and acetaminophen tablets, 100 mg/650 mg are indicated for the relief of mild to moderate pain, either when pain is present alone or when it is accompanied by fever."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic hepatitis C virus (HCV) infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:08a57555-7924-542e-960a-3d1aa284a146", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100311", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["interferon-based therapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d98c96b9-2fed-588f-8bb1-926d7d3f2ec0", "object": "MONDO:0002049", "object_location_in_text": [89, 105], "original_object": "thrombocytopenia", "original_subject": "eltrombopag", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eltrombopag-viatris", "https://www.ema.europa.eu/en/documents/product-information/eltrombopag-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eltrombopag-viatris"]}], "subject": "CHEBI:85010", "supporting_text": ["Eltrombopag Viatris is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Eltrombopag Viatris is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Eltrombopag Viatris is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.2 and 5.1)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic hepatitis C virus (HCV) infection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3548ca91-a10e-5e76-a0f3-18e629ba7fd2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100311", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["interferon-based therapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c9cb935b-1dd7-5b55-84fc-baab1d7da14b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d98c96b9-2fed-588f-8bb1-926d7d3f2ec0", "object": "MONDO:0002049", "object_location_in_text": [88, 104], "original_object": "thrombocytopenia", "original_subject": "eltrombopag", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:eltrombopag-accord", "https://www.ema.europa.eu/en/documents/product-information/eltrombopag-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/eltrombopag-accord"]}], "subject": "CHEBI:85010", "supporting_text": ["Eltrombopag Accord is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Eltrombopag Accord is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Eltrombopag Accord is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "decompensated cirrhosis type C", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f85a12f-7353-5540-a6af-923292a36847", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190108", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:8f14421e-67ac-50bb-8b40-92a682ccde1f", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:47bb9d0b-6c8c-5315-8262-fd4dc3dae2ed", "object": "HP:0020071", "object_location_in_text": [84, 91], "original_object": "viremia", "original_subject": "SOFOSBUVIR", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SOFOSBUVIR#79-20190108", "https://www.pmda.go.jp/files/000227564.pdf"]}], "subject": "CHEBI:85083", "supporting_text": ["A new combination drug with a new active ingredient indicated for: - Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. - Improvement of viremia in patients with decompensated cirrhosis type C. [Priority review]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "genotype 1 or 4 infection without cirrhosis, genotype 1 or 4 infection with compensated cirrhosis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:300abd13-4861-5be5-a8a8-e571fe1ab199", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131206", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56371fc3-abc1-549c-b9cf-f4a5d977e47c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47bb9d0b-6c8c-5315-8262-fd4dc3dae2ed", "object": "MONDO:0005354", "original_object": "chronic hepatitis C virus infection", "original_subject": "SOFOSBUVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older; liver transplant recipients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46f4a73b-0cd6-4902-9092-3ac79e882c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46f4a73b-0cd6-4902-9092-3ac79e882c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46f4a73b-0cd6-4902-9092-3ac79e882c1a"]}], "subject": "CHEBI:85083", "supporting_text": ["1 INDICATIONS AND USAGE Ledipasvir and sofosbuvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ]: genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin Ledipasvir and sofosbuvir is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1608426", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7202babf-2558-54c3-873b-b868cde5ad87", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131206", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_disease_context_ids": ["UMLS:C1608426", "UMLS:C1619727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56371fc3-abc1-549c-b9cf-f4a5d977e47c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47bb9d0b-6c8c-5315-8262-fd4dc3dae2ed", "object": "MONDO:0005354", "original_object": "chronic hepatitis C virus infection", "original_subject": "SOFOSBUVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f30631a-ee3b-4cfe-866b-964df3f0a44f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f"]}], "subject": "CHEBI:85083", "supporting_text": ["1 INDICATIONS AND USAGE EPCLUSA is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1608426", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d9687e26-defb-5b3b-899c-e0100593d571", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131206", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_disease_context_ids": ["UMLS:C1608426", "UMLS:C1619727"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56371fc3-abc1-549c-b9cf-f4a5d977e47c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47bb9d0b-6c8c-5315-8262-fd4dc3dae2ed", "object": "MONDO:0005354", "original_object": "chronic hepatitis C virus infection", "original_subject": "SOFOSBUVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0c1a945-4440-4b5c-81aa-693ed3db597c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0c1a945-4440-4b5c-81aa-693ed3db597c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0c1a945-4440-4b5c-81aa-693ed3db597c"]}], "subject": "CHEBI:85083", "supporting_text": ["1 INDICATIONS AND USAGE Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4 ) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. Sofosbuvir and velpatasvir is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection ( 1 ): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "compensated cirrhosis type C", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3c7c3e8-f9dd-5e86-9a65-7f897d51753e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180216", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:155dda6a-c2f6-5233-90c2-b433e09068ce", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:47bb9d0b-6c8c-5315-8262-fd4dc3dae2ed", "object": "MONDO:0005354", "object_location_in_text": [88, 107], "original_object": "chronic hepatitis C", "original_subject": "SOFOSBUVIR", "population_context_qualifier": "serogroup 2 (genotype 2)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:SOFOSBUVIR#89-20180216", "https://www.pmda.go.jp/files/000227564.pdf"]}], "subject": "CHEBI:85083", "supporting_text": ["A drug with a new additional indication for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:da7db188-cc42-5abb-92d6-93c6f9356162", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20131206", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:740a62bb-9817-5211-a962-119cbd50f5ed", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47bb9d0b-6c8c-5315-8262-fd4dc3dae2ed", "object": "UMLS:C0220847", "object_location_in_text": [126, 157], "original_object": "chronic hepatitis C virus (HCV)", "original_subject": "SOFOSBUVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older; liver transplant recipients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075"]}], "subject": "CHEBI:85083", "supporting_text": ["1 INDICATIONS AND USAGE HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ] : genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "genotype 1 or 4 infection without cirrhosis, genotype 1 or 4 infection with compensated cirrhosis", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:793fddbd-992f-5994-be4c-9e9c5f9c2c49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141010", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:56371fc3-abc1-549c-b9cf-f4a5d977e47c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b0245fc4-85f1-57f2-9c01-0adcc8f9e884", "object": "MONDO:0005354", "original_object": "chronic hepatitis C virus infection", "original_subject": "LEDIPASVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older; liver transplant recipients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46f4a73b-0cd6-4902-9092-3ac79e882c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46f4a73b-0cd6-4902-9092-3ac79e882c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46f4a73b-0cd6-4902-9092-3ac79e882c1a"]}], "subject": "CHEBI:85089", "supporting_text": ["1 INDICATIONS AND USAGE Ledipasvir and sofosbuvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ]: genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin Ledipasvir and sofosbuvir is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8329e31-b9bc-50ed-bb4d-138fa2abbec9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141010", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["ribavirin"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:740a62bb-9817-5211-a962-119cbd50f5ed", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b0245fc4-85f1-57f2-9c01-0adcc8f9e884", "object": "UMLS:C0220847", "object_location_in_text": [126, 157], "original_object": "chronic hepatitis C virus (HCV)", "original_subject": "LEDIPASVIR", "population_context_qualifier": "adults and pediatric patients 3 years of age and older; liver transplant recipients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075"]}], "subject": "CHEBI:85089", "supporting_text": ["1 INDICATIONS AND USAGE HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ] : genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f37748c2-5d29-59e8-8b83-e988144f4713", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150527", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:c6ce2e2e-e8ea-5da5-869a-13ec99e870b3", "object": "HP:0002017", "object_location_in_text": [73, 92], "original_object": "nausea and vomiting", "original_subject": "netupitant;palonosetron", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:akynzeo", "https://www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo"]}], "subject": "CHEBI:85155", "supporting_text": ["Akynzeo is indicated in adults for the:  Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy. Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy."], "temporal_context_qualifier": "acute and delayed"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c089ab5-cb70-5d11-8654-bc9696b729b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141010", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["dexamethasone"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50b805fa-a8fb-5ee0-baeb-eacacc5401a0", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "NETUPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d"]}], "subject": "CHEBI:85155", "supporting_text": ["1 INDICATIONS AND USAGE AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses of highly emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9c089ab5-cb70-5d11-8654-bc9696b729b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141010", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["dexamethasone"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50b805fa-a8fb-5ee0-baeb-eacacc5401a0", "object": "HP:0002017", "object_location_in_text": [138, 157], "original_object": "nausea and vomiting", "original_subject": "NETUPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d"]}], "subject": "CHEBI:85155", "supporting_text": ["1 INDICATIONS AND USAGE AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy."], "temporal_context_qualifier": "during both the acute and delayed phase after cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:09d5de48-1644-5196-967f-6dd28fb6fd17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20141010", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["dexamethasone"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:50b805fa-a8fb-5ee0-baeb-eacacc5401a0", "object": "UMLS:C3830545", "object_location_in_text": [130, 157], "original_object": "delayed nausea and vomiting", "original_subject": "NETUPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d"]}], "subject": "CHEBI:85155", "supporting_text": ["1 INDICATIONS AND USAGE AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses of highly emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:767b6225-d79b-5707-b668-bbc16e5cbfa3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050322", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002013", "object_location_in_text": [84, 92], "original_object": "vomiting", "original_subject": "palonosetron", "population_context_qualifier": "paediatric patients 1 month of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:palonosetron-accord", "https://www.ema.europa.eu/en/documents/product-information/palonosetron-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-accord"]}], "subject": "CHEBI:85161", "supporting_text": ["Palonosetron Accord is indicated in adults for:  the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.  Palonosetron Accord is indicated in paediatric patients 1 month of age and older for:  The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:136f9112-774b-5c1b-8424-88d09c5e0264", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002013", "original_object": "vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42e2d437-0712-4e9c-9c2a-00093c406d62", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42e2d437-0712-4e9c-9c2a-00093c406d62", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42e2d437-0712-4e9c-9c2a-00093c406d62"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3d7e03e-0bcf-56a3-ba15-e428373c03d2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002013", "object_location_in_text": [132, 140], "original_object": "vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:911783eb-91a8-4ef4-bd6f-809211e207d6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=911783eb-91a8-4ef4-bd6f-809211e207d6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911783eb-91a8-4ef4-bd6f-809211e207d6"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "associated with initial and repeat courses of emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73d0fffd-30e4-5d15-9ae7-dcc17c57ccdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050322", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [53, 78], "original_object": "acute nausea and vomiting", "original_subject": "palonosetron", "population_context_qualifier": "paediatric patients 1 month of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aloxi", "https://www.ema.europa.eu/en/documents/product-information/aloxi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi"]}], "subject": "CHEBI:85161", "supporting_text": ["Aloxi is indicated in adults for:  the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.  Aloxi is indicated in paediatric patients 1 month of age and older for:  the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:73d0fffd-30e4-5d15-9ae7-dcc17c57ccdb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050322", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [59, 78], "original_object": "nausea and vomiting", "original_subject": "palonosetron", "population_context_qualifier": "paediatric patients 1 month of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:aloxi", "https://www.ema.europa.eu/en/documents/product-information/aloxi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi"]}], "subject": "CHEBI:85161", "supporting_text": ["Aloxi is indicated in adults for:  the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.  Aloxi is indicated in paediatric patients 1 month of age and older for:  the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e84c77c-230d-5790-b3fc-40eb3ecfbc8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [288, 313], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fa9771d-bf0d-524e-a223-ccf5f04cbd0b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["initial and repeat courses of emetogenic cancer chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ee6f6f94-1ca7-481e-9909-b19ae64e80c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ee6f6f94-1ca7-481e-9909-b19ae64e80c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee6f6f94-1ca7-481e-9909-b19ae64e80c2"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 ) . • acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) ( 1 ). • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) . Pediatric patients aged 1 month to less than 17 years for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC) ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e258cc8-0ba4-5dc8-9509-e1e75e381823", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [288, 313], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11bb07b2-6530-45ab-a916-ba9dd3107fc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11bb07b2-6530-45ab-a916-ba9dd3107fc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11bb07b2-6530-45ab-a916-ba9dd3107fc3"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ffaa269-9b2d-5eda-8337-3d8f992ad962", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "Pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:689c953c-2120-2546-67a4-22bb34ba3330", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=689c953c-2120-2546-67a4-22bb34ba3330", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=689c953c-2120-2546-67a4-22bb34ba3330"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:372e1755-85d3-55cc-9418-484e3bb9bb61", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "medic_supporting_text_truncated": true, "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37e7ef89-fd77-44e0-9271-ae91f8822603", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37e7ef89-fd77-44e0-9271-ae91f8822603", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37e7ef89-fd77-44e0-9271-ae91f8822603"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in adults for: Moderately emetogenic cancer chemotherapy - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses ( 1 .1) Highly emetogenic cancer chemotherapy - prevention of acute nausea and vomiting associated with initial and repeat courses ( 1.1 ) Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1.3 ) Palonosetron Hydrochloride Injection is indicated in pediatric patients aged 1 month to less than 17 years for: Prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy ( 1.2 ) 1.1 Chemotherapy-Induced Nausea and Vomiting in Adults Palonosetron Hydrochloride Injection is indicated for: Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses 1.2 Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients Aged 1 Month to Less than 17 Years Palonosetron Hydrochloride Injection is indicated for prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. 1.3 Postoperative Nausea and Vomiting in Adults Palonosetron Hydrochloride Injection is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting"], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37724a25-342b-5f3e-837a-e57ec491fd6d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0f3bfe3d-75c8-42eb-84be-570f8e251fdd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0f3bfe3d-75c8-42eb-84be-570f8e251fdd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0f3bfe3d-75c8-42eb-84be-570f8e251fdd"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). • acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron hydrochloride is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). (1) • acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). (1) • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated (1) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d8a27c0-9088-5af5-b3bc-9e8c558786e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [236, 261], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e60d03d-eae6-4924-a507-e77ea077c1ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e60d03d-eae6-4924-a507-e77ea077c1ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e60d03d-eae6-4924-a507-e77ea077c1ab"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4dd98d9f-c390-5ad0-8db1-6a33f1fe4bda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["dexamethasone"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses of highly emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4dd98d9f-c390-5ad0-8db1-6a33f1fe4bda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["dexamethasone"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [138, 157], "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy."], "temporal_context_qualifier": "during both the acute and delayed phase after cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:554c98af-6663-5eb2-8164-a56dc1690c07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "Pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:991b8452-852c-c55c-7b1b-e97c4964777a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=991b8452-852c-c55c-7b1b-e97c4964777a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=991b8452-852c-c55c-7b1b-e97c4964777a"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:583eb1ac-51a5-5ea9-a99c-503185f72f1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [288, 313], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:633abdc2-a942-4eb2-a0f8-f9f4e727211e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=633abdc2-a942-4eb2-a0f8-f9f4e727211e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=633abdc2-a942-4eb2-a0f8-f9f4e727211e"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:719e17e7-2a28-5185-a9c6-dbc09c4fc001", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [207, 232], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE POSFREA is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, POSFREA is recommended even where the incidence of postoperative nausea and/or vomiting is low. POSFREA is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. POSFREA is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:71f46010-3601-5ee0-9f4e-fb2fc3897365", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [237, 262], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9132366b-b808-46c9-b167-c1900bc116b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9132366b-b808-46c9-b167-c1900bc116b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9132366b-b808-46c9-b167-c1900bc116b3"]}], "subject": "CHEBI:85161", "supporting_text": ["1. INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:779c7d4f-a37f-5c88-a307-7777212a6316", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0a781796-bb74-4c5f-8d26-9ce520b818f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0a781796-bb74-4c5f-8d26-9ce520b818f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0a781796-bb74-4c5f-8d26-9ce520b818f7"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). • acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron hydrochloride is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) • acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9924fc02-8e21-561a-aa1c-a3878d2459f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:52967728-bda7-56f7-8f32-af721b574294", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "original_object": "nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b93fae8e-2b76-421e-95bc-ba08c211a7ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b93fae8e-2b76-421e-95bc-ba08c211a7ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b93fae8e-2b76-421e-95bc-ba08c211a7ea"]}], "subject": "CHEBI:85161", "supporting_text": ["1. INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a48d6c19-ab1d-5833-a64b-31cd4c6f5da7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [288, 313], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4af600d1-0ab1-41c5-af2f-9dc24cf3c90e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4af600d1-0ab1-41c5-af2f-9dc24cf3c90e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4af600d1-0ab1-41c5-af2f-9dc24cf3c90e"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de53880e-6fa0-5146-b5f8-3a5316df9274", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [226, 251], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aff1505c-8d34-46e6-9559-c5b112887875", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aff1505c-8d34-46e6-9559-c5b112887875", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aff1505c-8d34-46e6-9559-c5b112887875"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron injection is indicated in adults for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). • acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron HCl injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) • acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7d0b329-cb93-562c-a82e-e66be95459ea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13f2d7e5-9e2a-5f6d-822d-b8ce4b100883", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002017", "object_location_in_text": [288, 313], "original_object": "acute nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:903d7aba-277e-6d28-4fee-fd2d605ab6a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=903d7aba-277e-6d28-4fee-fd2d605ab6a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=903d7aba-277e-6d28-4fee-fd2d605ab6a9"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:656c8f22-2a25-5d3d-8927-e935d6ad7235", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050322", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002018", "object_location_in_text": [73, 79], "original_object": "nausea", "original_subject": "palonosetron", "population_context_qualifier": "paediatric patients 1 month of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:palonosetron-accord", "https://www.ema.europa.eu/en/documents/product-information/palonosetron-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-accord"]}], "subject": "CHEBI:85161", "supporting_text": ["Palonosetron Accord is indicated in adults for:  the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.  Palonosetron Accord is indicated in paediatric patients 1 month of age and older for:  The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63795c61-6884-5f20-a6ab-178de34ca215", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002018", "object_location_in_text": [121, 127], "original_object": "nausea", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients 1 month to less than 17 years of age", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:911783eb-91a8-4ef4-bd6f-809211e207d6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=911783eb-91a8-4ef4-bd6f-809211e207d6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911783eb-91a8-4ef4-bd6f-809211e207d6"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "associated with initial and repeat courses of emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd85d70b-4e95-59b1-9e68-10f9b7f52873", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "HP:0002018", "object_location_in_text": [121, 127], "original_object": "nausea", "original_subject": "PALONOSETRON", "population_context_qualifier": "pediatric patients aged 1 month to less than 17 years", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42e2d437-0712-4e9c-9c2a-00093c406d62", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42e2d437-0712-4e9c-9c2a-00093c406d62", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42e2d437-0712-4e9c-9c2a-00093c406d62"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18a117b9-442d-519f-bf4d-52bb55d05956", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [159, 186], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:633abdc2-a942-4eb2-a0f8-f9f4e727211e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=633abdc2-a942-4eb2-a0f8-f9f4e727211e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=633abdc2-a942-4eb2-a0f8-f9f4e727211e"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b0b24db-7807-5c51-8e9a-3226acf10ae7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [159, 186], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:903d7aba-277e-6d28-4fee-fd2d605ab6a9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=903d7aba-277e-6d28-4fee-fd2d605ab6a9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=903d7aba-277e-6d28-4fee-fd2d605ab6a9"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53c05b05-6901-513d-b65d-79422aad7f7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [114, 141], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9132366b-b808-46c9-b167-c1900bc116b3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9132366b-b808-46c9-b167-c1900bc116b3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9132366b-b808-46c9-b167-c1900bc116b3"]}], "subject": "CHEBI:85161", "supporting_text": ["1. INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b5c83ec-66ab-50ee-8b70-546127f18c43", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [159, 186], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4af600d1-0ab1-41c5-af2f-9dc24cf3c90e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4af600d1-0ab1-41c5-af2f-9dc24cf3c90e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4af600d1-0ab1-41c5-af2f-9dc24cf3c90e"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ea3366e-f528-598c-8417-beeb29f01981", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [159, 186], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba3e1593-e238-55bc-9835-49ef514d61c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [159, 186], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11bb07b2-6530-45ab-a916-ba9dd3107fc3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11bb07b2-6530-45ab-a916-ba9dd3107fc3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11bb07b2-6530-45ab-a916-ba9dd3107fc3"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb8862ed-a71d-50b4-9fc5-fa78812d8b6b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [91, 128], "original_object": "acute and delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:aff1505c-8d34-46e6-9559-c5b112887875", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=aff1505c-8d34-46e6-9559-c5b112887875", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aff1505c-8d34-46e6-9559-c5b112887875"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron injection is indicated in adults for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). • acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron HCl injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) • acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) • postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "associated with initial and repeat courses of moderately emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc945e94-3f15-51f7-9627-16fe735bbec9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6494c369-890c-562d-91f9-4f7c338cf193", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [74, 111], "original_object": "acute and delayed nausea and vomiting", "original_subject": "PALONOSETRON", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE POSFREA is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, POSFREA is recommended even where the incidence of postoperative nausea and/or vomiting is low. POSFREA is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. POSFREA is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "highly emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ee82b940-af97-547e-8458-72e3c76324c6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["dexamethasone"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [130, 157], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e47618e-af46-4d82-94e8-1507c042252d"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy."], "temporal_context_qualifier": "associated with initial and repeat courses of highly emetogenic cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8558916-e013-56fd-8a81-a5d14f769dae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20030725", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b6618bcb-3002-54e3-81f5-f8b5476e9d45", "object": "UMLS:C3830545", "object_location_in_text": [113, 140], "original_object": "delayed nausea and vomiting", "original_subject": "PALONOSETRON", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e60d03d-eae6-4924-a507-e77ea077c1ab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e60d03d-eae6-4924-a507-e77ea077c1ab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e60d03d-eae6-4924-a507-e77ea077c1ab"]}], "subject": "CHEBI:85161", "supporting_text": ["1 INDICATIONS AND USAGE Palonosetron Hydrochloride Injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Palonosetron Hydrochloride Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron Hydrochloride Injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )"], "temporal_context_qualifier": "initial and repeat courses"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic agent administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c2144cf-fe8e-532b-bbc7-6c5f65a1b7e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100120", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:7985ad06-27ba-55db-9ed5-ffe25360d148", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:36d6e37a-3aa5-5426-8547-0e098fd34aa0", "object": "HP:0002013", "object_location_in_text": [98, 106], "original_object": "vomiting", "original_subject": "PALONOSETRON HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PALONOSETRON HYDROCHLORIDE#164-20100120", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:85161", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.)."], "temporal_context_qualifier": "delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "antineoplastic agent administration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aecee370-747b-5d50-af2b-e1dd7e21829c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100120", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ca9c1453-2635-54b8-ba69-bc1ee90c96b2", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:36d6e37a-3aa5-5426-8547-0e098fd34aa0", "object": "HP:0002018", "object_location_in_text": [87, 93], "original_object": "nausea", "original_subject": "PALONOSETRON HYDROCHLORIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PALONOSETRON HYDROCHLORIDE#164-20100120", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:85161", "supporting_text": ["A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.)."], "temporal_context_qualifier": "delayed phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0749225", "has_confidence_score": 0.684, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40de5acf-84aa-5de2-a312-4b18368b2b7f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20130101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_section"], "medic_co_administered_with": ["beta-blocker therapy"], "medic_disease_context_ids": ["UMLS:C0749225"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.684, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:57488063-b26a-5942-aef9-cc351fdecbfc", "object": "MONDO:0005009", "object_location_in_text": [39, 60], "original_object": "chronic heart failure", "original_subject": "Ivabradine HCL Tablets 5mg/7.5mg (Additional indication)", "population_context_qualifier": "patients in sinus rhythm and whose heart rate is > 75 bpm", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:85966", "supporting_text": ["Additional indication of \"treatment of chronic heart failure in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is > 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated”."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0749225", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3eea241b-38ed-5e2d-af73-a93028bf3b7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20051025", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0749225"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:a489ba7e-0558-5ae1-9ac0-db3ff8e8d95b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4c6ca5b2-38dd-57b6-927a-e41dde7babcd", "object": "MONDO:0005009", "object_location_in_text": [460, 481], "original_object": "chronic heart failure", "original_subject": "ivabradine", "population_context_qualifier": "NYHA II to IV class; patients in sinus rhythm and whose heart rate is ≥ 75 bpm", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ivabradine-anpharm", "https://www.ema.europa.eu/en/documents/product-information/ivabradine-anpharm-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-anpharm"]}], "subject": "CHEBI:85966", "supporting_text": ["Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated:  in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.  Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cisapride co-administration", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:af49885f-91b5-50d8-b588-5d9220876220", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisapride"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:26306969-7e47-5925-99cf-edcd61462699", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c96629be-3054-5f86-ae1a-71c7bb665d73", "object": "HP:0011675", "object_location_in_text": [811, 830], "original_object": "cardiac arrhythmias", "original_subject": "PROTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6c7c39e-e510-4f4a-bf7a-926f0e075d3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6c7c39e-e510-4f4a-bf7a-926f0e075d3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6c7c39e-e510-4f4a-bf7a-926f0e075d3a"]}], "subject": "CHEBI:8597", "supporting_text": ["Protriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. It should not be given concomitantly with a monoamine oxidase inhibiting compound. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. When it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. Protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. Protriptyline is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions including prolongation of the QT interval, cardiac arrhythmias and conduction system disturbances. This drug should not be used during the acute recovery phase following myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "cisapride co-administration", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f770e693-a2bc-52ea-ba06-2187dd6f2a45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cisapride"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:26306969-7e47-5925-99cf-edcd61462699", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c96629be-3054-5f86-ae1a-71c7bb665d73", "object": "HP:0011675", "object_location_in_text": [811, 830], "original_object": "cardiac arrhythmias", "original_subject": "PROTRIPTYLINE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a023e637-bee9-8c86-e053-2a95a90aa488", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a023e637-bee9-8c86-e053-2a95a90aa488", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a023e637-bee9-8c86-e053-2a95a90aa488"]}], "subject": "CHEBI:8597", "supporting_text": ["Protriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. It should not be given concomitantly with a monoamine oxidase inhibiting compound. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. When it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. Protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. Protriptyline is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions including prolongation of the QT interval, cardiac arrhythmias and conduction system disturbances. This drug should not be used during the acute recovery phase following myocardial infarction."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5a77eba-dff4-5282-8294-084b604aa761", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:95c8a1ed-3f10-56e6-8047-f3b01438fcd8", "object": "MONDO:0005098", "object_location_in_text": [17, 23], "original_object": "stroke", "original_subject": "Edoxaban Tablets 15mg, 30mg and 60mg", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack(TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:85973", "supporting_text": ["In prevention of stroke and systemic embolism in adult patients with non- valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack(TIA). For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1701d90d-d53a-563b-a97c-76c0c810b89d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150619", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:68e4910e-b1bf-51c5-8d67-0a629638223f", "object": "MONDO:0005098", "object_location_in_text": [14, 20], "original_object": "stroke", "original_subject": "edoxaban", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:roteas", "https://www.ema.europa.eu/en/documents/product-information/roteas-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/roteas"]}], "subject": "CHEBI:85973", "supporting_text": ["Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e7c85a6b-a1d7-5340-85c6-c3bfa4f79af3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150619", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:68e4910e-b1bf-51c5-8d67-0a629638223f", "object": "MONDO:0005098", "object_location_in_text": [14, 20], "original_object": "stroke", "original_subject": "edoxaban", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lixiana", "https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana"]}], "subject": "CHEBI:85973", "supporting_text": ["Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4b7f8063-525b-5b38-bae8-5a8d1f2ca343", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150108", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:68e4910e-b1bf-51c5-8d67-0a629638223f", "object": "MONDO:0005098", "object_location_in_text": [90, 96], "original_object": "stroke", "original_subject": "EDOXABAN", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e77d3400-56ad-11e3-949a-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66"]}], "subject": "CHEBI:85973", "supporting_text": ["1 INDICATIONS AND USAGE SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.72, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f3d1ad4b-1ed3-545a-aabf-6a7368d6662a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250220", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.72, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:95c8a1ed-3f10-56e6-8047-f3b01438fcd8", "object": "UMLS:C5400523", "object_location_in_text": [28, 45], "original_object": "systemic embolism", "original_subject": "Edoxaban Tablets 15mg, 30mg and 60mg", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack(TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:85973", "supporting_text": ["In prevention of stroke and systemic embolism in adult patients with non- valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack(TIA). For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2be794c-88e6-52b2-8f15-3f23cb20667d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150619", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:68e4910e-b1bf-51c5-8d67-0a629638223f", "object": "UMLS:C5400523", "object_location_in_text": [25, 42], "original_object": "systemic embolism", "original_subject": "edoxaban", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:roteas", "https://www.ema.europa.eu/en/documents/product-information/roteas-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/roteas"]}], "subject": "CHEBI:85973", "supporting_text": ["Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d652e9b5-f53e-57ea-a474-db6d8d017e2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150619", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:68e4910e-b1bf-51c5-8d67-0a629638223f", "object": "UMLS:C5400523", "object_location_in_text": [25, 42], "original_object": "systemic embolism", "original_subject": "edoxaban", "population_context_qualifier": "adult patients with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lixiana", "https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana"]}], "subject": "CHEBI:85973", "supporting_text": ["Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nonvalvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dad9534f-7115-5f8d-9653-ce7e3ce21c79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150108", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:68e4910e-b1bf-51c5-8d67-0a629638223f", "object": "UMLS:C5400523", "original_object": "systemic embolism", "original_subject": "EDOXABAN", "population_context_qualifier": "patients with nonvalvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e77d3400-56ad-11e3-949a-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66"]}], "subject": "CHEBI:85973", "supporting_text": ["1 INDICATIONS AND USAGE SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:194d4605-20cd-5879-852f-bc220e02d9f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140926", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:022f02f4-23ac-50b9-a831-9b6e56b1d7d7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:46b49a3b-b53c-5209-9d0c-714d9eb6600f", "object": "MONDO:1060198", "object_location_in_text": [125, 140], "original_object": "ischemic stroke", "original_subject": "EDOXABAN TOSILATE HYDRATE", "population_context_qualifier": "patients with non- valvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EDOXABAN TOSILATE HYDRATE#114-20140926", "https://www.pmda.go.jp/files/000220894.pdf"]}], "subject": "CHEBI:85975", "supporting_text": ["Drugs with new additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non- valvular atrial fibrillation, or for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "non-valvular atrial fibrillation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c45b360-81d3-5178-9c7d-606c920a88b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140926", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:664af17c-5cf9-5b7c-8f81-6c1a64688481", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:46b49a3b-b53c-5209-9d0c-714d9eb6600f", "object": "UMLS:C5400523", "object_location_in_text": [145, 162], "original_object": "systemic embolism", "original_subject": "EDOXABAN TOSILATE HYDRATE", "population_context_qualifier": "patients with non- valvular atrial fibrillation", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:EDOXABAN TOSILATE HYDRATE#114-20140926", "https://www.pmda.go.jp/files/000220894.pdf"]}], "subject": "CHEBI:85975", "supporting_text": ["Drugs with new additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non- valvular atrial fibrillation, or for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c061e412-76f3-516a-b67c-324c015be763", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20161109", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["aromatase inhibitor", "luteinizing hormone releasing hormone (LHRH) agonist"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:31ab9d60-7893-5554-8627-9fbc399ad3bc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "object": "MONDO:0007254", "original_object": "breast cancer", "original_subject": "palbociclib", "population_context_qualifier": "pre- or perimenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ibrance", "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance"]}], "subject": "CHEBI:85993", "supporting_text": ["Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:  in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy.  In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, disease progression following endocrine therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1208d94c-d91f-5fd4-86e0-604225bf458f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150203", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fulvestrant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [197, 233], "original_object": "advanced or metastatic breast cancer", "original_subject": "PALBOCICLIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0e6412f-50b4-4fd4-9364-62818d121a07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07"]}], "subject": "CHEBI:85993", "supporting_text": ["1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following indu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2348909", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1208d94c-d91f-5fd4-86e0-604225bf458f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150203", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["trastuzumab", "pertuzumab", "endocrine therapy"], "medic_disease_context_ids": ["UMLS:C2348909"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [571, 615], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "PALBOCICLIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0e6412f-50b4-4fd4-9364-62818d121a07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07"]}], "subject": "CHEBI:85993", "supporting_text": ["1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following indu"], "temporal_context_qualifier": "following induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, disease progression following endocrine therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb1b7a3b-f9bb-570a-a01b-f5ce934eecf3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150203", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fulvestrant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [197, 233], "original_object": "advanced or metastatic breast cancer", "original_subject": "PALBOCICLIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fecbdd7d-b729-41b5-9872-231b8fe104ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fecbdd7d-b729-41b5-9872-231b8fe104ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fecbdd7d-b729-41b5-9872-231b8fe104ce"]}], "subject": "CHEBI:85993", "supporting_text": ["1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following indu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb1b7a3b-f9bb-570a-a01b-f5ce934eecf3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150203", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["trastuzumab", "pertuzumab", "endocrine therapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [571, 615], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "PALBOCICLIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fecbdd7d-b729-41b5-9872-231b8fe104ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fecbdd7d-b729-41b5-9872-231b8fe104ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fecbdd7d-b729-41b5-9872-231b8fe104ce"]}], "subject": "CHEBI:85993", "supporting_text": ["1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following indu"], "temporal_context_qualifier": "following induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, disease progression following endocrine therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e11d08aa-6ea8-51be-a502-b7a0fadfd8fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150203", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fulvestrant"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 3, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [197, 233], "original_object": "advanced or metastatic breast cancer", "original_subject": "PALBOCICLIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89a142d5-7e61-48bf-9e77-e2cd124c4792", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89a142d5-7e61-48bf-9e77-e2cd124c4792", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89a142d5-7e61-48bf-9e77-e2cd124c4792"]}], "subject": "CHEBI:85993", "supporting_text": ["1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following indu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e11d08aa-6ea8-51be-a502-b7a0fadfd8fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150203", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_co_administered_with": ["trastuzumab", "pertuzumab", "endocrine therapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2795b63-0a0c-5018-b642-48a3a55f9968", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7f22ab52-79ba-5a8d-9698-d7468d01af91", "medic_supporting_text_truncated": true, "object": "MONDO:0007254", "object_location_in_text": [571, 615], "original_object": "locally advanced or metastatic breast cancer", "original_subject": "PALBOCICLIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89a142d5-7e61-48bf-9e77-e2cd124c4792", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89a142d5-7e61-48bf-9e77-e2cd124c4792", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89a142d5-7e61-48bf-9e77-e2cd124c4792"]}], "subject": "CHEBI:85993", "supporting_text": ["1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following indu"], "temporal_context_qualifier": "following induction treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4cfba4ed-dcd9-5a68-9898-d3e4c5c66a01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150213", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pembrolizumab", "pembrolizumab and berahyaluronidase alfa-pmph"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:146762fb-29a8-5edd-a71e-a78cf2f4f136", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ff76ede-6af0-505d-b98c-5cffc76acb16", "medic_supporting_text_truncated": true, "object": "MONDO:0002447", "object_location_in_text": [1122, 1143], "original_object": "endometrial carcinoma", "original_subject": "LENVATINIB", "population_context_qualifier": "patients who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e"]}], "subject": "CHEBI:85994", "supporting_text": ["1 INDICATIONS AND USAGE LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). LENVIMA, in combination with belzutifan, is indicated for the treatment of adult patients with advanced renal cell carcinoma with a clear cell"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "advanced RCC", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e3bfcafa-0d3c-5e5b-ab4f-03d10ffed590", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150213", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["everolimus"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:34419ab2-2f73-5f87-82d4-9de83301cf2f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ff76ede-6af0-505d-b98c-5cffc76acb16", "medic_supporting_text_truncated": true, "object": "MONDO:0005086", "object_location_in_text": [431, 451], "original_object": "renal cell carcinoma", "original_subject": "LENVATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e"]}], "subject": "CHEBI:85994", "supporting_text": ["1 INDICATIONS AND USAGE LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). LENVIMA, in combination with belzutifan, is indicated for the treatment of adult patients with advanced renal cell carcinoma with a clear cell"], "temporal_context_qualifier": "following one prior anti-angiogenic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1112459", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:decc3a86-4f79-5620-8067-3156113e0e4a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150213", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1112459"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3964b09-996d-5011-b111-6c0e6570413b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ff76ede-6af0-505d-b98c-5cffc76acb16", "medic_supporting_text_truncated": true, "object": "MONDO:0007256", "object_location_in_text": [932, 956], "original_object": "hepatocellular carcinoma", "original_subject": "LENVATINIB", "population_context_qualifier": "patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e"]}], "subject": "CHEBI:85994", "supporting_text": ["1 INDICATIONS AND USAGE LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). LENVIMA, in combination with belzutifan, is indicated for the treatment of adult patients with advanced renal cell carcinoma with a clear cell"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "radioactive iodine refractory disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e581be1d-1641-5d2f-a175-1c2dbde212c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150528", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:14c481b5-2257-50f7-a9f8-fb8559591708", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:5ff76ede-6af0-505d-b98c-5cffc76acb16", "object": "MONDO:0015447", "original_object": "differentiated thyroid carcinoma", "original_subject": "lenvatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:lenvima", "https://www.ema.europa.eu/en/documents/product-information/lenvima-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima"]}], "subject": "CHEBI:85994", "supporting_text": ["Lenvima&nbsp;is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima&nbsp;is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy."], "temporal_context_qualifier": "progressive, locally advanced or metastatic"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32da823f-e48c-58d6-8bd4-b35012457797", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150213", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dfa27201-d8f3-5cb3-b633-303ad7a63dfa", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5ff76ede-6af0-505d-b98c-5cffc76acb16", "medic_supporting_text_truncated": true, "object": "MONDO:0015447", "object_location_in_text": [220, 249], "original_object": "differentiated thyroid cancer", "original_subject": "LENVATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e"]}], "subject": "CHEBI:85994", "supporting_text": ["1 INDICATIONS AND USAGE LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). LENVIMA, in combination with belzutifan, is indicated for the treatment of adult patients with advanced renal cell carcinoma with a clear cell"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a31234e-6a6a-51a5-a84d-4d1b9b573119", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da562e3b-4411-e750-e053-2a95a90ad7e5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da562e3b-4411-e750-e053-2a95a90ad7e5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da562e3b-4411-e750-e053-2a95a90ad7e5"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69c0676f-799e-5a3d-849f-c3e068390f41", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ded0773-3aec-4e89-9836-d22a5a84abf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ded0773-3aec-4e89-9836-d22a5a84abf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ded0773-3aec-4e89-9836-d22a5a84abf0"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b0468df-3772-56c6-965a-db759aea0fc7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6cf2ffd-cf94-4f1c-a12e-ce0e93a6304d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6cf2ffd-cf94-4f1c-a12e-ce0e93a6304d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6cf2ffd-cf94-4f1c-a12e-ce0e93a6304d"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:be776605-1c97-53e6-93f0-07b7a5aa1adc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2efb2ede-a49b-4e3e-9c93-4c202f67211f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2efb2ede-a49b-4e3e-9c93-4c202f67211f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2efb2ede-a49b-4e3e-9c93-4c202f67211f"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ddb1ef04-77a4-5b3c-a8eb-dd1f36198920", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [218, 240], "original_object": "myocardial infarctions", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42e4f9dd-6032-4257-bd0f-8e9b71027f03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42e4f9dd-6032-4257-bd0f-8e9b71027f03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42e4f9dd-6032-4257-bd0f-8e9b71027f03"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varyin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25ae37fd-7618-5cf7-a81f-d632cdb47f8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [206, 213], "original_object": "strokes", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42e4f9dd-6032-4257-bd0f-8e9b71027f03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42e4f9dd-6032-4257-bd0f-8e9b71027f03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42e4f9dd-6032-4257-bd0f-8e9b71027f03"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varyin"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8eeb2269-4151-5be2-be19-d3a4219fe451", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6cf2ffd-cf94-4f1c-a12e-ce0e93a6304d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6cf2ffd-cf94-4f1c-a12e-ce0e93a6304d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6cf2ffd-cf94-4f1c-a12e-ce0e93a6304d"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b466b710-ad9e-55cd-9acb-9205147c17b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8ded0773-3aec-4e89-9836-d22a5a84abf0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8ded0773-3aec-4e89-9836-d22a5a84abf0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ded0773-3aec-4e89-9836-d22a5a84abf0"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b56d9b1e-4b98-5436-8e79-778fd4a088b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da562e3b-4411-e750-e053-2a95a90ad7e5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da562e3b-4411-e750-e053-2a95a90ad7e5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da562e3b-4411-e750-e053-2a95a90ad7e5"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4e8ac6c-4003-5770-bef5-0dbde055ba49", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19911119", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:af5b2564-ce9a-5162-bd6c-3b004b51223a", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "QUINAPRIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2efb2ede-a49b-4e3e-9c93-4c202f67211f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2efb2ede-a49b-4e3e-9c93-4c202f67211f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2efb2ede-a49b-4e3e-9c93-4c202f67211f"]}], "subject": "CHEBI:8713", "supporting_text": ["Hypertension Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:204207a1-a86f-590e-90b1-8f6f276413ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [105, 117], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85a59e0c-ff09-49a6-b7b8-616e033107b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85a59e0c-ff09-49a6-b7b8-616e033107b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85a59e0c-ff09-49a6-b7b8-616e033107b4"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -­adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23a7d7bb-37a1-5116-9c9c-2abe74216d55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [105, 117], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ba5fab26-c897-90e1-e053-2a95a90a6437", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ba5fab26-c897-90e1-e053-2a95a90a6437", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba5fab26-c897-90e1-e053-2a95a90a6437"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -­adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:30eb8687-3e79-5acf-974d-d7ddb49b47b5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:262c0b8b-8461-4bdf-b272-c829d33fd451", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=262c0b8b-8461-4bdf-b272-c829d33fd451", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=262c0b8b-8461-4bdf-b272-c829d33fd451"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32426fea-4acf-5b27-847d-62ba98c5d536", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5c8368a-49f9-45cf-9d42-a871f005edb9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5c8368a-49f9-45cf-9d42-a871f005edb9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5c8368a-49f9-45cf-9d42-a871f005edb9"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:37ba10d5-681c-5444-8e76-51164b9ebd1d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [105, 117], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3ce78d9-e923-400e-b3cd-3e6124ac7f6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b0809bf-bc34-5ef9-a5ac-008bb98764dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2f416dc8-62aa-4b6b-a745-2c8a72bb763d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2f416dc8-62aa-4b6b-a745-2c8a72bb763d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f416dc8-62aa-4b6b-a745-2c8a72bb763d"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b2c2066-ed2b-558f-a141-f04fa31fd0fa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e7e3d858-6a0d-482c-b71b-de90d3ef3169", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e7e3d858-6a0d-482c-b71b-de90d3ef3169", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e7e3d858-6a0d-482c-b71b-de90d3ef3169"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41f1e3b2-80ff-5e0f-ba22-ccd0b50ff73a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [105, 117], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f1c4f22-d420-495c-8f64-33532638215f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f1c4f22-d420-495c-8f64-33532638215f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f1c4f22-d420-495c-8f64-33532638215f"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4576b047-7c3e-5e51-b6c4-5ebe9fb29748", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [119, 131], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7e2644e6-36c5-4988-8e52-bec90e2cd2f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE XOPENEX (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. XOPENEX (levalbuterol hydrochloride) Inhalation Solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:460a0572-a81e-5602-9820-131f34ce4208", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58beb877-b94a-bbe0-e063-6294a90a7fe0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58beb877-b94a-bbe0-e063-6294a90a7fe0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58beb877-b94a-bbe0-e063-6294a90a7fe0"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:49f981be-6945-5311-b264-731a330ccfe3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [119, 131], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e1a9effb-6ef7-4651-b0ef-a9265600caff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e1a9effb-6ef7-4651-b0ef-a9265600caff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1a9effb-6ef7-4651-b0ef-a9265600caff"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol inhalation solution (concentrate) is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution (concentrate) is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e0d9dc4-ac95-5968-9595-756e8f8e13d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [105, 117], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:29eae75d-93da-7a5a-e063-6394a90ac0c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=29eae75d-93da-7a5a-e063-6394a90ac0c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29eae75d-93da-7a5a-e063-6394a90ac0c0"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:557b940b-2be8-594b-a2d8-412435de9069", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [131, 143], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0c47c47d-45f7-4eb4-b1f8-7d6c633a1f69", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0c47c47d-45f7-4eb4-b1f8-7d6c633a1f69", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c47c47d-45f7-4eb4-b1f8-7d6c633a1f69"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE XOPENEX (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. XOPENEX (levalbuterol hydrochloride) Inhalation Solution Concentrate is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60ffa3c7-137b-5b41-a1c0-034aa183be17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56cb1f4b-ddf4-0661-e063-6394a90a9c45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56cb1f4b-ddf4-0661-e063-6394a90a9c45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56cb1f4b-ddf4-0661-e063-6394a90a9c45"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:61c12db2-1bfa-53dc-8de8-432259a18685", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [113, 125], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70a35706-d7a8-4a48-98c6-1cab1c42fe8d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70a35706-d7a8-4a48-98c6-1cab1c42fe8d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70a35706-d7a8-4a48-98c6-1cab1c42fe8d"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE XOPENEX HFA is a beta 2 -adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) 1.1 Bronchospasm XOPENEX HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:656b3013-6403-525e-a250-ce2d922db43d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6998949-e1cb-4c86-a480-c0dfd9cb75b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6998949-e1cb-4c86-a480-c0dfd9cb75b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6998949-e1cb-4c86-a480-c0dfd9cb75b5"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a87f0d3f-d8aa-5a66-842d-56a7269e7106", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b4fa89e-aa46-4504-a275-246f3b4df1df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b4fa89e-aa46-4504-a275-246f3b4df1df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b4fa89e-aa46-4504-a275-246f3b4df1df"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: • Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aebeb9dc-3ac0-5c71-aef6-19dadb647198", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [146, 158], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 4 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ac85703a-17a2-4f0b-87f4-78f1756d2f85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ac85703a-17a2-4f0b-87f4-78f1756d2f85"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol tartrate HFA inhalation aerosol is a beta 2 -adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) 1.1 Bronchospasm Levalbuterol tartrate HFA inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df17eab1-5d42-5b61-8e22-a4512ce74c52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:737fe40b-798b-4d7f-bec9-7af952018ab5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=737fe40b-798b-4d7f-bec9-7af952018ab5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=737fe40b-798b-4d7f-bec9-7af952018ab5"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "reversible obstructive airway disease", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5f9f3da-c588-53e0-8f7d-2037bf80e022", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990325", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7d954493-2d3c-5ab4-b1f2-c8edc94b9103", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 18, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5d38078e-445b-5311-ace7-2bd53c3c758b", "object": "MONDO:0001358", "object_location_in_text": [110, 122], "original_object": "bronchospasm", "original_subject": "LEVALBUTEROL", "population_context_qualifier": "adults, adolescents, and children 6 years of age and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d4080fc5-50d6-49a9-8a63-7769d201968d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d4080fc5-50d6-49a9-8a63-7769d201968d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4080fc5-50d6-49a9-8a63-7769d201968d"]}], "subject": "CHEBI:8746", "supporting_text": ["1 INDICATIONS AND USAGE Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0025650", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b21491fc-15d8-5e13-8c58-415acb3823fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250919", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025650"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ed16fc24-bb16-5069-bf50-6612f2f5acde", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:3f7f4147-da52-55e0-a576-e2092d5297f3", "object": "MONDO:0005377", "object_location_in_text": [66, 95], "original_object": "refractory nephrotic syndrome", "original_subject": "MYCOPHENOLATE MOFETIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:MYCOPHENOLATE MOFETIL#7-20250919", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:8764", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of refractory nephrotic syndrome (for use frequent relapsing or steroid-dependent nephrotic syndrome). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7d0f299-9633-5b8c-a315-b813e333397a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990819", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66bf4855-8770-500f-bd57-fd395d433c77", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9aee99a7-a2ac-5034-adb4-26267c422235", "medic_supporting_text_truncated": true, "object": "HP:0002020", "original_object": "heartburn", "original_subject": "RABEPRAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04e88b86-e1dd-4c56-8359-45fbcc161f7d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04e88b86-e1dd-4c56-8359-45fbcc161f7d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04e88b86-e1dd-4c56-8359-45fbcc161f7d"]}], "subject": "CHEBI:8768", "supporting_text": ["1 INDICATIONS AND USAGE Rabeprazole sodium delayed-release tablets is a proton pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Treatment of Symptomatic GERD ( 1.3 ). Healing of Duodenal Ulcers ( 1.4 ). Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence ( 1.5 ). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( 1.6 ). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD ( 1.7 ). 1.1 Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. 1.4 Healing of Duodenal Ulcers in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Rabeprazole sodium delayed-release tablets, in combination "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:150c944d-5d7f-5df3-b11c-73b80e423d32", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071015", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fd479c45-822d-5ecf-a200-fe485accf29c", "object": "HP:0003124", "object_location_in_text": [53, 73], "original_object": "hypercholesterolemia", "original_subject": "Atorvastatin Calcium (10mg ) + Ramipril (2.5mg/5mg) tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:8774", "supporting_text": ["For treatment of patients with both hypertension and hypercholesterolemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0003124", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed5db987-80a3-5ab5-aa67-55bd63e4585a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20071015", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003124"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:fd479c45-822d-5ecf-a200-fe485accf29c", "object": "MONDO:0005044", "object_location_in_text": [36, 48], "original_object": "hypertension", "original_subject": "Atorvastatin Calcium (10mg ) + Ramipril (2.5mg/5mg) tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:8774", "supporting_text": ["For treatment of patients with both hypertension and hypercholesterolemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:02455093-7929-5039-8778-800d6b9215a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [547, 568], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68919f75-cd91-475b-b9fe-f6372a03f74b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68919f75-cd91-475b-b9fe-f6372a03f74b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68919f75-cd91-475b-b9fe-f6372a03f74b"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine tablets, USP is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Trials available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Trials available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:030101f4-b2af-5af9-9002-437e355b606d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [572, 593], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a10f978-be03-1362-e053-2991aa0a4c1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a10f978-be03-1362-e053-2991aa0a4c1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a10f978-be03-1362-e053-2991aa0a4c1f"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Syrup (Ranitidine Oral Solution USP) is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0306625a-af97-528d-9a16-fcee6e75bcff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [549, 570], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d733324-93c6-201c-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d733324-93c6-201c-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d733324-93c6-201c-e054-00144ff88e88"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg b.i.d. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg q.i.d. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06c7f4aa-c06d-5ff6-8ff8-796353724b15", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [547, 568], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9dfbd02-4f08-4983-86c9-64fde4ea2a0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9dfbd02-4f08-4983-86c9-64fde4ea2a0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9dfbd02-4f08-4983-86c9-64fde4ea2a0d"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine tablets, USP is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Trials available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Trials available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1db56d8f-80cc-5554-a15c-d82f82ea7cb9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [553, 574], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc729434-8340-40e3-9e5c-973c01460196", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc729434-8340-40e3-9e5c-973c01460196", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc729434-8340-40e3-9e5c-973c01460196"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets 150 mg twice daily. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets 150 mg 4 times daily. 8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21dd9280-84c1-59e6-ab7d-162a738d3e54", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [544, 565], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fcf27c99-8bd4-41fb-bff8-38fed9de76d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fcf27c99-8bd4-41fb-bff8-38fed9de76d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcf27c99-8bd4-41fb-bff8-38fed9de76d9"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo – controlled comparative studies have been carried out for periods longer than 1 year. The treatment of pathological hypersecretory conditions. (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. ​​​​​​​Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:233a3665-90ba-5d7b-a959-aaca60bd75a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [546, 567], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0fba6615-37c2-4ba6-b6e5-09599369a5bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0fba6615-37c2-4ba6-b6e5-09599369a5bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fba6615-37c2-4ba6-b6e5-09599369a5bc"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets are indicated in: Short- term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo- controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f96b106-211c-5070-8533-18a320825ffb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [572, 593], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0da9dd6-c691-4614-99c7-531b0bf34837", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0da9dd6-c691-4614-99c7-531b0bf34837", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0da9dd6-c691-4614-99c7-531b0bf34837"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Syrup (Ranitidine Oral Solution USP) is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:632b054a-c500-593e-9091-c56b77fee0ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [545, 566], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitdine Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8112dd03-f3a2-54f8-b354-cea95d5b1f20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [547, 568], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a897069a-0af0-499d-983f-afee0e9792fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a897069a-0af0-499d-983f-afee0e9792fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a897069a-0af0-499d-983f-afee0e9792fd"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine tablets, USP is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Trials available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Trials available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8c799d93-71ce-505e-93a4-099183a7093d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [557, 578], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f3348a9-ce69-48d6-89f4-5c0e7d38a255", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f3348a9-ce69-48d6-89f4-5c0e7d38a255", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f3348a9-ce69-48d6-89f4-5c0e7d38a255"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets, USP are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6.Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg twice daily. 7.Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg 4 times daily. 8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:935e2998-adeb-5497-b3e0-661c1fb8adc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [549, 570], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b38a3332-5c54-453f-aeb7-070f830955c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b38a3332-5c54-453f-aeb7-070f830955c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b38a3332-5c54-453f-aeb7-070f830955c2"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg b.i.d. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg q.i.d. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5ddbeb3-4dfc-5aa2-8fb8-b32391bb836f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [557, 578], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0af5ca1-9189-4c62-bdf1-f1124ec337e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0af5ca1-9189-4c62-bdf1-f1124ec337e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0af5ca1-9189-4c62-bdf1-f1124ec337e7"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine hydrochloride is indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative trials have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. 6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine hydrochloride 150 mg two times a day. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine hydrochloride 150 mg 4 times daily. 8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa8f61bc-44f0-5dc1-87d7-ee09e4576588", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7959ac88-4d9d-56c9-a28f-4d97320d8e7d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0016586", "object_location_in_text": [549, 570], "original_object": "systemic mastocytosis", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfe7c0d6-d166-45d3-a593-fa0069d40c0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfe7c0d6-d166-45d3-a593-fa0069d40c0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfe7c0d6-d166-45d3-a593-fa0069d40c0e"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine oral solution is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1590f587-5d23-5568-b5bc-d08639479f89", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [514, 540], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1dab5315-5027-57ad-e054-00144ff8d46c"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitdine Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e482419-28b0-5914-b880-f6ffced5ee36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [516, 542], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e9dfbd02-4f08-4983-86c9-64fde4ea2a0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e9dfbd02-4f08-4983-86c9-64fde4ea2a0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9dfbd02-4f08-4983-86c9-64fde4ea2a0d"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine tablets, USP is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Trials available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Trials available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32e7259e-9835-593f-900c-f02689384472", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [526, 552], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0af5ca1-9189-4c62-bdf1-f1124ec337e7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0af5ca1-9189-4c62-bdf1-f1124ec337e7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0af5ca1-9189-4c62-bdf1-f1124ec337e7"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine hydrochloride is indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative trials have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. 6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine hydrochloride 150 mg two times a day. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine hydrochloride 150 mg 4 times daily. 8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56646e4e-ce3b-513a-85e9-9faa154dc45c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [541, 567], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d0da9dd6-c691-4614-99c7-531b0bf34837", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d0da9dd6-c691-4614-99c7-531b0bf34837", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0da9dd6-c691-4614-99c7-531b0bf34837"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Syrup (Ranitidine Oral Solution USP) is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6991813e-2db5-546b-a52c-c9b62b1d4249", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [518, 544], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b38a3332-5c54-453f-aeb7-070f830955c2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b38a3332-5c54-453f-aeb7-070f830955c2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b38a3332-5c54-453f-aeb7-070f830955c2"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg b.i.d. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg q.i.d. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76975565-2645-54ff-aae1-1658b59c1ffc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [516, 542], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:68919f75-cd91-475b-b9fe-f6372a03f74b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=68919f75-cd91-475b-b9fe-f6372a03f74b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68919f75-cd91-475b-b9fe-f6372a03f74b"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine tablets, USP is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Trials available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Trials available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93335bdb-73b8-5e07-a95d-165c42ac09c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [516, 542], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a897069a-0af0-499d-983f-afee0e9792fd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a897069a-0af0-499d-983f-afee0e9792fd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a897069a-0af0-499d-983f-afee0e9792fd"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine tablets, USP is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Trials available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Trials available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled trials have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:98d1586d-d771-5424-ba5a-ba7543dde3fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [518, 544], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d733324-93c6-201c-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d733324-93c6-201c-e054-00144ff88e88", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d733324-93c6-201c-e054-00144ff88e88"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg b.i.d. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg q.i.d. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a140f0b6-4c7c-57f0-8d99-d9eec51b2cff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [526, 552], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f3348a9-ce69-48d6-89f4-5c0e7d38a255", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f3348a9-ce69-48d6-89f4-5c0e7d38a255", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f3348a9-ce69-48d6-89f4-5c0e7d38a255"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets, USP are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6.Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets, USP 150 mg twice daily. 7.Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets, USP 150 mg 4 times daily. 8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a189b013-1496-5c89-a5de-9ffc60e169d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [513, 539], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fcf27c99-8bd4-41fb-bff8-38fed9de76d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fcf27c99-8bd4-41fb-bff8-38fed9de76d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcf27c99-8bd4-41fb-bff8-38fed9de76d9"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo – controlled comparative studies have been carried out for periods longer than 1 year. The treatment of pathological hypersecretory conditions. (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. ​​​​​​​Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:abaeada6-8187-5b2b-ac93-e8298d3fc5b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [522, 548], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dc729434-8340-40e3-9e5c-973c01460196", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dc729434-8340-40e3-9e5c-973c01460196", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dc729434-8340-40e3-9e5c-973c01460196"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets are indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets 150 mg twice daily. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets 150 mg 4 times daily. 8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c33eecfe-e643-58f7-95e8-538707d9c236", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [541, 567], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a10f978-be03-1362-e053-2991aa0a4c1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a10f978-be03-1362-e053-2991aa0a4c1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a10f978-be03-1362-e053-2991aa0a4c1f"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Syrup (Ranitidine Oral Solution USP) is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cc7b639a-5356-5868-bcff-7b3f48ef9ab4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [515, 541], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0fba6615-37c2-4ba6-b6e5-09599369a5bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0fba6615-37c2-4ba6-b6e5-09599369a5bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fba6615-37c2-4ba6-b6e5-09599369a5bc"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine Tablets are indicated in: Short- term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo- controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "pathological hypersecretory conditions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cef6bb4d-919b-5b1b-b989-8504705537ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19830609", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7fc5ec12-b6bf-56be-943d-b10a97077d42", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:5535c97a-87d9-56c2-8289-773023e5f74c", "object": "MONDO:0019610", "object_location_in_text": [518, 544], "original_object": "Zollinger-Ellison syndrome", "original_subject": "RANITIDINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfe7c0d6-d166-45d3-a593-fa0069d40c0e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfe7c0d6-d166-45d3-a593-fa0069d40c0e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfe7c0d6-d166-45d3-a593-fa0069d40c0e"]}], "subject": "CHEBI:8776", "supporting_text": ["Ranitidine oral solution is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008679", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3265586b-8177-5cdb-aecf-db493aa188b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980327", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0008679"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf34f91e-6d1e-532e-9e82-b5b5ebe7ed4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c9ebd016-0273-5b9c-bca4-2512a098585a", "object": "MONDO:0000757", "object_location_in_text": [240, 275], "original_object": "glucocorticoid-induced osteoporosis", "original_subject": "RISEDRONIC ACID", "population_context_qualifier": "men and women initiating or continuing systemic glucocorticoid treatment", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89896dfe-f69d-4cb3-bb71-7a7c611071fa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89896dfe-f69d-4cb3-bb71-7a7c611071fa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89896dfe-f69d-4cb3-bb71-7a7c611071fa"]}], "subject": "CHEBI:8869", "supporting_text": ["1 INDICATIONS AND USAGE Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis (1.1) Treatment to increase bone mass in men with osteoporosis (1.2) Treatment and prevention of glucocorticoid-induced osteoporosis (1.3) Treatment of Paget’s disease (1.4)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008679", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ce8b17b-5177-57b2-b2b4-e3ccb3076e51", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980327", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0008679"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf34f91e-6d1e-532e-9e82-b5b5ebe7ed4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c9ebd016-0273-5b9c-bca4-2512a098585a", "object": "MONDO:0000757", "object_location_in_text": [251, 286], "original_object": "glucocorticoid-induced osteoporosis", "original_subject": "RISEDRONIC ACID", "population_context_qualifier": "men and women initiating or continuing systemic glucocorticoid treatment for chronic diseases", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:81702f21-3117-49ce-8e9b-2aa2648ba7c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=81702f21-3117-49ce-8e9b-2aa2648ba7c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81702f21-3117-49ce-8e9b-2aa2648ba7c3"]}], "subject": "CHEBI:8869", "supporting_text": ["1 INDICATIONS AND USAGE Risedronate sodium tablets, USP are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) • Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) • Treatment of Paget's disease ( 1.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0008679", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5d7b9ab-e575-554f-b0c4-80f2e8947534", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980327", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0008679"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:cf34f91e-6d1e-532e-9e82-b5b5ebe7ed4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c9ebd016-0273-5b9c-bca4-2512a098585a", "object": "MONDO:0000757", "object_location_in_text": [249, 284], "original_object": "glucocorticoid-induced osteoporosis", "original_subject": "RISEDRONIC ACID", "population_context_qualifier": "men and women initiating or continuing systemic glucocorticoid treatment", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b90f2e5b-10b8-29a7-0360-31bd0dae0ec2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b90f2e5b-10b8-29a7-0360-31bd0dae0ec2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b90f2e5b-10b8-29a7-0360-31bd0dae0ec2"]}], "subject": "CHEBI:8869", "supporting_text": ["1 INDICATIONS AND USAGE Risedronate sodium tablets, USP are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget's disease ( 1.4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "FLT3-ITD mutation-positive acute myeloid leukemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88702fdb-4d23-5149-993f-18b60340e58e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190618", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f2b8344a-38b8-5c1b-bab5-eb3e0a98e429", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:a860a393-288c-5488-a40a-3d3686758475", "object": "MONDO:0018874", "object_location_in_text": [116, 138], "original_object": "acute myeloid leukemia", "original_subject": "QUIZARTINIB HYDROCHLORIDE", "population_context_qualifier": "relapsed or refractory", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:QUIZARTINIB HYDROCHLORIDE#72-20190618", "https://www.pmda.go.jp/files/000240288.pdf"]}], "subject": "CHEBI:90217", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "advanced or metastatic transitional-cell carcinoma of the urothelial tract", "has_confidence_score": 0.6, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:108d839a-9e89-5078-9b0a-1513b09b0e17", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090921", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:dd21146b-aa5d-50e9-8e88-51d4d5319d5e", "medic_pair_confidence": 0.6, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:a9740e4d-5673-5410-90db-ef7869997111", "object": "MONDO:0040679", "object_location_in_text": [99, 150], "original_object": "transitional-cell carcinoma of the urothelial tract", "original_subject": "vinflunine", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:javlor", "https://www.ema.europa.eu/en/documents/product-information/javlor-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/javlor"]}], "subject": "CHEBI:90241", "supporting_text": ["Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status ? 2."], "temporal_context_qualifier": "after failure of a prior platinum-containing regimen"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3812172", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ae4823d-bfb7-5353-9266-7eef59607d7a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151120", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["vemurafenib"], "medic_disease_context_ids": ["UMLS:C3812172"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:36fd8efe-e038-5235-b659-0260430edb9c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b2ca683a-23ff-5a6b-8bf4-1523387acc40", "object": "MONDO:0005191", "object_location_in_text": [119, 138], "original_object": "metastatic melanoma", "original_subject": "cobimetinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cotellic", "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic"]}], "subject": "CHEBI:90851", "supporting_text": ["Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "BRAF V600E or V600K mutation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e64aa73-fb6e-5121-89d6-74fb5d5626fc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151110", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["vemurafenib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:36fd8efe-e038-5235-b659-0260430edb9c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2ca683a-23ff-5a6b-8bf4-1523387acc40", "object": "MONDO:0005191", "original_object": "metastatic melanoma", "original_subject": "COBIMETINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c387579e-cee0-4334-bd1e-73f93ac1bde6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6"]}], "subject": "CHEBI:90851", "supporting_text": ["1 INDICATIONS AND USAGE COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 ) 1.1 Unresectable or Metastatic Melanoma COTELLIC ® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. 1.2 Histiocytic Neoplasms COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3812172", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d6868e89-b466-5cee-aac6-5ec36206aa7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151120", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["vemurafenib"], "medic_disease_context_ids": ["UMLS:C3812172"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:219fe20c-9480-5ca2-9ea0-628fd0dc4df1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:b2ca683a-23ff-5a6b-8bf4-1523387acc40", "object": "UMLS:C4725093", "original_object": "unresectable melanoma", "original_subject": "cobimetinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:cotellic", "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic"]}], "subject": "CHEBI:90851", "supporting_text": ["Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "BRAF V600E or V600K mutation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6eb2a030-11fb-5f52-8cd9-feedf85f7f55", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151110", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["vemurafenib"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:219fe20c-9480-5ca2-9ea0-628fd0dc4df1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b2ca683a-23ff-5a6b-8bf4-1523387acc40", "object": "UMLS:C4725093", "original_object": "unresectable melanoma", "original_subject": "COBIMETINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c387579e-cee0-4334-bd1e-73f93ac1bde6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6"]}], "subject": "CHEBI:90851", "supporting_text": ["1 INDICATIONS AND USAGE COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 ) 1.1 Unresectable or Metastatic Melanoma COTELLIC ® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. 1.2 Histiocytic Neoplasms COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "acquired HSDD", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f562f6e8-9d7a-5329-9657-8f07f9102643", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150818", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5866fa6a-7ffa-574a-b634-1a521736e95c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:34b4671e-d7cb-5754-bccb-23848a659ad9", "object": "MONDO:0001821", "original_object": "hypoactive sexual desire disorder", "original_subject": "FLIBANSERIN", "population_context_qualifier": "women less than 65 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3819daf3-e935-2c53-c527-e1d57922f394", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394"]}], "subject": "CHEBI:90865", "supporting_text": ["1 INDICATIONS AND USAGE ADDYI is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: • A co-existing medical or psychiatric condition, • Problems within the relationship, or • The effects of a medication or other drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c259e71-f4d0-5c61-9b7d-8786e204c06d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150901", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b074accb-be2b-574a-84c7-9d763d3ec3e0", "object": "UMLS:C3830545", "object_location_in_text": [122, 149], "original_object": "delayed nausea and vomiting", "original_subject": "ROLAPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8670c3cf-82d9-466d-be49-de33d8c8742b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8670c3cf-82d9-466d-be49-de33d8c8742b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8670c3cf-82d9-466d-be49-de33d8c8742b"]}], "subject": "CHEBI:90908", "supporting_text": ["1 INDICATIONS AND USAGE VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "emetogenic cancer chemotherapy", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:70e903ad-6080-588b-8835-8f1ded8b7271", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150901", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_co_administered_with": ["other antiemetic agents"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:959846f7-66c0-5414-a08c-42a919e85374", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b074accb-be2b-574a-84c7-9d763d3ec3e0", "object": "UMLS:C3830545", "object_location_in_text": [122, 149], "original_object": "delayed nausea and vomiting", "original_subject": "ROLAPITANT", "population_context_qualifier": "adults", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a52896cd-4a98-49b8-82db-bf1985a64d97", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a52896cd-4a98-49b8-82db-bf1985a64d97", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a52896cd-4a98-49b8-82db-bf1985a64d97"]}], "subject": "CHEBI:90908", "supporting_text": ["1 INDICATIONS AND USAGE VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "manic or mixed episodes", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85131056-f97c-52d9-98ba-5770c23c5fdf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210716", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b21455a8-98e1-5340-8a2e-231d8d2f7d4f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0cf2324f-710f-5962-889c-f6ee9f9f3739", "object": "MONDO:0001866", "object_location_in_text": [105, 123], "original_object": "bipolar I disorder", "original_subject": "Cariprazine hydrochloride bulk and Cariprazine capsules 1.5mg/3mg/4.5mg and 6mg", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:90933", "supporting_text": ["For the treatment of Schizophrenia in adults. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults"], "temporal_context_qualifier": "acute treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "anaplastic lymphoma kinase (ALK)-positive", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f827e815-c7b9-5582-87c3-0c19e500a799", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151211", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:be05fbec-0eb9-5bb0-bb92-6b914e3ba132", "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "ALECTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:42c49deb-713b-427a-9670-08af08adcffb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb"]}], "subject": "CHEBI:90936", "supporting_text": ["1 INDICATIONS AND USAGE ALECENSA is a kinase inhibitor indicated for: adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive) as detected by an FDA-approved test. ( 1.1 ) treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. ( 1.2 ) 1.1 Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC) ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test [see Dosage &amp; Administration (2.1) ]. 1.2 Treatment of Metastatic ALK-Positive NSCLC ALECENSA is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test [see Dosage &amp; Administration (2.1) ] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C4684419", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cbed7ada-d5ca-5cc4-b229-b9a8cba8d27b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200221", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4684419"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:41b17f65-38ef-5f46-97bb-2b53c97f023b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:2b2931c2-f87c-57aa-a970-0b4815b28e7c", "object": "MONDO:0020325", "object_location_in_text": [115, 145], "original_object": "anaplastic large cell lymphoma", "original_subject": "ALECTINIB HYDROCHLORIDE", "population_context_qualifier": "relapsed or refractory", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:ALECTINIB HYDROCHLORIDE#74-20200221", "https://www.pmda.go.jp/files/000208811.pdf"]}], "subject": "CHEBI:90936", "supporting_text": ["A drug with a new indication and a new dosage for the treatment of relapsed or refractory ALK fusion gene-positive anaplastic large cell lymphoma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) T790M mutation-positive", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3140d34a-ad7a-5f26-82a1-8f78457fd12d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20151113", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7c2bd659-794e-5002-9a27-813beb662f9d", "medic_supporting_text_truncated": true, "object": "MONDO:0005233", "original_object": "non-small cell lung cancer", "original_subject": "OSIMERTINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7"]}], "subject": "CHEBI:90943", "supporting_text": ["1 INDICATIONS AND USAGE TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 ) 1.1 Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . 1.2 Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and"], "temporal_context_qualifier": "metastatic"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "epidermal growth factor receptor (EGFR) mutation-positive", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8bc3b362-f525-514c-a89a-7afccef9da4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20220824", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:a196e240-43da-5e08-8f35-5728bba607db", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b0d459a6-f4d1-5b8e-b60b-68c19d4e7dd8", "object": "MONDO:0005233", "object_location_in_text": [169, 195], "original_object": "non-small cell lung cancer", "original_subject": "OSIMERTINIB MESILATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OSIMERTINIB MESILATE#39-20220824", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:90948", "supporting_text": ["Drugs with a new indication, a new dosage, and other characteristics for postoperative adjuvant treatment for epidermal growth factor receptor (EGFR) mutation- positive non-small cell lung cancer."], "temporal_context_qualifier": "postoperative adjuvant treatment"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "EGFR tyrosine kinase inhibitor resistance", "has_confidence_score": 0.459, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d87991e-4065-5844-ae66-092077652715", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160328", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:13f5edbd-1726-5823-9bd7-96e4547bdd64", "medic_pair_confidence": 0.459, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:b0d459a6-f4d1-5b8e-b60b-68c19d4e7dd8", "object": "UMLS:C0278517", "original_object": "recurrent non-small-cell lung cancer", "original_subject": "OSIMERTINIB MESILATE", "population_context_qualifier": "patients with EGFR T790M mutation-positive disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:OSIMERTINIB MESILATE#112-20160328", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:90948", "supporting_text": ["Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) T790M mutation- positive non-small-cell lung cancer with resistance to EGFR tyrosine kinase inhibitors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "airway obstructive disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce1d2b6c-dfc0-5245-bee0-7a98d3bb4583", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160826", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:622b5bbc-9b53-5f84-81e2-4e499dfc0011", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:5276b73e-5921-5b37-86bb-5f1478a2920d", "object": "MONDO:0004979", "object_location_in_text": [164, 180], "original_object": "bronchial asthma", "original_subject": "TIOTROPIUM BROMIDE HYDRATE", "population_context_qualifier": "mild to moderate persistent", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TIOTROPIUM BROMIDE HYDRATE#101-20160826", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:90960", "supporting_text": ["Drugs with a new additional indication, dosage, and dosage form for the relief of symptoms secondary to airway obstructive disorders in mild to moderate persistent bronchial asthma."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "post-polycythemia vera, post-essential thrombocythemia", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e8d34be-62a5-59f9-b23b-4a85f5561c21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190816", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:857c8894-da82-5513-b341-81224675a123", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d7bba11c-c0df-50e8-8798-81ec131e2293", "object": "MONDO:0044903", "original_object": "myelofibrosis", "original_subject": "FEDRATINIB", "population_context_qualifier": "adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f0f55a2a-4e0c-4cba-8571-03e1424486d7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0f55a2a-4e0c-4cba-8571-03e1424486d7"]}], "subject": "CHEBI:91408", "supporting_text": ["1 INDICATIONS AND USAGE INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) ( 1 )."], "temporal_context_qualifier": "post-polycythemia vera ; post-essential thrombocythemia"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.76, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:75b3ce9e-eea6-5e70-8d30-8627980faab7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970925", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.76, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:8ff8af3e-fac6-5c9e-b5e7-8a6ccb27382b", "object": "MONDO:0005010", "original_object": "coronary artery disease", "original_subject": "Simvastatin 5mg/10mg/20mg/40mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:9150", "supporting_text": ["Primary hypercholesterolemia, type IIa & IIb alone or in association with CAD."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b69ef31-3547-54d3-997e-9cac922ef6ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [479, 501], "original_object": "myocardial infarctions", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a203ae4-0ed1-0099-e063-6294a90abc85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a203ae4-0ed1-0099-e063-6294a90abc85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a203ae4-0ed1-0099-e063-6294a90abc85"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone oral suspension is an antagonist of aldosterone indicated for: the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ) use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions ( 1.3 ) 1.1 Heart Failure Spironolactone oral suspension is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure. Spironolactone oral suspension is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone oral suspension is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Hi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:458e37ac-3bc2-59b7-a8c3-5a3e7b573691", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [461, 483], "original_object": "myocardial infarctions", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb29ea6f-c294-4895-9e9b-544d69651a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb29ea6f-c294-4895-9e9b-544d69651a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb29ea6f-c294-4895-9e9b-544d69651a35"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a55dd19-e47b-5aae-a9ee-30e86ffe29f1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [461, 483], "original_object": "myocardial infarctions", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d407f3f-fc59-331d-e063-6394a90ac10c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d407f3f-fc59-331d-e063-6394a90ac10c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d407f3f-fc59-331d-e063-6394a90ac10c"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d57100e6-b856-5780-8047-03ca74390f4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [461, 483], "original_object": "myocardial infarctions", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08738ad4-1607-4d55-af71-6790477353bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08738ad4-1607-4d55-af71-6790477353bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08738ad4-1607-4d55-af71-6790477353bd"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:df986f1c-fab0-55a8-a268-d6237c62eb88", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [461, 483], "original_object": "myocardial infarctions", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c328f555-2da8-43ac-bc04-0e89d4d2aa53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c328f555-2da8-43ac-bc04-0e89d4d2aa53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c328f555-2da8-43ac-bc04-0e89d4d2aa53"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35b62dcf-2870-5ba0-8064-b4d1c615bcca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [449, 456], "original_object": "strokes", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5d407f3f-fc59-331d-e063-6394a90ac10c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5d407f3f-fc59-331d-e063-6394a90ac10c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d407f3f-fc59-331d-e063-6394a90ac10c"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e2416e0-c56d-5efa-90f6-3e54eb3b40a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [449, 456], "original_object": "strokes", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb29ea6f-c294-4895-9e9b-544d69651a35", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb29ea6f-c294-4895-9e9b-544d69651a35", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb29ea6f-c294-4895-9e9b-544d69651a35"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62053a01-9298-5483-abd5-6c9f1bd44def", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [467, 474], "original_object": "strokes", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a203ae4-0ed1-0099-e063-6294a90abc85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a203ae4-0ed1-0099-e063-6294a90abc85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a203ae4-0ed1-0099-e063-6294a90abc85"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone oral suspension is an antagonist of aldosterone indicated for: the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ) use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions ( 1.3 ) 1.1 Heart Failure Spironolactone oral suspension is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure. Spironolactone oral suspension is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone oral suspension is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Hi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:88676fda-3a83-556b-8193-0a989ac6a37a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [449, 456], "original_object": "strokes", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:08738ad4-1607-4d55-af71-6790477353bd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=08738ad4-1607-4d55-af71-6790477353bd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08738ad4-1607-4d55-af71-6790477353bd"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c17b96fd-d6ed-5d3a-897a-a44195f02cf0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [449, 456], "original_object": "strokes", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c328f555-2da8-43ac-bc04-0e89d4d2aa53", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c328f555-2da8-43ac-bc04-0e89d4d2aa53", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c328f555-2da8-43ac-bc04-0e89d4d2aa53"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosteronism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, ant"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15855a27-95a2-5519-94d8-8aced0628773", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3b60de71-2afa-4922-ba3e-0664c2ae29a0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3b60de71-2afa-4922-ba3e-0664c2ae29a0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3b60de71-2afa-4922-ba3e-0664c2ae29a0"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27bf3b03-ba86-53ec-a7f8-658084b8274d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:753bbc6f-2e50-49c1-b5bf-18f8411a1e8e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=753bbc6f-2e50-49c1-b5bf-18f8411a1e8e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=753bbc6f-2e50-49c1-b5bf-18f8411a1e8e"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6be54fe9-4fd9-52ce-ba4f-99e78812dd05", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2efb4720-625f-6616-b6f0-8b13a17c9d7e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2efb4720-625f-6616-b6f0-8b13a17c9d7e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2efb4720-625f-6616-b6f0-8b13a17c9d7e"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:725195cf-0f2d-573c-aead-57bf17ae2e71", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b98b7780-e310-493a-83bd-bb3d93cf8dde", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b98b7780-e310-493a-83bd-bb3d93cf8dde", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b98b7780-e310-493a-83bd-bb3d93cf8dde"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e30e413-be64-502e-9439-eafdcb074f20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0cc23419-e6d5-4036-8011-dc1d2455e0cb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0cc23419-e6d5-4036-8011-dc1d2455e0cb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0cc23419-e6d5-4036-8011-dc1d2455e0cb"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ae38dacf-ef59-563c-a1cf-6584d0c0c253", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a6e0bf0e-42d3-41e4-854b-811df3bbaaa9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a6e0bf0e-42d3-41e4-854b-811df3bbaaa9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6e0bf0e-42d3-41e4-854b-811df3bbaaa9"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hepatic cirrhosis with ascites", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97147ebf-18f0-58e9-b0ff-14ea42256ca2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:9766cbb8-0d6b-5577-a9c9-e33234865507", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "object": "HP:0000969", "original_object": "edema", "original_subject": "spironolactone", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:qaialdo", "https://www.ema.europa.eu/en/documents/product-information/qaialdo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo"]}], "subject": "CHEBI:9241", "supporting_text": ["In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hepatic cirrhosis with ascites and oedema", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10f64fef-6a9d-5cbf-a4e4-d654b5b0f001", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230526", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:5cb6d5ad-5dd2-5625-84c5-bc2bf81a1d07", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "object": "HP:0001541", "object_location_in_text": [106, 113], "original_object": "ascites", "original_subject": "spironolactone", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:qaialdo", "https://www.ema.europa.eu/en/documents/product-information/qaialdo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo"]}], "subject": "CHEBI:9241", "supporting_text": ["In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "aldosterone-producing adrenal adenomas, bilateral micro or macronodular adrenal hyperplasia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:568df02c-9dce-5e72-aff1-b0fccd3f1363", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:55a074c0-f2ad-5abb-976c-ac071bcfa746", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001422", "original_object": "primary hyperaldosteronism", "original_subject": "SPIRONOLACTONE", "population_context_qualifier": "patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb27a2d2-1d28-4780-8e69-5fe613a0335e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb27a2d2-1d28-4780-8e69-5fe613a0335e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb27a2d2-1d28-4780-8e69-5fe613a0335e"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "aldosterone-producing adrenal adenomas, bilateral micro or macronodular adrenal hyperplasia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66669096-828b-5ef2-831a-0627143b7324", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:55a074c0-f2ad-5abb-976c-ac071bcfa746", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001422", "original_object": "primary hyperaldosteronism", "original_subject": "SPIRONOLACTONE", "population_context_qualifier": "patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b76a904-6c99-485a-a05f-13a36c5f720c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b76a904-6c99-485a-a05f-13a36c5f720c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b76a904-6c99-485a-a05f-13a36c5f720c"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "aldosterone-producing adrenal adenomas, bilateral micro or macronodular adrenal hyperplasia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8b647bca-ce32-5b6c-a3cd-845bc5327946", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:55a074c0-f2ad-5abb-976c-ac071bcfa746", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001422", "original_object": "primary hyperaldosteronism", "original_subject": "SPIRONOLACTONE", "population_context_qualifier": "patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd5ec154-b092-4c4d-8e72-ca2a2ef71a6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd5ec154-b092-4c4d-8e72-ca2a2ef71a6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd5ec154-b092-4c4d-8e72-ca2a2ef71a6d"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1) . Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2) . The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3) . Treatment of primary hyperaldosternism for: (1.4) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, dia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "aldosterone-producing adrenal adenomas, bilateral micro or macronodular adrenal hyperplasia", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed628c13-e8de-54b1-b265-25633b6b745f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:55a074c0-f2ad-5abb-976c-ac071bcfa746", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0001422", "original_object": "primary hyperaldosteronism", "original_subject": "SPIRONOLACTONE", "population_context_qualifier": "patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39d82d50-0b77-4ef5-96b8-c1e05044a82c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39d82d50-0b77-4ef5-96b8-c1e05044a82c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d82d50-0b77-4ef5-96b8-c1e05044a82c"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:63996e32-7d2a-5a63-b63b-b0d933def3e7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [118, 131], "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb27a2d2-1d28-4780-8e69-5fe613a0335e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb27a2d2-1d28-4780-8e69-5fe613a0335e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb27a2d2-1d28-4780-8e69-5fe613a0335e"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87477eab-4daa-5f45-bae2-a752a03f8a46", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [137, 150], "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a203ae4-0ed1-0099-e063-6294a90abc85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a203ae4-0ed1-0099-e063-6294a90abc85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a203ae4-0ed1-0099-e063-6294a90abc85"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone oral suspension is an antagonist of aldosterone indicated for: the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ) use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions ( 1.3 ) 1.1 Heart Failure Spironolactone oral suspension is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure. Spironolactone oral suspension is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone oral suspension is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Hi"], "temporal_context_qualifier": "to increase survival"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0012664", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93de9017-8921-505f-a351-90a3ee0462b6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0012664"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [118, 131], "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bd5ec154-b092-4c4d-8e72-ca2a2ef71a6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bd5ec154-b092-4c4d-8e72-ca2a2ef71a6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bd5ec154-b092-4c4d-8e72-ca2a2ef71a6d"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1) . Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2) . The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3) . Treatment of primary hyperaldosternism for: (1.4) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, dia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a12396ea-d8cb-5362-a899-377a8099189d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [118, 131], "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8b76a904-6c99-485a-a05f-13a36c5f720c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8b76a904-6c99-485a-a05f-13a36c5f720c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8b76a904-6c99-485a-a05f-13a36c5f720c"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA Class III-IV heart failure and reduced ejection fraction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8b6e7c2-01b8-5098-b873-fd40f4251ce8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:076f3056-74e4-5c84-8b3d-01f5cc6366ff", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "object_location_in_text": [118, 131], "original_object": "heart failure", "original_subject": "SPIRONOLACTONE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39d82d50-0b77-4ef5-96b8-c1e05044a82c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39d82d50-0b77-4ef5-96b8-c1e05044a82c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d82d50-0b77-4ef5-96b8-c1e05044a82c"]}], "subject": "CHEBI:9241", "supporting_text": ["1 INDICATIONS AND USAGE Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11f7d782-2499-59af-b34f-3cb30502098b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:accb5fe9-b3d0-4e2e-a3f0-e7d16873bbb9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=accb5fe9-b3d0-4e2e-a3f0-e7d16873bbb9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=accb5fe9-b3d0-4e2e-a3f0-e7d16873bbb9"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses For the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4001ab0c-61fe-551e-b19f-32039bf456a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d0146a9-5073-4e24-954f-75b84affadc2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d0146a9-5073-4e24-954f-75b84affadc2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d0146a9-5073-4e24-954f-75b84affadc2"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses For the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f2d6418-4f1f-5265-8fdd-3fe846ea8a7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ce8f926-c202-40d1-9dba-0477f1f49e14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ce8f926-c202-40d1-9dba-0477f1f49e14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ce8f926-c202-40d1-9dba-0477f1f49e14"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses for the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:59ec983d-b89a-55a3-88c7-c49ed32763c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:52c62397-58f1-d34d-e063-6294a90a6faf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=52c62397-58f1-d34d-e063-6294a90a6faf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=52c62397-58f1-d34d-e063-6294a90a6faf"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses For the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:774f08fe-3781-5ceb-b32a-dc129df895ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d3049296-0d15-4523-883c-25f8817bc735", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d3049296-0d15-4523-883c-25f8817bc735", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d3049296-0d15-4523-883c-25f8817bc735"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses for the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c04745ce-263e-5580-9690-bde5f58dc547", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b0eb7b54-4f4e-4ca2-8e4e-30d18d662401", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b0eb7b54-4f4e-4ca2-8e4e-30d18d662401", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b0eb7b54-4f4e-4ca2-8e4e-30d18d662401"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses for the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d73578e9-5071-5225-bb94-139c11077788", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb81286f-72b4-42b3-a596-439d0aeae93f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb81286f-72b4-42b3-a596-439d0aeae93f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb81286f-72b4-42b3-a596-439d0aeae93f"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses for the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e48d34b6-360b-5d85-9c52-10131f48c236", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b25106f8-436e-4c06-8780-b12368ede9fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b25106f8-436e-4c06-8780-b12368ede9fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b25106f8-436e-4c06-8780-b12368ede9fe"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses for the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f83dc188-7255-5b30-ac65-5cc9f15f7b9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5fccbb63-7859-484c-b7b3-9de711364c09", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5fccbb63-7859-484c-b7b3-9de711364c09", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fccbb63-7859-484c-b7b3-9de711364c09"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses for the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2938895", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa04f0b1-569f-5be6-aca5-1f7b718364b1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060509", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2938895", "MONDO:0005324", "UMLS:C1387134", "UMLS:C0700360"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:40a7b73b-393e-53ae-aa27-869fc0f9a13f", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:75a94178-48ab-5858-8d2a-2abfab80923d", "object": "HP:0033841", "object_location_in_text": [33, 43], "original_object": "itchy eyes", "original_subject": "KETOTIFEN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e5fd1246-c4a7-4be3-a3d3-83d82ec6cab8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e5fd1246-c4a7-4be3-a3d3-83d82ec6cab8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5fd1246-c4a7-4be3-a3d3-83d82ec6cab8"]}], "subject": "CHEBI:92511", "supporting_text": ["Uses For the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander."], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Acinetobacter baumannii-calcoaceticus complex", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94012418-85f4-5d58-97df-b87ae60e6945", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:84db3b32-9f97-57ae-9d7f-277971648f21", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:84ed3958-cd59-58ef-a12a-6c6160c83d14", "object": "UMLS:C2189270", "object_location_in_text": [293, 334], "original_object": "ventilator-associated bacterial pneumonia", "original_subject": "SULBACTAM", "population_context_qualifier": "patients 18 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72"]}], "subject": "CHEBI:9321", "supporting_text": ["1 INDICATIONS AND USAGE XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Acinetobacter baumannii-calcoaceticus complex", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8fe762b-eede-5c85-a77e-570362550b42", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:44fe585a-fe5c-5f41-9696-afd7501909bb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:84ed3958-cd59-58ef-a12a-6c6160c83d14", "object": "UMLS:C4727977", "object_location_in_text": [251, 288], "original_object": "hospital-acquired bacterial pneumonia", "original_subject": "SULBACTAM", "population_context_qualifier": "patients 18 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0167aec-a89d-4e96-afe5-2ccf3e89fe72"]}], "subject": "CHEBI:9321", "supporting_text": ["1 INDICATIONS AND USAGE XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. ( 1.1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ad2cf6f-55eb-53c0-8298-c5d22b054b96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850830", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad787140-a735-5231-a97c-7d1e8ac5e6dc", "object": "MONDO:0001461", "object_location_in_text": [136, 150], "original_object": "tinea corporis", "original_subject": "SULCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b73e83e-8d3c-4d96-b4f6-9f854430add8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b73e83e-8d3c-4d96-b4f6-9f854430add8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b73e83e-8d3c-4d96-b4f6-9f854430add8"]}], "subject": "CHEBI:9325", "supporting_text": ["EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting EXELDERM SOLUTION and clinical improvement usually occurs within one week."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6d0f0563-d963-56a7-bdcf-1b595b38958c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850830", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad787140-a735-5231-a97c-7d1e8ac5e6dc", "object": "MONDO:0001461", "object_location_in_text": [133, 147], "original_object": "tinea corporis", "original_subject": "SULCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b731aa0-fb3f-4a96-9034-636138cbca03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b731aa0-fb3f-4a96-9034-636138cbca03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b731aa0-fb3f-4a96-9034-636138cbca03"]}], "subject": "CHEBI:9325", "supporting_text": ["SULCONAZOLE NITRATE cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosum , and Microsporum canis ,* and for the treatment of tinea versicolor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5ffa1a7-9d0a-5b5f-845a-9c8fce6f65ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850830", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cf946a1-c82f-517b-b963-07ad7136d7ed", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad787140-a735-5231-a97c-7d1e8ac5e6dc", "object": "MONDO:0001461", "object_location_in_text": [127, 141], "original_object": "tinea corporis", "original_subject": "SULCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cf6f4340-940c-4a61-b675-456e3297d810", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cf6f4340-940c-4a61-b675-456e3297d810", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cf6f4340-940c-4a61-b675-456e3297d810"]}], "subject": "CHEBI:9325", "supporting_text": ["SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c45cbd7c-37f4-5882-9c15-496044cde4fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850830", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88d1be8c-36ee-55c1-815e-b930290caa1f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad787140-a735-5231-a97c-7d1e8ac5e6dc", "object": "MONDO:0005984", "original_object": "tinea pedis", "original_subject": "SULCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b731aa0-fb3f-4a96-9034-636138cbca03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b731aa0-fb3f-4a96-9034-636138cbca03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b731aa0-fb3f-4a96-9034-636138cbca03"]}], "subject": "CHEBI:9325", "supporting_text": ["SULCONAZOLE NITRATE cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosum , and Microsporum canis ,* and for the treatment of tinea versicolor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0040935", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d10175d-9a8a-5390-92b8-88a74714ba19", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19850830", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0040935", "UMLS:C2939454", "UMLS:C0014530", "UMLS:C0319582"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6e2b525-b9f0-5781-b96d-8d6fcb13b446", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad787140-a735-5231-a97c-7d1e8ac5e6dc", "object": "UMLS:C1384589", "object_location_in_text": [115, 127], "original_object": "tinea cruris", "original_subject": "SULCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5b731aa0-fb3f-4a96-9034-636138cbca03", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5b731aa0-fb3f-4a96-9034-636138cbca03", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5b731aa0-fb3f-4a96-9034-636138cbca03"]}], "subject": "CHEBI:9325", "supporting_text": ["SULCONAZOLE NITRATE cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosum , and Microsporum canis ,* and for the treatment of tinea versicolor."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:07060806-a3f7-5b57-9af5-eb1c1f7e18a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:37670ded-5d4a-4e98-e063-6394a90a1571", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=37670ded-5d4a-4e98-e063-6394a90a1571", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=37670ded-5d4a-4e98-e063-6394a90a1571"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11d5457c-a156-501c-93cf-7d214d6e4232", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:067895f9-a797-4cbd-a3d2-d611d512fe5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=067895f9-a797-4cbd-a3d2-d611d512fe5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=067895f9-a797-4cbd-a3d2-d611d512fe5b"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1992f38b-9724-5352-9b10-d86173263f1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1cfe8e5a-8951-acea-e063-6394a90a1811", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1cfe8e5a-8951-acea-e063-6394a90a1811", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1cfe8e5a-8951-acea-e063-6394a90a1811"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c072afc-1e68-54c3-8c3b-4efbb98247de", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:532d776e-54b3-4d4f-bb7a-94927bfba4d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=532d776e-54b3-4d4f-bb7a-94927bfba4d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=532d776e-54b3-4d4f-bb7a-94927bfba4d2"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3803430e-06c8-5dba-99bf-b9967976eb26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f1a0f489-0d9e-66c4-e053-2a95a90a063d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f1a0f489-0d9e-66c4-e053-2a95a90a063d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1a0f489-0d9e-66c4-e053-2a95a90a063d"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7027075c-c225-5351-836f-2a86065bb2fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d9aa72e-b8dc-4ea3-be44-80f03ba81982", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d9aa72e-b8dc-4ea3-be44-80f03ba81982", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d9aa72e-b8dc-4ea3-be44-80f03ba81982"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8139a958-9701-55e1-9c56-b4b28d13f324", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72ca5cb5-14d2-45e4-8b53-ed5809b0aeca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72ca5cb5-14d2-45e4-8b53-ed5809b0aeca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72ca5cb5-14d2-45e4-8b53-ed5809b0aeca"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ea2d712-b339-5858-b4b2-ca60d3cda011", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:24b01ac4-3ed5-db3d-e063-6394a90a0629", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=24b01ac4-3ed5-db3d-e063-6394a90a0629", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24b01ac4-3ed5-db3d-e063-6394a90a0629"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:93548067-2d8b-5cc4-9b72-bac6000e8293", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c6a40aee-ef43-e40b-e053-2995a90ae048", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c6a40aee-ef43-e40b-e053-2995a90ae048", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6a40aee-ef43-e40b-e053-2995a90ae048"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94f669d9-d4dc-516c-b57c-10e002dbdb3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cb7d2adf-d69d-4686-b9cf-c83d73acc441", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cb7d2adf-d69d-4686-b9cf-c83d73acc441", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb7d2adf-d69d-4686-b9cf-c83d73acc441"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aa622f13-e7bf-5390-a35e-d2b27a2dabfa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a4051ae4-f1ef-4082-920f-97d176b4cef2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a4051ae4-f1ef-4082-920f-97d176b4cef2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4051ae4-f1ef-4082-920f-97d176b4cef2"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b736b695-0f3d-5bc7-9f28-d3bcedcf812e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4d6694f-2b0a-4d64-9e05-2fef6d8e60d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4d6694f-2b0a-4d64-9e05-2fef6d8e60d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4d6694f-2b0a-4d64-9e05-2fef6d8e60d9"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0433445", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bcb8baac-a8f1-56db-8c9c-2daef7faff95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [126, 138], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:475953ba-b555-474c-9bcd-8cd314cc0d1f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=475953ba-b555-474c-9bcd-8cd314cc0d1f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=475953ba-b555-474c-9bcd-8cd314cc0d1f"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "second- and third-degree burns", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c96e3032-72da-560b-92b2-a4313b19e391", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [133, 145], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second- and third-degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c437213a-1cd4-445e-a39f-bbcacb9f746f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c437213a-1cd4-445e-a39f-bbcacb9f746f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c437213a-1cd4-445e-a39f-bbcacb9f746f"]}], "subject": "CHEBI:9328", "supporting_text": ["SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9d397fe-4427-5136-bbd2-e6ca3c465744", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:30d6dc33-e457-466b-9159-d8e7cd791820", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=30d6dc33-e457-466b-9159-d8e7cd791820", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30d6dc33-e457-466b-9159-d8e7cd791820"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0332687", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d72a0805-c060-5886-b28b-a46e28ef6b1c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0332687", "UMLS:C0433445"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [118, 130], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second and third degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf1367b4-3075-4373-8998-d9006f680df3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf1367b4-3075-4373-8998-d9006f680df3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf1367b4-3075-4373-8998-d9006f680df3"]}], "subject": "CHEBI:9328", "supporting_text": ["Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "second- and third-degree burns", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e28475b5-3c27-5b3a-8081-a90362a3bcc2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:488ce05a-dd4e-5975-a2c6-b0f7e64a25fa", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "object": "UMLS:C1141927", "object_location_in_text": [133, 145], "original_object": "wound sepsis", "original_subject": "SULFADIAZINE", "population_context_qualifier": "patients with second- and third-degree burns", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:54b77a36-205b-4044-9ecb-c5130f0934b5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=54b77a36-205b-4044-9ecb-c5130f0934b5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=54b77a36-205b-4044-9ecb-c5130f0934b5"]}], "subject": "CHEBI:9328", "supporting_text": ["SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine-resistant strains of Plasmodium falciparum", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24aad71c-7ed9-5098-87a5-8b5923fffba1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "medic_supporting_text_truncated": true, "object": "MONDO:0005136", "original_object": "malaria", "original_subject": "SULFADIAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8993651b-fff6-4e3f-9b60-78587bc9bcee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8993651b-fff6-4e3f-9b60-78587bc9bcee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8993651b-fff6-4e3f-9b60-78587bc9bcee"]}], "subject": "CHEBI:9328", "supporting_text": ["sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variatio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chloroquine-resistant malaria", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9362a181-4009-551f-9d5e-7a39d9fef055", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d9a385a2-5b34-51a8-af2d-d5aee037bf13", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "medic_supporting_text_truncated": true, "object": "MONDO:0005136", "original_object": "malaria", "original_subject": "SULFADIAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6032d6f7-cbce-4e5d-841c-a1e24b616f91", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6032d6f7-cbce-4e5d-841c-a1e24b616f91", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6032d6f7-cbce-4e5d-841c-a1e24b616f91"]}], "subject": "CHEBI:9328", "supporting_text": ["Sulfadiazine Tablets are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae , when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0018483", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6e24156-50f1-520e-8837-60fc27a4b0e6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["penicilin"], "medic_disease_context_ids": ["UMLS:C0018483"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bfb14e5-09f4-513b-aec3-0298aca160d5", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "original_object": "acute otitis media", "original_subject": "SULFADIAZINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8993651b-fff6-4e3f-9b60-78587bc9bcee", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8993651b-fff6-4e3f-9b60-78587bc9bcee", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8993651b-fff6-4e3f-9b60-78587bc9bcee"]}], "subject": "CHEBI:9328", "supporting_text": ["sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variatio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "inability to monitor renal function", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01295846-a2a4-54f4-a5c8-8e4b267f565a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f2869cec-4d7d-5906-92d8-319f52753490", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "object": "MONDO:0001106", "original_object": "severe renal insufficiency", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:69af86b4-9c9f-4a70-b448-97b36698f3cd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=69af86b4-9c9f-4a70-b448-97b36698f3cd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69af86b4-9c9f-4a70-b448-97b36698f3cd"]}], "subject": "CHEBI:9332", "supporting_text": ["Sulfamethoxazole and trimethoprim oral suspension is contraindicated in the following situations: known hypersensitivity to trimethoprim or sulfonamides history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides documented megaloblastic anemia due to folate deficiency pediatric patients less than 2 months of age marked hepatic damage severe renal insufficiency when renal function status cannot be monitored concomitant administration with dofetilide (see PRECAUTIONS )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0275791", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c5896df1-79b9-5ba5-974b-77d7b24370f4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0275791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:30c30e07-475c-51a5-bcde-c6a38ce22f28", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "object": "MONDO:0019345", "object_location_in_text": [1209, 1220], "original_object": "Shigellosis", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults and pediatric patients two months of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebb570bb-6e5e-489e-875c-9e7b3a6d716a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebb570bb-6e5e-489e-875c-9e7b3a6d716a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebb570bb-6e5e-489e-875c-9e7b3a6d716a"]}], "subject": "CHEBI:9332", "supporting_text": ["1 INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: Pneumocystis jirovecii Pneumonia (1.1) Shigellosis (1.2) Urinary Tract Infections (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and trimethoprim injection and other antibacterial drugs, Sulfamethoxazole and trimethoprim injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.4) 1.1 Pneumocystis jirovecii Pneumonia"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48e008ad-b3e1-5c68-a488-46c94955d59f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85303424-aa83-5ab6-9242-0f8ae61448d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9f7ac013-668e-5832-976a-3887e36c6269", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c34b705a-062a-52e9-b42a-a5135e13196d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d03b6039-5c27-51d6-bb68-3f2bd7a177ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e635d6df-764d-562a-a180-2b2f47bf0500", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0024330", "object_location_in_text": [1040, 1058], "original_object": "acute otitis media", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21354fec-5a68-5353-b2f4-45065851c59f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4ab917b6-c82e-5a76-be70-86681305953f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0275791", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a975b1c6-3d72-581a-9679-663fcfa54d90", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0275791"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1966, 1975], "original_object": "enteritis", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e3a49508-0ebe-1334-e053-2a95a90ae173", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e3a49508-0ebe-1334-e053-2a95a90ae173", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3a49508-0ebe-1334-e053-2a95a90ae173"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim tablets offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible st"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c63df5c3-347d-5a86-ac84-9ffddbd5aa86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e0522758-12b3-540d-be4a-962fa7b89d23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Shigella flexneri and Shigella sonnei", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e4581377-f18f-571b-a13d-763826fe58d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3ec8a6ef-fb95-5922-9f04-9aee3f6c94d8", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "MONDO:0043579", "object_location_in_text": [1958, 1967], "original_object": "enteritis", "original_subject": "SULFAMETHOXAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42017ab0-bb42-5eff-81e6-81de47e81df5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763883", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:56469127-ec25-5003-a4a0-eca13e80874c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c4da9c4f-0704-4ed5-9d19-5c949f37f726", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c4da9c4f-0704-4ed5-9d19-5c949f37f726", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4da9c4f-0704-4ed5-9d19-5c949f37f726"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57d6982d-73f5-5bb0-8943-cab88523cd8e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f1eaea6-ac5d-5914-ba4e-38ae7bf2c9f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763883", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96ecb1c6-af03-5261-9e3f-461642abe0d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:562e2547-db2d-e2d2-e063-6294a90a1f5d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=562e2547-db2d-e2d2-e063-6294a90a1f5d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=562e2547-db2d-e2d2-e063-6294a90a1f5d"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C4763883", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9d765418-1f33-5ba4-a9a6-da4c421a1fe5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C4763883"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ef62512-0dc3-4821-9b60-6b375841c4c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ef62512-0dc3-4821-9b60-6b375841c4c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ef62512-0dc3-4821-9b60-6b375841c4c0"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b186e398-b378-5a39-ba29-d111d39fb9a6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of enterotoxigenic E. coli", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e792fe03-c3c4-556a-9e26-ec80cf25ce1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5d28bba2-979d-57ca-b0d8-c93ce7e965e1", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0277528", "original_object": "traveler's diarrhea", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c03df7b-9247-574b-a028-77f17db73ef6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c45ac3a4-d397-486e-abd1-349916543068"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ebe22ff-0aa5-533e-ba9f-3c8b3872766e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ec2e335c-3357-40d8-9615-a09fc40ce5f4"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b2d214d8-ace4-5108-b7cf-e7d3638d70b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d60c218c-6529-4944-af0b-a9dc720f32e9"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de414d15-d063-59cf-b9b8-12d357ec85ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=518cc045-a12b-f08f-e063-6394a90acb0c"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9aba6a0-fbb8-5c21-9270-65dfc0c10c56", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e0ab401d-135d-56e9-8b6b-8dbd79fa9517", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 5, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6b380dfc-445c-5f70-9b59-2c37efc51b4a", "medic_supporting_text_truncated": true, "object": "UMLS:C0856695", "object_location_in_text": [1659, 1700], "original_object": "acute exacerbations of chronic bronchitis", "original_subject": "SULFAMETHOXAZOLE", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce44959b-4bfe-4ba9-9fc2-7f9d4663d542"]}], "subject": "CHEBI:9332", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim tablets could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0085394", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bdb50082-119c-5a3c-90ca-86e3564e6eca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191220", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_disease_context_ids": ["UMLS:C0085394", "UMLS:C0348321"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:ed957e52-4167-5f6b-a754-f715601f31d8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:57e63845-d4b6-5835-a5cd-f5d96d49cb86", "object": "HP:0100806", "object_location_in_text": [77, 83], "original_object": "sepsis", "original_subject": "TAZOBACTAM SODIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TAZOBACTAM SODIUM#71-20191220", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:9421", "supporting_text": ["A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0085394", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c8c2f0c8-7f8f-5ad2-aa09-1e0a0f195a59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191220", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_disease_context_ids": ["UMLS:C0085394", "UMLS:C0348321"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:12fca7a4-8d4c-5bc5-afa5-2c44384a93c2", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:57e63845-d4b6-5835-a5cd-f5d96d49cb86", "object": "MONDO:0005249", "object_location_in_text": [88, 97], "original_object": "pneumonia", "original_subject": "TAZOBACTAM SODIUM", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TAZOBACTAM SODIUM#71-20191220", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:9421", "supporting_text": ["A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3203359", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:27d7a0ac-fac4-5c07-a61a-71f4d53c38c6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_disease_context_ids": ["UMLS:C3203359", "MONDO:0005227"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1201, 1213], "original_object": "appendicitis", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a63ca653-27d4-45fe-a744-77e0efe45220", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a63ca653-27d4-45fe-a744-77e0efe45220", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a63ca653-27d4-45fe-a744-77e0efe45220"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and Tazobactam for Injection and Sodium Chloride Injection, is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection and Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycosi"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40a6cc02-30f0-54e7-b97a-6dbd874b9ca6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1046, 1058], "original_object": "appendicitis", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3203359", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f245cac-4a1e-51f1-8be0-d20a96cfcfd7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_disease_context_ids": ["UMLS:C3203359", "MONDO:0005227"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [891, 903], "original_object": "appendicitis", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8db6bd91-2106-4bfd-8cc8-38aaf1e18d17", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE ZOSYN is a combination of piperacillin, a penicillin‑class antibacterial and tazobactam, a beta‑lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) • Skin and skin structure infections in adults ( 1.3 ) • Female pelvic infections in adults ( 1.4 ) • Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN and other antibacterial drugs, ZOSYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections ZOSYN is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia ZOSYN is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections ZOSYN is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus . 1.4 Female Pelvic Inf"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95c28aa5-7781-5eba-9c8e-b3c8f804d0c4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1025, 1037], "original_object": "appendicitis", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aebc0e6-89db-4ef0-b5ab-d6b3199bcfc4"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [ see Dosage and Administration (2) ]. 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and complicated sk"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac76a74f-23c1-5f8e-aa3e-5effdeb8d695", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1035, 1047], "original_object": "appendicitis", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1cb1314-d3e0-4b44-a1df-de14c32e8cc6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1cb1314-d3e0-4b44-a1df-de14c32e8cc6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1cb1314-d3e0-4b44-a1df-de14c32e8cc6"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: • Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) • Skin and skin structure infections in adults ( 1.3 ) • Female pelvic infections in adults ( 1.4 ) • Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.6 ). 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration ( 2 )]. 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicated and compli"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "appendicitis complicated by rupture or abscess", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ceacc4f5-7b7f-5b4d-8464-61bb97f7a08a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1a14d6ce-10b6-59e0-8d73-4006f4515d8a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "MONDO:0005649", "object_location_in_text": [1046, 1058], "original_object": "appendicitis", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nosocomial pneumonia moderate to severe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e7e2e1d-7ef2-5cce-8b2b-03c9a9ce25a1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4852b1dd-cd0a-53dc-abd9-6571e1ae3443", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "UMLS:C0949083", "object_location_in_text": [1462, 1482], "original_object": "nosocomial pneumonia", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5d8625e-e630-4076-bc55-46ebe861c6a5"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "nosocomial pneumonia moderate to severe", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:94ac093b-c94c-58bb-90d7-b33b6405a01f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["wrong_pairing"], "medic_co_administered_with": ["aminoglycoside"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4852b1dd-cd0a-53dc-abd9-6571e1ae3443", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:61bd715b-3506-52f3-83f5-6b4b970593fb", "medic_supporting_text_truncated": true, "object": "UMLS:C0949083", "object_location_in_text": [1462, 1482], "original_object": "nosocomial pneumonia", "original_subject": "TAZOBACTAM", "population_context_qualifier": "adults and pediatric patients (2 months of age and older)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39e19789-de4b-4fd1-ab1c-92f59496f496"]}], "subject": "CHEBI:9421", "supporting_text": ["1 INDICATIONS AND USAGE Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Intra-abdominal Infections Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis , B. ovatus , B. thetaiotaomicron , or B. vulgatus . 1.2 Nosocomial Pneumonia Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii , Haemophilus influenzae , Klebsiella pneumoniae , and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ] . 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplicat"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:032b65b2-d7a8-516c-9d94-96a5698f8efb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:671d5a85-4146-43b4-9d7d-ca53268eb2a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=671d5a85-4146-43b4-9d7d-ca53268eb2a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=671d5a85-4146-43b4-9d7d-ca53268eb2a6"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:06ab0133-e9d8-5b26-acb7-340a03600abf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c22a318-d1f2-4788-9331-66fed71ebf38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c2811b9-cff0-5c47-bb57-dcbf1d5a6286", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6da5155-9c26-46bb-bc0f-ece4ea21405f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6da5155-9c26-46bb-bc0f-ece4ea21405f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6da5155-9c26-46bb-bc0f-ece4ea21405f"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1311a8aa-10e2-5228-ac35-816baed77f8c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5743c58e-deab-ac93-e063-6294a90ac1eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25d9fad6-4682-5c4a-a2be-e8af4fdeb552", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3296f730-4994-56d8-a7b8-9feed4d810c1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [257, 279], "original_object": "myocardial infarctions", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:830741dd-3f3c-4f8e-88c6-dc112166f477", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=830741dd-3f3c-4f8e-88c6-dc112166f477", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=830741dd-3f3c-4f8e-88c6-dc112166f477"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f5741c3-3669-500c-9a87-0a8f89df916b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd2b0604-f887-40d9-9109-dafcc9987e4e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd2b0604-f887-40d9-9109-dafcc9987e4e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd2b0604-f887-40d9-9109-dafcc9987e4e"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62955496-fbe0-575d-bca9-e31bf27f153f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4be6575f-ea8d-4cd8-a49d-3d1c93f2621a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4be6575f-ea8d-4cd8-a49d-3d1c93f2621a"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) 1.1 Hypertension Telmisartan is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b48b0d7b-85f2-5b07-8e14-6c740a6b9259", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:963e9245-ec7a-4bf6-9fc0-80f54e3657f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=963e9245-ec7a-4bf6-9fc0-80f54e3657f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=963e9245-ec7a-4bf6-9fc0-80f54e3657f0"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb94c727-6343-5129-ac31-876e1eb72e1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [257, 279], "original_object": "myocardial infarctions", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5ded796-3555-4476-8b37-0cdc88d7594a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5ded796-3555-4476-8b37-0cdc88d7594a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5ded796-3555-4476-8b37-0cdc88d7594a"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ce43e26a-6387-524b-983a-dfa9a45b9eee", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:beaaf383-730f-4411-b5e7-15c32b53a338", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=beaaf383-730f-4411-b5e7-15c32b53a338", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=beaaf383-730f-4411-b5e7-15c32b53a338"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5e418b1-6be6-5557-813f-2f8d1053dd8b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09d31eee-cd22-4918-a889-3eb4d2969525", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09d31eee-cd22-4918-a889-3eb4d2969525", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09d31eee-cd22-4918-a889-3eb4d2969525"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pres"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dabd36f4-1f58-50d6-9201-151c39b4bd02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91215664-6e19-4e04-9ae7-ab5664799426", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91215664-6e19-4e04-9ae7-ab5664799426", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91215664-6e19-4e04-9ae7-ab5664799426"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f6128f9a-5287-51d6-bce0-77054d5af8ce", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eaed12cd-5bfe-4c98-9afc-025ed86a294f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eaed12cd-5bfe-4c98-9afc-025ed86a294f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eaed12cd-5bfe-4c98-9afc-025ed86a294f"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:146dd603-a345-5f39-84df-90b1166b34f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:963e9245-ec7a-4bf6-9fc0-80f54e3657f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=963e9245-ec7a-4bf6-9fc0-80f54e3657f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=963e9245-ec7a-4bf6-9fc0-80f54e3657f0"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b408313-fb80-58c7-917d-e6bd2c9db230", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91215664-6e19-4e04-9ae7-ab5664799426", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91215664-6e19-4e04-9ae7-ab5664799426", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91215664-6e19-4e04-9ae7-ab5664799426"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40c5565b-f512-5b70-877b-00d96e2f00a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [245, 252], "original_object": "strokes", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:830741dd-3f3c-4f8e-88c6-dc112166f477", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=830741dd-3f3c-4f8e-88c6-dc112166f477", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=830741dd-3f3c-4f8e-88c6-dc112166f477"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:42f8deff-3e42-53bd-9b06-680b2128b528", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6da5155-9c26-46bb-bc0f-ece4ea21405f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6da5155-9c26-46bb-bc0f-ece4ea21405f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6da5155-9c26-46bb-bc0f-ece4ea21405f"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:573d6aa8-38f5-580e-9ed9-b488ac898003", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [245, 252], "original_object": "strokes", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a5ded796-3555-4476-8b37-0cdc88d7594a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a5ded796-3555-4476-8b37-0cdc88d7594a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5ded796-3555-4476-8b37-0cdc88d7594a"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at highe"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:644b4016-9b10-5cb4-b5bd-531cc7faa1f8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eaed12cd-5bfe-4c98-9afc-025ed86a294f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eaed12cd-5bfe-4c98-9afc-025ed86a294f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eaed12cd-5bfe-4c98-9afc-025ed86a294f"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure c"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:71a2744b-58c0-5c6f-a01b-bf7c636ed642", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd2b0604-f887-40d9-9109-dafcc9987e4e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd2b0604-f887-40d9-9109-dafcc9987e4e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd2b0604-f887-40d9-9109-dafcc9987e4e"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:868baee3-2c3f-5856-af2c-ed6b3ae026da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5743c58e-deab-ac93-e063-6294a90ac1eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8cf59912-ef37-5eb3-ba97-09dcb86eaef2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:671d5a85-4146-43b4-9d7d-ca53268eb2a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=671d5a85-4146-43b4-9d7d-ca53268eb2a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=671d5a85-4146-43b4-9d7d-ca53268eb2a6"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:952c3896-98f1-5b90-a82a-bec047056945", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a30ff81d-420b-40ea-83d8-670260a93fff"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Widaplik (telmisartan/amlodipine/indapamide) is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Widaplik may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers, dihydropyridine calcium channel blockers and thiazide-like diuretics. There are no controlled trials demonstrating risk reduction with Widaplik. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at h"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a046d7d6-ed56-582d-b7cc-3ab6eb05ec52", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09d31eee-cd22-4918-a889-3eb4d2969525", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09d31eee-cd22-4918-a889-3eb4d2969525", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09d31eee-cd22-4918-a889-3eb4d2969525"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pres"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bf0b152e-5a51-567c-b15c-67836959c9da", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:beaaf383-730f-4411-b5e7-15c32b53a338", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=beaaf383-730f-4411-b5e7-15c32b53a338", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=beaaf383-730f-4411-b5e7-15c32b53a338"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c6532e85-b013-5278-8307-a7ce8822d7b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c22a318-d1f2-4788-9331-66fed71ebf38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec486451-2810-536a-936f-ef9751824366", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 14, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4be6575f-ea8d-4cd8-a49d-3d1c93f2621a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4be6575f-ea8d-4cd8-a49d-3d1c93f2621a"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) 1.1 Hypertension Telmisartan is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "type-2 diabetes mellitus with documented target-organ damage", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38e28b58-b47f-50d1-905e-4fc80fa809be", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981211", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7b51ecdd-2eab-508b-a0a4-26a3158e0d12", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "object": "UMLS:C1301700", "object_location_in_text": [99, 123], "original_object": "cardiovascular morbidity", "original_subject": "telmisartan", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:kinzalmono", "https://www.ema.europa.eu/en/documents/product-information/kinzalmono-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/kinzalmono"]}], "subject": "CHEBI:9434", "supporting_text": ["Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with:  manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "type-2 diabetes mellitus with documented target-organ damage", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39d94bdf-aa92-567e-9e4b-863ba1da3d4f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981211", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7b51ecdd-2eab-508b-a0a4-26a3158e0d12", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "object": "UMLS:C1301700", "object_location_in_text": [99, 123], "original_object": "cardiovascular morbidity", "original_subject": "telmisartan", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:pritor", "https://www.ema.europa.eu/en/documents/product-information/pritor-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/pritor"]}], "subject": "CHEBI:9434", "supporting_text": ["Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with:  manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "type-2 diabetes mellitus with documented target-organ damage", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e4320bf-d3ff-56e9-bb99-6fcda793f791", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981211", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:7b51ecdd-2eab-508b-a0a4-26a3158e0d12", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "object": "UMLS:C1301700", "object_location_in_text": [99, 123], "original_object": "cardiovascular morbidity", "original_subject": "telmisartan", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:micardis", "https://www.ema.europa.eu/en/documents/product-information/micardis-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/micardis"]}], "subject": "CHEBI:9434", "supporting_text": ["Hypertension Treatment of essential hypertension in adults. Cardiovascular prevention Reduction of cardiovascular morbidity in patients with:  manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; type-2 diabetes mellitus with documented target-organ damage."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:04aecdfd-6cea-56ea-a644-aac8231155e1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91215664-6e19-4e04-9ae7-ab5664799426", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91215664-6e19-4e04-9ae7-ab5664799426", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91215664-6e19-4e04-9ae7-ab5664799426"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e4f679f-69e3-5571-a535-37e4f012d91d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:963e9245-ec7a-4bf6-9fc0-80f54e3657f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=963e9245-ec7a-4bf6-9fc0-80f54e3657f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=963e9245-ec7a-4bf6-9fc0-80f54e3657f0"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ee9e7c8-1fbc-5a03-bff4-09de0a2402b0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f6da5155-9c26-46bb-bc0f-ece4ea21405f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f6da5155-9c26-46bb-bc0f-ece4ea21405f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f6da5155-9c26-46bb-bc0f-ece4ea21405f"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:434d8788-9285-50f9-a459-2cdaf74c35c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:dd215b69-94ff-5efd-8c94-ef1ef8bd6a6e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular event", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:671d5a85-4146-43b4-9d7d-ca53268eb2a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=671d5a85-4146-43b4-9d7d-ca53268eb2a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=671d5a85-4146-43b4-9d7d-ca53268eb2a6"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6a01e35c-70b5-5cf7-96da-5b8ac25300bc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09d31eee-cd22-4918-a889-3eb4d2969525", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09d31eee-cd22-4918-a889-3eb4d2969525", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09d31eee-cd22-4918-a889-3eb4d2969525"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pres"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7eaaca3b-c7fe-53e1-a6f7-b68802f07842", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dd2b0604-f887-40d9-9109-dafcc9987e4e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dd2b0604-f887-40d9-9109-dafcc9987e4e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd2b0604-f887-40d9-9109-dafcc9987e4e"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c17622b7-5851-56aa-9c88-0df5abef35f6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5743c58e-deab-ac93-e063-6294a90ac1eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d7757c40-c9dd-5299-b2a3-66df00cbb65f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19981110", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:2b831ce0-4430-571e-b6d3-42e617c740a7", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4bbdb084-4242-5c6a-a1fe-ee9bc54aaf22", "medic_supporting_text_truncated": true, "object": "UMLS:C1320716", "original_object": "cardiovascular events", "original_subject": "TELMISARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c22a318-d1f2-4788-9331-66fed71ebf38", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c22a318-d1f2-4788-9331-66fed71ebf38"]}], "subject": "CHEBI:9434", "supporting_text": ["1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors ( 1.2 ) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure cause"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0594d0ee-8b30-55d3-90e4-bfe2cb9f761b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [71, 95], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "patients with confirmed diagnosis by KOH smears and/or cultures", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e0a5e163-741f-4f5e-9d2e-b733f9879c99", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e0a5e163-741f-4f5e-9d2e-b733f9879c99", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0a5e163-741f-4f5e-9d2e-b733f9879c99"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:21cc40ed-9b4a-5a68-a5c3-30a5de0f1b12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b922feb5-cd85-4f13-9a18-913e58f8da83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b922feb5-cd85-4f13-9a18-913e58f8da83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b922feb5-cd85-4f13-9a18-913e58f8da83"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35d68d1c-46b8-59e7-9b61-fc96488128d1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1e32bf0d-2a93-44ac-ae28-8d34e10380c0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1e32bf0d-2a93-44ac-ae28-8d34e10380c0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e32bf0d-2a93-44ac-ae28-8d34e10380c0"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3f9719c6-d30c-56af-ad4f-34eec5814a20", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [71, 95], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "patients with confirmed diagnosis by KOH smears and/or cultures", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:10e84353-93d2-461d-8b79-e9294df047ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=10e84353-93d2-461d-8b79-e9294df047ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10e84353-93d2-461d-8b79-e9294df047ae"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4304f858-3469-5d2f-a565-aaf5e1705a02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:71c13149-396e-edc6-e053-2a95a90af50c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=71c13149-396e-edc6-e053-2a95a90af50c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=71c13149-396e-edc6-e053-2a95a90af50c"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c9d1144-86e7-589c-a31f-2fb2d08e97e8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6d7a8fd6-7837-427e-9b18-89e33351b05e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6d7a8fd6-7837-427e-9b18-89e33351b05e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6d7a8fd6-7837-427e-9b18-89e33351b05e"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:997f00ba-6e6d-522e-a798-421eb6fbe3b4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:77271d50-de82-4345-a003-e383e8e6576b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=77271d50-de82-4345-a003-e383e8e6576b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77271d50-de82-4345-a003-e383e8e6576b"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec2d1832-80ab-5f11-832a-38253e92e272", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c46cf36e-cf06-4a64-963c-a55bb0194f74", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c46cf36e-cf06-4a64-963c-a55bb0194f74", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c46cf36e-cf06-4a64-963c-a55bb0194f74"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vulvovaginitis caused by the genus Candida", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0cd3080-54e7-55d7-903d-4fe3cdff33d0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:73f550f7-37a0-530a-a3e8-f844dc3c089f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0006014", "object_location_in_text": [66, 90], "original_object": "vulvovaginal candidiasis", "original_subject": "TERCONAZOLE", "population_context_qualifier": "not specified", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2b3923b5-0a97-428c-b8d2-4a3ceb3447a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b3923b5-0a97-428c-b8d2-4a3ceb3447a1"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5df1f8b4-d107-579a-98d2-ba6439ee9b23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6ad681a-6474-520b-9cba-305e89a95930", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0007019", "object_location_in_text": [166, 180], "original_object": "vulvovaginitis", "original_subject": "TERCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5527cd23-567b-4019-8e5c-f71ee7ed2689", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5527cd23-567b-4019-8e5c-f71ee7ed2689", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5527cd23-567b-4019-8e5c-f71ee7ed2689"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole Vaginal Cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As Terconazole Vaginal Cream 0.4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0006836", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f82f763d-9dde-585f-b939-10987f246ad4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19871231", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0006836"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6ad681a-6474-520b-9cba-305e89a95930", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e5ebf817-74f0-599a-b7d2-da302de317f2", "object": "MONDO:0007019", "object_location_in_text": [143, 157], "original_object": "vulvovaginitis", "original_subject": "TERCONAZOLE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91c8519c-314e-4b30-95a5-aefa3b0338d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91c8519c-314e-4b30-95a5-aefa3b0338d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91c8519c-314e-4b30-95a5-aefa3b0338d9"]}], "subject": "CHEBI:9451", "supporting_text": ["Terconazole Vaginal Cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic CNS conditions", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:621d4875-3e45-50c4-b34a-e98dcc0236a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990310", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:b207488e-61e5-5f80-a078-7fb54d5363b6", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:4ac8b6ee-db49-534c-8733-220cffbeab79", "object": "HP:0100248", "object_location_in_text": [100, 113], "original_object": "hemiballismus", "original_subject": "Tetrabenazine 25mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:9467", "supporting_text": ["In treatment of movement disorders associated with organic CNS conditions like Huntington's chorea, hemiballismus and senil chorea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic CNS conditions", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:11d57d85-1354-5f72-910d-3e89d00c46df", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990310", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:f0f475ba-9f0b-5c5b-80ac-5e8a66e65799", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:4ac8b6ee-db49-534c-8733-220cffbeab79", "object": "MONDO:0007739", "object_location_in_text": [79, 98], "original_object": "Huntington's chorea", "original_subject": "Tetrabenazine 25mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:9467", "supporting_text": ["In treatment of movement disorders associated with organic CNS conditions like Huntington's chorea, hemiballismus and senil chorea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "organic CNS conditions", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:69d0cebc-c215-5b0c-9297-d1c3662fac30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19990310", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a717b6fa-0ebe-5b7d-b5ee-c0a4f062d43a", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:4ac8b6ee-db49-534c-8733-220cffbeab79", "object": "UMLS:C0238056", "original_object": "senile chorea", "original_subject": "Tetrabenazine 25mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:9467", "supporting_text": ["In treatment of movement disorders associated with organic CNS conditions like Huntington's chorea, hemiballismus and senil chorea."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:055ff3b4-2d16-5f1d-ba2b-e1b2548e2af7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b330d020-5d63-5ea9-843c-aef7b61acf6e", "object": "HP:0000989", "object_location_in_text": [39, 46], "original_object": "itching", "original_subject": "TETRACAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1e3a1d-f42b-499d-a445-1d1d3dd26c19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1e3a1d-f42b-499d-a445-1d1d3dd26c19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1e3a1d-f42b-499d-a445-1d1d3dd26c19"]}], "subject": "CHEBI:9468", "supporting_text": ["​Uses For temporary relief of pain and itching due to minor skin irritation"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6112446a-7011-5ac4-932b-b50b92261bcd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b330d020-5d63-5ea9-843c-aef7b61acf6e", "object": "HP:0000989", "object_location_in_text": [39, 46], "original_object": "itching", "original_subject": "TETRACAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90f644b4-faa2-4f54-865a-44ccdab99ad3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90f644b4-faa2-4f54-865a-44ccdab99ad3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90f644b4-faa2-4f54-865a-44ccdab99ad3"]}], "subject": "CHEBI:9468", "supporting_text": ["​Uses For temporary relief of pain and itching due to minor skin irritation"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d3b7b9c-ff52-581d-a4bf-750347af6846", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b330d020-5d63-5ea9-843c-aef7b61acf6e", "object": "HP:0012531", "object_location_in_text": [30, 34], "original_object": "pain", "original_subject": "TETRACAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:90f644b4-faa2-4f54-865a-44ccdab99ad3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=90f644b4-faa2-4f54-865a-44ccdab99ad3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=90f644b4-faa2-4f54-865a-44ccdab99ad3"]}], "subject": "CHEBI:9468", "supporting_text": ["​Uses For temporary relief of pain and itching due to minor skin irritation"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "minor skin irritation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4acd6796-ade7-5fc5-b646-ec815e88fb84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20160229", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b330d020-5d63-5ea9-843c-aef7b61acf6e", "object": "HP:0012531", "object_location_in_text": [30, 34], "original_object": "pain", "original_subject": "TETRACAINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c1e3a1d-f42b-499d-a445-1d1d3dd26c19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c1e3a1d-f42b-499d-a445-1d1d3dd26c19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c1e3a1d-f42b-499d-a445-1d1d3dd26c19"]}], "subject": "CHEBI:9468", "supporting_text": ["​Uses For temporary relief of pain and itching due to minor skin irritation"], "temporal_context_qualifier": "temporary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0343466", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19fdb0e5-7232-50c7-947d-06e02633e676", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980716", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0343466"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0f4bb386-51f3-55c8-aaff-29bd57972043", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0e34c2c5-1bb4-5aea-bdf0-c456ec8d76b8", "object": "UMLS:C0343466", "object_location_in_text": [266, 291], "original_object": "erythema nodosum leprosum", "original_subject": "THALIDOMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2eda833b-1357-4ed4-a093-194524fcb061", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061"]}], "subject": "CHEBI:9513", "supporting_text": ["1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0457343", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d2a415b3-5c76-59bf-925d-722c0bdee844", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0457343"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:43933201-b655-54a7-89ce-79bd5342013a", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f58c6300-b241-548e-9b82-e19e9680c198", "object": "MONDO:0011996", "object_location_in_text": [1077, 1105], "original_object": "chronic myelogenous leukemia", "original_subject": "THIOGUANINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44b0c461-47fb-4106-ba11-6ed85530235c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44b0c461-47fb-4106-ba11-6ed85530235c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44b0c461-47fb-4106-ba11-6ed85530235c"]}], "subject": "CHEBI:9555", "supporting_text": ["a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. However, it is not recommended for use during maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity (see WARNINGS and ADVERSE REACTIONS). The response to this agent depends upon the age of the patient (younger patients faring better than older) and whether thioguanine is used in previously treated or previously untreated patients. Reliance upon thioguanine alone is seldom justified for initial remission induction of acute nonlymphocytic leukemias because combination chemotherapy including thioguanine results in more frequent remission induction and longer duration of remission than thioguanine alone. b) Other Neoplasms TABLOID brand Thioguanine is not effective in chronic lymphocytic leukemia, Hodgkin’s lymphoma, multiple myeloma, or solid tumors. Although thioguanine is one of several agents with activity in the treatment of the chronic phase of chronic myelogenous leukemia, more objective responses are observed with MYLERAN ® (busulfan), and therefore busulfan is usually regarded as the preferred drug."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "class 3 beta-thalassemia", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5d4e739d-7908-5bb7-8ac9-d80cabdfb56e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["high-dose busulfan", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12793e96-6151-525d-9231-dc1a5316c23e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7aeea5b1-2df9-5eb1-b48d-ce16ffe1b634", "object": "MONDO:1010185", "object_location_in_text": [104, 119], "original_object": "graft rejection", "original_subject": "THIOTEPA", "population_context_qualifier": "pediatric patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6cd6ae89-c553-4328-9262-4363610a1f19", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6cd6ae89-c553-4328-9262-4363610a1f19", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6cd6ae89-c553-4328-9262-4363610a1f19"]}], "subject": "CHEBI:9570", "supporting_text": ["1 INDICATIONS AND USAGE Thiotepa for injection is an alkylating drug indicated: • To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia. ( 1.1 , 14 ) • For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) • For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) • For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) 1.1 Class 3 Beta-Thalassemia Thiotepa for injection is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies ( 14 )] . 1.2 Adenocarcinoma of the Breast or Ovary Thiotepa for injection is indicated for treatment of adenocarcinoma of the breast or ovary. 1.3 Malignant Effusions Thiotepa for injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 1.4 Superficial Papillary Carcinoma of the Urinary Bladder Thiotepa for injection is indicated for treatment of superficial papillary carcinoma of the urinary bladder."], "temporal_context_qualifier": "as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "class 3 beta-thalassemia", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65fa058a-d813-5b35-ac9d-300606186985", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["high-dose busulfan", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12793e96-6151-525d-9231-dc1a5316c23e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7aeea5b1-2df9-5eb1-b48d-ce16ffe1b634", "object": "MONDO:1010185", "object_location_in_text": [102, 117], "original_object": "graft rejection", "original_subject": "THIOTEPA", "population_context_qualifier": "pediatric patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b702dcc9-dd0e-4386-b1e2-f20562fd2ad9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b702dcc9-dd0e-4386-b1e2-f20562fd2ad9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b702dcc9-dd0e-4386-b1e2-f20562fd2ad9"]}], "subject": "CHEBI:9570", "supporting_text": ["1 INDICATIONS AND USAGE Thiotepa for injection is an alkylating drug indicated: To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia. ( 1.1 , 14 ) For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) 1.1 Class 3 Beta-Thalassemia Thiotepa for injection is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies (14 )]. 1.2 Adenocarcinoma of the Breast or Ovary Thiotepa for injection is indicated for treatment of adenocarcinoma of the breast or ovary. 1.3 Malignant Effusions Thiotepa for injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 1.4 Superficial Papillary Carcinoma of the Urinary Bladder Thiotepa for injection is indicated for treatment of superficial papillary carcinoma of the urinary bladder."], "temporal_context_qualifier": "preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "class 3 beta-thalassemia", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6813ba5e-bafc-513b-bcba-b4148dfef54b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_co_administered_with": ["busulfan", "cyclophosphamide"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:12793e96-6151-525d-9231-dc1a5316c23e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7aeea5b1-2df9-5eb1-b48d-ce16ffe1b634", "object": "MONDO:1010185", "object_location_in_text": [99, 114], "original_object": "graft rejection", "original_subject": "THIOTEPA", "population_context_qualifier": "pediatric patients", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:559e353c-2dc0-16ba-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=559e353c-2dc0-16ba-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=559e353c-2dc0-16ba-e054-00144ff8d46c"]}], "subject": "CHEBI:9570", "supporting_text": ["1 INDICATIONS AND USAGE TEPADINA (thiotepa) is an alkylating drug indicated: To reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia. (1.1 , 14) For treatment of adenocarcinoma of the breast or ovary. (1.2) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. (1.3) For treatment of superficial papillary carcinoma of the urinary bladder. (1.4) 1.1 Class 3 Beta-Thalassemia TEPADINA is indicated to reduce the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia [see Clinical Studies ( 14 ) ] . 1.2 Adenocarcinoma of the Breast or Ovary TEPADINA is indicated for treatment of adenocarcinoma of the breast or ovary. 1.3 Malignant Effusions TEPADINA is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 1.4 Superficial Papillary Carcinoma of the Urinary Bladder TEPADINA is indicated for treatment of superficial papillary carcinoma of the urinary bladder."], "temporal_context_qualifier": "as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT)"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "(none - partial seizures is the target condition)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f03a6d8-fa33-5bb6-979c-a6492fed9702", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:adeeed95-73df-5bf1-9560-ee2a797b75a4", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b45cb343-38fc-54c0-8bfe-cf2e15eb1ef4", "object": "HP:0007359", "object_location_in_text": [132, 148], "original_object": "partial seizures", "original_subject": "TIAGABINE", "population_context_qualifier": "adults and children 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72b7f357-8827-4a8b-b55a-01fbce47ae80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72b7f357-8827-4a8b-b55a-01fbce47ae80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72b7f357-8827-4a8b-b55a-01fbce47ae80"]}], "subject": "CHEBI:9586", "supporting_text": ["GABITRIL (tiagabine hydrochloride) is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "(none - partial seizures is the target condition)", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4a06b21-18e8-5a5f-ae56-da25234fe957", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970930", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:adeeed95-73df-5bf1-9560-ee2a797b75a4", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b45cb343-38fc-54c0-8bfe-cf2e15eb1ef4", "object": "HP:0007359", "object_location_in_text": [132, 148], "original_object": "partial seizures", "original_subject": "TIAGABINE", "population_context_qualifier": "adults and children 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:175f2d9f-449b-4d95-a4b9-94f891f8e3ae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=175f2d9f-449b-4d95-a4b9-94f891f8e3ae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=175f2d9f-449b-4d95-a4b9-94f891f8e3ae"]}], "subject": "CHEBI:9586", "supporting_text": ["GABITRIL (tiagabine hydrochloride) is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0019004", "has_confidence_score": 0.5355, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0200dc38-809e-59fd-a914-e88d84863833", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930211", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0019004"], "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:93d38682-58d6-54dd-9a40-efbaf2e72fb4", "medic_pair_confidence": 0.5355, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:0fb7b9e2-aacd-5663-9981-726361109112", "object": "MONDO:0002245", "original_object": "platelet disorder", "original_subject": "Ticlopidine Hcl 250mg Tablet", "predicate": "biolink:treats", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "CHEBI:9589", "supporting_text": ["Antiplatelet agent- for the prevention of cerebro and cardio vascular accidents in patients suffering from asterial insufficiency in the legs and cerebral vessels and correction of platelet disorders induced by extra corporeal circuits during surgery with extra corporeal circulation or haemodialysis (artificial kidney)."], "temporal_context_qualifier": "during surgery with extra corporeal circulation"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f1693cd-39ff-5b10-a45a-8ea1cea5a189", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "MONDO:0005068", "object_location_in_text": [155, 176], "original_object": "myocardial infarction", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d554acff-22e9-4f28-b826-ee1b91daa2df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d554acff-22e9-4f28-b826-ee1b91daa2df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d554acff-22e9-4f28-b826-ee1b91daa2df"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a3d20979-5cc4-574a-be24-bfc9310dff04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "MONDO:0005068", "object_location_in_text": [155, 176], "original_object": "myocardial infarction", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13ea7fb8-4b01-4286-9464-26c0b624bc3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13ea7fb8-4b01-4286-9464-26c0b624bc3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13ea7fb8-4b01-4286-9464-26c0b624bc3b"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac8e370c-f504-5fbf-97be-533c42b01a23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "MONDO:0005068", "object_location_in_text": [155, 176], "original_object": "myocardial infarction", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7731e46a-2121-441b-b090-12dcefe240f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7731e46a-2121-441b-b090-12dcefe240f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7731e46a-2121-441b-b090-12dcefe240f0"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban Hydrochloride Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban Hydrochloride Injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c4be4c4e-3a23-564d-93c3-c0494a845e12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "MONDO:0005068", "object_location_in_text": [155, 176], "original_object": "myocardial infarction", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa3ac570-f9f6-474c-a920-bd0cf03045ac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa3ac570-f9f6-474c-a920-bd0cf03045ac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ac570-f9f6-474c-a920-bd0cf03045ac"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b2521e4-1c49-5909-82d0-b9523184d127", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c10b64b3-0c05-56fc-b8c4-c0d1f7166d45", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "UMLS:C4321499", "object_location_in_text": [181, 200], "original_object": "refractory ischemia", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d554acff-22e9-4f28-b826-ee1b91daa2df", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d554acff-22e9-4f28-b826-ee1b91daa2df", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d554acff-22e9-4f28-b826-ee1b91daa2df"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e1c85da-4ffd-585f-9a7c-40bb59cc48ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c10b64b3-0c05-56fc-b8c4-c0d1f7166d45", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "UMLS:C4321499", "object_location_in_text": [181, 200], "original_object": "refractory ischemia", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7731e46a-2121-441b-b090-12dcefe240f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7731e46a-2121-441b-b090-12dcefe240f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7731e46a-2121-441b-b090-12dcefe240f0"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban Hydrochloride Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban Hydrochloride Injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:71f09985-c4db-5819-9193-66aa23ee367b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c10b64b3-0c05-56fc-b8c4-c0d1f7166d45", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "UMLS:C4321499", "object_location_in_text": [181, 200], "original_object": "refractory ischemia", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:13ea7fb8-4b01-4286-9464-26c0b624bc3b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=13ea7fb8-4b01-4286-9464-26c0b624bc3b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13ea7fb8-4b01-4286-9464-26c0b624bc3b"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-ST elevation acute coronary syndrome", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e12b5c5d-2c93-5702-bec8-3b9118f5696e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980514", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c10b64b3-0c05-56fc-b8c4-c0d1f7166d45", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 4, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:aed20736-6053-56ba-b045-f2a4492332ef", "object": "UMLS:C4321499", "object_location_in_text": [181, 200], "original_object": "refractory ischemia", "original_subject": "TIROFIBAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa3ac570-f9f6-474c-a920-bd0cf03045ac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa3ac570-f9f6-474c-a920-bd0cf03045ac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ac570-f9f6-474c-a920-bd0cf03045ac"]}], "subject": "CHEBI:9605", "supporting_text": ["1 INDICATIONS AND USAGE Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . Tirofiban hydrochloride injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:659842f4-f9f8-5110-8930-5b5e0dda6c4c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cb120cb-c9f7-59ea-bb2a-14b84511f3f9", "object": "HP:0000989", "object_location_in_text": [49, 56], "original_object": "itching", "original_subject": "TOLNAFTATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f9edcf9-b99e-65a2-e053-2a91aa0af565", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f9edcf9-b99e-65a2-e053-2a91aa0af565", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f9edcf9-b99e-65a2-e053-2a91aa0af565"]}], "subject": "CHEBI:9620", "supporting_text": ["Uses cures most jock itch (tinea cruis) relieves itching, burning and crafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b3495e2-a000-5af8-9833-f90299e05e68", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cb120cb-c9f7-59ea-bb2a-14b84511f3f9", "object": "HP:0000989", "object_location_in_text": [49, 56], "original_object": "itching", "original_subject": "TOLNAFTATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f8ac6b7-c46c-226c-e053-2991aa0a9606", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f8ac6b7-c46c-226c-e053-2991aa0a9606", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f8ac6b7-c46c-226c-e053-2991aa0a9606"]}], "subject": "CHEBI:9620", "supporting_text": ["Uses cures most jock itch (tinea cruis) relieves itching, burning and crafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dd1cef8e-48d1-57a8-ac46-108a7a572a12", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cb120cb-c9f7-59ea-bb2a-14b84511f3f9", "object": "HP:0000989", "object_location_in_text": [195, 202], "original_object": "itching", "original_subject": "TOLNAFTATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9fdd129-9909-4747-bd9f-93a204b50724", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9fdd129-9909-4747-bd9f-93a204b50724", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9fdd129-9909-4747-bd9f-93a204b50724"]}], "subject": "CHEBI:9620", "supporting_text": ["Uses cures most athlete’s foot (tinea pedis), ringworm (tinea corporis), and jock itch (tinea cruris) can prevent recurrence of most athlete’s foot relieves symptoms of athlete’s foot, including itching, burning, cracking, and chafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:22322c1d-ce15-55ca-8d93-a46edad793f1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cb120cb-c9f7-59ea-bb2a-14b84511f3f9", "object": "UMLS:C0014724", "object_location_in_text": [58, 65], "original_object": "burning", "original_subject": "TOLNAFTATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f8ac6b7-c46c-226c-e053-2991aa0a9606", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f8ac6b7-c46c-226c-e053-2991aa0a9606", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f8ac6b7-c46c-226c-e053-2991aa0a9606"]}], "subject": "CHEBI:9620", "supporting_text": ["Uses cures most jock itch (tinea cruis) relieves itching, burning and crafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a090965c-8c74-5e26-8137-f7d971f34908", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cb120cb-c9f7-59ea-bb2a-14b84511f3f9", "object": "UMLS:C0014724", "object_location_in_text": [58, 65], "original_object": "burning", "original_subject": "TOLNAFTATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f9edcf9-b99e-65a2-e053-2a91aa0af565", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f9edcf9-b99e-65a2-e053-2a91aa0af565", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f9edcf9-b99e-65a2-e053-2a91aa0af565"]}], "subject": "CHEBI:9620", "supporting_text": ["Uses cures most jock itch (tinea cruis) relieves itching, burning and crafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1384589", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb323abd-e540-58ca-88b8-8fa83d76893f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1384589"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:635bc385-c392-5c90-a4bf-87d7fa5e84fb", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7cb120cb-c9f7-59ea-bb2a-14b84511f3f9", "object": "UMLS:C0014724", "object_location_in_text": [204, 211], "original_object": "burning", "original_subject": "TOLNAFTATE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a9fdd129-9909-4747-bd9f-93a204b50724", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a9fdd129-9909-4747-bd9f-93a204b50724", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a9fdd129-9909-4747-bd9f-93a204b50724"]}], "subject": "CHEBI:9620", "supporting_text": ["Uses cures most athlete’s foot (tinea pedis), ringworm (tinea corporis), and jock itch (tinea cruris) can prevent recurrence of most athlete’s foot relieves symptoms of athlete’s foot, including itching, burning, cracking, and chafing associated with jock itch"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0dd727a2-893b-5e42-b82e-888d73f9abd6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [106, 124], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8cd23ff7-71ba-4391-95bd-a3a7f347713d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8cd23ff7-71ba-4391-95bd-a3a7f347713d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8cd23ff7-71ba-4391-95bd-a3a7f347713d"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ]. Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e764a93-5b9c-5061-bb61-6e0854e140a0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [106, 124], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fcaca033-cd08-4b8c-9bad-7b6751faf2c9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fcaca033-cd08-4b8c-9bad-7b6751faf2c9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcaca033-cd08-4b8c-9bad-7b6751faf2c9"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES ( 14)]. Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1463802d-946e-5b14-993e-a3a9609f3b1b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [64, 82], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f67fce7c-69d3-42ae-8c1d-2e26fd4d7415", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f67fce7c-69d3-42ae-8c1d-2e26fd4d7415", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f67fce7c-69d3-42ae-8c1d-2e26fd4d7415"]}], "subject": "CHEBI:9622", "supporting_text": ["Tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:162805a7-0cb1-55a2-83d7-d0032111afda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [106, 124], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fd6c8b3d-a52a-4418-aa9c-0297db6c0807", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fd6c8b3d-a52a-4418-aa9c-0297db6c0807", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd6c8b3d-a52a-4418-aa9c-0297db6c0807"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [ see CLINICAL STUDIES ( 14 ) ]. Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:187122f6-83a2-5578-a639-4f4271392783", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [64, 82], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:25ce804d-b9cf-4ca7-9ec3-942eb79c0bd1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=25ce804d-b9cf-4ca7-9ec3-942eb79c0bd1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25ce804d-b9cf-4ca7-9ec3-942eb79c0bd1"]}], "subject": "CHEBI:9622", "supporting_text": ["Tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24c69ffd-fe07-5986-820d-acb77b9ccd16", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [106, 124], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bbbee85a-e5e2-24ec-e053-2995a90acfd8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bbbee85a-e5e2-24ec-e053-2995a90acfd8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bbbee85a-e5e2-24ec-e053-2995a90acfd8"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine Tartrate Extended-Release Capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ] . Tolterodine Tartrate Extended-Release Capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2516acb8-7c09-5637-87f6-efd85c3e6f2a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [106, 124], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:973f98b5-4e8a-42d9-ac69-d4333d21c362", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=973f98b5-4e8a-42d9-ac69-d4333d21c362", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=973f98b5-4e8a-42d9-ac69-d4333d21c362"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [ see CLINICAL STUDIES ( 14 ) ]. Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bd77b81-1c9a-5c3c-8721-49cb2512da9c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [50, 68], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:41eb00d2-64e3-4ec9-8732-4bfc81b04180", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=41eb00d2-64e3-4ec9-8732-4bfc81b04180", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41eb00d2-64e3-4ec9-8732-4bfc81b04180"]}], "subject": "CHEBI:9622", "supporting_text": ["DETROL Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e38b26a-76e8-5cc4-a17e-de8fa37a1f57", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [64, 82], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56e62829-5371-416a-90b3-4b6429532d25", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56e62829-5371-416a-90b3-4b6429532d25", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56e62829-5371-416a-90b3-4b6429532d25"]}], "subject": "CHEBI:9622", "supporting_text": ["Tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:468339c8-3091-5d26-a09c-694fc8dde9f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [112, 130], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4b9ef09-c750-4e35-96fc-e759ba4849d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4b9ef09-c750-4e35-96fc-e759ba4849d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4b9ef09-c750-4e35-96fc-e759ba4849d8"]}], "subject": "CHEBI:9622", "supporting_text": ["1. INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules, USP are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ] . Tolterodine tartrate extended-release capsules, USP are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:500e3d69-e6b2-5013-bd31-260e571fea95", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [106, 124], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9710ad7b-93c2-4ec1-95ff-597563be4314", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9710ad7b-93c2-4ec1-95ff-597563be4314", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9710ad7b-93c2-4ec1-95ff-597563be4314"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ] . Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d70c438-370f-5b11-afbf-be51d6b32eff", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [64, 82], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b9ba8ad2-27f6-4f18-bd84-73659047910e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b9ba8ad2-27f6-4f18-bd84-73659047910e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b9ba8ad2-27f6-4f18-bd84-73659047910e"]}], "subject": "CHEBI:9622", "supporting_text": ["Tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e712b80-ad30-5e08-b99c-2381ccb28635", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [124, 142], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:db6e0b6d-0ce5-41d7-881f-881c11f530a4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=db6e0b6d-0ce5-41d7-881f-881c11f530a4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=db6e0b6d-0ce5-41d7-881f-881c11f530a4"]}], "subject": "CHEBI:9622", "supporting_text": ["1 INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [ see CLINICAL STUDIES ( 14 ) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97b57206-93c3-547c-8881-03dcba889a22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [112, 130], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05b92da2-923b-3c04-e063-6394a90a69a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05b92da2-923b-3c04-e063-6394a90a69a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05b92da2-923b-3c04-e063-6394a90a69a1"]}], "subject": "CHEBI:9622", "supporting_text": ["1. INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules, USP are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ] . Tolterodine tartrate extended-release capsules, USP are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ceb62a72-f995-5727-850d-bfbafe766a9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [50, 68], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fa938543-29b3-46ce-a176-5563bc8f2f80", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fa938543-29b3-46ce-a176-5563bc8f2f80", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa938543-29b3-46ce-a176-5563bc8f2f80"]}], "subject": "CHEBI:9622", "supporting_text": ["DETROL Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0150045", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fd9f7494-b342-5c73-aaaa-e9dc946553c8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19980325", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0150045", "UMLS:C0439609", "UMLS:C0376249"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b6448454-0dac-58a2-bfef-99857953453d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a00624c6-a876-5ff2-b143-69a86f847ca3", "object": "MONDO:0006624", "object_location_in_text": [112, 130], "original_object": "overactive bladder", "original_subject": "TOLTERODINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:fc5bdc4a-a483-4d31-807b-c7f8d8869723", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=fc5bdc4a-a483-4d31-807b-c7f8d8869723", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc5bdc4a-a483-4d31-807b-c7f8d8869723"]}], "subject": "CHEBI:9622", "supporting_text": ["1. INDICATIONS AND USAGE Tolterodine tartrate extended-release capsules, USP are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ] . Tolterodine tartrate extended-release capsules, USP are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive or unknown tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4cb050cd-0cf6-5858-9dde-eadc7826ec3e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970529", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47d7acff-6cb3-5e17-b9c9-a562fe9d5a2d", "object": "UMLS:C0278488", "object_location_in_text": [117, 141], "original_object": "metastatic breast cancer", "original_subject": "TOREMIFENE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dbde10d5-c689-428f-841d-b34aa5addf2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dbde10d5-c689-428f-841d-b34aa5addf2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dbde10d5-c689-428f-841d-b34aa5addf2d"]}], "subject": "CHEBI:9635", "supporting_text": ["1 INDICATIONS AND USAGE Toremifene citrate tablets are an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. Toremifene citrate tablets are an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive or unknown tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2a1f8c5-eaed-5450-bafb-5ada295b1ee2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970529", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47d7acff-6cb3-5e17-b9c9-a562fe9d5a2d", "object": "UMLS:C0278488", "object_location_in_text": [114, 138], "original_object": "metastatic breast cancer", "original_subject": "TOREMIFENE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e897546b-4136-4cb5-a262-d94cf3fa3298", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e897546b-4136-4cb5-a262-d94cf3fa3298", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e897546b-4136-4cb5-a262-d94cf3fa3298"]}], "subject": "CHEBI:9635", "supporting_text": ["1 INDICATIONS AND USAGE Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "estrogen-receptor positive or unknown tumors", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7b1c2ee-c714-516e-880b-9e6dbccbda79", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19970529", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:267e8452-b8b9-5318-bef2-0e632b2eaba8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:47d7acff-6cb3-5e17-b9c9-a562fe9d5a2d", "object": "UMLS:C0278488", "object_location_in_text": [99, 123], "original_object": "metastatic breast cancer", "original_subject": "TOREMIFENE", "population_context_qualifier": "postmenopausal women", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2cab8dd1-3a10-48e6-86ce-0e5275ed49e5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5"]}], "subject": "CHEBI:9635", "supporting_text": ["1 INDICATIONS AND USAGE FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e51c914-df13-5532-8e13-d860c35beaf5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [341, 363], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05c8a6ee-9517-453f-8dd6-7e5ca83c5a68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05c8a6ee-9517-453f-8dd6-7e5ca83c5a68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05c8a6ee-9517-453f-8dd6-7e5ca83c5a68"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2bef165a-241f-5bf5-bdd9-0f66f9e42e9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [328, 350], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c755d94-b846-4336-a968-aa1b92dc0ac0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c755d94-b846-4336-a968-aa1b92dc0ac0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c755d94-b846-4336-a968-aa1b92dc0ac0"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide is indicated for the treatment of edema associated with heart failure, renal disease, or hepatic disease. 1.2 Hypertension Torsemide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c75f6fe-aadb-5a08-8fb6-478bc623c079", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [328, 350], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44f2f06d-7bc4-5239-e063-6394a90aac5e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44f2f06d-7bc4-5239-e063-6394a90aac5e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44f2f06d-7bc4-5239-e063-6394a90aac5e"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.765, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:53ae5462-0d36-543b-ae0d-f0bc72803fe8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fc14338-92e4-cf57-a3e8-ef64d8d1026c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fc14338-92e4-cf57-a3e8-ef64d8d1026c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fc14338-92e4-cf57-a3e8-ef64d8d1026c"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide tablets are a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f891de8-dde0-5400-9f0d-70185295c089", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [341, 363], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e58a7d1c-6584-44c3-98ce-a3e9b64e9c82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e58a7d1c-6584-44c3-98ce-a3e9b64e9c82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e58a7d1c-6584-44c3-98ce-a3e9b64e9c82"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92aa2829-7cae-5a74-b041-3915e0da11ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [341, 363], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09305350-e317-419c-96f5-aa8fbeb4044d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09305350-e317-419c-96f5-aa8fbeb4044d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09305350-e317-419c-96f5-aa8fbeb4044d"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e345a368-fc8a-56e0-8de4-9ab3a38cbb36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [339, 361], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:234ff9d7-a02e-417f-a1f9-94038783cc77", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=234ff9d7-a02e-417f-a1f9-94038783cc77", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=234ff9d7-a02e-417f-a1f9-94038783cc77"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.654075, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5bebf41-5963-5537-a99c-ec8b5f2252c3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.765, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [341, 363], "original_object": "myocardial infarctions", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3d2e662-fc99-b1f0-e053-2995a90afde5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3d2e662-fc99-b1f0-e053-2995a90afde5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3d2e662-fc99-b1f0-e053-2995a90afde5"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1f718edc-0aea-5362-83f5-9bb9f2206a68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [316, 323], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c755d94-b846-4336-a968-aa1b92dc0ac0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c755d94-b846-4336-a968-aa1b92dc0ac0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c755d94-b846-4336-a968-aa1b92dc0ac0"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide is indicated for the treatment of edema associated with heart failure, renal disease, or hepatic disease. 1.2 Hypertension Torsemide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reductio"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.72675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54fd117f-c10f-5a78-90ca-c3d27b93c3a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7fc14338-92e4-cf57-a3e8-ef64d8d1026c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7fc14338-92e4-cf57-a3e8-ef64d8d1026c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fc14338-92e4-cf57-a3e8-ef64d8d1026c"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide tablets are a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5dee74a0-6dfe-5aa9-a865-6b28cd4ec058", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [329, 336], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:09305350-e317-419c-96f5-aa8fbeb4044d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=09305350-e317-419c-96f5-aa8fbeb4044d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=09305350-e317-419c-96f5-aa8fbeb4044d"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e89a97b-826b-5b8f-95f9-e46417f6b3a7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [316, 323], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44f2f06d-7bc4-5239-e063-6394a90aac5e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44f2f06d-7bc4-5239-e063-6394a90aac5e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44f2f06d-7bc4-5239-e063-6394a90aac5e"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome be"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7ec3151c-1f11-506e-b763-a9eb46025dc4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [327, 334], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:234ff9d7-a02e-417f-a1f9-94038783cc77", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=234ff9d7-a02e-417f-a1f9-94038783cc77", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=234ff9d7-a02e-417f-a1f9-94038783cc77"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS AND USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome b"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85785491-20d1-5660-82df-ceddb2d86fa7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [329, 336], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e58a7d1c-6584-44c3-98ce-a3e9b64e9c82", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e58a7d1c-6584-44c3-98ce-a3e9b64e9c82", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e58a7d1c-6584-44c3-98ce-a3e9b64e9c82"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e63d1a9d-d877-53f4-ba6d-a5475756d7ed", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [329, 336], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f3d2e662-fc99-b1f0-e053-2995a90afde5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f3d2e662-fc99-b1f0-e053-2995a90afde5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f3d2e662-fc99-b1f0-e053-2995a90afde5"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.6885, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea5ce063-a0ff-5f51-b219-d2917980546e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19930823", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.72675, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d73fef6d-f14e-5e29-86da-ad571d829d44", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [329, 336], "original_object": "strokes", "original_subject": "TORSEMIDE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:05c8a6ee-9517-453f-8dd6-7e5ca83c5a68", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=05c8a6ee-9517-453f-8dd6-7e5ca83c5a68", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05c8a6ee-9517-453f-8dd6-7e5ca83c5a68"]}], "subject": "CHEBI:9637", "supporting_text": ["1 INDICATIONS &amp; USAGE Torsemide tablets are a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. (1.1) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0025169", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9eab51c5-b89e-59af-809d-60e7a61bde5b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960426", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025169", "MONDO:0005009"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:53479bc5-b9bf-5047-80c1-a75666be540a", "object": "MONDO:0005252", "object_location_in_text": [494, 507], "original_object": "heart failure", "original_subject": "TRANDOLAPRIL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f25ed16-e5e9-4170-b4b4-3b460887779e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f25ed16-e5e9-4170-b4b4-3b460887779e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f25ed16-e5e9-4170-b4b4-3b460887779e"]}], "subject": "CHEBI:9649", "supporting_text": ["Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY - Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial)."], "temporal_context_qualifier": "Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "elevated serum potassium", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e8753f2-53b4-5dfe-9b75-9d6bae278a04", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b008eb06-4d70-5285-9b91-b13064630436", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:96dc090e-717d-52ab-bd10-9825580806e9", "object": "HP:0002157", "object_location_in_text": [343, 351], "original_object": "azotemia", "original_subject": "TRIAMTERENE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcaa7b4d-9613-298a-5a39-f2032492096c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcaa7b4d-9613-298a-5a39-f2032492096c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcaa7b4d-9613-298a-5a39-f2032492096c"]}], "subject": "CHEBI:9671", "supporting_text": ["Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components. Triamterene Capsules should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with triamterene. Triamterene Capsules should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and triamterene or Dyazide ® . Although dosage recommendations were exceeded in one case and in the other serum electrolytes were not properly monitored, these two drugs should not be given concomitantly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "elevated serum potassium", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2b852646-2809-59e4-8a55-ecfe4bf85612", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1d4aefa4-30f5-5b54-98a2-32bdb6207568", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:96dc090e-717d-52ab-bd10-9825580806e9", "object": "UMLS:C1565489", "object_location_in_text": [316, 339], "original_object": "impaired renal function", "original_subject": "TRIAMTERENE", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcaa7b4d-9613-298a-5a39-f2032492096c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcaa7b4d-9613-298a-5a39-f2032492096c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcaa7b4d-9613-298a-5a39-f2032492096c"]}], "subject": "CHEBI:9671", "supporting_text": ["Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components. Triamterene Capsules should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with triamterene. Triamterene Capsules should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and triamterene or Dyazide ® . Although dosage recommendations were exceeded in one case and in the other serum electrolytes were not properly monitored, these two drugs should not be given concomitantly."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0011675", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d19691f3-767e-5b50-ab92-1cb374806d21", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["digitalis preparations"], "medic_disease_context_ids": ["HP:0011675"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7030c6dd-bae4-5458-a5d5-332f77df1790", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:96dc090e-717d-52ab-bd10-9825580806e9", "medic_supporting_text_truncated": true, "object": "MONDO:0005044", "object_location_in_text": [81, 93], "original_object": "hypertension", "original_subject": "TRIAMTERENE", "population_context_qualifier": "patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43425ec7-a2c0-41d8-b759-b7b5918949ce", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43425ec7-a2c0-41d8-b759-b7b5918949ce", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43425ec7-a2c0-41d8-b759-b7b5918949ce"]}], "subject": "CHEBI:9671", "supporting_text": ["This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide tablets are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumb"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0011741", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36fd412a-e104-573d-bef1-e2d90cbd7b36", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0011741"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f73c88c4-c75e-5546-8721-2e7788c70d06", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:96dc090e-717d-52ab-bd10-9825580806e9", "object": "UMLS:C0012797", "object_location_in_text": [405, 413], "original_object": "diuresis", "original_subject": "TRIAMTERENE", "population_context_qualifier": "patients prove resistant or only partially responsive to thiazides or other diuretics", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dcaa7b4d-9613-298a-5a39-f2032492096c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dcaa7b4d-9613-298a-5a39-f2032492096c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dcaa7b4d-9613-298a-5a39-f2032492096c"]}], "subject": "CHEBI:9671", "supporting_text": ["Triamterene Capsules are indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Triamterene Capsules may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2aa9b938-e39f-55b6-af32-631e5f534679", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b8ad285a-383a-46bc-90e8-8d58e9a01b94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b8ad285a-383a-46bc-90e8-8d58e9a01b94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8ad285a-383a-46bc-90e8-8d58e9a01b94"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ea00b33-7bca-5893-bc64-60f761271022", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [292, 316], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b7e4200c-feff-4537-aad1-cf9989fd8c14", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b7e4200c-feff-4537-aad1-cf9989fd8c14", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b7e4200c-feff-4537-aad1-cf9989fd8c14"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl HCl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3168fceb-b0b0-536e-a0d3-1651b6f39a23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [301, 325], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:55790126-5489-4c44-947b-5ac9850b9220", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=55790126-5489-4c44-947b-5ac9850b9220", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55790126-5489-4c44-947b-5ac9850b9220"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a02526a-01bc-5153-88b6-649280d4c996", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [306, 330], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c25ea809-5bdf-4917-97f1-610059fbd0b7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c25ea809-5bdf-4917-97f1-610059fbd0b7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c25ea809-5bdf-4917-97f1-610059fbd0b7"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS &amp; USAGE This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3bf78c07-193e-5712-9820-5d4271b43dbb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [301, 325], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d25fa10c-cc9c-4d8c-9896-4ccc544bbbde", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d25fa10c-cc9c-4d8c-9896-4ccc544bbbde", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d25fa10c-cc9c-4d8c-9896-4ccc544bbbde"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:48074504-a97c-55f7-a90a-cbf71f9f21af", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e34e1be1-0d59-4625-85a3-babbb7cbd6b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e34e1be1-0d59-4625-85a3-babbb7cbd6b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e34e1be1-0d59-4625-85a3-babbb7cbd6b8"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4872339d-0d21-5aef-a750-366f2c54cddc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [306, 330], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b60ef86c-b8b6-4530-baaf-d4671ce961af", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b60ef86c-b8b6-4530-baaf-d4671ce961af", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b60ef86c-b8b6-4530-baaf-d4671ce961af"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS &amp; USAGE This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5eab553e-e6ba-5ce4-b3c5-77280c00eab6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [288, 312], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9036c9f0-6d2d-4d0f-a20e-e36f9be228f7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9036c9f0-6d2d-4d0f-a20e-e36f9be228f7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9036c9f0-6d2d-4d0f-a20e-e36f9be228f7"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:76f49e55-546a-5d2c-889c-ff9ac32bd946", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1468533-a9b8-4377-ae6c-5640e73b9e08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1468533-a9b8-4377-ae6c-5640e73b9e08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1468533-a9b8-4377-ae6c-5640e73b9e08"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77494e21-5276-524e-b414-792af65fb5ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [306, 330], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:83608c13-509d-448b-8559-5f5e8a9a0d75", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=83608c13-509d-448b-8559-5f5e8a9a0d75", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=83608c13-509d-448b-8559-5f5e8a9a0d75"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS &amp; USAGE This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7a73894c-80aa-5fbb-a96c-530d66de8f7b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a44d7803-164d-4a67-9356-581c45de8596", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a44d7803-164d-4a67-9356-581c45de8596", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a44d7803-164d-4a67-9356-581c45de8596"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96cc5f12-6167-529e-a1ef-8da720173ddc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3ed3cdf1-1745-4c6f-bb90-fb7d9471270d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3ed3cdf1-1745-4c6f-bb90-fb7d9471270d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3ed3cdf1-1745-4c6f-bb90-fb7d9471270d"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9a8d9d8d-38f6-50d1-9cc1-37b161f49ca5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [292, 316], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7d7683c6-be72-49d5-a76c-d48e5143d0f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7d7683c6-be72-49d5-a76c-d48e5143d0f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7d7683c6-be72-49d5-a76c-d48e5143d0f0"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl HCl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a2c9ef9c-a643-516f-8e01-8f59ceb6c037", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [288, 312], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e8e2ac3b-80dc-4449-9365-2586d6d57e10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e8e2ac3b-80dc-4449-9365-2586d6d57e10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8e2ac3b-80dc-4449-9365-2586d6d57e10"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced extrapyramidal disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba217528-892d-5717-80fe-0cddcb637a1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [288, 312], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:294cd88d-d9e8-4938-b4be-c3adc4a35de0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=294cd88d-d9e8-4938-b4be-c3adc4a35de0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=294cd88d-d9e8-4938-b4be-c3adc4a35de0"]}], "subject": "CHEBI:9720", "supporting_text": ["Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dbf52b39-ed37-5916-aa35-f61f3b0395d6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:86a65e8a-10f4-4f12-8e65-2edf398daeaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=86a65e8a-10f4-4f12-8e65-2edf398daeaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86a65e8a-10f4-4f12-8e65-2edf398daeaa"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced movement disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f719b85e-f510-56dc-9689-4b456752b634", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [306, 330], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9040cb3b-13d2-e46d-e053-2a95a90ae9e6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9040cb3b-13d2-e46d-e053-2a95a90ae9e6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9040cb3b-13d2-e46d-e053-2a95a90ae9e6"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS &amp; USAGE This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "central nervous system drug-induced disorders", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fa2c2203-495d-5660-808d-82df0705d438", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c0a54740-f46b-5922-81d0-eff9a69fef1c", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e918cc27-7054-55f7-8322-37268fa43bc8", "object": "UMLS:C0015371", "object_location_in_text": [294, 318], "original_object": "extrapyramidal disorders", "original_subject": "TRIHEXYPHENIDYL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3e71b957-9495-4583-8f00-99eac715ff85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3e71b957-9495-4583-8f00-99eac715ff85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e71b957-9495-4583-8f00-99eac715ff85"]}], "subject": "CHEBI:9720", "supporting_text": ["INDICATIONS This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:66bafaac-f3af-5cd3-94c7-5ab0d43965a5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564", "MONDO:0005326"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a4a4ce77-5b83-548d-ac6c-f0c5db528302", "object": "HP:0000989", "object_location_in_text": [34, 41], "original_object": "itching", "original_subject": "TRIPELENNAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f72d74-018f-4bc6-acd4-175ca3af4c6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f72d74-018f-4bc6-acd4-175ca3af4c6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f72d74-018f-4bc6-acd4-175ca3af4c6d"]}], "subject": "CHEBI:9741", "supporting_text": ["Use Temporarily relieves pain and itching associated with: • insect bites • minor burns • minor cuts • minor skin irritations • scrapes • sunburn • rashes due to poison ivy, poison oak, or poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0021564", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36686bc7-5e9b-5b0e-a6d2-56594f55b9ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0021564", "MONDO:0005326"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e4239d47-0c7c-5a3a-9375-64ba747ff7ee", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a4a4ce77-5b83-548d-ac6c-f0c5db528302", "object": "HP:0012531", "object_location_in_text": [25, 29], "original_object": "pain", "original_subject": "TRIPELENNAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:12f72d74-018f-4bc6-acd4-175ca3af4c6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=12f72d74-018f-4bc6-acd4-175ca3af4c6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12f72d74-018f-4bc6-acd4-175ca3af4c6d"]}], "subject": "CHEBI:9741", "supporting_text": ["Use Temporarily relieves pain and itching associated with: • insect bites • minor burns • minor cuts • minor skin irritations • scrapes • sunburn • rashes due to poison ivy, poison oak, or poison sumac"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "conditions where short term pupil dilation is desired", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca2ec02f-bfcb-54dc-ac23-085e18c96cda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a84d18c3-1929-5bc5-84ee-5964d473b52b", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f87d4002-70d8-5f7e-81ba-e0e49955d370", "object": "UMLS:C0026961", "object_location_in_text": [200, 214], "original_object": "pupil dilation", "original_subject": "TROPICAMIDE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:dbff7eeb-a16a-4106-ae5e-4effdd33cc45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=dbff7eeb-a16a-4106-ae5e-4effdd33cc45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dbff7eeb-a16a-4106-ae5e-4effdd33cc45"]}], "subject": "CHEBI:9757", "supporting_text": ["1 INDICATIONS AND USAGE MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1% / 2.5% is indicated to induce mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. MYDCOMBI is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist indicated to induce mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:275e7422-ec03-5bed-b501-2290e6615375", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [295, 317], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3c66a7-d397-4df5-822f-4a1f797f54fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3c66a7-d397-4df5-822f-4a1f797f54fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3c66a7-d397-4df5-822f-4a1f797f54fc"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38329cd2-b2eb-5813-8cdb-ab9095f84bcb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [291, 313], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV) , to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and morta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:421fae93-1104-519f-858f-1c1807bef8fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59d3db05-2d63-9dbf-e063-6394a90a8dd3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59d3db05-2d63-9dbf-e063-6394a90a8dd3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59d3db05-2d63-9dbf-e063-6394a90a8dd3"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of heart failure (NYHA class II-IV); valsartan tablets significantly reduced hospitalization for heart failure. ( 1.2 ) Post-myocardial infarction; for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f1989be-04ea-59b4-abb7-dd78a4913a23", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablet is an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV),to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7c094c2c-5b39-543b-9670-77c107694f84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:47137b1a-f2b0-49af-99f0-6fb4f5a16578", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=47137b1a-f2b0-49af-99f0-6fb4f5a16578", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=47137b1a-f2b0-49af-99f0-6fb4f5a16578"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV); Valsartan oral solution significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets ( 1.2 ) Stable left ventricular failure or left ventricular dysfunction following myocardial infarction; Valsartan oral solution reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets ( 1.3 ) 1.1 Hypertension Valsartan is indicated for the treatment of hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:95b23b41-a6e3-58d2-93bf-e29b729840bf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a816ea6-2645-bd6e-e063-6294a90a908b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a816ea6-2645-bd6e-e063-6294a90a908b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a816ea6-2645-bd6e-e063-6294a90a908b"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of heart failure (NYHA class II-IV); valsartan tablets significantly reduced hospitalization for heart failure. ( 1.2 ) Post-myocardial infarction; for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e9b44f0-4757-5bb7-b456-f5ffda1755b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [290, 312], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4a5df78-157b-4996-845c-235234250f11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4a5df78-157b-4996-845c-235234250f11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4a5df78-157b-4996-845c-235234250f11"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults. ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and morta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b136f42e-2c80-5549-b7c8-34f0bfac79ba", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04b3c573-4ef7-5cf6-e063-6294a90a2c5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04b3c573-4ef7-5cf6-e063-6294a90a2c5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04b3c573-4ef7-5cf6-e063-6294a90a2c5f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablet is an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV),to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb2f895b-d2d5-5c50-b78a-db073eb34eb6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e9c4c57-e2c9-461b-9c09-669d3ada4c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e9c4c57-e2c9-461b-9c09-669d3ada4c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e9c4c57-e2c9-461b-9c09-669d3ada4c1a"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c77d0b3c-f3a3-5c48-8e1d-e7aee3e0fd59", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [278, 300], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddba454-f3e6-43c2-a7a6-58365d297213", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Diovan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with Diovan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfcafc7b-01b1-5408-8dd6-ed1bf7683226", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [295, 317], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=251ccff4-bf86-453b-9d1c-e3c1ecfd3a46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=251ccff4-bf86-453b-9d1c-e3c1ecfd3a46"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d463ce7e-5006-5e57-b828-23b3f89e3055", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [292, 314], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73e01dc6-7dd4-421a-a4f6-137e75f69f9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73e01dc6-7dd4-421a-a4f6-137e75f69f9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73e01dc6-7dd4-421a-a4f6-137e75f69f9a"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e431b965-5e13-529a-8933-72ffbf5cd590", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3eee9505-ebba-76e3-e063-6294a90acd6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3eee9505-ebba-76e3-e063-6294a90acd6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3eee9505-ebba-76e3-e063-6294a90acd6e"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e753f7f3-55fd-5ba9-ba2c-ccda70b0143e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04b3301f-e054-ed5d-e063-6294a90a819c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04b3301f-e054-ed5d-e063-6294a90a819c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04b3301f-e054-ed5d-e063-6294a90a819c"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f62361e3-4782-5d6a-ade6-508895723834", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b523502-62b3-425e-960b-f0a58919d3ec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b523502-62b3-425e-960b-f0a58919d3ec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b523502-62b3-425e-960b-f0a58919d3ec"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f77222ba-4d7d-53cc-94bc-509431949abd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [281, 303], "original_object": "myocardial infarctions", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a8af3d9-4053-4233-82a7-e8c7bc9e302f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a8af3d9-4053-4233-82a7-e8c7bc9e302f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a8af3d9-4053-4233-82a7-e8c7bc9e302f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:01533a32-8f58-5b86-b965-2656f6c5ff1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [269, 276], "original_object": "strokes", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a8af3d9-4053-4233-82a7-e8c7bc9e302f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a8af3d9-4053-4233-82a7-e8c7bc9e302f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a8af3d9-4053-4233-82a7-e8c7bc9e302f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:020b2db6-2a60-5892-966d-6ec506e8c587", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [280, 287], "original_object": "strokes", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04b3301f-e054-ed5d-e063-6294a90a819c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04b3301f-e054-ed5d-e063-6294a90a819c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04b3301f-e054-ed5d-e063-6294a90a819c"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1af28c38-1c9e-5ac9-be4b-cbe5c483bbad", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [280, 287], "original_object": "strokes", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3eee9505-ebba-76e3-e063-6294a90acd6e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3eee9505-ebba-76e3-e063-6294a90acd6e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3eee9505-ebba-76e3-e063-6294a90acd6e"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ea66c1a-5d0c-568f-9947-63730c21a11f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [266, 273], "original_object": "strokes", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5ddba454-f3e6-43c2-a7a6-58365d297213", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Diovan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Diovan ® is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with Diovan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that i"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d668d64-28b2-5e30-a283-065db1fdbc12", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:47137b1a-f2b0-49af-99f0-6fb4f5a16578", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=47137b1a-f2b0-49af-99f0-6fb4f5a16578", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=47137b1a-f2b0-49af-99f0-6fb4f5a16578"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan is an angiotensin II receptor blocker (ARB) indicated for: Hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV); Valsartan oral solution significantly reduces hospitalization for heart failure in patients who are unable to swallow valsartan tablets ( 1.2 ) Stable left ventricular failure or left ventricular dysfunction following myocardial infarction; Valsartan oral solution reduces cardiovascular mortality in patients who are unable to swallow valsartan tablets ( 1.3 ) 1.1 Hypertension Valsartan is indicated for the treatment of hypertension in adults and children six years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78b4a3f7-67b9-5778-80a1-8663f21dd5f5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [280, 287], "original_object": "strokes", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73e01dc6-7dd4-421a-a4f6-137e75f69f9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73e01dc6-7dd4-421a-a4f6-137e75f69f9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73e01dc6-7dd4-421a-a4f6-137e75f69f9a"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7d075e05-750b-50b2-b5dd-a2f249d133b2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5a816ea6-2645-bd6e-e063-6294a90a908b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5a816ea6-2645-bd6e-e063-6294a90a908b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5a816ea6-2645-bd6e-e063-6294a90a908b"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of heart failure (NYHA class II-IV); valsartan tablets significantly reduced hospitalization for heart failure. ( 1.2 ) Post-myocardial infarction; for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81367c34-b906-5b0c-b0dc-99784ccce811", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [278, 285], "original_object": "strokes", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f4a5df78-157b-4996-845c-235234250f11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f4a5df78-157b-4996-845c-235234250f11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4a5df78-157b-4996-845c-235234250f11"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults. ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and morta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81402380-31c0-5ad3-8625-a1c6f8dca7fd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [280, 287], "original_object": "strokes", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e9c4c57-e2c9-461b-9c09-669d3ada4c1a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e9c4c57-e2c9-461b-9c09-669d3ada4c1a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e9c4c57-e2c9-461b-9c09-669d3ada4c1a"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8f9cf94a-cde1-5649-9fc7-f5fe1006ddaf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [283, 290], "original_object": "strokes", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3c66a7-d397-4df5-822f-4a1f797f54fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3c66a7-d397-4df5-822f-4a1f797f54fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3c66a7-d397-4df5-822f-4a1f797f54fc"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9b82ada6-a240-5bef-a7bf-d6774095e3c4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04b3c573-4ef7-5cf6-e063-6294a90a2c5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04b3c573-4ef7-5cf6-e063-6294a90a2c5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04b3c573-4ef7-5cf6-e063-6294a90a2c5f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablet is an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV),to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a8a504b9-8da2-5fdd-a335-24b71f0cf734", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 6, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [280, 287], "original_object": "strokes", "original_subject": "VALSARTAN", "population_context_qualifier": "adults and children 1 year and older", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7b523502-62b3-425e-960b-f0a58919d3ec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7b523502-62b3-425e-960b-f0a58919d3ec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b523502-62b3-425e-960b-f0a58919d3ec"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac87f189-4560-5d00-aa55-ca0751aa0843", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59d3db05-2d63-9dbf-e063-6394a90a8dd3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59d3db05-2d63-9dbf-e063-6394a90a8dd3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59d3db05-2d63-9dbf-e063-6394a90a8dd3"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of heart failure (NYHA class II-IV); valsartan tablets significantly reduced hospitalization for heart failure. ( 1.2 ) Post-myocardial infarction; for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality,"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bc17530c-cde9-5823-b7c4-4eb867e1cda7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablet is an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV),to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2f0d5a2-88b9-58d7-aeea-55971d818ed6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [279, 286], "original_object": "strokes", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab5e0e5a-5bdf-4cfc-9d18-57ea4d642f65"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV) , to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and morta"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:efb80ea1-808b-53d9-be49-ea6bd3d47fbc", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 10, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [283, 290], "original_object": "strokes", "original_subject": "VALSARTAN", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=251ccff4-bf86-453b-9d1c-e3c1ecfd3a46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=251ccff4-bf86-453b-9d1c-e3c1ecfd3a46"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA class II-IV", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1cbbdbae-72be-5021-89a8-29bc9681afd4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7aaa0a16-d7c6-4952-aa27-0b4b8982dc5f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablet is an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV),to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA class II-IV", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5f8bd3c0-918b-519d-8fd1-cf6f39517de3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73e01dc6-7dd4-421a-a4f6-137e75f69f9a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73e01dc6-7dd4-421a-a4f6-137e75f69f9a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73e01dc6-7dd4-421a-a4f6-137e75f69f9a"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "heart failure (NYHA class II-IV)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:77e93acf-f0c1-5883-b754-5c5d1319b0b9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:251ccff4-bf86-453b-9d1c-e3c1ecfd3a46", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=251ccff4-bf86-453b-9d1c-e3c1ecfd3a46", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=251ccff4-bf86-453b-9d1c-e3c1ecfd3a46"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "NYHA class II-IV", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:790861ce-927e-5340-b7f0-0aff0700a03d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:04b3c573-4ef7-5cf6-e063-6294a90a2c5f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=04b3c573-4ef7-5cf6-e063-6294a90a2c5f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04b3c573-4ef7-5cf6-e063-6294a90a2c5f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Valsartan tablet is an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV),to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, an"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "heart failure (NYHA class II-IV)", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d67f78e6-fcf7-5d9e-b7b6-9edbd5ad7fe4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d5394c3a-e401-5d80-9da0-7f3fa5cbba3f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "medic_supporting_text_truncated": true, "object": "MONDO:0005252", "original_object": "heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb3c66a7-d397-4df5-822f-4a1f797f54fc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb3c66a7-d397-4df5-822f-4a1f797f54fc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb3c66a7-d397-4df5-822f-4a1f797f54fc"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension , to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) • Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) • Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients six years of age and older . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity a"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:062bf88e-fe45-5ce4-ad0b-3e1a8cd05443", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [369, 394], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4134afd2-a0a0-a64a-e063-6394a90ae580", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4134afd2-a0a0-a64a-e063-6394a90ae580", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4134afd2-a0a0-a64a-e063-6394a90ae580"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. Left ventricular ejection fraction (LVEF) is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f090a4f-cb12-515d-a49a-21d8ab2f2375", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [445, 470], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43bcdbc7-a635-bb4e-e063-6294a90a990f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43bcdbc7-a635-bb4e-e063-6294a90a990f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43bcdbc7-a635-bb4e-e063-6294a90a990f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, and are indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fb8402d-1d7f-5c9e-a082-1ec0afa8ce86", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [448, 473], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:46154d5f-7de1-db5e-e063-6394a90af86e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=46154d5f-7de1-db5e-e063-6394a90af86e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=46154d5f-7de1-db5e-e063-6394a90af86e"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablet is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduce NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablet is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1282d8e7-b565-5561-8e64-22863fd64f02", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:48714b95-b4ac-ef3c-e063-6294a90a9a5b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=48714b95-b4ac-ef3c-e063-6294a90a9a5b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=48714b95-b4ac-ef3c-e063-6294a90a9a5b"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and Valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1fb7dc24-29a4-5c0e-838a-d3b95e85ba07", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [369, 394], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4114a976-2e58-8437-e063-6394a90af298", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4114a976-2e58-8437-e063-6394a90af298", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4114a976-2e58-8437-e063-6394a90af298"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. Left ventricular ejection fraction (LVEF) is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3ee44c33-2e90-5af7-8e46-af63e4819992", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:487102e3-f319-836b-e063-6394a90a4438", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=487102e3-f319-836b-e063-6394a90a4438", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487102e3-f319-836b-e063-6394a90a4438"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and Valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5498bf0f-d502-5422-b656-9c1b7ff6b3d3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [444, 469], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f88efbb-3718-43a1-91d4-da5943ccfca1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f88efbb-3718-43a1-91d4-da5943ccfca1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f88efbb-3718-43a1-91d4-da5943ccfca1"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65c2302d-1242-5f18-bb86-90742762e602", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [446, 471], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:59b7a07a-96ee-44b1-8dae-2b42169aa2c5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=59b7a07a-96ee-44b1-8dae-2b42169aa2c5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59b7a07a-96ee-44b1-8dae-2b42169aa2c5"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9ce2678c-83d1-5d47-8816-06394d4c6593", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [446, 471], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3173e592-6f28-4864-9bf0-0ef0452da3de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3173e592-6f28-4864-9bf0-0ef0452da3de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3173e592-6f28-4864-9bf0-0ef0452da3de"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ba8565ee-7f0c-5e55-8d2d-b9d596cb898d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4870fbeb-ce93-7953-e063-6294a90a6142", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4870fbeb-ce93-7953-e063-6294a90a6142", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4870fbeb-ce93-7953-e063-6294a90a6142"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and Valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cca93165-7605-5c3c-ab11-3a69c0228003", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [450, 475], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:998db1e1-3f32-4812-a64b-5a6870ef7f8f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=998db1e1-3f32-4812-a64b-5a6870ef7f8f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=998db1e1-3f32-4812-a64b-5a6870ef7f8f"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:eb883490-9e08-5b7f-8069-4c3f3f22f059", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [444, 469], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d85015d5-f619-4a58-b6ab-5e39af3f79d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d85015d5-f619-4a58-b6ab-5e39af3f79d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d85015d5-f619-4a58-b6ab-5e39af3f79d8"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and is expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec326e34-2d82-5506-b83d-725f51c8e6a2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [448, 473], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8290ae4c-0d1e-47f6-8029-ddc1c0bd6f6d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8290ae4c-0d1e-47f6-8029-ddc1c0bd6f6d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8290ae4c-0d1e-47f6-8029-ddc1c0bd6f6d"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablet is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduce NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablet is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f0cdb61d-1cfa-54fc-82a4-477ac63050b3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [484, 509], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:064a7c51-de30-4759-8210-e18438e6a187", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=064a7c51-de30-4759-8210-e18438e6a187", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=064a7c51-de30-4759-8210-e18438e6a187"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and sacubitril and valsartan tablets are indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [ see Clinical Studies ( 14.1 )] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f68a6564-52e7-5643-9865-f9e897f345ae", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [446, 471], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a1fa7066-8ab4-47e3-a701-6c5170700d11", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a1fa7066-8ab4-47e3-a701-6c5170700d11", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1fa7066-8ab4-47e3-a701-6c5170700d11"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS &amp; USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. (1.1) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and are expected to improve cardiovascular outcomes. (1.2) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1)] . 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduce NT-proBNP and are expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "systemic left ventricular systolic dysfunction", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f86d35f9-3dbf-5891-b9c5-25f3989d8dcb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961223", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d985094a-ea0a-5a7b-b379-6d34aea2f0bd", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 16, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:194c650a-88cb-5eb3-a8c4-f17df65709ac", "object": "MONDO:0005254", "object_location_in_text": [369, 394], "original_object": "symptomatic heart failure", "original_subject": "VALSARTAN", "population_context_qualifier": "pediatric patients aged one year and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2c39c326-34a2-b7f4-e063-6294a90a6732", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2c39c326-34a2-b7f4-e063-6294a90a6732", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c39c326-34a2-b7f4-e063-6294a90a6732"]}], "subject": "CHEBI:9927", "supporting_text": ["1 INDICATIONS AND USAGE Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) 1.1 Adult Heart Failure Sacubitril and valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and reduced ejection fraction. Left ventricular ejection fraction (LVEF) is a variable measure, so use clinical judgment in deciding whom to treat [see Clinical Studies (14.1) ]. 1.2 Pediatric Heart Failure Sacubitril and valsartan tablets are indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablets reduces NT-proBNP and is expected to improve cardiovascular outcomes."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:05fd6eb3-0911-56df-b5fb-4485641f5bd7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0a43e6b9-b9b8-5237-9b95-5c3c4bc611f2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:386a8e67-1f18-6513-e063-6294a90a5ffe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=386a8e67-1f18-6513-e063-6294a90a5ffe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=386a8e67-1f18-6513-e063-6294a90a5ffe"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d39befd-18e7-5299-a753-ed9cb621a95c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3532868c-ac1d-43c8-e063-6394a90a4fd1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3532868c-ac1d-43c8-e063-6394a90a4fd1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3532868c-ac1d-43c8-e063-6394a90a4fd1"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15f289d2-5737-516b-b550-a2781e42216c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eadd82d7-e2cb-4144-9f0c-b340f54c6fa4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eadd82d7-e2cb-4144-9f0c-b340f54c6fa4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eadd82d7-e2cb-4144-9f0c-b340f54c6fa4"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1e574b5b-998e-5937-919c-c4dcd361e288", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cce1a220-3178-49ec-b046-f0cb134cf051", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cce1a220-3178-49ec-b046-f0cb134cf051", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cce1a220-3178-49ec-b046-f0cb134cf051"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:237101fb-7c1e-56fe-85f5-320dcef2c94f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:caf04d72-679e-daf9-e86f-4867f83b8ac5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=caf04d72-679e-daf9-e86f-4867f83b8ac5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=caf04d72-679e-daf9-e86f-4867f83b8ac5"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:23dc75ec-76e7-5ad5-acbf-3e5a1c4823f0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f5f03364-e71c-9bcd-e053-2995a90a8ada", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f5f03364-e71c-9bcd-e053-2995a90a8ada", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f03364-e71c-9bcd-e053-2995a90a8ada"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS &amp; USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines."], "temporal_context_qualifier": "who remain hypotensive despite fluids and catecholamines"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:26653246-7191-537c-a5d8-8c40ea75f215", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bf4b0b63-0055-40d8-b331-7f9f1ea3214c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bf4b0b63-0055-40d8-b331-7f9f1ea3214c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf4b0b63-0055-40d8-b331-7f9f1ea3214c"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"], "temporal_context_qualifier": "who remain hypotensive despite fluids and catecholamines"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3942c9c0-d933-5288-be4c-eacda78a5d83", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d9869345-b02c-4225-a97b-656f14c86dec", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d9869345-b02c-4225-a97b-656f14c86dec", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d9869345-b02c-4225-a97b-656f14c86dec"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3cb23156-a1c0-511a-a090-84ea065060e4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b1147beb-743e-4c62-8927-91192447f8b8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b1147beb-743e-4c62-8927-91192447f8b8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1147beb-743e-4c62-8927-91192447f8b8"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ae10bfb-e914-572d-ab28-9c39968da170", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b5b2c367-6b7e-40be-a296-c4632f3e783f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b5b2c367-6b7e-40be-a296-c4632f3e783f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5b2c367-6b7e-40be-a296-c4632f3e783f"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"], "temporal_context_qualifier": "who remain hypotensive despite fluids and catecholamines"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:793ede32-8ddd-5095-955a-80eb2357987d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:85e3dc1e-98ae-4c4c-8af9-237375475e08", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=85e3dc1e-98ae-4c4c-8af9-237375475e08", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85e3dc1e-98ae-4c4c-8af9-237375475e08"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b0c16a27-7fe4-508b-acc9-f3285832c235", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad3ac280-49da-4816-9097-14517d0c0f85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad3ac280-49da-4816-9097-14517d0c0f85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad3ac280-49da-4816-9097-14517d0c0f85"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C5400441", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f918d8f7-e6e7-50e6-ab3b-68b99fded816", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20140417", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fluids", "catecholamines"], "medic_disease_context_ids": ["UMLS:C5400441"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f7ff7161-7f6e-55a2-9a1c-86072576c5c2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f501e5f0-f42e-5d49-a6bf-86b3e2226828", "object": "MONDO:0005468", "original_object": "hypotension", "original_subject": "VASOPRESSIN", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0ab267f4-9ec9-44fd-8521-f975074667d9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0ab267f4-9ec9-44fd-8521-f975074667d9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ab267f4-9ec9-44fd-8521-f975074667d9"]}], "subject": "CHEBI:9937", "supporting_text": ["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:13b550ce-4606-5ff8-82a9-be0883f0600e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:806b3e38-3b2a-4aaa-973c-e2d921bb353e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=806b3e38-3b2a-4aaa-973c-e2d921bb353e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=806b3e38-3b2a-4aaa-973c-e2d921bb353e"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:160af632-858d-5683-a536-4a41201ea786", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4a82cef5-693e-46e9-90c4-bff753cdce37", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4a82cef5-693e-46e9-90c4-bff753cdce37", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a82cef5-693e-46e9-90c4-bff753cdce37"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a34334f-b2ae-59e4-b09a-fae61cfef7d7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:38fd2c97-cd30-2f7d-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=38fd2c97-cd30-2f7d-e054-00144ff8d46c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38fd2c97-cd30-2f7d-e054-00144ff8d46c"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets/venlafaxine hydrochloride extended-release capsules for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac59f60a-b047-55e2-a82c-b4400ee136a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b19ec628-4034-4316-ad3d-46c1ee220728", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b19ec628-4034-4316-ad3d-46c1ee220728", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b19ec628-4034-4316-ad3d-46c1ee220728"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b3b4aa9c-0b39-5545-a1ad-42960f5af117", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ddb51556-0292-4aa9-b781-a402c912591f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ddb51556-0292-4aa9-b781-a402c912591f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ddb51556-0292-4aa9-b781-a402c912591f"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b4fa9be3-3d39-5b97-8261-37573f902d73", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:53e5c5a2-b8e7-3d75-e063-6294a90a508b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=53e5c5a2-b8e7-3d75-e063-6294a90a508b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=53e5c5a2-b8e7-3d75-e063-6294a90a508b"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0221480", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e6e6b749-7283-5c56-bad9-fddb36a7921f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19931228", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0221480"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fe13d497-7e4b-5eda-8c9b-1f8e521d3b26", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d872252-8cac-5555-9087-0e3aa88d309e", "object": "MONDO:0002009", "original_object": "major depressive disorder", "original_subject": "VENLAFAXINE", "population_context_qualifier": "patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f56a0f70-bbb1-4e69-b969-965a72f0e2f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f56a0f70-bbb1-4e69-b969-965a72f0e2f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f56a0f70-bbb1-4e69-b969-965a72f0e2f0"]}], "subject": "CHEBI:9943", "supporting_text": ["Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets, USP in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets, USP/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless secondary to a supraventricular tachycardia amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f3a066e-ce7a-50a9-ac1e-ce18636ceda2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [299, 330], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4f6ae43f-c28a-4eac-9b19-8b5d0c12dfaa", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4f6ae43f-c28a-4eac-9b19-8b5d0c12dfaa", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4f6ae43f-c28a-4eac-9b19-8b5d0c12dfaa"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: Severe hypotension or cardiogenic shock. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless secondary to a supraventricular tachycardia amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3939903d-ce0a-5da5-958c-7d9b690221cb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [311, 342], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1c993365-1b62-4524-e781-d307f28f63bc", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1c993365-1b62-4524-e781-d307f28f63bc", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1c993365-1b62-4524-e781-d307f28f63bc"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: 1. Severe hypotension or cardiogenic shock. 2. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). 3. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. 6. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. 7. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless secondary to a supraventricular tachycardia amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4232876c-224d-5959-8f92-bad171856db0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [299, 330], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d7a749d0-4ab3-4fbb-8d7b-e09d68413c41", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d7a749d0-4ab3-4fbb-8d7b-e09d68413c41", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7a749d0-4ab3-4fbb-8d7b-e09d68413c41"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: Severe hypotension or cardiogenic shock. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless secondary to a supraventricular tachycardia amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4915780b-5bd0-5bfb-a3cd-e8a6a23f0d84", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [311, 342], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:70057a53-ca29-4848-ab3d-5e691e2a14a3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=70057a53-ca29-4848-ab3d-5e691e2a14a3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=70057a53-ca29-4848-ab3d-5e691e2a14a3"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: 1. Severe hypotension or cardiogenic shock. 2. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). 3. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. 6. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. 7. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "secondary to a supraventricular tachycardia amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:92066679-c610-5fee-bebf-429f05a269fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [311, 342], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df77b8d1-1d2b-4fea-a1e9-153bd25008a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df77b8d1-1d2b-4fea-a1e9-153bd25008a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df77b8d1-1d2b-4fea-a1e9-153bd25008a6"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: 1. Severe hypotension or cardiogenic shock. 2. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). 3. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. 6. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. 7. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless secondary to a supraventricular tachycardia amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d1d5147a-8e7b-5ad9-a181-6fbc60542f82", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [299, 330], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:50131bbc-ad43-4708-946f-e4000828137c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=50131bbc-ad43-4708-946f-e4000828137c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=50131bbc-ad43-4708-946f-e4000828137c"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: Severe hypotension or cardiogenic shock. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "supraventricular tachycardia not amenable to verapamil therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e91bfb16-72ab-5a5c-b364-94280a1c576f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "original_object": "severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9c89764e-ff07-4077-a40f-91eb1c179af2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9c89764e-ff07-4077-a40f-91eb1c179af2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c89764e-ff07-4077-a40f-91eb1c179af2"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection (intravenous) is contraindicated in: Severe hypotension or cardiogenic shock. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated. Ventricular Tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pre-therapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "unless secondary to a supraventricular tachycardia amenable to verapamil hydrochloride therapy", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e94de8e4-de14-5536-a22a-ed98905a2791", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0708be1d-73f8-5025-aa8f-a4aaa8793333", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "object": "MONDO:0005009", "object_location_in_text": [298, 329], "original_object": "Severe congestive heart failure", "original_subject": "VERAPAMIL", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:df79ee3a-f0ed-1cc7-e053-2995a90af97f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=df79ee3a-f0ed-1cc7-e053-2995a90af97f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df79ee3a-f0ed-1cc7-e053-2995a90af97f"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride injection is contraindicated in: Severe hypotension or cardiogenic shock. Second-or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil hydrochloride therapy). Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil hydrochloride and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil hydrochloride is administered. Therefore, the use of verapamil hydrochloride in these patients is contraindicated. Ventricular tachycardia: Administration of intravenous verapamil hydrochloride to patients with wide-complex ventricular-tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pre-therapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. Known hypersensitivity to verapamil hydrochloride."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2e526bf8-4cfc-54cd-a069-db815365ab98", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a390f77a-2c80-5306-98f3-82c8df78028f", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "original_object": "myocardial infarction", "original_subject": "VERAPAMIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a32f346e-71cf-cc11-e053-2a95a90ae88c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a32f346e-71cf-cc11-e053-2a95a90ae88c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a32f346e-71cf-cc11-e053-2a95a90ae88c"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride tablets USP are indicated for the treatment of the following: Angina 1.Angina at rest including: -Vasospastic (Prinzmetal's variant) angina -Unstable (crescendo, pre-infarction) angina 2.Chronic stable angina (classic effort-associated angina) Arrhythmias 1.In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS: Accessory bypass tract ) 2.Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential hypertension Verapamil hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62087b91-e842-5865-9fbf-90602e807979", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8a3f65ae-8a73-586d-988d-27b501f196fc", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:25cc53df-6b23-5d0b-9dc6-2c7cb4cc7141", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "original_object": "stroke", "original_subject": "VERAPAMIL", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a32f346e-71cf-cc11-e053-2a95a90ae88c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a32f346e-71cf-cc11-e053-2a95a90ae88c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a32f346e-71cf-cc11-e053-2a95a90ae88c"]}], "subject": "CHEBI:9948", "supporting_text": ["Verapamil hydrochloride tablets USP are indicated for the treatment of the following: Angina 1.Angina at rest including: -Vasospastic (Prinzmetal's variant) angina -Unstable (crescendo, pre-infarction) angina 2.Chronic stable angina (classic effort-associated angina) Arrhythmias 1.In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS: Accessory bypass tract ) 2.Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential hypertension Verapamil hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but re"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0080203", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c2d76d57-483b-5128-821c-5f1c199fe7a1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0080203"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:33a678ef-c8f6-5eb9-80b2-2d301d039b9e", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f663b01e-edb5-550e-93de-b74bbbe6eca7", "object": "HP:0004763", "object_location_in_text": [154, 193], "original_object": "paroxysmal supraventricular tachycardia", "original_subject": "VERAPAMIL HYDROCHLORIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VERAPAMIL HYDROCHLORIDE#145-20110520", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:9948", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0080203", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2da20a8e-35ec-506d-bd14-c05fa1aa9fe3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0080203"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:d08b0e8b-7be1-534e-b197-5e9765c741ee", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f663b01e-edb5-550e-93de-b74bbbe6eca7", "object": "MONDO:0004981", "object_location_in_text": [117, 136], "original_object": "atrial fibrillation", "original_subject": "VERAPAMIL HYDROCHLORIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VERAPAMIL HYDROCHLORIDE#145-20110520", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:9948", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C0080203", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:87a5e609-e2f6-5aa8-933e-24d11aeb3a34", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20110520", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0080203"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:25371315-92a9-537e-9f9c-83a38de62d5a", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:f663b01e-edb5-550e-93de-b74bbbe6eca7", "object": "MONDO:0005310", "object_location_in_text": [138, 152], "original_object": "atrial flutter", "original_subject": "VERAPAMIL HYDROCHLORIDE", "population_context_qualifier": "pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:VERAPAMIL HYDROCHLORIDE#145-20110520", "https://www.pmda.go.jp/PmdaSearch/iyakuSearch/"]}], "subject": "CHEBI:9948", "supporting_text": ["A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment]"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ACTH-dependent hypercortisolism", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2ddedc26-b487-515e-8001-13d396dd5003", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:67a49d1e-e90c-5f63-8d99-71f045d280a2", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3566613b-a572-577f-8a4c-1078d0aab145", "medic_supporting_text_truncated": true, "object": "MONDO:0009050", "object_location_in_text": [307, 324], "original_object": "Cushing's disease", "original_subject": "CORTICORELIN OVINE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c39dcea-d8f7-8594-01e6-24e8d6fa4d2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c39dcea-d8f7-8594-01e6-24e8d6fa4d2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c39dcea-d8f7-8594-01e6-24e8d6fa4d2f"]}], "subject": "DRON:00012842", "supporting_text": ["ACTHREL® is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. Differential Diagnosis There are two forms of Cushing's syndrome: ACTH-dependent (83%), in which hypercortisolism is due either to pituitary hypersecretion of ACTH (Cushing's disease) resulting from an adenoma (40%, usually microadenomas) or nonadenomatous hyperplasia, possibly of hypothalamic origin (28%), or to hypercortisolism that is secondary to ectopic secretion of ACTH (15%) and, ACTH- independent (17%), in which hypercortisolism is due to autonomous cortisol secretion by an adrenal tumor (9% adenomas, 8% carcinomas). After the establishment of hypercortisolism consistent with the presence of Cushing's syndrome, and following the elimination of autonomous adrenal hyperfunction as its cause, the corticorelin test is used to aid in establishing the source of excessive ACTH secretion. The corticorelin stimulation test helps to differentiate between the etiologies of ACTH-dependent hypercortisolism as follows: High basal plasma ACTH plus high basal plasma cortisol (20 - 40 mcg/dL). ACTHREL ® injection (1 mcg/kg) results in: Increased plasma ACTH levels Increased plasma cortisol levels Diagnosis: Cushing's disease (ACTH of pituitary origin) High basal plasma ACTH (may be very high) plus high basal plasma cortisol (20 - 40 mcg/dL). ACTHREL ® injection (1 mcg/kg) results in: Little or no response of plasma ACTH levels Little or no response of plasma cortisol levels Diagnosis: Ectopic ACTH syndrome Test Methodology To evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion, a corticorelin test procedure requires a minimum of five blood samples. Procedure Venous blood samples should be drawn 15 minutes before and immediately prior to ACTHREL ® administration. The ACTH baseline is obtained by averaging the values of the two samples. Administ"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "ACTH-dependent hypercortisolism", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b6e590a7-6447-5622-9cbf-d9dbb6373dfc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:51ea2f81-51f0-5fd7-aa2d-4ceff0fabeff", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3566613b-a572-577f-8a4c-1078d0aab145", "medic_supporting_text_truncated": true, "object": "MONDO:0043472", "original_object": "ectopic ACTH syndrome", "original_subject": "CORTICORELIN OVINE", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3c39dcea-d8f7-8594-01e6-24e8d6fa4d2f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3c39dcea-d8f7-8594-01e6-24e8d6fa4d2f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c39dcea-d8f7-8594-01e6-24e8d6fa4d2f"]}], "subject": "DRON:00012842", "supporting_text": ["ACTHREL® is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. Differential Diagnosis There are two forms of Cushing's syndrome: ACTH-dependent (83%), in which hypercortisolism is due either to pituitary hypersecretion of ACTH (Cushing's disease) resulting from an adenoma (40%, usually microadenomas) or nonadenomatous hyperplasia, possibly of hypothalamic origin (28%), or to hypercortisolism that is secondary to ectopic secretion of ACTH (15%) and, ACTH- independent (17%), in which hypercortisolism is due to autonomous cortisol secretion by an adrenal tumor (9% adenomas, 8% carcinomas). After the establishment of hypercortisolism consistent with the presence of Cushing's syndrome, and following the elimination of autonomous adrenal hyperfunction as its cause, the corticorelin test is used to aid in establishing the source of excessive ACTH secretion. The corticorelin stimulation test helps to differentiate between the etiologies of ACTH-dependent hypercortisolism as follows: High basal plasma ACTH plus high basal plasma cortisol (20 - 40 mcg/dL). ACTHREL ® injection (1 mcg/kg) results in: Increased plasma ACTH levels Increased plasma cortisol levels Diagnosis: Cushing's disease (ACTH of pituitary origin) High basal plasma ACTH (may be very high) plus high basal plasma cortisol (20 - 40 mcg/dL). ACTHREL ® injection (1 mcg/kg) results in: Little or no response of plasma ACTH levels Little or no response of plasma cortisol levels Diagnosis: Ectopic ACTH syndrome Test Methodology To evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion, a corticorelin test procedure requires a minimum of five blood samples. Procedure Venous blood samples should be drawn 15 minutes before and immediately prior to ACTHREL ® administration. The ACTH baseline is obtained by averaging the values of the two samples. Administ"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Previously untreated and previously treated CD20-positive CLL", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b380838d-157d-53da-8168-737ca18d0e66", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fludarabine", "cyclophosphamide (FC)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0004948", "original_object": "Chronic Lymphocytic Leukemia", "original_subject": "RITUXIMAB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: • Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent. o Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. o Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. o Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. • Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). o Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). • Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RUXIENCE is indicated for the treatment of adult patients with: • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintena"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously untreated and previously treated CD20-positive CLL", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4df18f1-c571-562b-9f13-9150879e18d4", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["fludarabine and cyclophosphamide (FC)"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b2fb2da9-acdc-5560-aaa6-8733980dd4d5", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0004948", "original_object": "Chronic Lymphocytic Leukemia", "original_subject": "RITUXIMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da1c4de7-0e5b-4f72-97ec-7a8d368f085f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing ("]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "HP:0025650", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:00779e52-4cb0-5d7b-af66-82bb8259f37a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20250327", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0025650"], "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:f072f011-4113-5daa-8c43-c557bc8dd055", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "object": "MONDO:0005377", "object_location_in_text": [66, 84], "original_object": "nephrotic syndrome", "original_subject": "RITUXIMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:RITUXIMAB#10-20250327", "https://www.pmda.go.jp/files/000265591.pdf"]}], "subject": "DRON:00013042", "supporting_text": ["Drugs with a new indication and a new dosage for the treatment of nephrotic syndrome (frequently relapsing or steroid-dependent nephrotic syndrome)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Moderate to severe Pemphigus Vulgaris (PV)", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1b43481a-cff3-5d53-ae13-ad4a9df8dbf0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fae89c0b-b4aa-5494-8a6e-8b725e932983", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0008219", "original_object": "Pemphigus Vulgaris", "original_subject": "RITUXIMAB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: • Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent. o Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. o Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. o Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. • Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). o Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). • Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RUXIENCE is indicated for the treatment of adult patients with: • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintena"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately-to-severely-active rheumatoid arthritis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:41985d50-ff4d-5243-ac06-234243b50346", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "original_object": "Rheumatoid Arthritis", "original_subject": "RITUXIMAB", "population_context_qualifier": "adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da1c4de7-0e5b-4f72-97ec-7a8d368f085f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing ("]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "moderately-to-severely-active rheumatoid arthritis", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9e592d81-6bd7-5d83-b47b-ebee67851edb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["methotrexate", "TNF antagonist therapies"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:686b8485-be7b-5191-9c56-a8e865e0d328", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0008383", "original_object": "Rheumatoid Arthritis", "original_subject": "RITUXIMAB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: • Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent. o Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. o Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. o Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. • Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). o Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). • Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RUXIENCE is indicated for the treatment of adult patients with: • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintena"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Previously untreated diffuse large B-cell, CD20-positive NHL", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40578f2a-b4e0-55f6-a273-9ef93593b1bd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cyclophosphamide", "doxorubicin", "vincristine", "prednisone (CHOP)", "anthracycline-based chemotherapy regimens"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:682277b4-d91a-5def-a1c9-2bb2e02755d7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0018908", "original_object": "Non-Hodgkin's Lymphoma", "original_subject": "RITUXIMAB", "population_context_qualifier": "Adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f941fc61-f7a3-4e4a-ab7c-87c1667fa05b"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: • Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent. o Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. o Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. o Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. • Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). o Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). • Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). • Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RUXIENCE is indicated for the treatment of adult patients with: • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintena"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "previously untreated diffuse large B-cell, CD20-positive NHL", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d5e69314-be23-5ce4-9865-5dfdbc4ebc94", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19971126", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:682277b4-d91a-5def-a1c9-2bb2e02755d7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:48ab881c-4fd9-5870-8f5c-dc582253304b", "medic_supporting_text_truncated": true, "object": "MONDO:0018908", "original_object": "Non-Hodgkin's Lymphoma", "original_subject": "RITUXIMAB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da1c4de7-0e5b-4f72-97ec-7a8d368f085f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da1c4de7-0e5b-4f72-97ec-7a8d368f085f"]}], "subject": "DRON:00013042", "supporting_text": ["1 INDICATIONS AND USAGE RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to-severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). 1.1 Non-Hodgkin's Lymphoma (NHL) RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing ("]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:229b16d8-275e-5f84-8d96-2bd0d6b04110", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:782e9856-9411-57c6-a6c9-cb50d68cb25b", "object": "MONDO:0000001", "object_location_in_text": [184, 220], "original_object": "active secondary progressive disease", "original_subject": "GLATIRAMER", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f01e40a-b6f6-40fb-b37c-3d06f1428e86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f01e40a-b6f6-40fb-b37c-3d06f1428e86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f01e40a-b6f6-40fb-b37c-3d06f1428e86"]}], "subject": "DRON:00016914", "supporting_text": ["1 INDICATIONS AND USAGE Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2921627", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f574db48-87f7-56df-badb-ced4a6a7e5ac", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2921627", "MONDO:0000001"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1436c4ca-b6eb-55a4-975a-a5dcdb58ed4e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:782e9856-9411-57c6-a6c9-cb50d68cb25b", "object": "MONDO:0005301", "original_object": "multiple sclerosis", "original_subject": "GLATIRAMER", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0679689e-8930-4d6a-b922-5125082b2716", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0679689e-8930-4d6a-b922-5125082b2716", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0679689e-8930-4d6a-b922-5125082b2716"]}], "subject": "DRON:00016914", "supporting_text": ["1 INDICATIONS AND USAGE Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatopa is indicated for the treatment of relapsing-forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C2921627", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f8d9f8dc-902a-52ac-992e-8f87f8843b1f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961220", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C2921627", "MONDO:0000001"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1436c4ca-b6eb-55a4-975a-a5dcdb58ed4e", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:782e9856-9411-57c6-a6c9-cb50d68cb25b", "object": "MONDO:0005301", "original_object": "multiple sclerosis", "original_subject": "GLATIRAMER", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:028fdf0e-2340-407b-bcd8-5a99accdddbf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=028fdf0e-2340-407b-bcd8-5a99accdddbf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=028fdf0e-2340-407b-bcd8-5a99accdddbf"]}], "subject": "DRON:00016914", "supporting_text": ["1 INDICATIONS AND USAGE Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatopa is indicated for the treatment of relapsing-forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36160f58-93ac-5fa9-93bd-5160da2bf50b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19961220", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:782e9856-9411-57c6-a6c9-cb50d68cb25b", "object": "UMLS:C2921627", "object_location_in_text": [121, 149], "original_object": "clinically isolated syndrome", "original_subject": "GLATIRAMER", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f01e40a-b6f6-40fb-b37c-3d06f1428e86", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f01e40a-b6f6-40fb-b37c-3d06f1428e86", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f01e40a-b6f6-40fb-b37c-3d06f1428e86"]}], "subject": "DRON:00016914", "supporting_text": ["1 INDICATIONS AND USAGE Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "exposure to wind or sun", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62d5e15f-312e-5b8d-87e4-09357f3043d1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6e3bec2a-ef29-5a26-8a4c-5e70eed8bbf1", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0ab8a28b-a5ba-54f9-8497-f90b9f10a5ad", "object": "UMLS:C0441723", "object_location_in_text": [152, 174], "original_object": "burning and irritation", "original_subject": "POLYETHYLENE GLYCOL 400", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0bc0d6e7-9195-db6b-e063-6294a90aef04", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0bc0d6e7-9195-db6b-e063-6294a90aef04", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0bc0d6e7-9195-db6b-e063-6294a90aef04"]}], "subject": "DRON:00017826", "supporting_text": ["Uses for the temporary relief of discomfort and redness of the eye due to minor eye irritations relieves dryness of the eye for the temporary relief of burning and irritation due to exposure to wind or sun for protection against further irritation"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c1954b8b-5f52-5fc5-9ebc-e3074f96783f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20090116", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "original_object": "cytokine release syndrome", "original_subject": "tocilizumab", "population_context_qualifier": "adults and paediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:tyenne", "https://www.ema.europa.eu/en/documents/product-information/tyenne-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tyenne"]}], "subject": "DRON:00019607", "supporting_text": ["Tyenne, in combination with methotrexate (MTX), is indicated for  the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.  In these patients, Tyenne can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. Tyenne is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. Tyenne is indicated for the treatment of active&nbsp;systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. Tyenne can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX. Tyenne in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX.Tyenne can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Tyenne is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. Tyenne is indicated for the treatment of Giant Cell Arteritis (G"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:39885b6c-d81a-5f67-b295-c601aa10bbea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "object_location_in_text": [1082, 1107], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13"]}], "subject": "DRON:00019607", "supporting_text": ["1 INDICATIONS AND USAGE ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) ACTEMRA ® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) ACTEMRA ® (tocilizumab) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ACTEMRA ® (tocilizumab) is indicated for slowing the rate of decline in pulmonary function in adult patie"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4c3b9fdb-c88c-53ea-9c41-c234995284fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "object_location_in_text": [876, 901], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1ab3207a-ebfe-4565-9ce5-3a1538815c83", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1ab3207a-ebfe-4565-9ce5-3a1538815c83", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1ab3207a-ebfe-4565-9ce5-3a1538815c83"]}], "subject": "DRON:00019607", "supporting_text": ["1 INDICATIONS AND USAGE TOFIDENCE ® (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.5 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.6 ) Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) TOFIDENCE ® (tocilizumab-bavi) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (PJIA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. 1.4 Systemic Juvenile Idiopathic Arthritis (SJIA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active systemic juvenile idiopathic arthritis in "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:757df3c5-70e4-5b7b-8b6c-ffffb246c323", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "object_location_in_text": [883, 908], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:87ac5047-4f2b-4571-a8a8-32e08865f379", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=87ac5047-4f2b-4571-a8a8-32e08865f379", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87ac5047-4f2b-4571-a8a8-32e08865f379"]}], "subject": "DRON:00019607", "supporting_text": ["1 INDICATIONS AND USAGE TYENNE ® (tocilizumab-aazg) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) • Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) • Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) • Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.5 ) • Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.6 ) • Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (PJIA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. 1.4 Systemic Juvenile Idiopathic Arthritis (SJIA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of active systemic juvenile idiopathic arthritis "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a4dda3d3-722a-5479-8416-5378c20d0c9a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "object_location_in_text": [883, 908], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e400bbe6-43c5-4de6-82b9-cb44ce3cd906", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e400bbe6-43c5-4de6-82b9-cb44ce3cd906", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e400bbe6-43c5-4de6-82b9-cb44ce3cd906"]}], "subject": "DRON:00019607", "supporting_text": ["1 INDICATIONS AND USAGE TYENNE ® (tocilizumab-aazg) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) • Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) • Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) • Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.5 ) • Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.6 ) • Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (PJIA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. 1.4 Systemic Juvenile Idiopathic Arthritis (SJIA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of active systemic juvenile idiopathic arthritis "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c865b846-d5b6-5c13-8c4f-25f8dedf5b9f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "object_location_in_text": [874, 899], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:581c288f-8015-40ef-a4c3-683c96db193d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=581c288f-8015-40ef-a4c3-683c96db193d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=581c288f-8015-40ef-a4c3-683c96db193d"]}], "subject": "DRON:00019607", "supporting_text": ["1 INDICATIONS AND USAGE AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.5 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.6 ) Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (PJIA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. 1.4 Systemic Juvenile Idiopathic Arthritis (SJIA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of active systemic juvenile idiopathic arthritis in pati"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ceccfe9f-0ddf-5e48-a695-72c7a6c513c2", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20100108", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "medic_supporting_text_truncated": true, "object": "MONDO:0600008", "object_location_in_text": [883, 908], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ad76441d-da59-47df-8d9d-2243005180f0", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ad76441d-da59-47df-8d9d-2243005180f0", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ad76441d-da59-47df-8d9d-2243005180f0"]}], "subject": "DRON:00019607", "supporting_text": ["1 INDICATIONS AND USAGE TYENNE ® (tocilizumab-aazg) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) • Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) • Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) • Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) • Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.5 ) • Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.6 ) • Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (PJIA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. 1.4 Systemic Juvenile Idiopathic Arthritis (SJIA) TYENNE ® (tocilizumab-aazg) is indicated for the treatment of active systemic juvenile idiopathic arthritis "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "tumor-specific T-cell infusion therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2c36d34d-4dc1-52f3-b075-d66f270ef331", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190326", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:96578247-59da-5a55-a766-74e68db53d57", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:67355659-e278-5400-89b1-86a89f1377f4", "object": "MONDO:0600008", "object_location_in_text": [77, 102], "original_object": "cytokine release syndrome", "original_subject": "TOCILIZUMAB", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:TOCILIZUMAB#80-20190326", "https://www.pmda.go.jp/files/000246328.pdf"]}], "subject": "DRON:00019607", "supporting_text": ["Drugs with a new additional indication and a new dosage for the treatment of cytokine release syndrome induced by tumor-specific T-cell infusion therapy. [Expedited review]"], "temporal_context_qualifier": "induced by tumor-specific T-cell infusion therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "anticoagulant treatment", "has_confidence_score": 0.56, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:fe28daad-00e4-57c0-9642-4f3f8f12c7b8", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20070101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_jurisdiction": "INDIA", "medic_object_mention_id": "MEDICNE:a01b4214-c24a-53ca-b15a-e9c1bf99ea5e", "medic_pair_confidence": 0.56, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "INDIA", "medic_subject_mention_id": "MEDICNE:ac6f0348-174e-5426-9457-310b9c4843e0", "object": "HP:0040184", "object_location_in_text": [18, 33], "original_object": "oral hemorrhage", "original_subject": "Tranexamic acid mouthwash (50mg/ml)", "population_context_qualifier": "patients undergoing oral surgery", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:cdsco", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:cdsco", "resource_id": "infores:cdsco", "resource_role": "primary_knowledge_source", "source_record_urls": ["INDIA:Approved-New-Drugs", "https://cdsco.gov.in/opencms/opencms/en/Approval_new/Approved-New-Drugs/"]}], "subject": "DRON:00030118", "supporting_text": ["For prevention of oral hemorrhage in anticoagulant treated patients undergoing oral surgery"], "temporal_context_qualifier": "undergoing oral surgery"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Stage IIB, IIC, or with Stage III melanoma and lymph node involvement", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7abb9865-22f7-52ff-85a0-2988be806396", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150717", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:69f8c6a8-386d-51fd-b56f-5b916cef0816", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:08620610-166b-5f3e-99d8-1746723f48c1", "medic_supporting_text_truncated": true, "object": "MONDO:0005105", "object_location_in_text": [157, 165], "original_object": "melanoma", "original_subject": "pembrolizumab", "population_context_qualifier": "adults and adolescents aged 12 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:keytruda", "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda"]}], "subject": "DRON:00750819", "supporting_text": ["Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda&nbsp;as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non small cell lung carcinoma at high risk of recurrence in adults Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5.1). Keytruda&nbsp;as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations. Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations. Keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. Keytruda&nbsp; as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a&nbsp;≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA. Malignant pleural mesoth"], "temporal_context_qualifier": "following complete resection"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "unresectable non-epithelioid malignant pleural mesothelioma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb47572d-9dc5-535e-bc0e-76e94a019dfb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20150717", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["pemetrexed", "platinum chemotherapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:be78ffac-5f99-515a-9d03-9b27ecfd123c", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:08620610-166b-5f3e-99d8-1746723f48c1", "medic_supporting_text_truncated": true, "object": "MONDO:0005112", "original_object": "malignant pleural mesothelioma", "original_subject": "pembrolizumab", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:keytruda", "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda"]}], "subject": "DRON:00750819", "supporting_text": ["Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda&nbsp;as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non small cell lung carcinoma at high risk of recurrence in adults Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5.1). Keytruda&nbsp;as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations. Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations. Keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. Keytruda&nbsp; as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a&nbsp;≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA. Malignant pleural mesoth"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "PD-L1-positive tumor", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c3c2128-ff0f-5c5d-bba9-64d08c879831", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200821", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "JAPAN", "medic_object_mention_id": "MEDICNE:3e3c1ac7-d31c-54c1-bab7-7c31be1ba2c7", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "PMDA", "medic_subject_mention_id": "MEDICNE:08620610-166b-5f3e-99d8-1746723f48c1", "object": "MONDO:0005580", "object_location_in_text": [118, 152], "original_object": "esophageal squamous cell carcinoma", "original_subject": "PEMBROLIZUMAB", "population_context_qualifier": "unresectable advanced or recurrent", "predicate": "biolink:treats", "primary_knowledge_source": "infores:pmda", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:pmda", "resource_id": "infores:pmda", "resource_role": "primary_knowledge_source", "source_record_urls": ["PMDA:PEMBROLIZUMAB#61-20200821", "https://www.pmda.go.jp/files/000245967.pdf"]}], "subject": "DRON:00750819", "supporting_text": ["A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent PD-L1- positive esophageal squamous cell carcinoma that has progressed after cancer chemotherapy."], "temporal_context_qualifier": "progressed after cancer chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0f06f813-74b5-5d6e-b7ae-2716445fe85e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191219", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d48d7a2-0923-506b-8e3a-3cebce93298e", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [317, 339], "original_object": "myocardial infarctions", "original_subject": "LEVAMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:664ea032-2dd4-41ef-8506-c453cba57144", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=664ea032-2dd4-41ef-8506-c453cba57144", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=664ea032-2dd4-41ef-8506-c453cba57144"]}], "subject": "DRON:00942702", "supporting_text": ["1. INDICATIONS AND USAGE LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension LEVAMLODIPINE TABLETS is indicated for the treatment of hypertension in adults and pediatric patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including levamlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3d5b01fa-d534-5d36-9d8f-69355489be45", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191219", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9963dda0-9d34-595e-b234-2525b4090e12", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d48d7a2-0923-506b-8e3a-3cebce93298e", "medic_supporting_text_truncated": true, "object": "MONDO:0005068", "object_location_in_text": [306, 328], "original_object": "myocardial infarctions", "original_subject": "LEVAMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f389d4dd-82fd-43a3-8fc4-d8d7a3706fd4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f389d4dd-82fd-43a3-8fc4-d8d7a3706fd4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f389d4dd-82fd-43a3-8fc4-d8d7a3706fd4"]}], "subject": "DRON:00942702", "supporting_text": ["1. INDICATIONS AND USAGE CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension CONJUPRI ® is indicated for the treatment of hypertension in adults and pediatric patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including levamlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the abso"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:62ce926a-4522-5845-89ba-8b9203e9a173", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191219", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d48d7a2-0923-506b-8e3a-3cebce93298e", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [294, 301], "original_object": "strokes", "original_subject": "LEVAMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f389d4dd-82fd-43a3-8fc4-d8d7a3706fd4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f389d4dd-82fd-43a3-8fc4-d8d7a3706fd4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f389d4dd-82fd-43a3-8fc4-d8d7a3706fd4"]}], "subject": "DRON:00942702", "supporting_text": ["1. INDICATIONS AND USAGE CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension CONJUPRI ® is indicated for the treatment of hypertension in adults and pediatric patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including levamlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the abso"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0000822", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f35da33-5d4f-5e10-8d4c-c81147555b14", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20191219", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0000822"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8df0c82b-a289-52af-b09b-e6cf624b7022", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:9d48d7a2-0923-506b-8e3a-3cebce93298e", "medic_supporting_text_truncated": true, "object": "MONDO:0005098", "object_location_in_text": [305, 312], "original_object": "strokes", "original_subject": "LEVAMLODIPINE", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:664ea032-2dd4-41ef-8506-c453cba57144", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=664ea032-2dd4-41ef-8506-c453cba57144", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=664ea032-2dd4-41ef-8506-c453cba57144"]}], "subject": "DRON:00942702", "supporting_text": ["1. INDICATIONS AND USAGE LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension LEVAMLODIPINE TABLETS is indicated for the treatment of hypertension in adults and pediatric patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including levamlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascu"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "molybdenum cofactor deficiency Type A", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c18af7a-14a9-5506-bba8-6fdc902782c7", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20210226", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7434223a-c116-5822-a499-6c01555831cc", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:55b7bd6c-f6ee-58cb-8921-62ae16af7896", "object": "UMLS:C0026566", "object_location_in_text": [67, 76], "original_object": "mortality", "original_subject": "FOSDENOPTERIN", "population_context_qualifier": "patients with molybdenum cofactor deficiency (MoCD) Type A", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:736aeea3-f206-454d-95d0-fd30964e8aab", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=736aeea3-f206-454d-95d0-fd30964e8aab", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=736aeea3-f206-454d-95d0-fd30964e8aab"]}], "subject": "DRON:00965870", "supporting_text": ["1 INDICATIONS AND USAGE NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. NULIBRY is cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002013", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:96007f47-3b26-5efb-b226-2edbb0bc1292", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002013"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b3984d82-b981-5f8f-9a1d-2fe4d546aa83", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:860daf97-d7be-58c5-bb5d-995c160148f6", "object": "MONDO:0002122", "original_object": "neuritis", "original_subject": "THIAMINE", "population_context_qualifier": "pregnancy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3bfe8ac7-9294-4980-9635-90f8e6f6dd8e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3bfe8ac7-9294-4980-9635-90f8e6f6dd8e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3bfe8ac7-9294-4980-9635-90f8e6f6dd8e"]}], "subject": "RXCUI:10454", "supporting_text": ["INDICATIONS Thiamine Hydrochloride Injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine Hydrochloride Injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine Hydrochloride Injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine Hydrochloride Injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given."], "temporal_context_qualifier": "where rapid restoration of thiamine is necessary"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0002039", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:20c8607b-a84f-5d6e-9646-1e8c89d01a3d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002039", "HP:0002018", "HP:0002013", "MONDO:0020598"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:0b70f455-381f-5822-ac59-d48a489b0738", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:860daf97-d7be-58c5-bb5d-995c160148f6", "object": "MONDO:0006676", "original_object": "thiamine deficiency", "original_subject": "THIAMINE", "population_context_qualifier": "patients who cannot take thiamine orally", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5982cf83-01d6-4acb-8373-339079b8a76e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5982cf83-01d6-4acb-8373-339079b8a76e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5982cf83-01d6-4acb-8373-339079b8a76e"]}], "subject": "RXCUI:10454", "supporting_text": ["Thiamine Hydrochloride Injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine Hydrochloride Injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine Hydrochloride Injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine Hydrochloride Injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "gastrointestinal disorders interfering with intake or absorption of vitamins", "has_confidence_score": 0.0, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bca05d38-e1ad-5b99-b09b-6d941664add9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_assertion_flags": ["polarity_unverified"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ba9eb56f-8a53-5d28-94ad-258959e1639c", "medic_pair_confidence": 0.0, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:860daf97-d7be-58c5-bb5d-995c160148f6", "object": "MONDO:0024298", "original_object": "vitamin deficiency", "original_subject": "THIAMINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=282ccec8-9bcd-4571-9b91-bbb96ef2620d"]}], "subject": "RXCUI:10454", "supporting_text": ["In disorders requiring parenteral administration of vitamins, i.e. pre- and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C3839044", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79832cba-a546-50d7-992e-a8662a2a6af0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3839044"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:8883e344-0863-5a13-b99c-ad99300afbb9", "object": "MONDO:0005366", "original_object": "chronic hepatitis B virus infection", "original_subject": "TENOFOVIR ANHYDROUS", "population_context_qualifier": "adults and pediatric patients 6 years of age and older and weighing at least 25 kg", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72e6b33c-0351-4070-9172-eeaa186c01d2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72e6b33c-0351-4070-9172-eeaa186c01d2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72e6b33c-0351-4070-9172-eeaa186c01d2"]}], "subject": "RXCUI:117466", "supporting_text": ["1 INDICATIONS AND USAGE VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease [see Clinical Studies (14) ] . VEMLIDY is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "acute myeloid leukaemia with > 30% marrow blasts, 30% marrow blasts", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3e199f76-2901-5a3a-b546-0616d03fe814", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0004808", "object_location_in_text": [376, 399], "original_object": "acute myeloid leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-mylan", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:  intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification, AML with &gt; 30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "AML with &gt, 30% marrow blasts, 30% marrow blasts", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5bb276b4-80d1-5db2-a199-5af5862c2c96", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0004808", "original_object": "acute myeloid leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-kabi", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-kabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-kabi"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation(HSCT) with:  Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the international prognostic scoring system (IPSS), Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification, AML with &gt; 30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "AML with >30% marrow blasts, 30% marrow blasts", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8ef9d008-d9d3-52ac-bb0f-b28f0bcc3a27", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0004808", "object_location_in_text": [383, 406], "original_object": "acute myeloid leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-accord", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: - intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), - chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder, - acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, - AML with &gt;30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "AML with >30% marrow blasts according to WHO classification, 30% marrow blasts according to the WHO classification", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd0e7cd4-ae45-5b13-a193-623962dff1a3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b13ed3e5-1fb9-589c-a3b9-55ffcd4288f2", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0004808", "original_object": "acute myeloid leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients aged 65 years or older not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vidaza", "https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza"]}], "subject": "RXCUI:1251", "supporting_text": ["Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:&nbsp;  intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.  Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with &gt;30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "chronic myelomonocytic leukaemia with 10 29% marrow blasts without myeloproliferative disorder", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3310991f-0595-573c-8810-e13051fd1c01", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:bb90d200-9bee-545c-9c72-62b972ea2d50", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0012325", "original_object": "chronic myelomonocytic leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-mylan", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:  intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification, AML with &gt; 30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "CMML with 10-29% marrow blasts without myeloproliferative disorder", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:442f42b7-4995-56eb-8a3c-9f160d81eaf5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:bb90d200-9bee-545c-9c72-62b972ea2d50", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0012325", "original_object": "chronic myelomonocytic leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-kabi", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-kabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-kabi"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation(HSCT) with:  Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the international prognostic scoring system (IPSS), Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification, AML with &gt; 30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "CMML with 10-29 % marrow blasts without myeloproliferative disorder", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81a90e92-db10-508b-ad26-7c0f09c7397e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:bb90d200-9bee-545c-9c72-62b972ea2d50", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0012325", "original_object": "chronic myelomonocytic leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vidaza", "https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza"]}], "subject": "RXCUI:1251", "supporting_text": ["Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:&nbsp;  intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.  Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with &gt;30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "CMML with 10-29 % marrow blasts without myeloproliferative disorder", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f9f7c318-6f57-5326-a309-ec99b58040c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:bb90d200-9bee-545c-9c72-62b972ea2d50", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "HP:0012325", "original_object": "chronic myelomonocytic leukaemia", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-accord", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: - intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), - chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder, - acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, - AML with &gt;30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "intermediate 2 and high-risk MDS according to the International Prognostic Scoring System (IPSS)", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:24777225-b201-5de3-ac53-1166844d0cd1", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ec8cded8-1479-5266-9e4e-d2e08bafb8df", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "MONDO:0018881", "original_object": "myelodysplastic syndromes", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:vidaza", "https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/vidaza"]}], "subject": "RXCUI:1251", "supporting_text": ["Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:&nbsp;  intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.  Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with &gt;30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "intermediate 2 and high risk myelodysplastic syndromes", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:25023d1f-2a39-55db-bd95-e9bd144c2315", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ec8cded8-1479-5266-9e4e-d2e08bafb8df", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "MONDO:0018881", "original_object": "myelodysplastic syndromes", "original_subject": "azacitidine", "population_context_qualifier": "adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-mylan", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-mylan-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:  intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification, AML with &gt; 30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "Intermediate-2 and high-risk MDS", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:983a838f-29d4-569e-bfd6-a51cf49edbe5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ec8cded8-1479-5266-9e4e-d2e08bafb8df", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "MONDO:0018881", "original_object": "myelodysplastic syndromes", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-kabi", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-kabi-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-kabi"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Kabi is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation(HSCT) with:  Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the international prognostic scoring system (IPSS), Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification, AML with &gt; 30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "intermediate-2 and high-risk MDS according to IPSS", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a9562c02-f804-5137-8b7f-8f9deac943c9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20081217", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ec8cded8-1479-5266-9e4e-d2e08bafb8df", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:721fc1ff-69be-5191-9a2b-44c7b5e985e0", "object": "MONDO:0018881", "original_object": "myelodysplastic syndromes", "original_subject": "azacitidine", "population_context_qualifier": "adult patients not eligible for haematopoietic stem cell transplantation (HSCT)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:azacitidine-accord", "https://www.ema.europa.eu/en/documents/product-information/azacitidine-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord"]}], "subject": "RXCUI:1251", "supporting_text": ["Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: - intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), - chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder, - acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, - AML with &gt;30% marrow blasts according to the WHO classification."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of aspiration", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:273448b3-b1e0-5ba5-8a29-2f398589c447", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6279717c-9c81-5362-998b-82b11e2b78e6", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6b97736-d47f-5c5d-9752-b141c00feb70", "object": "HP:0002835", "original_object": "aspiration", "original_subject": "BARIUM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c"]}], "subject": "RXCUI:1311067", "supporting_text": ["4 CONTRAINDICATIONS READI-CAT 2 products are contraindicated in patients: with known or suspected perforation of the GI tract with known obstruction of the GI tract at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES Known or suspected perforation of the GI tract ( 4 ) Known obstruction of the GI tract ( 4 ) Conditions associated with high risk of GI perforation or aspiration ( 4 ) Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of GI perforation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a58a79e-9719-5a59-87d4-d7394af3170b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f1161ff5-793a-5648-a939-ac7661937d2b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6b97736-d47f-5c5d-9752-b141c00feb70", "object": "MONDO:0002105", "object_location_in_text": [279, 294], "original_object": "toxic megacolon", "original_subject": "BARIUM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c"]}], "subject": "RXCUI:1311067", "supporting_text": ["4 CONTRAINDICATIONS READI-CAT 2 products are contraindicated in patients: with known or suspected perforation of the GI tract with known obstruction of the GI tract at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES Known or suspected perforation of the GI tract ( 4 ) Known obstruction of the GI tract ( 4 ) Conditions associated with high risk of GI perforation or aspiration ( 4 ) Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of GI perforation", "has_confidence_score": 0.675, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ed37d40f-f84c-58f8-82bb-1f6b0eb8bd88", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:003f417c-33b1-5883-9cc8-d2350a30c950", "medic_pair_confidence": 0.675, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6b97736-d47f-5c5d-9752-b141c00feb70", "object": "MONDO:0004567", "object_location_in_text": [296, 308], "original_object": "severe ileus", "original_subject": "BARIUM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c"]}], "subject": "RXCUI:1311067", "supporting_text": ["4 CONTRAINDICATIONS READI-CAT 2 products are contraindicated in patients: with known or suspected perforation of the GI tract with known obstruction of the GI tract at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES Known or suspected perforation of the GI tract ( 4 ) Known obstruction of the GI tract ( 4 ) Conditions associated with high risk of GI perforation or aspiration ( 4 ) Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of aspiration", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b950e70b-c3e7-5c4b-9b03-26a2faa3a7fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6cd99e56-46e2-5ddc-af6d-60eb68d8bf9c", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6b97736-d47f-5c5d-9752-b141c00feb70", "object": "MONDO:0018694", "object_location_in_text": [459, 485], "original_object": "tracheo-esophageal fistula", "original_subject": "BARIUM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c"]}], "subject": "RXCUI:1311067", "supporting_text": ["4 CONTRAINDICATIONS READI-CAT 2 products are contraindicated in patients: with known or suspected perforation of the GI tract with known obstruction of the GI tract at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES Known or suspected perforation of the GI tract ( 4 ) Known obstruction of the GI tract ( 4 ) Conditions associated with high risk of GI perforation or aspiration ( 4 ) Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of GI perforation", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c34af669-4393-5f54-bf41-93c47e1f4c2e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e6775f51-8450-557c-9194-8cc341468540", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6b97736-d47f-5c5d-9752-b141c00feb70", "object": "UMLS:C0151664", "original_object": "GI perforation", "original_subject": "BARIUM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c"]}], "subject": "RXCUI:1311067", "supporting_text": ["4 CONTRAINDICATIONS READI-CAT 2 products are contraindicated in patients: with known or suspected perforation of the GI tract with known obstruction of the GI tract at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES Known or suspected perforation of the GI tract ( 4 ) Known obstruction of the GI tract ( 4 ) Conditions associated with high risk of GI perforation or aspiration ( 4 ) Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "high risk of GI perforation", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:deffdf94-35f8-5688-8e3e-1f767d4743db", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:6236be20-3377-57a6-8a1e-474f929cbad3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e6b97736-d47f-5c5d-9752-b141c00feb70", "object": "UMLS:C0266807", "object_location_in_text": [246, 265], "original_object": "acute GI hemorrhage", "original_subject": "BARIUM", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d293d5-dcc9-0d3f-58ed-686ef0132d7c"]}], "subject": "RXCUI:1311067", "supporting_text": ["4 CONTRAINDICATIONS READI-CAT 2 products are contraindicated in patients: with known or suspected perforation of the GI tract with known obstruction of the GI tract at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES Known or suspected perforation of the GI tract ( 4 ) Known obstruction of the GI tract ( 4 ) Conditions associated with high risk of GI perforation or aspiration ( 4 ) Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "varicose veins of the lower extremities", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ff5a46d6-9083-5d8c-8e30-74c14876d2bc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c5e8a47c-f14a-52a5-b7b8-15628be218f8", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c32a7c5e-440a-51f1-be17-a3e76ca89877", "object": "HP:0002619", "object_location_in_text": [126, 140], "original_object": "varicose veins", "original_subject": "TETRADECYL HYDROGEN SULFATE (ESTER)", "population_context_qualifier": "patients with competent valves; great surgical risks", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c59db022-bda8-1732-e053-2a95a90a24f8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c59db022-bda8-1732-e053-2a95a90a24f8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c59db022-bda8-1732-e053-2a95a90a24f8"]}], "subject": "RXCUI:1370424", "supporting_text": ["INDICATIONS &amp; USAGE Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "refractoriness to retinoid and anthracycline chemotherapy", "has_confidence_score": 0.8, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3a5a9df5-0d39-5f77-a0db-e99d9df6ba3c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:006a9567-eebb-51a6-aba2-f08b5da600ac", "medic_pair_confidence": 0.8, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:6e25b6ff-7221-5997-b912-a41e5cf0c018", "object": "MONDO:0012883", "original_object": "acute promyelocytic leukemia", "original_subject": "ARSENIC CATION (3+)", "population_context_qualifier": "patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d1e2107c-26c3-40fc-978e-0ba5b84098ac", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d1e2107c-26c3-40fc-978e-0ba5b84098ac", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1e2107c-26c3-40fc-978e-0ba5b84098ac"]}], "subject": "RXCUI:1485046", "supporting_text": ["1 INDICATIONS AND USAGE Arsenic trioxide is an arsenical indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 ) 1.2 Relapsed or Refractory APL Arsenic trioxide injection is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002157", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10f44eca-610c-5b45-b62d-0bab906c21b0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002157"], "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c1a7f82-9ca4-58a0-9961-72a0f1b7b8ac", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b37b0b28-2ae2-5fcc-a1ba-7ec3205d65d1", "object": "HP:0001944", "original_object": "dehydration", "original_subject": "DIATRIZOIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:A0B58C0C-D67A-4BA6-8D84-CCDC78F24634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=A0B58C0C-D67A-4BA6-8D84-CCDC78F24634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=A0B58C0C-D67A-4BA6-8D84-CCDC78F24634"]}], "subject": "RXCUI:1546223", "supporting_text": ["CONTRAINDICATION—General HYPAQUE meglumine 60 percent has no absolute contraindications in its recommended uses (see general WARNINGS and PRECAUTIONS ). Do not use HYPAQUE meglumine 60 percent solution for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. Even a small amount in the subarachnoid space may produce convulsions and result in fatality. Epidural injection is also contraindicated. Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also PRECAUTIONS—General .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002157", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:54dc6b66-cc23-56ff-93e8-56a031bee734", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002157"], "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c1a7f82-9ca4-58a0-9961-72a0f1b7b8ac", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b37b0b28-2ae2-5fcc-a1ba-7ec3205d65d1", "object": "HP:0001944", "original_object": "dehydration", "original_subject": "DIATRIZOIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02FF6501-CCCC-4F7D-9988-856D4E169B0E", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02FF6501-CCCC-4F7D-9988-856D4E169B0E", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02FF6501-CCCC-4F7D-9988-856D4E169B0E"]}], "subject": "RXCUI:1546223", "supporting_text": ["—General HYPAQUE sodium 50 percent has no absolute contraindications in its recommended uses (see general WARNINGS and PRECAUTIONS ). Do not use HYPAQUE sodium 50 percent for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. Even a small amount in the subarachnoid space may produce convulsions and result in fatality. (See also AORTOGRAPHY, Warnings .) Epidural injection is also contraindicated. Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also PRECAUTIONS—General .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0001944", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2906ad59-2f23-581c-93b4-98ff6bdaa850", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001944"], "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b008eb06-4d70-5285-9b91-b13064630436", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b37b0b28-2ae2-5fcc-a1ba-7ec3205d65d1", "object": "HP:0002157", "original_object": "azotemia", "original_subject": "DIATRIZOIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:A0B58C0C-D67A-4BA6-8D84-CCDC78F24634", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=A0B58C0C-D67A-4BA6-8D84-CCDC78F24634", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=A0B58C0C-D67A-4BA6-8D84-CCDC78F24634"]}], "subject": "RXCUI:1546223", "supporting_text": ["CONTRAINDICATION—General HYPAQUE meglumine 60 percent has no absolute contraindications in its recommended uses (see general WARNINGS and PRECAUTIONS ). Do not use HYPAQUE meglumine 60 percent solution for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. Even a small amount in the subarachnoid space may produce convulsions and result in fatality. Epidural injection is also contraindicated. Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also PRECAUTIONS—General .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0001944", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:83f10d72-49ef-5fc8-ba35-65e28955e35b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0001944"], "medic_is_diagnostic_agent": true, "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:b008eb06-4d70-5285-9b91-b13064630436", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:b37b0b28-2ae2-5fcc-a1ba-7ec3205d65d1", "object": "HP:0002157", "original_object": "azotemia", "original_subject": "DIATRIZOIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02FF6501-CCCC-4F7D-9988-856D4E169B0E", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02FF6501-CCCC-4F7D-9988-856D4E169B0E", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02FF6501-CCCC-4F7D-9988-856D4E169B0E"]}], "subject": "RXCUI:1546223", "supporting_text": ["—General HYPAQUE sodium 50 percent has no absolute contraindications in its recommended uses (see general WARNINGS and PRECAUTIONS ). Do not use HYPAQUE sodium 50 percent for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. Even a small amount in the subarachnoid space may produce convulsions and result in fatality. (See also AORTOGRAPHY, Warnings .) Epidural injection is also contraindicated. Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also PRECAUTIONS—General .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "repeated blood transfusions", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ca4464e-a4f3-50ce-9768-8c4682040051", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c5b2f325-ae94-5f80-82e4-10dc31cee587", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "UMLS:C0282193", "original_object": "Iron overload", "original_subject": "FERRIC CATION", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:367ac157-2d25-4f34-99ce-b126e0f03851", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=367ac157-2d25-4f34-99ce-b126e0f03851", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=367ac157-2d25-4f34-99ce-b126e0f03851"]}], "subject": "RXCUI:1546357", "supporting_text": ["4 CONTRAINDICATIONS ACCRUFER is contraindicated in patients with a history of: Hypersensitivity to the active substance or to any of the excipients [see Description ( 11 )] . Reactions could include shock, clinically significant hypotension, loss of consciousness, and/or collapse. Hemochromatosis and other iron overload syndromes [see Warnings and Precautions ( 5.1 )] . Use may result in iron overdose [see Overdosage ( 10 )]. Receiving repeated blood transfusions. Use may result in iron overload [see Warnings and Precautions ( 5.2 ) and Overdosage ( 10 )]. Hypersensitivity to the active substance or any excipient ( 4 ) Hemochromatosis and other iron overload syndromes ( 4 ) Patients receiving repeated blood transfusions ( 4 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-dialysis dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:12c60b11-cf41-5dd4-8dcb-b00993eed459", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b8a7e39-d7f6-5422-8b7d-ba770505f2f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "MONDO:0001356", "original_object": "iron deficiency anemia", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bfdf7447-62e4-48ca-b903-11cb3b211064", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bfdf7447-62e4-48ca-b903-11cb3b211064", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfdf7447-62e4-48ca-b903-11cb3b211064"]}], "subject": "RXCUI:1546357", "supporting_text": ["1 INDICATIONS AND USAGE Ferric carboxymaltose injection is indicated for the treatment of: • Iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • Iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Ferric carboxymaltose injection is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-dialysis dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:81b53477-6a22-5152-ad10-2d767a568fcc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b8a7e39-d7f6-5422-8b7d-ba770505f2f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "MONDO:0001356", "original_object": "iron deficiency anemia", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8e8e95f4-8d3a-4658-9f6c-09edf2210341", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8e8e95f4-8d3a-4658-9f6c-09edf2210341", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e8e95f4-8d3a-4658-9f6c-09edf2210341"]}], "subject": "RXCUI:1546357", "supporting_text": ["1 INDICATIONS AND USAGE Ferric carboxymaltose injection is indicated for the treatment of: • iron deficiency anemia (IDA) in: o adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. o adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Ferric carboxymaltose injection is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: o adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) o adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-dialysis dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8a2b92d5-96bd-552c-b1f4-4760ff6767b9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b8a7e39-d7f6-5422-8b7d-ba770505f2f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "MONDO:0001356", "original_object": "iron deficiency anemia", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:7f05ab1e-aed4-4f87-b939-2dc9719aa34c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=7f05ab1e-aed4-4f87-b939-2dc9719aa34c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f05ab1e-aed4-4f87-b939-2dc9719aa34c"]}], "subject": "RXCUI:1546357", "supporting_text": ["1 INDICATIONS AND USAGE Ferric carboxymaltose injection is indicated for the treatment of: • iron deficiency anemia (IDA) in: o adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. o adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Ferric carboxymaltose injection is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: o adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) o adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-dialysis dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cefb1842-821d-5c43-9532-77662fa84e69", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b8a7e39-d7f6-5422-8b7d-ba770505f2f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "MONDO:0001356", "original_object": "iron deficiency anemia", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult patients who have non-dialysis dependent chronic kidney disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:517b4a19-45b3-4286-9f6a-ced4e10447de", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de"]}], "subject": "RXCUI:1546357", "supporting_text": ["1 INDICATIONS AND USAGE Injectafer is indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Injectafer is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-dialysis dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f37cfdc4-8138-5d84-9a7b-55ebfde6acb8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:7b8a7e39-d7f6-5422-8b7d-ba770505f2f9", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "MONDO:0001356", "original_object": "iron deficiency anemia", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d6a5cd2d-86bd-4042-974f-46e14d65fc2d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d6a5cd2d-86bd-4042-974f-46e14d65fc2d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6a5cd2d-86bd-4042-974f-46e14d65fc2d"]}], "subject": "RXCUI:1546357", "supporting_text": ["1 INDICATIONS AND USAGE Ferric carboxymaltose injection is indicated for the treatment of: • iron deficiency anemia (IDA) in: o adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. o adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Ferric carboxymaltose injection is an iron replacement product indicated for the treatment of: • iron deficiency anemia (IDA) in: o adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. ( 1 ) o adult patients who have non-dialysis dependent chronic kidney disease. ( 1 ) • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "hemodialysis-dependent chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c0157413-ae41-56b4-a0cb-55928b7d1ea5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "MONDO:0002280", "original_object": "anemia", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:51197a48-6078-42cd-b5ed-5ea22b6757b4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=51197a48-6078-42cd-b5ed-5ea22b6757b4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=51197a48-6078-42cd-b5ed-5ea22b6757b4"]}], "subject": "RXCUI:1546357", "supporting_text": ["1. INDICATIONS AND USAGE Triferic AVNU is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "intolerance to oral iron, unsatisfactory response to oral iron", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:50ed40dc-c85a-5642-8c68-d60fe68db4e4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f578a688-06ef-589f-b1ff-a688b2e823c5", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:876327ca-5e41-5bb5-8515-91f0dfe0057f", "object": "UMLS:C0240066", "object_location_in_text": [131, 146], "original_object": "iron deficiency", "original_subject": "FERRIC CATION", "population_context_qualifier": "adult and pediatric patients of age 4 months and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:99bf34be-cb8a-46d1-9637-5544dc2da287", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=99bf34be-cb8a-46d1-9637-5544dc2da287", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99bf34be-cb8a-46d1-9637-5544dc2da287"]}], "subject": "RXCUI:1546357", "supporting_text": ["1 INDICATIONS AND USAGE INFeD is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron. INFeD, an iron replacement product, is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or an unsatisfactory response to oral iron. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:830c3ccc-a183-5e6f-a8b5-88c268af43b8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e19f6e1c-71c4-56d3-9f50-8eb962e755db", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f38efbbb-7857-5c68-ae81-5be768eff722", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:693266fb-3f10-58a2-8df6-6d63df44f330", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0000737", "object_location_in_text": [132, 144], "original_object": "irritability", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0b90fcb4-0fd3-5256-bef8-bc8e1bcd5c9a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cd22974-3324-52a6-a78f-1a86e2713048", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7f1197de-029b-5201-bce4-e56179fdd455", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:42a5c6fc-a4af-5716-b87c-498585c35edb", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0002315", "object_location_in_text": [83, 91], "original_object": "headache", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0d3055bd-ec18-574e-ad40-4ec840574769", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d4eb0e55-0e15-5378-ab58-9c3d7dc48ee9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f5bd8db3-d45d-5ec1-bc33-0da948d11d85", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ea56e9f9-d133-5562-9d2b-6cbf3cf6f86a", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "HP:0003270", "object_location_in_text": [92, 100], "original_object": "bloating", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fa043a9-0167-5d31-bcda-ca22cff90be0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c848560-d066-5284-a645-25f1234627e0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2f8e2cd0-104b-57b9-ac4f-e4996033d9d7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a04ec5c0-2f9a-50da-be76-1e8ecdf25717", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "UMLS:C0004604", "object_location_in_text": [108, 116], "original_object": "backache", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cd7f9a9-46a8-558f-a3ae-74a7365b7389", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a945066-7714-45c0-9225-a921879f6a45"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:671e09d1-7fd0-5615-a083-ebc8684022fe", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92bb5cf5-5861-4f5e-91f7-9a546563c18e"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0025344", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dabf160c-868d-54ae-b05a-1958c321a762", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0025344"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d0d6516b-fd66-5ab1-a42d-5e444e714634", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 3, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2406c1e6-ba91-5d57-b52d-705edf45408a", "object": "UMLS:C0026821", "object_location_in_text": [101, 107], "original_object": "cramps", "original_subject": "BROMOTHEOPHYLLINE", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8df6e174-8ee3-46cc-98ef-2b9a801b7b78"]}], "subject": "RXCUI:1546386", "supporting_text": ["Uses for the temporary relief of these symptoms associated with menstrual periods: headache bloating cramps backache muscular aches irritability water-weight gain"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "curare overdosage", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:78b46c23-46a1-5ece-95c9-a852595a31b6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a9fb4ecc-e9ef-5ab3-b488-6af821a230f3", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:f6450f97-fd43-5383-91b0-01335a47cfa4", "object": "UMLS:C0235063", "object_location_in_text": [656, 678], "original_object": "respiratory depression", "original_subject": "EDROPHONIUM CATION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:312042cf-df60-4dc5-90dd-4e77ebd4a781", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=312042cf-df60-4dc5-90dd-4e77ebd4a781", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=312042cf-df60-4dc5-90dd-4e77ebd4a781"]}], "subject": "RXCUI:1546421", "supporting_text": ["INDICATIONS ENLON is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "known or suspected focal liver disease", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:550785c4-cf00-58d5-a415-ae8994980a32", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8c80d795-c59f-5ffa-84da-584cef744688", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:1589ecaa-e07e-5264-ae24-821b903176ac", "object": "UMLS:C0577053", "original_object": "liver lesions", "original_subject": "GADOLINIUM CATION (3+)", "population_context_qualifier": "adult and pediatric patients, including term neonates", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6218b1e1-cbc3-4c14-bec7-528ac163a561", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6218b1e1-cbc3-4c14-bec7-528ac163a561", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6218b1e1-cbc3-4c14-bec7-528ac163a561"]}], "subject": "RXCUI:1546429", "supporting_text": ["1 INDICATIONS AND USAGE EOVIST is indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. EOVIST is a gadolinium-based contrast agent indicated for use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adult and pediatric patients, including term neonates, with known or suspected focal liver disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:18313acf-d7b6-5f18-aa0e-f8b79acc928b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:91556a42-5e16-4f86-bae9-a8cdd6b182a6", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=91556a42-5e16-4f86-bae9-a8cdd6b182a6", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91556a42-5e16-4f86-bae9-a8cdd6b182a6"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE Lanthanum carbonate chewable tablet is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. Lanthanum carbonate chewable tablet is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1d7c77fa-d5e7-556f-a1ff-96069ab695da", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:22b07167-2b7b-42ba-9ae9-cf58c98a2ab2", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=22b07167-2b7b-42ba-9ae9-cf58c98a2ab2", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22b07167-2b7b-42ba-9ae9-cf58c98a2ab2"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE Lanthanum carbonate is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. Lanthanum carbonate is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c9b67b74-f196-54a7-b1c3-6e0da4f74d10", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f10776b2-2c25-4343-aabe-68f302e5cb54", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f10776b2-2c25-4343-aabe-68f302e5cb54", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f10776b2-2c25-4343-aabe-68f302e5cb54"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE FOSRENOL ® is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. FOSRENOL is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb519495-d3ad-5858-87f0-e10c692d643a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 4, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb263fe8-2bdf-4dba-807f-194f54a73654", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb263fe8-2bdf-4dba-807f-194f54a73654", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb263fe8-2bdf-4dba-807f-194f54a73654"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5fc84fe7-c719-5de5-99ed-597bb15739fc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4b88992-ecb0-455b-b68c-5c4e6d3cf521", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4b88992-ecb0-455b-b68c-5c4e6d3cf521", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4b88992-ecb0-455b-b68c-5c4e6d3cf521"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE Lanthanum carbonate chewable tablets are a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. Lanthanum carbonate chewable tablets are a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c60eec68-018c-5ea5-b8c2-764944a367f2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:16b0e6f5-4fc9-448c-994a-cb9dd8b03654", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=16b0e6f5-4fc9-448c-994a-cb9dd8b03654", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16b0e6f5-4fc9-448c-994a-cb9dd8b03654"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0003774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d84d115e-8bb8-5e6c-8a59-741568e2d319", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0003774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:859b2a5c-e6a4-5f3f-9fe6-47ea5ecde356", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 3, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:c605ca2e-4bf6-5351-8d25-19b98e76f4cf", "object": "MONDO:0000328", "original_object": "hyperphosphatemia", "original_subject": "LANTHANUM CATION (3+)", "population_context_qualifier": "patients with end-stage renal disease (ESRD)", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1d5ff930-1189-4e96-bdfb-9fd9c2c83d1b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1d5ff930-1189-4e96-bdfb-9fd9c2c83d1b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d5ff930-1189-4e96-bdfb-9fd9c2c83d1b"]}], "subject": "RXCUI:1546443", "supporting_text": ["1 INDICATIONS AND USAGE Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. Lanthanum carbonate chewable tablets are phosphate binder indicated to reduce serum phosphate in patients with end- stage renal disease (ESRD). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:140a6383-ec1a-5fb2-a1fb-51fc340f89f1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:7151a221-289d-598c-9d50-d133bade4b0a", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "THREONIC ACID, DL-", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "RXCUI:1547557", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "stage 3 or 4 chronic kidney disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b525970f-d5d6-5d3e-a2ba-6d031ed92202", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:13dc9a4f-4722-5b44-8c4e-1cfc1f71375d", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4c897bd6-e7fc-5b0f-a6e6-60bc8d998f11", "object": "MONDO:0006964", "object_location_in_text": [88, 117], "original_object": "secondary hyperparathyroidism", "original_subject": "CALCIFEDIOL", "population_context_qualifier": "adult patients with serum total 25-hydroxyvitamin D levels less than 30 ng/mL", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6a95effd-32a5-46b6-a30e-7f4f9bf8cc77", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6a95effd-32a5-46b6-a30e-7f4f9bf8cc77", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a95effd-32a5-46b6-a30e-7f4f9bf8cc77"]}], "subject": "RXCUI:1889", "supporting_text": ["1 INDICATIONS AND USAGE RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:253b49bc-3afe-534b-a2fd-b5c15f331bc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180926", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["endocrine therapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:92326e38-e180-5638-86cd-9cedbcd66cae", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8c1ba5c3-a9a1-5ba2-9f74-abfd83a6c714", "object": "MONDO:0007254", "object_location_in_text": [235, 254], "original_object": "early breast cancer", "original_subject": "abemaciclib", "population_context_qualifier": "adult patients at high risk of recurrence", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:verzenios", "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"]}], "subject": "RXCUI:1946825", "supporting_text": ["Early Breast Cancer Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1). In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Advanced or Metastatic Breast Cancer Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:253b49bc-3afe-534b-a2fd-b5c15f331bc6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20180926", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["endocrine therapy"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:ce8ef48a-ab9d-56c2-80a6-2262598e82b1", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:8c1ba5c3-a9a1-5ba2-9f74-abfd83a6c714", "object": "MONDO:0007254", "original_object": "advanced or metastatic breast cancer", "original_subject": "abemaciclib", "population_context_qualifier": "women who have received prior endocrine therapy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sex_qualifier": "PATO:0000383", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:verzenios", "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"]}], "subject": "RXCUI:1946825", "supporting_text": ["Early Breast Cancer Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1). In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Advanced or Metastatic Breast Cancer Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "inadequate blood phenylalanine control", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8876f6cf-fe54-5ea1-844b-957af467fdd0", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20190503", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:4ab94df1-bd0b-5fbe-bdb0-8e6448d892ce", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:92e4f2d6-015e-5b5a-8f8c-4331b4f42888", "object": "MONDO:0009861", "original_object": "phenylketonuria", "original_subject": "pegvaliase", "population_context_qualifier": "aged 16 years and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:palynziq", "https://www.ema.europa.eu/en/documents/product-information/palynziq-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/palynziq"]}], "subject": "RXCUI:2046360", "supporting_text": ["Palynziq is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening arrhythmias", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0c07e4dd-865a-5519-aaa7-96af030ab1a0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee741192-fc29-5ed3-87c6-3f2ecd36c6e9", "object": "HP:0004308", "object_location_in_text": [106, 129], "original_object": "ventricular arrhythmias", "original_subject": "BISULFITE ION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9508d1a2-da9a-5480-e053-2a95a90a73c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9508d1a2-da9a-5480-e053-2a95a90a73c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9508d1a2-da9a-5480-e053-2a95a90a73c7"]}], "subject": "RXCUI:2058420", "supporting_text": ["INDICATIONS &amp; USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and BOXED WARNING .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "life-threatening arrhythmias", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a60bbbe7-1160-553b-8b3a-6c4520ece078", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:475c2851-4fd3-550e-880f-9496def36031", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 2, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee741192-fc29-5ed3-87c6-3f2ecd36c6e9", "object": "HP:0004308", "object_location_in_text": [106, 129], "original_object": "ventricular arrhythmias", "original_subject": "BISULFITE ION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:8192d79d-da2b-2532-e053-2991aa0ae8ad", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=8192d79d-da2b-2532-e053-2991aa0ae8ad", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8192d79d-da2b-2532-e053-2991aa0ae8ad"]}], "subject": "RXCUI:2058420", "supporting_text": ["INDICATIONS &amp; USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and BOXED WARNING .)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0007684", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:51eb9411-64a6-5cda-acab-114f5d16f2df", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0007684"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:8b3c9845-f19d-5322-9ef1-4a7f8272f0e5", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ee741192-fc29-5ed3-87c6-3f2ecd36c6e9", "medic_supporting_text_truncated": true, "object": "MONDO:0006670", "original_object": "bacterial meningitis", "original_subject": "BISULFITE ION", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c1ff0cdc-ac5d-30ca-e053-2a95a90a5066", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c1ff0cdc-ac5d-30ca-e053-2a95a90a5066", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c1ff0cdc-ac5d-30ca-e053-2a95a90a5066"]}], "subject": "RXCUI:2058420", "supporting_text": ["To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the impo"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "painful skeletal metastases", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:57a2ac0a-6ff2-5876-adb4-0e005b426b5e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3b4fe075-e70f-53a8-a298-a37876f20817", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d32975b2-4214-575e-98fd-4b981913fcc5", "object": "HP:0002653", "object_location_in_text": [71, 80], "original_object": "bone pain", "original_subject": "STRONTIUM CATION SR-89", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c89bcf16-399d-48e0-a4e3-849261aaa310", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c89bcf16-399d-48e0-a4e3-849261aaa310", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c89bcf16-399d-48e0-a4e3-849261aaa310"]}], "subject": "RXCUI:2280602", "supporting_text": ["STRONTIUM CHLORIDE Sr-89 INJECTION, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "moderately to severely active ulcerative colitis", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:60219790-161c-5af2-94cb-8a3a261c7fc5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20200520", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:b06c7f6f-0273-5580-aa24-cc6b1c80adf9", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:797f7591-778b-5599-b392-7570d49b6b84", "object": "MONDO:0005101", "original_object": "ulcerative colitis", "original_subject": "ozanimod", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:zeposia", "https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia"]}], "subject": "RXCUI:2288236", "supporting_text": ["Multiple sclerosis  Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.  Ulcerative colitis  Zeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:282a51cf-98d5-5b32-98ba-150b69906a5a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20230726", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:73a49f97-04a4-51c1-83ad-2263e5cb6f16", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:47de3ee2-1e2c-53b0-89b6-f5e03d6b691a", "object": "MONDO:0005027", "object_location_in_text": [52, 70], "original_object": "epileptic seizures", "original_subject": "ganaxolone", "population_context_qualifier": "patients 2 to 17 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:ztalmy", "https://www.ema.europa.eu/en/documents/product-information/ztalmy-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/ztalmy"]}], "subject": "RXCUI:2604689", "supporting_text": ["Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3274012", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5b332055-7411-525e-8657-a09277daefc3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240105", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3274012"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:1714358f-f7ba-5d82-a059-2d4f4f999d48", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:4dff9946-7d79-5042-be53-5f720977fce9", "object": "MONDO:0005233", "object_location_in_text": [77, 112], "original_object": "advanced non-small cell lung cancer", "original_subject": "adagrasib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:krazati", "https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/krazati"]}], "subject": "RXCUI:2625882", "supporting_text": ["Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy."], "temporal_context_qualifier": "disease progression after at least one prior systemic therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "lamivudine-refractory hepatitis B", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15d20947-b632-5276-b295-1c31c3a79787", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060626", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "original_object": "chronic hepatitis B virus infection", "original_subject": "entecavir", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:entecavir-viatris", "https://www.ema.europa.eu/en/documents/product-information/entecavir-viatris-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/entecavir-viatris"]}], "subject": "RXCUI:306266", "supporting_text": ["Entecavir Viatris is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:  compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. decompensated liver disease.  For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Viatris is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to &lt;18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "UMLS:C3839044", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:787520b2-aef6-5d19-943f-1ec675287092", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060626", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C3839044"], "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "original_object": "chronic hepatitis B virus infection", "original_subject": "entecavir", "population_context_qualifier": "nucleoside naive paediatric patients from 2 to <18 years of age with evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:entecavir-accord", "https://www.ema.europa.eu/en/documents/product-information/entecavir-accord-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/entecavir-accord"]}], "subject": "RXCUI:306266", "supporting_text": ["Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:  compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. decompensated liver disease.  For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B. Entecavir Accord is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to &lt;18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fe2cd4b-0149-53da-afcc-93d0294de43c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [68, 103], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d69451df-e204-4a5c-a2bb-9e6d4d519302", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d69451df-e204-4a5c-a2bb-9e6d4d519302", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d69451df-e204-4a5c-a2bb-9e6d4d519302"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:35d187d4-aeef-5693-a6f8-603ec433ad22", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:def332bf-2906-4a6c-b85d-dfb56bb94312", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=def332bf-2906-4a6c-b85d-dfb56bb94312", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=def332bf-2906-4a6c-b85d-dfb56bb94312"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:38e397ff-c059-5af0-9d3b-2b9c58ddbb5d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [68, 103], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:92a5bebd-6408-463d-933c-bab8338a677e", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=92a5bebd-6408-463d-933c-bab8338a677e", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92a5bebd-6408-463d-933c-bab8338a677e"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:575ce320-41f1-5ba1-8b9e-b76838b8a311", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [68, 103], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bb1bb6dc-0120-46e2-ad1e-d9afc221fa16", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bb1bb6dc-0120-46e2-ad1e-d9afc221fa16", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb1bb6dc-0120-46e2-ad1e-d9afc221fa16"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5c58ce82-2556-53ec-9447-1ffac26dff26", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [147, 182], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:da705339-c349-444f-a058-4f0cef2864bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=da705339-c349-444f-a058-4f0cef2864bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=da705339-c349-444f-a058-4f0cef2864bf"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablet is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 ) Entecavir tablet is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6b06c1c6-6aa3-57b7-a7ec-65e47523c89d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [147, 182], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d59e9ea4-09ea-47bd-af2f-39f7a2e2aceb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d59e9ea4-09ea-47bd-af2f-39f7a2e2aceb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d59e9ea4-09ea-47bd-af2f-39f7a2e2aceb"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablet is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 ) Entecavir tablet is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6c73bc8d-149a-5536-aafb-93adfe838de6", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:af4f47e2-f556-40f2-a0fd-ff81e9f27429", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=af4f47e2-f556-40f2-a0fd-ff81e9f27429", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=af4f47e2-f556-40f2-a0fd-ff81e9f27429"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7e54de25-2029-59a6-8355-11b0b472b3e3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:01ec50a1-6c6c-46f0-8c74-73542b0a59c3", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=01ec50a1-6c6c-46f0-8c74-73542b0a59c3", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01ec50a1-6c6c-46f0-8c74-73542b0a59c3"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:85e3f0f0-3331-574b-b3d9-a7ebfb2fc9a9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [140, 175], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b4fd0e22-ad23-4f51-9b98-95182f63c2eb", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b4fd0e22-ad23-4f51-9b98-95182f63c2eb", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b4fd0e22-ad23-4f51-9b98-95182f63c2eb"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 ) Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9347725d-6f5a-516b-98d5-d6b8afdf6c38", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [68, 103], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:73dea2a4-a596-477f-b66d-5a80dd019837", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=73dea2a4-a596-477f-b66d-5a80dd019837", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73dea2a4-a596-477f-b66d-5a80dd019837"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7685af5-832f-529c-b522-67134bf9469f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1a905283-0057-a7dd-e063-6394a90a1909", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1a905283-0057-a7dd-e063-6394a90a1909", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a905283-0057-a7dd-e063-6394a90a1909"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cdec87a2-3d82-5cfb-ae3f-dd835b02b940", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [82, 117], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:046e61c9-9298-4b2e-b76e-b26b81fecd20", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=046e61c9-9298-4b2e-b76e-b26b81fecd20", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=046e61c9-9298-4b2e-b76e-b26b81fecd20"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE BARACLUDE ® (entecavir) is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. BARACLUDE is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cfcdca40-304b-58b5-a9cd-3f7bcbebc96c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and pediatric patients 2 years of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:007a6ad8-4d23-4543-ae48-c651cac7dd7b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=007a6ad8-4d23-4543-ae48-c651cac7dd7b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=007a6ad8-4d23-4543-ae48-c651cac7dd7b"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir tablets are a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2e95231-9591-514c-8ce3-de0a11eabd76", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 5, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a0d2e00d-21f0-4449-93b7-a19fa284d51d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a0d2e00d-21f0-4449-93b7-a19fa284d51d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0d2e00d-21f0-4449-93b7-a19fa284d51d"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0042774", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f7d04031-38f7-542d-9d42-093dec416e30", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20050329", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0042774"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4144c77-140a-5e69-92a5-b578cded3a20", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 7, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d34410b8-9411-5984-a4c0-b3a50f738847", "object": "MONDO:0005366", "object_location_in_text": [77, 112], "original_object": "chronic hepatitis B virus infection", "original_subject": "ENTECAVIR", "population_context_qualifier": "adults and children at least 2 years of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:20d62f1a-2e48-69dd-e063-6294a90ace31", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=20d62f1a-2e48-69dd-e063-6294a90ace31", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=20d62f1a-2e48-69dd-e063-6294a90ace31"]}], "subject": "RXCUI:306266", "supporting_text": ["1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior therapy including imatinib", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f4d87f4-73e1-51da-a505-42ebbc153d3b", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20240726", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "EU", "medic_object_mention_id": "MEDICNE:6c334119-86bd-544f-bc46-ee2782ed4518", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "EMA", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "HP:0005506", "original_object": "chronic myelogenous leukaemia", "original_subject": "dasatinib", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:ema", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:ema", "resource_id": "infores:ema", "resource_role": "primary_knowledge_source", "source_record_urls": ["EMA:dasatinib-accord-healthcare", "https://www.ema.europa.eu/en/documents/product-information/dasatinib-accord-healthcare-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accord-healthcare"]}], "subject": "RXCUI:475342", "supporting_text": ["Dasatinib Accord Healthcare is indicated for the treatment of adult patients with:  newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.  &nbsp;Dasatinib Accord Healthcare is indicated for the treatment of paediatric patients with:  newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. newly diagnosed Ph+ ALL in combination with chemotherapy."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0bd7dab4-62a9-5cd2-8809-09157abb33aa", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9b79d54-9bee-4c93-9c87-f3e65d91f146", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9b79d54-9bee-4c93-9c87-f3e65d91f146", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9b79d54-9bee-4c93-9c87-f3e65d91f146"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablet is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. Additional pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Dasatinib tablet is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15dfdeed-a51e-572d-b17d-f5c4cd83798a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb5ddff2-6521-b461-43ac-80ff8660b20b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb5ddff2-6521-b461-43ac-80ff8660b20b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb5ddff2-6521-b461-43ac-80ff8660b20b"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) • pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1c33ca18-8146-51f9-916b-6028150158e9", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older, newly diagnosed", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58ce42c6-10bd-4bb4-bf89-eae8ed82c339", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58ce42c6-10bd-4bb4-bf89-eae8ed82c339", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58ce42c6-10bd-4bb4-bf89-eae8ed82c339"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4f3a6026-f63f-5196-b826-f3fd701219fe", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11703145-29ea-480a-9810-bc70663b783f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11703145-29ea-480a-9810-bc70663b783f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11703145-29ea-480a-9810-bc70663b783f"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. Chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Pediatric use information is approved for Bristol-Myers Squibb Company's Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company's marketing exclusivity rights, this drug product is not labeled with that pediatric information. Dasatinib tablet is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 )"], "temporal_context_qualifier": "with resistance or intolerance to prior therapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5167f361-8cc3-5fa9-804d-5b58f79d9d2d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3000fd91-1b09-4d72-8522-1ca5e35ed956", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3000fd91-1b09-4d72-8522-1ca5e35ed956", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3000fd91-1b09-4d72-8522-1ca5e35ed956"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7adba754-cc7e-564c-ace6-179a84628d70", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43e078b9-4e0b-edeb-e063-6294a90a7586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43e078b9-4e0b-edeb-e063-6294a90a7586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43e078b9-4e0b-edeb-e063-6294a90a7586"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9dfe69c5-d7e1-53bb-b344-0aa4505965fb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e7f054c-7a27-4192-bd1c-6115d8be858f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE SPRYCEL ® (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates [see Clinical Studies (14.1) ] . The trial is ongoing and further data will be required to determine long-term outcome. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The trial is ongoing and further data will be required to determine long-term outcome. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a08386b3-6026-560c-814e-23c8bec2a8dd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a5ffa9a3-0913-5e45-a31d-7ecf6ea38232", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older with newly diagnosed disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1931e73f-918c-4d69-9543-de9643513d05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1931e73f-918c-4d69-9543-de9643513d05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1931e73f-918c-4d69-9543-de9643513d05"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1 , 14) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. (1 , 14)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a740aaf2-a94c-51a7-8730-7b2e80507cfd", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f60261dd-b8ea-4511-bed6-ad6d7f4dd828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f60261dd-b8ea-4511-bed6-ad6d7f4dd828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f60261dd-b8ea-4511-bed6-ad6d7f4dd828"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. Newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7f5f2bb-d698-503a-8e3b-542a6eb73b09", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76e1833c-e105-5a3d-0f01-1330d8cc7ae1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76e1833c-e105-5a3d-0f01-1330d8cc7ae1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76e1833c-e105-5a3d-0f01-1330d8cc7ae1"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b07d8f40-c6aa-58d1-87d9-7077fc3872ca", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bffb38c3-f556-492f-a9db-aa417ec0a856", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bffb38c3-f556-492f-a9db-aa417ec0a856", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bffb38c3-f556-492f-a9db-aa417ec0a856"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ca023ef3-a4a2-5efa-bf57-9f642d27fa7e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 8, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ed87763-f018-abdb-c0ab-daa5e441b397", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ed87763-f018-abdb-c0ab-daa5e441b397", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ed87763-f018-abdb-c0ab-daa5e441b397"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:de3b3028-51c7-532a-8673-9ea9c4826b4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["chemotherapy"], "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:88912ed9-4f68-58f2-bbfb-4caee1a17353", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0004967", "original_object": "acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older with newly diagnosed", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6179e6d0-7db8-51c4-7eef-389042849b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6179e6d0-7db8-51c4-7eef-389042849b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6179e6d0-7db8-51c4-7eef-389042849b85"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:075cbef7-4516-5036-9077-8f0000a653f3", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:bffb38c3-f556-492f-a9db-aa417ec0a856", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=bffb38c3-f556-492f-a9db-aa417ec0a856", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bffb38c3-f556-492f-a9db-aa417ec0a856"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3779e581-c5d1-554a-b64d-85cca62fd9d5", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:0e7f054c-7a27-4192-bd1c-6115d8be858f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0e7f054c-7a27-4192-bd1c-6115d8be858f"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE SPRYCEL ® (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates [see Clinical Studies (14.1) ] . The trial is ongoing and further data will be required to determine long-term outcome. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The trial is ongoing and further data will be required to determine long-term outcome. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4655ed4a-7625-5b74-8f20-4037f8ec7f1a", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f60261dd-b8ea-4511-bed6-ad6d7f4dd828", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f60261dd-b8ea-4511-bed6-ad6d7f4dd828", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f60261dd-b8ea-4511-bed6-ad6d7f4dd828"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. Newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6ca70dda-c2f8-52e5-8eb7-9320edb58cda", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6179e6d0-7db8-51c4-7eef-389042849b85", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6179e6d0-7db8-51c4-7eef-389042849b85", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6179e6d0-7db8-51c4-7eef-389042849b85"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:86b788b0-56e6-56e4-8614-804ce9e10894", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3000fd91-1b09-4d72-8522-1ca5e35ed956", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3000fd91-1b09-4d72-8522-1ca5e35ed956", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3000fd91-1b09-4d72-8522-1ca5e35ed956"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:9295e3e7-cfb3-5b3e-9a43-bd389f912338", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2ed87763-f018-abdb-c0ab-daa5e441b397", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2ed87763-f018-abdb-c0ab-daa5e441b397", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2ed87763-f018-abdb-c0ab-daa5e441b397"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a371a5ed-7ac3-529f-a959-f03d7e6583ec", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a7e2bc85-ddbc-5343-81e5-b72989eeba4c", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1931e73f-918c-4d69-9543-de9643513d05", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1931e73f-918c-4d69-9543-de9643513d05", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1931e73f-918c-4d69-9543-de9643513d05"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1 , 14) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. (1 , 14)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ac4bc6bf-d99a-53b7-af39-b34a8af73fea", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f9b79d54-9bee-4c93-9c87-f3e65d91f146", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f9b79d54-9bee-4c93-9c87-f3e65d91f146", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f9b79d54-9bee-4c93-9c87-f3e65d91f146"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablet is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. Additional pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Dasatinib tablet is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 )"], "temporal_context_qualifier": "chronic phase"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bb267d95-d415-588d-b158-050fdc1fce0f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:43e078b9-4e0b-edeb-e063-6294a90a7586", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=43e078b9-4e0b-edeb-e063-6294a90a7586", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=43e078b9-4e0b-edeb-e063-6294a90a7586"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cd25ff92-018b-5ec0-8e23-79d4d2ed87eb", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:11703145-29ea-480a-9810-bc70663b783f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=11703145-29ea-480a-9810-bc70663b783f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=11703145-29ea-480a-9810-bc70663b783f"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. Chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Pediatric use information is approved for Bristol-Myers Squibb Company's Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company's marketing exclusivity rights, this drug product is not labeled with that pediatric information. Dasatinib tablet is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 )"], "temporal_context_qualifier": "chronic, accelerated or myeloid or lymphoid blast phase with resistance or intolerance to prior therapy including imatinib"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d20284a0-6b4b-558a-8fae-ca97f04aef4e", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:76e1833c-e105-5a3d-0f01-1330d8cc7ae1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=76e1833c-e105-5a3d-0f01-1330d8cc7ae1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=76e1833c-e105-5a3d-0f01-1330d8cc7ae1"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfa6e625-a8fc-5d05-b1a9-98254196afbf", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:eb5ddff2-6521-b461-43ac-80ff8660b20b", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=eb5ddff2-6521-b461-43ac-80ff8660b20b", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb5ddff2-6521-b461-43ac-80ff8660b20b"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) • pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. ( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0856536", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ec3b827f-5cc8-521b-bcf8-0da0a5a2923f", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0856536"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:5cc1fd8c-7c9c-50eb-aaef-287f9d77d610", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 11, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "MONDO:0011996", "original_object": "chronic myeloid leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "pediatric patients 1 year of age and older", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:58ce42c6-10bd-4bb4-bf89-eae8ed82c339", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=58ce42c6-10bd-4bb4-bf89-eae8ed82c339", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58ce42c6-10bd-4bb4-bf89-eae8ed82c339"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. ( 1 , 14 ) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. ( 1 , 14 ) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. ( 1 , 14 ) pediatric patients 1 year of age and older with Ph+ CML in chronic phase. ( 1 , 14 ) pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.( 1 , 14 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:318fd81c-5287-53fe-a47d-7a2cdf76ce68", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4eaeeee-e7d7-543e-afcf-a88ad0300715", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "UMLS:C1709527", "original_object": "Philadelphia chromosome-positive acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:645fcf26-1b2f-40c5-881b-8effe02defbd", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=645fcf26-1b2f-40c5-881b-8effe02defbd", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=645fcf26-1b2f-40c5-881b-8effe02defbd"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablet is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. Additional pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Dasatinib tablet is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1, 14) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1, 14) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1, 14)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "resistance or intolerance to prior therapy", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8d5cf6b8-23b3-5bbb-af90-a55dd24232ef", "knowledge_level": "knowledge_assertion", "medic_approval_date": "20060628", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:c4eaeeee-e7d7-543e-afcf-a88ad0300715", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 2, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:0da69128-7b42-587c-ada8-064f7d051938", "object": "UMLS:C1709527", "original_object": "Philadelphia chromosome-positive acute lymphoblastic leukemia", "original_subject": "DASATINIB", "population_context_qualifier": "adult patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:de3215a4-d098-4bc3-ad81-c7c9e3493872", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=de3215a4-d098-4bc3-ad81-c7c9e3493872", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de3215a4-d098-4bc3-ad81-c7c9e3493872"]}], "subject": "RXCUI:475342", "supporting_text": ["1 INDICATIONS AND USAGE Dasatinib tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablet is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. Additional pediatric use information is approved for Bristol-Myers Squibb Company’s Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Dasatinib tablet is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1, 14) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1, 14) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1, 14)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "suspected coronary artery disease", "has_confidence_score": 0.855, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1cb60fa0-24c5-5a23-bfc9-3f6674daa75f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4cfaa74d-5dd9-5b3f-bdc8-a0c721b72b28", "medic_pair_confidence": 0.855, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a74ae3d3-a942-5503-b07e-3ea2e82481a0", "medic_supporting_text_truncated": true, "object": "MONDO:0005010", "object_location_in_text": [1020, 1043], "original_object": "coronary artery disease", "original_subject": "IODINE", "population_context_qualifier": "Adults and pediatric patients 12 years of age and over", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=798f3bc6-d976-49a6-87a2-fd30c784fc50"]}], "subject": "RXCUI:5933", "supporting_text": ["1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL). Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL). Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1.1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA). (320 mg Iodine/mL) angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. Pediatric patients less than 12 years of age (320 mg Iodine/mL) angiocardiography, cerebral arteriography, and visceral arteriography. 1.2 Intravenous Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) CT imaging of the head and body. (270 mg Iodine/mL and 320 mg Iodine/mL) excretory urography. (270 mg Iodine/mL) peripheral venography. (320 mg Iodine/mL) coronary computed tomography"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "known hepatocellular carcinoma", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:730049e5-e43f-5a05-baa6-d3af1ca9192a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a3964b09-996d-5011-b111-6c0e6570413b", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a74ae3d3-a942-5503-b07e-3ea2e82481a0", "object": "MONDO:0007256", "original_object": "hepatocellular carcinoma", "original_subject": "IODINE", "population_context_qualifier": "adults", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:511d1f64-5cb9-4baa-a123-96205467e59a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=511d1f64-5cb9-4baa-a123-96205467e59a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=511d1f64-5cb9-4baa-a123-96205467e59a"]}], "subject": "RXCUI:5933", "supporting_text": ["1 INDICATIONS AND USAGE Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) Lipiodol is an oil-based radiopaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)"], "temporal_context_qualifier": "selective hepatic intra-arterial use for imaging tumors"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0342879", "has_confidence_score": 0.81, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5986629f-9118-54c5-aaf8-fa512339fe92", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "reduces_risk_of", "medic_disease_context_ids": ["UMLS:C0342879"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fafc097d-1c5b-536a-bec8-e4eb6cb988b0", "medic_pair_confidence": 0.81, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cfe9c3c2-0dc1-5d57-b0b4-4517f5ed3797", "medic_supporting_text_truncated": true, "object": "HP:0003124", "original_object": "hypercholesterolemia", "original_subject": "NIACIN", "population_context_qualifier": "patients with primary hypercholesterolemia (Types IIa and IIb)", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f51f7e6d-b132-48d8-8bb1-54203472f0d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f51f7e6d-b132-48d8-8bb1-54203472f0d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f51f7e6d-b132-48d8-8bb1-54203472f0d8"]}], "subject": "RXCUI:7393", "supporting_text": ["I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylom"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "Types IV and V hyperlipidemia", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:d04e72ca-9d09-53d7-9d0f-bce1c3820194", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:f52ba5b8-7826-5211-909d-b8b2a990e8e6", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cfe9c3c2-0dc1-5d57-b0b4-4517f5ed3797", "medic_supporting_text_truncated": true, "object": "MONDO:0005347", "original_object": "hypertriglyceridemia", "original_subject": "NIACIN", "population_context_qualifier": "adult patients with very high serum triglyceride levels who present a risk of pancreatitis", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:f51f7e6d-b132-48d8-8bb1-54203472f0d8", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=f51f7e6d-b132-48d8-8bb1-54203472f0d8", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f51f7e6d-b132-48d8-8bb1-54203472f0d8"]}], "subject": "RXCUI:7393", "supporting_text": ["I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylom"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "atherosclerotic vascular disease", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:03daf5ec-425d-5a92-bd89-8ec0341ec777", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19820101", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:767eebd0-529f-52ce-9647-4f25015cf410", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:cfe9c3c2-0dc1-5d57-b0b4-4517f5ed3797", "object": "MONDO:0021187", "object_location_in_text": [216, 230], "original_object": "hyperlipidemia", "original_subject": "NIACIN", "population_context_qualifier": "individuals at significantly increased risk for atherosclerotic vascular disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6e604319-e164-4056-ab80-b78b98c519c7", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6e604319-e164-4056-ab80-b78b98c519c7", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e604319-e164-4056-ab80-b78b98c519c7"]}], "subject": "RXCUI:7393", "supporting_text": ["1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Niacin extended-release tablets are indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. Niacin extended-release tablets in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "direct intraocular injection", "has_confidence_score": 0.7695, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0fa286ea-6306-5dc1-bce1-9d680c94f436", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960626", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:41c837c8-584f-58b5-96ae-9c74ee17925b", "medic_pair_confidence": 0.7695, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1ade408-d4d1-5825-b65f-7ca0da206a2e", "object": "HP:0032547", "object_location_in_text": [810, 825], "original_object": "ocular hypotony", "original_subject": "CIDOFOVIR", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56541229-8c1a-4550-8951-2415ed08e7e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56541229-8c1a-4550-8951-2415ed08e7e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56541229-8c1a-4550-8951-2415ed08e7e9"]}], "subject": "RXCUI:83171", "supporting_text": ["Initiation of therapy with cidofovir injection is contraindicated in patients with a serum creatinine &gt; 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ proteinuria). Cidofovir injection is contraindicated in patients receiving agents with nephrotoxic potential. Such agents must be discontinued at least seven days prior to starting therapy with cidofovir injection. Cidofovir injection is contraindicated in patients with hypersensitivity to cidofovir. Cidofovir injection is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications. Direct intraocular injection of cidofovir injection is contraindicated; direct injection of cidofovir has been associated with iritis, ocular hypotony, and permanent impairment of vision."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "direct intraocular injection", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:65621f53-120e-5c92-aeb2-9e29f1c5f35d", "knowledge_level": "knowledge_assertion", "medic_approval_date": "19960626", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:e3f5ae77-6f35-59e3-83fb-70307e8514db", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "HIGH", "medic_reliability": "HIGH", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d1ade408-d4d1-5825-b65f-7ca0da206a2e", "object": "MONDO:0006814", "object_location_in_text": [802, 808], "original_object": "iritis", "original_subject": "CIDOFOVIR", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:56541229-8c1a-4550-8951-2415ed08e7e9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=56541229-8c1a-4550-8951-2415ed08e7e9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=56541229-8c1a-4550-8951-2415ed08e7e9"]}], "subject": "RXCUI:83171", "supporting_text": ["Initiation of therapy with cidofovir injection is contraindicated in patients with a serum creatinine &gt; 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ proteinuria). Cidofovir injection is contraindicated in patients receiving agents with nephrotoxic potential. Such agents must be discontinued at least seven days prior to starting therapy with cidofovir injection. Cidofovir injection is contraindicated in patients with hypersensitivity to cidofovir. Cidofovir injection is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications. Direct intraocular injection of cidofovir injection is contraindicated; direct injection of cidofovir has been associated with iritis, ocular hypotony, and permanent impairment of vision."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "alteration in the RES", "has_confidence_score": 0.54, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:998aafae-270e-531c-8b64-41476e51a96e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "diagnoses", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:bedbe1cc-9332-519e-bb42-abac7a0e544d", "medic_pair_confidence": 0.54, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e56ac03a-2a5a-5840-9c09-d967578c9963", "object": "UMLS:C0577053", "original_object": "hepatic lesions", "original_subject": "IRON", "population_context_qualifier": "adult patients", "predicate": "biolink:diagnoses", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:82CEB312-3AAA-4A5C-9849-7F246CC06DED", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=82CEB312-3AAA-4A5C-9849-7F246CC06DED", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82CEB312-3AAA-4A5C-9849-7F246CC06DED"]}], "subject": "RXCUI:90176", "supporting_text": ["Feridex I.V. is indicated for I.V. administration as an adjunct to MRI (in adult patients) to enhance the T2 weighted images used in the detection and evaluation of lesions of the liver that are associated with an alteration in the RES."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0240066", "has_confidence_score": 0.9, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:36566be0-fb69-5cad-99be-2135c1127c0a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0240066", "HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.9, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:e56ac03a-2a5a-5840-9c09-d967578c9963", "object": "MONDO:0002280", "object_location_in_text": [33, 39], "original_object": "anemia", "original_subject": "IRON", "population_context_qualifier": "patients with menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d4d823b-ff2f-4746-9bd7-44def2b81347"]}], "subject": "RXCUI:90176", "supporting_text": ["INDICATIONS For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1969290", "has_confidence_score": 0.5985, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c81f471b-c78b-54fd-9667-36438fdb1161", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C1969290", "MONDO:0024304"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:39a11c07-c02b-5af7-9226-6e2ca5365eb5", "medic_pair_confidence": 0.5985, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:434a1796-2a2b-537c-b0c8-20661b6a0eea", "object": "HP:0000989", "object_location_in_text": [129, 136], "original_object": "itching", "original_subject": "LACTIC ACID, DL-", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3d94a218-ae4d-4158-bd8e-92743c7c8e0d", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3d94a218-ae4d-4158-bd8e-92743c7c8e0d", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d94a218-ae4d-4158-bd8e-92743c7c8e0d"]}], "subject": "UNII:3B8D35Y7S4", "supporting_text": ["Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f00f7239-2462-5bb4-9b43-97d178d68b17", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:66637cc8-928c-51ae-90fc-b19405a311d6", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad2518dd-03f6-59f1-9916-683999b7d4fc", "object": "MONDO:0000001", "object_location_in_text": [186, 222], "original_object": "active secondary progressive disease", "original_subject": "MONOMETHYL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a161f9d4-70f1-4097-957a-eafb35d3274f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a161f9d4-70f1-4097-957a-eafb35d3274f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a161f9d4-70f1-4097-957a-eafb35d3274f"]}], "subject": "UNII:45IUB1PX8R", "supporting_text": ["1 INDICATIONS AND USAGE BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "relapsing forms of multiple sclerosis", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1bb4bf92-82a9-5aa4-a96e-02c3fd4d12e7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:d2cd79df-3bde-5573-aecd-c3ab4fd5d798", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:ad2518dd-03f6-59f1-9916-683999b7d4fc", "object": "UMLS:C2921627", "object_location_in_text": [123, 151], "original_object": "clinically isolated syndrome", "original_subject": "MONOMETHYL", "population_context_qualifier": "adults", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:a161f9d4-70f1-4097-957a-eafb35d3274f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=a161f9d4-70f1-4097-957a-eafb35d3274f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a161f9d4-70f1-4097-957a-eafb35d3274f"]}], "subject": "UNII:45IUB1PX8R", "supporting_text": ["1 INDICATIONS AND USAGE BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:aacaefe8-4ab9-5898-b5a5-d9242c407f3a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["myelosuppressive chemotherapy"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62a4845d-04c2-5951-88d6-9d02bdbcb953", "object": "MONDO:0002280", "object_location_in_text": [104, 110], "original_object": "anemia", "original_subject": "EPOETIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5"]}], "subject": "UNII:64FS3BFH5W", "supporting_text": ["1 INDICATIONS AND USAGE Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 )."], "temporal_context_qualifier": "where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "non-myeloid malignancies", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f481847c-5aad-5c05-8dec-41d976db2e71", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ca626c60-0cbc-54ba-a124-ae846e902e63", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:62a4845d-04c2-5951-88d6-9d02bdbcb953", "object": "MONDO:0002280", "object_location_in_text": [108, 114], "original_object": "anemia", "original_subject": "EPOETIN", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e6e4dd0c-25ca-40b2-ba6b-6138a68621fe", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e6e4dd0c-25ca-40b2-ba6b-6138a68621fe", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6e4dd0c-25ca-40b2-ba6b-6138a68621fe"]}], "subject": "UNII:64FS3BFH5W", "supporting_text": ["1 INDICATIONS AND USAGE RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 )."], "temporal_context_qualifier": "myelosuppressive chemotherapy planned for minimum two additional months"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "HP:0100507", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:daa9238d-54b1-50ce-8d7b-9e70b26a9ff8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0100507"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:832643bb-7861-5666-a372-4993d4170075", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:928b7065-58aa-583e-94e9-36f617311285", "object": "MONDO:0001700", "object_location_in_text": [111, 131], "original_object": "megaloblastic anemia", "original_subject": ".ALPHA.-TOCOPHEROL, DL-", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cee15842-4a9e-c6ba-e053-2a95a90aebc5"]}], "subject": "UNII:7QWA1RIO01", "supporting_text": [": Multitam™ is indicated to provide dietary support for men and women. Folate is effective in the treatment of megaloblastic anemia due to folate deficiency (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, as well as those associated with pregnancy, infancy, or childhood."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C1960448", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:803d4b36-a1d4-5f53-a8f5-0696e6286a17", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C1960448"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76968892-5e9b-548f-a174-3a196993bd48", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "HP:0001268", "original_object": "mental deterioration", "original_subject": "PHENYLBUTYRIC ACID", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:463a36fa-3eb2-4326-8bd0-c8c7a11bca3a", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=463a36fa-3eb2-4326-8bd0-c8c7a11bca3a", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=463a36fa-3eb2-4326-8bd0-c8c7a11bca3a"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["BUPHENYL is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. BUPHENYL must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamoyl phosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in t"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "late-onset urea cycle disorders", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0460669d-89b7-54cf-90b9-aaac6ac6a2a4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76968892-5e9b-548f-a174-3a196993bd48", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "HP:0001268", "original_object": "mental deterioration", "original_subject": "PHENYLBUTYRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c564778d-b285-4d1d-a641-9d4ee76079cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c564778d-b285-4d1d-a641-9d4ee76079cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c564778d-b285-4d1d-a641-9d4ee76079cf"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "late-onset urea cycle disorders", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f2518e5c-fa9b-5e69-bded-9e062117e501", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:76968892-5e9b-548f-a174-3a196993bd48", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "HP:0001268", "original_object": "mental deterioration", "original_subject": "PHENYLBUTYRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d08fd548-7eb8-4f6f-b664-b0fff6f30065", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:10d94780-a9c7-5d51-84d2-f7457a84f587", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbbf669e-20c4-557a-840e-11f94aab5ad0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "object": "MONDO:0004739", "original_object": "urea cycle disorders", "original_subject": "PHENYLBUTYRIC ACID", "population_context_qualifier": "adult and pediatric patients", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["1 INDICATIONS AND USAGE PHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS)."], "temporal_context_qualifier": "chronic management"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1265b5ae-6441-50d5-87d9-8d403859081e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbbf669e-20c4-557a-840e-11f94aab5ad0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "MONDO:0004739", "object_location_in_text": [109, 129], "original_object": "urea cycle disorders", "original_subject": "PHENYLBUTYRIC ACID", "population_context_qualifier": "late-onset disease (partial enzymatic deficiency, presenting after the first month of life) with history of hyperammonemic encephalopathy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c564778d-b285-4d1d-a641-9d4ee76079cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c564778d-b285-4d1d-a641-9d4ee76079cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c564778d-b285-4d1d-a641-9d4ee76079cf"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4682069d-29f0-5e22-952a-c8985f2403f3", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbbf669e-20c4-557a-840e-11f94aab5ad0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "object": "MONDO:0004739", "original_object": "urea cycle disorders", "original_subject": "PHENYLBUTYRIC ACID", "population_context_qualifier": "adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m 2 or greater", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:89abc31c-43e8-4809-9eb7-172cb31a86f1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=89abc31c-43e8-4809-9eb7-172cb31a86f1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89abc31c-43e8-4809-9eb7-172cb31a86f1"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["1 INDICATIONS AND USAGE OLPRUVA is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m 2 or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). OLPRUVA is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m 2 or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). ( 1 )"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5e29ae71-fb5b-5dfb-9eea-fe871635b769", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbbf669e-20c4-557a-840e-11f94aab5ad0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "MONDO:0004739", "object_location_in_text": [109, 129], "original_object": "urea cycle disorders", "original_subject": "PHENYLBUTYRIC ACID", "population_context_qualifier": "late-onset disease (partial enzymatic deficiency, presenting after the first month of life) with history of hyperammonemic encephalopathy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d08fd548-7eb8-4f6f-b664-b0fff6f30065", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:97425ba6-f3ab-54c6-8667-9071c98338e8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:1c3521fb-98f6-5e1a-a02d-93763d6b9169", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "MONDO:0004739", "original_object": "urea cycle disorder", "original_subject": "PHENYLBUTYRIC ACID", "population_context_qualifier": "late-onset disease with history of hyperammonemic encephalopathy", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:4020b962-eaee-4184-b04b-14ca757c51a1", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=4020b962-eaee-4184-b04b-14ca757c51a1", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4020b962-eaee-4184-b04b-14ca757c51a1"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium Phenylbutyrate Tablets is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patient"], "temporal_context_qualifier": "presenting after the first month of life"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0751753", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a431d05e-7aa8-5508-b2c0-aafa370e889b", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_co_administered_with": ["dietary protein restriction"], "medic_disease_context_ids": ["UMLS:C0751753", "MONDO:0010703", "MONDO:0008988"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fbbf669e-20c4-557a-840e-11f94aab5ad0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "MONDO:0004739", "object_location_in_text": [107, 127], "original_object": "urea cycle disorders", "original_subject": "PHENYLBUTYRIC ACID", "population_context_qualifier": "late-onset disease", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:639f5c7e-9f6d-47fb-a417-2be076176a78", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=639f5c7e-9f6d-47fb-a417-2be076176a78", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=639f5c7e-9f6d-47fb-a417-2be076176a78"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients "], "temporal_context_qualifier": "presenting after the first month of life"}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "late-onset urea cycle disorders", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:29318f28-41e7-5f68-9492-2244e04e28fa", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLBUTYRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:d08fd548-7eb8-4f6f-b664-b0fff6f30065", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "late-onset urea cycle disorders", "has_confidence_score": 0.63, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ad751bf9-4de7-586b-8cea-93e5f46f87d6", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "maintenance", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:82f6dc34-7e19-5ff5-a091-6ed0e99bc58a", "medic_pair_confidence": 0.63, "medic_pair_n_assertions": 2, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:a3eee5f9-9daf-5dc7-bcc8-4de2144a289f", "medic_supporting_text_truncated": true, "object": "UMLS:C1960448", "original_object": "hyperammonemic encephalopathy", "original_subject": "PHENYLBUTYRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:c564778d-b285-4d1d-a641-9d4ee76079cf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=c564778d-b285-4d1d-a641-9d4ee76079cf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c564778d-b285-4d1d-a641-9d4ee76079cf"]}], "subject": "UNII:7WY7YBI87E", "supporting_text": ["Sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patien"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "vitamin B12 and/or folate deficiency", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b9e5c9f5-6b52-5845-a06f-0d47961932a4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:11f079b2-73e4-53c8-a711-56aee69df5c0", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:d161a774-bb0d-5101-b223-b9770241be06", "object": "MONDO:0004743", "object_location_in_text": [135, 155], "original_object": "hyperhomocysteinemia", "original_subject": "1", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f14fa40-97ab-4ec5-b66b-793d6d1abac9"]}], "subject": "UNII:DVY07ILF1W", "supporting_text": ["INDICATIONS: EnBrace HR ® is indicated in the TREATMENT of vitamin deficiency - specifically vitamin B12 deficiency - and TREATMENT of hyperhomocysteinemia due to vitamin B12 and/or folate deficiency, and the PREVENTION of deficiency of the vitamin B12 cofactor, l-methylfolate. Requirements of vitamin B 9 and/or vitamin B 12 in excess of normal due to pregnancy can usually be met with oral supplementation."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0567312", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:1602365f-f798-58de-b9c2-ac71f12b7867", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["UMLS:C0567312"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:4ebd94fd-78a5-522c-95e3-d995cf4fcc32", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "LOW", "medic_reliability": "LOW", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:eac55e00-69a4-5502-8713-0e410b219b1b", "object": "MONDO:0002050", "object_location_in_text": [280, 290], "original_object": "depression", "original_subject": "FOOD YELLOW 3 FREE ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e4ff7b6b-ce78-402c-9c0e-b8b0d9636eae"]}], "subject": "UNII:G2B7JWK1GG", "supporting_text": ["Indications &amp; Usage COVARYXT® and COVARYX® H.S. are indicated in the treatment of Moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) COVARYXT® and COVARYX® H.S. HAVE NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (See BOXED WARNINGS)."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "toxin types A or B", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:e1a0bc6f-d7fc-5701-97aa-06bbcfca18e0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:3fb2996b-d2ca-5f50-b001-4f6e71a6d1f9", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:4adf38f4-337f-5716-9cec-72982c3b0601", "object": "MONDO:0015804", "object_location_in_text": [116, 131], "original_object": "infant botulism", "original_subject": "HUMAN BOTULINUM NEUROTOXIN A/B IMMUNE GLOBULIN", "population_context_qualifier": "patients below one year of age", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:9ec59262-35c1-4d8e-8451-a7cfbacb0675", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=9ec59262-35c1-4d8e-8451-a7cfbacb0675", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ec59262-35c1-4d8e-8451-a7cfbacb0675"]}], "subject": "UNII:X641Y30OA7", "supporting_text": ["1 INDICATIONS AND USAGE BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age. BabyBIG is an immune globulin intravenous (human) indicated for: Treatment of infant botulism caused by toxin types A or B in patients below one year of age ( 1 )."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0e601abf-59c2-5d82-ba12-710a14c79385", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [336, 353], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4e4e5a33-2611-5ad2-8e15-5ef3709cb173", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [336, 353], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a6e4489-49d4-5b23-9485-9e266d603062", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [335, 352], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6171f3aa-53ed-5dc3-a48f-cd36f451a7a8", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [335, 352], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:897054d3-2f55-5fb9-82ef-9b1db12cb191", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [336, 353], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:c66c2c28-bf8b-5e54-a60c-6b9bd1e1a94a", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [335, 352], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:cb84598b-0878-569e-9537-3eedd149764c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [302, 319], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Urocit ® -K is contraindicated: In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. In patients with peptic ulcer disease because of its ulcerogenic potential. In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Urocit ® -K to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from Urocit ® -K therapy might promote further bacterial growth. In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture (4) Patients with peptic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ea5b7acc-d1fe-585d-87d5-d97adaacddb7", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [336, 353], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.525, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ecce5666-181c-56a1-ab65-9dd97c123d41", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a4269a34-92e6-57c0-afcd-e026f32b5b3e", "medic_pair_confidence": 0.525, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "HP:0001944", "object_location_in_text": [336, 353], "original_object": "acute dehydration", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:3b35546a-bd41-5087-965f-1ff7ebe78260", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [412, 433], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4a3554fc-5093-5c22-9266-1d04d9e0038f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [412, 433], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6bb88bce-d3be-5c6d-ae07-53f346e84525", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [413, 434], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:79361735-659b-5e9b-81e4-014bc00c5849", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [413, 434], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7972d5de-1ebd-5043-9f07-fcc7375cb12e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [413, 434], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a63a5023-6d15-52b1-a6b7-1e657376f205", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [413, 434], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:bd22f7a4-42e8-58dc-b316-72d1f205cad5", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [379, 400], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Urocit ® -K is contraindicated: In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. In patients with peptic ulcer disease because of its ulcerogenic potential. In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Urocit ® -K to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from Urocit ® -K therapy might promote further bacterial growth. In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture (4) Patients with peptic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:daff53fb-6ecd-5931-8754-6d556e6e998c", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [412, 433], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dfe77745-8398-5183-8104-a53f4513f0fe", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:fff1dafc-ee7c-5872-9dc2-3cab7f90c2e0", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0000004", "object_location_in_text": [413, 434], "original_object": "adrenal insufficiency", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:0962ee34-5765-59b8-935c-5482e500266f", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [281, 302], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:2cb04847-2422-5cb3-aa61-d0011f6cc871", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [281, 302], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4121acad-4793-5913-8de9-0eb22c7f1b82", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [280, 301], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:6f63279d-658f-5765-845e-bac8bc3e68d9", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [281, 302], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:828d7be8-1d22-516e-bf7a-a32108f80e12", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [280, 301], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:8e61fff9-13f4-50f2-81c3-9a08f6b56edc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [281, 302], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:a886900e-ae83-5fa0-9815-8e8e5da68a8e", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [281, 302], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown ( 4 ) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, "]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b53e03e4-5613-52c9-a108-e660a1928008", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [247, 268], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Urocit ® -K is contraindicated: In patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. In patients with peptic ulcer disease because of its ulcerogenic potential. In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Urocit ® -K to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from Urocit ® -K therapy might promote further bacterial growth. In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture (4) Patients with peptic"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalEntityToDiseaseOrPhenotypicFeatureAssociation"], "disease_context_qualifier": "HP:0002153", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:f56618ed-be4a-5171-bd11-7806e0bd4467", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_disease_context_ids": ["HP:0002153"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:ec7adb04-21fd-5c18-b842-02a7f7c1c908", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 9, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "medic_supporting_text_truncated": true, "object": "MONDO:0024327", "object_location_in_text": [280, 301], "original_object": "chronic renal failure", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:contraindicated_in", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["4 CONTRAINDICATIONS Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. • In patients with peptic ulcer disease because of its ulcerogenic potential. • In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Potassium citrate extended–release tablets to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth. • In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. • Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) • Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, es"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b29adf37-c6c5-5fd4-90d1-83aba4a004dc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "HP:0001947", "original_object": "Renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2215dc1d-0b5a-469e-9b51-4d7480a51078", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2215dc1d-0b5a-469e-9b51-4d7480a51078", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2215dc1d-0b5a-469e-9b51-4d7480a51078"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium citrate is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal tubular acidosis (RTA) with calcium stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1) ]. 1.2 Hypocitraturic calcium oxalate nephrolithiasis of any etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2) ]. 1.3 Uric acid lithiasis with or without calcium stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3) ]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:15679892-bd44-5bac-9f94-59adc69ed1f2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [154, 176], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:b32fe71a-4a58-04a1-64d3-bc3cc4a895bf", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=b32fe71a-4a58-04a1-64d3-bc3cc4a895bf", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b32fe71a-4a58-04a1-64d3-bc3cc4a895bf"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE 1 INDICATIONS AND USAGE 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium Citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium Citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)]. 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium Citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)]. Potassium Citrate is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "renal tubular acidosis with calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:19c431b8-ccbf-5e08-a3de-20e9c5930fcc", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [431, 453], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=595343aa-b760-4158-9c49-dd5368f45e2c"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )] . 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:32d6b5fe-7075-5fe8-9578-7620fb8f7a1d", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [399, 421], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44ab2c4f-4a76-470d-98fb-8874c692a967"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium citrate is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones (1.1) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) • Uric acid lithiasis with or without calcium stones (1.3) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)] . 1.3 Uric Acid Llithiasis with or without Calcium Stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:40eb2694-e7dd-54e1-84cc-2215140aa9a4", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [399, 421], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f38b02c-703c-4fc2-b833-654e41bd617f"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium citrate is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones (1.1) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) • Uric acid lithiasis with or without calcium stones (1.3) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)] . 1.3 Uric Acid Llithiasis with or without Calcium Stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:4d74ba6c-97a4-555e-98fc-0a4ade78c6c1", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [399, 421], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3dd9c9eb-df19-4ec9-bc77-f3a159b33d94"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium citrate is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones (1.1) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) • Uric acid lithiasis with or without calcium stones (1.3) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)] . 1.3 Uric Acid Llithiasis with or without Calcium Stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "renal tubular acidosis with calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:5a215a40-1944-5b24-80b3-2430a8e5d751", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [431, 453], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebf1f1f1-4458-4d34-8432-21698a550e07"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )] . 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "renal tubular acidosis with calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:7618cec1-acf3-59e0-b900-0e157620a380", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [431, 453], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6271d84e-d991-4bb8-ac9f-6d5cc879b631"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )] . 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "renal tubular acidosis with calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:b5938f9c-2e33-54d1-97a1-982c87f18f87", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [431, 453], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff67f638-5b53-406a-962a-87773a91fc48"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )] . 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "renal tubular acidosis with calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:dc838263-75a8-58fb-a4fc-ce224f1fbd55", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [431, 453], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2fb31727-68b1-4183-947d-00e08bf99987"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )] . 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )] . 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see Clinical Studies ( 14.3 )] ."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "renal tubular acidosis with calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ebdc29e3-747e-5456-989e-620400d797c2", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 6, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [401, 423], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:164d9d05-fbb1-4d99-8ba3-ff9c172aa8ca", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=164d9d05-fbb1-4d99-8ba3-ff9c172aa8ca", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=164d9d05-fbb1-4d99-8ba3-ff9c172aa8ca"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS &amp; USAGE Potassium citrate is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies ( 14.1 )]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies ( 14.2 )]. 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies ( 14.3 )]."]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "calcium stones", "has_confidence_score": 0.7, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:ece58022-dda1-5fc6-b8cc-36bee62d68d0", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:a7c66f52-3ab0-52d9-bec3-76ee87102228", "medic_pair_confidence": 0.7, "medic_pair_n_assertions": 5, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:3d46674a-e718-5ba8-ac71-c7e9e5ac1c62", "object": "MONDO:0001909", "object_location_in_text": [130, 152], "original_object": "renal tubular acidosis", "original_subject": "ANHYDROUS CITRIC ACID", "predicate": "biolink:treats", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72cdea1b-2240-41db-987d-86d5c6aaa978"]}], "subject": "UNII:XF417D3PSL", "supporting_text": ["1 INDICATIONS AND USAGE 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)]. 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)]. Urocit-K is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3)"]}
{"agent_type": "text_mining_agent", "aggregator_knowledge_source": ["infores:medic"], "category": ["biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation"], "clinical_approval_status": "fda_approved_for_condition", "disease_context_qualifier": "UMLS:C0343752", "has_confidence_score": 0.665, "has_evidence": ["ECO:0006156"], "id": "MEDICEDGE:caece2ed-7243-5044-82f0-978cf87e4e46", "knowledge_level": "knowledge_assertion", "medic_approval_status_raw": "APPROVED", "medic_claim_relation": "prevents", "medic_disease_context_ids": ["UMLS:C0343752", "UMLS:C0019168"], "medic_jurisdiction": "USA", "medic_object_mention_id": "MEDICNE:9919261a-58e9-5397-9d31-5cbea5f0a124", "medic_pair_confidence": 0.665, "medic_pair_n_assertions": 1, "medic_pair_reliability": "MEDIUM", "medic_reliability": "MEDIUM", "medic_source": "DAILYMED", "medic_subject_mention_id": "MEDICNE:2763a661-ca7a-56ff-bb5e-f5d599ebe9b3", "object": "MONDO:0005344", "original_object": "hepatitis B infection", "original_subject": "HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN", "population_context_qualifier": "infants less than 12 months old whose mother or primary caregiver is positive for HBsAg; other household contacts with an identifiable blood exposure to the index patient", "predicate": "biolink:preventative_for_condition", "primary_knowledge_source": "infores:fda-dailymed", "sources": [{"category": ["biolink:RetrievalSource"], "id": "infores:fda-dailymed", "resource_id": "infores:fda-dailymed", "resource_role": "primary_knowledge_source", "source_record_urls": ["DailyMed:47fe1a99-5078-4b89-84fa-9e8387baec5c", "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setid=47fe1a99-5078-4b89-84fa-9e8387baec5c", "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=47fe1a99-5078-4b89-84fa-9e8387baec5c"]}], "subject": "UNII:XII270YC6M", "supporting_text": ["Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infec- tion in the following settings: Acute Exposure to Blood Containing HBsAg: Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident), involving HBsAg-positive materials such as blood, plasma, or serum. Perinatal Exposure of Infants Born to HBsAg-positive Mothers: Infants born to mothers positive for HBsAg with or without HBeAg 12 . Sexual Exposure to HBsAg-positive Persons: Sexual partners of HBsAg-positive persons. Household Exposure to Persons with Acute HBV Infection: Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg. Other household contacts with an identifiable blood exposure to the index patient. Nabi-HB is indicated for intramuscular use only."]}